{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Global Function in Healthcare Classification\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "#importing relevant libraries\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "import string \n",
    "import nltk\n",
    "import re\n",
    "import os\n",
    "import matplotlib.pyplot as plt\n",
    "%matplotlib inline\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer, CountVectorizer\n",
    "from sklearn.utils import shuffle\n",
    "from sklearn.model_selection import train_test_split, cross_val_predict, GridSearchCV, ShuffleSplit\n",
    "from sklearn.ensemble import RandomForestClassifier, GradientBoostingClassifier\n",
    "from sklearn.metrics import classification_report, confusion_matrix\n",
    "from sklearn.naive_bayes import MultinomialNB, GaussianNB\n",
    "from sklearn.linear_model import LogisticRegression\n",
    "import seaborn as sns\n",
    "from sklearn import svm\n",
    "from sklearn.svm import LinearSVC\n",
    "from sklearn.neural_network import MLPClassifier\n",
    "from keras.preprocessing.text import Tokenizer\n",
    "from sklearn.preprocessing import LabelEncoder\n",
    "from keras.utils.np_utils import to_categorical\n",
    "from keras.preprocessing.sequence import pad_sequences\n",
    "from keras.models import Sequential\n",
    "from keras.layers import Dense, Embedding, Flatten, SimpleRNN, LSTM, Bidirectional, Dropout, GlobalAveragePooling1D\n",
    "from keras.layers.convolutional import Conv1D, MaxPooling1D\n",
    "import keras as keras\n",
    "import nlpaug\n",
    "import nlpaug.augmenter.word as naw\n",
    "from itertools import repeat\n",
    "import random\n",
    "from pprint import pprint\n",
    "import xgboost as xgb\n",
    "from xgboost.sklearn import XGBClassifier\n",
    "import pickle"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Implementing probability models (statistical models)**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Donor.Name</th>\n",
       "      <th>Recipient.Name</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>Short.Description</th>\n",
       "      <th>Long.Description</th>\n",
       "      <th>Value</th>\n",
       "      <th>category</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2015</td>\n",
       "      <td>UNFPA</td>\n",
       "      <td>Mongolia</td>\n",
       "      <td>Output 04: HIV</td>\n",
       "      <td>16064</td>\n",
       "      <td>HIV</td>\n",
       "      <td>16064. Output 04: HIV. HIV. Mongolia -Ulaan Ba...</td>\n",
       "      <td>4.497275e-22</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2013</td>\n",
       "      <td>World Health Organisation</td>\n",
       "      <td>Bilateral, unspecified</td>\n",
       "      <td>CVCAGlobalLeadership and governance</td>\n",
       "      <td>12110</td>\n",
       "      <td>CVCA: GLOBALLEADERSHIP AND GOVERNANCE</td>\n",
       "      <td>12110. CVCAGlobalLeadership and governance. CV...</td>\n",
       "      <td>3.901426e-20</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2013</td>\n",
       "      <td>World Health Organisation</td>\n",
       "      <td>Far East Asia, regional</td>\n",
       "      <td>ACFar East Asia, regionalReduction of risk fac...</td>\n",
       "      <td>12110</td>\n",
       "      <td>AC: FAR EAST ASIA, REGIONALREDUCTION OF RISK F...</td>\n",
       "      <td>12110. ACFar East Asia, regionalReduction of r...</td>\n",
       "      <td>1.373741e-07</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2015</td>\n",
       "      <td>United States</td>\n",
       "      <td>Honduras</td>\n",
       "      <td>Maternal and Child Health</td>\n",
       "      <td>13020</td>\n",
       "      <td>MATERNAL AND CHILD HEALTH</td>\n",
       "      <td>13020. Maternal and Child Health. MATERNAL AND...</td>\n",
       "      <td>1.030151e-06</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2015</td>\n",
       "      <td>UNFPA</td>\n",
       "      <td>Mali</td>\n",
       "      <td>Output 13: Analysis on population dynamics</td>\n",
       "      <td>13081</td>\n",
       "      <td>ANALYSIS ON POPULATION DYNAMICS</td>\n",
       "      <td>13081. Output 13: Analysis on population dynam...</td>\n",
       "      <td>1.559553e-06</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                 Donor.Name           Recipient.Name  \\\n",
       "0  2015                      UNFPA                 Mongolia   \n",
       "1  2013  World Health Organisation   Bilateral, unspecified   \n",
       "2  2013  World Health Organisation  Far East Asia, regional   \n",
       "3  2015              United States                 Honduras   \n",
       "4  2015                      UNFPA                     Mali   \n",
       "\n",
       "                                       Project.title  Purpose.Code  \\\n",
       "0                                     Output 04: HIV         16064   \n",
       "1                CVCAGlobalLeadership and governance         12110   \n",
       "2  ACFar East Asia, regionalReduction of risk fac...         12110   \n",
       "3                          Maternal and Child Health         13020   \n",
       "4         Output 13: Analysis on population dynamics         13081   \n",
       "\n",
       "                                   Short.Description  \\\n",
       "0                                                HIV   \n",
       "1              CVCA: GLOBALLEADERSHIP AND GOVERNANCE   \n",
       "2  AC: FAR EAST ASIA, REGIONALREDUCTION OF RISK F...   \n",
       "3                          MATERNAL AND CHILD HEALTH   \n",
       "4                    ANALYSIS ON POPULATION DYNAMICS   \n",
       "\n",
       "                                    Long.Description         Value  \\\n",
       "0  16064. Output 04: HIV. HIV. Mongolia -Ulaan Ba...  4.497275e-22   \n",
       "1  12110. CVCAGlobalLeadership and governance. CV...  3.901426e-20   \n",
       "2  12110. ACFar East Asia, regionalReduction of r...  1.373741e-07   \n",
       "3  13020. Maternal and Child Health. MATERNAL AND...  1.030151e-06   \n",
       "4  13081. Output 13: Analysis on population dynam...  1.559553e-06   \n",
       "\n",
       "                category  \n",
       "0        not_global_func  \n",
       "1        Health_Advocacy  \n",
       "2        Health_Advocacy  \n",
       "3        not_global_func  \n",
       "4  Knowledge_Gen_Sharing  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#loading the file\n",
    "global_func=pd.read_csv(\"globalfunc_long_withpuposecode.csv\", engine=\"python\")\n",
    "global_func.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Creating a new column by combining the short.description and Long.description column\n",
    "#global_func[\"Long.Description\"]=global_func[\"Short.Description\"]+\". \"+ global_func[\"Long.Description\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "#dropping some columns\n",
    "global_func=global_func.drop([\"Donor.Name\", \"Recipient.Name\", \"Short.Description\"], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "   YEAR                                      Project.title  Purpose.Code  \\\n",
      "0  2015                                     Output 04: HIV         16064   \n",
      "1  2013                CVCAGlobalLeadership and governance         12110   \n",
      "2  2013  ACFar East Asia, regionalReduction of risk fac...         12110   \n",
      "3  2015                          Maternal and Child Health         13020   \n",
      "4  2015         Output 13: Analysis on population dynamics         13081   \n",
      "\n",
      "                                    Long.Description         Value  \\\n",
      "0  16064. Output 04: HIV. HIV. Mongolia -Ulaan Ba...  4.497275e-22   \n",
      "1  12110. CVCAGlobalLeadership and governance. CV...  3.901426e-20   \n",
      "2  12110. ACFar East Asia, regionalReduction of r...  1.373741e-07   \n",
      "3  13020. Maternal and Child Health. MATERNAL AND...  1.030151e-06   \n",
      "4  13081. Output 13: Analysis on population dynam...  1.559553e-06   \n",
      "\n",
      "                category  \n",
      "0        not_global_func  \n",
      "1        Health_Advocacy  \n",
      "2        Health_Advocacy  \n",
      "3        not_global_func  \n",
      "4  Knowledge_Gen_Sharing  \n",
      "(16764, 6)\n"
     ]
    }
   ],
   "source": [
    "print(global_func.head())\n",
    "\n",
    "print(global_func.shape)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "#renaming the category column to label\n",
    "global_func=global_func.rename(columns={\"category\":\"label\", \"Long.Description\":\"description\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['YEAR', 'Project.title', 'Purpose.Code', 'description', 'Value', 'label']"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list(global_func.columns)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2015</td>\n",
       "      <td>Output 04: HIV</td>\n",
       "      <td>16064</td>\n",
       "      <td>16064. Output 04: HIV. HIV. Mongolia -Ulaan Ba...</td>\n",
       "      <td>4.497275e-22</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2013</td>\n",
       "      <td>CVCAGlobalLeadership and governance</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. CVCAGlobalLeadership and governance. CV...</td>\n",
       "      <td>3.901426e-20</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2013</td>\n",
       "      <td>ACFar East Asia, regionalReduction of risk fac...</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. ACFar East Asia, regionalReduction of r...</td>\n",
       "      <td>1.373741e-07</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2015</td>\n",
       "      <td>Maternal and Child Health</td>\n",
       "      <td>13020</td>\n",
       "      <td>13020. Maternal and Child Health. MATERNAL AND...</td>\n",
       "      <td>1.030151e-06</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2015</td>\n",
       "      <td>Output 13: Analysis on population dynamics</td>\n",
       "      <td>13081</td>\n",
       "      <td>13081. Output 13: Analysis on population dynam...</td>\n",
       "      <td>1.559553e-06</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2015                                     Output 04: HIV         16064   \n",
       "1  2013                CVCAGlobalLeadership and governance         12110   \n",
       "2  2013  ACFar East Asia, regionalReduction of risk fac...         12110   \n",
       "3  2015                          Maternal and Child Health         13020   \n",
       "4  2015         Output 13: Analysis on population dynamics         13081   \n",
       "\n",
       "                                         description         Value  \\\n",
       "0  16064. Output 04: HIV. HIV. Mongolia -Ulaan Ba...  4.497275e-22   \n",
       "1  12110. CVCAGlobalLeadership and governance. CV...  3.901426e-20   \n",
       "2  12110. ACFar East Asia, regionalReduction of r...  1.373741e-07   \n",
       "3  13020. Maternal and Child Health. MATERNAL AND...  1.030151e-06   \n",
       "4  13081. Output 13: Analysis on population dynam...  1.559553e-06   \n",
       "\n",
       "                   label  \n",
       "0        not_global_func  \n",
       "1        Health_Advocacy  \n",
       "2        Health_Advocacy  \n",
       "3        not_global_func  \n",
       "4  Knowledge_Gen_Sharing  "
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "global_func.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "global_func[\"label\"]=global_func[\"label\"].replace({'RD_Blueprint_Diseases_Pandemic_Flu':'Epidemic_Pandemic_Prep'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['not_global_func',\n",
       " 'Health_Advocacy',\n",
       " 'Knowledge_Gen_Sharing',\n",
       " 'Dev_Harmonization_Int_Reg',\n",
       " 'Epidemic_Pandemic_Prep',\n",
       " 'Control_Cross_Border_Disease',\n",
       " 'Response_Unhealthy_Products',\n",
       " 'Market_Shaping',\n",
       " 'RD_New_Health_Tools',\n",
       " 'Promotion_Aid_Effectiveness']"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# checking the unique categories in the label column. These categories were created combining the sub categories in the\n",
    "#original dataset\n",
    "label_cat=list(global_func.label.unique())\n",
    "label_cat"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2015</td>\n",
       "      <td>Solomon Islands Health Sector Budget Support</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. Solomon Islands Health Sector Budget Su...</td>\n",
       "      <td>14.422510</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2015</td>\n",
       "      <td>Investing towards Malaria Elimination</td>\n",
       "      <td>12262</td>\n",
       "      <td>12262. Investing towards Malaria Elimination. ...</td>\n",
       "      <td>7.379632</td>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015</td>\n",
       "      <td>Output 04: HIV</td>\n",
       "      <td>16064</td>\n",
       "      <td>16064. Output 04: HIV. HIV. Niger - Niamey. Ou...</td>\n",
       "      <td>0.000506</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>13030</td>\n",
       "      <td>13030. Johns Hopkins University. JOHNS HOPKINS...</td>\n",
       "      <td>0.416566</td>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2017</td>\n",
       "      <td>Children's Hospital &amp; Research Center at Oakland</td>\n",
       "      <td>12250</td>\n",
       "      <td>12250. Children's Hospital &amp; Research Center a...</td>\n",
       "      <td>0.052983</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                                     Project.title  Purpose.Code  \\\n",
       "0  2015      Solomon Islands Health Sector Budget Support         12220   \n",
       "1  2015             Investing towards Malaria Elimination         12262   \n",
       "2  2015                                    Output 04: HIV         16064   \n",
       "3  2017                          Johns Hopkins University         13030   \n",
       "4  2017  Children's Hospital & Research Center at Oakland         12250   \n",
       "\n",
       "                                         description      Value  \\\n",
       "0  12220. Solomon Islands Health Sector Budget Su...  14.422510   \n",
       "1  12262. Investing towards Malaria Elimination. ...   7.379632   \n",
       "2  16064. Output 04: HIV. HIV. Niger - Niamey. Ou...   0.000506   \n",
       "3  13030. Johns Hopkins University. JOHNS HOPKINS...   0.416566   \n",
       "4  12250. Children's Hospital & Research Center a...   0.052983   \n",
       "\n",
       "                          label  \n",
       "0               not_global_func  \n",
       "1  Control_Cross_Border_Disease  \n",
       "2               not_global_func  \n",
       "3   Promotion_Aid_Effectiveness  \n",
       "4         Knowledge_Gen_Sharing  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## removing many duplicate observation in not_global_func category\n",
    "#creating a df with only not_global_function category\n",
    "df=global_func[global_func[\"label\"]==\"not_global_func\"]\n",
    "df=df.reset_index(drop=True)\n",
    "#droppping all the duplicate values\n",
    "df_not_glob_func=df.drop_duplicates(subset=[\"description\"]).reset_index(drop=True)\n",
    "#subsetting the original data frame with categories other than health_advocacy\n",
    "global_func=global_func[global_func[\"label\"]!=\"not_global_func\"].reset_index(drop=True)\n",
    "#combining the to df\n",
    "global_func=pd.concat([global_func, df_not_glob_func], axis=0).reset_index(drop=True)\n",
    "#shuffling the data\n",
    "global_func=shuffle(global_func).reset_index(drop=True)\n",
    "\n",
    "global_func.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(13168, 6)"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "global_func.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "not_global_func: 2455\n",
      "Control_Cross_Border_Disease: 1511\n",
      "Health_Advocacy: 1045\n",
      "Knowledge_Gen_Sharing: 3082\n",
      "Dev_Harmonization_Int_Reg: 246\n",
      "Epidemic_Pandemic_Prep: 1561\n",
      "Response_Unhealthy_Products: 293\n",
      "Market_Shaping: 1078\n",
      "RD_New_Health_Tools: 1637\n",
      "Promotion_Aid_Effectiveness: 260\n"
     ]
    }
   ],
   "source": [
    "#Counting the number of each label categories\n",
    "print(\"not_global_func:\", len(global_func[global_func[\"label\"]==\"not_global_func\"]))\n",
    "print(\"Control_Cross_Border_Disease:\", len(global_func[global_func[\"label\"]==\"Control_Cross_Border_Disease\"]))\n",
    "print(\"Health_Advocacy:\", len(global_func[global_func[\"label\"]==\"Health_Advocacy\"]))\n",
    "print(\"Knowledge_Gen_Sharing:\", len(global_func[global_func[\"label\"]==\"Knowledge_Gen_Sharing\"]))\n",
    "print(\"Dev_Harmonization_Int_Reg:\", len(global_func[global_func[\"label\"]==\"Dev_Harmonization_Int_Reg\"]))\n",
    "print(\"Epidemic_Pandemic_Prep:\", len(global_func[global_func[\"label\"]==\"Epidemic_Pandemic_Prep\"]))\n",
    "print(\"Response_Unhealthy_Products:\", len(global_func[global_func[\"label\"]==\"Response_Unhealthy_Products\"]))\n",
    "print(\"Market_Shaping:\", len(global_func[global_func[\"label\"]==\"Market_Shaping\"]))\n",
    "print(\"RD_New_Health_Tools:\", len(global_func[global_func[\"label\"]==\"RD_New_Health_Tools\"]))\n",
    "#print(\"RD_Blueprint_Diseases_Pandemic_Flu:\", len(global_func[global_func[\"label\"]==\"RD_Blueprint_Diseases_Pandemic_Flu\"]))\n",
    "print(\"Promotion_Aid_Effectiveness:\", len(global_func[global_func[\"label\"]==\"Promotion_Aid_Effectiveness\"]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[2455, 1045, 3082, 246, 1561, 1511, 293, 1078, 1637, 260]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#creating a list of all the category sizes\n",
    "cat_size= [len(global_func[global_func[\"label\"]==\"not_global_func\"]),\n",
    "           len(global_func[global_func[\"label\"]==\"Health_Advocacy\"]),\n",
    "           len(global_func[global_func[\"label\"]==\"Knowledge_Gen_Sharing\"]),          \n",
    "         len(global_func[global_func[\"label\"]==\"Dev_Harmonization_Int_Reg\"]),\n",
    "           len(global_func[global_func[\"label\"]==\"Epidemic_Pandemic_Prep\"]),\n",
    "           len(global_func[global_func[\"label\"]==\"Control_Cross_Border_Disease\"]),\n",
    "          len(global_func[global_func[\"label\"]==\"Response_Unhealthy_Products\"]),\n",
    "           len(global_func[global_func[\"label\"]==\"Market_Shaping\"]),\n",
    "          len(global_func[global_func[\"label\"]==\"RD_New_Health_Tools\"]),\n",
    "           len(global_func[global_func[\"label\"]==\"Promotion_Aid_Effectiveness\"]),\n",
    "           #len(global_func[global_func[\"label\"]==\"RD_Blueprint_Diseases_Pandemic_Flu\"])\n",
    "          ]\n",
    "cat_size"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>label_cat</th>\n",
       "      <th>cat_size</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>2455</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>1045</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>3082</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>246</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>1561</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>1511</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>293</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>1078</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>1637</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>260</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      label_cat  cat_size\n",
       "0               not_global_func      2455\n",
       "1               Health_Advocacy      1045\n",
       "2         Knowledge_Gen_Sharing      3082\n",
       "3     Dev_Harmonization_Int_Reg       246\n",
       "4        Epidemic_Pandemic_Prep      1561\n",
       "5  Control_Cross_Border_Disease      1511\n",
       "6   Response_Unhealthy_Products       293\n",
       "7                Market_Shaping      1078\n",
       "8           RD_New_Health_Tools      1637\n",
       "9   Promotion_Aid_Effectiveness       260"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#creating a df of cat_size and cat_label\n",
    "\n",
    "df={\"label_cat\":label_cat,\n",
    "    \"cat_size\":cat_size\n",
    "   }\n",
    "df=pd.DataFrame(df)\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "#create a sorted dataframe\n",
    "df_sorted=df.sort_values(\"cat_size\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#plotting the distribution of categories. Creating column chart\n",
    "#We can see there is  imbalance in the dataset\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(df_sorted[\"label_cat\"], df_sorted[\"cat_size\"])\n",
    "plt.xticks(rotation=90)\n",
    "\n",
    "for i, v in enumerate(df_sorted[\"cat_size\"]):\n",
    "    plt.text(i, v, str(v))\n",
    "\n",
    "#we can see there is huge data imbalance between various categories. \n",
    "#Not a global function has a lot of data than the other categories\n",
    "#This will be amjor problem when we run our model.\n",
    "# There is very high probability that our model will become biased due to the large imbalance in the data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Percent of not_global_func:18.6%\n",
      "Percent of Control_Cross_Border_Disease:11.5%\n",
      "Percent of Health_Advocacy:7.9399999999999995%\n",
      "Percent of Knowledge_Gen_Sharing:23.400000000000002%\n",
      "Percent of Dev_Harmonization_Int_Reg:1.9%\n",
      "Percent of Epidemic_Pandemic_Prep:11.899999999999999%\n",
      "Percent of Response_Unhealthy_Products:2.23%\n",
      "Percent of Market_Shaping:8.200000000000001%\n",
      "Percent of RD_New_Health_Tools:12.4%\n",
      "Percent of Promotion_Aid_Effectiveness:2.0%\n"
     ]
    }
   ],
   "source": [
    "#percentage share of label \n",
    "print(\"Percent of not_global_func:{}%\".format(round((len(global_func[global_func[\"label\"]==\"not_global_func\"])/global_func.shape[0]), 3)*100))\n",
    "print(\"Percent of Control_Cross_Border_Disease:{}%\".format(round((len(global_func[global_func[\"label\"]==\"Control_Cross_Border_Disease\"])/global_func.shape[0]), 3)*100))\n",
    "print(\"Percent of Health_Advocacy:{}%\".format(round((len(global_func[global_func[\"label\"]==\"Health_Advocacy\"])/global_func.shape[0]), 4)*100))\n",
    "print(\"Percent of Knowledge_Gen_Sharing:{}%\".format(round((len(global_func[global_func[\"label\"]==\"Knowledge_Gen_Sharing\"])/global_func.shape[0]),3)*100))\n",
    "print(\"Percent of Dev_Harmonization_Int_Reg:{}%\".format(round((len(global_func[global_func[\"label\"]==\"Dev_Harmonization_Int_Reg\"])/global_func.shape[0]),3)*100))\n",
    "print(\"Percent of Epidemic_Pandemic_Prep:{}%\".format(round((len(global_func[global_func[\"label\"]==\"Epidemic_Pandemic_Prep\"])/global_func.shape[0]),3)*100))\n",
    "print(\"Percent of Response_Unhealthy_Products:{}%\".format(round((len(global_func[global_func[\"label\"]==\"Response_Unhealthy_Products\"])/global_func.shape[0]),4)*100))\n",
    "print(\"Percent of Market_Shaping:{}%\".format(round((len(global_func[global_func[\"label\"]==\"Market_Shaping\"])/global_func.shape[0]),3)*100))\n",
    "print(\"Percent of RD_New_Health_Tools:{}%\".format(round((len(global_func[global_func[\"label\"]==\"RD_New_Health_Tools\"])/global_func.shape[0]),3)*100))\n",
    "#print(\"Percent of RD_Blueprint_Diseases_Pandemic_Flu:{}%\".format(round((len(global_func[global_func[\"label\"]==\"RD_Blueprint_Diseases_Pandemic_Flu\"])/global_func.shape[0]),3)*100))\n",
    "print(\"Percent of Promotion_Aid_Effectiveness:{}%\".format(round((len(global_func[global_func[\"label\"]==\"Promotion_Aid_Effectiveness\"])/global_func.shape[0]),3)*100))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "#dropping Promotion_Aid_Effectiveness\"  and \"RD_Blueprint_Diseases_Pandemic_Flu\" observation as these are very few in number\n",
    "#global_func=global_func[(global_func[\"label\"]!=(\"Promotion_Aid_Effectiveness\"))]\n",
    "#global_func=global_func[(global_func[\"label\"]!=(\"RD_Blueprint_Diseases_Pandemic_Flu\"))]\n",
    "#global_func=global_func[(global_func[\"label\"]!=(\"RD_New_Health_Tools\"))]\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['not_global_func', 'Control_Cross_Border_Disease',\n",
       "       'Promotion_Aid_Effectiveness', 'Knowledge_Gen_Sharing',\n",
       "       'Health_Advocacy', 'Market_Shaping', 'Epidemic_Pandemic_Prep',\n",
       "       'RD_New_Health_Tools', 'Dev_Harmonization_Int_Reg',\n",
       "       'Response_Unhealthy_Products'], dtype=object)"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "global_func.label.unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(13168, 6)"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "global_func.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Calculating 2017 total CGH funding"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>13030</td>\n",
       "      <td>13030. Johns Hopkins University. JOHNS HOPKINS...</td>\n",
       "      <td>0.416566</td>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2017</td>\n",
       "      <td>Children's Hospital &amp; Research Center at Oakland</td>\n",
       "      <td>12250</td>\n",
       "      <td>12250. Children's Hospital &amp; Research Center a...</td>\n",
       "      <td>0.052983</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>2017</td>\n",
       "      <td>Supporting the Fourth Global Symposium on Heal...</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. Supporting the Fourth Global Symposium ...</td>\n",
       "      <td>0.008455</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>2017</td>\n",
       "      <td>The University of Warwick</td>\n",
       "      <td>12250</td>\n",
       "      <td>12250. The University of Warwick. THE UNIVERSI...</td>\n",
       "      <td>0.068000</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>2017</td>\n",
       "      <td>Improving quality of maternal health care for ...</td>\n",
       "      <td>13020</td>\n",
       "      <td>13020. Improving quality of maternal health ca...</td>\n",
       "      <td>0.007900</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13153</th>\n",
       "      <td>2017</td>\n",
       "      <td>AIDS Vaccine Advocacy Coalition</td>\n",
       "      <td>13040</td>\n",
       "      <td>13040. AIDS Vaccine Advocacy Coalition. AIDS V...</td>\n",
       "      <td>0.903837</td>\n",
       "      <td>Market_Shaping</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13155</th>\n",
       "      <td>2017</td>\n",
       "      <td>Avenir Health, Inc.</td>\n",
       "      <td>13030</td>\n",
       "      <td>13030. Avenir Health, Inc.. AVENIR HEALTH, INC...</td>\n",
       "      <td>0.005065</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13158</th>\n",
       "      <td>2017</td>\n",
       "      <td>Pandemic Influenza and Other Emerging Threats ...</td>\n",
       "      <td>12250</td>\n",
       "      <td>12250. Pandemic Influenza and Other Emerging T...</td>\n",
       "      <td>0.000410</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13162</th>\n",
       "      <td>2017</td>\n",
       "      <td>The Aurum Institute NPC</td>\n",
       "      <td>12263</td>\n",
       "      <td>12263. The Aurum Institute NPC. THE AURUM INST...</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13163</th>\n",
       "      <td>2017</td>\n",
       "      <td>HHS/CDC: GH15-1632.NU2G GLOBAL HEALTH SECURITY...</td>\n",
       "      <td>12250</td>\n",
       "      <td>12250. HHS/CDC: GH15-1632.NU2G GLOBAL HEALTH S...</td>\n",
       "      <td>0.226520</td>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>4338 rows  6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       YEAR                                      Project.title  Purpose.Code  \\\n",
       "3      2017                           Johns Hopkins University         13030   \n",
       "4      2017   Children's Hospital & Research Center at Oakland         12250   \n",
       "6      2017  Supporting the Fourth Global Symposium on Heal...         12110   \n",
       "7      2017                          The University of Warwick         12250   \n",
       "9      2017  Improving quality of maternal health care for ...         13020   \n",
       "...     ...                                                ...           ...   \n",
       "13153  2017                    AIDS Vaccine Advocacy Coalition         13040   \n",
       "13155  2017                                Avenir Health, Inc.         13030   \n",
       "13158  2017  Pandemic Influenza and Other Emerging Threats ...         12250   \n",
       "13162  2017                            The Aurum Institute NPC         12263   \n",
       "13163  2017  HHS/CDC: GH15-1632.NU2G GLOBAL HEALTH SECURITY...         12250   \n",
       "\n",
       "                                             description     Value  \\\n",
       "3      13030. Johns Hopkins University. JOHNS HOPKINS...  0.416566   \n",
       "4      12250. Children's Hospital & Research Center a...  0.052983   \n",
       "6      12110. Supporting the Fourth Global Symposium ...  0.008455   \n",
       "7      12250. The University of Warwick. THE UNIVERSI...  0.068000   \n",
       "9      13020. Improving quality of maternal health ca...  0.007900   \n",
       "...                                                  ...       ...   \n",
       "13153  13040. AIDS Vaccine Advocacy Coalition. AIDS V...  0.903837   \n",
       "13155  13030. Avenir Health, Inc.. AVENIR HEALTH, INC...  0.005065   \n",
       "13158  12250. Pandemic Influenza and Other Emerging T...  0.000410   \n",
       "13162  12263. The Aurum Institute NPC. THE AURUM INST...  0.500000   \n",
       "13163  12250. HHS/CDC: GH15-1632.NU2G GLOBAL HEALTH S...  0.226520   \n",
       "\n",
       "                              label  \n",
       "3       Promotion_Aid_Effectiveness  \n",
       "4             Knowledge_Gen_Sharing  \n",
       "6             Knowledge_Gen_Sharing  \n",
       "7             Knowledge_Gen_Sharing  \n",
       "9             Knowledge_Gen_Sharing  \n",
       "...                             ...  \n",
       "13153                Market_Shaping  \n",
       "13155         Knowledge_Gen_Sharing  \n",
       "13158        Epidemic_Pandemic_Prep  \n",
       "13162         Knowledge_Gen_Sharing  \n",
       "13163  Control_Cross_Border_Disease  \n",
       "\n",
       "[4338 rows x 6 columns]"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Total CGH 2017\n",
    "df_2017=global_func[global_func[\"YEAR\"]==2017]\n",
    "\n",
    "df_CGH_2017=df_2017[df_2017[\"label\"]!=\"not_global_func\"]\n",
    "\n",
    "df_CGH_2017"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4409.058575764367"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_CGH_2017[\"Value\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2015</td>\n",
       "      <td>Investing towards Malaria Elimination</td>\n",
       "      <td>12262</td>\n",
       "      <td>12262. Investing towards Malaria Elimination. ...</td>\n",
       "      <td>7.379632</td>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2015</td>\n",
       "      <td>ACMiddle East, regionalLeadership and Governance</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. ACMiddle East, regionalLeadership and G...</td>\n",
       "      <td>3.670489</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>2015</td>\n",
       "      <td>Feasibility Study: Effectiveness of Public Hea...</td>\n",
       "      <td>12191</td>\n",
       "      <td>12191. Feasibility Study: Effectiveness of Pub...</td>\n",
       "      <td>0.013488</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>2015</td>\n",
       "      <td>Duke University</td>\n",
       "      <td>13040</td>\n",
       "      <td>13040. Duke University. DUKE UNIVERSITY. to fa...</td>\n",
       "      <td>1.215839</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>2015</td>\n",
       "      <td>CDC: International Ebola Activities</td>\n",
       "      <td>12250</td>\n",
       "      <td>12250. CDC: International Ebola Activities. CD...</td>\n",
       "      <td>0.069187</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13152</th>\n",
       "      <td>2015</td>\n",
       "      <td>U.S. Census Bureau Participating Agency Progra...</td>\n",
       "      <td>13030</td>\n",
       "      <td>13030. U.S. Census Bureau Participating Agency...</td>\n",
       "      <td>3.511814</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13156</th>\n",
       "      <td>2015</td>\n",
       "      <td>CVCASouth &amp; Central Asia, regionalLeadership a...</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. CVCASouth &amp; Central Asia, regionalLeade...</td>\n",
       "      <td>0.039168</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13157</th>\n",
       "      <td>2015</td>\n",
       "      <td>Regional Workshop to Prioritize and Coordinate...</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. Regional Workshop to Prioritize and Coo...</td>\n",
       "      <td>0.007166</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13161</th>\n",
       "      <td>2015</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>0.821743</td>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13164</th>\n",
       "      <td>2015</td>\n",
       "      <td>Lithuanian University of Health Sciences - Bil...</td>\n",
       "      <td>12261</td>\n",
       "      <td>12261. Lithuanian University of Health Science...</td>\n",
       "      <td>0.010730</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3797 rows  6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       YEAR                                      Project.title  Purpose.Code  \\\n",
       "1      2015              Investing towards Malaria Elimination         12262   \n",
       "8      2015   ACMiddle East, regionalLeadership and Governance         12110   \n",
       "16     2015  Feasibility Study: Effectiveness of Public Hea...         12191   \n",
       "19     2015                                    Duke University         13040   \n",
       "22     2015                CDC: International Ebola Activities         12250   \n",
       "...     ...                                                ...           ...   \n",
       "13152  2015  U.S. Census Bureau Participating Agency Progra...         13030   \n",
       "13156  2015  CVCASouth & Central Asia, regionalLeadership a...         12110   \n",
       "13157  2015  Regional Workshop to Prioritize and Coordinate...         12110   \n",
       "13161  2015                          New vaccine support (NVS)         12220   \n",
       "13164  2015  Lithuanian University of Health Sciences - Bil...         12261   \n",
       "\n",
       "                                             description     Value  \\\n",
       "1      12262. Investing towards Malaria Elimination. ...  7.379632   \n",
       "8      12110. ACMiddle East, regionalLeadership and G...  3.670489   \n",
       "16     12191. Feasibility Study: Effectiveness of Pub...  0.013488   \n",
       "19     13040. Duke University. DUKE UNIVERSITY. to fa...  1.215839   \n",
       "22     12250. CDC: International Ebola Activities. CD...  0.069187   \n",
       "...                                                  ...       ...   \n",
       "13152  13030. U.S. Census Bureau Participating Agency...  3.511814   \n",
       "13156  12110. CVCASouth & Central Asia, regionalLeade...  0.039168   \n",
       "13157  12110. Regional Workshop to Prioritize and Coo...  0.007166   \n",
       "13161  12220. New vaccine support (NVS). NEW VACCINE ...  0.821743   \n",
       "13164  12261. Lithuanian University of Health Science...  0.010730   \n",
       "\n",
       "                              label  \n",
       "1      Control_Cross_Border_Disease  \n",
       "8                   Health_Advocacy  \n",
       "16            Knowledge_Gen_Sharing  \n",
       "19              RD_New_Health_Tools  \n",
       "22           Epidemic_Pandemic_Prep  \n",
       "...                             ...  \n",
       "13152         Knowledge_Gen_Sharing  \n",
       "13156               Health_Advocacy  \n",
       "13157   Response_Unhealthy_Products  \n",
       "13161  Control_Cross_Border_Disease  \n",
       "13164         Knowledge_Gen_Sharing  \n",
       "\n",
       "[3797 rows x 6 columns]"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Total CGH 2015\n",
    "df_2015=global_func[global_func[\"YEAR\"]==2015]\n",
    "\n",
    "df_CGH_2015=df_2015[df_2015[\"label\"]!=\"not_global_func\"]\n",
    "\n",
    "df_CGH_2015"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "4670.615864680396"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_CGH_2015[\"Value\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>2013</td>\n",
       "      <td>CVCAEurope, regionalKey stages of life includi...</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. CVCAEurope, regionalKey stages of life ...</td>\n",
       "      <td>1.284838</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>5.392000</td>\n",
       "      <td>Market_Shaping</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>2013</td>\n",
       "      <td>Ecohealth Emerging Infectious Diseases Researc...</td>\n",
       "      <td>12250</td>\n",
       "      <td>12250. Ecohealth Emerging Infectious Diseases ...</td>\n",
       "      <td>0.000104</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>0.223940</td>\n",
       "      <td>Market_Shaping</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>2013</td>\n",
       "      <td>Quality Health Care Project (QHCP) - Other Pub...</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. Quality Health Care Project (QHCP) - Ot...</td>\n",
       "      <td>0.549825</td>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13145</th>\n",
       "      <td>2013</td>\n",
       "      <td>Oregon Health &amp; Science University</td>\n",
       "      <td>13040</td>\n",
       "      <td>13040. Oregon Health &amp; Science University. ORE...</td>\n",
       "      <td>3.640566</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13149</th>\n",
       "      <td>2013</td>\n",
       "      <td>Avenir Health, Inc.</td>\n",
       "      <td>13030</td>\n",
       "      <td>13030. Avenir Health, Inc.. AVENIR HEALTH, INC...</td>\n",
       "      <td>0.117092</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13150</th>\n",
       "      <td>2013</td>\n",
       "      <td>University of Pittsburgh</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. University of Pittsburgh. UNIVERSITY OF...</td>\n",
       "      <td>0.103629</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13154</th>\n",
       "      <td>2013</td>\n",
       "      <td>Development Innovation Ventures - Maternal and...</td>\n",
       "      <td>13020</td>\n",
       "      <td>13020. Development Innovation Ventures - Mater...</td>\n",
       "      <td>0.636519</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13160</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>2.207405</td>\n",
       "      <td>Market_Shaping</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2578 rows  6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       YEAR                                      Project.title  Purpose.Code  \\\n",
       "5      2013  CVCAEurope, regionalKey stages of life includi...         12110   \n",
       "10     2013                          New vaccine support (NVS)         12220   \n",
       "11     2013  Ecohealth Emerging Infectious Diseases Researc...         12250   \n",
       "14     2013                          New vaccine support (NVS)         12220   \n",
       "23     2013  Quality Health Care Project (QHCP) - Other Pub...         12220   \n",
       "...     ...                                                ...           ...   \n",
       "13145  2013                 Oregon Health & Science University         13040   \n",
       "13149  2013                                Avenir Health, Inc.         13030   \n",
       "13150  2013                           University of Pittsburgh         12182   \n",
       "13154  2013  Development Innovation Ventures - Maternal and...         13020   \n",
       "13160  2013                          New vaccine support (NVS)         12220   \n",
       "\n",
       "                                             description     Value  \\\n",
       "5      12110. CVCAEurope, regionalKey stages of life ...  1.284838   \n",
       "10     12220. New vaccine support (NVS). NEW VACCINE ...  5.392000   \n",
       "11     12250. Ecohealth Emerging Infectious Diseases ...  0.000104   \n",
       "14     12220. New vaccine support (NVS). NEW VACCINE ...  0.223940   \n",
       "23     12220. Quality Health Care Project (QHCP) - Ot...  0.549825   \n",
       "...                                                  ...       ...   \n",
       "13145  13040. Oregon Health & Science University. ORE...  3.640566   \n",
       "13149  13030. Avenir Health, Inc.. AVENIR HEALTH, INC...  0.117092   \n",
       "13150  12182. University of Pittsburgh. UNIVERSITY OF...  0.103629   \n",
       "13154  13020. Development Innovation Ventures - Mater...  0.636519   \n",
       "13160  12220. New vaccine support (NVS). NEW VACCINE ...  2.207405   \n",
       "\n",
       "                             label  \n",
       "5                  Health_Advocacy  \n",
       "10                  Market_Shaping  \n",
       "11           Knowledge_Gen_Sharing  \n",
       "14                  Market_Shaping  \n",
       "23     Promotion_Aid_Effectiveness  \n",
       "...                            ...  \n",
       "13145          RD_New_Health_Tools  \n",
       "13149        Knowledge_Gen_Sharing  \n",
       "13150          RD_New_Health_Tools  \n",
       "13154          RD_New_Health_Tools  \n",
       "13160               Market_Shaping  \n",
       "\n",
       "[2578 rows x 6 columns]"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Total CGH 2013\n",
    "df_2013=global_func[global_func[\"YEAR\"]==2013]\n",
    "\n",
    "df_CGH_2013=df_2013[df_2013[\"label\"]!=\"not_global_func\"]\n",
    "\n",
    "df_CGH_2013"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3315.379535934601"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_CGH_2013[\"Value\"].sum()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Splitting data into train and test set"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "#len(global_func[global_func[\"YEAR\"]==2015])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "#len(global_func[global_func[\"YEAR\"]==2013])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "#len(global_func[global_func[\"YEAR\"]==2017])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "#train=global_func[global_func[\"YEAR\"]!=2017]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "#test=global_func[global_func[\"YEAR\"]==2017]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "#train"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "#splitting the data in 20% test and 80% train. \n",
    "#test data will only be used on the best selected final model. \n",
    "#train data will be used for k-fold cross validation to select best model\n",
    "\n",
    "# X_train, X_test, y_train, y_test=train_test_split(global_func[\"description\"], global_func[\"label\"],\n",
    "#                                                   test_size=0.2, shuffle=True)\n",
    "\n",
    "train, test=train_test_split(global_func, test_size=0.2, shuffle=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2017</td>\n",
       "      <td>Assessing Zika transmission dynamics and mitig...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Assessing Zika transmission dynamics an...</td>\n",
       "      <td>0.031470</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2017</td>\n",
       "      <td>HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL DISEASE...</td>\n",
       "      <td>12250</td>\n",
       "      <td>12250. HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL ...</td>\n",
       "      <td>0.643220</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015</td>\n",
       "      <td>Asian Vegetable Research &amp; Development Center ...</td>\n",
       "      <td>13020</td>\n",
       "      <td>13020. Asian Vegetable Research &amp; Development ...</td>\n",
       "      <td>0.515076</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Enhanced Effective ICT</td>\n",
       "      <td>13040</td>\n",
       "      <td>13040. Enhanced Effective ICT. ENHANCED EFFECT...</td>\n",
       "      <td>0.000720</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2017</td>\n",
       "      <td>Avenir Health, Inc.</td>\n",
       "      <td>13030</td>\n",
       "      <td>13030. Avenir Health, Inc.. AVENIR HEALTH, INC...</td>\n",
       "      <td>0.005065</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2017  Assessing Zika transmission dynamics and mitig...         12182   \n",
       "1  2017  HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL DISEASE...         12250   \n",
       "2  2015  Asian Vegetable Research & Development Center ...         13020   \n",
       "3  2017                             Enhanced Effective ICT         13040   \n",
       "4  2017                                Avenir Health, Inc.         13030   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12182. Assessing Zika transmission dynamics an...  0.031470   \n",
       "1  12250. HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL ...  0.643220   \n",
       "2  13020. Asian Vegetable Research & Development ...  0.515076   \n",
       "3  13040. Enhanced Effective ICT. ENHANCED EFFECT...  0.000720   \n",
       "4  13030. Avenir Health, Inc.. AVENIR HEALTH, INC...  0.005065   \n",
       "\n",
       "                         label  \n",
       "0       Epidemic_Pandemic_Prep  \n",
       "1       Epidemic_Pandemic_Prep  \n",
       "2  Response_Unhealthy_Products  \n",
       "3              not_global_func  \n",
       "4        Knowledge_Gen_Sharing  "
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train.reset_index(inplace=True, drop=True)\n",
    "train=train.copy()\n",
    "train.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(10534, 6)"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['Epidemic_Pandemic_Prep', 'Response_Unhealthy_Products',\n",
       "       'not_global_func', 'Knowledge_Gen_Sharing', 'Market_Shaping',\n",
       "       'Control_Cross_Border_Disease', 'RD_New_Health_Tools',\n",
       "       'Health_Advocacy', 'Promotion_Aid_Effectiveness',\n",
       "       'Dev_Harmonization_Int_Reg'], dtype=object)"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train[\"label\"].unique()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2013</td>\n",
       "      <td>Projet de coopTration universitaire - Initiati...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Projet de coopTration universitaire - I...</td>\n",
       "      <td>0.073950</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>0.096651</td>\n",
       "      <td>Market_Shaping</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015</td>\n",
       "      <td>EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...</td>\n",
       "      <td>3.040122</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Scientific cooperation with other countries (n...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Scientific cooperation with other count...</td>\n",
       "      <td>0.038746</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2015</td>\n",
       "      <td>INT/Fund of the United Nations International D...</td>\n",
       "      <td>13010</td>\n",
       "      <td>13010. INT/Fund of the United Nations Internat...</td>\n",
       "      <td>0.914221</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2013  Projet de coopTration universitaire - Initiati...         12182   \n",
       "1  2013                          New vaccine support (NVS)         12220   \n",
       "2  2015  EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...         12182   \n",
       "3  2017  Scientific cooperation with other countries (n...         12182   \n",
       "4  2015  INT/Fund of the United Nations International D...         13010   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12182. Projet de coopTration universitaire - I...  0.073950   \n",
       "1  12220. New vaccine support (NVS). NEW VACCINE ...  0.096651   \n",
       "2  12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...  3.040122   \n",
       "3  12182. Scientific cooperation with other count...  0.038746   \n",
       "4  13010. INT/Fund of the United Nations Internat...  0.914221   \n",
       "\n",
       "                         label  \n",
       "0              not_global_func  \n",
       "1               Market_Shaping  \n",
       "2          RD_New_Health_Tools  \n",
       "3        Knowledge_Gen_Sharing  \n",
       "4  Response_Unhealthy_Products  "
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test.reset_index(inplace=True, drop=True)\n",
    "test.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "#creating a copy of the test dataframe as not doing this creates problem later (not sure why!)\n",
    "test=test.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2013</td>\n",
       "      <td>Projet de coopTration universitaire - Initiati...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Projet de coopTration universitaire - I...</td>\n",
       "      <td>0.073950</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>0.096651</td>\n",
       "      <td>Market_Shaping</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015</td>\n",
       "      <td>EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...</td>\n",
       "      <td>3.040122</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Scientific cooperation with other countries (n...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Scientific cooperation with other count...</td>\n",
       "      <td>0.038746</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2015</td>\n",
       "      <td>INT/Fund of the United Nations International D...</td>\n",
       "      <td>13010</td>\n",
       "      <td>13010. INT/Fund of the United Nations Internat...</td>\n",
       "      <td>0.914221</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2013  Projet de coopTration universitaire - Initiati...         12182   \n",
       "1  2013                          New vaccine support (NVS)         12220   \n",
       "2  2015  EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...         12182   \n",
       "3  2017  Scientific cooperation with other countries (n...         12182   \n",
       "4  2015  INT/Fund of the United Nations International D...         13010   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12182. Projet de coopTration universitaire - I...  0.073950   \n",
       "1  12220. New vaccine support (NVS). NEW VACCINE ...  0.096651   \n",
       "2  12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...  3.040122   \n",
       "3  12182. Scientific cooperation with other count...  0.038746   \n",
       "4  13010. INT/Fund of the United Nations Internat...  0.914221   \n",
       "\n",
       "                         label  \n",
       "0              not_global_func  \n",
       "1               Market_Shaping  \n",
       "2          RD_New_Health_Tools  \n",
       "3        Knowledge_Gen_Sharing  \n",
       "4  Response_Unhealthy_Products  "
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(2634, 6)"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Creating synthetic text to manage the imbalance in different categories--replacing some words with their synonyms\n",
    "\n",
    "**Note that we will only create synthetic text for training examples. We will not create synthetic text for test data."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['not_global_func',\n",
       " 'Control_Cross_Border_Disease',\n",
       " 'RD_New_Health_Tools',\n",
       " 'Health_Advocacy',\n",
       " 'Knowledge_Gen_Sharing',\n",
       " 'Response_Unhealthy_Products',\n",
       " 'Market_Shaping',\n",
       " 'Epidemic_Pandemic_Prep',\n",
       " 'Promotion_Aid_Effectiveness',\n",
       " 'Dev_Harmonization_Int_Reg']"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# checking the unique categories in the label column. These categories were created combining the sub categories in the\n",
    "#original dataset\n",
    "label_cat=list(global_func.label.unique())\n",
    "label_cat"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'not_global_func': 1971,\n",
       " 'Control_Cross_Border_Disease': 1201,\n",
       " 'RD_New_Health_Tools': 1307,\n",
       " 'Health_Advocacy': 842,\n",
       " 'Knowledge_Gen_Sharing': 2497,\n",
       " 'Response_Unhealthy_Products': 233,\n",
       " 'Market_Shaping': 854,\n",
       " 'Epidemic_Pandemic_Prep': 1233,\n",
       " 'Promotion_Aid_Effectiveness': 203,\n",
       " 'Dev_Harmonization_Int_Reg': 193}"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#observations in different classes\n",
    "dict_list={}\n",
    "for j in range(len(label_cat)):\n",
    "    count=0\n",
    "    for i in train[\"description\"].index:\n",
    "        if train[\"label\"][i]==label_cat[j]:\n",
    "            count +=1\n",
    "    dict_list[label_cat[j]]=count\n",
    "    #print(\"{}: {}\".format(label_cat[j], count))\n",
    "    \n",
    "dict_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Knowledge_Gen_Sharing': 2497,\n",
       " 'not_global_func': 1971,\n",
       " 'RD_New_Health_Tools': 1307,\n",
       " 'Epidemic_Pandemic_Prep': 1233,\n",
       " 'Control_Cross_Border_Disease': 1201,\n",
       " 'Market_Shaping': 854,\n",
       " 'Health_Advocacy': 842,\n",
       " 'Response_Unhealthy_Products': 233,\n",
       " 'Promotion_Aid_Effectiveness': 203,\n",
       " 'Dev_Harmonization_Int_Reg': 193}"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#sorting dictionary in descending order\n",
    "dict_list=dict(sorted(dict_list.items(), key=lambda x:x[1], reverse=True))\n",
    "dict_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Knowledge_Gen_Sharing',\n",
       " 'not_global_func',\n",
       " 'RD_New_Health_Tools',\n",
       " 'Epidemic_Pandemic_Prep',\n",
       " 'Control_Cross_Border_Disease',\n",
       " 'Market_Shaping',\n",
       " 'Health_Advocacy',\n",
       " 'Response_Unhealthy_Products',\n",
       " 'Promotion_Aid_Effectiveness',\n",
       " 'Dev_Harmonization_Int_Reg']"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#getting the list out of keys from dictionary\n",
    "label_cat=list(dict_list.keys())\n",
    "label_cat"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "#list to store augmented text from training set\n",
    "augmented_sentences=[]\n",
    "\n",
    "#list to store augmented text labels from training set\n",
    "augmented_sentences_labels=[]\n",
    "\n",
    "#function to create synthetic text\n",
    "def text_aug(label_cat): \n",
    "    \n",
    "    #observations in different classes\n",
    "    dict_list={}\n",
    "    for j in range(len(label_cat)):\n",
    "        count=0\n",
    "        for i in train[\"description\"].index:\n",
    "            if train[\"label\"][i]==label_cat[j]:\n",
    "                count +=1\n",
    "        dict_list[label_cat[j]]=count\n",
    "    \n",
    "    #initiating augmenter--replacing with 5 synonyms\n",
    "    aug = naw.SynonymAug(aug_src='wordnet',aug_max=5)\n",
    "       \n",
    "    for j in range(1, len(label_cat)):\n",
    "        class_list=[]\n",
    "        aug_temp=[]\n",
    "        aug_sent_temp=[]\n",
    "        for i in train[\"description\"].index:\n",
    "            if train[\"label\"][i]==label_cat[j]:\n",
    "                #creating and appending augmented sentences\n",
    "                aug_temp.append(aug.augment(train[\"description\"][i], \n",
    "                                                       n=round(((sorted(list(dict_list.values()))[-1]-dict_list[label_cat[j]])/dict_list[label_cat[j]]))))  \n",
    "                \n",
    "        #unlisting the nested lists when: \n",
    "        #(round((sorted(list(dict_list.values()))[-1]-dict_list[label_cat[j]])/dict_list[label_cat[j]]))>1)\n",
    "        if (round((sorted(list(dict_list.values()))[-1]-dict_list[label_cat[j]])/dict_list[label_cat[j]])>1):\n",
    "            for k in range(len(aug_temp)):\n",
    "                for m in range(round((sorted(list(dict_list.values()))[-1]-dict_list[label_cat[j]])/dict_list[label_cat[j]])):\n",
    "                    class_list.append((aug_temp[k][m]))                        \n",
    "        \n",
    "        #unlisting the nested lists when: \n",
    "        #(round((sorted(list(dict_list.values()))[-1]-dict_list[label_cat[j]])/dict_list[label_cat[j]]))==0)\n",
    "        elif(round((sorted(list(dict_list.values()))[-1]-dict_list[label_cat[j]])/dict_list[label_cat[j]])==0):            \n",
    "            for q in range(len(aug_temp)):\n",
    "                for r in range(round((sorted(list(dict_list.values()))[-1]-dict_list[label_cat[j]])/dict_list[label_cat[j]])+1):\n",
    "                    class_list.append((aug_temp[q][r])) \n",
    "                    \n",
    "        #unlisting the nested lists when: \n",
    "        #(round((sorted(list(dict_list.values()))[-1]-dict_list[label_cat[j]])/dict_list[label_cat[j]]))==1)\n",
    "        else:\n",
    "            for p in range(len(aug_temp)):\n",
    "                class_list.append((aug_temp[p])) \n",
    "    \n",
    "        #creating labels for the synthetic values\n",
    "        aug_sent_temp.extend(repeat(label_cat[j],len(class_list)))\n",
    "        \n",
    "        #subsetting the synthetic sentences to be equal to the length of highest category\n",
    "        if ((list(dict_list.values())[0]-(list(dict_list.values())[j]+len(class_list)))<0):\n",
    "            text_needed=len(class_list)-abs(list(dict_list.values())[0]-(list(dict_list.values())[j]+len(class_list)))\n",
    "            sample_text=random.sample(class_list, text_needed)\n",
    "            sample_label=random.sample(aug_sent_temp, text_needed)\n",
    "            augmented_sentences.extend(sample_text)\n",
    "            augmented_sentences_labels.extend(sample_label)\n",
    "        #if the length is smaller than the highest catgory then do nothing    \n",
    "        else:\n",
    "            augmented_sentences.extend(class_list)\n",
    "            augmented_sentences_labels.extend(aug_sent_temp)    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "#running the function sythetic text function\n",
    "text_aug(label_cat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['13010. National Endowment for Democracy Grant to Unspecified NGO. NATIONAL ENDOWMENT FOR DEMOCRACY GRANT TO UNSPECIFIED NGO. To encourage public discussion, transparency, and advocacy about Chinas family planning policies.  Research and reporting on the policies and practices of family planning agencies will be conducted, and legal assistance for victims and advocacy will be organized to advance respect for individual rights.',\n",
       " \"13020. Government Technical Assistance Provider (GoTAP). GOVERNMENT TECHNICAL ASSISTANCE PROVIDER (GOTAP). This contract provides technical assistance to entities that receive direct financing under USAID's government-to-government (G2G) program in the health sector. Assistance is in technical areas in the health sector (e.g. how to improve lagging health indicators) and capacity building in governance and management (e.g. ensuring government entities understand G2G requirements and effectively oversee implementation); it will enable target regions to sustain their health outcomes, reinforce the Ministry of Health's (MOH) stewardship role, and increase domestic spending on health. GoTAP also provides assistance to USAID to better align G2G investments with MOH processes, and provides analytical support to USAID and the MOH to improve use of data for decision-making and identify opportunities for adjustments in USAID health programming.\",\n",
       " '13020. Biotechnology Industry Research Assistance Council. BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL. to support the shared development of the Program Management Unit that will serve as the execution arm for joint projects between the India Department of Biotechnology and the Foundation as part of Grand Challenges India',\n",
       " '12220. Kidney stones in the Saharawi refugee camps: treatment and role of women in the prevention. KIDNEY STONES IN THE SAHARAWI REFUGEE CAMPS: TREATMENT AND ROLE OF WOMEN IN THE PREVENTION. Aims:Treatment of kidney stones. The observation and the direct study of the pediatric population have led to the following conclusions: high incidence of urinary lithiasis in the pediatric population for reasons related to the environment (dehydration, power, water chemistry); absolute impossibility of treating a medically kidney stones on site, except for some preventive aspect.',\n",
       " '12191. Ophthalmologistical Health Care in Assam. OPHTHALMOLOGISTICAL HEALTH CARE IN ASSAM. 8.000 eye screenings in 40 camps, organisation of 1.000 eye-surgeries, workshops for 70 teachers in early detection of eye problems.',\n",
       " \"12181. Assistance to Civil Society Organizations in Palestine Phase V: Juzzor for Health and Social Development. ASSISTANCE TO CIVIL SOCIETY ORGANIZATIONS IN PALESTINE PHASE V: JUZZOR FOR HEALTH AND SOCIAL DEVELOPMENT. The grant has been extended to support its program in 'Developing the Capacity of Palestinian Surgeons'.  The project improved the quality of healthcare in Palestine through surgical care, which was achieved through capacity building in basic surgical competencies.\",\n",
       " \"12110. Nauru Improved Health Partnership: Human Resources. NAURU IMPROVED HEALTH PARTNERSHIP: HUMAN RESOURCES. The Nauru Improved Health Partnership will support implementation of Nauru's Health Sector Strategy to deliver improvements in health outcomes with an emphasis on: strengthening health system management, in particular budget prioritisation, strategic planning, infrastructure redevelopment and improved health statistics; reduced prevalence of non-communicable diseases and sexually transmitted infections, through more effective preventative and public health programs; improving maternal and child health outcomes, by addressing child nutrition and improving access to and quality of ante and post natal care. The initiative has helped Nauru achieve: 95% child immunization coverage for key vaccines including tuberculosis, measles, hepatitis B and polio; and by 2010, infant mortality rates had almost halved from 40 per 1,000 live births to 24 per 1,000 live births. The total value of this initiative is $19.6 million over 7 years, starting 2009-10.\",\n",
       " '13040. Program to Build Leadership and Accountability in Nigeria health system (PLAN - Health) - HIV/AIDS. PROGRAM TO BUILD LEADERSHIP AND ACCOUNTABILITY IN NIGERIA HEALTH SYSTEM (PLAN - HEALTH) - HIV/AIDS. The Program to Build Leadership and Accountability in Nigeria s Health System (PLAN-Health) is a five-year, President s Emergency Fund for AIDS Relief (PEPFAR) associate award through the United States Agency for International Development (USAID). It is implemented by Management Sciences for Health (MSH) in Gombe and Akwa Ibom States and the Federal Capital Territory, Abuja. From commencement in 2010, the project aimed to strengthen the leadership and management capacities of 30 public sector health institutions (PSHIs) and civil society organizations (CSOs) for improved delivery of quality HIV and AIDS and other health services in Nigeria. PLAN-Health is assisting CSOs and PSHIs to become more adept at developing and maintaining the health services needed to meet health challenge targets by 2015. Through workshops, internships, embedded consultancies, technical assistance, coaching, and the PEPFAR Health Professionals Fellowship, PLAN-Health has helped to build strong and viable organizations by developing leadership skills and more capable managers.',\n",
       " '12220. CVCA_679_Antimicrobial resistance_12220. CVCA_679_ANTIMICROBIAL RESISTANCE_12220. Antimicrobial resistance',\n",
       " '12110. SELECTED EVALUATION STUDIES FOR 2014. SELECTED EVALUATION STUDIES FOR 2014. Description :. Product Type:',\n",
       " '12220. INTEGRATION OF CLIMATE TECHNOLOGY NEEDS INTO NTL DEVT STRATEGIES. INTEGRATION OF CLIMATE TECHNOLOGY NEEDS INTO NTL DEVT STRATEGIES. Description :. Product Type:',\n",
       " '12262. Replacement of Malaria Monotherapy Drugs through the private sector. REPLACEMENT OF MALARIA MONOTHERAPY DRUGS THROUGH THE PRIVATE SECTOR. To improve access to high quality treatment for malaria by replacing sub-standard drugs in the private sector',\n",
       " '12262. Malaria Eradication and Healthcare Empowerment in Blantyre, Malawi. MALARIA ERADICATION AND HEALTHCARE EMPOWERMENT IN BLANTYRE, MALAWI. Malaria prevention and management via installation of mosquito net, IRS implementation, treatment of malaria, conduction of malaria prevention education for the community, improvement of health awareness, etc',\n",
       " '12250. Health Services Improvement (HSI) Program Component - Pandemic Influenza and Other Emerging Threats (PIOET). HEALTH SERVICES IMPROVEMENT (HSI) PROGRAM COMPONENT - PANDEMIC INFLUENZA AND OTHER EMERGING THREATS (PIOET). The Health Services Improvement (HSI) Program is designed to improve the quality of and increase access to the Government of Senegals integrated package of services at formal health facilities. The program uses the TutoratPlus approach, with on-site mentoring by local health professionals trained on the strategy (peers or superiors). In each district, both public and private service providers are enrolled.',\n",
       " '13040. Output 04: HIV. HIV. Kenya - Nairobi. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " \"13020. Bajenu Gox: A Community Approach to Maternal and Child Health in Senegal (IMCHA). BAJENU GOX: A COMMUNITY APPROACH TO MATERNAL AND CHILD HEALTH IN SENEGAL (IMCHA). This project will examine how to strengthen the Bajenu Gox Initiative's contribution to improving maternal and child health across Senegal. Former President Abdoulye Wade founded this community-based health worker program to train women to be leaders in reproductive health. Based on the Wolof term for godmother, the Bajenu Gox Initiative provides support to women during the prenatal, delivery, and post-natal periods. It also provides advice about caring for children under 5. Community support for womenThis project aims to improve the Bajenu Gox Initiative's long-term stability at the community level and establish systems that will allow the program to scale up nationally. Researchers will use a community development approach based on a gender and social equity perspective to examine how to enhance the initiative's contribution. The research is structured in two phases: -literature searches on holistic community-based maternal and child health approaches that have been tested in Senegal and other African countries, and possibly in Canada-intervention research based on the findings in this literatureThe project team will share the results through-situation assessment and economic feasibility studies-training materials-a guide on how to effectively manage the initiative-documentary to highlight the initiative's impacts -scientific publications -presentations at international conferencesInnovating for Maternal and Child Health in AfricaThis project is part of the Innovating for Maternal and Child Health in Africa program, a seven-year $36 million initiative funded by Foreign Affairs, Trade and Development Canada (DFATD), Canada's International Development Research Centre (IDRC), and the Canadian Institutes of Health Research (CIHR).\",\n",
       " \"13020. UNFPA SRHR. UNFPA SRHR. UNFPA SRHR. The project main objective is to contribute to the fulfillment of adolescents and youth'ssexual and reproductive health and rights (SRHR) including the right to live a lifewithout sexual violence (SV). It aims, on one hand, to strengthen civil societyorganization's capacities to formulate, advocate and monitor the implementation ofpublic policies for SRHR; and on the other; to foment duty-bearers accountability toformulate political policies and implement mechanisms to guarantee the young peoples'SRHR. The project includes advocacy on national level, but will mainly be implementedby UNFPA in collaboration with social organizations including youth-led organizationsand state institutions in 12 municipalities in 5 regions. The national and departmentalworking groups on SRHR are key partners in the project.\",\n",
       " '12281. Pacific Paramedical Training Centre. PACIFIC PARAMEDICAL TRAINING CENTRE. The Pacific Paramedical Training Centre (PPTC) has provided technical training and development assistance to the clinical laboratories and blood transfusion services of the Pacific region since 1980.',\n",
       " \"12240. NGO VIDA - To Meet, produce and nourishing: capacity building of associations to strengthen food safety in Matutuine district. NGO VIDA - TO MEET, PRODUCE AND NOURISHING: CAPACITY BUILDING OF ASSOCIATIONS TO STRENGTHEN FOOD SAFETY IN MATUTUINE DISTRICT. Increase the production and consumption of local food of high nutritional value; Reduce the vulnerability of the poorest households in the District of Matutuine. The Matutine district is located in a dryland area with predominantly sandy soils where the population is extremely vulnerable to climate change and variability in food prices. Project awarded as 'Champions of drylands' 2016 by the portuguese National Coordination Commission to Combat Desertification (CNCCD)\",\n",
       " '13040. County Measurements, Learning and Accountability Program (CMLAP). COUNTY MEASUREMENTS, LEARNING AND ACCOUNTABILITY PROGRAM (CMLAP). County Measurements, Learning and Accountability Program (CMLAP)',\n",
       " '16064. Shout-it-Now/Uppsala PDC. SHOUT-IT-NOW/UPPSALA PDC. This study aims to investigate attitudes, perceptions and behaviors around gender roles and gender-based violence among South African young men and women, and to develop a scale that will identify youth who could benefit from gender-focused interventions. An online program will be designed and implemented, to deliver key messages around gender norms and gender-based violence. Pre- and post-test on',\n",
       " \"13040. President's Emergency Plan for AIDS Relief - Technical Leadership and Support: New Partners. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF - TECHNICAL LEADERSHIP AND SUPPORT: NEW PARTNERS. President's Emergency Plan for AIDS Relief - Technical Leadership and Support: New Partners\",\n",
       " '12182. Tracking Resistance to Artemisinin Collaboration with World Health Organisation - research. TRACKING RESISTANCE TO ARTEMISININ COLLABORATION WITH WORLD HEALTH ORGANISATION - RESEARCH. To rapidly identify new knowledge and put in place wider geographical research which can be used to contain resistance',\n",
       " '12261. 005. WASH LEADERSHIP AND TA. 005. WASH LEADERSHIP AND TA. NA',\n",
       " \"12110. Tonga Health Systems Support Program. TONGA HEALTH SYSTEMS SUPPORT PROGRAM. The Government of Tonga (GoT) has developed national objectives and priorities for health that are reflected in Tonga's Strategic Development Framework 2011  2014, the Ministry of Health (MoH) Corporate Plan (2008/09  2011/12) and National Strategy to Prevent and Control Non-Communicable Diseases (2010  2015) as follows: halting the rise in prevalence of non-communicable diseases risk factors; improving community health services; and increasing the budget utilised for preventative health. Funding under this initiative provides budget support to the Ministry of Health to implement and achieve its objectives outlined in its Corporate Plan, with a particular emphasis on combating the associated risk factors with non-communicable diseases (NCD) and preventative and primary health care. The key result areas of the Plan for reduced prevalence of NCD risk factors include targets of: tobacco use - 2% decease in prevalence of smokers by 2015; obesity - 2% decrease in overall prevalence of obesity by 2015; budget for preventive health care reaches 10% of total public health operational budget by 2015; and primary health care to all communities in Tonga to follow a common national standard including the utilisation of this service. The total value of this initiative is $8.3 million over 6 years, starting 2009-10.\",\n",
       " '13010. Nepal Health Sector Programme III - Technical Assistance for Monitoring, Evaluation and Operational Research. NEPAL HEALTH SECTOR PROGRAMME III - TECHNICAL ASSISTANCE FOR MONITORING, EVALUATION AND OPERATIONAL RESEARCH. To improve the health of women, children,  the poor and socially excluded in Nepal, including by restoring health services in areas affected by the 2015 earthquake, and improving the quality and governance of health services nationwide.',\n",
       " '12191. The Project for Improvement of the Exlusive Landury Area of the Labor and Delivery Department in University Hospital School in Tegucigalpa. THE PROJECT FOR IMPROVEMENT OF THE EXLUSIVE LANDURY AREA OF THE LABOR AND DELIVERY DEPARTMENT IN UNIVERSITY HOSPITAL SCHOOL IN TEGUCIGALPA. Providing an Industrial Washing Machine and a Drying Machine for the Labor and Delivery Department of University Hospital School',\n",
       " '12182. Determination of the dynamics of antimicrobial resistance genes in the human and animal gut microbiome.. DETERMINATION OF THE DYNAMICS OF ANTIMICROBIAL RESISTANCE GENES IN THE HUMAN AND ANIMAL GUT MICROBIOME.. Medical Research Council Cross Council AMR initiative grant  to develop a deep understanding of how antimicrobial resistance (AMR) resistance genes survive and spread within  ecosystems (in people, animals and the environment)  and the way they change over time and in response to the use of antibiotics, with a particular emphasis on the clinical outcomes in cases of human and animal disease.  this evidence is anticipated to inform practice and policy on use of antimicrobials worldwide.',\n",
       " \"13040. Ghar Ghar Ma Swasthya. GHAR GHAR MA SWASTHYA. Ghar Ghar Maa Swasthya, or Healthy Homes, is a social marketing program in Nepal that works through the private sector to strengthen the marketing and distribution of health products in rural and hard-to-reach areas. This project is managed by FHI 360 in collaboration with the Nepali-managed Nepal CRS Company. The program assists the Government of Nepal in expanding the depth, reach and impact of private-sector social marketing initiatives by providing a low-cost supply of maternal and child health, family planning and HIV prevention products and services. FHI 360 provides technical support in two major areas: improving Nepal CRS Company's institutional sustainability by building its leadership capacity, and increasing the availability and accessibility of health products in hard-to-reach rural areas through implementation of cutting-edge social marketing programs.\",\n",
       " '13030. Improving Availability of ReproduCtive HEalth Services in the Autonomous Region of Muslim Mindanao, Philippines (ARCHES). IMPROVING AVAILABILITY OF REPRODUCTIVE HEALTH SERVICES IN THE AUTONOMOUS REGION OF MUSLIM MINDANAO, PHILIPPINES (ARCHES). The main objective is to improve the availability of and access to basic sexual and reproductive health services for the underserved women and young peoples in ARMM. The target groups are: 150,000 women and adolescents  290 frontline health services providers in public and private sectors  at least 34 local CSO and 1 regional network.',\n",
       " '12220. Supporting self organisation of community health workers on provincial and national level+strengthening their democratic practice and health advocacy. SUPPORTING SELF ORGANISATION OF COMMUNITY HEALTH WORKERS ON PROVINCIAL AND NATIONAL LEVEL+STRENGTHENING THEIR DEMOCRATIC PRACTICE AND HEALTH ADVOCACY. Supporting self organisation of community health workers on provincial and national level+strengthening their democratic practice and health advocacy',\n",
       " '12240. 002. LEADER SHIP AND TA (NUTRITION). 002. LEADER SHIP AND TA (NUTRITION). NA',\n",
       " '13040. Centre for Advocacy and Research. CENTRE FOR ADVOCACY AND RESEARCH. to encourage resource mobilization skills amongst Avahan community-based organizations through small grant support for innovative projects to support children vulnerable to and living with HIV/AIDS',\n",
       " '12181. Appui institutionnel a l  Universidad Mayor de San Simon - UMSS Bolivia en matiFre d enseignement post graduat en mTdecine tropicale, organisation san. APPUI INSTITUTIONNEL + L  UNIVERSIDAD MAYOR DE SAN SIMON - UMSS BOLIVIA EN MATI+RE D ENSEIGNEMENT POST GRADUAT EN M+DECINE TROPICALE, ORGANISATION SAN. Background  La collaboration institutionnelle IMT-UMSS fait suite a des projets de recherche conjoints menTs depuis 1998 dans le cadre des conventions cadre DGCD-IMT (FA1, FA2 et FA3-I) General Objectives  To strengthen the rational basis and the country ownership of (human and animal) healthcare systems and policies in developing countries, in order to improve the health status ofthe populations and thereby to contribute to the reduction of poverty and inequity.  Specific Objectives  To strengthen the training capacity of the Faculty of Medicine of the UMSS and to jointly organise aDiploma Course in Tropical Medicine and Health Service Organisation and a Master in Tropical Medicine,Health Management and Disease Control, both of relevance and up to standards. Results  Result 1 The postgraduate programmes are implementedResult 2 ITM has provided adequate support to the course management and the teachingstaffResult 3 Optimal quality and innovation of the curriculum have been assuredResult 4 Academic support has been provided to participantsResult 5 Administrative support has been provided to participantsResult 6 Financial accessibility has been assuredResult 7 Social support has been provided to participantsResult 8 Alumni have been supportedResult 9 Student mobility and exchange with regional, ITM and European programmeshas been organised',\n",
       " '13030. Population Foundation of India. POPULATION FOUNDATION OF INDIA. to contribute to changing social norms around family planning, increase engagement of young people, and support the development of a sustainability plan for social and behavior change communication with a focus on entertainment education',\n",
       " \"12220. Partnership for Development: Health Sector Budget Support. PARTNERSHIP FOR DEVELOPMENT: HEALTH SECTOR BUDGET SUPPORT. Health is a priority focus of the Solomon Islands-Australia Partnership for Development and funding under this proposal supports the Health Sector Support Program - Phase 2 which continues Australia's long-term commitment to strengthen health systems and improve outcomes through a Sector Wide Approach (SWAp) which commenced with HSSP Phase 1 in 2008-12. The SWAp and partnership support the Solomon Islands Government in providing quality health services for all people in the Solomon Islands through its own National Health Strategic Plan (2011-2015). The SWAp emphasises the importance of partnership, mutual respect, mutual responsibility and the underlying principles of aid effectiveness. The total value of this initiative is $90.0 million over 4 years, starting 2012-13.\",\n",
       " '12263. CEPAT-JKM: Partnership to Improve Tuberculosis Care and Access to Services Through Community - Tuberculosis. CEPAT-JKM: PARTNERSHIP TO IMPROVE TUBERCULOSIS CARE AND ACCESS TO SERVICES THROUGH COMMUNITY - TUBERCULOSIS. CEPAT-JKM: Partnership to Improve Tuberculosis Care and Access to Services Through Community. TheCommunity Empowerment of People Against Tuberculosis (CEPAT) project is working at the community level, engaging religious leaders, with support from partner LKNU, the largest Muslim organization worldwide. CEPAT is coordinating the TB community support model with TB activities in the health system. In this way, the project ensures a continuum of care of TB patients from the health system to the community, strengthening TB prevention and control efforts.',\n",
       " '12182. Ecological and socio-economic factors impacting maintenance and dissemination of antibiotic resistance in the Greater Serengeti Ecosystem. ECOLOGICAL AND SOCIO-ECONOMIC FACTORS IMPACTING MAINTENANCE AND DISSEMINATION OF ANTIBIOTIC RESISTANCE IN THE GREATER SERENGETI ECOSYSTEM. this project models anitbiotic resistance in the Greater Serengeti ecosystem',\n",
       " \"13020. Sustainable Action For Resilience And Food Security (Sabal). SUSTAINABLE ACTION FOR RESILIENCE AND FOOD SECURITY (SABAL). Through the Sabal project, USAID will help vulnerable individuals, households (HHs), and communities in six districts in the Central Hills and the Eastern Hills of Nepal by:(1) reducing the exposure of HHs and communities to agricultural, public health, or climate-related hazards, and enhancing the ability to cope with shocks, (2) identifying adaptive innovations to help HHs and communities adjust to major trends, such as climate change or the expansion of markets into rural areas, and (3) developing a discrete number of promising innovations that will drive scalable improvement in people's lives. Each of the three CRP purposes operates at each resilience level: absorptive, adaptive, and transformative.\",\n",
       " '13040. Output 04: HIV. HIV. Ghana - Accra. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '13010. Procurement of Services. PROCUREMENT OF SERVICES. To improve the functionality of primary health care units, reducing health inequalities, and  increasing domestic financing  for health to sustain and accelerate the pace of improvement in adolescent, maternal and child health in Ethiopia. This will be ac',\n",
       " '12182. Costs towards Appraisal & Design for Global Research Partnerships. COSTS TOWARDS APPRAISAL & DESIGN FOR GLOBAL RESEARCH PARTNERSHIPS. Strengthened and broadened UK-India research partnerships with Low Income Countries (LICs) researchers will deliver evidence informed solutions for global development challenges in India and  LICs in the thematic areas of health,, food and women.',\n",
       " '13030. Jhpiego Corporation. JHPIEGO CORPORATION. to provide support to the Family Planning Division, MoHFW, GoI, as the GoI takes leadership and management in providing voluntary, high-quality FP services in India with a special focus on the six high TFR states of UP, Bihar, Jharkhand, Rajasthan, Madhya',\n",
       " '12220. Reducing health risks through Community Based Health. REDUCING HEALTH RISKS THROUGH COMMUNITY BASED HEALTH. Strenghen Red Cross/Crescent health/care programmes to reduce morbidity and mortality. Development of policies, guidelines, tools and training materials, evaluation and monitoring systems, innovation.',\n",
       " '12281. CDC: Field Epidemiology and Laboratory Training Program (FELTP). CDC: FIELD EPIDEMIOLOGY AND LABORATORY TRAINING PROGRAM (FELTP). CDC: Field Epidemiology and Laboratory Training Program (FELTP)',\n",
       " '13040. Good Governance Initiative Fund. GOOD GOVERNANCE INITIATIVE FUND. The project will identify and support the creativity and innovation inherent in civil society organizations and communities in Tajikistan in order to achieve institutionalized, permanent and durable reforms on particular good governance topics. The project will support initiatives that originate in civil society in Tajikistan that can lead to long-term impact, manifested in any one of a number of different ways, such as: changes to the legislative or regulatory environment; institutionalization of key reforms; changes in the procedures or internal systems that state bodies use to serve the public; and behavior change.This activity is part of a larger, regional project that is implemented in other countries that are part of the USAID/Central Asia Republics Mission. Please refer to other country-specific Operational Plans for details on activities in those countries.',\n",
       " '12263. ACBulgariaTuberculosis. AC: BULGARIATUBERCULOSIS. Tuberculosis',\n",
       " \"12191. Enhancing capacities of medical personnel from a children's haematology ward III. (part 3). ENHANCING CAPACITIES OF MEDICAL PERSONNEL FROM A CHILDREN'S HAEMATOLOGY WARD III. (PART 3). Within the project, the laboratory personnel from the department of children's haematology of the Iashvili hospital in Tbilisi is trained in methods of molacular and genetic diagnostics of leukemias, both in theory and through practical testing.\",\n",
       " '12240. Securing Ugandan s Right to Essential Medicines (SURE) - Nutrition. SECURING UGANDAN S RIGHT TO ESSENTIAL MEDICINES (SURE) - NUTRITION. Securing Ugandans  Right for Essential Medicines (Uganda SURE) aims to aims to assist the Government of Ugandas commitment to strengthen the national pharmaceutical supply system to ensure that the people of Uganda have access to adequate quantities of good quality essential medicines and health supplies. To achieve this goal, SURE s objectives are to: 1) Improve Uganda s policy, legal, and regulatory framework to produce pharmaceutical supply chain stability and sustainability; 2) Improve capacity and performance of central government entities to carry out their supply chain management responsibilities; 3) Improve capacity and performance of districts, health subdistricts, and implementing partners in their supply chain management roles. SURE works on integrating Uganda s supply chain and establishing a pharmaceutical management information system that provides full transparency to minimize medicine stock-outs and waste.',\n",
       " '12110. Selected Evaluation Studies for 2015. SELECTED EVALUATION STUDIES FOR 2015. Selected Evaluation Studies for 2015',\n",
       " \"12220. Health Program (Samoa). HEALTH PROGRAM (SAMOA). The Samoa Health Program (2014-2022) is currently being planned and designed as a follow on investment the sector-wide approach to health development (Health SWAp). The Health SWAp started in 2008 and has been implemented in partnership with Government of Samoa, New Zealand's Ministry of Foreign Affairs and Trade (MFAT) and the World Bank. Funding under this initiative represents Australia's contribution covering technical expertise in: sector assessment of national systems; quality at entry appraisal; civil society conducted health seeking behaviour study; technical assistance for a theory of change workshop for the sector; design technical assistance; and other ad-hoc technical input. The total value of this initiative is $9.2 million over 5 years, starting 2013-14.\",\n",
       " \"12191. Scaling Up Care for Perinatal Depression for Improved Maternal and Infant Health in Nigeria (IMCHA). SCALING UP CARE FOR PERINATAL DEPRESSION FOR IMPROVED MATERNAL AND INFANT HEALTH IN NIGERIA (IMCHA). Even though effective treatments are available, perinatal depression often goes untreated, especially in low- and middle-income countries where there are shortages of mental health specialist resources.  This project aims to address that challenge by demonstrating how community midwives who are trained to work in resource-constrained settings can deliver effective interventions for depression among new mothers.Community treatments for depression The World Health Organization (WHO) produced the Mental Health Gap Action Programme Intervention Guide to help non-specialists recognize and treat select mental health conditions, including perinatal depression. The project team will test the guide's effectiveness in providing support to mothers with perinatal depression at the community level. Using a participatory research approach, researchers will implement training for community midwives in Osun State, Nigeria. The training aims to enhance their skills so they can identify and support women with perinatal depression. The research will also identify organizational factors that can support the scaling up of mental health services in Nigeria. The project will help generate knowledge on the training methods that can equip midwives with skills to deliver care for perinatal depression. The findings will help strengthen efforts in other low- and middle-income countries to develop relevant strategies and programs to address perinatal depression.Innovating for Maternal and Child Health in AfricaThis project is part of the Innovating for Maternal and Child Health in Africa program, a seven-year $36 million initiative funded by Foreign Affairs, Trade and Development Canada (DFATD), Canada's International Development Research Centre (IDRC), and the Canadian Institutes of Health Research (CIHR).\",\n",
       " '13040. HIV Innovations For Improved Patient Outcomes For Priority Populations (Adolescent Friendly Services For Prenatally & Behaviorally Hiv Infected Adoles. HIV INNOVATIONS FOR IMPROVED PATIENT OUTCOMES FOR PRIORITY POPULATIONS (ADOLESCENT FRIENDLY SERVICES FOR PRENATALLY & BEHAVIORALLY HIV INFECTED ADOLES. This programme targets adolescents living with HIV (ALHIV) between 10-19 years of age within region F of the City of Johannesburg and the Matlosana sub-district of the North West Province. The goal is to in collaboration with the Departments of Health, Basic Education and other partners to develop, pilot, evaluate and support the scale-up of a replicable model of targeted and linked interventions across clinics, schools and communities (the 3 streams of the PHC re-engineering programme) to improve the screening, diagnosis, treatment, adherence, retention in care, and psychosocial and mental health of ALHIV. The programme is highly aligned with the HIV & AIDS and TB National Strategic Plan 2012-2016, the National Youth Policy 2009-2014, the Draft Adolescent Youth Health Policy and the Integrated Schools Health Policy.',\n",
       " \"13020. Urban Wash Alliance. URBAN WASH ALLIANCE. Improving the delivery and use of water and sanitation services to India's rapidly growing urban areas is critical to meeting U.S. Government (USG) health objectives for India, particularly in reducing child mortality. As per the Government of India's (GOI) Ministry of Urban Development (MOUD), in notified slums (slums registered by the municipality), 17 percent of the population is without access to improved sanitation, and in unofficial slums, around 50 percent do not have access to improved sanitation facilities. Program efforts to improve water and sanitation services (WSS) have the greatest beneficial impact on the health and hygiene of women and girls. India's growing population of more than one billion puts enormous strains on the ability of the GOI to provide water, sanitation, and health services. U.S. foreign assistance supports the GOI to address WSS needs of the urban poor. USG priorities include safe water access, basic sanitation, WSS policy and governance, and sustainable financing for water and sanitation services. The USG supports integration of water, sanitation and health programs with other sector development programs, such as the GOI's ambitious city and slum development schemes.\",\n",
       " \"13020. UNICEF PIO. UNICEF PIO. The Health Pooled Fund (HPF) is one of the Government of Ethiopia's preferred modalities for scaling up development partners' assistance in support of HSDP IV. UNICEF has been substantially involved in the implementation of the Health Sector Development Plan (HSDP IV) since the introduction of the Health Pooled Fund (HPF). Through this mechanism, USAID is contributing to the Health Pooled Fund. This activity is an effective and efficient way to achieve USAID objectives through ensuring the accessibility of effective health services at all levels of the health system. This activity supports HSDP IV implementation through monitoring and evaluation; the development of studies/research; development of standards, guidelines, and manuals; and promotion of policy dialogue workshops such as woreda-based planning and the Annual Review Meeting (ARM). The project also supports participation of Ministry staff in relevant seminars and study trips to enhance program excellence.\",\n",
       " \"13020. Selected Evaluation Studies for 2014. SELECTED EVALUATION STUDIES FOR 2014. This research and development technical assistance (TA) for Selected Evaluation Studies for 2014 supports the 2014-2016 program cycle,  focusing on studies due in 2015 and 2016. It will fund select evaluations and related outreach activities from both the derived operational (i.e., country and sector program evaluations) and knowledge (i.e., thematic,  corporate and impact evaluations, topical working papers) programs of the Independent Evaluation Department (IED). These include, but are not limited to:1. Country assistance program evaluations (CAPEs) and validations of country partnership strategy final reviews. The TA will fund at least two CAPEs (second-generation CAPEs for Papua New Guinea and the Peoples Republic of China), and validations of at least three country partnership strategy (CPS) final reviews (Bangladesh, Lao Peoples Democratic Republic, and Timor Leste). Each CAPE will evaluate ADB support to the country and cover ADB strategy, policy dialogue, completed and ongoing projects and TA, and ADB performance. It will provide ADB and the developing member country (DMC) with an evaluative basis of use for designing the future CPS. When appropriate, country sector assessments will provide inputs during the preparation of a CAPE. Each sector assessment will evaluate ADB performance within a given sector in the country, focusing again on strategy, policy dialogue, ongoing and completed projects and TA, and performance.2. Review of Asian Development Fund (ADF) Operations. The thematic evaluation study (TES) will review the commitments made under the ADF X and XI replenishments and assess the relevance, responsiveness, and results of ADF operations over the said period. It will comprise a desk review of selected project documents, evaluation reports, and pertinent literature. DMC consultations may be undertaken in a range of countries, a perception survey held, along with country portfolio reviews covering all five regions. 3. Environmentally Sustainable Growth. The TES will review the design and implementation of ADB's 2002 Environment Policy and subsequent directional documents. It will assess the responsiveness, results, and relevance of the policy and environmental elements of Strategy 2020 (S2020), to draw out lessons for future operations. The study will initially undertake a desk review of project documents, evaluation reports, and pertinent literature. It will also take stock of prior environmental evaluations to learn from best practice of development partners. Perception surveys, country case studies of important environmental projects, and key informant interviews of regional DMC stakeholders and other development partners undertaking environment-related work will also be conducted to elicit views about ADB's achievements. 4. Effectiveness of ADB's Partnerships. The TES will evaluate the effectiveness of ADB partnerships through a review of such agreements, co-financing partnership arrangements, and related documents. It will ana\",\n",
       " '12220. JSI Research & Training Institute, Inc.. JSI RESEARCH & TRAINING INSTITUTE, INC.. to contribute towards sustainably improving health practices within communities and the primary level health care system through the application of innovative solutions that are informed by evidence-based best practices',\n",
       " '13040. Output 04: HIV. HIV. South Africa - Pretoria. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12110. Center for Disease Dynamics, Economics & Policy. CENTER FOR DISEASE DYNAMICS, ECONOMICS & POLICY. to fund a project that will build capacity and develop tools for low- and middle-income countries to use antibiotics appropriately',\n",
       " '12263. Colorado State University. COLORADO STATE UNIVERSITY. to enable the discovery and development of more effective drug regimens for drug sensitive and drug resistant tuberculosis (TB) disease',\n",
       " '13030. Strengthening Human Resources for Health (SHRH) - Capacity follow on. STRENGTHENING HUMAN RESOURCES FOR HEALTH (SHRH) - CAPACITY FOLLOW ON. SHRH will be a bilateral associate award under the Capacity Plus Leader with Associate award. Building upon the Uganda Capacity Program and continuing HRH interventions which were shown to produce higher level results, SHRH will further expand in the area of pre-service training capacity and performance based incentives. SHRH will develop the capacities of the central ministries, districts and professional councils to effectively and efficiently manage their HR for delivery of health services. It will work with USG implementing partners to ensure targeted HRH improvements at the service delivery level. Expected results in FY 2014 includes: scale-up of HR information system and recruitment plans in all 112 districts; comprehensive support for district level HRH to all USG implementing partners; and improved regulation and functionality of health professional councils.',\n",
       " '12110. Trade-Related Training Program - Senior Healthcare Leadership Training Program, through Meridian International Center. TRADE-RELATED TRAINING PROGRAM - SENIOR HEALTHCARE LEADERSHIP TRAINING PROGRAM, THROUGH MERIDIAN INTERNATIONAL CENTER. Trade-Related Training Program - Senior Healthcare Leadership Training Program, through Meridian International Center',\n",
       " '12110. Health Accountability Project. HEALTH ACCOUNTABILITY PROJECT. Greater accountability in the use of public resources.',\n",
       " '12220. Maternal and Child Health - Treatment of Child Illness. MATERNAL AND CHILD HEALTH - TREATMENT OF CHILD ILLNESS. Maternal and Child Health - Increase boys and girls access to and utilization of appropriate treatment for diarrhea, pneumonia, and other potentially life-threatening childhood illnesses, including improved recognition of serious illness, community and facility-based treatment of uncomplicated pneumonia, recognition and treatment of severe and complicated pneumonia, Oral Rehydration Therapy, introduction of new formulation ORS, introduction and evaluation of zinc treatment, antibiotic treatment of dysentery, and management of persistent diarrhea. (Malaria detection in children should be budgeted here, but treatment and prevention in the malaria element.)',\n",
       " '12110. JPO WHO 2016 Manila Antimicrobial Resistance KK. JPO WHO 2016 MANILA ANTIMICROBIAL RESISTANCE KK. The contribution is addressing the Agenda 2030 goal 3: Good Health and Well-being. Thematic area is health with a focus on raising awareness of antimicrobial resistance and supporting strengthening surveillance, prevention and control efforts. The JPO programme (Junior Professional Officers) is an important part of Swedish strategy to increase Swedish participation in international organizations. The program offers young professionals (under 33 years of age) who hold a Master degree the opportunity to serve in the UN and other international organizations.',\n",
       " \"13040. Expanding HIV/AIDS Prevention in Bangladesh. EXPANDING HIV/AIDS PREVENTION IN BANGLADESH. The most important achievement of the grant has been its contribution to the low-prevalence of HIV in Bangladesh. Many countries experienced explosive increase of HIV from the epidemic of Injecting Drug Users (IDU). To a large degree, due to the activities supported by the grant this did not occur in Bangladesh. IDUs and Female Sex Workers (FSWs) are the focus of the grant. At the end of Phase 1 of the RCC Grant (December 2011), the performance of the grant against its targets was considered satisfactory. The average performance on the Top 10 indicators was 96% (A2). All indicators rating was at 98% (A2). Out of 14 Service Delivery Area indicators, 6 were overachieved, 5 were between 90-100%; two indicators were slightly below 90% and one - 'Number of IDU and FSW reached through Peer Education' - was at 68% and rapidly catching up from the previous level of 50%. The underachievement was partially due to the discontinuation of a Sub-Recipient (SR) agreement in September 2011 with an entity that was ensuring the coverage of up to one-third of IDU targets. The discontinuation of this SR agreement followed an investigation by the Global Fund's Office of the Inspector General which found disturbing signs of fraudulent practices by the SR. The PR acted decisively in order to safeguard the Global Fund money and took over the direct implementation of IDU-related activities. As a result, the PR managed to maintain the expected return of the grant by avoiding the prolonged discontinuation of preventive activities for IDUs, while at the same time reducing further risk.Overall, it is expected that a good level of performance will be maintained throughout the time remaining until the end of Phase 1 (in November 30, 2012) and, pending the Phase 2 approval, beyond Phase 1.'---1. Background and Summary:  With estimated HIV prevalence of less than 0.1% (2009 UNAIDS Country Brief), Bangladesh is a low HIV prevalence country. UNAIDS estimates about 12,000 people in Bangladesh to be living with HIV at the end of 2007. As of December 2008, a total of 1495 cases of HIV infection were confirmed, with 476 of them developing AIDS and 165 reported death cases (National HIV/AIDS Strategic Plan). The Sero Surveillance Report findings show that HIV infection rate is increasing among most-at-risk-population (MARP), particularly among injecting drug users (IDUs) with concentrated epidemic in Dhaka (7%), and among female sex workers (FSW) due to low level of condom use.Despite the low HIV prevalence in Bangladesh, several risk factors, including geographical location, high population mobility, a large number of migrant workers, poverty, and low level of awareness among young people threaten to hamper the continuing status of Bangladesh as a low HIV prevalence country. The HIV Joint Monitoring Mission organized by the World Bank and its key partners in February 2009 found that prompt and vigorous action is needed to strengthen the quality and coverage of HIV prevention programs,\",\n",
       " '12240. Chronic Disease Prevention and Education for Health and Nutrition Care. CHRONIC DISEASE PREVENTION AND EDUCATION FOR HEALTH AND NUTRITION CARE. 1. Trial operation of nutrition education center in public health center and Expantion education for participants',\n",
       " '13040. Strengthening Monitoring, Evaluation and Research Capacity of the Community Health and Social Service Programs in the United Republic of Tanzania - HI. STRENGTHENING MONITORING, EVALUATION AND RESEARCH CAPACITY OF THE COMMUNITY HEALTH AND SOCIAL SERVICE PROGRAMS IN THE UNITED REPUBLIC OF TANZANIA - HI. The project is designed to improve the use of information in decision making within the national health and social services systems. Over the life of the project, results will include better service, systems, and vital health-related outcomes. Activities funded through this OP are solely malaria funded, and will focus on malaria specific data demand and use approaches to build host country counterpart capacity. Capacity will be built in multiple areas, including data analysis and communication to inform different audiences, to help policy makers and program managers use data in decision making, and to improve structured supervision in monitoring and evaluation activities. The data tools are also used to identify barriers to data use, deficiencies in data quality, and to suggest opportunities for improved data use among stakeholders. The activity aims at addressing the cross-cutting intermediate result (CCIR) of the Country Development Cooperation Strategy (CDCS) in fostering using data for evidence decision making and planning.',\n",
       " '13040. World Health Organization. WORLD HEALTH ORGANIZATION. to strengthen individual level patient monitoring and case surveillance by scaling up effective approaches to unique patient identification to better measure and manage treatment outcomes.',\n",
       " '16064. Output 04: HIV. HIV. Niger - Niamey. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " \"12191. Enhancing capacities of medical personnel from a children's haematology ward III. (part 2). ENHANCING CAPACITIES OF MEDICAL PERSONNEL FROM A CHILDREN'S HAEMATOLOGY WARD III. (PART 2). Within the project, the laboratory personnel from the department of children's haematology of the Iashvili hospital in Tbilisi is trained in methods of molacular and genetic diagnostics of leukemias, both in theory and through practical testing.\",\n",
       " '13020. Strengthening Implementation of Program Budgeting. STRENGTHENING IMPLEMENTATION OF PROGRAM BUDGETING. Provide technical assistance to assist with strengthening public financial management (PFM) policies that will promote fiscal transparency. The objectives of the program support the following areas: (1) improved allocation of budget resources to programs of pilot ministries, including the Ministry of Health, (2) implementation of program budgeting in the remaining 30 national government line ministries, and (3) expansion of program budgeting to sub-national government institutions.',\n",
       " '12240. Asian Vegetable Research & Development Center (AVRDC). ASIAN VEGETABLE RESEARCH & DEVELOPMENT CENTER (AVRDC). the mission of alleviating poverty and malnutrition through the increased production and consumption of nutritious, health-promoting vegetables.',\n",
       " '12220. Observer Research Foundation. OBSERVER RESEARCH FOUNDATION. to maximize progress toward targets of health, hunger and nutrition by providing a body of knowledge and dialogues with stakeholders, aimed at developing an implementation framework for the Sustainable Development Goals',\n",
       " \"13010. Tanzania Results-Based Financing (RBF) Trust Fund. TANZANIA RESULTS-BASED FINANCING (RBF) TRUST FUND. The Tanzania Results-Based Financing Trust Fund will support the roll-out of the Government of Tanzania's Results-Based Financing program to improve accessibility, utilization and quality of health services through increased accountability and responsiveness. With an aim of providing equitable access to cost effective quality health care, the Tanzania Results-Based Financing Trust Fund will improve the accessibility and utilization of health care services in primary health care facilities, the quality of health services at all facilities within the local government authority, the productivity and efficiency of service delivery by health care providers, the quality and use of data for evidence-based decision making, and accountability and responsiveness of health management teams and facility governing committees. The geographic coverage for the coming year includes Shinyanga and Mwanza regions.\",\n",
       " '13040. Social Science Programme / The BREATHER Qualitative sub study. SOCIAL SCIENCE PROGRAMME / THE BREATHER QUALITATIVE SUB STUDY. Social Science Programme / The BREATHER Qualitative sub study',\n",
       " '13030. The Product Development Agreement - Family Planning and Reproductive Health. THE PRODUCT DEVELOPMENT AGREEMENT - FAMILY PLANNING AND REPRODUCTIVE HEALTH. The Product Development Agreement',\n",
       " '13010. Health Communication Capacity Collaborative (HC3). HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3). HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       " '12110. Desk Study - Quality Management Intelligence Dashboard for Chinese Hospitals, through OMMA Healthcare, LLC. DESK STUDY - QUALITY MANAGEMENT INTELLIGENCE DASHBOARD FOR CHINESE HOSPITALS, THROUGH OMMA HEALTHCARE, LLC. Desk Study - Quality Management Intelligence Dashboard for Chinese Hospitals, through OMMA Healthcare, LLC',\n",
       " '12230. The Project for Construction of Community Health Clinic in Khamrang Village, Kolasib District, Mizoram. THE PROJECT FOR CONSTRUCTION OF COMMUNITY HEALTH CLINIC IN KHAMRANG VILLAGE, KOLASIB DISTRICT, MIZORAM. Construction of a community health center in a rural village in Mizoram',\n",
       " '12250. Foundation for Innovative New Diagnostics FIND. FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND. The Foundation for Innovative New Diagnostics (FIND), working through a public-private partnership model, drives the development and early implementation of new diagnostic tests for poverty-related diseases. From a global public health perspective, accurate and affordable diagnosis is critical. It helps ensure better care to patients, enables equitable, timely and correct medical treatment in low-resource settings, and thus reduces wastage of medicines and antimicrobial resistance. It is essential also for emergency preparedness.',\n",
       " '13030. DHA-Empower Women on SRHR. DHA-EMPOWER WOMEN ON SRHR. Nirapod-2: Empowering women on SRHR and choice of Sage Menstrual Regulation (MR) and Family Planning (FP)',\n",
       " '12110. AGResults Contracts (via competition) component - Change to AgResults: Evaluation Contract One  - Reseach. AGRESULTS CONTRACTS (VIA COMPETITION) COMPONENT - CHANGE TO AGRESULTS: EVALUATION CONTRACT ONE  - RESEACH. The overall objective of the AgResults Initiative is to enhance smallholder welfare and food security for the poor and vulnerable in developing countries through increased investment in agricultural innovation and adoption.  It aims to do so by developing',\n",
       " '12181. Switching the poles;  Integrated control of mycobacteria endemic in West Africa: renforcement du Laboratoire de RTfTrence des MycobactTries (LRM). SWITCHING THE POLES;  INTEGRATED CONTROL OF MYCOBACTERIA ENDEMIC IN WEST AFRICA: RENFORCEMENT DU LABORATOIRE DE R+F+RENCE DES MYCOBACT+RIES (LRM). Background:  Brief overview of the FA collaboration during the past5 -year period (FA3). During the past 5 -year period, the FA institutional collaboration between ITM and LRM has improved LRM capacity in several domains:  -  -LRM has recently been designated as a supranational reference laboratory candidate for TB by the WHO and serves as a center of excellence for other countries in the West/ Central African Region  - LRM has established a well -functioning lab network for BU diagnosis with a specific manual available, conducts regular supervisions of peripheral labs, and completes external quality controls showing excellent results. This can serve as an example for other countries in the region  - Several PhDs have been defended by students from LRM and an increasing number of research articles are authored by LRM staff  Previous institutional collaborations between LRM and ITM were under FA1 (1998 -2002), FA2 (2003 -2007), FA3 -I (2008 -2010) and FA3 -II (2010 to 2013). Below are reports for the past 5 -year period: Progress 2012 A well -functioning lab network for BU diagnosis is now in place in Benin with a specific manual available, regular supervisions of peripheral labs and external quality controls showing excellent results.  LRM has also set up qPCR for BU diagnosis and a second study has been performed to compare it with classical PCR, which showed an increase in positivity rate of 33%. This technique has now been adopted at LRM and is routinely used on samples received from BU centres. However, new changes on the probe used for this technology suggest further improvements of the performance of this test are possible. Though it was not possible to establish formal links between LRM and labs from other countries, some lab technicians have been received from these countries for training. In addition, samples from BU suspected cases from neighbouring countries are received at LRM, and analysed with the different tests available. Finally, the differential diagnosis study is ongoing with more than 100 patients recruited to date.  Progress 2011 Activities to maintain a well -established laboratory for BU diagnosis in West -Africa as well as a good national microscopy network have been maintained and strengthened: National guidelines for the BU microscopy network have been validated and printed. The equipment for real time PCR has been provided to LRM by ITM, LRM staff has been trained on this technique which has been set up and is now routinely used in this laboratory. Samples from field centers (patients from Benin as well as from neighbouring countries) have been tested for BU diagnosis and peripheral laboratories were regularly supervised and controlled. In terms of research activities in 2011, two researchers from DRC have been received at LRM for joint training on immunological tests on BU. Studies to improve DNA extraction have been published (Affolabi et al., 2012). Other currently ongoing research focuses on drug susceptibility test',\n",
       " '12220. Program for Improved Accessibility and Quality of Health Services and Networks. PROGRAM FOR IMPROVED ACCESSIBILITY AND QUALITY OF HEALTH SERVICES AND NETWORKS. The objective of the program is to support the Ministry of Health (SESAL) in improving the coverage and quality of health services through the decentralized management modality, giving priority to the populations of the country+s poorest municipios and strengthening implementation of the family- and community-based comprehensive health care model. The expected outcomes are: (i) improved access to, and quality of, the guaranteed package of services for the project+s beneficiary population; (ii) strengthened maternal and child health networks in the beneficiary municipios and departments; and (iii) improved institutional capacity of SESAL to set policy, provide leadership, and manage the health services provided through management bodies under the decentralized management modality.',\n",
       " '13020. Stockholm Environment Institute. STOCKHOLM ENVIRONMENT INSTITUTE. to support a project designed to provide financial incentive for the women who honor all their clinic appointments while pregnant, deliver under skilled attendants and take their children for all health appointments in their first year of life',\n",
       " '12220. Fianancial Audit of two grant contrcats: AMREF  project ref: DCI NSAPVD2008 / 170 550 Putting Communities First: Better health for Pastora. FIANANCIAL AUDIT OF TWO GRANT CONTRCATS: AMREF  PROJECT REF: DCI NSAPVD2008 / 170 550 PUTTING COMMUNITIES FIRST: BETTER HEALTH FOR PASTORA. Fianancial Audit of two grant contrcats: AMREF  project ref: DCI-NSAPVD2008 / 170-550 Putting Communities First: Better health for Pastoralist in Afar and ONG-PVD/2007/134-889 Strengthening Pastoralist Health Care Systems in South Omo, Ethiopia',\n",
       " '16064. Output 04: HIV. HIV. Maldives - Male. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " \"13030. Health Information Policy and Advocacy Project. HEALTH INFORMATION POLICY AND ADVOCACY PROJECT. The Health Information, Policy, and Advocacy (HIPA) project will improve the quality and use of population and health data reported in the Cambodian government's health management information system and vital statistics registration database. HIPA will support the entry of tuberculosis program data into the health information system; development of analytic and user-friendly tools for use by non-health authorities to better allocate resources for community health priorities; and refinement of the host government's data quality audit tools and systems to improve the quality of reported data from both public and private health-care providers. Reliable data is essential for Cambodian government officials and other stakeholders to make informed decisions about policies and resource allocations leading to improved accountability of health-care service delivery.\",\n",
       " '12181. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016: Mycobacteriologie network. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016: MYCOBACTERIOLOGIE NETWORK. General objective:  Scientific support and networking on Mycobacteriology  The overall objective of the programme is to strengthen the rational basis and the country ownership of health care systems and policies in developing countries, in order to improve the health status of the populations and thereby contribute to the reduction of poverty and inequity.  The specific programme purpose is to build, reinforce and support appropriate and sustain -able capacity in developing countries to conduct research, training and delivery of reference services in order to meet the overall objective.  The target groups of the programme are, in order of impact and level: (1) The leaders, scientists and experts in the partner institutions in developing countries;  (2) The health professionals and policy makers that can implement the improved practices and policies resulting from the programme; (3) The communities and individuals that should benefit from the improved practices and policies.    - Specific objective:  To bring together the expertise on tuberculosis (TBa in research institutions, paritularly  in West  - and Central Africa, with links to ITM, in order to allow scientists at these institutions to jointly develop set and implement priorities for research and capacity building. - Results:  A regional TB Network is active, led through work packages.  Technical and scientific capacity is strengthened. Protocols and trainees are exchanged between network partners and collaborative proposals are submitted. -',\n",
       " '12110. HPSS  Health Promotion and System Strengthening Project in Dodoma, Morogoro and Shinyanga Regions. HPSS  HEALTH PROMOTION AND SYSTEM STRENGTHENING PROJECT IN DODOMA, MOROGORO AND SHINYANGA REGIONS. The Health Promotion and System Strengthening project (HPSS) is improving access to and the quality of health services both in terms of the demand (health promotion, health insurance) and the supply side (drug procurement; health technology maintenance). After a successful pilot phase in the Dodoma region, the Tanzanian government is requesting the SDC to expand this approach to two other regions with a focus on those most at risk (the poor, women, children, youth and the elderly).',\n",
       " '13010. MEASURE Evaluation Phase III - Program Design and Learning. MEASURE EVALUATION PHASE III - PROGRAM DESIGN AND LEARNING. MEASURE Evaluation Phase III continues the MEASURE program s 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3).increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       " '12182. The Evaluation of a Standardised Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB. THE EVALUATION OF A STANDARDISED TREATMENT REGIMEN OF ANTI-TUBERCULOSIS DRUGS FOR PATIENTS WITH MDR-TB. Medical Research Council. Clinical trial testing optimal therapy for  Patients with MDR-TB in  Ethiopia, India, Viet Nam, South Africa',\n",
       " '13040. Output 04: HIV. HIV. Lebanon - Beirut. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12281. Strengthening the health system in Sudan: equo access to services and specialized training of health personnel. STRENGTHENING THE HEALTH SYSTEM IN SUDAN: EQUO ACCESS TO SERVICES AND SPECIALIZED TRAINING OF HEALTH PERSONNEL. The project aims to ensure access to pediatric cardiology, cardiac surgery services and free high quality in Sudan and to increase the provision of training for health professions particularly in cardiology, cardiac surgery, anesthesia and pediatrics',\n",
       " '13020. Youth Leadership for Agriculture. YOUTH LEADERSHIP FOR AGRICULTURE. The aim of the Youth Leadership for Agriculture Activity is to build economic opportunities for youth ages 10 to 35 in agriculture-related fields in order to increase incomes and build entrepreneurial, leadership, and workforce readiness skills. With almost 50% of its population under age 14 and one of the highest population growth rates in the world, Uganda is in the midst of a quickly worsening youth crisis. This activity will address critical gaps in the human, social, financial, and physical capital of youth to increase the access of youth to viable livelihoods on a large scale.',\n",
       " '12181. Developing Hanoi University of Pharmacy to become a National Specialized University. DEVELOPING HANOI UNIVERSITY OF PHARMACY TO BECOME A NATIONAL SPECIALIZED UNIVERSITY. Developing Hanoi University of Pharmacy to become a national specialized university meeting regional standards by 2020',\n",
       " '12281. Exchanges with Other Countries in the Field of Vocational Education and Training and Scholarships. EXCHANGES WITH OTHER COUNTRIES IN THE FIELD OF VOCATIONAL EDUCATION AND TRAINING AND SCHOLARSHIPS. Collaborative project - Development and trialling of initial and continuing training modules in the care sector in Tunisia, Sub-project - Project management and coordination, development of the quality management system',\n",
       " \"12240. Nutrition and food security in rural China: An assessment of school feeding system. NUTRITION AND FOOD SECURITY IN RURAL CHINA: AN ASSESSMENT OF SCHOOL FEEDING SYSTEM. The school feeding system in China provides 180 to 200 days of meals a year to rural children from economically disadvantaged provinces that have a high incidence of malnutrition. The program covers 14 provinces, 100 counties, and over three million children. In order to make policy adjustments and expand the benefits to other low-income areas of the country, it is essential to measure the impact of the system. The purpose of this study is to assess China's school feeding system under its National Nutrition Improvement Plan to better understand the system's impact on rural students, local food security, and sustainable economic growth. Researchers will assess the quality of the meals and nutrient intake by children aged seven to 15 in relation to their health and nutritional status, school attendance, and educational outcomes. Economic impact on local communities will be monitored to understand if and how the system affects local food production, procurement, and employment, particularly for women. To improve the potential impacts of the system on nutritional outcomes, additional interventions (including nutrition education and capacity development for women and men) will be introduced in a selected number of schools over a period of two years, and their impact will be evaluated.     The project will be led by the China Development Research Foundation (CDRF) in collaboration with several strategic participating institutions, including the Chinese Center for Disease Control and Prevention, the World Food Program, the Ministry of Education, the Ministry of Agriculture, Microsoft, Amway Charity Foundation, and the Capital Healthcare and Nutrition Cuisine Society. Although the research focuses on China, results and outcomes have the potential to be used widely in other countries in Asia where school feeding programs are an entry point to target food security, nutrition, and school performance among school-aged children.\",\n",
       " '13040. Output 04: HIV. HIV. Philippines - Manila. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " \"12110. Reverse Trade Mission - Senior Healthcare Leadership Training Program, through Meridian International Center. REVERSE TRADE MISSION - SENIOR HEALTHCARE LEADERSHIP TRAINING PROGRAM, THROUGH MERIDIAN INTERNATIONAL CENTER. This funding partially supported a training program for Chinese senior healthcare leaders to strengthen the capacity of senior health executives in China and to introduce best practices in healthcare management and information technology (IT) solutions. The program was supported by members of USTDA's U.S.-China Healthcare Cooperation Program, which were responsible for developing the curriculum and itinerary, and China's Health Human Resources Development Center (HHRDC), which provided funding to cover the full cost of tuition as well as the cost of international airfare for some delegates. The training program was undertaken in conjunction with HHRDC, Johns Hopkins University, and University of Kansas Medical Center.\",\n",
       " '13030. Health Communication Capacity Collaborative (HC3) - Family Planning and Reproductive Health. HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3) - FAMILY PLANNING AND REPRODUCTIVE HEALTH. HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       " \"12191. Soins de santT spTcialisTs en palestine - phase III. SOINS DE SANT+ SP+CIALIS+S EN PALESTINE - PHASE III. General objective:  'To improve the global care in the Palestinian Autonomous Territories by reducing mortality and morbidity due to cardiac and congenital ailments in children and adults' - Specific objective:  To upgrade the diagnostic and therapeutic cardiac care facilities in three tertiary care hospitals (one in the Gaza strip, one in Jerusalem and one in the West Bank)  To upgrade the treatment capacity in one tertiary health centre in Gaza City - Results:  1. Establish a new Cardiac Intensive Care and Surgery Department in Khann Yunnis at the European Gaza Hospital and start interventional procedures in the Cath -lab in order to create a fully functional Cardiac Centre. 2. Extend therapeutic capacity at the Paediatric Intensive Care Unit in Jerusalem at Makassed hospital  3. Establish a new Cardiac Surgery department in Ramallah at the MoH hospital in order to complete the Cardiac Centre by including the existing Cathlab and Cardiology Department. 4. Reinforce therapeutic procedures at the Neonatology Department in Gaza city at Shifa hospital. -\",\n",
       " '12110. Community laboratories:health,food sovereignty and  female entrepreneurship in rural Senegal. COMMUNITY LABORATORIES:HEALTH,FOOD SOVEREIGNTY AND  FEMALE ENTREPRENEURSHIP IN RURAL SENEGAL. Aims:1) training of trainers newly elected councilors; 2) support for women entrepreneurs; 3) reproductive health  maternal and child; 4) prevention of sexual diseases; 5) education of women: 6) awareness  Kuminda EXPO 2015',\n",
       " \"12263. MEASURE Evaluation Phase III. MEASURE EVALUATION PHASE III. MEASURE Evaluation Phase III continues the MEASURE program's 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3)increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureau's primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.\",\n",
       " '13040. CapacityPlus. CAPACITYPLUS. This project strengthens the human resources (HR) needed to implement quality health programs, in both the public and private, particularly the not-for-profit private, sectors. It addresses both the number of healthcare workers needed and the quality and performance of those workers. The definition of healthcare worker is expanded to include HR managers, laboratory staff, pharmacists, social workers, information systems/monitoring and evaluation specialists and others essential to the effective functioning of the health system.',\n",
       " '16064. Output 04: HIV. HIV. Ghana - Accra. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '13040. Guyana HIV/AIDS Reduction and Prevention II (GHARP II) - HIV/AIDS. GUYANA HIV/AIDS REDUCTION AND PREVENTION II (GHARP II) - HIV/AIDS. The Guyana HIV/AIDS Reduction and Prevention (GHARP II) project provides technical support to USAID s HIV/AIDS prevention, care, and treatment program in Guyana. The project, a three and a half year task order under the AIDSTAR indefinite quantity contract (IQC) mechanism, includes partners from Management Sciences for Health (MSH), Howard Delafield International (HDI), and the AIDS Healthcare Foundation (AHF). GHARP II maintains and strengthens the achievements of the GHARP I program while focusing efforts to benefit Guyanese citizens that are at the greatest risk of acquiring HIV and least able to access HIV prevention, care, and treatment services.',\n",
       " \"12240. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       " \"12182. Implementation and evaluation of a smartphone teleconsultation system for acute burn injury care in resource-poor settings. IMPLEMENTATION AND EVALUATION OF A SMARTPHONE TELECONSULTATION SYSTEM FOR ACUTE BURN INJURY CARE IN RESOURCE-POOR SETTINGS. Burn injuries are a leading cause of premature death worldwide and are largely attributable to poor living conditions. Timely care is a prerequisite to reduce morbidity and mortality and it can be significantly improved in resource-poor settings by teleconsultation systems to support the provision of appropriate and timely care.A teleconsultation system for acute burn care is currently under implementation in the Western Cape, South Africa. An application (app) is installed on a smartphone located in each of the emergency services of 8 hospitals to transmit visual and textual information between emergency staff at point of care and a network of burn teleexperts. The burns specialist on call is informed via instant messaging that a case has been uploaded and can then review the visually transmitted information and images and provide diagnostic and treatment advice. The primary aim of the project is to assess how a teleconsultation system for acute burn injury care based on a smartphone application can impact on the delivery of emergency care for burns victims, both in terms of clinical management and site of care. Intermediate aims are to assess the clinical quality, clinical outcomes, user perspective, and costs and benefits of the teleconsultation system. The clinical quality will include assessments of diagnostic accuracy and patient management. Bedside diagnosis or image based diagnosis by burns experts will be used as gold standard. A historical cohort design will be used to assess the effect of the teleconsultation system on patient outcomes. The Health Information Technology Usability Evaluation Model will be used to assess how the users experience the system and the system's cost-utility will be assessed in terms of cost per quality-adjusted life-year gained. A stepwise implementation of the system is planned in Tanzania and Ethiopia starting the beginning of 2016. The burn specialists already involved in South Africa will act as experts for the two additional countries and the existing south-south network of emergency specialists will safeguard the communication and implementation of the system. This proposal will build on the evaluation already started in South Africa and will allow a more robust and comprehensive evaluation of the whole system. Furthermore, the inclusion of other settings will add important contextual aspects to the evaluation. The first part of the evaluation will include the hospitals currently using the teleconsultation system in the Western Cape, South Africa and 2-3 hospitals where the system will be introduced in Tanzania. Later on, 2-3 hospitals in Ethiopia will be introduced to the system, informed by the process in Tanzania, and those hospitals will be included in the evaluation.Low cost and timely alternatives to burn injury control are a pressing need in many low- and middle-income settings and countries. This project is a determinant step in that direction and can lead to the implementation of a viable, incl\",\n",
       " '12230. Renovation of the health centre and fire station buildings in the village of Vidovice in Bosnia and Herzegovina which were damaged by flooding. RENOVATION OF THE HEALTH CENTRE AND FIRE STATION BUILDINGS IN THE VILLAGE OF VIDOVICE IN BOSNIA AND HERZEGOVINA WHICH WERE DAMAGED BY FLOODING. During the 2014 floods in Bosnia and Herzegovina, many public buildings were destroyed or damaged. The State, NGOs and other entities joined in the renovation efforts. In July 2014, top priority was given to the renovation of schools so that instruction could start normally in November 2014. Major health centres were also high on the list of priorities. Some other public buildings in smaller villages were not included on this list, and due to insufficient funds many buildings have not yet been renovated. Consequently, work in these institutions is obstructed and residents are deprived of the services provided. The project was designed on the basis of identified local needs regarding public buildings in Bosnia and Herzegovina. The project foresees the renovation of the health centre and fire station in Vidovice damaged during the floods (both buildings were flooded for almost three weeks); the village of Vidovice is located in the Municipality of Oraje on the Sava River. Project goals: improve the conditions for providing basic health care to Vidovice residents and improve the conditions for ensuring fire protection and safety in the case of natural disasters in the area. Project results: renovation of the health centre premises in Vidovice and of the interior and exterior of the fire station in Vidovice.',\n",
       " '12240. MPI- Solutions for African Food Enterprises (SAFE). MPI- SOLUTIONS FOR AFRICAN FOOD ENTERPRISES (SAFE). Partners in Food Solutions (PFS), TechnoServe and USAID began implementation in 2013 of a Global Development Alliance (GDA) partnership to catalyze transformation of the local food processing sector in Africa. SAFE aims to increase the competitiveness of the African food processing sector and to expand availability of affordable and nutritious foods. PFS is a non-profit organization formed by General Mills to harness the global technical expertise of General Mills, Cargill, Royal DSM (DSM), and Band transfer technology and knowledge to African processors through its skilled volunteer employees and use of world-class facilities. SAFE began technical assistance in 2013 with the timely onboarding of food processors in Kenya, Malawi, and Zambia. This activity will increase demand for the crops of smallholder farmers who supply those businesses.',\n",
       " '12220. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Competence building and training of Health personnel and supportive services in the field of Reconstructive surgery with special emphasis on facial malformations and deformities.',\n",
       " '12191. Support to the Pediatric Orthopaedic Surgery and Rehabilitation Center St Marie de Rilima. SUPPORT TO THE PEDIATRIC ORTHOPAEDIC SURGERY AND REHABILITATION CENTER ST MARIE DE RILIMA. Management suppot to the Centre; Training local personnel; Networking and advocacy.',\n",
       " \"12220. Global Health Professional and Organizational Development (GHPOD) II program. GLOBAL HEALTH PROFESSIONAL AND ORGANIZATIONAL DEVELOPMENT (GHPOD) II PROGRAM. Under a five-year contract with USAID, EnCompass manages the Global Health Professional and Organizational Development (GHPOD) II program. GHPOD's role is to provide professional and organizational development support to USAID's health sector staff around the world to build their capacity to lead and manage health programs. Through the GHPOD mechanism, EnCompass provides a variety of training and learning programs to build capacity in technical areas, program management, leadership, personal and team effectiveness, retreats and strategic meetings, and staff performance management. Each year GHPOD II designs and delivers as many as 45 professional development programs and 50 OD interventions, and provides coaching to about 60 USAID global health professionals.\",\n",
       " \"12110. Visit to Health by Lieutenant General (Retired) Hotmangaradja Pandjaitan, Republic of Indonesia. VISIT TO HEALTH BY LIEUTENANT GENERAL (RETIRED) HOTMANGARADJA PANDJAITAN, REPUBLIC OF INDONESIA. Visit focused on the Australian health emergency management and associated global health issues and was part of General Hotman's Indonesian National Security Fellowship for 2013\",\n",
       " '12263. Critical Path Institute. CRITICAL PATH INSTITUTE. to accelerate the development of a safer, faster-acting and more efficacious drug regimen(s) for the treatment of tuberculosis (TB) by curating data to inform the development of new tests which rapidly detect drug-specific resistance and susceptibility',\n",
       " '12240. Food Safety and diversification of sustainable income sources of women and their families. FOOD SAFETY AND DIVERSIFICATION OF SUSTAINABLE INCOME SOURCES OF WOMEN AND THEIR FAMILIES. Food Safety and diversification of sustainable income sources of women and their families',\n",
       " '12110. Capacity-Building to Support Innovative Management of Health Public Investment. CAPACITY-BUILDING TO SUPPORT INNOVATIVE MANAGEMENT OF HEALTH PUBLIC INVESTMENT. This Technical Cooperation (TC) aims at supporting capacity building related to the management of public investment in health. The areas of the Ministry that would be strengthened are: infrastructure, planning, regulation, legal counsel, financial and adm',\n",
       " '13040. Observational 13042Studies Programme in Rural Uganda / General Population Cohort. OBSERVATIONAL 13042STUDIES PROGRAMME IN RURAL UGANDA / GENERAL POPULATION COHORT. Observational 13042Studies Programme in Rural Uganda / General Population Cohort',\n",
       " '12220. Health Sector Review and support to Strategic Planning of the Ministry of Public Health in Afghanistan. HEALTH SECTOR REVIEW AND SUPPORT TO STRATEGIC PLANNING OF THE MINISTRY OF PUBLIC HEALTH IN AFGHANISTAN. Assess the progress of the Health Sector in Afghanistan towards the ten strategic directions of the Strategic Plan 2011- 15, allow key stakeholders to take stock of the health sector progress and help to foster agreement on the way forward.',\n",
       " '13040. Output 04: HIV. HIV. Iran - Teheran. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12110. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 QUAMED. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 QUAMED. General objective:  QUAMED network: Quality medicines for all. - Specific objective:  To improve in a sustainable way the performance of 6 public sub -Saharan African procurement centres (PC) through a technical support aimed at meeting  international quality standards and a sensitization strategy aimed at their pharmaceutical market, in collaboration with the national regulatory authorities. - Results:  The result 1 aims at continuing the QA support provided to the Southern public PC under the framework agreement FA3 -II but will increase its focus on the implementation of QA policies (training sessions and development of procedures) within these partners so that they develop their capabilities with the objective of complying with the QA requirements of international mechanisms and organisations.  The result 2 is a pilot action -research which consists of developing and testing innovative strategies to make the supported PC sustainable and provide them with means to remain competitive despite their investment in quality. Strategies as certifications, quality marks, labels etc.. will be explored and tested with the following main steps:  (a) Identification of the country and setting of study. (b) Identification of the partner(s) for implementation of the intervention(s) and the data collection. (c) Co -development of the intervention with the procurement center, the Ministry of Health and of the action research protocol. (d) Approval by the institutional review board of the ITM and the national ethical review committee. (e) Implementation of the intervention. (f) Data collection/ monitoring and evaluation. (g) Data analysis. (h) Adjustment of Intervention if required (i) Lessons learned and dissemination at national level and within the QUAMED network (j). International dissemination The design of QUAMED as a long term network rooted in the South will also be explored as a support to this strategy. This will be developed with the regulatory authorities so that the possible gaps and discrepancies between the approaches of the 2 pillars of the pharmaceutical countries mechanisms are reduced.   The result 3 consists of coordinating, managing and further developing QUAMED network. The partners of QUAMED have numerous requests and needs for technical support for the management of their respective quality assurance systems. In addition, the issue of poor quality medicines in low income countries and QUAMED response also needs to be further promoted in donor, stakeholders and scientific fora and meetings.  -',\n",
       " '12110. Community laboratories:health,food sovereignty and female entrepreneurship in rural Senegal. COMMUNITY LABORATORIES:HEALTH,FOOD SOVEREIGNTY AND FEMALE ENTREPRENEURSHIP IN RURAL SENEGAL. Aims:1) training of trainers newly elected councilors; 2) support for women entrepreneurs; 3) reproductive health maternal and child; 4) prevention of sexual diseases; 5) education of women: 6) awareness Kuminda EXPO 2015',\n",
       " '12191. Lira Rehabilitation Centre (LRC). LIRA REHABILITATION CENTRE (LRC). The project targets underprivileged children and youth in Lira, Northern Uganda, especially children with disabilities (CWD) in order to enable them to participate as equal members of society. The project aims to achieve holistic rehabilitation by offering CWDs intensive services at Lira Rehabilitation Centre, and following up the children and their families in their local communities. Activities include physiotherapy, corrective surgery, education, psychosocial and livelihood support.',\n",
       " '12230. Medical equipment donation to the central laboratory of Suriname. MEDICAL EQUIPMENT DONATION TO THE CENTRAL LABORATORY OF SURINAME. Wire transfer of funds becuase the non-availability of the medical equipment and apparatus in Venezuela due to the present economic situation',\n",
       " '12281. Midwife Training and Central TB Reference Laboratory Strengthening. MIDWIFE TRAINING AND CENTRAL TB REFERENCE LABORATORY STRENGTHENING. Assisting National Health Development Goal of South Sudan. Supporting  MCH service delivery system by Midwife Training, Strengthening dignosis capability of central TB reference laboratory, and operation consulting on St. John Lee Hospital in pre-opening stage',\n",
       " \"13020. Sexual & Reproductive Health Rights. SEXUAL & REPRODUCTIVE HEALTH RIGHTS. The project will focus on encouraging the use of conventional methods of child birth as opposed to use of non conventional methods.  The project will also address women's reproductive rights such as choice of birth control methods . Activities will include informal education/training of young women and men in reproductive rights and gender relations.\",\n",
       " '16064. Output 04: HIV. HIV. Sudan - Khartoum. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '13081. The basic design study(BDS) for national IEC(Information, Educaiton, Com. THE BASIC DESIGN STUDY(BDS) FOR NATIONAL IEC(INFORMATION, EDUCAITON, COM. Strategic planning, recognition improvement campaign, support vehicle and contraceptic items, dispatch specialist, ME, invitaitonal training, project management',\n",
       " '12281. Accountability Can Transform Health. ACCOUNTABILITY CAN TRANSFORM HEALTH. Greater accountability in the use of public resources.',\n",
       " '12262. World Health Organisation - Emergency Response to Artemisinin Resistance in the Greater Mekong. WORLD HEALTH ORGANISATION - EMERGENCY RESPONSE TO ARTEMISININ RESISTANCE IN THE GREATER MEKONG. Funding under this initiative provides support through the World Health Organisation for the coordination of the emergency response to artemisinin resistance in the Greater Mekong subregion. Key outcomes will include: strengthened leadership, coordination and oversight mechanisms; maintenance and expansion of drug efficiency surveillance networks and acceleration of priority research; improved access for migrant and mobile populations to quality services; full implementation of the Myanmar Artemisinin Resistance Containment (MARC) Framework; strengthened response to Artemisinin resistance in Vietnam; and reduced availability of oral Artemisinin. The total value of this initiative is$5.0 million over 3 years, starting 2012-13.',\n",
       " '16064. Centre for Advocacy and Research. CENTRE FOR ADVOCACY AND RESEARCH. To mainstream Most-at-Risk-Populations (MARPs) through building social accountability and community leadership for collaboration with government, civil society and media for increased access to HIV reduction services.',\n",
       " '12182. Short term policy focussed research project to generate evidence on microbial drug resistance. SHORT TERM POLICY FOCUSSED RESEARCH PROJECT TO GENERATE EVIDENCE ON MICROBIAL DRUG RESISTANCE. To make DFIDs Research agenda more responsive through the production of short term policy research that will address the needs of policy makers by providing them with primary evidence that can subsequently be used for policy analysis in such areas as Heal',\n",
       " \"12220. Support to the Mother and Child Health Department of the Medical University Simulation Centre of Moldova. SUPPORT TO THE MOTHER AND CHILD HEALTH DEPARTMENT OF THE MEDICAL UNIVERSITY SIMULATION CENTRE OF MOLDOVA. The international evidence proves the effectiveness of training methods based on simulation in comparison with 'traditional education, improving the practical skills of medical staff. The project will support the introducing simulation training technologies in obstetric, gynecological, neonatal and pediatric emergencies and by this contributing to improving the high medical education in Moldova.\",\n",
       " '12191. Laboratory and Medical Equipment Project for Nork Marash Medical Center. LABORATORY AND MEDICAL EQUIPMENT PROJECT FOR NORK MARASH MEDICAL CENTER. Laboratory and Medical Equipment Project for Nork Marash Medical Center',\n",
       " '13040. Streamlining the Response to HIV/AIDS  Epidemic in Azerbaijan by Strengthening National Capacities and Scaling up Prevention and Treatment with Emphasis on the Most at Risk Population Groups and Civil Society Participation. STREAMLINING THE RESPONSE TO HIV/AIDS  EPIDEMIC IN AZERBAIJAN BY STRENGTHENING NATIONAL CAPACITIES AND SCALING UP PREVENTION AND TREATMENT. Azerbaijan is a lower-middle income country with a concentrated HIV epidemic. HIV prevalence in adults is estimated at 0.2 percent (UNAIDS, 2008 Report on the Global AIDS Epidemic). Although the national burden of HIV appears comparatively low, it is probably underestimated - due, in particular, to difficulties in accessing most-at-risk population groups. The predominant HIV transmission mode is sharing of injecting equipment among people who inject drugs. The government of Azerbaijan is committed to fighting the HIV epidemic and allocates increasing amounts of financial, human and infrastructural resources for this purpose, particularly to cover the substantial costs of staff, medical interventions and facility expenses. However, substantial financial and programmatic gaps exist, especially with regards to the complex and costly interventions in HIV prevention and treatment activities among most-at-risk population groups. The program supported by this grant aims to ensure the continuation and scaling-up of the activities initiated under the Round 4-supported program, which ended in June 2010. This program will initiate new activities, such as expansion of voluntary counseling and testing, ensuring universal access to prevention of mother-to-child transmission of HIV and establishing community-based care and support.',\n",
       " '12250. Kiribati Health. KIRIBATI HEALTH. Kiribati faces a number of development challenges including: highest number (68%) of Violence Against Women cases out of 9 other Pacific countries conducting the same study; 70% of Tuberculosis cases are in South Tarawa; increases in infant mortality rate as a result of pneumonia, diarrhoea and malnutrition; South Tarawa suffers from severe overcrowding. The Aid Investment Priority and Aid Partnership Arrangement aims to address these issues through delivering assistance that focuses on reducing the spread of communicable diseases, youth crime; alcohol consumption and domestic violence. The Kiribati Health program is identified as a key priority under new AIP and Aid Partnership Arrangement and will support ongoing strategic support to the health sector in addressing high burden disease such as in Tuberculosis, improving neonatal and maternal health, and health system strengthening. The total value of this initiative is $4.3 million over 6 years, starting 2009-10.',\n",
       " '12182. Applied Research in India, Partner Driven Cooperation within the health sector - 007 +ste, Innovative food design LU. APPLIED RESEARCH IN INDIA, PARTNER DRIVEN COOPERATION WITHIN THE HEALTH SECTOR - 007 +STE, INNOVATIVE FOOD DESIGN LU. Call for applications in the prioritised area of health in India.',\n",
       " \"13020. International Food Policy Research Institute (IFPRI). INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE (IFPRI). to assess the impact of the fourth phase of Ethiopia's Productive Safety Net Programme (PSNP) on the nutritional status of women and pre-school children\",\n",
       " '13010. Social-ecological research. SOCIAL-ECOLOGICAL RESEARCH. Collaborative project - Climate change, environmental  change and migration - Social-ecological conditions of population movements - the example of the Sahel countries of Mali and Senegal. Sub-project - Social ecology perspective and coordination - Improving knowledge on economical, ecological and social changes in the Developing Country',\n",
       " '12250. Rehabilitation of endemic diseases surveillance system for the national health service in the Zanzibar islands (SISME). Phase 2. REHABILITATION OF ENDEMIC DISEASES SURVEILLANCE SYSTEM FOR THE NATIONAL HEALTH SERVICE IN THE ZANZIBAR ISLANDS (SISME). PHASE 2. The project aims to operate in Zanzibar, United Republic of Tanzania, to support the reform of the monitoring system under the national health service started from september 2005 through the qualification of human resources',\n",
       " '12262. Scaling up Malaria prevention and control for universal coverage to achieve pre_elimination stage in the Gambia. SCALING UP MALARIA PREVENTION AND CONTROL FOR UNIVERSAL COVERAGE TO ACHIEVE PRE_ELIMINATION STAGE IN THE GAMBIA. NA',\n",
       " '13020. USAID Systems for Better Health (S4BH). USAID SYSTEMS FOR BETTER HEALTH (S4BH). This activity will work with the Zambian government (GRZ) to develop and implement national strategies and plans that address challenges faced by the health sector, including the shortage of human resources, limited management and leadership skills among staff, inadequate coordination and integration of health programs, and weak public financial management systems. ~The activity will provide technical assistance to the GRZ to build the capacity of health managers and providers at all levels of the health system to plan, implement, monitor, and evaluate programs. ~The activity will also strengthen the capacity of community structures, such as Neighborhood Health Committees, to enhance community-level participation in the health sector. ~Additionally, this activity will support the implementation of community-level nutrition interventions to address chronic malnutrition in targeted districts, and safe motherhood interventions that support the Saving Mothers, Giving Life endeavor.',\n",
       " '13020. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. The project aims to improve the care of sick and premature newborns, in line with international standards',\n",
       " '12110. PDC C STOP antibiotic resistance. PDC C STOP ANTIBIOTIC RESISTANCE. The main purpose of the cooperation is to improve antibiotic use and contain resistance development in major Vietnamese hospitals through evidence based intervention. Cooperation between Linkping University, Oxford University Clinical Research Unit (OUCRU), National Hospital for Infectious Diseases (NHTD), Cho Ray and 14 other collaborative hospitals in Vietnam.',\n",
       " '13020. Leadership, Management, Governance (LMG). LEADERSHIP, MANAGEMENT, GOVERNANCE (LMG). The Leadership, Management, Governance (LMG) project builds in-country health and education system capacity by increasing leadership, management, and governance knowledge of health care providers, program managers, and policy makers who work on health services.',\n",
       " '13040. Wings to Fly: OVC Scholarship and Leadership Program - HIV/AIDS. WINGS TO FLY: OVC SCHOLARSHIP AND LEADERSHIP PROGRAM - HIV/AIDS. Wings to Fly is a public-private partnership between USAID, Equity Group Foundation, Mastercard Foundation, UKaid, and KfW. The project provides full scholarships that include tuition, room, and board to enable academically gifted but economically disadvantaged and vulnerable children to pursue secondary and tertiary education. The selected young people also receive leadership training, career guidance, and personal mentoring to help them maximize their potential.',\n",
       " '13040. Output 04: HIV. HIV. Ukraine - Kiev. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12240. MEASURE Evaluation Phase III - Nutrition. MEASURE EVALUATION PHASE III - NUTRITION. MEASURE Evaluation Phase III continues the MEASURE programs 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3)increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       " '12191. Support to Cardiovascular Diagnosis and Treatment / Telemedicine Support to Cardiology, Maternal and Child Health and Oncology. SUPPORT TO CARDIOVASCULAR DIAGNOSIS AND TREATMENT / TELEMEDICINE SUPPORT TO CARDIOLOGY, MATERNAL AND CHILD HEALTH AND ONCOLOGY. At Shastin Central Hospital cardiac surgery is available to one patient a day 25 days per year',\n",
       " '13020. Program Activity Fund. PROGRAM ACTIVITY FUND. The Australia-Indonesia Partnership (AIP) for Maternal and Neonatal  Health (MNH) aims for selected provincial and district governments in Eastern Indonesia to have mechanisms in place to manage national, local and donor resources to achieve national target levels for priority indicators contained within the Indonesian National Making Pregnancy Safer (MPS) Strategy. The objectives are: provincial and district governments develop and implement maternal and neonatal health (MNH) programs based on the national MPS strategy and address supply and demand aspects to achieve annual performance targets; provincial and district government agencies and communities access and manage the technical, human and financial resources needed to achieve improvements in MNH; and provincial and district governments manage Government of Indonesia (GoI) and donor resources to improve accountability, performance, accessibility and sustainability of public health services. The total value of this initiative is $76.4 million over 8 years, starting 2006-07.',\n",
       " \"13040. Scaling Up Coverage and Quality of HIV & AIDS Prevention targeted to Most at Risk Population and Treatment Care and Support Services to PLHA. SCALING UP COVERAGE AND QUALITY OF HIV & AIDS PREVENTION TARGETED TO MOST AT RISK POPULATION AND TREATMENT CARE AND SUPPORT SERVICES TO PLHA. Just over half a percent of Nepal's adult population is estimated to be HIV-positive. The low prevalence rate masks the imminent threat of an HIV pandemic due to the country's large male migrant population, the lack of voluntary counseling and testing services and the limited capacities of the authorities and health workers to address existing cases. The overall goal of the program supported by this grant is to reduce HIV transmission in Nepal and enhance the quality of life of people living with HIV in the country, focusing on West, Mid-West and Far-West development regions of Nepal. The program's interventions target mobile populations, injecting drug users and men who have sex with men, as well as people who are HIV-positive. Under the program, prevention efforts and community outreach through peer education and interpersonal communication will be scaled up to reduce the stigma related to HIV and to lower the barriers to accessing HIV and AIDS treatment and counseling services.\",\n",
       " '12181. Competency Based Clinical Based Teaching and Preceptor Workshops. COMPETENCY BASED CLINICAL BASED TEACHING AND PRECEPTOR WORKSHOPS. Funding under this activity supports capacity building of nursing profession in the province of Da Nang, Vietnam. South Australia Health will fund a four (4) day Competency Based Clinical Teaching  Preceptor Workshops to be delivered by the Queensland University of Technology (QUT) over a five year timeframe commencing 2013 - 2017. Trained Vietnamese nurses will go out to hospitals to conduct these workshops with the aim to build capacity in the nursing profession.',\n",
       " '12240. CIVIL SOCIETY PROGRAMME FUNDING SUPPORT SCHEME - 5 Increased decision-making power of women regardi. CIVIL SOCIETY PROGRAMME FUNDING SUPPORT SCHEME - 5 INCREASED DECISION-MAKING POWER OF WOMEN REGARDI. CIVIL SOCIETY -  Four-year programme grants have been allocated through a competitive funding mechanism to established NGO partners with a strong focus on results and the capacity to operate on a strategic basis.    HUNGER-ACIVIL SOCIETY PROGRAMME FUNDING SUPPORT SCHEME - 5 Increased decision-making power of women regardi-ng health & nutrition practices (micro) AgriNut Inequality Outcome',\n",
       " '12191. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. The project aims to establish a sustainable Neurosurgery Service and Training Programme in Ethiopia',\n",
       " '12220. Mobile Solutions Technical Assistance and Research (mSTAR) project - Other Public Health Threats. MOBILE SOLUTIONS TECHNICAL ASSISTANCE AND RESEARCH (MSTAR) PROJECT - OTHER PUBLIC HEALTH THREATS. The FHI 360 Mobile Solutions Technical Assistance and Research (mSTAR) project is a broad, flexible and responsive technical assistance and research program that is fostering the rapid adoption and scale-up of digital finance, digital inclusion and mobile data in developing countries. Ultimately, mSTAR seeks to increase access to and use of mobile and digital technologies by low-income individuals, civil society, local government institutions and private-sector stakeholders.',\n",
       " '12262. Global Health Support Initiative II (GHSI II) - Malaria. GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II) - MALARIA. The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the programs vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.',\n",
       " \"12261. NGO Support / Health Education Project of Diabetic Children and Juveniles. NGO SUPPORT / HEALTH EDUCATION PROJECT OF DIABETIC CHILDREN AND JUVENILES. The aim of the project is to support diabetic children youngsters and families by organising camps. In the camps there will be offered information about diabetes it's treatment and the meaning of the diet and exercise. To the camps also healhty children will participate. This helps in the socialisation and acceptance of the diabetic children. Also the mums can participate.In one camp there will participate 60 children 30 mums and 30 non-diabetic children each year for two weeks. In addition Girl Meetings will be organised as well as the Youth Clubs. Volunteers will be educated to know more about the treatment of diabetes and to leaders to the camp. In this second phase of the project the guidance focused on mums will be added as well as the preparation of the suitable diet.\",\n",
       " '12240. International Rice Research Institute. INTERNATIONAL RICE RESEARCH INSTITUTE. to address the problem of Vitamin A deficiency among millions of people in the Philippines and Bangladesh',\n",
       " '12220. Junior Professional Officer - JPO - WHO - Technical Officer - Convention Secretariat, WHO framework Convention on Tobacco Control. JUNIOR PROFESSIONAL OFFICER - JPO - WHO - TECHNICAL OFFICER - CONVENTION SECRETARIAT, WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL. Background :  The Junior Professional Officers (JPO) Programme, also known as the Associate Experts Programme, is a multilateral technical cooperation initiative sponsored by the Directorate General for Development Cooperation and Humanitarian Aid of Belgium. The Programme originaates from a United Nations Economic and Social Council resolution adopted in 1961 which approved and encouraged the collaboration of volunteers, financed by their respective countries of origin, in implementing development cooperation initiatives and programmes.  Belgium joined the Programme in 1963, and over the years has developed it into a Programme, extending its sponsorship to the Multilateral partnerl organizations with which the Belgian Government stipulated in specific agreements   -Global objective:  The Junior Professional Officers (JPO) Programme, also known as the Associate Experts Programme, is a multilateral technical cooperation initiative sponsored by the Directorate General for Development Cooperation and Humanitarian Aid of Belgium. The Programme originaates from a United Nations Economic and Social Council resolution adopted in 1961 which approved and encouraged the collaboration of volunteers, financed by their respective countries of origin, in implementing development cooperation initiatives and programmes.  -Specific objective :  Essential Qualifications and Experience required for this position: -Master degree in political science, development studies or international relations -Minimum 2 years of relevant work experience with concenration on international cooperation/development or health -Minimum knowledge of international development agenda, mechanisms and principles of aid effectiveness, and intergovernmental processes -Good writing and anatycal skills -Good IT and database skills -Excellent knowledge of English and French   -Intended results :  Upon completion of the assignment, the JPO will be able to:assist in day to day coordination with the development partners and international organisations. The JPO will be able to assist in tasks related  to the joint needs assessments and necessary follow up with governments, required liaison with the relevant WHO country offices. The JPO will be able to contribute to the overall objectives of the Secretariat to strenghten aid effectiveness, national ownership through implementation activities mandated by the Conference of the parties.  -',\n",
       " '13040. Ensuring Quality HIV/AIDS Services by Consolidating and Strengthening Existing HIV/AIDS Prevention, Treatment, Care and Support Programs. ENSURING QUALITY HIV/AIDS SERVICES BY CONSOLIDATING AND STRENGTHENING EXISTING HIV/AIDS PREVENTION, TREATMENT, CARE AND SUPPORT PROGRAMS. Ethiopia is one of the countries most affected by the HIV and AIDS pandemic, with an estimated 2.2 million citizens currently living with HIV. The program supported by this grant is designed to strengthen and expand the scale-up of social mobilization, care and support programs for people living with HIV and AIDS as well as orphans and children made vulnerable by HIV and AIDS. The program intends to increase coverage and adherence to antiretroviral therapy in 40 districts of four major regional states. The program also aims to enhance community ownership and response to HIV and AIDS with community conversation and other means, and mobilizing local communities to support orphans and vulnerable children. Mitigation of the social and economic impact of HIV and AIDS on people living with the disease and their families through job creation, income-generating activities and the provision of food and nutritional support to people living with HIV and AIDS and their families is another important component of the program.',\n",
       " '12263. Capacity Building for Laboratory Diagnosis and Tuberculosis Control. CAPACITY BUILDING FOR LABORATORY DIAGNOSIS AND TUBERCULOSIS CONTROL. Capacity Building for Laboratory iagnosis and Tuberculosis Control Programs at the National Lung Center of the Philippines',\n",
       " '12110. Contribution to Malawi Health Sector Strategic Plan 2011-2016. CONTRIBUTION TO MALAWI HEALTH SECTOR STRATEGIC PLAN 2011-2016. Background:  The Vision of the health sector is to achieve a state of health for all the people of Malawi that would enable them to lead a quality and productive life.  The Mission of the health sector is to provide strategic leadership by the Ministry of Health for the delivery of a comprehensive range of quality, equitable and efficient health services to all people in Malawi by creating an enabling environment for health promoting activities.  The Goal of the Health Sector Strategic Plan is to improve the quality of life of all the people of Malawi by reducing the risk of ill health and the occurrence of premature deaths, thereby contributing to the social and economic development of the country. -',\n",
       " \"12110. Urban Primary Health Care Services Delivery Project. URBAN PRIMARY HEALTH CARE SERVICES DELIVERY PROJECT. The Asian Development Bank (ADB) supported Urban Primary Health Care Project (UPHCP) is one of the largest public-private partnerships (PPP) in the delivery of primary health care (PHC) in South Asia. The Government of Bangladesh with the assistance of ADB implemented the First Urban Primary Health Care Project (UPHCP-I) from March 1998 to June 2005.  The Second Urban Primary Health Care Project (UPHCP-II), supported by ADB and the Governments of the United Kingdom and Sweden, commenced in July 2005 and was completed in December 2012.  A provision of $50 million has been made for the Bangladesh Urban Primary Health Care Services Delivery Project (UPHCSDP) in ADB's lending pipeline for 2012 in addition to $400,000 grant support for Supporting the Urban Primary Health Care Services Delivery Project in 2012. The UPHCSDP and the grant continue the provision of urban PHC, among others, through successful PPPs pioneered by UPHCP-I and II.   With a density of 2,756 people per square kilometer (km2) in urban areas and 843 people per km2 overall, Bangladesh is the most densely populated country in the world (excluding a few city-states).  Bangladesh is urbanizing at a rapid pace and the country's urban population is expected to reach 89.5 million (from 39.5 million in 2005) by 2030.  According to one estimate, by 2020 the urban poor figure could be as high as 40%-60% of the urban population.  Notwithstanding higher economic growth in urban areas, the absolute number of poor households is increasing in urban Bangladesh due to migration of rural poor into urban areas. Studies have shown that the health indicators of the urban poor are as worse as those of the rural poor because of poorer living conditions, and limited urban PHC. Failure to provide urban PHC can have serious negative externalities - spread of communicable diseases, debilitating epidemics, reduction in economic productivity, among others.\",\n",
       " '13040. Therapeutic and Supplementary Products for Improved Nutrition (TASPIN) Project - HIV/AIDS. THERAPEUTIC AND SUPPLEMENTARY PRODUCTS FOR IMPROVED NUTRITION (TASPIN) PROJECT - HIV/AIDS. The Production of Improved Nutrition Project aims to reduce the burden of under nutrition in vulnerable groups throughout Uganda. Key objectives of this project include; 1) Providing adequate and timely supply of ready to Use Therapeutic and supplementary Foods and Fortified Blended Foods; 2) Strengthen agricultural practices of small scale farmers; and 3) Empower households with vulnerable children with basic skills to improve nutrition, health and boost their livelihoods.',\n",
       " '13040. Food and Nutrition Technical Assistance III (FANTA-III). FOOD AND NUTRITION TECHNICAL ASSISTANCE III (FANTA-III). The Food and Nutrition Technical Assistance Project (FANTA) has been working to improve the health and well-being of vulnerable individuals, families, and communities in developing countries by strengthening food security and nutrition policies, programs, and systems. The project provides comprehensive technical support to USAID and its partners, including host country governments, international organizations, and nongovernmental organizations. FANTA works at both the country and global levels, supporting the design and implementation of programs in focus countries, and building on field experience to strengthen the evidence base, methods, and global standards for food security and nutrition programming.',\n",
       " '12191. The Project for Modernization of Medical Equipment in Municipal Clinical Hospital Sfantul Arhanghel Mihail. THE PROJECT FOR MODERNIZATION OF MEDICAL EQUIPMENT IN MUNICIPAL CLINICAL HOSPITAL SFANTUL ARHANGHEL MIHAIL. Purchase of medical equipments of Electrosurgery, Anesthesia Equipment and Anesthesia ceiling mounted pendant',\n",
       " '13020. Health Communication Capacity Collaborative (HC3) - Maternal and Child Health. HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3) - MATERNAL AND CHILD HEALTH. HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       " '12220. Contribution to Confidence Building Measures Program in Transnistria  Promoting Confidence in the Health Sector. CONTRIBUTION TO CONFIDENCE BUILDING MEASURES PROGRAM IN TRANSNISTRIA  PROMOTING CONFIDENCE IN THE HEALTH SECTOR. Population living in Transnistria has limited access to quality maternal and child health care. The vaccination coverage rate is declining and the number of premature and underweight newborns is increasing. The project aims to approximate maternal and child health care in Transnistria to international standards, as well as to improve the access to and quality of maternal and child health services at secondary and primary level. A special focus is put on nutrition and immunization. The project offers good opportunities for building trust across borders through common trainings of professionals and concerted efforts on immunization.',\n",
       " '13010. Applying Science to Strengthen and Improve Systems (ASSIST) - Administration and Oversight. APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST) - ADMINISTRATION AND OVERSIGHT. The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       " '13010. 06. 4 COMM LEADERS & CSOS HAVE KNOWLEDGE. 06. 4 COMM LEADERS & CSOS HAVE KNOWLEDGE. 06. 4 COMM LEADERS & CSOS HAVE KNOWLEDGE',\n",
       " '12182. Artemisinin Resistant Malaria Programme Oxford Contract - research. ARTEMISININ RESISTANT MALARIA PROGRAMME OXFORD CONTRACT - RESEARCH. To rapidly identify new knowledge and put in place wider geographical research which can be used to contain resistance',\n",
       " '12182. RESEARCH COOPERATION WITH UEM, MOZ, 2011-2016 - INHACA 2014. RESEARCH COOPERATION WITH UEM, MOZ, 2011-2016 - INHACA 2014. The program objective is to strengthen higher education and national research systems, through direct support to research, postgraduate training and development of institutional capacity for research management within the University of Eduardo Mondlane (UEM). The contribution period covers 2011-2015. Comp. 3; financing of 4 MSc programs. Comp. 5; additional support to MBR at Inhaca.',\n",
       " '12110. Study visit - insurance against accidents at work and occupational diseases. STUDY VISIT - INSURANCE AGAINST ACCIDENTS AT WORK AND OCCUPATIONAL DISEASES. Familiarization with Slovak system of employer liability insurance for accidents at work and occupational diseases and diseases related to work and to the particular services to employees (for the payment of compensation). Slovak Republic as the only country from the former communist countries reformed the area of occupational accidents and occupational diseases within the insurance system, which is able to record and quantify the cost and source components.',\n",
       " '13010. Interrelations between public policies, migration and development of partner countries: case studies and policy recommendations. INTERRELATIONS BETWEEN PUBLIC POLICIES, MIGRATION AND DEVELOPMENT OF PARTNER COUNTRIES: CASE STUDIES AND POLICY RECOMMENDATIONS. The overarching objective of the project is to enhance partner countries  capacity to incorporate the migration dimension into the design and implementation of their development strategies and other public policies through a better understanding of the implications of public policies on migration matters.',\n",
       " '12181. ForSa - Training in Health services. FORSA - TRAINING IN HEALTH SERVICES. Increase the capacity and performance of health services by improving the pedagogical and organizational capabilities of the Faculty of Medicine and Health Science East Timor',\n",
       " '13020. OUTPUT 3.1:NORMES SOCIALES POSITIVES. OUTPUT 3.1:NORMES SOCIALES POSITIVES. NA',\n",
       " \"12240. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       " '12181. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Feasibility Study',\n",
       " '12220. AC_89_Antimicrobial resistance_12220. AC_89_ANTIMICROBIAL RESISTANCE_12220. Antimicrobial resistance',\n",
       " \"12110. Delivering Healthy Diets to Low-Income Families through Community Kitchens in Peru. DELIVERING HEALTHY DIETS TO LOW-INCOME FAMILIES THROUGH COMMUNITY KITCHENS IN PERU. Non-communicable diseases (NCDs) are a major cause of death in Peru, accounting for 60% of deaths in 2010. Unhealthy diet is one of the four major risk factors for NCDs. Researchers will explore ways to promote healthy dietary habits among residents of Lima's poor urban communities who use the city's Comedores Populares, or community kitchens. These kitchens provide more than 500,000 lunches to Peruvian families living in poverty. Established in 1978 to respond to poverty and the economic crisis, there are more than 15,500 Comedores Populares in Peru today, with 5,000 located in Lima. Low-income women serve soup plus a dish made of rice and legumes at a cost of CA$0.75 each. The menus rarely include fruits and vegetables.This project will combine qualitative methodologies and tools common to public health research, health economics, and behavioral economics to explore opportunities, barriers, and preferences for healthy foods. Researchers will use the information to design and implement strategies to promote healthier food choices in the Comedores Populares. One approach will increase the use of fruits and the other will reduce the use of products with high saturated fat and salt in prepared foods.\",\n",
       " '12240. GIMBUKA - Nutrition. GIMBUKA - NUTRITION. Caritas-Rwanda will continue to improve the nutritional status of mothers and children (especially those under 2 years of age) through community-based interventions in nine districts. The project will seek to improve the well-being of HIV/AIDS-affected orphans and vulnerable children (OVC) and improve the nutritional status of adults living with HIV through cooking demonstrations, nutrition assessments (anthropometric measurements) and nutrition counseling. Of the 73,482 people supported under this program, 14,416 are OVCs, 36,000 are children under five years, and 7,200 are pregnant and lactating women. The project uses cost effective community-based solutions like internal savings and loan groups, farmers field schools and the positive deviance hearth model to address nutritional and financial needs of beneficiaries, with emphasis on resilience and empowerment through economic strengthening, food security, nutrition and hygiene, and increased access to health services.',\n",
       " '12250. Global Health Support Initiative II (GHSI II) - Pandemic Influenza and Other Emerging Threats (PIOET). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II) - PANDEMIC INFLUENZA AND OTHER EMERGING THREATS (PIOET). Global Health Support Initiative II (GHSI II)',\n",
       " '12240. Nutrition Bio-fortification. NUTRITION BIO-FORTIFICATION. To improve the food and nutrition security of 350,000 small holder farmers in 8 rural districts of Zimbabwe by raising farm productivity through training of farmers and introducing improved agricultural practices, linking the farmer groups to input and ou',\n",
       " '12191. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Establishing a sustainable Neurosurgery Service and Training program in Malawi and giving Norwegian nurses important training',\n",
       " '12220. Health project to cure the hare lip. HEALTH PROJECT TO CURE THE HARE LIP. The project supports the surgery to treat the hare lips and provides health care to the infants affected by hare lips',\n",
       " \"12281. Strengthening primary care capacity in by training of practitioners in paediatrics to help China's economic development and the health of its poor.. STRENGTHENING PRIMARY CARE CAPACITY IN BY TRAINING OF PRACTITIONERS IN PAEDIATRICS TO HELP CHINA'S ECONOMIC DEVELOPMENT AND THE HEALTH OF ITS POOR.. The project is designed to draw on UK expertise to strengthen the training of Chinese GPs in paediatrics to improve their skills across diagnoses and treatments, in pilot cities. This project will enable primary care institutions to take on more responsibilities in dealing with child medical issues, relieving pressure on tertiary paediatric services. Chinese policy makers will use the pilot report to inform the establishment of tiered treatment guidelines. This is expected to generate commercial and collaborative opportunities for international entities, including UK ones.\",\n",
       " '13040. PEPFAR Health Bilateral Program. - HIV/AIDS. PEPFAR HEALTH BILATERAL PROGRAM. - HIV/AIDS. The program supports South African organizations that identify, strengthen, and institutionalize better, cost-effective practices and innovations in HIV and AIDS care and treatment for priority and at-risk populations in accordance with South African government (SAG) priorities and policies.',\n",
       " '12262. SANTE-HEALTH 2006/105-398 Integated project to malaria control program in ChokwT region. SANTE-HEALTH 2006/105-398 INTEGATED PROJECT TO MALARIA CONTROL PROGRAM IN CHOKW+ REGION. Fighting malaria in the region of ChokwT: a) Reduction of mortality rate caused by the disease, b) Prevent further outbreaks of infection.',\n",
       " \"12220. Voice of the Poor in Health Policy - Linking Voice of the Poor to Health Policy. VOICE OF THE POOR IN HEALTH POLICY - LINKING VOICE OF THE POOR TO HEALTH POLICY. Sida has been supporting the Health Sector Programme in Bangladesh implemented by the Ministry of Health and Family Welfare. Up to 15 000 000 SEK was allocated for follow up, reviews and studies to strengthened the work of Sida on sexual, reproductive health and rights, gender equality and universal health care. Sida also expressed its intention to monitor the sector program progress on these key issues in partnership with civil society organization. The proposed contribution will enable women, men and children living in poverty to influence the preparation of the 4th health sector program. The Embassy decided to engage UBINIG through a simplified tendering method to implement the assignment as per the agreed ToR ( Annex 1). The purpose of this intervention is to support the Embassy in the appraisal of the new sector programme support 2017-2020 and strengthen the grassroots' network by linking the voice of the poor to the new health sector policy. The total budget of the assignment is 450 000 SEK and it will be paid in three installments. The first payment on 180 000 SEK will be given as an advance for timely implementation of all scheduled activities. The reason for the advance payment is that UBINIG do not have special funds budgeted to get started with the assignment. The budget will be charged from already allocated Resources from the health sector programme HPNSDP (51060001, component 2 on Technical Assistance).\",\n",
       " '12110. Appui a la politique et reprTsentation pour assister les dTcideurs politiques dans la formulation des politiques et des stratTgies et les assister dan. APPUI + LA POLITIQUE ET REPR+SENTATION POUR ASSISTER LES D+CIDEURS POLITIQUES DANS LA FORMULATION DES POLITIQUES ET DES STRAT+GIES ET LES ASSISTER DAN. General Objectives  To strengthen the rational basis and the country ownership of (human and animal) healthcare systems and policies in developing countries, in order to improve the health status ofthe populations and thereby to contribute to the reduction of poverty and inequity.  Specific Objectives  To assist adequately Belgian policy makers in decision-making, policy formulation and representationregarding technical and strategic issues in international health. Results  Result 1 Belgian policy makers receive (up-to-date) information on technical and policyissues in international health when requested (2011 + 2013)Result 2 Policy Research Topics have been identified, research has been carried outand its results have been presented to DGDC (2011 + 2013)Result 3 The Belgian representation is scientifically supported at international forumsconsidered relevant by the policy makers (2011 + 2013)Result 4 Coordination mechanisms have been put in place between DGDC/FA and ITM(2011 + 2013)',\n",
       " '12240. Right to food and subsistence methods in Kenya in the counties of Isiolo, Garissa, Kissi, Kakamega. RIGHT TO FOOD AND SUBSISTENCE METHODS IN KENYA IN THE COUNTIES OF ISIOLO, GARISSA, KISSI, KAKAMEGA. The project wants to implement and extend to other counties (Garissa, Kissi, Kagamega) basic training for local communities and associations on rights to food security, the development of inculturated and sustainable technologies for food production and storage, participatory ideation and joint implementation of advocacy actions directed towards the local administration through the establishment of representative committees in villages and religious communities (parishes and Muslim communities). The expected beneficiaries are about 890 individuals divided into about 20 local associations, while awareness campaigns envisage reaching about 20,000 people.',\n",
       " '13030. Social Health Protection (SHP). SOCIAL HEALTH PROTECTION (SHP). The Social Health Protection project will reduce financial barriers to health services for the poor by increasing the nationwide coverage of the public-sector health insurance program known as the Health Equity Fund. This fund enables the poor to access and pay for quality health services, thereby mitigating the effects of disease and sickness while reducing the financial burden of health-care costs on the poor. Activities will strengthen the ability of the national and district-level governments to administer health insurance, link reimbursements to improved health services, include civil society and communities in oversight of the enrollment process to ensure more transparency, and revise the package of health services provided to the poor to include priority services. The U.S. government will help expand the Heath Equity Fund across all of Cambodia and provide three million poor Cambodians with access to healthcare without forcing them into further financial hardship.',\n",
       " '12250. The Royal Institute of International Affairs. THE ROYAL INSTITUTE OF INTERNATIONAL AFFAIRS. to convene a group of experts to discuss the value of vaccines in reducing the impact of antimicrobial resistance',\n",
       " '12181. Transfer of Know-How concerning medical techniques und practices of rehabilitation into the Pepublic of Moldova. TRANSFER OF KNOW-HOW CONCERNING MEDICAL TECHNIQUES UND PRACTICES OF REHABILITATION INTO THE PEPUBLIC OF MOLDOVA. Transfer of know-how in the medical field of rehabilitation and advanced training of young Moldavian doctors by German experts through theoretical and practical knowledge transfer in a workshop, a congress as well as job shadowing.',\n",
       " '12110. Improving the system of civil registrations for the child rights identity- Identification for development-phase 2. IMPROVING THE SYSTEM OF CIVIL REGISTRATIONS FOR THE CHILD RIGHTS IDENTITY- IDENTIFICATION FOR DEVELOPMENT-PHASE 2. The initiative seeks to ensure children s right to identity, to ensure their access to basic services and protect them from violence, abuse and exploitation, through the enhancement of of the regional system of birth registration and the standardization of the national system of civil records in two regions of Ethiopia to high incidence of migration.',\n",
       " '12263. Kinerja - Tuberculosis. KINERJA - TUBERCULOSIS. The overarching objective of this IM is the provision of innovative and improved service delivery by local governments to citizens. USAID focuses on the governance of service delivery in three sectors: education; health services and; and local business. Activities under this IM address both demand and supply side aspects of service delivery. These investments will result in strengthened accountability mechanisms that improve local government responses to citizens needs. USAID works through local institutions to build their capacity and foster sustainable partnerships with local government. This solidifies the links between stimulation of demand for good services through active civil society engagement and improved local government response.',\n",
       " '16064. Output 04: HIV. HIV. Angola - Luanda. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '13030. Afya Jijini. AFYA JIJINI. Afya Jijini will support integrated health service delivery in Nairobi County. Support for integrated services include HIV; tuberculosis; reproductive, maternal, newborn and child health; nutrition; WASH funds will support: HIV prevention, care and treatment interventionsANC, SBA, emergency obstetric care and essential newborn carePrevention and management of diarrhea and pneumonia through ORS/zinc, appropriate treatment and BCC in facility and community WASH activities through community sanitation, household and school-based hygiene practices ?Routine immunization; provision of quality nutrition services; capacity building on maternal and child nutrition; and provision of equipment, job aids and guidelinesForecasting, quantification and reporting of essential commodities at facility levelFP skills building, mentorship, counselling and provision of services in public and private sector facilities and by community health workers',\n",
       " '12240. International Food Policy Research Institute. INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE. to promote evidence-based nutrition policy and program decision-making and thus accelerate reductions in maternal and child undernutrition in India',\n",
       " '13020. HealthTech V. HEALTHTECH V. HealthTech develops, adapts, evaluates and/or facilitates the introduction of affordable and appropriate technology solutions for the safe, effective, and more equitable distribution of health care services in low-resource countries. This project will address implementation barriers (e.g., issues with technical design, supply chain management, and policy) that typically prevent innovative technologies from reaching the most vulnerable populations. A significant focus of this project will be the advancement of health technologies through commercialization efforts.',\n",
       " '12240. Project research. PROJECT RESEARCH. Project research',\n",
       " \"16064. NGO Support / AIDS Project  The Good Samaritan. NGO SUPPORT / AIDS PROJECT  THE GOOD SAMARITAN. Good Samaritan Program (GSP) is a pan-African program by the United Bible Societies. It is implemented in over 20 countries in Africa and coordinated by HIV service. Bible Society of C=te d'Ivoire (BSCI) has the main responsibility in the grass root level implementation.The overall objective of the project is to contribute to the reduction of the spread of HIV and stigmatization of people infected and affected. Project aims to involve church partners and communities to  HIV work. In the core of the GSP are human rights: PLHA as well as their families deserve to be treated equally with other members of the society. Rights based and gender sensitive approach is directly linked with Christian values. GSP is contributing to the C(te d'Ivoire national policies where reducing the stigma of PLHA and avoid new infections are the prioritiesGood Samaritan program will not intervene directly in the sector of health care but use partnership and guide people in need to the suitable aid providers. However through communication advocacy and disseminating adequate health information GSP has means to change opinions and contribute to the common goals defined by UNAIDSGSP trainings are based on multimedia package which includes booklets videos and flipcharts for trainees and manuals for trainers. The package is available in English and French (including Braille) and it is translated into local languages. The key project activities include Sensitization for leaders Training of Trainees (ToT) Decentralized Workshops (DWs) Follow up (FU) home visits and Take Charge (TC).Like during the 1st and 2nd project phase GSP targets churches local congregations and communities. However for the 3rd phase of the project BSCI has special focus on two topics:- To integrate deaf to the project - To focus on the families to prevent parent to child transmission and to reduce the infections among  couplesGSP staff has witnessed the lack of correct information about HIV among deaf communities. Deaf audiences can be heavily affected by HIV but often left out from development projects. GSP's aim is to integrate deaf to the project by cooperation with deaf schools and organizations with specifically designed materials. Fidida will provide external consultation in FinlandBecause of the high infection rates among couples GSP also focuses on pregnant women and couples. Objective is to raise awareness and responsible behavior and prevent parent to child transmiss\",\n",
       " '12240. Strengthening Partnerships, Results, and Innovations in Nutrition Globally (SPRING) - Nutrition. STRENGTHENING PARTNERSHIPS, RESULTS, AND INNOVATIONS IN NUTRITION GLOBALLY (SPRING) - NUTRITION. SPRING/Ghana aims to reduce stunting by 20 percent in two regionsNorthern Region and Upper East Region. Working in 15 districts within these two regions, SPRING/Ghanas activities include anemia reduction, infant and young child nutrition; water, sanitation, and hygiene; aflatoxin reduction; community video; and support to the LEAP 1000 cash transfers. SPRING/Ghana defines its activities through the 1,000 Day Household (linked to 2-pager) approach, which targets households with pregnant women and children 2 years of age and younger. This approach synthesizes each intervention area into a holistic approach designed to support the ability of the1,000 day household to care for and support the 1,000 day child.',\n",
       " '13040. Comprehensive District-Based Support for Better HIV/TB Patient Outcomes (Hybrid) - HIV/AIDS. COMPREHENSIVE DISTRICT-BASED SUPPORT FOR BETTER HIV/TB PATIENT OUTCOMES (HYBRID) - HIV/AIDS. FPD is implementing the Comprehensive District Health Team Support (CDHTS) TA model. The goal is to foster a public sector management culture that is based on effective leadership by professional managers who are committed to: providing integrated high quality services based on GoSA policy; working in partnership with civil society; using strategic information to guide decision making; and improving the quality of services and patient outcomes. In partnership with GoSA, FPD will: i) develop and inform strategies to help Districts realize the 10 Point Plan, including NSP on HIV/AIDS, PHC Re-Engineering Strategy, NHI and the Minister of Healths NSDA in line with the PIPF; ii) support district management to draft, implement and monitor progress against District Health Plans, related plans and expenditure reviews; and iii) support districts to achieve and maintain targeted levels of performance for PEPFARs priority areas, in particular TB/HIV.',\n",
       " '12250. 005 POLIO. 005 POLIO. 005 POLIO',\n",
       " '12110. Medical Education Reforms in the Kyrgyz Republic. MEDICAL EDUCATION REFORMS IN THE KYRGYZ REPUBLIC. SDC has been providing support to the Medical Education Reforms in Kyrgyzstan since 2008 with backstopping support from the H(pitaux Universitaires de GenFve. Despite several political disturbances, the reforms in medical education have made good progress in revising and introducing new standard curriculum at undergraduate level. There is however still need to further design and implement new modules at undergraduate level and to reform postgraduate and continued medical education. This project will thus further support the medical education reforms implemented under the leadership of the Ministry of Health.',\n",
       " \"13040. Scaling up HIV and AIDS Prevention, Care and Treatment and Strengthening Management, Increasing Demand and Ensuring Quality of HIV/AIDS/STI Interventions in Lao PDR. SCALING UP HIV AND AIDS PREVENTION, CARE AND TREATMENT AND STRENGTHENING MANAGEMENT, INCREASING DEMAND AND ENSURING QUALITY OF HIV/AIDS/STI INTERVENT. The Lao People's Democratic Republic is classified among countries suffering from a high burden of HIV/AIDS.  The prevalence among female sex workers (FSWs) doubled over the year of 2001 to 2004 from 0.9 percent to 2 percent and decreased to 0.5 percent in 2008.   The prevalence among men having sex with other men (MSM) appears to differ between locations, with 5.6 percent in the capital, Vientiane.  In 2008, responses to potentially growing threat of HIV resulted to drafting of an HIV law, funding approval of two Global Fund grants focusing on treatment and care efforts, continuing inclusion of HIV in national priorities, expansion of people living with HIV (PLHIV) networks and involving in their policy and program making, and development of a multi-sectorial monitoring and evaluating five-year strategic plan.  The current grant is a Single Stream Funding (SSF) consolidated Round 4, 6 and 8 HIV programs.  It is expanding the interventions to cover identified gaps in coverage, addressing weaknesses in implementation capacity, and strengthening civil society organizations.  The grant also aims to improve the regulatory process, including amending applicable laws and regulations to better enable enforcement and gain efficiencies in the registration process.\",\n",
       " '12263. IMPLEMENTATION OF NEW MOLECULAR TESTING FOR TUBERCULOSIS IN HIGH BURDEN SETTINGS IN SUB-SAHARAN AFRICA. IMPLEMENTATION OF NEW MOLECULAR TESTING FOR TUBERCULOSIS IN HIGH BURDEN SETTINGS IN SUB-SAHARAN AFRICA. The Project would be implemented as part of more comprehensive national plan to roll out Xpert technology in selcted countries in Sub-Saharan Africa (Burkina Faso, Ethipia, Mozambique) to increase access to rapid diagnosis of TB and MDR-TB and to strengthen capacity of local laboratories. An other objective of the Project is to coordinate and provide technical assistance and monitor establishment of sustainable models of programmatic management of TB and MDR-TB in proposed settings and to facilitate new policy making and production of guidelins at national level.',\n",
       " \"13020. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       " '12263. World Health Organization. WORLD HEALTH ORGANIZATION. to promote effective, affordable, cost-effective, and financially-sustainable diagnosis through treatment of multidrug-resistant tuberculosis in China',\n",
       " '12191. Building Palestinian resilience: improving psychosocial and mental health responses to emergency situations. BUILDING PALESTINIAN RESILIENCE: IMPROVING PSYCHOSOCIAL AND MENTAL HEALTH RESPONSES TO EMERGENCY SITUATIONS. The objective is to build and reinforce the resilience of Palestinian institutions and population to cope with conflict triggers and uncertainty, notably in post-conflict Gaza. Specific objectives include (i) to scale-up emergency preparedness and response  by developing national emergency response plan, establishing skilled mental health teams, providing psycho-tropics and integrating long-term rehabilitation service to trauma victims into health and education services  (ii) to support the Mini',\n",
       " '13040. HIV/AIDS - Treatment/ Pediatric Treatment - Assistance for HIV/AIDS. HIV/AIDS - TREATMENT/ PEDIATRIC TREATMENT - ASSISTANCE FOR HIV/AIDS. PEPFAR: HIV/AIDS - Including infrastructure, training clinicians and other providers, exams, clinical monitoring, related laboratory services, and community-adherence activities. Clinical monitoring and management of opportunistic infections is classified under Pediatric Care and Support. - Assistance for HIV/AIDS',\n",
       " '13030. Administration and Oversight (FP). ADMINISTRATION AND OVERSIGHT (FP). Supports the following illustrative program-funded costs: salaries of US, FSN, and TCN and other staff such as PSCs, RSSAs, PASAs, CASUs working for the US Government managing, administering, and supporting programs and their program-funded benefits such as housing, travel, transportation, education allowances etc; institutional contractors that provide such staff, rent, IT services, the program-funded share of utilities, staff training costs and the cost of developing and administering training programs, equipment and supplies, ICASS, vehicle fuel and maintenance, maintenance contracts, janitorial services, operational unit web page development and maintenance, outreach such as publications and the cost of their preparation (including staff costs), and technical assistance to ensure USG compliance with regulations.',\n",
       " '12191. Support to Psycho-Rehabilitation Center. SUPPORT TO PSYCHO-REHABILITATION CENTER. A Psycho-Rehab. Center provides free medical and psychological assistance to all locals in need. Center is a place to get primary medical observation, treatment, psychological aid, a spot for intercourse, to meet persons with similar interests, get moral support. Citizens of Gali, Ochamchire,Tkhvarcheli will be delivered psychological consultations, provided medical observation, given prescriptions for treatment; for them will be organized public meetings aiming at improving their psych. state and rise adultsO awareness of drug-related deceases, harm of smoking, contagious deceases, physiology, norms of hygiene, gender relations. Such kind of the activities will help them to improve and control their health, to better psychological state and return incentive to life so crucial in the current circumstances when access to similar psychosocial assistance on the GeorgiaOs controlled territory is almost impossible.',\n",
       " '13020. Society for Applied Studies. SOCIETY FOR APPLIED STUDIES. to enable these high quality sites in India to come together as a network, harmonize their protocols, collaborate both internally and globally to advance Healthy Birth Growth and Development agenda',\n",
       " '12240. Health Communication Capacity Collaborative (HC3). HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3). HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       " \"12261. F.a: Ebola wareness campaign. F.A: EBOLA WARENESS CAMPAIGN. The development problem is Ebola epidemic which has reversed the post-conflict economic and social development in the country. The project aims to increase the awareness and knowledge of people in the communities of Cape Mount, Bomi, Margibi and Bong counties on the issues affecting their well-being especially on Ebola, and to strengthen their ability to act in order to promote theirs, their families' and their communities' wellbeing, especially to prevent further contagion of the Ebola disease.  The immediate objectives of the Project are 1) 1000 facilitators have participated in Ebola awareness training and gained skills to facilitate Ebola dialogue session in the communities, 2) 500 communities has received participatory community training on Ebola and taken measures to prevent the spread of the disease. Communities are offered awareness raising trainings on Ebola delivered by facilitators trained in cooperation with National Adult Education Association in Liberia, FRC's national partner organisation. Other co-operating partners are national and local authorities, especially Liberian Ebola communication coordination group lead by UNICEF. It is estimated that the project will benefit 50000 households in 500 communities.\",\n",
       " '13030. CapacityPlus - Family Planning and Reproductive Health. CAPACITYPLUS - FAMILY PLANNING AND REPRODUCTIVE HEALTH. This project strengthens the human resources (HR) needed to implement quality health programs, in both the public and private, particularly the not-for-profit private, sectors. It addresses both the number of healthcare workers needed and the quality and performance of those workers. The definition of healthcare worker is expanded to include HR managers, laboratory staff, pharmacists, social workers, information systems/monitoring and evaluation specialists and others essential to the effective functioning of the health system.',\n",
       " '13030. UNICEF PIO - Family Planning and Reproductive Health. UNICEF PIO - FAMILY PLANNING AND REPRODUCTIVE HEALTH. The Health Pooled Fund (HPF) is one of the Government of Ethiopias preferred modalities for scaling up development partners assistance in support of HSDP IV. UNICEF has been substantially involved in the implementation of the Health Sector Development Plan (HSDP IV) since the introduction of the Health Pooled Fund (HPF). Through this mechanism, USAID is contributing to the Health Pooled Fund. This activity is an effective and efficient way to achieve USAID objectives through ensuring the accessibility of effective health services at all levels of the health system. This activity supports HSDP IV implementation through monitoring and evaluation; the development of studies/research; development of standards, guidelines, and manuals; and promotion of policy dialogue workshops such as woreda-based planning and the Annual Review Meeting (ARM). The project also supports participation of Ministry staff in relevant seminars and study trips to enhance program excellence.',\n",
       " '12181. MEDICAL TRAINING. MEDICAL TRAINING. Financing an agreement with the Kingdom of Morocco in the field of health sciences',\n",
       " '12110. Evaluation of Rajiv Aarogyasri Health Insurance Scheme in Andrha Pradesh, India. EVALUATION OF RAJIV AAROGYASRI HEALTH INSURANCE SCHEME IN ANDRHA PRADESH, INDIA. In 2007, out-of-pocket expenditures accounted for 90% of total private expenditure on healthcare in India. The cost of coping with serious disease can be ruinous for families living below the poverty line. The Rajiv Aarogyasri Health Insurance Scheme was established in Andrha Pradesh to mitigate catastrophic healthcare expenses for enrolled families, and to ensure that the target population has access to quality health services for serious illnesses.Aarogyasri currently covers more than 80% of the population of Andrha Pradesh. As one of the first schemes of its kind at this scale, Aarogyasri has generated national and international interest. A detailed evaluation is critical not only to keep improving the scheme, but also to ensure that the lessons learned from it benefit other states and countries. The Aarogyasri Trust Board has therefore asked a consortium of institutions to evaluate the scheme and consider its potential role in prevention and primary healthcare. This project is a response to that request. The evaluation will also establish a baseline for future evaluations, identify areas for further research, and build capacity for research, evaluation and evidence-based policymaking in India.',\n",
       " \"12263. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       " '12250. University of Chinese Academy of Sciences. UNIVERSITY OF CHINESE ACADEMY OF SCIENCES. to develop and conduct the first Chinese Version Vaccinology Course, in order to enhance the scientific perspectives of vaccine and immunization in all the stakeholders and optimize the ecosystem of immune community in China',\n",
       " '13040. The Scripps Research Institute. THE SCRIPPS RESEARCH INSTITUTE. to provide general operating support',\n",
       " '12230. Egypt-Swiss Radiology Project Phase III. EGYPT-SWISS RADIOLOGY PROJECT PHASE III. Egypt-Swiss Radiology Project Phase III. After the successful implementation of the First Phase, which started in 2002, with the financing of 80 radiology equipments and film processors, a second phase was initiated in 2007 and completed in 2011. The objective of this phase was to extend the modernisation of the radiology services in Egyptian hospitals. Digital radiology was introduced in pilot sites. These activities were performed in this project: the rehabilitation of sites receiving improved radiology services and equipment, the provision of radiology equipment, the assistance for the maintenance of the radiology technology and the training and capacity building programme for the radiology staff. At the end of the project, over 100 radiology departments in selected hospitals, including structural radiation safety were renovated and rehabilitated according to defined standards. Moreover, the equipment maintenance and technology management was strengthened and the radiation safety by training measures and supervision schemes was applied. Finally, digital radiology was tested in pilot sites to be extended in the 3rd phase that started in 2012. The implementing agency for this project is the Egyptian Ministry of Health and Population. This is a project mixed-financed by Switzerland (50% by SECO, 50% by Swiss banks).',\n",
       " '12182. DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE: EQUITABLE PREVENTION ACROSS GENERATIONS? FOLLOW-UP OF THE MINIMAT RANDOMIZED TRIAL IN BANGLADESH. DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE: EQUITABLE PREVENTION ACROSS GENERATIONS? FOLLOW-UP OF THE MINIMAT RANDOMIZED TRIAL IN BANGLADESH. This project - follow-up of the MINIMat trial - is implemented in Bangladesh, in a context, where food insecurity and maternal malnutrition still prevail, but where changing lifestyles and economic growth potentially increase the risk for future chronic disease of the offspring. Pregnant women were randomised to an early (E) start of prenatal food supplementation vs. usual program start, and multiple micronutrient supplementation (MMS) vs. iron-folate. Participants were followed-up for primary outcomes (maternal haemoglobin, birth weight, and infant survival) and for a series of secondary outcomes based on the Developmental Origin of Health and Disease hypothesis. So far we have demonstrated a remarkable effect of E-MMS on infant and under-five survival, and effects of the interventions on childhood stunting and metabolic markers at 4.5 years. We aim at studying whether the effects of the prenatal interventions on growth and metabolic markers up to 4.5 years are sustained at 10 years, to evaluate if these interventions reduce health disparities, and whether social conditions and maternal stressors modify the effect on children of the interventions, and to analyse the public health impact and the cost-utility of the interventions in order to inform policy and possibilities for scaling-up.',\n",
       " '13020. Strengthening Human Resources for Health (SHRH) - Capacity follow on. STRENGTHENING HUMAN RESOURCES FOR HEALTH (SHRH) - CAPACITY FOLLOW ON. SHRH will be a bilateral associate award under the Capacity Plus Leader with Associate award. Building upon the Uganda Capacity Program and continuing HRH interventions which were shown to produce higher level results, SHRH will further expand in the area of pre-service training capacity and performance based incentives. SHRH will develop the capacities of the central ministries, districts and professional councils to effectively and efficiently manage their HR for delivery of health services. It will work with USG implementing partners to ensure targeted HRH improvements at the service delivery level. Expected results in FY 2014 includes: scale-up of HR information system and recruitment plans in all 112 districts; comprehensive support for district level HRH to all USG implementing partners; and improved regulation and functionality of health professional councils.',\n",
       " '12110. Technical Assistance to Strengthen Leadership for Reform in Ministry of Health. TECHNICAL ASSISTANCE TO STRENGTHEN LEADERSHIP FOR REFORM IN MINISTRY OF HEALTH. To improve the performance of the Zambian public sector by providing advice and equipment to the Government of Zambia. This will strengthen performance management and contribute towards our MDGs by improving the quality of public services for 13 million Z',\n",
       " '13040. Strengthening Partnerships, Results, and Innovations in Nutrition Globally (SPRING) - HIV/AIDS. STRENGTHENING PARTNERSHIPS, RESULTS, AND INNOVATIONS IN NUTRITION GLOBALLY (SPRING) - HIV/AIDS. Strengthening Partnerships, Results, Innovations in Nutrition Globally (SPRING)',\n",
       " '12262. Malaria - Administration and Oversight (Malaria). MALARIA - ADMINISTRATION AND OVERSIGHT (MALARIA). Malaria - Supports the following illustrative program-funded costs: salaries of US, FSN, and TCN and other staff such as PSCs, RSSAs, PASAs, CASUs working for the US Government managing, administering, and supporting programs and their program-funded benefits such as housing, travel, transportation, education allowances etc; institutional contractors that provide such staff, rent, IT services, the program-funded share of utilities, staff training costs and the cost of developing and administering training programs, equipment and supplies, ICASS, vehicle fuel and maintenance, maintenance contracts, janitorial services, operational unit web page development and maintenance, outreach such as publications and the cost of their preparation (including staff costs), and technical assistance to ensure USG compliance with regulations.',\n",
       " '12181. University of Geneva. UNIVERSITY OF GENEVA. To train health leaders from developing countries in decision-processes related to vaccination policies and assessment of new vaccines against major infectious diseases through participation in 12th annual Advanced Courses of Vaccinology',\n",
       " '12182. RESEARCH COOPERATION WITH UEM, MOZ, 2011-2016 - ISP MSC-PROGRAMMES, ADD 1. RESEARCH COOPERATION WITH UEM, MOZ, 2011-2016 - ISP MSC-PROGRAMMES, ADD 1. The program objective is to strengthen higher education and national research systems, through direct support to research, postgraduate training and development of institutional capacity for research management within the University of Eduardo Mondlane (UEM). The contribution period covers 2011-2015. Comp. 3; financing of 4 MSc programs. Comp. 5; additional support to MBR at Inhaca.',\n",
       " \"13020. Strengthening the Public Financial Management (PFM) Systems. STRENGTHENING THE PUBLIC FINANCIAL MANAGEMENT (PFM) SYSTEMS. This contract will operationalize the Mission's Country Development Cooperation Strategy by supporting collaboration among targeted government ministries, local government bodies, USAID, and other donors. Activities will include targeted technical and organizational capacity building to strengthen the Government of Nepal's (GON) ability to meet demands for increased and improved public services. The activities will address issues of transparency, reporting and public financial management, especially targeted at good governance interventions impacting Presidential Initiative programming. Using technical assistance for targeted GON Ministries and their sub-national representatives, the governance activities will focus on capacity building and service delivery, while supplementing the reach of the current democracy and governance portfolio. The activity will be based on a targeted Ministry-level Public Financial Management Risk Assessment Framework conducted in 2012-2013. These assessments, including for Ministry of Health and Population (MOHP) and Ministry of Education (MOE), laid the foundation for future investments in building the capacity of targeted Ministry's financial and administrative processes by revealing several major areas of need. These gaps include critical deficiencies in the areas of: budget execution; procurement; ordering of goods and services and payment of invoices; performance; external audit; and the control environment.Strengthening PFM project will support building the capacity of targeted Government of Nepal (GON) Ministries to improve transparency and accountability of public financial management (PFM) systems.\",\n",
       " '13040. Social Accountability Assessment - HIV/AIDS. SOCIAL ACCOUNTABILITY ASSESSMENT - HIV/AIDS. IBTCI was contracted by USAID/Ethiopia to provide a Social Accountability assessment for select programs across a broad set of technical sectors. Offices included Assets and Livelihoods Transition, Basic Education Services, Economic Growth and Transformation and Health, and finally AIDS, Population and Nutrition. The goal of these assessments was to provide the Democracy and Governance Office at USAID the tools need to strengthen the principles and practices of social accountability resulting in more accessible, affordable, responsive and effective service delivery. This was achieved by harvesting lessons learned, identifying success stories as well as innovative best practices that were in use. These lessons would be incorporated in future USAID Ethiopia programming.',\n",
       " '12230. Contribution Laboratory Equipment for Health Centre. CONTRIBUTION LABORATORY EQUIPMENT FOR HEALTH CENTRE. Buy new equipment for health centre.',\n",
       " '12191. Strengthening surgical and trauma health response in two most affected areas by Ebola in Sierra Leone: Port Loko and Western Area. STRENGTHENING SURGICAL AND TRAUMA HEALTH RESPONSE IN TWO MOST AFFECTED AREAS BY EBOLA IN SIERRA LEONE: PORT LOKO AND WESTERN AREA. Strengthening surgical and trauma health response in two most affected areas by Ebola in Sierra Leone: Port Loko and Western Area',\n",
       " '12263. Programme to Combat Tuberculosis. PROGRAMME TO COMBAT TUBERCULOSIS. Financing of laboratory equipment, medical technical equipment, transportation measure for monitoring and supervision as well as consulting services for the Tuberculosis Control Program.',\n",
       " '12262. From Malaria control towards malaria eradication: speed up malaria control activities with a view to eradication in Madagascar. FROM MALARIA CONTROL TOWARDS MALARIA ERADICATION: SPEED UP MALARIA CONTROL ACTIVITIES WITH A VIEW TO ERADICATION IN MADAGASCAR. Malaria is a major public health issue in Madagascar with 92 percent of the population exposed to risk. The program supported by this grant aims to increase the correct use of affordable, high-quality artemisinin-based combination therapies (ACTs) by adolescents and adults to 75 percent by 2012. To reach this goal, the program will create publicity campaigns to raise awareness about the availability of affordable, high-quality ACTs; conduct behavior change communication activities among the population at large to encourage the use of ACTs; train doctors and nurses on the proper way of treating malaria, i.e. with ACTs and drug monitoring; build technical capacity for drug monitoring in 769 private health care facilities; and supervise private health care facilities, pharmacies and small dispensaries with an aim to promote ACTs and monitor the prevalence of antimalarial monotherapies.',\n",
       " '13040. Building social capital to prevent HIV and improve access to comprehenseive healthcare without transphobia or homophobia for the transsexual, gay/MSM population in Peru. BUILDING SOCIAL CAPITAL TO PREVENT HIV AND IMPROVE ACCESS TO COMPREHENSEIVE HEALTHCARE WITHOUT TRANSPHOBIA OR HOMOPHOBIA FOR THE TRANSSEXUAL, GAY/MSM. The HIV and AIDS epidemic in Peru is concentrated in most-at-risk populations (MARPs), mainly the men who have sex with men (MSM) population, with the highest prevalence in the transsexual population. The program will focus on 8 regions of the country (Lambayeque, La Libertad, Lima, Callao, Ica, Loreto, San Martin and Ucayali) which account for 80% of the total HIV and AIDS cases reported so far. The Program will address different needs of the MARPs sub-populations in Peru, confronting the barriers they face in terms of stigma and discrimination, socio-economical, educational and employment challenges and the prevalence of sexual work. The Program aims to strengthen the capacity of transsexuals and gay/MSM community based organizations (CBOs) by improving their technical and management capacities to be better equipped to exercise community surveillance; support the fight against homophobia, stigma and discrimination; produce quality data and studies about most at risk groups, and to improve access to comprehensive healthcare. The goal is to help MSM populations gain universal access to high quality comprehensive healthcare, intensifying and increasing preventive actions and strengthening their base organizations in an environment that respects their rights and guarantees equal opportunities.',\n",
       " \"13040. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       " '12191. Construction of an orthopedics workshop, advanced training and education in orthopedics technology, job creation, a mutual exchange of trainees. CONSTRUCTION OF AN ORTHOPEDICS WORKSHOP, ADVANCED TRAINING AND EDUCATION IN ORTHOPEDICS TECHNOLOGY, JOB CREATION, A MUTUAL EXCHANGE OF TRAINEES. Construction of an orthopedics workshop as well as a vocational training centre and an advanced training academy in Mukono, Uganda.',\n",
       " '12240. Baby food: food production for childhood protection in Benin. BABY FOOD: FOOD PRODUCTION FOR CHILDHOOD PROTECTION IN BENIN. Restoring the functionality of some devices of the production of high-protein flour for weaning of the UBETA (UnitT de Technologie Alimentaire BTninoise) babies , and adaptation to the quality standards of the finished product',\n",
       " '12110. Visit to Health by a Delegation from the Ministry of Finance of the Socialist Republic of Vietnam. VISIT TO HEALTH BY A DELEGATION FROM THE MINISTRY OF FINANCE OF THE SOCIALIST REPUBLIC OF VIETNAM. Facilitated visit focused on taxation and pricing mechanisms to curb tobacco consumption',\n",
       " '13040. Reseau Africain de Recherche sur le SIDA. RESEAU AFRICAIN DE RECHERCHE SUR LE SIDA. to support the building of a sustainable HIV PrEP program for female sex workers in Dakar, Senegal',\n",
       " '12191. Increase in health services at the St. John Paul II Hospital in Pathein - Kangyi. INCREASE IN HEALTH SERVICES AT THE ST. JOHN PAUL II HOSPITAL IN PATHEIN - KANGYI. Construction of a new hospital, consisting of two floors with maternity wards, pediatric wards, new clinics, small laboratory analysis, new patient room for patients, bathrooms, medicine storage room with fridge, a complete kitchen, food warehouse , service room cleaning, maintenance rooms and staff room, building with patients for the medical staff and any accompanying persons, a nutritional center for new mothers. There is also a vegetable garden with a relative henhouse, a security fence and an incinerator for medical equipment. Finally, we intend to organize professional training courses for health personnel.',\n",
       " '12240. Improving the livelihoods of small holder farmers through capacity building and the establishment of sustainable economic structures in Hayakavan. IMPROVING THE LIVELIHOODS OF SMALL HOLDER FARMERS THROUGH CAPACITY BUILDING AND THE ESTABLISHMENT OF SUSTAINABLE ECONOMIC STRUCTURES IN HAYAKAVAN. Improving the livelihoods of small holder farmers through capacity building and the establishment of sustainable economic structures in Hayakavan',\n",
       " '13040. Family AIDS Initiative (FAI) Project - HIV/AIDS. FAMILY AIDS INITIATIVE (FAI) PROJECT - HIV/AIDS. Through this project, EGPAF has been the primary partner in providing technical support to Zimbabwes Ministry of Health and Child Welfare (MOHCW) to increase access to comprehensive, high-quality prevention of mother-to-child transmission of HIV (PMTCT) services that are closely linked to HIV/AIDS treatment, care, and support for families, including children living with HIV. Over the five-year period, the program expanded its partnership with the MOHCW by supporting a package of district-level activities to strengthen district-level PMTCT and pediatric services nationwide towards achieving full-scale elimination of pediatric HIV and AIDS in Zimbabwe.',\n",
       " '16064. UNAIDS baseline study. UNAIDS BASELINE STUDY. This project will undertake a study to establish an evidence-base for the impact of youth participation and a baseline of youth participation and leadership in the AIDS and sexual and reproductive health and rights processes at country, regional, and global level.',\n",
       " '13040. Academic Model Providing Access to Healthcare - People-centered, Leadership, Universal Access, Sustainability (AMPATH plus) - HIV/AIDS. ACADEMIC MODEL PROVIDING ACCESS TO HEALTHCARE - PEOPLE-CENTERED, LEADERSHIP, UNIVERSAL ACCESS, SUSTAINABILITY (AMPATH PLUS) - HIV/AIDS. AMPATHplus aims to augment HIV care and control program and expand AMPATHpluss primary care activities. AMPATH PLUS will be a new phase in which the Moi University, Moi Teaching and Referral Hospital, and the Ministry of Health facilities work together to improve the health of our catchment area in Kenya. In this new phase, not only will we seek to find, link, treat, and retain all HIV-infected people within our catchment area, but we will also dramatically increase our primary care and chronic disease management services. AMPATH is poised to serve as a model of innovation, ultimately creating knowledge on the best practices that can be shared with other USAID programs, with the Government of Kenya and with healthcare systems throughout the world.',\n",
       " '13020. Marketing Innovations for Health (MIH) - Maternal and Child Health. MARKETING INNOVATIONS FOR HEALTH (MIH) - MATERNAL AND CHILD HEALTH. MIH is a four-year project that started in July 2012 under a cooperative agreement with USAID. SMC is implementing this integrated social marketing program along with several local and international partners, to help bring about behavior change and improve health practices, increase access to and use of family planning products including Long Acting Reversible Contraceptive methods, Reproductive Health and Nutritional products, and improve the capacity of community based health practitioners in the private sector. The program is implementing community mobilization activities in 19 low-performing districts of Bangladesh. In addition, it includes national distribution and communication of existing SMC products as well as several new innovations through the private sector. SMC partners in the project include BRAC, Concerned Women for Family Development (CWFD), Population Services and Training Centre (PSTC) and Shimantik. Engender Health and PSI are associated as training and technical partners respectively. Under MIH, SMC is implementing a large health communications program with focused messaging on five core communication areas as follows: Healthy Timing and Spacing of Pregnancies; First 1000 Days of a Childs life (from conception to 2 years of age); Healthy Pregnancy; Adolescent Health; TB Prevention and Management. The program will also expand SMCs network of Blue Star providers and build capacity of formal and non-formal health providers through basic and refreshers training.',\n",
       " '12261. Project Concern International. PROJECT CONCERN INTERNATIONAL. to build and strengthen community-based structures in Bihar so that these structures can be leveraged for behavior change to drive increases in coverage of key family health and sanitation interventions, improve social accountability for health and sanita',\n",
       " '13020. Applying Science to Strengthen and Improve Systems (ASSIST). APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST). The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       " \"13081. Uzazi Uzima II: Safe Deliveries in Simiyu Region/Uzazi Uzima II: Accoucher en sTcuritT dans la rTgion de Simiyu. UZAZI UZIMA II: SAFE DELIVERIES IN SIMIYU REGION/UZAZI UZIMA II: ACCOUCHER EN S+CURIT+ DANS LA R+GION DE SIMIYU. The Uzazi Uzima II project seeks to reduce maternal and newborn mortality and morbidity in all five districts of Simiyu region, Tanzania by improving the availability of quality adolescent, maternal and newborn health services in underserved districts through three mutually supportive mechanisms. The project will: improve the knowledge and skills of healthcare providers on maternal, newborn and sexual/reproductive health to ensure they can provide critical services to their beneficiaries in a gender sensitive and responsive way;  improve the infrastructure and supply-chain for health facilities to encourage women, girls and their families to use services; and improve gender responsive health management systems (such as planning, prioritization and management of services). The project will also increase awareness and understanding of sexual, reproductive, maternal and child health with special focus on men's participation in reproductive, maternal and newborn health and decision making.Project activities include: (1) training health workers from four health centres and 24 dispensaries on: essential maternal and newborn health skills, such as Basic Emergency Obstetric and Newborn Care (BEmONC); Comprehensive Emergency Obstetric and Newborn Care (CEmONC), family planning; nutrition counselling; and newborn resuscitation; (2) refurbishing four health centres and 24 dispensaries to provide CEmONC, BEmONC, water, sanitation and hygiene and family planning services, including a satellite safe blood center at the regional hospital; (3) equipping targeted health facilities with the necessary stocks of equipment and commodities to provide BEmONC, CEmONC, family planning and safe blood services; (4) establishing a referral system for maternal and newborn health care and family planning services across all tiers of the health system; (5) training and supporting Ministry of Health and facility-based managers, and health workers to improve community to facility linkages (enhanced data collection, consolidation, analysis and reporting); and (6) training and equipping community health workers, traditional birth attendants, traditional healers, and local leaders to provide community-level health promotion services (including maternal and newborn health, water, sanitation and hygiene, family planning, nutrition, gender issues and use of mobile health technology to mobilize communities).The project is implemented in collaboration with Amref Health Africa in Tanzania, Marie Stopes Tanzania and Deloitte./ Le projet vise a rTduire la mortalitT et la morbiditT des mFres et des nouveau-nTs dans les cinq districts de la rTgion de Simiyu, en Tanzanie. Cet objectif est atteint en assurant une meilleure disponibilitT des services de santT maternelle et nTonatale de qualitT dans les quartiers mal desservis et en augmentant l'utilisation de ces services par les femmes et leurs familles dans les districts ciblTs au moyen d'interventions a covt modique, mais de vaste portTe. Le\",\n",
       " \"12220. Bone Marrow Transplantation Program. BONE MARROW TRANSPLANTATION PROGRAM. The prime partner for this project is Augusta Victoria Hospital (AVH). AVH plans to establish a new bone marrow transplantation and stem cell therapy program that serves West Bank and Gaza patients in East Jerusalem. The project is expected to reduce Palestinian Ministry of Health (MoH) burden of referring patients externally to Jordan or Israel and increasing local capacity to provide specialized health services.Nongovernmental organization (NGO) hospitals like AVH are an integral part of the Palestinian health care system. The Palestinian Authority's MoH relies heavily on NGO hospitals in the West Bank to provide essential secondary and tertiary care to Palestinians that the MoH is unable to provide.AVH, through its provision of specialty health care services, is committed to introducing services that are most commonly sought abroad, reduce overall health care costs, and increase the capacity of Palestinian providers to perform modern and innovative procedures. AVH currently has an on-going contract with the MoH to provide care and treatment for cancer patients. With prior year funding, the hospital is procuring the equipment needed to establish a bone marrow transplantation unit at AVH.Bone marrow transplantation services are not available within the Palestinian health system partially due to a lack of health professionals, especially nurses and allied health staff. With this funding hospital staff will be trained to perform their duties properly and in accordance with accreditation requirements and international standards.\",\n",
       " '12240. Maternal and Child Health Integrated Program (MCHIP) - Nutrition. MATERNAL AND CHILD HEALTH INTEGRATED PROGRAM (MCHIP) - NUTRITION. The Maternal and Child Health Integrated Program (MCHIP) is a $600 million Leader with Associates Cooperative Agreement (LWA) designed to support the introduction, scale-up and further development of high impact Maternal, Neonatal, and Child Health (MNCH) interventions, including the program approaches to effectively deliver those interventions, to achieve measurable reductions in under-five and maternal mortality and morbidity.',\n",
       " \"13020. RENFORCEMENT DU SYSTFME DE MATERN.ANJOUA. RENFORCEMENT DU SYST+ME DE MATERN.ANJOUA. AmTlioration de la santT maternelle et nTonatale en vue de contribuer a la rTduction de la mortalitT maternelle et nTonatale. Le projet vise a amTliorer l'accFs aux services et aux soins obstTtricaux dans le Nyumakele et a augmenter le nombre d'accouchements assistTs par du personnel qualifiT dans le district de M'rTmani par la reconstruction de la maternitT de M'rTmani, l'augmentation des accouchements assistTs dans le Nyumakele et la mise en place d'un service expTrimental d'ambulance.\",\n",
       " '12220. Commander s Emergency Response Program (CERP): Other Public Health Threats. COMMANDER S EMERGENCY RESPONSE PROGRAM (CERP): OTHER PUBLIC HEALTH THREATS. The Commander s Emergency Response Program (CERP) authorizes U.S. military commanders in Afghanistan to carry out small-scale projects designed to meet urgent humanitarian relief or reconstruction requirements within their areas of responsibility.',\n",
       " \"13040. Prevention Organizational Systems AIDS Care and Treatment (Pro-ACT). PREVENTION ORGANIZATIONAL SYSTEMS AIDS CARE AND TREATMENT (PRO-ACT). The Prevention Organizational Systems AIDS Care and Treatment (Pro-ACT) project goal is to build the capacity of Nigeria's public, private, and community sectors for sustainable HIV and AIDS and Tuberculosis prevention, control, care and treatment. Management Sciences for Health (MSH) is implementing Pro-ACT project in five Nigerian States: Niger, Kwara, Kebbi, Sokoto, and Zamfara.\",\n",
       " '13010. Health Communication Capacity Collaborative (HC3) - Program Design and Learning. HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3) - PROGRAM DESIGN AND LEARNING. HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       " '12182. Antimicrobial Resistance in a Global Context. ANTIMICROBIAL RESISTANCE IN A GLOBAL CONTEXT. Investments in interdisciplinary and focussed research at international levels to identify the burden and primary drivers of antimicrobial resistance and specifically antibacterial resistance in low- and middle-income countries',\n",
       " '12230. Technology Modernization Project at the clinic of Mutual Nikkai. TECHNOLOGY MODERNIZATION PROJECT AT THE CLINIC OF MUTUAL NIKKAI. In order to buy the necessary medical equipment to clinic operated by Mutual Nikkai to provide an environment of stable medical services to the community.',\n",
       " '12240. Provincial Health and Nutrition Programme - Empowerment, Voice and Accountability (EVA). PROVINCIAL HEALTH AND NUTRITION PROGRAMME - EMPOWERMENT, VOICE AND ACCOUNTABILITY (EVA). To improve reproductive, maternal, new born and child health services to the population of Punjab (Pb) and Khyber Pakhtunkhwa (KP), which comprises 70% of the total population in Pakistan.',\n",
       " \"13020. Aiding the campaign to end fistula. AIDING THE CAMPAIGN TO END FISTULA. United Nations Population fund (UNFPA) supports poor countries in policy making and projects that aim at eradicate poverty, improve women's safety when giving birth, and fighting AIDS/HIV. One of the fund's projects is campaigning to end fistula. Fistula is an injury that happens at child birth due to prolonged obstructed labour when a passage opens between urethra and the vagina or between the vagina and the rectum. Because of the smell of leaking urine or faeces is hard to eliminate and difficult to ignore and because of this the girls face exclusion from the society they belong to and suffer mentally as well as physically. Those mainly affected are young girls between 12 and 15 that live in densely populated and poorer areas. The condition nearly always leads to death of a child at birth. UNFPA has prioritized this campaign but it has been only 20 years since the problem was dealt with. The fund considers this to be one of it's most important projects since around 93% of the cases can be mended by surgery. Fistula is an extensive problem in Africa, Asia and the Middle-East.\",\n",
       " '13020. MEASURE Phase III, Demographic and Health Surveys (DHS) - Maternal and Child Health. MEASURE PHASE III, DEMOGRAPHIC AND HEALTH SURVEYS (DHS) - MATERNAL AND CHILD HEALTH. The purpose of MEASURE Phase III DHS is to improve the collection, analysis and presentation of data and promote better use in planning, policymaking, managing, monitoring and evaluating population, health and nutrition programs. The project seeks to increase understanding of a wide range of health issues by improving the quality and availability of data on health status and services and enhancing the ability of local organizations to collect, analyze and disseminate such information.',\n",
       " '12263. MEASURE Evaluation Phase III - Tuberculosis. MEASURE EVALUATION PHASE III - TUBERCULOSIS. MEASURE Evaluation Phase III continues the MEASURE programs 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3)increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       " '13040. HIV Innovations for Improved Patient Outcomes for Priority Populations (Innovative Models for Capacity Building & Support of Scale Up of Effective HIV-related Services for MSM). HIV INNOVATIONS FOR IMPROVED PATIENT OUTCOMES FOR PRIORITY POPULATIONS (INNOVATIVE MODELS FOR CAPACITY BUILDING & SUPPORT OF SCALE UP OF EFFECTIVE HIV. HIV Innovations for Improved Patient Outcomes for Priority Populations (Innovative Models for Capacity Building & Support of Scale Up of Effective HIV-related Services for MSM)',\n",
       " '12220. Nasarawa State Primary Healthcare Development Agency (NAPHDA). NASARAWA STATE PRIMARY HEALTHCARE DEVELOPMENT AGENCY (NAPHDA). to support the improvement of structures and systems of governance and leadership, performance management, and financing of Primary Health Care for the benefits of the people of Nasarawa state',\n",
       " '13020. Strengthening Implementation of Program Budgeting - Maternal and Child Health. STRENGTHENING IMPLEMENTATION OF PROGRAM BUDGETING - MATERNAL AND CHILD HEALTH. Provide technical assistance to assist with strengthening public financial management (PFM) policies that will promote fiscal transparency. The objectives of the program support the following areas: (1) improved allocation of budget resources to programs of pilot ministries, including the Ministry of Health, (2) implementation of program budgeting in the remaining 30 national government line ministries, and (3) expansion of program budgeting to sub-national government institutions.',\n",
       " '12110. Alcohol, Drugs and Development - Local Prevention Dolakha, NEP. ALCOHOL, DRUGS AND DEVELOPMENT - LOCAL PREVENTION DOLAKHA, NEP. Local enforcement of, and knowlge about, the laws and policies regulating alcohol and tobacco. Improved performance by state and other relevant actors the local level in Dolakha district. Create awareness of relations to child rights, gender rights, and HIV/AIDS.',\n",
       " '13020. Health Communication Capacity Collaborative (HC3). HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3). HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       " '12240. Nutrition: Advocacy for Regulation of Marketing of Breast Mil k Sub SLE.ACF.2017.01 DCD22515. NUTRITION: ADVOCACY FOR REGULATION OF MARKETING OF BREAST MIL K SUB SLE.ACF.2017.01 DCD22515. Nutrition: Advocacy for Regulation of Marketing of Breast Mil k Sub SLE.ACF.2017.01 DCD22515',\n",
       " '12240. FEEDING PROJECTFOR CHILDREN. FEEDING PROJECTFOR CHILDREN. The Catholic Hostel is a school that welcomes children, males and females from very poor families of the city and surrounding areas.  The majority of children who show up at the school are underweight and ill. To allow children to study in the school it is provided, therefore, the opportunity of medical assistance. To reduce cases of malnutrition was organized a nutritional program. Thanks to a balanced diet, vitamin supplements and healthy foods, many children can reach an optimal weight.',\n",
       " \"12181. Training - 2016 Healthcare Executive Leadership Training Program, through Meridian International Center. TRAINING - 2016 HEALTHCARE EXECUTIVE LEADERSHIP TRAINING PROGRAM, THROUGH MERIDIAN INTERNATIONAL CENTER. USTDA partially funded two separate and distinct 14-day training programs for 25 senior Chinese healthcare executives and officials to introduce them to best practices in healthcare management and U.S. advanced medical technologies and solutions. This was the fifth USTDA training program for Chinese healthcare executives, and was supported by members of the U.S.-China Healthcare Cooperation Program (HCP) and China's Health Human Resources Development Center (HHRDC).\",\n",
       " '13020. Opening of the clinical for medicine, maternity and surgery in Antsiranana. OPENING OF THE CLINICAL FOR MEDICINE, MATERNITY AND SURGERY IN ANTSIRANANA. Opening of the clinical for medicine, maternity and surgery in Antsiranana',\n",
       " \"13040. Voluntary Medical Male Circumcision III Program. VOLUNTARY MEDICAL MALE CIRCUMCISION III PROGRAM. The Voluntary Medical Male Circumcision (VMMC) Service Delivery III Project (Siyasoka) scales up VMMC services in South Africa. The purpose of this activity is to provide direct service delivery to support high quality, high volume VMMC and related services in rural and urban areas of the country. Siyasoka draws upon the experience of the previous VMMC I and II projects, managed by the Right To Care Consortium in South Africa, and builds on URC's experience in implementing continuous quality improvement in VMMC services in over eight countries since 2012. Working at fixed, outreach, and mobile VMMC sites in rural and urban priority districts, the Siyasoka project aims to reach 80% coverage of the target population in order to prevent new HIV infections. We will also work to coordinate the forecasting, procurement, quality assurance, distribution, and storage of VMMC surgical kits and commodities. In addition to providing direct service delivery throughout the country, the project will also support the transition of direct VMMC service delivery to the South Africa Government National Department of Health (NDOH).\",\n",
       " '12110. China National Health Development Research Center. CHINA NATIONAL HEALTH DEVELOPMENT RESEARCH CENTER. to explore and develop three components of a China National Institute for Health and Care Excellence like Health Technology Assessment mechanism - HTA process, methodology development and dissemination',\n",
       " '13020. DAR AMREF II. DAR AMREF II. National Fistula Program Extension',\n",
       " '12263. KwaZulu-Natal Research Institute for TB & HIV. KWAZULU-NATAL RESEARCH INSTITUTE FOR TB & HIV. to hold a series of four biostatistics courses for African scientists',\n",
       " '13040. Output 04: HIV. HIV. China - Beijing. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12191. A dental laboratory equipment in the clinic NS Guadalupe. A DENTAL LABORATORY EQUIPMENT IN THE CLINIC NS GUADALUPE. A dental laboratory equipment in the clinic NS Guadalupe',\n",
       " '12281. Healthcare Centre MAMA CARLA, La Joie de Vivre Center Bangui, (Analysis laboratory, Dispensary of primary care for children and Telemedicine). HEALTHCARE CENTRE MAMA CARLA, LA JOIE DE VIVRE CENTER BANGUI, (ANALYSIS LABORATORY, DISPENSARY OF PRIMARY CARE FOR CHILDREN AND TELEMEDICINE). The Health Medical Centre MAMA CARLA give the possibility to the needy children, orphans or abandoned housed in the Centre La Joie de Vivre to have free access to the medical services. Medical examination, ambulatory treatments, infectious disease and malaria control, urgent pharmacological treatments and assistance to undernourished are opened also for all the students of the School Nicolas BarrT and to the children living in the surrounding areas from 0 to 14 ages. The Centre organizes hygienic consulting, education and training for mothers. Assistance and training to pregnant women AIDS infected. Health personnel development.',\n",
       " '13040. Improved Services for AIDS and Basic Healthcare through Empowerment of Local Democracy (ISABEL). IMPROVED SERVICES FOR AIDS AND BASIC HEALTHCARE THROUGH EMPOWERMENT OF LOCAL DEMOCRACY (ISABEL). The main aim of this Action is that in Malawi, by 2018, there should be inclusive, empowered communities enjoy more healthcare rights, and that governance and accountability in healthcare are improved.  To achive this, the project will focus on the interface between healthcare actors and coomunities at district level  and how they hold each other to account.',\n",
       " '13020. Communication for Change (C-Change) in DRC - Maternal and Child Health. COMMUNICATION FOR CHANGE (C-CHANGE) IN DRC - MATERNAL AND CHILD HEALTH. FHI 360s Communication for Change (C-Change) project in the Democratic Republic of the Congo (DRC) seeks to increase positive health behaviors through evidence-based, social and behavior change communication (SBCC) programs that focus on family planning, HIV/AIDS, gender-based violence, malaria, tuberculosis, water sanitation, maternal and child health, nutrition and HIV, and prevention of mother-to-child transmission of HIV. C-Change is working at central and provincial levels to build managerial and SBCC skills within the government, nongovernmental organizations and civil society organizations. We envision building local capacity to plan, monitor and evaluate scientifically based SBCC interventions, so the DRC becomes a regional leader offering state-of-the-art SBCC approaches to neighboring countries.',\n",
       " '12250. Scientific cooperation with other countries (not included in other areas). SCIENTIFIC COOPERATION WITH OTHER COUNTRIES (NOT INCLUDED IN OTHER AREAS). RENOMAB - Research network on melioidosis and Burholderia pseudomallei - Capacity building in the field of education and research',\n",
       " '12220. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Community based health care services and leadership training',\n",
       " \"12250. Support to the Government of Ghana's response to the ongoing cholera outbreak and mitigate the threat of Ebola in the region.. SUPPORT TO THE GOVERNMENT OF GHANA'S RESPONSE TO THE ONGOING CHOLERA OUTBREAK AND MITIGATE THE THREAT OF EBOLA IN THE REGION.. To improve the health system in Ghana, by providing the Ministry of Health with direct budget support, materials, goods and technical assistance. This support will improve coverage and quality of primary care services and create a sustainable health syste\",\n",
       " '13040. CapacityPlus - HIV/AIDS. CAPACITYPLUS - HIV/AIDS. This project strengthens the human resources (HR) needed to implement quality health programs, in both the public and private, particularly the not-for-profit private, sectors. It addresses both the number of healthcare workers needed and the quality and performance of those workers. The definition of healthcare worker is expanded to include HR managers, laboratory staff, pharmacists, social workers, information systems/monitoring and evaluation specialists and others essential to the effective functioning of the health system.',\n",
       " '12182. Integrated Health, education and environmental (HEE) intervention to optimise infant feeding practices through schools and Anganwadi networks in India. INTEGRATED HEALTH, EDUCATION AND ENVIRONMENTAL (HEE) INTERVENTION TO OPTIMISE INFANT FEEDING PRACTICES THROUGH SCHOOLS AND ANGANWADI NETWORKS IN INDIA. GCRF Foundation NCDs 2016 examining methods enhancing feeding practices for children 6-24 months. Directly benefiting residents in 9 rural communities in Banswara district in Rajasthan India. Supporting mothers to improve living conditions and lifestyle in the community, and enhance capabilities of local schools and Anganwadis operating as community education and innovation hubs',\n",
       " '12281. Trade-Related Training Program - Healthcare Leadership Training Program, through Meridian International Center. TRADE-RELATED TRAINING PROGRAM - HEALTHCARE LEADERSHIP TRAINING PROGRAM, THROUGH MERIDIAN INTERNATIONAL CENTER. USTDA funding in the amount of $380,000 partially supported a three-week training program for senior Chinese healthcare executives and officials to introduce them to best practices in healthcare management and U.S. advanced medical technologies and solutions. This was the fourth USTDA training program for Chinese healthcare executives, and was supported by members of the U.S.-China Healthcare Cooperation Program (HCP) and Chinas Health Human Resources Development Center (HHRDC). Delegates met with administrators and clinicians affiliated with the University of Pittsburgh Medical Center (UPMC) and the University of Illinois at Chicago (UIC) for trainings and tours.',\n",
       " \"13030. Rights, Equality, SRHR & Adolescents in Mozambique. RIGHTS, EQUALITY, SRHR & ADOLESCENTS IN MOZAMBIQUE. The initiative aims to consolidate and expand on previous support initiative. The project will address inequitable gender norms to strengthen adolescents' SRHR outcomes while improving the availability and accessibility of quality Gender Based Violence (GBV) primary and secondary prevention, Comprehensive Abortion Care (CAC), and SRHR services. The aim is to improve adolescent sexual reproductive health in Maputo, Gaza, Inhambane and Cabo Delgado provinces by increasing gender equality\",\n",
       " \"12263. Preventing multi-resistant tuberculosis by improving comprehensive care of tuberculosis. PREVENTING MULTI-RESISTANT TUBERCULOSIS BY IMPROVING COMPREHENSIVE CARE OF TUBERCULOSIS. C(te d'Ivoire is deeply affected by the problem of Tuberculosis (TB).  According to the 2008 WHO report, the prevalence for all TB forms constituted 747 cases per 100,000 inhabitants whereas the incidence  420 cases.  Based on a national survey conducted in 2006, the rate of Multi-Drug Resistant TB (MDR-TB) is 2.5 percent for new cases, and 8.6 percent for cases in re-treatment.  The Program is a consolidation of the Round 6 and Round 9 proposals and is implemented by two Principal Recipients (PR) through the dual-track financing scheme.  It continues to strengthen the extension of Directly Observed Treatment Short course (DOTS) strategy by increasing and de-centralizing the available care, by improving the management of MDR-TB cases, and by making better use of mass media for communication about TB.  The activities implemented by this PR include renovation and equipment of health facilities, procurement of drugs and laboratory products, TB and MDR-TB screening and treatment, nutritional support for vulnerable patients, and training of health workers.\",\n",
       " '12110. Develop, Customize and implement an open source harmonized Laboratory Information Management System (LIMS) at CARPHA laboratories. DEVELOP, CUSTOMIZE AND IMPLEMENT AN OPEN SOURCE HARMONIZED LABORATORY INFORMATION MANAGEMENT SYSTEM (LIMS) AT CARPHA LABORATORIES. The purpose of the TA is to assist CARPHA with the implantation of an harmonized Laboratory Information Management System (LIMS). This will target the three regional laboratories based in Trinidad, Jamaica and Saint Lucia.',\n",
       " '12240. Improving Living Conditions and Health in Rural and Indigenous Communities in Chuquisaca/AmTliorer les conditions de vie et la santT des communautTs rurales et autochtones de Chuquisaca. IMPROVING LIVING CONDITIONS AND HEALTH IN RURAL AND INDIGENOUS COMMUNITIES IN CHUQUISACA/AM+LIORER LES CONDITIONS DE VIE ET LA SANT+ DES COMMUNAUT+S R. This project will work in 14 communities in Chuquisaca, Bolivia, to strengthen income generation and address health challenges affecting maternal and child health, including nutrition, hygiene practices and access to health services. The project beneficiaries are primarily women and men at the community level as well as local and departmental governments. Project activities include: (1) support for increasing family enterprise profitability; (2) adopting good nutritional and environmental health practices; and (3) improving government support services through better management, coordination and leadership. Empowering rural women and youth in economic enterprise management is an important objective of the project./ a venir',\n",
       " '12220. SELECTED EVALUATION STUDIES FOR 2014. SELECTED EVALUATION STUDIES FOR 2014. Description :. Product Type:',\n",
       " '12182. Measuring the impact of research - Researchfish  research. MEASURING THE IMPACT OF RESEARCH - RESEARCHFISH  RESEARCH. To increase the impact of DFID funded health research by providing improved data on research outputs and outcomes',\n",
       " '12110. Management Sciences for Health. MANAGEMENT SCIENCES FOR HEALTH. to increase the coverage of efficient, effective, and equitable primary health care services in Africa',\n",
       " '13020. Gender Based Violence and reproductive health in Gao. GENDER BASED VIOLENCE AND REPRODUCTIVE HEALTH IN GAO. Awareness building and lobbying against FGM, targeting men and women, religious and community leaders',\n",
       " \"16064. Good Samaritan HIV-project Malawi. GOOD SAMARITAN HIV-PROJECT MALAWI. Malawi Good Samaritan HIV project is part of Africa wide HIV program (GSP) by African Bible Societies that is running in over 20 Sub-Saharan countries. The long term objective of the project is to contribute to the reduction of the spread of HIV and stigma of people infected and affected. The main focus is to reduce stigmatization and discrimination of PLHA. The overall objectives of GSP are to strengthen the involvement of churches in  response to HIV by enabling people and organizations to: Get knowledge about HIV and AIDS and risky behaviour; Encourage VCT and sexual education; Eradicate stigma and discrimination; Restore PLHA?s human rights dignity and equality and; To renew churches and local congregations' social responsibility. The programme has two main target groups: People with influence as opinion leaders and/or with the capacity to act as facilitators and trainers; and people who are particularly vulnerable to HIV  such as the youth women PLHA  and married couples. Third phase  is especially  targeting PVDs  as they are one of the most HIV vulnerable groups. Through PVD strategy the aim is to include PVDs to existing structure of activities. The strategy is based on Information Education and Communication with a focus on behavioral change communication and to work with individuals and communities through sharing and providing supportive and enabling environments. The implementation is based on a two tier strategy: (i) advocacy sensitization and mobilization of community&religious leaders; and (ii) conduct training of trainers to reach local communities. The training uses the workshop as a platform to facilitate interaction sharing and reflection to  promote change in attitudes and behavior. The programme also encourages the formation of local groups for mutual support and action. Issues of gender will continue to be addressed as was the case in previous phases. Project staff will be equipped with training skills on gender and  human dignity since they  are key elements in the GS program. Project is implemented in existing structures that include governmental HIV coordination religious networks and local communities.The key project activities include different workshops: training of trainers (ToT) decentralized workshops (DWs) Follow up (FU) Take Charge youth program (TC). There is also an annual capacity building workshops for project staff (Joint Program Review and anglophone capacity building workshop).\",\n",
       " \"12230. Le Projet d'Tquipement de laboratoire du Centre IntTgrT de Recherches Biocliniques d'Abidjan. LE PROJET D'+QUIPEMENT DE LABORATOIRE DU CENTRE INT+GR+ DE RECHERCHES BIOCLINIQUES D'ABIDJAN. The project is aimed to purchase the equippements at the  laboratory of the Researches Bioclinics of Abidjan Integrated Center to improve the medical examination system.\",\n",
       " '12240. Migration, Remittances, and Forest Dependence in Ethiopia: Implications for Food Security, Gender, and Forest Conservation. MIGRATION, REMITTANCES, AND FOREST DEPENDENCE IN ETHIOPIA: IMPLICATIONS FOR FOOD SECURITY, GENDER, AND FOREST CONSERVATION. This project will provide evidence that offers important insight into the connection between migration, gender, and forest dependence in rural Ethiopia. Need for labour migration, forest resources While most rural households rely on agriculture for their livelihood, many poor households in developing countries use labour migration and forest resources to improve their welfare. Existing research offers simplistic assumptions that migration invariably leads to deforestation in the tropics, and that forest recovery is always a consequence of people leaving rural areas. These assumptions are being questioned, particularly as researchers analyze and document the complex factors that influence migration outcomes. As a result, it is not clear whether labour migration complements, or serves as a substitute, for forest product extraction by migrant-sending households. Furthermore, whether and how labour migration influences intra-household gender relations, food security, and forest dependence at the places of origin is unclear. Insights into the effects on households The Ethiopian Economic Association/Ethiopian Economic Policy Research Institute (EEA-EEPRI) will collaborate with the Center for International Forestry Research (CIFOR) on this project. They will explore the effects of migration and remittances on household forest dependence, food security, and intra-household gender division of work. Researchers will investigate the degree to which those effects vary across different migration types (for example, domestic versus international migration, and rural versus urban) and across socio-economic groups and locations. A better understanding of these issues is of crucial importance in Ethiopia for a number of reasons. The government has formulated and implemented specific policies on gender, forestry, and food security. However, the ways in which rural out-migration is influencing the achievement of gender equity, forest conservation, and rural food security goals are not well understood. This research will aim to propose options for policymakers and development partners. Project leadership This project is made possible through the Think Tank Initiative (TTI). TTI is a multi-funder program dedicated to strengthening independent policy research institutions, or think tanks, in developing countries. The program aims to enhance their ability to provide sound research that informs and influences policy.',\n",
       " '12263. MEASURE Evaluation Phase III - Tuberculosis. MEASURE EVALUATION PHASE III - TUBERCULOSIS. MEASURE Evaluation Phase III continues the MEASURE program s 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3).increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       " '13040. Maternal and Child Health - Assistance for HIV/AIDS. MATERNAL AND CHILD HEALTH - ASSISTANCE FOR HIV/AIDS. PEPFAR: Increase the availability and use of proven life-saving interventions that address the major killers of mothers and children and improve their health and nutrition status, including effective maternity care and management of obstetric complications; prevention services including newborn care, routine immunization, polio eradication, safe water and hygiene, and micronutrients; improved maternal, infant and young child feeding; and treatment of life-threatening childhood illnesses. - Assistance for HIV/AIDS',\n",
       " '12262. Expanding the Use of Selected Health Services and Products Task Order under Population, Health and Nutrition Technical Support Contract III-Global Hea. EXPANDING THE USE OF SELECTED HEALTH SERVICES AND PRODUCTS TASK ORDER UNDER POPULATION, HEALTH AND NUTRITION TECHNICAL SUPPORT CONTRACT III-GLOBAL HEA. The purpose of this contract is to build on previous USAID/Madagascar Health Population and Nutrition (HPN) activities, expand services broader and deeper into communities to provide quality services to the poor, and to strengthen specific health systems and the capacity of the Ministry of Health and Family Planning to undertake its normative functions to ensure the delivery of critical health services.',\n",
       " \"12250. JSI Research & Training Institute, Inc.. JSI RESEARCH & TRAINING INSTITUTE, INC.. to strengthen Uganda's routine immunization (RI) system through affordable, proven approaches so that it is capable of protecting children from vaccine-preventable diseases on a sustained basis\",\n",
       " '12240. Afya Jijini. AFYA JIJINI. Afya Jijini will support integrated health service delivery in Nairobi County. Support for integrated services include HIV; tuberculosis; reproductive, maternal, newborn and child health; nutrition; WASH funds will support: HIV prevention, care and treatment interventionsANC, SBA, emergency obstetric care and essential newborn carePrevention and management of diarrhea and pneumonia through ORS/zinc, appropriate treatment and BCC in facility and community WASH activities through community sanitation, household and school-based hygiene practices ?Routine immunization; provision of quality nutrition services; capacity building on maternal and child nutrition; and provision of equipment, job aids and guidelinesForecasting, quantification and reporting of essential commodities at facility levelFP skills building, mentorship, counselling and provision of services in public and private sector facilities and by community health workers',\n",
       " \"12250. Elimination of Blinding Trachoma in Mali and Niger. ELIMINATION OF BLINDING TRACHOMA IN MALI AND NIGER. This project reduced avoidable and premature blindness and improved the quality of life of persons suffering from trachoma. The project encompassed: Supporting trachealis surgery eye camps through provision of training and procurement of necessary equipment; Reducing the prevalence of 'trachomatous inflammation follicular' among children ages one to nine years old to less than five percent at the sub-district level through the distribution of azithromycin and tetracycline eye ointment.\",\n",
       " '12240. Rwanda Rutsiro Nutrition and Health Project. RWANDA RUTSIRO NUTRITION AND HEALTH PROJECT. supports to improve utilization of nutritious foods through community-d nutrition interventions, such PD Hearth session, nutrition and health education to PLW and caregivers. Also, this project will advocate community people through provision of knowledge to local leaders (who are influential to community people), advocacy campaign and broadcasting so that will empower community and the nutrition  health is improved',\n",
       " '13040. Output 04: HIV. HIV. Bangladesh - Dhaka. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12182. Consultancy for quality assurance of Operations Research and Impact Evaluation Oversight Committee reports. CONSULTANCY FOR QUALITY ASSURANCE OF OPERATIONS RESEARCH AND IMPACT EVALUATION OVERSIGHT COMMITTEE REPORTS. To provide increased coverage with essential reproductive, maternal and child health services in DFID-supported health zones. To increase coverage with essential health services in 52 DFID-supported health zones in five provinces (Nord Ubangi, Kasai-Centr',\n",
       " '12250. The Program for capacity building of infectious diseases control in Uzbekistan. THE PROGRAM FOR CAPACITY BUILDING OF INFECTIOUS DISEASES CONTROL IN UZBEKISTAN. Establishment of epidemiology training mastre plan, Dispatch korean experts for the development for epidemiology training master plan, KOICA felloship, Provision of high performance labaratory dignostics equipment within microbilology and parasitology laboratories, Pilot study for Echinococcosis',\n",
       " '12191. Health Emergency Assistance to internally displaced, refugees and Conflict-affected Populations in Central African Republic. HEALTH EMERGENCY ASSISTANCE TO INTERNALLY DISPLACED, REFUGEES AND CONFLICT-AFFECTED POPULATIONS IN CENTRAL AFRICAN REPUBLIC. Reduce morbidity and mortality among internally displaced population, refugees and people  affected by conflict in Central African Republic',\n",
       " '12230. F.a: Developing District Level Hospitals. F.A: DEVELOPING DISTRICT LEVEL HOSPITALS. The Health care system in North Korea is still in need of external assistance in order to provide the essential basic services. The Patients of the catchment area of four district/county level hospitals with 460 000 people and one province level hospital with 1 510 000 people will have better health services. The number of doctors and nurses in the partnering hospitals is about 1000 and through training, the impact will spread among workers of other hospitals. In 2016, the project will continue teaching in the hospitals to increase the capacity of the hospitals regarding cardiology, radiology and operations. The goal is improved health of population in the selected district/counties. The purpose of the project is improved provision of health services of selected hospitals. Last year the number of diagnostic examinations annually made in the hospitals by the equipment provided by Fida International was about 52 400. The number of appropriate safe surgical procedures annually made by the equipment provided by Fida in the hospitals is about 6 800. Increasing number of serious diseases can be correctly diagnosed and treated due to practical training of medical personnel. More and more patients are coming to our contact hospitals from other districts/counties in order to get access to quality health services because of their good reputation. Medical students are coming to have a practicing period in the district hospitals due to work of Fida International. The project benefits poor and vulnerable families with children, like ordinary farmers and workers. Also the medical personnel of the hospitals and medical students from university hospitals will benefit. Fida International is an implementing agency, but in close collaboration with Korea-EU Cooperation Coordinating Agency (KECCA). The project is carried out in cooperation of the leadership and the medical personnel of the five hospitals.',\n",
       " '13040. Securing Ugandan s Right to Essential Medicines (SURE) - HIV/AIDS. SECURING UGANDAN S RIGHT TO ESSENTIAL MEDICINES (SURE) - HIV/AIDS. Securing Ugandans  Right for Essential Medicines (Uganda SURE) aims to aims to assist the Government of Ugandas commitment to strengthen the national pharmaceutical supply system to ensure that the people of Uganda have access to adequate quantities of good quality essential medicines and health supplies. To achieve this goal, SURE s objectives are to: 1) Improve Uganda s policy, legal, and regulatory framework to produce pharmaceutical supply chain stability and sustainability; 2) Improve capacity and performance of central government entities to carry out their supply chain management responsibilities; 3) Improve capacity and performance of districts, health subdistricts, and implementing partners in their supply chain management roles. SURE works on integrating Uganda s supply chain and establishing a pharmaceutical management information system that provides full transparency to minimize medicine stock-outs and waste.',\n",
       " \"13030. Empowering Communities for Health (ECH) project. EMPOWERING COMMUNITIES FOR HEALTH (ECH) PROJECT. The ECH mechanism is working to build the capacity of CCs to manage and support the health system functions delegated to communities. ECH supports community agents to promote appropriate home health and nutrition behaviors, optimal health care-seeking, and improving community-based provision of tuberculosis (TB) treatment and contraceptive services. Additionally, it is working to improve community awareness of the rights of health care consumers (as set forth in the MOH's Client Rights Charter), strengthen social accountability and assist CCs to fully exert the health care stewardship role envisioned for them in the MOH's Guidelines for Operational Districts.\",\n",
       " \"12250. Global Health Support Initiatives III (GHSI-III). GLOBAL HEALTH SUPPORT INITIATIVES III (GHSI-III). Global Health Support Initiatives III (GHSI-III) procurement. GHSI-III is the successor to GHSI-II. GHSI III will provide non-direct hire global health support services for USAID's Bureau for Global Health (GH) at its offices in Washington, D.C. and overseas. The activity will recruit, hire and maintain a contracted technical, professional, operational, and support staff that supply support services to USAID's health programs worldwide. The staff provided under the activity will support seven health program areas: (1) HIV/AIDS; (2) Tuberculosis; (3) Malaria; (4) Avian Influenza; (5) Other Public Health Threats; (6) Maternal and Child Health; and (7) Family Planning and Reproductive Health.\",\n",
       " '12191. Pediatric neurosurgery and neurology. PEDIATRIC NEUROSURGERY AND NEUROLOGY. The Neurosurgery has been identified as one of the priority areas in the field of health care, promoting a reduction in the number of evacuations of Cape Verde patients to Portugal.',\n",
       " '12110. Project research. PROJECT RESEARCH. Project research',\n",
       " '12281. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Feasibility study',\n",
       " \"12250. Network ReACt. NETWORK REACT. ReAct is a non-profit international network to improve the management of antibiotic resistance. ReAct's vision is that current and future generations will have access to effective prevention and treatment of bacterial infections as part of their right to health. ReAct aims to increase the global awareness of the negative effects of ABR, to increase the evidence generation, to promote innovation etc.\",\n",
       " \"13040. National Institute of Health - International Research. NATIONAL INSTITUTE OF HEALTH - INTERNATIONAL RESEARCH. PEPFAR - The President's Emergency Plan for AIDS Relief is committed to prevent new HIV infections; treat HIV-infected individuals and those orphaned by AIDs.\",\n",
       " '12182. 10-CO1-064/ACH/PARAGUAY AND PER+/$TOTAL INITIAL 5M/Food and nutritional security. 10-CO1-064/ACH/PARAGUAY AND PER+/$TOTAL INITIAL 5M/FOOD AND NUTRITIONAL SECURITY. 10-CO1-064/ACH/PARAGUAY Y PER+/$TOTAL INICIAL 5M?/SEGURIDAD ALIMENTARIA Y NUTRICIONAL',\n",
       " '16064. Output 04: HIV. HIV. Mexico - Mexico City. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12281. Exchanges with Other Countries in the Field of Vocational Education and Training and Scholarships. EXCHANGES WITH OTHER COUNTRIES IN THE FIELD OF VOCATIONAL EDUCATION AND TRAINING AND SCHOLARSHIPS. Collaborative project - ChinaCare - Cooperative training of carers for the elderly in China, Sub-project - Research of conditions for training, drawing up of customised pedagogical plans and transfer in China and Germany - Knowledge Transfer',\n",
       " '12263. Applying Science to Strengthen and Improve Systems (ASSIST). APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST). The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       " '12110. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 Policy support research and representation (including reference centres). INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 POLICY SUPPORT RESEARCH AND REPRESENTATION (INCLUDING REFERENCE CENTRES). General objective:  Policy support, research and representation - Specific objective:  To adequately assist Belgian policy makers in decision making, policy formulation and representation regarding technical and strategic issues related to international health. - Results:  The project will result in making available the expertise present at the ITM for the Belgian policy makers. This will be done through providing expert briefings, carrying out relevant research, and providing scientific support before, during and/or after national or international meetings. -',\n",
       " '12220. PATH. PATH. to focus on innovation introduction and reducing policy barriers to service delivery implementation',\n",
       " '12110. Foundation for Innovative New Diagnostics FIND. FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND. The Foundation for Innovative New Diagnostics (FIND), working through a public-private partnership model, drives the development and early implementation of new diagnostic tests for poverty-related diseases. From a global public health perspective, accurate and affordable diagnosis is critical. It helps ensure better care to patients, enables equitable, timely and correct medical treatment in low-resource settings, and thus reduces wastage of medicines and antimicrobial resistance. It is essential also for emergency preparedness.',\n",
       " \"12182. ICDDR,B exit 2017-2019. ICDDR,B EXIT 2017-2019. Exit support to icddr,b 2017-2018. During the exit phase Sweden will provide SEK 21 400 000 over the period 2017 - 2019 to support icddr,b in the implementation of the Strategic Plan 2015 - 2018. Sweden has been providing research and core support to icddr,b since 1981 with the aim to ensure that research in health addressed key policy issues for health system in Bangladesh, and that the research findings were communicated to policy users and influenced policy decisions. This objective remains at the core of the Swedish funding during the suggested agreement phase.Core support is suggested as the continued financing modality and it is also suggested to phase out the core support during the 2-year agreement period 2017-2019. Research funding from Sida HQ will continue through an specific agreement for the period 2016-2020 on the amount of MSEK 30,5. icddr,b has demonstrated the ability to control its own development and preparedness to invest core funds particularly in neglected areas in order to build future capacity. In the coming three years, ambitious efforts are planned to strengthen the capacity of icddr,b with improved monitoring, evaluation and reporting structures and processes as key targets.Achievements in the strategic objectives will be assessed against icddr,b's framework for results that will track output and outcome indicators to monitor progress. Fiduciary risks have been assessed as high but the internal systems related to financial management have been strengthened during the last years and icddr,b has made rapid progress towards reducing these risks. Through its participation in the Core Donor Group, Sweden together with Canada (Global Affairs) and the United Kingdom (Department for International Development - DfID) will ensure that the risks in the programme are carefully monitored and managed. An external evaluation will be conducted at the end of the agreement to assess the overall success of the programme. The budget for the evaluation has been allocated and is earmarked in the contribution budget.\",\n",
       " '12191. Equipment of an analysis laboratory at the Sacred Heart Medical Center of BoussT. EQUIPMENT OF AN ANALYSIS LABORATORY AT THE SACRED HEART MEDICAL CENTER OF BOUSS+. The project involves the restructuring and equipment of the Sacred Heart Medical Center in BoussF, the launch of an analysis laboratory, in order to contribute to reducing child mortality and improving the health of the population, especially for young mothers',\n",
       " '16064. HIV/AIDS II - Coordination and leadership of national response. HIV/AIDS II - COORDINATION AND LEADERSHIP OF NATIONAL RESPONSE. Support to Uganda AIDS Commission and the HIV/AIDS Partnership for coordinating and leading the national response. In addition, support is provided to 1) research coordination and 2) integration of HIV and reproductive heatlh and family planning.',\n",
       " '12262. AAAS Diplomacy Program for Science Fellows II - GCC, EG and NRM Participation - Malaria. AAAS DIPLOMACY PROGRAM FOR SCIENCE FELLOWS II - GCC, EG AND NRM PARTICIPATION - MALARIA. AAAS Diplomacy Program for Science Fellows II - GCC, EG and NRM Participation',\n",
       " '12191. Talita Kum. TALIT+ KUM. Supporting health and human rights for people with disabilities in the Njombe region. Strengthening the Laboratory and outpatient s department in the Inuka Rehabilitation Centre: Providing new equipment and training staff',\n",
       " '16064. Output 04: HIV. HIV. Somalia - Mogadiscio. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12110. Ag Results Contract (via Competition) Additional Evaluation Deliverables - Change to AgResults: Evaluation Contract Two - Research. AG RESULTS CONTRACT (VIA COMPETITION) ADDITIONAL EVALUATION DELIVERABLES - CHANGE TO AGRESULTS: EVALUATION CONTRACT TWO - RESEARCH. The overall objective of the AgResults Initiative is to enhance smallholder welfare and food security for the poor and vulnerable in developing countries through increased investment in agricultural innovation and adoption.  It aims to do so by developing',\n",
       " \"13010. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       " '12262. Reducing the Risk of Artemisinin Resistant Malaria spreading to Africa - Trust Fund. REDUCING THE RISK OF ARTEMISININ RESISTANT MALARIA SPREADING TO AFRICA - TRUST FUND. To address urgent gaps in the response to drug resistant malaria in the Greater Mekong Sub-region (GMS) of South East Asia, with the aim of helping to contain its spread to other countries and regions.',\n",
       " '12110. Feasibility Studies and Detailed Design for the National Hospital in Mbabane. FEASIBILITY STUDIES AND DETAILED DESIGN FOR THE NATIONAL HOSPITAL IN MBABANE. Social/Health',\n",
       " '13040. Scaling up Universal Access for Most at Risk Population in Bosnia and Herzegovina. SCALING UP UNIVERSAL ACCESS FOR MOST AT RISK POPULATION IN BOSNIA AND HERZEGOVINA. The first case of HIV was registered in Bosnia and Herzegovina in 1986. By the end of 2009 the country had registered 134 people living with HIV. The goal of the program supported by this grant is to reduce HIV transmission and improve HIV treatment, care and support in the country. This program will target the following groups that have been identified as being at higher risk of becoming infected with HIV: people who inject drugs, men who have sex with men, sex workers and their clients, cross-border migrants, migrant workers, internally displaced persons, refugees and prisoners, as well as the Roma population and youth who are not referred to specifically as target groups in the National HIV Strategy. The activities funded by this grant will build on those funded under the Round 5 grant to help ensure that HIV prevalence remains below 1 percent in the general population  a key outcome under the current national strategy  and to improve quality of life for people living with and affected by HIV.',\n",
       " '13040. YouthPower - Implementation - HIV/AIDS. YOUTHPOWER - IMPLEMENTATION - HIV/AIDS. The YouthPower - Implementation task order supports missions buying into the YouthPower IDIQ contract for cross-sectoral youth development activities. The task order cover activities including : 1) the implementation of centrally funded pilot activities at the country or regional level; 2) small grant funds for learning and knowledge-sharing within projects; 3) innovation grants; 4) learning events; 5) making available technical assistance and training to missions; 6) stakeholder workshops; and 7) the creation of other appropriate innovation and learning platforms. Because this mechanism is in procurement development, the following key information has not yet been determined: Mechanism No. (Award #), Prime Partner, Start and End dates, Total Estimated Cost. The estimated Start and End dates are 2015 and 2020, respectively.',\n",
       " '12181. Improving health by supporting the formation of quality of doctors and the development of operational research. IMPROVING HEALTH BY SUPPORTING THE FORMATION OF QUALITY OF DOCTORS AND THE DEVELOPMENT OF OPERATIONAL RESEARCH. Improving health by supporting the formation of quality of doctors and the development of operational research. Faculty of Medicine of the Catholic University of Mozambique',\n",
       " '12181. Women Care Sanitary Napkin Project. WOMEN CARE SANITARY NAPKIN PROJECT. The project aims to improve understanding of health and hygiene issues; to establish a sanitary napkin production unit based on training, techniques, equipment and resources to produce hygienic, cost-effective, eco-disposable sanitary napkins; to trial safe modes of eco-friendly/discreet disposal of sanitary napkins within 2 schools and within the 25 target villages; to improve the socio-economic status of women by establishing and running an economically-viable sanitary napkins production unit while marketing and selling sanitary napkins within target area.',\n",
       " '13040. Adult 13042clinical trials. ADULT 13042CLINICAL TRIALS. Adult 13042clinical trials',\n",
       " '12220. Measures to reduce disease and mortality among at-risk groups in South Sudan. MEASURES TO REDUCE DISEASE AND MORTALITY AMONG AT-RISK GROUPS IN SOUTH SUDAN. The overall goal of this project is to strengthen interventions in the health sector in three selected locations of South Sudan = Renk, Leer and Awail. The submitted project is part of a much wider multisectoral program of the implementing partner of the applicant. The project has as its ambition to significantly reduce disease and mortality among groups at risk from conflict, internally displaced people and weakened urban host communities in S. Sudan. A specific emphasis will be placed on women and children, neglected older populations, handicapped and pregnant and nursing women. The provision of long- term supplies of medicine will strengthen the basic health security and prevention of the occurrence of epidemics. The dramatic humanitarian crisis and the high number of needy people creates the need to focus on increasing the capacity of health workers and the provision of critical expert training. Part of this project is also the support of a number of malnutrition centres. We will support the operations of these centres providing health and malnutrition services, which currently are in 28 locations in the regions of Aweil, Leer Mayendit and Renk. According to the need we will initiate mobile service capacity wherever the need emerges and/or wherever the distance from the centre for the population groups is more than 2 hours. The number of recipients of support within this project is projected at nearly 65 000 people.',\n",
       " \"13040. YouthPower - Implementation. YOUTHPOWER - IMPLEMENTATION. The 'YouthPower - Implementation' task order supports missions buying into the' YouthPower' IDIQ contract for cross-sectoral youth development activities. The task order cover activities including : 1) the implementation of centrally funded pilot activities at the country or regional level; 2) small grant funds for learning and knowledge-sharing within projects; 3) innovation grants; 4) learning events; 5) making available technical assistance and training to missions; 6) stakeholder workshops; and 7) the creation of other appropriate innovation and learning platforms. Because this mechanism is in procurement development, the following key information has not yet been determined: Mechanism No. (Award #), Prime Partner, Start and End dates, Total Estimated Cost. The estimated Start and End dates are 2015 and 2020, respectively.\",\n",
       " '13040. Kinerja - HIV/AIDS. KINERJA - HIV/AIDS. The overarching objective of this IM is the provision of innovative and improved service delivery by local governments to citizens. USAID focuses on the governance of service delivery in three sectors: education; health services and; and local business. Activities under this IM address both demand and supply side aspects of service delivery. These investments will result in strengthened accountability mechanisms that improve local government responses to citizens needs. USAID works through local institutions to build their capacity and foster sustainable partnerships with local government. This solidifies the links between stimulation of demand for good services through active civil society engagement and improved local government response.',\n",
       " \"12220. Support to the Mother and Child Health Department of the Medical University Simulation Centre of Moldova.. SUPPORT TO THE MOTHER AND CHILD HEALTH DEPARTMENT OF THE MEDICAL UNIVERSITY SIMULATION CENTRE OF MOLDOVA.. The international evidence proves the effectiveness of training methods based on simulation in comparison with 'traditional  education, improving the practical skills of medical staff. The project will support the introducing simulation training technologies in obstetric, gynecological, neonatal and pediatric emergencies and by this contributing to improving the high medical education in Moldova.\",\n",
       " \"12263. Consolidation and Expansion of the 'Directly Observed Treatment, Short Term (DOTS) Program in Kyrgyzstan by Providing Access to Diagnostics and Treatment of Drug-Resistant Tuberculosis. EXPANSION OF DIRECTLY OBSERVED TREATMENT SHORT TERM (DOTS) PROGRAM KYRGYZSTAN BY PROVIDING ACCESS TO DIAGNOSTICS AND TREATMENT OF DRUG-RESISTANT TB. In Kyrgyzstan, Tuberculosis (TB) re-emerged as an important public health problem after the independence and its burden remains high in the country. The case notification rate is 117 per 100,000 populations and is the third highest among the 53 countries of the World Health Organization European Region. According to the Drug Resistance Survey in 2007, Kyrgyzstan faces a very high multi drug-resistant TB (MDR-TB) prevalence of 25 percent among new positive cases and 54 percent among previously treated cases. The program consolidates Round 6 TB grant by strengthening TB information system, patient incentives, support to local authorities and community involvement in TB control. The goal of the program is to reduce the burden of TB by strengthening of Directly Observed Treatment Short-term (DOTS) framework and by scaling-up the management of Drug Resistance-TB (DR-TB). The program will be implemented using a Dual-Track Financing approach under 2 Principal Recipients, Project Hope and United Nations Development Programme (UNDP). This grant will focus on several activities such as strengthening the human and infrastructural capacities, establishing routine drug resistance surveillance throughout the country, upgrading the laboratory services and providing up-to-date treatment of DR-TB cases with appropriate patient support to ensure adherence.\",\n",
       " '12250. Healthcare Centre MAMA CARLA, La Joie de Vivre Center Bangui, (Analysis laboratory, Dispensary of primary care for children and Telemedicine). HEALTHCARE CENTRE MAMA CARLA, LA JOIE DE VIVRE CENTER BANGUI, (ANALYSIS LABORATORY, DISPENSARY OF PRIMARY CARE FOR CHILDREN AND TELEMEDICINE). The Health Medical Centre MAMA CARLA give the possibility to the needy children, orphans or abandoned housed in the Centre La Joie de Vivre to have free access to the medical services. Medical examination, ambulatory treatments, infectious disease and malaria control, urgent pharmacological treatments and assistance to undernourished are opened also for all the students of the School Nicolas BarrT and to the children living in the surrounding areas from 0 to 14 ages. The Centre organizes hygienic consulting, education and training for mothers. Assistance and training to pregnant women AIDS infected. Health personnel development.',\n",
       " '12182. Targeting cell wall glycans: an untapped approach for therapeutics and diagnostics to combat antimicrobial resistance?. TARGETING CELL WALL GLYCANS: AN UNTAPPED APPROACH FOR THERAPEUTICS AND DIAGNOSTICS TO COMBAT ANTIMICROBIAL RESISTANCE?. Medical Research Council AMR initiative grant looking at cell wall properties  of  TB bacteria  to enable development of new therapies and diagnostics given the current significant issue of multi-drug resistance in this bacteria',\n",
       " '12191. Establishing a network of services for the diagnosis and prevention of oncological diseases in the Horn of Africa. ESTABLISHING A NETWORK OF SERVICES FOR THE DIAGNOSIS AND PREVENTION OF ONCOLOGICAL DISEASES IN THE HORN OF AFRICA. Establishing a service for the diagnosis and prevention of oncological diseases, through the establishment of a Pathology laboratory in Somaliland. Supporting the same on-going service in Djibouti. Starting a cooperation protocol between the two of them',\n",
       " '12181. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 Master and short courses scholarships. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 MASTER AND SHORT COURSES SCHOLARSHIPS. General objective:  Scholarship programme: master and short courses - Specific objective:  To provide a scholarship programme to experienced health professionals from the South, for training at advanced master level and as experts in specific fields of science through short courses - Results:  Financial accessibility has been assured for training at advanced master level in the fields of public health (international health, health systems policy and management and disease control) and tropical animal health  as well as for training at expert short course level (2014 -2016) -',\n",
       " '12250. Nigeria Centre for Disease Control. NIGERIA CENTRE FOR DISEASE CONTROL. to support an emergency response to populations affected by a Meningitis outbreak in Nigeria',\n",
       " '12263. Health Leadership and Governance Program (HLGP). HEALTH LEADERSHIP AND GOVERNANCE PROGRAM (HLGP). To improve health outcomes in USAID areas of maternal and child health (MCH), family planning (FP) and tuberculosis (TB) by enhancing leadership and governance capabilities of local chief executives and local health officers. PROJECT OBJECTIVES: Train local chief executives and local health officers on Bridging Leadership competencies, Improve local health systems to make them more responsive to the needs for MCH, FP and TB prevention and control, Increase community participation and health- seeking behavior in target areas through improved local health systems and local health leadership.',\n",
       " '13030. Nicaragua Media program - Family Planning and Reproductive Health. NICARAGUA MEDIA PROGRAM - FAMILY PLANNING AND REPRODUCTIVE HEALTH. The Nicaragua Media program is a cross-cutting project, managed by FHI 360, designed to support the countrys efforts to improve democracy, governance, economic growth, health, education and the environment. The program works with independent mass media organizations to convey information that supplements and strengthens democracy, development and health messages and assistance programs to a wide array of target audiences. FHI 360 assists independent media at both national and regional levels in designing radio and television shows, print journalism and other communication programs, using state-of-the-art interactive technologies.',\n",
       " '13081. AiN KU- Hospital Midwifery Training. AIN KU- HOSPITAL MIDWIFERY TRAINING. Midwife education and Reproductive health.Agreement partner before PTA 4.0: Institute of Health Science in Jalalabad',\n",
       " \"12110. PNIPH Transition phase. PNIPH TRANSITION PHASE. provide assistance to PNIPH primarily to support the transition of the institute's governance, ownership, and leadership from WHO to PA, while assuring the continuation and development of the Institute's technical and scientific work.During this period, PNIPH will develop long-term plans, bring local and international expertise, and build and adapt approaches that address the main challenges of the Palestinian people.\",\n",
       " '12240. Nutrition Security Program - Nutrition. NUTRITION SECURITY PROGRAM - NUTRITION. The Haiti Nutrition Security Program (NSP) strategy, implemented by Partners of the Americas, is based on a holistic community health, nutrition, and livelihood approach. With FY 2015 resources, the project will continue to recruit and provide support to Mother Leaders, and organize them into Care Groups. Each Mother Leader is then responsible for directing and chairing local neighborhood womens clubs, through which nutrition counseling and best health practices will be shared with additional young pregnant and lactating mothers (of children under the age of five).',\n",
       " '13030. Health Leadership and Governance Program (HLGP). HEALTH LEADERSHIP AND GOVERNANCE PROGRAM (HLGP). To improve health outcomes in USAID areas of maternal and child health (MCH), family planning (FP) and tuberculosis (TB) by enhancing leadership and governance capabilities of local chief executives and local health officers. PROJECT OBJECTIVES: Train local chief executives and local health officers on Bridging Leadership competencies, Improve local health systems to make them more responsive to the needs for MCH, FP and TB prevention and control, Increase community participation and health- seeking behavior in target areas through improved local health systems and local health leadership.',\n",
       " '12182. A knowledge translation through complex interventions - Improving health and care for children and adolescents living with long-term illnesses in Ethi. A KNOWLEDGE TRANSLATION THROUGH COMPLEX INTERVENTIONS - IMPROVING HEALTH AND CARE FOR CHILDREN AND ADOLESCENTS LIVING WITH LONG-TERM ILLNESSES IN ETHI. This collaborative capacity-building project is an extension of a VR-funded project ending 2016. New collaborators are University of Nairobi and International Pregnancy Advisory Services (Ipas). Unsafe abortion is a leading cause of maternal mortality (MM) and morbidity in Kenya. Social stigma surrounding abortion and contraceptive use plays a critical role in social, medical, and legal marginalization of abortion- and contraceptive service. In 2013, Ipas developed the Stigmatizing Attitudes, Beliefs and Actions Scale (SABAS) to measure abortion stigma at individual and community level. Objective: I) to conceptualize abortion stigma among health care providers in youth friendly centres, teachers and students in secondary school (14-18 y) in a sub-urban area with high MM, and II) to determine if a school based abortion- and contraceptive-stigma reduction intervention will decrease stigma, and increase contraceptive use among students. Design, Setting, Participants: I) focus group discussions with providers, teachers and students, and II) a quantitative quasi-experimental intervention study involving 800 students from schools in western Kenya that will be cluster-randomised into intervention and control units. Main Outcome: abortion-stigma. Secondary outcome: contraceptive use. Outcome measured by using the validated SABA-scale before and after intervention and comparing intervention and control schools. Analyses: Qualitative content analysis and repeated measures ANOVA (PASW).',\n",
       " '12220. National Health and Family Planning Commission. NATIONAL HEALTH AND FAMILY PLANNING COMMISSION. to reduce health-related poverty through the improvement of basic healthcare system performance in rural China, and facilitate the sharing of the learning to benefit other developing countries',\n",
       " \"12191. KHARTOUM  SALAM  CARDIAC CENTRE. KHARTOUM  SALAM  CARDIAC CENTRE. EMERGENCY's Salam Centre for Cardiac Surgery in Khartoum provides cardiological examinations and cardiac surgery free of charge. Since 2007, the Salam Centre has treated over 61,000 patients from 27 different countries.\",\n",
       " '12263. Leadership, Management, Governance (LMG). LEADERSHIP, MANAGEMENT, GOVERNANCE (LMG). The Leadership, Management, Governance (LMG) project builds in-country health and education system capacity by increasing leadership, management, and governance knowledge of health care providers, program managers, and policy makers who work on health services.',\n",
       " '13020. Mapping of actors - migration & SRHR ESA region. MAPPING OF ACTORS - MIGRATION & SRHR ESA REGION. The purpose with this deskstudy is to identify potential collaborating partners to the Regional SRHR Team in Lusaka with focus on migration and SRHR. KIT will be contracted to undertake this study.',\n",
       " '12240. Support to Operational Trial project  in Zambia to reduce child mortality from diarrhoea. SUPPORT TO OPERATIONAL TRIAL PROJECT  IN ZAMBIA TO REDUCE CHILD MORTALITY FROM DIARRHOEA. To improve child nutrition by providing children under 5 with direct nutrition support (Vitamin A and deworming tablets), piloting improved access to anti-diarrhoea kits, testing the efficacy of vitamin A enriched maize and supporting the government of Za',\n",
       " \"13040. Strengthening of the national response to HIV/AIDS for transition to the scale of prevention structures and global treatment. STRENGTHENING OF THE NATIONAL RESPONSE TO HIV/AIDS FOR TRANSITION TO THE SCALE OF PREVENTION STRUCTURES AND GLOBAL TREATMENT. Chad ranks among the least developed countries. A 2003 epidemiological study estimated HIV prevalence at around 8 percent of the adult population, with 200,000 individuals infected with HIV. The program supported by this grant aims to decentralize services through coordination with the National AIDS Committee A 'minimum activity package' for prevention, health care and treatment will also be set up in 57 health care districts according to criteria based on the characteristics of the epidemic, the health care chart, the possibility of progression for the health care system, the demographic and cultural context, and the geographic disparities of Chad. The program targets women living in vulnerable situations; people living with HIV; young people; orphans and other vulnerable children; people who sell sex; and mobile groups and nomads. It will focus on behavior change communication and community outreach and on strengthening managerial and organizational capacities of community-based organizations and networks of people living with HIV.\",\n",
       " '13020. Innovations in Maternal Child Health. INNOVATIONS IN MATERNAL CHILD HEALTH. The Clinton Health Access Initiative supports the development of high quality basic health care for all, by facilitating the effective distribution of health services and an efficient management of health systems, in cooperation with the government. This project supports the national initiative of the Mozambican government to achieve the health targets by 2015 by reinforcing the national health system and increasing the number of HIV patients in treatment.The project has the following specific objectives:1. the early detection of infections, with specific attention to mothers and children2. the reduction of mother-to-child transmission 3. increased access and better health results for a population of 8.8 million patients.  Expected outcome: 1. early detection of diseases, with specific attention for mothers and children;2. reduction of mother-child transmission;3. improved access to health care for the general population. Document available at  https://drive.google.com/file/d/0B-IUzKYaN-QSZzlVNVNmM0RMY1E/edit?usp=sharing',\n",
       " \"12110. LAUNCH Food. LAUNCH FOOD. Health LAUNCH is an open innovation process that seeks to discover new solutions to intractable development challenges facing the Indo-Pacific region. The programme will focus on malnutrition caused by poor food intakes and seeks to (i) reduce the amount of permanent stunting and wasting and under 5 deaths caused by under nutrition in the Indo-Pacific and (ii) reduce the incidence of non-communicable disease caused by malnutrition. Currently up to 50 per cent of all child hood deaths in the region are caused by under nutrition and up to 1 in 2 children are physically or mentally stunted as a result of chronic under nutrition in the first thousand days of life. 98 per cent of all Tongans are at medium to high risk of premature death as a result of non-communicable disease. This initiative is a co-investment between Australia's Department of Foreign Affairs and Trade and USAID valued at $2.3 million over 3 years, starting 2015-16.\",\n",
       " '13040. Enhanced Effective ICT. ENHANCED EFFECTIVE ICT. The objective is to bridge the digital divide and spur information access and use for innovation and development in Kenya.',\n",
       " '13040. Projet de prTvention du SIDA chez les travailleurs(euses)  du sexe au Kenya pour identifier les bonnes pratiques dans la prTvention du VIH chez ces pe. PROJET DE PR+VENTION DU SIDA CHEZ LES TRAVAILLEURS(EUSES)  DU SEXE AU KENYA POUR IDENTIFIER LES BONNES PRATIQUES DANS LA PR+VENTION DU VIH CHEZ CES PE. General Objectives  To strengthen the rational basis and the country ownership of (human and animal) healthcare systems and policies in developing countries, in order to improve the health status ofthe populations and thereby to contribute to the reduction of poverty and inequity.  Specific Objectives  To identify best practices for the scaling up and evaluation of HIV prevention among sexworkers in developing countries (sub-Saharan Africa in particular) Results  Result 1 different methods for measuring the coverage of sex worker projects are evaluatedResult 2 Guidelines for quality assessment of sex workers interventions are elaboratedResult 3 A generic study protocol for measuring outcome indicators including condom useand STI/HIV prevalence rates is available and pretestedResult 4 Strategies for improving safe sex behaviour of sex workers on ART are identified',\n",
       " \"12262. Government Technical Assistance Provider (GoTAP). GOVERNMENT TECHNICAL ASSISTANCE PROVIDER (GOTAP). This contract provides technical assistance to entities that receive direct financing under USAID's government-to-government (G2G) program in the health sector. Assistance is in technical areas in the health sector (e.g. how to improve lagging health indicators) and capacity building in governance and management (e.g. ensuring government entities understand G2G requirements and effectively oversee implementation); it will enable target regions to sustain their health outcomes, reinforce the Ministry of Health's (MOH) stewardship role, and increase domestic spending on health. GoTAP also provides assistance to USAID to better align G2G investments with MOH processes, and provides analytical support to USAID and the MOH to improve use of data for decision-making and identify opportunities for adjustments in USAID health programming.\",\n",
       " \"12110. Supporting the development and functioning of Moldovan health insurance system. SUPPORTING THE DEVELOPMENT AND FUNCTIONING OF MOLDOVAN HEALTH INSURANCE SYSTEM. The objective of the project is to support the development and functioning of Moldovan health insurance system through sharing Estonian experience and practices. The project entails 5 study visits, including the round-up visit at the end of the project. Throughout all visits, one specific topic of the visit will be covered thoroughly.The main topics covered are strategic purchasing, quality systems development, benefit package development, partner management, organization's and health insurance system's development. The initial visit of the project will take place between Estonian and Moldovan health insurance funds in spring 2016 according to the collaboration agreement between the EHIF and the CNAM. The expenditures of this visit are not included to the cost report of this project.\",\n",
       " '13020. HED Partnership: Center for Excellence in Health and Life Sciences - Maternal and Child Health. HED PARTNERSHIP: CENTER FOR EXCELLENCE IN HEALTH AND LIFE SCIENCES - MATERNAL AND CHILD HEALTH. University of Liberia/Indiana University/University of Massachusetts Medical School: Center for Excellence in Health and Life Sciences - This partnership seeks to address the challenges that the University of Liberia (UL) and its sister public institution, the Tubman National Institute of Medical Arts (TNIMA), face in supplying health care workers equipped to address Liberia healthcare needs. The U.S. partners have shared expertise in a variety of ways, from collecting and sending current textbooks in biology, chemistry, mathematics, nursing, and other courses to providing six-week summer study tours for Liberian faculty in the United States. In addition, the partners have collaborated to create a new two-year Core Health and Life Science Undergraduate Program and begin planning for a joint four-year bachelors program in nursing science. Partners have also worked together to improve instructional quality in introductory science courses, develop upgrades to the preclinical science curriculum at the University of Liberias medical and pharmacy Colleges, and modernize the University of Liberias teaching and learning resources.',\n",
       " '13020. Maternal and Child Health - Treatment of Obstetric Complications and Disabilities. MATERNAL AND CHILD HEALTH - TREATMENT OF OBSTETRIC COMPLICATIONS AND DISABILITIES. Maternal and Child Health - Promote recognition and treatment of obstetric complications by women, their partners and the community, such as post-abortion care, management of hypertension, induction or augmentation of labor, assisted delivery, blood transfusion, surgery (including cesarean section, repair of lacerations, and management of postpartum hemorrhage); and management of pregnancy-related disabilities including case identification, medical management of chronic problems such as anemia, and surgical repair and postoperative rehabilitation of obstetric fistula.',\n",
       " '12110. Global Health Support Initiative II (GHSI II) - Administration and Oversight. GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II) - ADMINISTRATION AND OVERSIGHT. The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the programs vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.',\n",
       " \"12220. AmTliorer les rTsultats liTs a la santT des femmes et des enfants/Strengthening Health Outcomes for Women and Children. AM+LIORER LES R+SULTATS LI+S + LA SANT+ DES FEMMES ET DES ENFANTS/STRENGTHENING HEALTH OUTCOMES FOR WOMEN AND CHILDREN. This project seeks to improving the health of women, adolescent girls, mothers, newborns and children in under-served areas taking a community-based approach and working with local health authorities.All project countries have established meaningful health legislation, governance bodies, and in some instances, the necessary infrastructure. Due to weak quality, inclusiveness (e.g. youth-friendliness), and gender-responsiveness of health services delivery and health care management, service delivery, operationalization and increased access and utilization of maternal newborn child health/sexual and reproductive health services (MNCH/SRH) require support. Specific challenges include: 1) weak health seeking behaviour by disadvantaged, vulnerable and marginalised women of child bearing age (WCBA) and their families; Particularly high MNCH/SRH risks exist for adolescent mothers and high rates of child, early, and forced marriage (CEFM); 3) WCBA's lack of decision-making capacity and low access to and control over social and economic assets due, to pervasive gender inequality; 4) inaccessible, fragmented and client-unfriendly health systems; 5) low numbers and inadequate skills of Community Health Workers and frontline workers to provide quality, gender responsive, adolescent friendly health care; and 6) irregular tracking and use of data by Ministry of Health, and poor accountability of health services to local communities.Project activities include: (1) raising awareness of local leaders, role models and various community groups on ongoing MNCH services, positive healthcare practices, including health care seeking behaviours; (2) training health care providers at both community and health facility levels on key MNCH interventions; (3) providing essential medicines and other medical supplies; (4) training health administrators and local health committees on planning, supervision and oversight of health resources and facilities; (5) training for health workers and drivers in referring patients requiring more advanced care at specialized facilities, including providing health facilities with mobile technology and vehicles to facilitate emergency transportation; (6) training and mentoring health care staff on improved data collection and reporting to inform local government resource planning; and, (7) implementing digital and media campaigns to raise awareness of Canadian public on global MNCH issues. This initiative is expected to contribute directly to the improved health of approximately 1 million women, more than 900,000 children under five years of age, and over 200,000 adolescent girls, as well as over 1.1 million men with improved MNCH services. An estimated 1.8 million individuals are expected to benefit from the initiative's results indirectly. In addition, activities targeting Canadian awareness of MNCH are expected to reach over 700,000 Canadians.Plan International Canada is implementing this project in partnership with Promundo and the Hospit\",\n",
       " '12220. development Research and Projects Centre. DEVELOPMENT RESEARCH AND PROJECTS CENTRE. to improve the lives of women and girls, particularly through promoting the use of modern Primary Health Care services including routine immunization, Maternal health services and promoting girls education in Kano state',\n",
       " '12191. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Establishing neurosurgery unit at Addis Ababa University Hospital and a training program.',\n",
       " '13010. Support Georgia for proper and balanced immigration policy formation. SUPPORT GEORGIA FOR PROPER AND BALANCED IMMIGRATION POLICY FORMATION. Overall objective: to enhance the role of Geo NGO sector and increase their involvement in implementation of activities directly linked to ENP and promotes fulfilment of its objectives. Specific objectives: 1) Study on immigration of foreigners in Georgia: 2) Formation of immigration and visa policy and policy building methodology, in partnership with civil society.',\n",
       " '12182. Developing and evaluating a framework for the rational design of antibiotic prescribing policies in resource-constrained hospital settings. DEVELOPING AND EVALUATING A FRAMEWORK FOR THE RATIONAL DESIGN OF ANTIBIOTIC PRESCRIBING POLICIES IN RESOURCE-CONSTRAINED HOSPITAL SETTINGS. Medical Research Council. Fellowship  to model a framework for better antibiotic prescribing policies in resource-constrained hospital settings',\n",
       " \"12240. USAID/Uganda Social Marketing Activity. USAID/UGANDA SOCIAL MARKETING ACTIVITY. The Social Marketing Activity will serve as USAID Uganda's flagship program for Social Marketing and successor to USAID Uganda's AFFORD program, which ends in September 2014. The program's goal is to contribute to a reduction in new HIV infections, total fertility, maternal and child mortality, malnutrition and malaria, and to improve access to family planning.This four-year activity aims to improve utilization of health-related social marketing products and services among under-served Ugandan consumers in rural and urban areas.\",\n",
       " '13030. Improving the Performance of Nurses (IPN). IMPROVING THE PERFORMANCE OF NURSES (IPN). Improving the Performance of Nurses (IPN) in Upper Egypt is a partnership between MSH and the Nursing Program of the Om Habibeh Foundation, an Aga Khan Foundation affiliate. The programs goal is to build the leadership and management capacity of hospital and primary health care facility nurses for .improvement in the areas of infection control, basic nursing skills, and communication, in the governorates of Aswan, Luxor, Qena, Sohag and Assiut. The IPN program applies the Leadership Development Program as the core technical approach for the intervention. In the first phase of the project, the IPN will target facilities in Aswan. The second and third phases will target hospitals in Luxor and Quena, and in Sohag and Assiut respectively.',\n",
       " \"12263. Communication for Change (C-Change) in DRC. COMMUNICATION FOR CHANGE (C-CHANGE) IN DRC. FHI 360's Communication for Change (C-Change) project in the Democratic Republic of the Congo (DRC) seeks to increase positive health behaviors through evidence-based, social and behavior change communication (SBCC) programs that focus on family planning, HIV/AIDS, gender-based violence, malaria, tuberculosis, water sanitation, maternal and child health, nutrition and HIV, and prevention of mother-to-child transmission of HIV. C-Change is working at central and provincial levels to build managerial and SBCC skills within the government, nongovernmental organizations and civil society organizations. We envision building local capacity to plan, monitor and evaluate scientifically based SBCC interventions, so the DRC becomes a regional leader offering state-of-the-art SBCC approaches to neighboring countries.\",\n",
       " '16064. Output 04: HIV. HIV. Iran - Teheran. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12220. Children first: Strengthening the capacity of medical staff to provide quality referral services for managing paediatric emergency responses in Orotta. CHILDREN FIRST: STRENGTHENING THE CAPACITY OF MEDICAL STAFF TO PROVIDE QUALITY REFERRAL SERVICES FOR MANAGING PAEDIATRIC EMERGENCY RESPONSES IN OROTTA. The project aims at strengthening the capacity of medical staff to provide quality referral services for managing paediatric emergency responses in Orotta Paediatric Hospital.',\n",
       " '13040. Support to the HIV/AIDS Response in Zambia (SHARe II) - HIV/AIDS. SUPPORT TO THE HIV/AIDS RESPONSE IN ZAMBIA (SHARE II) - HIV/AIDS. Support to the HIV/AIDS Response in Zambia (SHARe II) is a continuation of the work begun in 2004, and the overall assistance objective remains to strengthen and support the mutisectoral response to HIV & AIDS in Zambia. The previous project built a solid foundation of systems, tools, communications, and information sharing and policies. This next phase of the project is focusing on the continuation of enhanced assistance, with an emphasis on quality, equitable implementation, and leadership accountability, with an added emphasis on the documenting and sharing of best practices. The project is examining and working to address the structural drivers of HIV as well as the behavioral drivers of the disease. SHARe II supports the Government of Republic of Zambia (GRZ)s vision of a nation free from the threat of HIV, and is working in partnership with the National HIV/AIDS/STI/TB Council, cooperating partners (including the Global Fund, UNFPA, DfID, and other bilateral, multilateral, and private sector partners), and other stakeholders to support efforts to mitigate the impact of HIV in Zambia.',\n",
       " '13020. Leadership, Management, Governance (LMG) - Maternal and Child Health. LEADERSHIP, MANAGEMENT, GOVERNANCE (LMG) - MATERNAL AND CHILD HEALTH. The Leadership, Management, Governance (LMG) project builds in-country health and education system capacity by increasing leadership, management, and governance knowledge of health care providers, program managers, and policy makers who work on health services.',\n",
       " '12110. Technical Assistance for Hospital Management and Human Resources Policies. TECHNICAL ASSISTANCE FOR HOSPITAL MANAGEMENT AND HUMAN RESOURCES POLICIES. The Bolivian ministry of health (MS) is immersed in a process of modernization of all his healthcare levels, management decentralization from the national level to the County Health Services (in Spanish, Servicios Departamentales de Salud + SEDES) and Str',\n",
       " '12263. African Collaborative for Health Financing Solutions (ACS). AFRICAN COLLABORATIVE FOR HEALTH FINANCING SOLUTIONS (ACS). The African Collaborative for Health Financing Solutions (ACS) will advance Universal Health Coverage (UHC) in Sub-Saharan Africa by working with regional bodies and country-level multi-stakeholder platforms to share knowledge, strengthen accountability and promote sound health financing policies. ACS will partner with regional institutions to strengthen their role in policy, advocacy, and regional learning on health financing approaches.',\n",
       " '12191. Egypt-Swiss Radiology Project. EGYPT-SWISS RADIOLOGY PROJECT. Egytp-Swiss Radiology Project III - TAP. After the successful implementation of the Second Phase, which lasted between 2007 and 2011, a Third Phase to extend the digital radiology services has been initiated. The objective of the new phase is to expand the digital radiology services in Egypt based on the experiences and lessons learned from the pilot sites for digital radiology introduced in the 2nd Phase. In addition, the Project shall also support and have synergies with the Egyptian national initiative initiated in late 2009, the Picture Archiving and Communication System. Following activities are planned to reach this objective: the rehabilitation of sites receiving mainly digital radiology services and equipment, the provision of radiology equipment, the assistance for the maintenance and financial sustainability of the radiology technology and the training and capacity building programme for the radiology staff. At project completion, it is expected that about 22 radiology departments in selected hospitals shall be renovated and rehabilitated, the equipmment maintenance and technology management shall be strenthened and financially sustainable, radiation safety is applied by training measures and supervision schemes. The implementing agency for this project is the Egyptian Ministry of Health and Population. This is a project mixed-financed by Switzerland (50% by SECO, 50% by Swiss banks).',\n",
       " \"13030. YouthPower - Implementation. YOUTHPOWER - IMPLEMENTATION. The 'YouthPower - Implementation' task order supports missions buying into the' YouthPower' IDIQ contract for cross-sectoral youth development activities. The task order cover activities including : 1) the implementation of centrally funded pilot activities at the country or regional level; 2) small grant funds for learning and knowledge-sharing within projects; 3) innovation grants; 4) learning events; 5) making available technical assistance and training to missions; 6) stakeholder workshops; and 7) the creation of other appropriate innovation and learning platforms. Because this mechanism is in procurement development, the following key information has not yet been determined: Mechanism No. (Award #), Prime Partner, Start and End dates, Total Estimated Cost. The estimated Start and End dates are 2015 and 2020, respectively.\",\n",
       " '12240. Food and Nutrition Technical Assistance III (FANTA-III) - Nutrition. FOOD AND NUTRITION TECHNICAL ASSISTANCE III (FANTA-III) - NUTRITION. The Food and Nutrition Technical Assistance Project (FANTA) has been working to improve the health and well-being of vulnerable individuals, families, and communities in developing countries by strengthening food security and nutrition policies, programs, and systems. The project provides comprehensive technical support to USAID and its partners, including host country governments, international organizations, and nongovernmental organizations. FANTA works at both the country and global levels, supporting the design and implementation of programs in focus countries, and building on field experience to strengthen the evidence base, methods, and global standards for food security and nutrition programming.',\n",
       " '12182. Applied Research in India, Partner Driven Cooperation within the health sector - 016 StslsbyLundborg,Antibiotic stewardship netw,KI. APPLIED RESEARCH IN INDIA, PARTNER DRIVEN COOPERATION WITHIN THE HEALTH SECTOR - 016 ST+LSBYLUNDBORG,ANTIBIOTIC STEWARDSHIP NETW,KI. Call for applications in the prioritised area of health in India.',\n",
       " '12110. Global Antimicrobial Resistance (AMR) Innovation Fund  UK China AMR Bilateral Research and Development Competition  Project Support Officer. GLOBAL ANTIMICROBIAL RESISTANCE (AMR) INNOVATION FUND  UK CHINA AMR BILATERAL RESEARCH AND DEVELOPMENT COMPETITION  PROJECT SUPPORT OFFICER. UK-China Innovation Collaboration to address the challenges of AMR for the benefit of low and middle income countries. Project Support Officer based in British Embassy Beijing to provide assistance for building and strengthening the GAMRIF collaboration with MoST.',\n",
       " '12261. Going to health. GOING TO HEALTH. Enhancement of health education for the vulnerable population, especially women and children exposed, cause infected waters, to the spread of malaria and TB, to sexually transmitted diseases and to the pathologies of motherhood. The project includes a medical laboratory with basic sanitary equipment, a kitchen equipped for simulation, computer equipment, training activities on the context of extreme poverty and gender violence on women',\n",
       " '12263. CEPAT-NU: Increase Community Participation and Demand for Quality Diagnosis and Treatment Services - Tuberculosis. CEPAT-NU: INCREASE COMMUNITY PARTICIPATION AND DEMAND FOR QUALITY DIAGNOSIS AND TREATMENT SERVICES - TUBERCULOSIS. CEPAT-NU: Increase Community Participation and Demand for Quality Diagnosis and Treatment Services for TB Patients and to Advocate for Increased TB Resources and Improved TB Services in Indonesia. The Community Empowerment of People Against Tuberculosis (CEPAT) project is working at the community level, engaging religious leaders, with support from partner LKNU, the largest Muslim organization worldwide. CEPAT is coordinating the TB community support model with TB activities in the health system. In this way, the project ensures a continuum of care of TB patients from the health system to the community, strengthening TB prevention and control efforts.',\n",
       " '12110. Budget Support to the Health Sector in Kyrgyzstan. BUDGET SUPPORT TO THE HEALTH SECTOR IN KYRGYZSTAN. SDC has provided support to the health care reforms in Kyrgyzstan since early 2000. Despite several political disturbances, the Kyrgyz Government has made good progress in reforming the health sector and has achieved universal coverage for basic health services. There is however still scope to further improve quality of health services to reach health outcomes (MDGs) during the next reform period (2012-2016). SDC will thus support reforms through a Sector Wide Approach under strong leadership of the Ministry of Health.',\n",
       " '16064. Restless Development ( formerly SPW) Phase II - Restless Development (formerly SPW) Phase II. RESTLESS DEVELOPMENT ( FORMERLY SPW) PHASE II - RESTLESS DEVELOPMENT (FORMERLY SPW) PHASE II. Restless Development is a Tanzanian NGO that delivers youth development and leadership programmes. It places young people at the forefront of change and development. It implements programmes that mobilise young people so they can empower others to make informed decisions about issues affecting their lives and those of their communities.',\n",
       " \"13040. Global Broadband Internet Partner (GBIP) - NetHope Plus Up. GLOBAL BROADBAND INTERNET PARTNER (GBIP) - NETHOPE PLUS UP. This activity is now known as Women and the Web. It is a public-private partnership among USAID, NetHope, Intel Corporation, World Pulse, World Vision, UN Women, and Women in Technology in Nigeria. Alliance partners will combine efforts to transform the lives and livelihoods of girls and women in Africa through digital literacy training, relevant content, policy work, and online social networks. The Alliance will introduce girls and women to the transformative benefits of the Internet. All partners share a common interest in increasing access to and use of the Internet to realize the socio-economic benefits for all of bringing more girls and women online. This effort will expand opportunities for young women to generate greater income, receive a quality education, increase their sense of empowerment and equity, extend their support networks, and increase their political participation. Funding to support this activity comes from the Women's Leadership initiative.\",\n",
       " \"12220. Health Sector Reform Support Programme. HEALTH SECTOR REFORM SUPPORT PROGRAMME. The Health Basket Fund has played a crucial role for the devolution ('decentralisation') of health services' responsibility to the Local Government Authorities. The regular dialogue between the Development Partners and the Government on the use of this funding has allowed important improvements in the implementation of the sector reform. The combination of increase of funding with financial decentralisation and technical support for more equity has given the councils the possibility to increase resources for evidence based interventions.The Health Basket Fund respects the principles of the Paris Declaration and the Joint Assistance Strategy for Tanzania. For this new phase of support, the objectives and indicators of the HSSP 3 will be used to follow up the progresses in the performance of the sector. In order to improve the efficiency in the use of the funds, the basket partners will further align to Government procedures, but at the same time implement measures to strengthen the management (both at district and central level), streamline the fund transfer procedure to avoid delays and improve the quality of planning and reporting. The share of the Health Basket funding for the councils will be further increased and more discretion given to the Local Health Authorities to develop their own solution to respond to general or local challenges.\",\n",
       " '13081. Action Plan on the Guidelines for the introduction of the issue of disability in the policies and activities of the Cooperation. ACTION PLAN ON THE GUIDELINES FOR THE INTRODUCTION OF THE ISSUE OF DISABILITY IN THE POLICIES AND ACTIVITIES OF THE COOPERATION. This project aims at promoting the action plan concerning the guidelines for the introduction of the issue of the disability in the Cooperation policies and activities',\n",
       " '12110. Healthy China 2020 : Policy and Technology Evaluation. HEALTHY CHINA 2020 : POLICY AND TECHNOLOGY EVALUATION. In April 2009, China issued a new round of health sector reform policies aimed at providing a blueprint for universal basic healthcare coverage for all by 2020. The China Health Economics Institute (CHEI) within the Chinese Ministry of Health is responsible for research and evaluation in support of the new policies through the newly created China Centre for Health Policy and Technology Evaluation (CHPTE). This grant will provide the Institute and the Centre with the necessary capacity building to carry out their mandate of monitoring and evaluating progress toward the 2020 goal. It will also enable the Institute to become a leading regional centre in health policy evaluation.',\n",
       " '12182. Gender and health in org, Gbg university etc. GENDER AND HEALTH IN ORG, GBG UNIVERSITY ETC. GU together with SIGN partners has submitted a proposal for  Gender, Leadership and Health Promotion in Working Life  with a total budget of 6.4 MSEK of which Sida is asked to cover almost 3 MSEK. The aim is a long-term cooperation in research, exchange programs for teachers, students and practitioners as well as knowledge dissemination between universities and organizations in India and Sweden.',\n",
       " \"13040. Church of Sweden Framework agreement 2014-2016, 2017. CHURCH OF SWEDEN FRAMEWORK AGREEMENT 2014-2016, 2017. This contribution is implemented by Church of Sweden in partnership with about 110 local civil society organisations in several cooperation countries in Africa, Asia, Latin America and the Middle East during 2014-2016 with support from Sida/CIVSAM amounting to 291 000 000 SEK, with the aim to strengthen civil society capacities and contribute to the following programme objectives:- Strengthening of people's sexual and reproductive health and rights.- People living in poverty have the right to protection and their social and economic emancipation is strengthened.- People have increased safety and protection, and are empowered to deal with conflicts and to participate in peace processes.- Women and men have improved opportunities and possibilities to equal participation, voice and leadership in the church and in society.- People's right to physical and sexual integrity in the church and in society is strengthened.Church of Sweden has proposed an extension of this contribution, on basis of the existing results framework, and with a budget of 119 419 916 for the year 2017, thereby increasing the total budget to 410 419 916 SEK for the period 2014-2017.Appraisal of the contribution:The appraisal during 2016 of this contribution is made in accordance with a decision on an additional contribution, since it builds upon the appraisal of the same programme for the period 2014-2016. Hence the assessment made for the period 2014-2016 is still relevant and referred to, whereas an update is given for the period 2017 with special emphasis on:- The relevance of the contribution in the light of the strategy for CSO support 2016-2022.- The development of the contribution during 2014-2016 and focus for 2017.- Capacities, internal management and control during 2016-2016.\",\n",
       " '12110. Scholarship Talent Spotting Programe (2017-2018 course). SCHOLARSHIP TALENT SPOTTING PROGRAME (2017-2018 COURSE). Promgrama de becas de atracci=n al talento de la Universidad de JaTn para cursar estudios de grado y master en la UJA',\n",
       " '13040. Reinforcing the Scaling Up of HIV Services: Strengthening HIV Prevention and Effective Targeting. REINFORCING THE SCALING UP OF HIV SERVICES: STRENGTHENING HIV PREVENTION AND EFFECTIVE TARGETING. Ghana has a generalized HIV epidemic with pockets of high prevalence among most-at-risk populations (MARPs), namely men having sex with men (MSM) and their female partners, female sex workers (FSWs), prison inmates, most-at-risk youth (15-24), workers (miners, uniformed services, transport workers), and vulnerable groups such as young boys and girls and female porters, as well as population in some geographic areas which are disproportionally affected by the epidemic. The prevalence rate has remained stable and below 5% over the past 16 years. The current national prevalence is 1.9% and prevalence among pregnant women is 2.6% (2007 sentinel surveillance report: National AIDS Control Program/Ghana Health Services).This Program addresses gaps in the national response such as 1) superficial understanding of HIV in many segments of the population including youth, and an inability to move people from general knowledge and awareness of risk to actually adopting safer behaviors; 2) insufficient targeting of MARPs and vulnerable groups; 3) slow integration of HIV/AIDS and Sexual Reproductive Health (SRH); 4) shortfalls in institutional and community capacities to rapidly scale-up comprehensive HIV services.Recognizing that clients of MARPs serve as a bridge between MARPs and general population in HIV transmission, this Program targets MARPs, vulnerable groups and general population. As part of health system strengthening measures directly related to HIV services, this Program targets blood safety, prevention of mother-to-child transmission (PMTCT), early infant diagnosis, and integration of HIV and sexually transmitted infections (STI) services.As a part of the strengthening national health system in its response to HIV epidemic and emphasizing the need of stronger partnerships between the public health sector, civil society and the private sector, this Program will be implemented by multiple Principal Recipients, as of the effective date of this Agreement, the Ministry of Health/Ghana Health Services, Ghana AIDS Commission (the Principal Recipient), Planned Parenthood Association of Ghana, Adventist Development and Relief Agency of Ghana. 2.Goal:  To reduce new HIV infections in the general population.Target Group/Beneficiaries:People living with HIV/AIDS (PLHIV);MARPs: MSM and their female partners, FSWs, Prison inmates, most-at-risk youth (15-24), Workers (miners, uniformed services, transport workers);Vulnerable groups: young people (aged 15-24), female porters;Pregnant women;Infants born to HIV-positive pregnant women; andGeneral population4.Strategies:To promote the adoption of safer sexual practices in the general population;To promote healthy behaviors and the adoption of safer sexual practices among PLHIV, MARPs and vulnerable groups; To promote the integration of SRH and HIV/AIDS services with emphasis on PMTCT and safe blood transfusions; andTo strengthen the institutional capacity and community systems for scaling-up HIV/AIDS, STI a',\n",
       " \"12263. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       " '12230. The Project for Improvement of Medical Environment at Railway Hospital in Bishkek City. THE PROJECT FOR IMPROVEMENT OF MEDICAL ENVIRONMENT AT RAILWAY HOSPITAL IN BISHKEK CITY. The Project for improvement of medical environment by providing medical equipment including Endosurgery Set, Anesthesia Respiratory Apparatus.',\n",
       " '16064. Output 04: HIV. HIV. Turkey - Ankara. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '13040. Output 04: HIV. HIV. Timor Leste. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '13040. Chinese Association of STD & AIDS Prevention and Control. CHINESE ASSOCIATION OF STD & AIDS PREVENTION AND CONTROL. to ensure greater access to HIV/AIDS and tuberculosis (TB) health resources through strategic and global advocacy',\n",
       " '13040. Support to the HIV/AIDS Response in Zambia (SHARe II) - HIV/AIDS. SUPPORT TO THE HIV/AIDS RESPONSE IN ZAMBIA (SHARE II) - HIV/AIDS. Support to the HIV/AIDS Response in Zambia (SHARe II) is a continuation of the work begun in 2004, and the overall assistance objective remains to strengthen and support the mutisectoral response to HIV & AIDS in Zambia. The previous project built a solid foundation of systems, tools, communications, and information sharing and policies. This next phase of the project is focusing on the continuation of enhanced assistance, with an emphasis on quality, equitable implementation, and leadership accountability, with an added emphasis on the documenting and sharing of best practices. The project is examining and working to address the structural drivers of HIV as well as the behavioral drivers of the disease. SHARe II supports the Government of Republic of Zambia (GRZ) s vision of  a nation free from the threat of HIV,  and is working in partnership with the National HIV/AIDS/STI/TB Council, cooperating partners (including the Global Fund, UNFPA, DfID, and other bilateral, multilateral, and private sector partners), and other stakeholders to support efforts to mitigate the impact of HIV in Zambia.',\n",
       " \"12281. Upgrade and standardization of the 'Orthopedic Technician Training' -Strengthening Disability and Rehabilitation Health Services through Increased num. UPGRADE AND STANDARDIZATION OF THE 'ORTHOPEDIC TECHNICIAN TRAINING' -STRENGTHENING DISABILITY AND REHABILITATION HEALTH SERVICES THROUGH INCREASED NUM. The specific objective of this procedure is:   1.To implement the three years curriculum of orthopaedic technologists in close coordination with MoPH.  2.Improving the quality of the training and filling the human resource shortage in the specific public orthopaedic centres.\",\n",
       " '13030. Roads to a Healthy Future II (ROADS II) Project - Family Planning and Reproductive Health. ROADS TO A HEALTHY FUTURE II (ROADS II) PROJECT - FAMILY PLANNING AND REPRODUCTIVE HEALTH. Regional Outreach Addressing AIDS through Development Strategies (ROADS) project has linked communities along these corridors with critical HIV/AIDS and other health services by collaborating closely with national AIDS control programs; government ministries; district health management teams; health facilities; and local, national and international companies. The project helps individuals and communities reduce their vulnerability to HIV by expanding economic opportunities and improving food security. The project s LifeWorks component provides training and technical assistance in group savings and loan, livestock management (chickens, rabbits and goats), urban and organic gardening and microenterprise development. The ROADS project also provides care and support for orphans and other at-risk children, and it works to protect women and girls from sexual exploitation and abuse.',\n",
       " '13030. GOAL. GOAL. to help develop new family planning methods for young people in urban regions of Kenya by using mobile technology to conduct surveys to find out their opinions on contraceptives, and engaging them to brainstorm solutions',\n",
       " \"13040. Systems Strengthening for Better HIV/TB Patient Outcomes (Wits Reproductive Health and HIV Institute). SYSTEMS STRENGTHENING FOR BETTER HIV/TB PATIENT OUTCOMES (WITS REPRODUCTIVE HEALTH AND HIV INSTITUTE). This award supports the facility management, the district management and its District Health Management Teams and the provincial management. The goal of the project is to improve HIV-related population outcomes by: strengthening management systems at facilities; building the capacity of facility teams and management systems in coordination with the North West and Gauteng Provinces to support and integrate TB/HIV related services; supporting facilities in identifying and setting up policies and programs to improve the district's facility response to providing HIV/TB care, treatment, laboratory and prevention services to support transition to a sustained national comprehensive HIV/TB care and treatment program in line with GoSA's key priorities of PHC re-engineering and national health insurance. The overall strategy involves a roving team allocated to each sub-district's PHCs and CHCs, who are managed by a sub-district manager and supported by a back-up team based in the sub-district. These teams develop the capacity of DoH staff through targeted, on-site training and mentoring and mentor facility staff to apply their learning from previous training interventions to improve quality of care and services. Roving teams also provide additional training as required with follow-on mentoring.\",\n",
       " '12110. SARPAM[ Southern Africa Regional Programme on Access to Medicines]. SARPAM[ SOUTHERN AFRICA REGIONAL PROGRAMME ON ACCESS TO MEDICINES]. To improve the availability, affordability and quality of essential medicines and diagnostics in the Southern Africa Region by strengthening capacity in procurement, regulation and monitoring, and by accessing private capital for innovations in the pharma',\n",
       " '12191. Services for Palestinian children with multiple special needs and their families in Lebanon Acronym MSN-services. SERVICES FOR PALESTINIAN CHILDREN WITH MULTIPLE SPECIAL NEEDS AND THEIR FAMILIES IN LEBANON ACRONYM MSN-SERVICES. Palestinian refugee population has no available mental health services in Lebanon. Beit Atfal Assumoud (BAS) started the mental health program: Family Guidance Center for children in 1997. So far there are five operational Centers in Lebanon. Significant number of learning difficulties or developmental problems are found in major part of the children. Required specialized rehabilitation services are scarce more often too expensive for the families. The cases are often multidisciplinary since the child has several problems. Large scale professional efforts are required the rehabilitation efforts are enormous. BAS initiated a Sponsorship Program in 2009 in order to provide special education and rehabilitation services for children in need. BAS covers the expenses for the children. The profound ethical guideline in the project: Children with special needs have the right for decent human development and protection regardless of their condition as well as being refugees. The purpose of the project is:1) to secure places (36) in special schools institutions or individually tailored rehabilitation process for children and adolescents with multiple special needs referred by Family Guidance Centers of BAS2)  to arrange for parents and siblings meetings workshops and recreational activities for rest recovery and peer support and encouraging them to advocacy and making proposals.3) promote access to special education and rehabilitation services and possibilities of BAS to enhance services in reduced price offered by specialised entities. Find out and define prerequisites needed for the special education and rehabilitation service delivery by BAS itself.The project develops more extensive service delivery system of special education and further rehabilitation for children and adolescents with special needs and their families. The project is based on the Sponsorship Programme started already in 2009. There were rehabilitation sponsors for 20 children among them five from Finland in May 2012. 139 were on the waiting list.BAS is for equality of genders against discrimination and acts for good environmental practices. BAS follows service statistics also by gender and nationality.',\n",
       " '12191. Preparation of the Technical specifications for the tender dossier and evaluation of supply offers for testing laboratories for medical products. PREPARATION OF THE TECHNICAL SPECIFICATIONS FOR THE TENDER DOSSIER AND EVALUATION OF SUPPLY OFFERS FOR TESTING LABORATORIES FOR MEDICAL PRODUCTS. The purpose of this contract is to carry out an equipment needs assessment of four Belarus testing laboratories under the Ministry of Health of the Republic of Belarus, to produce Technical Specifications and a market research, taking into account applicable eligibility rules allowing a competitive supply tender procedure, to produce a report on the technical evaluation of offers received for the supply tender procedure',\n",
       " '12110. Using the London model to influence guidelines for the Beijing Low-Emission Zone.. USING THE LONDON MODEL TO INFLUENCE GUIDELINES FOR THE BEIJING LOW-EMISSION ZONE.. This project will support low carbon infrastructure development. By May 2015, Beijing Municipal Commission of Transport (BMCT) should bring forward plans for how they will integrate the Low-Emission Zone (LEZ) guideline and the public communication strat',\n",
       " '12240. EVALUATION OF BUDGET SUPPORT IN PERU 2009-2015. EVALUATION OF BUDGET SUPPORT IN PERU 2009-2015. Systematic and timely evaluation of its programmes, activities, instruments, legislation and non-spending activities is a priority  of the European Commission  in order to demonstrate accountability and to promote lesson learning to improve policy and practice .    The main objective of this evaluation is to assess to what extent Budget Support in Peru contributed to achieve sustainable results on poverty and inequality reduction with particular regard to the sectoral policies:',\n",
       " '12220. Jacaranda Health. JACARANDA HEALTH. to assess the implementation of the new, globally-validated measurement tools from the INTERGROWTH-21st Project, and test the effects these new tools have on antenatal care',\n",
       " '13040. Targeted HIV/AIDS and Laboratory Services (THALAS) - HIV/AIDS. TARGETED HIV/AIDS AND LABORATORY SERVICES (THALAS) - HIV/AIDS. The Targeted HIV/AIDS and Laboratory Services (THALAS) project will provide specialized laboratory services and advanced care and treatment in seven sites including Kampala. The project will work collaboratively with the Ministry of Health and the Strengthening Uganda s Systems for Treating AIDS Nationally (SUSTAIN) project to build the capacity of lab personnel in regional and district hospitals in the provision of high-quality lab services.',\n",
       " '13040. Applying Science to Strengthen and Improve Systems (ASSIST) - Administration and Oversight. APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST) - ADMINISTRATION AND OVERSIGHT. The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       " '12262. Administration and Oversight (Malaria). ADMINISTRATION AND OVERSIGHT (MALARIA). Supports the following illustrative program-funded costs: salaries of US, FSN, and TCN and other staff such as PSCs, RSSAs, PASAs, CASUs working for the US Government managing, administering, and supporting programs and their program-funded benefits such as housing, travel, transportation, education allowances etc; institutional contractors that provide such staff, rent, IT services, the program-funded share of utilities, staff training costs and the cost of developing and administering training programs, equipment and supplies, ICASS, vehicle fuel and maintenance, maintenance contracts, janitorial services, operational unit web page development and maintenance, outreach such as publications and the cost of their preparation (including staff costs), and technical assistance to ensure USG compliance with regulations.',\n",
       " '13020. Darfur FGM 2014. DARFUR FGM 2014. The project will promote abandonment of FGM in Zalingei, Nertiti and Garsila localities in Central Darfur through training of medical personnel and conducting awareness raising among community leaders, religious leaders teachers and other opinion formers',\n",
       " '12220. JPO WHO 2017 Egypt NCD and Mental Health NP. JPO WHO 2017 EGYPT NCD AND MENTAL HEALTH NP. The contribution refers to a Junior Professional Officer (JPO) position. The position is addressing the Agenda 2030 goal 3: Good Health and Well-being. Thematic area is health with a focus on reducing burden and mortality of non-communicable diseases. Reduce morbidity and mortality related to tobacco use and promote mental health and well-being and ensure access to relevant care units. The contribution contributes to the implementation of the Strategy for Capacity Development and Exchanges 2014-2017 and the subsequent strategy (2018-2021), and will contribute to the following objectives: 1) Increased number of qualified Swedes in by the government-prioritized international and regional organizations and institutions and 2) an expanded Swedish resource base for multilateral, bilateral and regional assistance through special skills development and education programs for younger people.',\n",
       " '12110. Reviews, studies. REVIEWS, STUDIES. Reviews and studies of the components under the Health Sector Programme in Tanzania',\n",
       " '12110. Fleming Fund  Food and Agriculture Organisation (FAO) Secondment. FLEMING FUND  FOOD AND AGRICULTURE ORGANISATION (FAO) SECONDMENT. The Department has seconded an antimicrobial resistance (AMR) expert to work in the FAO, to lead the promotion of the Fleming Fund in low and middle income countries and to support tripartite working between FAO, OIE and WHO.',\n",
       " '12110. Develop and pilot a practical educational package against antimicrobial resistance in rural Anhui, China. DEVELOP AND PILOT A PRACTICAL EDUCATIONAL PACKAGE AGAINST ANTIMICROBIAL RESISTANCE IN RURAL ANHUI, CHINA. Develop a low cost, effective and sustainable educational intervention package against antimicrobial resistance at a rural level.',\n",
       " '12250. PATH. PATH. To achieve sustained increases in immunization coverage through support for country-owned, country-led policies, practices, and information system tools that enable evidence-based decision-making.',\n",
       " \"12220. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       " '12110. Study tour to the Program Bolsa Familia, Brazil. STUDY TOUR TO THE PROGRAM BOLSA FAMILIA, BRAZIL. This CT will finance a study tour composed by the Secretarfa de Desarrollo Social (SEDESOL) (Chief Coordinator and team) to Brazil to meet the team of the Brazilian CCT Program Bolsa Familia.',\n",
       " '12220. Leadership, Management, Governance (LMG) - Other Public Health Threats. LEADERSHIP, MANAGEMENT, GOVERNANCE (LMG) - OTHER PUBLIC HEALTH THREATS. The Leadership, Management, Governance (LMG) project builds in-country health and education system capacity by increasing leadership, management, and governance knowledge of health care providers, program managers, and policy makers who work on health services.',\n",
       " '12263. Early case finding and correct management of leprosy and TB, inclusive MDR-TB, in the project areas with special emphasis to gender and to the female. EARLY CASE FINDING AND CORRECT MANAGEMENT OF LEPRO. NA',\n",
       " \"13020. MEASURE Evaluation Phase III. MEASURE EVALUATION PHASE III. MEASURE Evaluation Phase III continues the MEASURE program's 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3)increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureau's primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.\",\n",
       " '12250. Applying Science to Strengthen and Improve Systems (ASSIST). APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST). The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       " '12191. Purdue University. PURDUE UNIVERSITY. to improve maternal health in Uganda by developing a cloud-based digital tracking tool to record health and stock data at local health clinics, as well as diagnostic laboratory data, to optimize ordering of medical supplies',\n",
       " '13020. Improving Models of Health Interventions Follow-on - Maternal and Child Health. IMPROVING MODELS OF HEALTH INTERVENTIONS FOLLOW-ON - MATERNAL AND CHILD HEALTH. To scale-up to national level an improved package of basic health services for the Extension of Coverage Program and to conduct feasibility studies aimed to explore new models for the provision of health services for the most unprivileged and not previously served populations of Guatemala.',\n",
       " '13040. Output 04: HIV. HIV. Uganda - Kampala. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12261. Frame agreement with NGO (Fida Int.). FRAME AGREEMENT WITH NGO (FIDA INT.). Community Health Development Project. This is a new project and detailed planning is still under way. The project seeks to improve the community health situation in Kangwon province, Sepo county. Health care services in North Korea are insufficient especially qualitively and the knowledge of health issues is generally low. There are clear health risks in hygiene and sanitation and the project seeks to reduce these risks. The health care system suffers from lack of resources. The basic level of the health care system are the village clinics. This project aims at strengthening the service capacity at this level. The project will study possibilities to expand the Primary Dental Care Support Programme (5212) to Kangwon Province. The project also includes Fida country coordination as a component, covering all the activities in the country.',\n",
       " \"13040. Sustaining the Momentum: The March Towards Universal Access to HIV and AIDS Services in Tanzania. SUSTAINING THE MOMENTUM: THE MARCH TOWARDS UNIVERSAL ACCESS TO HIV AND AIDS SERVICES IN TANZANIA. 1. Background and Summary:  The primary goal of this Program is to reinforce the Government of Tanzania's response to the HIV/AIDS epidemic by expanding service delivery to the lower tiers of the health system. Attaining this goal requires financing recurring costs, such as Health Products and consumables, as well as supporting activities that maintain and strengthen the system in place, such as refresher training for community health workers, supervision and mentoring. Experience with previous Global Fund grants has highlighted the need for greater coordination among relevant stakeholders. Accordingly, this grant will support the scale up of HIV/AIDS services by strengthening capacity and coordination among key stakeholders in the public and private sectors, including: Civil Society Organizations (CSOs), Faith-based Organizations (FBOs), People Living with HIV/AIDS (PLHA) groups, as well as the Tanzania Commission for AIDS (TACAIDS), the national coordination body for Tanzania's multi-sectoral HIV/AIDS programming.  Tanzania faces an urgent need for drugs and commodities for the delivery of HIV/AIDS services. The scale-up of the national anti-retroviral therapy (ART) program has resulted in a seven-fold increase in the number of patients enrolled in treatment, from 23,951 in 2005 to 189,494 in October 2008. Funding for commodities that are key to the delivery of key services such as HIV testing, Sexually Transmitted Infection (STI) management, Prevention of Mother to Child Transmission (PMTCT), ART, Opportunistic Infection (OI) treatment and prophylaxis, and early infant diagnosis will therefore form an integral part of the Program. The Program will additionally measure the outputs, outcomes and impact of HIV/AIDS interventions addressed by the Program. Specifically, this program's main objectives are to scale up through expansion of care and treatment services to primary health care facilities, increase coverage of key prevention services all over the country, ensure continuous quality service delivery and strengthen the national-level stakeholders and coordination mechanisms.  Two Principal Recipients will work on attaining the goals of the program, namely the Ministry of Finance and African Medical Research Foundation (AMREF). 2. Goals:   Secure and sustain Tanzania's HIV/AIDS prevention, care, treatment and support services; and  Strengthen coordination and implementation capacity of key stakeholders.  3. Target Group/Beneficiaries:  PLHA who are eligible for care and treatment  PLHA suffering from chronic illness and/or malnourishment  Patients on care and treatment  In- and out-patients at health facilities  Pregnant women and their partners  Infants born to HIV positive mothers  Sexually active population, especially youth  Health care workers and PLHA accessing HIV/AIDS services   Private sector and Individuals and groups served by FBOs, PLHA, CSOs  General population of Tanzania 4. Strategies:  Expand care and treatment ser\",\n",
       " '13020. Health Improvement Project - Maternal and Child Health. HEALTH IMPROVEMENT PROJECT - MATERNAL AND CHILD HEALTH. The Timor-Leste Health Improvement Project (TL HIP) will support TL in improving the quality and impact of health services. Guided by the vision that health care quality can be significantly improved by applying proven health improvement methods, the TL HIP will assist programs to scale up evidence-based interventions to improve outcomes in Maternal Newborn Child Health, Nutrition, and Family Planning. The project will build on current strategies of the MoH and USAID successes including, Basic Service Package implementation, support to SISCas, assistance with guidelines and protocols, training, development and piloting of job aids( flip charts, flow-charts, instructional videos) and supportive supervision. TL HIP will complement the strengths identified by partner organizations throughout the Ministry of Health system. The project will support the National, District, Sub-district, and community levels, but will primarily be focused at the district level. At the National level, the TL HIP will provide support for policy, system strengthening, guidelines, working groups and flexible technical assistance in the areas of Quality Control, Health Promotion, District HMIS, and Family Planning. The technical assistance is flexible and will depend on the MoH needs. This flexible TA will also have responsibility for specific districts and sub-districts. At the District and Sub-district levels, the TL HIP will work with DPHOs, Health Center Managers and Health Workers in the areas of BPS implementation, District Implementation Plans (DIPs), supportive supervision, HMIS, Human Resource Management, service delivery, referral systems and other areas as needed. In local communities, TL HIP will help strengthen community participation and engagement systems to support appropriate health concepts and practices and help solve physical and cultural access of the population to health care. The TL HIP can facilitate advocacy, communication, and social mobilization efforts, inc',\n",
       " \"12262. Sudan Health Transformation Project (SHTP). SUDAN HEALTH TRANSFORMATION PROJECT (SHTP). The Sudan Health Transformation Project (SHTP) targets increased access to and utilization of health, water, and sanitation services to improve the well-being of children, mothers, and families. The project, funded by USAID, is being implemented by JSI Research & Training Institute, Inc. in collaboration with the Secretariat of Health of the Sudan People'sc Liberation Movement (SPLM).\",\n",
       " \"12220. Solomon Islands-Australia Partnership for Development - Malaria Program. SOLOMON ISLANDS-AUSTRALIA PARTNERSHIP FOR DEVELOPMENT - MALARIA PROGRAM. Health is a priority focus of the Solomon Islands-Australia Partnership for Development and funding under this proposal supports the Health Sector Support Program - Phase 2 which continues Australia's long-term commitment to strengthen health systems and improve outcomes through a Sector Wide Approach (SWAp) which commenced with HSSP Phase 1 in 2008-12. The SWAp and partnership support the Solomon Islands Government in providing quality health services for all people in the Solomon Islands through its own National Health Strategic Plan (2011-2015). The SWAp emphasises the importance of partnership, mutual respect, mutual responsibility and the underlying principles of aid effectiveness. The total value of this initiative is $90.0 million over 4 years, starting 2012-13.\",\n",
       " '13010. Global Health Support Initiative II (GHSI II) - Program Design and Learning. GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II) - PROGRAM DESIGN AND LEARNING. The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the programs vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.',\n",
       " '13020. Purdue University. PURDUE UNIVERSITY. to improve maternal health in Uganda by developing a cloud-based digital tracking tool to record health and stock data at local health clinics, as well as diagnostic laboratory data, to optimize ordering of medical supplies',\n",
       " '12262. University of Oxford. UNIVERSITY OF OXFORD. to identify a laboratory marker for Artemisinin resistance in P.falciparum to guide containment, control and elimination',\n",
       " '12230. Equipment for the obstetrical-gynecological medical department, clinic and analysis center. EQUIPMENT FOR THE OBSTETRICAL-GYNECOLOGICAL MEDICAL DEPARTMENT, CLINIC AND ANALYSIS CENTER. Setting up a local doctor in the Diocese of Benguela, with appropriate equipment of the delivery room and postpartum, gynecological surgery, general surgery, laboratory, pharmacy, waiting room, facilities and warehouses.',\n",
       " '12181. Educational and Research Competency Enhancement of Nursing Leaders in Cambodia. EDUCATIONAL AND RESEARCH COMPETENCY ENHANCEMENT OF NURSING LEADERS IN CAMBODIA. to produce many well-qualified nursing leaders contributing to improve quality of health care and ultimately improving health levels of the public in Cambodia',\n",
       " '12181. Assistance for training in public health in the region Chin, Myanmar. ASSISTANCE FOR TRAINING IN PUBLIC HEALTH IN THE REGION CHIN, MYANMAR. The project presented by the Office for the Development of the Diocese of Hakha concerns the training and sensitization of the local population on issues of personal hygiene, health security, sexual education. The project will directly involve the population of 50 villages.',\n",
       " '12191. Soins de santT spTcialisTs en palestine - phase III. SOINS DE SANT+ SP+CIALIS+S EN PALESTINE - PHASE III. General Objectives  +To improve the global care in the Palestinian Autonomous Territories by reducing mortality and morbidity due to cardiac and congenital ailments in children and adults+  Specific Objectives  To upgrade the diagnostic and therapeutic cardiac care facilities in three tertiary care hospitals (one in the Gazastrip, one in Jerusalem and one in the West Bank) To upgrade the treatment capacity in one tertiary health centre in Gaza City Results  1. Establish a new Cardiac Intensive Care and Surgery Department in Khann Yunnis at the EuropeanGaza Hospital and start interventional procedures in the Cath-lab in order to create a fully functional Cardiac Centre.2. Extend therapeutic capacity at the Paediatric Intensive Care Unit in Jerusalem at Makassed hospital 3. Establish a new Cardiac Surgery department in Ramallah at the MoH hospital in order to complete the Cardiac Centre by including the existing Cathlab and Cardiology Department.4. Reinforce therapeutic procedures at the Neonatology Department in Gaza city at Shifahospital.',\n",
       " '12263. Improved detection of tuberculosis in Mozambique. IMPROVED DETECTION OF TUBERCULOSIS IN MOZAMBIQUE. Despite all the efforts that have been made in the field of tuberculosis control in Mozambique, one of the biggest challenges in combating this rapidly spreading disease is to increase the TB detection rate. One of the main reasons for this is the lack of a simple, fast and accurate diagnostic method. Due to this alarming situation, the Mozambican government has declared this epidemic to be a national emergency and for this reason drafted a National Strategic Plan 2008-2012. In 2011, the Mozambican government wants to raise the detection rate from 53% to 58% and substantially increase the recovery rate and the number of TB patients that is tested for HIV/AIDS.  With an eye to finding a solution to this pressing problem of TB diagnosis in countries with limited resources and infrastructure, Apopo has started exploring the possibility of using African HeroRATs to detect tuberculosis. By implementing its unique TB detection technology Apopo aims:(1) to contribute to the national TB control programme of Mozambique by effectively increasing the number of detected TB patients in the short term;(2) to build a local capacity of TB detection rats and trainers to also have a continued long-term impact on the reduction of the TB problem in Mozambique.  Expected outcome: (1) delivery of support to the national TB-program of Mozambique in the short run by effectively increased numbers of treated TB-patients;(2) increased capacity of trainers and rodents for TB-detection in the country.   Document available at  https://drive.google.com/file/d/0B-IUzKYaN-QSY0ZBZU5tZTJ2cTg/edit?usp=sharing',\n",
       " '13040. Training of Ukrainian diagnosticians in the field of the newest laboratory techniques  improvement of care standard of persons living with HIV/AIDS in Ukraine. TRAINING OF UKRAINIAN DIAGNOSTICIANS IN THE FIELD OF THE NEWEST LABORATORY TECHNIQUES  IMPROVEMENT OF CARE STANDARD OF PERSONS LIVING WITH HIV/AIDS I. NA',\n",
       " '13040. Output 04: HIV. HIV. Sierra Leone - Freetown. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " \"13020. Kinerja. KINERJA. The overarching objective of this activity is the provision of innovative and improved service delivery by local governments to citizens. USAID focuses on the governance of service delivery in three sectors: education; health services and; and local business. Activities under this IM address both demand and supply side aspects of service delivery. These investments will result in strengthened accountability mechanisms that improve local government responses to citizens' needs. USAID works through local institutions to build their capacity and foster sustainable partnerships with local government. This solidifies the links between stimulation of demand for good services through active civil society engagement and improved local government response.\",\n",
       " \"12181. 2017 Healthcare Executive Leadership Training Programs, through Meridian International Center. 2017 HEALTHCARE EXECUTIVE LEADERSHIP TRAINING PROGRAMS, THROUGH MERIDIAN INTERNATIONAL CENTER. USTDA funding partially supported two separate and distinct 14-day training programs for 25 senior Chinese healthcare executives and officials. The training programs were designed to introduce the delegates to best practices in healthcare management and U.S. advanced medical technologies and solutions. This was the sixth USTDA training program for Chinese healthcare executives, and was supported by members of the U.S.-China Healthcare Cooperation Program (HCP) and China's Health Human Resources Development Center (HHRDC).\",\n",
       " \"13020. Leadership, Management and Sustainability (LMS) Project. LEADERSHIP, MANAGEMENT AND SUSTAINABILITY (LMS) PROJECT. The Leadership, Management and Sustainability (LMS) Program supports people and organizations around the world to strengthen the way they lead and manage their own programs to achieve widespread improvements in health. LMS/Kenya's programs work to strengthen leadership, management and governance for sustained health programs. Program activities focus on building leadership and management skills through training, mentoring and coaching. Allactivities are structured around the achievement of three intermediate results: 1) Improved management and leadership of the health sector and priority health programs on HIV/AIDS, tuberculosis, family planning/ reproductive health, maternal and child health, and malaria; 2) Improved management and systems in health organizations and priority health programs; and 3) Increased sustainability and ability to manage change.\",\n",
       " \"12240. Scale Up of Homestead Food Production for Improved Nutrition in Cambodia (CIFSRF Phase 2). SCALE UP OF HOMESTEAD FOOD PRODUCTION FOR IMPROVED NUTRITION IN CAMBODIA (CIFSRF PHASE 2). Household food insecurity, seasonal food shortages, and nutritional deficiencies among women and children are prevalent in Cambodia. This project will refine proven innovations in homestead food production and will test cost-sharing, financial, and social impact models at scale to improve nutrition, income, and gender equity. Testing homestead food production approaches Homestead food production empowers the poor with the education and resources they need to raise their own nutritious foods. The project team will ask men and women smallholders living in Cambodia's upland, lowland, and forested regions to self-select from four food production options: -backyard gardens alone -gardens plus fish -gardens plus poultry -gardens plus poultry and fish Researchers from the University of British Columbia and Helen Keller International will identify barriers to participation and factors that motivate farmers to adopt and invest in the intervention. They will integrate underlying factors that influence nutritional outcomes including water, sanitation, and hygiene practices. The project builds on previous research testing homestead food production with vegetable gardens in combination with fish ponds to grow nutrient-dense small fish for household consumption and large fish for sale. The earlier research found that nutritional quality was enhanced, incomes improved, and women had a greater role in household decision-making. Better nutrition, improved food security At the end of three years, 22,500 households and 135,000 individuals are expected to benefit directly and indirectly. The project will provide a package of homestead food production options that can be quickly implemented by government, the public, and the private sector across a Asia and in Africa. The project's focus on scalable innovations that improve the quality of diets (using strategies for vegetable production integrated with aquaculture and poultry) aligns well with Cambodia's new National Strategy for Food Security and Nutrition.\",\n",
       " '12110. Sectoral budget support (SWAp): Malawi Health Sector Strategic Plan 2011-2016. SECTORAL BUDGET SUPPORT (SWAP): MALAWI HEALTH SECTOR STRATEGIC PLAN 2011-2016. The Vision of the health sector is to achieve a state of health for all the people of Malawi that would enable them to lead a quality and productive life.The Mission of the health sector is to provide strategic leadership by the Ministry of Health for the delivery of a comprehensive range of quality, equitable and efficient health services to all people in Malawi by creating an enabling environment for health promoting activities.The Goal of the Health Sector Strategic Plan is to improve the quality of life of all the people of Malawi by reducing the risk of ill health and the occurrence of premature deaths, thereby contributing to the social and economic development of the country. Expected outcome: 1. Increase coverage of the Essential Health Package interventions, paying attention to impact and quality.2. Strengthen the performance of the health system to support delivery of EHP services.3. Reduce risk factors to health.4. Improve equity and efficiency in the delivery of quality EHP services. Document available at  https://docs.google.com/open?id=0B-IUzKYaN-QSbTJ4a2ZkdHZrWkk',\n",
       " '12191. Government Direct Grants - Fuanda medical institution for industrial joints. GOVERNMENT DIRECT GRANTS - FUANDA MEDICAL INSTITUTION FOR INDUSTRIAL JOINTS. NA',\n",
       " '12191. Eradication and prevention of blindness in remote areas of Sidama Zone in Ethiopia. ERADICATION AND PREVENTION OF BLINDNESS IN REMOTE AREAS OF SIDAMA ZONE IN ETHIOPIA. The goal of the project is to secure access to quality eye care of people living in remote areas of Sidama Zone and Borena Zone and thus dicrease blindness incidence in the region.',\n",
       " '13040. Public service policies. PUBLIC SERVICE POLICIES. Under this output, emphasis will be on aligning public service policies, rules, regulations and strategies with the Malawi Constitution and other regulations to ensure efficient and effective public service delivery.',\n",
       " '12191. Providing medical equipments for Surgery section in Wetchakarurasm hospital, in Nanghshouk neighborhood, in the Capital city Bangkok. PROVIDING MEDICAL EQUIPMENTS FOR SURGERY SECTION IN WETCHAKARURASM HOSPITAL, IN NANGHSHOUK NEIGHBORHOOD, IN THE CAPITAL CITY BANGKOK. Extending agency: Khalifa Bin Zayed Al Nahyan Foundation - UAE aid modality: Direct Project Implementation',\n",
       " '12262. Cooperation with foreign research institutions (not included in other areas). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (NOT INCLUDED IN OTHER AREAS). Malaria drugs - AntiMalariaDrug - Biotechnological production of new natural drugs to be used against malaria and other poverty-related diseases - Capacity building in the field of education and research',\n",
       " '13020. International Centre for Diarrhoeal Disease Research, Bangladesh. INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH. to determine the efficacy of three community based interventions using e-platform in improving the recall of the date of last menstrual period and thereby increase the accuracy of gestational age estimation in rural resource poor settings',\n",
       " '12220. Healthcare Centre MAMA CARLA, La Joie de Vivre Center Bangui, (Analysis laboratory, Dispensary of primary care for children and Telemedicine). HEALTHCARE CENTRE MAMA CARLA, LA JOIE DE VIVRE CENTER BANGUI, (ANALYSIS LABORATORY, DISPENSARY OF PRIMARY CARE FOR CHILDREN AND TELEMEDICINE). The Health Medical Centre MAMA CARLA give the possibility to the needy children, orphans or abandoned housed in the Centre La Joie de Vivre to have free access to the medical services. Medical examination, ambulatory treatments, infectious disease and malaria control, urgent pharmacological treatments and assistance to undernourished are opened also for all the students of the School Nicolas BarrT and to the children living in the surrounding areas from 0 to 14 ages. The Centre organizes hygienic consulting, education and training for mothers. Assistance and training to pregnant women AIDS infected. Health personnel development.',\n",
       " '13040. HIV/AIDS - Palliative Care: Basic Health Care and Support - Assistance for HIV/AIDS. HIV/AIDS - PALLIATIVE CARE: BASIC HEALTH CARE AND SUPPORT - ASSISTANCE FOR HIV/AIDS. PEPFAR: HIV/AIDS - Basic health care and support, which includes: all clinic-based and home/community-based activities for HIV-infected adults, children, and their families that are aimed at optimizing the quality of life for HIV-infected clients and their families throughout the continuum of illness by the means of symptom diagnosis and relief, psychological and spiritual support, clinical monitoring, related laboratory services and management of opportunistic infections (excluding TB) and other HIV/AIDS-related complications (including pharmaceuticals), and culturally-appropriate end-of-life care. Basic health care and support also includes clinic-based and home/community-based support, social and material support such as nutrition support, legal aid, and housing, and training and support of caregivers. Clinic-based and home/community-based care and support activities for HIV-positive children within programs for orphans and other vulnerable children affected by HIV/AIDS would fall under sub-element 1.1.8 (Orphans and Vulnerable Children). ARV treatment should be coded under sub-element 1.1.10 (HIV/AIDS Treatment and Anti-Retroviral Drugs) and sub-element 1.1.11 (HIV/AIDS Treatment and Anti-Retroviral Services). - Assistance for HIV/AIDS',\n",
       " '13020. Australia-Indonesia Partnership For Maternal And Neonatal  Health: Program Management. AUSTRALIA-INDONESIA PARTNERSHIP FOR MATERNAL AND NEONATAL  HEALTH: PROGRAM MANAGEMENT. The Australia-Indonesia Partnership (AIP) for Maternal and Neonatal  Health (MNH) aims for selected provincial and district governments in Eastern Indonesia to have mechanisms in place to manage national, local and donor resources to achieve national target levels for priority indicators contained within the Indonesian National Making Pregnancy Safer (MPS) Strategy. The objectives are: provincial and district governments develop and implement maternal and neonatal health (MNH) programs based on the national MPS strategy and address supply and demand aspects to achieve annual performance targets; provincial and district government agencies and communities access and manage the technical, human and financial resources needed to achieve improvements in MNH; and provincial and district governments manage Government of Indonesia (GoI) and donor resources to improve accountability, performance, accessibility and sustainability of public health services. The total value of this initiative is $76.4 million over 8 years, starting 2006-07.',\n",
       " \"12250. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       " '12240. Initiative of food safety and protection of children in Karamoja. INITIATIVE OF FOOD SAFETY AND PROTECTION OF CHILDREN IN KARAMOJA. Initiative of food safety and protection of children in Karamoja',\n",
       " '13040. Enhancing the Transformative Capacity of Religious Leaders. ENHANCING THE TRANSFORMATIVE CAPACITY OF RELIGIOUS LEADERS. Enhancing the Transformative Capacity of Religious Leaders',\n",
       " '12220. FIGHT AGANIST EBOLA. FIGHT AGANIST EBOLA. Health care actions (Technical education included)',\n",
       " '16064. Output 04: HIV. HIV. Sub-Regional Office/Suva. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12261. Frame Agreement with NGO (Finnish Red Cross). FRAME AGREEMENT WITH NGO (FINNISH RED CROSS). Community Based Health Programme.To improve the health and decrease the diseases through increased knowledge sharing, to reduce impact of disasters on vulnerable population and increase capacity of the population to respond and recover.',\n",
       " \"13040. Output 04: HIV. HIV. Chad - N'Djamena. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments\",\n",
       " '12181. Advanced Training for Medical Personnel on High-Tech Medical Equipment. ADVANCED TRAINING FOR MEDICAL PERSONNEL ON HIGH-TECH MEDICAL EQUIPMENT. Preconditions for the use of High-Tech Medical Equipment in the capital Tashkent and other selected areas are improved , area of application medical imaging diagnostics and minimal-invasive surgery',\n",
       " '13040. Roads to a Healthy Future II (ROADS II) Project - HIV/AIDS. ROADS TO A HEALTHY FUTURE II (ROADS II) PROJECT - HIV/AIDS. Regional Outreach Addressing AIDS through Development Strategies (ROADS) project has linked communities along these corridors with critical HIV/AIDS and other health services by collaborating closely with national AIDS control programs; government ministries; district health management teams; health facilities; and local, national and international companies. The project helps individuals and communities reduce their vulnerability to HIV by expanding economic opportunities and improving food security. The project s LifeWorks component provides training and technical assistance in group savings and loan, livestock management (chickens, rabbits and goats), urban and organic gardening and microenterprise development. The ROADS project also provides care and support for orphans and other at-risk children, and it works to protect women and girls from sexual exploitation and abuse.',\n",
       " '12110. Promotion of the perinatal health in Kyrgyzstan. PROMOTION OF THE PERINATAL HEALTH IN KYRGYZSTAN. The normative, personell and organisational conditions for demandoriented MEDICAL SERVICE-supply of risk pregnancies and sick newborns in the program region are created.',\n",
       " '12110. DTveloppement des capacitTs institutionnelles en planification, leadership et gestion dans le secteur de la santT. D+VELOPPEMENT DES CAPACIT+S INSTITUTIONNELLES EN PLANIFICATION, LEADERSHIP ET GESTION DANS LE SECTEUR DE LA SANT+. General Objectives  To improve effective delivery of an integrated Uganda National Health Care Package  Specific Objectives  The strengthening of the planning, leadership and management capacities of the health staff at national level and local government levels Results  - The Ministry of Health is strengthened in its organisational and institutional capacity- One selected regional referral hospital (Fort Portal) and two general hospitals, located within the catchments area of the RRH, are strengthened in their instituti',\n",
       " \"13030. Uzazi Uzima II: Safe Deliveries in Simiyu Region/Uzazi Uzima II: Accoucher en sTcuritT dans la rTgion de Simiyu. UZAZI UZIMA II: SAFE DELIVERIES IN SIMIYU REGION/UZAZI UZIMA II: ACCOUCHER EN S+CURIT+ DANS LA R+GION DE SIMIYU. The Uzazi Uzima II project seeks to reduce maternal and newborn mortality and morbidity in all five districts of Simiyu region, Tanzania by improving the availability of quality adolescent, maternal and newborn health services in underserved districts through three mutually supportive mechanisms. The project will: improve the knowledge and skills of healthcare providers on maternal, newborn and sexual/reproductive health to ensure they can provide critical services to their beneficiaries in a gender sensitive and responsive way;  improve the infrastructure and supply-chain for health facilities to encourage women, girls and their families to use services; and improve gender responsive health management systems (such as planning, prioritization and management of services). The project will also increase awareness and understanding of sexual, reproductive, maternal and child health with special focus on men's participation in reproductive, maternal and newborn health and decision making.Project activities include: (1) training health workers from four health centres and 24 dispensaries on: essential maternal and newborn health skills, such as Basic Emergency Obstetric and Newborn Care (BEmONC); Comprehensive Emergency Obstetric and Newborn Care (CEmONC), family planning; nutrition counselling; and newborn resuscitation; (2) refurbishing four health centres and 24 dispensaries to provide CEmONC, BEmONC, water, sanitation and hygiene and family planning services, including a satellite safe blood center at the regional hospital; (3) equipping targeted health facilities with the necessary stocks of equipment and commodities to provide BEmONC, CEmONC, family planning and safe blood services; (4) establishing a referral system for maternal and newborn health care and family planning services across all tiers of the health system; (5) training and supporting Ministry of Health and facility-based managers, and health workers to improve community to facility linkages (enhanced data collection, consolidation, analysis and reporting); and (6) training and equipping community health workers, traditional birth attendants, traditional healers, and local leaders to provide community-level health promotion services (including maternal and newborn health, water, sanitation and hygiene, family planning, nutrition, gender issues and use of mobile health technology to mobilize communities).The project is implemented in collaboration with Amref Health Africa in Tanzania, Marie Stopes Tanzania and Deloitte./ Le projet vise a rTduire la mortalitT et la morbiditT des mFres et des nouveau-nTs dans les cinq districts de la rTgion de Simiyu, en Tanzanie. Cet objectif est atteint en assurant une meilleure disponibilitT des services de santT maternelle et nTonatale de qualitT dans les quartiers mal desservis et en augmentant l'utilisation de ces services par les femmes et leurs familles dans les districts ciblTs au moyen d'interventions a covt modique, mais de vaste portTe. Le\",\n",
       " '12261. Governance And Gender : Human rights : Irish Aid Payment for Contract SCF SL 15 01 for : Fambul Welbodi II programme IRISH AID - FAMBUL WELBODI II. GOVERNANCE AND GENDER : HUMAN RIGHTS : IRISH AID PAYMENT FOR CONTRACT SCF SL 15 01 FOR : FAMBUL WELBODI II PROGRAMME IRISH AID - FAMBUL WELBODI II. Governance And Gender : To Enhance Good Governance Through Strengthening Democratic Mechanisms, Improving Domestic Accountability Mechanisms And Promoting Gender Equality. : Human rights : Irish Aid Payment for Contract SCF SL 15 01 for : Fambul Welbodi II programme IRISH AID - FAMBUL WELBODI II',\n",
       " '13040. Output 04: HIV. HIV. Central African Rep - Bangui. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       " '12230. The Project for Renovation of Surgery Unit of Ganja City Urgent Medical Assistance Hospital. THE PROJECT FOR RENOVATION OF SURGERY UNIT OF GANJA CITY URGENT MEDICAL ASSISTANCE HOSPITAL. Renovation of Surgery Unit of Ganja City Urgent Medical Assistance Hospital in Ganja City',\n",
       " '12181. Institutional Capacity Building in planning, leadership and management in the Ugandan health sector - ICB phase II. INSTITUTIONAL CAPACITY BUILDING IN PLANNING, LEADE. The project should further support capacity buildi',\n",
       " '12262. Partnership for containment of artemisinin resistance and moving towards the elimination of plasmodium in Thailand. PARTNERSHIP FOR CONTAINMENT OF ARTEMISININ RESISTANCE AND MOVING TOWARDS THE ELIMINATION OF PLASMODIUM IN THAILAND. NA',\n",
       " '13030. PACTO - Active Prevention and Communication for All - Family Planning and Reproductive Health. PACTO - ACTIVE PREVENTION AND COMMUNICATION FOR ALL - FAMILY PLANNING AND REPRODUCTIVE HEALTH. PACTO (Prevenao Activa e Comunicaao para todos) is a 4 year project funded by USAID with the goal of increasing safer sexual behaviors and uptake of HIV prevention services among the Mozambican general population primarily in the three highest prevalence provinces of Maputo City, Maputo, and Gaza, and to strengthen Mozambican public institutions technical leadership and coordination to guide the implementation of combination HIV prevention programs.',\n",
       " '12220. Humanitarian Assistance. HUMANITARIAN ASSISTANCE. Humanitarian Assistance. Pakistan Institute of Medical Sciences (PIMS), Hospital Medical Supplies. The program is run through the Department of Defense s Overseas Humanitarian, Disaster and Civic Aid (OHDCA).',\n",
       " \"16064. NGO Support / HIV and Aids Project  The Good Samaritan  Malawi. NGO SUPPORT / HIV AND AIDS PROJECT  THE GOOD SAMARITAN  MALAWI. The long term objective of the project is to contribute to the reduction of the spread of HIV and stigmatization of infected and affected people. The main focus is to reduce stigmatization and discrimination of PLHA. The overall objectives of the Good Samaritan HIV programme (GSP) is to strengthen the involvement of churches in the response to HIV by enabling people and organisations to: ?Get knowledge about HIV and AIDS and risky behaviour; Encourage VCT and sexual education; Eradicate stigma and condemnation; Restore PLHA's human rights dignity and equality and; To renew churches and local congregations' social responsibility. The programme has two main target groups: influental people and opinion leaders with the capacity to act as facilitators and trainers; and people who are particularly vulnerable to HIV: youth women PLHA and married persons. The strategy is based on information education and communication with a focus on behavioural change communication and to work with individuals and communities through sharing and providing supportive and enabling environments. The implementation is based on a two tier strategy: (i) advocacy sensitisation and mobilisation of community and religious leaders; and (ii) cascade training of trainers to reach local congregations and communities. The training uses the workshop as a platform to facilitate inter-action sharing and reflection to promote change in attitudes and behaviour. The programme also encourages the formation of local groups for mutual support and action.Gender equality is embedded in training materials and teachings and project staff. Implementing Bible Societies will be further trained on gender issues. Human dignity is one the key elements in the Good Samaritan program. Project is implemented within national HIV coordinating structures that include governmental HIV coordination religious network and local communities.The direct beneficiaries include PLHIV and non-infected people. Special emphasis is put on women and youth aim is also try to better address PVDs.The key project activities include four kind of workshops: sensitization for various leaders training of trainees (ToT) decentralized workshops (DWs) Follow up (FU) Take Charge youth program (TC) and annual capacity building workshops for project staff (Joint Program Review / JPR and anglophone capacity building workshop).\",\n",
       " '13040. USAID Innovations Grant - HIV/AIDS. USAID INNOVATIONS GRANT - HIV/AIDS. The USAID funding for Witkoppen Health and Welfare Centre (WHWC) (AID-674-A-12-00033 from 01/10/2012 to 30/09/2017) is for providing HIV and TB diagnosis, care, support, treatment and referral services at primary care level to residents of informal settlements; interventions that build capacity in the local Department of Health (DoH) clinics; transition of the USAID-funded direct service delivery to the DoH and the implementation and evaluation of effective innovative approaches to integrated primary care for HIV and TB. Underpinning these innovations are five operational research projects, including specific focus on paediatric care, comprehensive PMTCT services over the spectrum from pre-pregnancy to maternal and infant care, intensified TB and HIV case finding at clinic and community level, and improving adherence and retention-in-care among children, adolescents and adults.',\n",
       " '12262. Global Health Program Cycle Improvement Project - Malaria. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT - MALARIA. Globl Health Program Cycle Improvement Project will support for the MCH team to complete a pre activity design (MCH Flagship redesign) systems analysis, which includes consolidation of existing information and identification of information gaps for further study. This activity will deliver a comprehensive write up of the political, technical and systems components of the Indonesian health system that need to be taken into full consideration and~adequately~studied prior to~designing the new MCH flagship activity. This will be followed up with defining a clear way forward for future investments in the MCH portfolio.',\n",
       " '12182. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Feasibility Study',\n",
       " '13040. Scaling Up for Most-at-Risk Populations  Technical Support Project (SUM I) - HIV/AIDS. SCALING UP FOR MOST-AT-RISK POPULATIONS  TECHNICAL SUPPORT PROJECT (SUM I) - HIV/AIDS. In Indonesia, FHI 360 serves as a leader in the prevention and treatment of HIV among the countrys most-at-risk populations, including injecting drug users, sex workers, men who have sex with men, waria (transgender people) and the sexual partners of individuals from these groups. The five-year Scaling Up for Most-at-Risk Populations Technical Support Project (SUM I) works to accelerate the implementation of comprehensive and effective interventions for people at risk of HIV infection.',\n",
       " '12262. Walter Reed Army Institute of Research. WALTER REED ARMY INSTITUTE OF RESEARCH. to support the Armed Forces Research Institute of Medical Sciences to conceptualize and pilot a system for malaria radical cure, diagnosis, and surveillance amongst Cambodian servicemen and women and their dependents',\n",
       " '12182. AMR Phase 1 Theme 4 Behaviour within and beyond the healthcare setting (MRC contribution, ESRC lead on the call). AMR PHASE 1 THEME 4 BEHAVIOUR WITHIN AND BEYOND THE HEALTHCARE SETTING (MRC CONTRIBUTION, ESRC LEAD ON THE CALL). Understanding/influencing the behaviour of public, professionals and organisations impacts on Anti-Microbial Resistance How Anti-Microbial Resistance is affected by social, psychological and organisational context, cultures and history; and how it can be influenced to create different future scenarios within multiple Low and Middle Income Countries.',\n",
       " '13020. Social Health Protection (SHP) - Maternal and Child Health. SOCIAL HEALTH PROTECTION (SHP) - MATERNAL AND CHILD HEALTH. The Social Health Protection project will reduce financial barriers to health services for the poor by increasing the nationwide coverage of the public-sector health insurance program known as the Health Equity Fund. This fund enables the poor to access and pay for quality health services, thereby mitigating the effects of disease and sickness while reducing the financial burden of health-care costs on the poor. Activities will strengthen the ability of the national and district-level governments to administer health insurance, link reimbursements to improved health services, include civil society and communities in oversight of the enrollment process to ensure more transparency, and revise the package of health services provided to the poor to include priority services. The U.S. government will help expand the Heath Equity Fund across all of Cambodia and provide three million poor Cambodians with access to healthcare without forcing them into further financial hardship.',\n",
       " '12240. OUTPUT 1.2: REGULATIONS AND DIRECTIVES. OUTPUT 1.2: REGULATIONS AND DIRECTIVES. NA',\n",
       " '13030. Tanzania Human Resource Capacity Project - Family Planning and Reproductive Health. TANZANIA HUMAN RESOURCE CAPACITY PROJECT - FAMILY PLANNING AND REPRODUCTIVE HEALTH. IntraHealth led the Tanzania Human Resource Capacity Project, which identified and filled staffing shortfalls, building on the earlier work of the global Capacity Project. The project collaborated with more than 20 health sector leaders and managers from three regions to plan for and manage a larger and better trained health workforce.',\n",
       " \"13020. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       " '12240. Algae/Duckweed Innovation Activity. ALGAE/DUCKWEED INNOVATION ACTIVITY. The goal of this project is tofight childhood malnutritionby empowering vulnerable young mothers in Ethiopia to improve their income. The young mothers are organized into groups of 20 women to plan for, save for, start and run poultry, dairy, and tilapia farms. These women are given acompetitive advantage, by teaching them an innovative technology - namely, algae and duckweed production as a novel, low-cost supplement for livestock feed.',\n",
       " '12191. Operation Hernia Humanitarian Mission 2014-2015. OPERATION HERNIA HUMANITARIAN MISSION 2014-2015. Taking part in Operation Hernia Mission to India. Operation Hernia is an independent not-for-profit organization  that provides professional and educational opportunities to surgeons and surgical trainees in the repair of long-standing groin hernias at rural hospitals in low income countries. Surgeon Volunteers are drawn  mainly from  members of the European and American Hernia Societies. Inguinal hernia is a public health problem in many low income countries. Although inguinal hernia develops at all ages (mainly in men)and in all parts of the world with the same frequency, in poor communities they are not treated due to lack of hospitals and surgeons.',\n",
       " '12182. Nepal Health Sector Programme III - Technical Assistance for Monitoring, Evaluation and Operational Research. NEPAL HEALTH SECTOR PROGRAMME III - TECHNICAL ASSISTANCE FOR MONITORING, EVALUATION AND OPERATIONAL RESEARCH. To improve the health of women, children,  the poor and socially excluded in Nepal, including by restoring health services in areas affected by the 2015 earthquake, and improving the quality and governance of health services nationwide.',\n",
       " '12110. Human Development Innovation Fund. HUMAN DEVELOPMENT INNOVATION FUND. To support innovative approaches to improving the quality, value for money and sustainability of basic services in the education, health and water and sanitation sectors in Tanzania',\n",
       " '12240. WASHPlus: Supportive Environments for Healthy Communities - Nutrition. WASHPLUS: SUPPORTIVE ENVIRONMENTS FOR HEALTHY COMMUNITIES - NUTRITION. WASHPlus is a Cooperative Agreement managed by FHI 360 with CARE and Winrock International as core partners, and teamed with a highly talented group of university, private and public sector resource partners in areas such as creative financing, innovation, and public-private partnerships in addition to WASH service delivery. The project is designed to support the further development, introduction and delivery of high-impact interventions in water supply, sanitation and hygiene (WASH) and indoor air quality (IAQ).',\n",
       " '13040. Shanghai Zerun Biotechnology Co., Ltd.. SHANGHAI ZERUN BIOTECHNOLOGY CO., LTD.. to improve womens access to low-cost bivalent HPV vaccine in GAVI-supported countries',\n",
       " '13020. Governance, Accountability, Participation and Performance (GAPP) - Maternal and Child Health. GOVERNANCE, ACCOUNTABILITY, PARTICIPATION AND PERFORMANCE (GAPP) - MATERNAL AND CHILD HEALTH. The primary objective of the GAPP program is to increase participation, accountability and local governance for effective service delivery. To achieve this goal, GAPP will focus on three key components highlighted below: to enhance accountability, improve local government governance, and support CSOs and other non-state actors to increase their voice and demand for improved services.',\n",
       " '12182. DBT-MRC Joint Centre Partnerships. DBT-MRC JOINT CENTRE PARTNERSHIPS. An MRC-DBT Joint Centre Partnership Call to support three UK-India joint centres, to support joint research activities and capacity building in areas of key importance to healthcare in India including antimicrobial resistance and cancer biology. Social f',\n",
       " '12110. TANZANIA CLEARING A/C - Irish Aid contribution to special health basket. TANZANIA CLEARING A/C - IRISH AID CONTRIBUTION TO SPECIAL HEALTH BASKET. Tanzania Country Programme  - ZZ-HEAGEN-Health General-Innovation Funding-1HEA-Irish Aid contribution to special health basket',\n",
       " '12262. African Collaborative for Health Financing Solutions (ACS). AFRICAN COLLABORATIVE FOR HEALTH FINANCING SOLUTIONS (ACS). The African Collaborative for Health Financing Solutions (ACS) will advance Universal Health Coverage (UHC) in Sub-Saharan Africa by working with regional bodies and country-level multi-stakeholder platforms to share knowledge, strengthen accountability and promote sound health financing policies. ACS will partner with regional institutions to strengthen their role in policy, advocacy, and regional learning on health financing approaches.',\n",
       " '13030. Expanding the Use of Selected Health Services and Products Task Order under Population, Health and Nutrition Technical Support Contract III-Global Health. EXPANDING THE USE OF SELECTED HEALTH SERVICES AND PRODUCTS TASK ORDER UNDER POPULATION, HEALTH AND NUTRITION TECHNICAL SUPPORT CONTRACT III-GLOBAL HEA. The purpose of this contract is to build on previous USAID/Madagascar Health Population and Nutrition (HPN) activities, expand services broader and deeper into communities to provide quality services to the poor, and to strengthen specific health systems and the capacity of the Ministry of Health and Family Planning to undertake its normative functions to ensure the delivery of critical health services.',\n",
       " '12250. CDC: Global Disease Detection Program (GDD). CDC: GLOBAL DISEASE DETECTION PROGRAM (GDD). The Global Disease Detection Program (GDD) is CDCs principal and most visible program for developing and strengthening global capacity to rapidly detect, accurately identify, and promptly contain emerging infectious disease and bioterrorist threats that occur internationally. We respond to high-profile public health events such as Ebola, polio eradication, MERS-CoV, cholera, and Nipah virus, while increasing our engagement in the agencys global health security activities.',\n",
       " '13040. BRIDGE II - HIV/AIDS. BRIDGE II - HIV/AIDS. BRIDGE II is a USAID-funded five-year strategic, evidence-based communication program that encourages Malawians in 11 districts in the southern region of Malawi to adopt behaviors that prevent HIV transmission. BRIDGE II aims to reduce new HIV infections through eliminating barriers to individual action and shifting social norms. It addresses key risk factors for HIV in Malawi such as having more than one sexual partner at a time, lack of condom use, and alcohol abuse. Gender norms and inequities often lie beneath these risky behaviors, and BRIDGE II openly addresses these issues. A multi-sectoral project with a strong community focus, BRIDGE works directly through creative multi-media campaigns, transformative and participatory toolkits (like the Hope Kit, PDF), interactive radio programs, service referral and linkages, and community theater. BRIDGE also builds local capacity by providing support to community and faith-based networks to strengthen their HIV prevention programs. The goal is lasting, positive change that not only prevents new HIV infections, but also strengthens the ability of Malawis communities to care for and protect themselves.',\n",
       " '12250. Higher Education for Development (HED) - Pandemic Influenza and Other Emerging Threats (PIOET). HIGHER EDUCATION FOR DEVELOPMENT (HED) - PANDEMIC INFLUENZA AND OTHER EMERGING THREATS (PIOET). Higher Education for Development (HED) works in close partnership with the United States Agency for International Development (USAID) and operates with the advice and counsel of the six major U.S. higher education associations to support the engagement of higher education in development issues worldwide. HED manages innovative partnerships that join U.S. colleges and universities with institutions of higher learning in developing nations. In this way, we support and facilitate the engagement of U.S. higher education in global development.',\n",
       " '13040. Health Communication Capacity Collaborative (HC3) - Program Design and Learning. HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3) - PROGRAM DESIGN AND LEARNING. HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       " '12191. The Project for the Provision of Ambulances for Improved Emergency Response in Jamaica. THE PROJECT FOR THE PROVISION OF AMBULANCES FOR IMPROVED EMERGENCY RESPONSE IN JAMAICA. Provision of re-cycled ambulances in order to deploy better emergency services in Jamaica',\n",
       " \"13020. Establishing a harmonized Reproductive Health Registry in Jordan to improve Maternal and Child Health. ESTABLISHING A HARMONIZED REPRODUCTIVE HEALTH REGISTRY IN JORDAN TO IMPROVE MATERNAL AND CHILD HEALTH. This project seeks to improve the quality and timely collection and use of reproductive health data in the Mafraq governorate of Jordan by establishing a harmonized Reproductive Health Registry (hRHR). The dearth and lack of reliable data limits the ability to make informed decisions by health providers, planners and community members, which can influence the well-being of women and children. The proposed implementation research project involving the participatory development of an electronic harmonized reproductive health registry is expected to link timely and accurate health data from local primary care health centres to hospital settings and governorate-level planning bodies, and back to communities. Issues of expanding services to cover vulnerable and undercounted populations are central to the proposed implementation and related research activities. Given the high numbers of Syrian refugees in the Mafraq governorate, the registry will be designed to serve both refugee and non-refugee populations to address different health needs and social contexts of the various groups. The project will also focus on strengthening the capacities of decision-makers at different levels of the health system and other sectors to use the data collected and analyzed through the registry. The project will apply mixed methods to conduct a situational analysis of existing systems and tools of sexual and reproductive health data collection and use; develop a harmonized electronic registry system using participatory approaches and established guidelines from the World Health Organization; strengthen representation of underserved groups of women, men and youth in stakeholder meetings and governance processes; develop a dashboard of data and related analysis; assess the quality, timeliness and reliability of data; and build capacities of researchers and decision-makers. The main outcomes include improved quality and timeliness of reproductive health data, better integration and interoperability among different health facilities, a strengthened referral system, increased capacities by decision-makers and providers to use health data, and costed plans to scale up the hRHR effort to other parts of the country.  This proposal represents one of nine selected as a cohort of implementation research projects spanning two regions (West Africa and the Middle East) and two thematic topics (adolescent sexual and reproductive health and health information systems).  The project is closely aligned with the Government of Canada's new feminist international assistance policy, the strategic priorities detailed in the 2016-2030 WHO led Global Strategy for Women, Children and Adolescents, and the overarching 2030 global agenda for sustainable development.\",\n",
       " '12230. The Project for Installing Medical Equipment at Chamkar Leu Referral Hospital in Kampong Cham Province. THE PROJECT FOR INSTALLING MEDICAL EQUIPMENT AT CHAMKAR LEU REFERRAL HOSPITAL IN KAMPONG CHAM PROVINCE. Project for installing medical equipment at Chamkar Leu Referral Hospital in Kampong Cham Province to build its capacity to perform surgery.',\n",
       " '13040. Program Support. PROGRAM SUPPORT. Develop and conduct needs assessments, baseline studies, targeted evaluations, special studies or other information-gathering efforts specifically for the design, monitoring and evaluation of USG-funded operating unit wide programs, not for a specific functional objective. This sub-element may also include developing and disseminating best practices and lessons learned, testing demonstration and/or pilot models, public outreach, or the preparation of strategic plans and other short-term programming tasks. Funding for similar activities that are directed to specific functional objectives should be entered in the PD&L sub-element of the appropriate program area(s) within that objective.',\n",
       " '13040. HIV-Innovations for Improved Patient Outcomes in South Africa. HIV-INNOVATIONS FOR IMPROVED PATIENT OUTCOMES IN SOUTH AFRICA. The purpose of this program is to support South African organizations that identify, strengthen, and institutionalize better, cost-effective practices and innovations in HIV and AIDS care and treatment for priority and at-risk populations in accordance with South African government (SAG) priorities and policies. Targeted priority and at-risk populations for this program include pregnant women; infants, children, and adolescents; men who have sex with men (MSM); commercial sex workers (CSWs); hard to reach populations; and those co-infected with HIV/TB. This program will support the scale-up of SAG priorities through capacity building, operations research, including cost and cost effectiveness analyses, monitoring and evaluation, and plans for transition of limited service provision to key populations. Successful programs will demonstrate a strong capacity for integration of policy, technical approaches, as well as collaboration and coordination with partners and stakeholders and must also be in accordance with the Partnership Framework between the USG and SAG.O',\n",
       " '13020. Sustainable Development Goals Performance Fund  for basic emergency maternal, obstetric, neonatal and child health care services. SUSTAINABLE DEVELOPMENT GOALS PERFORMANCE FUND  FOR BASIC EMERGENCY MATERNAL, OBSTETRIC, NEONATAL AND CHILD HEALTH CARE SERVICES. To improve the functionality of primary health care units, reducing health inequalities, and  increasing domestic financing  for health to sustain and accelerate the pace of improvement in adolescent, maternal and child health in Ethiopia. This will be ac',\n",
       " '12263. ACCroatiaTuberculosis. AC: CROATIATUBERCULOSIS. Tuberculosis',\n",
       " \"12181. A STUDY OF THE SANA'A UNIVERSITY TEACHING HOSPITAL PROJECT. A STUDY OF THE SANA'A UNIVERSITY TEACHING HOSPITAL PROJECT. NA\",\n",
       " '12263. Control and Prevention of Tuberculosis (CAP-TB) in the Mekong Region - Tuberculosis. CONTROL AND PREVENTION OF TUBERCULOSIS (CAP-TB) IN THE MEKONG REGION - TUBERCULOSIS. Control and Prevention of Tuberculosis (CAP-TB) is a five-year project funded by the U.S. Agency for International Development (USAID) to reduce the incidence and mortality from Multi-Drug Resistant TB (MDR-TB.) The projects overall aim is to develop a model for cost-effective MDR-TB control that can be sustainably expanded throughout Myanmar, China, and Thailand. The objectives of the project are to prevent disease transmission, to increase early MDR-TB diagnosis, and to maximize treatment success.',\n",
       " \"13020. Pacific Women Fiji Country Plan. PACIFIC WOMEN FIJI COUNTRY PLAN. Pacific Women Shaping Pacific Development is a ten-year commitment by the Australian Government to support the Pacific to address gender inequality. The Fiji Country Plan is the Fiji-specific investments and strategies to address gender inequality in Fiji. The first four years of the Fiji Country Plan aims to support initiatives that will: increase women's economic empowerment; support women's organisations and coalitions for change; increase women's participation in leadership and decision-making; enhance knowledge and evidence to inform policy and practice; and improve gender outcomes within Australia's bilateral aid program to Fiji. Subsequent Fiji country plans will be developed over the life of the investment to respond to emerging gender issues in Fiji. The country plan will include an annual reflection process with implementing partners to maintain ongoing relevance of the investment. The country plan also aims to establish a local Fiji Women's Fund by the end of the life of the investment. The fund will be independently owned and managed and provide support to local women's NGOs and networks to advance gender equality in Fiji. The total value of this initiative is $26.3 million over 9 years, starting 2013-14.\",\n",
       " '12191. SUPPORT TO THE MEDICAL AND SURGICAL ACTIVITIES OF THE EMERGENCY REGIONAL PROGRAM OF PAEDIATRICS AND HEART - SURGERY IN AFRICA - SOCIAL SECURITY CHARGES AND INSURANCE FOR VOLUNTEERS. SUPPORT TO THE MEDICAL AND SURGICAL ACTIVITIES OF THE EMERGENCY REGIONAL PROGRAM OF PAEDIATRICS AND HEART - SURGERY IN AFRICA - SOCIAL SECURITY CHARG. THE PROJECT AIMS AT OFFERING HEART- SURGICAL AND CHILDHOOD HEALTH-CARE ASSISTANCE THROUGH THE SALAM CENTRE IN KHARTOUM, CREATED BY EMERGENCY IN 2004, AND THE OTHER SATELLITE CLINICS IN PORT SUDAN, MAYO AND NYALA',\n",
       " '12261. LAAMScience, Iraqi national congress. . LAAMSCIENCE, INC. . to develop a hygienic, reusable menstrual diaper to decrease the incidence of reproductive tract infections acquired from current catamenial practices in developing countries',\n",
       " '12250. Mechanisms of Th2 cell - intrinsic hypo - responsiveness, and its impact on protective unsusceptibility and memory to parasitic parasitic worm. MECHANISMS OF TH2 CELL - INTRINSIC HYPO - RESPONSIVENESS, AND ITS IMPACT ON PROTECTIVE IMMUNITY AND computer storage TO PARASITIC HELMINTHS. Medical Research Council. Research Grant to investigate human immune response to worm infections',\n",
       " '13040. Regulation of HIV - 1 Laugh expression by SR proteins. REGULATION OF HIV - 1 jape EXPRESSION BY SR PROTEINS. Medical Research Council. Research Grant to investigate the interaction between boniface cell and HIV virus',\n",
       " '13030. MEASURE Evaluation Phase III - Family Preparation and Reproductive Health. measuring rod EVALUATION PHASE III - FAMILY PLANNING AND REPRODUCTIVE HEALTH. MEASURE Evaluation Phase III continues the MEASURE programs 10 year initiative to improve the collection, analysis and presentation of data to promote in effect use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3) increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increase facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       " '12262. Medicines for Malaria Venture (MMV) - Malaria. medicine FOR MALARIA VENTURE (MMV) - MALARIA. The Medicines for Malaria Venture was established in 1999 to build and manage a research and development portfolio capable of leading to the readjustment of at least one new antimalarial drug every five years. Although partnered with industry, MMVs focus is on discovery and development of drugs that will be affordable to populations living in malaria endemic areas. MMV manages and directs research and development activities carried out at a broad variety of institutions, comprising 42 academic and pharmaceutical organizations located in 10 different countries.',\n",
       " '12263. Technology, Research, Education and Technical Assistance for Tuberculosis (TREAT TB) - Tuberculosis. TECHNOLOGY, RESEARCH, EDUCATION AND TECHNICAL ASSISTANCE FOR TUBERCULOSIS (TREAT TB) - TUBERCULOSIS. Technology, Research, Education and Technical Assistance for Tuberculosis (TREAT TB) is a cooperative agreement with the International Union Against Tuberculosis and Lung Disease (IUATLD ), also known as The Union. TREAT TB focalize on field evaluations of diagnostic techniques for TB, clinical trials and operations research to ameliorate patient management, treatment efficacy, disease prevention, and contagion control measures for TB and MDR TB. TREAT TB also provides for field support to address key TB and TB / HIV issues through with operational research to improve the national TB programs performance.',\n",
       " '12182. Structure guided design of a transmission - blocking malaria vaccine targeting Pfs48 / forty five. STRUCTURE GUIDED DESIGN OF A TRANSMISSION - BLOCKING MALARIA VACCINE TARGETING PFS48 / 45. IIB - Research Boards January / Feb 2017 - RM 2018 awarding to create a structure guided design of a transmission - blocking malaria vaccinum.',\n",
       " '12240. New York Academy of Sciences. NEW YORK ACADEMY OF SCIENCES. to carry out a full range of activities take aim at improving the power to assess population thiamine status, determining the extent of thiamine deficiency in selected countries in Asia and Africa, and developing intervention strategies and national plans',\n",
       " '12250. Funding for exchange of scientists, grants. financial backing FOR EXCHANGE OF SCIENTISTS, GRANTS. Collaborative project - Molecular parasitology working mathematical group in Rwanda (MOPACUR) - Participation in study on geohelminths',\n",
       " '12240. SHINE research uptake and communications. SHINE enquiry UPTAKE AND communicating. New knowledge in Body of water / Sanitation / Hygiene, Infant Nutrition, and health sytems management is generated and disseminated and informs child health computer programme in Zimbabwe and globally',\n",
       " '12263. To fund the development of new, safe and effective drugs for tb through the Global Alliance for TB Drug Development organisation. . TO FUND THE DEVELOPMENT OF NEW, SAFE AND EFFECTIVE DRUGS FOR TUBERCULOSIS THROUGH THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT formation. . To research and develop new drugs for the treatment of tuberculosis (TB) through public private partnership. This research will advance the development of new, easier to use, and cheaper drugs for the treatment of TB, multi - drug resistant TB and extremely',\n",
       " '12220. Monell Chemical substance Senses. MONELL chemical substance SENSES. to demonstrate that taste cell technologies will lead to discovery of compounds that pharmacologically block the bitter and off - tastes of life - saving unwritten medicines, thereby significantly better compliance in pediatric populations',\n",
       " '12250. Global Health Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE engineering monetary fund. to develop new wellness technologies as a result of funding and development quislingism with Japanese industry and government',\n",
       " '12263. Defining the metabolic phenotype of intracellular Mycobacteria tuberculosis. DEFINING THE METABOLIC PHENOTYPE OF INTRACELLULAR mycobacteria tb. Medical Research Council. Research Grant to investigate the TB bacteria within the human cell',\n",
       " '12250. Urban Drinking Water and Health Outcomes  Early Phase Study for a Randomized Controlled Trial in Accra, Ghana. URBAN DRINKING WATER AND HEALTH OUTCOMES  EARLY PHASE written report FOR A RANDOMIZED CONTROLLED TRIAL IN ACCRA, GHANA. Medical Research Council. Research Grant for development work result to trial of different wasy of providng safe drinking water in towns in Ghana',\n",
       " '12250. Common diseases. COMMON DISEASES. Collaborative project - German - Indonesian Aniinfective Cooperation (GINAICO ), subproject - Application of novel microbiological and ecological methods for the discovery of novel antimicrobial natural substances in marine invertebrates and their associated microorganisms - Medical research of particular importance for developing countries',\n",
       " '12250. Cooperation with foreign research institutions (not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (NOT INCLUDED IN OTHER AREAS ). Deactivation of hepatitis B virus replication with designer transcription factors and Designer nucleases - Capacity building in the field of education and research',\n",
       " '12262. From malaria control to sustainable elimination: Cluster randomised trial comparing targeted versus generalised transmitter control in South Africa. FROM MALARIA CONTROL TO SUSTAINABLE ELIMINATION: CLUSTER RANDOMISED TRIAL COMPARING TARGETED VERSUS GENERALISED VECTOR CONTROL IN SOUTH AFRICA. Medical Research Council Joint (MRC / WT / DfID) Global Health Trial grant to trial to compare effectiveness, price, coverage and homeowner acceptability between targeted focal indoor residual insecticide spray against mosquitos in South Africa',\n",
       " '12220. Infectious Disease Research Institute. INFECTIOUS DISEASE RESEARCH INSTITUTE. to provide foundation grantees with novel and innovative industry quality adjuvants and formulations to raise the success of pre - clinical and clinical vaccinum growth',\n",
       " '12182. Human Decoy Trap; operational and social acceptability of novel tool to improve surveillance and control of mosquitoes and other disease vectors. HUMAN lure TRAP; OPERATIONAL AND SOCIAL ACCEPTABILITY OF NOVEL TOOL TO IMPROVE SURVEILLANCE AND CONTROL OF MOSQUITOES AND OTHER DISEASE VECTORS. GCRF Foundation Infections 2016 to determine whether a mosquito trap, (the Human Decoy Trap) can overcome the limitations of the most frequently apply surveillance tools across sub - Saharan Africa, providing a standardised, cost - effective trap for sampling human - biting mosquitoes.',\n",
       " '12250. The Beijing Huayi Health and Drug Research Institute. THE BEIJING HUAYI wellness AND DRUG inquiry INSTITUTE. to identify new drug candidates for diseases that disproportionally affect the worlds poorest populations.',\n",
       " '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS enquiry INSTITUTE. to overcome the many challenges of getting oxygen to seriously ill children with severe pneumonia in remote rural hospitals and health centers',\n",
       " '12182. Understanding the transmission of tuberculosis using Mycobacterium tuberculosis sequence data. UNDERSTANDING THE TRANSMISSION OF TUBERCULOSIS USING MYCOBACTERIUM TUBERCULOSIS SEQUENCE DATA. IIB - Research Board May / Jun 2015 - RM 2016 award to understand the transmission of tuberculosis using Mycobacterium tuberculosis succession data in Malawi',\n",
       " '12262. Global Health Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE engineering FUND. to develop new drugs for the prevention and treatment of malaria, tuberculosis, Chagas, and visceral leishmaniasis',\n",
       " '12250. Surveillance of Crim - Congean Hem Fever in Kosovo. SURVEILLANCE OF CRIM - CONGEAN HEM FEVER IN KOSOVO. Nosology and Surveillance of Crim - Congean Hem Fever in Kosovo',\n",
       " '12261. Resources for the Future. RESOURCES FOR THE FUTURE. to help identify innovative policy solutions in which resource recovery from treatment of non - fecal waste can cross - subsidize intervention of fecal permissive waste, thus price effectively reducing the prevalence of pathogens in the environment',\n",
       " '12250. Funding for scientist exchanges, subsidization. FUNDING FOR SCIENTIST EXCHANGES, GRANTS. Antibiotics and antiquorum sensung compounds from African fungous endophytes inhabiting medicinal plants and cultures of macromycetes - Capacity building in the field of education and research',\n",
       " '12182. Modes of action and resistance mechanisms towards anti - trypanosomal benzoxaboroles. MODES OF ACTION AND immunity MECHANISMS TOWARDS ANTI - TRYPANOSOMAL BENZOXABOROLES. MRC / IIB  Research Grant to study new drug development against Human African trypanosomes often known as sleeping sickness. A disease found primarily in rural Africa.',\n",
       " '12250. A double blind randomise community - based trial of amoxicillin versus placebo for non - severe pneumonia in children aged 2 - 59 months in Pakistan. A DOUBLE BLIND RANDOMIZED COMMUNITY - BASED TRIAL OF AMOXICILLIN VERSUS PLACEBO FOR NON - SEVERE PNEUMONIA IN tyke AGED 2 - 59 MONTHS IN PAKISTAN. Medical Research Council Joint (MRC / WT / DfID) Global Health Trial grant to test the utility of antibiotic therapy in non - severe pneumonia in children aged 2 - 59 months in Pakistan',\n",
       " '12250. University of Maryland, Baltimore. UNIVERSITY OF old line state, BALTIMORE. to understand what drives sustained low - level typhoid transmission in Santiago, Chilly, where typhoid was once highly endemic, and to use these lessons to assess the feasibility of typhoid elimination',\n",
       " '12262. Developmental Clinical Studies - Clinical evaluation of an AdCh63 - MVA PvDBP_RII vaccine for blood - stage Plasmodium vivax. DEVELOPMENTAL CLINICAL STUDIES - CLINICAL EVALUATION OF AN ADCH63 - MVA PVDBP_RII VACCINE FOR BLOOD - STAGE PLASMODIUM VIVAX. Developmental Clinical Studies - Clinical rating of an AdCh63 - MVA PvDBP_RII vaccinum for blood - stage Plasmodium vivax',\n",
       " '12262. Malaria Vaccine Development Program (MVDP) - Malaria. MALARIA VACCINE DEVELOPMENT PROGRAM (MVDP) - MALARIA. MVDP, is committed to take in charge, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccine againstP. falciparumandP. vivaxmalaria identified by Research Institutes.',\n",
       " '13040. The Aaron Diamond AIDS Research Center. THE AARON DIAMOND AIDS inquiry CENTER. to support the development, optimization, and selection of engineer bispecific bNabs for HIV bar.',\n",
       " '12250. An integrated geospatial analysis framework for neglected zoonotic diseases. AN INTEGRATED GEOSPATIAL ANALYSIS model FOR NEGLECTED ZOONOTIC DISEASES. Medical Research Council. Fellowship to investigate models of transmittance in zoonotic disease',\n",
       " '12110. Chronic Disease Control Research Fellowship Program (Guatemala ). CHRONIC DISEASE CONTROL RESEARCH FELLOWSHIP PROGRAM (GUATEMALA ). Guatemala is at stage three of the five stages of the epidemiologic transition, which refers to the transition from infectious to inveterate diseases as the leading cause of death. In this stage, chronic disease account for between 35% and 65% of total mortality. In Guatemala, strategies to halt the growing epidemic of chronic disease are scarce and rarely evidence - based. The Chronic Disease Control Research Fellowship Program therefore aims to strengthen national research capacity to generate policy - relevant knowledge and evidence leading to chronic disease control and improved healthcare provision. The Program will recruit and mentor research chap to study policy - relevant issues and translate the resulting knowledge into action. The program will focus initially on tobacco control research (smoking prevention, cessation ), in recognition that tobacco use is the leading cause of chronic disease. However, as the program evolves, the potential exists to address other issues relate to chronic disease control as well.',\n",
       " '12110. Mapping and Analysis of Public Health Research and Capacity Strengthening Initiatives in Africa. MAPPING AND ANALYSIS OF PUBLIC HEALTH RESEARCH AND CAPACITY STRENGTHENING INITIATIVES IN AFRICA. Health care across much of the African continent is restrain by meager resources and a growing onus of disease, with HIV / AIDS, tuberculosis and malaria leading the charge. A growing body of evidence points to the need for a health scheme approach when designing, implementing and evaluating public health interventions. Although various organizations support health systems research in Africa, few have been devoted to systematically identifying, mapping, analyzing and reporting synergies between ongoing and emerging programs. This project will endeavor to address the gap through periodic analysis of different health policy and research first step, including those of funding, implementing and collaborating entities. Particular emphasis will be placed on identifying successful strategies for integrating HIV / AIDS into broader health and education systems. The exercise is expected to enhance knowledge networking and opportunity sharing between southern institutions, as well as strengthening South - North linkages.',\n",
       " '13081. Output 13: Analysis on population dynamics. ANALYSIS ON POPULATION DYNAMICS. Republic of bolivia - La Paz. Output thirteen: Increased availability of evidence through cutting - edge in - depth analysis on universe dynamics, sexual and generative health, HIV and their linkages to poverty eradication and sustainable development',\n",
       " '12263. Ontogeny Invention Ventures (DIV) - Tuberculosis. DEVELOPMENT INNOVATION VENTURES (DIV) - TUBERCULOSIS. Ontogenesis Invention Ventures (DIV )',\n",
       " '12182. RCT to evaluate an intervention for depressed HIV - positive women in the perinatal period, to enhance child development and reduce maternal depression. RCT TO EVALUATE AN INTERVENTION FOR DEPRESSED HIV - POSITIVE WOMEN IN THE PERINATAL PERIOD, TO ENHANCE CHILD ontogeny AND REDUCE MATERNAL DEPRESSION. MRC / JGHT 6 Full 2016 - A Randomised control trial to evaluate an intervention for depressed HIV - positive women in the perinatal period, to enhance child development and reduce maternal depression in Sub - Saharan Africa',\n",
       " \"12250. PATH. PATH. to make available a rapid, low priced, and field - friendly Ov - 16 antigen - base antibody test (' Ov - 16 rapid test ') for use in onchocerciasis programs for disease control and eventual elimination in Africa\",\n",
       " '12263. Streamlined TB Diagnosis and Treatment. STREAMLINED TB DIAGNOSIS AND TREATMENT. Medical Research Council Joint (MRC / WT / DfID) Global Health Trial grant to improve t.b. diagnosis and discussion in Uganda Vietnam Pakistan',\n",
       " '12250. Alveo Technology. ALVEO TECHNOLOGIES. to assess novel, low price nucleic acerb detection technologies for use in low resource settings',\n",
       " '13040. Common diseases. park DISEASES. European and Develop Countries Clinical Trials Partnership (EDCTP) - HIV treatment contribution to a randomized controlled trial using lithium carbonate in patients with HIV - C associate neurocognitive disorders - phase IIb proof - of - principle trial - Medical research of particular importance for Developing Countries',\n",
       " '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to bring home the bacon evidence to help read wherefore vaccine recipients in some instances do not respond to an oral rotavirus vaccine',\n",
       " '12182. Child Health Research Foundation (CHRF ). CHILD wellness RESEARCH FOUNDATION (CHRF ). for etiology (bacterial and viral agents) of neonatal sepsis in Asia and Africa',\n",
       " '12262. IDENTIFYING legion - PATHOGEN INTERACTIONS WHICH CAUSE SEVERE MALARIA. IDENTIFYING HOST - PATHOGEN fundamental interaction WHICH causa SEVERE MALARIA. Checkup Research Council. Fellowship to investigate host parasite interaction in severe malaria',\n",
       " '12250. University of Maryland, Baltimore. UNIVERSITY OF MARYLAND, BALTIMORE. to support a clinical study of the impact of rotavirus vaccinum introduction on moderate to severe diarrhea among children ages 0  59 months in Gambia, Kenya, and Mali',\n",
       " '13040. Oregon Health & Science University. OREGON wellness & skill UNIVERSITY. to support CMV vector - found Vaccine Concept',\n",
       " '12182. Funding for exchange of scientist, president grant. FUNDING FOR EXCHANGE OF SCIENTISTS, GRANTS. Identification of new approaches to treat epilepsy through genetics survey among the Moroccan universe - pilot project',\n",
       " '12262. Medicines for Malaria Venture. MEDICINES FOR MALARIA VENTURE. to make an open - source compound collection of 400 molecules as a resource to jump - start drug discovery efforts across a wide range of pathogens',\n",
       " '12182. Investigating the Human Malaria Reservoir of Transmission system during Pregnancy. INVESTIGATING THE man MALARIA artificial lake OF TRANSMISSION DURING PREGNANCY. MRC / DfID African Research Leader award investigating malaria transmission during pregnancy',\n",
       " '12110. Reasoned Approach to Setting Priorities in Health. REASONED APPROACH TO SETTING PRIORITIES IN wellness. This project will develop a concise set of guidelines and tools for priority setting, and employ them to two different resource allocation problems, the one focusing on equitable redistribution of health services toward the most vulnerable in Namibia, and the other on the sustainability of the Aarogyasri Health Insurance Scheme for the poor in Andhra Pradesh, India. The project will provide essential capacity building and enhanced technical inputs from the World Health Organization (WHO) in supporting of the long - expressed aim of these two governance to reduce existing inequities with respect to the allocation of and access to resources for health.',\n",
       " \"12250. Onchocerciasis Elimination Program of the Americas (OEPA) The Carter Center. ONCHOCERCIASIS excretion PROGRAM OF THE AMERICAS (OEPA) THE CARTER CENTER. The Carter Center ' s Onchocerciasis Elimination Program for the Americas (OEPA) coordinates the regional initiative to end illness and transmission of onchocerciasis (or river blindness) in the Americas.\",\n",
       " '13040. Magee - Womens Enquiry Institute and Foundation. MAGEE - WOMENS RESEARCH INSTITUTE AND FOUNDATION. to accelerate the development of the x vivo challenge assay to leave an optimized bio - indicator of product efficacy',\n",
       " '13040. Global Wellness Innovative Technology Store. GLOBAL HEALTH INNOVATIVE TECHNOLOGY investment firm. to develop new health technologies as a result of funding and development collaborations with Japanese industry and government',\n",
       " '13040. Fred Anne hutchinson Cancer Research Center. FRED HUTCHINSON CANCER RESEARCH CENTER. to develop methods and computational instrument in biostatistics, computational biology, and mathematical modeling that will improve the quantitative science insightfulness and rigor of the HVTN 701 and 702 trial design and psychoanalysis for assessing immune correl',\n",
       " '12263. GlaxoSmithKline Iodine + D, S. L. . GLAXOSMITHKLINE I + D, Sulfur. L. . to access a first in class technology program to identify the molecular targets of up to 10 anti - TB and anti - malaria lead compounds for the benefit of the wider Malaria and TB drug find communities',\n",
       " '12182. A Dose Reduction Immunobridging Study of two HPV vaccines in Tanzanian girls. A DOSE REDUCTION IMMUNOBRIDGING STUDY OF TWO HPV VACCINES IN TANZANIAN GIRLS. Jt Fund Health Tri Y5 Feb 2015 award to plan a randomized trial in healthy Tanzanian females aged 9 - fourteen years. To establish whether a single dose of HPV vaccine produces immune responses that live likely to be effective in preventing cervical cancer in Africa.',\n",
       " '12263. TASK Foundation. TASK creation. To support electrical capacity to enable TB drug development globally through with conservation and strengthening of a microbiology laboratory for early bactericidal activity (EBA) studies',\n",
       " '12182. DSO PDP subsidie IAVI 2011 / 14. DSO PDP SUBSIDIE IAVI 2011 / 14. PDP Subsidie IAVI 2011 t / grand 2014',\n",
       " \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering area through multi - country collaboration. The project squad will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and societal variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scaled up in other high - risk areas of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       " '13040. HIV EPIDEMIOLOGY AND PREVENTION / RANDOMISED, PLACEBO - CONTROLLED SAFETY AND EFFICACY TRIAL OF A DAPIVIRINE VAGINAL RING indium HEALTHY HIV - NEGATIVE WOME. HIV EPIDEMIOLOGY AND PREVENTION / RANDOMISED, PLACEBO - CONTROLLED SAFETY AND EFFICACY TRIAL OF A DAPIVIRINE VAGINAL tintinnabulation IN HEALTHY HIV - NEGATIVE WOME. Medical Research Council. Intramural Grant Epidemiology and Prevention of HIV in Uganda, a microbicide tryout',\n",
       " '12262. Defining the mechanism of action of the 8 - aminoquinolines: A pre - requisite to rationally designed safe antimalarials for the elimination era. DEFINING THE MECHANISM OF ACTION OF THE 8 - AMINOQUINOLINES: A PRE - REQUISITE TO RATIONALLY DESIGNED SAFE antimalarial FOR THE ELIMINATION ERA. Medical Research Council. Research Grant to develop new drgus against malaria',\n",
       " '12262. The University of Lone star state at Austin. THE UNIVERSITY OF TEXAS AT AUSTIN. to reduce mosquito - borne diseases by developing a depleted cost and easy to use handheld device that utilizes widely useable maternity test strips to identify mosquitoes carrying specific pathogens such as the dengue virus',\n",
       " '12250. John Hopkins University. JOHNS gerard manley hopkins UNIVERSITY. to support the Pneumonia Etiology Research for Child Health (PERCH) Labor',\n",
       " '12250. Akonni Biosystems. AKONNI BIOSYSTEMS. to assess novel, low cost nucleic acid detection engineering for use in low imagination context',\n",
       " '12110. Strengthening Equity through Applied Research Capacity Edifice in e - Health. STRENGTHENING EQUITY THROUGH APPLIED RESEARCH CAPACITY BUILDING IN E - HEALTH. There exists limited understanding of how e - Health solutions are perceived, designed, carry out and used. This goes beyond considerations related to automation, power supplies and affordability. Rather, it refers to context - specific, politically - aware and socially sensitive examination of how various ICTs are being appropriated, who is being included and excluded in the process, and whether the incorporation of ICTs is leading to more equitable health outcomes. The Strengthening Equity through Applied Research Capacity Building in e - Health (SEARCH) program will cultivate local research capacity to examine e - health and whether it leads to improved health equity and stronger health systems. Emphasis will be placed on methodological and analytical rigor, and policy dialogue. The first phase of SEARCH will involve scoping studies and workshops, with will elaborate the research schedule for the remainder of the programme.',\n",
       " '13040. Family Health International. sept HEALTH INTERNATIONAL. to project, design, and initiate technical and ethical review article of a four - armed multi - center prospective randomized clinical trial of progestin - only hormonal contraceptive method and the copper intrauterine device (IUD )',\n",
       " '12182. Undertaking research. task inquiry. Project research',\n",
       " '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to contribute to the understanding of whether the frequency and intensity of social contact affects pneumococcal carriage rates and density, and if so, whether pneumococcal conjugate vaccination is able to overcome the effects of social contact on the elevator car',\n",
       " '12182. PATH Meningitis Vaccine Project (MVP) 2017 - 2021 for the development of vaccines to prevent meningitis. PATH MENINGITIS VACCINE PROJECT (MVP) 2017 - 2021 FOR THE DEVELOPMENT OF VACCINES TO PREVENT MENINGITIS. This programme in the Ross Fund Portfolio (which focusses on neglected tropical diseases, diseases of emerging electrical resistance and diseases of epidemic potential) will support the development of new products (such as drugs, diagnostics and insecticides) for ta',\n",
       " '12182. TBVI - Support for TB vaccine R & D activities. TBVI - SUPPORT FOR TB VACCINE R & D ACTIVITIES. TBVI is a European non - profit organization established in 2008, which supports, integrates, translates and prioritizes European R & D efforts to discover and develop new accessible and affordable terabyte Vaccines and correlates of protective covering for global use. With support from Norad, TBVI proposes to support its vaccine and biomarker R & D activities by focusing its activities on 4 of 7 of its R & Viosterol strategic areas.',\n",
       " '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will cost on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asiatic experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       " '13030. Apex Medical Technologies, Iraqi national congress. . APEX MEDICAL TECHNOLOGIES, INC. . to enhance the sensitivity and strength of male condoms by using collagen fibrils from bovine tendons, which provide a hydrated micro - rough skin - like control surface texture that facilitate heat transfer to produce a to a greater extent rude sensation.',\n",
       " '13040. Global Wellness Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND. to develop unexampled health technologies as a result of funding and maturation collaboration with Japanese industry and government activity',\n",
       " '12182. Mechanisms of helminth induced antiviral immunity to RSV infection. mechanism OF HELMINTH INDUCED ANTIVIRAL IMMUNITY TO RSV INFECTION. Medical Research Council. Research Grant to investigate immune response modulation of one infection on another by comparing Ugandan children with and without gut helminth infection to find out if this also enhances antiviral responses in the human respiratory tract.',\n",
       " '13040. Microbicides Research, Development, and Introduction - HIV / AIDS. MICROBICIDES inquiry, DEVELOPMENT, AND INTRODUCTION - HIV / AIDS. Microbicides Research, Development, and Instauration',\n",
       " '12262. Human race Health Organisation. WORLD HEALTH ORGANIZATION. to earn evidence on impact of insecticide resistance on the efficacy of malaria transmitter control and on feasibility of managing resistance',\n",
       " '12110. Lithuanian University of Health Sciences - bilateral cooperation with Ministry of Health of the Republic of White russia. LITHUANIAN UNIVERSITY OF HEALTH SCIENCES - BILATERAL COOPERATION WITH MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS. Experience sharing bodily function.',\n",
       " '13040. Duke University. DUKE UNIVERSITY. to alleviate the discovery of a safe, effective and practical HIV - 1 vaccine by using valid laboratory touchstone and Good Clinical Laboratory Practices to monitor antibody responses in the systemic and mucosal compartment in vaccine examination',\n",
       " '12250. Regulation Of The Innate And Adaptive Immune Response Against Pathogens And Their Products. regularization OF THE INNATE AND ADAPTIVE IMMUNE RESPONSE AGAINST PATHOGENS AND THEIR product. Medical Inquiry Council. Intramural Grant to study immune responses to TB',\n",
       " '12262. University of Booker t. washington Foundation. UNIVERSITY OF WASHINGTON FOUNDATION. to correctly identify infected individual with grim parasite densities who contribute to transmission and to improve the demeanor of malaria clinical trials',\n",
       " '12250. University of California San Francisco. UNIVERSITY OF CALIFORNIA SAN FRANCISCO. to use a novel animal model to determine the relative attenuation phenotype or immunogenicity of new oral polio vaccinum (OPV) viruses including those make by the consortium for a new OPV - 2 as benchmarked against virus Sabin - 2',\n",
       " \"12182. Function of immune cell populations in hypopigmentation disorders of autoimmune and infectious origin. FUNCTION OF IMMUNE cellular phone POPULATIONS IN HYPOPIGMENTATION DISORDERS OF AUTOIMMUNE AND INFECTIOUS ORIGIN. Why do citizens pay taxes? This question is surprisingly underexplored. Understanding when citizens pay taxes and wherefore they find it relevant and purposeful is central for answer this question. Tax compliance is a major concern in developing countries and particularly in Sub - Saharan Africa, in order to reduce dependency of foreign aid and increase state revenues for providing adequate health, educational and infrastructural services for their populations. In a nutshell, taxes are needed to build capable states that can provide for their citizens. Remarkably, taxation has not figured centrally on the agenda among scholars working on statebuilding in Africa or the African voter. Determinants of willingness to pay taxes in developing countries need to be scrutinized using an insiders ' perspective of what it means to be a tax payer on an everyday basis across different socioeconomic groups. This project expands on current explanations through focusing on the social practice of taxes; when, how and where taxation occurs and how this practice forms part of the everyday for ordinary citizens. This is studied through an ethnographic study of the practices surrounding tax payment in three cases in Sub - Saharan Africa (Lesotho, Tanzania and Zambia ), where the willingness to pay taxes and the relative tax burden vary. A comparative micro - study of citizens ' experience with taxes, using interviews and observations, will reveal the room for building a tax paying culture.\",\n",
       " '12250. California Institute of Technology. CALIFORNIA INSTITUTE OF TECHNOLOGY. to develop a Micro? Electro? Mechanical Scheme as a portable and reliable microbial monitoring system that can be integrated into safe and sustainable sanitation solutions in the developing world and enable onsite testing for pathogen',\n",
       " '12262. Mahidol University. MAHIDOL UNIVERSITY. to accelerate advancement of medical research for discourse, prevention and evacuation of malaria diseases',\n",
       " '12262. Naval Medical Research Center. NAVAL MEDICAL RESEARCH CENTER. to characterize the resistant profiles of humans protect against malaria following immunization with radiation syndrome - weakened Plasmodium falciparum sporozoite, in order to promote the development of malaria vaccines',\n",
       " '12261. Oklahoma State University. OKLAHOMA dos UNIVERSITY. to develop technology to reduce the pathogen load of helminthes and bacteria obtain in fecal wastes; thereby lowering the transmission rate of infectious diseases',\n",
       " '12250. Massachusetts Institute of Technology. MASSACHUSETTS INSTITUTE OF TECHNOLOGY. to develop novel pulsed antigen - releasing unmarried - injection vaccine delivery systems to facilitate pediatric immunization in developing world circumstances in which repeated patient access may be problematic',\n",
       " '13040. Weill Medical College of Cornell University. WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY. to advance the development of prophylactic HIV - 1 vaccine based on trimeric forms of the viral envelope glycoproteins contrive to induce protective neutralizing antibodies in clinical studies.',\n",
       " '12262. Improving Malaria Diagnostics (IMaD) - Malaria. IMPROVING MALARIA DIAGNOSTICS (IMAD) - MALARIA. Under IMaD, MCDI and its partners work to improve laboratory - based diagnosis of malaria (primarily at Ministry of Health facilities ), and to increase understanding, acceptance, and correct use of microscopy and Rapid Diagnostic Tests (RDTs) by laboratory staff and health care practitioner providing direct care to patients.',\n",
       " '12182. STUDIES TOWARDS DEVELOPEMNT OF VACCINES AGAINST ETEC AND H. PYLORI FOR USE IN DEVELOPING COUNTRIES. . STUDIES TOWARDS DEVELOPEMNT OF VACCINES AGAINST ETEC AND H. PYLORI FOR USE IN DEVELOPING COUNTRIES. . The overall aim of this project is to develop effective vaccines against two of the most common gastrointestinal pathogens, i. e. enterotoxin - producing Escherichia coli (ETEC) and Helicobacter pylori, especially for use in developing countries. This include studies to elucidate immune mechanisms and antigens of importance for protection against diseases caused by these bacteria and to construct and evaluate promising candidate vaccines for safety and immunogenicity, initially in animals and subsequently in humans. It also includes a search for new ETEC colonization factors and analyses of emerging ETEC clones by means of whole genome sequencing. A new oral ETEC candidate vaccine developed by us, consisting of recombinant E. coli bacteria over - expressing the most important ETEC colonization factors and a anatoxin will be evaluated alone and together with a promising mucosal adjuvant for safety and immunogenicity in Phase I / II studies, initially in Sweden and subsequently in descending age groups in Bangladesh. The aim is also to identify simple interventions such as calorie and micronutrient supplementation, changed breast feeding patterns, anti - parasite treatment that may improve immune responses against enteric vaccines in children in developing countries. Vaccine strains that overexpress putative protective H. pylori antigens will also be constructed and tested for protective efficaciousness in experimental animals.',\n",
       " '12250. Wits Wellness Pool. WITS HEALTH syndicate. to elucidate associations between RSV, influenza and pneumococcal colonization',\n",
       " \"12182. European and Developing Country Clinical Trials Partnership phase II: funding to support two enquiry calls. EUROPEAN AND DEVELOPING COUNTRY CLINICAL TRIALS PARTNERSHIP phase angle II: FUNDING TO SUPPORT TWO RESEARCH CALLS. Support for two research calls: ' Research and clinical management of patients in poverty - related disease epidemics in sub - Saharan Africa ' and ' Clinical trials and operational research studies to optimise the use of products for poverty - related diseases in mothers, newborns, children and / or adolescents '\",\n",
       " '12250. Capital of the united states University. WASHINGTON UNIVERSITY. to make new find that will head to development of diagnostic tests for habit in onchocerciasis elimination programs',\n",
       " '12182. DSO PDP subsidie IAVI 2011 / 14. DSO PDP SUBSIDIE IAVI 2011 / 14. PDP Subsidie IAVI 2011 triiodothyronine / chiliad 2014',\n",
       " '12250. Market Study into the Praziquantel drug that is used for the Integrated Control of Schistosomiasis and Intestinal Helminths in Sub - Saharan Africa. MARKET STUDY INTO THE PRAZIQUANTEL DRUG THAT be USED FOR THE INTEGRATED CONTROL OF SCHISTOSOMIASIS AND INTESTINAL HELMINTHS IN SUB - SAHARAN AFRICA. To reduce morbidness and mortality in up to ten African countries by fork over a total of 203. 5 million treatments for Schistosomiasis and Soil - Transmitted Helminths.',\n",
       " '13040. The Aaron Diamond AIDS Research Center. THE AARON rhomb AIDS RESEARCH CENTER. to avail develop an effective long - represent bar intervention that could substantially reduce HIV - 1 incidence',\n",
       " '12182. Abubakar; Pwani; Adolescent Executive Functioning Association with Scholastic Outcomes, Risk Taking Behavior and Medical Adherence in the Circumstance of human immunodeficiency virus. ABUBAKAR; PWANI; ADOLESCENT EXECUTIVE FUNCTIONING ASSOCIATION WITH SCHOLASTIC OUTCOMES, RISK TAKING BEHAVIOR AND MEDICAL ADHERENCE IN THE CONTEXT OF HIV. Medical Inquiry Council / DfID African Research leadership award for mental health and HIV research in Kenya',\n",
       " '13040. Microbicide Enquiry, Development, and Introduction, Round 3 - human immunodeficiency virus / AIDS. MICROBICIDE RESEARCH, DEVELOPMENT, AND INTRODUCTION, ROUND 3 - HIV / AIDS. Microbicide Research, Growth, and Presentation, Round 3',\n",
       " '12262. Dissecting the Red Blood Cell Invasion Pathways of the Malaria Parasite Plasmodium knowlesi. DISSECTING THE RED BLOOD CELL INVASION PATHWAYS OF THE MALARIA PARASITE PLASMODIUM KNOWLESI. Medical Research Council inquiry fellowship award to expect at cell entry mechanisms of a novel zoonotic malaria',\n",
       " '12220. University of Maryland, Baltimore. UNIVERSITY OF MARYLAND, BALTIMORE. to develop broadly effective vaccines and interventions against enteric infections by conducting multi - country case - control studies using standardized methods to measure the etiology and burden of diarrhea among tyke in develop countries',\n",
       " '13040. HIV Vaccine and Biomedical Bar Research Projection. HIV VACCINE AND BIOMEDICAL PREVENTION RESEARCH PROJECT. HIV Vaccinum and Biomedical Prevention Research Project',\n",
       " '12250. A phase III randomised controlled trial of oral fluconazole plus flucytosine versus amphotericin B - based therapy for o. A PHASE terzetto RANDOMISED CONTROLLED TRIAL OF ORAL FLUCONAZOLE PLUS FLUCYTOSINE VERSUS AMPHOTERICIN B - BASED THERAPY FOR Group o. A phase III randomised control trial of oral fluconazole plus flucytosine versus amphotericin B - based therapy for oxygen',\n",
       " '12110. Strengthening Fairness through Applied Research Capacity Building in e - Health. STRENGTHENING EQUITY THROUGH APPLIED RESEARCH CAPACITY BUILDING IN E - HEALTH. There exists limited understanding of how e - Health solutions are perceived, designed, implemented and used. This goes beyond considerations related to automation, power supplies and affordability. Kind of, it refers to context - specific, politically - aware and socially sensitive examination of how various ICTs are being appropriated, who is being included and excluded in the process, and whether the incorporation of ICTs is leading to more equitable health outcomes. The Strengthening Equity through Applied Inquiry Capacity Building in e - Health (SEARCH) program will cultivate local research capacity to examine e - health and whether it leads to improved health equity and stronger health systems. Emphasis will be placed on methodological and analytical rigor, and policy dialogue. The first phase of SEARCH will affect scoping studies and workshops, with will elaborate the research agenda for the remainder of the program.',\n",
       " \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the egress or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategy in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each rural area, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scaled up in other high - risk areas of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       " '12263. Development Innovation Ventures (DIV) - T.b.. DEVELOPMENT INNOVATION VENTURES (DIV) - tb. Development Creation Ventures (DIV )',\n",
       " '12263. University of George washington Foundation. UNIVERSITY OF booker t. washington FOUNDATION. to develop new tools to discover and manage tuberculosis',\n",
       " '13040. Family Health International. kin HEALTH INTERNATIONAL. to plan, design, and initiate sealed activities to prepare for implementation of a quartet - armed multi - center prospective randomized clinical test of progestin - only hormonal contraception and the copper intrauterine device (IUD )',\n",
       " '12182. Novel therapeutic approaches to malnutrition enteropathy. NOVEL THERAPEUTIC APPROACHES TO MALNUTRITION ENTEROPATHY. GCRF Foundation NCDs 2016 support phase II trial of treatments for severely malnourished child with diarrhoea complications. With the aim to reduce mortality through mucosal healing. Particularly in Africa, South Asia, Zambia.',\n",
       " \"12182. NFR - GLOBVAC Global health and vaccination research. NFR - GLOBVAC GLOBAL HEALTH AND VACCINATION RESEARCH. An annual allocation of NOK 7 000 000 is set apart for research on global health and NOK 55 000 000 for research on vaccination. The funding is managed by Norse Research Council. The funds shall assure Norway ' s responisbility for research on global health challenges and povery - related diseases affectiong developing countries. The activity comprise basic research, clinical research and research on health systems direkted towards prevention and treatment of provery - related diseases\",\n",
       " '12250. Cost of pilot projects to increase efficiency in union administration. COST OF PILOT PROJECTS TO INCREASE EFFICIENCY IN FEDERAL ADMINISTRATION. Confocal Raman microspectroscopy and confocal laser microscopy to study the effects of antimicrobial agentive role on structure and composition of biofilms produced by pathogens recovered from cystic fibrosis patients. - Capacity building in the field of education and research - medical research',\n",
       " '12250. Innovation funding in the new LSnder. INNOVATION FUNDING IN THE NEW L - NDER. Molecular serology for rapid determination of vaccination titer against vaccinum - preventable infectious diseases (STIKO list) in migrants and other groups of affected role - Medical research of particular importance for developing countries',\n",
       " '13030. Contraceptive and Reproductive Health Technology Research and Utilization (CRTU) - Family Planning and Reproductive Health. CONTRACEPTIVE AND REPRODUCTIVE HEALTH TECHNOLOGY RESEARCH AND UTILIZATION (CRTU) - FAMILY PLANNING AND REPRODUCTIVE HEALTH. To develop, evaluate, and introduce a range of good, effective, and acceptable contraceptive and human immunodeficiency virus / AIDS prevention technologies (e. g. , microbicides and barrier methods) and other reproductive health (RH) technologies and to enhance the capacity of phratry planning (FP) and RH programs in developing countries to provide these technologies.',\n",
       " '12182. Miscellaneous in the area of external understanding. MISCELLANEOUS IN THE AREA OF INTERNATIONAL UNDERSTANDING. Collaborative project - Development of a cost - efficient vaccine against cervix carcinoma - a prophylactic approach, sub - project - upscaling a chloroplastidary vaccine expression system and transformation of new candidate antigens in tobacco plant and salad - Knowledge Transfer',\n",
       " '12182. To fund the development of new diagnostic testing for neglected diseases through the organisation Foundation for Innovative New Diagnostics. . TO FUND THE DEVELOPMENT OF NEW DIAGNOSTIC TESTING FOR NEGLECTED DISEASES THROUGH THE ORGANISATION FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS. . To research and develop new diagnostic tests for the unattended diseases of the hapless, include Tuberculosis, Sleeping Illness, Leishmaniasis, Malaria and Non - malarial febrile illness, through public private partnership. This research will advance the dev',\n",
       " '13040. Preventive Technologies Correspondence (PTA) - HIV / AIDS. PREVENTIVE TECHNOLOGIES AGREEMENT (PTA) - human immunodeficiency virus / AIDS. To develop, evaluate, and introduce a range of safe, effective, and acceptable HIV / AIDS prevention technologies (e. g. , microbicides and barrier methods) and other reproductive health technologies and to enhance the capacity of field programme to allow services to populations at high risk.',\n",
       " '13030. Population Council. POPULATION COUNCIL. to develop and test the acceptability of a vaginal ring engineering aimed at amplify contraceptive choice, improving maternal and newborn health, and building relationships with private and public sector stakeholders',\n",
       " '12182. Studies of hepatic latency in human ovale malaria. STUDIES OF HEPATIC LATENCY IN homo OVALE MALARIA. Medical examination Research Council. Research Grant to investigate the abeyant phase of malaria',\n",
       " '13030. Population Council. POPULATION COUNCIL. to develop and test the acceptableness of a vaginal ring technology aimed at expanding contraceptive choice, improving maternal and newborn wellness, and build relationships with private and public sector stakeholders',\n",
       " '12262. University of Kentucky Research Foundation. UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION. to aid mass bringing up of different disease - relevant mosquito species for control efforts',\n",
       " '13040. Arcady Radical, LLC. ARCADY chemical group, LLC. to develop and source a medication event monitor box seat for use in clinical trial and ultimately scale for deployment in Indian and Chinese TB control programs',\n",
       " '13040. Duke University. DUKE UNIVERSITY. to rapidly test the MPER liposome immunogen in a small phase 0 / 1 clinical trial in club to determine if relevant unsubtle neutralizing antibody (BnAb) germline antibody - producing B cells can be engaged by the immunogen, and BnAb Type b cell lineages can be driv',\n",
       " '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competitor in Southeast Asia for funding multi - nation studies coordinated by an institution or consortium of institutions located in the region. The vehemence will be on capacity building, networking and policy impact at the regional story. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       " '12240. University of Nottingham. UNIVERSITY OF NOTTINGHAM. to better delicacy diarrheal diseases by identifying bacteriophage (viruses that infect bacteria) that can ruin iii different infective gut bacterium to restore healthy bacterial populations using their pig enteric model.',\n",
       " '12110. Strengthening Equity through Applied Research Capacity Building in e - Health. STRENGTHENING EQUITY THROUGH APPLIED RESEARCH CAPACITY BUILDING IN E - HEALTH. There exists limited understanding of how e - Health solutions are perceived, designed, implemented and used. This goes beyond considerations related to automation, power supplies and affordability. Rather, it refers to context - specific, politically - aware and socially sensitive examination of how various ICTs are being appropriated, who is being included and excluded in the process, and whether the incorporation of ICTs is leading to more equitable health outcomes. The Strengthening Equity through Applied Research Capacity Edifice in e - Health (SEARCH) program will cultivate local research capacity to examine e - health and whether it leads to improved health equity and stronger health systems. Emphasis will be placed on methodological and analytical rigor, and policy dialogue. The first phase of SEARCH will involve scoping studies and workshops, with will elaborate the research agenda for the remainder of the program.',\n",
       " '12182. A randomized trial to evaluate the toxicity and efficacy of 1200mg and 1800mg rifampicin daily for 4 months in the treatment of pulmonary tuberculosis. A RANDOMIZED TRIAL TO EVALUATE THE TOXICITY AND EFFICACY OF 1200MG AND 1800MG RIFAMPICIN DAILY FOR 4 MONTHS IN THE TREATMENT OF PULMONARY TUBERCULOSIS. Jt Fund Health Tri Y5 Feb 2015 award to run a trial in Uganda. On the effectivity of increasing the current dosage to help heal tuberculosis and the impact of these changes to the completion of treatment and cure rates for Lower and Middle income countries.',\n",
       " '12262. Global Wellness Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE TECHNOLOGY investment firm. to develop new drugs for the bar and treatment of malaria, tuberculosis, Chagas, and visceral leishmaniasis',\n",
       " '12263. Augmentation and regulation of immune responses to Tuberculosis by vitamin D. AUGMENTATION AND REGULATION OF IMMUNE RESPONSES TO tb BY VITAMIN D. Medical Inquiry Council. Fellowship to investigate how Vit D may affect the immune response to TB',\n",
       " '12110. Assessing the Posture and Practices of Public Health Professionals Regarding Funding from For - Profit Corporations. ASSESSING THE ATTITUDES AND PRACTICES OF PUBLIC HEALTH PROFESSIONALS REGARDING FUNDING FROM FOR - PROFIT CORPORATIONS. Over the past two decades, many corporations have begun philanthropic contributions to universities under the rubric of corporate social responsibility (CSR ). In an era of dwindling support from governments and foundations, many university have, in turn, begun to solicit funds from businesses. In the case of schools of public health, some potential corporate funders make products that may be considered harmful to health or a threat to the environment, creating a potential conflict of interest. The overall aim of this project is to inform a policy debate about potential guidelines for making decisions about accepting funds from for - profit corporations. At present, there are no generalized guidelines to govern the receipt of research and sponsorship funds from for - profit corporations - practices differ by schools and programs of public health. This project, managed by the American University of Beirut, will survey public health academics and practitioners around the world about their attitudes and practices around funding from for - profit corporations, particularly those whose products are associated with non - communicable diseases. The project will also review existing policies that govern schools of public health around the globe with respect to taking funds from for - profit corporations. The project will focus on schools and programs of public health in the Eastern Mediterranean region, North America, Africa, and Southeast Asia.',\n",
       " '12250. Trustees of Dartmouth College. TRUSTEES OF DARTMOUTH COLLEGE. to develop more than accurate and timely measurement of population immunity sire by polio vaccines',\n",
       " \"12182. PATH Product Development Partnership Programme 2013 - 2018. itinerary PRODUCT DEVELOPMENT PARTNERSHIP PROGRAMME 2013 - 2018. ' To reduce poverty through investing in inquiry to develop effective and affordable, diagnostics, treatment, drugs and vaccines for diarrhoea and malaria. In the longer term this has the potential to significantly reduce death and illness among the poor\",\n",
       " '13030. The Product Development Agreement - Family Planning and Reproductive Health. THE intersection growth accord - kinsperson PLANNING AND REPRODUCTIVE HEALTH. The Product Development Agreement',\n",
       " '12263. tb Vaccine Opening move. TUBERCULOSIS VACCINE enterprisingness. to improve tuberculosis control by developing and introducing modern technologies to forbid, diagnose and treat the disease',\n",
       " '13040. WHO - IARC (International Agency for Research on Cancer ). WHO - IARC (INTERNATIONAL AGENCY FOR RESEARCH ON CANCER ). to verify effectiveness and safety of 2 vs 3 state of HPV vaccinum in preventing cervical cancer in a population in a developing country and to facilitate the rapid introduction of HPV vaccinum programs in poor countries at high cervical cancer risk',\n",
       " '12182. IAVI - International AIDS Vaccine Initiative - burden support 2013 - 2015. IAVI - INTERNATIONAL AIDS VACCINE INITIATIVE - CORE SUPPORT 2013 - 2015. IAVI is a Product Development Partnership found to ensure the development of safe, good, accessible, preventive HIV vaccines for use throughout the world. With support from Norad, IAVI aims to address the key scientific issue currently impeding vaccine development, i. eastward. HIV hyper - variability.',\n",
       " '12182. Scientific Cooperation with Other Countries (in so far as not included in other areas ). SCIENTIFIC COOPERATION WITH OTHER COUNTRIES (IN SO FAR AS NOT INCLUDED IN OTHER AREAS ). Studies on dermal invasion of polymer nanocapsules and nanoencapsulated clobetasol from nanocapsules',\n",
       " '12263. The Aurum Institute nonproliferation center. THE AURUM INSTITUTE NPC. to fund a clinical trial to examine if adding host - directed therapy to standard antimicrobic treatment could leave in a shorter and improved treatment of TB',\n",
       " '12250. University of Washington. UNIVERSITY OF WASHINGTON. to find out therapeutics for prevention of antibiotic resistance exploitation',\n",
       " '12182. Characterisation of the breakdown in immune competence of the lung that favours development of tuberculosis in HIV - infected adults. CHARACTERISATION OF THE crack up IN IMMUNE COMPETENCE OF THE LUNG THAT FAVOURS DEVELOPMENT OF TUBERCULOSIS IN HIV - INFECTED grownup. MRC / DfID African Research Leader inquire lung health and tuberculosis in HIV infected adults',\n",
       " '12262. Stanford University. STANFORD UNIVERSITY. for the psychoanalysis of sample and data from Scientific Advisory Board - sanction vaccine trials and natural history studies',\n",
       " '12191. AMENET - The African Melioidosis Meshing: improving health through an integrated microbiological, clinical and environmental research approach. AMENET - THE AFRICAN MELIOIDOSIS NETWORK: IMPROVING HEALTH THROUGH AN INTEGRATED MICROBIOLOGICAL, CLINICAL AND ENVIRONMENTAL RESEARCH APPROACH. AMENET - The African Melioidosis Network: improving wellness through an integrated microbiological, clinical and environmental research approach',\n",
       " '13040. Microbicide Research, Ontogenesis, and Introduction, Round 3 - HIV / AIDS. MICROBICIDE RESEARCH, DEVELOPMENT, AND origination, ROUND 3 - HIV / AIDS. Microbicide Research, Maturation, and Introduction, Round 3',\n",
       " '12262. University of Iowa. UNIVERSITY OF ioway. to learn antibody mediated protection against malaria parasite sporozoites',\n",
       " '12182. Improving the radical cure of vivax malaria: A multicentre randomised equivalence of short and long course primaquine regimens. IMPROVING THE RADICAL CURE OF VIVAX MALARIA: A MULTICENTRE RANDOMISED COMPARISON OF shortstop AND LONG COURSE PRIMAQUINE REGIMENS. Medical Research Council. Research Grant to trial compare treatment strategies for vivax malaria',\n",
       " '13040. Basic Science Program / Research aimed at designing an effective 13042vaccine. BASIC SCIENCE PROGRAMME / RESEARCH AIMED AT DESIGNING associate in nursing EFFECTIVE 13042VACCINE. Basic Science Programme / Research aimed at designing an effective 13042vaccine',\n",
       " '12262. GlaxoSmithKline Biologicals. GLAXOSMITHKLINE BIOLOGICALS. to provide a new dimension to vaccine development for malaria and tuberculosis (TB) by deeper analysis of transcriptomics data that are being generated in clinical study, by promoting collaboration between different partners involved in Systems Biological science',\n",
       " '12262. THE PREECLAMPSIA - MALARIA CONNECTION: PREDICTION, DIAGNOSIS, AND HOPE FOR TREATMENT. THE PREECLAMPSIA - MALARIA CONNECTION: PREDICTION, DIAGNOSIS, AND bob hope FOR TREATMENT. Women are particularly vulnerable to malaria during pregnancy because malaria parasites accumulate in the placenta and the condition is calculate to be responsible for 200 000 infant deaths annually. The disease mechanisms are poorly understood, mostly due to the lack of adequate animal models. We propose to use a placental perfusion model to study the interaction between malaria parasites accumulated in the human placenta in relation to the development of preeclampsia with ot without intrauterine growth restriction. The studies will also provide immediate guidance for ongoing efforts to develop a vaccine, protecting women from pregnancy malaria, and basic insight about the disease processes, which can lead to new treatment and prevention strategies for these complicated pregnancies affecting women in the sub - Saharan region. The specific aims of this undertaking are to uncover common disease mechanisms behind PE with or without IUGR and pregnancy - associated malaria (PAM ); to enable predictive diagnosis of high risk cases in the field; to prove feasibility of a cure using A1M in perfusion experiments. This work involves personnel and high risk pregnancy patients from Kenya, Egypt, Tanzania, and Ghana.',\n",
       " \"13020. Menstrual cups and unconditional cash transfer to reduce sexual and reproductive harm and school drop - out in adolescent schoolgirls in western Kenya. MENSTRUAL CUPS AND UNCONDITIONAL CASH TRANSFER TO REDUCE SEXUAL AND REPRODUCTIVE HARM AND SCHOOL DROP - OUT indium ADOLESCENT SCHOOLGIRLS IN WESTERN KENYA. Medical Research Council Joint (MRC / WT / DfID) Global Health Trial grant examining the impingement and monetary value - effectiveness of menstrual cups, compared or combined with unconditional cash transfer, to meliorate rural girls ' retention in secondary school and protec\",\n",
       " '12262. malaria parasite protein and erythrocyte encroachment. MALARIA PARASITE protein AND ERYTHROCYTE INVASION. Medical Research Council. Intramural Grant to study the molecules involved in the invasion process of the red cell by the malaria parasite',\n",
       " '13081. Output thirteen: Analysis on universe dynamics. ANALYSIS ON universe DYNAMICS. Guatemala - Guatemala City. Output 13: Increased availability of evidence through cutting - edge in - depth analysis on universe dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       " '13010. Promoting Punter Health for Marginalized Migrants in Southeast and East Asia. PROMOTING BETTER HEALTH FOR MARGINALIZED MIGRANTS IN SOUTHEAST AND EAST ASIA. In Southeast and East Asia, low - skilled migrant workers are highly vulnerable to exploitation, discrimination, and abuse. However, their health (particularly their sexual and reproductive health, with the exception of HIV) is relatively overlooked in public discourse and policies. This undertaking aims to draw attention to the gender and health needs of these migrant workers by facilitating knowledge creation and translation, and dissemination among researchers, policymakers, and implementers in the region. The grant will support two sets of activities. First, it will foster knowledge creation and translation by enabling the Asian - Pacific Resource & Research Centre for Women (ARROW) to develop an annotated bibliography of resources about the intersections of migration, gender, and health in Southeast Asia. Related resources to be developed include electronic and print versions of an annotated bibliography and a bulletin on Migration, Gender and Sexual and Reproductive Wellness and Rights in Southeast and Orient Asia. A directory of organizations and networks working on migration will be produced and used as a mailing list for the bulletin. An event will be held at a regional forum to foster awareness of issues related to migration, gender, and sexual and reproductive health and rights done presentation of the bulletin and a discussion session that will lead to a summary paper.',\n",
       " '13010. Output 13: Analysis on population dynamic. ANALYSIS ON POPULATION DYNAMICS. Occupied Palestine Territories. Output 13: Increased availability of evidence through with cutting - edge in - profoundness analysis on population dynamics, intimate and reproductive wellness, HIV and their linkages to poverty eradication and sustainable development',\n",
       " \"13010. Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems. CENTRE OF EXCELLENCE FOR CIVIL REGISTRATION AND VITAL STATISTICS (CRVS) SYSTEMS. Registration of events, such as birth, death, causes of death, marriage, and divorce, is critical for improving maternal, newborn, child, and adolescent health. These statistics provide policymakers and practitioners with the necessary evidence to design interventions and enact appropriate policies on maternal and child health. Many low - and center - income countries, however, do not systematically collect such crucial information. It is estimated that one - third of the world ' s births and two - thirds of the world ' s deaths are not registered or are incorrectly certified. In many cases, global norms, standards, tools, and good practices are not readily accessible and useable to those who need them most. The project will establish the Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems to provide information, tools, and expertise to facilitate the development and implementation of integrated CRVS systems. Funded by Global Affairs Canada and the International Development Research Centre (IDRC ), and based at IDRC, the Centre of Excellence will coordinate with existing expert chemical group to generate, consolidate, and share information and resources in an open and collaborative electronic platform. It will also assist countries needing more direct support by facilitating the exchange of good practices and capacity strengthening, and will play an important role brokering technical assistance for countries needing more direct support. The Centre of Excellence will work closely with the Global Financing Facility in support of the Every Woman Every Child initiative to enable the development and implementation of CRVS systems plans as part of country - led investment cases for financing by the Global Financing Facility.\",\n",
       " '12250. NTD Highlight Notice - Defining PK / PD relationships of anti - leishmanial drugs - a refreshing approach for anti - leishmanial drug development. NTD HIGHLIGHT observance - DEFINING PK / PD RELATIONSHIPS OF ANTI - LEISHMANIAL DRUGS - A NOVEL APPROACH FOR ANTI - LEISHMANIAL DRUG DEVELOPMENT. Medical Research Council. Research Grant to investigate development of potential new drugs against genus leishmania',\n",
       " '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infective diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Se Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on capacity building, networking and policy encroachment at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       " '12250. Keith rupert murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to monitor pneumococcal baby buggy and vaccine impact',\n",
       " '13040. Microbial translocation in HIV - septic tike in Uganda. MICROBIAL TRANSLOCATION IN HIV - INFECTED CHILDREN IN UGANDA. Medical Research Council. Fellowship to investigate gut permeability in human immunodeficiency virus infected children',\n",
       " '12182. Research to Improve Health Systems in Developing Countries. inquiry TO IMPROVE HEALTH SYSTEMS IN DEVELOPING COUNTRIES. To support enquiry into health systems in developing res publica in partnership with Wellcome Trust, the Medical Research Council and the Economic and Social Research Council. This research will improve our understanding of the most effective health interv',\n",
       " '12250. A clinical trial of oradexon to reduce deathrate in cryptococcal meningitis. A CLINICAL TRIAL OF DEXAMETHASONE TO REDUCE MORTALITY inch CRYPTOCOCCAL MENINGITIS. A clinical trial of dexamethasone to reduce mortality in cryptococcal meningitis',\n",
       " '13030. Preventive Technologies Arrangement (PTA) - Family Planning and Reproductive Health. PREVENTIVE TECHNOLOGIES AGREEMENT (PTA) - kinsperson PLANNING AND REPRODUCTIVE HEALTH. To develop, evaluate, and introduce a range of safe, effective, and acceptable HIV / AIDS prevention technologies (e. g. , microbicides and barrier methods) and other reproductive wellness engineering science and to enhance the capacity of field programs to provide services to populations at high risk.',\n",
       " '12250. Meningococcal Vaccine and Other Product Development 2010 - 2018. MENINGOCOCCAL VACCINE AND OTHER PRODUCT DEVELOPMENT 2010 - 2018. The UK is supporting a Product Development Partnership (PDP ), the Meningitis Vaccine Project to develop a polyvalent meningitis vaccinum for Sub - Saharan Africa that will hold in the remaining 15% to 20% of meningococcal infections non covered by the existi',\n",
       " '12182. Plasmodium falciparum malaria: understanding the role of conserved versus polymorphic antigens in acquired immunity. PLASMODIUM FALCIPARUM MALARIA: UNDERSTANDING THE ROLE OF CONSERVED VERSUS POLYMORPHIC ANTIGENS IN ACQUIRED IMMUNITY. A vaccine against malaria is urgently needed. The aim of this collaborative research project is to examine the role of antigen diversity on the antibody response and acquired immunity against clinical episodes of malaria; with the overall purpose of identifying candidate antigens to be included in a multi - component malaria vaccine. The project will describe parasite diversity in relation to antibody responses and protective immunity in individuals with different degree of exposure within defined geographical regions in Ghana and Kenya, as well as in travellers experiencing first time infections. We will focus on a subset of antigens (n = 10) that have been shown to be potential targets of protective immunity and include both conserved and polymorphic proteins. We will sequence the sponger collected from the community to define precisely the diversity at the selected loci, express these antigens and then analyse the antibody responses to conserve and diverse antigens. We will specifically investigate compounding of antigens and variants of antigens to which antibodies confer protection. The project will use samples that are and have been collected within longitudinal well - established cohorts in Ghana and Kenya, as well as Swedish travelers. The proposed collaboration includes workshops and involves several PhD students including a joint PhD supervision between Ghana, Kenya and Sweden, and will be mutually beneficially for the research development of all partners.',\n",
       " '12250. Emory University. EMORY UNIVERSITY. to support a study that will further apprehension of the impact of pneumococcal conjugate vaccine through with the sequencing and comparison of whole genome sequence of a species before and after vaccination',\n",
       " '13040. Completion of Phase III Microbicide Clinical Trial for Tenofovir 1% Gel - HIV / AIDS. COMPLETION OF PHASE III MICROBICIDE CLINICAL TRIAL FOR TENOFOVIR 1% GEL - HIV / AIDS. The objectives of this program are to complete clinical and regulatory activities required for licensure of tenofovir (TFV) 1% gel for the prevention of vaginal HIV acquisition in women and to provide information about its implementation in African populations. This project includes the following activities: 1) Completing clinical activities required for TFV 1% gel licensure; 2) Completing regulatory activities required for TFV 1% gel licensure; 3) Conducting open - label TFV 1% gel Implementation Study in South Africa and other African countries; 4) Conducting a bridging study for the approval of one TFV 1% gel that is safe and acceptable for vaginal and rectal use.',\n",
       " \"12110. Communications and knowledge translation fund for maternal and child health research. COMMUNICATIONS AND KNOWLEDGE TRANSLATION FUND FOR MATERNAL AND CHILD HEALTH inquiry. Maternal, newborn, child, and adolescent health, one of the Canadian government ' s development priorities, is a key element of the third Sustainable Development Goal (SDG) Good health and well - being. Evidence for building integrated and equitable health systems for women, adolescents, and children is urgently needed as countries strive to improve accountability and access to quality health services. IDRC ' s Maternal and Child Health program have supported a rich portfolio of research projects and a large number of researchers, research networks, and global institutions that contribute to sustainable solutions that strengthen primary health care systems in low - and middle - income countries (LMICs ). Building on this strong foundation, IDRC is ensuring that its approach of addressing the structural and root problems to strengthen health systems is communicate, understood, and adopted. The Maternal and Child Health program is supporting LMIC researchers, policymakers and implementers in a participatory manner and providing them with opportunities to influence national, regional, and global agendas through the dissemination and use of research results. This project aspire to disseminate the approach and work supported by the Maternal and Child Health program in order to give the results greater visibility and reach. This will be accomplished through the evolution of a suite of communication products that disseminate research results and the strategic involvement of grantees in key events to influence policies, practices, agendas, and funding priorities. Funds will also support knowledge translation activities to take advantage of opportunities that enable the mobilization of knowledge into policy processes.\",\n",
       " '12250. Gihon Laboratorios Quimicos S. R. L. . GIHON LABORATORIOS QUIMICOS S. R. Fifty. . to manufacture a twelve - month stockpile of thimerosal to be used in the case of an unexpected change in policy or unavailability of thimerosal ware, ensuring the continuous production and conservation of human and veterinary vaccines',\n",
       " '12182. Phenotypic picture of non - smoke COPD. PHENOTYPIC CHARACTERISATION OF NON - SMOKING COPD. Medical Research Council. Research Duncan grant to study chronic obstructive pulmonary disease in India',\n",
       " '12262. IVCC. IVCC. to support the Product Development Partnership to eliminate transmission of mosquito - borne pathogens through improved insect transmitter control with advanced products',\n",
       " \"12110. Contributions of Global Health Diplomacy to Health Systems in Sub - Saharan Africa: Evidence and Information to Support Capabilities for Health Diplomacy. CONTRIBUTIONS OF GLOBAL HEALTH DIPLOMACY TO HEALTH SYSTEMS IN SUB - SAHARAN AFRICA: EVIDENCE AND INFORMATION TO SUPPORT CAPABILITIES FOR HEALTH DIPLOMACY. Health is suit a core feature of global negotiations, whether they relate to trade, economic growth, or social development. New research will help boost Africa ' s bargaining power in global health diplomacy, The term global health diplomacy has been coined to describe the multidisciplinary work related to diplomacy, public policy, and global health. But an underlying North - South divide exists in this area, leaving Africa - and sub - Saharan Africa in particular - at a disadvantage. Although the region is highly integrated in the global economy, it has little bargaining power in such high - level negotiations. In health, for example, this has consequences when global level agreements and negotiations limit the space for national policy decisions on the development and strengthening of equitable health systems. This research aims to examine and communicate the most important elements countries need to assert their public health interests in global wellness diplomacy from an African perspective. The research will look at three examples of global health diplomacy important to sub - Saharan Africa: 1) the implementation of the World Health Organization ' s Code on International Recruitment of Health Personnel; 2) new collaboration on access to essential drugs through South - South relationships involving Africa, China, Brazil, and India; and 3) the involvement of African actors in getting universal access to prevention, treatment, and care for HIV and AIDS. The research will be led by the African - based organization EQUINET / Training and Research Support Centre, working with the Eastern African Trade Information and Negotiations Institute. Research teams conducting the case studies will be selected through an open call. African policymakers, knowledge brokers, and other key stakeholders will be involved throughout the research process. Expected outcomes of the research include some 200 publications consisting of background literature reviews, in - depth case studies, and scientific publications in international peer - reviewed journals that will be posted on the EQUINET website. African policymakers and other relevant actors will be exposed to the arguments, methods, and challenge of global health diplomacy so they can engage more effectively in this emerging field.\",\n",
       " '12182. MICA: Immunotherapy for oral cancer prevention and handling. MICA: IMMUNOTHERAPY FOR oral examination crab bar AND TREATMENT. GCRF Foundation NCDs 2016 Immunotherapy for oral cancer prevention and treatment. by constructing plant computer virus - based vaccines, using technologies developed for preclinical testing for the prevention of oral cancers. Ideally suited for healthcare delivery in low and middle income countries',\n",
       " '12262. Alliance for Emerging and Re - emerging Infectious Diseases Threats in Asia Foundation. ALLIANCE FOR EMERGING AND RE - EMERGING INFECTIOUS DISEASES THREATS IN ASIA FOUNDATION. to demonstrate a reduction in community - level malaria incidence expend a spatial repellant interference',\n",
       " '13040. HIV Care Research Programme / Follow up of slow disease progressors and of individuals on long term ART. HIV CARE enquiry PROGRAMME / FOLLOW UP OF SLOW DISEASE PROGRESSORS AND OF INDIVIDUALS ON LONG TERM ART. Checkup Research Council. Intramural Grant to undertake clinical trials or longer term follow up for new care regimes for HIV',\n",
       " '12250. Janssen Vaccines & Prevention B. Phoebe. . JANSSEN VACCINES & PREVENTION B. V. . to execute pre - clinical immunogenicity studies to determine if inactivated acute anterior poliomyelitis vaccine (IPV) derived from PER. C6 produced virus has the biological properties that would justify investments in farther development',\n",
       " '12250. Demonstration projects for innovative health research and development. DEMONSTRATION PROJECTS FOR INNOVATIVE HEALTH RESEARCH AND DEVELOPMENT. A major global health concern is the gap in research and development (R & D) of medical products against diseases disproportionately affecting poor people in developing countries. The World Health Organization (WHO) has selected several novel R & D projects. Through innovative approaches to coordination and financing of R & D, they aim to develop a series of cost - good diagnostic kits and discussion for disease such as leishmaniasis.',\n",
       " '13030. Support to the IMPT. SUPPORT TO THE IMPT. The Initiative for Multipurpose Prevention Applied science (IMPT) works to advance the development of products that simultaneously address the interconnected risks of HIV, other sexually transmitted infections (STIs ), and unintended pregnancy. Comprised of members from across disciplines and more than 15 countries, the IMPT is the central body that researchers, product developers, funders, policymakers, and advocates rely on for objective technical guidance and strategic planning related to MPTs. By facilitating interdisciplinary partnerships, the IMPT enables experts from across the family planning, HIV, and STI fields to strategize around the unique technological, market access, and regulatory challenges presented by developing combined prevention, thus refining the pathway to impactful MPT development. The objective of the project is to support the IMPT Secretariat in its role as the product - neutral coordinator of the MPT field.',\n",
       " '12250. International Centre for Diarrhoeal Disease Research, Bangladesh. INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH. to develop a universally accepted communications protocol for prevention, diagnosis and intervention of Environmental Enteropathy',\n",
       " '12182. Former Prospective Studies (A6, A10 ). OTHER PROSPECTIVE field of study (A6, A10 ). Early Prospective Studies (A6, A10 )',\n",
       " '12250. Medicines for Malaria Venture (MMV ). MEDICINES FOR MALARIA VENTURE (MMV ). The pharmaceutical industry has largely withdrawn from the active pursuit of new drug for malaria. The extremely high costs involved in discovering, developing and registering pharmaceutical products to current regulatory standards (800 million to 1. 2 billion U $ per drug) requires that the returns on drug sales be very gamey to be commercially justified. Between 1975 and 2004, only eight verboten of 1556 new registered drugs were antimalarials. This long standing sluggishness in drug Research and Development (R & D) of antimalarials has emerged as a critical global public health issue.',\n",
       " '12262. Wistar Institute of Anatomy & Biology. WISTAR INSTITUTE OF figure & BIOLOGY. to develop new synthetic DNA vaccines encoding design CSP antigens to allow a new generation advanced CSP component for a prophylactic malaria vaccinum',\n",
       " '12250. PATH. track. to develop safer, novel, univalent oral infantile paralysis vaccines against poliovirus type 1 and 3 for outbreak use',\n",
       " '12250. Jomo Kenyatta University of Agriculture and Technology. JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND engineering. to ensure quality vaccines are useable when needed by developing an application along with blockchain technology to monitor the supply chains delivering vaccines from producers to health workers',\n",
       " '12250. Sirenas, LLC. SIRENAS, LLC. to bring forth a set of other leads from marine born products with promise in neglected diseases, with a specific focus on tuberculosis (TB ), malaria and cryptosporidium',\n",
       " '12262. Genome - wide association studies to map genetical variation underlie mosquito susceptibleness to human 12262aria. GENOME - WIDE ASSOCIATION STUDIES TO MAP GENETIC VARIATION UNDERLYING MOSQUITO SUSCEPTIBILITY TO HUMAN 12262ARIA. Genome - all encompassing association studies to map genetic variation underlying mosquito susceptibility to human 12262aria',\n",
       " '12262. MICA: Development and GMP manufacture of a PfRH5 protein vaccine to induce strain - transcending immunity against blood - stage Plasmodium falciparum. . isinglass: DEVELOPMENT AND GMP MANUFACTURE OF A PFRH5 PROTEIN VACCINE TO INDUCE STRAIN - TRANSCENDING IMMUNITY AGAINST ancestry - STAGE PLASMODIUM FALCIPARUM. . Medical Research Council. Enquiry grant to develop new malaria vaccine candidate',\n",
       " \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brasil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three country by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Player will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scaled up in other high - risk area of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       " '13040. California Institute of Engineering. golden state INSTITUTE OF TECHNOLOGY. to develop reagents for HIV - 1 based diagnostics that are high performance, and are also stable in harsh environments, with architectural plan to adapt those reagents into multiplexed and quantitative point - of - care diagnostics platforms',\n",
       " '12250. Funding for scientist exchanges, duncan grant. FUNDING FOR SCIENTIST EXCHANGES, GRANTS. Vasco da gamma delta T - lymphocytes and the role of galectines in the pathogenesis of THLV1 - associated diseases - Capacity building in the field of education and research',\n",
       " '12262. PERSONALISING ANTI MALARIA THERAPY THROUGH HAND - HELD POINT OF CARE NANOTECHNOLOGY DEVICES. . PERSONALISING ANTI MALARIA THERAPY THROUGH HAND - HELD POINT OF CARE NANOTECHNOLOGY DEVICES. . Aim: to test the first point of care application of drug resistance molecular markers for optimal antimalarial treatment, through a novel nanotechnology - based device with the potential of allowing optimal, personalized, malaria chemotherapy. Three studies: 1 - lab fine tuning of the hand - held device for point of care parasite analysis in terms of specificity and sensitivity for genetic polymorphism call, vs established methods; information feedback to the technology developers for machine optimization. The device will fastly genotype the parasite prior to treatment, giving information for optimal ACT choices. 2 - The force field (Mali ): an artemether - lumefantrine (AL) vs artesunate - amodiaquine (ASAQ) efficacy trial will be conducted in high transmission regions of Mali. The pfmdr1 N86Y mutation will be used as the reference (86N allele: resistance to AL; 86Y allele: resistance to ASAQ ). In one arm the infection is genotyped. If 86Y, it represent treated with AL, if 86N, with ASAQ. In another arm AL and ASAQ are used randomly without support information, in accordance to the national guidelines for the treatment of unsophisticated malaria. An increased in efficacy, as well as decreased selection of resistance associated alleles is expected at arm1. 3 - Finally, the output of the trial will be re - analysed with reference methods (PCR - RFLP, direct PCR amplicon sequencing) for the post - hoc evaluation of the specificity and sensitivity of the device in the field conditions',\n",
       " '13040. University College London. UNIVERSITY COLLEGE LONDON. to model the population level effects of availability of likely young HIV diagnostic technology with defined specifications in order to generate a quarry product visibility for one or more potential new diagnostic tools',\n",
       " '12250. AJ Vaccines A. Sec. . AJ vaccine A. S. . to get and clinically test economically donor - friendly adjuvanted trivalent Inactivated Polio virus (IPV) vaccines with reduced IPV doses',\n",
       " '13040. General Hospital Corporation d / b / a Massachuset Full general Hospital. GENERAL HOSPITAL CORPORATION D / Bacillus / A MASSACHUSETTS GENERAL HOSPITAL. to support a genetical approach to optimizing the antigenicity of HIV - ane envelope immunogens',\n",
       " '12262. Improving Malaria Diagnostics (IMaD) - Malaria. IMPROVING MALARIA nosology (IMAD) - MALARIA. Under IMaD, MCDI and its partners act upon to improve laboratory - based diagnosis of malaria (primarily at Ministry of Health facilities ), and to increase understanding, acceptance, and right habit of microscopy and Rapid Diagnostic Tests (RDTs) by laboratory staff and health care practitioners providing direct care to patients.',\n",
       " '12182. VACCINE - Development of novel picornavirus virus - like particle vaccines. VACCINE - evolution OF NOVEL PICORNAVIRUS VIRUS - LIKE PARTICLE VACCINES. IIB - Research Boards Sept / Oct 2016 - RM 2017 award to apply Virus - like particles (VLPs) to causative agents of human bridge player, foot and mouth disease which are of interest as novel vaccines to reduce outbreaks impact children in South East Asia',\n",
       " '12250. VillageReach. VILLAGEREACH. to improve vaccine availability, safety, and cost - efficiency of immunisation supply chains by accelerating the transition of modernistic, next - generation immunization supply chains across Gavi - eligible countries',\n",
       " '12182. Cluster randomised controlled trial for late life history depression in socioeconomically deprived areas of Spo Paulo, Brazil. CLUSTER RANDOMISED CONTROLLED TRIAL FOR LATE life story DEPRESSION hoosier state SOCIOECONOMICALLY DEPRIVED AREAS OF S + O PAULO, BRAZIL. Medical Research Council GH trial to look at treatment for depression in older adults in Brazil',\n",
       " \"13040. DSO PDP womens condom (PATH ). DSO PDP woman CONDOM (PATH ). PDP Subsidie voor PATH Programma ' Protection Options for Women ' (prisoner of war) 2011 - 2014\",\n",
       " \"12263. Two - month Regimens Victimization Novel Combinations to Augment Treatment Effectiveness for drug - sensitive Tuberculosis: the ' TRUNCATE - TB ' trial. TWO - MONTH REGIMENS USING NOVEL COMBINATIONS TO AUGMENT TREATMENT EFFECTIVENESS FOR DRUG - SENSITIVE TUBERCULOSIS: THE ' TRUNCATE - TB ' TRIAL. Medical Research Council Joint (MRC / WT / DfID) Global Wellness Trial grant to test the effectiveness of shorter TB treatment regimens in Viet Nam, Myanmar, India, China, Indonesia, Philippines, Malaya\",\n",
       " '12263. Public Health England. PUBLIC HEALTH ENGLAND. to contrive and repurpose from existing facilities a capability to perform large - scale studies using a natural transmission infection model of tb',\n",
       " '12182. Efficacy of mobile earphone brusk message service (SMS) on malaria treatment adherence and post - treatment review. EFFICACY OF MOBILE PHONE SHORT MESSAGE SERVICE (SMS) ON MALARIA TREATMENT ADHERENCE AND POST - TREATMENT REVIEW. Medical Inquiry Council. Research Grant to trial the use of text electronic messaging to improve malaria treatment adherence',\n",
       " '12250. PATH. PATH. to provide quantified sampling panel to diagnostic trial run developers being funded by the Bill & Melinda Gates Foundation and perform unbiased evaluations and appraisals of diagnostic technologies upon request',\n",
       " '12250. Meningitis Enquiry Foundation (MRF ): Action Meningitis. MENINGITIS inquiry FOUNDATION (MRF ): military action MENINGITIS. Meningitis Research Foundation (MRF ): Action Meningitis',\n",
       " \"12182. Funding through Grand Challenges Canada in support of the Saving Lives at Birth programme  research. FUNDING THROUGH GRAND CHALLENGES CANADA IN SUPPORT OF THE SAVING LIVES AT BIRTH PROGRAMME  RESEARCH. To identify and support transformational approaches to women ' due south and newborns ' health that can be scaled up to reduce deaths and poor birth outcomes for millions of women and newborns in the hardest to reach community of the world.\",\n",
       " '12250. VACCINOLOGY Research MRC Whole, The Gambia. VACCINOLOGY RESEARCH MRC UNIT, THE GAMBIA. Medical Research Council. Intramural Cary grant for clinical research studies in The Gambia tbit and other infections',\n",
       " \"12182. Development of oral eflornithine for former - stage African sleeping sickness. DEVELOPMENT OF ORAL EFLORNITHINE FOR LATE - STAGE AFRICAN SLEEPING SICKNESS. The project Sustainable development, Fiscal Policy and Natural Resources Management. Bolivia, Chile and Peru in the Nordic countries ' mirror is a collaborative network of scholars in Europe and Latin America. These researchers will develop a three year project with the aim of consolidate a high quality network in Natural Resources studies in the Sustainable development framework. They will do three workshops, two in Sweden and one in Bolivia. In the planning, there are six clause and one book, written in collaboration between the researchers of this project and with other scholars whom will enhance our proposal. Also, and in the aim to extract lessons from successful countries to the underdeveloped and developing regions, the group will share the results to a broader public and authorities through a web page and periodical policy briefs. The ambition is that the joint work envisaged in this proposal will generate a flexible but consistent research network, which will continue to cooperate in further directions. Specific focus may change, but it will be kept in the general idea of extracting lessons for development from successful experiences of countries that today are both rich and just in comparative international terms.\",\n",
       " '12262. Seattle Biomedical Enquiry Institute. SEATTLE BIOMEDICAL RESEARCH INSTITUTE. to identify biomarkers of correlates of protection against pre - erythrocytic (PE) malaria infection that will enable down selection of vaccine antigens and predict outcomes of trials for anti - infection vaccines against Plasmodium falciparum',\n",
       " '12250. University of Calif., Los Angeles. UNIVERSITY OF CALIFORNIA, LOS ANGELES. to support the goals of lid elimination through the development of a demographic model for the Democratic Republic of the Congo',\n",
       " '12240. Washington State University. capital STATE UNIVERSITY. to good understand how human milk river helps agitate off pathogen in the breastfed infant',\n",
       " '12263. Administrators of the Tulane Educational Fund. ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND. to build imaging capacity (PET - CT scanning) of the Tulane National Prelate Research Center for TB vaccinum field of study as a part of a serve component of the Collaboration for TB Vaccine Discovery (CTVD )',\n",
       " '12220. University of Maryland, Baltimore. UNIVERSITY OF md, BALTIMORE. to develop broadly effective vaccines and interventions against enteric infections by conducting multi - country case - ascendance studies using standardized methods to measure the etiology and load of diarrhea among children in uprise countries',\n",
       " '12250. Basic Science Programme / Analyze the immunological interplay between poverty - relaeted diseases and helminth infection (IDEA Project ). BASIC SCIENCE program / DISSECTING THE IMMUNOLOGICAL INTERPLAY BETWEEN POVERTY - RELAETED DISEASES AND HELMINTH INFECTION (IDEA PROJECT ). Medical Research Council. Intramural Grant for epidemiology and clinical research on infections - worms',\n",
       " '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will lead off with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       " '12263. KwaZulu - Natal Research Institute for TB & HIV. KWAZULU - NATAL RESEARCH INSTITUTE FOR TB & human immunodeficiency virus. to investigate the hypothesis that there exists a tipping point for tuberculosis (tebibyte) infection, where cell death of some of the TB infected immune cells which are also responsible for tebibyte control leads to the creation of a new niche for mycobacterial grow',\n",
       " '12262. Harvard School of Public Health. HARVARD SCHOOL OF PUBLIC HEALTH. to develop a robust in vitro culture system for the human malaria parasite, Plasmodium vivax, that will help biological work and support the design of wellness intervention',\n",
       " '12250. Vaxess Technologies Inc. . VAXESS technology iraqi national congress. . to support the preclinical development and manufacture of a thermostable microneedle patch with the aim of lowering barriers to vaccine access by simplifying dosing and administration, alleviating cold chain constraints, and lowering costs',\n",
       " '12250. University of Old dominion. UNIVERSITY OF VIRGINIA. to employ highly sensitive quantitative molecular diagnostics for pathogens to understand the etiology of community diarrhea and the relationship and effects of enteropathogens on healthy increase',\n",
       " \"13010. Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems. CENTRE OF EXCELLENCE FOR CIVIL REGISTRATION AND VITAL STATISTICS (CRVS) SYSTEMS. Registration of events, such as birth, death, causes of death, marriage, and divorce, is critical for improving maternal, newborn, child, and adolescent health. These statistics provide policymakers and practitioners with the necessary evidence to design interventions and enact appropriate policies on maternal and child health. Many low - and middle - income countries, however, do not systematically collect such crucial information. It is estimated that one - third of the world ' s births and two - thirds of the world ' s deaths are not registered or are incorrectly certified. In many cases, global norms, standards, tools, and good practices are not readily accessible and useable to those who need them most. The project will establish the Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems to provide information, tools, and expertise to facilitate the development and implementation of integrated CRVS systems. Funded by Global Affairs Canada and the International Development Research Centre (IDRC ), and based at IDRC, the Centre of Excellence will coordinate with existing expert groups to generate, consolidate, and share information and resources in an open and collaborative electronic platform. It will also assist countries needing more direct support by facilitating the exchange of good practices and capability strengthening, and will play an important purpose brokering technical assistance for countries needing more direct support. The Centre of Excellence will work closely with the Global Financing Adroitness in support of the Every Woman Every Small fry go ahead to enable the development and implementation of CRVS systems plans as part of country - led investment cases for financing by the Global Financing Facility.\",\n",
       " '12262. JSI Enquiry & Training Institute, Inc. . JSI RESEARCH & education INSTITUTE, INC. . to demonstrate and document the how - to of at - scale delivery of accessible intermittent preventative treatment of malaria in pregnancy (IPTp) and the expected ancillary welfare of a reduction in the prevalence of low birthweight and in stillbirths',\n",
       " '12250. Institut Pasteur de Dakar. INSTITUT PASTEUR DE DAKAR. to improve disease diagnosis and assist researchers in low - resource settings by developing a platform for real - time remote sensing and monitoring of specimens during transport from health centres to laboratories',\n",
       " '13040. Support to the IMPT. SUPPORT TO THE IMPT. The Initiative for Multipurpose Prevention Technologies (IMPT) works to advance the development of products that simultaneously address the interconnected risks of HIV, other sexually transmitted infections (STIs ), and unintended pregnancy. Incorporate of members from across disciplines and more than 15 countries, the IMPT is the central body that researchers, product developers, funders, policymakers, and advocates rely on for objective technical guidance and strategic planning related to MPTs. By facilitating interdisciplinary partnerships, the IMPT enables experts from across the family planning, HIV, and STI fields to strategize around the unique technological, market access, and regulatory challenges presented by developing combined bar, thus refining the pathway to impactful MPT development. The objective of the project is to support the IMPT Secretariat in its role as the product - neutral coordinator of the MPT field.',\n",
       " '12250. PATH. PATH. to identify the best in class nucleic acid extraction technologies that may better enable diagnosis of disease at the spot - of - aid',\n",
       " '12182. This programme in the Ross Fund Portfolio (which focusses on neglected tropical diseases, diseases of emerging resistance and disease of epidemic pot. THIS PROGRAMME IN THE ROSS FUND PORTFOLIO (WHICH FOCUSSES ON NEGLECTED TROPICAL DISEASES, DISEASES OF EMERGING RESISTANCE AND DISEASES OF EPIDEMIC POT. This programme in the Ross Fund Portfolio (which focalise on neglected tropic diseases, diseases of emerging resistance and diseases of epidemic potential) aims to build the evidence based on effective interventions and delivery mechanisms to tackle inf',\n",
       " '12182. Cooperation with foreign research institutions (not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (NOT INCLUDED atomic number 49 OTHER AREAS ). Systems biology study of the effect of antimicrobial heart using integrative OMICs data analysis - Capacity building in the field of education and research',\n",
       " '12182. EDCTP2: European & Dev. Countries Clinical Trials Partnership 2015 - 2019. EDCTP2: EUROPEAN & DEV. COUNTRIES CLINICAL TRIALS PARTNERSHIP 2015 - 2019. Support to European and Developing Countries Clinical Trials Partnership to accelerate development of new or improved druugs, vaccine, microbicides and diagnostics against HIV / AIDS; TB and malaria. Reenforcement provided since 2004. A new expanded programme is planned within Horizon2020 which leave be called EDCTP2.',\n",
       " '12182. Miscellaneous in the area of international understanding. MISCELLANEOUS IN THE arena OF INTERNATIONAL UNDERSTANDING. Collaborative task - Development of a cost - efficient vaccine against cervix carcinoma - a prophylactic approach, sub - project - Development of cleaned antigens and evaluation of immunogenicity - Knowledge Transferral',\n",
       " '13040. Cryptococcal meningitis: addressing an urgent global health problem using a translational pharmacologic approach. CRYPTOCOCCAL MENINGITIS: ADDRESSING AN URGENT GLOBAL HEALTH job USING A TRANSLATIONAL PHARMACOLOGICAL APPROACH. Checkup Research Council. Research Grant to develop new drugs against cryptococcus a major secondary infection of HIV in LMIC',\n",
       " '12182. Development of an improved, single - strain, locally produced oral epidemic cholera vaccine. DEVELOPMENT OF AN IMPROVED, SINGLE - STRAIN, LOCALLY PRODUCED ORAL CHOLERA VACCINE. We have previously been deeply involved in the development of the internationally available, closely related oral cholera vaccines (OCVs) Dukoral  and Shanchol . These vaccines are effective, but the use of several strains and two inactivation methods makes their manufacture complex and relatively expensive, and OCVs are therefore still severely underused globally. In developing a new generation of OCVs, a central aim is to make it affordable for the populations in greatest need. This can be achieved by simplifying manufacture whilst maintaining the levels of protection afforded by currently available OCVs. Using a single vaccine strain and one inactivation method would considerably simplify and reduce the cost of manufacture. We have recently developed a novel concept and also engineered a new type of vaccine strains for such a new generation of OCVs, whereby the several V. cholerae O1 components in Dukoral and Shanchol can be replaced by a single - mental strain / single - formulation component with full retention of protective immunogenicity. We now propose, in collaboration with partners in India and Bangladesh, (1) to develop this novel single - strain OCV prototype combined with recombinantly produced cholera toxin B subunit into a truly low - cost, and also thermo - and pH - stable vaccine formulation for worldwide use including stockpiling purposes. A first - generation of the new OCV is planned to go into clinical testing in Bangladesh in early 2017 with product approval hoped for already in 2018 / 19. In parallel, (2) we will also develop a second - generation OCV formulation, which by including a novel cholera - toxin - derived mucosal adjuvant may provide adequate protection after single - dose administration, a feature which would be especially valuable for use in cholera outbreaks. The projected novel, low - cost, thermo - and pH - stable vaccine can be produced at a fraction of the cost of current vaccines, and should equal attractive for worldwide use including stockpiling purposes. Relevant countries: Most countries in South and South - East Asia, the same for Sub - Saharan Africa, and selected low - income countries in the Western hemisphere, e. g. Haiti, Dominican rep.',\n",
       " '13040. Vindico NanoBioTechnology Inc. . VINDICO NANOBIOTECHNOLOGY INC. . to develop a vaginal gel that apply nano - sacs called polymersomes, which can control the delivery of spermicides as a contraceptive and other sexually transmitted agents',\n",
       " '12250. Two Stoma Guys. TWO PORE GUYS. to assess novel, low price nucleic acrid detection engineering for use in low imagination settings',\n",
       " '13040. Doctoral Awards to Strengthen Sub - Saharan Africa Leadership in HIV Prevention Research. DOCTORAL AWARDS TO STRENGTHEN SUB - SAHARAN AFRICA LEADERSHIP IN HIV PREVENTION RESEARCH. Africa remains the region most affected by the AIDS epidemic and HIV / AIDS prevention remains a global health priority. This project supports the emergence of African HIV scientists able to lead high quality multidisciplinary HIV prevention and vaccine research to fight the biomedical, social and behavioral factors that underpin the epidemic. It will increase access to high - quality academic and professional trainings for doctoral and post - doctoral students in sub - Saharan Africa. Benefiting competitively selected students at a point in their careers when support is often lacking, it will facilitate the transition from research team member to research leader. The chosen institutions will also benefit, as funds to attract post - doctoral students are rare and hosting post - doctoral students can present a great opportunity for African universities and institutions. This project builds and strengthens the sustainability of the Global Health Research Initiative program entitled HIV / AIDS Prevention Trials Capacity Building Grants Phase 2 program. The program is co - funded by IDRC and Foreign Affairs, Trade and Development Canada (DFATD) with the goal of helping to create sustainable African capacity and leadership to conduct future HIV / AIDS prevention trials. In keeping with this goal, this project will support doctoral and post - doctoral awards in Africa.',\n",
       " '12110. Strengthening Fairness through Applied Research Capacity Building in e - Health. STRENGTHENING EQUITY THROUGH APPLIED RESEARCH CAPACITY BUILDING inch E - HEALTH. There exists limited understanding of how e - Health solutions are perceived, designed, implemented and used. This goes beyond considerations related to automation, power supplies and affordability. Rather, it refers to context - specific, politically - aware and socially sensitive examination of how various ICTs are being appropriated, world health organization is being included and excluded in the process, and whether the incorporation of ICTs is leading to to a greater extent equitable health outcomes. The Strengthening Equity through Applied Research Capacity Building in e - Health (SEARCH) program will school local research capacity to examine e - health and whether it leads to improved health equity and stronger health systems. Emphasis will be placed on methodological and analytical rigor, and policy dialogue. The first phase of SEARCH will involve scoping studies and workshops, with will elaborate the research agenda for the remainder of the program.',\n",
       " '12182. Study of disease mechanisms in enteric fever to qualify innate & adaptive immunity in mucosa & blood in controlled human infection model. STUDY OF DISEASE MECHANISMS IN ENTERIC FEVER TO CHARACTERISE INNATE & ADAPTIVE IMMUNITY IN MUCOSA & BLOOD IN CONTROLLED HUMAN INFECTION MODEL. Medical Research Council. Enquiry Grant to investigate disease mechanism and immune mechanisms during gut infection',\n",
       " '13040. Applied science for Health Program - HIV / AIDS. TECHNOLOGIES FOR HEALTH PROGRAM - human immunodeficiency virus / AIDS. Technologies for Wellness Computer program',\n",
       " '12263. FIND. FIND. to enable accelerated research and development of ground - break TB diagnostic tools that are suitable for use at low levels of care in resource - limited countries',\n",
       " '12182. Cooperation with foreign research institutions (in so far as not included in former areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (IN SO FAR AS NOT INCLUDED IN OTHER AREAS ). Glycoproteomics Network - Biomarkers for human disease',\n",
       " '12250. California Institute of Technology. golden state INSTITUTE OF TECHNOLOGY. to develop a Micro? Electro? Mechanical System as a portable and dependable microbic monitoring system that can be integrated into safe and sustainable sanitation solutions in the underdeveloped world and enable onsite testing for pathogens',\n",
       " '12182. Support to scientific research of Institute of Tropical Medicine (convenant with the Flemish government ). SUPPORT TO SCIENTIFIC RESEARCH OF INSTITUTE OF TRO. The Institute of Tropical Medicine in Antwerp, Bel',\n",
       " '12261. University of Massachusetts. UNIVERSITY OF MASSACHUSETTS. to convert the energy contained in human waste into electricity and remove the organic matter and nutrients that devolve ecosystems and permit pathogens to persist in water using a modular Microbial Fuel Cell (MFC) designed to retrofit live compost',\n",
       " \"12110. International Vaccinum Institute. INTERNATIONAL VACCINE INSTITUTE. to support find, development and delivery of proven life - save technologies to suffer the unmet needs of the world ' s poorest populations\",\n",
       " '12220. Zvitambo Institute for Maternal and Child Health Inquiry. ZVITAMBO INSTITUTE FOR MATERNAL AND CHILD HEALTH RESEARCH. to bring home the bacon causal evidence for the independent and combined effects of interrupting fecal ingestion and optimizing infant dietary quality on stunting and anaemia at 18 months',\n",
       " '12240. University of Leeds. UNIVERSITY OF LEEDS. to explore the mechanistic pathways by which aflatoxin, a frequent food for thought fungal metabolite, may lead to child growth faltering in sub - Saharan Africa. Relevant biomarkers will be identified for applications in child age bracket and intervention studies',\n",
       " '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) health care delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the realm. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       " '13040. Oregon Wellness & Scientific discipline University. OREGON HEALTH & SCIENCE UNIVERSITY. to provide fundamental research on a new type of vaccine - elicited CD8 + T cell immunity with the potential to control and clear HIV, and therefore to enable development of a safe and effective human immunodeficiency virus / AIDS vaccinum for use in high burden countries',\n",
       " '12263. GlaxoSmithKline Biologicals. GLAXOSMITHKLINE BIOLOGICALS. to provide a newfangled dimension to vaccine development for malaria and tuberculosis (TB) by deeper analysis of transcriptomics data that are being generated in clinical study, by boost collaboration between different partners involved in Systems Biology',\n",
       " \"12263. DSO PDP terabyte Vaccins (AERAS ). DSO PDP TB VACCINS (AERAS ). 2011 - 2014 PDP subsidie AERAS ' Developing and Licensing Improved Tuberculoses Vaccines for Use in High Burden Countries '\",\n",
       " '12182. MICA: Ad4HIV, A Phase I Trial Investigating Ad4, MVA and Protein Immunisation Strategies to Maximise Protective Antibody Responses to HIV - 1 Envelope. MICA: AD4HIV, A PHASE I TRIAL INVESTIGATING AD4, MVA AND PROTEIN IMMUNISATION STRATEGIES TO MAXIMISE PROTECTIVE ANTIBODY RESPONSES TO HIV - 1 ENVELOPE. Medical Research Council / DPFS grant on acquire new vaccine candidates against HIV',\n",
       " '12182. BIOBASED SCAFFOLDS, MEMBRANES AND HYDROGELS FOR IMPROVED WOUND HEALING AND BONE REGENERATION (BIOHEAL ). BIOBASED SCAFFOLDS, MEMBRANES AND HYDROGELS FOR IMPROVED WOUND HEALING AND BONE REGENERATION (BIOHEAL ). In 2012, one in eight deaths worldwide resulted from air pollution. For Africa lack of data is a barrier to estimate effects. Satellite images indicate detrimental levels, but monitoring and high resolution outdoor air pollution modelling is lacking. Household air pollution is also a major source of pic, more knowledge on how different cook stoves, fuels and habits affect picture is crucial. No high quality study of the effect of outdoor and indoor air pollution on pregnant women in Africa has so far been conducted. We will investigate consequences of air pollution in a prospective cohort of women recruited during pregnancy at public health facilities in Ethiopia. Outdoor air pollution will be assessed by high quality modelling which combines measurements with Geographical Information System tools and aerial and topographical imaging. Individual exposure will be linked to the model by residential address. Indoor exposure will be assessed by questionnaires and validated by measurements. Emission factors from different fuels and cooking methods, and particle characteristics will be assessed in our Aerosol Lab in Lund. Data on gestation outcomes, photograph and confounders will be compiled and epidemiological studies on the effect of outdoor and household air pollution on pregnancy complications will be done. This study, which will increase knowledge of not only health impact but also of source characteristics, will provide important knowledge for appropriate policy making.',\n",
       " '12250. European & Rise Countries Clinical Trials Partnership. EUROPEAN & DEVELOPING COUNTRIES CLINICAL test PARTNERSHIP. Medical Research Council. Partnership Contribution to a multi nation activity to support large scale multi land trials of new vaccines and drugs against infections in Africa.',\n",
       " \"12110. The West Africa Initiative to Strengthen Capacities through Health Systems Research. THE WEST AFRICA INITIATIVE TO STRENGTHEN CAPACITIES THROUGH HEALTH SYSTEMS RESEARCH. West Africa has many of the lowest development indicators in the world - 10 of the 15 member states of the West African Community number among the world ' s 35 low - income countries. The World Health Organization reports that 14 of the member states have a high maternal mortality ratio, defined as 300 or more maternal deaths per 100, 000 live births. These grim statistics tell the story of a region facing dysfunctional health and social services with a limited capacity to conduct research that informs sound health policies and practices. Of the health research that is undertaken in the region, much is done in isolation, and findings are non shared operating room disseminated across governments or health systems. The result: synergies across findings are not made and links between researchers and decision - makers are often weak. This project sets the foundation for producing and using rigorous and relevant evidence to strengthen equitable and sustainable health systems in West Africa. Four teams will be funded through a call for proposals focusing on research on how to strengthen health systems in West Africa. A group of leaders with regional expertise will be mobilized and supported to advise on the call and guide the overall project. The project will also help the West African Health Organisation, a respected stakeholder and the mandated body coordinating efforts to improve health in the region, promote interest in the call and encourage the use of research findings by ministers of health from member countries. Research results will be disseminated through a special issue of a peer - reviewed journal, insurance briefs, and articles to further inform health policy and practice in West Africa.\",\n",
       " '13040. Microbicide Inquiry, Development, and Unveiling, Beat 3. MICROBICIDE RESEARCH, DEVELOPMENT, AND INTRODUCTION, ROUND trinity. Microbicide Research, Development, and Introduction, Round 3',\n",
       " \"12250. Intersectoral Municipal Leadership for Health in Latin America. INTERSECTORAL MUNICIPAL LEADERSHIP FOR HEALTH IN LATIN AMERICA. This project aims to build ecohealth leadership at the municipal level in Colombia and Venezuela to address wellness priorities, including vector - borne diseases and food systems interventions for non - communicable disease prevention. Dengue fever and chikungunyaIn Colombia and Venezuela, research and governmental institutions from the Latin American Ecohealth Leadership Consortium on Vector - borne Diseases have decreased Aedes mosquito populations significantly through municipal interventions. This mosquito is responsible for transmitting two viral diseases: dengue fever and chikungunya. Dengue and chikungunya interventions will be scaled up in three affected municipalities. Both diseases are responsible for rapidly growing health and economic burdens in the two countries. The project is expected to generate new knowledge on factors affecting policy adoption and scaling up: - institutional capacity gaps - early involvement and leadership of municipal players - good governance - costs - validating impact on disease incidenceThe evidence should help researchers and governments replicate the project at a larger scale. National and municipal governments and the World Health Organization are providing co - funding for the project. Food systems, healthy diet, and incentivesThe food systems and healthy diets study will take place in a rural municipality of Colombia. This region has one of the highest agricultural outputs in the country. However, it also has high rates of malnutrition among children and obesity in adult populations. The study will analyze local factors associated with the rising of obesity and diabetes, such as food systems and lifestyle determinants that favour unhealthy diets in rural areas. In the study ' s second step, researchers will pilot test an inter - sector approach. The aim is to promote municipal regulatory incentives for food and health systems, and community and workplace environments. Researchers will use a participatory methodology that involves multi - sector municipal committees, together with qualitative and quantitative methods. Testing ways to decrease diseasesThe project will analyze the feasibility, cost - effectiveness, and sustainability of scaling up interventions aimed at dealing with two emerging mosquito - borne diseases. The food and healthy diets study will analyze the basic food basket per home, family anthropometric indicators for nutritional position (underweight, stunting, etc. ), feeding habits, and blood glucose levels. The project is expected to contribute to - stronger municipal players acting as public health leaders - effective scaled up solutions that decrease dengue and chikungunya incidence rates - municipal inter - sectoral approaches that contribute to preventing obesity and diabetes\",\n",
       " '12262. A trial of the benefit of including azithromycin in the drug combination habituate for seasonal malaria chemoprevention in African children. A TRIAL OF THE BENEFIT OF INCLUDING AZITHROMYCIN IN THE DRUG COMBINATION USED FOR SEASONAL MALARIA CHEMOPREVENTION IN AFRICAN CHILDREN. Medical Research Council. Research Grant to trial malaria treatment strategies',\n",
       " '12182. Improving HIV testing and care for adolescents in Zimbabwe: A targeted, community - based approach. IMPROVING HIV TESTING AND forethought FOR adolescent IN republic of zimbabwe: A TARGETED, COMMUNITY - BASED advance. Medical Research Council / DFID Research Grant Adolescent Health in LMICs Improving HIV testing and care for adolescents in Zimbabwe: A targeted, community - based approach',\n",
       " '12262. Seattle Biomedical Research Institute. SEATTLE BIOMEDICAL RESEARCH INSTITUTE. to identify and produce new liver stage (LS) - aim interventions against malaria and interrogate underlying biology using novel check and model systems',\n",
       " '12250. Georgia Tech Research Corporation. GEORGIA TECH RESEARCH CORPORATION. To improve candidate drug testing and evolution for lymphatic filariasis parasite infections by develop a model of a human lymphatic vessel to support adult - stage lymphatic filariasis parasites in vitro.',\n",
       " '12263. Miscellaneous Disease - related and Inter - disease Focuses. MISCELLANEOUS DISEASE - RELATED AND INTER - DISEASE FOCUSES. The Project will embody carried out in the framework of the EDCTP funded undertaking Epidemiology of PZA underground in TB Clinical trials in Africa  an essential prerequisite for evaluating novel TB drug combinations.',\n",
       " '13040. West African Platform for HIV Intercession Research (WAPHIR ). WEST AFRICAN PLATFORM FOR HIV INTERVENTION RESEARCH (WAPHIR ). This grant will establish a West African - driven partnership with Canadian and European collaborator to enhance HIV research and carry out clinical trials in STnTgal (UniversitT Cheikh Anta Diop ), the Gambia (Medical Research Council) and Guinea Bissau (Bandim Health Project ). The partners will jointly finagle and share their cohort and bio - resource data, thereby providing access to an expanded HIV population. The project will involve constructing a unified database, reinforcing the existing laboratory infrastructure, providing training in clinical trial support, and applying social science research in support of intervention preparedness and evaluation. The project will also offer specialized grad student training with a view to building African research leadership in the management of clinical trials.',\n",
       " '12262. Global Health Innovative Technology Fund. GLOBAL wellness INNOVATIVE TECHNOLOGY FUND. to recrudesce new wellness technologies as a effect of funding and development collaborations with Nipponese industry and government',\n",
       " '12263. Infectious Disease Research Institute. INFECTIOUS DISEASE RESEARCH INSTITUTE. to identify new leads and new drug targets for tuberculosis suitable for further drug ontogenesis with the ultimate goal of produce new drugs to treat t.b.',\n",
       " '12263. TuBerculosis Vaccine Go ahead. TUBERCULOSIS VACCINE INITIATIVE. to improve tuberculosis control by developing and introducing new technologies to prevent, name and treat the disease',\n",
       " '12250. Global Health Innovative Engineering Fund. GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND. to develop new health technologies as a result of funding and development collaborations with Nipponese industry and authorities',\n",
       " '12262. Common disease. COMMON DISEASES. Malaria Vaccinum Development - two European & Developing Countries Clinical Trials Partnership (EDCTP) project - Medical research of particular importance for Developing Country',\n",
       " '12182. BIOLOGICAL IMPLICATIONS OF POLYPARASITISM AND MALNUTRITION. BIOLOGICAL IMPLICATIONS OF POLYPARASITISM AND MALNUTRITION. The outcome of an infection is influenced by multiple genetic and environmental factors. How the combined impact of more than one factor influence infection is at large unknown in both humans and experimental models. Intestinal parasitic infections are the rule sort of than the exception in poor rural communities, where clean water, proper housing and sewage systems are not available allowing a continuous transmission of helminths and other water - born infectious organisms. In this project we aim to see how gastro - intestinal parasitic infections influence and are influenced by nutritional status and if the combination of malnutrition and intestinal parasitic infection is a risk factor for development of trypanosomal disease in humans. In animal models we will explore how the combination of gastrointestinal infection and malnourishment influences the outcome of Leishmania and Trypanosoma cruzi infection, two related parasitic infections, which are endemic in Bolivia. The project will be divided into two parts, in Bolivia clinico - epidemiological studies will provide information on nutritional status and how this correlates with polyparasitism and different immune parameters. The other part, which primarily will follow conducted at Karolinska Institutet, Sweden, is an experimental animal set up, where the impact of the most common nutritional deficiencies of poor populations can be tested on trypanosome infections in a mono or polyparasitic context.',\n",
       " '13040. Microbial translocation and immune activation  a substudy of the COSTOP trial. MICROBIAL TRANSLOCATION AND IMMUNE ACTIVATION  A SUBSTUDY OF THE COSTOP test. Medical Research Council. Intramural Duncan grant for an immunology study of human immunodeficiency virus patients',\n",
       " '13030. Hervana Bio. HERVANA BIO. to further test a biological vaginal conceptualisation to go far at a long - playacting, safe, and effective contraceptive that is ready for rating in human trials',\n",
       " '12263. FIND. FIND. To enable accelerated research and development for new diagnostic tools that are suitable for use at the full stop - of - care (POC) in resource - modified endemic countries and can serve to diagnose patients who equal currently difficult to name (i. e. patients wh',\n",
       " '13040. Magee - Womens Inquiry Institute and Foundation. MAGEE - WOMENS RESEARCH INSTITUTE AND FOUNDATION. to place changes in HIV - aim cells occuring in the genital tract of women initiating hormonal contraceptive method',\n",
       " '12250. Randomised trial of HPV vaccination for the control of HPV - related diseases in HIV positive African populations: Preparatory phase. RANDOMISED TRIAL OF HPV VACCINATION FOR THE CONTROL OF HPV - RELATED DISEASES IN HIV positive degree AFRICAN POPULATIONS: PREPARATORY PHASE. Medical Inquiry Council. Research Grant for a trial of HPV vaccination for the control of HPV - related to diseases in human immunodeficiency virus patient',\n",
       " '12182. ODA Programmes within Francis Crick Institute. ODA PROGRAMMES WITHIN FRANCIS CRICK INSTITUTE. Medical Research Council supported group studying TB, Malaria, HIV, and other viral and parasitic infections of relevance to LMICs',\n",
       " '12182. DFID / Medical examination Research Council Concordat 2008 - 2013. DFID / medical checkup RESEARCH COUNCIL covenant 2008 - 2013. TO SUPPORT HIGH QUALITY MEDICAL SCIENCE AND HEALTH RESEARCH THAT TACKLES THE PRIORITY HEALTH PROBLEMS OF PEOPLE IN DEVELOPING res publica',\n",
       " '12182. VECTOR CONTROL BY MULTIPLE CLASSES OF SMALL ORGANIC COMPOUNDS TO COMBAT MOSQUITO - BORNE INFECTIOUS DISEASES AND SUPPRESS INSECTICIDE RESISTANCE. VECTOR CONTROL BY MULTIPLE CLASSES OF SMALL ORGANIC COMPOUNDS TO COMBAT MOSQUITO - BORNE INFECTIOUS DISEASES AND SUPPRESS INSECTICIDE RESISTANCE. Insect vectors transmit numerous viral - and parasite infections between humans or from animals to humans. Worst affected are poor people living in vulnerable communities in tropical and sub - tropical regions. Vector control by insecticides is the dominant way to combat and prevent transmission of mosquito - borne diseases. Due to globalization, environmental changes and increased insecticide resistance, there is an urgent need for new approaches and strategies for efficient vector control. This proposal aims to design, synthesize and develop multiple novel chemical classes of insecticides for control of Aedes aegypti (transmits e. g. dengue and chikungunya) and Anopheles gambiae (transmits malaria ). We will target a form of acetylcholinesterase (AChE1) not present in vertebrates, and identify diverse selective chemical starting points by high throughput screening (HTS ). Evaluation of a performed HTS targeting mosquito AChE1 has shown promising results. We have identified several classes of substances that are selective for the mosquito - form over human AChE. These multiple chemical starting points will be synthetically explored and optimized into insect powder. Early on in the discovery process we will include, in addition to the target - specific endpoints, response estimates that address human safety, environmental fate and effect, resistance sensitivity, and cost of goods. Mosquito testing, including laboratory testing and field studies, will be performed in Kenya.',\n",
       " \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than deuce million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and controller strategies. It will also help ensure that results are replicated and scaled up in other high - risk areas of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       " '12262. Genome - wide connexion studies to map genetic variation underlying mosquito susceptibility to human malaria. GENOME - WIDE ASSOCIATION STUDIES TO MAP GENETIC VARIATION UNDERLYING MOSQUITO SUSCEPTIBILITY TO HUMAN MALARIA. Medical Research Council. Fellowship to study why some mosquitos are more susceblible to infection with human malaria',\n",
       " '12250. Pace University. PACE UNIVERSITY. to develop a robust continuous culture system that will provide researchers with a consistent population of Cryptosporidium parvum and Cryptosporidium hominis to better understand the complex interaction between pathogens, host nutrition, inflammation an',\n",
       " '12262. IVCC. IVCC. to fend for the Product Development Partnership to eliminate infection of mosquito - borne pathogens through improve insect vector ascendancy with innovative products',\n",
       " '12182. Definition and evocation of broadly protective responses against HIV - 1. DEFINITION AND INDUCTION OF BROADLY PROTECTIVE reply AGAINST HIV - 1. IIB - Research Boards Sep / Oct 2015 - RM 2016 award to see assess how the 2nd generation vaccine works. To look to remove HIV from infected individuals. And for larger scale testing in HIV - 1 minus healthy volunteers in Africa to help prevent them from being infected',\n",
       " '12181. Advanced course for training in tropical medicine and public health in Sub - Saharan Africa. ADVANCED COURSE FOR TRAINING IN TROPICAL MEDICINE AND PUBLIC HEALTH IN SUB - SAHARAN AFRICA. Aimed at health care workers in Africa and Europe (20 doctors, nanny, biologists ), is focused on synergism and technical / cultural cooperation between experts and health workers. Information technology consist in interactives lectures, complemented by practical classes conducted in the laboratory, visits to sites of transmission, training field classes focused on checking waters, and practice in clinics and hospitals. It takes place in an international center (Populace Health Laboratory Ivo de  Carneri ).',\n",
       " '12262. Innovative Vector Ascendance Consortium (IVCC ). INNOVATIVE VECTOR CONTROL CONSORTIUM (IVCC ). The Innovative Vector Control Consortium (IVCC) is an international public - private partnership whose aim is to foster research and development of new transmitter control products and tools for public health, including new insecticides and insecticide conceptualisation. IVCC was awarded a 5 - year Cooperative Agreement in September 2013 to support its work to advance 3 new insecticide candidates to the final stages of development by 2019.',\n",
       " '13010. Production 13: Analysis on population dynamics. ANALYSIS ON POPULATION DYNAMICS. Kingdom of swaziland - Mbabane. Output 13: Increased availability of evidence through cutting - sharpness in - depth analysis on population dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       " '13040. New tools and model projection in the field of knowledge and technology transfer. NEW TOOLS AND MODEL PROJECTS IN THE FIELD OF KNOWLEDGE AND TECHNOLOGY TRANSFER. Collaborative project - New inoculation dodge for the induction of protective cytotoxic T cells - Validation in mouse and primate models for use in infectious diseases of humans, Submarine sandwich - project - A - Research funding of particular significance for Developing Countries / Knowledge transfer',\n",
       " \"12182. PATH Product Development Partnership Programme 2013 - 2018. PATH PRODUCT DEVELOPMENT PARTNERSHIP PROGRAMME 2013 - 2018. ' To reduce poverty through investment funds in research to develop effective and affordable, diagnostics, treatment, drugs and vaccines for diarrhoea and malaria. In the longer term this has the potential to significantly abbreviate death and illness among the poor\",\n",
       " \"12182. DSO PDP diagnostics (FIND ). DSO PDP nosology (discovery ). PDP subsidie 2011 - 2014 ' programme funding for the elaboration of diagnostic platforms and the developments of Point - of - Care diagnostic tests\",\n",
       " '12250. University of Md, Baltimore. UNIVERSITY OF old line state, BALTIMORE. to understand the impact of rotavirus vaccine introduction on rotavirus intestinal flu and other key diarrheal disease pathogens in sub - Saharan Africa',\n",
       " '12250. Emory University. EMORY UNIVERSITY. to support a study that will farther understanding of the impact of pneumococcal conjugate vaccine through the sequencing and comparison of whole genome sequences of a species before and after inoculation',\n",
       " '12262. Biomedical Primate Research Centre. BIOMEDICAL PRIMATE RESEARCH center. to accost the present limitations in the long - term cultivation of Atomic number 15. vivax (Pv) that seriously hamper research into the biology of this malaria leech and vaccine / drug development',\n",
       " '12262. Research in active substances - pharmaceutical research. inquiry IN ACTIVE centre - PHARMACEUTICAL RESEARCH. Insect - infer anti - Infectives from Indonesia against the casuative agent of tuberculosis and malaria - Medical inquiry of particular importance for Develop Countries - malaria abatement',\n",
       " '12182. CVCASouth & Central Asia, regionalHealth systems and services. CVCA: southward & telephone exchange ASIA, REGIONALHEALTH SYSTEMS AND armed service. Medical inquiry',\n",
       " \"13010. Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems. CENTRE OF EXCELLENCE FOR CIVIL REGISTRATION AND VITAL STATISTICS (CRVS) SYSTEMS. Registration of events, such as birth, death, causes of death, marriage, and divorce, is critical for improving maternal, newborn, child, and adolescent health. These statistics provide policymakers and practitioners with the necessary evidence to design interventions and enact appropriate policies on maternal and child health. Many low - and middle - income countries, however, do not systematically collect such all important information. It is estimated that one - third of the world ' s births and two - thirds of the world ' s deaths are not registered or are incorrectly certified. In many cases, global average, standards, tools, and good practices are non readily accessible and useable to those who need them most. The project will establish the Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems to provide information, tools, and expertise to facilitate the development and implementation of integrated CRVS systems. Funded by Global Affairs Canada and the International Development Research Middle (IDRC ), and based at IDRC, the Centre of Excellence will coordinate with existing expert groups to generate, consolidate, and share information and resources in an open and collaborative electronic platform. It will also assist countries needing more direct support by facilitating the exchange of good practices and capacity strengthening, and will play an important role brokering technical assistance for countries needing more direct support. The Centre of Excellence will work closely with the Global Financing Facility in support of the Every Woman Every Child initiative to enable the development and implementation of CRVS systems plans as part of country - led investment cases for financing by the Global Financing Facility.\",\n",
       " '12182. Atomic number 9 Osier, KEMRI - CGMRC, Defining the merozoite targets of protective immunity against Plasmodium falciparum malaria through multi - centre cohort studies. F OSIER, KEMRI - CGMRC, DEFINING THE MEROZOITE TARGETS OF PROTECTIVE IMMUNITY AGAINST PLASMODIUM FALCIPARUM MALARIA THROUGH MULTI - CENTRE COHORT STUDIES. Medical Inquiry Council African Research Leaders Award. Research grant to look for potential fresh vaccine candidates in malaria parasite that will generate good protective immunity',\n",
       " \"12250. Linking Emerging Infectious Diseases Research and Policy Networks in Southeast Asia and China: APEIR Phase II. LINKING EMERGING INFECTIOUS DISEASES RESEARCH AND POLICY NETWORKS IN SOUTHEAST ASIA AND CHINA: APEIR PHASE II. The Asian Partnership on Emerging Infectious Diseases Research (APEIR) is a multi - country, multi - disciplinary and multi - sectoral research network that enables researchers and experts from several sectors, including agriculture and health, to explore joint research and policy questions in animal and public health. The partnership uses an ecohealth approach to address the complexity of emerging infectious diseases. This project presents a new phase of APEIR research on emerging threats from antimicrobial resistance and wildlife trade. It aims to strengthen the field of ecohealth and enhance emerging infectious disease control in Asia through research, capacity building, social and policy advocacy, and stronger knowledge and response networks. The wide use and abuse of antimicrobials as anti - infective drugs and non - therapeutic treatments are key contributors to persistent infections caused by resistance to antimicrobials. This use and abuse is also a major cause of morbidity and mortality around the world. In China and Southeast Asia, the lack of policy or regulation enforcements means that the use of antibiotics is not well - controlled. This research will provide evidence and guidance to make grow country - specific and regional strategies to improve the responsible use of antibiotics and to reduce the emergence of resistant infectious agents in China, Indonesia, Laos, Thailand, and Vietnam. Southeast Asia ' s thriving wildlife trade supports disease transmission to humans. It also threatens livestock, international trade, rural livelihoods, native wildlife populations, and ecosystem health. Little is known about the zoonotic disease risks involved in transmitting diseases between brute and humans. This study will assess the pathogens that circulate and will explore possible pathways of transmission to humans, specifically in China, Laos, Thailand, and Vietnam. It will help prevent emerging zoonotic infectious diseases. It will also decrease wildlife consumption, while educating people about the safe and wise use of wildlife as a source of food protein for poor people. Finally, it will support wildlife diversity and mitigate illegal wildlife trade in the region. Building on past research on avian influenza and ongoing knowledge - translation activities in the health field, this new phase of work will help APEIR build and support regional capacity to communicate and share knowledge to promptly address emerging infectious disease threats.\",\n",
       " '12182. How does the trypanosome haptoglobin - hemoglobin receptor interact with nutrients and immunity molecules? Receptor structure to cellular mechanism. . HOW DOES THE TRYPANOSOME HAPTOGLOBIN - HEMOGLOBIN RECEPTOR INTERACT WITH NUTRIENTS AND IMMUNITY MOLECULES? RECEPTOR STRUCTURE TO CELLULAR MECHANISM. . MRC / IIB Research Grant to investigate the host parasite interaction during trypanosome infection. In the long term, information technology may also have an economical and societal effect in Sub - Saharan Africa done the better exploitation of the trypanolytic factors and through improved uptake route for therapeutics to direct trypanosomes.',\n",
       " '12262. Atomic number 9 Osier, KEMRI - CGMRC, Defining the merozoite targets of protective exemption against Plasmodium falciparum malaria through multi - centre cohort studies. F OSIER, KEMRI - CGMRC, DEFINING THE MEROZOITE TARGETS OF PROTECTIVE IMMUNITY AGAINST PLASMODIUM FALCIPARUM MALARIA THROUGH MULTI - CENTRE COHORT STUDIES. F Osier, KEMRI - CGMRC, Defining the merozoite targets of protective immunity against Plasmodium falciparum malaria through multi - centre age bracket studies',\n",
       " \"12182. Delivering Effective Health Services COMDIS (Inquiry and Development for Communicable Disease Control ). DELIVERING EFFECTIVE HEALTH SERVICES COMDIS (RESEARCH AND DEVELOPMENT FOR COMMUNICABLE DISEASE CONTROL ). The purpose of DFID ' s Research Programme Consortia in push poverty and achieving the MDGs is two fold: (1) to help produce new knowledge and technologies to tackle the most important exploitation challenges; (two) to help make sure that countries and the\",\n",
       " '12250. Centre Hospitalier Universitaire Vaudois. CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS. to evaluate novel diagnostic platforms that could inform heath authority on the current loading of infections, as well as on emerging infections and potential outbreaks',\n",
       " '12250. Development of a statistical modelling fabric to 12250orm real - time immunization strategies for elimination of poliomyelitis and other diseases. DEVELOPMENT OF A STATISTICAL MODELLING FRAMEWORK TO 12250ORM REAL - TIME IMMUNIZATION STRATEGIES FOR ELIMINATION OF POLIOMYELITIS AND OTHER DISEASES. Development of a statistical modelling framework to 12250orm real - time immunization strategies for elimination of poliomyelitis and other diseases',\n",
       " '12220. University of Mantle Town. UNIVERSITY OF CAPE TOWN. to support a longitudinal cohort report of children evaluating the number, severity, and etiology of respiratory disease, and evaluate the potential effect modifiers that may influence the incidence and severity of acute lower respiratory infections',\n",
       " '12250. Centers for Disease Control and Prevention. CENTERS FOR DISEASE CONTROL AND bar. to perform the laboratory psychoanalysis for Inactivated Polio Computer virus (IPV) clinical trials',\n",
       " '12262. ACQUIRED IMMUNITY TO MALARIA: IMPORTANCE OF THE GENETIC DIVERSITY OF PLASMODIUM FALCIPARUM. ACQUIRED IMMUNITY TO MALARIA: IMPORTANCE OF THE GENETIC DIVERSITY OF PLASMODIUM FALCIPARUM. Malaria caused by Plasmodium falciparum is a potentially fatal infection. Understanding how the extensive genetic polymorphism of the parasite affects the acquisition and maintenance of immunity is a prerequisite for the development of efficacious control tools such as vaccines. In our previous studies, we have shown that persistent asymptomatic multiclonal infections predict a reduced risk of disease in high transmission settings. The aim of this project is to further establish how the hereditary diversity of P. falciparum infection affects protective immunity to malaria. We will investigate polymorphisms in P. falciparum antigen genes, i. e. genes under immune selection, in person with different levels of exposure and immunity both within and between geographical areas, and identify potential? hotspots? of transmission. The genetic diversity of P. falciparum infections will be related to the breadth and magnitude of antibody responses directed to a panel of several P. falciparum antigens. The longevity of immune responses (antimalarial antibody and memory B cell responses) will be studied. The project includes well defined and closely monitored cohorts living in areas of different transmission in Kenya, Tanzania and Mali, as well as Swedish traveller who experience malaria for the first time. The project will contribute to the understanding of the molecular epidemiology of P. falciparum and the acquisition and maintenance of protective immunity against malaria.',\n",
       " '12182. To fund the development of new vaccines to prevent tuberculosis transmission through the organisation Aeras  research. TO FUND THE DEVELOPMENT OF NEW VACCINES TO PREVENT TUBERCULOSIS INFECTION THROUGH THE ORGANISATION AERAS  RESEARCH. To develop new affordable vaccinum for TB at scale which have the potential to reduce many millions of new cases of TB over a period of twenty year contributing to MDG 6 which includes halting and reducing the spread of Tuberculosis.',\n",
       " \"12262. DSO PDP Hookworm disease vaccineSABIN. DSO PDP hookworm disease VACCINESABIN. PDP subsidie voor ' The Human Hookworm Vaccine Initiative: Clinical Development of the NaGST - 1 and Atomic number 11 - APR - 1 Hookworm Vaccine Antigen\",\n",
       " '13010. Output 13: Analysis on population dynamic. ANALYSIS ON POPULATION DYNAMICS. El Salvador - San El salvador. Output long dozen: Increased availability of evidence through cutting - edge in - depth analysis on population dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       " '12240. Full general Hospital Corporation. GENERAL HOSPITAL CORPORATION. to better treat environmental enteropathy and other potentially deadly childhood diseases caused by enteric pathogens such as Escherichia coli by isolating and / or engine room selective bacteriophage (viruses that infect bacteria )',\n",
       " '12263. Cornell University. CORNELL UNIVERSITY. to develop and apply fresh mass spectrometry - based technologies to rationally key new drugs to treat TB',\n",
       " \"12250. Intersectoral Municipal Leadership for Health in Latin America. INTERSECTORAL MUNICIPAL LEADERSHIP FOR HEALTH IN LATIN AMERICA. This project aims to build ecohealth leadership at the municipal level in Colombia and Venezuela to address health priorities, including vector - borne diseases and food systems interventions for non - communicable disease prevention. Dengue fever and chikungunyaIn Colombia and Venezuela, research and governmental institutions from the Latin American Ecohealth Leadership Consortium on Vector - borne Diseases have decreased Aedes mosquito populations significantly through municipal interventions. This mosquito is responsible for transmitting two viral diseases: dengue fever and chikungunya. Dengue and chikungunya interventions bequeath be scaled up in three affected municipalities. Both diseases are responsible for rapidly growing health and economic burdens in the two countries. The project is expect to generate new knowledge on factors affecting policy adoption and scaling up: - institutional capacity gaps - early involvement and leadership of municipal players - good governance - costs - validating impact on disease incidenceThe evidence should help researchers and governments replicate the project at a larger scale. National and municipal governments and the World Health Organization are providing co - funding for the project. Food systems, healthy diet, and incentivesThe food systems and healthy diets study will take place in a rural municipality of Colombia. This region has one of the highest agricultural outputs in the country. However, it also has high rates of malnutrition among children and obesity in adult populations. The study testament analyze local factors associated with the rise of obesity and diabetes, such as food systems and lifestyle determinants that favour unhealthy diets in rural areas. In the study ' s second step, researchers will pilot test an inter - sector approach. The aim is to promote municipal regulatory incentives for food and health systems, and community and workplace environments. Researchers will practice a participatory methodology that involves multi - sector municipal committees, together with qualitative and quantitative methods. Testing ways to decrease diseasesThe project will analyze the feasibility, cost - effectiveness, and sustainability of scaling up interventions aimed at dealing with two emerging mosquito - borne diseases. The food and tidy diets study will analyze the basic food basket per home, family anthropometric indicators for nutritional status (underweight, stunting, etc. ), feeding habits, and blood glucose levels. The project is expected to contribute to - stronger municipal players acting as public health leaders - effective scaled up solutions that decrease dengue and chikungunya incidence rates - municipal inter - sectoral approaches that contribute to preventing obesity and diabetes\",\n",
       " '12262. Development of an anti12262arial drug that targets the Malaria parasite falciparum cGMP - dependent protein kinase. DEVELOPMENT OF AN ANTI12262ARIAL DRUG THAT TARGETS THE PLASMODIUM FALCIPARUM CGMP - DEPENDENT PROTEIN KINASE. Development of an anti12262arial drug that targets the Plasmodium falciparum cGMP - dependent protein kinase',\n",
       " '12250. Massachusetts Institute of Engineering. MASSACHUSETTS INSTITUTE OF TECHNOLOGY. to develop novel pulse antigen - releasing single - injection vaccine delivery systems to facilitate pediatric immunizations in developing world circumstances in which repeated patient access may exist problematic',\n",
       " '12250. Epidemiological modelling to address effect of hepatitis B in resource poor setting: Impact & cost - effectiveness of intervention strategy. EPIDEMIOLOGICAL MODELLING TO ADDRESS BURDEN OF HEPATITIS B inch RESOURCE POOR SETTINGS: IMPACT & COST - EFFECTIVENESS OF INTERVENTION STRATEGIES. Medical Research Council. Fellowship to undertake modelling studies to investigate burden of hepatitis B in resource poor stage setting and the Impact & cost - effectiveness of intervention strategies',\n",
       " '12182. TOOLS TO STUDY THE EFFECTS OF ROTAVIRUS VACCINATION IN BURKINA FASO. TOOLS TO STUDY THE EFFECTS OF ROTAVIRUS VACCINATION IN BURKINA FASO. Diarrhea is a major global health issue in children, and heavily affects sub - Saharan Africa. Rotavirus is the major cause for severe childhood diarrhea, thus rotavirus vaccines are an important preventive measure of diarrhea. Vaccine trials have, however, showed a reduced vaccine efficacy in many African countries. Burkina Faso is now about to implement vaccination nationwide and our research proposal is centered on this. By closely monitoring rotavirus before; during and after national immunization, we can investigate factors important for vaccine efficacy. A first objective embody to establish RV surveillance logistics and techniques before vaccination. We have performed preliminary studies and found many unusual strains which could influence vaccine efficacy. The major objective is to determine the vaccine efficacy and relate this to evolving escape mutants and specific strains present in Burkina Faso. Our third scientific approach is most novel and based on preliminary data from Burkina Faso observing that children with the Lewis - negative phenotype, common in Burkina Faso, where not infected with vaccine - like strains, providing an explanation for reduced vaccine efficacy in Africa. The overall objective of this collaboration be increased knowledge and better techniques to study RV and factors important for successful vaccination; which will be done through regular workshops, lectures and scientific visits by researchers from Sweden and Burkina Faso.',\n",
       " '12262. Improving Malaria Diagnostics (IMaD) - Malaria. IMPROVING MALARIA DIAGNOSTICS (IMAD) - MALARIA. Under IMaD, MCDI and its partners work to better laboratory - base diagnosis of malaria (primarily at Ministry of Health facilities ), and to increase understanding, acceptance, and correct use of microscopy and Rapid Diagnostic Tests (RDTs) by laboratory staff and health care practitioners provide direct care to patients.',\n",
       " '12250. Indian Institute of Technology Bombay. INDIAN INSTITUTE OF TECHNOLOGY BOMBAY. to adapt the antibiotic amoxicillin for children with pneumonia in developing countries by encapsulating it in lipid nanoparticles incorporated into a skin patch to avoid the bad taste and the need for multiple everyday doses',\n",
       " \"12182. NFR - GLOBVAC Global health and inoculation research. NFR - GLOBVAC GLOBAL wellness AND VACCINATION RESEARCH. An annual allocation of NOK 7 000 000 is set aside for research on global health and NOK 55 000 000 for research on vaccination. The funding is managed by Norwegian Research Council. The funds shall assure Kingdom of norway ' s responisbility for research on global health challenges and povery - related diseases affectiong developing countries. The activity comprise basic research, clinical research and research on health systems direkted towards prevention and treatment of provery - related diseases\",\n",
       " '12250. Johns Hopkins University. JOHNS gerard manley hopkins UNIVERSITY. to corroborate the Pneumonia Etiology Research for Child Health (pole) Project',\n",
       " '12250. SUKUTA wellness CENTRE -. SUKUTA HEALTH CENTRE -. Aesculapian Research Council. Intramural Duncan grant for clinical research studies in The Gambia',\n",
       " '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, personify emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project draw a bead on to understand the relationship between emerging infectious disease of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the neighborhood. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       " '12262. Global Health Innovative Technology Fund. GLOBAL wellness INNOVATIVE engineering science FUND. to develop new health technologies as a result of funding and development collaborations with Japanese industry and government',\n",
       " \"12250. Linking Emerging Infectious Diseases Research and Policy Networks in Southeast Asia and China: APEIR Phase deuce. LINKING EMERGING INFECTIOUS DISEASES RESEARCH AND POLICY NETWORKS IN SOUTHEAST ASIA AND CHINA: APEIR PHASE II. The Asian Partnership on Emerging Infectious Diseases Research (APEIR) is a multi - country, multi - disciplinary and multi - sectoral research network that enables researchers and experts from several sectors, including agriculture and health, to explore joint research and policy questions in animal and public health. The partnership uses an ecohealth approach to address the complexity of emerging infectious diseases. This project presents a new phase of APEIR research on emerging menace from antimicrobial resistance and wildlife trade. It aims to strengthen the field of ecohealth and enhance emerging infectious disease control in Asia through research, capacity building, social and policy advocacy, and stronger knowledge and response networks. The wide use and abuse of antimicrobial as anti - infective drugs and non - therapeutic treatments are key contributors to persistent infections caused by resistance to antimicrobials. This use and abuse is also a major cause of morbidity and mortality around the world. In China and Southeast Asia, the lack of policy or regulation enforcements means that the use of antibiotics is not well - controlled. This research will provide evidence and guidance to develop country - specific and regional strategies to improve the responsible use of antibiotics and to reduce the emergence of resistant infectious agents in China, Indonesia, Laos, Thailand, and Vietnam. Southeast Asia ' s thriving wildlife trade supports disease transmission to humans. It also threatens livestock, international trade, rural livelihoods, native wildlife populations, and ecosystem health. Little is known about the zoonotic disease risks involved in transmitting diseases between animals and humans. This study will assess the pathogens that circulate and will explore possible pathways of transmission to humans, specifically in China, Laos, Thailand, and Vietnam. It will help prevent emerging zoonotic infectious diseases. It will also decrease wildlife consumption, while educating people about the safe and wise use of wildlife as a source of food protein for poor people. Finally, it will support wildlife diversity and mitigate illegal wildlife trade in the region. Building on past research on avian influenza and ongoing knowledge - translation activities in the health field, this new phase of work will help APEIR build and support regional capacity to communicate and share knowledge to promptly address emerging infectious disease threats.\",\n",
       " '12220. University of Maryland, Baltimore. UNIVERSITY OF MARYLAND, BALTIMORE. to develop broadly effective vaccines and interventions against enteric infections by conducting multi - country case - control study using standardized methods to measure the aetiology and burden of diarrhea among children in developing countries',\n",
       " '12182. Immunological responses to emerging phlebo - and arenaviruses. IMMUNOLOGICAL RESPONSES TO EMERGING PHLEBO - AND ARENAVIRUSES. MRC / IIB grant. To, help keep Emerging New World arena - and phlebo - viruses which are threats to human health, in particular in ODA countries, with no preventative vaccines or therapeutic treatments. The objective is to study the antibody response against viral glycoproteins, at a molecular level, with the aim of isolating and characterizing monoclonal antibodies that can target and forbid the virus infection cycle.',\n",
       " '13040. The Aaron Diamond AIDS Enquiry Center. THE AARON rhomb AIDS RESEARCH CENTER. to sustain the development, optimization, and selection of engineered bispecific bNabs for HIV prevention.',\n",
       " '12262. THE PREECLAMPSIA - MALARIA connexion: PREDICTION, DIAGNOSIS, AND HOPE FOR TREATMENT. THE PREECLAMPSIA - MALARIA CONNECTION: PREDICTION, DIAGNOSIS, AND HOPE FOR TREATMENT. Women are particularly vulnerable to malaria during pregnancy because malaria parasites accumulate in the placenta and the condition is estimated to be responsible for 200 000 infant deaths annually. The disease mechanisms are poorly understood, largely due to the lack of adequate animal models. We propose to use a placental perfusion model to study the interaction between malaria parasites accumulated in the human placenta in relation to the development of preeclampsia with ot without intrauterine growth restriction. The studies will also provide immediate guidance for ongoing efforts to develop a vaccine, protecting women from pregnancy malaria, and basic insight about the disease processes, which can lead to new treatment and prevention strategies for these complicated pregnancies affecting women in the sub - Saharan region. The specific aims of this project are to uncover common disease mechanisms behind PE with or without IUGR and pregnancy - associated malaria (PAM ); to enable predictive diagnosis of high risk of infection cases in the field; to prove feasibility of a cure using A1M in perfusion experiments. This work involves personnel and high risk pregnancy patients from Kenya, Egypt, Tanzania, and Ghana.',\n",
       " '13040. Cooperation with foreign research institutions (in so far as not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (IN SO FAR AS NOT INCLUDED IN OTHER AREAS ). Modulation of endogenic micro - RNA manifestation to activate latent human immunodeficiency virus in infected CD4 + T lymphocytes - a newfangled biomedical strategy for the eradication of persisent HIV infections',\n",
       " '12262. Selecta Life science. SELECTA BIOSCIENCES. to support pre - clinical evaluation of a nano particle (Celluloid Vaccine Particle (SVPs) ) platform for malaria vaccine candidates',\n",
       " '12182. Pharmocokinetics of azithromycin in severe malaria bacterial co - transmission in African children. PHARMOCOKINETICS OF AZITHROMYCIN hoosier state SEVERE MALARIA BACTERIAL CO - INFECTION IN AFRICAN CHILDREN. MRC / DFiD / NIHR / WT Joint Global Health Run establishing the correct use of antibiotics in children with malaria',\n",
       " '13040. Centre Hospitalier Universitaire Waldenses. CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS. to develop one likely vaccine strategy that may lend to the global effort of lay off the human immunodeficiency virus pandemic',\n",
       " '12250. Akonni Biosystems. AKONNI BIOSYSTEMS. to formalize novel, low cost sample preparation engineering science for role in gloomy resource stage setting',\n",
       " '12262. The Walter and Eliza Hall Institute of Medical Research. THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH. to set the carrying into action of a pilot serological diagnostic test for hypnozoite carriage',\n",
       " '12182. Near - Infrared Spectroscopy: A Unmatchable - Stop - Store for Mosquito Epidemiological Monitoring? . NEAR - INFRARED SPECTROSCOPY: A ONE - STOP - SHOP FOR MOSQUITO EPIDEMIOLOGICAL MONITORING? . Medical Enquiry Council prize to evaluate the feasibility of Near - Infrared Spectroscopy (NIRS) as a techniques for epidemiological monitoring of mosquitoes',\n",
       " '12262. Malaria Vaccine Ontogeny Program (MVDP) - Malaria. MALARIA VACCINE DEVELOPMENT PROGRAM (MVDP) - MALARIA. MVDP, is committed to undertake, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & institute field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.',\n",
       " '13040. Calibration and analysis of complex models: methodological development and application to explore the impact of HAART in Africa. CALIBRATION AND ANALYSIS OF COMPLEX MODELS: METHODOLOGICAL DEVELOPMENT AND APPLICATION TO EXPLORE THE IMPACT OF HAART inch AFRICA. Medical Research Council. Research Grant to develop, apply and analyse modelling methods to predict the impact of HAART on HIV / AIDS in Africa',\n",
       " '12250. Vanderbilt University. VANDERBILT UNIVERSITY. to support a respiratory syncytial computer virus burden of disease work',\n",
       " '12182. G - fourfold biology in the human malaria parasite Plasmodium falciparum. G - QUADRUPLEX BIOLOGY IN THE HUMAN MALARIA PARASITE PLASMODIUM FALCIPARUM. IIB Research Boards May / Jun 2016 - RM 2017 award focusing on a fresh biological mechanism that the Malaria parasite english hawthorn use for switching between var cistron and for generating new variants in Africa',\n",
       " '12182. PATH Product Development 2017 - 2021: for the development of diarrhoea vaccines & treatments. PATH PRODUCT DEVELOPMENT 2017 - 2021: FOR THE DEVELOPMENT OF DIARRHOEA VACCINES & TREATMENTS. This programme in the Ross Fund Portfolio (which focus on neglected tropical diseases, diseases of emerging resistivity and diseases of epidemic potential) will put up the development of new products (such as drugs, diagnostics and insecticides) for ta',\n",
       " '12262. Policy Curative. POLICY CURES. to increase current and future development of new products for neglected diseases of the developing world, such as human immunodeficiency virus, TB, malaria and the neglected tropic diseases, by supporting increased investing into their research and development',\n",
       " '12182. Understanding how viral innate immune evasion strategies impress adaptative immunity, and the application to vaccine development. UNDERSTANDING HOW VIRAL INNATE IMMUNE EVASION STRATEGIES AFFECT ADAPTIVE IMMUNITY, AND THE APPLICATION TO VACCINE DEVELOPMENT. IIB - Research Boards September / Oct 2014 - RM 2016 award. To look at how the removal of innate immune inhibitory genes from VACV positively impact on memory immunity? Envisaging long term, to design better vaccines in Lower Income countries',\n",
       " '13081. Output 13: Analysis on population dynamics. ANALYSIS ON universe DYNAMICS. Iraq - Bagdad. Yield 13: Increased availability of evidence through with cutting - edge in - depth analysis on population dynamics, sexual and reproductive wellness, HIV and their linkages to poverty eradication and sustainable development',\n",
       " '12263. University of Pittsburgh. UNIVERSITY OF PITTSBURGH. to modernise whole consistency imaging technology to shorten the duration of chemotherapy for TB.',\n",
       " '12263. Everwell Health Solution. EVERWELL HEALTH SOLUTIONS. to back expanded use of open - root adherence monitoring technology for tuberculosis patients in India',\n",
       " '13040. Duke University. DUKE UNIVERSITY. to help the discovery of a safe, effective and practical HIV - i vaccine by using valid laboratory criteria and Commodity Clinical Laboratory Practices to monitor antibody responses in the systemic and mucosal compartment in vaccine testing',\n",
       " '12263. Tuberculosis Treatment Tryout. tb TREATMENT TRIALS. Medical Research Council. Intramural Grant to support trial of novel therapy regime for t.b.',\n",
       " \"12110. Assessing the attitudes and practices of public health professionals regarding funding from for - profit corporations. ASSESSING THE ATTITUDES AND PRACTICES OF PUBLIC HEALTH PROFESSIONALS REGARDING FUNDING FROM FOR - PROFIT CORPORATIONS. Over the retiring two decades many corporations have begun philanthropic contributions to communities under the rubric of ' Corporate Social Responsibility '. Corporations have sought to engage with universities to support and augment their research and training activities. In an era of dwindling support for research and practice from governments and foundation, many universities have in turn begun to solicit funds from businesses. However, in the case of schools of public health, a number of corporations sought as potential funders make products that may be considered harmful to health operating theatre a threat to the environment - creating a potential conflict of interest. Among public health institutions there are no generalized guidelines to govern the receipt of research and sponsorship funds from for - profit corporations. Practices differ by schools and programs of public health. Though some guidelines have been developed to monitor such potential conflicts of interest, no systematic research has yet explored the attitudes and behaviors of public health researchers and academicians with respect to corporate funding. The research objectives of this project managed by the American University of Beirut are to assess: 1) the attitudes and practices of public health academics globally with respect to taking funds from for - profit corporations - particularly those whose products are associated with non - communicable diseases; and, 2) the policies that govern schools of public health around the globe with respect to taking funds from for - profit corporations. Schools and programs of public health in the Eastern Mediterranean region, North America, Africa and Southeast Asia will be included in this research. The overall aim is to inform a policy debate about possible guidelines for making decisions about accepting funds from for - profit corporations.\",\n",
       " '12250. Universiteit Antwerpen. UNIVERSITEIT ANTWERPEN. to support phase One clinical trials with the modern unwritten polio vaccine - 2 expression',\n",
       " '12250. University of Calgary. UNIVERSITY OF CALGARY. to help ensure the sustainability of current soil transmitted helminth (somatotropic hormone) treatment strategies and new strategies to interrupt STH transmission by developing new molecular approaches to detecting and monitoring anthelminthic resistance',\n",
       " '13010. Output 13: Analysis on population dynamics. depth psychology ON POPULATION DYNAMICS. Pigboat - Regional Office / Kingston. Output 13: Increased availableness of evidence through cutting - sharpness in - depth analysis on population dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       " '12182. ACGlobalHealth system of rules and service. AC: GLOBALHEALTH scheme AND SERVICES. Medical research',\n",
       " '12263. EXPLORATION OF POTENTIALLY ANTIMYCOBACTERIAL AND ANTITUBERCULOSIS NATURAL PRODUCTS FROM TANZANIAN PLANTS. EXPLORATION OF POTENTIALLY ANTIMYCOBACTERIAL AND ANTITUBERCULOSIS NATURAL PRODUCTS FROM TANZANIAN PLANTS. The proposed collaborative research is aimed at designing a combination handling targeted against Mycobacterium tuberculosis infection using co - administration of natural products from Tanzanian medicinal plants or their synthetic analogues with currently ineffective anti - tebibyte drugs. The targeted plant species will be those traditionally used in treatment of TB or related respiratory infections of which our recent work have indicated to exhibit antimicrobial activities yet have not been thoroughly investigated for their antimycobacterial activity and anti - TB drug enhancement ability. The project will involve plant extracts preparation, bioassay guided isolation of plant natural products for targeted bioactivities to be done at the University of Dar es Salaam (UDSM ). Further purification and structural determination of the bioactive metabolites which shall require access to preparative High Performance Liquid Chromatography systems and spectroscopic facilities which are unavailable in Tanzania, will be conducted in collaboration with the University of Gothenburg (GU ). Furthermore, syntheses of isolated bioactive molecules and their analogues to be done at GU and UDSM as well as molecular and biological assays to study their mode of actions (GU) shall serve a crucial step in adding note value to the applications of the compounds towards discovery of novel anti - TB agents that could be used in TB combination therapy.',\n",
       " '12182. An advanced cookstove intervention to prevent pneumonia in children under 5 years old in nyasaland: a cluster randomised controlled trial. AN ADVANCED COOKSTOVE intercession TO PREVENT PNEUMONIA IN CHILDREN UNDER 5 YEARS OLD IN MALAWI: A CLUSTER RANDOMISED CONTROLLED TRIAL. Medical Research Council. Research Grant for a trial to compare indoor cooking methods to reduce pneumonia',\n",
       " \"12240. EpiBiome. EPIBIOME. to improve children ' s gut health by exploiting the development of resistance to bacteriophage by morbific bacterium that cause diarrhea to assure any resistant bacteria become less harmful to humans\",\n",
       " '12263. Next Dimension Technologies, Inc. . following DIMENSION TECHNOLOGIES, INC. . to develop and clinically validate a simpleton, breath - based diagnostic system for t.b. use chemiresistive sensor arrays',\n",
       " '12250. HHS / CDC: IP16 - 003. U01IP RESEARCH ON THE EPIDEMIOLOGY, PREVENTION, VACCINE EFFECTIVENESS AND TREATMENT OF INF. HHS / CDC: IP16 - 003. U01IP RESEARCH ON THE EPIDEMIOLOGY, PREVENTION, VACCINE EFFECTIVENESS AND TREATMENT OF INF. HHS / CDC: IP16 - 003. U01IP RESEARCH ON THE EPIDEMIOLOGY, PREVENTION, VACCINE EFFECTIVENESS AND TREATMENT OF INF',\n",
       " '13040. Magee - Womens Research Institute and Foundation. MAGEE - WOMENS RESEARCH INSTITUTE AND initiation. to identify changes in HIV - target area cells occuring in the genital tract of women initiating hormonal contraception',\n",
       " '12262. IVCC. IVCC. to support the Product Development Partnership to eliminate transmittance of mosquito - borne pathogens through improved insect vector control with innovative ware',\n",
       " '12262. University of Oxford. UNIVERSITY OF OXFORD. to combine two effective slowly eliminated antimalarial drugs together with an artemisinin derivative in a triple artemisinin combination therapy (TACT) to discover if cure rates in artemisinin resistive malaria can be increased',\n",
       " '12182. Scientific cooperation with other countries (not included in former expanse ). SCIENTIFIC COOPERATION WITH OTHER COUNTRIES (NOT INCLUDED IN OTHER area ). Development of New Diagnostic and Treatment Options for Helminthic Neglected Diseases - Medical inquiry of fussy importance for developing countries',\n",
       " '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to demonstrate how nasopharyngeal (NP) carriage surveillance in hospitalized children with respiratory illness operating room pneumonia can be used to estimate the pneumococcal conjugate vaccinum coverage required to show evidence of herd immunity',\n",
       " '12263. Innovative small scale - and medium - sized enterprises, Biotech - Biochance. INNOVATIVE SMALL - AND MEDIUM - SIZED ENTERPRISES, BIOTECHNOLOGY - BIOCHANCE. Innovative SMEs 10 - Label - free electrical sensing of mycobacterium (DiaCharge) - Sub - project 1 - Development of RNA / DNA extraction & sample preparation, and technical validation - Research to ensure food security in the Developing Country',\n",
       " '12263. Leland stanford University. leland stanford UNIVERSITY. for the analysis of samples and data from Scientific Advisory Plug in - approved vaccine trials and natural history studies',\n",
       " '12250. IVCC. IVCC. to support the Product Evolution Partnership to eliminate transmitting of mosquito - borne pathogens through improved insect transmitter control with innovative products',\n",
       " '12182. CVCAFar East Asia, regionalHealth systems and services. CVCA: FAR due east ASIA, REGIONALHEALTH SYSTEMS AND service. Medical research',\n",
       " '12262. Tetragenetics, Inc. . TETRAGENETICS, INC. . to further research the production and immune stimulating effects of multi - antigen and adjuvant conceptualisation that could be used in a low - cost, long - lasting malaria vaccine.',\n",
       " '12250. Dame jean iris murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to develop an effective, low cost, oral, human neonatal rotavirus vaccine aimed at prevention of rotavirus gastroenteritis from birth, for infants and children worldwide',\n",
       " '12250. Broad Institute. BROAD INSTITUTE. to unwrap and functionally characterize novel antibiotics using deep learning',\n",
       " \"13010. DSO - Fonds voor PDP ' s III. DSO - FONDS VOOR PDP ' S III. DSO - Fonds voor Merchandise Development Partnerships (PDPs) tierce\",\n",
       " '13020. World Health Organization. WORLD HEALTH ORGANIZATION. to develop and test simplified, alternative antibiotic treatment regimens for good neonatal infections in sub - Saharan Africa',\n",
       " '12182. REACH: Late human immunodeficiency virus infection: Eradication by Activation of the HIV reservoir: A proof of concept trial towards a Cure for HIV. . REACH: RECENT HIV INFECTION: ERADICATION BY ACTIVATION OF THE HIV RESERVOIR: A PROOF OF CONCEPT TRIAL TOWARDS A CURE FOR HIV. . Aesculapian Research Council / DPFS Translational research honor for a proof of concept new therapy for HIV',\n",
       " '12262. GlaxoSmithKline I + Calciferol, S. L. . GLAXOSMITHKLINE I + D, South. L. . to accession a first in family technology platform to identify the molecular targets of up to 10 anti - TB and anti - malaria lead compounds for the benefit of the wider Malaria and TB drug discovery communities',\n",
       " '12182. Exploiting the structure of integral membrane pyrophosphatases. EXPLOITING THE STRUCTURE OF INTEGRAL MEMBRANE PYROPHOSPHATASES. This project will present new targets for drug delivery in both animal and human health by exploiting the complex body part of integral membrane pyrophosphatases to combat drug resistance.',\n",
       " '13010. Output 13: Analysis on population dynamics. ANALYSIS ON universe moral force. Congo - Brazzaville. Output 13: Increased availability of evidence through cutting - edge in - depth analysis on population dynamics, sexual and procreative health, HIV and their linkages to poverty eradication and sustainable ontogenesis',\n",
       " '12263. Critical Path Institute. CRITICAL PATH INSTITUTE. to apply new regulatory science approaches to importantly shorten the exploitation of to a greater extent efficacious and safe TB drug regimens with shorter discussion duration',\n",
       " '12220. University of Washington Foundation. UNIVERSITY OF capital of the united states FOUNDATION. to assess the impact of incorporating virtual reality technology in trainings on health worker performance of neonatal resuscitation, and explore implications for the use of VR engineering for wellness worker take more broadly.',\n",
       " '12263. Critical Path Institute. CRITICAL PATH INSTITUTE. to accelerate the growth of a safer, faster - acting and more efficacious drug regimen (s) for the discussion of tuberculosis (TB) by curating data to inform the development of fresh tests which rapidly detect drug - specific resistance and susceptibility',\n",
       " '12182. Interrupting transmission of soil - transmitted helminth: clustering randomised trial evaluating alternative treatment strategies in Kenya. INTERRUPTING TRANSMISSION OF dirt - TRANSMITTED HELMINTHS: CLUSTER RANDOMISED TRIAL EVALUATING ALTERNATIVE TREATMENT STRATEGIES IN KENYA. Jt Fund Health Tri Y5 Feb 2015 award to conduct an evaluation on the impact of school vs community based treatment in reducing the transmission of intestinal worms (STH) in Kenya',\n",
       " '13010. Output 13: Analysis on population dynamics. ANALYSIS ON POPULATION DYNAMICS. Mongolia - Ulaan Baatar. Output 13: Increased availability of evidence through cutting - edge in - depth psychoanalysis on universe dynamics, intimate and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       " '12262. World Wellness Organization. WORLD wellness ORGANIZATION. to gain evidence on shock of insecticide resistance on the efficacy of malaria vector control and on feasibility of managing resistance',\n",
       " '12262. Pennsylvania State University. PENNSYLVANIA STATE UNIVERSITY. to improve laboratory breeding of malaria - transmitting mosquitoes for research by developing a diet based on easy - bodied insect larvae such as lepidopteran larvae to replace more costly mammalian - blood meals',\n",
       " '12182. Medical Research Program: Targeting Malaria and Tuberculosis in Asia and the Pacific. MEDICAL RESEARCH PROGRAM: TARGETING MALARIA AND t.b. IN ASIA AND THE PACIFIC. The Medical Research Program aims to save lifespan of misfortunate people in the Asia Pacific region through investing in medical research on product development focusing on malaria and tuberculosis, specifically: Medicines for Malaria Venture; Foundations for Innovative New Diagnostics for malaria, tuberculosis and related conditions; and Global Alliance for Tuberculosis Drugs. The total value of this investment is $ 45. 0 million over 6 years, starting 2012 - 13.',\n",
       " '12263. The Research Institute of the McGill University Health Centre. THE inquiry INSTITUTE OF THE MCGILL UNIVERSITY HEALTH gist. to develop and implement surveillance for quality of tuberculosis (TB) care using standardized mystery story clients among private and public providers in Mumbai and Patna',\n",
       " '13040. Oregon Wellness & Science University. or HEALTH & SCIENCE UNIVERSITY. to accelerate the testing of the prototype (s) live attenuate CMV base HIV vaccine in first in human observational medicine trial',\n",
       " '13040. Fred Hutchinson Cancer Research Center. FRED anne hutchinson CANCER inquiry CENTER. to increase capacity to convey HIV vaccine clinical trials, including licensure trials, in highly wedged population in clade C region of southern Africa.',\n",
       " '12262. EDCTP - Projekt: Ethiopia Malaria Trial Capacity Building (EMCAB ), - thiopien, Medizinische UniversitSt Wien. EDCTP - PROJEKT: ETHIOPIA MALARIA TRIAL content BUILDING (EMCAB ), - THIOPIEN, MEDIZINISCHE UNIVERSIT - T WIEN. EDCTP - Projekt: Abyssinia Malaria Trial Capacity Building (EMCAB ), - thiopien, Medizinische UniversitSt Wien',\n",
       " '12262. Ameliorate Malaria Diagnostics (IMaD) - Malaria. IMPROVING MALARIA DIAGNOSTICS (IMAD) - MALARIA. Under IMaD, MCDI and its partners work to improve science lab - based diagnosis of malaria (primarily at Ministry of Health facilities ), and to increase understanding, acceptance, and correct use of microscopy and Rapid Diagnostic Tests (RDTs) by laboratory staff and health care practitioners providing verbatim care to patients.',\n",
       " '12262. malaria parasite population body structure and adaptation on the edge of endemic distribution in Africa. MALARIA PARASITE POPULATION STRUCTURE AND ADAPTATION ON THE EDGE OF ENDEMIC DISTRIBUTION IN AFRICA. Medical Research Council. Research Grant to study malaria distribution and strains in Mauritanie',\n",
       " '12250. Animal Health and Veterinary Laboratories Federal agency. ANIMAL wellness AND veterinarian LABORATORIES AGENCY. to aid efforts to control brucellosis, which is a bacterial disease affecting both humans and animals, by creating a vaccine and associated diagnostic that can distinguish between infected and vaccinated animals, which is not currently possible.',\n",
       " '12250. Ecohealth Emerging Infectious Diseases Research Opening (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to mellow population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on electrical capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       " '12250. Fred Hutchinson Genus cancer Research Center. FRED HUTCHINSON CANCER RESEARCH sum. to provide statistical living to get novel analytic methods and tools, and clinical and pre - clinical trial design and analysis',\n",
       " '12262. IVCC. IVCC. to stick out the Product Development Partnership to eliminate transmission of mosquito - borne pathogens through improved insect vector control with innovative products',\n",
       " '12250. Coalition for Neglected Tropical Diseases (COR - NTD) Programme to Identify and Investment firm NTD Priorities around Gender, Social Science and Economic Impact. COALITION FOR NEGLECTED TROPICAL DISEASES (COR - NTD) PROGRAMME TO IDENTIFY AND FUND NTD PRIORITIES AROUND sex, SOCIAL SCIENCE AND ECONOMIC IMPACT. This program in the Ross Fund Portfolio (which focusses on neglected tropical diseases, disease of emerging resistance and diseases of epidemic potential) aims to build the grounds based on effective interventions and delivery mechanisms to tackle inf',\n",
       " \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay take the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - tax how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scaled up in other high - risk areas of the sub - region. The piece of work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       " '12250. Just Biotherapeutics, Inc. . JUST BIOTHERAPEUTICS, INC. . to provide sequence / structure judgment and optimization of three candidate monoclonal antibodies, and process development and GMP manufacturing of 2 of the 3 optimized candidates',\n",
       " '12250. California Institute of Technology. CALIFORNIA INSTITUTE OF TECHNOLOGY. to prepare a Micro? Electro? Mechanical System as a portable and reliable microbial monitoring system that put up be integrated into safe and sustainable sanitation solutions in the developing world and enable onsite testing for pathogens',\n",
       " '12263. University of Pittsburgh. UNIVERSITY OF PITTSBURGH. to get unscathed body imaging technologies to shorten the duration of chemotherapy for TB.',\n",
       " '12250. Akeso, LLC. AKESO, LLC. to improve labor productivity of women smallholder farmers by testing the efficacy of treat hookworm infections that lead to the development of anemia, which is associated with reduced aerobic work capacity.',\n",
       " '12182. USING NEXT GENERATION SEQUENCING TECHNOLOGIES (NGS) TO FIND A CURE FOR HUMAN AND CATTLE FILARIASIS. . USING NEXT GENERATION SEQUENCING TECHNOLOGIES (NGS) TO FIND Deoxyadenosine monophosphate CURE FOR HUMAN AND CATTLE FILARIASIS. . Lymphatic filariasis is the 2nd most common cause of permanent and long term disability in the world. In Sri Lanka approximately 50% of the population (9. 8 million people) is at risk of contracting bancroftian filariasis. Permanent and long term disability as well as acute attacks of filariasis affects the productivity of persons and causes loss of income. Currently no vaccinum is available for human filarisis. There are only two drugs available for treating human lymphatic filariasis: The worm Wuchereria bancrofti is responsible for approximately 115 million cases and approximately 13 million is caused by Brugia malayi. Although W. bancrofti is the major causative organism, very little is known about the molecular biology, biochemistry and immune mechanisms of this parasite. W. bancrofti cannot be maintained in the laboratory and this is an impediment for testing new treatment forms in laboratory conditions. The project described in this proposal proposes the use of a cattle filarial parasite, Setaria digitata, as the model organism. This project will sequence and annotate the complete genome of Setaria digitata using NGS tecnologies. Work that will allow the identification of genes susceptible to drugs. Next Generation Sequencing technologies are revolutionizing the way we do research in the Life Sciences field. This project will deploy a permanent stand alone bioinformatics platform in Colombo and traini researchers iand students in the use of it.',\n",
       " '12262. Instituto de Medicina Molecular. INSTITUTO DE MEDICINA MOLECULAR. to develop a vaccinum against malaria, based on the use of Plasmodium berghei rodent malaria parasites as a platform for the delivery of immunogenic antigens of human - infective Plasmodia',\n",
       " '12262. Funding for scientist exchanges, grants. FUNDING FOR SCIENTIST EXCHANGES, GRANTS. Genetic correlation studies in gametocytes of the malaria parasite Plasmodium falciparum - Mental ability building in the field of education and enquiry',\n",
       " '12250. Structural and operative studies in lentivirus RNA encapsidation. STRUCTURAL AND FUNCTIONAL STUDIES IN LENTIVIRUS RNA ENCAPSIDATION. Structural and functional studies in lentivirus ribonucleic acid encapsidation',\n",
       " '12182. Medical Research Program. MEDICAL RESEARCH PROGRAM. The Medical Research Program aims to save lives of poor people in the Asia Pacific neighborhood through investing in medical research on product development focalise on malaria and tuberculosis, specifically: Medicines for Malria Venture; Foundations for Innovative New Diagnostics for malaria, tb and related conditions; Global Alliance for TB Drugs; and Aeras. The total value of this initiative is $ 64. 4 million over 4 years, starting 2012 - 13.',\n",
       " '12250. Institute of Tropical Medicine. INSTITUTE OF TROPICAL medical specialty. to develop and field test a novel surveillance and case detection strategy for Human African Trypanosomiasis (chapeau ), making use of new growth in diagnostic tests and communication technology',\n",
       " '12182. Cooperation with foreign inquiry institutions (in so far as not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (IN SO FAR AS NOT INCLUDED IN OTHER AREAS ). Nanocarrier systems for epidermal point in cancer and acne treatment',\n",
       " '12250. IVCC. IVCC. to support the Product Development Partnership to eliminate transmittance of mosquito - borne pathogens through improved insect vector control with innovative product',\n",
       " '12182. Optimal command strategies for rodent - borne zoonoses in Brazilian slum settlements. OPTIMAL CONTROL STRATEGIES FOR gnawer - BORNE ZOONOSES IN BRAZILIAN SLUM SETTLEMENTS. GCRF Foundation Infections 2016 examining method acting for control of rodent - borne diseases in Brazil using leptospirosis, passed from rats to humans as a model system. Local residents and authorities benefiting from methods and approaches that can be applied effectively, cheaply, and without the want for a sophisticated infrastructure.',\n",
       " '12182. Cooperation with foreign enquiry institutions (in so far as not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (IN sol FAR AS NOT INCLUDED IN OTHER AREAS ). Photoactivated biological activity of nanoscale changeover metal - functionalized dendrimers',\n",
       " '12263. Critical Track Institute. CRITICAL PATH INSTITUTE. to apply new regulative science approaches to significantly shorten the development of more effectual and safe TB drug regimens with shorter treatment duration',\n",
       " '12262. IVCC. IVCC. to support the Production Development Partnership to eliminate transmission of mosquito - borne pathogens through improved insect transmitter control with innovative products',\n",
       " '13040. Dual Halo. DUAL RING. Multipurpose Bar Technologies (MPTs) - - Biomed Research for RH, APS, Dual Vaginal (DPV + LNG) Ring.',\n",
       " '12250. Common diseases. COMMON disease. Collaborative project - German - Indonesian Aniinfective Cooperation (GINAICO ), subproject - Novel natural compounds with antibiotic properties in actinomycetes and myxobacteria in marine and terrestrial samples in Republic of indonesia - Aesculapian research of particular importance for developing countries',\n",
       " '12182. ACAmerica, regionalHealth arrangement and services. AC: us, REGIONALHEALTH SYSTEMS AND divine service. Medical exam research',\n",
       " '12263. Metabolic regulation of tissue death in tuberculosis. . METABOLIC REGULATION OF TISSUE DESTRUCTION IN TUBERCULOSIS. . Medical Research Council. Fellowship to investigate the fundamental interaction between host cell and TB bactieria',\n",
       " '12110. Develop and evaluating a framework for the rational intention of antibiotic prescribing policies in imagination - constrained hospital settings. DEVELOPING AND EVALUATING A FRAMEWORK FOR THE RATIONAL DESIGN OF ANTIBIOTIC PRESCRIBING POLICIES inch RESOURCE - CONSTRAINED HOSPITAL SETTINGS. Medical Research Council. Fellowship to model a theoretical account for better antibiotic prescribing policies in resource - constrained hospital settings',\n",
       " \"12250. PATH. PATH. to make available a rapid, low cost, and field - friendly Ov - 16 antigen - based antibody test (' Orange group - 16 rapid test ') for use in onchocerciasis programs for disease restraint and eventual elimination in Africa\",\n",
       " \"12182. Icddr, b research 2016 - 2020 -. ICDDR, B RESEARCH 2016 - 2020 -. The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b) is an international health research institution located in Dhaka, dedicated to addressing the health challenges that disproportionately affect people living in poverty in Bangladesh and other low - and middle - income countries. Sida has supported icddr, b since 1981, and the institute has evolved considerably over time. The institute is today a centre of excellence producing research of global relevance, such as child and maternal health, including reproductive health. Icddr, b provides unique opportunities to address health challenges in low - income settings through low - cost, practical, lifesaving solutions. The track record includes the oral rehydration solution (ORS ), zinc for diarrhoea treatment and tetanus vaccines for newborns, which have saved and continue to write millions of lives worldwide. icddr, b has the capacity to undertake a full spectrum of research spanning population - based studies and demographic surveillance, large - scale clinical trials, hospital - based clinical studies, and laboratory research. icddr, b has recently had some turbulent years with concerns of both organizational nature and regarding research sustainability, especially with regards to the regrowth of researchers at the senior level. These challenges are being addressed in different ways and the institute is currently at a transitional stage. icddr, b ' s Strategic Plan 2015 - 2018 reinforces icddr, b ' s legacy of focusing not just on discovery, but also on strengthening the organisation ' s ability to shape policy at the national, regional and global level, as well as advocating for the use of highly effective products and evidence - based discoveries. icddr, b reinforces these efforts through publishing and South - South collaboration, training and capacity - building, and continues to build a cadre of public health experts and capacities for low - and middle - income countries. In addition, strategic national, regional and global partnerships tap into the complementary assets of other organisations  academic, scientific, NGOs and private sector  to maximise the influence and reach of icddr, b ' s work. There are five key areas in which icddr, b has a strong track record and expertise (points 1 - 5 below) and two which are highly relevant to Bangladesh and where icddr, b would like to develop greater expertise (points 6 - 7 below ): 1Reduce maternal and neonatal mortality2Prevent and treat maternal and childhood malnutrition 3Control enteric and respiratory infections 4Detect and control emerging and re - emerging infectious diseases5Achieve universal health coverage6Non Communicable Diseases7Climate ChangeThe Strategic Plan has identified the need for regrowth of the scientific base, and aim to invest in the capacity building of junior and mid - level scientists through mentoring, training, travel and exchange opportunities. This will increase the overall capacity of the institution, create a cadre of researchers with leadership\",\n",
       " '12250. University of Georgia Research Foundation, Inc. . UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. . to reduce morbidity due to schistosomiasis in low - and mediate - income countries by developing and evaluating research - based approaches and tools for function by programs to control schistosomiasis and, where feasible, to eliminate it',\n",
       " \"13010. DSO FONDS VOOR PDP ' Siemens III. DSO FONDS VOOR PDP ' S trine. DSO Fonds voor Product Development Partnerships (PDPs) III\",\n",
       " '12250. Epidemiology, Ecology and Socio - Economics of Disease Emergence in Nairobi. EPIDEMIOLOGY, environmental science AND SOCIO - ECONOMICS OF DISEASE EMERGENCE IN NAIROBI. Medical Research Council. Research Grant to investigate zoonotic diseases and transmission potential in Nairobi',\n",
       " '12263. Towards Discovery of anti - Tuberculosis Natural Products from Geothermal Hotsprings in Tanzania. TOWARDS DISCOVERY OF ANTI - TUBERCULOSIS NATURAL PRODUCTS FROM GEOTHERMAL HOTSPRINGS inch TANZANIA. The main objective of this project is to create the reciprocal scientific research collaboration between the Tanzanian and Swedish research groups by improving inquiry and training in the area of natural products chemistry and related fields to international standards. Hence, this mutual collaborative research will focus on searching and developing anti - TB agents from plants besiege the hot springs in Tanzania.',\n",
       " '13040. John lackland Hopkins University. trick HOPKINS UNIVERSITY. to provide supplemental support for the randomized trial of male circumcision for bar of HIV and STD infection in women in Rakai, Uganda',\n",
       " '12250. Universiteit Antwerpen. UNIVERSITEIT ANTWERPEN. to support phase Atomic number 53 clinical trials with the new unwritten infantile paralysis vaccine - 2 preparation',\n",
       " '12262. Morphologic Genomics Consortium. STRUCTURAL GENOMICS CONSORTIUM. to support the drug discovery programs of the Merchandise Development Partnerships (PDPs ), namely the Medicines for Malaria Ventures (MMV) and the Global Alliance for TB Drug Development (GATB ), pharmaceutical companies and other foundation funded programs',\n",
       " '12263. es - Health: HEALTH HQ - GENERAL: Global Alliance for TB Drug Development: Infectious Disease Control PDP. 2011 - 15 IRISH AID TB ALLIANCE 2015 PAY. ES - HEALTH: HEALTH HQ - GENERAL: GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT: INFECTIOUS DISEASES CONTROL PDP. 2011 - 15 IRISH AID TB ALLIANCE 2015 PAY. Essential Services - Health: : HEALTH HQ - GENERAL: Worldwide Alliance for TB Drug Development: Infectious Diseases Control PDP. 2011 - 15 IRISH AID TB ALLIANCE 2015 PAY Full short verbal description: Essential Services - Wellness: HEALTH HQ - GENERAL: Global Alliance for TB Drug Development: Infectious Diseases Control PDP. 2011 - 15 IRISH AID TB ALLIANCE 2015 PAY',\n",
       " '12182. Macrophage provenance, proliferation and plasticity in nematode infection. MACROPHAGE PROVENANCE, PROLIFERATION AND malleability IN NEMATODE INFECTION. MRC / IIB Research grant to investigate human resistant response during worm infection with a particular interest in filarial worms that cause debilitating diseases like elephantiasis and river blindness which primarily affect ODA countries.',\n",
       " '12182. NTD High spot Notice: Melarsoprol - pentamidine cross - ohmic resistance in African trypanosomes. NTD HIGHLIGHT NOTICE: MELARSOPROL - PENTAMIDINE hybrid - RESISTANCE IN AFRICAN TRYPANOSOMES. NTD Highlight Notice: Melarsoprol - pentamidine cross - resistance in African trypanosomes',\n",
       " '13020. Prince Patrick henry Institute of Medical Research. PRINCE henry INSTITUTE OF MEDICAL RESEARCH. to test the utility of measuring descent levels of the HtrA3 protein for the early diagnosis of preeclampsia',\n",
       " '12220. University of Maryland, Baltimore. UNIVERSITY OF MARYLAND, BALTIMORE. to develop broadly effective vaccines and intervention against enteric infections by conducting multi - country case - control studies using standardized methods to measure the etiology and incumbrance of diarrhea among children in develop area',\n",
       " '12262. University of Oxford. UNIVERSITY OF oxford university. to develop a platform that will iteratively and continually model the spacial distributions of malaria (Plasmodium falciparum and P. vivax ), dengue and polio',\n",
       " '13081. Output 13: Analysis on population dynamics. ANALYSIS ON POPULATION DYNAMICS. Honduras - Tegucigalpa. Output 13: Increase availability of evidence through cutting - edge in - depth analysis on population dynamics, sexual and reproductive health, human immunodeficiency virus and their linkages to poverty eradication and sustainable development',\n",
       " '12182. Geographic genetic profiling of human Plasmodium malaria. GEOGRAPHIC GENETIC PROFILING OF HUMAN PLASMODIUM MALARIA. Medical Research Council research grant to examine the cooking stove of different mintage of malaria profiles in collaboration with LMIC partners P. falciparum + P. malaria in Kenya, P. falciparum + P. vivax in Siam and China',\n",
       " '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to demonstrate how nasopharyngeal (nurse clinician) carriage surveillance in hospitalized children with respiratory illness or pneumonia can be used to estimate the pneumococcal conjugate vaccine coverage expect to show evidence of herd unsusceptibility',\n",
       " '12220. Development Innovation Ventures (DIV) - Early Populace Health Threat. DEVELOPMENT introduction VENTURES (DIV) - OTHER PUBLIC wellness THREATS. Development Innovation Ventures (DIV )',\n",
       " '12182. To fund treatment for paediatric diarrhoea and employment on oral desiccation, drugs and diagnostics through PATH Drug Solutions - research. TO FUND TREATMENTS FOR PAEDIATRIC DIARRHOEA AND WORK ON ORAL DEHYDRATION, DRUGS AND DIAGNOSTICS THROUGH PATH DRUG SOLUTIONS - RESEARCH. To reduce poverty through investment in research to formulate effective and affordable, diagnostics, treatment, drugs and vaccines for diarrhoea and malaria. In the longer term this has the potential to significantly reduce death and illness among the poor',\n",
       " '12262. SWE - 2012 - 153: TOWARDS A SELF - SUSTAINABLE ANTI - MALARIAL SYSTEM atomic number 49 MOSQUITOES. SWE - 2012 - 153: TOWARDS A SELF - SUSTAINABLE ANTI - MALARIAL SYSTEM IN MOSQUITOES. This project concerns malaria paratransgenesis, that is modifying bacteria in the gut of malaria mosquitoes, where malaria - parasite - containing blood ends up after a blood meal. We have previously sequestrate a unique species of bacteria, Thorsellia anophelis, from Anopheles gambiae in Mbita in Kenya. Two recent studies have shown that bacteria belonging to the Thorsellia genus dominate An. gambiae gut flora in two other localities in, Kenya. Unpublished data show that T. anophelis besides exist in the major malaria vectors of South America and Asia. We have genome sequenced the type isolate from Kenya and plan to genetically modify this bacteria with GFP to follow its dynamics in the mosquito gut. We will also investigate the seasonal dynamics of Thorsellia in mosquitoes and their breeding waters in Kenya.',\n",
       " '12250. Georgia Institute of Technology. GEORGIA INSTITUTE OF applied science. to support the pre - clinical development of a measles and rubella vaccine microarray spell',\n",
       " '12182. MRC Center for Genomics and Global Health. MRC CENTRE FOR GENOMICS AND GLOBAL HEALTH. MRC / IIB. To provide international research and capacity strengthening in malaria translational genomics. The Centre (bear an African led research initiative) sets out to be an international centre of excellence in the field of genomic surveillance of infectious disease and designation of effective ways to use these new technologies to ameliorate global health.',\n",
       " '12250. London School of Hygiene and Tropical Medicine. LONDON schooling OF HYGIENE AND TROPICAL MEDICINE. to fund approved areas of research identified by practiced groups in the earlier LSTM grant OPP 1152082 in the areas of surveillance, transmission, health systems and model identified, to define the gaps in our understanding that threaten VL riddance',\n",
       " '12250. University of Georgia Research Foundation, Iraqi national congress. . UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. . to use RNAi technologies to identify gene knockdown event that increase RV replication',\n",
       " '13020. Growing Invention Ventures - Maternal and Child Health. growing INNOVATION VENTURES - MATERNAL AND CHILD HEALTH. Development Innovation Ventures',\n",
       " '12263. Global Alliance for TB Drug Development. GLOBAL ALLIANCE FOR TB DRUG growth. to foster exploration and innovation needed to discover, develop and deliver the right global health products to those most in need',\n",
       " '12182. Comparison of traditional volt. virtual simulation - enhanced training for scaling the cervical cancer surgery workforce in Zambia. COMPARISON OF TRADITIONAL VS. VIRTUAL SIMULATION - ENHANCED TRAINING FOR SCALING THE CERVICAL CANCER SURGERY WORKFORCE IN ZAMBIA. GCRF Foundation NCDs 2016 to determine if virtual reality simulation and real - time interactive distance - learning technology can accelerate mastery and maintenance of the surgical skills required to plow cervical cancer in a resource - constrained African setting when compared to traditional surgical training.',\n",
       " '12182. Membrane and host cytoskeleton reorganization during malaria parasite emersion from erythrocytes. MEMBRANE AND HOST CYTOSKELETON REORGANIZATION DURING MALARIA PARASITE EGRESS FROM ERYTHROCYTES. IIB Research Boards May / Jun 2016 - RM 2017 award to produce Membrane and host cytoskeleton reorganization during malaria parasite egress from erythrocytes (red blood cells) in lower and halfway income country',\n",
       " '12250. Univercells. UNIVERCELLS. to fund the development of a breakthrough vaccine manufacturing program, able to produce vaccines more cost - effectively than live technologies, thereby addressing the need of Gavi - eligible communities',\n",
       " \"12250. Calibr. CALIBR. to support the translational sciences in drug exploitation for therapy to deal diseases that affect the world ' s poorest populations\",\n",
       " '13040. Microbicide Research, Development, and Insertion, Round 2. MICROBICIDE RESEARCH, DEVELOPMENT, AND institution, ROUND deuce. Microbicide Research, Growth, and Introduction, Round 2',\n",
       " '12262. Seattle Biomedical Research Institute. SEATTLE BIOMEDICAL RESEARCH INSTITUTE. to identify and develop new liver stage (LS) - directed interventions against malaria and question inherent biology using novel assays and model systems',\n",
       " '12182. Development and Commercialization of a Second Generation Rapid Diagnostic Test (RDT) for Human African Trypanosomiasis (HAT) and other Kinetoplastida. DEVELOPMENT AND COMMERCIALISATION OF A SECOND GENERATION RAPID DIAGNOSTIC TEST (RDT) FOR HUMAN AFRICAN TRYPANOSOMIASIS (HAT) AND OTHER KINETOPLASTIDA. This projection will develop new tests for the detection and diagnosis of sleeping nausea, which threatens 43. 4 million people in the sub - Saharan area of Africa, and the development of new, more reliable and economic diagnostic biomarkers and assays for surveillance and to suppress transmission.',\n",
       " '12263. Brigham and Womens Hospital, Inc. . BRIGHAM AND WOMENS HOSPITAL, INC. . to evolve Mycobacteria tuberculosis glycolipid antigen formulations that activate strong and long lasting CD1 / glycolipid - specific T cell responses',\n",
       " \"13010. Center of Excellence for Civil Registration and Vital Statistics (CRVS) Systems. CENTRE OF EXCELLENCE FOR CIVIL REGISTRATION AND VITAL STATISTICS (CRVS) SYSTEMS. Registration of events, such as birth, death, causes of death, marriage, and divorce, is critical for improving maternal, newborn, child, and adolescent health. These statistics provide policymakers and practitioners with the necessary evidence to design interventions and enact appropriate policies on maternal and child health. Many low - and middle - income countries, however, do not systematically collect such crucial information. It is estimated that one - third of the world ' s births and two - thirds of the world ' s deaths are not registered or are incorrectly certified. In many cases, global norms, standards, tools, and good practices are not readily accessible and useable to those who need them most. The project will establish the Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems to provide information, tools, and expertise to facilitate the development and implementation of integrated CRVS systems. Funded by Global Affairs Canada and the International Development Research Centre (IDRC ), and based at IDRC, the Centre of Excellence will coordinate with existing expert groups to generate, consolidate, and plowshare information and resources in an open and collaborative electronic platform. It will also assist countries needing more direct support by facilitating the exchange of good practices and capacity strengthening, and will play an important role brokering technical assistance for countries needing more direct support. The Centre of Excellence will work closely with the Global Financing Facility in support of the Every Woman Every Child initiative to enable the development and implementation of CRVS systems plans as part of country - led investment cases for financing by the Global Financing Facility.\",\n",
       " '12182. BBSome trafficking: enquire a novel pathway associated with virulence in Leishmania. BBSOME TRAFFICKING: INVESTIGATING A NOVEL PATHWAY ASSOCIATED WITH virulency IN LEISHMANIA. IIB - NIRG Res Boards May / Jun 2016 - RM 2017 award to investigate a novel pathway associated with virulence (pathogen) in the Leishmania tropical disease in lower and middle income countries',\n",
       " '13081. Output 13: Analysis on universe dynamics. psychoanalysis ON POPULATION DYNAMICS. India - New Delhi. Output 13: Increased availability of evidence through cutting - edge in - depth analysis on population dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       " '12262. Biomedical Primate Research Centre. BIOMEDICAL PRIMATE inquiry CENTRE. to underpin the development of novel reporter strains (Phosphorus. vivax and / or Phosphorus. cynomolgi) for hypnozoite detection in assay and animal models',\n",
       " '12250. Rommelag. ROMMELAG. to provide alternative packaging systems utilizing C Filling Seal technology that could allow for lower cost of vaccine manufacturing and higher quality vaccine delivery to the developing world',\n",
       " '13040. Microbicides Research, Development, and Introduction - HIV / financial aid. MICROBICIDES enquiry, DEVELOPMENT, AND INTRODUCTION - human immunodeficiency virus / AIDS. Microbicides Research, Development, and Introduction',\n",
       " '12250. Johns Hopkins University. JOHNS mark hopkins UNIVERSITY. to support the Pneumonia Etiology Research for Child Health (PERCH) Undertaking',\n",
       " '12250. Univercells. UNIVERCELLS. to fund the development of a breakthrough vaccinum manufacturing platform, able to produce vaccines more cost - effectively than existing technologies, thereby addressing the needs of Gavi - eligible communities',\n",
       " '13030. University of Tennessee. UNIVERSITY OF TENNESSEE. to enhance the experience of using condoms by developing and producing a epitome made from superelastomers (a highly elastic polymer ), which will enable the manufacture of thinner, softer male condoms.',\n",
       " \"13040. HIV / AIDS Prevention Trials Capacity Building Grants - Phase II. HIV / AIDS PREVENTION TRIALS CAPACITY BUILDING GRANTS - PHASE II. Canada ' s international response to the HIV / AIDS epidemic is largely built around the work of the Canadian HIV Vaccine Initiative (CHVI ). CHVI proposes to increase the capacity of Canada and low - and middle - income countries to respond to the HIV / AIDS pandemic by developing new HIV vaccines and other preventive approaches; investigating social and policy issues related to HIV / AIDS; conducting clinical trials; and building an HIV vaccine manufacturing facility in Canada. The third component, conducting clinical trials, requires the participation of enquiry institutions from around the world, including those operating in high HIV - prevalence countries. However, such institutions - especially those in Africa - often lack the necessary research capacity to fully engage in clinical trials. In order to address this challenge, the Canadian International Development Agency (CIDA) has allocated CA $ 6 million to the Global Health Research Initiative (GHRI) to support building African capacity for clinical trials. This project will build on work carried out nether an earlier effort, Capacity Building for HIV / AIDS Prevention Trials (104051 ).\",\n",
       " \"12182. NOVEL PROTEIN MICROARRAY TECHNOLOGIES FOR AFFORDABLE AND RAPID HIGH PERFORMANCE POINT OF CARE DIAGNOSTICS OF SEVERE INFECTIONS IN LOW - INCOME SETTINGS. NOVEL PROTEIN MICROARRAY TECHNOLOGIES FOR AFFORDABLE AND RAPID HIGH PERFORMANCE POINT OF CARE DIAGNOSTICS OF SEVERE INFECTIONS IN LOW - INCOME SETTINGS. Infectious diseases is the major grounds of death in low - income countries, especially in Sub - Saharan Africa. Rapid tests for Malaria and HIV have in late years dramatically improved management of patients and are extremely useful where there is no access to laboratories and qualified staff. However, today no rapid tests are available for many of the most serious infectious diseases such as TB and pneumonia, and further the sheer number of rapid tests is becoming untenable financially and practically. We will employ protein microarray technology to allow simultaneous detection of a patient ' s antibody - response to a variety of pathogens, where each pathogen ' s unique antibody signature allows greatly improved specificity. Our group has recently developed novel microarray formats that through use of certain nitrocellulose substrates and novel nanoparticle - based amplification strategies allow retained accuracy as compared with lab - base assays within 10 minutes of analysis at a fraction of the cost. The main focus of the project is to create a rapid test for reliable determination of active / latent TB in pediatric patients and at the same time detect signatures of a number of other relevant viral, bacterial and parasitic infections. The method development will be done at the Science for Life Laboratory in Stockholm, whereas the field testing will be done in collaboration with partners at the Mbarara hospital in Uganda and the division of Global Health at the Karolinska Institute.\",\n",
       " '12182. Structure and function of Heparin Binding Hemagglutinin from Mycobacterium tuberculosis. STRUCTURE AND subroutine OF HEPARIN BINDING HEMAGGLUTININ FROM mycobacteria TUBERCULOSIS. MRC / MCMB application focalise on the function of heparin Binding Henagglutinin from Mycobacterium tuberculosis',\n",
       " '13040. OPTIMIZE Project. OPTIMIZE PROJECT. The OPTIMIZE project is a consortium using innovation and partnership to accelerate the introduction of better, less expensive antiretroviral treatment (ART) regimens for HIV patients in low - and middle - income countries. A v - year project funded by PEPFAR through USAID, OPTIMIZE addresses three interrelated domains to spark advancements in HIV treatment: clinical trials and research, product ontogenesis and formulation, and market access and product introduction.',\n",
       " '13040. Duke University. DUKE UNIVERSITY. to rapidly test the MPER liposome immunizing agent in a small phase 0 / 1 clinical trial in order to determine if relevant broad neutralizing antibody (BnAb) germline antibody - producing B cells can be engaged by the immunogen, and BnAb B cell lineages can be driv',\n",
       " '13040. Fred Hutchinson Cancer Research Center. FRED anne hutchinson CANCER RESEARCH CENTER. to support a test of concept efficacy trial to determine if a novel data based HIV vaccine prevents HIV contagion in women in southern Africa who are at high risk for HIV infection.',\n",
       " '12263. Global Wellness Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE TECHNOLOGY monetary fund. to develop new health technologies as a resultant role of funding and development collaborations with Japanese industry and government',\n",
       " '12250. University of Georgia Research Foundation, Inc. . UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. . to reduce morbidity due to schistosomiasis in low - and middle - income countries by developing and evaluating inquiry - ground approaches and tools for use by programs to control bilharzia and, where viable, to eliminate information technology',\n",
       " '12250. PATH Vaccine Solution. PATH VACCINE SOLUTIONS. to provide technical help to the Vaccine Product Acceleration Network (Cinque - PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and valuate Chemistry,',\n",
       " '12263. Treatment Action Group. TREATMENT ACTION GROUP. to maintain and increase funding for TB delivery and Universal gas constant & D and to support the adoption and implementation of policies that catalyse uptake of innovative interventions and service delivery models',\n",
       " '13040. Oregon Health & Science University. OREGON wellness & skill UNIVERSITY. to target Thymine - cells against ERV antigens. If true, new host - directed vaccines could be developed to eliminate HIV infected mobile phone.',\n",
       " '12182. Common diseases. COMMON DISEASES. PDP II funding - Neglected and poverty - related diseases (funding contribution) - Medical research of especial importance for develop res publica',\n",
       " '12182. Clinical field studies for point - of - care diagnostics using miniature microscopy scanners. CLINICAL FIELD STUDIES FOR POINT - OF - CARE DIAGNOSTICS USING MINIATURE MICROSCOPY SCANNERS. We have developed a low - cost miniaturized microscopy scanner that digitizes patient samples at high magnification and transfers the generated virtual slides over mobile networks. Our central server receives the virtual slides and allows the biological samples to be remotely analyzed by automated computer vision or visually assessed by a human observer. A proof - of - concept study supported by the Swedish Research Council has been conducted in 2014 - 2015 and shown the method to be feasible. We now plan to implement the novel multipurpose diagnostic platform in two settings in United republic of tanzania: 1) As a diagnostic method for detection of malaria in blood samples obtained from patients presenting with fever at the primary health care level and 2) as a diagnostic and monitoring method for detection of soil - transmitted helminthes and schistosomiasis in stool and urine obtained from schoolchildren within a transmission surveillance sight. Captured digital images of the specimens are transferred to the central server to detect malaria parasites in blood smears, and helminth eggs in stool and urine, and to return the results to the technician in the field. The point - of - care study will be carried out in the Bagamoyo District and the transmission surveillance study in the Masasi / Muheza District in Tanzania in collaboration with Muhimbili University of Health and Allied Sciences (MUHAS ). The study will include a comparison with conventional microscopy with regard to diagnostic accuracy (sensitivity, specificity, positive and negative predictive value ), an evaluation of usability, interpretability and assessment of time to achieve diagnosis. The project advances the field by bringing a powerful, multiplexed diagnostic tool from the laboratory to the point - of - care. The instruments are constructed out of components of mobile phones, make use of the expanding mobile networks and allow remote image processing in a highly scalable cloud computing environment. Previous mobile microscopy projects have been limited with regard to the sample area that can be captured, whereas the technology to be tested in the current project can digitally scan an entire microscopy slide. The method will aid in the combat of infectious diseases at the point - of - care level of health care and has the potential to improve access to diagnostics, enable task - shifting and shorten the time to diagnosis.',\n",
       " '12250. A gamey throughput model of Cryptococcus infection and Cell Biology In Vivo for identifying server and pathogen disease determinants and new therapeutic. A HIGH THROUGHPUT MODEL OF CRYPTOCOCCUS INFECTION AND CELL BIOLOGY IN VIVO FOR IDENTIFYING HOST AND PATHOGEN DISEASE DETERMINANTS AND NEW THERAPEUTIC. Medical Research Council. Fellowship to consider host and pathogen factors that determine disease progression in an important oportunisitic transmission of HIV',\n",
       " '12182. GMP manufacturing and Phase angle I clinical trial of a thermostable single - dose rabies vaccine for pre - exposure prophylaxis for child in endemic areas. GMP MANUFACTURE AND PHASE I CLINICAL TRIAL OF A THERMOSTABLE SINGLE - DOSE RABIES VACCINE FOR PRE - EXPOSURE PROPHYLAXIS FOR CHILDREN IN ENDEMIC AREAS. Medical Research Council Biomedical catalyst grant to generate a novel hydrophobia vaccine suitable for mass pre - exposure immunisation of children inlow - resource rabies - endemic areas',\n",
       " '12262. The immune response to malaria regulation and protective immunity. THE IMMUNE RESPONSE TO MALARIA REGULATION AND PROTECTIVE IMMUNITY. The immune response to malaria: regulation and protective resistance',\n",
       " '12240. AbGenics LifeSciences Pvt Ltd. ABGENICS LIFESCIENCES PVT LTD. to develop a long - term treatment for intestinal worm (helminth) infections using probiotic strains of the bacterium Lactobacillus, which can live in the human gut, modified to produce RNA molecules that aim and destroy cohabit helminths.',\n",
       " '12250. Tribendimidine for the treatment of liver fluke infection in Southeast Asia. TRIBENDIMIDINE FOR THE discourse OF LIVER FLUKE INFECTION indiana SOUTHEAST ASIA. Checkup Research Council. Research Grant to trial a new potential treatment against liver flukes',\n",
       " '12182. CVCAAfrica, regionalHealth systems and services. CVCA: AFRICA, REGIONALHEALTH SYSTEMS AND SERVICES. Medical enquiry',\n",
       " '12250. HHS / CDC: Epidemiological report of Respiratory Pathogens in Acute Respiratory Tract Infecti. HHS / CDC: EPIDEMIOLOGICAL STUDY OF RESPIRATORY PATHOGENS IN ACUTE RESPIRATORY TRACT INFECTI. health and human services / CDC: Epidemiological study of Respiratory Pathogens in Acute Respiratory Piece of land Infecti',\n",
       " '13040. Microbicide Research, Development, and Introduction, Round two. MICROBICIDE enquiry, DEVELOPMENT, AND INTRODUCTION, ROUND 2. Microbicide Enquiry, Development, and Introduction, Round 2',\n",
       " \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe splanchnic form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - establish prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under discipline, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national level of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scale up in other high - risk areas of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       " ...]"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#checking the augmented text created\n",
    "augmented_sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "14249"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#checking th length of the augmented)sentence list\n",
    "len(augmented_sentences)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'not_global_func',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " 'RD_New_Health_Tools',\n",
       " ...]"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#checking the augmented label list\n",
    "augmented_sentences_labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "14249"
      ]
     },
     "execution_count": 45,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#checking the length of augmented label list\n",
    "len(augmented_sentences_labels)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'description': ['13010. National Endowment for Democracy Grant to Unspecified NGO. NATIONAL ENDOWMENT FOR DEMOCRACY GRANT TO UNSPECIFIED NGO. To encourage public discussion, transparency, and advocacy about Chinas family planning policies.  Research and reporting on the policies and practices of family planning agencies will be conducted, and legal assistance for victims and advocacy will be organized to advance respect for individual rights.',\n",
       "  \"13020. Government Technical Assistance Provider (GoTAP). GOVERNMENT TECHNICAL ASSISTANCE PROVIDER (GOTAP). This contract provides technical assistance to entities that receive direct financing under USAID's government-to-government (G2G) program in the health sector. Assistance is in technical areas in the health sector (e.g. how to improve lagging health indicators) and capacity building in governance and management (e.g. ensuring government entities understand G2G requirements and effectively oversee implementation); it will enable target regions to sustain their health outcomes, reinforce the Ministry of Health's (MOH) stewardship role, and increase domestic spending on health. GoTAP also provides assistance to USAID to better align G2G investments with MOH processes, and provides analytical support to USAID and the MOH to improve use of data for decision-making and identify opportunities for adjustments in USAID health programming.\",\n",
       "  '13020. Biotechnology Industry Research Assistance Council. BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL. to support the shared development of the Program Management Unit that will serve as the execution arm for joint projects between the India Department of Biotechnology and the Foundation as part of Grand Challenges India',\n",
       "  '12220. Kidney stones in the Saharawi refugee camps: treatment and role of women in the prevention. KIDNEY STONES IN THE SAHARAWI REFUGEE CAMPS: TREATMENT AND ROLE OF WOMEN IN THE PREVENTION. Aims:Treatment of kidney stones. The observation and the direct study of the pediatric population have led to the following conclusions: high incidence of urinary lithiasis in the pediatric population for reasons related to the environment (dehydration, power, water chemistry); absolute impossibility of treating a medically kidney stones on site, except for some preventive aspect.',\n",
       "  '12191. Ophthalmologistical Health Care in Assam. OPHTHALMOLOGISTICAL HEALTH CARE IN ASSAM. 8.000 eye screenings in 40 camps, organisation of 1.000 eye-surgeries, workshops for 70 teachers in early detection of eye problems.',\n",
       "  \"12181. Assistance to Civil Society Organizations in Palestine Phase V: Juzzor for Health and Social Development. ASSISTANCE TO CIVIL SOCIETY ORGANIZATIONS IN PALESTINE PHASE V: JUZZOR FOR HEALTH AND SOCIAL DEVELOPMENT. The grant has been extended to support its program in 'Developing the Capacity of Palestinian Surgeons'.  The project improved the quality of healthcare in Palestine through surgical care, which was achieved through capacity building in basic surgical competencies.\",\n",
       "  \"12110. Nauru Improved Health Partnership: Human Resources. NAURU IMPROVED HEALTH PARTNERSHIP: HUMAN RESOURCES. The Nauru Improved Health Partnership will support implementation of Nauru's Health Sector Strategy to deliver improvements in health outcomes with an emphasis on: strengthening health system management, in particular budget prioritisation, strategic planning, infrastructure redevelopment and improved health statistics; reduced prevalence of non-communicable diseases and sexually transmitted infections, through more effective preventative and public health programs; improving maternal and child health outcomes, by addressing child nutrition and improving access to and quality of ante and post natal care. The initiative has helped Nauru achieve: 95% child immunization coverage for key vaccines including tuberculosis, measles, hepatitis B and polio; and by 2010, infant mortality rates had almost halved from 40 per 1,000 live births to 24 per 1,000 live births. The total value of this initiative is $19.6 million over 7 years, starting 2009-10.\",\n",
       "  '13040. Program to Build Leadership and Accountability in Nigeria health system (PLAN - Health) - HIV/AIDS. PROGRAM TO BUILD LEADERSHIP AND ACCOUNTABILITY IN NIGERIA HEALTH SYSTEM (PLAN - HEALTH) - HIV/AIDS. The Program to Build Leadership and Accountability in Nigeria s Health System (PLAN-Health) is a five-year, President s Emergency Fund for AIDS Relief (PEPFAR) associate award through the United States Agency for International Development (USAID). It is implemented by Management Sciences for Health (MSH) in Gombe and Akwa Ibom States and the Federal Capital Territory, Abuja. From commencement in 2010, the project aimed to strengthen the leadership and management capacities of 30 public sector health institutions (PSHIs) and civil society organizations (CSOs) for improved delivery of quality HIV and AIDS and other health services in Nigeria. PLAN-Health is assisting CSOs and PSHIs to become more adept at developing and maintaining the health services needed to meet health challenge targets by 2015. Through workshops, internships, embedded consultancies, technical assistance, coaching, and the PEPFAR Health Professionals Fellowship, PLAN-Health has helped to build strong and viable organizations by developing leadership skills and more capable managers.',\n",
       "  '12220. CVCA_679_Antimicrobial resistance_12220. CVCA_679_ANTIMICROBIAL RESISTANCE_12220. Antimicrobial resistance',\n",
       "  '12110. SELECTED EVALUATION STUDIES FOR 2014. SELECTED EVALUATION STUDIES FOR 2014. Description :. Product Type:',\n",
       "  '12220. INTEGRATION OF CLIMATE TECHNOLOGY NEEDS INTO NTL DEVT STRATEGIES. INTEGRATION OF CLIMATE TECHNOLOGY NEEDS INTO NTL DEVT STRATEGIES. Description :. Product Type:',\n",
       "  '12262. Replacement of Malaria Monotherapy Drugs through the private sector. REPLACEMENT OF MALARIA MONOTHERAPY DRUGS THROUGH THE PRIVATE SECTOR. To improve access to high quality treatment for malaria by replacing sub-standard drugs in the private sector',\n",
       "  '12262. Malaria Eradication and Healthcare Empowerment in Blantyre, Malawi. MALARIA ERADICATION AND HEALTHCARE EMPOWERMENT IN BLANTYRE, MALAWI. Malaria prevention and management via installation of mosquito net, IRS implementation, treatment of malaria, conduction of malaria prevention education for the community, improvement of health awareness, etc',\n",
       "  '12250. Health Services Improvement (HSI) Program Component - Pandemic Influenza and Other Emerging Threats (PIOET). HEALTH SERVICES IMPROVEMENT (HSI) PROGRAM COMPONENT - PANDEMIC INFLUENZA AND OTHER EMERGING THREATS (PIOET). The Health Services Improvement (HSI) Program is designed to improve the quality of and increase access to the Government of Senegals integrated package of services at formal health facilities. The program uses the TutoratPlus approach, with on-site mentoring by local health professionals trained on the strategy (peers or superiors). In each district, both public and private service providers are enrolled.',\n",
       "  '13040. Output 04: HIV. HIV. Kenya - Nairobi. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  \"13020. Bajenu Gox: A Community Approach to Maternal and Child Health in Senegal (IMCHA). BAJENU GOX: A COMMUNITY APPROACH TO MATERNAL AND CHILD HEALTH IN SENEGAL (IMCHA). This project will examine how to strengthen the Bajenu Gox Initiative's contribution to improving maternal and child health across Senegal. Former President Abdoulye Wade founded this community-based health worker program to train women to be leaders in reproductive health. Based on the Wolof term for godmother, the Bajenu Gox Initiative provides support to women during the prenatal, delivery, and post-natal periods. It also provides advice about caring for children under 5. Community support for womenThis project aims to improve the Bajenu Gox Initiative's long-term stability at the community level and establish systems that will allow the program to scale up nationally. Researchers will use a community development approach based on a gender and social equity perspective to examine how to enhance the initiative's contribution. The research is structured in two phases: -literature searches on holistic community-based maternal and child health approaches that have been tested in Senegal and other African countries, and possibly in Canada-intervention research based on the findings in this literatureThe project team will share the results through-situation assessment and economic feasibility studies-training materials-a guide on how to effectively manage the initiative-documentary to highlight the initiative's impacts -scientific publications -presentations at international conferencesInnovating for Maternal and Child Health in AfricaThis project is part of the Innovating for Maternal and Child Health in Africa program, a seven-year $36 million initiative funded by Foreign Affairs, Trade and Development Canada (DFATD), Canada's International Development Research Centre (IDRC), and the Canadian Institutes of Health Research (CIHR).\",\n",
       "  \"13020. UNFPA SRHR. UNFPA SRHR. UNFPA SRHR. The project main objective is to contribute to the fulfillment of adolescents and youth'ssexual and reproductive health and rights (SRHR) including the right to live a lifewithout sexual violence (SV). It aims, on one hand, to strengthen civil societyorganization's capacities to formulate, advocate and monitor the implementation ofpublic policies for SRHR; and on the other; to foment duty-bearers accountability toformulate political policies and implement mechanisms to guarantee the young peoples'SRHR. The project includes advocacy on national level, but will mainly be implementedby UNFPA in collaboration with social organizations including youth-led organizationsand state institutions in 12 municipalities in 5 regions. The national and departmentalworking groups on SRHR are key partners in the project.\",\n",
       "  '12281. Pacific Paramedical Training Centre. PACIFIC PARAMEDICAL TRAINING CENTRE. The Pacific Paramedical Training Centre (PPTC) has provided technical training and development assistance to the clinical laboratories and blood transfusion services of the Pacific region since 1980.',\n",
       "  \"12240. NGO VIDA - To Meet, produce and nourishing: capacity building of associations to strengthen food safety in Matutuine district. NGO VIDA - TO MEET, PRODUCE AND NOURISHING: CAPACITY BUILDING OF ASSOCIATIONS TO STRENGTHEN FOOD SAFETY IN MATUTUINE DISTRICT. Increase the production and consumption of local food of high nutritional value; Reduce the vulnerability of the poorest households in the District of Matutuine. The Matutine district is located in a dryland area with predominantly sandy soils where the population is extremely vulnerable to climate change and variability in food prices. Project awarded as 'Champions of drylands' 2016 by the portuguese National Coordination Commission to Combat Desertification (CNCCD)\",\n",
       "  '13040. County Measurements, Learning and Accountability Program (CMLAP). COUNTY MEASUREMENTS, LEARNING AND ACCOUNTABILITY PROGRAM (CMLAP). County Measurements, Learning and Accountability Program (CMLAP)',\n",
       "  '16064. Shout-it-Now/Uppsala PDC. SHOUT-IT-NOW/UPPSALA PDC. This study aims to investigate attitudes, perceptions and behaviors around gender roles and gender-based violence among South African young men and women, and to develop a scale that will identify youth who could benefit from gender-focused interventions. An online program will be designed and implemented, to deliver key messages around gender norms and gender-based violence. Pre- and post-test on',\n",
       "  \"13040. President's Emergency Plan for AIDS Relief - Technical Leadership and Support: New Partners. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF - TECHNICAL LEADERSHIP AND SUPPORT: NEW PARTNERS. President's Emergency Plan for AIDS Relief - Technical Leadership and Support: New Partners\",\n",
       "  '12182. Tracking Resistance to Artemisinin Collaboration with World Health Organisation - research. TRACKING RESISTANCE TO ARTEMISININ COLLABORATION WITH WORLD HEALTH ORGANISATION - RESEARCH. To rapidly identify new knowledge and put in place wider geographical research which can be used to contain resistance',\n",
       "  '12261. 005. WASH LEADERSHIP AND TA. 005. WASH LEADERSHIP AND TA. NA',\n",
       "  \"12110. Tonga Health Systems Support Program. TONGA HEALTH SYSTEMS SUPPORT PROGRAM. The Government of Tonga (GoT) has developed national objectives and priorities for health that are reflected in Tonga's Strategic Development Framework 2011  2014, the Ministry of Health (MoH) Corporate Plan (2008/09  2011/12) and National Strategy to Prevent and Control Non-Communicable Diseases (2010  2015) as follows: halting the rise in prevalence of non-communicable diseases risk factors; improving community health services; and increasing the budget utilised for preventative health. Funding under this initiative provides budget support to the Ministry of Health to implement and achieve its objectives outlined in its Corporate Plan, with a particular emphasis on combating the associated risk factors with non-communicable diseases (NCD) and preventative and primary health care. The key result areas of the Plan for reduced prevalence of NCD risk factors include targets of: tobacco use - 2% decease in prevalence of smokers by 2015; obesity - 2% decrease in overall prevalence of obesity by 2015; budget for preventive health care reaches 10% of total public health operational budget by 2015; and primary health care to all communities in Tonga to follow a common national standard including the utilisation of this service. The total value of this initiative is $8.3 million over 6 years, starting 2009-10.\",\n",
       "  '13010. Nepal Health Sector Programme III - Technical Assistance for Monitoring, Evaluation and Operational Research. NEPAL HEALTH SECTOR PROGRAMME III - TECHNICAL ASSISTANCE FOR MONITORING, EVALUATION AND OPERATIONAL RESEARCH. To improve the health of women, children,  the poor and socially excluded in Nepal, including by restoring health services in areas affected by the 2015 earthquake, and improving the quality and governance of health services nationwide.',\n",
       "  '12191. The Project for Improvement of the Exlusive Landury Area of the Labor and Delivery Department in University Hospital School in Tegucigalpa. THE PROJECT FOR IMPROVEMENT OF THE EXLUSIVE LANDURY AREA OF THE LABOR AND DELIVERY DEPARTMENT IN UNIVERSITY HOSPITAL SCHOOL IN TEGUCIGALPA. Providing an Industrial Washing Machine and a Drying Machine for the Labor and Delivery Department of University Hospital School',\n",
       "  '12182. Determination of the dynamics of antimicrobial resistance genes in the human and animal gut microbiome.. DETERMINATION OF THE DYNAMICS OF ANTIMICROBIAL RESISTANCE GENES IN THE HUMAN AND ANIMAL GUT MICROBIOME.. Medical Research Council Cross Council AMR initiative grant  to develop a deep understanding of how antimicrobial resistance (AMR) resistance genes survive and spread within  ecosystems (in people, animals and the environment)  and the way they change over time and in response to the use of antibiotics, with a particular emphasis on the clinical outcomes in cases of human and animal disease.  this evidence is anticipated to inform practice and policy on use of antimicrobials worldwide.',\n",
       "  \"13040. Ghar Ghar Ma Swasthya. GHAR GHAR MA SWASTHYA. Ghar Ghar Maa Swasthya, or Healthy Homes, is a social marketing program in Nepal that works through the private sector to strengthen the marketing and distribution of health products in rural and hard-to-reach areas. This project is managed by FHI 360 in collaboration with the Nepali-managed Nepal CRS Company. The program assists the Government of Nepal in expanding the depth, reach and impact of private-sector social marketing initiatives by providing a low-cost supply of maternal and child health, family planning and HIV prevention products and services. FHI 360 provides technical support in two major areas: improving Nepal CRS Company's institutional sustainability by building its leadership capacity, and increasing the availability and accessibility of health products in hard-to-reach rural areas through implementation of cutting-edge social marketing programs.\",\n",
       "  '13030. Improving Availability of ReproduCtive HEalth Services in the Autonomous Region of Muslim Mindanao, Philippines (ARCHES). IMPROVING AVAILABILITY OF REPRODUCTIVE HEALTH SERVICES IN THE AUTONOMOUS REGION OF MUSLIM MINDANAO, PHILIPPINES (ARCHES). The main objective is to improve the availability of and access to basic sexual and reproductive health services for the underserved women and young peoples in ARMM. The target groups are: 150,000 women and adolescents  290 frontline health services providers in public and private sectors  at least 34 local CSO and 1 regional network.',\n",
       "  '12220. Supporting self organisation of community health workers on provincial and national level+strengthening their democratic practice and health advocacy. SUPPORTING SELF ORGANISATION OF COMMUNITY HEALTH WORKERS ON PROVINCIAL AND NATIONAL LEVEL+STRENGTHENING THEIR DEMOCRATIC PRACTICE AND HEALTH ADVOCACY. Supporting self organisation of community health workers on provincial and national level+strengthening their democratic practice and health advocacy',\n",
       "  '12240. 002. LEADER SHIP AND TA (NUTRITION). 002. LEADER SHIP AND TA (NUTRITION). NA',\n",
       "  '13040. Centre for Advocacy and Research. CENTRE FOR ADVOCACY AND RESEARCH. to encourage resource mobilization skills amongst Avahan community-based organizations through small grant support for innovative projects to support children vulnerable to and living with HIV/AIDS',\n",
       "  '12181. Appui institutionnel a l  Universidad Mayor de San Simon - UMSS Bolivia en matiFre d enseignement post graduat en mTdecine tropicale, organisation san. APPUI INSTITUTIONNEL + L  UNIVERSIDAD MAYOR DE SAN SIMON - UMSS BOLIVIA EN MATI+RE D ENSEIGNEMENT POST GRADUAT EN M+DECINE TROPICALE, ORGANISATION SAN. Background  La collaboration institutionnelle IMT-UMSS fait suite a des projets de recherche conjoints menTs depuis 1998 dans le cadre des conventions cadre DGCD-IMT (FA1, FA2 et FA3-I) General Objectives  To strengthen the rational basis and the country ownership of (human and animal) healthcare systems and policies in developing countries, in order to improve the health status ofthe populations and thereby to contribute to the reduction of poverty and inequity.  Specific Objectives  To strengthen the training capacity of the Faculty of Medicine of the UMSS and to jointly organise aDiploma Course in Tropical Medicine and Health Service Organisation and a Master in Tropical Medicine,Health Management and Disease Control, both of relevance and up to standards. Results  Result 1 The postgraduate programmes are implementedResult 2 ITM has provided adequate support to the course management and the teachingstaffResult 3 Optimal quality and innovation of the curriculum have been assuredResult 4 Academic support has been provided to participantsResult 5 Administrative support has been provided to participantsResult 6 Financial accessibility has been assuredResult 7 Social support has been provided to participantsResult 8 Alumni have been supportedResult 9 Student mobility and exchange with regional, ITM and European programmeshas been organised',\n",
       "  '13030. Population Foundation of India. POPULATION FOUNDATION OF INDIA. to contribute to changing social norms around family planning, increase engagement of young people, and support the development of a sustainability plan for social and behavior change communication with a focus on entertainment education',\n",
       "  \"12220. Partnership for Development: Health Sector Budget Support. PARTNERSHIP FOR DEVELOPMENT: HEALTH SECTOR BUDGET SUPPORT. Health is a priority focus of the Solomon Islands-Australia Partnership for Development and funding under this proposal supports the Health Sector Support Program - Phase 2 which continues Australia's long-term commitment to strengthen health systems and improve outcomes through a Sector Wide Approach (SWAp) which commenced with HSSP Phase 1 in 2008-12. The SWAp and partnership support the Solomon Islands Government in providing quality health services for all people in the Solomon Islands through its own National Health Strategic Plan (2011-2015). The SWAp emphasises the importance of partnership, mutual respect, mutual responsibility and the underlying principles of aid effectiveness. The total value of this initiative is $90.0 million over 4 years, starting 2012-13.\",\n",
       "  '12263. CEPAT-JKM: Partnership to Improve Tuberculosis Care and Access to Services Through Community - Tuberculosis. CEPAT-JKM: PARTNERSHIP TO IMPROVE TUBERCULOSIS CARE AND ACCESS TO SERVICES THROUGH COMMUNITY - TUBERCULOSIS. CEPAT-JKM: Partnership to Improve Tuberculosis Care and Access to Services Through Community. TheCommunity Empowerment of People Against Tuberculosis (CEPAT) project is working at the community level, engaging religious leaders, with support from partner LKNU, the largest Muslim organization worldwide. CEPAT is coordinating the TB community support model with TB activities in the health system. In this way, the project ensures a continuum of care of TB patients from the health system to the community, strengthening TB prevention and control efforts.',\n",
       "  '12182. Ecological and socio-economic factors impacting maintenance and dissemination of antibiotic resistance in the Greater Serengeti Ecosystem. ECOLOGICAL AND SOCIO-ECONOMIC FACTORS IMPACTING MAINTENANCE AND DISSEMINATION OF ANTIBIOTIC RESISTANCE IN THE GREATER SERENGETI ECOSYSTEM. this project models anitbiotic resistance in the Greater Serengeti ecosystem',\n",
       "  \"13020. Sustainable Action For Resilience And Food Security (Sabal). SUSTAINABLE ACTION FOR RESILIENCE AND FOOD SECURITY (SABAL). Through the Sabal project, USAID will help vulnerable individuals, households (HHs), and communities in six districts in the Central Hills and the Eastern Hills of Nepal by:(1) reducing the exposure of HHs and communities to agricultural, public health, or climate-related hazards, and enhancing the ability to cope with shocks, (2) identifying adaptive innovations to help HHs and communities adjust to major trends, such as climate change or the expansion of markets into rural areas, and (3) developing a discrete number of promising innovations that will drive scalable improvement in people's lives. Each of the three CRP purposes operates at each resilience level: absorptive, adaptive, and transformative.\",\n",
       "  '13040. Output 04: HIV. HIV. Ghana - Accra. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '13010. Procurement of Services. PROCUREMENT OF SERVICES. To improve the functionality of primary health care units, reducing health inequalities, and  increasing domestic financing  for health to sustain and accelerate the pace of improvement in adolescent, maternal and child health in Ethiopia. This will be ac',\n",
       "  '12182. Costs towards Appraisal & Design for Global Research Partnerships. COSTS TOWARDS APPRAISAL & DESIGN FOR GLOBAL RESEARCH PARTNERSHIPS. Strengthened and broadened UK-India research partnerships with Low Income Countries (LICs) researchers will deliver evidence informed solutions for global development challenges in India and  LICs in the thematic areas of health,, food and women.',\n",
       "  '13030. Jhpiego Corporation. JHPIEGO CORPORATION. to provide support to the Family Planning Division, MoHFW, GoI, as the GoI takes leadership and management in providing voluntary, high-quality FP services in India with a special focus on the six high TFR states of UP, Bihar, Jharkhand, Rajasthan, Madhya',\n",
       "  '12220. Reducing health risks through Community Based Health. REDUCING HEALTH RISKS THROUGH COMMUNITY BASED HEALTH. Strenghen Red Cross/Crescent health/care programmes to reduce morbidity and mortality. Development of policies, guidelines, tools and training materials, evaluation and monitoring systems, innovation.',\n",
       "  '12281. CDC: Field Epidemiology and Laboratory Training Program (FELTP). CDC: FIELD EPIDEMIOLOGY AND LABORATORY TRAINING PROGRAM (FELTP). CDC: Field Epidemiology and Laboratory Training Program (FELTP)',\n",
       "  '13040. Good Governance Initiative Fund. GOOD GOVERNANCE INITIATIVE FUND. The project will identify and support the creativity and innovation inherent in civil society organizations and communities in Tajikistan in order to achieve institutionalized, permanent and durable reforms on particular good governance topics. The project will support initiatives that originate in civil society in Tajikistan that can lead to long-term impact, manifested in any one of a number of different ways, such as: changes to the legislative or regulatory environment; institutionalization of key reforms; changes in the procedures or internal systems that state bodies use to serve the public; and behavior change.This activity is part of a larger, regional project that is implemented in other countries that are part of the USAID/Central Asia Republics Mission. Please refer to other country-specific Operational Plans for details on activities in those countries.',\n",
       "  '12263. ACBulgariaTuberculosis. AC: BULGARIATUBERCULOSIS. Tuberculosis',\n",
       "  \"12191. Enhancing capacities of medical personnel from a children's haematology ward III. (part 3). ENHANCING CAPACITIES OF MEDICAL PERSONNEL FROM A CHILDREN'S HAEMATOLOGY WARD III. (PART 3). Within the project, the laboratory personnel from the department of children's haematology of the Iashvili hospital in Tbilisi is trained in methods of molacular and genetic diagnostics of leukemias, both in theory and through practical testing.\",\n",
       "  '12240. Securing Ugandan s Right to Essential Medicines (SURE) - Nutrition. SECURING UGANDAN S RIGHT TO ESSENTIAL MEDICINES (SURE) - NUTRITION. Securing Ugandans  Right for Essential Medicines (Uganda SURE) aims to aims to assist the Government of Ugandas commitment to strengthen the national pharmaceutical supply system to ensure that the people of Uganda have access to adequate quantities of good quality essential medicines and health supplies. To achieve this goal, SURE s objectives are to: 1) Improve Uganda s policy, legal, and regulatory framework to produce pharmaceutical supply chain stability and sustainability; 2) Improve capacity and performance of central government entities to carry out their supply chain management responsibilities; 3) Improve capacity and performance of districts, health subdistricts, and implementing partners in their supply chain management roles. SURE works on integrating Uganda s supply chain and establishing a pharmaceutical management information system that provides full transparency to minimize medicine stock-outs and waste.',\n",
       "  '12110. Selected Evaluation Studies for 2015. SELECTED EVALUATION STUDIES FOR 2015. Selected Evaluation Studies for 2015',\n",
       "  \"12220. Health Program (Samoa). HEALTH PROGRAM (SAMOA). The Samoa Health Program (2014-2022) is currently being planned and designed as a follow on investment the sector-wide approach to health development (Health SWAp). The Health SWAp started in 2008 and has been implemented in partnership with Government of Samoa, New Zealand's Ministry of Foreign Affairs and Trade (MFAT) and the World Bank. Funding under this initiative represents Australia's contribution covering technical expertise in: sector assessment of national systems; quality at entry appraisal; civil society conducted health seeking behaviour study; technical assistance for a theory of change workshop for the sector; design technical assistance; and other ad-hoc technical input. The total value of this initiative is $9.2 million over 5 years, starting 2013-14.\",\n",
       "  \"12191. Scaling Up Care for Perinatal Depression for Improved Maternal and Infant Health in Nigeria (IMCHA). SCALING UP CARE FOR PERINATAL DEPRESSION FOR IMPROVED MATERNAL AND INFANT HEALTH IN NIGERIA (IMCHA). Even though effective treatments are available, perinatal depression often goes untreated, especially in low- and middle-income countries where there are shortages of mental health specialist resources.  This project aims to address that challenge by demonstrating how community midwives who are trained to work in resource-constrained settings can deliver effective interventions for depression among new mothers.Community treatments for depression The World Health Organization (WHO) produced the Mental Health Gap Action Programme Intervention Guide to help non-specialists recognize and treat select mental health conditions, including perinatal depression. The project team will test the guide's effectiveness in providing support to mothers with perinatal depression at the community level. Using a participatory research approach, researchers will implement training for community midwives in Osun State, Nigeria. The training aims to enhance their skills so they can identify and support women with perinatal depression. The research will also identify organizational factors that can support the scaling up of mental health services in Nigeria. The project will help generate knowledge on the training methods that can equip midwives with skills to deliver care for perinatal depression. The findings will help strengthen efforts in other low- and middle-income countries to develop relevant strategies and programs to address perinatal depression.Innovating for Maternal and Child Health in AfricaThis project is part of the Innovating for Maternal and Child Health in Africa program, a seven-year $36 million initiative funded by Foreign Affairs, Trade and Development Canada (DFATD), Canada's International Development Research Centre (IDRC), and the Canadian Institutes of Health Research (CIHR).\",\n",
       "  '13040. HIV Innovations For Improved Patient Outcomes For Priority Populations (Adolescent Friendly Services For Prenatally & Behaviorally Hiv Infected Adoles. HIV INNOVATIONS FOR IMPROVED PATIENT OUTCOMES FOR PRIORITY POPULATIONS (ADOLESCENT FRIENDLY SERVICES FOR PRENATALLY & BEHAVIORALLY HIV INFECTED ADOLES. This programme targets adolescents living with HIV (ALHIV) between 10-19 years of age within region F of the City of Johannesburg and the Matlosana sub-district of the North West Province. The goal is to in collaboration with the Departments of Health, Basic Education and other partners to develop, pilot, evaluate and support the scale-up of a replicable model of targeted and linked interventions across clinics, schools and communities (the 3 streams of the PHC re-engineering programme) to improve the screening, diagnosis, treatment, adherence, retention in care, and psychosocial and mental health of ALHIV. The programme is highly aligned with the HIV & AIDS and TB National Strategic Plan 2012-2016, the National Youth Policy 2009-2014, the Draft Adolescent Youth Health Policy and the Integrated Schools Health Policy.',\n",
       "  \"13020. Urban Wash Alliance. URBAN WASH ALLIANCE. Improving the delivery and use of water and sanitation services to India's rapidly growing urban areas is critical to meeting U.S. Government (USG) health objectives for India, particularly in reducing child mortality. As per the Government of India's (GOI) Ministry of Urban Development (MOUD), in notified slums (slums registered by the municipality), 17 percent of the population is without access to improved sanitation, and in unofficial slums, around 50 percent do not have access to improved sanitation facilities. Program efforts to improve water and sanitation services (WSS) have the greatest beneficial impact on the health and hygiene of women and girls. India's growing population of more than one billion puts enormous strains on the ability of the GOI to provide water, sanitation, and health services. U.S. foreign assistance supports the GOI to address WSS needs of the urban poor. USG priorities include safe water access, basic sanitation, WSS policy and governance, and sustainable financing for water and sanitation services. The USG supports integration of water, sanitation and health programs with other sector development programs, such as the GOI's ambitious city and slum development schemes.\",\n",
       "  \"13020. UNICEF PIO. UNICEF PIO. The Health Pooled Fund (HPF) is one of the Government of Ethiopia's preferred modalities for scaling up development partners' assistance in support of HSDP IV. UNICEF has been substantially involved in the implementation of the Health Sector Development Plan (HSDP IV) since the introduction of the Health Pooled Fund (HPF). Through this mechanism, USAID is contributing to the Health Pooled Fund. This activity is an effective and efficient way to achieve USAID objectives through ensuring the accessibility of effective health services at all levels of the health system. This activity supports HSDP IV implementation through monitoring and evaluation; the development of studies/research; development of standards, guidelines, and manuals; and promotion of policy dialogue workshops such as woreda-based planning and the Annual Review Meeting (ARM). The project also supports participation of Ministry staff in relevant seminars and study trips to enhance program excellence.\",\n",
       "  \"13020. Selected Evaluation Studies for 2014. SELECTED EVALUATION STUDIES FOR 2014. This research and development technical assistance (TA) for Selected Evaluation Studies for 2014 supports the 2014-2016 program cycle,  focusing on studies due in 2015 and 2016. It will fund select evaluations and related outreach activities from both the derived operational (i.e., country and sector program evaluations) and knowledge (i.e., thematic,  corporate and impact evaluations, topical working papers) programs of the Independent Evaluation Department (IED). These include, but are not limited to:1. Country assistance program evaluations (CAPEs) and validations of country partnership strategy final reviews. The TA will fund at least two CAPEs (second-generation CAPEs for Papua New Guinea and the Peoples Republic of China), and validations of at least three country partnership strategy (CPS) final reviews (Bangladesh, Lao Peoples Democratic Republic, and Timor Leste). Each CAPE will evaluate ADB support to the country and cover ADB strategy, policy dialogue, completed and ongoing projects and TA, and ADB performance. It will provide ADB and the developing member country (DMC) with an evaluative basis of use for designing the future CPS. When appropriate, country sector assessments will provide inputs during the preparation of a CAPE. Each sector assessment will evaluate ADB performance within a given sector in the country, focusing again on strategy, policy dialogue, ongoing and completed projects and TA, and performance.2. Review of Asian Development Fund (ADF) Operations. The thematic evaluation study (TES) will review the commitments made under the ADF X and XI replenishments and assess the relevance, responsiveness, and results of ADF operations over the said period. It will comprise a desk review of selected project documents, evaluation reports, and pertinent literature. DMC consultations may be undertaken in a range of countries, a perception survey held, along with country portfolio reviews covering all five regions. 3. Environmentally Sustainable Growth. The TES will review the design and implementation of ADB's 2002 Environment Policy and subsequent directional documents. It will assess the responsiveness, results, and relevance of the policy and environmental elements of Strategy 2020 (S2020), to draw out lessons for future operations. The study will initially undertake a desk review of project documents, evaluation reports, and pertinent literature. It will also take stock of prior environmental evaluations to learn from best practice of development partners. Perception surveys, country case studies of important environmental projects, and key informant interviews of regional DMC stakeholders and other development partners undertaking environment-related work will also be conducted to elicit views about ADB's achievements. 4. Effectiveness of ADB's Partnerships. The TES will evaluate the effectiveness of ADB partnerships through a review of such agreements, co-financing partnership arrangements, and related documents. It will ana\",\n",
       "  '12220. JSI Research & Training Institute, Inc.. JSI RESEARCH & TRAINING INSTITUTE, INC.. to contribute towards sustainably improving health practices within communities and the primary level health care system through the application of innovative solutions that are informed by evidence-based best practices',\n",
       "  '13040. Output 04: HIV. HIV. South Africa - Pretoria. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12110. Center for Disease Dynamics, Economics & Policy. CENTER FOR DISEASE DYNAMICS, ECONOMICS & POLICY. to fund a project that will build capacity and develop tools for low- and middle-income countries to use antibiotics appropriately',\n",
       "  '12263. Colorado State University. COLORADO STATE UNIVERSITY. to enable the discovery and development of more effective drug regimens for drug sensitive and drug resistant tuberculosis (TB) disease',\n",
       "  '13030. Strengthening Human Resources for Health (SHRH) - Capacity follow on. STRENGTHENING HUMAN RESOURCES FOR HEALTH (SHRH) - CAPACITY FOLLOW ON. SHRH will be a bilateral associate award under the Capacity Plus Leader with Associate award. Building upon the Uganda Capacity Program and continuing HRH interventions which were shown to produce higher level results, SHRH will further expand in the area of pre-service training capacity and performance based incentives. SHRH will develop the capacities of the central ministries, districts and professional councils to effectively and efficiently manage their HR for delivery of health services. It will work with USG implementing partners to ensure targeted HRH improvements at the service delivery level. Expected results in FY 2014 includes: scale-up of HR information system and recruitment plans in all 112 districts; comprehensive support for district level HRH to all USG implementing partners; and improved regulation and functionality of health professional councils.',\n",
       "  '12110. Trade-Related Training Program - Senior Healthcare Leadership Training Program, through Meridian International Center. TRADE-RELATED TRAINING PROGRAM - SENIOR HEALTHCARE LEADERSHIP TRAINING PROGRAM, THROUGH MERIDIAN INTERNATIONAL CENTER. Trade-Related Training Program - Senior Healthcare Leadership Training Program, through Meridian International Center',\n",
       "  '12110. Health Accountability Project. HEALTH ACCOUNTABILITY PROJECT. Greater accountability in the use of public resources.',\n",
       "  '12220. Maternal and Child Health - Treatment of Child Illness. MATERNAL AND CHILD HEALTH - TREATMENT OF CHILD ILLNESS. Maternal and Child Health - Increase boys and girls access to and utilization of appropriate treatment for diarrhea, pneumonia, and other potentially life-threatening childhood illnesses, including improved recognition of serious illness, community and facility-based treatment of uncomplicated pneumonia, recognition and treatment of severe and complicated pneumonia, Oral Rehydration Therapy, introduction of new formulation ORS, introduction and evaluation of zinc treatment, antibiotic treatment of dysentery, and management of persistent diarrhea. (Malaria detection in children should be budgeted here, but treatment and prevention in the malaria element.)',\n",
       "  '12110. JPO WHO 2016 Manila Antimicrobial Resistance KK. JPO WHO 2016 MANILA ANTIMICROBIAL RESISTANCE KK. The contribution is addressing the Agenda 2030 goal 3: Good Health and Well-being. Thematic area is health with a focus on raising awareness of antimicrobial resistance and supporting strengthening surveillance, prevention and control efforts. The JPO programme (Junior Professional Officers) is an important part of Swedish strategy to increase Swedish participation in international organizations. The program offers young professionals (under 33 years of age) who hold a Master degree the opportunity to serve in the UN and other international organizations.',\n",
       "  \"13040. Expanding HIV/AIDS Prevention in Bangladesh. EXPANDING HIV/AIDS PREVENTION IN BANGLADESH. The most important achievement of the grant has been its contribution to the low-prevalence of HIV in Bangladesh. Many countries experienced explosive increase of HIV from the epidemic of Injecting Drug Users (IDU). To a large degree, due to the activities supported by the grant this did not occur in Bangladesh. IDUs and Female Sex Workers (FSWs) are the focus of the grant. At the end of Phase 1 of the RCC Grant (December 2011), the performance of the grant against its targets was considered satisfactory. The average performance on the Top 10 indicators was 96% (A2). All indicators rating was at 98% (A2). Out of 14 Service Delivery Area indicators, 6 were overachieved, 5 were between 90-100%; two indicators were slightly below 90% and one - 'Number of IDU and FSW reached through Peer Education' - was at 68% and rapidly catching up from the previous level of 50%. The underachievement was partially due to the discontinuation of a Sub-Recipient (SR) agreement in September 2011 with an entity that was ensuring the coverage of up to one-third of IDU targets. The discontinuation of this SR agreement followed an investigation by the Global Fund's Office of the Inspector General which found disturbing signs of fraudulent practices by the SR. The PR acted decisively in order to safeguard the Global Fund money and took over the direct implementation of IDU-related activities. As a result, the PR managed to maintain the expected return of the grant by avoiding the prolonged discontinuation of preventive activities for IDUs, while at the same time reducing further risk.Overall, it is expected that a good level of performance will be maintained throughout the time remaining until the end of Phase 1 (in November 30, 2012) and, pending the Phase 2 approval, beyond Phase 1.'---1. Background and Summary:  With estimated HIV prevalence of less than 0.1% (2009 UNAIDS Country Brief), Bangladesh is a low HIV prevalence country. UNAIDS estimates about 12,000 people in Bangladesh to be living with HIV at the end of 2007. As of December 2008, a total of 1495 cases of HIV infection were confirmed, with 476 of them developing AIDS and 165 reported death cases (National HIV/AIDS Strategic Plan). The Sero Surveillance Report findings show that HIV infection rate is increasing among most-at-risk-population (MARP), particularly among injecting drug users (IDUs) with concentrated epidemic in Dhaka (7%), and among female sex workers (FSW) due to low level of condom use.Despite the low HIV prevalence in Bangladesh, several risk factors, including geographical location, high population mobility, a large number of migrant workers, poverty, and low level of awareness among young people threaten to hamper the continuing status of Bangladesh as a low HIV prevalence country. The HIV Joint Monitoring Mission organized by the World Bank and its key partners in February 2009 found that prompt and vigorous action is needed to strengthen the quality and coverage of HIV prevention programs,\",\n",
       "  '12240. Chronic Disease Prevention and Education for Health and Nutrition Care. CHRONIC DISEASE PREVENTION AND EDUCATION FOR HEALTH AND NUTRITION CARE. 1. Trial operation of nutrition education center in public health center and Expantion education for participants',\n",
       "  '13040. Strengthening Monitoring, Evaluation and Research Capacity of the Community Health and Social Service Programs in the United Republic of Tanzania - HI. STRENGTHENING MONITORING, EVALUATION AND RESEARCH CAPACITY OF THE COMMUNITY HEALTH AND SOCIAL SERVICE PROGRAMS IN THE UNITED REPUBLIC OF TANZANIA - HI. The project is designed to improve the use of information in decision making within the national health and social services systems. Over the life of the project, results will include better service, systems, and vital health-related outcomes. Activities funded through this OP are solely malaria funded, and will focus on malaria specific data demand and use approaches to build host country counterpart capacity. Capacity will be built in multiple areas, including data analysis and communication to inform different audiences, to help policy makers and program managers use data in decision making, and to improve structured supervision in monitoring and evaluation activities. The data tools are also used to identify barriers to data use, deficiencies in data quality, and to suggest opportunities for improved data use among stakeholders. The activity aims at addressing the cross-cutting intermediate result (CCIR) of the Country Development Cooperation Strategy (CDCS) in fostering using data for evidence decision making and planning.',\n",
       "  '13040. World Health Organization. WORLD HEALTH ORGANIZATION. to strengthen individual level patient monitoring and case surveillance by scaling up effective approaches to unique patient identification to better measure and manage treatment outcomes.',\n",
       "  '16064. Output 04: HIV. HIV. Niger - Niamey. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  \"12191. Enhancing capacities of medical personnel from a children's haematology ward III. (part 2). ENHANCING CAPACITIES OF MEDICAL PERSONNEL FROM A CHILDREN'S HAEMATOLOGY WARD III. (PART 2). Within the project, the laboratory personnel from the department of children's haematology of the Iashvili hospital in Tbilisi is trained in methods of molacular and genetic diagnostics of leukemias, both in theory and through practical testing.\",\n",
       "  '13020. Strengthening Implementation of Program Budgeting. STRENGTHENING IMPLEMENTATION OF PROGRAM BUDGETING. Provide technical assistance to assist with strengthening public financial management (PFM) policies that will promote fiscal transparency. The objectives of the program support the following areas: (1) improved allocation of budget resources to programs of pilot ministries, including the Ministry of Health, (2) implementation of program budgeting in the remaining 30 national government line ministries, and (3) expansion of program budgeting to sub-national government institutions.',\n",
       "  '12240. Asian Vegetable Research & Development Center (AVRDC). ASIAN VEGETABLE RESEARCH & DEVELOPMENT CENTER (AVRDC). the mission of alleviating poverty and malnutrition through the increased production and consumption of nutritious, health-promoting vegetables.',\n",
       "  '12220. Observer Research Foundation. OBSERVER RESEARCH FOUNDATION. to maximize progress toward targets of health, hunger and nutrition by providing a body of knowledge and dialogues with stakeholders, aimed at developing an implementation framework for the Sustainable Development Goals',\n",
       "  \"13010. Tanzania Results-Based Financing (RBF) Trust Fund. TANZANIA RESULTS-BASED FINANCING (RBF) TRUST FUND. The Tanzania Results-Based Financing Trust Fund will support the roll-out of the Government of Tanzania's Results-Based Financing program to improve accessibility, utilization and quality of health services through increased accountability and responsiveness. With an aim of providing equitable access to cost effective quality health care, the Tanzania Results-Based Financing Trust Fund will improve the accessibility and utilization of health care services in primary health care facilities, the quality of health services at all facilities within the local government authority, the productivity and efficiency of service delivery by health care providers, the quality and use of data for evidence-based decision making, and accountability and responsiveness of health management teams and facility governing committees. The geographic coverage for the coming year includes Shinyanga and Mwanza regions.\",\n",
       "  '13040. Social Science Programme / The BREATHER Qualitative sub study. SOCIAL SCIENCE PROGRAMME / THE BREATHER QUALITATIVE SUB STUDY. Social Science Programme / The BREATHER Qualitative sub study',\n",
       "  '13030. The Product Development Agreement - Family Planning and Reproductive Health. THE PRODUCT DEVELOPMENT AGREEMENT - FAMILY PLANNING AND REPRODUCTIVE HEALTH. The Product Development Agreement',\n",
       "  '13010. Health Communication Capacity Collaborative (HC3). HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3). HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       "  '12110. Desk Study - Quality Management Intelligence Dashboard for Chinese Hospitals, through OMMA Healthcare, LLC. DESK STUDY - QUALITY MANAGEMENT INTELLIGENCE DASHBOARD FOR CHINESE HOSPITALS, THROUGH OMMA HEALTHCARE, LLC. Desk Study - Quality Management Intelligence Dashboard for Chinese Hospitals, through OMMA Healthcare, LLC',\n",
       "  '12230. The Project for Construction of Community Health Clinic in Khamrang Village, Kolasib District, Mizoram. THE PROJECT FOR CONSTRUCTION OF COMMUNITY HEALTH CLINIC IN KHAMRANG VILLAGE, KOLASIB DISTRICT, MIZORAM. Construction of a community health center in a rural village in Mizoram',\n",
       "  '12250. Foundation for Innovative New Diagnostics FIND. FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND. The Foundation for Innovative New Diagnostics (FIND), working through a public-private partnership model, drives the development and early implementation of new diagnostic tests for poverty-related diseases. From a global public health perspective, accurate and affordable diagnosis is critical. It helps ensure better care to patients, enables equitable, timely and correct medical treatment in low-resource settings, and thus reduces wastage of medicines and antimicrobial resistance. It is essential also for emergency preparedness.',\n",
       "  '13030. DHA-Empower Women on SRHR. DHA-EMPOWER WOMEN ON SRHR. Nirapod-2: Empowering women on SRHR and choice of Sage Menstrual Regulation (MR) and Family Planning (FP)',\n",
       "  '12110. AGResults Contracts (via competition) component - Change to AgResults: Evaluation Contract One  - Reseach. AGRESULTS CONTRACTS (VIA COMPETITION) COMPONENT - CHANGE TO AGRESULTS: EVALUATION CONTRACT ONE  - RESEACH. The overall objective of the AgResults Initiative is to enhance smallholder welfare and food security for the poor and vulnerable in developing countries through increased investment in agricultural innovation and adoption.  It aims to do so by developing',\n",
       "  '12181. Switching the poles;  Integrated control of mycobacteria endemic in West Africa: renforcement du Laboratoire de RTfTrence des MycobactTries (LRM). SWITCHING THE POLES;  INTEGRATED CONTROL OF MYCOBACTERIA ENDEMIC IN WEST AFRICA: RENFORCEMENT DU LABORATOIRE DE R+F+RENCE DES MYCOBACT+RIES (LRM). Background:  Brief overview of the FA collaboration during the past5 -year period (FA3). During the past 5 -year period, the FA institutional collaboration between ITM and LRM has improved LRM capacity in several domains:  -  -LRM has recently been designated as a supranational reference laboratory candidate for TB by the WHO and serves as a center of excellence for other countries in the West/ Central African Region  - LRM has established a well -functioning lab network for BU diagnosis with a specific manual available, conducts regular supervisions of peripheral labs, and completes external quality controls showing excellent results. This can serve as an example for other countries in the region  - Several PhDs have been defended by students from LRM and an increasing number of research articles are authored by LRM staff  Previous institutional collaborations between LRM and ITM were under FA1 (1998 -2002), FA2 (2003 -2007), FA3 -I (2008 -2010) and FA3 -II (2010 to 2013). Below are reports for the past 5 -year period: Progress 2012 A well -functioning lab network for BU diagnosis is now in place in Benin with a specific manual available, regular supervisions of peripheral labs and external quality controls showing excellent results.  LRM has also set up qPCR for BU diagnosis and a second study has been performed to compare it with classical PCR, which showed an increase in positivity rate of 33%. This technique has now been adopted at LRM and is routinely used on samples received from BU centres. However, new changes on the probe used for this technology suggest further improvements of the performance of this test are possible. Though it was not possible to establish formal links between LRM and labs from other countries, some lab technicians have been received from these countries for training. In addition, samples from BU suspected cases from neighbouring countries are received at LRM, and analysed with the different tests available. Finally, the differential diagnosis study is ongoing with more than 100 patients recruited to date.  Progress 2011 Activities to maintain a well -established laboratory for BU diagnosis in West -Africa as well as a good national microscopy network have been maintained and strengthened: National guidelines for the BU microscopy network have been validated and printed. The equipment for real time PCR has been provided to LRM by ITM, LRM staff has been trained on this technique which has been set up and is now routinely used in this laboratory. Samples from field centers (patients from Benin as well as from neighbouring countries) have been tested for BU diagnosis and peripheral laboratories were regularly supervised and controlled. In terms of research activities in 2011, two researchers from DRC have been received at LRM for joint training on immunological tests on BU. Studies to improve DNA extraction have been published (Affolabi et al., 2012). Other currently ongoing research focuses on drug susceptibility test',\n",
       "  '12220. Program for Improved Accessibility and Quality of Health Services and Networks. PROGRAM FOR IMPROVED ACCESSIBILITY AND QUALITY OF HEALTH SERVICES AND NETWORKS. The objective of the program is to support the Ministry of Health (SESAL) in improving the coverage and quality of health services through the decentralized management modality, giving priority to the populations of the country+s poorest municipios and strengthening implementation of the family- and community-based comprehensive health care model. The expected outcomes are: (i) improved access to, and quality of, the guaranteed package of services for the project+s beneficiary population; (ii) strengthened maternal and child health networks in the beneficiary municipios and departments; and (iii) improved institutional capacity of SESAL to set policy, provide leadership, and manage the health services provided through management bodies under the decentralized management modality.',\n",
       "  '13020. Stockholm Environment Institute. STOCKHOLM ENVIRONMENT INSTITUTE. to support a project designed to provide financial incentive for the women who honor all their clinic appointments while pregnant, deliver under skilled attendants and take their children for all health appointments in their first year of life',\n",
       "  '12220. Fianancial Audit of two grant contrcats: AMREF  project ref: DCI NSAPVD2008 / 170 550 Putting Communities First: Better health for Pastora. FIANANCIAL AUDIT OF TWO GRANT CONTRCATS: AMREF  PROJECT REF: DCI NSAPVD2008 / 170 550 PUTTING COMMUNITIES FIRST: BETTER HEALTH FOR PASTORA. Fianancial Audit of two grant contrcats: AMREF  project ref: DCI-NSAPVD2008 / 170-550 Putting Communities First: Better health for Pastoralist in Afar and ONG-PVD/2007/134-889 Strengthening Pastoralist Health Care Systems in South Omo, Ethiopia',\n",
       "  '16064. Output 04: HIV. HIV. Maldives - Male. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  \"13030. Health Information Policy and Advocacy Project. HEALTH INFORMATION POLICY AND ADVOCACY PROJECT. The Health Information, Policy, and Advocacy (HIPA) project will improve the quality and use of population and health data reported in the Cambodian government's health management information system and vital statistics registration database. HIPA will support the entry of tuberculosis program data into the health information system; development of analytic and user-friendly tools for use by non-health authorities to better allocate resources for community health priorities; and refinement of the host government's data quality audit tools and systems to improve the quality of reported data from both public and private health-care providers. Reliable data is essential for Cambodian government officials and other stakeholders to make informed decisions about policies and resource allocations leading to improved accountability of health-care service delivery.\",\n",
       "  '12181. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016: Mycobacteriologie network. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016: MYCOBACTERIOLOGIE NETWORK. General objective:  Scientific support and networking on Mycobacteriology  The overall objective of the programme is to strengthen the rational basis and the country ownership of health care systems and policies in developing countries, in order to improve the health status of the populations and thereby contribute to the reduction of poverty and inequity.  The specific programme purpose is to build, reinforce and support appropriate and sustain -able capacity in developing countries to conduct research, training and delivery of reference services in order to meet the overall objective.  The target groups of the programme are, in order of impact and level: (1) The leaders, scientists and experts in the partner institutions in developing countries;  (2) The health professionals and policy makers that can implement the improved practices and policies resulting from the programme; (3) The communities and individuals that should benefit from the improved practices and policies.    - Specific objective:  To bring together the expertise on tuberculosis (TBa in research institutions, paritularly  in West  - and Central Africa, with links to ITM, in order to allow scientists at these institutions to jointly develop set and implement priorities for research and capacity building. - Results:  A regional TB Network is active, led through work packages.  Technical and scientific capacity is strengthened. Protocols and trainees are exchanged between network partners and collaborative proposals are submitted. -',\n",
       "  '12110. HPSS  Health Promotion and System Strengthening Project in Dodoma, Morogoro and Shinyanga Regions. HPSS  HEALTH PROMOTION AND SYSTEM STRENGTHENING PROJECT IN DODOMA, MOROGORO AND SHINYANGA REGIONS. The Health Promotion and System Strengthening project (HPSS) is improving access to and the quality of health services both in terms of the demand (health promotion, health insurance) and the supply side (drug procurement; health technology maintenance). After a successful pilot phase in the Dodoma region, the Tanzanian government is requesting the SDC to expand this approach to two other regions with a focus on those most at risk (the poor, women, children, youth and the elderly).',\n",
       "  '13010. MEASURE Evaluation Phase III - Program Design and Learning. MEASURE EVALUATION PHASE III - PROGRAM DESIGN AND LEARNING. MEASURE Evaluation Phase III continues the MEASURE program s 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3).increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       "  '12182. The Evaluation of a Standardised Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB. THE EVALUATION OF A STANDARDISED TREATMENT REGIMEN OF ANTI-TUBERCULOSIS DRUGS FOR PATIENTS WITH MDR-TB. Medical Research Council. Clinical trial testing optimal therapy for  Patients with MDR-TB in  Ethiopia, India, Viet Nam, South Africa',\n",
       "  '13040. Output 04: HIV. HIV. Lebanon - Beirut. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12281. Strengthening the health system in Sudan: equo access to services and specialized training of health personnel. STRENGTHENING THE HEALTH SYSTEM IN SUDAN: EQUO ACCESS TO SERVICES AND SPECIALIZED TRAINING OF HEALTH PERSONNEL. The project aims to ensure access to pediatric cardiology, cardiac surgery services and free high quality in Sudan and to increase the provision of training for health professions particularly in cardiology, cardiac surgery, anesthesia and pediatrics',\n",
       "  '13020. Youth Leadership for Agriculture. YOUTH LEADERSHIP FOR AGRICULTURE. The aim of the Youth Leadership for Agriculture Activity is to build economic opportunities for youth ages 10 to 35 in agriculture-related fields in order to increase incomes and build entrepreneurial, leadership, and workforce readiness skills. With almost 50% of its population under age 14 and one of the highest population growth rates in the world, Uganda is in the midst of a quickly worsening youth crisis. This activity will address critical gaps in the human, social, financial, and physical capital of youth to increase the access of youth to viable livelihoods on a large scale.',\n",
       "  '12181. Developing Hanoi University of Pharmacy to become a National Specialized University. DEVELOPING HANOI UNIVERSITY OF PHARMACY TO BECOME A NATIONAL SPECIALIZED UNIVERSITY. Developing Hanoi University of Pharmacy to become a national specialized university meeting regional standards by 2020',\n",
       "  '12281. Exchanges with Other Countries in the Field of Vocational Education and Training and Scholarships. EXCHANGES WITH OTHER COUNTRIES IN THE FIELD OF VOCATIONAL EDUCATION AND TRAINING AND SCHOLARSHIPS. Collaborative project - Development and trialling of initial and continuing training modules in the care sector in Tunisia, Sub-project - Project management and coordination, development of the quality management system',\n",
       "  \"12240. Nutrition and food security in rural China: An assessment of school feeding system. NUTRITION AND FOOD SECURITY IN RURAL CHINA: AN ASSESSMENT OF SCHOOL FEEDING SYSTEM. The school feeding system in China provides 180 to 200 days of meals a year to rural children from economically disadvantaged provinces that have a high incidence of malnutrition. The program covers 14 provinces, 100 counties, and over three million children. In order to make policy adjustments and expand the benefits to other low-income areas of the country, it is essential to measure the impact of the system. The purpose of this study is to assess China's school feeding system under its National Nutrition Improvement Plan to better understand the system's impact on rural students, local food security, and sustainable economic growth. Researchers will assess the quality of the meals and nutrient intake by children aged seven to 15 in relation to their health and nutritional status, school attendance, and educational outcomes. Economic impact on local communities will be monitored to understand if and how the system affects local food production, procurement, and employment, particularly for women. To improve the potential impacts of the system on nutritional outcomes, additional interventions (including nutrition education and capacity development for women and men) will be introduced in a selected number of schools over a period of two years, and their impact will be evaluated.     The project will be led by the China Development Research Foundation (CDRF) in collaboration with several strategic participating institutions, including the Chinese Center for Disease Control and Prevention, the World Food Program, the Ministry of Education, the Ministry of Agriculture, Microsoft, Amway Charity Foundation, and the Capital Healthcare and Nutrition Cuisine Society. Although the research focuses on China, results and outcomes have the potential to be used widely in other countries in Asia where school feeding programs are an entry point to target food security, nutrition, and school performance among school-aged children.\",\n",
       "  '13040. Output 04: HIV. HIV. Philippines - Manila. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  \"12110. Reverse Trade Mission - Senior Healthcare Leadership Training Program, through Meridian International Center. REVERSE TRADE MISSION - SENIOR HEALTHCARE LEADERSHIP TRAINING PROGRAM, THROUGH MERIDIAN INTERNATIONAL CENTER. This funding partially supported a training program for Chinese senior healthcare leaders to strengthen the capacity of senior health executives in China and to introduce best practices in healthcare management and information technology (IT) solutions. The program was supported by members of USTDA's U.S.-China Healthcare Cooperation Program, which were responsible for developing the curriculum and itinerary, and China's Health Human Resources Development Center (HHRDC), which provided funding to cover the full cost of tuition as well as the cost of international airfare for some delegates. The training program was undertaken in conjunction with HHRDC, Johns Hopkins University, and University of Kansas Medical Center.\",\n",
       "  '13030. Health Communication Capacity Collaborative (HC3) - Family Planning and Reproductive Health. HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3) - FAMILY PLANNING AND REPRODUCTIVE HEALTH. HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       "  \"12191. Soins de santT spTcialisTs en palestine - phase III. SOINS DE SANT+ SP+CIALIS+S EN PALESTINE - PHASE III. General objective:  'To improve the global care in the Palestinian Autonomous Territories by reducing mortality and morbidity due to cardiac and congenital ailments in children and adults' - Specific objective:  To upgrade the diagnostic and therapeutic cardiac care facilities in three tertiary care hospitals (one in the Gaza strip, one in Jerusalem and one in the West Bank)  To upgrade the treatment capacity in one tertiary health centre in Gaza City - Results:  1. Establish a new Cardiac Intensive Care and Surgery Department in Khann Yunnis at the European Gaza Hospital and start interventional procedures in the Cath -lab in order to create a fully functional Cardiac Centre. 2. Extend therapeutic capacity at the Paediatric Intensive Care Unit in Jerusalem at Makassed hospital  3. Establish a new Cardiac Surgery department in Ramallah at the MoH hospital in order to complete the Cardiac Centre by including the existing Cathlab and Cardiology Department. 4. Reinforce therapeutic procedures at the Neonatology Department in Gaza city at Shifa hospital. -\",\n",
       "  '12110. Community laboratories:health,food sovereignty and  female entrepreneurship in rural Senegal. COMMUNITY LABORATORIES:HEALTH,FOOD SOVEREIGNTY AND  FEMALE ENTREPRENEURSHIP IN RURAL SENEGAL. Aims:1) training of trainers newly elected councilors; 2) support for women entrepreneurs; 3) reproductive health  maternal and child; 4) prevention of sexual diseases; 5) education of women: 6) awareness  Kuminda EXPO 2015',\n",
       "  \"12263. MEASURE Evaluation Phase III. MEASURE EVALUATION PHASE III. MEASURE Evaluation Phase III continues the MEASURE program's 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3)increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureau's primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.\",\n",
       "  '13040. CapacityPlus. CAPACITYPLUS. This project strengthens the human resources (HR) needed to implement quality health programs, in both the public and private, particularly the not-for-profit private, sectors. It addresses both the number of healthcare workers needed and the quality and performance of those workers. The definition of healthcare worker is expanded to include HR managers, laboratory staff, pharmacists, social workers, information systems/monitoring and evaluation specialists and others essential to the effective functioning of the health system.',\n",
       "  '16064. Output 04: HIV. HIV. Ghana - Accra. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '13040. Guyana HIV/AIDS Reduction and Prevention II (GHARP II) - HIV/AIDS. GUYANA HIV/AIDS REDUCTION AND PREVENTION II (GHARP II) - HIV/AIDS. The Guyana HIV/AIDS Reduction and Prevention (GHARP II) project provides technical support to USAID s HIV/AIDS prevention, care, and treatment program in Guyana. The project, a three and a half year task order under the AIDSTAR indefinite quantity contract (IQC) mechanism, includes partners from Management Sciences for Health (MSH), Howard Delafield International (HDI), and the AIDS Healthcare Foundation (AHF). GHARP II maintains and strengthens the achievements of the GHARP I program while focusing efforts to benefit Guyanese citizens that are at the greatest risk of acquiring HIV and least able to access HIV prevention, care, and treatment services.',\n",
       "  \"12240. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       "  \"12182. Implementation and evaluation of a smartphone teleconsultation system for acute burn injury care in resource-poor settings. IMPLEMENTATION AND EVALUATION OF A SMARTPHONE TELECONSULTATION SYSTEM FOR ACUTE BURN INJURY CARE IN RESOURCE-POOR SETTINGS. Burn injuries are a leading cause of premature death worldwide and are largely attributable to poor living conditions. Timely care is a prerequisite to reduce morbidity and mortality and it can be significantly improved in resource-poor settings by teleconsultation systems to support the provision of appropriate and timely care.A teleconsultation system for acute burn care is currently under implementation in the Western Cape, South Africa. An application (app) is installed on a smartphone located in each of the emergency services of 8 hospitals to transmit visual and textual information between emergency staff at point of care and a network of burn teleexperts. The burns specialist on call is informed via instant messaging that a case has been uploaded and can then review the visually transmitted information and images and provide diagnostic and treatment advice. The primary aim of the project is to assess how a teleconsultation system for acute burn injury care based on a smartphone application can impact on the delivery of emergency care for burns victims, both in terms of clinical management and site of care. Intermediate aims are to assess the clinical quality, clinical outcomes, user perspective, and costs and benefits of the teleconsultation system. The clinical quality will include assessments of diagnostic accuracy and patient management. Bedside diagnosis or image based diagnosis by burns experts will be used as gold standard. A historical cohort design will be used to assess the effect of the teleconsultation system on patient outcomes. The Health Information Technology Usability Evaluation Model will be used to assess how the users experience the system and the system's cost-utility will be assessed in terms of cost per quality-adjusted life-year gained. A stepwise implementation of the system is planned in Tanzania and Ethiopia starting the beginning of 2016. The burn specialists already involved in South Africa will act as experts for the two additional countries and the existing south-south network of emergency specialists will safeguard the communication and implementation of the system. This proposal will build on the evaluation already started in South Africa and will allow a more robust and comprehensive evaluation of the whole system. Furthermore, the inclusion of other settings will add important contextual aspects to the evaluation. The first part of the evaluation will include the hospitals currently using the teleconsultation system in the Western Cape, South Africa and 2-3 hospitals where the system will be introduced in Tanzania. Later on, 2-3 hospitals in Ethiopia will be introduced to the system, informed by the process in Tanzania, and those hospitals will be included in the evaluation.Low cost and timely alternatives to burn injury control are a pressing need in many low- and middle-income settings and countries. This project is a determinant step in that direction and can lead to the implementation of a viable, incl\",\n",
       "  '12230. Renovation of the health centre and fire station buildings in the village of Vidovice in Bosnia and Herzegovina which were damaged by flooding. RENOVATION OF THE HEALTH CENTRE AND FIRE STATION BUILDINGS IN THE VILLAGE OF VIDOVICE IN BOSNIA AND HERZEGOVINA WHICH WERE DAMAGED BY FLOODING. During the 2014 floods in Bosnia and Herzegovina, many public buildings were destroyed or damaged. The State, NGOs and other entities joined in the renovation efforts. In July 2014, top priority was given to the renovation of schools so that instruction could start normally in November 2014. Major health centres were also high on the list of priorities. Some other public buildings in smaller villages were not included on this list, and due to insufficient funds many buildings have not yet been renovated. Consequently, work in these institutions is obstructed and residents are deprived of the services provided. The project was designed on the basis of identified local needs regarding public buildings in Bosnia and Herzegovina. The project foresees the renovation of the health centre and fire station in Vidovice damaged during the floods (both buildings were flooded for almost three weeks); the village of Vidovice is located in the Municipality of Oraje on the Sava River. Project goals: improve the conditions for providing basic health care to Vidovice residents and improve the conditions for ensuring fire protection and safety in the case of natural disasters in the area. Project results: renovation of the health centre premises in Vidovice and of the interior and exterior of the fire station in Vidovice.',\n",
       "  '12240. MPI- Solutions for African Food Enterprises (SAFE). MPI- SOLUTIONS FOR AFRICAN FOOD ENTERPRISES (SAFE). Partners in Food Solutions (PFS), TechnoServe and USAID began implementation in 2013 of a Global Development Alliance (GDA) partnership to catalyze transformation of the local food processing sector in Africa. SAFE aims to increase the competitiveness of the African food processing sector and to expand availability of affordable and nutritious foods. PFS is a non-profit organization formed by General Mills to harness the global technical expertise of General Mills, Cargill, Royal DSM (DSM), and Band transfer technology and knowledge to African processors through its skilled volunteer employees and use of world-class facilities. SAFE began technical assistance in 2013 with the timely onboarding of food processors in Kenya, Malawi, and Zambia. This activity will increase demand for the crops of smallholder farmers who supply those businesses.',\n",
       "  '12220. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Competence building and training of Health personnel and supportive services in the field of Reconstructive surgery with special emphasis on facial malformations and deformities.',\n",
       "  '12191. Support to the Pediatric Orthopaedic Surgery and Rehabilitation Center St Marie de Rilima. SUPPORT TO THE PEDIATRIC ORTHOPAEDIC SURGERY AND REHABILITATION CENTER ST MARIE DE RILIMA. Management suppot to the Centre; Training local personnel; Networking and advocacy.',\n",
       "  \"12220. Global Health Professional and Organizational Development (GHPOD) II program. GLOBAL HEALTH PROFESSIONAL AND ORGANIZATIONAL DEVELOPMENT (GHPOD) II PROGRAM. Under a five-year contract with USAID, EnCompass manages the Global Health Professional and Organizational Development (GHPOD) II program. GHPOD's role is to provide professional and organizational development support to USAID's health sector staff around the world to build their capacity to lead and manage health programs. Through the GHPOD mechanism, EnCompass provides a variety of training and learning programs to build capacity in technical areas, program management, leadership, personal and team effectiveness, retreats and strategic meetings, and staff performance management. Each year GHPOD II designs and delivers as many as 45 professional development programs and 50 OD interventions, and provides coaching to about 60 USAID global health professionals.\",\n",
       "  \"12110. Visit to Health by Lieutenant General (Retired) Hotmangaradja Pandjaitan, Republic of Indonesia. VISIT TO HEALTH BY LIEUTENANT GENERAL (RETIRED) HOTMANGARADJA PANDJAITAN, REPUBLIC OF INDONESIA. Visit focused on the Australian health emergency management and associated global health issues and was part of General Hotman's Indonesian National Security Fellowship for 2013\",\n",
       "  '12263. Critical Path Institute. CRITICAL PATH INSTITUTE. to accelerate the development of a safer, faster-acting and more efficacious drug regimen(s) for the treatment of tuberculosis (TB) by curating data to inform the development of new tests which rapidly detect drug-specific resistance and susceptibility',\n",
       "  '12240. Food Safety and diversification of sustainable income sources of women and their families. FOOD SAFETY AND DIVERSIFICATION OF SUSTAINABLE INCOME SOURCES OF WOMEN AND THEIR FAMILIES. Food Safety and diversification of sustainable income sources of women and their families',\n",
       "  '12110. Capacity-Building to Support Innovative Management of Health Public Investment. CAPACITY-BUILDING TO SUPPORT INNOVATIVE MANAGEMENT OF HEALTH PUBLIC INVESTMENT. This Technical Cooperation (TC) aims at supporting capacity building related to the management of public investment in health. The areas of the Ministry that would be strengthened are: infrastructure, planning, regulation, legal counsel, financial and adm',\n",
       "  '13040. Observational 13042Studies Programme in Rural Uganda / General Population Cohort. OBSERVATIONAL 13042STUDIES PROGRAMME IN RURAL UGANDA / GENERAL POPULATION COHORT. Observational 13042Studies Programme in Rural Uganda / General Population Cohort',\n",
       "  '12220. Health Sector Review and support to Strategic Planning of the Ministry of Public Health in Afghanistan. HEALTH SECTOR REVIEW AND SUPPORT TO STRATEGIC PLANNING OF THE MINISTRY OF PUBLIC HEALTH IN AFGHANISTAN. Assess the progress of the Health Sector in Afghanistan towards the ten strategic directions of the Strategic Plan 2011- 15, allow key stakeholders to take stock of the health sector progress and help to foster agreement on the way forward.',\n",
       "  '13040. Output 04: HIV. HIV. Iran - Teheran. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12110. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 QUAMED. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 QUAMED. General objective:  QUAMED network: Quality medicines for all. - Specific objective:  To improve in a sustainable way the performance of 6 public sub -Saharan African procurement centres (PC) through a technical support aimed at meeting  international quality standards and a sensitization strategy aimed at their pharmaceutical market, in collaboration with the national regulatory authorities. - Results:  The result 1 aims at continuing the QA support provided to the Southern public PC under the framework agreement FA3 -II but will increase its focus on the implementation of QA policies (training sessions and development of procedures) within these partners so that they develop their capabilities with the objective of complying with the QA requirements of international mechanisms and organisations.  The result 2 is a pilot action -research which consists of developing and testing innovative strategies to make the supported PC sustainable and provide them with means to remain competitive despite their investment in quality. Strategies as certifications, quality marks, labels etc.. will be explored and tested with the following main steps:  (a) Identification of the country and setting of study. (b) Identification of the partner(s) for implementation of the intervention(s) and the data collection. (c) Co -development of the intervention with the procurement center, the Ministry of Health and of the action research protocol. (d) Approval by the institutional review board of the ITM and the national ethical review committee. (e) Implementation of the intervention. (f) Data collection/ monitoring and evaluation. (g) Data analysis. (h) Adjustment of Intervention if required (i) Lessons learned and dissemination at national level and within the QUAMED network (j). International dissemination The design of QUAMED as a long term network rooted in the South will also be explored as a support to this strategy. This will be developed with the regulatory authorities so that the possible gaps and discrepancies between the approaches of the 2 pillars of the pharmaceutical countries mechanisms are reduced.   The result 3 consists of coordinating, managing and further developing QUAMED network. The partners of QUAMED have numerous requests and needs for technical support for the management of their respective quality assurance systems. In addition, the issue of poor quality medicines in low income countries and QUAMED response also needs to be further promoted in donor, stakeholders and scientific fora and meetings.  -',\n",
       "  '12110. Community laboratories:health,food sovereignty and female entrepreneurship in rural Senegal. COMMUNITY LABORATORIES:HEALTH,FOOD SOVEREIGNTY AND FEMALE ENTREPRENEURSHIP IN RURAL SENEGAL. Aims:1) training of trainers newly elected councilors; 2) support for women entrepreneurs; 3) reproductive health maternal and child; 4) prevention of sexual diseases; 5) education of women: 6) awareness Kuminda EXPO 2015',\n",
       "  '12191. Lira Rehabilitation Centre (LRC). LIRA REHABILITATION CENTRE (LRC). The project targets underprivileged children and youth in Lira, Northern Uganda, especially children with disabilities (CWD) in order to enable them to participate as equal members of society. The project aims to achieve holistic rehabilitation by offering CWDs intensive services at Lira Rehabilitation Centre, and following up the children and their families in their local communities. Activities include physiotherapy, corrective surgery, education, psychosocial and livelihood support.',\n",
       "  '12230. Medical equipment donation to the central laboratory of Suriname. MEDICAL EQUIPMENT DONATION TO THE CENTRAL LABORATORY OF SURINAME. Wire transfer of funds becuase the non-availability of the medical equipment and apparatus in Venezuela due to the present economic situation',\n",
       "  '12281. Midwife Training and Central TB Reference Laboratory Strengthening. MIDWIFE TRAINING AND CENTRAL TB REFERENCE LABORATORY STRENGTHENING. Assisting National Health Development Goal of South Sudan. Supporting  MCH service delivery system by Midwife Training, Strengthening dignosis capability of central TB reference laboratory, and operation consulting on St. John Lee Hospital in pre-opening stage',\n",
       "  \"13020. Sexual & Reproductive Health Rights. SEXUAL & REPRODUCTIVE HEALTH RIGHTS. The project will focus on encouraging the use of conventional methods of child birth as opposed to use of non conventional methods.  The project will also address women's reproductive rights such as choice of birth control methods . Activities will include informal education/training of young women and men in reproductive rights and gender relations.\",\n",
       "  '16064. Output 04: HIV. HIV. Sudan - Khartoum. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '13081. The basic design study(BDS) for national IEC(Information, Educaiton, Com. THE BASIC DESIGN STUDY(BDS) FOR NATIONAL IEC(INFORMATION, EDUCAITON, COM. Strategic planning, recognition improvement campaign, support vehicle and contraceptic items, dispatch specialist, ME, invitaitonal training, project management',\n",
       "  '12281. Accountability Can Transform Health. ACCOUNTABILITY CAN TRANSFORM HEALTH. Greater accountability in the use of public resources.',\n",
       "  '12262. World Health Organisation - Emergency Response to Artemisinin Resistance in the Greater Mekong. WORLD HEALTH ORGANISATION - EMERGENCY RESPONSE TO ARTEMISININ RESISTANCE IN THE GREATER MEKONG. Funding under this initiative provides support through the World Health Organisation for the coordination of the emergency response to artemisinin resistance in the Greater Mekong subregion. Key outcomes will include: strengthened leadership, coordination and oversight mechanisms; maintenance and expansion of drug efficiency surveillance networks and acceleration of priority research; improved access for migrant and mobile populations to quality services; full implementation of the Myanmar Artemisinin Resistance Containment (MARC) Framework; strengthened response to Artemisinin resistance in Vietnam; and reduced availability of oral Artemisinin. The total value of this initiative is$5.0 million over 3 years, starting 2012-13.',\n",
       "  '16064. Centre for Advocacy and Research. CENTRE FOR ADVOCACY AND RESEARCH. To mainstream Most-at-Risk-Populations (MARPs) through building social accountability and community leadership for collaboration with government, civil society and media for increased access to HIV reduction services.',\n",
       "  '12182. Short term policy focussed research project to generate evidence on microbial drug resistance. SHORT TERM POLICY FOCUSSED RESEARCH PROJECT TO GENERATE EVIDENCE ON MICROBIAL DRUG RESISTANCE. To make DFIDs Research agenda more responsive through the production of short term policy research that will address the needs of policy makers by providing them with primary evidence that can subsequently be used for policy analysis in such areas as Heal',\n",
       "  \"12220. Support to the Mother and Child Health Department of the Medical University Simulation Centre of Moldova. SUPPORT TO THE MOTHER AND CHILD HEALTH DEPARTMENT OF THE MEDICAL UNIVERSITY SIMULATION CENTRE OF MOLDOVA. The international evidence proves the effectiveness of training methods based on simulation in comparison with 'traditional education, improving the practical skills of medical staff. The project will support the introducing simulation training technologies in obstetric, gynecological, neonatal and pediatric emergencies and by this contributing to improving the high medical education in Moldova.\",\n",
       "  '12191. Laboratory and Medical Equipment Project for Nork Marash Medical Center. LABORATORY AND MEDICAL EQUIPMENT PROJECT FOR NORK MARASH MEDICAL CENTER. Laboratory and Medical Equipment Project for Nork Marash Medical Center',\n",
       "  '13040. Streamlining the Response to HIV/AIDS  Epidemic in Azerbaijan by Strengthening National Capacities and Scaling up Prevention and Treatment with Emphasis on the Most at Risk Population Groups and Civil Society Participation. STREAMLINING THE RESPONSE TO HIV/AIDS  EPIDEMIC IN AZERBAIJAN BY STRENGTHENING NATIONAL CAPACITIES AND SCALING UP PREVENTION AND TREATMENT. Azerbaijan is a lower-middle income country with a concentrated HIV epidemic. HIV prevalence in adults is estimated at 0.2 percent (UNAIDS, 2008 Report on the Global AIDS Epidemic). Although the national burden of HIV appears comparatively low, it is probably underestimated - due, in particular, to difficulties in accessing most-at-risk population groups. The predominant HIV transmission mode is sharing of injecting equipment among people who inject drugs. The government of Azerbaijan is committed to fighting the HIV epidemic and allocates increasing amounts of financial, human and infrastructural resources for this purpose, particularly to cover the substantial costs of staff, medical interventions and facility expenses. However, substantial financial and programmatic gaps exist, especially with regards to the complex and costly interventions in HIV prevention and treatment activities among most-at-risk population groups. The program supported by this grant aims to ensure the continuation and scaling-up of the activities initiated under the Round 4-supported program, which ended in June 2010. This program will initiate new activities, such as expansion of voluntary counseling and testing, ensuring universal access to prevention of mother-to-child transmission of HIV and establishing community-based care and support.',\n",
       "  '12250. Kiribati Health. KIRIBATI HEALTH. Kiribati faces a number of development challenges including: highest number (68%) of Violence Against Women cases out of 9 other Pacific countries conducting the same study; 70% of Tuberculosis cases are in South Tarawa; increases in infant mortality rate as a result of pneumonia, diarrhoea and malnutrition; South Tarawa suffers from severe overcrowding. The Aid Investment Priority and Aid Partnership Arrangement aims to address these issues through delivering assistance that focuses on reducing the spread of communicable diseases, youth crime; alcohol consumption and domestic violence. The Kiribati Health program is identified as a key priority under new AIP and Aid Partnership Arrangement and will support ongoing strategic support to the health sector in addressing high burden disease such as in Tuberculosis, improving neonatal and maternal health, and health system strengthening. The total value of this initiative is $4.3 million over 6 years, starting 2009-10.',\n",
       "  '12182. Applied Research in India, Partner Driven Cooperation within the health sector - 007 +ste, Innovative food design LU. APPLIED RESEARCH IN INDIA, PARTNER DRIVEN COOPERATION WITHIN THE HEALTH SECTOR - 007 +STE, INNOVATIVE FOOD DESIGN LU. Call for applications in the prioritised area of health in India.',\n",
       "  \"13020. International Food Policy Research Institute (IFPRI). INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE (IFPRI). to assess the impact of the fourth phase of Ethiopia's Productive Safety Net Programme (PSNP) on the nutritional status of women and pre-school children\",\n",
       "  '13010. Social-ecological research. SOCIAL-ECOLOGICAL RESEARCH. Collaborative project - Climate change, environmental  change and migration - Social-ecological conditions of population movements - the example of the Sahel countries of Mali and Senegal. Sub-project - Social ecology perspective and coordination - Improving knowledge on economical, ecological and social changes in the Developing Country',\n",
       "  '12250. Rehabilitation of endemic diseases surveillance system for the national health service in the Zanzibar islands (SISME). Phase 2. REHABILITATION OF ENDEMIC DISEASES SURVEILLANCE SYSTEM FOR THE NATIONAL HEALTH SERVICE IN THE ZANZIBAR ISLANDS (SISME). PHASE 2. The project aims to operate in Zanzibar, United Republic of Tanzania, to support the reform of the monitoring system under the national health service started from september 2005 through the qualification of human resources',\n",
       "  '12262. Scaling up Malaria prevention and control for universal coverage to achieve pre_elimination stage in the Gambia. SCALING UP MALARIA PREVENTION AND CONTROL FOR UNIVERSAL COVERAGE TO ACHIEVE PRE_ELIMINATION STAGE IN THE GAMBIA. NA',\n",
       "  '13020. USAID Systems for Better Health (S4BH). USAID SYSTEMS FOR BETTER HEALTH (S4BH). This activity will work with the Zambian government (GRZ) to develop and implement national strategies and plans that address challenges faced by the health sector, including the shortage of human resources, limited management and leadership skills among staff, inadequate coordination and integration of health programs, and weak public financial management systems. ~The activity will provide technical assistance to the GRZ to build the capacity of health managers and providers at all levels of the health system to plan, implement, monitor, and evaluate programs. ~The activity will also strengthen the capacity of community structures, such as Neighborhood Health Committees, to enhance community-level participation in the health sector. ~Additionally, this activity will support the implementation of community-level nutrition interventions to address chronic malnutrition in targeted districts, and safe motherhood interventions that support the Saving Mothers, Giving Life endeavor.',\n",
       "  '13020. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. The project aims to improve the care of sick and premature newborns, in line with international standards',\n",
       "  '12110. PDC C STOP antibiotic resistance. PDC C STOP ANTIBIOTIC RESISTANCE. The main purpose of the cooperation is to improve antibiotic use and contain resistance development in major Vietnamese hospitals through evidence based intervention. Cooperation between Linkping University, Oxford University Clinical Research Unit (OUCRU), National Hospital for Infectious Diseases (NHTD), Cho Ray and 14 other collaborative hospitals in Vietnam.',\n",
       "  '13020. Leadership, Management, Governance (LMG). LEADERSHIP, MANAGEMENT, GOVERNANCE (LMG). The Leadership, Management, Governance (LMG) project builds in-country health and education system capacity by increasing leadership, management, and governance knowledge of health care providers, program managers, and policy makers who work on health services.',\n",
       "  '13040. Wings to Fly: OVC Scholarship and Leadership Program - HIV/AIDS. WINGS TO FLY: OVC SCHOLARSHIP AND LEADERSHIP PROGRAM - HIV/AIDS. Wings to Fly is a public-private partnership between USAID, Equity Group Foundation, Mastercard Foundation, UKaid, and KfW. The project provides full scholarships that include tuition, room, and board to enable academically gifted but economically disadvantaged and vulnerable children to pursue secondary and tertiary education. The selected young people also receive leadership training, career guidance, and personal mentoring to help them maximize their potential.',\n",
       "  '13040. Output 04: HIV. HIV. Ukraine - Kiev. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12240. MEASURE Evaluation Phase III - Nutrition. MEASURE EVALUATION PHASE III - NUTRITION. MEASURE Evaluation Phase III continues the MEASURE programs 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3)increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       "  '12191. Support to Cardiovascular Diagnosis and Treatment / Telemedicine Support to Cardiology, Maternal and Child Health and Oncology. SUPPORT TO CARDIOVASCULAR DIAGNOSIS AND TREATMENT / TELEMEDICINE SUPPORT TO CARDIOLOGY, MATERNAL AND CHILD HEALTH AND ONCOLOGY. At Shastin Central Hospital cardiac surgery is available to one patient a day 25 days per year',\n",
       "  '13020. Program Activity Fund. PROGRAM ACTIVITY FUND. The Australia-Indonesia Partnership (AIP) for Maternal and Neonatal  Health (MNH) aims for selected provincial and district governments in Eastern Indonesia to have mechanisms in place to manage national, local and donor resources to achieve national target levels for priority indicators contained within the Indonesian National Making Pregnancy Safer (MPS) Strategy. The objectives are: provincial and district governments develop and implement maternal and neonatal health (MNH) programs based on the national MPS strategy and address supply and demand aspects to achieve annual performance targets; provincial and district government agencies and communities access and manage the technical, human and financial resources needed to achieve improvements in MNH; and provincial and district governments manage Government of Indonesia (GoI) and donor resources to improve accountability, performance, accessibility and sustainability of public health services. The total value of this initiative is $76.4 million over 8 years, starting 2006-07.',\n",
       "  \"13040. Scaling Up Coverage and Quality of HIV & AIDS Prevention targeted to Most at Risk Population and Treatment Care and Support Services to PLHA. SCALING UP COVERAGE AND QUALITY OF HIV & AIDS PREVENTION TARGETED TO MOST AT RISK POPULATION AND TREATMENT CARE AND SUPPORT SERVICES TO PLHA. Just over half a percent of Nepal's adult population is estimated to be HIV-positive. The low prevalence rate masks the imminent threat of an HIV pandemic due to the country's large male migrant population, the lack of voluntary counseling and testing services and the limited capacities of the authorities and health workers to address existing cases. The overall goal of the program supported by this grant is to reduce HIV transmission in Nepal and enhance the quality of life of people living with HIV in the country, focusing on West, Mid-West and Far-West development regions of Nepal. The program's interventions target mobile populations, injecting drug users and men who have sex with men, as well as people who are HIV-positive. Under the program, prevention efforts and community outreach through peer education and interpersonal communication will be scaled up to reduce the stigma related to HIV and to lower the barriers to accessing HIV and AIDS treatment and counseling services.\",\n",
       "  '12181. Competency Based Clinical Based Teaching and Preceptor Workshops. COMPETENCY BASED CLINICAL BASED TEACHING AND PRECEPTOR WORKSHOPS. Funding under this activity supports capacity building of nursing profession in the province of Da Nang, Vietnam. South Australia Health will fund a four (4) day Competency Based Clinical Teaching  Preceptor Workshops to be delivered by the Queensland University of Technology (QUT) over a five year timeframe commencing 2013 - 2017. Trained Vietnamese nurses will go out to hospitals to conduct these workshops with the aim to build capacity in the nursing profession.',\n",
       "  '12240. CIVIL SOCIETY PROGRAMME FUNDING SUPPORT SCHEME - 5 Increased decision-making power of women regardi. CIVIL SOCIETY PROGRAMME FUNDING SUPPORT SCHEME - 5 INCREASED DECISION-MAKING POWER OF WOMEN REGARDI. CIVIL SOCIETY -  Four-year programme grants have been allocated through a competitive funding mechanism to established NGO partners with a strong focus on results and the capacity to operate on a strategic basis.    HUNGER-ACIVIL SOCIETY PROGRAMME FUNDING SUPPORT SCHEME - 5 Increased decision-making power of women regardi-ng health & nutrition practices (micro) AgriNut Inequality Outcome',\n",
       "  '12191. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. The project aims to establish a sustainable Neurosurgery Service and Training Programme in Ethiopia',\n",
       "  '12220. Mobile Solutions Technical Assistance and Research (mSTAR) project - Other Public Health Threats. MOBILE SOLUTIONS TECHNICAL ASSISTANCE AND RESEARCH (MSTAR) PROJECT - OTHER PUBLIC HEALTH THREATS. The FHI 360 Mobile Solutions Technical Assistance and Research (mSTAR) project is a broad, flexible and responsive technical assistance and research program that is fostering the rapid adoption and scale-up of digital finance, digital inclusion and mobile data in developing countries. Ultimately, mSTAR seeks to increase access to and use of mobile and digital technologies by low-income individuals, civil society, local government institutions and private-sector stakeholders.',\n",
       "  '12262. Global Health Support Initiative II (GHSI II) - Malaria. GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II) - MALARIA. The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the programs vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.',\n",
       "  \"12261. NGO Support / Health Education Project of Diabetic Children and Juveniles. NGO SUPPORT / HEALTH EDUCATION PROJECT OF DIABETIC CHILDREN AND JUVENILES. The aim of the project is to support diabetic children youngsters and families by organising camps. In the camps there will be offered information about diabetes it's treatment and the meaning of the diet and exercise. To the camps also healhty children will participate. This helps in the socialisation and acceptance of the diabetic children. Also the mums can participate.In one camp there will participate 60 children 30 mums and 30 non-diabetic children each year for two weeks. In addition Girl Meetings will be organised as well as the Youth Clubs. Volunteers will be educated to know more about the treatment of diabetes and to leaders to the camp. In this second phase of the project the guidance focused on mums will be added as well as the preparation of the suitable diet.\",\n",
       "  '12240. International Rice Research Institute. INTERNATIONAL RICE RESEARCH INSTITUTE. to address the problem of Vitamin A deficiency among millions of people in the Philippines and Bangladesh',\n",
       "  '12220. Junior Professional Officer - JPO - WHO - Technical Officer - Convention Secretariat, WHO framework Convention on Tobacco Control. JUNIOR PROFESSIONAL OFFICER - JPO - WHO - TECHNICAL OFFICER - CONVENTION SECRETARIAT, WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL. Background :  The Junior Professional Officers (JPO) Programme, also known as the Associate Experts Programme, is a multilateral technical cooperation initiative sponsored by the Directorate General for Development Cooperation and Humanitarian Aid of Belgium. The Programme originaates from a United Nations Economic and Social Council resolution adopted in 1961 which approved and encouraged the collaboration of volunteers, financed by their respective countries of origin, in implementing development cooperation initiatives and programmes.  Belgium joined the Programme in 1963, and over the years has developed it into a Programme, extending its sponsorship to the Multilateral partnerl organizations with which the Belgian Government stipulated in specific agreements   -Global objective:  The Junior Professional Officers (JPO) Programme, also known as the Associate Experts Programme, is a multilateral technical cooperation initiative sponsored by the Directorate General for Development Cooperation and Humanitarian Aid of Belgium. The Programme originaates from a United Nations Economic and Social Council resolution adopted in 1961 which approved and encouraged the collaboration of volunteers, financed by their respective countries of origin, in implementing development cooperation initiatives and programmes.  -Specific objective :  Essential Qualifications and Experience required for this position: -Master degree in political science, development studies or international relations -Minimum 2 years of relevant work experience with concenration on international cooperation/development or health -Minimum knowledge of international development agenda, mechanisms and principles of aid effectiveness, and intergovernmental processes -Good writing and anatycal skills -Good IT and database skills -Excellent knowledge of English and French   -Intended results :  Upon completion of the assignment, the JPO will be able to:assist in day to day coordination with the development partners and international organisations. The JPO will be able to assist in tasks related  to the joint needs assessments and necessary follow up with governments, required liaison with the relevant WHO country offices. The JPO will be able to contribute to the overall objectives of the Secretariat to strenghten aid effectiveness, national ownership through implementation activities mandated by the Conference of the parties.  -',\n",
       "  '13040. Ensuring Quality HIV/AIDS Services by Consolidating and Strengthening Existing HIV/AIDS Prevention, Treatment, Care and Support Programs. ENSURING QUALITY HIV/AIDS SERVICES BY CONSOLIDATING AND STRENGTHENING EXISTING HIV/AIDS PREVENTION, TREATMENT, CARE AND SUPPORT PROGRAMS. Ethiopia is one of the countries most affected by the HIV and AIDS pandemic, with an estimated 2.2 million citizens currently living with HIV. The program supported by this grant is designed to strengthen and expand the scale-up of social mobilization, care and support programs for people living with HIV and AIDS as well as orphans and children made vulnerable by HIV and AIDS. The program intends to increase coverage and adherence to antiretroviral therapy in 40 districts of four major regional states. The program also aims to enhance community ownership and response to HIV and AIDS with community conversation and other means, and mobilizing local communities to support orphans and vulnerable children. Mitigation of the social and economic impact of HIV and AIDS on people living with the disease and their families through job creation, income-generating activities and the provision of food and nutritional support to people living with HIV and AIDS and their families is another important component of the program.',\n",
       "  '12263. Capacity Building for Laboratory Diagnosis and Tuberculosis Control. CAPACITY BUILDING FOR LABORATORY DIAGNOSIS AND TUBERCULOSIS CONTROL. Capacity Building for Laboratory iagnosis and Tuberculosis Control Programs at the National Lung Center of the Philippines',\n",
       "  '12110. Contribution to Malawi Health Sector Strategic Plan 2011-2016. CONTRIBUTION TO MALAWI HEALTH SECTOR STRATEGIC PLAN 2011-2016. Background:  The Vision of the health sector is to achieve a state of health for all the people of Malawi that would enable them to lead a quality and productive life.  The Mission of the health sector is to provide strategic leadership by the Ministry of Health for the delivery of a comprehensive range of quality, equitable and efficient health services to all people in Malawi by creating an enabling environment for health promoting activities.  The Goal of the Health Sector Strategic Plan is to improve the quality of life of all the people of Malawi by reducing the risk of ill health and the occurrence of premature deaths, thereby contributing to the social and economic development of the country. -',\n",
       "  \"12110. Urban Primary Health Care Services Delivery Project. URBAN PRIMARY HEALTH CARE SERVICES DELIVERY PROJECT. The Asian Development Bank (ADB) supported Urban Primary Health Care Project (UPHCP) is one of the largest public-private partnerships (PPP) in the delivery of primary health care (PHC) in South Asia. The Government of Bangladesh with the assistance of ADB implemented the First Urban Primary Health Care Project (UPHCP-I) from March 1998 to June 2005.  The Second Urban Primary Health Care Project (UPHCP-II), supported by ADB and the Governments of the United Kingdom and Sweden, commenced in July 2005 and was completed in December 2012.  A provision of $50 million has been made for the Bangladesh Urban Primary Health Care Services Delivery Project (UPHCSDP) in ADB's lending pipeline for 2012 in addition to $400,000 grant support for Supporting the Urban Primary Health Care Services Delivery Project in 2012. The UPHCSDP and the grant continue the provision of urban PHC, among others, through successful PPPs pioneered by UPHCP-I and II.   With a density of 2,756 people per square kilometer (km2) in urban areas and 843 people per km2 overall, Bangladesh is the most densely populated country in the world (excluding a few city-states).  Bangladesh is urbanizing at a rapid pace and the country's urban population is expected to reach 89.5 million (from 39.5 million in 2005) by 2030.  According to one estimate, by 2020 the urban poor figure could be as high as 40%-60% of the urban population.  Notwithstanding higher economic growth in urban areas, the absolute number of poor households is increasing in urban Bangladesh due to migration of rural poor into urban areas. Studies have shown that the health indicators of the urban poor are as worse as those of the rural poor because of poorer living conditions, and limited urban PHC. Failure to provide urban PHC can have serious negative externalities - spread of communicable diseases, debilitating epidemics, reduction in economic productivity, among others.\",\n",
       "  '13040. Therapeutic and Supplementary Products for Improved Nutrition (TASPIN) Project - HIV/AIDS. THERAPEUTIC AND SUPPLEMENTARY PRODUCTS FOR IMPROVED NUTRITION (TASPIN) PROJECT - HIV/AIDS. The Production of Improved Nutrition Project aims to reduce the burden of under nutrition in vulnerable groups throughout Uganda. Key objectives of this project include; 1) Providing adequate and timely supply of ready to Use Therapeutic and supplementary Foods and Fortified Blended Foods; 2) Strengthen agricultural practices of small scale farmers; and 3) Empower households with vulnerable children with basic skills to improve nutrition, health and boost their livelihoods.',\n",
       "  '13040. Food and Nutrition Technical Assistance III (FANTA-III). FOOD AND NUTRITION TECHNICAL ASSISTANCE III (FANTA-III). The Food and Nutrition Technical Assistance Project (FANTA) has been working to improve the health and well-being of vulnerable individuals, families, and communities in developing countries by strengthening food security and nutrition policies, programs, and systems. The project provides comprehensive technical support to USAID and its partners, including host country governments, international organizations, and nongovernmental organizations. FANTA works at both the country and global levels, supporting the design and implementation of programs in focus countries, and building on field experience to strengthen the evidence base, methods, and global standards for food security and nutrition programming.',\n",
       "  '12191. The Project for Modernization of Medical Equipment in Municipal Clinical Hospital Sfantul Arhanghel Mihail. THE PROJECT FOR MODERNIZATION OF MEDICAL EQUIPMENT IN MUNICIPAL CLINICAL HOSPITAL SFANTUL ARHANGHEL MIHAIL. Purchase of medical equipments of Electrosurgery, Anesthesia Equipment and Anesthesia ceiling mounted pendant',\n",
       "  '13020. Health Communication Capacity Collaborative (HC3) - Maternal and Child Health. HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3) - MATERNAL AND CHILD HEALTH. HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       "  '12220. Contribution to Confidence Building Measures Program in Transnistria  Promoting Confidence in the Health Sector. CONTRIBUTION TO CONFIDENCE BUILDING MEASURES PROGRAM IN TRANSNISTRIA  PROMOTING CONFIDENCE IN THE HEALTH SECTOR. Population living in Transnistria has limited access to quality maternal and child health care. The vaccination coverage rate is declining and the number of premature and underweight newborns is increasing. The project aims to approximate maternal and child health care in Transnistria to international standards, as well as to improve the access to and quality of maternal and child health services at secondary and primary level. A special focus is put on nutrition and immunization. The project offers good opportunities for building trust across borders through common trainings of professionals and concerted efforts on immunization.',\n",
       "  '13010. Applying Science to Strengthen and Improve Systems (ASSIST) - Administration and Oversight. APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST) - ADMINISTRATION AND OVERSIGHT. The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       "  '13010. 06. 4 COMM LEADERS & CSOS HAVE KNOWLEDGE. 06. 4 COMM LEADERS & CSOS HAVE KNOWLEDGE. 06. 4 COMM LEADERS & CSOS HAVE KNOWLEDGE',\n",
       "  '12182. Artemisinin Resistant Malaria Programme Oxford Contract - research. ARTEMISININ RESISTANT MALARIA PROGRAMME OXFORD CONTRACT - RESEARCH. To rapidly identify new knowledge and put in place wider geographical research which can be used to contain resistance',\n",
       "  '12182. RESEARCH COOPERATION WITH UEM, MOZ, 2011-2016 - INHACA 2014. RESEARCH COOPERATION WITH UEM, MOZ, 2011-2016 - INHACA 2014. The program objective is to strengthen higher education and national research systems, through direct support to research, postgraduate training and development of institutional capacity for research management within the University of Eduardo Mondlane (UEM). The contribution period covers 2011-2015. Comp. 3; financing of 4 MSc programs. Comp. 5; additional support to MBR at Inhaca.',\n",
       "  '12110. Study visit - insurance against accidents at work and occupational diseases. STUDY VISIT - INSURANCE AGAINST ACCIDENTS AT WORK AND OCCUPATIONAL DISEASES. Familiarization with Slovak system of employer liability insurance for accidents at work and occupational diseases and diseases related to work and to the particular services to employees (for the payment of compensation). Slovak Republic as the only country from the former communist countries reformed the area of occupational accidents and occupational diseases within the insurance system, which is able to record and quantify the cost and source components.',\n",
       "  '13010. Interrelations between public policies, migration and development of partner countries: case studies and policy recommendations. INTERRELATIONS BETWEEN PUBLIC POLICIES, MIGRATION AND DEVELOPMENT OF PARTNER COUNTRIES: CASE STUDIES AND POLICY RECOMMENDATIONS. The overarching objective of the project is to enhance partner countries  capacity to incorporate the migration dimension into the design and implementation of their development strategies and other public policies through a better understanding of the implications of public policies on migration matters.',\n",
       "  '12181. ForSa - Training in Health services. FORSA - TRAINING IN HEALTH SERVICES. Increase the capacity and performance of health services by improving the pedagogical and organizational capabilities of the Faculty of Medicine and Health Science East Timor',\n",
       "  '13020. OUTPUT 3.1:NORMES SOCIALES POSITIVES. OUTPUT 3.1:NORMES SOCIALES POSITIVES. NA',\n",
       "  \"12240. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       "  '12181. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Feasibility Study',\n",
       "  '12220. AC_89_Antimicrobial resistance_12220. AC_89_ANTIMICROBIAL RESISTANCE_12220. Antimicrobial resistance',\n",
       "  \"12110. Delivering Healthy Diets to Low-Income Families through Community Kitchens in Peru. DELIVERING HEALTHY DIETS TO LOW-INCOME FAMILIES THROUGH COMMUNITY KITCHENS IN PERU. Non-communicable diseases (NCDs) are a major cause of death in Peru, accounting for 60% of deaths in 2010. Unhealthy diet is one of the four major risk factors for NCDs. Researchers will explore ways to promote healthy dietary habits among residents of Lima's poor urban communities who use the city's Comedores Populares, or community kitchens. These kitchens provide more than 500,000 lunches to Peruvian families living in poverty. Established in 1978 to respond to poverty and the economic crisis, there are more than 15,500 Comedores Populares in Peru today, with 5,000 located in Lima. Low-income women serve soup plus a dish made of rice and legumes at a cost of CA$0.75 each. The menus rarely include fruits and vegetables.This project will combine qualitative methodologies and tools common to public health research, health economics, and behavioral economics to explore opportunities, barriers, and preferences for healthy foods. Researchers will use the information to design and implement strategies to promote healthier food choices in the Comedores Populares. One approach will increase the use of fruits and the other will reduce the use of products with high saturated fat and salt in prepared foods.\",\n",
       "  '12240. GIMBUKA - Nutrition. GIMBUKA - NUTRITION. Caritas-Rwanda will continue to improve the nutritional status of mothers and children (especially those under 2 years of age) through community-based interventions in nine districts. The project will seek to improve the well-being of HIV/AIDS-affected orphans and vulnerable children (OVC) and improve the nutritional status of adults living with HIV through cooking demonstrations, nutrition assessments (anthropometric measurements) and nutrition counseling. Of the 73,482 people supported under this program, 14,416 are OVCs, 36,000 are children under five years, and 7,200 are pregnant and lactating women. The project uses cost effective community-based solutions like internal savings and loan groups, farmers field schools and the positive deviance hearth model to address nutritional and financial needs of beneficiaries, with emphasis on resilience and empowerment through economic strengthening, food security, nutrition and hygiene, and increased access to health services.',\n",
       "  '12250. Global Health Support Initiative II (GHSI II) - Pandemic Influenza and Other Emerging Threats (PIOET). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II) - PANDEMIC INFLUENZA AND OTHER EMERGING THREATS (PIOET). Global Health Support Initiative II (GHSI II)',\n",
       "  '12240. Nutrition Bio-fortification. NUTRITION BIO-FORTIFICATION. To improve the food and nutrition security of 350,000 small holder farmers in 8 rural districts of Zimbabwe by raising farm productivity through training of farmers and introducing improved agricultural practices, linking the farmer groups to input and ou',\n",
       "  '12191. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Establishing a sustainable Neurosurgery Service and Training program in Malawi and giving Norwegian nurses important training',\n",
       "  '12220. Health project to cure the hare lip. HEALTH PROJECT TO CURE THE HARE LIP. The project supports the surgery to treat the hare lips and provides health care to the infants affected by hare lips',\n",
       "  \"12281. Strengthening primary care capacity in by training of practitioners in paediatrics to help China's economic development and the health of its poor.. STRENGTHENING PRIMARY CARE CAPACITY IN BY TRAINING OF PRACTITIONERS IN PAEDIATRICS TO HELP CHINA'S ECONOMIC DEVELOPMENT AND THE HEALTH OF ITS POOR.. The project is designed to draw on UK expertise to strengthen the training of Chinese GPs in paediatrics to improve their skills across diagnoses and treatments, in pilot cities. This project will enable primary care institutions to take on more responsibilities in dealing with child medical issues, relieving pressure on tertiary paediatric services. Chinese policy makers will use the pilot report to inform the establishment of tiered treatment guidelines. This is expected to generate commercial and collaborative opportunities for international entities, including UK ones.\",\n",
       "  '13040. PEPFAR Health Bilateral Program. - HIV/AIDS. PEPFAR HEALTH BILATERAL PROGRAM. - HIV/AIDS. The program supports South African organizations that identify, strengthen, and institutionalize better, cost-effective practices and innovations in HIV and AIDS care and treatment for priority and at-risk populations in accordance with South African government (SAG) priorities and policies.',\n",
       "  '12262. SANTE-HEALTH 2006/105-398 Integated project to malaria control program in ChokwT region. SANTE-HEALTH 2006/105-398 INTEGATED PROJECT TO MALARIA CONTROL PROGRAM IN CHOKW+ REGION. Fighting malaria in the region of ChokwT: a) Reduction of mortality rate caused by the disease, b) Prevent further outbreaks of infection.',\n",
       "  \"12220. Voice of the Poor in Health Policy - Linking Voice of the Poor to Health Policy. VOICE OF THE POOR IN HEALTH POLICY - LINKING VOICE OF THE POOR TO HEALTH POLICY. Sida has been supporting the Health Sector Programme in Bangladesh implemented by the Ministry of Health and Family Welfare. Up to 15 000 000 SEK was allocated for follow up, reviews and studies to strengthened the work of Sida on sexual, reproductive health and rights, gender equality and universal health care. Sida also expressed its intention to monitor the sector program progress on these key issues in partnership with civil society organization. The proposed contribution will enable women, men and children living in poverty to influence the preparation of the 4th health sector program. The Embassy decided to engage UBINIG through a simplified tendering method to implement the assignment as per the agreed ToR ( Annex 1). The purpose of this intervention is to support the Embassy in the appraisal of the new sector programme support 2017-2020 and strengthen the grassroots' network by linking the voice of the poor to the new health sector policy. The total budget of the assignment is 450 000 SEK and it will be paid in three installments. The first payment on 180 000 SEK will be given as an advance for timely implementation of all scheduled activities. The reason for the advance payment is that UBINIG do not have special funds budgeted to get started with the assignment. The budget will be charged from already allocated Resources from the health sector programme HPNSDP (51060001, component 2 on Technical Assistance).\",\n",
       "  '12110. Appui a la politique et reprTsentation pour assister les dTcideurs politiques dans la formulation des politiques et des stratTgies et les assister dan. APPUI + LA POLITIQUE ET REPR+SENTATION POUR ASSISTER LES D+CIDEURS POLITIQUES DANS LA FORMULATION DES POLITIQUES ET DES STRAT+GIES ET LES ASSISTER DAN. General Objectives  To strengthen the rational basis and the country ownership of (human and animal) healthcare systems and policies in developing countries, in order to improve the health status ofthe populations and thereby to contribute to the reduction of poverty and inequity.  Specific Objectives  To assist adequately Belgian policy makers in decision-making, policy formulation and representationregarding technical and strategic issues in international health. Results  Result 1 Belgian policy makers receive (up-to-date) information on technical and policyissues in international health when requested (2011 + 2013)Result 2 Policy Research Topics have been identified, research has been carried outand its results have been presented to DGDC (2011 + 2013)Result 3 The Belgian representation is scientifically supported at international forumsconsidered relevant by the policy makers (2011 + 2013)Result 4 Coordination mechanisms have been put in place between DGDC/FA and ITM(2011 + 2013)',\n",
       "  '12240. Right to food and subsistence methods in Kenya in the counties of Isiolo, Garissa, Kissi, Kakamega. RIGHT TO FOOD AND SUBSISTENCE METHODS IN KENYA IN THE COUNTIES OF ISIOLO, GARISSA, KISSI, KAKAMEGA. The project wants to implement and extend to other counties (Garissa, Kissi, Kagamega) basic training for local communities and associations on rights to food security, the development of inculturated and sustainable technologies for food production and storage, participatory ideation and joint implementation of advocacy actions directed towards the local administration through the establishment of representative committees in villages and religious communities (parishes and Muslim communities). The expected beneficiaries are about 890 individuals divided into about 20 local associations, while awareness campaigns envisage reaching about 20,000 people.',\n",
       "  '13030. Social Health Protection (SHP). SOCIAL HEALTH PROTECTION (SHP). The Social Health Protection project will reduce financial barriers to health services for the poor by increasing the nationwide coverage of the public-sector health insurance program known as the Health Equity Fund. This fund enables the poor to access and pay for quality health services, thereby mitigating the effects of disease and sickness while reducing the financial burden of health-care costs on the poor. Activities will strengthen the ability of the national and district-level governments to administer health insurance, link reimbursements to improved health services, include civil society and communities in oversight of the enrollment process to ensure more transparency, and revise the package of health services provided to the poor to include priority services. The U.S. government will help expand the Heath Equity Fund across all of Cambodia and provide three million poor Cambodians with access to healthcare without forcing them into further financial hardship.',\n",
       "  '12250. The Royal Institute of International Affairs. THE ROYAL INSTITUTE OF INTERNATIONAL AFFAIRS. to convene a group of experts to discuss the value of vaccines in reducing the impact of antimicrobial resistance',\n",
       "  '12181. Transfer of Know-How concerning medical techniques und practices of rehabilitation into the Pepublic of Moldova. TRANSFER OF KNOW-HOW CONCERNING MEDICAL TECHNIQUES UND PRACTICES OF REHABILITATION INTO THE PEPUBLIC OF MOLDOVA. Transfer of know-how in the medical field of rehabilitation and advanced training of young Moldavian doctors by German experts through theoretical and practical knowledge transfer in a workshop, a congress as well as job shadowing.',\n",
       "  '12110. Improving the system of civil registrations for the child rights identity- Identification for development-phase 2. IMPROVING THE SYSTEM OF CIVIL REGISTRATIONS FOR THE CHILD RIGHTS IDENTITY- IDENTIFICATION FOR DEVELOPMENT-PHASE 2. The initiative seeks to ensure children s right to identity, to ensure their access to basic services and protect them from violence, abuse and exploitation, through the enhancement of of the regional system of birth registration and the standardization of the national system of civil records in two regions of Ethiopia to high incidence of migration.',\n",
       "  '12263. Kinerja - Tuberculosis. KINERJA - TUBERCULOSIS. The overarching objective of this IM is the provision of innovative and improved service delivery by local governments to citizens. USAID focuses on the governance of service delivery in three sectors: education; health services and; and local business. Activities under this IM address both demand and supply side aspects of service delivery. These investments will result in strengthened accountability mechanisms that improve local government responses to citizens needs. USAID works through local institutions to build their capacity and foster sustainable partnerships with local government. This solidifies the links between stimulation of demand for good services through active civil society engagement and improved local government response.',\n",
       "  '16064. Output 04: HIV. HIV. Angola - Luanda. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '13030. Afya Jijini. AFYA JIJINI. Afya Jijini will support integrated health service delivery in Nairobi County. Support for integrated services include HIV; tuberculosis; reproductive, maternal, newborn and child health; nutrition; WASH funds will support: HIV prevention, care and treatment interventionsANC, SBA, emergency obstetric care and essential newborn carePrevention and management of diarrhea and pneumonia through ORS/zinc, appropriate treatment and BCC in facility and community WASH activities through community sanitation, household and school-based hygiene practices ?Routine immunization; provision of quality nutrition services; capacity building on maternal and child nutrition; and provision of equipment, job aids and guidelinesForecasting, quantification and reporting of essential commodities at facility levelFP skills building, mentorship, counselling and provision of services in public and private sector facilities and by community health workers',\n",
       "  '12240. International Food Policy Research Institute. INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE. to promote evidence-based nutrition policy and program decision-making and thus accelerate reductions in maternal and child undernutrition in India',\n",
       "  '13020. HealthTech V. HEALTHTECH V. HealthTech develops, adapts, evaluates and/or facilitates the introduction of affordable and appropriate technology solutions for the safe, effective, and more equitable distribution of health care services in low-resource countries. This project will address implementation barriers (e.g., issues with technical design, supply chain management, and policy) that typically prevent innovative technologies from reaching the most vulnerable populations. A significant focus of this project will be the advancement of health technologies through commercialization efforts.',\n",
       "  '12240. Project research. PROJECT RESEARCH. Project research',\n",
       "  \"16064. NGO Support / AIDS Project  The Good Samaritan. NGO SUPPORT / AIDS PROJECT  THE GOOD SAMARITAN. Good Samaritan Program (GSP) is a pan-African program by the United Bible Societies. It is implemented in over 20 countries in Africa and coordinated by HIV service. Bible Society of C=te d'Ivoire (BSCI) has the main responsibility in the grass root level implementation.The overall objective of the project is to contribute to the reduction of the spread of HIV and stigmatization of people infected and affected. Project aims to involve church partners and communities to  HIV work. In the core of the GSP are human rights: PLHA as well as their families deserve to be treated equally with other members of the society. Rights based and gender sensitive approach is directly linked with Christian values. GSP is contributing to the C(te d'Ivoire national policies where reducing the stigma of PLHA and avoid new infections are the prioritiesGood Samaritan program will not intervene directly in the sector of health care but use partnership and guide people in need to the suitable aid providers. However through communication advocacy and disseminating adequate health information GSP has means to change opinions and contribute to the common goals defined by UNAIDSGSP trainings are based on multimedia package which includes booklets videos and flipcharts for trainees and manuals for trainers. The package is available in English and French (including Braille) and it is translated into local languages. The key project activities include Sensitization for leaders Training of Trainees (ToT) Decentralized Workshops (DWs) Follow up (FU) home visits and Take Charge (TC).Like during the 1st and 2nd project phase GSP targets churches local congregations and communities. However for the 3rd phase of the project BSCI has special focus on two topics:- To integrate deaf to the project - To focus on the families to prevent parent to child transmission and to reduce the infections among  couplesGSP staff has witnessed the lack of correct information about HIV among deaf communities. Deaf audiences can be heavily affected by HIV but often left out from development projects. GSP's aim is to integrate deaf to the project by cooperation with deaf schools and organizations with specifically designed materials. Fidida will provide external consultation in FinlandBecause of the high infection rates among couples GSP also focuses on pregnant women and couples. Objective is to raise awareness and responsible behavior and prevent parent to child transmiss\",\n",
       "  '12240. Strengthening Partnerships, Results, and Innovations in Nutrition Globally (SPRING) - Nutrition. STRENGTHENING PARTNERSHIPS, RESULTS, AND INNOVATIONS IN NUTRITION GLOBALLY (SPRING) - NUTRITION. SPRING/Ghana aims to reduce stunting by 20 percent in two regionsNorthern Region and Upper East Region. Working in 15 districts within these two regions, SPRING/Ghanas activities include anemia reduction, infant and young child nutrition; water, sanitation, and hygiene; aflatoxin reduction; community video; and support to the LEAP 1000 cash transfers. SPRING/Ghana defines its activities through the 1,000 Day Household (linked to 2-pager) approach, which targets households with pregnant women and children 2 years of age and younger. This approach synthesizes each intervention area into a holistic approach designed to support the ability of the1,000 day household to care for and support the 1,000 day child.',\n",
       "  '13040. Comprehensive District-Based Support for Better HIV/TB Patient Outcomes (Hybrid) - HIV/AIDS. COMPREHENSIVE DISTRICT-BASED SUPPORT FOR BETTER HIV/TB PATIENT OUTCOMES (HYBRID) - HIV/AIDS. FPD is implementing the Comprehensive District Health Team Support (CDHTS) TA model. The goal is to foster a public sector management culture that is based on effective leadership by professional managers who are committed to: providing integrated high quality services based on GoSA policy; working in partnership with civil society; using strategic information to guide decision making; and improving the quality of services and patient outcomes. In partnership with GoSA, FPD will: i) develop and inform strategies to help Districts realize the 10 Point Plan, including NSP on HIV/AIDS, PHC Re-Engineering Strategy, NHI and the Minister of Healths NSDA in line with the PIPF; ii) support district management to draft, implement and monitor progress against District Health Plans, related plans and expenditure reviews; and iii) support districts to achieve and maintain targeted levels of performance for PEPFARs priority areas, in particular TB/HIV.',\n",
       "  '12250. 005 POLIO. 005 POLIO. 005 POLIO',\n",
       "  '12110. Medical Education Reforms in the Kyrgyz Republic. MEDICAL EDUCATION REFORMS IN THE KYRGYZ REPUBLIC. SDC has been providing support to the Medical Education Reforms in Kyrgyzstan since 2008 with backstopping support from the H(pitaux Universitaires de GenFve. Despite several political disturbances, the reforms in medical education have made good progress in revising and introducing new standard curriculum at undergraduate level. There is however still need to further design and implement new modules at undergraduate level and to reform postgraduate and continued medical education. This project will thus further support the medical education reforms implemented under the leadership of the Ministry of Health.',\n",
       "  \"13040. Scaling up HIV and AIDS Prevention, Care and Treatment and Strengthening Management, Increasing Demand and Ensuring Quality of HIV/AIDS/STI Interventions in Lao PDR. SCALING UP HIV AND AIDS PREVENTION, CARE AND TREATMENT AND STRENGTHENING MANAGEMENT, INCREASING DEMAND AND ENSURING QUALITY OF HIV/AIDS/STI INTERVENT. The Lao People's Democratic Republic is classified among countries suffering from a high burden of HIV/AIDS.  The prevalence among female sex workers (FSWs) doubled over the year of 2001 to 2004 from 0.9 percent to 2 percent and decreased to 0.5 percent in 2008.   The prevalence among men having sex with other men (MSM) appears to differ between locations, with 5.6 percent in the capital, Vientiane.  In 2008, responses to potentially growing threat of HIV resulted to drafting of an HIV law, funding approval of two Global Fund grants focusing on treatment and care efforts, continuing inclusion of HIV in national priorities, expansion of people living with HIV (PLHIV) networks and involving in their policy and program making, and development of a multi-sectorial monitoring and evaluating five-year strategic plan.  The current grant is a Single Stream Funding (SSF) consolidated Round 4, 6 and 8 HIV programs.  It is expanding the interventions to cover identified gaps in coverage, addressing weaknesses in implementation capacity, and strengthening civil society organizations.  The grant also aims to improve the regulatory process, including amending applicable laws and regulations to better enable enforcement and gain efficiencies in the registration process.\",\n",
       "  '12263. IMPLEMENTATION OF NEW MOLECULAR TESTING FOR TUBERCULOSIS IN HIGH BURDEN SETTINGS IN SUB-SAHARAN AFRICA. IMPLEMENTATION OF NEW MOLECULAR TESTING FOR TUBERCULOSIS IN HIGH BURDEN SETTINGS IN SUB-SAHARAN AFRICA. The Project would be implemented as part of more comprehensive national plan to roll out Xpert technology in selcted countries in Sub-Saharan Africa (Burkina Faso, Ethipia, Mozambique) to increase access to rapid diagnosis of TB and MDR-TB and to strengthen capacity of local laboratories. An other objective of the Project is to coordinate and provide technical assistance and monitor establishment of sustainable models of programmatic management of TB and MDR-TB in proposed settings and to facilitate new policy making and production of guidelins at national level.',\n",
       "  \"13020. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       "  '12263. World Health Organization. WORLD HEALTH ORGANIZATION. to promote effective, affordable, cost-effective, and financially-sustainable diagnosis through treatment of multidrug-resistant tuberculosis in China',\n",
       "  '12191. Building Palestinian resilience: improving psychosocial and mental health responses to emergency situations. BUILDING PALESTINIAN RESILIENCE: IMPROVING PSYCHOSOCIAL AND MENTAL HEALTH RESPONSES TO EMERGENCY SITUATIONS. The objective is to build and reinforce the resilience of Palestinian institutions and population to cope with conflict triggers and uncertainty, notably in post-conflict Gaza. Specific objectives include (i) to scale-up emergency preparedness and response  by developing national emergency response plan, establishing skilled mental health teams, providing psycho-tropics and integrating long-term rehabilitation service to trauma victims into health and education services  (ii) to support the Mini',\n",
       "  '13040. HIV/AIDS - Treatment/ Pediatric Treatment - Assistance for HIV/AIDS. HIV/AIDS - TREATMENT/ PEDIATRIC TREATMENT - ASSISTANCE FOR HIV/AIDS. PEPFAR: HIV/AIDS - Including infrastructure, training clinicians and other providers, exams, clinical monitoring, related laboratory services, and community-adherence activities. Clinical monitoring and management of opportunistic infections is classified under Pediatric Care and Support. - Assistance for HIV/AIDS',\n",
       "  '13030. Administration and Oversight (FP). ADMINISTRATION AND OVERSIGHT (FP). Supports the following illustrative program-funded costs: salaries of US, FSN, and TCN and other staff such as PSCs, RSSAs, PASAs, CASUs working for the US Government managing, administering, and supporting programs and their program-funded benefits such as housing, travel, transportation, education allowances etc; institutional contractors that provide such staff, rent, IT services, the program-funded share of utilities, staff training costs and the cost of developing and administering training programs, equipment and supplies, ICASS, vehicle fuel and maintenance, maintenance contracts, janitorial services, operational unit web page development and maintenance, outreach such as publications and the cost of their preparation (including staff costs), and technical assistance to ensure USG compliance with regulations.',\n",
       "  '12191. Support to Psycho-Rehabilitation Center. SUPPORT TO PSYCHO-REHABILITATION CENTER. A Psycho-Rehab. Center provides free medical and psychological assistance to all locals in need. Center is a place to get primary medical observation, treatment, psychological aid, a spot for intercourse, to meet persons with similar interests, get moral support. Citizens of Gali, Ochamchire,Tkhvarcheli will be delivered psychological consultations, provided medical observation, given prescriptions for treatment; for them will be organized public meetings aiming at improving their psych. state and rise adultsO awareness of drug-related deceases, harm of smoking, contagious deceases, physiology, norms of hygiene, gender relations. Such kind of the activities will help them to improve and control their health, to better psychological state and return incentive to life so crucial in the current circumstances when access to similar psychosocial assistance on the GeorgiaOs controlled territory is almost impossible.',\n",
       "  '13020. Society for Applied Studies. SOCIETY FOR APPLIED STUDIES. to enable these high quality sites in India to come together as a network, harmonize their protocols, collaborate both internally and globally to advance Healthy Birth Growth and Development agenda',\n",
       "  '12240. Health Communication Capacity Collaborative (HC3). HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3). HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       "  \"12261. F.a: Ebola wareness campaign. F.A: EBOLA WARENESS CAMPAIGN. The development problem is Ebola epidemic which has reversed the post-conflict economic and social development in the country. The project aims to increase the awareness and knowledge of people in the communities of Cape Mount, Bomi, Margibi and Bong counties on the issues affecting their well-being especially on Ebola, and to strengthen their ability to act in order to promote theirs, their families' and their communities' wellbeing, especially to prevent further contagion of the Ebola disease.  The immediate objectives of the Project are 1) 1000 facilitators have participated in Ebola awareness training and gained skills to facilitate Ebola dialogue session in the communities, 2) 500 communities has received participatory community training on Ebola and taken measures to prevent the spread of the disease. Communities are offered awareness raising trainings on Ebola delivered by facilitators trained in cooperation with National Adult Education Association in Liberia, FRC's national partner organisation. Other co-operating partners are national and local authorities, especially Liberian Ebola communication coordination group lead by UNICEF. It is estimated that the project will benefit 50000 households in 500 communities.\",\n",
       "  '13030. CapacityPlus - Family Planning and Reproductive Health. CAPACITYPLUS - FAMILY PLANNING AND REPRODUCTIVE HEALTH. This project strengthens the human resources (HR) needed to implement quality health programs, in both the public and private, particularly the not-for-profit private, sectors. It addresses both the number of healthcare workers needed and the quality and performance of those workers. The definition of healthcare worker is expanded to include HR managers, laboratory staff, pharmacists, social workers, information systems/monitoring and evaluation specialists and others essential to the effective functioning of the health system.',\n",
       "  '13030. UNICEF PIO - Family Planning and Reproductive Health. UNICEF PIO - FAMILY PLANNING AND REPRODUCTIVE HEALTH. The Health Pooled Fund (HPF) is one of the Government of Ethiopias preferred modalities for scaling up development partners assistance in support of HSDP IV. UNICEF has been substantially involved in the implementation of the Health Sector Development Plan (HSDP IV) since the introduction of the Health Pooled Fund (HPF). Through this mechanism, USAID is contributing to the Health Pooled Fund. This activity is an effective and efficient way to achieve USAID objectives through ensuring the accessibility of effective health services at all levels of the health system. This activity supports HSDP IV implementation through monitoring and evaluation; the development of studies/research; development of standards, guidelines, and manuals; and promotion of policy dialogue workshops such as woreda-based planning and the Annual Review Meeting (ARM). The project also supports participation of Ministry staff in relevant seminars and study trips to enhance program excellence.',\n",
       "  '12181. MEDICAL TRAINING. MEDICAL TRAINING. Financing an agreement with the Kingdom of Morocco in the field of health sciences',\n",
       "  '12110. Evaluation of Rajiv Aarogyasri Health Insurance Scheme in Andrha Pradesh, India. EVALUATION OF RAJIV AAROGYASRI HEALTH INSURANCE SCHEME IN ANDRHA PRADESH, INDIA. In 2007, out-of-pocket expenditures accounted for 90% of total private expenditure on healthcare in India. The cost of coping with serious disease can be ruinous for families living below the poverty line. The Rajiv Aarogyasri Health Insurance Scheme was established in Andrha Pradesh to mitigate catastrophic healthcare expenses for enrolled families, and to ensure that the target population has access to quality health services for serious illnesses.Aarogyasri currently covers more than 80% of the population of Andrha Pradesh. As one of the first schemes of its kind at this scale, Aarogyasri has generated national and international interest. A detailed evaluation is critical not only to keep improving the scheme, but also to ensure that the lessons learned from it benefit other states and countries. The Aarogyasri Trust Board has therefore asked a consortium of institutions to evaluate the scheme and consider its potential role in prevention and primary healthcare. This project is a response to that request. The evaluation will also establish a baseline for future evaluations, identify areas for further research, and build capacity for research, evaluation and evidence-based policymaking in India.',\n",
       "  \"12263. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       "  '12250. University of Chinese Academy of Sciences. UNIVERSITY OF CHINESE ACADEMY OF SCIENCES. to develop and conduct the first Chinese Version Vaccinology Course, in order to enhance the scientific perspectives of vaccine and immunization in all the stakeholders and optimize the ecosystem of immune community in China',\n",
       "  '13040. The Scripps Research Institute. THE SCRIPPS RESEARCH INSTITUTE. to provide general operating support',\n",
       "  '12230. Egypt-Swiss Radiology Project Phase III. EGYPT-SWISS RADIOLOGY PROJECT PHASE III. Egypt-Swiss Radiology Project Phase III. After the successful implementation of the First Phase, which started in 2002, with the financing of 80 radiology equipments and film processors, a second phase was initiated in 2007 and completed in 2011. The objective of this phase was to extend the modernisation of the radiology services in Egyptian hospitals. Digital radiology was introduced in pilot sites. These activities were performed in this project: the rehabilitation of sites receiving improved radiology services and equipment, the provision of radiology equipment, the assistance for the maintenance of the radiology technology and the training and capacity building programme for the radiology staff. At the end of the project, over 100 radiology departments in selected hospitals, including structural radiation safety were renovated and rehabilitated according to defined standards. Moreover, the equipment maintenance and technology management was strengthened and the radiation safety by training measures and supervision schemes was applied. Finally, digital radiology was tested in pilot sites to be extended in the 3rd phase that started in 2012. The implementing agency for this project is the Egyptian Ministry of Health and Population. This is a project mixed-financed by Switzerland (50% by SECO, 50% by Swiss banks).',\n",
       "  '12182. DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE: EQUITABLE PREVENTION ACROSS GENERATIONS? FOLLOW-UP OF THE MINIMAT RANDOMIZED TRIAL IN BANGLADESH. DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE: EQUITABLE PREVENTION ACROSS GENERATIONS? FOLLOW-UP OF THE MINIMAT RANDOMIZED TRIAL IN BANGLADESH. This project - follow-up of the MINIMat trial - is implemented in Bangladesh, in a context, where food insecurity and maternal malnutrition still prevail, but where changing lifestyles and economic growth potentially increase the risk for future chronic disease of the offspring. Pregnant women were randomised to an early (E) start of prenatal food supplementation vs. usual program start, and multiple micronutrient supplementation (MMS) vs. iron-folate. Participants were followed-up for primary outcomes (maternal haemoglobin, birth weight, and infant survival) and for a series of secondary outcomes based on the Developmental Origin of Health and Disease hypothesis. So far we have demonstrated a remarkable effect of E-MMS on infant and under-five survival, and effects of the interventions on childhood stunting and metabolic markers at 4.5 years. We aim at studying whether the effects of the prenatal interventions on growth and metabolic markers up to 4.5 years are sustained at 10 years, to evaluate if these interventions reduce health disparities, and whether social conditions and maternal stressors modify the effect on children of the interventions, and to analyse the public health impact and the cost-utility of the interventions in order to inform policy and possibilities for scaling-up.',\n",
       "  '13020. Strengthening Human Resources for Health (SHRH) - Capacity follow on. STRENGTHENING HUMAN RESOURCES FOR HEALTH (SHRH) - CAPACITY FOLLOW ON. SHRH will be a bilateral associate award under the Capacity Plus Leader with Associate award. Building upon the Uganda Capacity Program and continuing HRH interventions which were shown to produce higher level results, SHRH will further expand in the area of pre-service training capacity and performance based incentives. SHRH will develop the capacities of the central ministries, districts and professional councils to effectively and efficiently manage their HR for delivery of health services. It will work with USG implementing partners to ensure targeted HRH improvements at the service delivery level. Expected results in FY 2014 includes: scale-up of HR information system and recruitment plans in all 112 districts; comprehensive support for district level HRH to all USG implementing partners; and improved regulation and functionality of health professional councils.',\n",
       "  '12110. Technical Assistance to Strengthen Leadership for Reform in Ministry of Health. TECHNICAL ASSISTANCE TO STRENGTHEN LEADERSHIP FOR REFORM IN MINISTRY OF HEALTH. To improve the performance of the Zambian public sector by providing advice and equipment to the Government of Zambia. This will strengthen performance management and contribute towards our MDGs by improving the quality of public services for 13 million Z',\n",
       "  '13040. Strengthening Partnerships, Results, and Innovations in Nutrition Globally (SPRING) - HIV/AIDS. STRENGTHENING PARTNERSHIPS, RESULTS, AND INNOVATIONS IN NUTRITION GLOBALLY (SPRING) - HIV/AIDS. Strengthening Partnerships, Results, Innovations in Nutrition Globally (SPRING)',\n",
       "  '12262. Malaria - Administration and Oversight (Malaria). MALARIA - ADMINISTRATION AND OVERSIGHT (MALARIA). Malaria - Supports the following illustrative program-funded costs: salaries of US, FSN, and TCN and other staff such as PSCs, RSSAs, PASAs, CASUs working for the US Government managing, administering, and supporting programs and their program-funded benefits such as housing, travel, transportation, education allowances etc; institutional contractors that provide such staff, rent, IT services, the program-funded share of utilities, staff training costs and the cost of developing and administering training programs, equipment and supplies, ICASS, vehicle fuel and maintenance, maintenance contracts, janitorial services, operational unit web page development and maintenance, outreach such as publications and the cost of their preparation (including staff costs), and technical assistance to ensure USG compliance with regulations.',\n",
       "  '12181. University of Geneva. UNIVERSITY OF GENEVA. To train health leaders from developing countries in decision-processes related to vaccination policies and assessment of new vaccines against major infectious diseases through participation in 12th annual Advanced Courses of Vaccinology',\n",
       "  '12182. RESEARCH COOPERATION WITH UEM, MOZ, 2011-2016 - ISP MSC-PROGRAMMES, ADD 1. RESEARCH COOPERATION WITH UEM, MOZ, 2011-2016 - ISP MSC-PROGRAMMES, ADD 1. The program objective is to strengthen higher education and national research systems, through direct support to research, postgraduate training and development of institutional capacity for research management within the University of Eduardo Mondlane (UEM). The contribution period covers 2011-2015. Comp. 3; financing of 4 MSc programs. Comp. 5; additional support to MBR at Inhaca.',\n",
       "  \"13020. Strengthening the Public Financial Management (PFM) Systems. STRENGTHENING THE PUBLIC FINANCIAL MANAGEMENT (PFM) SYSTEMS. This contract will operationalize the Mission's Country Development Cooperation Strategy by supporting collaboration among targeted government ministries, local government bodies, USAID, and other donors. Activities will include targeted technical and organizational capacity building to strengthen the Government of Nepal's (GON) ability to meet demands for increased and improved public services. The activities will address issues of transparency, reporting and public financial management, especially targeted at good governance interventions impacting Presidential Initiative programming. Using technical assistance for targeted GON Ministries and their sub-national representatives, the governance activities will focus on capacity building and service delivery, while supplementing the reach of the current democracy and governance portfolio. The activity will be based on a targeted Ministry-level Public Financial Management Risk Assessment Framework conducted in 2012-2013. These assessments, including for Ministry of Health and Population (MOHP) and Ministry of Education (MOE), laid the foundation for future investments in building the capacity of targeted Ministry's financial and administrative processes by revealing several major areas of need. These gaps include critical deficiencies in the areas of: budget execution; procurement; ordering of goods and services and payment of invoices; performance; external audit; and the control environment.Strengthening PFM project will support building the capacity of targeted Government of Nepal (GON) Ministries to improve transparency and accountability of public financial management (PFM) systems.\",\n",
       "  '13040. Social Accountability Assessment - HIV/AIDS. SOCIAL ACCOUNTABILITY ASSESSMENT - HIV/AIDS. IBTCI was contracted by USAID/Ethiopia to provide a Social Accountability assessment for select programs across a broad set of technical sectors. Offices included Assets and Livelihoods Transition, Basic Education Services, Economic Growth and Transformation and Health, and finally AIDS, Population and Nutrition. The goal of these assessments was to provide the Democracy and Governance Office at USAID the tools need to strengthen the principles and practices of social accountability resulting in more accessible, affordable, responsive and effective service delivery. This was achieved by harvesting lessons learned, identifying success stories as well as innovative best practices that were in use. These lessons would be incorporated in future USAID Ethiopia programming.',\n",
       "  '12230. Contribution Laboratory Equipment for Health Centre. CONTRIBUTION LABORATORY EQUIPMENT FOR HEALTH CENTRE. Buy new equipment for health centre.',\n",
       "  '12191. Strengthening surgical and trauma health response in two most affected areas by Ebola in Sierra Leone: Port Loko and Western Area. STRENGTHENING SURGICAL AND TRAUMA HEALTH RESPONSE IN TWO MOST AFFECTED AREAS BY EBOLA IN SIERRA LEONE: PORT LOKO AND WESTERN AREA. Strengthening surgical and trauma health response in two most affected areas by Ebola in Sierra Leone: Port Loko and Western Area',\n",
       "  '12263. Programme to Combat Tuberculosis. PROGRAMME TO COMBAT TUBERCULOSIS. Financing of laboratory equipment, medical technical equipment, transportation measure for monitoring and supervision as well as consulting services for the Tuberculosis Control Program.',\n",
       "  '12262. From Malaria control towards malaria eradication: speed up malaria control activities with a view to eradication in Madagascar. FROM MALARIA CONTROL TOWARDS MALARIA ERADICATION: SPEED UP MALARIA CONTROL ACTIVITIES WITH A VIEW TO ERADICATION IN MADAGASCAR. Malaria is a major public health issue in Madagascar with 92 percent of the population exposed to risk. The program supported by this grant aims to increase the correct use of affordable, high-quality artemisinin-based combination therapies (ACTs) by adolescents and adults to 75 percent by 2012. To reach this goal, the program will create publicity campaigns to raise awareness about the availability of affordable, high-quality ACTs; conduct behavior change communication activities among the population at large to encourage the use of ACTs; train doctors and nurses on the proper way of treating malaria, i.e. with ACTs and drug monitoring; build technical capacity for drug monitoring in 769 private health care facilities; and supervise private health care facilities, pharmacies and small dispensaries with an aim to promote ACTs and monitor the prevalence of antimalarial monotherapies.',\n",
       "  '13040. Building social capital to prevent HIV and improve access to comprehenseive healthcare without transphobia or homophobia for the transsexual, gay/MSM population in Peru. BUILDING SOCIAL CAPITAL TO PREVENT HIV AND IMPROVE ACCESS TO COMPREHENSEIVE HEALTHCARE WITHOUT TRANSPHOBIA OR HOMOPHOBIA FOR THE TRANSSEXUAL, GAY/MSM. The HIV and AIDS epidemic in Peru is concentrated in most-at-risk populations (MARPs), mainly the men who have sex with men (MSM) population, with the highest prevalence in the transsexual population. The program will focus on 8 regions of the country (Lambayeque, La Libertad, Lima, Callao, Ica, Loreto, San Martin and Ucayali) which account for 80% of the total HIV and AIDS cases reported so far. The Program will address different needs of the MARPs sub-populations in Peru, confronting the barriers they face in terms of stigma and discrimination, socio-economical, educational and employment challenges and the prevalence of sexual work. The Program aims to strengthen the capacity of transsexuals and gay/MSM community based organizations (CBOs) by improving their technical and management capacities to be better equipped to exercise community surveillance; support the fight against homophobia, stigma and discrimination; produce quality data and studies about most at risk groups, and to improve access to comprehensive healthcare. The goal is to help MSM populations gain universal access to high quality comprehensive healthcare, intensifying and increasing preventive actions and strengthening their base organizations in an environment that respects their rights and guarantees equal opportunities.',\n",
       "  \"13040. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       "  '12191. Construction of an orthopedics workshop, advanced training and education in orthopedics technology, job creation, a mutual exchange of trainees. CONSTRUCTION OF AN ORTHOPEDICS WORKSHOP, ADVANCED TRAINING AND EDUCATION IN ORTHOPEDICS TECHNOLOGY, JOB CREATION, A MUTUAL EXCHANGE OF TRAINEES. Construction of an orthopedics workshop as well as a vocational training centre and an advanced training academy in Mukono, Uganda.',\n",
       "  '12240. Baby food: food production for childhood protection in Benin. BABY FOOD: FOOD PRODUCTION FOR CHILDHOOD PROTECTION IN BENIN. Restoring the functionality of some devices of the production of high-protein flour for weaning of the UBETA (UnitT de Technologie Alimentaire BTninoise) babies , and adaptation to the quality standards of the finished product',\n",
       "  '12110. Visit to Health by a Delegation from the Ministry of Finance of the Socialist Republic of Vietnam. VISIT TO HEALTH BY A DELEGATION FROM THE MINISTRY OF FINANCE OF THE SOCIALIST REPUBLIC OF VIETNAM. Facilitated visit focused on taxation and pricing mechanisms to curb tobacco consumption',\n",
       "  '13040. Reseau Africain de Recherche sur le SIDA. RESEAU AFRICAIN DE RECHERCHE SUR LE SIDA. to support the building of a sustainable HIV PrEP program for female sex workers in Dakar, Senegal',\n",
       "  '12191. Increase in health services at the St. John Paul II Hospital in Pathein - Kangyi. INCREASE IN HEALTH SERVICES AT THE ST. JOHN PAUL II HOSPITAL IN PATHEIN - KANGYI. Construction of a new hospital, consisting of two floors with maternity wards, pediatric wards, new clinics, small laboratory analysis, new patient room for patients, bathrooms, medicine storage room with fridge, a complete kitchen, food warehouse , service room cleaning, maintenance rooms and staff room, building with patients for the medical staff and any accompanying persons, a nutritional center for new mothers. There is also a vegetable garden with a relative henhouse, a security fence and an incinerator for medical equipment. Finally, we intend to organize professional training courses for health personnel.',\n",
       "  '12240. Improving the livelihoods of small holder farmers through capacity building and the establishment of sustainable economic structures in Hayakavan. IMPROVING THE LIVELIHOODS OF SMALL HOLDER FARMERS THROUGH CAPACITY BUILDING AND THE ESTABLISHMENT OF SUSTAINABLE ECONOMIC STRUCTURES IN HAYAKAVAN. Improving the livelihoods of small holder farmers through capacity building and the establishment of sustainable economic structures in Hayakavan',\n",
       "  '13040. Family AIDS Initiative (FAI) Project - HIV/AIDS. FAMILY AIDS INITIATIVE (FAI) PROJECT - HIV/AIDS. Through this project, EGPAF has been the primary partner in providing technical support to Zimbabwes Ministry of Health and Child Welfare (MOHCW) to increase access to comprehensive, high-quality prevention of mother-to-child transmission of HIV (PMTCT) services that are closely linked to HIV/AIDS treatment, care, and support for families, including children living with HIV. Over the five-year period, the program expanded its partnership with the MOHCW by supporting a package of district-level activities to strengthen district-level PMTCT and pediatric services nationwide towards achieving full-scale elimination of pediatric HIV and AIDS in Zimbabwe.',\n",
       "  '16064. UNAIDS baseline study. UNAIDS BASELINE STUDY. This project will undertake a study to establish an evidence-base for the impact of youth participation and a baseline of youth participation and leadership in the AIDS and sexual and reproductive health and rights processes at country, regional, and global level.',\n",
       "  '13040. Academic Model Providing Access to Healthcare - People-centered, Leadership, Universal Access, Sustainability (AMPATH plus) - HIV/AIDS. ACADEMIC MODEL PROVIDING ACCESS TO HEALTHCARE - PEOPLE-CENTERED, LEADERSHIP, UNIVERSAL ACCESS, SUSTAINABILITY (AMPATH PLUS) - HIV/AIDS. AMPATHplus aims to augment HIV care and control program and expand AMPATHpluss primary care activities. AMPATH PLUS will be a new phase in which the Moi University, Moi Teaching and Referral Hospital, and the Ministry of Health facilities work together to improve the health of our catchment area in Kenya. In this new phase, not only will we seek to find, link, treat, and retain all HIV-infected people within our catchment area, but we will also dramatically increase our primary care and chronic disease management services. AMPATH is poised to serve as a model of innovation, ultimately creating knowledge on the best practices that can be shared with other USAID programs, with the Government of Kenya and with healthcare systems throughout the world.',\n",
       "  '13020. Marketing Innovations for Health (MIH) - Maternal and Child Health. MARKETING INNOVATIONS FOR HEALTH (MIH) - MATERNAL AND CHILD HEALTH. MIH is a four-year project that started in July 2012 under a cooperative agreement with USAID. SMC is implementing this integrated social marketing program along with several local and international partners, to help bring about behavior change and improve health practices, increase access to and use of family planning products including Long Acting Reversible Contraceptive methods, Reproductive Health and Nutritional products, and improve the capacity of community based health practitioners in the private sector. The program is implementing community mobilization activities in 19 low-performing districts of Bangladesh. In addition, it includes national distribution and communication of existing SMC products as well as several new innovations through the private sector. SMC partners in the project include BRAC, Concerned Women for Family Development (CWFD), Population Services and Training Centre (PSTC) and Shimantik. Engender Health and PSI are associated as training and technical partners respectively. Under MIH, SMC is implementing a large health communications program with focused messaging on five core communication areas as follows: Healthy Timing and Spacing of Pregnancies; First 1000 Days of a Childs life (from conception to 2 years of age); Healthy Pregnancy; Adolescent Health; TB Prevention and Management. The program will also expand SMCs network of Blue Star providers and build capacity of formal and non-formal health providers through basic and refreshers training.',\n",
       "  '12261. Project Concern International. PROJECT CONCERN INTERNATIONAL. to build and strengthen community-based structures in Bihar so that these structures can be leveraged for behavior change to drive increases in coverage of key family health and sanitation interventions, improve social accountability for health and sanita',\n",
       "  '13020. Applying Science to Strengthen and Improve Systems (ASSIST). APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST). The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       "  \"13081. Uzazi Uzima II: Safe Deliveries in Simiyu Region/Uzazi Uzima II: Accoucher en sTcuritT dans la rTgion de Simiyu. UZAZI UZIMA II: SAFE DELIVERIES IN SIMIYU REGION/UZAZI UZIMA II: ACCOUCHER EN S+CURIT+ DANS LA R+GION DE SIMIYU. The Uzazi Uzima II project seeks to reduce maternal and newborn mortality and morbidity in all five districts of Simiyu region, Tanzania by improving the availability of quality adolescent, maternal and newborn health services in underserved districts through three mutually supportive mechanisms. The project will: improve the knowledge and skills of healthcare providers on maternal, newborn and sexual/reproductive health to ensure they can provide critical services to their beneficiaries in a gender sensitive and responsive way;  improve the infrastructure and supply-chain for health facilities to encourage women, girls and their families to use services; and improve gender responsive health management systems (such as planning, prioritization and management of services). The project will also increase awareness and understanding of sexual, reproductive, maternal and child health with special focus on men's participation in reproductive, maternal and newborn health and decision making.Project activities include: (1) training health workers from four health centres and 24 dispensaries on: essential maternal and newborn health skills, such as Basic Emergency Obstetric and Newborn Care (BEmONC); Comprehensive Emergency Obstetric and Newborn Care (CEmONC), family planning; nutrition counselling; and newborn resuscitation; (2) refurbishing four health centres and 24 dispensaries to provide CEmONC, BEmONC, water, sanitation and hygiene and family planning services, including a satellite safe blood center at the regional hospital; (3) equipping targeted health facilities with the necessary stocks of equipment and commodities to provide BEmONC, CEmONC, family planning and safe blood services; (4) establishing a referral system for maternal and newborn health care and family planning services across all tiers of the health system; (5) training and supporting Ministry of Health and facility-based managers, and health workers to improve community to facility linkages (enhanced data collection, consolidation, analysis and reporting); and (6) training and equipping community health workers, traditional birth attendants, traditional healers, and local leaders to provide community-level health promotion services (including maternal and newborn health, water, sanitation and hygiene, family planning, nutrition, gender issues and use of mobile health technology to mobilize communities).The project is implemented in collaboration with Amref Health Africa in Tanzania, Marie Stopes Tanzania and Deloitte./ Le projet vise a rTduire la mortalitT et la morbiditT des mFres et des nouveau-nTs dans les cinq districts de la rTgion de Simiyu, en Tanzanie. Cet objectif est atteint en assurant une meilleure disponibilitT des services de santT maternelle et nTonatale de qualitT dans les quartiers mal desservis et en augmentant l'utilisation de ces services par les femmes et leurs familles dans les districts ciblTs au moyen d'interventions a covt modique, mais de vaste portTe. Le\",\n",
       "  \"12220. Bone Marrow Transplantation Program. BONE MARROW TRANSPLANTATION PROGRAM. The prime partner for this project is Augusta Victoria Hospital (AVH). AVH plans to establish a new bone marrow transplantation and stem cell therapy program that serves West Bank and Gaza patients in East Jerusalem. The project is expected to reduce Palestinian Ministry of Health (MoH) burden of referring patients externally to Jordan or Israel and increasing local capacity to provide specialized health services.Nongovernmental organization (NGO) hospitals like AVH are an integral part of the Palestinian health care system. The Palestinian Authority's MoH relies heavily on NGO hospitals in the West Bank to provide essential secondary and tertiary care to Palestinians that the MoH is unable to provide.AVH, through its provision of specialty health care services, is committed to introducing services that are most commonly sought abroad, reduce overall health care costs, and increase the capacity of Palestinian providers to perform modern and innovative procedures. AVH currently has an on-going contract with the MoH to provide care and treatment for cancer patients. With prior year funding, the hospital is procuring the equipment needed to establish a bone marrow transplantation unit at AVH.Bone marrow transplantation services are not available within the Palestinian health system partially due to a lack of health professionals, especially nurses and allied health staff. With this funding hospital staff will be trained to perform their duties properly and in accordance with accreditation requirements and international standards.\",\n",
       "  '12240. Maternal and Child Health Integrated Program (MCHIP) - Nutrition. MATERNAL AND CHILD HEALTH INTEGRATED PROGRAM (MCHIP) - NUTRITION. The Maternal and Child Health Integrated Program (MCHIP) is a $600 million Leader with Associates Cooperative Agreement (LWA) designed to support the introduction, scale-up and further development of high impact Maternal, Neonatal, and Child Health (MNCH) interventions, including the program approaches to effectively deliver those interventions, to achieve measurable reductions in under-five and maternal mortality and morbidity.',\n",
       "  \"13020. RENFORCEMENT DU SYSTFME DE MATERN.ANJOUA. RENFORCEMENT DU SYST+ME DE MATERN.ANJOUA. AmTlioration de la santT maternelle et nTonatale en vue de contribuer a la rTduction de la mortalitT maternelle et nTonatale. Le projet vise a amTliorer l'accFs aux services et aux soins obstTtricaux dans le Nyumakele et a augmenter le nombre d'accouchements assistTs par du personnel qualifiT dans le district de M'rTmani par la reconstruction de la maternitT de M'rTmani, l'augmentation des accouchements assistTs dans le Nyumakele et la mise en place d'un service expTrimental d'ambulance.\",\n",
       "  '12220. Commander s Emergency Response Program (CERP): Other Public Health Threats. COMMANDER S EMERGENCY RESPONSE PROGRAM (CERP): OTHER PUBLIC HEALTH THREATS. The Commander s Emergency Response Program (CERP) authorizes U.S. military commanders in Afghanistan to carry out small-scale projects designed to meet urgent humanitarian relief or reconstruction requirements within their areas of responsibility.',\n",
       "  \"13040. Prevention Organizational Systems AIDS Care and Treatment (Pro-ACT). PREVENTION ORGANIZATIONAL SYSTEMS AIDS CARE AND TREATMENT (PRO-ACT). The Prevention Organizational Systems AIDS Care and Treatment (Pro-ACT) project goal is to build the capacity of Nigeria's public, private, and community sectors for sustainable HIV and AIDS and Tuberculosis prevention, control, care and treatment. Management Sciences for Health (MSH) is implementing Pro-ACT project in five Nigerian States: Niger, Kwara, Kebbi, Sokoto, and Zamfara.\",\n",
       "  '13010. Health Communication Capacity Collaborative (HC3) - Program Design and Learning. HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3) - PROGRAM DESIGN AND LEARNING. HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       "  '12182. Antimicrobial Resistance in a Global Context. ANTIMICROBIAL RESISTANCE IN A GLOBAL CONTEXT. Investments in interdisciplinary and focussed research at international levels to identify the burden and primary drivers of antimicrobial resistance and specifically antibacterial resistance in low- and middle-income countries',\n",
       "  '12230. Technology Modernization Project at the clinic of Mutual Nikkai. TECHNOLOGY MODERNIZATION PROJECT AT THE CLINIC OF MUTUAL NIKKAI. In order to buy the necessary medical equipment to clinic operated by Mutual Nikkai to provide an environment of stable medical services to the community.',\n",
       "  '12240. Provincial Health and Nutrition Programme - Empowerment, Voice and Accountability (EVA). PROVINCIAL HEALTH AND NUTRITION PROGRAMME - EMPOWERMENT, VOICE AND ACCOUNTABILITY (EVA). To improve reproductive, maternal, new born and child health services to the population of Punjab (Pb) and Khyber Pakhtunkhwa (KP), which comprises 70% of the total population in Pakistan.',\n",
       "  \"13020. Aiding the campaign to end fistula. AIDING THE CAMPAIGN TO END FISTULA. United Nations Population fund (UNFPA) supports poor countries in policy making and projects that aim at eradicate poverty, improve women's safety when giving birth, and fighting AIDS/HIV. One of the fund's projects is campaigning to end fistula. Fistula is an injury that happens at child birth due to prolonged obstructed labour when a passage opens between urethra and the vagina or between the vagina and the rectum. Because of the smell of leaking urine or faeces is hard to eliminate and difficult to ignore and because of this the girls face exclusion from the society they belong to and suffer mentally as well as physically. Those mainly affected are young girls between 12 and 15 that live in densely populated and poorer areas. The condition nearly always leads to death of a child at birth. UNFPA has prioritized this campaign but it has been only 20 years since the problem was dealt with. The fund considers this to be one of it's most important projects since around 93% of the cases can be mended by surgery. Fistula is an extensive problem in Africa, Asia and the Middle-East.\",\n",
       "  '13020. MEASURE Phase III, Demographic and Health Surveys (DHS) - Maternal and Child Health. MEASURE PHASE III, DEMOGRAPHIC AND HEALTH SURVEYS (DHS) - MATERNAL AND CHILD HEALTH. The purpose of MEASURE Phase III DHS is to improve the collection, analysis and presentation of data and promote better use in planning, policymaking, managing, monitoring and evaluating population, health and nutrition programs. The project seeks to increase understanding of a wide range of health issues by improving the quality and availability of data on health status and services and enhancing the ability of local organizations to collect, analyze and disseminate such information.',\n",
       "  '12263. MEASURE Evaluation Phase III - Tuberculosis. MEASURE EVALUATION PHASE III - TUBERCULOSIS. MEASURE Evaluation Phase III continues the MEASURE programs 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3)increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       "  '13040. HIV Innovations for Improved Patient Outcomes for Priority Populations (Innovative Models for Capacity Building & Support of Scale Up of Effective HIV-related Services for MSM). HIV INNOVATIONS FOR IMPROVED PATIENT OUTCOMES FOR PRIORITY POPULATIONS (INNOVATIVE MODELS FOR CAPACITY BUILDING & SUPPORT OF SCALE UP OF EFFECTIVE HIV. HIV Innovations for Improved Patient Outcomes for Priority Populations (Innovative Models for Capacity Building & Support of Scale Up of Effective HIV-related Services for MSM)',\n",
       "  '12220. Nasarawa State Primary Healthcare Development Agency (NAPHDA). NASARAWA STATE PRIMARY HEALTHCARE DEVELOPMENT AGENCY (NAPHDA). to support the improvement of structures and systems of governance and leadership, performance management, and financing of Primary Health Care for the benefits of the people of Nasarawa state',\n",
       "  '13020. Strengthening Implementation of Program Budgeting - Maternal and Child Health. STRENGTHENING IMPLEMENTATION OF PROGRAM BUDGETING - MATERNAL AND CHILD HEALTH. Provide technical assistance to assist with strengthening public financial management (PFM) policies that will promote fiscal transparency. The objectives of the program support the following areas: (1) improved allocation of budget resources to programs of pilot ministries, including the Ministry of Health, (2) implementation of program budgeting in the remaining 30 national government line ministries, and (3) expansion of program budgeting to sub-national government institutions.',\n",
       "  '12110. Alcohol, Drugs and Development - Local Prevention Dolakha, NEP. ALCOHOL, DRUGS AND DEVELOPMENT - LOCAL PREVENTION DOLAKHA, NEP. Local enforcement of, and knowlge about, the laws and policies regulating alcohol and tobacco. Improved performance by state and other relevant actors the local level in Dolakha district. Create awareness of relations to child rights, gender rights, and HIV/AIDS.',\n",
       "  '13020. Health Communication Capacity Collaborative (HC3). HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3). HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       "  '12240. Nutrition: Advocacy for Regulation of Marketing of Breast Mil k Sub SLE.ACF.2017.01 DCD22515. NUTRITION: ADVOCACY FOR REGULATION OF MARKETING OF BREAST MIL K SUB SLE.ACF.2017.01 DCD22515. Nutrition: Advocacy for Regulation of Marketing of Breast Mil k Sub SLE.ACF.2017.01 DCD22515',\n",
       "  '12240. FEEDING PROJECTFOR CHILDREN. FEEDING PROJECTFOR CHILDREN. The Catholic Hostel is a school that welcomes children, males and females from very poor families of the city and surrounding areas.  The majority of children who show up at the school are underweight and ill. To allow children to study in the school it is provided, therefore, the opportunity of medical assistance. To reduce cases of malnutrition was organized a nutritional program. Thanks to a balanced diet, vitamin supplements and healthy foods, many children can reach an optimal weight.',\n",
       "  \"12181. Training - 2016 Healthcare Executive Leadership Training Program, through Meridian International Center. TRAINING - 2016 HEALTHCARE EXECUTIVE LEADERSHIP TRAINING PROGRAM, THROUGH MERIDIAN INTERNATIONAL CENTER. USTDA partially funded two separate and distinct 14-day training programs for 25 senior Chinese healthcare executives and officials to introduce them to best practices in healthcare management and U.S. advanced medical technologies and solutions. This was the fifth USTDA training program for Chinese healthcare executives, and was supported by members of the U.S.-China Healthcare Cooperation Program (HCP) and China's Health Human Resources Development Center (HHRDC).\",\n",
       "  '13020. Opening of the clinical for medicine, maternity and surgery in Antsiranana. OPENING OF THE CLINICAL FOR MEDICINE, MATERNITY AND SURGERY IN ANTSIRANANA. Opening of the clinical for medicine, maternity and surgery in Antsiranana',\n",
       "  \"13040. Voluntary Medical Male Circumcision III Program. VOLUNTARY MEDICAL MALE CIRCUMCISION III PROGRAM. The Voluntary Medical Male Circumcision (VMMC) Service Delivery III Project (Siyasoka) scales up VMMC services in South Africa. The purpose of this activity is to provide direct service delivery to support high quality, high volume VMMC and related services in rural and urban areas of the country. Siyasoka draws upon the experience of the previous VMMC I and II projects, managed by the Right To Care Consortium in South Africa, and builds on URC's experience in implementing continuous quality improvement in VMMC services in over eight countries since 2012. Working at fixed, outreach, and mobile VMMC sites in rural and urban priority districts, the Siyasoka project aims to reach 80% coverage of the target population in order to prevent new HIV infections. We will also work to coordinate the forecasting, procurement, quality assurance, distribution, and storage of VMMC surgical kits and commodities. In addition to providing direct service delivery throughout the country, the project will also support the transition of direct VMMC service delivery to the South Africa Government National Department of Health (NDOH).\",\n",
       "  '12110. China National Health Development Research Center. CHINA NATIONAL HEALTH DEVELOPMENT RESEARCH CENTER. to explore and develop three components of a China National Institute for Health and Care Excellence like Health Technology Assessment mechanism - HTA process, methodology development and dissemination',\n",
       "  '13020. DAR AMREF II. DAR AMREF II. National Fistula Program Extension',\n",
       "  '12263. KwaZulu-Natal Research Institute for TB & HIV. KWAZULU-NATAL RESEARCH INSTITUTE FOR TB & HIV. to hold a series of four biostatistics courses for African scientists',\n",
       "  '13040. Output 04: HIV. HIV. China - Beijing. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12191. A dental laboratory equipment in the clinic NS Guadalupe. A DENTAL LABORATORY EQUIPMENT IN THE CLINIC NS GUADALUPE. A dental laboratory equipment in the clinic NS Guadalupe',\n",
       "  '12281. Healthcare Centre MAMA CARLA, La Joie de Vivre Center Bangui, (Analysis laboratory, Dispensary of primary care for children and Telemedicine). HEALTHCARE CENTRE MAMA CARLA, LA JOIE DE VIVRE CENTER BANGUI, (ANALYSIS LABORATORY, DISPENSARY OF PRIMARY CARE FOR CHILDREN AND TELEMEDICINE). The Health Medical Centre MAMA CARLA give the possibility to the needy children, orphans or abandoned housed in the Centre La Joie de Vivre to have free access to the medical services. Medical examination, ambulatory treatments, infectious disease and malaria control, urgent pharmacological treatments and assistance to undernourished are opened also for all the students of the School Nicolas BarrT and to the children living in the surrounding areas from 0 to 14 ages. The Centre organizes hygienic consulting, education and training for mothers. Assistance and training to pregnant women AIDS infected. Health personnel development.',\n",
       "  '13040. Improved Services for AIDS and Basic Healthcare through Empowerment of Local Democracy (ISABEL). IMPROVED SERVICES FOR AIDS AND BASIC HEALTHCARE THROUGH EMPOWERMENT OF LOCAL DEMOCRACY (ISABEL). The main aim of this Action is that in Malawi, by 2018, there should be inclusive, empowered communities enjoy more healthcare rights, and that governance and accountability in healthcare are improved.  To achive this, the project will focus on the interface between healthcare actors and coomunities at district level  and how they hold each other to account.',\n",
       "  '13020. Communication for Change (C-Change) in DRC - Maternal and Child Health. COMMUNICATION FOR CHANGE (C-CHANGE) IN DRC - MATERNAL AND CHILD HEALTH. FHI 360s Communication for Change (C-Change) project in the Democratic Republic of the Congo (DRC) seeks to increase positive health behaviors through evidence-based, social and behavior change communication (SBCC) programs that focus on family planning, HIV/AIDS, gender-based violence, malaria, tuberculosis, water sanitation, maternal and child health, nutrition and HIV, and prevention of mother-to-child transmission of HIV. C-Change is working at central and provincial levels to build managerial and SBCC skills within the government, nongovernmental organizations and civil society organizations. We envision building local capacity to plan, monitor and evaluate scientifically based SBCC interventions, so the DRC becomes a regional leader offering state-of-the-art SBCC approaches to neighboring countries.',\n",
       "  '12250. Scientific cooperation with other countries (not included in other areas). SCIENTIFIC COOPERATION WITH OTHER COUNTRIES (NOT INCLUDED IN OTHER AREAS). RENOMAB - Research network on melioidosis and Burholderia pseudomallei - Capacity building in the field of education and research',\n",
       "  '12220. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Community based health care services and leadership training',\n",
       "  \"12250. Support to the Government of Ghana's response to the ongoing cholera outbreak and mitigate the threat of Ebola in the region.. SUPPORT TO THE GOVERNMENT OF GHANA'S RESPONSE TO THE ONGOING CHOLERA OUTBREAK AND MITIGATE THE THREAT OF EBOLA IN THE REGION.. To improve the health system in Ghana, by providing the Ministry of Health with direct budget support, materials, goods and technical assistance. This support will improve coverage and quality of primary care services and create a sustainable health syste\",\n",
       "  '13040. CapacityPlus - HIV/AIDS. CAPACITYPLUS - HIV/AIDS. This project strengthens the human resources (HR) needed to implement quality health programs, in both the public and private, particularly the not-for-profit private, sectors. It addresses both the number of healthcare workers needed and the quality and performance of those workers. The definition of healthcare worker is expanded to include HR managers, laboratory staff, pharmacists, social workers, information systems/monitoring and evaluation specialists and others essential to the effective functioning of the health system.',\n",
       "  '12182. Integrated Health, education and environmental (HEE) intervention to optimise infant feeding practices through schools and Anganwadi networks in India. INTEGRATED HEALTH, EDUCATION AND ENVIRONMENTAL (HEE) INTERVENTION TO OPTIMISE INFANT FEEDING PRACTICES THROUGH SCHOOLS AND ANGANWADI NETWORKS IN INDIA. GCRF Foundation NCDs 2016 examining methods enhancing feeding practices for children 6-24 months. Directly benefiting residents in 9 rural communities in Banswara district in Rajasthan India. Supporting mothers to improve living conditions and lifestyle in the community, and enhance capabilities of local schools and Anganwadis operating as community education and innovation hubs',\n",
       "  '12281. Trade-Related Training Program - Healthcare Leadership Training Program, through Meridian International Center. TRADE-RELATED TRAINING PROGRAM - HEALTHCARE LEADERSHIP TRAINING PROGRAM, THROUGH MERIDIAN INTERNATIONAL CENTER. USTDA funding in the amount of $380,000 partially supported a three-week training program for senior Chinese healthcare executives and officials to introduce them to best practices in healthcare management and U.S. advanced medical technologies and solutions. This was the fourth USTDA training program for Chinese healthcare executives, and was supported by members of the U.S.-China Healthcare Cooperation Program (HCP) and Chinas Health Human Resources Development Center (HHRDC). Delegates met with administrators and clinicians affiliated with the University of Pittsburgh Medical Center (UPMC) and the University of Illinois at Chicago (UIC) for trainings and tours.',\n",
       "  \"13030. Rights, Equality, SRHR & Adolescents in Mozambique. RIGHTS, EQUALITY, SRHR & ADOLESCENTS IN MOZAMBIQUE. The initiative aims to consolidate and expand on previous support initiative. The project will address inequitable gender norms to strengthen adolescents' SRHR outcomes while improving the availability and accessibility of quality Gender Based Violence (GBV) primary and secondary prevention, Comprehensive Abortion Care (CAC), and SRHR services. The aim is to improve adolescent sexual reproductive health in Maputo, Gaza, Inhambane and Cabo Delgado provinces by increasing gender equality\",\n",
       "  \"12263. Preventing multi-resistant tuberculosis by improving comprehensive care of tuberculosis. PREVENTING MULTI-RESISTANT TUBERCULOSIS BY IMPROVING COMPREHENSIVE CARE OF TUBERCULOSIS. C(te d'Ivoire is deeply affected by the problem of Tuberculosis (TB).  According to the 2008 WHO report, the prevalence for all TB forms constituted 747 cases per 100,000 inhabitants whereas the incidence  420 cases.  Based on a national survey conducted in 2006, the rate of Multi-Drug Resistant TB (MDR-TB) is 2.5 percent for new cases, and 8.6 percent for cases in re-treatment.  The Program is a consolidation of the Round 6 and Round 9 proposals and is implemented by two Principal Recipients (PR) through the dual-track financing scheme.  It continues to strengthen the extension of Directly Observed Treatment Short course (DOTS) strategy by increasing and de-centralizing the available care, by improving the management of MDR-TB cases, and by making better use of mass media for communication about TB.  The activities implemented by this PR include renovation and equipment of health facilities, procurement of drugs and laboratory products, TB and MDR-TB screening and treatment, nutritional support for vulnerable patients, and training of health workers.\",\n",
       "  '12110. Develop, Customize and implement an open source harmonized Laboratory Information Management System (LIMS) at CARPHA laboratories. DEVELOP, CUSTOMIZE AND IMPLEMENT AN OPEN SOURCE HARMONIZED LABORATORY INFORMATION MANAGEMENT SYSTEM (LIMS) AT CARPHA LABORATORIES. The purpose of the TA is to assist CARPHA with the implantation of an harmonized Laboratory Information Management System (LIMS). This will target the three regional laboratories based in Trinidad, Jamaica and Saint Lucia.',\n",
       "  '12240. Improving Living Conditions and Health in Rural and Indigenous Communities in Chuquisaca/AmTliorer les conditions de vie et la santT des communautTs rurales et autochtones de Chuquisaca. IMPROVING LIVING CONDITIONS AND HEALTH IN RURAL AND INDIGENOUS COMMUNITIES IN CHUQUISACA/AM+LIORER LES CONDITIONS DE VIE ET LA SANT+ DES COMMUNAUT+S R. This project will work in 14 communities in Chuquisaca, Bolivia, to strengthen income generation and address health challenges affecting maternal and child health, including nutrition, hygiene practices and access to health services. The project beneficiaries are primarily women and men at the community level as well as local and departmental governments. Project activities include: (1) support for increasing family enterprise profitability; (2) adopting good nutritional and environmental health practices; and (3) improving government support services through better management, coordination and leadership. Empowering rural women and youth in economic enterprise management is an important objective of the project./ a venir',\n",
       "  '12220. SELECTED EVALUATION STUDIES FOR 2014. SELECTED EVALUATION STUDIES FOR 2014. Description :. Product Type:',\n",
       "  '12182. Measuring the impact of research - Researchfish  research. MEASURING THE IMPACT OF RESEARCH - RESEARCHFISH  RESEARCH. To increase the impact of DFID funded health research by providing improved data on research outputs and outcomes',\n",
       "  '12110. Management Sciences for Health. MANAGEMENT SCIENCES FOR HEALTH. to increase the coverage of efficient, effective, and equitable primary health care services in Africa',\n",
       "  '13020. Gender Based Violence and reproductive health in Gao. GENDER BASED VIOLENCE AND REPRODUCTIVE HEALTH IN GAO. Awareness building and lobbying against FGM, targeting men and women, religious and community leaders',\n",
       "  \"16064. Good Samaritan HIV-project Malawi. GOOD SAMARITAN HIV-PROJECT MALAWI. Malawi Good Samaritan HIV project is part of Africa wide HIV program (GSP) by African Bible Societies that is running in over 20 Sub-Saharan countries. The long term objective of the project is to contribute to the reduction of the spread of HIV and stigma of people infected and affected. The main focus is to reduce stigmatization and discrimination of PLHA. The overall objectives of GSP are to strengthen the involvement of churches in  response to HIV by enabling people and organizations to: Get knowledge about HIV and AIDS and risky behaviour; Encourage VCT and sexual education; Eradicate stigma and discrimination; Restore PLHA?s human rights dignity and equality and; To renew churches and local congregations' social responsibility. The programme has two main target groups: People with influence as opinion leaders and/or with the capacity to act as facilitators and trainers; and people who are particularly vulnerable to HIV  such as the youth women PLHA  and married couples. Third phase  is especially  targeting PVDs  as they are one of the most HIV vulnerable groups. Through PVD strategy the aim is to include PVDs to existing structure of activities. The strategy is based on Information Education and Communication with a focus on behavioral change communication and to work with individuals and communities through sharing and providing supportive and enabling environments. The implementation is based on a two tier strategy: (i) advocacy sensitization and mobilization of community&religious leaders; and (ii) conduct training of trainers to reach local communities. The training uses the workshop as a platform to facilitate interaction sharing and reflection to  promote change in attitudes and behavior. The programme also encourages the formation of local groups for mutual support and action. Issues of gender will continue to be addressed as was the case in previous phases. Project staff will be equipped with training skills on gender and  human dignity since they  are key elements in the GS program. Project is implemented in existing structures that include governmental HIV coordination religious networks and local communities.The key project activities include different workshops: training of trainers (ToT) decentralized workshops (DWs) Follow up (FU) Take Charge youth program (TC). There is also an annual capacity building workshops for project staff (Joint Program Review and anglophone capacity building workshop).\",\n",
       "  \"12230. Le Projet d'Tquipement de laboratoire du Centre IntTgrT de Recherches Biocliniques d'Abidjan. LE PROJET D'+QUIPEMENT DE LABORATOIRE DU CENTRE INT+GR+ DE RECHERCHES BIOCLINIQUES D'ABIDJAN. The project is aimed to purchase the equippements at the  laboratory of the Researches Bioclinics of Abidjan Integrated Center to improve the medical examination system.\",\n",
       "  '12240. Migration, Remittances, and Forest Dependence in Ethiopia: Implications for Food Security, Gender, and Forest Conservation. MIGRATION, REMITTANCES, AND FOREST DEPENDENCE IN ETHIOPIA: IMPLICATIONS FOR FOOD SECURITY, GENDER, AND FOREST CONSERVATION. This project will provide evidence that offers important insight into the connection between migration, gender, and forest dependence in rural Ethiopia. Need for labour migration, forest resources While most rural households rely on agriculture for their livelihood, many poor households in developing countries use labour migration and forest resources to improve their welfare. Existing research offers simplistic assumptions that migration invariably leads to deforestation in the tropics, and that forest recovery is always a consequence of people leaving rural areas. These assumptions are being questioned, particularly as researchers analyze and document the complex factors that influence migration outcomes. As a result, it is not clear whether labour migration complements, or serves as a substitute, for forest product extraction by migrant-sending households. Furthermore, whether and how labour migration influences intra-household gender relations, food security, and forest dependence at the places of origin is unclear. Insights into the effects on households The Ethiopian Economic Association/Ethiopian Economic Policy Research Institute (EEA-EEPRI) will collaborate with the Center for International Forestry Research (CIFOR) on this project. They will explore the effects of migration and remittances on household forest dependence, food security, and intra-household gender division of work. Researchers will investigate the degree to which those effects vary across different migration types (for example, domestic versus international migration, and rural versus urban) and across socio-economic groups and locations. A better understanding of these issues is of crucial importance in Ethiopia for a number of reasons. The government has formulated and implemented specific policies on gender, forestry, and food security. However, the ways in which rural out-migration is influencing the achievement of gender equity, forest conservation, and rural food security goals are not well understood. This research will aim to propose options for policymakers and development partners. Project leadership This project is made possible through the Think Tank Initiative (TTI). TTI is a multi-funder program dedicated to strengthening independent policy research institutions, or think tanks, in developing countries. The program aims to enhance their ability to provide sound research that informs and influences policy.',\n",
       "  '12263. MEASURE Evaluation Phase III - Tuberculosis. MEASURE EVALUATION PHASE III - TUBERCULOSIS. MEASURE Evaluation Phase III continues the MEASURE program s 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3).increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       "  '13040. Maternal and Child Health - Assistance for HIV/AIDS. MATERNAL AND CHILD HEALTH - ASSISTANCE FOR HIV/AIDS. PEPFAR: Increase the availability and use of proven life-saving interventions that address the major killers of mothers and children and improve their health and nutrition status, including effective maternity care and management of obstetric complications; prevention services including newborn care, routine immunization, polio eradication, safe water and hygiene, and micronutrients; improved maternal, infant and young child feeding; and treatment of life-threatening childhood illnesses. - Assistance for HIV/AIDS',\n",
       "  '12262. Expanding the Use of Selected Health Services and Products Task Order under Population, Health and Nutrition Technical Support Contract III-Global Hea. EXPANDING THE USE OF SELECTED HEALTH SERVICES AND PRODUCTS TASK ORDER UNDER POPULATION, HEALTH AND NUTRITION TECHNICAL SUPPORT CONTRACT III-GLOBAL HEA. The purpose of this contract is to build on previous USAID/Madagascar Health Population and Nutrition (HPN) activities, expand services broader and deeper into communities to provide quality services to the poor, and to strengthen specific health systems and the capacity of the Ministry of Health and Family Planning to undertake its normative functions to ensure the delivery of critical health services.',\n",
       "  \"12250. JSI Research & Training Institute, Inc.. JSI RESEARCH & TRAINING INSTITUTE, INC.. to strengthen Uganda's routine immunization (RI) system through affordable, proven approaches so that it is capable of protecting children from vaccine-preventable diseases on a sustained basis\",\n",
       "  '12240. Afya Jijini. AFYA JIJINI. Afya Jijini will support integrated health service delivery in Nairobi County. Support for integrated services include HIV; tuberculosis; reproductive, maternal, newborn and child health; nutrition; WASH funds will support: HIV prevention, care and treatment interventionsANC, SBA, emergency obstetric care and essential newborn carePrevention and management of diarrhea and pneumonia through ORS/zinc, appropriate treatment and BCC in facility and community WASH activities through community sanitation, household and school-based hygiene practices ?Routine immunization; provision of quality nutrition services; capacity building on maternal and child nutrition; and provision of equipment, job aids and guidelinesForecasting, quantification and reporting of essential commodities at facility levelFP skills building, mentorship, counselling and provision of services in public and private sector facilities and by community health workers',\n",
       "  \"12250. Elimination of Blinding Trachoma in Mali and Niger. ELIMINATION OF BLINDING TRACHOMA IN MALI AND NIGER. This project reduced avoidable and premature blindness and improved the quality of life of persons suffering from trachoma. The project encompassed: Supporting trachealis surgery eye camps through provision of training and procurement of necessary equipment; Reducing the prevalence of 'trachomatous inflammation follicular' among children ages one to nine years old to less than five percent at the sub-district level through the distribution of azithromycin and tetracycline eye ointment.\",\n",
       "  '12240. Rwanda Rutsiro Nutrition and Health Project. RWANDA RUTSIRO NUTRITION AND HEALTH PROJECT. supports to improve utilization of nutritious foods through community-d nutrition interventions, such PD Hearth session, nutrition and health education to PLW and caregivers. Also, this project will advocate community people through provision of knowledge to local leaders (who are influential to community people), advocacy campaign and broadcasting so that will empower community and the nutrition  health is improved',\n",
       "  '13040. Output 04: HIV. HIV. Bangladesh - Dhaka. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12182. Consultancy for quality assurance of Operations Research and Impact Evaluation Oversight Committee reports. CONSULTANCY FOR QUALITY ASSURANCE OF OPERATIONS RESEARCH AND IMPACT EVALUATION OVERSIGHT COMMITTEE REPORTS. To provide increased coverage with essential reproductive, maternal and child health services in DFID-supported health zones. To increase coverage with essential health services in 52 DFID-supported health zones in five provinces (Nord Ubangi, Kasai-Centr',\n",
       "  '12250. The Program for capacity building of infectious diseases control in Uzbekistan. THE PROGRAM FOR CAPACITY BUILDING OF INFECTIOUS DISEASES CONTROL IN UZBEKISTAN. Establishment of epidemiology training mastre plan, Dispatch korean experts for the development for epidemiology training master plan, KOICA felloship, Provision of high performance labaratory dignostics equipment within microbilology and parasitology laboratories, Pilot study for Echinococcosis',\n",
       "  '12191. Health Emergency Assistance to internally displaced, refugees and Conflict-affected Populations in Central African Republic. HEALTH EMERGENCY ASSISTANCE TO INTERNALLY DISPLACED, REFUGEES AND CONFLICT-AFFECTED POPULATIONS IN CENTRAL AFRICAN REPUBLIC. Reduce morbidity and mortality among internally displaced population, refugees and people  affected by conflict in Central African Republic',\n",
       "  '12230. F.a: Developing District Level Hospitals. F.A: DEVELOPING DISTRICT LEVEL HOSPITALS. The Health care system in North Korea is still in need of external assistance in order to provide the essential basic services. The Patients of the catchment area of four district/county level hospitals with 460 000 people and one province level hospital with 1 510 000 people will have better health services. The number of doctors and nurses in the partnering hospitals is about 1000 and through training, the impact will spread among workers of other hospitals. In 2016, the project will continue teaching in the hospitals to increase the capacity of the hospitals regarding cardiology, radiology and operations. The goal is improved health of population in the selected district/counties. The purpose of the project is improved provision of health services of selected hospitals. Last year the number of diagnostic examinations annually made in the hospitals by the equipment provided by Fida International was about 52 400. The number of appropriate safe surgical procedures annually made by the equipment provided by Fida in the hospitals is about 6 800. Increasing number of serious diseases can be correctly diagnosed and treated due to practical training of medical personnel. More and more patients are coming to our contact hospitals from other districts/counties in order to get access to quality health services because of their good reputation. Medical students are coming to have a practicing period in the district hospitals due to work of Fida International. The project benefits poor and vulnerable families with children, like ordinary farmers and workers. Also the medical personnel of the hospitals and medical students from university hospitals will benefit. Fida International is an implementing agency, but in close collaboration with Korea-EU Cooperation Coordinating Agency (KECCA). The project is carried out in cooperation of the leadership and the medical personnel of the five hospitals.',\n",
       "  '13040. Securing Ugandan s Right to Essential Medicines (SURE) - HIV/AIDS. SECURING UGANDAN S RIGHT TO ESSENTIAL MEDICINES (SURE) - HIV/AIDS. Securing Ugandans  Right for Essential Medicines (Uganda SURE) aims to aims to assist the Government of Ugandas commitment to strengthen the national pharmaceutical supply system to ensure that the people of Uganda have access to adequate quantities of good quality essential medicines and health supplies. To achieve this goal, SURE s objectives are to: 1) Improve Uganda s policy, legal, and regulatory framework to produce pharmaceutical supply chain stability and sustainability; 2) Improve capacity and performance of central government entities to carry out their supply chain management responsibilities; 3) Improve capacity and performance of districts, health subdistricts, and implementing partners in their supply chain management roles. SURE works on integrating Uganda s supply chain and establishing a pharmaceutical management information system that provides full transparency to minimize medicine stock-outs and waste.',\n",
       "  \"13030. Empowering Communities for Health (ECH) project. EMPOWERING COMMUNITIES FOR HEALTH (ECH) PROJECT. The ECH mechanism is working to build the capacity of CCs to manage and support the health system functions delegated to communities. ECH supports community agents to promote appropriate home health and nutrition behaviors, optimal health care-seeking, and improving community-based provision of tuberculosis (TB) treatment and contraceptive services. Additionally, it is working to improve community awareness of the rights of health care consumers (as set forth in the MOH's Client Rights Charter), strengthen social accountability and assist CCs to fully exert the health care stewardship role envisioned for them in the MOH's Guidelines for Operational Districts.\",\n",
       "  \"12250. Global Health Support Initiatives III (GHSI-III). GLOBAL HEALTH SUPPORT INITIATIVES III (GHSI-III). Global Health Support Initiatives III (GHSI-III) procurement. GHSI-III is the successor to GHSI-II. GHSI III will provide non-direct hire global health support services for USAID's Bureau for Global Health (GH) at its offices in Washington, D.C. and overseas. The activity will recruit, hire and maintain a contracted technical, professional, operational, and support staff that supply support services to USAID's health programs worldwide. The staff provided under the activity will support seven health program areas: (1) HIV/AIDS; (2) Tuberculosis; (3) Malaria; (4) Avian Influenza; (5) Other Public Health Threats; (6) Maternal and Child Health; and (7) Family Planning and Reproductive Health.\",\n",
       "  '12191. Pediatric neurosurgery and neurology. PEDIATRIC NEUROSURGERY AND NEUROLOGY. The Neurosurgery has been identified as one of the priority areas in the field of health care, promoting a reduction in the number of evacuations of Cape Verde patients to Portugal.',\n",
       "  '12110. Project research. PROJECT RESEARCH. Project research',\n",
       "  '12281. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Feasibility study',\n",
       "  \"12250. Network ReACt. NETWORK REACT. ReAct is a non-profit international network to improve the management of antibiotic resistance. ReAct's vision is that current and future generations will have access to effective prevention and treatment of bacterial infections as part of their right to health. ReAct aims to increase the global awareness of the negative effects of ABR, to increase the evidence generation, to promote innovation etc.\",\n",
       "  \"13040. National Institute of Health - International Research. NATIONAL INSTITUTE OF HEALTH - INTERNATIONAL RESEARCH. PEPFAR - The President's Emergency Plan for AIDS Relief is committed to prevent new HIV infections; treat HIV-infected individuals and those orphaned by AIDs.\",\n",
       "  '12182. 10-CO1-064/ACH/PARAGUAY AND PER+/$TOTAL INITIAL 5M/Food and nutritional security. 10-CO1-064/ACH/PARAGUAY AND PER+/$TOTAL INITIAL 5M/FOOD AND NUTRITIONAL SECURITY. 10-CO1-064/ACH/PARAGUAY Y PER+/$TOTAL INICIAL 5M?/SEGURIDAD ALIMENTARIA Y NUTRICIONAL',\n",
       "  '16064. Output 04: HIV. HIV. Mexico - Mexico City. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12281. Exchanges with Other Countries in the Field of Vocational Education and Training and Scholarships. EXCHANGES WITH OTHER COUNTRIES IN THE FIELD OF VOCATIONAL EDUCATION AND TRAINING AND SCHOLARSHIPS. Collaborative project - ChinaCare - Cooperative training of carers for the elderly in China, Sub-project - Research of conditions for training, drawing up of customised pedagogical plans and transfer in China and Germany - Knowledge Transfer',\n",
       "  '12263. Applying Science to Strengthen and Improve Systems (ASSIST). APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST). The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       "  '12110. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 Policy support research and representation (including reference centres). INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 POLICY SUPPORT RESEARCH AND REPRESENTATION (INCLUDING REFERENCE CENTRES). General objective:  Policy support, research and representation - Specific objective:  To adequately assist Belgian policy makers in decision making, policy formulation and representation regarding technical and strategic issues related to international health. - Results:  The project will result in making available the expertise present at the ITM for the Belgian policy makers. This will be done through providing expert briefings, carrying out relevant research, and providing scientific support before, during and/or after national or international meetings. -',\n",
       "  '12220. PATH. PATH. to focus on innovation introduction and reducing policy barriers to service delivery implementation',\n",
       "  '12110. Foundation for Innovative New Diagnostics FIND. FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND. The Foundation for Innovative New Diagnostics (FIND), working through a public-private partnership model, drives the development and early implementation of new diagnostic tests for poverty-related diseases. From a global public health perspective, accurate and affordable diagnosis is critical. It helps ensure better care to patients, enables equitable, timely and correct medical treatment in low-resource settings, and thus reduces wastage of medicines and antimicrobial resistance. It is essential also for emergency preparedness.',\n",
       "  \"12182. ICDDR,B exit 2017-2019. ICDDR,B EXIT 2017-2019. Exit support to icddr,b 2017-2018. During the exit phase Sweden will provide SEK 21 400 000 over the period 2017 - 2019 to support icddr,b in the implementation of the Strategic Plan 2015 - 2018. Sweden has been providing research and core support to icddr,b since 1981 with the aim to ensure that research in health addressed key policy issues for health system in Bangladesh, and that the research findings were communicated to policy users and influenced policy decisions. This objective remains at the core of the Swedish funding during the suggested agreement phase.Core support is suggested as the continued financing modality and it is also suggested to phase out the core support during the 2-year agreement period 2017-2019. Research funding from Sida HQ will continue through an specific agreement for the period 2016-2020 on the amount of MSEK 30,5. icddr,b has demonstrated the ability to control its own development and preparedness to invest core funds particularly in neglected areas in order to build future capacity. In the coming three years, ambitious efforts are planned to strengthen the capacity of icddr,b with improved monitoring, evaluation and reporting structures and processes as key targets.Achievements in the strategic objectives will be assessed against icddr,b's framework for results that will track output and outcome indicators to monitor progress. Fiduciary risks have been assessed as high but the internal systems related to financial management have been strengthened during the last years and icddr,b has made rapid progress towards reducing these risks. Through its participation in the Core Donor Group, Sweden together with Canada (Global Affairs) and the United Kingdom (Department for International Development - DfID) will ensure that the risks in the programme are carefully monitored and managed. An external evaluation will be conducted at the end of the agreement to assess the overall success of the programme. The budget for the evaluation has been allocated and is earmarked in the contribution budget.\",\n",
       "  '12191. Equipment of an analysis laboratory at the Sacred Heart Medical Center of BoussT. EQUIPMENT OF AN ANALYSIS LABORATORY AT THE SACRED HEART MEDICAL CENTER OF BOUSS+. The project involves the restructuring and equipment of the Sacred Heart Medical Center in BoussF, the launch of an analysis laboratory, in order to contribute to reducing child mortality and improving the health of the population, especially for young mothers',\n",
       "  '16064. HIV/AIDS II - Coordination and leadership of national response. HIV/AIDS II - COORDINATION AND LEADERSHIP OF NATIONAL RESPONSE. Support to Uganda AIDS Commission and the HIV/AIDS Partnership for coordinating and leading the national response. In addition, support is provided to 1) research coordination and 2) integration of HIV and reproductive heatlh and family planning.',\n",
       "  '12262. AAAS Diplomacy Program for Science Fellows II - GCC, EG and NRM Participation - Malaria. AAAS DIPLOMACY PROGRAM FOR SCIENCE FELLOWS II - GCC, EG AND NRM PARTICIPATION - MALARIA. AAAS Diplomacy Program for Science Fellows II - GCC, EG and NRM Participation',\n",
       "  '12191. Talita Kum. TALIT+ KUM. Supporting health and human rights for people with disabilities in the Njombe region. Strengthening the Laboratory and outpatient s department in the Inuka Rehabilitation Centre: Providing new equipment and training staff',\n",
       "  '16064. Output 04: HIV. HIV. Somalia - Mogadiscio. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12110. Ag Results Contract (via Competition) Additional Evaluation Deliverables - Change to AgResults: Evaluation Contract Two - Research. AG RESULTS CONTRACT (VIA COMPETITION) ADDITIONAL EVALUATION DELIVERABLES - CHANGE TO AGRESULTS: EVALUATION CONTRACT TWO - RESEARCH. The overall objective of the AgResults Initiative is to enhance smallholder welfare and food security for the poor and vulnerable in developing countries through increased investment in agricultural innovation and adoption.  It aims to do so by developing',\n",
       "  \"13010. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       "  '12262. Reducing the Risk of Artemisinin Resistant Malaria spreading to Africa - Trust Fund. REDUCING THE RISK OF ARTEMISININ RESISTANT MALARIA SPREADING TO AFRICA - TRUST FUND. To address urgent gaps in the response to drug resistant malaria in the Greater Mekong Sub-region (GMS) of South East Asia, with the aim of helping to contain its spread to other countries and regions.',\n",
       "  '12110. Feasibility Studies and Detailed Design for the National Hospital in Mbabane. FEASIBILITY STUDIES AND DETAILED DESIGN FOR THE NATIONAL HOSPITAL IN MBABANE. Social/Health',\n",
       "  '13040. Scaling up Universal Access for Most at Risk Population in Bosnia and Herzegovina. SCALING UP UNIVERSAL ACCESS FOR MOST AT RISK POPULATION IN BOSNIA AND HERZEGOVINA. The first case of HIV was registered in Bosnia and Herzegovina in 1986. By the end of 2009 the country had registered 134 people living with HIV. The goal of the program supported by this grant is to reduce HIV transmission and improve HIV treatment, care and support in the country. This program will target the following groups that have been identified as being at higher risk of becoming infected with HIV: people who inject drugs, men who have sex with men, sex workers and their clients, cross-border migrants, migrant workers, internally displaced persons, refugees and prisoners, as well as the Roma population and youth who are not referred to specifically as target groups in the National HIV Strategy. The activities funded by this grant will build on those funded under the Round 5 grant to help ensure that HIV prevalence remains below 1 percent in the general population  a key outcome under the current national strategy  and to improve quality of life for people living with and affected by HIV.',\n",
       "  '13040. YouthPower - Implementation - HIV/AIDS. YOUTHPOWER - IMPLEMENTATION - HIV/AIDS. The YouthPower - Implementation task order supports missions buying into the YouthPower IDIQ contract for cross-sectoral youth development activities. The task order cover activities including : 1) the implementation of centrally funded pilot activities at the country or regional level; 2) small grant funds for learning and knowledge-sharing within projects; 3) innovation grants; 4) learning events; 5) making available technical assistance and training to missions; 6) stakeholder workshops; and 7) the creation of other appropriate innovation and learning platforms. Because this mechanism is in procurement development, the following key information has not yet been determined: Mechanism No. (Award #), Prime Partner, Start and End dates, Total Estimated Cost. The estimated Start and End dates are 2015 and 2020, respectively.',\n",
       "  '12181. Improving health by supporting the formation of quality of doctors and the development of operational research. IMPROVING HEALTH BY SUPPORTING THE FORMATION OF QUALITY OF DOCTORS AND THE DEVELOPMENT OF OPERATIONAL RESEARCH. Improving health by supporting the formation of quality of doctors and the development of operational research. Faculty of Medicine of the Catholic University of Mozambique',\n",
       "  '12181. Women Care Sanitary Napkin Project. WOMEN CARE SANITARY NAPKIN PROJECT. The project aims to improve understanding of health and hygiene issues; to establish a sanitary napkin production unit based on training, techniques, equipment and resources to produce hygienic, cost-effective, eco-disposable sanitary napkins; to trial safe modes of eco-friendly/discreet disposal of sanitary napkins within 2 schools and within the 25 target villages; to improve the socio-economic status of women by establishing and running an economically-viable sanitary napkins production unit while marketing and selling sanitary napkins within target area.',\n",
       "  '13040. Adult 13042clinical trials. ADULT 13042CLINICAL TRIALS. Adult 13042clinical trials',\n",
       "  '12220. Measures to reduce disease and mortality among at-risk groups in South Sudan. MEASURES TO REDUCE DISEASE AND MORTALITY AMONG AT-RISK GROUPS IN SOUTH SUDAN. The overall goal of this project is to strengthen interventions in the health sector in three selected locations of South Sudan = Renk, Leer and Awail. The submitted project is part of a much wider multisectoral program of the implementing partner of the applicant. The project has as its ambition to significantly reduce disease and mortality among groups at risk from conflict, internally displaced people and weakened urban host communities in S. Sudan. A specific emphasis will be placed on women and children, neglected older populations, handicapped and pregnant and nursing women. The provision of long- term supplies of medicine will strengthen the basic health security and prevention of the occurrence of epidemics. The dramatic humanitarian crisis and the high number of needy people creates the need to focus on increasing the capacity of health workers and the provision of critical expert training. Part of this project is also the support of a number of malnutrition centres. We will support the operations of these centres providing health and malnutrition services, which currently are in 28 locations in the regions of Aweil, Leer Mayendit and Renk. According to the need we will initiate mobile service capacity wherever the need emerges and/or wherever the distance from the centre for the population groups is more than 2 hours. The number of recipients of support within this project is projected at nearly 65 000 people.',\n",
       "  \"13040. YouthPower - Implementation. YOUTHPOWER - IMPLEMENTATION. The 'YouthPower - Implementation' task order supports missions buying into the' YouthPower' IDIQ contract for cross-sectoral youth development activities. The task order cover activities including : 1) the implementation of centrally funded pilot activities at the country or regional level; 2) small grant funds for learning and knowledge-sharing within projects; 3) innovation grants; 4) learning events; 5) making available technical assistance and training to missions; 6) stakeholder workshops; and 7) the creation of other appropriate innovation and learning platforms. Because this mechanism is in procurement development, the following key information has not yet been determined: Mechanism No. (Award #), Prime Partner, Start and End dates, Total Estimated Cost. The estimated Start and End dates are 2015 and 2020, respectively.\",\n",
       "  '13040. Kinerja - HIV/AIDS. KINERJA - HIV/AIDS. The overarching objective of this IM is the provision of innovative and improved service delivery by local governments to citizens. USAID focuses on the governance of service delivery in three sectors: education; health services and; and local business. Activities under this IM address both demand and supply side aspects of service delivery. These investments will result in strengthened accountability mechanisms that improve local government responses to citizens needs. USAID works through local institutions to build their capacity and foster sustainable partnerships with local government. This solidifies the links between stimulation of demand for good services through active civil society engagement and improved local government response.',\n",
       "  \"12220. Support to the Mother and Child Health Department of the Medical University Simulation Centre of Moldova.. SUPPORT TO THE MOTHER AND CHILD HEALTH DEPARTMENT OF THE MEDICAL UNIVERSITY SIMULATION CENTRE OF MOLDOVA.. The international evidence proves the effectiveness of training methods based on simulation in comparison with 'traditional  education, improving the practical skills of medical staff. The project will support the introducing simulation training technologies in obstetric, gynecological, neonatal and pediatric emergencies and by this contributing to improving the high medical education in Moldova.\",\n",
       "  \"12263. Consolidation and Expansion of the 'Directly Observed Treatment, Short Term (DOTS) Program in Kyrgyzstan by Providing Access to Diagnostics and Treatment of Drug-Resistant Tuberculosis. EXPANSION OF DIRECTLY OBSERVED TREATMENT SHORT TERM (DOTS) PROGRAM KYRGYZSTAN BY PROVIDING ACCESS TO DIAGNOSTICS AND TREATMENT OF DRUG-RESISTANT TB. In Kyrgyzstan, Tuberculosis (TB) re-emerged as an important public health problem after the independence and its burden remains high in the country. The case notification rate is 117 per 100,000 populations and is the third highest among the 53 countries of the World Health Organization European Region. According to the Drug Resistance Survey in 2007, Kyrgyzstan faces a very high multi drug-resistant TB (MDR-TB) prevalence of 25 percent among new positive cases and 54 percent among previously treated cases. The program consolidates Round 6 TB grant by strengthening TB information system, patient incentives, support to local authorities and community involvement in TB control. The goal of the program is to reduce the burden of TB by strengthening of Directly Observed Treatment Short-term (DOTS) framework and by scaling-up the management of Drug Resistance-TB (DR-TB). The program will be implemented using a Dual-Track Financing approach under 2 Principal Recipients, Project Hope and United Nations Development Programme (UNDP). This grant will focus on several activities such as strengthening the human and infrastructural capacities, establishing routine drug resistance surveillance throughout the country, upgrading the laboratory services and providing up-to-date treatment of DR-TB cases with appropriate patient support to ensure adherence.\",\n",
       "  '12250. Healthcare Centre MAMA CARLA, La Joie de Vivre Center Bangui, (Analysis laboratory, Dispensary of primary care for children and Telemedicine). HEALTHCARE CENTRE MAMA CARLA, LA JOIE DE VIVRE CENTER BANGUI, (ANALYSIS LABORATORY, DISPENSARY OF PRIMARY CARE FOR CHILDREN AND TELEMEDICINE). The Health Medical Centre MAMA CARLA give the possibility to the needy children, orphans or abandoned housed in the Centre La Joie de Vivre to have free access to the medical services. Medical examination, ambulatory treatments, infectious disease and malaria control, urgent pharmacological treatments and assistance to undernourished are opened also for all the students of the School Nicolas BarrT and to the children living in the surrounding areas from 0 to 14 ages. The Centre organizes hygienic consulting, education and training for mothers. Assistance and training to pregnant women AIDS infected. Health personnel development.',\n",
       "  '12182. Targeting cell wall glycans: an untapped approach for therapeutics and diagnostics to combat antimicrobial resistance?. TARGETING CELL WALL GLYCANS: AN UNTAPPED APPROACH FOR THERAPEUTICS AND DIAGNOSTICS TO COMBAT ANTIMICROBIAL RESISTANCE?. Medical Research Council AMR initiative grant looking at cell wall properties  of  TB bacteria  to enable development of new therapies and diagnostics given the current significant issue of multi-drug resistance in this bacteria',\n",
       "  '12191. Establishing a network of services for the diagnosis and prevention of oncological diseases in the Horn of Africa. ESTABLISHING A NETWORK OF SERVICES FOR THE DIAGNOSIS AND PREVENTION OF ONCOLOGICAL DISEASES IN THE HORN OF AFRICA. Establishing a service for the diagnosis and prevention of oncological diseases, through the establishment of a Pathology laboratory in Somaliland. Supporting the same on-going service in Djibouti. Starting a cooperation protocol between the two of them',\n",
       "  '12181. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 Master and short courses scholarships. INST. MEDECINE TROPICALE /  PROG.PLURIANNUELS  2014-2016 MASTER AND SHORT COURSES SCHOLARSHIPS. General objective:  Scholarship programme: master and short courses - Specific objective:  To provide a scholarship programme to experienced health professionals from the South, for training at advanced master level and as experts in specific fields of science through short courses - Results:  Financial accessibility has been assured for training at advanced master level in the fields of public health (international health, health systems policy and management and disease control) and tropical animal health  as well as for training at expert short course level (2014 -2016) -',\n",
       "  '12250. Nigeria Centre for Disease Control. NIGERIA CENTRE FOR DISEASE CONTROL. to support an emergency response to populations affected by a Meningitis outbreak in Nigeria',\n",
       "  '12263. Health Leadership and Governance Program (HLGP). HEALTH LEADERSHIP AND GOVERNANCE PROGRAM (HLGP). To improve health outcomes in USAID areas of maternal and child health (MCH), family planning (FP) and tuberculosis (TB) by enhancing leadership and governance capabilities of local chief executives and local health officers. PROJECT OBJECTIVES: Train local chief executives and local health officers on Bridging Leadership competencies, Improve local health systems to make them more responsive to the needs for MCH, FP and TB prevention and control, Increase community participation and health- seeking behavior in target areas through improved local health systems and local health leadership.',\n",
       "  '13030. Nicaragua Media program - Family Planning and Reproductive Health. NICARAGUA MEDIA PROGRAM - FAMILY PLANNING AND REPRODUCTIVE HEALTH. The Nicaragua Media program is a cross-cutting project, managed by FHI 360, designed to support the countrys efforts to improve democracy, governance, economic growth, health, education and the environment. The program works with independent mass media organizations to convey information that supplements and strengthens democracy, development and health messages and assistance programs to a wide array of target audiences. FHI 360 assists independent media at both national and regional levels in designing radio and television shows, print journalism and other communication programs, using state-of-the-art interactive technologies.',\n",
       "  '13081. AiN KU- Hospital Midwifery Training. AIN KU- HOSPITAL MIDWIFERY TRAINING. Midwife education and Reproductive health.Agreement partner before PTA 4.0: Institute of Health Science in Jalalabad',\n",
       "  \"12110. PNIPH Transition phase. PNIPH TRANSITION PHASE. provide assistance to PNIPH primarily to support the transition of the institute's governance, ownership, and leadership from WHO to PA, while assuring the continuation and development of the Institute's technical and scientific work.During this period, PNIPH will develop long-term plans, bring local and international expertise, and build and adapt approaches that address the main challenges of the Palestinian people.\",\n",
       "  '12240. Nutrition Security Program - Nutrition. NUTRITION SECURITY PROGRAM - NUTRITION. The Haiti Nutrition Security Program (NSP) strategy, implemented by Partners of the Americas, is based on a holistic community health, nutrition, and livelihood approach. With FY 2015 resources, the project will continue to recruit and provide support to Mother Leaders, and organize them into Care Groups. Each Mother Leader is then responsible for directing and chairing local neighborhood womens clubs, through which nutrition counseling and best health practices will be shared with additional young pregnant and lactating mothers (of children under the age of five).',\n",
       "  '13030. Health Leadership and Governance Program (HLGP). HEALTH LEADERSHIP AND GOVERNANCE PROGRAM (HLGP). To improve health outcomes in USAID areas of maternal and child health (MCH), family planning (FP) and tuberculosis (TB) by enhancing leadership and governance capabilities of local chief executives and local health officers. PROJECT OBJECTIVES: Train local chief executives and local health officers on Bridging Leadership competencies, Improve local health systems to make them more responsive to the needs for MCH, FP and TB prevention and control, Increase community participation and health- seeking behavior in target areas through improved local health systems and local health leadership.',\n",
       "  '12182. A knowledge translation through complex interventions - Improving health and care for children and adolescents living with long-term illnesses in Ethi. A KNOWLEDGE TRANSLATION THROUGH COMPLEX INTERVENTIONS - IMPROVING HEALTH AND CARE FOR CHILDREN AND ADOLESCENTS LIVING WITH LONG-TERM ILLNESSES IN ETHI. This collaborative capacity-building project is an extension of a VR-funded project ending 2016. New collaborators are University of Nairobi and International Pregnancy Advisory Services (Ipas). Unsafe abortion is a leading cause of maternal mortality (MM) and morbidity in Kenya. Social stigma surrounding abortion and contraceptive use plays a critical role in social, medical, and legal marginalization of abortion- and contraceptive service. In 2013, Ipas developed the Stigmatizing Attitudes, Beliefs and Actions Scale (SABAS) to measure abortion stigma at individual and community level. Objective: I) to conceptualize abortion stigma among health care providers in youth friendly centres, teachers and students in secondary school (14-18 y) in a sub-urban area with high MM, and II) to determine if a school based abortion- and contraceptive-stigma reduction intervention will decrease stigma, and increase contraceptive use among students. Design, Setting, Participants: I) focus group discussions with providers, teachers and students, and II) a quantitative quasi-experimental intervention study involving 800 students from schools in western Kenya that will be cluster-randomised into intervention and control units. Main Outcome: abortion-stigma. Secondary outcome: contraceptive use. Outcome measured by using the validated SABA-scale before and after intervention and comparing intervention and control schools. Analyses: Qualitative content analysis and repeated measures ANOVA (PASW).',\n",
       "  '12220. National Health and Family Planning Commission. NATIONAL HEALTH AND FAMILY PLANNING COMMISSION. to reduce health-related poverty through the improvement of basic healthcare system performance in rural China, and facilitate the sharing of the learning to benefit other developing countries',\n",
       "  \"12191. KHARTOUM  SALAM  CARDIAC CENTRE. KHARTOUM  SALAM  CARDIAC CENTRE. EMERGENCY's Salam Centre for Cardiac Surgery in Khartoum provides cardiological examinations and cardiac surgery free of charge. Since 2007, the Salam Centre has treated over 61,000 patients from 27 different countries.\",\n",
       "  '12263. Leadership, Management, Governance (LMG). LEADERSHIP, MANAGEMENT, GOVERNANCE (LMG). The Leadership, Management, Governance (LMG) project builds in-country health and education system capacity by increasing leadership, management, and governance knowledge of health care providers, program managers, and policy makers who work on health services.',\n",
       "  '13020. Mapping of actors - migration & SRHR ESA region. MAPPING OF ACTORS - MIGRATION & SRHR ESA REGION. The purpose with this deskstudy is to identify potential collaborating partners to the Regional SRHR Team in Lusaka with focus on migration and SRHR. KIT will be contracted to undertake this study.',\n",
       "  '12240. Support to Operational Trial project  in Zambia to reduce child mortality from diarrhoea. SUPPORT TO OPERATIONAL TRIAL PROJECT  IN ZAMBIA TO REDUCE CHILD MORTALITY FROM DIARRHOEA. To improve child nutrition by providing children under 5 with direct nutrition support (Vitamin A and deworming tablets), piloting improved access to anti-diarrhoea kits, testing the efficacy of vitamin A enriched maize and supporting the government of Za',\n",
       "  \"13040. Strengthening of the national response to HIV/AIDS for transition to the scale of prevention structures and global treatment. STRENGTHENING OF THE NATIONAL RESPONSE TO HIV/AIDS FOR TRANSITION TO THE SCALE OF PREVENTION STRUCTURES AND GLOBAL TREATMENT. Chad ranks among the least developed countries. A 2003 epidemiological study estimated HIV prevalence at around 8 percent of the adult population, with 200,000 individuals infected with HIV. The program supported by this grant aims to decentralize services through coordination with the National AIDS Committee A 'minimum activity package' for prevention, health care and treatment will also be set up in 57 health care districts according to criteria based on the characteristics of the epidemic, the health care chart, the possibility of progression for the health care system, the demographic and cultural context, and the geographic disparities of Chad. The program targets women living in vulnerable situations; people living with HIV; young people; orphans and other vulnerable children; people who sell sex; and mobile groups and nomads. It will focus on behavior change communication and community outreach and on strengthening managerial and organizational capacities of community-based organizations and networks of people living with HIV.\",\n",
       "  '13020. Innovations in Maternal Child Health. INNOVATIONS IN MATERNAL CHILD HEALTH. The Clinton Health Access Initiative supports the development of high quality basic health care for all, by facilitating the effective distribution of health services and an efficient management of health systems, in cooperation with the government. This project supports the national initiative of the Mozambican government to achieve the health targets by 2015 by reinforcing the national health system and increasing the number of HIV patients in treatment.The project has the following specific objectives:1. the early detection of infections, with specific attention to mothers and children2. the reduction of mother-to-child transmission 3. increased access and better health results for a population of 8.8 million patients.  Expected outcome: 1. early detection of diseases, with specific attention for mothers and children;2. reduction of mother-child transmission;3. improved access to health care for the general population. Document available at  https://drive.google.com/file/d/0B-IUzKYaN-QSZzlVNVNmM0RMY1E/edit?usp=sharing',\n",
       "  \"12110. LAUNCH Food. LAUNCH FOOD. Health LAUNCH is an open innovation process that seeks to discover new solutions to intractable development challenges facing the Indo-Pacific region. The programme will focus on malnutrition caused by poor food intakes and seeks to (i) reduce the amount of permanent stunting and wasting and under 5 deaths caused by under nutrition in the Indo-Pacific and (ii) reduce the incidence of non-communicable disease caused by malnutrition. Currently up to 50 per cent of all child hood deaths in the region are caused by under nutrition and up to 1 in 2 children are physically or mentally stunted as a result of chronic under nutrition in the first thousand days of life. 98 per cent of all Tongans are at medium to high risk of premature death as a result of non-communicable disease. This initiative is a co-investment between Australia's Department of Foreign Affairs and Trade and USAID valued at $2.3 million over 3 years, starting 2015-16.\",\n",
       "  '13040. Enhanced Effective ICT. ENHANCED EFFECTIVE ICT. The objective is to bridge the digital divide and spur information access and use for innovation and development in Kenya.',\n",
       "  '13040. Projet de prTvention du SIDA chez les travailleurs(euses)  du sexe au Kenya pour identifier les bonnes pratiques dans la prTvention du VIH chez ces pe. PROJET DE PR+VENTION DU SIDA CHEZ LES TRAVAILLEURS(EUSES)  DU SEXE AU KENYA POUR IDENTIFIER LES BONNES PRATIQUES DANS LA PR+VENTION DU VIH CHEZ CES PE. General Objectives  To strengthen the rational basis and the country ownership of (human and animal) healthcare systems and policies in developing countries, in order to improve the health status ofthe populations and thereby to contribute to the reduction of poverty and inequity.  Specific Objectives  To identify best practices for the scaling up and evaluation of HIV prevention among sexworkers in developing countries (sub-Saharan Africa in particular) Results  Result 1 different methods for measuring the coverage of sex worker projects are evaluatedResult 2 Guidelines for quality assessment of sex workers interventions are elaboratedResult 3 A generic study protocol for measuring outcome indicators including condom useand STI/HIV prevalence rates is available and pretestedResult 4 Strategies for improving safe sex behaviour of sex workers on ART are identified',\n",
       "  \"12262. Government Technical Assistance Provider (GoTAP). GOVERNMENT TECHNICAL ASSISTANCE PROVIDER (GOTAP). This contract provides technical assistance to entities that receive direct financing under USAID's government-to-government (G2G) program in the health sector. Assistance is in technical areas in the health sector (e.g. how to improve lagging health indicators) and capacity building in governance and management (e.g. ensuring government entities understand G2G requirements and effectively oversee implementation); it will enable target regions to sustain their health outcomes, reinforce the Ministry of Health's (MOH) stewardship role, and increase domestic spending on health. GoTAP also provides assistance to USAID to better align G2G investments with MOH processes, and provides analytical support to USAID and the MOH to improve use of data for decision-making and identify opportunities for adjustments in USAID health programming.\",\n",
       "  \"12110. Supporting the development and functioning of Moldovan health insurance system. SUPPORTING THE DEVELOPMENT AND FUNCTIONING OF MOLDOVAN HEALTH INSURANCE SYSTEM. The objective of the project is to support the development and functioning of Moldovan health insurance system through sharing Estonian experience and practices. The project entails 5 study visits, including the round-up visit at the end of the project. Throughout all visits, one specific topic of the visit will be covered thoroughly.The main topics covered are strategic purchasing, quality systems development, benefit package development, partner management, organization's and health insurance system's development. The initial visit of the project will take place between Estonian and Moldovan health insurance funds in spring 2016 according to the collaboration agreement between the EHIF and the CNAM. The expenditures of this visit are not included to the cost report of this project.\",\n",
       "  '13020. HED Partnership: Center for Excellence in Health and Life Sciences - Maternal and Child Health. HED PARTNERSHIP: CENTER FOR EXCELLENCE IN HEALTH AND LIFE SCIENCES - MATERNAL AND CHILD HEALTH. University of Liberia/Indiana University/University of Massachusetts Medical School: Center for Excellence in Health and Life Sciences - This partnership seeks to address the challenges that the University of Liberia (UL) and its sister public institution, the Tubman National Institute of Medical Arts (TNIMA), face in supplying health care workers equipped to address Liberia healthcare needs. The U.S. partners have shared expertise in a variety of ways, from collecting and sending current textbooks in biology, chemistry, mathematics, nursing, and other courses to providing six-week summer study tours for Liberian faculty in the United States. In addition, the partners have collaborated to create a new two-year Core Health and Life Science Undergraduate Program and begin planning for a joint four-year bachelors program in nursing science. Partners have also worked together to improve instructional quality in introductory science courses, develop upgrades to the preclinical science curriculum at the University of Liberias medical and pharmacy Colleges, and modernize the University of Liberias teaching and learning resources.',\n",
       "  '13020. Maternal and Child Health - Treatment of Obstetric Complications and Disabilities. MATERNAL AND CHILD HEALTH - TREATMENT OF OBSTETRIC COMPLICATIONS AND DISABILITIES. Maternal and Child Health - Promote recognition and treatment of obstetric complications by women, their partners and the community, such as post-abortion care, management of hypertension, induction or augmentation of labor, assisted delivery, blood transfusion, surgery (including cesarean section, repair of lacerations, and management of postpartum hemorrhage); and management of pregnancy-related disabilities including case identification, medical management of chronic problems such as anemia, and surgical repair and postoperative rehabilitation of obstetric fistula.',\n",
       "  '12110. Global Health Support Initiative II (GHSI II) - Administration and Oversight. GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II) - ADMINISTRATION AND OVERSIGHT. The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the programs vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.',\n",
       "  \"12220. AmTliorer les rTsultats liTs a la santT des femmes et des enfants/Strengthening Health Outcomes for Women and Children. AM+LIORER LES R+SULTATS LI+S + LA SANT+ DES FEMMES ET DES ENFANTS/STRENGTHENING HEALTH OUTCOMES FOR WOMEN AND CHILDREN. This project seeks to improving the health of women, adolescent girls, mothers, newborns and children in under-served areas taking a community-based approach and working with local health authorities.All project countries have established meaningful health legislation, governance bodies, and in some instances, the necessary infrastructure. Due to weak quality, inclusiveness (e.g. youth-friendliness), and gender-responsiveness of health services delivery and health care management, service delivery, operationalization and increased access and utilization of maternal newborn child health/sexual and reproductive health services (MNCH/SRH) require support. Specific challenges include: 1) weak health seeking behaviour by disadvantaged, vulnerable and marginalised women of child bearing age (WCBA) and their families; Particularly high MNCH/SRH risks exist for adolescent mothers and high rates of child, early, and forced marriage (CEFM); 3) WCBA's lack of decision-making capacity and low access to and control over social and economic assets due, to pervasive gender inequality; 4) inaccessible, fragmented and client-unfriendly health systems; 5) low numbers and inadequate skills of Community Health Workers and frontline workers to provide quality, gender responsive, adolescent friendly health care; and 6) irregular tracking and use of data by Ministry of Health, and poor accountability of health services to local communities.Project activities include: (1) raising awareness of local leaders, role models and various community groups on ongoing MNCH services, positive healthcare practices, including health care seeking behaviours; (2) training health care providers at both community and health facility levels on key MNCH interventions; (3) providing essential medicines and other medical supplies; (4) training health administrators and local health committees on planning, supervision and oversight of health resources and facilities; (5) training for health workers and drivers in referring patients requiring more advanced care at specialized facilities, including providing health facilities with mobile technology and vehicles to facilitate emergency transportation; (6) training and mentoring health care staff on improved data collection and reporting to inform local government resource planning; and, (7) implementing digital and media campaigns to raise awareness of Canadian public on global MNCH issues. This initiative is expected to contribute directly to the improved health of approximately 1 million women, more than 900,000 children under five years of age, and over 200,000 adolescent girls, as well as over 1.1 million men with improved MNCH services. An estimated 1.8 million individuals are expected to benefit from the initiative's results indirectly. In addition, activities targeting Canadian awareness of MNCH are expected to reach over 700,000 Canadians.Plan International Canada is implementing this project in partnership with Promundo and the Hospit\",\n",
       "  '12220. development Research and Projects Centre. DEVELOPMENT RESEARCH AND PROJECTS CENTRE. to improve the lives of women and girls, particularly through promoting the use of modern Primary Health Care services including routine immunization, Maternal health services and promoting girls education in Kano state',\n",
       "  '12191. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Establishing neurosurgery unit at Addis Ababa University Hospital and a training program.',\n",
       "  '13010. Support Georgia for proper and balanced immigration policy formation. SUPPORT GEORGIA FOR PROPER AND BALANCED IMMIGRATION POLICY FORMATION. Overall objective: to enhance the role of Geo NGO sector and increase their involvement in implementation of activities directly linked to ENP and promotes fulfilment of its objectives. Specific objectives: 1) Study on immigration of foreigners in Georgia: 2) Formation of immigration and visa policy and policy building methodology, in partnership with civil society.',\n",
       "  '12182. Developing and evaluating a framework for the rational design of antibiotic prescribing policies in resource-constrained hospital settings. DEVELOPING AND EVALUATING A FRAMEWORK FOR THE RATIONAL DESIGN OF ANTIBIOTIC PRESCRIBING POLICIES IN RESOURCE-CONSTRAINED HOSPITAL SETTINGS. Medical Research Council. Fellowship  to model a framework for better antibiotic prescribing policies in resource-constrained hospital settings',\n",
       "  \"12240. USAID/Uganda Social Marketing Activity. USAID/UGANDA SOCIAL MARKETING ACTIVITY. The Social Marketing Activity will serve as USAID Uganda's flagship program for Social Marketing and successor to USAID Uganda's AFFORD program, which ends in September 2014. The program's goal is to contribute to a reduction in new HIV infections, total fertility, maternal and child mortality, malnutrition and malaria, and to improve access to family planning.This four-year activity aims to improve utilization of health-related social marketing products and services among under-served Ugandan consumers in rural and urban areas.\",\n",
       "  '13030. Improving the Performance of Nurses (IPN). IMPROVING THE PERFORMANCE OF NURSES (IPN). Improving the Performance of Nurses (IPN) in Upper Egypt is a partnership between MSH and the Nursing Program of the Om Habibeh Foundation, an Aga Khan Foundation affiliate. The programs goal is to build the leadership and management capacity of hospital and primary health care facility nurses for .improvement in the areas of infection control, basic nursing skills, and communication, in the governorates of Aswan, Luxor, Qena, Sohag and Assiut. The IPN program applies the Leadership Development Program as the core technical approach for the intervention. In the first phase of the project, the IPN will target facilities in Aswan. The second and third phases will target hospitals in Luxor and Quena, and in Sohag and Assiut respectively.',\n",
       "  \"12263. Communication for Change (C-Change) in DRC. COMMUNICATION FOR CHANGE (C-CHANGE) IN DRC. FHI 360's Communication for Change (C-Change) project in the Democratic Republic of the Congo (DRC) seeks to increase positive health behaviors through evidence-based, social and behavior change communication (SBCC) programs that focus on family planning, HIV/AIDS, gender-based violence, malaria, tuberculosis, water sanitation, maternal and child health, nutrition and HIV, and prevention of mother-to-child transmission of HIV. C-Change is working at central and provincial levels to build managerial and SBCC skills within the government, nongovernmental organizations and civil society organizations. We envision building local capacity to plan, monitor and evaluate scientifically based SBCC interventions, so the DRC becomes a regional leader offering state-of-the-art SBCC approaches to neighboring countries.\",\n",
       "  '16064. Output 04: HIV. HIV. Iran - Teheran. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12220. Children first: Strengthening the capacity of medical staff to provide quality referral services for managing paediatric emergency responses in Orotta. CHILDREN FIRST: STRENGTHENING THE CAPACITY OF MEDICAL STAFF TO PROVIDE QUALITY REFERRAL SERVICES FOR MANAGING PAEDIATRIC EMERGENCY RESPONSES IN OROTTA. The project aims at strengthening the capacity of medical staff to provide quality referral services for managing paediatric emergency responses in Orotta Paediatric Hospital.',\n",
       "  '13040. Support to the HIV/AIDS Response in Zambia (SHARe II) - HIV/AIDS. SUPPORT TO THE HIV/AIDS RESPONSE IN ZAMBIA (SHARE II) - HIV/AIDS. Support to the HIV/AIDS Response in Zambia (SHARe II) is a continuation of the work begun in 2004, and the overall assistance objective remains to strengthen and support the mutisectoral response to HIV & AIDS in Zambia. The previous project built a solid foundation of systems, tools, communications, and information sharing and policies. This next phase of the project is focusing on the continuation of enhanced assistance, with an emphasis on quality, equitable implementation, and leadership accountability, with an added emphasis on the documenting and sharing of best practices. The project is examining and working to address the structural drivers of HIV as well as the behavioral drivers of the disease. SHARe II supports the Government of Republic of Zambia (GRZ)s vision of a nation free from the threat of HIV, and is working in partnership with the National HIV/AIDS/STI/TB Council, cooperating partners (including the Global Fund, UNFPA, DfID, and other bilateral, multilateral, and private sector partners), and other stakeholders to support efforts to mitigate the impact of HIV in Zambia.',\n",
       "  '13020. Leadership, Management, Governance (LMG) - Maternal and Child Health. LEADERSHIP, MANAGEMENT, GOVERNANCE (LMG) - MATERNAL AND CHILD HEALTH. The Leadership, Management, Governance (LMG) project builds in-country health and education system capacity by increasing leadership, management, and governance knowledge of health care providers, program managers, and policy makers who work on health services.',\n",
       "  '12110. Technical Assistance for Hospital Management and Human Resources Policies. TECHNICAL ASSISTANCE FOR HOSPITAL MANAGEMENT AND HUMAN RESOURCES POLICIES. The Bolivian ministry of health (MS) is immersed in a process of modernization of all his healthcare levels, management decentralization from the national level to the County Health Services (in Spanish, Servicios Departamentales de Salud + SEDES) and Str',\n",
       "  '12263. African Collaborative for Health Financing Solutions (ACS). AFRICAN COLLABORATIVE FOR HEALTH FINANCING SOLUTIONS (ACS). The African Collaborative for Health Financing Solutions (ACS) will advance Universal Health Coverage (UHC) in Sub-Saharan Africa by working with regional bodies and country-level multi-stakeholder platforms to share knowledge, strengthen accountability and promote sound health financing policies. ACS will partner with regional institutions to strengthen their role in policy, advocacy, and regional learning on health financing approaches.',\n",
       "  '12191. Egypt-Swiss Radiology Project. EGYPT-SWISS RADIOLOGY PROJECT. Egytp-Swiss Radiology Project III - TAP. After the successful implementation of the Second Phase, which lasted between 2007 and 2011, a Third Phase to extend the digital radiology services has been initiated. The objective of the new phase is to expand the digital radiology services in Egypt based on the experiences and lessons learned from the pilot sites for digital radiology introduced in the 2nd Phase. In addition, the Project shall also support and have synergies with the Egyptian national initiative initiated in late 2009, the Picture Archiving and Communication System. Following activities are planned to reach this objective: the rehabilitation of sites receiving mainly digital radiology services and equipment, the provision of radiology equipment, the assistance for the maintenance and financial sustainability of the radiology technology and the training and capacity building programme for the radiology staff. At project completion, it is expected that about 22 radiology departments in selected hospitals shall be renovated and rehabilitated, the equipmment maintenance and technology management shall be strenthened and financially sustainable, radiation safety is applied by training measures and supervision schemes. The implementing agency for this project is the Egyptian Ministry of Health and Population. This is a project mixed-financed by Switzerland (50% by SECO, 50% by Swiss banks).',\n",
       "  \"13030. YouthPower - Implementation. YOUTHPOWER - IMPLEMENTATION. The 'YouthPower - Implementation' task order supports missions buying into the' YouthPower' IDIQ contract for cross-sectoral youth development activities. The task order cover activities including : 1) the implementation of centrally funded pilot activities at the country or regional level; 2) small grant funds for learning and knowledge-sharing within projects; 3) innovation grants; 4) learning events; 5) making available technical assistance and training to missions; 6) stakeholder workshops; and 7) the creation of other appropriate innovation and learning platforms. Because this mechanism is in procurement development, the following key information has not yet been determined: Mechanism No. (Award #), Prime Partner, Start and End dates, Total Estimated Cost. The estimated Start and End dates are 2015 and 2020, respectively.\",\n",
       "  '12240. Food and Nutrition Technical Assistance III (FANTA-III) - Nutrition. FOOD AND NUTRITION TECHNICAL ASSISTANCE III (FANTA-III) - NUTRITION. The Food and Nutrition Technical Assistance Project (FANTA) has been working to improve the health and well-being of vulnerable individuals, families, and communities in developing countries by strengthening food security and nutrition policies, programs, and systems. The project provides comprehensive technical support to USAID and its partners, including host country governments, international organizations, and nongovernmental organizations. FANTA works at both the country and global levels, supporting the design and implementation of programs in focus countries, and building on field experience to strengthen the evidence base, methods, and global standards for food security and nutrition programming.',\n",
       "  '12182. Applied Research in India, Partner Driven Cooperation within the health sector - 016 StslsbyLundborg,Antibiotic stewardship netw,KI. APPLIED RESEARCH IN INDIA, PARTNER DRIVEN COOPERATION WITHIN THE HEALTH SECTOR - 016 ST+LSBYLUNDBORG,ANTIBIOTIC STEWARDSHIP NETW,KI. Call for applications in the prioritised area of health in India.',\n",
       "  '12110. Global Antimicrobial Resistance (AMR) Innovation Fund  UK China AMR Bilateral Research and Development Competition  Project Support Officer. GLOBAL ANTIMICROBIAL RESISTANCE (AMR) INNOVATION FUND  UK CHINA AMR BILATERAL RESEARCH AND DEVELOPMENT COMPETITION  PROJECT SUPPORT OFFICER. UK-China Innovation Collaboration to address the challenges of AMR for the benefit of low and middle income countries. Project Support Officer based in British Embassy Beijing to provide assistance for building and strengthening the GAMRIF collaboration with MoST.',\n",
       "  '12261. Going to health. GOING TO HEALTH. Enhancement of health education for the vulnerable population, especially women and children exposed, cause infected waters, to the spread of malaria and TB, to sexually transmitted diseases and to the pathologies of motherhood. The project includes a medical laboratory with basic sanitary equipment, a kitchen equipped for simulation, computer equipment, training activities on the context of extreme poverty and gender violence on women',\n",
       "  '12263. CEPAT-NU: Increase Community Participation and Demand for Quality Diagnosis and Treatment Services - Tuberculosis. CEPAT-NU: INCREASE COMMUNITY PARTICIPATION AND DEMAND FOR QUALITY DIAGNOSIS AND TREATMENT SERVICES - TUBERCULOSIS. CEPAT-NU: Increase Community Participation and Demand for Quality Diagnosis and Treatment Services for TB Patients and to Advocate for Increased TB Resources and Improved TB Services in Indonesia. The Community Empowerment of People Against Tuberculosis (CEPAT) project is working at the community level, engaging religious leaders, with support from partner LKNU, the largest Muslim organization worldwide. CEPAT is coordinating the TB community support model with TB activities in the health system. In this way, the project ensures a continuum of care of TB patients from the health system to the community, strengthening TB prevention and control efforts.',\n",
       "  '12110. Budget Support to the Health Sector in Kyrgyzstan. BUDGET SUPPORT TO THE HEALTH SECTOR IN KYRGYZSTAN. SDC has provided support to the health care reforms in Kyrgyzstan since early 2000. Despite several political disturbances, the Kyrgyz Government has made good progress in reforming the health sector and has achieved universal coverage for basic health services. There is however still scope to further improve quality of health services to reach health outcomes (MDGs) during the next reform period (2012-2016). SDC will thus support reforms through a Sector Wide Approach under strong leadership of the Ministry of Health.',\n",
       "  '16064. Restless Development ( formerly SPW) Phase II - Restless Development (formerly SPW) Phase II. RESTLESS DEVELOPMENT ( FORMERLY SPW) PHASE II - RESTLESS DEVELOPMENT (FORMERLY SPW) PHASE II. Restless Development is a Tanzanian NGO that delivers youth development and leadership programmes. It places young people at the forefront of change and development. It implements programmes that mobilise young people so they can empower others to make informed decisions about issues affecting their lives and those of their communities.',\n",
       "  \"13040. Global Broadband Internet Partner (GBIP) - NetHope Plus Up. GLOBAL BROADBAND INTERNET PARTNER (GBIP) - NETHOPE PLUS UP. This activity is now known as Women and the Web. It is a public-private partnership among USAID, NetHope, Intel Corporation, World Pulse, World Vision, UN Women, and Women in Technology in Nigeria. Alliance partners will combine efforts to transform the lives and livelihoods of girls and women in Africa through digital literacy training, relevant content, policy work, and online social networks. The Alliance will introduce girls and women to the transformative benefits of the Internet. All partners share a common interest in increasing access to and use of the Internet to realize the socio-economic benefits for all of bringing more girls and women online. This effort will expand opportunities for young women to generate greater income, receive a quality education, increase their sense of empowerment and equity, extend their support networks, and increase their political participation. Funding to support this activity comes from the Women's Leadership initiative.\",\n",
       "  \"12220. Health Sector Reform Support Programme. HEALTH SECTOR REFORM SUPPORT PROGRAMME. The Health Basket Fund has played a crucial role for the devolution ('decentralisation') of health services' responsibility to the Local Government Authorities. The regular dialogue between the Development Partners and the Government on the use of this funding has allowed important improvements in the implementation of the sector reform. The combination of increase of funding with financial decentralisation and technical support for more equity has given the councils the possibility to increase resources for evidence based interventions.The Health Basket Fund respects the principles of the Paris Declaration and the Joint Assistance Strategy for Tanzania. For this new phase of support, the objectives and indicators of the HSSP 3 will be used to follow up the progresses in the performance of the sector. In order to improve the efficiency in the use of the funds, the basket partners will further align to Government procedures, but at the same time implement measures to strengthen the management (both at district and central level), streamline the fund transfer procedure to avoid delays and improve the quality of planning and reporting. The share of the Health Basket funding for the councils will be further increased and more discretion given to the Local Health Authorities to develop their own solution to respond to general or local challenges.\",\n",
       "  '13081. Action Plan on the Guidelines for the introduction of the issue of disability in the policies and activities of the Cooperation. ACTION PLAN ON THE GUIDELINES FOR THE INTRODUCTION OF THE ISSUE OF DISABILITY IN THE POLICIES AND ACTIVITIES OF THE COOPERATION. This project aims at promoting the action plan concerning the guidelines for the introduction of the issue of the disability in the Cooperation policies and activities',\n",
       "  '12110. Healthy China 2020 : Policy and Technology Evaluation. HEALTHY CHINA 2020 : POLICY AND TECHNOLOGY EVALUATION. In April 2009, China issued a new round of health sector reform policies aimed at providing a blueprint for universal basic healthcare coverage for all by 2020. The China Health Economics Institute (CHEI) within the Chinese Ministry of Health is responsible for research and evaluation in support of the new policies through the newly created China Centre for Health Policy and Technology Evaluation (CHPTE). This grant will provide the Institute and the Centre with the necessary capacity building to carry out their mandate of monitoring and evaluating progress toward the 2020 goal. It will also enable the Institute to become a leading regional centre in health policy evaluation.',\n",
       "  '12182. Gender and health in org, Gbg university etc. GENDER AND HEALTH IN ORG, GBG UNIVERSITY ETC. GU together with SIGN partners has submitted a proposal for  Gender, Leadership and Health Promotion in Working Life  with a total budget of 6.4 MSEK of which Sida is asked to cover almost 3 MSEK. The aim is a long-term cooperation in research, exchange programs for teachers, students and practitioners as well as knowledge dissemination between universities and organizations in India and Sweden.',\n",
       "  \"13040. Church of Sweden Framework agreement 2014-2016, 2017. CHURCH OF SWEDEN FRAMEWORK AGREEMENT 2014-2016, 2017. This contribution is implemented by Church of Sweden in partnership with about 110 local civil society organisations in several cooperation countries in Africa, Asia, Latin America and the Middle East during 2014-2016 with support from Sida/CIVSAM amounting to 291 000 000 SEK, with the aim to strengthen civil society capacities and contribute to the following programme objectives:- Strengthening of people's sexual and reproductive health and rights.- People living in poverty have the right to protection and their social and economic emancipation is strengthened.- People have increased safety and protection, and are empowered to deal with conflicts and to participate in peace processes.- Women and men have improved opportunities and possibilities to equal participation, voice and leadership in the church and in society.- People's right to physical and sexual integrity in the church and in society is strengthened.Church of Sweden has proposed an extension of this contribution, on basis of the existing results framework, and with a budget of 119 419 916 for the year 2017, thereby increasing the total budget to 410 419 916 SEK for the period 2014-2017.Appraisal of the contribution:The appraisal during 2016 of this contribution is made in accordance with a decision on an additional contribution, since it builds upon the appraisal of the same programme for the period 2014-2016. Hence the assessment made for the period 2014-2016 is still relevant and referred to, whereas an update is given for the period 2017 with special emphasis on:- The relevance of the contribution in the light of the strategy for CSO support 2016-2022.- The development of the contribution during 2014-2016 and focus for 2017.- Capacities, internal management and control during 2016-2016.\",\n",
       "  '12110. Scholarship Talent Spotting Programe (2017-2018 course). SCHOLARSHIP TALENT SPOTTING PROGRAME (2017-2018 COURSE). Promgrama de becas de atracci=n al talento de la Universidad de JaTn para cursar estudios de grado y master en la UJA',\n",
       "  '13040. Reinforcing the Scaling Up of HIV Services: Strengthening HIV Prevention and Effective Targeting. REINFORCING THE SCALING UP OF HIV SERVICES: STRENGTHENING HIV PREVENTION AND EFFECTIVE TARGETING. Ghana has a generalized HIV epidemic with pockets of high prevalence among most-at-risk populations (MARPs), namely men having sex with men (MSM) and their female partners, female sex workers (FSWs), prison inmates, most-at-risk youth (15-24), workers (miners, uniformed services, transport workers), and vulnerable groups such as young boys and girls and female porters, as well as population in some geographic areas which are disproportionally affected by the epidemic. The prevalence rate has remained stable and below 5% over the past 16 years. The current national prevalence is 1.9% and prevalence among pregnant women is 2.6% (2007 sentinel surveillance report: National AIDS Control Program/Ghana Health Services).This Program addresses gaps in the national response such as 1) superficial understanding of HIV in many segments of the population including youth, and an inability to move people from general knowledge and awareness of risk to actually adopting safer behaviors; 2) insufficient targeting of MARPs and vulnerable groups; 3) slow integration of HIV/AIDS and Sexual Reproductive Health (SRH); 4) shortfalls in institutional and community capacities to rapidly scale-up comprehensive HIV services.Recognizing that clients of MARPs serve as a bridge between MARPs and general population in HIV transmission, this Program targets MARPs, vulnerable groups and general population. As part of health system strengthening measures directly related to HIV services, this Program targets blood safety, prevention of mother-to-child transmission (PMTCT), early infant diagnosis, and integration of HIV and sexually transmitted infections (STI) services.As a part of the strengthening national health system in its response to HIV epidemic and emphasizing the need of stronger partnerships between the public health sector, civil society and the private sector, this Program will be implemented by multiple Principal Recipients, as of the effective date of this Agreement, the Ministry of Health/Ghana Health Services, Ghana AIDS Commission (the Principal Recipient), Planned Parenthood Association of Ghana, Adventist Development and Relief Agency of Ghana. 2.Goal:  To reduce new HIV infections in the general population.Target Group/Beneficiaries:People living with HIV/AIDS (PLHIV);MARPs: MSM and their female partners, FSWs, Prison inmates, most-at-risk youth (15-24), Workers (miners, uniformed services, transport workers);Vulnerable groups: young people (aged 15-24), female porters;Pregnant women;Infants born to HIV-positive pregnant women; andGeneral population4.Strategies:To promote the adoption of safer sexual practices in the general population;To promote healthy behaviors and the adoption of safer sexual practices among PLHIV, MARPs and vulnerable groups; To promote the integration of SRH and HIV/AIDS services with emphasis on PMTCT and safe blood transfusions; andTo strengthen the institutional capacity and community systems for scaling-up HIV/AIDS, STI a',\n",
       "  \"12263. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       "  '12230. The Project for Improvement of Medical Environment at Railway Hospital in Bishkek City. THE PROJECT FOR IMPROVEMENT OF MEDICAL ENVIRONMENT AT RAILWAY HOSPITAL IN BISHKEK CITY. The Project for improvement of medical environment by providing medical equipment including Endosurgery Set, Anesthesia Respiratory Apparatus.',\n",
       "  '16064. Output 04: HIV. HIV. Turkey - Ankara. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '13040. Output 04: HIV. HIV. Timor Leste. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '13040. Chinese Association of STD & AIDS Prevention and Control. CHINESE ASSOCIATION OF STD & AIDS PREVENTION AND CONTROL. to ensure greater access to HIV/AIDS and tuberculosis (TB) health resources through strategic and global advocacy',\n",
       "  '13040. Support to the HIV/AIDS Response in Zambia (SHARe II) - HIV/AIDS. SUPPORT TO THE HIV/AIDS RESPONSE IN ZAMBIA (SHARE II) - HIV/AIDS. Support to the HIV/AIDS Response in Zambia (SHARe II) is a continuation of the work begun in 2004, and the overall assistance objective remains to strengthen and support the mutisectoral response to HIV & AIDS in Zambia. The previous project built a solid foundation of systems, tools, communications, and information sharing and policies. This next phase of the project is focusing on the continuation of enhanced assistance, with an emphasis on quality, equitable implementation, and leadership accountability, with an added emphasis on the documenting and sharing of best practices. The project is examining and working to address the structural drivers of HIV as well as the behavioral drivers of the disease. SHARe II supports the Government of Republic of Zambia (GRZ) s vision of  a nation free from the threat of HIV,  and is working in partnership with the National HIV/AIDS/STI/TB Council, cooperating partners (including the Global Fund, UNFPA, DfID, and other bilateral, multilateral, and private sector partners), and other stakeholders to support efforts to mitigate the impact of HIV in Zambia.',\n",
       "  \"12281. Upgrade and standardization of the 'Orthopedic Technician Training' -Strengthening Disability and Rehabilitation Health Services through Increased num. UPGRADE AND STANDARDIZATION OF THE 'ORTHOPEDIC TECHNICIAN TRAINING' -STRENGTHENING DISABILITY AND REHABILITATION HEALTH SERVICES THROUGH INCREASED NUM. The specific objective of this procedure is:   1.To implement the three years curriculum of orthopaedic technologists in close coordination with MoPH.  2.Improving the quality of the training and filling the human resource shortage in the specific public orthopaedic centres.\",\n",
       "  '13030. Roads to a Healthy Future II (ROADS II) Project - Family Planning and Reproductive Health. ROADS TO A HEALTHY FUTURE II (ROADS II) PROJECT - FAMILY PLANNING AND REPRODUCTIVE HEALTH. Regional Outreach Addressing AIDS through Development Strategies (ROADS) project has linked communities along these corridors with critical HIV/AIDS and other health services by collaborating closely with national AIDS control programs; government ministries; district health management teams; health facilities; and local, national and international companies. The project helps individuals and communities reduce their vulnerability to HIV by expanding economic opportunities and improving food security. The project s LifeWorks component provides training and technical assistance in group savings and loan, livestock management (chickens, rabbits and goats), urban and organic gardening and microenterprise development. The ROADS project also provides care and support for orphans and other at-risk children, and it works to protect women and girls from sexual exploitation and abuse.',\n",
       "  '13030. GOAL. GOAL. to help develop new family planning methods for young people in urban regions of Kenya by using mobile technology to conduct surveys to find out their opinions on contraceptives, and engaging them to brainstorm solutions',\n",
       "  \"13040. Systems Strengthening for Better HIV/TB Patient Outcomes (Wits Reproductive Health and HIV Institute). SYSTEMS STRENGTHENING FOR BETTER HIV/TB PATIENT OUTCOMES (WITS REPRODUCTIVE HEALTH AND HIV INSTITUTE). This award supports the facility management, the district management and its District Health Management Teams and the provincial management. The goal of the project is to improve HIV-related population outcomes by: strengthening management systems at facilities; building the capacity of facility teams and management systems in coordination with the North West and Gauteng Provinces to support and integrate TB/HIV related services; supporting facilities in identifying and setting up policies and programs to improve the district's facility response to providing HIV/TB care, treatment, laboratory and prevention services to support transition to a sustained national comprehensive HIV/TB care and treatment program in line with GoSA's key priorities of PHC re-engineering and national health insurance. The overall strategy involves a roving team allocated to each sub-district's PHCs and CHCs, who are managed by a sub-district manager and supported by a back-up team based in the sub-district. These teams develop the capacity of DoH staff through targeted, on-site training and mentoring and mentor facility staff to apply their learning from previous training interventions to improve quality of care and services. Roving teams also provide additional training as required with follow-on mentoring.\",\n",
       "  '12110. SARPAM[ Southern Africa Regional Programme on Access to Medicines]. SARPAM[ SOUTHERN AFRICA REGIONAL PROGRAMME ON ACCESS TO MEDICINES]. To improve the availability, affordability and quality of essential medicines and diagnostics in the Southern Africa Region by strengthening capacity in procurement, regulation and monitoring, and by accessing private capital for innovations in the pharma',\n",
       "  '12191. Services for Palestinian children with multiple special needs and their families in Lebanon Acronym MSN-services. SERVICES FOR PALESTINIAN CHILDREN WITH MULTIPLE SPECIAL NEEDS AND THEIR FAMILIES IN LEBANON ACRONYM MSN-SERVICES. Palestinian refugee population has no available mental health services in Lebanon. Beit Atfal Assumoud (BAS) started the mental health program: Family Guidance Center for children in 1997. So far there are five operational Centers in Lebanon. Significant number of learning difficulties or developmental problems are found in major part of the children. Required specialized rehabilitation services are scarce more often too expensive for the families. The cases are often multidisciplinary since the child has several problems. Large scale professional efforts are required the rehabilitation efforts are enormous. BAS initiated a Sponsorship Program in 2009 in order to provide special education and rehabilitation services for children in need. BAS covers the expenses for the children. The profound ethical guideline in the project: Children with special needs have the right for decent human development and protection regardless of their condition as well as being refugees. The purpose of the project is:1) to secure places (36) in special schools institutions or individually tailored rehabilitation process for children and adolescents with multiple special needs referred by Family Guidance Centers of BAS2)  to arrange for parents and siblings meetings workshops and recreational activities for rest recovery and peer support and encouraging them to advocacy and making proposals.3) promote access to special education and rehabilitation services and possibilities of BAS to enhance services in reduced price offered by specialised entities. Find out and define prerequisites needed for the special education and rehabilitation service delivery by BAS itself.The project develops more extensive service delivery system of special education and further rehabilitation for children and adolescents with special needs and their families. The project is based on the Sponsorship Programme started already in 2009. There were rehabilitation sponsors for 20 children among them five from Finland in May 2012. 139 were on the waiting list.BAS is for equality of genders against discrimination and acts for good environmental practices. BAS follows service statistics also by gender and nationality.',\n",
       "  '12191. Preparation of the Technical specifications for the tender dossier and evaluation of supply offers for testing laboratories for medical products. PREPARATION OF THE TECHNICAL SPECIFICATIONS FOR THE TENDER DOSSIER AND EVALUATION OF SUPPLY OFFERS FOR TESTING LABORATORIES FOR MEDICAL PRODUCTS. The purpose of this contract is to carry out an equipment needs assessment of four Belarus testing laboratories under the Ministry of Health of the Republic of Belarus, to produce Technical Specifications and a market research, taking into account applicable eligibility rules allowing a competitive supply tender procedure, to produce a report on the technical evaluation of offers received for the supply tender procedure',\n",
       "  '12110. Using the London model to influence guidelines for the Beijing Low-Emission Zone.. USING THE LONDON MODEL TO INFLUENCE GUIDELINES FOR THE BEIJING LOW-EMISSION ZONE.. This project will support low carbon infrastructure development. By May 2015, Beijing Municipal Commission of Transport (BMCT) should bring forward plans for how they will integrate the Low-Emission Zone (LEZ) guideline and the public communication strat',\n",
       "  '12240. EVALUATION OF BUDGET SUPPORT IN PERU 2009-2015. EVALUATION OF BUDGET SUPPORT IN PERU 2009-2015. Systematic and timely evaluation of its programmes, activities, instruments, legislation and non-spending activities is a priority  of the European Commission  in order to demonstrate accountability and to promote lesson learning to improve policy and practice .    The main objective of this evaluation is to assess to what extent Budget Support in Peru contributed to achieve sustainable results on poverty and inequality reduction with particular regard to the sectoral policies:',\n",
       "  '12220. Jacaranda Health. JACARANDA HEALTH. to assess the implementation of the new, globally-validated measurement tools from the INTERGROWTH-21st Project, and test the effects these new tools have on antenatal care',\n",
       "  '13040. Targeted HIV/AIDS and Laboratory Services (THALAS) - HIV/AIDS. TARGETED HIV/AIDS AND LABORATORY SERVICES (THALAS) - HIV/AIDS. The Targeted HIV/AIDS and Laboratory Services (THALAS) project will provide specialized laboratory services and advanced care and treatment in seven sites including Kampala. The project will work collaboratively with the Ministry of Health and the Strengthening Uganda s Systems for Treating AIDS Nationally (SUSTAIN) project to build the capacity of lab personnel in regional and district hospitals in the provision of high-quality lab services.',\n",
       "  '13040. Applying Science to Strengthen and Improve Systems (ASSIST) - Administration and Oversight. APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST) - ADMINISTRATION AND OVERSIGHT. The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       "  '12262. Administration and Oversight (Malaria). ADMINISTRATION AND OVERSIGHT (MALARIA). Supports the following illustrative program-funded costs: salaries of US, FSN, and TCN and other staff such as PSCs, RSSAs, PASAs, CASUs working for the US Government managing, administering, and supporting programs and their program-funded benefits such as housing, travel, transportation, education allowances etc; institutional contractors that provide such staff, rent, IT services, the program-funded share of utilities, staff training costs and the cost of developing and administering training programs, equipment and supplies, ICASS, vehicle fuel and maintenance, maintenance contracts, janitorial services, operational unit web page development and maintenance, outreach such as publications and the cost of their preparation (including staff costs), and technical assistance to ensure USG compliance with regulations.',\n",
       "  '13020. Darfur FGM 2014. DARFUR FGM 2014. The project will promote abandonment of FGM in Zalingei, Nertiti and Garsila localities in Central Darfur through training of medical personnel and conducting awareness raising among community leaders, religious leaders teachers and other opinion formers',\n",
       "  '12220. JPO WHO 2017 Egypt NCD and Mental Health NP. JPO WHO 2017 EGYPT NCD AND MENTAL HEALTH NP. The contribution refers to a Junior Professional Officer (JPO) position. The position is addressing the Agenda 2030 goal 3: Good Health and Well-being. Thematic area is health with a focus on reducing burden and mortality of non-communicable diseases. Reduce morbidity and mortality related to tobacco use and promote mental health and well-being and ensure access to relevant care units. The contribution contributes to the implementation of the Strategy for Capacity Development and Exchanges 2014-2017 and the subsequent strategy (2018-2021), and will contribute to the following objectives: 1) Increased number of qualified Swedes in by the government-prioritized international and regional organizations and institutions and 2) an expanded Swedish resource base for multilateral, bilateral and regional assistance through special skills development and education programs for younger people.',\n",
       "  '12110. Reviews, studies. REVIEWS, STUDIES. Reviews and studies of the components under the Health Sector Programme in Tanzania',\n",
       "  '12110. Fleming Fund  Food and Agriculture Organisation (FAO) Secondment. FLEMING FUND  FOOD AND AGRICULTURE ORGANISATION (FAO) SECONDMENT. The Department has seconded an antimicrobial resistance (AMR) expert to work in the FAO, to lead the promotion of the Fleming Fund in low and middle income countries and to support tripartite working between FAO, OIE and WHO.',\n",
       "  '12110. Develop and pilot a practical educational package against antimicrobial resistance in rural Anhui, China. DEVELOP AND PILOT A PRACTICAL EDUCATIONAL PACKAGE AGAINST ANTIMICROBIAL RESISTANCE IN RURAL ANHUI, CHINA. Develop a low cost, effective and sustainable educational intervention package against antimicrobial resistance at a rural level.',\n",
       "  '12250. PATH. PATH. To achieve sustained increases in immunization coverage through support for country-owned, country-led policies, practices, and information system tools that enable evidence-based decision-making.',\n",
       "  \"12220. Global Health Support Initiative II (GHSI II). GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II). The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the program's vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.\",\n",
       "  '12110. Study tour to the Program Bolsa Familia, Brazil. STUDY TOUR TO THE PROGRAM BOLSA FAMILIA, BRAZIL. This CT will finance a study tour composed by the Secretarfa de Desarrollo Social (SEDESOL) (Chief Coordinator and team) to Brazil to meet the team of the Brazilian CCT Program Bolsa Familia.',\n",
       "  '12220. Leadership, Management, Governance (LMG) - Other Public Health Threats. LEADERSHIP, MANAGEMENT, GOVERNANCE (LMG) - OTHER PUBLIC HEALTH THREATS. The Leadership, Management, Governance (LMG) project builds in-country health and education system capacity by increasing leadership, management, and governance knowledge of health care providers, program managers, and policy makers who work on health services.',\n",
       "  '12263. Early case finding and correct management of leprosy and TB, inclusive MDR-TB, in the project areas with special emphasis to gender and to the female. EARLY CASE FINDING AND CORRECT MANAGEMENT OF LEPRO. NA',\n",
       "  \"13020. MEASURE Evaluation Phase III. MEASURE EVALUATION PHASE III. MEASURE Evaluation Phase III continues the MEASURE program's 10 year initiative to improve the collection, analysis and presentation of data to promote better use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3)increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increased facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureau's primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.\",\n",
       "  '12250. Applying Science to Strengthen and Improve Systems (ASSIST). APPLYING SCIENCE TO STRENGTHEN AND IMPROVE SYSTEMS (ASSIST). The objective of the USAID Applying Science to Strengthen and Improve Systems (ASSIST) Project is to improve the quality and outcomes of health care and other services by enabling host country providers and managers to apply the science of improvement. The project seeks to build the capacity of host country service delivery organizations in USAID-assisted countries to improve the effectiveness, efficiency, client-centeredness, safety, accessibility, and equity of the health and family services they provide. USAID ASSIST also seeks to institutionalize the capacity to improve through competency development at the pre- and in-service levels as well as engaging with host country governments at the policy level.',\n",
       "  '12191. Purdue University. PURDUE UNIVERSITY. to improve maternal health in Uganda by developing a cloud-based digital tracking tool to record health and stock data at local health clinics, as well as diagnostic laboratory data, to optimize ordering of medical supplies',\n",
       "  '13020. Improving Models of Health Interventions Follow-on - Maternal and Child Health. IMPROVING MODELS OF HEALTH INTERVENTIONS FOLLOW-ON - MATERNAL AND CHILD HEALTH. To scale-up to national level an improved package of basic health services for the Extension of Coverage Program and to conduct feasibility studies aimed to explore new models for the provision of health services for the most unprivileged and not previously served populations of Guatemala.',\n",
       "  '13040. Output 04: HIV. HIV. Uganda - Kampala. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12261. Frame agreement with NGO (Fida Int.). FRAME AGREEMENT WITH NGO (FIDA INT.). Community Health Development Project. This is a new project and detailed planning is still under way. The project seeks to improve the community health situation in Kangwon province, Sepo county. Health care services in North Korea are insufficient especially qualitively and the knowledge of health issues is generally low. There are clear health risks in hygiene and sanitation and the project seeks to reduce these risks. The health care system suffers from lack of resources. The basic level of the health care system are the village clinics. This project aims at strengthening the service capacity at this level. The project will study possibilities to expand the Primary Dental Care Support Programme (5212) to Kangwon Province. The project also includes Fida country coordination as a component, covering all the activities in the country.',\n",
       "  \"13040. Sustaining the Momentum: The March Towards Universal Access to HIV and AIDS Services in Tanzania. SUSTAINING THE MOMENTUM: THE MARCH TOWARDS UNIVERSAL ACCESS TO HIV AND AIDS SERVICES IN TANZANIA. 1. Background and Summary:  The primary goal of this Program is to reinforce the Government of Tanzania's response to the HIV/AIDS epidemic by expanding service delivery to the lower tiers of the health system. Attaining this goal requires financing recurring costs, such as Health Products and consumables, as well as supporting activities that maintain and strengthen the system in place, such as refresher training for community health workers, supervision and mentoring. Experience with previous Global Fund grants has highlighted the need for greater coordination among relevant stakeholders. Accordingly, this grant will support the scale up of HIV/AIDS services by strengthening capacity and coordination among key stakeholders in the public and private sectors, including: Civil Society Organizations (CSOs), Faith-based Organizations (FBOs), People Living with HIV/AIDS (PLHA) groups, as well as the Tanzania Commission for AIDS (TACAIDS), the national coordination body for Tanzania's multi-sectoral HIV/AIDS programming.  Tanzania faces an urgent need for drugs and commodities for the delivery of HIV/AIDS services. The scale-up of the national anti-retroviral therapy (ART) program has resulted in a seven-fold increase in the number of patients enrolled in treatment, from 23,951 in 2005 to 189,494 in October 2008. Funding for commodities that are key to the delivery of key services such as HIV testing, Sexually Transmitted Infection (STI) management, Prevention of Mother to Child Transmission (PMTCT), ART, Opportunistic Infection (OI) treatment and prophylaxis, and early infant diagnosis will therefore form an integral part of the Program. The Program will additionally measure the outputs, outcomes and impact of HIV/AIDS interventions addressed by the Program. Specifically, this program's main objectives are to scale up through expansion of care and treatment services to primary health care facilities, increase coverage of key prevention services all over the country, ensure continuous quality service delivery and strengthen the national-level stakeholders and coordination mechanisms.  Two Principal Recipients will work on attaining the goals of the program, namely the Ministry of Finance and African Medical Research Foundation (AMREF). 2. Goals:   Secure and sustain Tanzania's HIV/AIDS prevention, care, treatment and support services; and  Strengthen coordination and implementation capacity of key stakeholders.  3. Target Group/Beneficiaries:  PLHA who are eligible for care and treatment  PLHA suffering from chronic illness and/or malnourishment  Patients on care and treatment  In- and out-patients at health facilities  Pregnant women and their partners  Infants born to HIV positive mothers  Sexually active population, especially youth  Health care workers and PLHA accessing HIV/AIDS services   Private sector and Individuals and groups served by FBOs, PLHA, CSOs  General population of Tanzania 4. Strategies:  Expand care and treatment ser\",\n",
       "  '13020. Health Improvement Project - Maternal and Child Health. HEALTH IMPROVEMENT PROJECT - MATERNAL AND CHILD HEALTH. The Timor-Leste Health Improvement Project (TL HIP) will support TL in improving the quality and impact of health services. Guided by the vision that health care quality can be significantly improved by applying proven health improvement methods, the TL HIP will assist programs to scale up evidence-based interventions to improve outcomes in Maternal Newborn Child Health, Nutrition, and Family Planning. The project will build on current strategies of the MoH and USAID successes including, Basic Service Package implementation, support to SISCas, assistance with guidelines and protocols, training, development and piloting of job aids( flip charts, flow-charts, instructional videos) and supportive supervision. TL HIP will complement the strengths identified by partner organizations throughout the Ministry of Health system. The project will support the National, District, Sub-district, and community levels, but will primarily be focused at the district level. At the National level, the TL HIP will provide support for policy, system strengthening, guidelines, working groups and flexible technical assistance in the areas of Quality Control, Health Promotion, District HMIS, and Family Planning. The technical assistance is flexible and will depend on the MoH needs. This flexible TA will also have responsibility for specific districts and sub-districts. At the District and Sub-district levels, the TL HIP will work with DPHOs, Health Center Managers and Health Workers in the areas of BPS implementation, District Implementation Plans (DIPs), supportive supervision, HMIS, Human Resource Management, service delivery, referral systems and other areas as needed. In local communities, TL HIP will help strengthen community participation and engagement systems to support appropriate health concepts and practices and help solve physical and cultural access of the population to health care. The TL HIP can facilitate advocacy, communication, and social mobilization efforts, inc',\n",
       "  \"12262. Sudan Health Transformation Project (SHTP). SUDAN HEALTH TRANSFORMATION PROJECT (SHTP). The Sudan Health Transformation Project (SHTP) targets increased access to and utilization of health, water, and sanitation services to improve the well-being of children, mothers, and families. The project, funded by USAID, is being implemented by JSI Research & Training Institute, Inc. in collaboration with the Secretariat of Health of the Sudan People'sc Liberation Movement (SPLM).\",\n",
       "  \"12220. Solomon Islands-Australia Partnership for Development - Malaria Program. SOLOMON ISLANDS-AUSTRALIA PARTNERSHIP FOR DEVELOPMENT - MALARIA PROGRAM. Health is a priority focus of the Solomon Islands-Australia Partnership for Development and funding under this proposal supports the Health Sector Support Program - Phase 2 which continues Australia's long-term commitment to strengthen health systems and improve outcomes through a Sector Wide Approach (SWAp) which commenced with HSSP Phase 1 in 2008-12. The SWAp and partnership support the Solomon Islands Government in providing quality health services for all people in the Solomon Islands through its own National Health Strategic Plan (2011-2015). The SWAp emphasises the importance of partnership, mutual respect, mutual responsibility and the underlying principles of aid effectiveness. The total value of this initiative is $90.0 million over 4 years, starting 2012-13.\",\n",
       "  '13010. Global Health Support Initiative II (GHSI II) - Program Design and Learning. GLOBAL HEALTH SUPPORT INITIATIVE II (GHSI II) - PROGRAM DESIGN AND LEARNING. The Global Health Support Initiative improves the effectiveness of USAID population, health and nutrition programs. Using evidence-based best practices, the programs vision is to create a large, sustainable pool of talented global health professionals and responsive organizational and professional development programs. GHSI main areas of focus include: 1) the recruitment, placement, career development and mentoring of fellows and interns both in Washington DC and abroad; 2) implementation of a diversity initiative that creates opportunities for underrepresented populations in the field of global health; and 3) organizational development support for USAID staff in Washington, DC and USAID Missions and professional development opportunities for fellows and USAID staff.In Indonesia, the GHSI program supports three technical staff within the USAID/Indonesia health office - the Senior Infectious Disease and Science Advisor, the Senior Maternal Child Advisor, and the Global Fund Liaison.',\n",
       "  '13020. Purdue University. PURDUE UNIVERSITY. to improve maternal health in Uganda by developing a cloud-based digital tracking tool to record health and stock data at local health clinics, as well as diagnostic laboratory data, to optimize ordering of medical supplies',\n",
       "  '12262. University of Oxford. UNIVERSITY OF OXFORD. to identify a laboratory marker for Artemisinin resistance in P.falciparum to guide containment, control and elimination',\n",
       "  '12230. Equipment for the obstetrical-gynecological medical department, clinic and analysis center. EQUIPMENT FOR THE OBSTETRICAL-GYNECOLOGICAL MEDICAL DEPARTMENT, CLINIC AND ANALYSIS CENTER. Setting up a local doctor in the Diocese of Benguela, with appropriate equipment of the delivery room and postpartum, gynecological surgery, general surgery, laboratory, pharmacy, waiting room, facilities and warehouses.',\n",
       "  '12181. Educational and Research Competency Enhancement of Nursing Leaders in Cambodia. EDUCATIONAL AND RESEARCH COMPETENCY ENHANCEMENT OF NURSING LEADERS IN CAMBODIA. to produce many well-qualified nursing leaders contributing to improve quality of health care and ultimately improving health levels of the public in Cambodia',\n",
       "  '12181. Assistance for training in public health in the region Chin, Myanmar. ASSISTANCE FOR TRAINING IN PUBLIC HEALTH IN THE REGION CHIN, MYANMAR. The project presented by the Office for the Development of the Diocese of Hakha concerns the training and sensitization of the local population on issues of personal hygiene, health security, sexual education. The project will directly involve the population of 50 villages.',\n",
       "  '12191. Soins de santT spTcialisTs en palestine - phase III. SOINS DE SANT+ SP+CIALIS+S EN PALESTINE - PHASE III. General Objectives  +To improve the global care in the Palestinian Autonomous Territories by reducing mortality and morbidity due to cardiac and congenital ailments in children and adults+  Specific Objectives  To upgrade the diagnostic and therapeutic cardiac care facilities in three tertiary care hospitals (one in the Gazastrip, one in Jerusalem and one in the West Bank) To upgrade the treatment capacity in one tertiary health centre in Gaza City Results  1. Establish a new Cardiac Intensive Care and Surgery Department in Khann Yunnis at the EuropeanGaza Hospital and start interventional procedures in the Cath-lab in order to create a fully functional Cardiac Centre.2. Extend therapeutic capacity at the Paediatric Intensive Care Unit in Jerusalem at Makassed hospital 3. Establish a new Cardiac Surgery department in Ramallah at the MoH hospital in order to complete the Cardiac Centre by including the existing Cathlab and Cardiology Department.4. Reinforce therapeutic procedures at the Neonatology Department in Gaza city at Shifahospital.',\n",
       "  '12263. Improved detection of tuberculosis in Mozambique. IMPROVED DETECTION OF TUBERCULOSIS IN MOZAMBIQUE. Despite all the efforts that have been made in the field of tuberculosis control in Mozambique, one of the biggest challenges in combating this rapidly spreading disease is to increase the TB detection rate. One of the main reasons for this is the lack of a simple, fast and accurate diagnostic method. Due to this alarming situation, the Mozambican government has declared this epidemic to be a national emergency and for this reason drafted a National Strategic Plan 2008-2012. In 2011, the Mozambican government wants to raise the detection rate from 53% to 58% and substantially increase the recovery rate and the number of TB patients that is tested for HIV/AIDS.  With an eye to finding a solution to this pressing problem of TB diagnosis in countries with limited resources and infrastructure, Apopo has started exploring the possibility of using African HeroRATs to detect tuberculosis. By implementing its unique TB detection technology Apopo aims:(1) to contribute to the national TB control programme of Mozambique by effectively increasing the number of detected TB patients in the short term;(2) to build a local capacity of TB detection rats and trainers to also have a continued long-term impact on the reduction of the TB problem in Mozambique.  Expected outcome: (1) delivery of support to the national TB-program of Mozambique in the short run by effectively increased numbers of treated TB-patients;(2) increased capacity of trainers and rodents for TB-detection in the country.   Document available at  https://drive.google.com/file/d/0B-IUzKYaN-QSY0ZBZU5tZTJ2cTg/edit?usp=sharing',\n",
       "  '13040. Training of Ukrainian diagnosticians in the field of the newest laboratory techniques  improvement of care standard of persons living with HIV/AIDS in Ukraine. TRAINING OF UKRAINIAN DIAGNOSTICIANS IN THE FIELD OF THE NEWEST LABORATORY TECHNIQUES  IMPROVEMENT OF CARE STANDARD OF PERSONS LIVING WITH HIV/AIDS I. NA',\n",
       "  '13040. Output 04: HIV. HIV. Sierra Leone - Freetown. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  \"13020. Kinerja. KINERJA. The overarching objective of this activity is the provision of innovative and improved service delivery by local governments to citizens. USAID focuses on the governance of service delivery in three sectors: education; health services and; and local business. Activities under this IM address both demand and supply side aspects of service delivery. These investments will result in strengthened accountability mechanisms that improve local government responses to citizens' needs. USAID works through local institutions to build their capacity and foster sustainable partnerships with local government. This solidifies the links between stimulation of demand for good services through active civil society engagement and improved local government response.\",\n",
       "  \"12181. 2017 Healthcare Executive Leadership Training Programs, through Meridian International Center. 2017 HEALTHCARE EXECUTIVE LEADERSHIP TRAINING PROGRAMS, THROUGH MERIDIAN INTERNATIONAL CENTER. USTDA funding partially supported two separate and distinct 14-day training programs for 25 senior Chinese healthcare executives and officials. The training programs were designed to introduce the delegates to best practices in healthcare management and U.S. advanced medical technologies and solutions. This was the sixth USTDA training program for Chinese healthcare executives, and was supported by members of the U.S.-China Healthcare Cooperation Program (HCP) and China's Health Human Resources Development Center (HHRDC).\",\n",
       "  \"13020. Leadership, Management and Sustainability (LMS) Project. LEADERSHIP, MANAGEMENT AND SUSTAINABILITY (LMS) PROJECT. The Leadership, Management and Sustainability (LMS) Program supports people and organizations around the world to strengthen the way they lead and manage their own programs to achieve widespread improvements in health. LMS/Kenya's programs work to strengthen leadership, management and governance for sustained health programs. Program activities focus on building leadership and management skills through training, mentoring and coaching. Allactivities are structured around the achievement of three intermediate results: 1) Improved management and leadership of the health sector and priority health programs on HIV/AIDS, tuberculosis, family planning/ reproductive health, maternal and child health, and malaria; 2) Improved management and systems in health organizations and priority health programs; and 3) Increased sustainability and ability to manage change.\",\n",
       "  \"12240. Scale Up of Homestead Food Production for Improved Nutrition in Cambodia (CIFSRF Phase 2). SCALE UP OF HOMESTEAD FOOD PRODUCTION FOR IMPROVED NUTRITION IN CAMBODIA (CIFSRF PHASE 2). Household food insecurity, seasonal food shortages, and nutritional deficiencies among women and children are prevalent in Cambodia. This project will refine proven innovations in homestead food production and will test cost-sharing, financial, and social impact models at scale to improve nutrition, income, and gender equity. Testing homestead food production approaches Homestead food production empowers the poor with the education and resources they need to raise their own nutritious foods. The project team will ask men and women smallholders living in Cambodia's upland, lowland, and forested regions to self-select from four food production options: -backyard gardens alone -gardens plus fish -gardens plus poultry -gardens plus poultry and fish Researchers from the University of British Columbia and Helen Keller International will identify barriers to participation and factors that motivate farmers to adopt and invest in the intervention. They will integrate underlying factors that influence nutritional outcomes including water, sanitation, and hygiene practices. The project builds on previous research testing homestead food production with vegetable gardens in combination with fish ponds to grow nutrient-dense small fish for household consumption and large fish for sale. The earlier research found that nutritional quality was enhanced, incomes improved, and women had a greater role in household decision-making. Better nutrition, improved food security At the end of three years, 22,500 households and 135,000 individuals are expected to benefit directly and indirectly. The project will provide a package of homestead food production options that can be quickly implemented by government, the public, and the private sector across a Asia and in Africa. The project's focus on scalable innovations that improve the quality of diets (using strategies for vegetable production integrated with aquaculture and poultry) aligns well with Cambodia's new National Strategy for Food Security and Nutrition.\",\n",
       "  '12110. Sectoral budget support (SWAp): Malawi Health Sector Strategic Plan 2011-2016. SECTORAL BUDGET SUPPORT (SWAP): MALAWI HEALTH SECTOR STRATEGIC PLAN 2011-2016. The Vision of the health sector is to achieve a state of health for all the people of Malawi that would enable them to lead a quality and productive life.The Mission of the health sector is to provide strategic leadership by the Ministry of Health for the delivery of a comprehensive range of quality, equitable and efficient health services to all people in Malawi by creating an enabling environment for health promoting activities.The Goal of the Health Sector Strategic Plan is to improve the quality of life of all the people of Malawi by reducing the risk of ill health and the occurrence of premature deaths, thereby contributing to the social and economic development of the country. Expected outcome: 1. Increase coverage of the Essential Health Package interventions, paying attention to impact and quality.2. Strengthen the performance of the health system to support delivery of EHP services.3. Reduce risk factors to health.4. Improve equity and efficiency in the delivery of quality EHP services. Document available at  https://docs.google.com/open?id=0B-IUzKYaN-QSbTJ4a2ZkdHZrWkk',\n",
       "  '12191. Government Direct Grants - Fuanda medical institution for industrial joints. GOVERNMENT DIRECT GRANTS - FUANDA MEDICAL INSTITUTION FOR INDUSTRIAL JOINTS. NA',\n",
       "  '12191. Eradication and prevention of blindness in remote areas of Sidama Zone in Ethiopia. ERADICATION AND PREVENTION OF BLINDNESS IN REMOTE AREAS OF SIDAMA ZONE IN ETHIOPIA. The goal of the project is to secure access to quality eye care of people living in remote areas of Sidama Zone and Borena Zone and thus dicrease blindness incidence in the region.',\n",
       "  '13040. Public service policies. PUBLIC SERVICE POLICIES. Under this output, emphasis will be on aligning public service policies, rules, regulations and strategies with the Malawi Constitution and other regulations to ensure efficient and effective public service delivery.',\n",
       "  '12191. Providing medical equipments for Surgery section in Wetchakarurasm hospital, in Nanghshouk neighborhood, in the Capital city Bangkok. PROVIDING MEDICAL EQUIPMENTS FOR SURGERY SECTION IN WETCHAKARURASM HOSPITAL, IN NANGHSHOUK NEIGHBORHOOD, IN THE CAPITAL CITY BANGKOK. Extending agency: Khalifa Bin Zayed Al Nahyan Foundation - UAE aid modality: Direct Project Implementation',\n",
       "  '12262. Cooperation with foreign research institutions (not included in other areas). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (NOT INCLUDED IN OTHER AREAS). Malaria drugs - AntiMalariaDrug - Biotechnological production of new natural drugs to be used against malaria and other poverty-related diseases - Capacity building in the field of education and research',\n",
       "  '13020. International Centre for Diarrhoeal Disease Research, Bangladesh. INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH. to determine the efficacy of three community based interventions using e-platform in improving the recall of the date of last menstrual period and thereby increase the accuracy of gestational age estimation in rural resource poor settings',\n",
       "  '12220. Healthcare Centre MAMA CARLA, La Joie de Vivre Center Bangui, (Analysis laboratory, Dispensary of primary care for children and Telemedicine). HEALTHCARE CENTRE MAMA CARLA, LA JOIE DE VIVRE CENTER BANGUI, (ANALYSIS LABORATORY, DISPENSARY OF PRIMARY CARE FOR CHILDREN AND TELEMEDICINE). The Health Medical Centre MAMA CARLA give the possibility to the needy children, orphans or abandoned housed in the Centre La Joie de Vivre to have free access to the medical services. Medical examination, ambulatory treatments, infectious disease and malaria control, urgent pharmacological treatments and assistance to undernourished are opened also for all the students of the School Nicolas BarrT and to the children living in the surrounding areas from 0 to 14 ages. The Centre organizes hygienic consulting, education and training for mothers. Assistance and training to pregnant women AIDS infected. Health personnel development.',\n",
       "  '13040. HIV/AIDS - Palliative Care: Basic Health Care and Support - Assistance for HIV/AIDS. HIV/AIDS - PALLIATIVE CARE: BASIC HEALTH CARE AND SUPPORT - ASSISTANCE FOR HIV/AIDS. PEPFAR: HIV/AIDS - Basic health care and support, which includes: all clinic-based and home/community-based activities for HIV-infected adults, children, and their families that are aimed at optimizing the quality of life for HIV-infected clients and their families throughout the continuum of illness by the means of symptom diagnosis and relief, psychological and spiritual support, clinical monitoring, related laboratory services and management of opportunistic infections (excluding TB) and other HIV/AIDS-related complications (including pharmaceuticals), and culturally-appropriate end-of-life care. Basic health care and support also includes clinic-based and home/community-based support, social and material support such as nutrition support, legal aid, and housing, and training and support of caregivers. Clinic-based and home/community-based care and support activities for HIV-positive children within programs for orphans and other vulnerable children affected by HIV/AIDS would fall under sub-element 1.1.8 (Orphans and Vulnerable Children). ARV treatment should be coded under sub-element 1.1.10 (HIV/AIDS Treatment and Anti-Retroviral Drugs) and sub-element 1.1.11 (HIV/AIDS Treatment and Anti-Retroviral Services). - Assistance for HIV/AIDS',\n",
       "  '13020. Australia-Indonesia Partnership For Maternal And Neonatal  Health: Program Management. AUSTRALIA-INDONESIA PARTNERSHIP FOR MATERNAL AND NEONATAL  HEALTH: PROGRAM MANAGEMENT. The Australia-Indonesia Partnership (AIP) for Maternal and Neonatal  Health (MNH) aims for selected provincial and district governments in Eastern Indonesia to have mechanisms in place to manage national, local and donor resources to achieve national target levels for priority indicators contained within the Indonesian National Making Pregnancy Safer (MPS) Strategy. The objectives are: provincial and district governments develop and implement maternal and neonatal health (MNH) programs based on the national MPS strategy and address supply and demand aspects to achieve annual performance targets; provincial and district government agencies and communities access and manage the technical, human and financial resources needed to achieve improvements in MNH; and provincial and district governments manage Government of Indonesia (GoI) and donor resources to improve accountability, performance, accessibility and sustainability of public health services. The total value of this initiative is $76.4 million over 8 years, starting 2006-07.',\n",
       "  \"12250. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       "  '12240. Initiative of food safety and protection of children in Karamoja. INITIATIVE OF FOOD SAFETY AND PROTECTION OF CHILDREN IN KARAMOJA. Initiative of food safety and protection of children in Karamoja',\n",
       "  '13040. Enhancing the Transformative Capacity of Religious Leaders. ENHANCING THE TRANSFORMATIVE CAPACITY OF RELIGIOUS LEADERS. Enhancing the Transformative Capacity of Religious Leaders',\n",
       "  '12220. FIGHT AGANIST EBOLA. FIGHT AGANIST EBOLA. Health care actions (Technical education included)',\n",
       "  '16064. Output 04: HIV. HIV. Sub-Regional Office/Suva. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12261. Frame Agreement with NGO (Finnish Red Cross). FRAME AGREEMENT WITH NGO (FINNISH RED CROSS). Community Based Health Programme.To improve the health and decrease the diseases through increased knowledge sharing, to reduce impact of disasters on vulnerable population and increase capacity of the population to respond and recover.',\n",
       "  \"13040. Output 04: HIV. HIV. Chad - N'Djamena. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments\",\n",
       "  '12181. Advanced Training for Medical Personnel on High-Tech Medical Equipment. ADVANCED TRAINING FOR MEDICAL PERSONNEL ON HIGH-TECH MEDICAL EQUIPMENT. Preconditions for the use of High-Tech Medical Equipment in the capital Tashkent and other selected areas are improved , area of application medical imaging diagnostics and minimal-invasive surgery',\n",
       "  '13040. Roads to a Healthy Future II (ROADS II) Project - HIV/AIDS. ROADS TO A HEALTHY FUTURE II (ROADS II) PROJECT - HIV/AIDS. Regional Outreach Addressing AIDS through Development Strategies (ROADS) project has linked communities along these corridors with critical HIV/AIDS and other health services by collaborating closely with national AIDS control programs; government ministries; district health management teams; health facilities; and local, national and international companies. The project helps individuals and communities reduce their vulnerability to HIV by expanding economic opportunities and improving food security. The project s LifeWorks component provides training and technical assistance in group savings and loan, livestock management (chickens, rabbits and goats), urban and organic gardening and microenterprise development. The ROADS project also provides care and support for orphans and other at-risk children, and it works to protect women and girls from sexual exploitation and abuse.',\n",
       "  '12110. Promotion of the perinatal health in Kyrgyzstan. PROMOTION OF THE PERINATAL HEALTH IN KYRGYZSTAN. The normative, personell and organisational conditions for demandoriented MEDICAL SERVICE-supply of risk pregnancies and sick newborns in the program region are created.',\n",
       "  '12110. DTveloppement des capacitTs institutionnelles en planification, leadership et gestion dans le secteur de la santT. D+VELOPPEMENT DES CAPACIT+S INSTITUTIONNELLES EN PLANIFICATION, LEADERSHIP ET GESTION DANS LE SECTEUR DE LA SANT+. General Objectives  To improve effective delivery of an integrated Uganda National Health Care Package  Specific Objectives  The strengthening of the planning, leadership and management capacities of the health staff at national level and local government levels Results  - The Ministry of Health is strengthened in its organisational and institutional capacity- One selected regional referral hospital (Fort Portal) and two general hospitals, located within the catchments area of the RRH, are strengthened in their instituti',\n",
       "  \"13030. Uzazi Uzima II: Safe Deliveries in Simiyu Region/Uzazi Uzima II: Accoucher en sTcuritT dans la rTgion de Simiyu. UZAZI UZIMA II: SAFE DELIVERIES IN SIMIYU REGION/UZAZI UZIMA II: ACCOUCHER EN S+CURIT+ DANS LA R+GION DE SIMIYU. The Uzazi Uzima II project seeks to reduce maternal and newborn mortality and morbidity in all five districts of Simiyu region, Tanzania by improving the availability of quality adolescent, maternal and newborn health services in underserved districts through three mutually supportive mechanisms. The project will: improve the knowledge and skills of healthcare providers on maternal, newborn and sexual/reproductive health to ensure they can provide critical services to their beneficiaries in a gender sensitive and responsive way;  improve the infrastructure and supply-chain for health facilities to encourage women, girls and their families to use services; and improve gender responsive health management systems (such as planning, prioritization and management of services). The project will also increase awareness and understanding of sexual, reproductive, maternal and child health with special focus on men's participation in reproductive, maternal and newborn health and decision making.Project activities include: (1) training health workers from four health centres and 24 dispensaries on: essential maternal and newborn health skills, such as Basic Emergency Obstetric and Newborn Care (BEmONC); Comprehensive Emergency Obstetric and Newborn Care (CEmONC), family planning; nutrition counselling; and newborn resuscitation; (2) refurbishing four health centres and 24 dispensaries to provide CEmONC, BEmONC, water, sanitation and hygiene and family planning services, including a satellite safe blood center at the regional hospital; (3) equipping targeted health facilities with the necessary stocks of equipment and commodities to provide BEmONC, CEmONC, family planning and safe blood services; (4) establishing a referral system for maternal and newborn health care and family planning services across all tiers of the health system; (5) training and supporting Ministry of Health and facility-based managers, and health workers to improve community to facility linkages (enhanced data collection, consolidation, analysis and reporting); and (6) training and equipping community health workers, traditional birth attendants, traditional healers, and local leaders to provide community-level health promotion services (including maternal and newborn health, water, sanitation and hygiene, family planning, nutrition, gender issues and use of mobile health technology to mobilize communities).The project is implemented in collaboration with Amref Health Africa in Tanzania, Marie Stopes Tanzania and Deloitte./ Le projet vise a rTduire la mortalitT et la morbiditT des mFres et des nouveau-nTs dans les cinq districts de la rTgion de Simiyu, en Tanzanie. Cet objectif est atteint en assurant une meilleure disponibilitT des services de santT maternelle et nTonatale de qualitT dans les quartiers mal desservis et en augmentant l'utilisation de ces services par les femmes et leurs familles dans les districts ciblTs au moyen d'interventions a covt modique, mais de vaste portTe. Le\",\n",
       "  '12261. Governance And Gender : Human rights : Irish Aid Payment for Contract SCF SL 15 01 for : Fambul Welbodi II programme IRISH AID - FAMBUL WELBODI II. GOVERNANCE AND GENDER : HUMAN RIGHTS : IRISH AID PAYMENT FOR CONTRACT SCF SL 15 01 FOR : FAMBUL WELBODI II PROGRAMME IRISH AID - FAMBUL WELBODI II. Governance And Gender : To Enhance Good Governance Through Strengthening Democratic Mechanisms, Improving Domestic Accountability Mechanisms And Promoting Gender Equality. : Human rights : Irish Aid Payment for Contract SCF SL 15 01 for : Fambul Welbodi II programme IRISH AID - FAMBUL WELBODI II',\n",
       "  '13040. Output 04: HIV. HIV. Central African Rep - Bangui. Output 4: Increased national capacity to deliver HIV programmes that are free of stigma and discrimination, consistent with the UNAIDS unified budget results and accountability framework (UBRAF) commitments',\n",
       "  '12230. The Project for Renovation of Surgery Unit of Ganja City Urgent Medical Assistance Hospital. THE PROJECT FOR RENOVATION OF SURGERY UNIT OF GANJA CITY URGENT MEDICAL ASSISTANCE HOSPITAL. Renovation of Surgery Unit of Ganja City Urgent Medical Assistance Hospital in Ganja City',\n",
       "  '12181. Institutional Capacity Building in planning, leadership and management in the Ugandan health sector - ICB phase II. INSTITUTIONAL CAPACITY BUILDING IN PLANNING, LEADE. The project should further support capacity buildi',\n",
       "  '12262. Partnership for containment of artemisinin resistance and moving towards the elimination of plasmodium in Thailand. PARTNERSHIP FOR CONTAINMENT OF ARTEMISININ RESISTANCE AND MOVING TOWARDS THE ELIMINATION OF PLASMODIUM IN THAILAND. NA',\n",
       "  '13030. PACTO - Active Prevention and Communication for All - Family Planning and Reproductive Health. PACTO - ACTIVE PREVENTION AND COMMUNICATION FOR ALL - FAMILY PLANNING AND REPRODUCTIVE HEALTH. PACTO (Prevenao Activa e Comunicaao para todos) is a 4 year project funded by USAID with the goal of increasing safer sexual behaviors and uptake of HIV prevention services among the Mozambican general population primarily in the three highest prevalence provinces of Maputo City, Maputo, and Gaza, and to strengthen Mozambican public institutions technical leadership and coordination to guide the implementation of combination HIV prevention programs.',\n",
       "  '12220. Humanitarian Assistance. HUMANITARIAN ASSISTANCE. Humanitarian Assistance. Pakistan Institute of Medical Sciences (PIMS), Hospital Medical Supplies. The program is run through the Department of Defense s Overseas Humanitarian, Disaster and Civic Aid (OHDCA).',\n",
       "  \"16064. NGO Support / HIV and Aids Project  The Good Samaritan  Malawi. NGO SUPPORT / HIV AND AIDS PROJECT  THE GOOD SAMARITAN  MALAWI. The long term objective of the project is to contribute to the reduction of the spread of HIV and stigmatization of infected and affected people. The main focus is to reduce stigmatization and discrimination of PLHA. The overall objectives of the Good Samaritan HIV programme (GSP) is to strengthen the involvement of churches in the response to HIV by enabling people and organisations to: ?Get knowledge about HIV and AIDS and risky behaviour; Encourage VCT and sexual education; Eradicate stigma and condemnation; Restore PLHA's human rights dignity and equality and; To renew churches and local congregations' social responsibility. The programme has two main target groups: influental people and opinion leaders with the capacity to act as facilitators and trainers; and people who are particularly vulnerable to HIV: youth women PLHA and married persons. The strategy is based on information education and communication with a focus on behavioural change communication and to work with individuals and communities through sharing and providing supportive and enabling environments. The implementation is based on a two tier strategy: (i) advocacy sensitisation and mobilisation of community and religious leaders; and (ii) cascade training of trainers to reach local congregations and communities. The training uses the workshop as a platform to facilitate inter-action sharing and reflection to promote change in attitudes and behaviour. The programme also encourages the formation of local groups for mutual support and action.Gender equality is embedded in training materials and teachings and project staff. Implementing Bible Societies will be further trained on gender issues. Human dignity is one the key elements in the Good Samaritan program. Project is implemented within national HIV coordinating structures that include governmental HIV coordination religious network and local communities.The direct beneficiaries include PLHIV and non-infected people. Special emphasis is put on women and youth aim is also try to better address PVDs.The key project activities include four kind of workshops: sensitization for various leaders training of trainees (ToT) decentralized workshops (DWs) Follow up (FU) Take Charge youth program (TC) and annual capacity building workshops for project staff (Joint Program Review / JPR and anglophone capacity building workshop).\",\n",
       "  '13040. USAID Innovations Grant - HIV/AIDS. USAID INNOVATIONS GRANT - HIV/AIDS. The USAID funding for Witkoppen Health and Welfare Centre (WHWC) (AID-674-A-12-00033 from 01/10/2012 to 30/09/2017) is for providing HIV and TB diagnosis, care, support, treatment and referral services at primary care level to residents of informal settlements; interventions that build capacity in the local Department of Health (DoH) clinics; transition of the USAID-funded direct service delivery to the DoH and the implementation and evaluation of effective innovative approaches to integrated primary care for HIV and TB. Underpinning these innovations are five operational research projects, including specific focus on paediatric care, comprehensive PMTCT services over the spectrum from pre-pregnancy to maternal and infant care, intensified TB and HIV case finding at clinic and community level, and improving adherence and retention-in-care among children, adolescents and adults.',\n",
       "  '12262. Global Health Program Cycle Improvement Project - Malaria. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT - MALARIA. Globl Health Program Cycle Improvement Project will support for the MCH team to complete a pre activity design (MCH Flagship redesign) systems analysis, which includes consolidation of existing information and identification of information gaps for further study. This activity will deliver a comprehensive write up of the political, technical and systems components of the Indonesian health system that need to be taken into full consideration and~adequately~studied prior to~designing the new MCH flagship activity. This will be followed up with defining a clear way forward for future investments in the MCH portfolio.',\n",
       "  '12182. Peace Corps, FK Norway, personnel exchange. PEACE CORPS, FK NORWAY, PERSONNEL EXCHANGE. Feasibility Study',\n",
       "  '13040. Scaling Up for Most-at-Risk Populations  Technical Support Project (SUM I) - HIV/AIDS. SCALING UP FOR MOST-AT-RISK POPULATIONS  TECHNICAL SUPPORT PROJECT (SUM I) - HIV/AIDS. In Indonesia, FHI 360 serves as a leader in the prevention and treatment of HIV among the countrys most-at-risk populations, including injecting drug users, sex workers, men who have sex with men, waria (transgender people) and the sexual partners of individuals from these groups. The five-year Scaling Up for Most-at-Risk Populations Technical Support Project (SUM I) works to accelerate the implementation of comprehensive and effective interventions for people at risk of HIV infection.',\n",
       "  '12262. Walter Reed Army Institute of Research. WALTER REED ARMY INSTITUTE OF RESEARCH. to support the Armed Forces Research Institute of Medical Sciences to conceptualize and pilot a system for malaria radical cure, diagnosis, and surveillance amongst Cambodian servicemen and women and their dependents',\n",
       "  '12182. AMR Phase 1 Theme 4 Behaviour within and beyond the healthcare setting (MRC contribution, ESRC lead on the call). AMR PHASE 1 THEME 4 BEHAVIOUR WITHIN AND BEYOND THE HEALTHCARE SETTING (MRC CONTRIBUTION, ESRC LEAD ON THE CALL). Understanding/influencing the behaviour of public, professionals and organisations impacts on Anti-Microbial Resistance How Anti-Microbial Resistance is affected by social, psychological and organisational context, cultures and history; and how it can be influenced to create different future scenarios within multiple Low and Middle Income Countries.',\n",
       "  '13020. Social Health Protection (SHP) - Maternal and Child Health. SOCIAL HEALTH PROTECTION (SHP) - MATERNAL AND CHILD HEALTH. The Social Health Protection project will reduce financial barriers to health services for the poor by increasing the nationwide coverage of the public-sector health insurance program known as the Health Equity Fund. This fund enables the poor to access and pay for quality health services, thereby mitigating the effects of disease and sickness while reducing the financial burden of health-care costs on the poor. Activities will strengthen the ability of the national and district-level governments to administer health insurance, link reimbursements to improved health services, include civil society and communities in oversight of the enrollment process to ensure more transparency, and revise the package of health services provided to the poor to include priority services. The U.S. government will help expand the Heath Equity Fund across all of Cambodia and provide three million poor Cambodians with access to healthcare without forcing them into further financial hardship.',\n",
       "  '12240. OUTPUT 1.2: REGULATIONS AND DIRECTIVES. OUTPUT 1.2: REGULATIONS AND DIRECTIVES. NA',\n",
       "  '13030. Tanzania Human Resource Capacity Project - Family Planning and Reproductive Health. TANZANIA HUMAN RESOURCE CAPACITY PROJECT - FAMILY PLANNING AND REPRODUCTIVE HEALTH. IntraHealth led the Tanzania Human Resource Capacity Project, which identified and filled staffing shortfalls, building on the earlier work of the global Capacity Project. The project collaborated with more than 20 health sector leaders and managers from three regions to plan for and manage a larger and better trained health workforce.',\n",
       "  \"13020. Global Health Program Cycle Improvement Project. GLOBAL HEALTH PROGRAM CYCLE IMPROVEMENT PROJECT. The Global Health Program Cycle Improvement Project (GH Pro) is a five-year contract that is available to the Bureau for Global Health offices, regional and other bureaus, and field missions of USAID in health program assessment, design, monitoring and evaluation, and program support. GH Pro works across USAID's health portfolio in support of its goals of preventing and managing major health challenges of poor, underserved, and vulnerable people, leading to improved health outcomes. In support of these goals, the project also advances expertise in cross-cutting health issues such as gender, health systems strengthening, and science and technology.\",\n",
       "  '12240. Algae/Duckweed Innovation Activity. ALGAE/DUCKWEED INNOVATION ACTIVITY. The goal of this project is tofight childhood malnutritionby empowering vulnerable young mothers in Ethiopia to improve their income. The young mothers are organized into groups of 20 women to plan for, save for, start and run poultry, dairy, and tilapia farms. These women are given acompetitive advantage, by teaching them an innovative technology - namely, algae and duckweed production as a novel, low-cost supplement for livestock feed.',\n",
       "  '12191. Operation Hernia Humanitarian Mission 2014-2015. OPERATION HERNIA HUMANITARIAN MISSION 2014-2015. Taking part in Operation Hernia Mission to India. Operation Hernia is an independent not-for-profit organization  that provides professional and educational opportunities to surgeons and surgical trainees in the repair of long-standing groin hernias at rural hospitals in low income countries. Surgeon Volunteers are drawn  mainly from  members of the European and American Hernia Societies. Inguinal hernia is a public health problem in many low income countries. Although inguinal hernia develops at all ages (mainly in men)and in all parts of the world with the same frequency, in poor communities they are not treated due to lack of hospitals and surgeons.',\n",
       "  '12182. Nepal Health Sector Programme III - Technical Assistance for Monitoring, Evaluation and Operational Research. NEPAL HEALTH SECTOR PROGRAMME III - TECHNICAL ASSISTANCE FOR MONITORING, EVALUATION AND OPERATIONAL RESEARCH. To improve the health of women, children,  the poor and socially excluded in Nepal, including by restoring health services in areas affected by the 2015 earthquake, and improving the quality and governance of health services nationwide.',\n",
       "  '12110. Human Development Innovation Fund. HUMAN DEVELOPMENT INNOVATION FUND. To support innovative approaches to improving the quality, value for money and sustainability of basic services in the education, health and water and sanitation sectors in Tanzania',\n",
       "  '12240. WASHPlus: Supportive Environments for Healthy Communities - Nutrition. WASHPLUS: SUPPORTIVE ENVIRONMENTS FOR HEALTHY COMMUNITIES - NUTRITION. WASHPlus is a Cooperative Agreement managed by FHI 360 with CARE and Winrock International as core partners, and teamed with a highly talented group of university, private and public sector resource partners in areas such as creative financing, innovation, and public-private partnerships in addition to WASH service delivery. The project is designed to support the further development, introduction and delivery of high-impact interventions in water supply, sanitation and hygiene (WASH) and indoor air quality (IAQ).',\n",
       "  '13040. Shanghai Zerun Biotechnology Co., Ltd.. SHANGHAI ZERUN BIOTECHNOLOGY CO., LTD.. to improve womens access to low-cost bivalent HPV vaccine in GAVI-supported countries',\n",
       "  '13020. Governance, Accountability, Participation and Performance (GAPP) - Maternal and Child Health. GOVERNANCE, ACCOUNTABILITY, PARTICIPATION AND PERFORMANCE (GAPP) - MATERNAL AND CHILD HEALTH. The primary objective of the GAPP program is to increase participation, accountability and local governance for effective service delivery. To achieve this goal, GAPP will focus on three key components highlighted below: to enhance accountability, improve local government governance, and support CSOs and other non-state actors to increase their voice and demand for improved services.',\n",
       "  '12182. DBT-MRC Joint Centre Partnerships. DBT-MRC JOINT CENTRE PARTNERSHIPS. An MRC-DBT Joint Centre Partnership Call to support three UK-India joint centres, to support joint research activities and capacity building in areas of key importance to healthcare in India including antimicrobial resistance and cancer biology. Social f',\n",
       "  '12110. TANZANIA CLEARING A/C - Irish Aid contribution to special health basket. TANZANIA CLEARING A/C - IRISH AID CONTRIBUTION TO SPECIAL HEALTH BASKET. Tanzania Country Programme  - ZZ-HEAGEN-Health General-Innovation Funding-1HEA-Irish Aid contribution to special health basket',\n",
       "  '12262. African Collaborative for Health Financing Solutions (ACS). AFRICAN COLLABORATIVE FOR HEALTH FINANCING SOLUTIONS (ACS). The African Collaborative for Health Financing Solutions (ACS) will advance Universal Health Coverage (UHC) in Sub-Saharan Africa by working with regional bodies and country-level multi-stakeholder platforms to share knowledge, strengthen accountability and promote sound health financing policies. ACS will partner with regional institutions to strengthen their role in policy, advocacy, and regional learning on health financing approaches.',\n",
       "  '13030. Expanding the Use of Selected Health Services and Products Task Order under Population, Health and Nutrition Technical Support Contract III-Global Health. EXPANDING THE USE OF SELECTED HEALTH SERVICES AND PRODUCTS TASK ORDER UNDER POPULATION, HEALTH AND NUTRITION TECHNICAL SUPPORT CONTRACT III-GLOBAL HEA. The purpose of this contract is to build on previous USAID/Madagascar Health Population and Nutrition (HPN) activities, expand services broader and deeper into communities to provide quality services to the poor, and to strengthen specific health systems and the capacity of the Ministry of Health and Family Planning to undertake its normative functions to ensure the delivery of critical health services.',\n",
       "  '12250. CDC: Global Disease Detection Program (GDD). CDC: GLOBAL DISEASE DETECTION PROGRAM (GDD). The Global Disease Detection Program (GDD) is CDCs principal and most visible program for developing and strengthening global capacity to rapidly detect, accurately identify, and promptly contain emerging infectious disease and bioterrorist threats that occur internationally. We respond to high-profile public health events such as Ebola, polio eradication, MERS-CoV, cholera, and Nipah virus, while increasing our engagement in the agencys global health security activities.',\n",
       "  '13040. BRIDGE II - HIV/AIDS. BRIDGE II - HIV/AIDS. BRIDGE II is a USAID-funded five-year strategic, evidence-based communication program that encourages Malawians in 11 districts in the southern region of Malawi to adopt behaviors that prevent HIV transmission. BRIDGE II aims to reduce new HIV infections through eliminating barriers to individual action and shifting social norms. It addresses key risk factors for HIV in Malawi such as having more than one sexual partner at a time, lack of condom use, and alcohol abuse. Gender norms and inequities often lie beneath these risky behaviors, and BRIDGE II openly addresses these issues. A multi-sectoral project with a strong community focus, BRIDGE works directly through creative multi-media campaigns, transformative and participatory toolkits (like the Hope Kit, PDF), interactive radio programs, service referral and linkages, and community theater. BRIDGE also builds local capacity by providing support to community and faith-based networks to strengthen their HIV prevention programs. The goal is lasting, positive change that not only prevents new HIV infections, but also strengthens the ability of Malawis communities to care for and protect themselves.',\n",
       "  '12250. Higher Education for Development (HED) - Pandemic Influenza and Other Emerging Threats (PIOET). HIGHER EDUCATION FOR DEVELOPMENT (HED) - PANDEMIC INFLUENZA AND OTHER EMERGING THREATS (PIOET). Higher Education for Development (HED) works in close partnership with the United States Agency for International Development (USAID) and operates with the advice and counsel of the six major U.S. higher education associations to support the engagement of higher education in development issues worldwide. HED manages innovative partnerships that join U.S. colleges and universities with institutions of higher learning in developing nations. In this way, we support and facilitate the engagement of U.S. higher education in global development.',\n",
       "  '13040. Health Communication Capacity Collaborative (HC3) - Program Design and Learning. HEALTH COMMUNICATION CAPACITY COLLABORATIVE (HC3) - PROGRAM DESIGN AND LEARNING. HC3 is the flagship project for behavior change in the Global Health Bureau. It is designed to complement and add value to behavior change activities supported by USAID Missions worldwide by responding to critical needs in technical leadership, capacity strengthening, research, and innovation. It focuses on the technical areas of family planning/reproductive health, HIV/AIDS, malaria, and maternal and child health. HC3 will focus on strengthening in-country capacity to implement state-of-the art health communication, including mass media, community-level activities, interpersonal communication, and new media. The project will provide tailored, capacity strengthening to a range of indigenous partners, including governments, NGOs, creative professionals, and academics, with activities to develop individuals, organizations, and national systems. HC3 will also provide technical leadership in health communication that includes professional exchange, analysis of emerging trends, and development and dissemination of technical and operational guidance. The project will be characterized by a strong focus on implementation science, emphasizing rigorous evaluation, documentation, and diffusion of effective practices.',\n",
       "  '12191. The Project for the Provision of Ambulances for Improved Emergency Response in Jamaica. THE PROJECT FOR THE PROVISION OF AMBULANCES FOR IMPROVED EMERGENCY RESPONSE IN JAMAICA. Provision of re-cycled ambulances in order to deploy better emergency services in Jamaica',\n",
       "  \"13020. Establishing a harmonized Reproductive Health Registry in Jordan to improve Maternal and Child Health. ESTABLISHING A HARMONIZED REPRODUCTIVE HEALTH REGISTRY IN JORDAN TO IMPROVE MATERNAL AND CHILD HEALTH. This project seeks to improve the quality and timely collection and use of reproductive health data in the Mafraq governorate of Jordan by establishing a harmonized Reproductive Health Registry (hRHR). The dearth and lack of reliable data limits the ability to make informed decisions by health providers, planners and community members, which can influence the well-being of women and children. The proposed implementation research project involving the participatory development of an electronic harmonized reproductive health registry is expected to link timely and accurate health data from local primary care health centres to hospital settings and governorate-level planning bodies, and back to communities. Issues of expanding services to cover vulnerable and undercounted populations are central to the proposed implementation and related research activities. Given the high numbers of Syrian refugees in the Mafraq governorate, the registry will be designed to serve both refugee and non-refugee populations to address different health needs and social contexts of the various groups. The project will also focus on strengthening the capacities of decision-makers at different levels of the health system and other sectors to use the data collected and analyzed through the registry. The project will apply mixed methods to conduct a situational analysis of existing systems and tools of sexual and reproductive health data collection and use; develop a harmonized electronic registry system using participatory approaches and established guidelines from the World Health Organization; strengthen representation of underserved groups of women, men and youth in stakeholder meetings and governance processes; develop a dashboard of data and related analysis; assess the quality, timeliness and reliability of data; and build capacities of researchers and decision-makers. The main outcomes include improved quality and timeliness of reproductive health data, better integration and interoperability among different health facilities, a strengthened referral system, increased capacities by decision-makers and providers to use health data, and costed plans to scale up the hRHR effort to other parts of the country.  This proposal represents one of nine selected as a cohort of implementation research projects spanning two regions (West Africa and the Middle East) and two thematic topics (adolescent sexual and reproductive health and health information systems).  The project is closely aligned with the Government of Canada's new feminist international assistance policy, the strategic priorities detailed in the 2016-2030 WHO led Global Strategy for Women, Children and Adolescents, and the overarching 2030 global agenda for sustainable development.\",\n",
       "  '12230. The Project for Installing Medical Equipment at Chamkar Leu Referral Hospital in Kampong Cham Province. THE PROJECT FOR INSTALLING MEDICAL EQUIPMENT AT CHAMKAR LEU REFERRAL HOSPITAL IN KAMPONG CHAM PROVINCE. Project for installing medical equipment at Chamkar Leu Referral Hospital in Kampong Cham Province to build its capacity to perform surgery.',\n",
       "  '13040. Program Support. PROGRAM SUPPORT. Develop and conduct needs assessments, baseline studies, targeted evaluations, special studies or other information-gathering efforts specifically for the design, monitoring and evaluation of USG-funded operating unit wide programs, not for a specific functional objective. This sub-element may also include developing and disseminating best practices and lessons learned, testing demonstration and/or pilot models, public outreach, or the preparation of strategic plans and other short-term programming tasks. Funding for similar activities that are directed to specific functional objectives should be entered in the PD&L sub-element of the appropriate program area(s) within that objective.',\n",
       "  '13040. HIV-Innovations for Improved Patient Outcomes in South Africa. HIV-INNOVATIONS FOR IMPROVED PATIENT OUTCOMES IN SOUTH AFRICA. The purpose of this program is to support South African organizations that identify, strengthen, and institutionalize better, cost-effective practices and innovations in HIV and AIDS care and treatment for priority and at-risk populations in accordance with South African government (SAG) priorities and policies. Targeted priority and at-risk populations for this program include pregnant women; infants, children, and adolescents; men who have sex with men (MSM); commercial sex workers (CSWs); hard to reach populations; and those co-infected with HIV/TB. This program will support the scale-up of SAG priorities through capacity building, operations research, including cost and cost effectiveness analyses, monitoring and evaluation, and plans for transition of limited service provision to key populations. Successful programs will demonstrate a strong capacity for integration of policy, technical approaches, as well as collaboration and coordination with partners and stakeholders and must also be in accordance with the Partnership Framework between the USG and SAG.O',\n",
       "  '13020. Sustainable Development Goals Performance Fund  for basic emergency maternal, obstetric, neonatal and child health care services. SUSTAINABLE DEVELOPMENT GOALS PERFORMANCE FUND  FOR BASIC EMERGENCY MATERNAL, OBSTETRIC, NEONATAL AND CHILD HEALTH CARE SERVICES. To improve the functionality of primary health care units, reducing health inequalities, and  increasing domestic financing  for health to sustain and accelerate the pace of improvement in adolescent, maternal and child health in Ethiopia. This will be ac',\n",
       "  '12263. ACCroatiaTuberculosis. AC: CROATIATUBERCULOSIS. Tuberculosis',\n",
       "  \"12181. A STUDY OF THE SANA'A UNIVERSITY TEACHING HOSPITAL PROJECT. A STUDY OF THE SANA'A UNIVERSITY TEACHING HOSPITAL PROJECT. NA\",\n",
       "  '12263. Control and Prevention of Tuberculosis (CAP-TB) in the Mekong Region - Tuberculosis. CONTROL AND PREVENTION OF TUBERCULOSIS (CAP-TB) IN THE MEKONG REGION - TUBERCULOSIS. Control and Prevention of Tuberculosis (CAP-TB) is a five-year project funded by the U.S. Agency for International Development (USAID) to reduce the incidence and mortality from Multi-Drug Resistant TB (MDR-TB.) The projects overall aim is to develop a model for cost-effective MDR-TB control that can be sustainably expanded throughout Myanmar, China, and Thailand. The objectives of the project are to prevent disease transmission, to increase early MDR-TB diagnosis, and to maximize treatment success.',\n",
       "  \"13020. Pacific Women Fiji Country Plan. PACIFIC WOMEN FIJI COUNTRY PLAN. Pacific Women Shaping Pacific Development is a ten-year commitment by the Australian Government to support the Pacific to address gender inequality. The Fiji Country Plan is the Fiji-specific investments and strategies to address gender inequality in Fiji. The first four years of the Fiji Country Plan aims to support initiatives that will: increase women's economic empowerment; support women's organisations and coalitions for change; increase women's participation in leadership and decision-making; enhance knowledge and evidence to inform policy and practice; and improve gender outcomes within Australia's bilateral aid program to Fiji. Subsequent Fiji country plans will be developed over the life of the investment to respond to emerging gender issues in Fiji. The country plan will include an annual reflection process with implementing partners to maintain ongoing relevance of the investment. The country plan also aims to establish a local Fiji Women's Fund by the end of the life of the investment. The fund will be independently owned and managed and provide support to local women's NGOs and networks to advance gender equality in Fiji. The total value of this initiative is $26.3 million over 9 years, starting 2013-14.\",\n",
       "  '12191. SUPPORT TO THE MEDICAL AND SURGICAL ACTIVITIES OF THE EMERGENCY REGIONAL PROGRAM OF PAEDIATRICS AND HEART - SURGERY IN AFRICA - SOCIAL SECURITY CHARGES AND INSURANCE FOR VOLUNTEERS. SUPPORT TO THE MEDICAL AND SURGICAL ACTIVITIES OF THE EMERGENCY REGIONAL PROGRAM OF PAEDIATRICS AND HEART - SURGERY IN AFRICA - SOCIAL SECURITY CHARG. THE PROJECT AIMS AT OFFERING HEART- SURGICAL AND CHILDHOOD HEALTH-CARE ASSISTANCE THROUGH THE SALAM CENTRE IN KHARTOUM, CREATED BY EMERGENCY IN 2004, AND THE OTHER SATELLITE CLINICS IN PORT SUDAN, MAYO AND NYALA',\n",
       "  '12261. LAAMScience, Iraqi national congress. . LAAMSCIENCE, INC. . to develop a hygienic, reusable menstrual diaper to decrease the incidence of reproductive tract infections acquired from current catamenial practices in developing countries',\n",
       "  '12250. Mechanisms of Th2 cell - intrinsic hypo - responsiveness, and its impact on protective unsusceptibility and memory to parasitic parasitic worm. MECHANISMS OF TH2 CELL - INTRINSIC HYPO - RESPONSIVENESS, AND ITS IMPACT ON PROTECTIVE IMMUNITY AND computer storage TO PARASITIC HELMINTHS. Medical Research Council. Research Grant to investigate human immune response to worm infections',\n",
       "  '13040. Regulation of HIV - 1 Laugh expression by SR proteins. REGULATION OF HIV - 1 jape EXPRESSION BY SR PROTEINS. Medical Research Council. Research Grant to investigate the interaction between boniface cell and HIV virus',\n",
       "  '13030. MEASURE Evaluation Phase III - Family Preparation and Reproductive Health. measuring rod EVALUATION PHASE III - FAMILY PLANNING AND REPRODUCTIVE HEALTH. MEASURE Evaluation Phase III continues the MEASURE programs 10 year initiative to improve the collection, analysis and presentation of data to promote in effect use in planning, policymaking, managing, monitoring and evaluating of population, health and nutrition programs. The program aims to accomplish this through achieving the following six results: (1) increased user demand for data and tools; (2) increased individual and institutional capacity in monitoring and evaluation; (3) increased collaboration and coordination in obtaining and sharing health sector data; (4) improved tools, methodologies and technical guidance; (5) increased availability of data, methods and tools; and (6) increase facilitation of data use. MEASURE Evaluation Phase III is the Global Health Bureaus primary vehicle for supporting improvements in monitoring and evaluation in population, health and nutrition worldwide.',\n",
       "  '12262. Medicines for Malaria Venture (MMV) - Malaria. medicine FOR MALARIA VENTURE (MMV) - MALARIA. The Medicines for Malaria Venture was established in 1999 to build and manage a research and development portfolio capable of leading to the readjustment of at least one new antimalarial drug every five years. Although partnered with industry, MMVs focus is on discovery and development of drugs that will be affordable to populations living in malaria endemic areas. MMV manages and directs research and development activities carried out at a broad variety of institutions, comprising 42 academic and pharmaceutical organizations located in 10 different countries.',\n",
       "  '12263. Technology, Research, Education and Technical Assistance for Tuberculosis (TREAT TB) - Tuberculosis. TECHNOLOGY, RESEARCH, EDUCATION AND TECHNICAL ASSISTANCE FOR TUBERCULOSIS (TREAT TB) - TUBERCULOSIS. Technology, Research, Education and Technical Assistance for Tuberculosis (TREAT TB) is a cooperative agreement with the International Union Against Tuberculosis and Lung Disease (IUATLD ), also known as The Union. TREAT TB focalize on field evaluations of diagnostic techniques for TB, clinical trials and operations research to ameliorate patient management, treatment efficacy, disease prevention, and contagion control measures for TB and MDR TB. TREAT TB also provides for field support to address key TB and TB / HIV issues through with operational research to improve the national TB programs performance.',\n",
       "  '12182. Structure guided design of a transmission - blocking malaria vaccine targeting Pfs48 / forty five. STRUCTURE GUIDED DESIGN OF A TRANSMISSION - BLOCKING MALARIA VACCINE TARGETING PFS48 / 45. IIB - Research Boards January / Feb 2017 - RM 2018 awarding to create a structure guided design of a transmission - blocking malaria vaccinum.',\n",
       "  '12240. New York Academy of Sciences. NEW YORK ACADEMY OF SCIENCES. to carry out a full range of activities take aim at improving the power to assess population thiamine status, determining the extent of thiamine deficiency in selected countries in Asia and Africa, and developing intervention strategies and national plans',\n",
       "  '12250. Funding for exchange of scientists, grants. financial backing FOR EXCHANGE OF SCIENTISTS, GRANTS. Collaborative project - Molecular parasitology working mathematical group in Rwanda (MOPACUR) - Participation in study on geohelminths',\n",
       "  '12240. SHINE research uptake and communications. SHINE enquiry UPTAKE AND communicating. New knowledge in Body of water / Sanitation / Hygiene, Infant Nutrition, and health sytems management is generated and disseminated and informs child health computer programme in Zimbabwe and globally',\n",
       "  '12263. To fund the development of new, safe and effective drugs for tb through the Global Alliance for TB Drug Development organisation. . TO FUND THE DEVELOPMENT OF NEW, SAFE AND EFFECTIVE DRUGS FOR TUBERCULOSIS THROUGH THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT formation. . To research and develop new drugs for the treatment of tuberculosis (TB) through public private partnership. This research will advance the development of new, easier to use, and cheaper drugs for the treatment of TB, multi - drug resistant TB and extremely',\n",
       "  '12220. Monell Chemical substance Senses. MONELL chemical substance SENSES. to demonstrate that taste cell technologies will lead to discovery of compounds that pharmacologically block the bitter and off - tastes of life - saving unwritten medicines, thereby significantly better compliance in pediatric populations',\n",
       "  '12250. Global Health Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE engineering monetary fund. to develop new wellness technologies as a result of funding and development quislingism with Japanese industry and government',\n",
       "  '12263. Defining the metabolic phenotype of intracellular Mycobacteria tuberculosis. DEFINING THE METABOLIC PHENOTYPE OF INTRACELLULAR mycobacteria tb. Medical Research Council. Research Grant to investigate the TB bacteria within the human cell',\n",
       "  '12250. Urban Drinking Water and Health Outcomes  Early Phase Study for a Randomized Controlled Trial in Accra, Ghana. URBAN DRINKING WATER AND HEALTH OUTCOMES  EARLY PHASE written report FOR A RANDOMIZED CONTROLLED TRIAL IN ACCRA, GHANA. Medical Research Council. Research Grant for development work result to trial of different wasy of providng safe drinking water in towns in Ghana',\n",
       "  '12250. Common diseases. COMMON DISEASES. Collaborative project - German - Indonesian Aniinfective Cooperation (GINAICO ), subproject - Application of novel microbiological and ecological methods for the discovery of novel antimicrobial natural substances in marine invertebrates and their associated microorganisms - Medical research of particular importance for developing countries',\n",
       "  '12250. Cooperation with foreign research institutions (not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (NOT INCLUDED IN OTHER AREAS ). Deactivation of hepatitis B virus replication with designer transcription factors and Designer nucleases - Capacity building in the field of education and research',\n",
       "  '12262. From malaria control to sustainable elimination: Cluster randomised trial comparing targeted versus generalised transmitter control in South Africa. FROM MALARIA CONTROL TO SUSTAINABLE ELIMINATION: CLUSTER RANDOMISED TRIAL COMPARING TARGETED VERSUS GENERALISED VECTOR CONTROL IN SOUTH AFRICA. Medical Research Council Joint (MRC / WT / DfID) Global Health Trial grant to trial to compare effectiveness, price, coverage and homeowner acceptability between targeted focal indoor residual insecticide spray against mosquitos in South Africa',\n",
       "  '12220. Infectious Disease Research Institute. INFECTIOUS DISEASE RESEARCH INSTITUTE. to provide foundation grantees with novel and innovative industry quality adjuvants and formulations to raise the success of pre - clinical and clinical vaccinum growth',\n",
       "  '12182. Human Decoy Trap; operational and social acceptability of novel tool to improve surveillance and control of mosquitoes and other disease vectors. HUMAN lure TRAP; OPERATIONAL AND SOCIAL ACCEPTABILITY OF NOVEL TOOL TO IMPROVE SURVEILLANCE AND CONTROL OF MOSQUITOES AND OTHER DISEASE VECTORS. GCRF Foundation Infections 2016 to determine whether a mosquito trap, (the Human Decoy Trap) can overcome the limitations of the most frequently apply surveillance tools across sub - Saharan Africa, providing a standardised, cost - effective trap for sampling human - biting mosquitoes.',\n",
       "  '12250. The Beijing Huayi Health and Drug Research Institute. THE BEIJING HUAYI wellness AND DRUG inquiry INSTITUTE. to identify new drug candidates for diseases that disproportionally affect the worlds poorest populations.',\n",
       "  '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS enquiry INSTITUTE. to overcome the many challenges of getting oxygen to seriously ill children with severe pneumonia in remote rural hospitals and health centers',\n",
       "  '12182. Understanding the transmission of tuberculosis using Mycobacterium tuberculosis sequence data. UNDERSTANDING THE TRANSMISSION OF TUBERCULOSIS USING MYCOBACTERIUM TUBERCULOSIS SEQUENCE DATA. IIB - Research Board May / Jun 2015 - RM 2016 award to understand the transmission of tuberculosis using Mycobacterium tuberculosis succession data in Malawi',\n",
       "  '12262. Global Health Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE engineering FUND. to develop new drugs for the prevention and treatment of malaria, tuberculosis, Chagas, and visceral leishmaniasis',\n",
       "  '12250. Surveillance of Crim - Congean Hem Fever in Kosovo. SURVEILLANCE OF CRIM - CONGEAN HEM FEVER IN KOSOVO. Nosology and Surveillance of Crim - Congean Hem Fever in Kosovo',\n",
       "  '12261. Resources for the Future. RESOURCES FOR THE FUTURE. to help identify innovative policy solutions in which resource recovery from treatment of non - fecal waste can cross - subsidize intervention of fecal permissive waste, thus price effectively reducing the prevalence of pathogens in the environment',\n",
       "  '12250. Funding for scientist exchanges, subsidization. FUNDING FOR SCIENTIST EXCHANGES, GRANTS. Antibiotics and antiquorum sensung compounds from African fungous endophytes inhabiting medicinal plants and cultures of macromycetes - Capacity building in the field of education and research',\n",
       "  '12182. Modes of action and resistance mechanisms towards anti - trypanosomal benzoxaboroles. MODES OF ACTION AND immunity MECHANISMS TOWARDS ANTI - TRYPANOSOMAL BENZOXABOROLES. MRC / IIB  Research Grant to study new drug development against Human African trypanosomes often known as sleeping sickness. A disease found primarily in rural Africa.',\n",
       "  '12250. A double blind randomise community - based trial of amoxicillin versus placebo for non - severe pneumonia in children aged 2 - 59 months in Pakistan. A DOUBLE BLIND RANDOMIZED COMMUNITY - BASED TRIAL OF AMOXICILLIN VERSUS PLACEBO FOR NON - SEVERE PNEUMONIA IN tyke AGED 2 - 59 MONTHS IN PAKISTAN. Medical Research Council Joint (MRC / WT / DfID) Global Health Trial grant to test the utility of antibiotic therapy in non - severe pneumonia in children aged 2 - 59 months in Pakistan',\n",
       "  '12250. University of Maryland, Baltimore. UNIVERSITY OF old line state, BALTIMORE. to understand what drives sustained low - level typhoid transmission in Santiago, Chilly, where typhoid was once highly endemic, and to use these lessons to assess the feasibility of typhoid elimination',\n",
       "  '12262. Developmental Clinical Studies - Clinical evaluation of an AdCh63 - MVA PvDBP_RII vaccine for blood - stage Plasmodium vivax. DEVELOPMENTAL CLINICAL STUDIES - CLINICAL EVALUATION OF AN ADCH63 - MVA PVDBP_RII VACCINE FOR BLOOD - STAGE PLASMODIUM VIVAX. Developmental Clinical Studies - Clinical rating of an AdCh63 - MVA PvDBP_RII vaccinum for blood - stage Plasmodium vivax',\n",
       "  '12262. Malaria Vaccine Development Program (MVDP) - Malaria. MALARIA VACCINE DEVELOPMENT PROGRAM (MVDP) - MALARIA. MVDP, is committed to take in charge, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & establish field sites with the object of advancing the development of vaccine againstP. falciparumandP. vivaxmalaria identified by Research Institutes.',\n",
       "  '13040. The Aaron Diamond AIDS Research Center. THE AARON DIAMOND AIDS inquiry CENTER. to support the development, optimization, and selection of engineer bispecific bNabs for HIV bar.',\n",
       "  '12250. An integrated geospatial analysis framework for neglected zoonotic diseases. AN INTEGRATED GEOSPATIAL ANALYSIS model FOR NEGLECTED ZOONOTIC DISEASES. Medical Research Council. Fellowship to investigate models of transmittance in zoonotic disease',\n",
       "  '12110. Chronic Disease Control Research Fellowship Program (Guatemala ). CHRONIC DISEASE CONTROL RESEARCH FELLOWSHIP PROGRAM (GUATEMALA ). Guatemala is at stage three of the five stages of the epidemiologic transition, which refers to the transition from infectious to inveterate diseases as the leading cause of death. In this stage, chronic disease account for between 35% and 65% of total mortality. In Guatemala, strategies to halt the growing epidemic of chronic disease are scarce and rarely evidence - based. The Chronic Disease Control Research Fellowship Program therefore aims to strengthen national research capacity to generate policy - relevant knowledge and evidence leading to chronic disease control and improved healthcare provision. The Program will recruit and mentor research chap to study policy - relevant issues and translate the resulting knowledge into action. The program will focus initially on tobacco control research (smoking prevention, cessation ), in recognition that tobacco use is the leading cause of chronic disease. However, as the program evolves, the potential exists to address other issues relate to chronic disease control as well.',\n",
       "  '12110. Mapping and Analysis of Public Health Research and Capacity Strengthening Initiatives in Africa. MAPPING AND ANALYSIS OF PUBLIC HEALTH RESEARCH AND CAPACITY STRENGTHENING INITIATIVES IN AFRICA. Health care across much of the African continent is restrain by meager resources and a growing onus of disease, with HIV / AIDS, tuberculosis and malaria leading the charge. A growing body of evidence points to the need for a health scheme approach when designing, implementing and evaluating public health interventions. Although various organizations support health systems research in Africa, few have been devoted to systematically identifying, mapping, analyzing and reporting synergies between ongoing and emerging programs. This project will endeavor to address the gap through periodic analysis of different health policy and research first step, including those of funding, implementing and collaborating entities. Particular emphasis will be placed on identifying successful strategies for integrating HIV / AIDS into broader health and education systems. The exercise is expected to enhance knowledge networking and opportunity sharing between southern institutions, as well as strengthening South - North linkages.',\n",
       "  '13081. Output 13: Analysis on population dynamics. ANALYSIS ON POPULATION DYNAMICS. Republic of bolivia - La Paz. Output thirteen: Increased availability of evidence through cutting - edge in - depth analysis on universe dynamics, sexual and generative health, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  '12263. Ontogeny Invention Ventures (DIV) - Tuberculosis. DEVELOPMENT INNOVATION VENTURES (DIV) - TUBERCULOSIS. Ontogenesis Invention Ventures (DIV )',\n",
       "  '12182. RCT to evaluate an intervention for depressed HIV - positive women in the perinatal period, to enhance child development and reduce maternal depression. RCT TO EVALUATE AN INTERVENTION FOR DEPRESSED HIV - POSITIVE WOMEN IN THE PERINATAL PERIOD, TO ENHANCE CHILD ontogeny AND REDUCE MATERNAL DEPRESSION. MRC / JGHT 6 Full 2016 - A Randomised control trial to evaluate an intervention for depressed HIV - positive women in the perinatal period, to enhance child development and reduce maternal depression in Sub - Saharan Africa',\n",
       "  \"12250. PATH. PATH. to make available a rapid, low priced, and field - friendly Ov - 16 antigen - base antibody test (' Ov - 16 rapid test ') for use in onchocerciasis programs for disease control and eventual elimination in Africa\",\n",
       "  '12263. Streamlined TB Diagnosis and Treatment. STREAMLINED TB DIAGNOSIS AND TREATMENT. Medical Research Council Joint (MRC / WT / DfID) Global Health Trial grant to improve t.b. diagnosis and discussion in Uganda Vietnam Pakistan',\n",
       "  '12250. Alveo Technology. ALVEO TECHNOLOGIES. to assess novel, low price nucleic acerb detection technologies for use in low resource settings',\n",
       "  '13040. Common diseases. park DISEASES. European and Develop Countries Clinical Trials Partnership (EDCTP) - HIV treatment contribution to a randomized controlled trial using lithium carbonate in patients with HIV - C associate neurocognitive disorders - phase IIb proof - of - principle trial - Medical research of particular importance for Developing Countries',\n",
       "  '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to bring home the bacon evidence to help read wherefore vaccine recipients in some instances do not respond to an oral rotavirus vaccine',\n",
       "  '12182. Child Health Research Foundation (CHRF ). CHILD wellness RESEARCH FOUNDATION (CHRF ). for etiology (bacterial and viral agents) of neonatal sepsis in Asia and Africa',\n",
       "  '12262. IDENTIFYING legion - PATHOGEN INTERACTIONS WHICH CAUSE SEVERE MALARIA. IDENTIFYING HOST - PATHOGEN fundamental interaction WHICH causa SEVERE MALARIA. Checkup Research Council. Fellowship to investigate host parasite interaction in severe malaria',\n",
       "  '12250. University of Maryland, Baltimore. UNIVERSITY OF MARYLAND, BALTIMORE. to support a clinical study of the impact of rotavirus vaccinum introduction on moderate to severe diarrhea among children ages 0  59 months in Gambia, Kenya, and Mali',\n",
       "  '13040. Oregon Health & Science University. OREGON wellness & skill UNIVERSITY. to support CMV vector - found Vaccine Concept',\n",
       "  '12182. Funding for exchange of scientist, president grant. FUNDING FOR EXCHANGE OF SCIENTISTS, GRANTS. Identification of new approaches to treat epilepsy through genetics survey among the Moroccan universe - pilot project',\n",
       "  '12262. Medicines for Malaria Venture. MEDICINES FOR MALARIA VENTURE. to make an open - source compound collection of 400 molecules as a resource to jump - start drug discovery efforts across a wide range of pathogens',\n",
       "  '12182. Investigating the Human Malaria Reservoir of Transmission system during Pregnancy. INVESTIGATING THE man MALARIA artificial lake OF TRANSMISSION DURING PREGNANCY. MRC / DfID African Research Leader award investigating malaria transmission during pregnancy',\n",
       "  '12110. Reasoned Approach to Setting Priorities in Health. REASONED APPROACH TO SETTING PRIORITIES IN wellness. This project will develop a concise set of guidelines and tools for priority setting, and employ them to two different resource allocation problems, the one focusing on equitable redistribution of health services toward the most vulnerable in Namibia, and the other on the sustainability of the Aarogyasri Health Insurance Scheme for the poor in Andhra Pradesh, India. The project will provide essential capacity building and enhanced technical inputs from the World Health Organization (WHO) in supporting of the long - expressed aim of these two governance to reduce existing inequities with respect to the allocation of and access to resources for health.',\n",
       "  \"12250. Onchocerciasis Elimination Program of the Americas (OEPA) The Carter Center. ONCHOCERCIASIS excretion PROGRAM OF THE AMERICAS (OEPA) THE CARTER CENTER. The Carter Center ' s Onchocerciasis Elimination Program for the Americas (OEPA) coordinates the regional initiative to end illness and transmission of onchocerciasis (or river blindness) in the Americas.\",\n",
       "  '13040. Magee - Womens Enquiry Institute and Foundation. MAGEE - WOMENS RESEARCH INSTITUTE AND FOUNDATION. to accelerate the development of the x vivo challenge assay to leave an optimized bio - indicator of product efficacy',\n",
       "  '13040. Global Wellness Innovative Technology Store. GLOBAL HEALTH INNOVATIVE TECHNOLOGY investment firm. to develop new health technologies as a result of funding and development collaborations with Japanese industry and government',\n",
       "  '13040. Fred Anne hutchinson Cancer Research Center. FRED HUTCHINSON CANCER RESEARCH CENTER. to develop methods and computational instrument in biostatistics, computational biology, and mathematical modeling that will improve the quantitative science insightfulness and rigor of the HVTN 701 and 702 trial design and psychoanalysis for assessing immune correl',\n",
       "  '12263. GlaxoSmithKline Iodine + D, S. L. . GLAXOSMITHKLINE I + D, Sulfur. L. . to access a first in class technology program to identify the molecular targets of up to 10 anti - TB and anti - malaria lead compounds for the benefit of the wider Malaria and TB drug find communities',\n",
       "  '12182. A Dose Reduction Immunobridging Study of two HPV vaccines in Tanzanian girls. A DOSE REDUCTION IMMUNOBRIDGING STUDY OF TWO HPV VACCINES IN TANZANIAN GIRLS. Jt Fund Health Tri Y5 Feb 2015 award to plan a randomized trial in healthy Tanzanian females aged 9 - fourteen years. To establish whether a single dose of HPV vaccine produces immune responses that live likely to be effective in preventing cervical cancer in Africa.',\n",
       "  '12263. TASK Foundation. TASK creation. To support electrical capacity to enable TB drug development globally through with conservation and strengthening of a microbiology laboratory for early bactericidal activity (EBA) studies',\n",
       "  '12182. DSO PDP subsidie IAVI 2011 / 14. DSO PDP SUBSIDIE IAVI 2011 / 14. PDP Subsidie IAVI 2011 t / grand 2014',\n",
       "  \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering area through multi - country collaboration. The project squad will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and societal variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scaled up in other high - risk areas of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       "  '13040. HIV EPIDEMIOLOGY AND PREVENTION / RANDOMISED, PLACEBO - CONTROLLED SAFETY AND EFFICACY TRIAL OF A DAPIVIRINE VAGINAL RING indium HEALTHY HIV - NEGATIVE WOME. HIV EPIDEMIOLOGY AND PREVENTION / RANDOMISED, PLACEBO - CONTROLLED SAFETY AND EFFICACY TRIAL OF A DAPIVIRINE VAGINAL tintinnabulation IN HEALTHY HIV - NEGATIVE WOME. Medical Research Council. Intramural Grant Epidemiology and Prevention of HIV in Uganda, a microbicide tryout',\n",
       "  '12262. Defining the mechanism of action of the 8 - aminoquinolines: A pre - requisite to rationally designed safe antimalarials for the elimination era. DEFINING THE MECHANISM OF ACTION OF THE 8 - AMINOQUINOLINES: A PRE - REQUISITE TO RATIONALLY DESIGNED SAFE antimalarial FOR THE ELIMINATION ERA. Medical Research Council. Research Grant to develop new drgus against malaria',\n",
       "  '12262. The University of Lone star state at Austin. THE UNIVERSITY OF TEXAS AT AUSTIN. to reduce mosquito - borne diseases by developing a depleted cost and easy to use handheld device that utilizes widely useable maternity test strips to identify mosquitoes carrying specific pathogens such as the dengue virus',\n",
       "  '12250. John Hopkins University. JOHNS gerard manley hopkins UNIVERSITY. to support the Pneumonia Etiology Research for Child Health (PERCH) Labor',\n",
       "  '12250. Akonni Biosystems. AKONNI BIOSYSTEMS. to assess novel, low cost nucleic acid detection engineering for use in low imagination context',\n",
       "  '12110. Strengthening Equity through Applied Research Capacity Edifice in e - Health. STRENGTHENING EQUITY THROUGH APPLIED RESEARCH CAPACITY BUILDING IN E - HEALTH. There exists limited understanding of how e - Health solutions are perceived, designed, carry out and used. This goes beyond considerations related to automation, power supplies and affordability. Rather, it refers to context - specific, politically - aware and socially sensitive examination of how various ICTs are being appropriated, who is being included and excluded in the process, and whether the incorporation of ICTs is leading to more equitable health outcomes. The Strengthening Equity through Applied Research Capacity Building in e - Health (SEARCH) program will cultivate local research capacity to examine e - health and whether it leads to improved health equity and stronger health systems. Emphasis will be placed on methodological and analytical rigor, and policy dialogue. The first phase of SEARCH will involve scoping studies and workshops, with will elaborate the research schedule for the remainder of the programme.',\n",
       "  '13040. Family Health International. sept HEALTH INTERNATIONAL. to project, design, and initiate technical and ethical review article of a four - armed multi - center prospective randomized clinical trial of progestin - only hormonal contraceptive method and the copper intrauterine device (IUD )',\n",
       "  '12182. Undertaking research. task inquiry. Project research',\n",
       "  '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to contribute to the understanding of whether the frequency and intensity of social contact affects pneumococcal carriage rates and density, and if so, whether pneumococcal conjugate vaccination is able to overcome the effects of social contact on the elevator car',\n",
       "  '12182. PATH Meningitis Vaccine Project (MVP) 2017 - 2021 for the development of vaccines to prevent meningitis. PATH MENINGITIS VACCINE PROJECT (MVP) 2017 - 2021 FOR THE DEVELOPMENT OF VACCINES TO PREVENT MENINGITIS. This programme in the Ross Fund Portfolio (which focusses on neglected tropical diseases, diseases of emerging electrical resistance and diseases of epidemic potential) will support the development of new products (such as drugs, diagnostics and insecticides) for ta',\n",
       "  '12182. TBVI - Support for TB vaccine R & D activities. TBVI - SUPPORT FOR TB VACCINE R & D ACTIVITIES. TBVI is a European non - profit organization established in 2008, which supports, integrates, translates and prioritizes European R & D efforts to discover and develop new accessible and affordable terabyte Vaccines and correlates of protective covering for global use. With support from Norad, TBVI proposes to support its vaccine and biomarker R & D activities by focusing its activities on 4 of 7 of its R & Viosterol strategic areas.',\n",
       "  '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will cost on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asiatic experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       "  '13030. Apex Medical Technologies, Iraqi national congress. . APEX MEDICAL TECHNOLOGIES, INC. . to enhance the sensitivity and strength of male condoms by using collagen fibrils from bovine tendons, which provide a hydrated micro - rough skin - like control surface texture that facilitate heat transfer to produce a to a greater extent rude sensation.',\n",
       "  '13040. Global Wellness Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND. to develop unexampled health technologies as a result of funding and maturation collaboration with Japanese industry and government activity',\n",
       "  '12182. Mechanisms of helminth induced antiviral immunity to RSV infection. mechanism OF HELMINTH INDUCED ANTIVIRAL IMMUNITY TO RSV INFECTION. Medical Research Council. Research Grant to investigate immune response modulation of one infection on another by comparing Ugandan children with and without gut helminth infection to find out if this also enhances antiviral responses in the human respiratory tract.',\n",
       "  '13040. Microbicides Research, Development, and Introduction - HIV / AIDS. MICROBICIDES inquiry, DEVELOPMENT, AND INTRODUCTION - HIV / AIDS. Microbicides Research, Development, and Instauration',\n",
       "  '12262. Human race Health Organisation. WORLD HEALTH ORGANIZATION. to earn evidence on impact of insecticide resistance on the efficacy of malaria transmitter control and on feasibility of managing resistance',\n",
       "  '12110. Lithuanian University of Health Sciences - bilateral cooperation with Ministry of Health of the Republic of White russia. LITHUANIAN UNIVERSITY OF HEALTH SCIENCES - BILATERAL COOPERATION WITH MINISTRY OF HEALTH OF THE REPUBLIC OF BELARUS. Experience sharing bodily function.',\n",
       "  '13040. Duke University. DUKE UNIVERSITY. to alleviate the discovery of a safe, effective and practical HIV - 1 vaccine by using valid laboratory touchstone and Good Clinical Laboratory Practices to monitor antibody responses in the systemic and mucosal compartment in vaccine examination',\n",
       "  '12250. Regulation Of The Innate And Adaptive Immune Response Against Pathogens And Their Products. regularization OF THE INNATE AND ADAPTIVE IMMUNE RESPONSE AGAINST PATHOGENS AND THEIR product. Medical Inquiry Council. Intramural Grant to study immune responses to TB',\n",
       "  '12262. University of Booker t. washington Foundation. UNIVERSITY OF WASHINGTON FOUNDATION. to correctly identify infected individual with grim parasite densities who contribute to transmission and to improve the demeanor of malaria clinical trials',\n",
       "  '12250. University of California San Francisco. UNIVERSITY OF CALIFORNIA SAN FRANCISCO. to use a novel animal model to determine the relative attenuation phenotype or immunogenicity of new oral polio vaccinum (OPV) viruses including those make by the consortium for a new OPV - 2 as benchmarked against virus Sabin - 2',\n",
       "  \"12182. Function of immune cell populations in hypopigmentation disorders of autoimmune and infectious origin. FUNCTION OF IMMUNE cellular phone POPULATIONS IN HYPOPIGMENTATION DISORDERS OF AUTOIMMUNE AND INFECTIOUS ORIGIN. Why do citizens pay taxes? This question is surprisingly underexplored. Understanding when citizens pay taxes and wherefore they find it relevant and purposeful is central for answer this question. Tax compliance is a major concern in developing countries and particularly in Sub - Saharan Africa, in order to reduce dependency of foreign aid and increase state revenues for providing adequate health, educational and infrastructural services for their populations. In a nutshell, taxes are needed to build capable states that can provide for their citizens. Remarkably, taxation has not figured centrally on the agenda among scholars working on statebuilding in Africa or the African voter. Determinants of willingness to pay taxes in developing countries need to be scrutinized using an insiders ' perspective of what it means to be a tax payer on an everyday basis across different socioeconomic groups. This project expands on current explanations through focusing on the social practice of taxes; when, how and where taxation occurs and how this practice forms part of the everyday for ordinary citizens. This is studied through an ethnographic study of the practices surrounding tax payment in three cases in Sub - Saharan Africa (Lesotho, Tanzania and Zambia ), where the willingness to pay taxes and the relative tax burden vary. A comparative micro - study of citizens ' experience with taxes, using interviews and observations, will reveal the room for building a tax paying culture.\",\n",
       "  '12250. California Institute of Technology. CALIFORNIA INSTITUTE OF TECHNOLOGY. to develop a Micro? Electro? Mechanical Scheme as a portable and reliable microbial monitoring system that can be integrated into safe and sustainable sanitation solutions in the developing world and enable onsite testing for pathogen',\n",
       "  '12262. Mahidol University. MAHIDOL UNIVERSITY. to accelerate advancement of medical research for discourse, prevention and evacuation of malaria diseases',\n",
       "  '12262. Naval Medical Research Center. NAVAL MEDICAL RESEARCH CENTER. to characterize the resistant profiles of humans protect against malaria following immunization with radiation syndrome - weakened Plasmodium falciparum sporozoite, in order to promote the development of malaria vaccines',\n",
       "  '12261. Oklahoma State University. OKLAHOMA dos UNIVERSITY. to develop technology to reduce the pathogen load of helminthes and bacteria obtain in fecal wastes; thereby lowering the transmission rate of infectious diseases',\n",
       "  '12250. Massachusetts Institute of Technology. MASSACHUSETTS INSTITUTE OF TECHNOLOGY. to develop novel pulsed antigen - releasing unmarried - injection vaccine delivery systems to facilitate pediatric immunization in developing world circumstances in which repeated patient access may be problematic',\n",
       "  '13040. Weill Medical College of Cornell University. WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY. to advance the development of prophylactic HIV - 1 vaccine based on trimeric forms of the viral envelope glycoproteins contrive to induce protective neutralizing antibodies in clinical studies.',\n",
       "  '12262. Improving Malaria Diagnostics (IMaD) - Malaria. IMPROVING MALARIA DIAGNOSTICS (IMAD) - MALARIA. Under IMaD, MCDI and its partners work to improve laboratory - based diagnosis of malaria (primarily at Ministry of Health facilities ), and to increase understanding, acceptance, and correct use of microscopy and Rapid Diagnostic Tests (RDTs) by laboratory staff and health care practitioner providing direct care to patients.',\n",
       "  '12182. STUDIES TOWARDS DEVELOPEMNT OF VACCINES AGAINST ETEC AND H. PYLORI FOR USE IN DEVELOPING COUNTRIES. . STUDIES TOWARDS DEVELOPEMNT OF VACCINES AGAINST ETEC AND H. PYLORI FOR USE IN DEVELOPING COUNTRIES. . The overall aim of this project is to develop effective vaccines against two of the most common gastrointestinal pathogens, i. e. enterotoxin - producing Escherichia coli (ETEC) and Helicobacter pylori, especially for use in developing countries. This include studies to elucidate immune mechanisms and antigens of importance for protection against diseases caused by these bacteria and to construct and evaluate promising candidate vaccines for safety and immunogenicity, initially in animals and subsequently in humans. It also includes a search for new ETEC colonization factors and analyses of emerging ETEC clones by means of whole genome sequencing. A new oral ETEC candidate vaccine developed by us, consisting of recombinant E. coli bacteria over - expressing the most important ETEC colonization factors and a anatoxin will be evaluated alone and together with a promising mucosal adjuvant for safety and immunogenicity in Phase I / II studies, initially in Sweden and subsequently in descending age groups in Bangladesh. The aim is also to identify simple interventions such as calorie and micronutrient supplementation, changed breast feeding patterns, anti - parasite treatment that may improve immune responses against enteric vaccines in children in developing countries. Vaccine strains that overexpress putative protective H. pylori antigens will also be constructed and tested for protective efficaciousness in experimental animals.',\n",
       "  '12250. Wits Wellness Pool. WITS HEALTH syndicate. to elucidate associations between RSV, influenza and pneumococcal colonization',\n",
       "  \"12182. European and Developing Country Clinical Trials Partnership phase II: funding to support two enquiry calls. EUROPEAN AND DEVELOPING COUNTRY CLINICAL TRIALS PARTNERSHIP phase angle II: FUNDING TO SUPPORT TWO RESEARCH CALLS. Support for two research calls: ' Research and clinical management of patients in poverty - related disease epidemics in sub - Saharan Africa ' and ' Clinical trials and operational research studies to optimise the use of products for poverty - related diseases in mothers, newborns, children and / or adolescents '\",\n",
       "  '12250. Capital of the united states University. WASHINGTON UNIVERSITY. to make new find that will head to development of diagnostic tests for habit in onchocerciasis elimination programs',\n",
       "  '12182. DSO PDP subsidie IAVI 2011 / 14. DSO PDP SUBSIDIE IAVI 2011 / 14. PDP Subsidie IAVI 2011 triiodothyronine / chiliad 2014',\n",
       "  '12250. Market Study into the Praziquantel drug that is used for the Integrated Control of Schistosomiasis and Intestinal Helminths in Sub - Saharan Africa. MARKET STUDY INTO THE PRAZIQUANTEL DRUG THAT be USED FOR THE INTEGRATED CONTROL OF SCHISTOSOMIASIS AND INTESTINAL HELMINTHS IN SUB - SAHARAN AFRICA. To reduce morbidness and mortality in up to ten African countries by fork over a total of 203. 5 million treatments for Schistosomiasis and Soil - Transmitted Helminths.',\n",
       "  '13040. The Aaron Diamond AIDS Research Center. THE AARON rhomb AIDS RESEARCH CENTER. to avail develop an effective long - represent bar intervention that could substantially reduce HIV - 1 incidence',\n",
       "  '12182. Abubakar; Pwani; Adolescent Executive Functioning Association with Scholastic Outcomes, Risk Taking Behavior and Medical Adherence in the Circumstance of human immunodeficiency virus. ABUBAKAR; PWANI; ADOLESCENT EXECUTIVE FUNCTIONING ASSOCIATION WITH SCHOLASTIC OUTCOMES, RISK TAKING BEHAVIOR AND MEDICAL ADHERENCE IN THE CONTEXT OF HIV. Medical Inquiry Council / DfID African Research leadership award for mental health and HIV research in Kenya',\n",
       "  '13040. Microbicide Enquiry, Development, and Introduction, Round 3 - human immunodeficiency virus / AIDS. MICROBICIDE RESEARCH, DEVELOPMENT, AND INTRODUCTION, ROUND 3 - HIV / AIDS. Microbicide Research, Growth, and Presentation, Round 3',\n",
       "  '12262. Dissecting the Red Blood Cell Invasion Pathways of the Malaria Parasite Plasmodium knowlesi. DISSECTING THE RED BLOOD CELL INVASION PATHWAYS OF THE MALARIA PARASITE PLASMODIUM KNOWLESI. Medical Research Council inquiry fellowship award to expect at cell entry mechanisms of a novel zoonotic malaria',\n",
       "  '12220. University of Maryland, Baltimore. UNIVERSITY OF MARYLAND, BALTIMORE. to develop broadly effective vaccines and interventions against enteric infections by conducting multi - country case - control studies using standardized methods to measure the etiology and burden of diarrhea among tyke in develop countries',\n",
       "  '13040. HIV Vaccine and Biomedical Bar Research Projection. HIV VACCINE AND BIOMEDICAL PREVENTION RESEARCH PROJECT. HIV Vaccinum and Biomedical Prevention Research Project',\n",
       "  '12250. A phase III randomised controlled trial of oral fluconazole plus flucytosine versus amphotericin B - based therapy for o. A PHASE terzetto RANDOMISED CONTROLLED TRIAL OF ORAL FLUCONAZOLE PLUS FLUCYTOSINE VERSUS AMPHOTERICIN B - BASED THERAPY FOR Group o. A phase III randomised control trial of oral fluconazole plus flucytosine versus amphotericin B - based therapy for oxygen',\n",
       "  '12110. Strengthening Fairness through Applied Research Capacity Building in e - Health. STRENGTHENING EQUITY THROUGH APPLIED RESEARCH CAPACITY BUILDING IN E - HEALTH. There exists limited understanding of how e - Health solutions are perceived, designed, implemented and used. This goes beyond considerations related to automation, power supplies and affordability. Kind of, it refers to context - specific, politically - aware and socially sensitive examination of how various ICTs are being appropriated, who is being included and excluded in the process, and whether the incorporation of ICTs is leading to more equitable health outcomes. The Strengthening Equity through Applied Inquiry Capacity Building in e - Health (SEARCH) program will cultivate local research capacity to examine e - health and whether it leads to improved health equity and stronger health systems. Emphasis will be placed on methodological and analytical rigor, and policy dialogue. The first phase of SEARCH will affect scoping studies and workshops, with will elaborate the research agenda for the remainder of the program.',\n",
       "  \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the egress or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategy in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each rural area, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scaled up in other high - risk areas of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       "  '12263. Development Innovation Ventures (DIV) - T.b.. DEVELOPMENT INNOVATION VENTURES (DIV) - tb. Development Creation Ventures (DIV )',\n",
       "  '12263. University of George washington Foundation. UNIVERSITY OF booker t. washington FOUNDATION. to develop new tools to discover and manage tuberculosis',\n",
       "  '13040. Family Health International. kin HEALTH INTERNATIONAL. to plan, design, and initiate sealed activities to prepare for implementation of a quartet - armed multi - center prospective randomized clinical test of progestin - only hormonal contraception and the copper intrauterine device (IUD )',\n",
       "  '12182. Novel therapeutic approaches to malnutrition enteropathy. NOVEL THERAPEUTIC APPROACHES TO MALNUTRITION ENTEROPATHY. GCRF Foundation NCDs 2016 support phase II trial of treatments for severely malnourished child with diarrhoea complications. With the aim to reduce mortality through mucosal healing. Particularly in Africa, South Asia, Zambia.',\n",
       "  \"12182. NFR - GLOBVAC Global health and vaccination research. NFR - GLOBVAC GLOBAL HEALTH AND VACCINATION RESEARCH. An annual allocation of NOK 7 000 000 is set apart for research on global health and NOK 55 000 000 for research on vaccination. The funding is managed by Norse Research Council. The funds shall assure Norway ' s responisbility for research on global health challenges and povery - related diseases affectiong developing countries. The activity comprise basic research, clinical research and research on health systems direkted towards prevention and treatment of provery - related diseases\",\n",
       "  '12250. Cost of pilot projects to increase efficiency in union administration. COST OF PILOT PROJECTS TO INCREASE EFFICIENCY IN FEDERAL ADMINISTRATION. Confocal Raman microspectroscopy and confocal laser microscopy to study the effects of antimicrobial agentive role on structure and composition of biofilms produced by pathogens recovered from cystic fibrosis patients. - Capacity building in the field of education and research - medical research',\n",
       "  '12250. Innovation funding in the new LSnder. INNOVATION FUNDING IN THE NEW L - NDER. Molecular serology for rapid determination of vaccination titer against vaccinum - preventable infectious diseases (STIKO list) in migrants and other groups of affected role - Medical research of particular importance for developing countries',\n",
       "  '13030. Contraceptive and Reproductive Health Technology Research and Utilization (CRTU) - Family Planning and Reproductive Health. CONTRACEPTIVE AND REPRODUCTIVE HEALTH TECHNOLOGY RESEARCH AND UTILIZATION (CRTU) - FAMILY PLANNING AND REPRODUCTIVE HEALTH. To develop, evaluate, and introduce a range of good, effective, and acceptable contraceptive and human immunodeficiency virus / AIDS prevention technologies (e. g. , microbicides and barrier methods) and other reproductive health (RH) technologies and to enhance the capacity of phratry planning (FP) and RH programs in developing countries to provide these technologies.',\n",
       "  '12182. Miscellaneous in the area of external understanding. MISCELLANEOUS IN THE AREA OF INTERNATIONAL UNDERSTANDING. Collaborative project - Development of a cost - efficient vaccine against cervix carcinoma - a prophylactic approach, sub - project - upscaling a chloroplastidary vaccine expression system and transformation of new candidate antigens in tobacco plant and salad - Knowledge Transfer',\n",
       "  '12182. To fund the development of new diagnostic testing for neglected diseases through the organisation Foundation for Innovative New Diagnostics. . TO FUND THE DEVELOPMENT OF NEW DIAGNOSTIC TESTING FOR NEGLECTED DISEASES THROUGH THE ORGANISATION FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS. . To research and develop new diagnostic tests for the unattended diseases of the hapless, include Tuberculosis, Sleeping Illness, Leishmaniasis, Malaria and Non - malarial febrile illness, through public private partnership. This research will advance the dev',\n",
       "  '13040. Preventive Technologies Correspondence (PTA) - HIV / AIDS. PREVENTIVE TECHNOLOGIES AGREEMENT (PTA) - human immunodeficiency virus / AIDS. To develop, evaluate, and introduce a range of safe, effective, and acceptable HIV / AIDS prevention technologies (e. g. , microbicides and barrier methods) and other reproductive health technologies and to enhance the capacity of field programme to allow services to populations at high risk.',\n",
       "  '13030. Population Council. POPULATION COUNCIL. to develop and test the acceptability of a vaginal ring engineering aimed at amplify contraceptive choice, improving maternal and newborn health, and building relationships with private and public sector stakeholders',\n",
       "  '12182. Studies of hepatic latency in human ovale malaria. STUDIES OF HEPATIC LATENCY IN homo OVALE MALARIA. Medical examination Research Council. Research Grant to investigate the abeyant phase of malaria',\n",
       "  '13030. Population Council. POPULATION COUNCIL. to develop and test the acceptableness of a vaginal ring technology aimed at expanding contraceptive choice, improving maternal and newborn wellness, and build relationships with private and public sector stakeholders',\n",
       "  '12262. University of Kentucky Research Foundation. UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION. to aid mass bringing up of different disease - relevant mosquito species for control efforts',\n",
       "  '13040. Arcady Radical, LLC. ARCADY chemical group, LLC. to develop and source a medication event monitor box seat for use in clinical trial and ultimately scale for deployment in Indian and Chinese TB control programs',\n",
       "  '13040. Duke University. DUKE UNIVERSITY. to rapidly test the MPER liposome immunogen in a small phase 0 / 1 clinical trial in club to determine if relevant unsubtle neutralizing antibody (BnAb) germline antibody - producing B cells can be engaged by the immunogen, and BnAb Type b cell lineages can be driv',\n",
       "  '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competitor in Southeast Asia for funding multi - nation studies coordinated by an institution or consortium of institutions located in the region. The vehemence will be on capacity building, networking and policy impact at the regional story. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       "  '12240. University of Nottingham. UNIVERSITY OF NOTTINGHAM. to better delicacy diarrheal diseases by identifying bacteriophage (viruses that infect bacteria) that can ruin iii different infective gut bacterium to restore healthy bacterial populations using their pig enteric model.',\n",
       "  '12110. Strengthening Equity through Applied Research Capacity Building in e - Health. STRENGTHENING EQUITY THROUGH APPLIED RESEARCH CAPACITY BUILDING IN E - HEALTH. There exists limited understanding of how e - Health solutions are perceived, designed, implemented and used. This goes beyond considerations related to automation, power supplies and affordability. Rather, it refers to context - specific, politically - aware and socially sensitive examination of how various ICTs are being appropriated, who is being included and excluded in the process, and whether the incorporation of ICTs is leading to more equitable health outcomes. The Strengthening Equity through Applied Research Capacity Edifice in e - Health (SEARCH) program will cultivate local research capacity to examine e - health and whether it leads to improved health equity and stronger health systems. Emphasis will be placed on methodological and analytical rigor, and policy dialogue. The first phase of SEARCH will involve scoping studies and workshops, with will elaborate the research agenda for the remainder of the program.',\n",
       "  '12182. A randomized trial to evaluate the toxicity and efficacy of 1200mg and 1800mg rifampicin daily for 4 months in the treatment of pulmonary tuberculosis. A RANDOMIZED TRIAL TO EVALUATE THE TOXICITY AND EFFICACY OF 1200MG AND 1800MG RIFAMPICIN DAILY FOR 4 MONTHS IN THE TREATMENT OF PULMONARY TUBERCULOSIS. Jt Fund Health Tri Y5 Feb 2015 award to run a trial in Uganda. On the effectivity of increasing the current dosage to help heal tuberculosis and the impact of these changes to the completion of treatment and cure rates for Lower and Middle income countries.',\n",
       "  '12262. Global Wellness Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE TECHNOLOGY investment firm. to develop new drugs for the bar and treatment of malaria, tuberculosis, Chagas, and visceral leishmaniasis',\n",
       "  '12263. Augmentation and regulation of immune responses to Tuberculosis by vitamin D. AUGMENTATION AND REGULATION OF IMMUNE RESPONSES TO tb BY VITAMIN D. Medical Inquiry Council. Fellowship to investigate how Vit D may affect the immune response to TB',\n",
       "  '12110. Assessing the Posture and Practices of Public Health Professionals Regarding Funding from For - Profit Corporations. ASSESSING THE ATTITUDES AND PRACTICES OF PUBLIC HEALTH PROFESSIONALS REGARDING FUNDING FROM FOR - PROFIT CORPORATIONS. Over the past two decades, many corporations have begun philanthropic contributions to universities under the rubric of corporate social responsibility (CSR ). In an era of dwindling support from governments and foundations, many university have, in turn, begun to solicit funds from businesses. In the case of schools of public health, some potential corporate funders make products that may be considered harmful to health or a threat to the environment, creating a potential conflict of interest. The overall aim of this project is to inform a policy debate about potential guidelines for making decisions about accepting funds from for - profit corporations. At present, there are no generalized guidelines to govern the receipt of research and sponsorship funds from for - profit corporations - practices differ by schools and programs of public health. This project, managed by the American University of Beirut, will survey public health academics and practitioners around the world about their attitudes and practices around funding from for - profit corporations, particularly those whose products are associated with non - communicable diseases. The project will also review existing policies that govern schools of public health around the globe with respect to taking funds from for - profit corporations. The project will focus on schools and programs of public health in the Eastern Mediterranean region, North America, Africa, and Southeast Asia.',\n",
       "  '12250. Trustees of Dartmouth College. TRUSTEES OF DARTMOUTH COLLEGE. to develop more than accurate and timely measurement of population immunity sire by polio vaccines',\n",
       "  \"12182. PATH Product Development Partnership Programme 2013 - 2018. itinerary PRODUCT DEVELOPMENT PARTNERSHIP PROGRAMME 2013 - 2018. ' To reduce poverty through investing in inquiry to develop effective and affordable, diagnostics, treatment, drugs and vaccines for diarrhoea and malaria. In the longer term this has the potential to significantly reduce death and illness among the poor\",\n",
       "  '13030. The Product Development Agreement - Family Planning and Reproductive Health. THE intersection growth accord - kinsperson PLANNING AND REPRODUCTIVE HEALTH. The Product Development Agreement',\n",
       "  '12263. tb Vaccine Opening move. TUBERCULOSIS VACCINE enterprisingness. to improve tuberculosis control by developing and introducing modern technologies to forbid, diagnose and treat the disease',\n",
       "  '13040. WHO - IARC (International Agency for Research on Cancer ). WHO - IARC (INTERNATIONAL AGENCY FOR RESEARCH ON CANCER ). to verify effectiveness and safety of 2 vs 3 state of HPV vaccinum in preventing cervical cancer in a population in a developing country and to facilitate the rapid introduction of HPV vaccinum programs in poor countries at high cervical cancer risk',\n",
       "  '12182. IAVI - International AIDS Vaccine Initiative - burden support 2013 - 2015. IAVI - INTERNATIONAL AIDS VACCINE INITIATIVE - CORE SUPPORT 2013 - 2015. IAVI is a Product Development Partnership found to ensure the development of safe, good, accessible, preventive HIV vaccines for use throughout the world. With support from Norad, IAVI aims to address the key scientific issue currently impeding vaccine development, i. eastward. HIV hyper - variability.',\n",
       "  '12182. Scientific Cooperation with Other Countries (in so far as not included in other areas ). SCIENTIFIC COOPERATION WITH OTHER COUNTRIES (IN SO FAR AS NOT INCLUDED IN OTHER AREAS ). Studies on dermal invasion of polymer nanocapsules and nanoencapsulated clobetasol from nanocapsules',\n",
       "  '12263. The Aurum Institute nonproliferation center. THE AURUM INSTITUTE NPC. to fund a clinical trial to examine if adding host - directed therapy to standard antimicrobic treatment could leave in a shorter and improved treatment of TB',\n",
       "  '12250. University of Washington. UNIVERSITY OF WASHINGTON. to find out therapeutics for prevention of antibiotic resistance exploitation',\n",
       "  '12182. Characterisation of the breakdown in immune competence of the lung that favours development of tuberculosis in HIV - infected adults. CHARACTERISATION OF THE crack up IN IMMUNE COMPETENCE OF THE LUNG THAT FAVOURS DEVELOPMENT OF TUBERCULOSIS IN HIV - INFECTED grownup. MRC / DfID African Research Leader inquire lung health and tuberculosis in HIV infected adults',\n",
       "  '12262. Stanford University. STANFORD UNIVERSITY. for the psychoanalysis of sample and data from Scientific Advisory Board - sanction vaccine trials and natural history studies',\n",
       "  '12191. AMENET - The African Melioidosis Meshing: improving health through an integrated microbiological, clinical and environmental research approach. AMENET - THE AFRICAN MELIOIDOSIS NETWORK: IMPROVING HEALTH THROUGH AN INTEGRATED MICROBIOLOGICAL, CLINICAL AND ENVIRONMENTAL RESEARCH APPROACH. AMENET - The African Melioidosis Network: improving wellness through an integrated microbiological, clinical and environmental research approach',\n",
       "  '13040. Microbicide Research, Ontogenesis, and Introduction, Round 3 - HIV / AIDS. MICROBICIDE RESEARCH, DEVELOPMENT, AND origination, ROUND 3 - HIV / AIDS. Microbicide Research, Maturation, and Introduction, Round 3',\n",
       "  '12262. University of Iowa. UNIVERSITY OF ioway. to learn antibody mediated protection against malaria parasite sporozoites',\n",
       "  '12182. Improving the radical cure of vivax malaria: A multicentre randomised equivalence of short and long course primaquine regimens. IMPROVING THE RADICAL CURE OF VIVAX MALARIA: A MULTICENTRE RANDOMISED COMPARISON OF shortstop AND LONG COURSE PRIMAQUINE REGIMENS. Medical Research Council. Research Grant to trial compare treatment strategies for vivax malaria',\n",
       "  '13040. Basic Science Program / Research aimed at designing an effective 13042vaccine. BASIC SCIENCE PROGRAMME / RESEARCH AIMED AT DESIGNING associate in nursing EFFECTIVE 13042VACCINE. Basic Science Programme / Research aimed at designing an effective 13042vaccine',\n",
       "  '12262. GlaxoSmithKline Biologicals. GLAXOSMITHKLINE BIOLOGICALS. to provide a new dimension to vaccine development for malaria and tuberculosis (TB) by deeper analysis of transcriptomics data that are being generated in clinical study, by promoting collaboration between different partners involved in Systems Biological science',\n",
       "  '12262. THE PREECLAMPSIA - MALARIA CONNECTION: PREDICTION, DIAGNOSIS, AND HOPE FOR TREATMENT. THE PREECLAMPSIA - MALARIA CONNECTION: PREDICTION, DIAGNOSIS, AND bob hope FOR TREATMENT. Women are particularly vulnerable to malaria during pregnancy because malaria parasites accumulate in the placenta and the condition is calculate to be responsible for 200 000 infant deaths annually. The disease mechanisms are poorly understood, mostly due to the lack of adequate animal models. We propose to use a placental perfusion model to study the interaction between malaria parasites accumulated in the human placenta in relation to the development of preeclampsia with ot without intrauterine growth restriction. The studies will also provide immediate guidance for ongoing efforts to develop a vaccine, protecting women from pregnancy malaria, and basic insight about the disease processes, which can lead to new treatment and prevention strategies for these complicated pregnancies affecting women in the sub - Saharan region. The specific aims of this undertaking are to uncover common disease mechanisms behind PE with or without IUGR and pregnancy - associated malaria (PAM ); to enable predictive diagnosis of high risk cases in the field; to prove feasibility of a cure using A1M in perfusion experiments. This work involves personnel and high risk pregnancy patients from Kenya, Egypt, Tanzania, and Ghana.',\n",
       "  \"13020. Menstrual cups and unconditional cash transfer to reduce sexual and reproductive harm and school drop - out in adolescent schoolgirls in western Kenya. MENSTRUAL CUPS AND UNCONDITIONAL CASH TRANSFER TO REDUCE SEXUAL AND REPRODUCTIVE HARM AND SCHOOL DROP - OUT indium ADOLESCENT SCHOOLGIRLS IN WESTERN KENYA. Medical Research Council Joint (MRC / WT / DfID) Global Health Trial grant examining the impingement and monetary value - effectiveness of menstrual cups, compared or combined with unconditional cash transfer, to meliorate rural girls ' retention in secondary school and protec\",\n",
       "  '12262. malaria parasite protein and erythrocyte encroachment. MALARIA PARASITE protein AND ERYTHROCYTE INVASION. Medical Research Council. Intramural Grant to study the molecules involved in the invasion process of the red cell by the malaria parasite',\n",
       "  '13081. Output thirteen: Analysis on universe dynamics. ANALYSIS ON universe DYNAMICS. Guatemala - Guatemala City. Output 13: Increased availability of evidence through cutting - edge in - depth analysis on universe dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  '13010. Promoting Punter Health for Marginalized Migrants in Southeast and East Asia. PROMOTING BETTER HEALTH FOR MARGINALIZED MIGRANTS IN SOUTHEAST AND EAST ASIA. In Southeast and East Asia, low - skilled migrant workers are highly vulnerable to exploitation, discrimination, and abuse. However, their health (particularly their sexual and reproductive health, with the exception of HIV) is relatively overlooked in public discourse and policies. This undertaking aims to draw attention to the gender and health needs of these migrant workers by facilitating knowledge creation and translation, and dissemination among researchers, policymakers, and implementers in the region. The grant will support two sets of activities. First, it will foster knowledge creation and translation by enabling the Asian - Pacific Resource & Research Centre for Women (ARROW) to develop an annotated bibliography of resources about the intersections of migration, gender, and health in Southeast Asia. Related resources to be developed include electronic and print versions of an annotated bibliography and a bulletin on Migration, Gender and Sexual and Reproductive Wellness and Rights in Southeast and Orient Asia. A directory of organizations and networks working on migration will be produced and used as a mailing list for the bulletin. An event will be held at a regional forum to foster awareness of issues related to migration, gender, and sexual and reproductive health and rights done presentation of the bulletin and a discussion session that will lead to a summary paper.',\n",
       "  '13010. Output 13: Analysis on population dynamic. ANALYSIS ON POPULATION DYNAMICS. Occupied Palestine Territories. Output 13: Increased availability of evidence through with cutting - edge in - profoundness analysis on population dynamics, intimate and reproductive wellness, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  \"13010. Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems. CENTRE OF EXCELLENCE FOR CIVIL REGISTRATION AND VITAL STATISTICS (CRVS) SYSTEMS. Registration of events, such as birth, death, causes of death, marriage, and divorce, is critical for improving maternal, newborn, child, and adolescent health. These statistics provide policymakers and practitioners with the necessary evidence to design interventions and enact appropriate policies on maternal and child health. Many low - and center - income countries, however, do not systematically collect such crucial information. It is estimated that one - third of the world ' s births and two - thirds of the world ' s deaths are not registered or are incorrectly certified. In many cases, global norms, standards, tools, and good practices are not readily accessible and useable to those who need them most. The project will establish the Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems to provide information, tools, and expertise to facilitate the development and implementation of integrated CRVS systems. Funded by Global Affairs Canada and the International Development Research Centre (IDRC ), and based at IDRC, the Centre of Excellence will coordinate with existing expert chemical group to generate, consolidate, and share information and resources in an open and collaborative electronic platform. It will also assist countries needing more direct support by facilitating the exchange of good practices and capacity strengthening, and will play an important role brokering technical assistance for countries needing more direct support. The Centre of Excellence will work closely with the Global Financing Facility in support of the Every Woman Every Child initiative to enable the development and implementation of CRVS systems plans as part of country - led investment cases for financing by the Global Financing Facility.\",\n",
       "  '12250. NTD Highlight Notice - Defining PK / PD relationships of anti - leishmanial drugs - a refreshing approach for anti - leishmanial drug development. NTD HIGHLIGHT observance - DEFINING PK / PD RELATIONSHIPS OF ANTI - LEISHMANIAL DRUGS - A NOVEL APPROACH FOR ANTI - LEISHMANIAL DRUG DEVELOPMENT. Medical Research Council. Research Grant to investigate development of potential new drugs against genus leishmania',\n",
       "  '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infective diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Se Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on capacity building, networking and policy encroachment at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       "  '12250. Keith rupert murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to monitor pneumococcal baby buggy and vaccine impact',\n",
       "  '13040. Microbial translocation in HIV - septic tike in Uganda. MICROBIAL TRANSLOCATION IN HIV - INFECTED CHILDREN IN UGANDA. Medical Research Council. Fellowship to investigate gut permeability in human immunodeficiency virus infected children',\n",
       "  '12182. Research to Improve Health Systems in Developing Countries. inquiry TO IMPROVE HEALTH SYSTEMS IN DEVELOPING COUNTRIES. To support enquiry into health systems in developing res publica in partnership with Wellcome Trust, the Medical Research Council and the Economic and Social Research Council. This research will improve our understanding of the most effective health interv',\n",
       "  '12250. A clinical trial of oradexon to reduce deathrate in cryptococcal meningitis. A CLINICAL TRIAL OF DEXAMETHASONE TO REDUCE MORTALITY inch CRYPTOCOCCAL MENINGITIS. A clinical trial of dexamethasone to reduce mortality in cryptococcal meningitis',\n",
       "  '13030. Preventive Technologies Arrangement (PTA) - Family Planning and Reproductive Health. PREVENTIVE TECHNOLOGIES AGREEMENT (PTA) - kinsperson PLANNING AND REPRODUCTIVE HEALTH. To develop, evaluate, and introduce a range of safe, effective, and acceptable HIV / AIDS prevention technologies (e. g. , microbicides and barrier methods) and other reproductive wellness engineering science and to enhance the capacity of field programs to provide services to populations at high risk.',\n",
       "  '12250. Meningococcal Vaccine and Other Product Development 2010 - 2018. MENINGOCOCCAL VACCINE AND OTHER PRODUCT DEVELOPMENT 2010 - 2018. The UK is supporting a Product Development Partnership (PDP ), the Meningitis Vaccine Project to develop a polyvalent meningitis vaccinum for Sub - Saharan Africa that will hold in the remaining 15% to 20% of meningococcal infections non covered by the existi',\n",
       "  '12182. Plasmodium falciparum malaria: understanding the role of conserved versus polymorphic antigens in acquired immunity. PLASMODIUM FALCIPARUM MALARIA: UNDERSTANDING THE ROLE OF CONSERVED VERSUS POLYMORPHIC ANTIGENS IN ACQUIRED IMMUNITY. A vaccine against malaria is urgently needed. The aim of this collaborative research project is to examine the role of antigen diversity on the antibody response and acquired immunity against clinical episodes of malaria; with the overall purpose of identifying candidate antigens to be included in a multi - component malaria vaccine. The project will describe parasite diversity in relation to antibody responses and protective immunity in individuals with different degree of exposure within defined geographical regions in Ghana and Kenya, as well as in travellers experiencing first time infections. We will focus on a subset of antigens (n = 10) that have been shown to be potential targets of protective immunity and include both conserved and polymorphic proteins. We will sequence the sponger collected from the community to define precisely the diversity at the selected loci, express these antigens and then analyse the antibody responses to conserve and diverse antigens. We will specifically investigate compounding of antigens and variants of antigens to which antibodies confer protection. The project will use samples that are and have been collected within longitudinal well - established cohorts in Ghana and Kenya, as well as Swedish travelers. The proposed collaboration includes workshops and involves several PhD students including a joint PhD supervision between Ghana, Kenya and Sweden, and will be mutually beneficially for the research development of all partners.',\n",
       "  '12250. Emory University. EMORY UNIVERSITY. to support a study that will further apprehension of the impact of pneumococcal conjugate vaccine through with the sequencing and comparison of whole genome sequence of a species before and after vaccination',\n",
       "  '13040. Completion of Phase III Microbicide Clinical Trial for Tenofovir 1% Gel - HIV / AIDS. COMPLETION OF PHASE III MICROBICIDE CLINICAL TRIAL FOR TENOFOVIR 1% GEL - HIV / AIDS. The objectives of this program are to complete clinical and regulatory activities required for licensure of tenofovir (TFV) 1% gel for the prevention of vaginal HIV acquisition in women and to provide information about its implementation in African populations. This project includes the following activities: 1) Completing clinical activities required for TFV 1% gel licensure; 2) Completing regulatory activities required for TFV 1% gel licensure; 3) Conducting open - label TFV 1% gel Implementation Study in South Africa and other African countries; 4) Conducting a bridging study for the approval of one TFV 1% gel that is safe and acceptable for vaginal and rectal use.',\n",
       "  \"12110. Communications and knowledge translation fund for maternal and child health research. COMMUNICATIONS AND KNOWLEDGE TRANSLATION FUND FOR MATERNAL AND CHILD HEALTH inquiry. Maternal, newborn, child, and adolescent health, one of the Canadian government ' s development priorities, is a key element of the third Sustainable Development Goal (SDG) Good health and well - being. Evidence for building integrated and equitable health systems for women, adolescents, and children is urgently needed as countries strive to improve accountability and access to quality health services. IDRC ' s Maternal and Child Health program have supported a rich portfolio of research projects and a large number of researchers, research networks, and global institutions that contribute to sustainable solutions that strengthen primary health care systems in low - and middle - income countries (LMICs ). Building on this strong foundation, IDRC is ensuring that its approach of addressing the structural and root problems to strengthen health systems is communicate, understood, and adopted. The Maternal and Child Health program is supporting LMIC researchers, policymakers and implementers in a participatory manner and providing them with opportunities to influence national, regional, and global agendas through the dissemination and use of research results. This project aspire to disseminate the approach and work supported by the Maternal and Child Health program in order to give the results greater visibility and reach. This will be accomplished through the evolution of a suite of communication products that disseminate research results and the strategic involvement of grantees in key events to influence policies, practices, agendas, and funding priorities. Funds will also support knowledge translation activities to take advantage of opportunities that enable the mobilization of knowledge into policy processes.\",\n",
       "  '12250. Gihon Laboratorios Quimicos S. R. L. . GIHON LABORATORIOS QUIMICOS S. R. Fifty. . to manufacture a twelve - month stockpile of thimerosal to be used in the case of an unexpected change in policy or unavailability of thimerosal ware, ensuring the continuous production and conservation of human and veterinary vaccines',\n",
       "  '12182. Phenotypic picture of non - smoke COPD. PHENOTYPIC CHARACTERISATION OF NON - SMOKING COPD. Medical Research Council. Research Duncan grant to study chronic obstructive pulmonary disease in India',\n",
       "  '12262. IVCC. IVCC. to support the Product Development Partnership to eliminate transmission of mosquito - borne pathogens through improved insect transmitter control with advanced products',\n",
       "  \"12110. Contributions of Global Health Diplomacy to Health Systems in Sub - Saharan Africa: Evidence and Information to Support Capabilities for Health Diplomacy. CONTRIBUTIONS OF GLOBAL HEALTH DIPLOMACY TO HEALTH SYSTEMS IN SUB - SAHARAN AFRICA: EVIDENCE AND INFORMATION TO SUPPORT CAPABILITIES FOR HEALTH DIPLOMACY. Health is suit a core feature of global negotiations, whether they relate to trade, economic growth, or social development. New research will help boost Africa ' s bargaining power in global health diplomacy, The term global health diplomacy has been coined to describe the multidisciplinary work related to diplomacy, public policy, and global health. But an underlying North - South divide exists in this area, leaving Africa - and sub - Saharan Africa in particular - at a disadvantage. Although the region is highly integrated in the global economy, it has little bargaining power in such high - level negotiations. In health, for example, this has consequences when global level agreements and negotiations limit the space for national policy decisions on the development and strengthening of equitable health systems. This research aims to examine and communicate the most important elements countries need to assert their public health interests in global wellness diplomacy from an African perspective. The research will look at three examples of global health diplomacy important to sub - Saharan Africa: 1) the implementation of the World Health Organization ' s Code on International Recruitment of Health Personnel; 2) new collaboration on access to essential drugs through South - South relationships involving Africa, China, Brazil, and India; and 3) the involvement of African actors in getting universal access to prevention, treatment, and care for HIV and AIDS. The research will be led by the African - based organization EQUINET / Training and Research Support Centre, working with the Eastern African Trade Information and Negotiations Institute. Research teams conducting the case studies will be selected through an open call. African policymakers, knowledge brokers, and other key stakeholders will be involved throughout the research process. Expected outcomes of the research include some 200 publications consisting of background literature reviews, in - depth case studies, and scientific publications in international peer - reviewed journals that will be posted on the EQUINET website. African policymakers and other relevant actors will be exposed to the arguments, methods, and challenge of global health diplomacy so they can engage more effectively in this emerging field.\",\n",
       "  '12182. MICA: Immunotherapy for oral cancer prevention and handling. MICA: IMMUNOTHERAPY FOR oral examination crab bar AND TREATMENT. GCRF Foundation NCDs 2016 Immunotherapy for oral cancer prevention and treatment. by constructing plant computer virus - based vaccines, using technologies developed for preclinical testing for the prevention of oral cancers. Ideally suited for healthcare delivery in low and middle income countries',\n",
       "  '12262. Alliance for Emerging and Re - emerging Infectious Diseases Threats in Asia Foundation. ALLIANCE FOR EMERGING AND RE - EMERGING INFECTIOUS DISEASES THREATS IN ASIA FOUNDATION. to demonstrate a reduction in community - level malaria incidence expend a spatial repellant interference',\n",
       "  '13040. HIV Care Research Programme / Follow up of slow disease progressors and of individuals on long term ART. HIV CARE enquiry PROGRAMME / FOLLOW UP OF SLOW DISEASE PROGRESSORS AND OF INDIVIDUALS ON LONG TERM ART. Checkup Research Council. Intramural Grant to undertake clinical trials or longer term follow up for new care regimes for HIV',\n",
       "  '12250. Janssen Vaccines & Prevention B. Phoebe. . JANSSEN VACCINES & PREVENTION B. V. . to execute pre - clinical immunogenicity studies to determine if inactivated acute anterior poliomyelitis vaccine (IPV) derived from PER. C6 produced virus has the biological properties that would justify investments in farther development',\n",
       "  '12250. Demonstration projects for innovative health research and development. DEMONSTRATION PROJECTS FOR INNOVATIVE HEALTH RESEARCH AND DEVELOPMENT. A major global health concern is the gap in research and development (R & D) of medical products against diseases disproportionately affecting poor people in developing countries. The World Health Organization (WHO) has selected several novel R & D projects. Through innovative approaches to coordination and financing of R & D, they aim to develop a series of cost - good diagnostic kits and discussion for disease such as leishmaniasis.',\n",
       "  '13030. Support to the IMPT. SUPPORT TO THE IMPT. The Initiative for Multipurpose Prevention Applied science (IMPT) works to advance the development of products that simultaneously address the interconnected risks of HIV, other sexually transmitted infections (STIs ), and unintended pregnancy. Comprised of members from across disciplines and more than 15 countries, the IMPT is the central body that researchers, product developers, funders, policymakers, and advocates rely on for objective technical guidance and strategic planning related to MPTs. By facilitating interdisciplinary partnerships, the IMPT enables experts from across the family planning, HIV, and STI fields to strategize around the unique technological, market access, and regulatory challenges presented by developing combined prevention, thus refining the pathway to impactful MPT development. The objective of the project is to support the IMPT Secretariat in its role as the product - neutral coordinator of the MPT field.',\n",
       "  '12250. International Centre for Diarrhoeal Disease Research, Bangladesh. INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH, BANGLADESH. to develop a universally accepted communications protocol for prevention, diagnosis and intervention of Environmental Enteropathy',\n",
       "  '12182. Former Prospective Studies (A6, A10 ). OTHER PROSPECTIVE field of study (A6, A10 ). Early Prospective Studies (A6, A10 )',\n",
       "  '12250. Medicines for Malaria Venture (MMV ). MEDICINES FOR MALARIA VENTURE (MMV ). The pharmaceutical industry has largely withdrawn from the active pursuit of new drug for malaria. The extremely high costs involved in discovering, developing and registering pharmaceutical products to current regulatory standards (800 million to 1. 2 billion U $ per drug) requires that the returns on drug sales be very gamey to be commercially justified. Between 1975 and 2004, only eight verboten of 1556 new registered drugs were antimalarials. This long standing sluggishness in drug Research and Development (R & D) of antimalarials has emerged as a critical global public health issue.',\n",
       "  '12262. Wistar Institute of Anatomy & Biology. WISTAR INSTITUTE OF figure & BIOLOGY. to develop new synthetic DNA vaccines encoding design CSP antigens to allow a new generation advanced CSP component for a prophylactic malaria vaccinum',\n",
       "  '12250. PATH. track. to develop safer, novel, univalent oral infantile paralysis vaccines against poliovirus type 1 and 3 for outbreak use',\n",
       "  '12250. Jomo Kenyatta University of Agriculture and Technology. JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND engineering. to ensure quality vaccines are useable when needed by developing an application along with blockchain technology to monitor the supply chains delivering vaccines from producers to health workers',\n",
       "  '12250. Sirenas, LLC. SIRENAS, LLC. to bring forth a set of other leads from marine born products with promise in neglected diseases, with a specific focus on tuberculosis (TB ), malaria and cryptosporidium',\n",
       "  '12262. Genome - wide association studies to map genetical variation underlie mosquito susceptibleness to human 12262aria. GENOME - WIDE ASSOCIATION STUDIES TO MAP GENETIC VARIATION UNDERLYING MOSQUITO SUSCEPTIBILITY TO HUMAN 12262ARIA. Genome - all encompassing association studies to map genetic variation underlying mosquito susceptibility to human 12262aria',\n",
       "  '12262. MICA: Development and GMP manufacture of a PfRH5 protein vaccine to induce strain - transcending immunity against blood - stage Plasmodium falciparum. . isinglass: DEVELOPMENT AND GMP MANUFACTURE OF A PFRH5 PROTEIN VACCINE TO INDUCE STRAIN - TRANSCENDING IMMUNITY AGAINST ancestry - STAGE PLASMODIUM FALCIPARUM. . Medical Research Council. Enquiry grant to develop new malaria vaccine candidate',\n",
       "  \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brasil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three country by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Player will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scaled up in other high - risk area of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       "  '13040. California Institute of Engineering. golden state INSTITUTE OF TECHNOLOGY. to develop reagents for HIV - 1 based diagnostics that are high performance, and are also stable in harsh environments, with architectural plan to adapt those reagents into multiplexed and quantitative point - of - care diagnostics platforms',\n",
       "  '12250. Funding for scientist exchanges, duncan grant. FUNDING FOR SCIENTIST EXCHANGES, GRANTS. Vasco da gamma delta T - lymphocytes and the role of galectines in the pathogenesis of THLV1 - associated diseases - Capacity building in the field of education and research',\n",
       "  '12262. PERSONALISING ANTI MALARIA THERAPY THROUGH HAND - HELD POINT OF CARE NANOTECHNOLOGY DEVICES. . PERSONALISING ANTI MALARIA THERAPY THROUGH HAND - HELD POINT OF CARE NANOTECHNOLOGY DEVICES. . Aim: to test the first point of care application of drug resistance molecular markers for optimal antimalarial treatment, through a novel nanotechnology - based device with the potential of allowing optimal, personalized, malaria chemotherapy. Three studies: 1 - lab fine tuning of the hand - held device for point of care parasite analysis in terms of specificity and sensitivity for genetic polymorphism call, vs established methods; information feedback to the technology developers for machine optimization. The device will fastly genotype the parasite prior to treatment, giving information for optimal ACT choices. 2 - The force field (Mali ): an artemether - lumefantrine (AL) vs artesunate - amodiaquine (ASAQ) efficacy trial will be conducted in high transmission regions of Mali. The pfmdr1 N86Y mutation will be used as the reference (86N allele: resistance to AL; 86Y allele: resistance to ASAQ ). In one arm the infection is genotyped. If 86Y, it represent treated with AL, if 86N, with ASAQ. In another arm AL and ASAQ are used randomly without support information, in accordance to the national guidelines for the treatment of unsophisticated malaria. An increased in efficacy, as well as decreased selection of resistance associated alleles is expected at arm1. 3 - Finally, the output of the trial will be re - analysed with reference methods (PCR - RFLP, direct PCR amplicon sequencing) for the post - hoc evaluation of the specificity and sensitivity of the device in the field conditions',\n",
       "  '13040. University College London. UNIVERSITY COLLEGE LONDON. to model the population level effects of availability of likely young HIV diagnostic technology with defined specifications in order to generate a quarry product visibility for one or more potential new diagnostic tools',\n",
       "  '12250. AJ Vaccines A. Sec. . AJ vaccine A. S. . to get and clinically test economically donor - friendly adjuvanted trivalent Inactivated Polio virus (IPV) vaccines with reduced IPV doses',\n",
       "  '13040. General Hospital Corporation d / b / a Massachuset Full general Hospital. GENERAL HOSPITAL CORPORATION D / Bacillus / A MASSACHUSETTS GENERAL HOSPITAL. to support a genetical approach to optimizing the antigenicity of HIV - ane envelope immunogens',\n",
       "  '12262. Improving Malaria Diagnostics (IMaD) - Malaria. IMPROVING MALARIA nosology (IMAD) - MALARIA. Under IMaD, MCDI and its partners act upon to improve laboratory - based diagnosis of malaria (primarily at Ministry of Health facilities ), and to increase understanding, acceptance, and right habit of microscopy and Rapid Diagnostic Tests (RDTs) by laboratory staff and health care practitioners providing direct care to patients.',\n",
       "  '12182. VACCINE - Development of novel picornavirus virus - like particle vaccines. VACCINE - evolution OF NOVEL PICORNAVIRUS VIRUS - LIKE PARTICLE VACCINES. IIB - Research Boards Sept / Oct 2016 - RM 2017 award to apply Virus - like particles (VLPs) to causative agents of human bridge player, foot and mouth disease which are of interest as novel vaccines to reduce outbreaks impact children in South East Asia',\n",
       "  '12250. VillageReach. VILLAGEREACH. to improve vaccine availability, safety, and cost - efficiency of immunisation supply chains by accelerating the transition of modernistic, next - generation immunization supply chains across Gavi - eligible countries',\n",
       "  '12182. Cluster randomised controlled trial for late life history depression in socioeconomically deprived areas of Spo Paulo, Brazil. CLUSTER RANDOMISED CONTROLLED TRIAL FOR LATE life story DEPRESSION hoosier state SOCIOECONOMICALLY DEPRIVED AREAS OF S + O PAULO, BRAZIL. Medical Research Council GH trial to look at treatment for depression in older adults in Brazil',\n",
       "  \"13040. DSO PDP womens condom (PATH ). DSO PDP woman CONDOM (PATH ). PDP Subsidie voor PATH Programma ' Protection Options for Women ' (prisoner of war) 2011 - 2014\",\n",
       "  \"12263. Two - month Regimens Victimization Novel Combinations to Augment Treatment Effectiveness for drug - sensitive Tuberculosis: the ' TRUNCATE - TB ' trial. TWO - MONTH REGIMENS USING NOVEL COMBINATIONS TO AUGMENT TREATMENT EFFECTIVENESS FOR DRUG - SENSITIVE TUBERCULOSIS: THE ' TRUNCATE - TB ' TRIAL. Medical Research Council Joint (MRC / WT / DfID) Global Wellness Trial grant to test the effectiveness of shorter TB treatment regimens in Viet Nam, Myanmar, India, China, Indonesia, Philippines, Malaya\",\n",
       "  '12263. Public Health England. PUBLIC HEALTH ENGLAND. to contrive and repurpose from existing facilities a capability to perform large - scale studies using a natural transmission infection model of tb',\n",
       "  '12182. Efficacy of mobile earphone brusk message service (SMS) on malaria treatment adherence and post - treatment review. EFFICACY OF MOBILE PHONE SHORT MESSAGE SERVICE (SMS) ON MALARIA TREATMENT ADHERENCE AND POST - TREATMENT REVIEW. Medical Inquiry Council. Research Grant to trial the use of text electronic messaging to improve malaria treatment adherence',\n",
       "  '12250. PATH. PATH. to provide quantified sampling panel to diagnostic trial run developers being funded by the Bill & Melinda Gates Foundation and perform unbiased evaluations and appraisals of diagnostic technologies upon request',\n",
       "  '12250. Meningitis Enquiry Foundation (MRF ): Action Meningitis. MENINGITIS inquiry FOUNDATION (MRF ): military action MENINGITIS. Meningitis Research Foundation (MRF ): Action Meningitis',\n",
       "  \"12182. Funding through Grand Challenges Canada in support of the Saving Lives at Birth programme  research. FUNDING THROUGH GRAND CHALLENGES CANADA IN SUPPORT OF THE SAVING LIVES AT BIRTH PROGRAMME  RESEARCH. To identify and support transformational approaches to women ' due south and newborns ' health that can be scaled up to reduce deaths and poor birth outcomes for millions of women and newborns in the hardest to reach community of the world.\",\n",
       "  '12250. VACCINOLOGY Research MRC Whole, The Gambia. VACCINOLOGY RESEARCH MRC UNIT, THE GAMBIA. Medical Research Council. Intramural Cary grant for clinical research studies in The Gambia tbit and other infections',\n",
       "  \"12182. Development of oral eflornithine for former - stage African sleeping sickness. DEVELOPMENT OF ORAL EFLORNITHINE FOR LATE - STAGE AFRICAN SLEEPING SICKNESS. The project Sustainable development, Fiscal Policy and Natural Resources Management. Bolivia, Chile and Peru in the Nordic countries ' mirror is a collaborative network of scholars in Europe and Latin America. These researchers will develop a three year project with the aim of consolidate a high quality network in Natural Resources studies in the Sustainable development framework. They will do three workshops, two in Sweden and one in Bolivia. In the planning, there are six clause and one book, written in collaboration between the researchers of this project and with other scholars whom will enhance our proposal. Also, and in the aim to extract lessons from successful countries to the underdeveloped and developing regions, the group will share the results to a broader public and authorities through a web page and periodical policy briefs. The ambition is that the joint work envisaged in this proposal will generate a flexible but consistent research network, which will continue to cooperate in further directions. Specific focus may change, but it will be kept in the general idea of extracting lessons for development from successful experiences of countries that today are both rich and just in comparative international terms.\",\n",
       "  '12262. Seattle Biomedical Enquiry Institute. SEATTLE BIOMEDICAL RESEARCH INSTITUTE. to identify biomarkers of correlates of protection against pre - erythrocytic (PE) malaria infection that will enable down selection of vaccine antigens and predict outcomes of trials for anti - infection vaccines against Plasmodium falciparum',\n",
       "  '12250. University of Calif., Los Angeles. UNIVERSITY OF CALIFORNIA, LOS ANGELES. to support the goals of lid elimination through the development of a demographic model for the Democratic Republic of the Congo',\n",
       "  '12240. Washington State University. capital STATE UNIVERSITY. to good understand how human milk river helps agitate off pathogen in the breastfed infant',\n",
       "  '12263. Administrators of the Tulane Educational Fund. ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND. to build imaging capacity (PET - CT scanning) of the Tulane National Prelate Research Center for TB vaccinum field of study as a part of a serve component of the Collaboration for TB Vaccine Discovery (CTVD )',\n",
       "  '12220. University of Maryland, Baltimore. UNIVERSITY OF md, BALTIMORE. to develop broadly effective vaccines and interventions against enteric infections by conducting multi - country case - ascendance studies using standardized methods to measure the etiology and load of diarrhea among children in uprise countries',\n",
       "  '12250. Basic Science Programme / Analyze the immunological interplay between poverty - relaeted diseases and helminth infection (IDEA Project ). BASIC SCIENCE program / DISSECTING THE IMMUNOLOGICAL INTERPLAY BETWEEN POVERTY - RELAETED DISEASES AND HELMINTH INFECTION (IDEA PROJECT ). Medical Research Council. Intramural Grant for epidemiology and clinical research on infections - worms',\n",
       "  '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will lead off with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       "  '12263. KwaZulu - Natal Research Institute for TB & HIV. KWAZULU - NATAL RESEARCH INSTITUTE FOR TB & human immunodeficiency virus. to investigate the hypothesis that there exists a tipping point for tuberculosis (tebibyte) infection, where cell death of some of the TB infected immune cells which are also responsible for tebibyte control leads to the creation of a new niche for mycobacterial grow',\n",
       "  '12262. Harvard School of Public Health. HARVARD SCHOOL OF PUBLIC HEALTH. to develop a robust in vitro culture system for the human malaria parasite, Plasmodium vivax, that will help biological work and support the design of wellness intervention',\n",
       "  '12250. Vaxess Technologies Inc. . VAXESS technology iraqi national congress. . to support the preclinical development and manufacture of a thermostable microneedle patch with the aim of lowering barriers to vaccine access by simplifying dosing and administration, alleviating cold chain constraints, and lowering costs',\n",
       "  '12250. University of Old dominion. UNIVERSITY OF VIRGINIA. to employ highly sensitive quantitative molecular diagnostics for pathogens to understand the etiology of community diarrhea and the relationship and effects of enteropathogens on healthy increase',\n",
       "  \"13010. Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems. CENTRE OF EXCELLENCE FOR CIVIL REGISTRATION AND VITAL STATISTICS (CRVS) SYSTEMS. Registration of events, such as birth, death, causes of death, marriage, and divorce, is critical for improving maternal, newborn, child, and adolescent health. These statistics provide policymakers and practitioners with the necessary evidence to design interventions and enact appropriate policies on maternal and child health. Many low - and middle - income countries, however, do not systematically collect such crucial information. It is estimated that one - third of the world ' s births and two - thirds of the world ' s deaths are not registered or are incorrectly certified. In many cases, global norms, standards, tools, and good practices are not readily accessible and useable to those who need them most. The project will establish the Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems to provide information, tools, and expertise to facilitate the development and implementation of integrated CRVS systems. Funded by Global Affairs Canada and the International Development Research Centre (IDRC ), and based at IDRC, the Centre of Excellence will coordinate with existing expert groups to generate, consolidate, and share information and resources in an open and collaborative electronic platform. It will also assist countries needing more direct support by facilitating the exchange of good practices and capability strengthening, and will play an important purpose brokering technical assistance for countries needing more direct support. The Centre of Excellence will work closely with the Global Financing Adroitness in support of the Every Woman Every Small fry go ahead to enable the development and implementation of CRVS systems plans as part of country - led investment cases for financing by the Global Financing Facility.\",\n",
       "  '12262. JSI Enquiry & Training Institute, Inc. . JSI RESEARCH & education INSTITUTE, INC. . to demonstrate and document the how - to of at - scale delivery of accessible intermittent preventative treatment of malaria in pregnancy (IPTp) and the expected ancillary welfare of a reduction in the prevalence of low birthweight and in stillbirths',\n",
       "  '12250. Institut Pasteur de Dakar. INSTITUT PASTEUR DE DAKAR. to improve disease diagnosis and assist researchers in low - resource settings by developing a platform for real - time remote sensing and monitoring of specimens during transport from health centres to laboratories',\n",
       "  '13040. Support to the IMPT. SUPPORT TO THE IMPT. The Initiative for Multipurpose Prevention Technologies (IMPT) works to advance the development of products that simultaneously address the interconnected risks of HIV, other sexually transmitted infections (STIs ), and unintended pregnancy. Incorporate of members from across disciplines and more than 15 countries, the IMPT is the central body that researchers, product developers, funders, policymakers, and advocates rely on for objective technical guidance and strategic planning related to MPTs. By facilitating interdisciplinary partnerships, the IMPT enables experts from across the family planning, HIV, and STI fields to strategize around the unique technological, market access, and regulatory challenges presented by developing combined bar, thus refining the pathway to impactful MPT development. The objective of the project is to support the IMPT Secretariat in its role as the product - neutral coordinator of the MPT field.',\n",
       "  '12250. PATH. PATH. to identify the best in class nucleic acid extraction technologies that may better enable diagnosis of disease at the spot - of - aid',\n",
       "  '12182. This programme in the Ross Fund Portfolio (which focusses on neglected tropical diseases, diseases of emerging resistance and disease of epidemic pot. THIS PROGRAMME IN THE ROSS FUND PORTFOLIO (WHICH FOCUSSES ON NEGLECTED TROPICAL DISEASES, DISEASES OF EMERGING RESISTANCE AND DISEASES OF EPIDEMIC POT. This programme in the Ross Fund Portfolio (which focalise on neglected tropic diseases, diseases of emerging resistance and diseases of epidemic potential) aims to build the evidence based on effective interventions and delivery mechanisms to tackle inf',\n",
       "  '12182. Cooperation with foreign research institutions (not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (NOT INCLUDED atomic number 49 OTHER AREAS ). Systems biology study of the effect of antimicrobial heart using integrative OMICs data analysis - Capacity building in the field of education and research',\n",
       "  '12182. EDCTP2: European & Dev. Countries Clinical Trials Partnership 2015 - 2019. EDCTP2: EUROPEAN & DEV. COUNTRIES CLINICAL TRIALS PARTNERSHIP 2015 - 2019. Support to European and Developing Countries Clinical Trials Partnership to accelerate development of new or improved druugs, vaccine, microbicides and diagnostics against HIV / AIDS; TB and malaria. Reenforcement provided since 2004. A new expanded programme is planned within Horizon2020 which leave be called EDCTP2.',\n",
       "  '12182. Miscellaneous in the area of international understanding. MISCELLANEOUS IN THE arena OF INTERNATIONAL UNDERSTANDING. Collaborative task - Development of a cost - efficient vaccine against cervix carcinoma - a prophylactic approach, sub - project - Development of cleaned antigens and evaluation of immunogenicity - Knowledge Transferral',\n",
       "  '13040. Cryptococcal meningitis: addressing an urgent global health problem using a translational pharmacologic approach. CRYPTOCOCCAL MENINGITIS: ADDRESSING AN URGENT GLOBAL HEALTH job USING A TRANSLATIONAL PHARMACOLOGICAL APPROACH. Checkup Research Council. Research Grant to develop new drugs against cryptococcus a major secondary infection of HIV in LMIC',\n",
       "  '12182. Development of an improved, single - strain, locally produced oral epidemic cholera vaccine. DEVELOPMENT OF AN IMPROVED, SINGLE - STRAIN, LOCALLY PRODUCED ORAL CHOLERA VACCINE. We have previously been deeply involved in the development of the internationally available, closely related oral cholera vaccines (OCVs) Dukoral  and Shanchol . These vaccines are effective, but the use of several strains and two inactivation methods makes their manufacture complex and relatively expensive, and OCVs are therefore still severely underused globally. In developing a new generation of OCVs, a central aim is to make it affordable for the populations in greatest need. This can be achieved by simplifying manufacture whilst maintaining the levels of protection afforded by currently available OCVs. Using a single vaccine strain and one inactivation method would considerably simplify and reduce the cost of manufacture. We have recently developed a novel concept and also engineered a new type of vaccine strains for such a new generation of OCVs, whereby the several V. cholerae O1 components in Dukoral and Shanchol can be replaced by a single - mental strain / single - formulation component with full retention of protective immunogenicity. We now propose, in collaboration with partners in India and Bangladesh, (1) to develop this novel single - strain OCV prototype combined with recombinantly produced cholera toxin B subunit into a truly low - cost, and also thermo - and pH - stable vaccine formulation for worldwide use including stockpiling purposes. A first - generation of the new OCV is planned to go into clinical testing in Bangladesh in early 2017 with product approval hoped for already in 2018 / 19. In parallel, (2) we will also develop a second - generation OCV formulation, which by including a novel cholera - toxin - derived mucosal adjuvant may provide adequate protection after single - dose administration, a feature which would be especially valuable for use in cholera outbreaks. The projected novel, low - cost, thermo - and pH - stable vaccine can be produced at a fraction of the cost of current vaccines, and should equal attractive for worldwide use including stockpiling purposes. Relevant countries: Most countries in South and South - East Asia, the same for Sub - Saharan Africa, and selected low - income countries in the Western hemisphere, e. g. Haiti, Dominican rep.',\n",
       "  '13040. Vindico NanoBioTechnology Inc. . VINDICO NANOBIOTECHNOLOGY INC. . to develop a vaginal gel that apply nano - sacs called polymersomes, which can control the delivery of spermicides as a contraceptive and other sexually transmitted agents',\n",
       "  '12250. Two Stoma Guys. TWO PORE GUYS. to assess novel, low price nucleic acrid detection engineering for use in low imagination settings',\n",
       "  '13040. Doctoral Awards to Strengthen Sub - Saharan Africa Leadership in HIV Prevention Research. DOCTORAL AWARDS TO STRENGTHEN SUB - SAHARAN AFRICA LEADERSHIP IN HIV PREVENTION RESEARCH. Africa remains the region most affected by the AIDS epidemic and HIV / AIDS prevention remains a global health priority. This project supports the emergence of African HIV scientists able to lead high quality multidisciplinary HIV prevention and vaccine research to fight the biomedical, social and behavioral factors that underpin the epidemic. It will increase access to high - quality academic and professional trainings for doctoral and post - doctoral students in sub - Saharan Africa. Benefiting competitively selected students at a point in their careers when support is often lacking, it will facilitate the transition from research team member to research leader. The chosen institutions will also benefit, as funds to attract post - doctoral students are rare and hosting post - doctoral students can present a great opportunity for African universities and institutions. This project builds and strengthens the sustainability of the Global Health Research Initiative program entitled HIV / AIDS Prevention Trials Capacity Building Grants Phase 2 program. The program is co - funded by IDRC and Foreign Affairs, Trade and Development Canada (DFATD) with the goal of helping to create sustainable African capacity and leadership to conduct future HIV / AIDS prevention trials. In keeping with this goal, this project will support doctoral and post - doctoral awards in Africa.',\n",
       "  '12110. Strengthening Fairness through Applied Research Capacity Building in e - Health. STRENGTHENING EQUITY THROUGH APPLIED RESEARCH CAPACITY BUILDING inch E - HEALTH. There exists limited understanding of how e - Health solutions are perceived, designed, implemented and used. This goes beyond considerations related to automation, power supplies and affordability. Rather, it refers to context - specific, politically - aware and socially sensitive examination of how various ICTs are being appropriated, world health organization is being included and excluded in the process, and whether the incorporation of ICTs is leading to to a greater extent equitable health outcomes. The Strengthening Equity through Applied Research Capacity Building in e - Health (SEARCH) program will school local research capacity to examine e - health and whether it leads to improved health equity and stronger health systems. Emphasis will be placed on methodological and analytical rigor, and policy dialogue. The first phase of SEARCH will involve scoping studies and workshops, with will elaborate the research agenda for the remainder of the program.',\n",
       "  '12182. Study of disease mechanisms in enteric fever to qualify innate & adaptive immunity in mucosa & blood in controlled human infection model. STUDY OF DISEASE MECHANISMS IN ENTERIC FEVER TO CHARACTERISE INNATE & ADAPTIVE IMMUNITY IN MUCOSA & BLOOD IN CONTROLLED HUMAN INFECTION MODEL. Medical Research Council. Enquiry Grant to investigate disease mechanism and immune mechanisms during gut infection',\n",
       "  '13040. Applied science for Health Program - HIV / AIDS. TECHNOLOGIES FOR HEALTH PROGRAM - human immunodeficiency virus / AIDS. Technologies for Wellness Computer program',\n",
       "  '12263. FIND. FIND. to enable accelerated research and development of ground - break TB diagnostic tools that are suitable for use at low levels of care in resource - limited countries',\n",
       "  '12182. Cooperation with foreign research institutions (in so far as not included in former areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (IN SO FAR AS NOT INCLUDED IN OTHER AREAS ). Glycoproteomics Network - Biomarkers for human disease',\n",
       "  '12250. California Institute of Technology. golden state INSTITUTE OF TECHNOLOGY. to develop a Micro? Electro? Mechanical System as a portable and dependable microbic monitoring system that can be integrated into safe and sustainable sanitation solutions in the underdeveloped world and enable onsite testing for pathogens',\n",
       "  '12182. Support to scientific research of Institute of Tropical Medicine (convenant with the Flemish government ). SUPPORT TO SCIENTIFIC RESEARCH OF INSTITUTE OF TRO. The Institute of Tropical Medicine in Antwerp, Bel',\n",
       "  '12261. University of Massachusetts. UNIVERSITY OF MASSACHUSETTS. to convert the energy contained in human waste into electricity and remove the organic matter and nutrients that devolve ecosystems and permit pathogens to persist in water using a modular Microbial Fuel Cell (MFC) designed to retrofit live compost',\n",
       "  \"12110. International Vaccinum Institute. INTERNATIONAL VACCINE INSTITUTE. to support find, development and delivery of proven life - save technologies to suffer the unmet needs of the world ' s poorest populations\",\n",
       "  '12220. Zvitambo Institute for Maternal and Child Health Inquiry. ZVITAMBO INSTITUTE FOR MATERNAL AND CHILD HEALTH RESEARCH. to bring home the bacon causal evidence for the independent and combined effects of interrupting fecal ingestion and optimizing infant dietary quality on stunting and anaemia at 18 months',\n",
       "  '12240. University of Leeds. UNIVERSITY OF LEEDS. to explore the mechanistic pathways by which aflatoxin, a frequent food for thought fungal metabolite, may lead to child growth faltering in sub - Saharan Africa. Relevant biomarkers will be identified for applications in child age bracket and intervention studies',\n",
       "  '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) health care delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the realm. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       "  '13040. Oregon Wellness & Scientific discipline University. OREGON HEALTH & SCIENCE UNIVERSITY. to provide fundamental research on a new type of vaccine - elicited CD8 + T cell immunity with the potential to control and clear HIV, and therefore to enable development of a safe and effective human immunodeficiency virus / AIDS vaccinum for use in high burden countries',\n",
       "  '12263. GlaxoSmithKline Biologicals. GLAXOSMITHKLINE BIOLOGICALS. to provide a newfangled dimension to vaccine development for malaria and tuberculosis (TB) by deeper analysis of transcriptomics data that are being generated in clinical study, by boost collaboration between different partners involved in Systems Biology',\n",
       "  \"12263. DSO PDP terabyte Vaccins (AERAS ). DSO PDP TB VACCINS (AERAS ). 2011 - 2014 PDP subsidie AERAS ' Developing and Licensing Improved Tuberculoses Vaccines for Use in High Burden Countries '\",\n",
       "  '12182. MICA: Ad4HIV, A Phase I Trial Investigating Ad4, MVA and Protein Immunisation Strategies to Maximise Protective Antibody Responses to HIV - 1 Envelope. MICA: AD4HIV, A PHASE I TRIAL INVESTIGATING AD4, MVA AND PROTEIN IMMUNISATION STRATEGIES TO MAXIMISE PROTECTIVE ANTIBODY RESPONSES TO HIV - 1 ENVELOPE. Medical Research Council / DPFS grant on acquire new vaccine candidates against HIV',\n",
       "  '12182. BIOBASED SCAFFOLDS, MEMBRANES AND HYDROGELS FOR IMPROVED WOUND HEALING AND BONE REGENERATION (BIOHEAL ). BIOBASED SCAFFOLDS, MEMBRANES AND HYDROGELS FOR IMPROVED WOUND HEALING AND BONE REGENERATION (BIOHEAL ). In 2012, one in eight deaths worldwide resulted from air pollution. For Africa lack of data is a barrier to estimate effects. Satellite images indicate detrimental levels, but monitoring and high resolution outdoor air pollution modelling is lacking. Household air pollution is also a major source of pic, more knowledge on how different cook stoves, fuels and habits affect picture is crucial. No high quality study of the effect of outdoor and indoor air pollution on pregnant women in Africa has so far been conducted. We will investigate consequences of air pollution in a prospective cohort of women recruited during pregnancy at public health facilities in Ethiopia. Outdoor air pollution will be assessed by high quality modelling which combines measurements with Geographical Information System tools and aerial and topographical imaging. Individual exposure will be linked to the model by residential address. Indoor exposure will be assessed by questionnaires and validated by measurements. Emission factors from different fuels and cooking methods, and particle characteristics will be assessed in our Aerosol Lab in Lund. Data on gestation outcomes, photograph and confounders will be compiled and epidemiological studies on the effect of outdoor and household air pollution on pregnancy complications will be done. This study, which will increase knowledge of not only health impact but also of source characteristics, will provide important knowledge for appropriate policy making.',\n",
       "  '12250. European & Rise Countries Clinical Trials Partnership. EUROPEAN & DEVELOPING COUNTRIES CLINICAL test PARTNERSHIP. Medical Research Council. Partnership Contribution to a multi nation activity to support large scale multi land trials of new vaccines and drugs against infections in Africa.',\n",
       "  \"12110. The West Africa Initiative to Strengthen Capacities through Health Systems Research. THE WEST AFRICA INITIATIVE TO STRENGTHEN CAPACITIES THROUGH HEALTH SYSTEMS RESEARCH. West Africa has many of the lowest development indicators in the world - 10 of the 15 member states of the West African Community number among the world ' s 35 low - income countries. The World Health Organization reports that 14 of the member states have a high maternal mortality ratio, defined as 300 or more maternal deaths per 100, 000 live births. These grim statistics tell the story of a region facing dysfunctional health and social services with a limited capacity to conduct research that informs sound health policies and practices. Of the health research that is undertaken in the region, much is done in isolation, and findings are non shared operating room disseminated across governments or health systems. The result: synergies across findings are not made and links between researchers and decision - makers are often weak. This project sets the foundation for producing and using rigorous and relevant evidence to strengthen equitable and sustainable health systems in West Africa. Four teams will be funded through a call for proposals focusing on research on how to strengthen health systems in West Africa. A group of leaders with regional expertise will be mobilized and supported to advise on the call and guide the overall project. The project will also help the West African Health Organisation, a respected stakeholder and the mandated body coordinating efforts to improve health in the region, promote interest in the call and encourage the use of research findings by ministers of health from member countries. Research results will be disseminated through a special issue of a peer - reviewed journal, insurance briefs, and articles to further inform health policy and practice in West Africa.\",\n",
       "  '13040. Microbicide Inquiry, Development, and Unveiling, Beat 3. MICROBICIDE RESEARCH, DEVELOPMENT, AND INTRODUCTION, ROUND trinity. Microbicide Research, Development, and Introduction, Round 3',\n",
       "  \"12250. Intersectoral Municipal Leadership for Health in Latin America. INTERSECTORAL MUNICIPAL LEADERSHIP FOR HEALTH IN LATIN AMERICA. This project aims to build ecohealth leadership at the municipal level in Colombia and Venezuela to address wellness priorities, including vector - borne diseases and food systems interventions for non - communicable disease prevention. Dengue fever and chikungunyaIn Colombia and Venezuela, research and governmental institutions from the Latin American Ecohealth Leadership Consortium on Vector - borne Diseases have decreased Aedes mosquito populations significantly through municipal interventions. This mosquito is responsible for transmitting two viral diseases: dengue fever and chikungunya. Dengue and chikungunya interventions will be scaled up in three affected municipalities. Both diseases are responsible for rapidly growing health and economic burdens in the two countries. The project is expected to generate new knowledge on factors affecting policy adoption and scaling up: - institutional capacity gaps - early involvement and leadership of municipal players - good governance - costs - validating impact on disease incidenceThe evidence should help researchers and governments replicate the project at a larger scale. National and municipal governments and the World Health Organization are providing co - funding for the project. Food systems, healthy diet, and incentivesThe food systems and healthy diets study will take place in a rural municipality of Colombia. This region has one of the highest agricultural outputs in the country. However, it also has high rates of malnutrition among children and obesity in adult populations. The study will analyze local factors associated with the rising of obesity and diabetes, such as food systems and lifestyle determinants that favour unhealthy diets in rural areas. In the study ' s second step, researchers will pilot test an inter - sector approach. The aim is to promote municipal regulatory incentives for food and health systems, and community and workplace environments. Researchers will use a participatory methodology that involves multi - sector municipal committees, together with qualitative and quantitative methods. Testing ways to decrease diseasesThe project will analyze the feasibility, cost - effectiveness, and sustainability of scaling up interventions aimed at dealing with two emerging mosquito - borne diseases. The food and healthy diets study will analyze the basic food basket per home, family anthropometric indicators for nutritional position (underweight, stunting, etc. ), feeding habits, and blood glucose levels. The project is expected to contribute to - stronger municipal players acting as public health leaders - effective scaled up solutions that decrease dengue and chikungunya incidence rates - municipal inter - sectoral approaches that contribute to preventing obesity and diabetes\",\n",
       "  '12262. A trial of the benefit of including azithromycin in the drug combination habituate for seasonal malaria chemoprevention in African children. A TRIAL OF THE BENEFIT OF INCLUDING AZITHROMYCIN IN THE DRUG COMBINATION USED FOR SEASONAL MALARIA CHEMOPREVENTION IN AFRICAN CHILDREN. Medical Research Council. Research Grant to trial malaria treatment strategies',\n",
       "  '12182. Improving HIV testing and care for adolescents in Zimbabwe: A targeted, community - based approach. IMPROVING HIV TESTING AND forethought FOR adolescent IN republic of zimbabwe: A TARGETED, COMMUNITY - BASED advance. Medical Research Council / DFID Research Grant Adolescent Health in LMICs Improving HIV testing and care for adolescents in Zimbabwe: A targeted, community - based approach',\n",
       "  '12262. Seattle Biomedical Research Institute. SEATTLE BIOMEDICAL RESEARCH INSTITUTE. to identify and produce new liver stage (LS) - aim interventions against malaria and interrogate underlying biology using novel check and model systems',\n",
       "  '12250. Georgia Tech Research Corporation. GEORGIA TECH RESEARCH CORPORATION. To improve candidate drug testing and evolution for lymphatic filariasis parasite infections by develop a model of a human lymphatic vessel to support adult - stage lymphatic filariasis parasites in vitro.',\n",
       "  '12263. Miscellaneous Disease - related and Inter - disease Focuses. MISCELLANEOUS DISEASE - RELATED AND INTER - DISEASE FOCUSES. The Project will embody carried out in the framework of the EDCTP funded undertaking Epidemiology of PZA underground in TB Clinical trials in Africa  an essential prerequisite for evaluating novel TB drug combinations.',\n",
       "  '13040. West African Platform for HIV Intercession Research (WAPHIR ). WEST AFRICAN PLATFORM FOR HIV INTERVENTION RESEARCH (WAPHIR ). This grant will establish a West African - driven partnership with Canadian and European collaborator to enhance HIV research and carry out clinical trials in STnTgal (UniversitT Cheikh Anta Diop ), the Gambia (Medical Research Council) and Guinea Bissau (Bandim Health Project ). The partners will jointly finagle and share their cohort and bio - resource data, thereby providing access to an expanded HIV population. The project will involve constructing a unified database, reinforcing the existing laboratory infrastructure, providing training in clinical trial support, and applying social science research in support of intervention preparedness and evaluation. The project will also offer specialized grad student training with a view to building African research leadership in the management of clinical trials.',\n",
       "  '12262. Global Health Innovative Technology Fund. GLOBAL wellness INNOVATIVE TECHNOLOGY FUND. to recrudesce new wellness technologies as a effect of funding and development collaborations with Nipponese industry and government',\n",
       "  '12263. Infectious Disease Research Institute. INFECTIOUS DISEASE RESEARCH INSTITUTE. to identify new leads and new drug targets for tuberculosis suitable for further drug ontogenesis with the ultimate goal of produce new drugs to treat t.b.',\n",
       "  '12263. TuBerculosis Vaccine Go ahead. TUBERCULOSIS VACCINE INITIATIVE. to improve tuberculosis control by developing and introducing new technologies to prevent, name and treat the disease',\n",
       "  '12250. Global Health Innovative Engineering Fund. GLOBAL HEALTH INNOVATIVE TECHNOLOGY FUND. to develop new health technologies as a result of funding and development collaborations with Nipponese industry and authorities',\n",
       "  '12262. Common disease. COMMON DISEASES. Malaria Vaccinum Development - two European & Developing Countries Clinical Trials Partnership (EDCTP) project - Medical research of particular importance for Developing Country',\n",
       "  '12182. BIOLOGICAL IMPLICATIONS OF POLYPARASITISM AND MALNUTRITION. BIOLOGICAL IMPLICATIONS OF POLYPARASITISM AND MALNUTRITION. The outcome of an infection is influenced by multiple genetic and environmental factors. How the combined impact of more than one factor influence infection is at large unknown in both humans and experimental models. Intestinal parasitic infections are the rule sort of than the exception in poor rural communities, where clean water, proper housing and sewage systems are not available allowing a continuous transmission of helminths and other water - born infectious organisms. In this project we aim to see how gastro - intestinal parasitic infections influence and are influenced by nutritional status and if the combination of malnutrition and intestinal parasitic infection is a risk factor for development of trypanosomal disease in humans. In animal models we will explore how the combination of gastrointestinal infection and malnourishment influences the outcome of Leishmania and Trypanosoma cruzi infection, two related parasitic infections, which are endemic in Bolivia. The project will be divided into two parts, in Bolivia clinico - epidemiological studies will provide information on nutritional status and how this correlates with polyparasitism and different immune parameters. The other part, which primarily will follow conducted at Karolinska Institutet, Sweden, is an experimental animal set up, where the impact of the most common nutritional deficiencies of poor populations can be tested on trypanosome infections in a mono or polyparasitic context.',\n",
       "  '13040. Microbial translocation and immune activation  a substudy of the COSTOP trial. MICROBIAL TRANSLOCATION AND IMMUNE ACTIVATION  A SUBSTUDY OF THE COSTOP test. Medical Research Council. Intramural Duncan grant for an immunology study of human immunodeficiency virus patients',\n",
       "  '13030. Hervana Bio. HERVANA BIO. to further test a biological vaginal conceptualisation to go far at a long - playacting, safe, and effective contraceptive that is ready for rating in human trials',\n",
       "  '12263. FIND. FIND. To enable accelerated research and development for new diagnostic tools that are suitable for use at the full stop - of - care (POC) in resource - modified endemic countries and can serve to diagnose patients who equal currently difficult to name (i. e. patients wh',\n",
       "  '13040. Magee - Womens Inquiry Institute and Foundation. MAGEE - WOMENS RESEARCH INSTITUTE AND FOUNDATION. to place changes in HIV - aim cells occuring in the genital tract of women initiating hormonal contraceptive method',\n",
       "  '12250. Randomised trial of HPV vaccination for the control of HPV - related diseases in HIV positive African populations: Preparatory phase. RANDOMISED TRIAL OF HPV VACCINATION FOR THE CONTROL OF HPV - RELATED DISEASES IN HIV positive degree AFRICAN POPULATIONS: PREPARATORY PHASE. Medical Inquiry Council. Research Grant for a trial of HPV vaccination for the control of HPV - related to diseases in human immunodeficiency virus patient',\n",
       "  '12182. ODA Programmes within Francis Crick Institute. ODA PROGRAMMES WITHIN FRANCIS CRICK INSTITUTE. Medical Research Council supported group studying TB, Malaria, HIV, and other viral and parasitic infections of relevance to LMICs',\n",
       "  '12182. DFID / Medical examination Research Council Concordat 2008 - 2013. DFID / medical checkup RESEARCH COUNCIL covenant 2008 - 2013. TO SUPPORT HIGH QUALITY MEDICAL SCIENCE AND HEALTH RESEARCH THAT TACKLES THE PRIORITY HEALTH PROBLEMS OF PEOPLE IN DEVELOPING res publica',\n",
       "  '12182. VECTOR CONTROL BY MULTIPLE CLASSES OF SMALL ORGANIC COMPOUNDS TO COMBAT MOSQUITO - BORNE INFECTIOUS DISEASES AND SUPPRESS INSECTICIDE RESISTANCE. VECTOR CONTROL BY MULTIPLE CLASSES OF SMALL ORGANIC COMPOUNDS TO COMBAT MOSQUITO - BORNE INFECTIOUS DISEASES AND SUPPRESS INSECTICIDE RESISTANCE. Insect vectors transmit numerous viral - and parasite infections between humans or from animals to humans. Worst affected are poor people living in vulnerable communities in tropical and sub - tropical regions. Vector control by insecticides is the dominant way to combat and prevent transmission of mosquito - borne diseases. Due to globalization, environmental changes and increased insecticide resistance, there is an urgent need for new approaches and strategies for efficient vector control. This proposal aims to design, synthesize and develop multiple novel chemical classes of insecticides for control of Aedes aegypti (transmits e. g. dengue and chikungunya) and Anopheles gambiae (transmits malaria ). We will target a form of acetylcholinesterase (AChE1) not present in vertebrates, and identify diverse selective chemical starting points by high throughput screening (HTS ). Evaluation of a performed HTS targeting mosquito AChE1 has shown promising results. We have identified several classes of substances that are selective for the mosquito - form over human AChE. These multiple chemical starting points will be synthetically explored and optimized into insect powder. Early on in the discovery process we will include, in addition to the target - specific endpoints, response estimates that address human safety, environmental fate and effect, resistance sensitivity, and cost of goods. Mosquito testing, including laboratory testing and field studies, will be performed in Kenya.',\n",
       "  \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than deuce million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and controller strategies. It will also help ensure that results are replicated and scaled up in other high - risk areas of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       "  '12262. Genome - wide connexion studies to map genetic variation underlying mosquito susceptibility to human malaria. GENOME - WIDE ASSOCIATION STUDIES TO MAP GENETIC VARIATION UNDERLYING MOSQUITO SUSCEPTIBILITY TO HUMAN MALARIA. Medical Research Council. Fellowship to study why some mosquitos are more susceblible to infection with human malaria',\n",
       "  '12250. Pace University. PACE UNIVERSITY. to develop a robust continuous culture system that will provide researchers with a consistent population of Cryptosporidium parvum and Cryptosporidium hominis to better understand the complex interaction between pathogens, host nutrition, inflammation an',\n",
       "  '12262. IVCC. IVCC. to fend for the Product Development Partnership to eliminate infection of mosquito - borne pathogens through improve insect vector ascendancy with innovative products',\n",
       "  '12182. Definition and evocation of broadly protective responses against HIV - 1. DEFINITION AND INDUCTION OF BROADLY PROTECTIVE reply AGAINST HIV - 1. IIB - Research Boards Sep / Oct 2015 - RM 2016 award to see assess how the 2nd generation vaccine works. To look to remove HIV from infected individuals. And for larger scale testing in HIV - 1 minus healthy volunteers in Africa to help prevent them from being infected',\n",
       "  '12181. Advanced course for training in tropical medicine and public health in Sub - Saharan Africa. ADVANCED COURSE FOR TRAINING IN TROPICAL MEDICINE AND PUBLIC HEALTH IN SUB - SAHARAN AFRICA. Aimed at health care workers in Africa and Europe (20 doctors, nanny, biologists ), is focused on synergism and technical / cultural cooperation between experts and health workers. Information technology consist in interactives lectures, complemented by practical classes conducted in the laboratory, visits to sites of transmission, training field classes focused on checking waters, and practice in clinics and hospitals. It takes place in an international center (Populace Health Laboratory Ivo de  Carneri ).',\n",
       "  '12262. Innovative Vector Ascendance Consortium (IVCC ). INNOVATIVE VECTOR CONTROL CONSORTIUM (IVCC ). The Innovative Vector Control Consortium (IVCC) is an international public - private partnership whose aim is to foster research and development of new transmitter control products and tools for public health, including new insecticides and insecticide conceptualisation. IVCC was awarded a 5 - year Cooperative Agreement in September 2013 to support its work to advance 3 new insecticide candidates to the final stages of development by 2019.',\n",
       "  '13010. Production 13: Analysis on population dynamics. ANALYSIS ON POPULATION DYNAMICS. Kingdom of swaziland - Mbabane. Output 13: Increased availability of evidence through cutting - sharpness in - depth analysis on population dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  '13040. New tools and model projection in the field of knowledge and technology transfer. NEW TOOLS AND MODEL PROJECTS IN THE FIELD OF KNOWLEDGE AND TECHNOLOGY TRANSFER. Collaborative project - New inoculation dodge for the induction of protective cytotoxic T cells - Validation in mouse and primate models for use in infectious diseases of humans, Submarine sandwich - project - A - Research funding of particular significance for Developing Countries / Knowledge transfer',\n",
       "  \"12182. PATH Product Development Partnership Programme 2013 - 2018. PATH PRODUCT DEVELOPMENT PARTNERSHIP PROGRAMME 2013 - 2018. ' To reduce poverty through investment funds in research to develop effective and affordable, diagnostics, treatment, drugs and vaccines for diarrhoea and malaria. In the longer term this has the potential to significantly abbreviate death and illness among the poor\",\n",
       "  \"12182. DSO PDP diagnostics (FIND ). DSO PDP nosology (discovery ). PDP subsidie 2011 - 2014 ' programme funding for the elaboration of diagnostic platforms and the developments of Point - of - Care diagnostic tests\",\n",
       "  '12250. University of Md, Baltimore. UNIVERSITY OF old line state, BALTIMORE. to understand the impact of rotavirus vaccine introduction on rotavirus intestinal flu and other key diarrheal disease pathogens in sub - Saharan Africa',\n",
       "  '12250. Emory University. EMORY UNIVERSITY. to support a study that will farther understanding of the impact of pneumococcal conjugate vaccine through the sequencing and comparison of whole genome sequences of a species before and after inoculation',\n",
       "  '12262. Biomedical Primate Research Centre. BIOMEDICAL PRIMATE RESEARCH center. to accost the present limitations in the long - term cultivation of Atomic number 15. vivax (Pv) that seriously hamper research into the biology of this malaria leech and vaccine / drug development',\n",
       "  '12262. Research in active substances - pharmaceutical research. inquiry IN ACTIVE centre - PHARMACEUTICAL RESEARCH. Insect - infer anti - Infectives from Indonesia against the casuative agent of tuberculosis and malaria - Medical inquiry of particular importance for Develop Countries - malaria abatement',\n",
       "  '12182. CVCASouth & Central Asia, regionalHealth systems and services. CVCA: southward & telephone exchange ASIA, REGIONALHEALTH SYSTEMS AND armed service. Medical inquiry',\n",
       "  \"13010. Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems. CENTRE OF EXCELLENCE FOR CIVIL REGISTRATION AND VITAL STATISTICS (CRVS) SYSTEMS. Registration of events, such as birth, death, causes of death, marriage, and divorce, is critical for improving maternal, newborn, child, and adolescent health. These statistics provide policymakers and practitioners with the necessary evidence to design interventions and enact appropriate policies on maternal and child health. Many low - and middle - income countries, however, do not systematically collect such all important information. It is estimated that one - third of the world ' s births and two - thirds of the world ' s deaths are not registered or are incorrectly certified. In many cases, global average, standards, tools, and good practices are non readily accessible and useable to those who need them most. The project will establish the Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems to provide information, tools, and expertise to facilitate the development and implementation of integrated CRVS systems. Funded by Global Affairs Canada and the International Development Research Middle (IDRC ), and based at IDRC, the Centre of Excellence will coordinate with existing expert groups to generate, consolidate, and share information and resources in an open and collaborative electronic platform. It will also assist countries needing more direct support by facilitating the exchange of good practices and capacity strengthening, and will play an important role brokering technical assistance for countries needing more direct support. The Centre of Excellence will work closely with the Global Financing Facility in support of the Every Woman Every Child initiative to enable the development and implementation of CRVS systems plans as part of country - led investment cases for financing by the Global Financing Facility.\",\n",
       "  '12182. Atomic number 9 Osier, KEMRI - CGMRC, Defining the merozoite targets of protective immunity against Plasmodium falciparum malaria through multi - centre cohort studies. F OSIER, KEMRI - CGMRC, DEFINING THE MEROZOITE TARGETS OF PROTECTIVE IMMUNITY AGAINST PLASMODIUM FALCIPARUM MALARIA THROUGH MULTI - CENTRE COHORT STUDIES. Medical Inquiry Council African Research Leaders Award. Research grant to look for potential fresh vaccine candidates in malaria parasite that will generate good protective immunity',\n",
       "  \"12250. Linking Emerging Infectious Diseases Research and Policy Networks in Southeast Asia and China: APEIR Phase II. LINKING EMERGING INFECTIOUS DISEASES RESEARCH AND POLICY NETWORKS IN SOUTHEAST ASIA AND CHINA: APEIR PHASE II. The Asian Partnership on Emerging Infectious Diseases Research (APEIR) is a multi - country, multi - disciplinary and multi - sectoral research network that enables researchers and experts from several sectors, including agriculture and health, to explore joint research and policy questions in animal and public health. The partnership uses an ecohealth approach to address the complexity of emerging infectious diseases. This project presents a new phase of APEIR research on emerging threats from antimicrobial resistance and wildlife trade. It aims to strengthen the field of ecohealth and enhance emerging infectious disease control in Asia through research, capacity building, social and policy advocacy, and stronger knowledge and response networks. The wide use and abuse of antimicrobials as anti - infective drugs and non - therapeutic treatments are key contributors to persistent infections caused by resistance to antimicrobials. This use and abuse is also a major cause of morbidity and mortality around the world. In China and Southeast Asia, the lack of policy or regulation enforcements means that the use of antibiotics is not well - controlled. This research will provide evidence and guidance to make grow country - specific and regional strategies to improve the responsible use of antibiotics and to reduce the emergence of resistant infectious agents in China, Indonesia, Laos, Thailand, and Vietnam. Southeast Asia ' s thriving wildlife trade supports disease transmission to humans. It also threatens livestock, international trade, rural livelihoods, native wildlife populations, and ecosystem health. Little is known about the zoonotic disease risks involved in transmitting diseases between brute and humans. This study will assess the pathogens that circulate and will explore possible pathways of transmission to humans, specifically in China, Laos, Thailand, and Vietnam. It will help prevent emerging zoonotic infectious diseases. It will also decrease wildlife consumption, while educating people about the safe and wise use of wildlife as a source of food protein for poor people. Finally, it will support wildlife diversity and mitigate illegal wildlife trade in the region. Building on past research on avian influenza and ongoing knowledge - translation activities in the health field, this new phase of work will help APEIR build and support regional capacity to communicate and share knowledge to promptly address emerging infectious disease threats.\",\n",
       "  '12182. How does the trypanosome haptoglobin - hemoglobin receptor interact with nutrients and immunity molecules? Receptor structure to cellular mechanism. . HOW DOES THE TRYPANOSOME HAPTOGLOBIN - HEMOGLOBIN RECEPTOR INTERACT WITH NUTRIENTS AND IMMUNITY MOLECULES? RECEPTOR STRUCTURE TO CELLULAR MECHANISM. . MRC / IIB Research Grant to investigate the host parasite interaction during trypanosome infection. In the long term, information technology may also have an economical and societal effect in Sub - Saharan Africa done the better exploitation of the trypanolytic factors and through improved uptake route for therapeutics to direct trypanosomes.',\n",
       "  '12262. Atomic number 9 Osier, KEMRI - CGMRC, Defining the merozoite targets of protective exemption against Plasmodium falciparum malaria through multi - centre cohort studies. F OSIER, KEMRI - CGMRC, DEFINING THE MEROZOITE TARGETS OF PROTECTIVE IMMUNITY AGAINST PLASMODIUM FALCIPARUM MALARIA THROUGH MULTI - CENTRE COHORT STUDIES. F Osier, KEMRI - CGMRC, Defining the merozoite targets of protective immunity against Plasmodium falciparum malaria through multi - centre age bracket studies',\n",
       "  \"12182. Delivering Effective Health Services COMDIS (Inquiry and Development for Communicable Disease Control ). DELIVERING EFFECTIVE HEALTH SERVICES COMDIS (RESEARCH AND DEVELOPMENT FOR COMMUNICABLE DISEASE CONTROL ). The purpose of DFID ' s Research Programme Consortia in push poverty and achieving the MDGs is two fold: (1) to help produce new knowledge and technologies to tackle the most important exploitation challenges; (two) to help make sure that countries and the\",\n",
       "  '12250. Centre Hospitalier Universitaire Vaudois. CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS. to evaluate novel diagnostic platforms that could inform heath authority on the current loading of infections, as well as on emerging infections and potential outbreaks',\n",
       "  '12250. Development of a statistical modelling fabric to 12250orm real - time immunization strategies for elimination of poliomyelitis and other diseases. DEVELOPMENT OF A STATISTICAL MODELLING FRAMEWORK TO 12250ORM REAL - TIME IMMUNIZATION STRATEGIES FOR ELIMINATION OF POLIOMYELITIS AND OTHER DISEASES. Development of a statistical modelling framework to 12250orm real - time immunization strategies for elimination of poliomyelitis and other diseases',\n",
       "  '12220. University of Mantle Town. UNIVERSITY OF CAPE TOWN. to support a longitudinal cohort report of children evaluating the number, severity, and etiology of respiratory disease, and evaluate the potential effect modifiers that may influence the incidence and severity of acute lower respiratory infections',\n",
       "  '12250. Centers for Disease Control and Prevention. CENTERS FOR DISEASE CONTROL AND bar. to perform the laboratory psychoanalysis for Inactivated Polio Computer virus (IPV) clinical trials',\n",
       "  '12262. ACQUIRED IMMUNITY TO MALARIA: IMPORTANCE OF THE GENETIC DIVERSITY OF PLASMODIUM FALCIPARUM. ACQUIRED IMMUNITY TO MALARIA: IMPORTANCE OF THE GENETIC DIVERSITY OF PLASMODIUM FALCIPARUM. Malaria caused by Plasmodium falciparum is a potentially fatal infection. Understanding how the extensive genetic polymorphism of the parasite affects the acquisition and maintenance of immunity is a prerequisite for the development of efficacious control tools such as vaccines. In our previous studies, we have shown that persistent asymptomatic multiclonal infections predict a reduced risk of disease in high transmission settings. The aim of this project is to further establish how the hereditary diversity of P. falciparum infection affects protective immunity to malaria. We will investigate polymorphisms in P. falciparum antigen genes, i. e. genes under immune selection, in person with different levels of exposure and immunity both within and between geographical areas, and identify potential? hotspots? of transmission. The genetic diversity of P. falciparum infections will be related to the breadth and magnitude of antibody responses directed to a panel of several P. falciparum antigens. The longevity of immune responses (antimalarial antibody and memory B cell responses) will be studied. The project includes well defined and closely monitored cohorts living in areas of different transmission in Kenya, Tanzania and Mali, as well as Swedish traveller who experience malaria for the first time. The project will contribute to the understanding of the molecular epidemiology of P. falciparum and the acquisition and maintenance of protective immunity against malaria.',\n",
       "  '12182. To fund the development of new vaccines to prevent tuberculosis transmission through the organisation Aeras  research. TO FUND THE DEVELOPMENT OF NEW VACCINES TO PREVENT TUBERCULOSIS INFECTION THROUGH THE ORGANISATION AERAS  RESEARCH. To develop new affordable vaccinum for TB at scale which have the potential to reduce many millions of new cases of TB over a period of twenty year contributing to MDG 6 which includes halting and reducing the spread of Tuberculosis.',\n",
       "  \"12262. DSO PDP Hookworm disease vaccineSABIN. DSO PDP hookworm disease VACCINESABIN. PDP subsidie voor ' The Human Hookworm Vaccine Initiative: Clinical Development of the NaGST - 1 and Atomic number 11 - APR - 1 Hookworm Vaccine Antigen\",\n",
       "  '13010. Output 13: Analysis on population dynamic. ANALYSIS ON POPULATION DYNAMICS. El Salvador - San El salvador. Output long dozen: Increased availability of evidence through cutting - edge in - depth analysis on population dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  '12240. Full general Hospital Corporation. GENERAL HOSPITAL CORPORATION. to better treat environmental enteropathy and other potentially deadly childhood diseases caused by enteric pathogens such as Escherichia coli by isolating and / or engine room selective bacteriophage (viruses that infect bacteria )',\n",
       "  '12263. Cornell University. CORNELL UNIVERSITY. to develop and apply fresh mass spectrometry - based technologies to rationally key new drugs to treat TB',\n",
       "  \"12250. Intersectoral Municipal Leadership for Health in Latin America. INTERSECTORAL MUNICIPAL LEADERSHIP FOR HEALTH IN LATIN AMERICA. This project aims to build ecohealth leadership at the municipal level in Colombia and Venezuela to address health priorities, including vector - borne diseases and food systems interventions for non - communicable disease prevention. Dengue fever and chikungunyaIn Colombia and Venezuela, research and governmental institutions from the Latin American Ecohealth Leadership Consortium on Vector - borne Diseases have decreased Aedes mosquito populations significantly through municipal interventions. This mosquito is responsible for transmitting two viral diseases: dengue fever and chikungunya. Dengue and chikungunya interventions bequeath be scaled up in three affected municipalities. Both diseases are responsible for rapidly growing health and economic burdens in the two countries. The project is expect to generate new knowledge on factors affecting policy adoption and scaling up: - institutional capacity gaps - early involvement and leadership of municipal players - good governance - costs - validating impact on disease incidenceThe evidence should help researchers and governments replicate the project at a larger scale. National and municipal governments and the World Health Organization are providing co - funding for the project. Food systems, healthy diet, and incentivesThe food systems and healthy diets study will take place in a rural municipality of Colombia. This region has one of the highest agricultural outputs in the country. However, it also has high rates of malnutrition among children and obesity in adult populations. The study testament analyze local factors associated with the rise of obesity and diabetes, such as food systems and lifestyle determinants that favour unhealthy diets in rural areas. In the study ' s second step, researchers will pilot test an inter - sector approach. The aim is to promote municipal regulatory incentives for food and health systems, and community and workplace environments. Researchers will practice a participatory methodology that involves multi - sector municipal committees, together with qualitative and quantitative methods. Testing ways to decrease diseasesThe project will analyze the feasibility, cost - effectiveness, and sustainability of scaling up interventions aimed at dealing with two emerging mosquito - borne diseases. The food and tidy diets study will analyze the basic food basket per home, family anthropometric indicators for nutritional status (underweight, stunting, etc. ), feeding habits, and blood glucose levels. The project is expected to contribute to - stronger municipal players acting as public health leaders - effective scaled up solutions that decrease dengue and chikungunya incidence rates - municipal inter - sectoral approaches that contribute to preventing obesity and diabetes\",\n",
       "  '12262. Development of an anti12262arial drug that targets the Malaria parasite falciparum cGMP - dependent protein kinase. DEVELOPMENT OF AN ANTI12262ARIAL DRUG THAT TARGETS THE PLASMODIUM FALCIPARUM CGMP - DEPENDENT PROTEIN KINASE. Development of an anti12262arial drug that targets the Plasmodium falciparum cGMP - dependent protein kinase',\n",
       "  '12250. Massachusetts Institute of Engineering. MASSACHUSETTS INSTITUTE OF TECHNOLOGY. to develop novel pulse antigen - releasing single - injection vaccine delivery systems to facilitate pediatric immunizations in developing world circumstances in which repeated patient access may exist problematic',\n",
       "  '12250. Epidemiological modelling to address effect of hepatitis B in resource poor setting: Impact & cost - effectiveness of intervention strategy. EPIDEMIOLOGICAL MODELLING TO ADDRESS BURDEN OF HEPATITIS B inch RESOURCE POOR SETTINGS: IMPACT & COST - EFFECTIVENESS OF INTERVENTION STRATEGIES. Medical Research Council. Fellowship to undertake modelling studies to investigate burden of hepatitis B in resource poor stage setting and the Impact & cost - effectiveness of intervention strategies',\n",
       "  '12182. TOOLS TO STUDY THE EFFECTS OF ROTAVIRUS VACCINATION IN BURKINA FASO. TOOLS TO STUDY THE EFFECTS OF ROTAVIRUS VACCINATION IN BURKINA FASO. Diarrhea is a major global health issue in children, and heavily affects sub - Saharan Africa. Rotavirus is the major cause for severe childhood diarrhea, thus rotavirus vaccines are an important preventive measure of diarrhea. Vaccine trials have, however, showed a reduced vaccine efficacy in many African countries. Burkina Faso is now about to implement vaccination nationwide and our research proposal is centered on this. By closely monitoring rotavirus before; during and after national immunization, we can investigate factors important for vaccine efficacy. A first objective embody to establish RV surveillance logistics and techniques before vaccination. We have performed preliminary studies and found many unusual strains which could influence vaccine efficacy. The major objective is to determine the vaccine efficacy and relate this to evolving escape mutants and specific strains present in Burkina Faso. Our third scientific approach is most novel and based on preliminary data from Burkina Faso observing that children with the Lewis - negative phenotype, common in Burkina Faso, where not infected with vaccine - like strains, providing an explanation for reduced vaccine efficacy in Africa. The overall objective of this collaboration be increased knowledge and better techniques to study RV and factors important for successful vaccination; which will be done through regular workshops, lectures and scientific visits by researchers from Sweden and Burkina Faso.',\n",
       "  '12262. Improving Malaria Diagnostics (IMaD) - Malaria. IMPROVING MALARIA DIAGNOSTICS (IMAD) - MALARIA. Under IMaD, MCDI and its partners work to better laboratory - base diagnosis of malaria (primarily at Ministry of Health facilities ), and to increase understanding, acceptance, and correct use of microscopy and Rapid Diagnostic Tests (RDTs) by laboratory staff and health care practitioners provide direct care to patients.',\n",
       "  '12250. Indian Institute of Technology Bombay. INDIAN INSTITUTE OF TECHNOLOGY BOMBAY. to adapt the antibiotic amoxicillin for children with pneumonia in developing countries by encapsulating it in lipid nanoparticles incorporated into a skin patch to avoid the bad taste and the need for multiple everyday doses',\n",
       "  \"12182. NFR - GLOBVAC Global health and inoculation research. NFR - GLOBVAC GLOBAL wellness AND VACCINATION RESEARCH. An annual allocation of NOK 7 000 000 is set aside for research on global health and NOK 55 000 000 for research on vaccination. The funding is managed by Norwegian Research Council. The funds shall assure Kingdom of norway ' s responisbility for research on global health challenges and povery - related diseases affectiong developing countries. The activity comprise basic research, clinical research and research on health systems direkted towards prevention and treatment of provery - related diseases\",\n",
       "  '12250. Johns Hopkins University. JOHNS gerard manley hopkins UNIVERSITY. to corroborate the Pneumonia Etiology Research for Child Health (pole) Project',\n",
       "  '12250. SUKUTA wellness CENTRE -. SUKUTA HEALTH CENTRE -. Aesculapian Research Council. Intramural Duncan grant for clinical research studies in The Gambia',\n",
       "  '12250. Ecohealth Emerging Infectious Diseases Research Initiative (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, personify emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to high population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project draw a bead on to understand the relationship between emerging infectious disease of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the neighborhood. The emphasis will be on capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       "  '12262. Global Health Innovative Technology Fund. GLOBAL wellness INNOVATIVE engineering science FUND. to develop new health technologies as a result of funding and development collaborations with Japanese industry and government',\n",
       "  \"12250. Linking Emerging Infectious Diseases Research and Policy Networks in Southeast Asia and China: APEIR Phase deuce. LINKING EMERGING INFECTIOUS DISEASES RESEARCH AND POLICY NETWORKS IN SOUTHEAST ASIA AND CHINA: APEIR PHASE II. The Asian Partnership on Emerging Infectious Diseases Research (APEIR) is a multi - country, multi - disciplinary and multi - sectoral research network that enables researchers and experts from several sectors, including agriculture and health, to explore joint research and policy questions in animal and public health. The partnership uses an ecohealth approach to address the complexity of emerging infectious diseases. This project presents a new phase of APEIR research on emerging menace from antimicrobial resistance and wildlife trade. It aims to strengthen the field of ecohealth and enhance emerging infectious disease control in Asia through research, capacity building, social and policy advocacy, and stronger knowledge and response networks. The wide use and abuse of antimicrobial as anti - infective drugs and non - therapeutic treatments are key contributors to persistent infections caused by resistance to antimicrobials. This use and abuse is also a major cause of morbidity and mortality around the world. In China and Southeast Asia, the lack of policy or regulation enforcements means that the use of antibiotics is not well - controlled. This research will provide evidence and guidance to develop country - specific and regional strategies to improve the responsible use of antibiotics and to reduce the emergence of resistant infectious agents in China, Indonesia, Laos, Thailand, and Vietnam. Southeast Asia ' s thriving wildlife trade supports disease transmission to humans. It also threatens livestock, international trade, rural livelihoods, native wildlife populations, and ecosystem health. Little is known about the zoonotic disease risks involved in transmitting diseases between animals and humans. This study will assess the pathogens that circulate and will explore possible pathways of transmission to humans, specifically in China, Laos, Thailand, and Vietnam. It will help prevent emerging zoonotic infectious diseases. It will also decrease wildlife consumption, while educating people about the safe and wise use of wildlife as a source of food protein for poor people. Finally, it will support wildlife diversity and mitigate illegal wildlife trade in the region. Building on past research on avian influenza and ongoing knowledge - translation activities in the health field, this new phase of work will help APEIR build and support regional capacity to communicate and share knowledge to promptly address emerging infectious disease threats.\",\n",
       "  '12220. University of Maryland, Baltimore. UNIVERSITY OF MARYLAND, BALTIMORE. to develop broadly effective vaccines and interventions against enteric infections by conducting multi - country case - control study using standardized methods to measure the aetiology and burden of diarrhea among children in developing countries',\n",
       "  '12182. Immunological responses to emerging phlebo - and arenaviruses. IMMUNOLOGICAL RESPONSES TO EMERGING PHLEBO - AND ARENAVIRUSES. MRC / IIB grant. To, help keep Emerging New World arena - and phlebo - viruses which are threats to human health, in particular in ODA countries, with no preventative vaccines or therapeutic treatments. The objective is to study the antibody response against viral glycoproteins, at a molecular level, with the aim of isolating and characterizing monoclonal antibodies that can target and forbid the virus infection cycle.',\n",
       "  '13040. The Aaron Diamond AIDS Enquiry Center. THE AARON rhomb AIDS RESEARCH CENTER. to sustain the development, optimization, and selection of engineered bispecific bNabs for HIV prevention.',\n",
       "  '12262. THE PREECLAMPSIA - MALARIA connexion: PREDICTION, DIAGNOSIS, AND HOPE FOR TREATMENT. THE PREECLAMPSIA - MALARIA CONNECTION: PREDICTION, DIAGNOSIS, AND HOPE FOR TREATMENT. Women are particularly vulnerable to malaria during pregnancy because malaria parasites accumulate in the placenta and the condition is estimated to be responsible for 200 000 infant deaths annually. The disease mechanisms are poorly understood, largely due to the lack of adequate animal models. We propose to use a placental perfusion model to study the interaction between malaria parasites accumulated in the human placenta in relation to the development of preeclampsia with ot without intrauterine growth restriction. The studies will also provide immediate guidance for ongoing efforts to develop a vaccine, protecting women from pregnancy malaria, and basic insight about the disease processes, which can lead to new treatment and prevention strategies for these complicated pregnancies affecting women in the sub - Saharan region. The specific aims of this project are to uncover common disease mechanisms behind PE with or without IUGR and pregnancy - associated malaria (PAM ); to enable predictive diagnosis of high risk of infection cases in the field; to prove feasibility of a cure using A1M in perfusion experiments. This work involves personnel and high risk pregnancy patients from Kenya, Egypt, Tanzania, and Ghana.',\n",
       "  '13040. Cooperation with foreign research institutions (in so far as not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (IN SO FAR AS NOT INCLUDED IN OTHER AREAS ). Modulation of endogenic micro - RNA manifestation to activate latent human immunodeficiency virus in infected CD4 + T lymphocytes - a newfangled biomedical strategy for the eradication of persisent HIV infections',\n",
       "  '12262. Selecta Life science. SELECTA BIOSCIENCES. to support pre - clinical evaluation of a nano particle (Celluloid Vaccine Particle (SVPs) ) platform for malaria vaccine candidates',\n",
       "  '12182. Pharmocokinetics of azithromycin in severe malaria bacterial co - transmission in African children. PHARMOCOKINETICS OF AZITHROMYCIN hoosier state SEVERE MALARIA BACTERIAL CO - INFECTION IN AFRICAN CHILDREN. MRC / DFiD / NIHR / WT Joint Global Health Run establishing the correct use of antibiotics in children with malaria',\n",
       "  '13040. Centre Hospitalier Universitaire Waldenses. CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS. to develop one likely vaccine strategy that may lend to the global effort of lay off the human immunodeficiency virus pandemic',\n",
       "  '12250. Akonni Biosystems. AKONNI BIOSYSTEMS. to formalize novel, low cost sample preparation engineering science for role in gloomy resource stage setting',\n",
       "  '12262. The Walter and Eliza Hall Institute of Medical Research. THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH. to set the carrying into action of a pilot serological diagnostic test for hypnozoite carriage',\n",
       "  '12182. Near - Infrared Spectroscopy: A Unmatchable - Stop - Store for Mosquito Epidemiological Monitoring? . NEAR - INFRARED SPECTROSCOPY: A ONE - STOP - SHOP FOR MOSQUITO EPIDEMIOLOGICAL MONITORING? . Medical Enquiry Council prize to evaluate the feasibility of Near - Infrared Spectroscopy (NIRS) as a techniques for epidemiological monitoring of mosquitoes',\n",
       "  '12262. Malaria Vaccine Ontogeny Program (MVDP) - Malaria. MALARIA VACCINE DEVELOPMENT PROGRAM (MVDP) - MALARIA. MVDP, is committed to undertake, outsource, assist, promote and encourage scientific studies, epidemiology studies, product development, clinical studies & institute field sites with the object of advancing the development of vaccines againstP. falciparumandP. vivaxmalaria identified by Research Institutes.',\n",
       "  '13040. Calibration and analysis of complex models: methodological development and application to explore the impact of HAART in Africa. CALIBRATION AND ANALYSIS OF COMPLEX MODELS: METHODOLOGICAL DEVELOPMENT AND APPLICATION TO EXPLORE THE IMPACT OF HAART inch AFRICA. Medical Research Council. Research Grant to develop, apply and analyse modelling methods to predict the impact of HAART on HIV / AIDS in Africa',\n",
       "  '12250. Vanderbilt University. VANDERBILT UNIVERSITY. to support a respiratory syncytial computer virus burden of disease work',\n",
       "  '12182. G - fourfold biology in the human malaria parasite Plasmodium falciparum. G - QUADRUPLEX BIOLOGY IN THE HUMAN MALARIA PARASITE PLASMODIUM FALCIPARUM. IIB Research Boards May / Jun 2016 - RM 2017 award focusing on a fresh biological mechanism that the Malaria parasite english hawthorn use for switching between var cistron and for generating new variants in Africa',\n",
       "  '12182. PATH Product Development 2017 - 2021: for the development of diarrhoea vaccines & treatments. PATH PRODUCT DEVELOPMENT 2017 - 2021: FOR THE DEVELOPMENT OF DIARRHOEA VACCINES & TREATMENTS. This programme in the Ross Fund Portfolio (which focus on neglected tropical diseases, diseases of emerging resistivity and diseases of epidemic potential) will put up the development of new products (such as drugs, diagnostics and insecticides) for ta',\n",
       "  '12262. Policy Curative. POLICY CURES. to increase current and future development of new products for neglected diseases of the developing world, such as human immunodeficiency virus, TB, malaria and the neglected tropic diseases, by supporting increased investing into their research and development',\n",
       "  '12182. Understanding how viral innate immune evasion strategies impress adaptative immunity, and the application to vaccine development. UNDERSTANDING HOW VIRAL INNATE IMMUNE EVASION STRATEGIES AFFECT ADAPTIVE IMMUNITY, AND THE APPLICATION TO VACCINE DEVELOPMENT. IIB - Research Boards September / Oct 2014 - RM 2016 award. To look at how the removal of innate immune inhibitory genes from VACV positively impact on memory immunity? Envisaging long term, to design better vaccines in Lower Income countries',\n",
       "  '13081. Output 13: Analysis on population dynamics. ANALYSIS ON universe DYNAMICS. Iraq - Bagdad. Yield 13: Increased availability of evidence through with cutting - edge in - depth analysis on population dynamics, sexual and reproductive wellness, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  '12263. University of Pittsburgh. UNIVERSITY OF PITTSBURGH. to modernise whole consistency imaging technology to shorten the duration of chemotherapy for TB.',\n",
       "  '12263. Everwell Health Solution. EVERWELL HEALTH SOLUTIONS. to back expanded use of open - root adherence monitoring technology for tuberculosis patients in India',\n",
       "  '13040. Duke University. DUKE UNIVERSITY. to help the discovery of a safe, effective and practical HIV - i vaccine by using valid laboratory criteria and Commodity Clinical Laboratory Practices to monitor antibody responses in the systemic and mucosal compartment in vaccine testing',\n",
       "  '12263. Tuberculosis Treatment Tryout. tb TREATMENT TRIALS. Medical Research Council. Intramural Grant to support trial of novel therapy regime for t.b.',\n",
       "  \"12110. Assessing the attitudes and practices of public health professionals regarding funding from for - profit corporations. ASSESSING THE ATTITUDES AND PRACTICES OF PUBLIC HEALTH PROFESSIONALS REGARDING FUNDING FROM FOR - PROFIT CORPORATIONS. Over the retiring two decades many corporations have begun philanthropic contributions to communities under the rubric of ' Corporate Social Responsibility '. Corporations have sought to engage with universities to support and augment their research and training activities. In an era of dwindling support for research and practice from governments and foundation, many universities have in turn begun to solicit funds from businesses. However, in the case of schools of public health, a number of corporations sought as potential funders make products that may be considered harmful to health operating theatre a threat to the environment - creating a potential conflict of interest. Among public health institutions there are no generalized guidelines to govern the receipt of research and sponsorship funds from for - profit corporations. Practices differ by schools and programs of public health. Though some guidelines have been developed to monitor such potential conflicts of interest, no systematic research has yet explored the attitudes and behaviors of public health researchers and academicians with respect to corporate funding. The research objectives of this project managed by the American University of Beirut are to assess: 1) the attitudes and practices of public health academics globally with respect to taking funds from for - profit corporations - particularly those whose products are associated with non - communicable diseases; and, 2) the policies that govern schools of public health around the globe with respect to taking funds from for - profit corporations. Schools and programs of public health in the Eastern Mediterranean region, North America, Africa and Southeast Asia will be included in this research. The overall aim is to inform a policy debate about possible guidelines for making decisions about accepting funds from for - profit corporations.\",\n",
       "  '12250. Universiteit Antwerpen. UNIVERSITEIT ANTWERPEN. to support phase One clinical trials with the modern unwritten polio vaccine - 2 expression',\n",
       "  '12250. University of Calgary. UNIVERSITY OF CALGARY. to help ensure the sustainability of current soil transmitted helminth (somatotropic hormone) treatment strategies and new strategies to interrupt STH transmission by developing new molecular approaches to detecting and monitoring anthelminthic resistance',\n",
       "  '13010. Output 13: Analysis on population dynamics. depth psychology ON POPULATION DYNAMICS. Pigboat - Regional Office / Kingston. Output 13: Increased availableness of evidence through cutting - sharpness in - depth analysis on population dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  '12182. ACGlobalHealth system of rules and service. AC: GLOBALHEALTH scheme AND SERVICES. Medical research',\n",
       "  '12263. EXPLORATION OF POTENTIALLY ANTIMYCOBACTERIAL AND ANTITUBERCULOSIS NATURAL PRODUCTS FROM TANZANIAN PLANTS. EXPLORATION OF POTENTIALLY ANTIMYCOBACTERIAL AND ANTITUBERCULOSIS NATURAL PRODUCTS FROM TANZANIAN PLANTS. The proposed collaborative research is aimed at designing a combination handling targeted against Mycobacterium tuberculosis infection using co - administration of natural products from Tanzanian medicinal plants or their synthetic analogues with currently ineffective anti - tebibyte drugs. The targeted plant species will be those traditionally used in treatment of TB or related respiratory infections of which our recent work have indicated to exhibit antimicrobial activities yet have not been thoroughly investigated for their antimycobacterial activity and anti - TB drug enhancement ability. The project will involve plant extracts preparation, bioassay guided isolation of plant natural products for targeted bioactivities to be done at the University of Dar es Salaam (UDSM ). Further purification and structural determination of the bioactive metabolites which shall require access to preparative High Performance Liquid Chromatography systems and spectroscopic facilities which are unavailable in Tanzania, will be conducted in collaboration with the University of Gothenburg (GU ). Furthermore, syntheses of isolated bioactive molecules and their analogues to be done at GU and UDSM as well as molecular and biological assays to study their mode of actions (GU) shall serve a crucial step in adding note value to the applications of the compounds towards discovery of novel anti - TB agents that could be used in TB combination therapy.',\n",
       "  '12182. An advanced cookstove intervention to prevent pneumonia in children under 5 years old in nyasaland: a cluster randomised controlled trial. AN ADVANCED COOKSTOVE intercession TO PREVENT PNEUMONIA IN CHILDREN UNDER 5 YEARS OLD IN MALAWI: A CLUSTER RANDOMISED CONTROLLED TRIAL. Medical Research Council. Research Grant for a trial to compare indoor cooking methods to reduce pneumonia',\n",
       "  \"12240. EpiBiome. EPIBIOME. to improve children ' s gut health by exploiting the development of resistance to bacteriophage by morbific bacterium that cause diarrhea to assure any resistant bacteria become less harmful to humans\",\n",
       "  '12263. Next Dimension Technologies, Inc. . following DIMENSION TECHNOLOGIES, INC. . to develop and clinically validate a simpleton, breath - based diagnostic system for t.b. use chemiresistive sensor arrays',\n",
       "  '12250. HHS / CDC: IP16 - 003. U01IP RESEARCH ON THE EPIDEMIOLOGY, PREVENTION, VACCINE EFFECTIVENESS AND TREATMENT OF INF. HHS / CDC: IP16 - 003. U01IP RESEARCH ON THE EPIDEMIOLOGY, PREVENTION, VACCINE EFFECTIVENESS AND TREATMENT OF INF. HHS / CDC: IP16 - 003. U01IP RESEARCH ON THE EPIDEMIOLOGY, PREVENTION, VACCINE EFFECTIVENESS AND TREATMENT OF INF',\n",
       "  '13040. Magee - Womens Research Institute and Foundation. MAGEE - WOMENS RESEARCH INSTITUTE AND initiation. to identify changes in HIV - target area cells occuring in the genital tract of women initiating hormonal contraception',\n",
       "  '12262. IVCC. IVCC. to support the Product Development Partnership to eliminate transmittance of mosquito - borne pathogens through improved insect vector control with innovative ware',\n",
       "  '12262. University of Oxford. UNIVERSITY OF OXFORD. to combine two effective slowly eliminated antimalarial drugs together with an artemisinin derivative in a triple artemisinin combination therapy (TACT) to discover if cure rates in artemisinin resistive malaria can be increased',\n",
       "  '12182. Scientific cooperation with other countries (not included in former expanse ). SCIENTIFIC COOPERATION WITH OTHER COUNTRIES (NOT INCLUDED IN OTHER area ). Development of New Diagnostic and Treatment Options for Helminthic Neglected Diseases - Medical inquiry of fussy importance for developing countries',\n",
       "  '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to demonstrate how nasopharyngeal (NP) carriage surveillance in hospitalized children with respiratory illness operating room pneumonia can be used to estimate the pneumococcal conjugate vaccinum coverage required to show evidence of herd immunity',\n",
       "  '12263. Innovative small scale - and medium - sized enterprises, Biotech - Biochance. INNOVATIVE SMALL - AND MEDIUM - SIZED ENTERPRISES, BIOTECHNOLOGY - BIOCHANCE. Innovative SMEs 10 - Label - free electrical sensing of mycobacterium (DiaCharge) - Sub - project 1 - Development of RNA / DNA extraction & sample preparation, and technical validation - Research to ensure food security in the Developing Country',\n",
       "  '12263. Leland stanford University. leland stanford UNIVERSITY. for the analysis of samples and data from Scientific Advisory Plug in - approved vaccine trials and natural history studies',\n",
       "  '12250. IVCC. IVCC. to support the Product Evolution Partnership to eliminate transmitting of mosquito - borne pathogens through improved insect transmitter control with innovative products',\n",
       "  '12182. CVCAFar East Asia, regionalHealth systems and services. CVCA: FAR due east ASIA, REGIONALHEALTH SYSTEMS AND service. Medical research',\n",
       "  '12262. Tetragenetics, Inc. . TETRAGENETICS, INC. . to further research the production and immune stimulating effects of multi - antigen and adjuvant conceptualisation that could be used in a low - cost, long - lasting malaria vaccine.',\n",
       "  '12250. Dame jean iris murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to develop an effective, low cost, oral, human neonatal rotavirus vaccine aimed at prevention of rotavirus gastroenteritis from birth, for infants and children worldwide',\n",
       "  '12250. Broad Institute. BROAD INSTITUTE. to unwrap and functionally characterize novel antibiotics using deep learning',\n",
       "  \"13010. DSO - Fonds voor PDP ' s III. DSO - FONDS VOOR PDP ' S III. DSO - Fonds voor Merchandise Development Partnerships (PDPs) tierce\",\n",
       "  '13020. World Health Organization. WORLD HEALTH ORGANIZATION. to develop and test simplified, alternative antibiotic treatment regimens for good neonatal infections in sub - Saharan Africa',\n",
       "  '12182. REACH: Late human immunodeficiency virus infection: Eradication by Activation of the HIV reservoir: A proof of concept trial towards a Cure for HIV. . REACH: RECENT HIV INFECTION: ERADICATION BY ACTIVATION OF THE HIV RESERVOIR: A PROOF OF CONCEPT TRIAL TOWARDS A CURE FOR HIV. . Aesculapian Research Council / DPFS Translational research honor for a proof of concept new therapy for HIV',\n",
       "  '12262. GlaxoSmithKline I + Calciferol, S. L. . GLAXOSMITHKLINE I + D, South. L. . to accession a first in family technology platform to identify the molecular targets of up to 10 anti - TB and anti - malaria lead compounds for the benefit of the wider Malaria and TB drug discovery communities',\n",
       "  '12182. Exploiting the structure of integral membrane pyrophosphatases. EXPLOITING THE STRUCTURE OF INTEGRAL MEMBRANE PYROPHOSPHATASES. This project will present new targets for drug delivery in both animal and human health by exploiting the complex body part of integral membrane pyrophosphatases to combat drug resistance.',\n",
       "  '13010. Output 13: Analysis on population dynamics. ANALYSIS ON universe moral force. Congo - Brazzaville. Output 13: Increased availability of evidence through cutting - edge in - depth analysis on population dynamics, sexual and procreative health, HIV and their linkages to poverty eradication and sustainable ontogenesis',\n",
       "  '12263. Critical Path Institute. CRITICAL PATH INSTITUTE. to apply new regulatory science approaches to importantly shorten the exploitation of to a greater extent efficacious and safe TB drug regimens with shorter discussion duration',\n",
       "  '12220. University of Washington Foundation. UNIVERSITY OF capital of the united states FOUNDATION. to assess the impact of incorporating virtual reality technology in trainings on health worker performance of neonatal resuscitation, and explore implications for the use of VR engineering for wellness worker take more broadly.',\n",
       "  '12263. Critical Path Institute. CRITICAL PATH INSTITUTE. to accelerate the growth of a safer, faster - acting and more efficacious drug regimen (s) for the discussion of tuberculosis (TB) by curating data to inform the development of fresh tests which rapidly detect drug - specific resistance and susceptibility',\n",
       "  '12182. Interrupting transmission of soil - transmitted helminth: clustering randomised trial evaluating alternative treatment strategies in Kenya. INTERRUPTING TRANSMISSION OF dirt - TRANSMITTED HELMINTHS: CLUSTER RANDOMISED TRIAL EVALUATING ALTERNATIVE TREATMENT STRATEGIES IN KENYA. Jt Fund Health Tri Y5 Feb 2015 award to conduct an evaluation on the impact of school vs community based treatment in reducing the transmission of intestinal worms (STH) in Kenya',\n",
       "  '13010. Output 13: Analysis on population dynamics. ANALYSIS ON POPULATION DYNAMICS. Mongolia - Ulaan Baatar. Output 13: Increased availability of evidence through cutting - edge in - depth psychoanalysis on universe dynamics, intimate and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  '12262. World Wellness Organization. WORLD wellness ORGANIZATION. to gain evidence on shock of insecticide resistance on the efficacy of malaria vector control and on feasibility of managing resistance',\n",
       "  '12262. Pennsylvania State University. PENNSYLVANIA STATE UNIVERSITY. to improve laboratory breeding of malaria - transmitting mosquitoes for research by developing a diet based on easy - bodied insect larvae such as lepidopteran larvae to replace more costly mammalian - blood meals',\n",
       "  '12182. Medical Research Program: Targeting Malaria and Tuberculosis in Asia and the Pacific. MEDICAL RESEARCH PROGRAM: TARGETING MALARIA AND t.b. IN ASIA AND THE PACIFIC. The Medical Research Program aims to save lifespan of misfortunate people in the Asia Pacific region through investing in medical research on product development focusing on malaria and tuberculosis, specifically: Medicines for Malaria Venture; Foundations for Innovative New Diagnostics for malaria, tuberculosis and related conditions; and Global Alliance for Tuberculosis Drugs. The total value of this investment is $ 45. 0 million over 6 years, starting 2012 - 13.',\n",
       "  '12263. The Research Institute of the McGill University Health Centre. THE inquiry INSTITUTE OF THE MCGILL UNIVERSITY HEALTH gist. to develop and implement surveillance for quality of tuberculosis (TB) care using standardized mystery story clients among private and public providers in Mumbai and Patna',\n",
       "  '13040. Oregon Wellness & Science University. or HEALTH & SCIENCE UNIVERSITY. to accelerate the testing of the prototype (s) live attenuate CMV base HIV vaccine in first in human observational medicine trial',\n",
       "  '13040. Fred Hutchinson Cancer Research Center. FRED anne hutchinson CANCER inquiry CENTER. to increase capacity to convey HIV vaccine clinical trials, including licensure trials, in highly wedged population in clade C region of southern Africa.',\n",
       "  '12262. EDCTP - Projekt: Ethiopia Malaria Trial Capacity Building (EMCAB ), - thiopien, Medizinische UniversitSt Wien. EDCTP - PROJEKT: ETHIOPIA MALARIA TRIAL content BUILDING (EMCAB ), - THIOPIEN, MEDIZINISCHE UNIVERSIT - T WIEN. EDCTP - Projekt: Abyssinia Malaria Trial Capacity Building (EMCAB ), - thiopien, Medizinische UniversitSt Wien',\n",
       "  '12262. Ameliorate Malaria Diagnostics (IMaD) - Malaria. IMPROVING MALARIA DIAGNOSTICS (IMAD) - MALARIA. Under IMaD, MCDI and its partners work to improve science lab - based diagnosis of malaria (primarily at Ministry of Health facilities ), and to increase understanding, acceptance, and correct use of microscopy and Rapid Diagnostic Tests (RDTs) by laboratory staff and health care practitioners providing verbatim care to patients.',\n",
       "  '12262. malaria parasite population body structure and adaptation on the edge of endemic distribution in Africa. MALARIA PARASITE POPULATION STRUCTURE AND ADAPTATION ON THE EDGE OF ENDEMIC DISTRIBUTION IN AFRICA. Medical Research Council. Research Grant to study malaria distribution and strains in Mauritanie',\n",
       "  '12250. Animal Health and Veterinary Laboratories Federal agency. ANIMAL wellness AND veterinarian LABORATORIES AGENCY. to aid efforts to control brucellosis, which is a bacterial disease affecting both humans and animals, by creating a vaccine and associated diagnostic that can distinguish between infected and vaccinated animals, which is not currently possible.',\n",
       "  '12250. Ecohealth Emerging Infectious Diseases Research Opening (EcoEID ). ECOHEALTH EMERGING INFECTIOUS DISEASES RESEARCH INITIATIVE (ECOEID ). New infectious diseases, mostly of animal origin, are emerging more rapidly than ever. Southeast Asia is the current hotspot of disease emergence due to mellow population and animal densities, on the one hand, and relatively limited (human and animal) healthcare delivery capacity, on the other. This project aims to understand the relationship between emerging infectious diseases of potentially pandemic proportions, and the agricultural, land utilization and ecosystem management practices that give rise to them. The project will begin with a competition in Southeast Asia for funding multi - country studies coordinated by an institution or consortium of institutions located in the region. The emphasis will be on electrical capacity building, networking and policy impact at the regional level. Lessons learned from the Southeast Asian experience will inform similar activities in other regions such as South Asia, West Africa and Egypt.',\n",
       "  '12250. Fred Hutchinson Genus cancer Research Center. FRED HUTCHINSON CANCER RESEARCH sum. to provide statistical living to get novel analytic methods and tools, and clinical and pre - clinical trial design and analysis',\n",
       "  '12262. IVCC. IVCC. to stick out the Product Development Partnership to eliminate transmission of mosquito - borne pathogens through improved insect vector control with innovative products',\n",
       "  '12250. Coalition for Neglected Tropical Diseases (COR - NTD) Programme to Identify and Investment firm NTD Priorities around Gender, Social Science and Economic Impact. COALITION FOR NEGLECTED TROPICAL DISEASES (COR - NTD) PROGRAMME TO IDENTIFY AND FUND NTD PRIORITIES AROUND sex, SOCIAL SCIENCE AND ECONOMIC IMPACT. This program in the Ross Fund Portfolio (which focusses on neglected tropical diseases, disease of emerging resistance and diseases of epidemic potential) aims to build the grounds based on effective interventions and delivery mechanisms to tackle inf',\n",
       "  \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe visceral form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay take the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - tax how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - based prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under study, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national levels of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scaled up in other high - risk areas of the sub - region. The piece of work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       "  '12250. Just Biotherapeutics, Inc. . JUST BIOTHERAPEUTICS, INC. . to provide sequence / structure judgment and optimization of three candidate monoclonal antibodies, and process development and GMP manufacturing of 2 of the 3 optimized candidates',\n",
       "  '12250. California Institute of Technology. CALIFORNIA INSTITUTE OF TECHNOLOGY. to prepare a Micro? Electro? Mechanical System as a portable and reliable microbial monitoring system that put up be integrated into safe and sustainable sanitation solutions in the developing world and enable onsite testing for pathogens',\n",
       "  '12263. University of Pittsburgh. UNIVERSITY OF PITTSBURGH. to get unscathed body imaging technologies to shorten the duration of chemotherapy for TB.',\n",
       "  '12250. Akeso, LLC. AKESO, LLC. to improve labor productivity of women smallholder farmers by testing the efficacy of treat hookworm infections that lead to the development of anemia, which is associated with reduced aerobic work capacity.',\n",
       "  '12182. USING NEXT GENERATION SEQUENCING TECHNOLOGIES (NGS) TO FIND A CURE FOR HUMAN AND CATTLE FILARIASIS. . USING NEXT GENERATION SEQUENCING TECHNOLOGIES (NGS) TO FIND Deoxyadenosine monophosphate CURE FOR HUMAN AND CATTLE FILARIASIS. . Lymphatic filariasis is the 2nd most common cause of permanent and long term disability in the world. In Sri Lanka approximately 50% of the population (9. 8 million people) is at risk of contracting bancroftian filariasis. Permanent and long term disability as well as acute attacks of filariasis affects the productivity of persons and causes loss of income. Currently no vaccinum is available for human filarisis. There are only two drugs available for treating human lymphatic filariasis: The worm Wuchereria bancrofti is responsible for approximately 115 million cases and approximately 13 million is caused by Brugia malayi. Although W. bancrofti is the major causative organism, very little is known about the molecular biology, biochemistry and immune mechanisms of this parasite. W. bancrofti cannot be maintained in the laboratory and this is an impediment for testing new treatment forms in laboratory conditions. The project described in this proposal proposes the use of a cattle filarial parasite, Setaria digitata, as the model organism. This project will sequence and annotate the complete genome of Setaria digitata using NGS tecnologies. Work that will allow the identification of genes susceptible to drugs. Next Generation Sequencing technologies are revolutionizing the way we do research in the Life Sciences field. This project will deploy a permanent stand alone bioinformatics platform in Colombo and traini researchers iand students in the use of it.',\n",
       "  '12262. Instituto de Medicina Molecular. INSTITUTO DE MEDICINA MOLECULAR. to develop a vaccinum against malaria, based on the use of Plasmodium berghei rodent malaria parasites as a platform for the delivery of immunogenic antigens of human - infective Plasmodia',\n",
       "  '12262. Funding for scientist exchanges, grants. FUNDING FOR SCIENTIST EXCHANGES, GRANTS. Genetic correlation studies in gametocytes of the malaria parasite Plasmodium falciparum - Mental ability building in the field of education and enquiry',\n",
       "  '12250. Structural and operative studies in lentivirus RNA encapsidation. STRUCTURAL AND FUNCTIONAL STUDIES IN LENTIVIRUS RNA ENCAPSIDATION. Structural and functional studies in lentivirus ribonucleic acid encapsidation',\n",
       "  '12182. Medical Research Program. MEDICAL RESEARCH PROGRAM. The Medical Research Program aims to save lives of poor people in the Asia Pacific neighborhood through investing in medical research on product development focalise on malaria and tuberculosis, specifically: Medicines for Malria Venture; Foundations for Innovative New Diagnostics for malaria, tb and related conditions; Global Alliance for TB Drugs; and Aeras. The total value of this initiative is $ 64. 4 million over 4 years, starting 2012 - 13.',\n",
       "  '12250. Institute of Tropical Medicine. INSTITUTE OF TROPICAL medical specialty. to develop and field test a novel surveillance and case detection strategy for Human African Trypanosomiasis (chapeau ), making use of new growth in diagnostic tests and communication technology',\n",
       "  '12182. Cooperation with foreign inquiry institutions (in so far as not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (IN SO FAR AS NOT INCLUDED IN OTHER AREAS ). Nanocarrier systems for epidermal point in cancer and acne treatment',\n",
       "  '12250. IVCC. IVCC. to support the Product Development Partnership to eliminate transmittance of mosquito - borne pathogens through improved insect vector control with innovative product',\n",
       "  '12182. Optimal command strategies for rodent - borne zoonoses in Brazilian slum settlements. OPTIMAL CONTROL STRATEGIES FOR gnawer - BORNE ZOONOSES IN BRAZILIAN SLUM SETTLEMENTS. GCRF Foundation Infections 2016 examining method acting for control of rodent - borne diseases in Brazil using leptospirosis, passed from rats to humans as a model system. Local residents and authorities benefiting from methods and approaches that can be applied effectively, cheaply, and without the want for a sophisticated infrastructure.',\n",
       "  '12182. Cooperation with foreign enquiry institutions (in so far as not included in other areas ). COOPERATION WITH FOREIGN RESEARCH INSTITUTIONS (IN sol FAR AS NOT INCLUDED IN OTHER AREAS ). Photoactivated biological activity of nanoscale changeover metal - functionalized dendrimers',\n",
       "  '12263. Critical Track Institute. CRITICAL PATH INSTITUTE. to apply new regulative science approaches to significantly shorten the development of more effectual and safe TB drug regimens with shorter treatment duration',\n",
       "  '12262. IVCC. IVCC. to support the Production Development Partnership to eliminate transmission of mosquito - borne pathogens through improved insect transmitter control with innovative products',\n",
       "  '13040. Dual Halo. DUAL RING. Multipurpose Bar Technologies (MPTs) - - Biomed Research for RH, APS, Dual Vaginal (DPV + LNG) Ring.',\n",
       "  '12250. Common diseases. COMMON disease. Collaborative project - German - Indonesian Aniinfective Cooperation (GINAICO ), subproject - Novel natural compounds with antibiotic properties in actinomycetes and myxobacteria in marine and terrestrial samples in Republic of indonesia - Aesculapian research of particular importance for developing countries',\n",
       "  '12182. ACAmerica, regionalHealth arrangement and services. AC: us, REGIONALHEALTH SYSTEMS AND divine service. Medical exam research',\n",
       "  '12263. Metabolic regulation of tissue death in tuberculosis. . METABOLIC REGULATION OF TISSUE DESTRUCTION IN TUBERCULOSIS. . Medical Research Council. Fellowship to investigate the fundamental interaction between host cell and TB bactieria',\n",
       "  '12110. Develop and evaluating a framework for the rational intention of antibiotic prescribing policies in imagination - constrained hospital settings. DEVELOPING AND EVALUATING A FRAMEWORK FOR THE RATIONAL DESIGN OF ANTIBIOTIC PRESCRIBING POLICIES inch RESOURCE - CONSTRAINED HOSPITAL SETTINGS. Medical Research Council. Fellowship to model a theoretical account for better antibiotic prescribing policies in resource - constrained hospital settings',\n",
       "  \"12250. PATH. PATH. to make available a rapid, low cost, and field - friendly Ov - 16 antigen - based antibody test (' Orange group - 16 rapid test ') for use in onchocerciasis programs for disease restraint and eventual elimination in Africa\",\n",
       "  \"12182. Icddr, b research 2016 - 2020 -. ICDDR, B RESEARCH 2016 - 2020 -. The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr, b) is an international health research institution located in Dhaka, dedicated to addressing the health challenges that disproportionately affect people living in poverty in Bangladesh and other low - and middle - income countries. Sida has supported icddr, b since 1981, and the institute has evolved considerably over time. The institute is today a centre of excellence producing research of global relevance, such as child and maternal health, including reproductive health. Icddr, b provides unique opportunities to address health challenges in low - income settings through low - cost, practical, lifesaving solutions. The track record includes the oral rehydration solution (ORS ), zinc for diarrhoea treatment and tetanus vaccines for newborns, which have saved and continue to write millions of lives worldwide. icddr, b has the capacity to undertake a full spectrum of research spanning population - based studies and demographic surveillance, large - scale clinical trials, hospital - based clinical studies, and laboratory research. icddr, b has recently had some turbulent years with concerns of both organizational nature and regarding research sustainability, especially with regards to the regrowth of researchers at the senior level. These challenges are being addressed in different ways and the institute is currently at a transitional stage. icddr, b ' s Strategic Plan 2015 - 2018 reinforces icddr, b ' s legacy of focusing not just on discovery, but also on strengthening the organisation ' s ability to shape policy at the national, regional and global level, as well as advocating for the use of highly effective products and evidence - based discoveries. icddr, b reinforces these efforts through publishing and South - South collaboration, training and capacity - building, and continues to build a cadre of public health experts and capacities for low - and middle - income countries. In addition, strategic national, regional and global partnerships tap into the complementary assets of other organisations  academic, scientific, NGOs and private sector  to maximise the influence and reach of icddr, b ' s work. There are five key areas in which icddr, b has a strong track record and expertise (points 1 - 5 below) and two which are highly relevant to Bangladesh and where icddr, b would like to develop greater expertise (points 6 - 7 below ): 1Reduce maternal and neonatal mortality2Prevent and treat maternal and childhood malnutrition 3Control enteric and respiratory infections 4Detect and control emerging and re - emerging infectious diseases5Achieve universal health coverage6Non Communicable Diseases7Climate ChangeThe Strategic Plan has identified the need for regrowth of the scientific base, and aim to invest in the capacity building of junior and mid - level scientists through mentoring, training, travel and exchange opportunities. This will increase the overall capacity of the institution, create a cadre of researchers with leadership\",\n",
       "  '12250. University of Georgia Research Foundation, Inc. . UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. . to reduce morbidity due to schistosomiasis in low - and mediate - income countries by developing and evaluating research - based approaches and tools for function by programs to control schistosomiasis and, where feasible, to eliminate it',\n",
       "  \"13010. DSO FONDS VOOR PDP ' Siemens III. DSO FONDS VOOR PDP ' S trine. DSO Fonds voor Product Development Partnerships (PDPs) III\",\n",
       "  '12250. Epidemiology, Ecology and Socio - Economics of Disease Emergence in Nairobi. EPIDEMIOLOGY, environmental science AND SOCIO - ECONOMICS OF DISEASE EMERGENCE IN NAIROBI. Medical Research Council. Research Grant to investigate zoonotic diseases and transmission potential in Nairobi',\n",
       "  '12263. Towards Discovery of anti - Tuberculosis Natural Products from Geothermal Hotsprings in Tanzania. TOWARDS DISCOVERY OF ANTI - TUBERCULOSIS NATURAL PRODUCTS FROM GEOTHERMAL HOTSPRINGS inch TANZANIA. The main objective of this project is to create the reciprocal scientific research collaboration between the Tanzanian and Swedish research groups by improving inquiry and training in the area of natural products chemistry and related fields to international standards. Hence, this mutual collaborative research will focus on searching and developing anti - TB agents from plants besiege the hot springs in Tanzania.',\n",
       "  '13040. John lackland Hopkins University. trick HOPKINS UNIVERSITY. to provide supplemental support for the randomized trial of male circumcision for bar of HIV and STD infection in women in Rakai, Uganda',\n",
       "  '12250. Universiteit Antwerpen. UNIVERSITEIT ANTWERPEN. to support phase Atomic number 53 clinical trials with the new unwritten infantile paralysis vaccine - 2 preparation',\n",
       "  '12262. Morphologic Genomics Consortium. STRUCTURAL GENOMICS CONSORTIUM. to support the drug discovery programs of the Merchandise Development Partnerships (PDPs ), namely the Medicines for Malaria Ventures (MMV) and the Global Alliance for TB Drug Development (GATB ), pharmaceutical companies and other foundation funded programs',\n",
       "  '12263. es - Health: HEALTH HQ - GENERAL: Global Alliance for TB Drug Development: Infectious Disease Control PDP. 2011 - 15 IRISH AID TB ALLIANCE 2015 PAY. ES - HEALTH: HEALTH HQ - GENERAL: GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT: INFECTIOUS DISEASES CONTROL PDP. 2011 - 15 IRISH AID TB ALLIANCE 2015 PAY. Essential Services - Health: : HEALTH HQ - GENERAL: Worldwide Alliance for TB Drug Development: Infectious Diseases Control PDP. 2011 - 15 IRISH AID TB ALLIANCE 2015 PAY Full short verbal description: Essential Services - Wellness: HEALTH HQ - GENERAL: Global Alliance for TB Drug Development: Infectious Diseases Control PDP. 2011 - 15 IRISH AID TB ALLIANCE 2015 PAY',\n",
       "  '12182. Macrophage provenance, proliferation and plasticity in nematode infection. MACROPHAGE PROVENANCE, PROLIFERATION AND malleability IN NEMATODE INFECTION. MRC / IIB Research grant to investigate human resistant response during worm infection with a particular interest in filarial worms that cause debilitating diseases like elephantiasis and river blindness which primarily affect ODA countries.',\n",
       "  '12182. NTD High spot Notice: Melarsoprol - pentamidine cross - ohmic resistance in African trypanosomes. NTD HIGHLIGHT NOTICE: MELARSOPROL - PENTAMIDINE hybrid - RESISTANCE IN AFRICAN TRYPANOSOMES. NTD Highlight Notice: Melarsoprol - pentamidine cross - resistance in African trypanosomes',\n",
       "  '13020. Prince Patrick henry Institute of Medical Research. PRINCE henry INSTITUTE OF MEDICAL RESEARCH. to test the utility of measuring descent levels of the HtrA3 protein for the early diagnosis of preeclampsia',\n",
       "  '12220. University of Maryland, Baltimore. UNIVERSITY OF MARYLAND, BALTIMORE. to develop broadly effective vaccines and intervention against enteric infections by conducting multi - country case - control studies using standardized methods to measure the etiology and incumbrance of diarrhea among children in develop area',\n",
       "  '12262. University of Oxford. UNIVERSITY OF oxford university. to develop a platform that will iteratively and continually model the spacial distributions of malaria (Plasmodium falciparum and P. vivax ), dengue and polio',\n",
       "  '13081. Output 13: Analysis on population dynamics. ANALYSIS ON POPULATION DYNAMICS. Honduras - Tegucigalpa. Output 13: Increase availability of evidence through cutting - edge in - depth analysis on population dynamics, sexual and reproductive health, human immunodeficiency virus and their linkages to poverty eradication and sustainable development',\n",
       "  '12182. Geographic genetic profiling of human Plasmodium malaria. GEOGRAPHIC GENETIC PROFILING OF HUMAN PLASMODIUM MALARIA. Medical Research Council research grant to examine the cooking stove of different mintage of malaria profiles in collaboration with LMIC partners P. falciparum + P. malaria in Kenya, P. falciparum + P. vivax in Siam and China',\n",
       "  '12250. Murdoch Childrens Research Institute. MURDOCH CHILDRENS RESEARCH INSTITUTE. to demonstrate how nasopharyngeal (nurse clinician) carriage surveillance in hospitalized children with respiratory illness or pneumonia can be used to estimate the pneumococcal conjugate vaccine coverage expect to show evidence of herd unsusceptibility',\n",
       "  '12220. Development Innovation Ventures (DIV) - Early Populace Health Threat. DEVELOPMENT introduction VENTURES (DIV) - OTHER PUBLIC wellness THREATS. Development Innovation Ventures (DIV )',\n",
       "  '12182. To fund treatment for paediatric diarrhoea and employment on oral desiccation, drugs and diagnostics through PATH Drug Solutions - research. TO FUND TREATMENTS FOR PAEDIATRIC DIARRHOEA AND WORK ON ORAL DEHYDRATION, DRUGS AND DIAGNOSTICS THROUGH PATH DRUG SOLUTIONS - RESEARCH. To reduce poverty through investment in research to formulate effective and affordable, diagnostics, treatment, drugs and vaccines for diarrhoea and malaria. In the longer term this has the potential to significantly reduce death and illness among the poor',\n",
       "  '12262. SWE - 2012 - 153: TOWARDS A SELF - SUSTAINABLE ANTI - MALARIAL SYSTEM atomic number 49 MOSQUITOES. SWE - 2012 - 153: TOWARDS A SELF - SUSTAINABLE ANTI - MALARIAL SYSTEM IN MOSQUITOES. This project concerns malaria paratransgenesis, that is modifying bacteria in the gut of malaria mosquitoes, where malaria - parasite - containing blood ends up after a blood meal. We have previously sequestrate a unique species of bacteria, Thorsellia anophelis, from Anopheles gambiae in Mbita in Kenya. Two recent studies have shown that bacteria belonging to the Thorsellia genus dominate An. gambiae gut flora in two other localities in, Kenya. Unpublished data show that T. anophelis besides exist in the major malaria vectors of South America and Asia. We have genome sequenced the type isolate from Kenya and plan to genetically modify this bacteria with GFP to follow its dynamics in the mosquito gut. We will also investigate the seasonal dynamics of Thorsellia in mosquitoes and their breeding waters in Kenya.',\n",
       "  '12250. Georgia Institute of Technology. GEORGIA INSTITUTE OF applied science. to support the pre - clinical development of a measles and rubella vaccine microarray spell',\n",
       "  '12182. MRC Center for Genomics and Global Health. MRC CENTRE FOR GENOMICS AND GLOBAL HEALTH. MRC / IIB. To provide international research and capacity strengthening in malaria translational genomics. The Centre (bear an African led research initiative) sets out to be an international centre of excellence in the field of genomic surveillance of infectious disease and designation of effective ways to use these new technologies to ameliorate global health.',\n",
       "  '12250. London School of Hygiene and Tropical Medicine. LONDON schooling OF HYGIENE AND TROPICAL MEDICINE. to fund approved areas of research identified by practiced groups in the earlier LSTM grant OPP 1152082 in the areas of surveillance, transmission, health systems and model identified, to define the gaps in our understanding that threaten VL riddance',\n",
       "  '12250. University of Georgia Research Foundation, Iraqi national congress. . UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. . to use RNAi technologies to identify gene knockdown event that increase RV replication',\n",
       "  '13020. Growing Invention Ventures - Maternal and Child Health. growing INNOVATION VENTURES - MATERNAL AND CHILD HEALTH. Development Innovation Ventures',\n",
       "  '12263. Global Alliance for TB Drug Development. GLOBAL ALLIANCE FOR TB DRUG growth. to foster exploration and innovation needed to discover, develop and deliver the right global health products to those most in need',\n",
       "  '12182. Comparison of traditional volt. virtual simulation - enhanced training for scaling the cervical cancer surgery workforce in Zambia. COMPARISON OF TRADITIONAL VS. VIRTUAL SIMULATION - ENHANCED TRAINING FOR SCALING THE CERVICAL CANCER SURGERY WORKFORCE IN ZAMBIA. GCRF Foundation NCDs 2016 to determine if virtual reality simulation and real - time interactive distance - learning technology can accelerate mastery and maintenance of the surgical skills required to plow cervical cancer in a resource - constrained African setting when compared to traditional surgical training.',\n",
       "  '12182. Membrane and host cytoskeleton reorganization during malaria parasite emersion from erythrocytes. MEMBRANE AND HOST CYTOSKELETON REORGANIZATION DURING MALARIA PARASITE EGRESS FROM ERYTHROCYTES. IIB Research Boards May / Jun 2016 - RM 2017 award to produce Membrane and host cytoskeleton reorganization during malaria parasite egress from erythrocytes (red blood cells) in lower and halfway income country',\n",
       "  '12250. Univercells. UNIVERCELLS. to fund the development of a breakthrough vaccine manufacturing program, able to produce vaccines more cost - effectively than live technologies, thereby addressing the need of Gavi - eligible communities',\n",
       "  \"12250. Calibr. CALIBR. to support the translational sciences in drug exploitation for therapy to deal diseases that affect the world ' s poorest populations\",\n",
       "  '13040. Microbicide Research, Development, and Insertion, Round 2. MICROBICIDE RESEARCH, DEVELOPMENT, AND institution, ROUND deuce. Microbicide Research, Growth, and Introduction, Round 2',\n",
       "  '12262. Seattle Biomedical Research Institute. SEATTLE BIOMEDICAL RESEARCH INSTITUTE. to identify and develop new liver stage (LS) - directed interventions against malaria and question inherent biology using novel assays and model systems',\n",
       "  '12182. Development and Commercialization of a Second Generation Rapid Diagnostic Test (RDT) for Human African Trypanosomiasis (HAT) and other Kinetoplastida. DEVELOPMENT AND COMMERCIALISATION OF A SECOND GENERATION RAPID DIAGNOSTIC TEST (RDT) FOR HUMAN AFRICAN TRYPANOSOMIASIS (HAT) AND OTHER KINETOPLASTIDA. This projection will develop new tests for the detection and diagnosis of sleeping nausea, which threatens 43. 4 million people in the sub - Saharan area of Africa, and the development of new, more reliable and economic diagnostic biomarkers and assays for surveillance and to suppress transmission.',\n",
       "  '12263. Brigham and Womens Hospital, Inc. . BRIGHAM AND WOMENS HOSPITAL, INC. . to evolve Mycobacteria tuberculosis glycolipid antigen formulations that activate strong and long lasting CD1 / glycolipid - specific T cell responses',\n",
       "  \"13010. Center of Excellence for Civil Registration and Vital Statistics (CRVS) Systems. CENTRE OF EXCELLENCE FOR CIVIL REGISTRATION AND VITAL STATISTICS (CRVS) SYSTEMS. Registration of events, such as birth, death, causes of death, marriage, and divorce, is critical for improving maternal, newborn, child, and adolescent health. These statistics provide policymakers and practitioners with the necessary evidence to design interventions and enact appropriate policies on maternal and child health. Many low - and middle - income countries, however, do not systematically collect such crucial information. It is estimated that one - third of the world ' s births and two - thirds of the world ' s deaths are not registered or are incorrectly certified. In many cases, global norms, standards, tools, and good practices are not readily accessible and useable to those who need them most. The project will establish the Centre of Excellence for Civil Registration and Vital Statistics (CRVS) Systems to provide information, tools, and expertise to facilitate the development and implementation of integrated CRVS systems. Funded by Global Affairs Canada and the International Development Research Centre (IDRC ), and based at IDRC, the Centre of Excellence will coordinate with existing expert groups to generate, consolidate, and plowshare information and resources in an open and collaborative electronic platform. It will also assist countries needing more direct support by facilitating the exchange of good practices and capacity strengthening, and will play an important role brokering technical assistance for countries needing more direct support. The Centre of Excellence will work closely with the Global Financing Facility in support of the Every Woman Every Child initiative to enable the development and implementation of CRVS systems plans as part of country - led investment cases for financing by the Global Financing Facility.\",\n",
       "  '12182. BBSome trafficking: enquire a novel pathway associated with virulence in Leishmania. BBSOME TRAFFICKING: INVESTIGATING A NOVEL PATHWAY ASSOCIATED WITH virulency IN LEISHMANIA. IIB - NIRG Res Boards May / Jun 2016 - RM 2017 award to investigate a novel pathway associated with virulence (pathogen) in the Leishmania tropical disease in lower and middle income countries',\n",
       "  '13081. Output 13: Analysis on universe dynamics. psychoanalysis ON POPULATION DYNAMICS. India - New Delhi. Output 13: Increased availability of evidence through cutting - edge in - depth analysis on population dynamics, sexual and reproductive health, HIV and their linkages to poverty eradication and sustainable development',\n",
       "  '12262. Biomedical Primate Research Centre. BIOMEDICAL PRIMATE inquiry CENTRE. to underpin the development of novel reporter strains (Phosphorus. vivax and / or Phosphorus. cynomolgi) for hypnozoite detection in assay and animal models',\n",
       "  '12250. Rommelag. ROMMELAG. to provide alternative packaging systems utilizing C Filling Seal technology that could allow for lower cost of vaccine manufacturing and higher quality vaccine delivery to the developing world',\n",
       "  '13040. Microbicides Research, Development, and Introduction - HIV / financial aid. MICROBICIDES enquiry, DEVELOPMENT, AND INTRODUCTION - human immunodeficiency virus / AIDS. Microbicides Research, Development, and Introduction',\n",
       "  '12250. Johns Hopkins University. JOHNS mark hopkins UNIVERSITY. to support the Pneumonia Etiology Research for Child Health (PERCH) Undertaking',\n",
       "  '12250. Univercells. UNIVERCELLS. to fund the development of a breakthrough vaccinum manufacturing platform, able to produce vaccines more cost - effectively than existing technologies, thereby addressing the needs of Gavi - eligible communities',\n",
       "  '13030. University of Tennessee. UNIVERSITY OF TENNESSEE. to enhance the experience of using condoms by developing and producing a epitome made from superelastomers (a highly elastic polymer ), which will enable the manufacture of thinner, softer male condoms.',\n",
       "  \"13040. HIV / AIDS Prevention Trials Capacity Building Grants - Phase II. HIV / AIDS PREVENTION TRIALS CAPACITY BUILDING GRANTS - PHASE II. Canada ' s international response to the HIV / AIDS epidemic is largely built around the work of the Canadian HIV Vaccine Initiative (CHVI ). CHVI proposes to increase the capacity of Canada and low - and middle - income countries to respond to the HIV / AIDS pandemic by developing new HIV vaccines and other preventive approaches; investigating social and policy issues related to HIV / AIDS; conducting clinical trials; and building an HIV vaccine manufacturing facility in Canada. The third component, conducting clinical trials, requires the participation of enquiry institutions from around the world, including those operating in high HIV - prevalence countries. However, such institutions - especially those in Africa - often lack the necessary research capacity to fully engage in clinical trials. In order to address this challenge, the Canadian International Development Agency (CIDA) has allocated CA $ 6 million to the Global Health Research Initiative (GHRI) to support building African capacity for clinical trials. This project will build on work carried out nether an earlier effort, Capacity Building for HIV / AIDS Prevention Trials (104051 ).\",\n",
       "  \"12182. NOVEL PROTEIN MICROARRAY TECHNOLOGIES FOR AFFORDABLE AND RAPID HIGH PERFORMANCE POINT OF CARE DIAGNOSTICS OF SEVERE INFECTIONS IN LOW - INCOME SETTINGS. NOVEL PROTEIN MICROARRAY TECHNOLOGIES FOR AFFORDABLE AND RAPID HIGH PERFORMANCE POINT OF CARE DIAGNOSTICS OF SEVERE INFECTIONS IN LOW - INCOME SETTINGS. Infectious diseases is the major grounds of death in low - income countries, especially in Sub - Saharan Africa. Rapid tests for Malaria and HIV have in late years dramatically improved management of patients and are extremely useful where there is no access to laboratories and qualified staff. However, today no rapid tests are available for many of the most serious infectious diseases such as TB and pneumonia, and further the sheer number of rapid tests is becoming untenable financially and practically. We will employ protein microarray technology to allow simultaneous detection of a patient ' s antibody - response to a variety of pathogens, where each pathogen ' s unique antibody signature allows greatly improved specificity. Our group has recently developed novel microarray formats that through use of certain nitrocellulose substrates and novel nanoparticle - based amplification strategies allow retained accuracy as compared with lab - base assays within 10 minutes of analysis at a fraction of the cost. The main focus of the project is to create a rapid test for reliable determination of active / latent TB in pediatric patients and at the same time detect signatures of a number of other relevant viral, bacterial and parasitic infections. The method development will be done at the Science for Life Laboratory in Stockholm, whereas the field testing will be done in collaboration with partners at the Mbarara hospital in Uganda and the division of Global Health at the Karolinska Institute.\",\n",
       "  '12182. Structure and function of Heparin Binding Hemagglutinin from Mycobacterium tuberculosis. STRUCTURE AND subroutine OF HEPARIN BINDING HEMAGGLUTININ FROM mycobacteria TUBERCULOSIS. MRC / MCMB application focalise on the function of heparin Binding Henagglutinin from Mycobacterium tuberculosis',\n",
       "  '13040. OPTIMIZE Project. OPTIMIZE PROJECT. The OPTIMIZE project is a consortium using innovation and partnership to accelerate the introduction of better, less expensive antiretroviral treatment (ART) regimens for HIV patients in low - and middle - income countries. A v - year project funded by PEPFAR through USAID, OPTIMIZE addresses three interrelated domains to spark advancements in HIV treatment: clinical trials and research, product ontogenesis and formulation, and market access and product introduction.',\n",
       "  '13040. Duke University. DUKE UNIVERSITY. to rapidly test the MPER liposome immunizing agent in a small phase 0 / 1 clinical trial in order to determine if relevant broad neutralizing antibody (BnAb) germline antibody - producing B cells can be engaged by the immunogen, and BnAb B cell lineages can be driv',\n",
       "  '13040. Fred Hutchinson Cancer Research Center. FRED anne hutchinson CANCER RESEARCH CENTER. to support a test of concept efficacy trial to determine if a novel data based HIV vaccine prevents HIV contagion in women in southern Africa who are at high risk for HIV infection.',\n",
       "  '12263. Global Wellness Innovative Technology Fund. GLOBAL HEALTH INNOVATIVE TECHNOLOGY monetary fund. to develop new health technologies as a resultant role of funding and development collaborations with Japanese industry and government',\n",
       "  '12250. University of Georgia Research Foundation, Inc. . UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. . to reduce morbidity due to schistosomiasis in low - and middle - income countries by developing and evaluating inquiry - ground approaches and tools for use by programs to control bilharzia and, where viable, to eliminate information technology',\n",
       "  '12250. PATH Vaccine Solution. PATH VACCINE SOLUTIONS. to provide technical help to the Vaccine Product Acceleration Network (Cinque - PAN) that was discussed at the 2013 Global Health Product Development Forum in Seattle, Washington. Specifically, PATH Vaccine Solutions (PVS) will audit and valuate Chemistry,',\n",
       "  '12263. Treatment Action Group. TREATMENT ACTION GROUP. to maintain and increase funding for TB delivery and Universal gas constant & D and to support the adoption and implementation of policies that catalyse uptake of innovative interventions and service delivery models',\n",
       "  '13040. Oregon Health & Science University. OREGON wellness & skill UNIVERSITY. to target Thymine - cells against ERV antigens. If true, new host - directed vaccines could be developed to eliminate HIV infected mobile phone.',\n",
       "  '12182. Common diseases. COMMON DISEASES. PDP II funding - Neglected and poverty - related diseases (funding contribution) - Medical research of especial importance for develop res publica',\n",
       "  '12182. Clinical field studies for point - of - care diagnostics using miniature microscopy scanners. CLINICAL FIELD STUDIES FOR POINT - OF - CARE DIAGNOSTICS USING MINIATURE MICROSCOPY SCANNERS. We have developed a low - cost miniaturized microscopy scanner that digitizes patient samples at high magnification and transfers the generated virtual slides over mobile networks. Our central server receives the virtual slides and allows the biological samples to be remotely analyzed by automated computer vision or visually assessed by a human observer. A proof - of - concept study supported by the Swedish Research Council has been conducted in 2014 - 2015 and shown the method to be feasible. We now plan to implement the novel multipurpose diagnostic platform in two settings in United republic of tanzania: 1) As a diagnostic method for detection of malaria in blood samples obtained from patients presenting with fever at the primary health care level and 2) as a diagnostic and monitoring method for detection of soil - transmitted helminthes and schistosomiasis in stool and urine obtained from schoolchildren within a transmission surveillance sight. Captured digital images of the specimens are transferred to the central server to detect malaria parasites in blood smears, and helminth eggs in stool and urine, and to return the results to the technician in the field. The point - of - care study will be carried out in the Bagamoyo District and the transmission surveillance study in the Masasi / Muheza District in Tanzania in collaboration with Muhimbili University of Health and Allied Sciences (MUHAS ). The study will include a comparison with conventional microscopy with regard to diagnostic accuracy (sensitivity, specificity, positive and negative predictive value ), an evaluation of usability, interpretability and assessment of time to achieve diagnosis. The project advances the field by bringing a powerful, multiplexed diagnostic tool from the laboratory to the point - of - care. The instruments are constructed out of components of mobile phones, make use of the expanding mobile networks and allow remote image processing in a highly scalable cloud computing environment. Previous mobile microscopy projects have been limited with regard to the sample area that can be captured, whereas the technology to be tested in the current project can digitally scan an entire microscopy slide. The method will aid in the combat of infectious diseases at the point - of - care level of health care and has the potential to improve access to diagnostics, enable task - shifting and shorten the time to diagnosis.',\n",
       "  '12250. A gamey throughput model of Cryptococcus infection and Cell Biology In Vivo for identifying server and pathogen disease determinants and new therapeutic. A HIGH THROUGHPUT MODEL OF CRYPTOCOCCUS INFECTION AND CELL BIOLOGY IN VIVO FOR IDENTIFYING HOST AND PATHOGEN DISEASE DETERMINANTS AND NEW THERAPEUTIC. Medical Research Council. Fellowship to consider host and pathogen factors that determine disease progression in an important oportunisitic transmission of HIV',\n",
       "  '12182. GMP manufacturing and Phase angle I clinical trial of a thermostable single - dose rabies vaccine for pre - exposure prophylaxis for child in endemic areas. GMP MANUFACTURE AND PHASE I CLINICAL TRIAL OF A THERMOSTABLE SINGLE - DOSE RABIES VACCINE FOR PRE - EXPOSURE PROPHYLAXIS FOR CHILDREN IN ENDEMIC AREAS. Medical Research Council Biomedical catalyst grant to generate a novel hydrophobia vaccine suitable for mass pre - exposure immunisation of children inlow - resource rabies - endemic areas',\n",
       "  '12262. The immune response to malaria regulation and protective immunity. THE IMMUNE RESPONSE TO MALARIA REGULATION AND PROTECTIVE IMMUNITY. The immune response to malaria: regulation and protective resistance',\n",
       "  '12240. AbGenics LifeSciences Pvt Ltd. ABGENICS LIFESCIENCES PVT LTD. to develop a long - term treatment for intestinal worm (helminth) infections using probiotic strains of the bacterium Lactobacillus, which can live in the human gut, modified to produce RNA molecules that aim and destroy cohabit helminths.',\n",
       "  '12250. Tribendimidine for the treatment of liver fluke infection in Southeast Asia. TRIBENDIMIDINE FOR THE discourse OF LIVER FLUKE INFECTION indiana SOUTHEAST ASIA. Checkup Research Council. Research Grant to trial a new potential treatment against liver flukes',\n",
       "  '12182. CVCAAfrica, regionalHealth systems and services. CVCA: AFRICA, REGIONALHEALTH SYSTEMS AND SERVICES. Medical enquiry',\n",
       "  '12250. HHS / CDC: Epidemiological report of Respiratory Pathogens in Acute Respiratory Tract Infecti. HHS / CDC: EPIDEMIOLOGICAL STUDY OF RESPIRATORY PATHOGENS IN ACUTE RESPIRATORY TRACT INFECTI. health and human services / CDC: Epidemiological study of Respiratory Pathogens in Acute Respiratory Piece of land Infecti',\n",
       "  '13040. Microbicide Research, Development, and Introduction, Round two. MICROBICIDE enquiry, DEVELOPMENT, AND INTRODUCTION, ROUND 2. Microbicide Enquiry, Development, and Introduction, Round 2',\n",
       "  \"12182. Addressing the Emergence and Spread of Leishmaniasis in the Borders of Argentina, Brazil, and Paraguay. ADDRESSING THE EMERGENCE AND SPREAD OF LEISHMANIASIS IN THE BORDERS OF ARGENTINA, BRAZIL, AND PARAGUAY. Leishmaniasis is one of the most significant vector - borne diseases worldwide, with more than 2 million new cases recorded every year. In South America, both cutaneous leishmaniasis (skin infections) and the more severe splanchnic form of the disease (affecting vital organs) are emerging in many countries and expanding northward and southward. The border areas of Argentina, Brazil, and Paraguay have the highest burden of the disease in the region. Its emergence is strongly associated with environmental and anthropogenic changes, or pollution caused by humans. This research project aims to enhance prevention and control responses to the disease ' s emergence and spread in the bordering regions through multi - country collaboration. The project team will develop evidence - based interventions which can be adapted to diverse socio - cultural and ecological settings. More specifically, researchers will: - analyze social, environmental, and biological drivers causing the emergence or re - emergence of leishmaniasis; - assess how the disease is distributed and spread in time and space in the common borders between the three countries; - identify and develop innovative and effective ecohealth - establish prevention strategies involving communities, researchers, and decision - makers from different jurisdictional levels and sectors; and, - improve vector and leishmaniasis control strategies in the three countries by strengthening cross - country collaboration, skills building, and knowledge exchange. In the area under discipline, different forms of transmission occur in a diversity of settings, ranging from forest to urban ecosystems, and from work to domestic environments. The region also has a diverse population, including the Guarani people, migrants (transient and permanent settlements ), and tourists. Researchers will study biological, environmental, and social variables associated with disease transmission risks in different types of landscapes. In each country, a specific set of interventions will be developed to address the disease ' s emergence and spread. The project will engage researchers and decision - makers from the three countries to respond to public health authorities ' explicit demands to improve the effectiveness of control programs. Participants will include decision - makers from the local, subnational, and national level of the three countries, and technical experts from the Pan - American Health Organization. This will enhance uptake of results and implementation of multi - sector prevention and control strategies. It will also help ensure that results are replicated and scale up in other high - risk areas of the sub - region. The work is expected to set the foundation for novel control strategies and programs in the three countries and inform possible regional responses.\",\n",
       "  ...],\n",
       " 'label': ['not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'not_global_func',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  'RD_New_Health_Tools',\n",
       "  ...]}"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#now we will add the synthetic/augmented text to the train dataframe\n",
    "\n",
    "#creating a dict with the synthetic description and labels\n",
    "augmented_dict={\n",
    "    \"description\": augmented_sentences,\n",
    "    \"label\": augmented_sentences_labels\n",
    "}\n",
    "augmented_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Assessing Zika transmission dynamics and mitig...</td>\n",
       "      <td>12182.0</td>\n",
       "      <td>12182. Assessing Zika transmission dynamics an...</td>\n",
       "      <td>0.031470</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL DISEASE...</td>\n",
       "      <td>12250.0</td>\n",
       "      <td>12250. HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL ...</td>\n",
       "      <td>0.643220</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015.0</td>\n",
       "      <td>Asian Vegetable Research &amp; Development Center ...</td>\n",
       "      <td>13020.0</td>\n",
       "      <td>13020. Asian Vegetable Research &amp; Development ...</td>\n",
       "      <td>0.515076</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Enhanced Effective ICT</td>\n",
       "      <td>13040.0</td>\n",
       "      <td>13040. Enhanced Effective ICT. ENHANCED EFFECT...</td>\n",
       "      <td>0.000720</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Avenir Health, Inc.</td>\n",
       "      <td>13030.0</td>\n",
       "      <td>13030. Avenir Health, Inc.. AVENIR HEALTH, INC...</td>\n",
       "      <td>0.005065</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24778</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13040. Framework Contribution LO - TCO 2013 So...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24779</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13020. PLAN SWEDEN FRAMEWORK AGREEMENT 2015 - ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24780</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12250. International Alliance for Biological S...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24781</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12263. RESULTS Educational Fund, Iraqi nationa...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24782</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13040. Framework Contribution LO - TCO 2013 So...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>24783 rows  6 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         YEAR                                      Project.title  \\\n",
       "0      2017.0  Assessing Zika transmission dynamics and mitig...   \n",
       "1      2017.0  HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL DISEASE...   \n",
       "2      2015.0  Asian Vegetable Research & Development Center ...   \n",
       "3      2017.0                             Enhanced Effective ICT   \n",
       "4      2017.0                                Avenir Health, Inc.   \n",
       "...       ...                                                ...   \n",
       "24778     NaN                                                NaN   \n",
       "24779     NaN                                                NaN   \n",
       "24780     NaN                                                NaN   \n",
       "24781     NaN                                                NaN   \n",
       "24782     NaN                                                NaN   \n",
       "\n",
       "       Purpose.Code                                        description  \\\n",
       "0           12182.0  12182. Assessing Zika transmission dynamics an...   \n",
       "1           12250.0  12250. HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL ...   \n",
       "2           13020.0  13020. Asian Vegetable Research & Development ...   \n",
       "3           13040.0  13040. Enhanced Effective ICT. ENHANCED EFFECT...   \n",
       "4           13030.0  13030. Avenir Health, Inc.. AVENIR HEALTH, INC...   \n",
       "...             ...                                                ...   \n",
       "24778           NaN  13040. Framework Contribution LO - TCO 2013 So...   \n",
       "24779           NaN  13020. PLAN SWEDEN FRAMEWORK AGREEMENT 2015 - ...   \n",
       "24780           NaN  12250. International Alliance for Biological S...   \n",
       "24781           NaN  12263. RESULTS Educational Fund, Iraqi nationa...   \n",
       "24782           NaN  13040. Framework Contribution LO - TCO 2013 So...   \n",
       "\n",
       "          Value                        label  \n",
       "0      0.031470       Epidemic_Pandemic_Prep  \n",
       "1      0.643220       Epidemic_Pandemic_Prep  \n",
       "2      0.515076  Response_Unhealthy_Products  \n",
       "3      0.000720              not_global_func  \n",
       "4      0.005065        Knowledge_Gen_Sharing  \n",
       "...         ...                          ...  \n",
       "24778       NaN    Dev_Harmonization_Int_Reg  \n",
       "24779       NaN    Dev_Harmonization_Int_Reg  \n",
       "24780       NaN    Dev_Harmonization_Int_Reg  \n",
       "24781       NaN    Dev_Harmonization_Int_Reg  \n",
       "24782       NaN    Dev_Harmonization_Int_Reg  \n",
       "\n",
       "[24783 rows x 6 columns]"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#adding the synthetic description and labels to the global_func dataframe\n",
    "train=train.append(pd.DataFrame(augmented_dict, columns=[\"description\", \"label\"]), ignore_index=True)\n",
    "train"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[2497, 2497, 2497, 2497, 2466, 2402, 2497, 2497, 2497, 2436]"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#creating a list of all the category sizes\n",
    "cat_size_aug= [len(train[train[\"label\"]==\"not_global_func\"]),\n",
    "           len(train[train[\"label\"]==\"Health_Advocacy\"]),\n",
    "           len(train[train[\"label\"]==\"Knowledge_Gen_Sharing\"]),          \n",
    "         len(train[train[\"label\"]==\"Dev_Harmonization_Int_Reg\"]),\n",
    "           len(train[train[\"label\"]==\"Epidemic_Pandemic_Prep\"]),\n",
    "           len(train[train[\"label\"]==\"Control_Cross_Border_Disease\"]),\n",
    "          len(train[train[\"label\"]==\"Response_Unhealthy_Products\"]),\n",
    "           len(train[train[\"label\"]==\"Market_Shaping\"]),\n",
    "          len(train[train[\"label\"]==\"RD_New_Health_Tools\"]),\n",
    "           len(train[train[\"label\"]==\"Promotion_Aid_Effectiveness\"]),\n",
    "          # len(train[train[\"label\"]==\"RD_Blueprint_Diseases_Pandemic_Flu\"])\n",
    "              ]\n",
    "cat_size_aug"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>label_cat</th>\n",
       "      <th>cat_size_aug</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>2497</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>2497</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>2497</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>2497</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>2466</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>2402</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>2497</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>2497</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>2497</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>2436</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                      label_cat  cat_size_aug\n",
       "0         Knowledge_Gen_Sharing          2497\n",
       "1               not_global_func          2497\n",
       "2           RD_New_Health_Tools          2497\n",
       "3        Epidemic_Pandemic_Prep          2497\n",
       "4  Control_Cross_Border_Disease          2466\n",
       "5                Market_Shaping          2402\n",
       "6               Health_Advocacy          2497\n",
       "7   Response_Unhealthy_Products          2497\n",
       "8   Promotion_Aid_Effectiveness          2497\n",
       "9     Dev_Harmonization_Int_Reg          2436"
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#creating a df of cat_size and cat_label\n",
    "\n",
    "df_aug={\"label_cat\":label_cat,\n",
    "    \"cat_size_aug\":cat_size_aug\n",
    "   }\n",
    "df_aug=pd.DataFrame(df_aug)\n",
    "df_aug"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "#create a sorted dataframe\n",
    "df_aug_sorted=df_aug.sort_values(\"cat_size_aug\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#plotting the distribution of categories. Creating column chart\n",
    "\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(df_aug_sorted[\"label_cat\"], df_aug_sorted[\"cat_size_aug\"])\n",
    "plt.xticks(rotation=90)\n",
    "\n",
    "for i, v in enumerate(df_aug_sorted[\"cat_size_aug\"]):\n",
    "    plt.text(i, v, str(v))\n",
    "\n",
    "# we can see that we the augmented data has reduced the huge imbalance between different categories    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Feature Engineering\n",
    "\n",
    "**We will first create features for train dataset and then we will create features for the test data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "*** Feature creation for train data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Feature creation\n",
    "\n",
    "#Creating function for calculating the length and punctuation percentage feature in the description column of data\n",
    "def count_punct(text):\n",
    "    count = sum([1 for char in text if char in string.punctuation])\n",
    "    return round(count/(len(text)-text.count(\" \")), 3)*100\n",
    "\n",
    "#creating feature of number of sentences in the text\n",
    "def count_sent(text):\n",
    "    return len(nltk.sent_tokenize(text))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "#creating features for the train dataframe\n",
    "train[\"body_len\"]=train[\"description\"].apply(lambda x: len(x)- x.count(\" \"))\n",
    "train[\"body_sent\"]=train[\"description\"].apply(lambda x: count_sent(x))\n",
    "train[\"punct%\"]=train[\"description\"].apply(lambda x: count_punct(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Assessing Zika transmission dynamics and mitig...</td>\n",
       "      <td>12182.0</td>\n",
       "      <td>12182. Assessing Zika transmission dynamics an...</td>\n",
       "      <td>0.031470</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>1776</td>\n",
       "      <td>13</td>\n",
       "      <td>1.8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL DISEASE...</td>\n",
       "      <td>12250.0</td>\n",
       "      <td>12250. HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL ...</td>\n",
       "      <td>0.643220</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>417</td>\n",
       "      <td>4</td>\n",
       "      <td>2.2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015.0</td>\n",
       "      <td>Asian Vegetable Research &amp; Development Center ...</td>\n",
       "      <td>13020.0</td>\n",
       "      <td>13020. Asian Vegetable Research &amp; Development ...</td>\n",
       "      <td>0.515076</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>276</td>\n",
       "      <td>4</td>\n",
       "      <td>5.1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Enhanced Effective ICT</td>\n",
       "      <td>13040.0</td>\n",
       "      <td>13040. Enhanced Effective ICT. ENHANCED EFFECT...</td>\n",
       "      <td>0.000720</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>151</td>\n",
       "      <td>4</td>\n",
       "      <td>2.6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Avenir Health, Inc.</td>\n",
       "      <td>13030.0</td>\n",
       "      <td>13030. Avenir Health, Inc.. AVENIR HEALTH, INC...</td>\n",
       "      <td>0.005065</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>251</td>\n",
       "      <td>2</td>\n",
       "      <td>4.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2017.0  Assessing Zika transmission dynamics and mitig...       12182.0   \n",
       "1  2017.0  HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL DISEASE...       12250.0   \n",
       "2  2015.0  Asian Vegetable Research & Development Center ...       13020.0   \n",
       "3  2017.0                             Enhanced Effective ICT       13040.0   \n",
       "4  2017.0                                Avenir Health, Inc.       13030.0   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12182. Assessing Zika transmission dynamics an...  0.031470   \n",
       "1  12250. HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL ...  0.643220   \n",
       "2  13020. Asian Vegetable Research & Development ...  0.515076   \n",
       "3  13040. Enhanced Effective ICT. ENHANCED EFFECT...  0.000720   \n",
       "4  13030. Avenir Health, Inc.. AVENIR HEALTH, INC...  0.005065   \n",
       "\n",
       "                         label  body_len  body_sent  punct%  \n",
       "0       Epidemic_Pandemic_Prep      1776         13     1.8  \n",
       "1       Epidemic_Pandemic_Prep       417          4     2.2  \n",
       "2  Response_Unhealthy_Products       276          4     5.1  \n",
       "3              not_global_func       151          4     2.6  \n",
       "4        Knowledge_Gen_Sharing       251          2     4.0  "
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(24783, 9)"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x360 with 3 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#lets evaluate the new features that we created and see if any of these need any transformation\n",
    "plt.figure(figsize=(12,5))\n",
    "plt.subplot(221)\n",
    "plt.hist(train[\"punct%\"], bins=20, label=\"punct%\");\n",
    "plt.legend();\n",
    "plt.subplot(222)\n",
    "plt.hist(train[\"body_len\"], bins=20, label=\"body_len\");\n",
    "plt.legend();\n",
    "plt.subplot(223)\n",
    "plt.hist(train[\"body_sent\"], bins=20, label=\"body_sent\");\n",
    "plt.legend();\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "It looks like `body_len`, and `body_sent` have a prominant right skew. `punt%` doesnt have a long skew but a transformation of all three variables might be helpful."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### We will use the box-cox power transformation to transform \"body_len\", \"punt%\" \"body_sent\" feature vectors\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# checking different exponents on body len and printing the hist to see how the distribution changes\n",
    "\n",
    "for i in [1,2,4,6,7, 8, 9]:\n",
    "    plt.hist((train[\"body_len\"])**(1/i), bins=60)\n",
    "    plt.title(\"Transformations: 1/{}\".format(str(i)))\n",
    "    plt.show();\n",
    "    \n",
    "plt.hist(np.log10(train[\"body_len\"]), bins=60)\n",
    "plt.title(\"Transformations: log\")\n",
    "plt.show();\n",
    "\n",
    "#after 6th power the histograms look very similar. However, the log transformation look better than than other powers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [],
   "source": [
    "#applying logrithmic transformation on \"body_len\" column \n",
    "train[\"body_len\"]=train[\"body_len\"].apply(lambda x: np.log10(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "## checking different exponents on number of sentences and printing the hist to see how the distribution changes\n",
    "for i in [1,2,4,6,7, 8, 9]:\n",
    "    plt.hist((train[\"body_sent\"])**(1/i), bins=40)\n",
    "    plt.title(\"Transformations: 1/{}\".format(str(i)))\n",
    "    plt.show();\n",
    "    \n",
    "plt.hist(np.log10(train[\"body_sent\"]), bins=40)\n",
    "plt.title(\"Transformations: log\")\n",
    "plt.show();\n",
    "\n",
    "# the log transformation look better than than other powers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [],
   "source": [
    "#applying logrithmic transformation on \"body_len\" column\n",
    "train[\"body_sent\"]=train[\"body_sent\"].apply(lambda x: np.log10(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAX0AAAEICAYAAACzliQjAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjMuNCwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8QVMy6AAAACXBIWXMAAAsTAAALEwEAmpwYAAAWqElEQVR4nO3df7RdZX3n8fenCJSKSDABIUFDFUaBUatpZOrU4qIVBC0wo9NYR6iDK1Zxpq7BVnC6xLaTWUyr1WEcsPgTqoWhVQoVUH5UxSoIF0R+U1OJEpOSIApBGUrCd/44O3q83B8nufeee8Lzfq111tnn2Xuf/T07uZ/znGfvs0+qCklSG35uvguQJA2PoS9JDTH0Jakhhr4kNcTQl6SGGPqS1BBDX5IaYujrSSHJPkmuSbIpyfvnu57xkrw7yUfnuw7J0NeMJXm47/Z4kkf6Hr9hSGWsBO4H9qiqU4a0zQklOTzJ2v62qvofVfXm+aoJIMmfJLk1yeYk751kmXOSrOymFyX5qyQ/TPKDJJ8easGaE0+Z7wK046uq3bdOJ1kDvLmqrhq/XJKnVNXmOSrj2cAdtR1fMZ/jukbJauAPgN+dYpmjgD/upj8L3EBv3/4YOHROq9NQ2NPXnNna403yriT/DHwiyYIkn0uyses9fi7Jkr51vtT1SL/aDdVckWRhN+/nk3wqyfe73ucN3bDOJ4ETgT/oPl38epJdk3wwybru9sEku05R13uT/HX3/Ju6HvFBSU5LsiHJvUle2Vfnm5Lc2S377SRv6dqfClwO7Nf3aWe/7vk/1bf+bya5vXsdX0ry/L55a5K8M8ktSR5M8n+T/Hw3b2G3z36Y5IEkX0ky0N9xVZ1bVZcDmyb593oB8MOqWtu91v2B36+qB6vqsar6xiDb0Wgz9DXXngnsRa+3uJLe/7lPdI+fBTwCfGjcOr8NvAnYG9gFeGfXfiLwdHph9Ax6PdZHqup3gE8Df1pVu3efMv4bcBjwIuCFwHLgD6eoC+A1wF8CC4BvAF/o6l1Mr/f7F33rbwBeDezR1fqBJC+uqh8BrwLWdbXsXlXr+l9ckoOA84F3AIuAy4C/S7JL32L/gV6v+wDgBcDvdO2nAGu79fYB3g1U97xnJTmL7Xc0cGk3fRhwN3Bu9yZ7Q5Jfm8Fza0QY+pprjwOnV9WjVfVIVX2/qj5TVT+uqk3AKmB8mHyiqv6xqh4BLqQX3ACP0Qv751bVlqq6saoemmS7bwD+uKo2VNVG4I+AN05WV9f2lar6QjfU89f0gvWMqnoMuABYmmRPgKq6tKr+qXq+DFwB/OqA++S3gEur6sruud8H7Ab8St8yZ1bVuqp6APi7cftgX+DZXe/7K1uHtKrqbVX1tgFrmMgx9N6AAJYArwS+SO8N8v3AxVs/dWnHZehrrm2sqv+39UGSX0jyF0m+k+Qh4BpgzyQ79a3zz33TPwa2HjP4S3q97wu6IZs/TbLzJNvdD/hO3+PvdG0T1tW5r2/6EeD+qtrS95ittSR5VZLruiGWH9LrJQ8aiD9TW1U9DtxL7xPFVpPtgz+jNzZ/RTesdOqA25xS92b2POBrXdMjwJqq+lj35nJBV+PLZmN7mj+Gvuba+AOrpwD/CnhpVe0BvLxrz7RP1AufP6qqg+n1il8NnDDJ4uvoDd1s9ayubbK6BtYdG/gMvR76PlW1J70e8tbXMN1z/0xtSUJvyOp70227qjZV1SlV9Yv0hqP+a5IjtvlFPNGRwNV9b3K3MIN9pNFl6GvYnkavF/nDJHsBpw+6YpJXJPnX3aeCh+gNdWyZZPHzgT/sTjtcCLwH+NQky26rXYBdgY3A5iSvojcUstV9wDOSPH2S9S8EjklyRPdJ5RTgUX7ay55UklcneW73RvEQvdc/2T4Yv+7O3QHhnwOe0h0Y3/oJq39oB+AiYEGSE5PslOS19D6JfHWQbWl0Gfoatg/SG7++H7gO+Pw2rPtM4G/ohd2dwJeZPMj/OzBGr8d6K3BT1zZj3bGI/0IvvH9A78DzJX3z76L3pvPt7iyb/catfzfwH4H/TW8/vAZ4TVX9ywCbPxC4CngYuBY4q6q+BJDkw0k+PMW6H6H3hvt6ege6HwHe2L2B/AZ9/xbdsYTfpHcQ/UHgVODYqrp/gBo1wuIvZ0ltS7Ic+FBVLZ/vWjT37OlLgm0YZtOOzZ6+JDXEnr4kNWTkr72zcOHCWrp06XyXIUk7lBtvvPH+qlo0vn3kQ3/p0qWMjY3NdxmStENJ8p2J2h3ekaSGGPqS1BBDX5IaYuhLUkMMfUlqiKEvSQ0x9CWpIYa+JDXE0Jekhoz8N3Kl6Sw99dJJ560545ghViKNPnv6ktQQQ1+SGmLoS1JDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIYY+pLUEENfkhpi6EtSQwx9SWqIoS9JDTH0Jakhhr4kNcTQl6SGGPqS1BBDX5IaYuhLUkOmDf0k+yf5YpI7k9ye5Pe69vcm+V6Sm7vb0X3rnJZkdZK7kxzZ1/6SJLd2885Mkrl5WZKkiQzyw+ibgVOq6qYkTwNuTHJlN+8DVfW+/oWTHAysAA4B9gOuSnJQVW0BzgZWAtcBlwFHAZfPzkuRJE1n2p5+Va2vqpu66U3AncDiKVY5Frigqh6tqnuA1cDyJPsCe1TVtVVVwHnAcTN9AZKkwW3TmH6SpcAvAV/vmt6e5JYkH0+yoGtbDNzbt9rarm1xNz2+XZI0JAOHfpLdgc8A76iqh+gN1TwHeBGwHnj/1kUnWL2maJ9oWyuTjCUZ27hx46AlSpKmMVDoJ9mZXuB/uqo+C1BV91XVlqp6HPgIsLxbfC2wf9/qS4B1XfuSCdqfoKrOqaplVbVs0aJF2/J6JElTGOTsnQAfA+6sqj/va9+3b7Hjgdu66UuAFUl2TXIAcCBwfVWtBzYlOax7zhOAi2fpdUiSBjDI2TsvA94I3Jrk5q7t3cDrk7yI3hDNGuAtAFV1e5ILgTvonflzcnfmDsBbgU8Cu9E7a8czdyRpiKYN/ar6ByYej79sinVWAasmaB8DDt2WAiVJs8dv5EpSQwx9SWqIoS9JDTH0Jakhhr4kNcTQl6SGGPqS1BBDX5IaYuhLUkMMfUlqiKEvSQ0x9CWpIYa+JDXE0Jekhhj6ktQQQ1+SGmLoS1JDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIYY+pLUEENfkhpi6EtSQ54y3wVIc2npqZdOOX/NGccMqRJpNNjTl6SGGPqS1JBpQz/J/km+mOTOJLcn+b2ufa8kVyb5Vne/oG+d05KsTnJ3kiP72l+S5NZu3plJMjcvS5I0kUF6+puBU6rq+cBhwMlJDgZOBa6uqgOBq7vHdPNWAIcARwFnJdmpe66zgZXAgd3tqFl8LZKkaUwb+lW1vqpu6qY3AXcCi4FjgXO7xc4FjuumjwUuqKpHq+oeYDWwPMm+wB5VdW1VFXBe3zqSpCHYpjH9JEuBXwK+DuxTVeuh98YA7N0tthi4t2+1tV3b4m56fPtE21mZZCzJ2MaNG7elREnSFAYO/SS7A58B3lFVD0216ARtNUX7ExurzqmqZVW1bNGiRYOWKEmaxkChn2RneoH/6ar6bNd8XzdkQ3e/oWtfC+zft/oSYF3XvmSCdknSkAxy9k6AjwF3VtWf9826BDixmz4RuLivfUWSXZMcQO+A7fXdENCmJId1z3lC3zqSpCEY5Bu5LwPeCNya5Oau7d3AGcCFSU4Cvgu8DqCqbk9yIXAHvTN/Tq6qLd16bwU+CewGXN7dJElDMm3oV9U/MPF4PMARk6yzClg1QfsYcOi2FChJmj1+I1eSGmLoS1JDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIYY+pLUEENfkhriD6NrKKb6gXJ/nFwaHnv6ktQQQ1+SGmLoS1JDDH1JaoihL0kN8ewdjbypzvyRtG3s6UtSQwx9SWqIoS9JDTH0Jakhhr4kNcTQl6SGGPqS1BBDX5Ia4pezNO/88pU0PPb0Jakhhr4kNcTQl6SGTBv6ST6eZEOS2/ra3pvke0lu7m5H9807LcnqJHcnObKv/SVJbu3mnZkks/9yJElTGeRA7ieBDwHnjWv/QFW9r78hycHACuAQYD/gqiQHVdUW4GxgJXAdcBlwFHD5jKqXZsjf7lVrpu3pV9U1wAMDPt+xwAVV9WhV3QOsBpYn2RfYo6quraqi9wZy3HbWLEnaTjMZ0397klu64Z8FXdti4N6+ZdZ2bYu76fHtE0qyMslYkrGNGzfOoERJUr/tDf2zgecALwLWA+/v2icap68p2idUVedU1bKqWrZo0aLtLFGSNN52hX5V3VdVW6rqceAjwPJu1lpg/75FlwDruvYlE7RLkoZou0K/G6Pf6nhg65k9lwArkuya5ADgQOD6qloPbEpyWHfWzgnAxTOoW5K0HaY9eyfJ+cDhwMIka4HTgcOTvIjeEM0a4C0AVXV7kguBO4DNwMndmTsAb6V3JtBu9M7a8cydJxEvpSDtGKYN/ap6/QTNH5ti+VXAqgnax4BDt6k6SdKs8hu5ktQQQ1+SGmLoS1JDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIYY+pLUEENfkhpi6EtSQwx9SWqIoS9JDTH0Jakhhr4kNcTQl6SGTPsjKpKGb7pfIltzxjFDqkRPNvb0Jakhhr4kNcTQl6SGGPqS1BBDX5IaYuhLUkM8ZVMDm+40Qkmjz56+JDXE0Jekhji8I01ilL8VO1VtfltXU5m2p5/k40k2JLmtr22vJFcm+VZ3v6Bv3mlJVie5O8mRfe0vSXJrN+/MJJn9lyNJmsogwzufBI4a13YqcHVVHQhc3T0mycHACuCQbp2zkuzUrXM2sBI4sLuNf05J0hybNvSr6hrggXHNxwLndtPnAsf1tV9QVY9W1T3AamB5kn2BParq2qoq4Ly+dSRJQ7K9B3L3qar1AN393l37YuDevuXWdm2Lu+nx7RNKsjLJWJKxjRs3bmeJkqTxZvvsnYnG6WuK9glV1TlVtayqli1atGjWipOk1m1v6N/XDdnQ3W/o2tcC+/cttwRY17UvmaBdkjRE2xv6lwAndtMnAhf3ta9IsmuSA+gdsL2+GwLalOSw7qydE/rWkSQNybTn6Sc5HzgcWJhkLXA6cAZwYZKTgO8CrwOoqtuTXAjcAWwGTq6qLd1TvZXemUC7AZd3N0nSEE0b+lX1+klmHTHJ8quAVRO0jwGHblN1kqRZ5WUYJKkhXoZBP+FVNGeXl0rQKLKnL0kNMfQlqSGGviQ1xDH9hjhmL8meviQ1xNCXpIYY+pLUEENfkhpi6EtSQwx9SWqIoS9JDTH0Jakhhr4kNcTQl6SGeBmGJxkvtTA87mvtiOzpS1JDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIYY+pLUEENfkhril7OkeeAXuzRf7OlLUkPs6e9g7CFKmokZ9fSTrElya5Kbk4x1bXsluTLJt7r7BX3Ln5ZkdZK7kxw50+IlSdtmNnr6r6iq+/senwpcXVVnJDm1e/yuJAcDK4BDgP2Aq5IcVFVbZqEGSQOa6tPimjOOGWIlmg9zMaZ/LHBuN30ucFxf+wVV9WhV3QOsBpbPwfYlSZOYaegXcEWSG5Os7Nr2qar1AN393l37YuDevnXXdm1PkGRlkrEkYxs3bpxhiZKkrWY6vPOyqlqXZG/gyiR3TbFsJmiriRasqnOAcwCWLVs24TKSpG03o9CvqnXd/YYkF9Ebrrkvyb5VtT7JvsCGbvG1wP59qy8B1s1k+5KeyDO8NJXtHt5J8tQkT9s6DbwSuA24BDixW+xE4OJu+hJgRZJdkxwAHAhcv73blyRtu5n09PcBLkqy9Xn+qqo+n+QG4MIkJwHfBV4HUFW3J7kQuAPYDJzsmTuSNFzbHfpV9W3ghRO0fx84YpJ1VgGrtnebkqSZ8TIMktQQQ1+SGmLoS1JDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIYY+pLUEENfkhpi6EtSQwx9SWqIoS9JDTH0Jakhhr4kNcTQl6SGGPqS1JAZ/TC6pLZM96Pra844ZkiVaHsZ+pJ+YrpQ147P0B9B/uFJmiuO6UtSQwx9SWqIoS9JDTH0JakhHsidAx6IlTSqDP1JeD6yNDr8e5w9hr6kWTNVOBvMo8HQ304O4Ujbxr+Z0TD0A7lJjkpyd5LVSU4d9vYlqWVD7ekn2Qn4P8BvAGuBG5JcUlV3DLMOSU8ujvkPbtjDO8uB1VX1bYAkFwDHAoa+pDnjsYafGnboLwbu7Xu8Fnjp+IWSrARWdg8fTnL3FM+5ELh/1iqcPaNaF4xubaNaF4xubaNaF4xubT9TV/7nPFbys2Z7fz17osZhh34maKsnNFSdA5wz0BMmY1W1bKaFzbZRrQtGt7ZRrQtGt7ZRrQtGt7bW6xr2gdy1wP59j5cA64ZcgyQ1a9ihfwNwYJIDkuwCrAAuGXINktSsoQ7vVNXmJG8HvgDsBHy8qm6f4dMONAw0D0a1Lhjd2ka1Lhjd2ka1Lhjd2pquK1VPGFKXJD1JeZVNSWqIoS9JDdkhQn+6SzckWZDkoiS3JLk+yaFDquvjSTYkuW2S+UlyZlf3LUlePIy6BqzteUmuTfJokneOUF1v6PbVLUm+luSFI1TbsV1dNycZS/JvR6GuvuV+OcmWJK8dRl2D1Jbk8CQPdvvs5iTvGYW6+mq7OcntSb48jLoGqS3J7/ftr9u6f9O9Zq2AqhrpG70Dvv8E/CKwC/BN4OBxy/wZcHo3/Tzg6iHV9nLgxcBtk8w/Gric3vcTDgO+PsT9Nl1tewO/DKwC3jlCdf0KsKCbftWI7bPd+elxsBcAd41CXd0yOwF/D1wGvHaE9tnhwOeGVc821LUnvSsBPKt7vPeo1DZu2dcAfz+b298Revo/uXRDVf0LsPXSDf0OBq4GqKq7gKVJ9pnrwqrqGuCBKRY5Fjiveq4D9kyy71zXNUhtVbWhqm4AHhtGPX3bna6ur1XVD7qH19H7LsdQDFDbw9X9JQJPZYIvFs5HXZ3/DHwG2DD3Ff3UgLUN3QB1/Tbw2ar6brf80PbbNu6z1wPnz+b2d4TQn+jSDYvHLfNN4N8BJFlO7+vHQwuLKQxSuyZ3Er1PSiMjyfFJ7gIuBf7TfNcDkGQxcDzw4fmuZRL/Jsk3k1ye5JD5LqZzELAgyZeS3JjkhPkuaLwkvwAcRe/NfNbsCNfTH+TSDWcA/yvJzcCtwDeAzXNc1yAGuuyEnijJK+iF/lDGzQdVVRcBFyV5OfAnwK/Pc0kAHwTeVVVbkon+y82rm4BnV9XDSY4G/hY4cH5LAnrZ9xLgCGA34Nok11XVP85vWT/jNcBXq2pWP0ntCKE/7aUbquoh4E3QO3gK3NPd5puXndgOSV4AfBR4VVV9f77rmUhVXZPkOUkWVtV8X1RsGXBBF/gLgaOTbK6qv53XqvjJ3+bW6cuSnDUi+2wtcH9V/Qj4UZJrgBcCoxT6K5jloR3YMYZ3pr10Q5I9u3kAbwau6f/PNo8uAU7ozuI5DHiwqtbPd1GjLMmzgM8CbxyxXhdJntt1KujOxNoFmPc3pao6oKqWVtVS4G+At41C4AMkeWbfPltOL3PmfZ8BFwO/muQp3TDKS4E757mmn0jydODX6NU5q0a+p1+TXLohye928z8MPB84L8kWekfkTxpGbUnOp3d2wsIka4HTgZ376rqM3hk8q4Ef030aGYXakjwTGAP2AB5P8g56Z0XN6ZvlAPvsPcAzgLO6rNhcQ7oi4gC1/Xt6b+KPAY8Av9V3YHc+65o3A9T2WuCtSTbT22crRmGfVdWdST4P3AI8Dny0qqY8JXZYtXWLHQ9c0X0Smd3tD2H/S5JGxI4wvCNJmiWGviQ1xNCXpIYY+pLUEENfkhpi6EtSQwx9SWrI/wePIb+t7ZlqWwAAAABJRU5ErkJggg==\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAX0AAAEICAYAAACzliQjAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjMuNCwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8QVMy6AAAACXBIWXMAAAsTAAALEwEAmpwYAAAVe0lEQVR4nO3df7RlZX3f8fcnBIhVieAMvwZwiEINWCE6HWlNG1xUQdEOrmoz1goxpGMRY1zFFYFmiTGha5KaaIgFM1EciBZKggYMoCKrBlMhMFAqvyROBWUyE2YQkaFSysC3f+x943G4P879de7ced6vtc66+zx773O+z70zn/Oc5+y9T6oKSVIbfmKhC5AkjY6hL0kNMfQlqSGGviQ1xNCXpIYY+pLUEENfkhpi6Gu3kOSAJDcm2Z7k9xa6np0lOTfJJxe6DsnQ16wleXzg9kySJwbuv31EZawBHgb2qaqzRvSc40pyfJJNg21V9Z+q6lcWqiaAJL+V5M4kO5J8aIJt1iVZ0y//apL7kzyWZEOSnx9pwZoXhr5mraqeN3YDvgu8aaDts2PbJfnJeSzjRcA9NYNTzOe5rl3JRuDXgWsm2eYk4NokrwLWAm8Bfhr4FPD5JHvMe5WaV4a+5s3YiDfJB5L8HfDpJPsm+Ysk25J8v18+ZGCfr/Yj0v/RT9V8OcmSft1PJflMku8leTTJrf20znrgNODX+3cX/yLJ3kk+lmRzf/tYkr0nqetDSf60f/zt/Yj4yCTnJNma5MEkrxuo851J7u23/XaSd/XtzwWuAw4eeLdzcP/4nxnY/18mubvvx1eT/OzAugeSvD/JN5L8IMl/S/JT/bol/e/s0SSPJPlakqH+H1fVJVV1HbB9gr/Xy4FHq2oTsBy4u6pu619ILwWWAPsP81zadRn6mm8HAvvRjcTX0P2b+3R//zDgCeDjO+3zb4B30gXMXsD7+/bT6EadhwIvBP498ERV/RLwWeB3+3cXXwH+I3AccCxwDLAS+I1J6gJ4E/AnwL7A/wS+1Ne7DPgw8EcD+28F3gjs09f60SSvqKr/A7we2DzwbmfzYOeSHAlcBrwPWApcC3whyV4Dm/1rulH34cDLgV/q288CNvX7HQCcC1T/uBcmuZCZewM/ehdwHbBHklf1o/tfBu4A/m4Wj69dgKGv+fYMcF5VPVlVT1TV96rqyqr6YVVtB84HfmGnfT5dVX9TVU8AV9AFN8BTdGH/kqp6uh+FPjbB874d+HBVba2qbcBvAu+YqK6+7WtV9aWq2gH8KV2wrq2qp4DLgeVJXgBQVddU1f+uzl8CXwb+2ZC/k18Erqmq6/vH/gjwHOCfDmxzQVVtrqpHgC/s9Ds4CHhRVT1VVV8bm9KqqndX1buHrGE8J9O9AEH3buBK4K+AJ4HzgDUzmT7TrsXQ13zbVlX/d+xOkn+Q5I+SfCfJY8CNwAt2miseHE3+EHhev/wndKPvy/spm99NsucEz3sw8J2B+9/p28atq/fQwPITwMNV9fTAfcZqSfL6JDf3UyyP0o2Sl0xQy6S1VdUzwIN07yjGTPQ7+M90c/Nf7qeVzh7yOSfVv5i9FPh63/QrdKP7o+nebf1b4C+SHDzuA2jRMPQ133YeGZ4F/EPgVVW1D/DP+/ZM+UDdyPY3q+ooulHxG4FTJ9h8M93UzZjD+raJ6hpa/9nAlXQj9AOq6gV0I+SxPkz12D9WW5LQTVn97VTPXVXbq+qsqvoZuumo/5DkhGl34tlOBG4YeJE7BvhC/47rmar6IrCFH383okXI0NeoPZ9u1Pxokv3opg2GkuQ1Sf5R/67gMbqpjqcn2Pwy4DeSLO0/CP4g8JkJtp2uvYC9gW3AjiSvB143sP4h4IVJfnqC/a8ATk5yQv9O5Sy6KZSvT7D930vyxiQv6V8oHqPr/0S/g5333bP/QPgngJ/sPxgfe4c1OLUDcGtf48+k81rgSOCuYZ5Luy5DX6P2Mbr564eBm4EvTmPfA4E/owu7e4G/ZOIg/21gA/AN4E7g9r5t1vrPIt5LF97fp/vg+eqB9d+ke9H5dn+UzcE77X8f3XTJH9L9Ht5Ed5jr/xvi6Y8AvgI8DtwEXFhVXwVI8okkn5hk3z+me8F9G90H3U8A7+hfQF7Lj/8tLqX7HOOrdL/vC4B39X3TIhY/l5HalmQl8PGqWrnQtWj+OdKXBNOYZtPi5khfkhriSF+SGjLlNUeSHEr3oc6BdCe0rKuqP0h3waZ/R3cEA8C5VXVtv885wOl0RxW8t6q+1Le/ElhP90HetcCvTXWyx5IlS2r58uXT7pgktey22257uKqW7tw+zIWmdgBnVdXtSZ4P3Jbk+n7dR6vqI4MbJzkKWE13UsfBwFeSHNkf/3sR3SnvN9OF/kl0p3tPaPny5WzYsGGIMiVJY5J8Z7z2Kad3qmpLVd3eL2+nO1Ru2SS7rAIu709vv5/u7MGVSQ6iu+ztTQMXcDplet2QJM3GtOb0kywHfg74677pPf2VAC9Osm/ftozulPIxm/q2Zf3yzu2SpBEZOvSTPI/u1PP39Re5ugh4Md2FoLYAY99WNN7p9DVJ+3jPtSbdlzZs2LZt23ibSJJmYKjQ708VvxL4bFV9DqCqHuqvdPgM3Zl+Yyd2bKK7jsiYQ+iuNbKpX965/Vmqal1VraiqFUuXPutzCEnSDE0Z+v0p2p8C7q2q3x9oP2hgszfzo2tyXA2sTvclFofTnTZ+S1VtAbYnOa5/zFOBq+aoH5KkIQxz9M6r6a5DfmeSO/q2c4G3JTmWbormAeBdAFV1d5IrgHvojvw5c+DKfWfwo0M2r2OKI3ckSXNrlz8jd8WKFeUhm5I0PUluq6oVO7d7Rq4kNcTQl6SGDDOnL+22lp99zYTrHlh78ggrkUbDkb4kNcTQl6SGGPqS1BBDX5IaYuhLUkMMfUlqiKEvSQ0x9CWpIYa+JDXE0Jekhhj6ktQQQ1+SGmLoS1JDDH1JaoihL0kNMfQlqSF+iYp2eZN90Qn4ZSfSdBj62q1N9YIhtcbpHUlqiKEvSQ0x9CWpIYa+JDXE0Jekhhj6ktQQQ1+SGmLoS1JDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIZMGfpJDk3y35Pcm+TuJL/Wt++X5Pok3+p/7juwzzlJNia5L8mJA+2vTHJnv+6CJJmfbkmSxjPMSH8HcFZV/SxwHHBmkqOAs4EbquoI4Ib+Pv261cDRwEnAhUn26B/rImANcER/O2kO+yJJmsKUoV9VW6rq9n55O3AvsAxYBVzSb3YJcEq/vAq4vKqerKr7gY3AyiQHAftU1U1VVcClA/tIkkZgWnP6SZYDPwf8NXBAVW2B7oUB2L/fbBnw4MBum/q2Zf3yzu3jPc+aJBuSbNi2bdt0SpQkTWLo0E/yPOBK4H1V9dhkm47TVpO0P7uxal1VraiqFUuXLh22REnSFIYK/SR70gX+Z6vqc33zQ/2UDf3PrX37JuDQgd0PATb37YeM0y5JGpFhjt4J8Cng3qr6/YFVVwOn9cunAVcNtK9OsneSw+k+sL2lnwLanuS4/jFPHdhHkjQCw3wx+quBdwB3JrmjbzsXWAtckeR04LvAWwGq6u4kVwD30B35c2ZVPd3vdwawHngOcF1/kySNyJShX1V/xfjz8QAnTLDP+cD547RvAF42nQIlSXPHM3IlqSGGviQ1xNCXpIYY+pLUEENfkhpi6EtSQwx9SWqIoS9JDTH0Jakhhr4kNcTQl6SGGPqS1BBDX5IaYuhLUkMMfUlqiKEvSQ0x9CWpIYa+JDVkmO/IlXZpy8++ZqFLkBYNR/qS1BBDX5IaYuhLUkMMfUlqiKEvSQ0x9CWpIYa+JDXE0JekhnhylkZishOoHlh78ggrkdrmSF+SGmLoS1JDDH1JaoihL0kNMfQlqSGGviQ1ZMrQT3Jxkq1J7hpo+1CSv01yR397w8C6c5JsTHJfkhMH2l+Z5M5+3QVJMvfdkSRNZpiR/nrgpHHaP1pVx/a3awGSHAWsBo7u97kwyR799hcBa4Aj+tt4jylJmkdThn5V3Qg8MuTjrQIur6onq+p+YCOwMslBwD5VdVNVFXApcMoMa5YkzdBszsh9T5JTgQ3AWVX1fWAZcPPANpv6tqf65Z3bx5VkDd27Ag477LBZlCjN3FRfw+iZxFqMZvpB7kXAi4FjgS3A7/Xt483T1yTt46qqdVW1oqpWLF26dIYlSpJ2NqPQr6qHqurpqnoG+GNgZb9qE3DowKaHAJv79kPGaZckjdCMQr+fox/zZmDsyJ6rgdVJ9k5yON0HtrdU1RZge5Lj+qN2TgWumkXdkqQZmHJOP8llwPHAkiSbgPOA45McSzdF8wDwLoCqujvJFcA9wA7gzKp6un+oM+iOBHoOcF1/kySN0JShX1VvG6f5U5Nsfz5w/jjtG4CXTas6SdKc8oxcSWqIoS9JDTH0Jakhhr4kNcTQl6SGGPqS1BBDX5IaYuhLUkMMfUlqiKEvSQ0x9CWpIYa+JDXE0Jekhhj6ktQQQ1+SGmLoS1JDDH1JasiU35wladez/OxrJlz3wNqTR1iJFhtH+pLUEENfkhpi6EtSQwx9SWqIH+RqwU32oaSkueVIX5IaYuhLUkMMfUlqiKEvSQ0x9CWpIYa+JDXE0Jekhhj6ktQQQ1+SGmLoS1JDDH1JasiUoZ/k4iRbk9w10LZfkuuTfKv/ue/AunOSbExyX5ITB9pfmeTOft0FSTL33ZEkTWaYC66tBz4OXDrQdjZwQ1WtTXJ2f/8DSY4CVgNHAwcDX0lyZFU9DVwErAFuBq4FTgKum6uOSOpMdQE7v1mrbVOO9KvqRuCRnZpXAZf0y5cApwy0X15VT1bV/cBGYGWSg4B9quqmqiq6F5BTkCSN1EwvrXxAVW0BqKotSfbv25fRjeTHbOrbnuqXd24fV5I1dO8KOOyww2ZYouaa38sqLX5zfT398ebpa5L2cVXVOmAdwIoVKybcTrsOr4kvLQ4zPXrnoX7Khv7n1r59E3DowHaHAJv79kPGaZckjdBMQ/9q4LR++TTgqoH21Un2TnI4cARwSz8VtD3Jcf1RO6cO7CNJGpEpp3eSXAYcDyxJsgk4D1gLXJHkdOC7wFsBquruJFcA9wA7gDP7I3cAzqA7Eug5dEfteOSOJI3YlKFfVW+bYNUJE2x/PnD+OO0bgJdNqzpJ0pzyjFxJashcH70jaQieQKWFYuhLM2RwazFyekeSGuJIX3/PE6yk3Z8jfUlqiKEvSQ0x9CWpIYa+JDXE0Jekhhj6ktQQQ1+SGmLoS1JDPDmrIZ58JcmRviQ1xNCXpIYY+pLUEENfkhpi6EtSQwx9SWqIoS9JDTH0Jakhhr4kNcTQl6SGeBkGaZ542QvtihzpS1JDHOnvZhxdaiqT/Rt5YO3JI6xEC8HQl3ZBvnhrvji9I0kNMfQlqSGGviQ1xNCXpIYY+pLUEENfkhoyq9BP8kCSO5PckWRD37ZfkuuTfKv/ue/A9uck2ZjkviQnzrZ4SdL0zMVI/zVVdWxVrejvnw3cUFVHADf090lyFLAaOBo4CbgwyR5z8PySpCHNx/TOKuCSfvkS4JSB9sur6smquh/YCKych+eXJE1gtqFfwJeT3JZkTd92QFVtAeh/7t+3LwMeHNh3U9/2LEnWJNmQZMO2bdtmWaIkacxsL8Pw6qranGR/4Pok35xk24zTVuNtWFXrgHUAK1asGHcbSdL0zWqkX1Wb+59bgc/TTdc8lOQggP7n1n7zTcChA7sfAmyezfNLkqZnxqGf5LlJnj+2DLwOuAu4Gjit3+w04Kp++WpgdZK9kxwOHAHcMtPnlyRN32ymdw4APp9k7HH+a1V9McmtwBVJTge+C7wVoKruTnIFcA+wAzizqp6eVfWSpGmZcehX1beBY8Zp/x5wwgT7nA+cP9PnlCTNjmfkSlJDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIYY+pLUkNlee0fSbmT52ddMuv6BtSePqBLNF0f6ktQQQ1+SGmLoS1JDDH1JaoihL0kN8eidRWaqoyskaTKO9CWpIY70d0GO5iXNF0f6ktQQQ1+SGmLoS1JDDH1JaoihL0kNMfQlqSGGviQ1xNCXpIZ4cpakoc3mxEG/gGXX4Ehfkhpi6EtSQwx9SWqIoS9JDTH0JakhHr0zgamOUvBIBGl0/P84dxzpS1JDHOnP0GQjj6lGHX5Jilrkv/tdg6EvadFz+md4Iw/9JCcBfwDsAXyyqtaOuob55ohG0q5qpKGfZA/gvwCvBTYBtya5uqruGWUdktoym+nY3c2oR/orgY1V9W2AJJcDq4AFCX1H5JJaM+rQXwY8OHB/E/CqnTdKsgZY0999PMl9I6htPi0BHl7oIubB7tovsG+L0Yz6ld+Zh0rm3kz69qLxGkcd+hmnrZ7VULUOWDf/5YxGkg1VtWKh65hru2u/wL4tRrtrv2Bu+zbq4/Q3AYcO3D8E2DziGiSpWaMO/VuBI5IcnmQvYDVw9YhrkKRmjXR6p6p2JHkP8CW6QzYvrqq7R1nDAtltpqp2srv2C+zbYrS79gvmsG+petaUuiRpN+W1dySpIYa+JDXE0J8jSS5OsjXJXROsT5ILkmxM8o0krxh1jTMxRL9emuSmJE8mef+o65uNIfr29v5v9Y0kX09yzKhrnKkh+raq79cdSTYk+flR1zgTU/VrYLt/nOTpJG8ZVW2zNcTf7PgkP+j/Znck+eBMnsfQnzvrgZMmWf964Ij+tga4aAQ1zYX1TN6vR4D3Ah8ZSTVzaz2T9+1+4Beq6uXAb7G4Pihcz+R9uwE4pqqOBX4Z+OQIapoL65m8X2OXe/kdugNGFpP1TNE34GtVdWx/+/BMnsTQnyNVdSNdAE5kFXBpdW4GXpDkoNFUN3NT9auqtlbVrcBTo6tqbgzRt69X1ff7uzfTnVeyKAzRt8frR0dxPJdxTpLcFQ3x/wzgV4Erga3zX9HcGbJvs2boj854l6BYtkC1aPpOB65b6CLmUpI3J/kmcA3daH/RS7IMeDPwiYWuZZ78kyT/K8l1SY6eyQMY+qMz1CUotOtJ8hq60P/AQtcyl6rq81X1UuAUuumr3cHHgA9U1dMLXcg8uB14UVUdA/wh8OczeRBDf3S8BMUilOTldPPdq6rqewtdz3zopxVenGTJQtcyB1YAlyd5AHgLcGGSUxa0ojlSVY9V1eP98rXAnjP5mxn6o3M1cGp/FM9xwA+qastCF6WJJTkM+Bzwjqr6m4WuZy4leUmS9MuvAPYCFv2LWlUdXlXLq2o58GfAu6vqzxe2qrmR5MCBv9lKuvye9t/Mr0ucI0kuA44HliTZBJwH7AlQVZ8ArgXeAGwEfgi8c2EqnZ6p+pXkQGADsA/wTJL3AUdV1WMLU/HwhvibfRB4Id1oEWDHYrmK4xB9+1d0g5CngCeAXxz4YHeXNUS/Fq0h+vYW4IwkO+j+Zqtn8jfzMgyS1BCndySpIYa+JDXE0Jekhhj6ktQQQ1+SGmLoS1JDDH1Jasj/B+smeBhzEJ2uAAAAAElFTkSuQmCC\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAX0AAAEICAYAAACzliQjAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjMuNCwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8QVMy6AAAACXBIWXMAAAsTAAALEwEAmpwYAAAWgUlEQVR4nO3df7TkdX3f8ecriISoRHAXhF10qa41QBXjdsOpbaMlEfxVsK11rRViSdcqVj3FE8HkBJN0ezD1V2kKBhUXopVuohYSIIocDVpBvFgKAhK3grAuYReVsERK3eXdP+azdVzm3jt3d+/cu3yej3PmzHfe8/nOfL534TWf+Xy/8/2mqpAk9eFnFroDkqTJMfQlqSOGviR1xNCXpI4Y+pLUEUNfkjpi6EtSRwx9PS4kOSzJtUm2JXn/QvdnV0neneSjC90PydDXHkvy0NDt0SQPDz1+/YS6sRa4Hzioqs6c0HuOlOTFSTYN16rqP1TVry9UnwCS/F6SW5JsT/KeadpcmGRtBn4zyd1JHkxyaZKDJtxlzQNDX3usqp688wbcDbxqqPbJne2SPGEeu/FM4LbajZ+Yz3O/FpONwG8AV8zQ5iTgSuBU4A3Ai4AjgAOB/zzfHdT8M/Q1b3aOeJO8K8lfAR9PcnCSP0uyNckP2/LyoXW+1Eak/6NN1Xw+yZL23M8m+USS7yd5IMnX27TOeuA04Dfat4tfSXJAkg8l2dxuH0pywAz9ek+SP26vv62NiJ+T5OwkW5Lck+SlQ/18Y5LbW9vvJHlTqz8JuAo4YujbzhHt9T8xtP4/TnJr244vJfmFoefuSvLOJDcn+esk/y3Jz7bnlrS/2QNJfpDky0nG+v+4qi6uqquAbdP8ez0PeKCqNgGvAj5WVfdU1UPAe4HXJvm5cd5Li5ehr/n2dOAQBiPxtQz+m/t4e/wM4GHgD3ZZ518AbwQOBZ4IvLPVTwN+HjgSeBrwb4CHq+rXgE8Cv9++XXwB+E3geOA44PnAauC3ZugXDILuj4CDgf8JfK71dxnwu8AfDq2/BXglcFDr6weT/GJV/Q3wMmDz0LedzcMbl+Q5wKeAdwBLGYys/zTJE4ea/XMGo+6jgOcBv9bqZwKb2nqHAe8Gqr3u+UnOZ/e9nJ98C0i7MfT4AGDlHry+FgFDX/PtUeCcqnqkqh6uqu9X1aer6kdVtQ1YB/zyLut8vKr+sqoeBjYwCG6AHzMI+2dX1Y6qurGqHpzmfV8P/G5VbamqrcDvMJiuGNmvVvtyVX2uqrYDf8wgWM+tqh8DlwIrkjwVoKquqKr/XQN/AXwe+Adj/k1eC1xRVVe3134fg+mTvzfU5ryq2lxVPwD+dJe/weHAM6vqx1X15Z1TWlX1lqp6y5h9GOUVDD6AYPBt5deTrEjy88C7Wt2R/j7O0Nd821pV/2fngyQ/l+QPk3w3yYPAtcBTk+w3tM5fDS3/CHhyW/4jBqPvS9uUze8n2X+a9z0C+O7Q4++22sh+NfcNLT8M3F9VO4Yes7MvSV6W5Po2xfIAg1Hykmn6MmPfqupR4B4G3yh2mu5v8B8ZzM1/vk0rnTXme86ofZg9F/hqK13E4NvIl4BbgS+2+qZd19W+xdDXfNt1x+qZwN8GfqmqDgL+YauHWbSR7e9U1dEMRsWvZLDDcZTNDKZudnpGq03Xr7G1fQOfZjBCP6yqnspghLxzG2Z77Z/qW5IwmLL63mzvXVXbqurMqvpbDKaj/l2SE+a8EY91InDNzg+5qnq0qs6pqhVVtZxB8H9vnD5qcTP0NWlPYTBqfiDJIcA5466Y5CVJ/k77VvAgg6mOHdM0/xTwW0mWth3Bvw18Ypq2c/VEBvPbW4HtSV4GvHTo+fuAp7VpkVE2AK9IckL7pnIm8Ag/GWVPK8krkzy7fVA8yGD7p/sb7Lru/m2H8M8AT2g7xnd+wxqe2iHJIUmelYGjgQ8wmC57dJz30uJl6GvSPsRg/vp+4Hrgz+ew7tOBP2EQdrcDf8H0Qf7vgSngZuAW4Buttsfavoi3MQjvHzLY8Xz50PPfYvCh8512lM0Ru6x/B/AvGRwCeT+DEfurqur/jvH2K4EvAA8B1wHnV9WXAJJ8OMmHZ1j3Iww+cF/HYEf3w8Ab2gfIr/LT/xZLGHwI/A2D+f2LqurCMfqnRS5eOUvqW5LVwB9U1eqF7ovmnyN9STCHaTbt2xzpS1JHHOlLUkcW/TlHlixZUitWrFjobkjSPuXGG2+8v6qW7lpf9KG/YsUKpqamFrobkrRPSfLdUXWndySpI4a+JHXE0Jekjhj6ktQRQ1+SOmLoS1JHDH1J6oihL0kdmTX02zm3b0jyv9qFnH+n1Q9JcnWSb7f7g4fWOTvJxiR3JDlxqP7CdsHpjUnOa6d0lSRNyDi/yH0E+EdV9VC74MNXklwF/BMGV9o5t12y7SzgXe2CC2uAYxhcFu4LSZ7TrshzAYOLUF/P4FzdJzE4V7e0IFacdcW0z9117ism2BNpMmYd6bcLPz/UHu7fbgWcDFzc6hcDp7Tlk4FL2wWn72RwPc/VSQ4HDqqq69qFnC8ZWkeSNAFjzekn2S/JTcAW4Oqq+hqDa4PeC9DuD23NlzG4yPNOm1ptGT99UeWd9VHvtzbJVJKprVu3zmFzJEkzGSv0q2pHVR0HLGcwaj92huaj5ulrhvqo97uwqlZV1aqlSx9zkjhJ0m6a09E7VfUA8CUGc/H3tSkb2v2W1mwTcOTQasuBza2+fERdkjQh4xy9szTJU9vygcCvAN9icCHo01qz04DL2vLlwJokByQ5isGFnG9oU0Dbkhzfjto5dWgdSdIEjHP0zuHAxUn2Y/AhsaGq/izJdcCGJKcDdwOvAaiqW5NsAG4DtgNntCN3AN4MrAcOZHDUjkfuSNIEzRr6VXUz8IIR9e8DJ0yzzjpg3Yj6FDDT/gBJ0jzyF7mS1BFDX5I6YuhLUkcMfUnqiKEvSR0x9CWpI4a+JHXE0Jekjhj6ktQRQ1+SOmLoS1JHDH1J6oihL0kdMfQlqSOGviR1xNCXpI4Y+pLUEUNfkjpi6EtSRwx9SeqIoS9JHTH0Jakjhr4kdcTQl6SOGPqS1JFZQz/JkUm+mOT2JLcmeXurvyfJ95Lc1G4vH1rn7CQbk9yR5MSh+guT3NKeOy9J5mezJEmjPGGMNtuBM6vqG0meAtyY5Or23Aer6n3DjZMcDawBjgGOAL6Q5DlVtQO4AFgLXA9cCZwEXLV3NkWSNJtZR/pVdW9VfaMtbwNuB5bNsMrJwKVV9UhV3QlsBFYnORw4qKquq6oCLgFO2dMNkCSNb05z+klWAC8AvtZKb01yc5KLkhzcasuAe4ZW29Rqy9ryrvVR77M2yVSSqa1bt86li5KkGYwd+kmeDHwaeEdVPchgquZZwHHAvcD7dzYdsXrNUH9sserCqlpVVauWLl06bhclSbMYK/ST7M8g8D9ZVZ8BqKr7qmpHVT0KfARY3ZpvAo4cWn05sLnVl4+oS5ImZJyjdwJ8DLi9qj4wVD98qNmrgW+25cuBNUkOSHIUsBK4oaruBbYlOb695qnAZXtpOyRJYxjn6J0XAW8AbklyU6u9G3hdkuMYTNHcBbwJoKpuTbIBuI3BkT9ntCN3AN4MrAcOZHDUjkfuSNIEzRr6VfUVRs/HXznDOuuAdSPqU8Cxc+mgJGnv8Re5ktQRQ1+SOmLoS1JHDH1J6oihL0kdMfQlqSOGviR1xNCXpI4Y+pLUEUNfkjpi6EtSRwx9SeqIoS9JHTH0Jakjhr4kdcTQl6SOGPqS1BFDX5I6YuhLUkcMfUnqiKEvSR0x9CWpI4a+JHXE0Jekjhj6ktSRWUM/yZFJvpjk9iS3Jnl7qx+S5Ook3273Bw+tc3aSjUnuSHLiUP2FSW5pz52XJPOzWZKkUcYZ6W8HzqyqXwCOB85IcjRwFnBNVa0ErmmPac+tAY4BTgLOT7Jfe60LgLXAynY7aS9uiyRpFrOGflXdW1XfaMvbgNuBZcDJwMWt2cXAKW35ZODSqnqkqu4ENgKrkxwOHFRV11VVAZcMrSNJmoA5zeknWQG8APgacFhV3QuDDwbg0NZsGXDP0GqbWm1ZW961Pup91iaZSjK1devWuXRRkjSDsUM/yZOBTwPvqKoHZ2o6olYz1B9brLqwqlZV1aqlS5eO20VJ0izGCv0k+zMI/E9W1Wda+b42ZUO739Lqm4Ajh1ZfDmxu9eUj6pKkCRnn6J0AHwNur6oPDD11OXBaWz4NuGyovibJAUmOYrDD9oY2BbQtyfHtNU8dWkeSNAFPGKPNi4A3ALckuanV3g2cC2xIcjpwN/AagKq6NckG4DYGR/6cUVU72npvBtYDBwJXtZskaUJmDf2q+gqj5+MBTphmnXXAuhH1KeDYuXRQkrT3+ItcSeqIoS9JHTH0Jakj4+zIlfZZK866YqG7IC0qjvQlqSOGviR1xNCXpI4Y+pLUEXfkasHNtrP1rnNfMaGeSI9/jvQlqSOGviR1xNCXpI4Y+pLUEUNfkjri0Tva53mqBWl8jvQlqSOGviR1xNCXpI4Y+pLUEUNfkjpi6EtSRwx9SeqIx+lr0fM4fGnvcaQvSR0x9CWpI7NO7yS5CHglsKWqjm219wD/Gtjamr27qq5sz50NnA7sAN5WVZ9r9RcC64EDgSuBt1dV7c2N0cLxQijSvmGckf564KQR9Q9W1XHttjPwjwbWAMe0dc5Psl9rfwGwFljZbqNeU5I0j2YN/aq6FvjBmK93MnBpVT1SVXcCG4HVSQ4HDqqq69ro/hLglN3ssyRpN+3JnP5bk9yc5KIkB7faMuCeoTabWm1ZW961PlKStUmmkkxt3bp1umaSpDna3dC/AHgWcBxwL/D+Vs+ItjVDfaSqurCqVlXVqqVLl+5mFyVJu9qt0K+q+6pqR1U9CnwEWN2e2gQcOdR0ObC51ZePqEuSJmi3Qr/N0e/0auCbbflyYE2SA5IcxWCH7Q1VdS+wLcnxSQKcCly2B/2WJO2GcQ7Z/BTwYmBJkk3AOcCLkxzHYIrmLuBNAFV1a5INwG3AduCMqtrRXurN/OSQzavaTZI0QbOGflW9bkT5YzO0XwesG1GfAo6dU+8kSXuVv8iVpI4Y+pLUEUNfkjpi6EtSRwx9SeqIoS9JHTH0JakjXi5R2k1eQ0D7Ikf6ktQRQ1+SOuL0jjSN2aZvpH2RI31J6oihL0kdMfQlqSOGviR1xB250j5opp3M/j5AM3GkL0kdMfQlqSNO70iPM54eQjNxpC9JHTH0Jakjhr4kdcTQl6SOGPqS1BFDX5I6MmvoJ7koyZYk3xyqHZLk6iTfbvcHDz13dpKNSe5IcuJQ/YVJbmnPnZcke39zJEkzGWekvx44aZfaWcA1VbUSuKY9JsnRwBrgmLbO+Un2a+tcAKwFVrbbrq8pSZpns4Z+VV0L/GCX8snAxW35YuCUofqlVfVIVd0JbARWJzkcOKiqrquqAi4ZWkeSNCG7O6d/WFXdC9DuD231ZcA9Q+02tdqytrxrXZI0QXv7NAyj5ulrhvroF0nWMpgK4hnPeMbe6ZkWlJcelBaH3R3p39embGj3W1p9E3DkULvlwOZWXz6iPlJVXVhVq6pq1dKlS3ezi5KkXe1u6F8OnNaWTwMuG6qvSXJAkqMY7LC9oU0BbUtyfDtq59ShdSRJEzLr9E6STwEvBpYk2QScA5wLbEhyOnA38BqAqro1yQbgNmA7cEZV7Wgv9WYGRwIdCFzVbpKkCZo19KvqddM8dcI07dcB60bUp4Bj59Q7SdJe5S9yJakjXkRFY/MInL3HC51ooTjSl6SOGPqS1BGnd/T/OX0jPf450pekjhj6ktQRQ1+SOmLoS1JHDH1J6oihL0kdMfQlqSOGviR1xNCXpI4Y+pLUEU/DIM0TT2uhxciRviR1xNCXpI4Y+pLUEUNfkjrijtzHmZl2HnoJPkmO9CWpI4a+JHXE6R1pEfIYf80XQ1/qjPt9+ub0jiR1ZI9CP8ldSW5JclOSqVY7JMnVSb7d7g8ean92ko1J7khy4p52XpI0N3tjpP+Sqjquqla1x2cB11TVSuCa9pgkRwNrgGOAk4Dzk+y3F95fkjSm+ZjeORm4uC1fDJwyVL+0qh6pqjuBjcDqeXh/SdI09jT0C/h8khuTrG21w6rqXoB2f2irLwPuGVp3U6s9RpK1SaaSTG3dunUPuyhJ2mlPj955UVVtTnIocHWSb83QNiNqNaphVV0IXAiwatWqkW0kSXO3RyP9qtrc7rcAn2UwXXNfksMB2v2W1nwTcOTQ6suBzXvy/pKkudnt0E/ypCRP2bkMvBT4JnA5cFprdhpwWVu+HFiT5IAkRwErgRt29/0lSXO3J9M7hwGfTbLzdf5rVf15kq8DG5KcDtwNvAagqm5NsgG4DdgOnFFVO/ao95KkOdnt0K+q7wDPH1H/PnDCNOusA9bt7ntKml+znf7BX+zu+/xFriR1xNCXpI4Y+pLUEUNfkjriqZU74jnaJTnSl6SOGPqS1BFDX5I6YuhLUkfckbuPcWespD1h6C9CBruk+eL0jiR1xNCXpI4Y+pLUEUNfkjpi6EtSRwx9SeqIoS9JHfE4fUlj25PfkHipxcXBkb4kdcTQl6SOGPqS1BHn9Kcx29yl85OS9kWGvqSJ2JOBlIOwvSdVtdB9mNGqVatqampq4u87n0cpeBZNabJ6/FBIcmNVrdq1PvGRfpKTgP8E7Ad8tKrOnXQf5puhLmmxmmjoJ9kP+C/ArwKbgK8nubyqbptkPyT1ZaaBWG/fAiY90l8NbKyq7wAkuRQ4GTD0JS2I3vYXTDr0lwH3DD3eBPzSro2SrAXWtocPJbljAn2bb0uA+xe6Ewug1+0Gt/1xse1575yaL6btfuao4qRDPyNqj9mTXFUXAhfOf3cmJ8nUqJ0qj3e9bje47T1u+76w3ZP+cdYm4Mihx8uBzRPugyR1a9Kh/3VgZZKjkjwRWANcPuE+SFK3Jjq9U1Xbk7wV+ByDQzYvqqpbJ9mHBfS4mq6ag163G9z2Hi367V70P86SJO09nnBNkjpi6EtSRwz9vSjJRUm2JPnmNM8nyXlJNia5OckvTrqP82GM7X5ukuuSPJLknZPu33waY9tf3/6tb07y1STPn3Qf58sY235y2+6bkkwl+fuT7uN8mW3bh9r93SQ7kvyzSfVtNob+3rUeOGmG518GrGy3tcAFE+jTJKxn5u3+AfA24H0T6c1krWfmbb8T+OWqeh7we+wDO/rmYD0zb/s1wPOr6jjgXwEfnUCfJmU9M2/7ztPOvJfBgSuLhqG/F1XVtQwCbjonA5fUwPXAU5McPpnezZ/ZtruqtlTV14EfT65XkzHGtn+1qn7YHl7P4LcpjwtjbPtD9ZMjRZ7EiB9i7qvG+H8d4N8Cnwa2zH+PxmfoT9ao01AsW6C+aPJOB65a6E5MUpJXJ/kWcAWD0X4XkiwDXg18eKH7sitDf7LGOg2FHn+SvIRB6L9rofsySVX12ap6LnAKg+mtXnwIeFdV7VjojuzKK2dNlqeh6FCS5zGYz35ZVX1/ofuzEKrq2iTPSrKkqhbLCcnm0yrg0iQwOAnby5Nsr6r/vqC9wpH+pF0OnNqO4jke+OuqunehO6X5k+QZwGeAN1TVXy50fyYpybPTUq8dqfZEoIsPvao6qqpWVNUK4E+AtyyGwAdH+ntVkk8BLwaWJNkEnAPsD1BVHwauBF4ObAR+BLxxYXq6d8223UmeDkwBBwGPJnkHcHRVPbgwPd57xvg3/23gacD5Lf+2L/azMI5rjG3/pwwGOT8GHgZeO7Rjd582xrYvWp6GQZI64vSOJHXE0Jekjhj6ktQRQ1+SOmLoS1JHDH1J6oihL0kd+X8W2etgsiO2HAAAAABJRU5ErkJggg==\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    },
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAX0AAAEICAYAAACzliQjAAAAOXRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjMuNCwgaHR0cHM6Ly9tYXRwbG90bGliLm9yZy8QVMy6AAAACXBIWXMAAAsTAAALEwEAmpwYAAAYO0lEQVR4nO3df7RdZX3n8fdn+CUWEDABQxIMKk4FpqJkKEtnOlgciWgHnFU7sR2hLmZiLXZwla7hR11V28ms1NZKmQ5YVASqlUlHHbCCiIyIjiBGBwkhoikgxKQk+GMI6lATvvPHeTIeL+fee25y77k32e/XWmfdfZ7963tOdj73uc/eZ59UFZKkbvhHs12AJGl0DH1J6hBDX5I6xNCXpA4x9CWpQwx9SeoQQ197jSRHJrk9ybYk75ntesZKckmSD8xyDZXkBbNZg2bXvrNdgPYOSZ7oe/pM4ElgR3v+5qr6yAjKWAE8BhxSs/wBlCSnAh+uqkU726rqP89aQVJj6GtaVNVBO6eTPAT8u6r67NjlkuxbVdtnqIznAvftSuDPcF3SnOHwjmZUklOTbExyYZK/Bz6U5LAkf5tka5Lvt+lFfevcluSPkvyvNlTzmSTz2rxnJPlwku8m+UGSr7RhnauBc4D/mOSJJK9MckCSS5Nsao9LkxwwQV3vTPI3bfvbkqxN8sIkFyfZkuSRJK/qq/NNSda3ZR9I8ubW/nPATcBRrZYnkhzVtv/hvvX/VZJ17XXcluRFffMeSvJ7Se5J8n+S/Lckz2jz5rX37AdJvpfkC0mm/H85ybOSXNv+Hb6d5O07t5NknyTvSfJYkgeTvLUNDdlR3MMZ+hqF5wCH0+uJr6B33H2oPT8a+DHwF2PW+XXgTcARwP7A77X2c4BnAYuBZwO/Bfy4qn4T+Ajw7qo6qP2V8fvAKcCJwIuBk4G3T1AXwK8AfwUcBvxv4OZW70LgD4G/7Ft/C/Ba4JBW63uTvLSqfgi8GtjUajmoqjb1v7gkLwQ+CrwNmA/cCHwyyf59i/0asAw4BvgF4Ddb+wXAxrbekcAlQLXtXp7kcobzX+i9l88D/gVwdnsdAP++vYYTgZcCZw25Tc1xhr5G4SngHVX1ZFX9uKq+W1Ufq6ofVdU2YCW90On3oar6ZlX9GFhNL3wAfkIv7F9QVTuq6qtV9fg4+/0N4A+raktVbQXeBbxxvLpa2xeq6uY21PM39IJ1VVX9BLgOWJLkUICq+lRV/V31fB74DPDPh3xP/g3wqaq6pW37T4EDgZf1LXNZVW2qqu8BnxzzHiwAnltVP6mqL+wc0qqq366q355s50n2aTVcXFXbquoh4D1978+vAX9eVRur6vvAqiFfl+Y4Q1+jsLWq/u/OJ0memeQv25DC48DtwKEtiHb6+77pHwE7zxn8Fb3e93VtyObdSfYbZ79HAd/ue/7t1jawrubRvukfA49V1Y6+5+ysJcmrk9zZhlh+AJwBzBunlglrq6qngEfo/UWx03jvwZ8AG4DPtGGli4bcZ7959P6CGvv+7Nz/Ua2enfqntQcz9DUKY0+sXgD8Y+AXq+oQ4JdaeybdUK9n+66qOo5er/i19IYlBtlEb+hmp6Nb23h1Da2dG/gYvR76kVV1KL0hmp2vYbJt/0xtSUJvyOo7k+279cwvqKrn0RuO+t0kp03xJTxG7y+Gse/Pzv1vBhb1zVs8xe1rjjL0NRsOptdr/kGSw4F3DLtiklck+Sftr4LH6QXXjnEW/yjw9iTz24ngPwA+PM6yU7U/cACwFdie5NXAq/rmPwo8O8mzxll/NfCaJKe1v1QuoHeZ65cm23GS1yZ5QftF8Ti91z/eezBQ++tlNbAyycFJngv8Lj99f1YD5ydZ2IazLpzK9jV3GfqaDZfSG79+DLgT+PQU1n0O8N/phd164POMH+T/CVgD3AOsBb7W2nZbOxfxH+iF4/fpnXi+oW/+N+j90nmgXWVz1Jj17wf+Lb2TqY/R67H/SlX9wxC7Pxb4LPAEcAdweVXdBpDkfUneN+TL+B3gh8ADwBeBvwauavPeT+8cxT30TmjfCGxnir9cNPfEL1GRNJn2l8z7quq5ky6sOc2evqSnSXJgkjOS7JtkIb0huE/Mdl3affb0JT1NkmfSGzr7eXrnXz4FnD/B5bHaQxj6ktQhDu9IUofM+ftozJs3r5YsWTLbZUjSHmPevHncfPPNN1fVsrHz5nzoL1myhDVr1sx2GZK0R2mfTXkah3ckqUMMfUnqEENfkjrE0JekDjH0JalDDH1J6hBDX5I6xNCXpA6ZNPSTPCPJXUm+nmRdkne19sOT3JLkW+3nYX3rXJxkQ5L7k5ze135SkrVt3mXtSyAkSSMyzCdynwR+uaqeaN/w88UkNwH/Gri1qla17+i8CLgwyXHAcuB4et+z+dkkL2zf1HMFsILeF2fcCCwDbpr2VyWNwJKLPjXh/IdWvWZElUjDm7SnXz1PtKf7tUcBZwLXtPZrgLPa9JnAdVX1ZFU9SO8LnE9OsgA4pKruqN6tPa/tW0eSNAJDjekn2SfJ3cAW4Jaq+jK9L4PeDNB+HtEWXwg80rf6xta2sE2PbR+0vxVJ1iRZs3Xr1im8HEnSRIYK/araUVUnAovo9dpPmGDxQeP0NUH7oP1dWVVLq2rp/PnzhylRkjSEKV29U1U/AG6jNxb/aBuyof3c0hbbCCzuW20RsKm1LxrQLkkakWGu3pmf5NA2fSDwSuAbwA3AOW2xc4Dr2/QNwPIkByQ5BjgWuKsNAW1Lckq7aufsvnUkSSMwzNU7C4BrkuxD75fE6qr62yR3AKuTnAs8DLweoKrWJVkN3AdsB85rV+4AvAW4GjiQ3lU7XrkjSSM0aehX1T3ASwa0fxc4bZx1VgIrB7SvASY6HyBJmkF+IleSOsTQl6QOMfQlqUMMfUnqEENfkjrE0JekDjH0JalDDH1J6hBDX5I6xNCXpA4x9CWpQwx9SeoQQ1+SOsTQl6QOMfQlqUMMfUnqEENfkjrE0JekDjH0JalDDH1J6hBDX5I6xNCXpA4x9CWpQwx9SeoQQ1+SOmTS0E+yOMnnkqxPsi7J+a39nUm+k+Tu9jijb52Lk2xIcn+S0/vaT0qyts27LElm5mVJkgbZd4hltgMXVNXXkhwMfDXJLW3ee6vqT/sXTnIcsBw4HjgK+GySF1bVDuAKYAVwJ3AjsAy4aXpeiiRpMpP29Ktqc1V9rU1vA9YDCydY5Uzguqp6sqoeBDYAJydZABxSVXdUVQHXAmft7guQJA1vSmP6SZYALwG+3JremuSeJFclOay1LQQe6VttY2tb2KbHtg/az4oka5Ks2bp161RKlCRNYOjQT3IQ8DHgbVX1OL2hmucDJwKbgffsXHTA6jVB+9Mbq66sqqVVtXT+/PnDlihJmsRQoZ9kP3qB/5Gq+jhAVT1aVTuq6ing/cDJbfGNwOK+1RcBm1r7ogHtkqQRGebqnQAfBNZX1Z/1tS/oW+x1wL1t+gZgeZIDkhwDHAvcVVWbgW1JTmnbPBu4fppehyRpCMNcvfNy4I3A2iR3t7ZLgDckOZHeEM1DwJsBqmpdktXAffSu/DmvXbkD8BbgauBAelfteOWOJI3QpKFfVV9k8Hj8jROssxJYOaB9DXDCVAqUJE0fP5ErSR1i6EtShxj6ktQhhr4kdYihL0kdYuhLUocY+pLUIYa+JHWIoS9JHWLoS1KHGPqS1CGGviR1iKEvSR1i6EtShxj6ktQhhr4kdYihL0kdYuhLUocY+pLUIYa+JHWIoS9JHWLoS1KHGPqS1CGGviR1iKEvSR0yaegnWZzkc0nWJ1mX5PzWfniSW5J8q/08rG+di5NsSHJ/ktP72k9KsrbNuyxJZuZlSZIGGaanvx24oKpeBJwCnJfkOOAi4NaqOha4tT2nzVsOHA8sAy5Psk/b1hXACuDY9lg2ja9FkjSJSUO/qjZX1dfa9DZgPbAQOBO4pi12DXBWmz4TuK6qnqyqB4ENwMlJFgCHVNUdVVXAtX3rSJJGYEpj+kmWAC8BvgwcWVWbofeLATiiLbYQeKRvtY2tbWGbHts+aD8rkqxJsmbr1q1TKVGSNIGhQz/JQcDHgLdV1eMTLTqgrSZof3pj1ZVVtbSqls6fP3/YEiVJkxgq9JPsRy/wP1JVH2/Nj7YhG9rPLa19I7C4b/VFwKbWvmhAuyRpRIa5eifAB4H1VfVnfbNuAM5p0+cA1/e1L09yQJJj6J2wvasNAW1Lckrb5tl960iSRmDfIZZ5OfBGYG2Su1vbJcAqYHWSc4GHgdcDVNW6JKuB++hd+XNeVe1o670FuBo4ELipPSRJIzJp6FfVFxk8Hg9w2jjrrARWDmhfA5wwlQIlSdPHT+RKUocY+pLUIYa+JHXIMCdypU5actGnZrsEadrZ05ekDjH0JalDDH1J6hBDX5I6xBO52uNNdML1oVWvGWEl0txnT1+SOsTQl6QOMfQlqUMMfUnqEENfkjrEq3fUad5qQV1jT1+SOsTQl6QOMfQlqUMMfUnqEENfkjrE0JekDjH0JalDvE5fezWvw5d+lj19SeoQQ1+SOmTS0E9yVZItSe7ta3tnku8kubs9zuibd3GSDUnuT3J6X/tJSda2eZclyfS/HEnSRIbp6V8NLBvQ/t6qOrE9bgRIchywHDi+rXN5kn3a8lcAK4Bj22PQNiVJM2jS0K+q24HvDbm9M4HrqurJqnoQ2ACcnGQBcEhV3VFVBVwLnLWLNUuSdtHujOm/Nck9bfjnsNa2EHikb5mNrW1hmx7bPlCSFUnWJFmzdevW3ShRktRvV0P/CuD5wInAZuA9rX3QOH1N0D5QVV1ZVUuraun8+fN3sURJ0li7FPpV9WhV7aiqp4D3Aye3WRuBxX2LLgI2tfZFA9olSSO0S6Hfxuh3eh2w88qeG4DlSQ5Icgy9E7Z3VdVmYFuSU9pVO2cD1+9G3ZKkXTDpJ3KTfBQ4FZiXZCPwDuDUJCfSG6J5CHgzQFWtS7IauA/YDpxXVTvapt5C70qgA4Gb2kOSNEKThn5VvWFA8wcnWH4lsHJA+xrghClVJ0maVn4iV5I6xNCXpA4x9CWpQ7y1stQxE91u+qFVrxlhJZoN9vQlqUMMfUnqEENfkjrEMX1pFkz2NY6OrWum2NOXpA4x9CWpQxzekWbIZEM40mywpy9JHWLoS1KHGPqS1CGGviR1iKEvSR1i6EtShxj6ktQhhr4kdYihL0kdYuhLUocY+pLUIYa+JHWIoS9JHWLoS1KHTBr6Sa5KsiXJvX1thye5Jcm32s/D+uZdnGRDkvuTnN7XflKStW3eZUky/S9HkjSRYXr6VwPLxrRdBNxaVccCt7bnJDkOWA4c39a5PMk+bZ0rgBXAse0xdpuSpBk26ZeoVNXtSZaMaT4TOLVNXwPcBlzY2q+rqieBB5NsAE5O8hBwSFXdAZDkWuAs4KbdfgWSpo3f3bv329VvzjqyqjYDVNXmJEe09oXAnX3LbWxtP2nTY9vVEROFiUEijc50f13ioHH6mqB98EaSFfSGgjj66KOnpzLNWX6toDQ6u3r1zqNJFgC0n1ta+0Zgcd9yi4BNrX3RgPaBqurKqlpaVUvnz5+/iyVKksba1dC/ATinTZ8DXN/XvjzJAUmOoXfC9q42FLQtySntqp2z+9aRJI3IpMM7ST5K76TtvCQbgXcAq4DVSc4FHgZeD1BV65KsBu4DtgPnVdWOtqm30LsS6EB6J3A9iStJIzbM1TtvGGfWaeMsvxJYOaB9DXDClKqTJE0rP5ErSR0y3VfvSBoBL4HVrjL0NS287FLaMzi8I0kdYuhLUocY+pLUIYa+JHWIoS9JHWLoS1KHGPqS1CFep6+heS2+tOezpy9JHWLoS1KHGPqS1CGGviR1iCdypTnIk+aaKfb0JalDDH1J6hBDX5I6xNCXpA7xRK6koU12gtmvapz77OlLUocY+pLUIQ7vSHsZr/HXROzpS1KH2NPvEE/CSdqtnn6Sh5KsTXJ3kjWt7fAktyT5Vvt5WN/yFyfZkOT+JKfvbvGSpKmZjuGdV1TViVW1tD2/CLi1qo4Fbm3PSXIcsBw4HlgGXJ5kn2nYvyRpSDMxpn8mcE2bvgY4q6/9uqp6sqoeBDYAJ8/A/iVJ49jd0C/gM0m+mmRFazuyqjYDtJ9HtPaFwCN9625sbU+TZEWSNUnWbN26dTdLlCTttLsncl9eVZuSHAHckuQbEyybAW01aMGquhK4EmDp0qUDl5EkTd1u9fSralP7uQX4BL3hmkeTLABoP7e0xTcCi/tWXwRs2p39S5KmZpdDP8nPJTl45zTwKuBe4AbgnLbYOcD1bfoGYHmSA5IcAxwL3LWr+5ckTd3uDO8cCXwiyc7t/HVVfTrJV4DVSc4FHgZeD1BV65KsBu4DtgPnVdWO3apekjQluxz6VfUA8OIB7d8FThtnnZXAyl3dpyRp93gbBknqEENfkjrEe+9ImjYT3d/JezvNDfb0JalD7Onr//M+7NLez56+JHWIoS9JHWLoS1KHGPqS1CGGviR1iKEvSR1i6EtShxj6ktQhhr4kdYihL0kd4m0YJI3EZLf58IZso2FPX5I6xJ7+XsabpkmaiD19SeoQQ1+SOsThHUlzgt+6NRr29CWpQ+zp76LZ6pV4olZ6Oi8HHZ6hL2nOs7MzfQz9GbC7vQ4PcGl6eb7gp0Ye+kmWAX8O7AN8oKpWjbqG2WaoS5otIw39JPsA/xX4l8BG4CtJbqiq+0ZZhyTt1LXzAaO+eudkYENVPVBV/wBcB5w54hokqbNGPbyzEHik7/lG4BfHLpRkBbCiPX0iyf3TtP95wGPTtK3pNBfrmos1wdysay7WBNY1FePWlD8ecSU/a1ffq3HXGXXoZ0BbPa2h6krgymnfebKmqpZO93Z311ysay7WBHOzrrlYE1jXVMzFmmBm6hr18M5GYHHf80XAphHXIEmdNerQ/wpwbJJjkuwPLAduGHENktRZIx3eqartSd4K3Ezvks2rqmrdCEuY9iGjaTIX65qLNcHcrGsu1gTWNRVzsSaYiWHuqqcNqUuS9lLecE2SOsTQl6QO2atDP8nhSW5J8q3287AByyxO8rkk65OsS3L+DNWyLMn9STYkuWjA/CS5rM2/J8lLZ6KOXajrN1o99yT5UpIXz3ZNfcv90yQ7kvzqTNc0bF1JTk1ydzuWPj8X6kryrCSfTPL1VtebRlDTVUm2JLl3nPkjP96HqGnkx/owdfUtNz3He1XttQ/g3cBFbfoi4I8HLLMAeGmbPhj4JnDcNNexD/B3wPOA/YGvj90HcAZwE73PMpwCfHkE788wdb0MOKxNv3qm6xqmpr7l/idwI/Crc+S9OhS4Dzi6PT9ijtR1yc5jH5gPfA/Yf4br+iXgpcC948yfjeN9sppGeqwPW1ffv/O0HO97dU+f3i0ermnT1wBnjV2gqjZX1dfa9DZgPb1PDk+nYW4/cSZwbfXcCRyaZME01zHluqrqS1X1/fb0TnqfrZjVmprfAT4GbJnheqZS168DH6+qhwGqahS1DVNXAQcnCXAQvdDfPpNFVdXtbT/jGfnxPllNs3CsD1VXM23H+94e+kdW1WbohTtwxEQLJ1kCvAT48jTXMej2E2N/sQyzzHSb6j7Ppdc7m0mT1pRkIfA64H0zXMuU6gJeCByW5LYkX01y9hyp6y+AF9H7IORa4PyqemoEtU1kNo73qRjFsT6U6T7e9/j76Sf5LPCcAbN+f4rbOYjeb9K3VdXj01Fb/+YHtI29VnaoW1RMs6H3meQV9P4j/LMZrWi4mi4FLqyqHb3O60gMU9e+wEnAacCBwB1J7qyqb85yXacDdwO/DDwfuCXJF2bgOJ+K2TjehzLCY31YlzKNx/seH/pV9crx5iV5NMmCqtrc/nQc+KdRkv3oBf5HqurjM1DmMLefmI1bVAy1zyS/AHwAeHVVfXcO1LQUuK79B5gHnJFke1X9j1muayPwWFX9EPhhktuBF9M7TzSbdb0JWFW9weENSR4Efh64awbrmsycvCXLiI/1YU3v8T6KExWz9QD+hJ89kfvuAcsEuBa4dAbr2Bd4ADiGn55sO37MMq/hZ09s3TWC92eYuo4GNgAvG9G/2aQ1jVn+akZzIneY9+pFwK1t2WcC9wInzIG6rgDe2aaPBL4DzBvBe7aE8U+ajvx4H6KmkR7rw9Y1ZrndPt73+J7+JFYBq5OcCzwMvB4gyVH0vrXrDODlwBuBtUnubutdUlU3TlcRNc7tJ5L8Vpv/Pnpn5c+gd9D9iF7vbEYNWdcfAM8GLm89je01g3cjHLKmkRumrqpan+TTwD3AU/SOsQkvwxtFXcAfAVcnWUsvZC+sqhm9tXGSjwKnAvOSbATeAezXV9PIj/chahrpsT6FuqZ3f+23hySpA/b2q3ckSX0MfUnqEENfkjrE0JekDjH0JalDDH1J6hBDX5I65P8BQgL93jEEgE8AAAAASUVORK5CYII=\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "## checking different exponents on number of sentences and printing the hist to see how the distribution changes\n",
    "for i in [1,2,4,6,7, 8, 9]:\n",
    "    plt.hist((train[\"punct%\"])**(1/i), bins=40)\n",
    "    plt.title(\"Transformations: 1/{}\".format(str(i)))\n",
    "    plt.show();\n",
    "    \n",
    "plt.hist(np.log10(train[\"punct%\"]), bins=40)\n",
    "plt.title(\"Transformations: log\")\n",
    "plt.show();\n",
    "\n",
    "#the 6th transformation look better than than other powers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "train[\"punct%\"]=train[\"punct%\"].apply(lambda x: x**(1/6))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Assessing Zika transmission dynamics and mitig...</td>\n",
       "      <td>12182.0</td>\n",
       "      <td>12182. Assessing Zika transmission dynamics an...</td>\n",
       "      <td>0.031470</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>3.249443</td>\n",
       "      <td>1.113943</td>\n",
       "      <td>1.102924</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL DISEASE...</td>\n",
       "      <td>12250.0</td>\n",
       "      <td>12250. HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL ...</td>\n",
       "      <td>0.643220</td>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>2.620136</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.140435</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015.0</td>\n",
       "      <td>Asian Vegetable Research &amp; Development Center ...</td>\n",
       "      <td>13020.0</td>\n",
       "      <td>13020. Asian Vegetable Research &amp; Development ...</td>\n",
       "      <td>0.515076</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>2.440909</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.311983</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Enhanced Effective ICT</td>\n",
       "      <td>13040.0</td>\n",
       "      <td>13040. Enhanced Effective ICT. ENHANCED EFFECT...</td>\n",
       "      <td>0.000720</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>2.178977</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.172633</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2017.0</td>\n",
       "      <td>Avenir Health, Inc.</td>\n",
       "      <td>13030.0</td>\n",
       "      <td>13030. Avenir Health, Inc.. AVENIR HEALTH, INC...</td>\n",
       "      <td>0.005065</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>2.399674</td>\n",
       "      <td>0.301030</td>\n",
       "      <td>1.259921</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2017.0  Assessing Zika transmission dynamics and mitig...       12182.0   \n",
       "1  2017.0  HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL DISEASE...       12250.0   \n",
       "2  2015.0  Asian Vegetable Research & Development Center ...       13020.0   \n",
       "3  2017.0                             Enhanced Effective ICT       13040.0   \n",
       "4  2017.0                                Avenir Health, Inc.       13030.0   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12182. Assessing Zika transmission dynamics an...  0.031470   \n",
       "1  12250. HHS/CDC: RAPID RESPONSE TO EBOLA VIRAL ...  0.643220   \n",
       "2  13020. Asian Vegetable Research & Development ...  0.515076   \n",
       "3  13040. Enhanced Effective ICT. ENHANCED EFFECT...  0.000720   \n",
       "4  13030. Avenir Health, Inc.. AVENIR HEALTH, INC...  0.005065   \n",
       "\n",
       "                         label  body_len  body_sent    punct%  \n",
       "0       Epidemic_Pandemic_Prep  3.249443   1.113943  1.102924  \n",
       "1       Epidemic_Pandemic_Prep  2.620136   0.602060  1.140435  \n",
       "2  Response_Unhealthy_Products  2.440909   0.602060  1.311983  \n",
       "3              not_global_func  2.178977   0.602060  1.172633  \n",
       "4        Knowledge_Gen_Sharing  2.399674   0.301030  1.259921  "
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Now we will clean our data. This means we will do the following step:\n",
    "\n",
    "    1. First we remove the punctuations.\n",
    "    2. Then we will remove the stopwords like the, a, etc.\n",
    "    3. Finally we will stem or lemmatize the work. We will explore both stemming and lemmatization.\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "#initializing stopwords, and stemmer\n",
    "stopwords= nltk.corpus.stopwords.words(\"english\")\n",
    "ps= nltk.PorterStemmer()\n",
    "wn=nltk.WordNetLemmatizer()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_text(text):\n",
    "    \n",
    "    #removing punctuation\n",
    "    text_nopunct=\"\".join([char for char in text if char not in string.punctuation])\n",
    "    \n",
    "    #clean_punct=re.sub(r'\\w*[0-9]\\w*',\"\", text_nopunct)\n",
    "    \n",
    "    #spitting into token based on word end\n",
    "    token=re.split(\"\\W+\",text_nopunct)\n",
    "    \n",
    "    #decided to use lemmetizer instead of stemmer as lemmetizer provids better results and also understands language semantics\n",
    "    clean_lemma= [wn.lemmatize(word.upper()) for word in token if word not in stopwords] \n",
    "    \n",
    "    #removing \"NA\" token\n",
    "    remove_na= [word for word in clean_lemma if word !=\"NA\"]\n",
    "    \n",
    "    #returning the cleaned text\n",
    "    return remove_na"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "#cleaning the dataframe using clean_text()--we will not clean text here as our vectorizer will do this for us \n",
    "#using this function\n",
    "#global_func[\"description\"]=global_func[\"description\"].apply(lambda x: clean_text(x))\n",
    "#global_func[\"description\"].head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>15939</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12220. New vaccine support (sagebrush state )....</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>2.120574</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.376422</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20991</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13030. Avenir Wellness, Inc. . AVENIR HEALTH, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>2.408240</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.254616</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15182</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12220. New vaccine support (NVS ). young VACCI...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>1.949390</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.442250</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8198</th>\n",
       "      <td>2015.0</td>\n",
       "      <td>Vihara Innovation Network Private Limited</td>\n",
       "      <td>13020.0</td>\n",
       "      <td>13020. Vihara Innovation Network Private Limit...</td>\n",
       "      <td>0.137340</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>2.451786</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.254616</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5978</th>\n",
       "      <td>2013.0</td>\n",
       "      <td>GLOBAL HIV / AIDS PROGRAMMES - Gender Transfor...</td>\n",
       "      <td>13040.0</td>\n",
       "      <td>13040. GLOBAL HIV / AIDS PROGRAMMES - Gender T...</td>\n",
       "      <td>0.428005</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>2.826723</td>\n",
       "      <td>0.69897</td>\n",
       "      <td>1.207518</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         YEAR                                      Project.title  \\\n",
       "15939     NaN                                                NaN   \n",
       "20991     NaN                                                NaN   \n",
       "15182     NaN                                                NaN   \n",
       "8198   2015.0          Vihara Innovation Network Private Limited   \n",
       "5978   2013.0  GLOBAL HIV / AIDS PROGRAMMES - Gender Transfor...   \n",
       "\n",
       "       Purpose.Code                                        description  \\\n",
       "15939           NaN  12220. New vaccine support (sagebrush state )....   \n",
       "20991           NaN  13030. Avenir Wellness, Inc. . AVENIR HEALTH, ...   \n",
       "15182           NaN  12220. New vaccine support (NVS ). young VACCI...   \n",
       "8198        13020.0  13020. Vihara Innovation Network Private Limit...   \n",
       "5978        13040.0  13040. GLOBAL HIV / AIDS PROGRAMMES - Gender T...   \n",
       "\n",
       "          Value                        label  body_len  body_sent    punct%  \n",
       "15939       NaN               Market_Shaping  2.120574    0.60206  1.376422  \n",
       "20991       NaN  Promotion_Aid_Effectiveness  2.408240    0.60206  1.254616  \n",
       "15182       NaN               Market_Shaping  1.949390    0.60206  1.442250  \n",
       "8198   0.137340              not_global_func  2.451786    0.60206  1.254616  \n",
       "5978   0.428005              not_global_func  2.826723    0.69897  1.207518  "
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#shuffling the dataframe using sklearn function\n",
    "train=shuffle(train)\n",
    "train.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [],
   "source": [
    "#resetting the index\n",
    "train.reset_index(inplace=True, drop=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12220. New vaccine support (sagebrush state )....</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>2.120574</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.376422</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>13030. Avenir Wellness, Inc. . AVENIR HEALTH, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>2.408240</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.254616</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>12220. New vaccine support (NVS ). young VACCI...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>1.949390</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.442250</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2015.0</td>\n",
       "      <td>Vihara Innovation Network Private Limited</td>\n",
       "      <td>13020.0</td>\n",
       "      <td>13020. Vihara Innovation Network Private Limit...</td>\n",
       "      <td>0.137340</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>2.451786</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.254616</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2013.0</td>\n",
       "      <td>GLOBAL HIV / AIDS PROGRAMMES - Gender Transfor...</td>\n",
       "      <td>13040.0</td>\n",
       "      <td>13040. GLOBAL HIV / AIDS PROGRAMMES - Gender T...</td>\n",
       "      <td>0.428005</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>2.826723</td>\n",
       "      <td>0.69897</td>\n",
       "      <td>1.207518</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     YEAR                                      Project.title  Purpose.Code  \\\n",
       "0     NaN                                                NaN           NaN   \n",
       "1     NaN                                                NaN           NaN   \n",
       "2     NaN                                                NaN           NaN   \n",
       "3  2015.0          Vihara Innovation Network Private Limited       13020.0   \n",
       "4  2013.0  GLOBAL HIV / AIDS PROGRAMMES - Gender Transfor...       13040.0   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12220. New vaccine support (sagebrush state )....       NaN   \n",
       "1  13030. Avenir Wellness, Inc. . AVENIR HEALTH, ...       NaN   \n",
       "2  12220. New vaccine support (NVS ). young VACCI...       NaN   \n",
       "3  13020. Vihara Innovation Network Private Limit...  0.137340   \n",
       "4  13040. GLOBAL HIV / AIDS PROGRAMMES - Gender T...  0.428005   \n",
       "\n",
       "                         label  body_len  body_sent    punct%  \n",
       "0               Market_Shaping  2.120574    0.60206  1.376422  \n",
       "1  Promotion_Aid_Effectiveness  2.408240    0.60206  1.254616  \n",
       "2               Market_Shaping  1.949390    0.60206  1.442250  \n",
       "3              not_global_func  2.451786    0.60206  1.254616  \n",
       "4              not_global_func  2.826723    0.69897  1.207518  "
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "train.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### Feature creation for test data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "#creating features for the train dataframe\n",
    "test[\"body_len\"]=test[\"description\"].apply(lambda x: len(x)- x.count(\" \"))\n",
    "test[\"body_sent\"]=test[\"description\"].apply(lambda x: count_sent(x))\n",
    "test[\"punct%\"]=test[\"description\"].apply(lambda x: count_punct(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2013</td>\n",
       "      <td>Projet de coopTration universitaire - Initiati...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Projet de coopTration universitaire - I...</td>\n",
       "      <td>0.073950</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>2804</td>\n",
       "      <td>23</td>\n",
       "      <td>2.4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>0.096651</td>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>227</td>\n",
       "      <td>5</td>\n",
       "      <td>7.5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015</td>\n",
       "      <td>EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...</td>\n",
       "      <td>3.040122</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>463</td>\n",
       "      <td>6</td>\n",
       "      <td>3.9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Scientific cooperation with other countries (n...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Scientific cooperation with other count...</td>\n",
       "      <td>0.038746</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>419</td>\n",
       "      <td>6</td>\n",
       "      <td>3.3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2015</td>\n",
       "      <td>INT/Fund of the United Nations International D...</td>\n",
       "      <td>13010</td>\n",
       "      <td>13010. INT/Fund of the United Nations Internat...</td>\n",
       "      <td>0.914221</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>645</td>\n",
       "      <td>9</td>\n",
       "      <td>1.9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2629</th>\n",
       "      <td>2017</td>\n",
       "      <td>AC_889_Mental health and substance abuse_12110</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. AC_889_Mental health and substance abus...</td>\n",
       "      <td>0.183818</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>121</td>\n",
       "      <td>4</td>\n",
       "      <td>7.4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2630</th>\n",
       "      <td>2017</td>\n",
       "      <td>Global Health Innovative Technology Fund</td>\n",
       "      <td>13040</td>\n",
       "      <td>13040. Global Health Innovative Technology Fun...</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>189</td>\n",
       "      <td>4</td>\n",
       "      <td>1.6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2631</th>\n",
       "      <td>2015</td>\n",
       "      <td>Implementation Science Research to Support Pro...</td>\n",
       "      <td>13040</td>\n",
       "      <td>13040. Implementation Science Research to Supp...</td>\n",
       "      <td>1.021588</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>197</td>\n",
       "      <td>4</td>\n",
       "      <td>3.6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2632</th>\n",
       "      <td>2013</td>\n",
       "      <td>IR13-WB-RESEARCH FOR POLICY &amp; ADVOCACY</td>\n",
       "      <td>12110</td>\n",
       "      <td>12110. IR13-WB-RESEARCH FOR POLICY &amp; ADVOCACY....</td>\n",
       "      <td>0.000762</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>110</td>\n",
       "      <td>4</td>\n",
       "      <td>10.9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2633</th>\n",
       "      <td>2015</td>\n",
       "      <td>United Nations Country Technical Cooperation: ...</td>\n",
       "      <td>13020</td>\n",
       "      <td>13020. United Nations Country Technical Cooper...</td>\n",
       "      <td>0.100310</td>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>1099</td>\n",
       "      <td>8</td>\n",
       "      <td>4.8</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2634 rows  9 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      YEAR                                      Project.title  Purpose.Code  \\\n",
       "0     2013  Projet de coopTration universitaire - Initiati...         12182   \n",
       "1     2013                          New vaccine support (NVS)         12220   \n",
       "2     2015  EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...         12182   \n",
       "3     2017  Scientific cooperation with other countries (n...         12182   \n",
       "4     2015  INT/Fund of the United Nations International D...         13010   \n",
       "...    ...                                                ...           ...   \n",
       "2629  2017     AC_889_Mental health and substance abuse_12110         12110   \n",
       "2630  2017           Global Health Innovative Technology Fund         13040   \n",
       "2631  2015  Implementation Science Research to Support Pro...         13040   \n",
       "2632  2013             IR13-WB-RESEARCH FOR POLICY & ADVOCACY         12110   \n",
       "2633  2015  United Nations Country Technical Cooperation: ...         13020   \n",
       "\n",
       "                                            description     Value  \\\n",
       "0     12182. Projet de coopTration universitaire - I...  0.073950   \n",
       "1     12220. New vaccine support (NVS). NEW VACCINE ...  0.096651   \n",
       "2     12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...  3.040122   \n",
       "3     12182. Scientific cooperation with other count...  0.038746   \n",
       "4     13010. INT/Fund of the United Nations Internat...  0.914221   \n",
       "...                                                 ...       ...   \n",
       "2629  12110. AC_889_Mental health and substance abus...  0.183818   \n",
       "2630  13040. Global Health Innovative Technology Fun...  0.750000   \n",
       "2631  13040. Implementation Science Research to Supp...  1.021588   \n",
       "2632  12110. IR13-WB-RESEARCH FOR POLICY & ADVOCACY....  0.000762   \n",
       "2633  13020. United Nations Country Technical Cooper...  0.100310   \n",
       "\n",
       "                             label  body_len  body_sent  punct%  \n",
       "0                  not_global_func      2804         23     2.4  \n",
       "1                   Market_Shaping       227          5     7.5  \n",
       "2              RD_New_Health_Tools       463          6     3.9  \n",
       "3            Knowledge_Gen_Sharing       419          6     3.3  \n",
       "4      Response_Unhealthy_Products       645          9     1.9  \n",
       "...                            ...       ...        ...     ...  \n",
       "2629   Response_Unhealthy_Products       121          4     7.4  \n",
       "2630           RD_New_Health_Tools       189          4     1.6  \n",
       "2631         Knowledge_Gen_Sharing       197          4     3.6  \n",
       "2632           RD_New_Health_Tools       110          4    10.9  \n",
       "2633  Control_Cross_Border_Disease      1099          8     4.8  \n",
       "\n",
       "[2634 rows x 9 columns]"
      ]
     },
     "execution_count": 71,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x360 with 3 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#lets evaluate the new features that we created and see if any of these need any transformation\n",
    "plt.figure(figsize=(12,5))\n",
    "plt.subplot(221)\n",
    "plt.hist(test[\"punct%\"], bins=20, label=\"punct%\");\n",
    "plt.legend();\n",
    "plt.subplot(222)\n",
    "plt.hist(test[\"body_len\"], bins=20, label=\"body_len\");\n",
    "plt.legend();\n",
    "plt.subplot(223)\n",
    "plt.hist(test[\"body_sent\"], bins=20, label=\"body_sent\");\n",
    "plt.legend();\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**** We can see from the above charts that they have similar skew as the train data. So, we will use the same box-cox transformation with the same powers as used in the train data transformation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2013</td>\n",
       "      <td>Projet de coopTration universitaire - Initiati...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Projet de coopTration universitaire - I...</td>\n",
       "      <td>0.073950</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>3.447778</td>\n",
       "      <td>1.361728</td>\n",
       "      <td>1.157094</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>0.096651</td>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>2.356026</td>\n",
       "      <td>0.698970</td>\n",
       "      <td>1.399083</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015</td>\n",
       "      <td>EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...</td>\n",
       "      <td>3.040122</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>2.665581</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.254616</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Scientific cooperation with other countries (n...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Scientific cooperation with other count...</td>\n",
       "      <td>0.038746</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>2.622214</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.220166</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2015</td>\n",
       "      <td>INT/Fund of the United Nations International D...</td>\n",
       "      <td>13010</td>\n",
       "      <td>13010. INT/Fund of the United Nations Internat...</td>\n",
       "      <td>0.914221</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>2.809560</td>\n",
       "      <td>0.954243</td>\n",
       "      <td>1.112907</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2013  Projet de coopTration universitaire - Initiati...         12182   \n",
       "1  2013                          New vaccine support (NVS)         12220   \n",
       "2  2015  EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...         12182   \n",
       "3  2017  Scientific cooperation with other countries (n...         12182   \n",
       "4  2015  INT/Fund of the United Nations International D...         13010   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12182. Projet de coopTration universitaire - I...  0.073950   \n",
       "1  12220. New vaccine support (NVS). NEW VACCINE ...  0.096651   \n",
       "2  12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...  3.040122   \n",
       "3  12182. Scientific cooperation with other count...  0.038746   \n",
       "4  13010. INT/Fund of the United Nations Internat...  0.914221   \n",
       "\n",
       "                         label  body_len  body_sent    punct%  \n",
       "0              not_global_func  3.447778   1.361728  1.157094  \n",
       "1               Market_Shaping  2.356026   0.698970  1.399083  \n",
       "2          RD_New_Health_Tools  2.665581   0.778151  1.254616  \n",
       "3        Knowledge_Gen_Sharing  2.622214   0.778151  1.220166  \n",
       "4  Response_Unhealthy_Products  2.809560   0.954243  1.112907  "
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#applying logrithmic transformation on \"body_len\" column\n",
    "test[\"body_len\"]=test[\"body_len\"].apply(lambda x: np.log10(x))\n",
    "\n",
    "#applying logrithmic transformation on \"body_len\" column\n",
    "test[\"body_sent\"]=test[\"body_sent\"].apply(lambda x: np.log10(x))\n",
    "\n",
    "test[\"punct%\"]=test[\"punct%\"].apply(lambda x: x**(1/6))\n",
    "\n",
    "test.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Vectorizing Raw Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(24783, 22257)\n",
      "['', '0', '000', '001', '001ELIMINATION', '002', '003', '005', '007', '01', '01008', '01102012', '012', '015', '015162', '016', '019', '019651', '02', '02002', '02003', '02004', '02007', '02008', '0217', '025', '029', '03', '04', '05', '059', '06', '075', '08', '08SER013112', '09', '0B', '1', '10', '100', '1000', '100000', '1000000', '10000000', '1001', '100160', '1009', '100ODA', '101', '1014', '10141', '1015', '1018', '101812', '101818', '1019', '102', '1020', '1020FOLD', '1024', '102692', '103234', '103457', '103760', '104', '104051', '105', '105053', '105819', '106439', '106641', '107', '1075000', '10CO1064ACHPARAGUAY', '10VALENT', '11', '110', '1100717', '1101174', '1101576JFR', '1106', '111', '1110', '1111', '1113', '1114', '112', '113', '114', '115', '1152082', '116', '116E', '117', '118', '119', '11TH', '12', '120', '1200', '12000', '1200MG', '121', '12110', '12181', '12182', '12191', '12200', '12220', '12230', '12240', '12240CLEOPROTEIN', '12250', '12250ECTED', '12250ECTION', '12250ORM', '12261', '12262', '12262ARIA', '12262ARIAREFRACTORY', '12262AWI', '12263', '12263CC', '12281', '124', '125', '1258', '1262', '1291', '12M', '12TH', '12YEAROLDS', '13', '130', '1300', '13010', '13020', '130227', '13030', '13040', '1304212250ECTION', '13042CARE', '13042CLINICAL', '13042STI', '13042STUDIES', '13042VACCINE', '1304EC', '1305', '1306', '13081', '13135', '133', '1335', '1337', '134', '135', '1350', '135000', '136', '1365', '137000', '139', '13TH', '14', '140000', '1402', '1403', '1418', '143', '14416', '148', '1495', '14DAY', '15', '150', '1500', '15000', '150000', '1501', '1505', '1519', '1520', '152000', '1524', '153', '1530', '1535', '1545', '1549', '155', '15500', '1556', '156', '15M', '15TH', '16', '160', '1600000', '1602', '1605', '16064', '1607', '1612', '1617', '162', '1621', '1622', '1627', '1629', '1632', '164', '165', '169', '16ENTRE', '16S', '17', '170', '17025', '170550', '1719', '1720', '1721', '17377287', '175', '175000', '176', '177', '17A', '18', '180', '180000', '1800MG', '184', '1843', '185', '1873', '189494', '18TH', '19', '190', '1921ST', '194', '1946', '1947', '1948', '1959', '196', '1961', '1963', '1969', '1970S', '1973', '1975', '1976', '1978', '1980', '1980S', '1981', '1986', '1988', '199', '1990', '1990S', '1991', '1993', '1994', '1995', '19951998', '1996', '1997', '1998', '1999', '1BACKGROUND', '1DIFFERENT', '1G', '1INCREASE', '1OFFER', '1PHARMACY', '1REDUCE', '1RELATED', '1SOCIAL', '1ST', '1STOCK', '1THE', '1TO', '1Y', '2', '20', '200', '2000', '20000', '200000', '2001', '2002', '200250', '2003', '20032007', '2003HEALTH', '2004', '2005', '20056', '2006', '200607', '2006105398', '20062011', '20062013', '20062015', '2007', '200708', '20078201213', '2008', '200809', '200812', '200813', '20082011', '20082012', '20082013', '20082015', '2008THE', '2009', '200910', '20092010', '20092014', '20092015', '20092019', '2010', '201011', '201014', '201015', '20102011', '20102013', '20102014', '20102015', '2010HK0009', '2010HK0009MOLECULAR', '2010HK0010', '2010HK0010SNAIL', '2010PATHFINDER', '2011', '201112', '201113', '201114', '201115', '20112013', '20112014', '20112015', '20112016', '2012', '201213', '20122013', '20122014', '20122015', '20122016', '2013', '201314', '201315', '201317', '201318', '20132014', '20132015', '20132016', '20132017', '20132018', '20134', '2013HUNGERENN001', '2013JULY', '2013RESULT', '2014', '20141016', '201415', '201417', '201419', '20142015', '20142016', '20142017', '20142017APPRAISAL', '20142018', '20142020', '20142020THE', '20142022', '2014RESULT', '2014SPECIFIC', '2015', '201516', '2015171', '201518', '201519', '20152016', '20152017', '20152018', '20152019', '20152020', '2015LIFESAVING', '2015V', '2016', '201617', '201620', '20162016', '20162017', '201620171', '20162018', '20162019', '20162020', '20162020PARTNERSHIP', '20162021', '20162022', '20162030', '201621', '2016A', '2017', '201718', '20172018', '20172019', '20172020', '20172021', '20172021THE', '20172022', '2018', '201819', '20182020', '20182021', '2019', '20192020', '2020', '2020FIRST', '2020THE', '2021', '2021THE', '2022', '2024', '2025', '2025CHAGAS', '203', '2030', '2035', '2040', '207', '20M', '20TH', '21', '210000', '2119101', '213', '216', '2176', '219', '21DAY', '22', '220', '221', '225', '22500', '227', '228000', '22ND', '23', '2300000', '234', '235', '238M', '23951', '23RD', '24', '2400', '240000', '241', '241000', '24129', '245', '24900000', '24MONTH', '25', '250', '250000', '2530', '2550', '259', '26', '263', '27', '27000000', '273', '2756', '28', '280', '280000', '2829', '287', '288', '289', '28MONTH', '29', '290', '291', '29WHILE', '2B', '2B13', '2B4', '2CONDUCT', '2D', '2ENHANCING', '2GOAL', '2IMPROVING', '2ND', '2PAGER', '2PREPAREDNESS', '2THE', '2TO', '2YEAR', '3', '30', '300', '3000', '30000', '300000', '30062012', '30092017', '300BED', '3019', '30400', '305', '308000', '30TH', '30YEAR', '31', '312', '31523', '316', '31COUNTRY', '31NORMES', '32', '320', '32000', '320132014', '32400', '329', '33', '330', '331250GHS', '334', '34', '340', '340000', '35', '350', '3500', '350000', '351000', '35M', '35YEAR', '36', '360', '36000', '360S', '36358', '365000', '37', '370420', '375', '375000', '3755000', '38', '380000', '386', '39', '390', '3900', '395', '3A', '3CONTROL', '3DAY', '3DIMENSIONAL', '3IE', '3INCREASED', '3M', '3MDG', '3RD', '3REFRESH', '3S', '3TARGET', '3THE', '3TO', '3YEAR', '4', '40', '400', '4000', '400000', '405', '4060', '4072', '408000', '4088', '41', '410', '412', '41326', '419', '42', '420', '43', '430', '431', '434', '436', '43YEAR', '44', '45', '450', '454', '45M', '46', '460', '4600', '47', '4700', '476', '48', '4800', '48000', '49', '490000', '49528', '49529', '4DETECT', '4KENIA', '4M', '4SUPPORTED', '4TH', '4THE', '4TOILET', '4YEAROLD', '5', '50', '500', '5000', '50000', '500000', '500PLUS', '5050', '506', '50GHS', '50M', '50MMOLL', '510', '51060001', '512000', '5122683', '5199', '52', '5212', '53', '532', '5320', '54', '5400', '546', '548000', '55', '550', '55000', '56', '560', '57', '575', '576', '58', '59', '5M', '5MSEGURIDAD', '5TH', '5TO', '5YEAR', '5YRS', '6', '60', '600', '6000', '60000', '6080', '61', '610', '61000', '612', '623', '624', '63', '63000', '64', '6405866', '6405867', '644', '65', '650', '65000', '6502', '651', '659', '66', '666', '67', '67MAC', '68', '68000', '69', '6MONTH', '6TH', '7', '70', '700', '7000', '700000', '701', '702', '710', '710000', '711', '7121', '7169638', '72', '7200', '72010', '73', '73482', '73500', '74', '740000', '747', '75', '750', '75000000', '750KM', '76', '764', '769', '76ODA', '77', '78', '78000', '785', '79', '7YEAR', '8', '80', '800', '8000', '8090', '81', '810', '82', '83', '834', '835000', '843', '85', '850', '85886', '86', '866', '867', '86N', '86Y', '87', '87000', '88', '880', '89', '890', '895', '8AMINOQUINOLINES', '8TH', '9', '90', '900', '900000', '90100', '906', '909090', '91', '914', '916', '92', '93', '93000', '935', '94', '95', '96', '98', '989', '99', '9980', '9TH', 'A', 'A1', 'A10', 'A1M', 'A2', 'A5', 'A6', 'A7', 'A9', 'AA', 'AAAS', 'AAI', 'AAN', 'AARDEXS', 'AAROGYASRI', 'AARON', 'AB', 'ABABA', 'ABAD', 'ABANDONED', 'ABANDONEMENT', 'ABANDONING', 'ABANDONMENT', 'ABATEMENT', 'ABBREVIATE', 'ABBREVIATED', 'ABCD', 'ABDOULYE', 'ABE', 'ABERDEEN', 'ABERRATIONS', 'ABEYANT', 'ABGENICS', 'ABIDANCE', 'ABIDE', 'ABIDJAN', 'ABIDJANLAGOS', 'ABILITIES', 'ABILITY', 'ABIOTIC', 'ABLE', 'ABN', 'ABNORMAL', 'ABNORMALITIES', 'ABNORMALLY', 'ABODE', 'ABOLISHMENT', 'ABOLITION', 'ABOLITITION', 'ABORGUT', 'ABORIGINAL', 'ABORTION', 'ABORTIONCARE', 'ABORTIONHONED', 'ABORTIONRELATED', 'ABORTIONS', 'ABORTIONSTIGMA', 'ABOUT', 'ABOVEMENTIONED', 'ABR', 'ABROAD', 'ABRUPT', 'ABSENCE', 'ABSENT', 'ABSOLUTE', 'ABSOLVED', 'ABSORB', 'ABSORPTION', 'ABSORPTIVE', 'ABSTINENCE', 'ABSTINENCEBE', 'ABSTRACT', 'ABSTRACTS', 'ABT', 'ABU', 'ABUBAKAR', 'ABUBAKARPWANIADOLESCENT', 'ABUJA', 'ABUSE', 'ABUSE12110', 'ABUSESPECIFIC', 'ABYAN', 'ABYSSINIA', 'AC', 'AC298ACCESS', 'AC298AGEING', 'AC298GENDER', 'AC298HEALTH', 'AC298HIV', 'AC298LEADERSHIP', 'AC298MALARIA12262', 'AC298MANAGEMENT', 'AC298MENTAL', 'AC298NEGLECTED', 'AC298NONCOMMUNICABLE', 'AC298NUTRITION12240', 'AC298POLIO', 'AC298REPRODUCTIVE', 'AC298SOCIAL', 'AC298STRATEGIC', 'AC298VACCINE', 'AC298VIOLENCE', 'AC380ACCESS', 'AC380FOOD', 'AC380GENDER', 'AC380HEALTH', 'AC380HIV', 'AC380INTEGRATED', 'AC380LEADERSHIP', 'AC380MALARIA12262', 'AC380MANAGEMENT', 'AC380NATIONAL', 'AC380NONCOMMUNICABLE', 'AC380NUTRITION12240', 'AC380REPRODUCTIVE', 'AC380SOCIAL', 'AC380VACCINE', 'AC380VIOLENCE', 'AC389ACCESS', 'AC389ANTIMICROBIAL', 'AC389GENDER', 'AC389LEADERSHIP', 'AC389MENTAL', 'AC498AGEING', 'AC498ANTIMICROBIAL', 'AC498DISABILITY', 'AC498FOOD', 'AC498GENDER', 'AC498HEALTH', 'AC498HIV', 'AC498INFECTIOUS', 'AC498LEADERSHIP', 'AC498MALARIA12262', 'AC498MENTAL', 'AC498NATIONAL', 'AC498NONCOMMUNICABLE', 'AC498NUTRITION12240', 'AC498POLIO', 'AC498REPRODUCTIVE', 'AC498SOCIAL', 'AC498STRATEGIC', 'AC498TRANSPARENCY', 'AC498VACCINE', 'AC498VIOLENCE', 'AC589ACCESS', 'AC589AGEING', 'AC589ANTIMICROBIAL', 'AC589FOOD', 'AC589HEALTH', 'AC589HIV', 'AC589INTEGRATED', 'AC589LEADERSHIP', 'AC589MALARIA12262', 'AC589MANAGEMENT', 'AC589MENTAL', 'AC589NATIONAL', 'AC589NONCOMMUNICABLE', 'AC589NUTRITION12240', 'AC589SOCIAL', 'AC589STRATEGIC', 'AC589TRANSPARENCY', 'AC589VACCINE', 'AC589VIOLENCE', 'AC679ACCESS', 'AC679AGEING', 'AC679FOOD', 'AC679GENDER', 'AC679HEALTH', 'AC679INFECTIOUS', 'AC679LEADERSHIP', 'AC679MALARIA12262', 'AC679MANAGEMENT', 'AC679MENTAL', 'AC679NATIONAL', 'AC679NONCOMMUNICABLE', 'AC679NUTRITION12240', 'AC679REPRODUCTIVE', 'AC679SOCIAL', 'AC679STRATEGIC', 'AC679TRANSPARENCY', 'AC679VACCINE', 'AC679VIOLENCE', 'AC789ACCESS', 'AC789FOOD', 'AC789GENDER', 'AC789HEALTH', 'AC789HIV', 'AC789INTEGRATED', 'AC789MALARIA12262', 'AC789MANAGEMENT', 'AC789MENTAL', 'AC789NATIONAL', 'AC789NEGLECTED', 'AC789NONCOMMUNICABLE', 'AC789NUTRITION12240', 'AC789REPRODUCTIVE', 'AC789SOCIAL', 'AC789STRATEGIC', 'AC789TRANSPARENCY', 'AC789VACCINE', 'AC889ACCESS', 'AC889HEALTH', 'AC889NATIONAL', 'AC889NONCOMMUNICABLE', 'AC889VACCINE', 'AC89ACCESS', 'AC89AGEING', 'AC89ANTIMICROBIAL', 'AC89DISABILITY', 'AC89FOOD', 'AC89GENDER', 'AC89HEALTH', 'AC89HIV', 'AC89INFECTIOUS', 'AC89MALARIA12262', 'AC89MANAGEMENT', 'AC89NATIONAL', 'AC89NEGLECTED', 'AC89NONCOMMUNICABLE', 'AC89NUTRITION12240', 'AC89POLIO', 'AC89REPRODUCTIVE', 'AC89SOCIAL', 'AC89STRATEGIC', 'AC89TRANSPARENCY', 'AC998ACCESS', 'AC998AGEING', 'AC998ANTIMICROBIAL', 'AC998DISABILITY', 'AC998FOOD', 'AC998GENDER', 'AC998HEALTH', 'AC998HIV', 'AC998INFECTIOUS', 'AC998INTEGRATED', 'AC998MANAGEMENT', 'AC998MENTAL', 'AC998NONCOMMUNICABLE', 'AC998NUTRITION12240', 'AC998REPRODUCTIVE', 'AC998STRATEGIC', 'AC998TRANSPARENCY', 'AC998VACCINE', 'AC998VIOLENCE', 'ACA', 'ACADEME', 'ACADEMIA', 'ACADEMIAS', 'ACADEMIC', 'ACADEMICALLY', 'ACADEMICIANS', 'ACADEMICPERFORMANCE', 'ACADEMICPSYCHOSOCIAL', 'ACADEMICRESEARCH', 'ACADEMICS', 'ACADEMY', 'ACADTMICOS', 'ACAFRICA', 'ACAMERICA', 'ACAMR', 'ACBAHRAINMENTAL', 'ACBAHRAINNONCOMMUNICABLE', 'ACBAHRAINVIOLENCE', 'ACBRUNEI', 'ACBULGARIAHEALTH', 'ACBULGARIAINTERGRATED', 'ACBULGARIALEADERSHIP', 'ACBULGARIAMENTAL', 'ACBULGARIANATIONAL', 'ACBULGARIANUTRITION', 'ACBULGARIASOCIAL', 'ACBULGARIASTRATEGIC', 'ACBULGARIATUBERCULOSIS', 'ACC', 'ACCELARATE', 'ACCELERATE', 'ACCELERATED', 'ACCELERATES', 'ACCELERATING', 'ACCELERATION', 'ACCELERATOR', 'ACCELERATORS', 'ACCENT', 'ACCEPT', 'ACCEPTABILITY', 'ACCEPTABLE', 'ACCEPTABLENESS', 'ACCEPTANCE', 'ACCEPTATION', 'ACCEPTED', 'ACCEPTING', 'ACCESO', 'ACCESS', 'ACCESSABILITY', 'ACCESSED', 'ACCESSIBILITY', 'ACCESSIBLE', 'ACCESSING', 'ACCESSION', 'ACCFS', 'ACCIDENTAL', 'ACCIDENTS', 'ACCION', 'ACCOLADE', 'ACCOMMODATED', 'ACCOMMODATION', 'ACCOMMODATIONS', 'ACCOMMONWEALTH', 'ACCOMPANIED', 'ACCOMPANIMENT', 'ACCOMPANY', 'ACCOMPANYING', 'ACCOMPLISH', 'ACCOMPLISHED', 'ACCOMPLISHED3', 'ACCOMPLISHING', 'ACCOMPLISHMENT', 'ACCORD', 'ACCORDANCE', 'ACCORDANCEWITH', 'ACCORDING', 'ACCORDINGLY', 'ACCOST', 'ACCOUCHEMENTS', 'ACCOUCHER', 'ACCOUCHEUSE', 'ACCOUNT', 'ACCOUNTABILITY', 'ACCOUNTABILITY3INFORM', 'ACCOUNTABILITYTHE', 'ACCOUNTABLE', 'ACCOUNTABLE3', 'ACCOUNTABLY', 'ACCOUNTED', 'ACCOUNTING', 'ACCOUNTS', 'ACCRA', 'ACCREDITATION', 'ACCREDITED', 'ACCROATIAACCESS', 'ACCROATIAHEALTH', 'ACCROATIAHIV', 'ACCROATIAHIVAIDS', 'ACCROATIAINTERGRATED', 'ACCROATIALEADERSHIP', 'ACCROATIANONCOMMUNICABLE', 'ACCROATIASOCIAL', 'ACCROATIATUBERCULOSIS', 'ACCS', 'ACCUMALATED', 'ACCUMULATE', 'ACCUMULATED', 'ACCUMULATES', 'ACCUMULATION', 'ACCURACY', 'ACCURATE', 'ACCURATELY', 'ACDX', 'ACE', 'ACELERANDO', 'ACERB', 'ACESTONIAACCESS', 'ACESTONIAHEALTH', 'ACESTONIALEADERSHIP', 'ACESTONIAMENTAL', 'ACESTONIANATIONAL', 'ACESTONIANONCOMMUNICABLE', 'ACESTONIASTRATEGIC', 'ACETYLCHOLINESTERASE', 'ACEUROPE', 'ACF', 'ACFAR', 'ACFRENCH', 'ACGLOBALACCESS', 'ACGLOBALAGEING', 'ACGLOBALCHRONIC', 'ACGLOBALCOMMUNICABLE', 'ACGLOBALDISABILITIES', 'ACGLOBALFOOD', 'ACGLOBALHEALTH', 'ACGLOBALHEALTHY', 'ACGLOBALHIV', 'ACGLOBALHIVAIDS', 'ACGLOBALHIVAIDSTBMALARIA', 'ACGLOBALIMPROVED', 'ACGLOBALINTERGRATED', 'ACGLOBALKEY', 'ACGLOBALLEADERSHIP', 'ACGLOBALMALARIA', 'ACGLOBALMENTAL', 'ACGLOBALNATIONAL', 'ACGLOBALNEGLCTED', 'ACGLOBALNONCOMMUNICABLE', 'ACGLOBALNUTRITION', 'ACGLOBALREDUCTION', 'ACGLOBALREPRODUCTIVE', 'ACGLOBALSOCIAL', 'ACGLOBALSTRATEGIC', 'ACGLOBALTUBERCULOSIS', 'ACGLOBALVACCINE', 'ACGLOBALVACCINEPREVENTABLE', 'ACGLOBALVIOLENCE', 'ACGUAMINTERGRATED', 'ACHAT', 'ACHE', 'ACHE1', 'ACHEST', 'ACHIEVE', 'ACHIEVED', 'ACHIEVEM', 'ACHIEVEMENT', 'ACHIEVEMENTS', 'ACHIEVES', 'ACHIEVIN', 'ACHIEVING', 'ACHIVE', 'ACHIVEMENT', 'ACHUNGARYACCESS', 'ACHUNGARYHEALTH', 'ACHUNGARYINTERGRATED', 'ACHUNGARYLEADERSHIP', 'ACHUNGARYNONCOMMUNICABLE', 'ACHUNGARYSTRATEGIC', 'ACHUNGARYTUBERCULOSIS', 'ACHUNGARYVIOLENCE', 'ACHUTHA', 'ACID', 'ACIDBASE', 'ACIDBASED', 'ACIDIC', 'ACIDS', 'ACISAM', 'ACKNOWLEDGE', 'ACKNOWLEDGED', 'ACKNOWLEDGES', 'ACKNOWLEDGMENT', 'ACLATVIAHEALTH', 'ACLATVIAINTERGRATED', 'ACLATVIALEADERSHIP', 'ACLATVIAMENTAL', 'ACLATVIANATIONAL', 'ACLATVIANONCOMMUNICABLE', 'ACLATVIAREPRODUCTIVE', 'ACLATVIASTRATEGIC', 'ACLATVIAVIOLENCE', 'ACLITHUANIAHEALTH', 'ACLITHUANIAHIV', 'ACLITHUANIAHIVAIDS', 'ACLITHUANIALEADERSHIP', 'ACLITHUANIAMENTAL', 'ACLITHUANIANATIONAL', 'ACLITHUANIANONCOMMUNICABLE', 'ACLITHUANIASTRATEGIC', 'ACLITHUANIATUBERCULOSIS', 'ACLITHUANIAVIOLENCE', 'ACM', 'ACMALTAINTERGRATED', 'ACMALTANATIONAL', 'ACMALTANUTRITION', 'ACMIDDLE', 'ACNE', 'ACOCEANIA', 'ACOMANACCESS', 'ACOMANDISABILITIES', 'ACOMANHEALTH', 'ACOMANHIV', 'ACOMANHIVAIDS', 'ACOMANINTERGRATED', 'ACOMANLEADERSHIP', 'ACOMANMANAGEMENT', 'ACOMANMENTAL', 'ACOMANNATIONAL', 'ACOMANNONCOMMUNICABLE', 'ACOMBINATION', 'ACOMPETITIVE', 'ACPL', 'ACPOLANDHEALTH', 'ACPOLANDINTERGRATED', 'ACPOLANDLEADERSHIP', 'ACPOLANDNATIONAL', 'ACPOLANDNONCOMMUNICABLE', 'ACPOLANDNUTRITION', 'ACPOLANDSOCIAL', 'ACQATARHEALTH', 'ACQUIRE', 'ACQUIRED', 'ACQUIREDRESULT', 'ACQUIREMENT', 'ACQUIRING', 'ACQUISITION', 'ACREUNION', 'ACRID', 'ACROMANIAFOOD', 'ACROMANIAHEALTH', 'ACROMANIALEADERSHIP', 'ACROMANIAMENTAL', 'ACROMANIANONCOMMUNICABLE', 'ACROMANIASOCIAL', 'ACROMANIAVIOLENCE', 'ACRONYM', 'ACROSS', 'ACRUSSIAN', 'ACS', 'ACSAUDI', 'ACSINGAPORENONCOMMUNICABLE', 'ACSINGAPOREVACCINE', 'ACSINGAPOREVACCINEPREVENTABLE', 'ACSLOVAKIAAGEING', 'ACSLOVAKIAHEALTH', 'ACSLOVAKIAINTERGRATED', 'ACSLOVAKIALEADERSHIP', 'ACSLOVAKIAMENTAL', 'ACSLOVAKIANATIONAL', 'ACSLOVAKIANONCOMMUNICABLE', 'ACSLOVAKIANUTRITION', 'ACSLOVAKIAREPRODUCTIVE', 'ACSLOVAKIASOCIAL', 'ACSLOVAKIASTRATEGIC', 'ACSLOVENIAHEALTH', 'ACSLOVENIAINTERGRATED', 'ACSLOVENIALEADERSHIP', 'ACSLOVENIAMENTAL', 'ACSLOVENIANATIONAL', 'ACSLOVENIANONCOMMUNICABLE', 'ACSLOVENIAREPRODUCTIVE', 'ACSLOVENIASOCIAL', 'ACSLOVENIASTRATEGIC', 'ACSOUTH', 'ACT', 'ACTED', 'ACTES', 'ACTEURS', 'ACTHEALTH', 'ACTING', 'ACTINIUM', 'ACTINOMYCETES', 'ACTION', 'ACTIONABLE', 'ACTIONGENDER', 'ACTIONS', 'ACTIONSPROUT', 'ACTIONSRESULT', 'ACTIVA', 'ACTIVATE', 'ACTIVATED', 'ACTIVATES', 'ACTIVATING', 'ACTIVATION', 'ACTIVATIONINFLAMMATION', 'ACTIVATOR', 'ACTIVE', 'ACTIVELATENT', 'ACTIVELY', 'ACTIVENESS', 'ACTIVISM', 'ACTIVISTS', 'ACTIVITIE', 'ACTIVITIES', 'ACTIVITIES1', 'ACTIVITIES6', 'ACTIVITIESEXTENDING', 'ACTIVITIESPROMPT', 'ACTIVITIESRESULT', 'ACTIVITIESSCOPING', 'ACTIVITIESTHE', 'ACTIVITIESVANCE', 'ACTIVITIESWILL', 'ACTIVITY', 'ACTIVITYOUTPUTS', 'ACTIVITYRELATED', 'ACTIVITYS', 'ACTLVITIES', 'ACTOR', 'ACTORS', 'ACTS', 'ACTUAL', 'ACTUALLY', 'ACTUARIAL', 'ACUMEN', 'ACUTE', 'ACUTELY', 'AD', 'AD4', 'AD4HIV', 'ADANA', 'ADAPT', 'ADAPTABLE', 'ADAPTADO', 'ADAPTATION', 'ADAPTATIVE', 'ADAPTED', 'ADAPTING', 'ADAPTIVE', 'ADAPTS', 'ADB', 'ADBS', 'ADCH63', 'ADCH63MVA', 'ADD', 'ADDED', 'ADDEDVALUE', 'ADDICTION', 'ADDICTIVE', 'ADDING', 'ADDIS', 'ADDITIO', 'ADDITION', 'ADDITIONAL', 'ADDITIONALLY', 'ADDITIONS', 'ADDITIVE', 'ADDRESS', 'ADDRESSED', 'ADDRESSEDRESULT', 'ADDRESSES', 'ADDRESSING', 'ADDRF', 'ADDRFS', 'ADDS', 'ADEN', 'ADEPT', 'ADEPTNESS', 'ADEQUAT', 'ADEQUATE', 'ADEQUATELY', 'ADEQUATERESULTS', 'ADF', 'ADHERE', 'ADHERENCE', 'ADHESION', 'ADHESIVE', 'ADHESIVENESS', 'ADHOC', 'ADI', 'ADICTIVAS', 'ADIPLOMA', 'ADIPOSITY', 'ADJACENT', 'ADJANHAU', 'ADJUNCTIVE', 'ADJUST', 'ADJUSTABLE', 'ADJUSTED', 'ADJUSTMENT', 'ADJUSTMENTS', 'ADJUVANT', 'ADJUVANTED', 'ADJUVANTS', 'ADL', 'ADLINTERVENTION', 'ADM', 'ADMIN', 'ADMINISTER', 'ADMINISTERED', 'ADMINISTERING', 'ADMINISTRATE', 'ADMINISTRATING', 'ADMINISTRATION', 'ADMINISTRATION12110', 'ADMINISTRATIVE', 'ADMINISTRATOR', 'ADMINISTRATORS', 'ADMISSION', 'ADMISSIONS', 'ADMIT', 'ADMITTANCE', 'ADMITTED', 'ADMIXED', 'ADMIXTURE', 'ADMONITION', 'ADOLES', 'ADOLESCENCE', 'ADOLESCENT', 'ADOLESCENTES', 'ADOLESCENTS', 'ADOPT', 'ADOPTED', 'ADOPTING', 'ADOPTION', 'ADOPTIONUSE', 'ADOPTS', 'ADRA', 'ADRAS', 'ADRENERGIC', 'ADROITNESS', 'ADS', 'ADTHE', 'ADULT', 'ADULTHOOD', 'ADULTS', 'ADULTSO', 'ADULTSTAGE', 'ADVANCE', 'ADVANCED', 'ADVANCEMENT', 'ADVANCEMENTS', 'ADVANCES', 'ADVANCING', 'ADVANTAGE', 'ADVANTAGEOUSLY', 'ADVANTAGES', 'ADVENTIST', 'ADVERSE', 'ADVERTISE', 'ADVERTISEMENTS', 'ADVERTISING', 'ADVERTIZE', 'ADVICE', 'ADVICED', 'ADVICETO', 'ADVISE', 'ADVISOR', 'ADVISORS', 'ADVISORY', 'ADVOCACY', 'ADVOCATE', 'ADVOCATES', 'ADVOCATING', 'ADVOCATOR', 'AECID', 'AEDES', 'AEDESTRANSMITTED', 'AEGIS', 'AEGYPTI', 'AEGYPTIBORNE', 'AEP', 'AERAS', 'AERIAL', 'AEROBIC', 'AEROSOL', 'AEROSOLS', 'AESCULAPIAN', 'AESTIVUM', 'AETIOLOGY', 'AETIOLOGYONE', 'AF', 'AFAR', 'AFCC2', 'AFCC2RI3A', 'AFCC2RIEAST', 'AFDB', 'AFFAIR', 'AFFAIRE', 'AFFAIRS', 'AFFECT', 'AFFECTED', 'AFFECTEDNESS', 'AFFECTEDTHE', 'AFFECTING', 'AFFECTIONG', 'AFFECTS', 'AFFILIATE', 'AFFILIATED', 'AFFILIATES', 'AFFINITY', 'AFFIRM', 'AFFIRMATION', 'AFFIRMED', 'AFFLICT', 'AFFLICTED', 'AFFOLABI', 'AFFORD', 'AFFORDABILITY', 'AFFORDABLE', 'AFFORDABLY', 'AFFORDED', 'AFG', 'AFGANISTAN', 'AFGENDER', 'AFGHAN', 'AFGHANISTAN', 'AFGHANISTANS', 'AFGHANS', 'AFHEA', 'AFHIVAIDS', 'AFICAN', 'AFIDEP', 'AFLATOXIN', 'AFMADOW', 'AFOREMENTIONED', 'AFORTIFIED', 'AFP', 'AFRICA', 'AFRICAEVIDENCE', 'AFRICAFOUR', 'AFRICAGENERATE', 'AFRICAIN', 'AFRICAINTERACT', 'AFRICAN', 'AFRICANBASED', 'AFRICANCANADIAN', 'AFRICANDRIVEN', 'AFRICANINDIAN', 'AFRICANLED', 'AFRICANORIGIN', 'AFRICANORIGINATED', 'AFRICANPART', 'AFRICANS', 'AFRICAPROJECT', 'AFRICARE', 'AFRICAS', 'AFRICATHIS', 'AFRIKA', 'AFRIKAGRUPPERNA', 'AFRIQUE', 'AFRO', 'AFRONTAR', 'AFS', 'AFSA', 'AFTER', 'AFTERCARE', 'AFTERMATH', 'AFYA', 'AG', 'AGA', 'AGAINST', 'AGAINSTP', 'AGAISNT', 'AGANIST', 'AGANST', 'AGCTB', 'AGCTBTREATED', 'AGCTBVACCINATED', 'AGE', 'AGEAPPROPRIATE', 'AGED', 'AGEING', 'AGENCE', 'AGENCIES', 'AGENCY', 'AGENCYS', 'AGENCYSPECIFIC', 'AGENDA', 'AGENDAINCREASE', 'AGENDAS', 'AGENDUM', 'AGENT', 'AGENTIVE', 'AGENTS', 'AGES', 'AGETHIS', 'AGGRAVATED', 'AGGRAVATES', 'AGGREGATE', 'AGGREGATED', 'AGGREGATION', 'AGGRESSIVE', 'AGGRESSIVELY', 'AGHA', 'AGHANISTAN', 'AGING', 'AGIR', 'AGISAR', 'AGITATE', 'AGO', 'AGOFNYIVT', 'AGONYIV', 'AGOSTINHO', 'AGP', 'AGR', 'AGRARIA', 'AGREE', 'AGREED', 'AGREEMENT', 'AGREEMENTPARTNERS', 'AGREEMENTS', 'AGRESULTS', 'AGRI', 'AGRIBUSINESS', 'AGRICU', 'AGRICULTURAL', 'AGRICULTURE', 'AGRICULTURERELATED', 'AGRICULTURES', 'AGRICULTURETRADE', 'AGRIFOOD', 'AGRILIFE', 'AGRINUT', 'AGRO', 'AGROCHEMICAL', 'AGROECOLOGICAL', 'AGROECOLOGICO', 'AGROECOLOGY', 'AGROFOOD', 'AGROFORESTRY', 'AGRONOMIC', 'AGRONOMICAL', 'AGROPASTORAL', 'AGROPASTORALISTS', 'AH5N1', 'AHEAD', 'AHEM', 'AHF', 'AHI', 'AHPSR', 'AHPSRS', 'AHRI', 'AHRIAAU', 'AHRICORE', 'AI', 'AID', 'AID674A1200033', 'AIDING', 'AIDS', 'AIDSCHILDREN', 'AIDSFREE', 'AIDSHIV', 'AIDSORPHANS', 'AIDSORPHANSTHE', 'AIDSOVERALL', 'AIDSPAN', 'AIDSPANS', 'AIDSRELATED', 'AIDSTAR', 'AIDSTARONE', 'AIDSTARTWO', 'AILIV', 'AILMENTS', 'AIM', 'AIMAG', 'AIMED', 'AIMEDAT', 'AIMING', 'AIMS', 'AIMS1', 'AIMSAT', 'AIMSTHE', 'AIMSTREATMENT', 'AIN', 'AIP', 'AIPEID', 'AIR', 'AIRES', 'AIRFARE', 'AIRPORT', 'AIRPORTS', 'AIRWAY', 'AIWG', 'AJ', 'AJLM', 'AKESO', 'AKONNI', 'AKWA', 'AKWAIBOM', 'AL', 'ALA', 'ALAHLI', 'ALAHMAD', 'ALAN', 'ALARM', 'ALARMING', 'ALARMS', 'ALBANIA', 'ALBANIJE', 'ALBENDAZOLE', 'ALBENDAZOLEIVERMECTIN', 'ALBERT', 'ALBERTA', 'ALCHOL', 'ALCO', 'ALCOHOL', 'ALCOHOLFOCUSED', 'ALCOHOLIC', 'ALCOHOLRELATED', 'ALCOHOLTHE', 'ALERE', 'ALERT', 'ALERTA', 'ALERTS', 'ALEXANDER', 'ALEXANDRIA', 'ALGAE', 'ALGAEDUCKWEED', 'ALGERIA', 'ALGERIAN', 'ALGIERS', 'ALGORITHM', 'ALGORITHMS', 'ALHIV', 'ALIA', 'ALIGN', 'ALIGNED', 'ALIGNING', 'ALIGNMENT', 'ALIGNS', 'ALIMENT', 'ALIMENTAIRE', 'ALIMENTAL', 'ALIMENTARIA', 'ALIMENTARIUS', 'ALIMENTARY', 'ALIMENTATION', 'ALIMENTOS', 'ALIMONY', 'ALINEMENT', 'ALIR', 'ALIVE', 'ALIVENESS', 'ALJABER', 'ALJUMHURIAH', 'ALL', 'ALLACTIVITIES', 'ALLAN', 'ALLEGEDLY', 'ALLEGIANCE', 'ALLELE', 'ALLELES', 'ALLERGENS', 'ALLERGIC', 'ALLERGOLOGY', 'ALLERGY', 'ALLEVIATE', 'ALLEVIATING', 'ALLEVIATION', 'ALLHAZARDAPPROACH', 'ALLIANCE', 'ALLIANCES', 'ALLIED', 'ALLOCATE', 'ALLOCATED', 'ALLOCATES', 'ALLOCATING', 'ALLOCATIO', 'ALLOCATION', 'ALLOCATIONS', 'ALLOCATIONSEXECUTION', 'ALLOT', 'ALLOW', 'ALLOWABLE', 'ALLOWANCES', 'ALLOWED', 'ALLOWING', 'ALLOWS', 'ALMA', 'ALMATY', 'ALMOST', 'ALONE', 'ALONEGARDENS', 'ALONG', 'ALONGSIDE', 'ALPHA', 'ALPHA2AR', 'ALQUDS', 'ALREADY', 'ALREADYFRAIL', 'ALSABAH', 'ALSO', 'ALTASCIENCES', 'ALTER', 'ALTERATION', 'ALTERATIONS', 'ALTERATIVE', 'ALTERED', 'ALTERING', 'ALTERNATE', 'ALTERNATING', 'ALTERNATIVE', 'ALTERNATIVES', 'ALTERS', 'ALTHABE', 'ALTHOUGH', 'ALTO', 'ALUA', 'ALUMNI', 'ALVEO', 'ALWAYS', 'ALZHEIMER', 'ALZHEIMERS', 'AM', 'AMAYIRI', 'AMAZON', 'AMAZONIA', 'AMAZONIAN', 'AMBASSADORSTECHNICAL', 'AMBIENTE', 'AMBITION', 'AMBITIOUS', 'AMBULANCE', 'AMBULANCES', 'AMBULATORY', 'AMC', 'AMCHI', 'AMD', 'AMDE', 'AMELIA', 'AMELIORATE', 'AMENABLE', 'AMEND', 'AMENDING', 'AMENDMENT', 'AMENDMENTS', 'AMENET', 'AMENETTHE', 'AMENITIES', 'AMERICA', 'AMERICAEFFORTS', 'AMERICAINTERSECTORAL', 'AMERICAN', 'AMERICANS', 'AMERICAS', 'AMHARA', 'AMINOQUINOLINES', 'AMLIORATION', 'AMLIORER', 'AMMAN', 'AMNGST', 'AMODIAQUINE', 'AMODUAQUINE', 'AMONG', 'AMONGST', 'AMOUNF', 'AMOUNT', 'AMOUNTING', 'AMOUNTS', 'AMOUTED', 'AMOXICILLIN', 'AMOXIL', 'AMP', 'AMPATH', 'AMPATHPLUS', 'AMPATHPLUSS', 'AMPERE', 'AMPHOTERICIN', 'AMPHOTERICINBASED', 'AMPLICON', 'AMPLIFICATION', 'AMPLIFIED', 'AMPLIFY', 'AMPLIFYING', 'AMPUTEES', 'AMPUTEESWAR', 'AMR', 'AMRAN', 'AMRBSI', 'AMRBSI3TO', 'AMRC', 'AMRDRI', 'AMREF', 'AMRRDT', 'AMTLIORATION', 'AMTLIORER', 'AMTRICA', 'AMULTIDISCIPLINARY', 'AMWAY', 'AMYGADALOID', 'AMYGDALOID', 'AN', 'ANA', 'ANAEMIA', 'ANAESTHESIA', 'ANAESTHETIC', 'ANAL', 'ANALOGUES', 'ANALYSE', 'ANALYSED', 'ANALYSER', 'ANALYSES', 'ANALYSING', 'ANALYSIS', 'ANALYSISCEHAT', 'ANALYTIC', 'ANALYTICAL', 'ANALYTICS', 'ANALYTIK', 'ANALYTIKCONSULTING', 'ANALYZE', 'ANALYZED', 'ANALYZED2TO', 'ANALYZER', 'ANALYZES', 'ANALYZING', 'ANAMBRA', 'ANATOLE', 'ANATOMICAL', 'ANATOMY', 'ANATOXIN', 'ANATYCAL', 'ANCESTRY', 'ANCILLARY', 'ANCP', 'AND', 'AND3', 'ANDADEQUATELYSTUDIED', 'ANDAPPLY', 'ANDBUILD', 'ANDC', 'ANDCONDUCT', 'ANDCTO', 'ANDDISTANCE', 'ANDDIVERSIFICATION', 'ANDDOCUMENT', 'ANDEAN', 'ANDEMIA', 'ANDENGAGING', 'ANDES', 'ANDESTABLISH', 'ANDEVALUATIONIPAS', 'ANDFINALIZE', 'ANDHRA', 'ANDIMPLEMENT', 'ANDIMPROVE', 'ANDNETWORKS', 'ANDOFFER', 'ANDOR', 'ANDPOLICIES', 'ANDPOLICY', 'ANDREA', 'ANDRECEIVE', 'ANDREPRODUCTIVE', 'ANDRES', 'ANDRHA', 'ANDTO', 'ANDTRANSFER', 'ANE', 'ANECCA', 'ANEITYUM', 'ANEMIA', 'ANEQUAL', 'ANERELASUPPORT', 'ANESTHESIA', 'ANESTHETIC', 'ANGANWADI', 'ANGANWADIS', 'ANGEL', 'ANGELES', 'ANGER', 'ANGIOGENESIS', 'ANGLE', 'ANGLOPHONE', 'ANGOLA', 'ANGOLAS', 'ANGOLATHE', 'ANGSTROM', 'ANHACANAU', 'ANHUI', 'ANI', 'ANIINFECTIVE', 'ANIMAL', 'ANIMALE', 'ANIMALHUMAN', 'ANIMALHUMANENVIRONMENT', 'ANIMALS', 'ANIMALSHUMANS', 'ANIMATE', 'ANIMATION', 'ANIMICROBIAL', 'ANINTEGRAL', 'ANITBIOTIC', 'ANKARA', 'ANLISIS', 'ANLYSERS', 'ANNA', 'ANNAM', 'ANNAN', 'ANNAPOORNI', 'ANNE', 'ANNECY', 'ANNEX', 'ANNIHILATE', 'ANNIVERSARY', 'ANNOTATE', 'ANNOTATED', 'ANNOUNCED', 'ANNOUNCEMENT', 'ANNUAL', 'ANNUALLY', 'ANNUEL', 'ANNUM', 'ANNUNZIO', 'ANOMALY', 'ANOPHELES', 'ANOPHELIS', 'ANOTHER', 'ANOVA', 'ANSAF', 'ANSWER', 'ANSWERABILITY', 'ANSWERABLENESS', 'ANSWERER', 'ANSWERING', 'ANSWERS', 'ANTA', 'ANTAGONISTIC', 'ANTANANARIVO', 'ANTE', 'ANTECEDENCE', 'ANTECEDENCY', 'ANTENATAL', 'ANTERIOR', 'ANTERIORITY', 'ANTHELMINTHIC', 'ANTHELMINTIC', 'ANTHOCYANINS', 'ANTHONY', 'ANTHROPOGENIC', 'ANTHROPOLOGY', 'ANTHROPOMETRIC', 'ANTHROPOMETRY', 'ANTI', 'ANTI12262ARIAL', 'ANTIBACTERIAL', 'ANTIBIOFILM', 'ANTIBIOTCS', 'ANTIBIOTIC', 'ANTIBIOTICS', 'ANTIBIOTICSRECENT', 'ANTIBIOTICSSENSITIVE', 'ANTIBIOTICTOLERANT', 'ANTIBITICOS', 'ANTIBODIES', 'ANTIBODY', 'ANTIBODYBASED', 'ANTIBODYPRODUCING', 'ANTIBODYRESPONSE', 'ANTICANCER', 'ANTICARCINOGENIC', 'ANTICIPATE', 'ANTICIPATED', 'ANTICIPATES', 'ANTICOAGULATION', 'ANTICORRUPTION', 'ANTICSP', 'ANTIDIABETIC', 'ANTIDIARRHOEA', 'ANTIDISCRIMINATION', 'ANTIEBOLA', 'ANTIEPILEPTIC', 'ANTIGEN', 'ANTIGENBASED', 'ANTIGENENCODING', 'ANTIGENIC', 'ANTIGENICITY', 'ANTIGENRELEASING', 'ANTIGENS', 'ANTIGUA', 'ANTIHELMINTH', 'ANTIHIV', 'ANTIINFECTION', 'ANTIINFECTIVE', 'ANTIINFECTIVES', 'ANTIINFLAMMATORY', 'ANTILEISHMANIAL', 'ANTILEISHMANIALS', 'ANTIMALARIA', 'ANTIMALARIADRUG', 'ANTIMALARIAL', 'ANTIMALARIALS', 'ANTIMICROBIA', 'ANTIMICROBIAL', 'ANTIMICROBIALRESISTANT', 'ANTIMICROBIALS', 'ANTIMICROBIC', 'ANTIMONIALS', 'ANTIMORBIDITY', 'ANTIMYCOBACTERIAL', 'ANTIMYCOBACTERIUM', 'ANTIOBIOTIC', 'ANTIOPHTHALMIC', 'ANTIOXIDANT', 'ANTIPARASITE', 'ANTIPARASITIC', 'ANTIPATHOGENIC', 'ANTIPLASMODIAL', 'ANTIQUORUM', 'ANTIRETROVIRAL', 'ANTIRETROVIRALS', 'ANTITABAC', 'ANTITB', 'ANTITHROMBIC', 'ANTITICK', 'ANTITOBACCO', 'ANTITRYPANOSOMAL', 'ANTITUBERCULAR', 'ANTITUBERCULOSIS', 'ANTITUMOR', 'ANTIVENOM', 'ANTIVENOMS', 'ANTIVIRAL', 'ANTIVIRALS', 'ANTSIRANANA', 'ANTWERP', 'ANTWERPEN', 'ANURADHAPRUA', 'ANUSANDHAN', 'ANXIETY', 'ANXIETYTHROUGH', 'ANYTHING', 'ANYWHERE', 'AO', 'APA', 'APACE', 'APAINE', 'APART', 'APCS', 'APEIR', 'APES', 'APEX', 'APHIDPATHOGENIC', 'APHL', 'APHLCDC', 'APHRC', 'API', 'APICAL', 'APICOMPLEXA', 'APICOMPLEXAN', 'APII', 'APIS', 'APLMA', 'APOPO', 'APOPTOTIC', 'APOSTLE', 'APOSTLES', 'APOYO', 'APP', 'APPARATUS', 'APPARENT', 'APPEAL', 'APPEALING', 'APPEALINGNESS', 'APPEALS', 'APPEARANCE', 'APPEARED', 'APPEARS', 'APPEND', 'APPENDAGE', 'APPENDIX', 'APPLICABILITY', 'APPLICABLE', 'APPLICANT', 'APPLICANTS', 'APPLICATION', 'APPLICATIONS', 'APPLICATIONSRESULTS', 'APPLIED', 'APPLIEDCLINICAL', 'APPLIEDFIELD', 'APPLIER', 'APPLIES', 'APPLIQUE', 'APPLIQUTE', 'APPLY', 'APPLYING', 'APPOINTMENT', 'APPOINTMENTS', 'APPORTIONING', 'APPORTIONMENT', 'APPR', 'APPRAISAL', 'APPRAISALS', 'APPRAISE', 'APPRASIAL', 'APPRECIATION', 'APPREHENSION', 'APPRENTICESHIPBASED', 'APPRENTISSAGE', 'APPROACH', 'APPROACHABILITY', 'APPROACHABLE', 'APPROACHBECAUSE', 'APPROACHE', 'APPROACHED', 'APPROACHER', 'APPROACHES', 'APPROACHESHOMESTEAD', 'APPROACHING', 'APPROPRIATE', 'APPROPRIATED', 'APPROPRIATELY', 'APPROVAL', 'APPROVED', 'APPROX', 'APPROXIMATE', 'APPROXIMATELY', 'APPROXIMATION', 'APPUI', 'APPUIE', 'APR', 'APRIL', 'APROPOS', 'APS', 'APSECTS', 'APSED', 'APTAMER', 'APTAMERS', 'AQUACULTURE', 'AQUATAB', 'AQUATABS', 'AQUEOUS', 'AR', 'ARAB', 'ARABIA', 'ARABIAHEALTH', 'ARABIAHIV', 'ARABIAHIVAIDS', 'ARABIALEADERSHIP', 'ARABIAMANAGEMENT', 'ARABIAMENTAL', 'ARABIAN', 'ARABIANONCOMMUNICABLE', 'ARABIAREPRODUCTIVE', 'ARABIASOCIAL', 'ARABIATUBERCULOSIS', 'ARABIAVIOLENCE', 'ARBEIDES', 'ARBEIDSFASER', 'ARBOVIRUS', 'ARBOVIRUSES', 'ARC', 'ARCADY', 'ARCH', 'ARCHES', 'ARCHIPELAGO', 'ARCHITECT', 'ARCHITECTURAL', 'ARCHITECTURE', 'ARCHIVE', 'ARCHIVING', 'ARCPOH', 'ARE', 'ARE1', 'ARE1TO', 'AREA', 'AREAS', 'AREASDEVELOPING', 'AREASHUMAN', 'AREASINSTITUTIONALIZE', 'AREASOUTPUT', 'AREASPECIAL', 'AREASPOLICY', 'AREASTO', 'AREATHE', 'AREATO', 'AREAVAILABLE', 'AREB', 'AREIDENTIFIED', 'AREMALI', 'ARENA', 'ARENAVIRUSES', 'ARFH', 'ARG', 'ARGENTINA', 'ARGENTINAINCREASE', 'ARGENTINE', 'ARGENTINIAN', 'ARGININE', 'ARGOS', 'ARGS', 'ARGUE', 'ARGUED', 'ARGUMENT', 'ARGUMENTATION', 'ARGUMENTS', 'ARHANGHEL', 'ARI', 'ARID', 'ARIES', 'ARISE', 'ARISES', 'ARISING', 'ARISTOTLE', 'ARIZONA', 'ARM', 'ARM1', 'ARMAMENT', 'ARMAUER', 'ARMED', 'ARMENIA', 'ARMING', 'ARMM', 'ARMOR', 'ARMS', 'ARMY', 'ARORATATA', 'AROUND', 'ARRANGE', 'ARRANGED', 'ARRANGEMENT', 'ARRANGEMENTS', 'ARRANGING', 'ARRAY', 'ARRAYS', 'ARRESTED', 'ARRESTS', 'ARRIVAL', 'ARRIVE', 'ARROW', 'ARSENIC', 'ARSI', 'ART', 'ARTEMETHER', 'ARTEMETHERLUMEFANTRINE', 'ARTEMIA', 'ARTEMISININ', 'ARTEMISININBASED', 'ARTESUNATE', 'ARTESUNATEAMODIAQUINE', 'ARTESUNATEAMODUAQUINE', 'ARTF', 'ARTHRITIS', 'ARTHROPOD', 'ARTHROPODS', 'ARTICLE', 'ARTICLES', 'ARTICULADO', 'ARTICULATE', 'ARTICULATION', 'ARTIFICIAL', 'ARTISANAL', 'ARTIST', 'ARTISTIC', 'ARTISTRY', 'ARTS', 'ARTWORK', 'ARUA', 'ARV', 'ARVS', 'AS', 'AS01', 'AS3MT', 'ASAFEM', 'ASAQ', 'ASBESTOS', 'ASBI', 'ASBL', 'ASCENDANCE', 'ASCENDANCY', 'ASCENDENCE', 'ASCENDENCY', 'ASCERTAIN', 'ASCERTAINMENT', 'ASCORBIC', 'ASCRIBABLE', 'ASD', 'ASDEPLOYING', 'ASEAN', 'ASEANS', 'ASEANUS', 'ASEGUREN', 'ASEOWA', 'ASH', 'ASHKHABAD', 'ASHRAM', 'ASIA', 'ASIAAMLIORER', 'ASIAAMTLIORER', 'ASIAN', 'ASIANPACIFIC', 'ASIANS', 'ASIANSOUTH', 'ASIAPACIFIC', 'ASIAS', 'ASIATIC', 'ASIDE', 'ASILOMAR', 'ASK', 'ASKED', 'ASLM', 'ASMARA', 'ASND', 'ASOCIACI', 'ASOCIACIN', 'ASP', 'ASPECT', 'ASPECTS', 'ASPIRATION', 'ASPIRE', 'ASPIRES', 'ASPIRIN', 'ASPR', 'ASREQUESTED', 'ASSAM', 'ASSAULT', 'ASSAY', 'ASSAYS', 'ASSEMBLE', 'ASSEMBLED', 'ASSEMBLY', 'ASSENTING', 'ASSERT', 'ASSERTION', 'ASSESS', 'ASSESSED', 'ASSESSES', 'ASSESSING', 'ASSESSMENT', 'ASSESSMENTS', 'ASSESSMENTSPROVIDING', 'ASSET', 'ASSETKNOWLEDGE', 'ASSETS', 'ASSIGN', 'ASSIGNED', 'ASSIGNMENT', 'ASSIGNMENTS', 'ASSIS', 'ASSIST', 'ASSISTANCE', 'ASSISTANCEELIGIBLE', 'ASSISTANCEIMPROVE', 'ASSISTANCES', 'ASSISTANT', 'ASSISTANTS', 'ASSISTED', 'ASSISTER', 'ASSISTING', 'ASSISTS', 'ASSISTTS', 'ASSIUT', 'ASSOCI', 'ASSOCIATE', 'ASSOCIATED', 'ASSOCIATES', 'ASSOCIATION', 'ASSOCIATIONETHIOPIAN', 'ASSOCIATIONS', 'ASSOCIS', 'ASSOCIT', 'ASSOCITS', 'ASSORT', 'ASSORTED', 'ASSSESMENT', 'ASSUMED', 'ASSUMING', 'ASSUMOUD', 'ASSUMPTIONS', 'ASSURANCE', 'ASSURANCEINSECTICI', 'ASSURANT', 'ASSURE', 'ASSURED', 'ASSUREDRESULT', 'ASSURING', 'ASTATINE', 'ASTHMA', 'ASTHMATIC', 'ASTIR', 'ASTONPROLA', 'ASTUTENESS', 'ASUNCION', 'ASWAN', 'ASYLUM', 'ASYMPTOMATIC', 'AT', 'ATENCIN', 'ATENDIDAS', 'ATEP', 'ATFAL', 'ATHENA', 'ATHEROSCLEROSIS', 'ATLANTA', 'ATLANTAUSA', 'ATLANTIC', 'ATLANTICA', 'ATLAS', 'ATMOSPHERE', 'ATMOSPHERIC', 'ATOMIC', 'ATRACCIN', 'ATRISK', 'ATROPHIC', 'ATS', 'ATSA', 'ATSCALE', 'ATSIMO', 'ATTACH', 'ATTACHED', 'ATTACHING', 'ATTACHMENT', 'ATTACK', 'ATTACKS', 'ATTAIN', 'ATTAINING', 'ATTAINMENT', 'ATTEINT', 'ATTEMPT', 'ATTEMPTED', 'ATTEND', 'ATTENDANCE', 'ATTENDANT', 'ATTENDANTS', 'ATTENDED', 'ATTENDING', 'ATTENDS', 'ATTENTION', 'ATTENUATE', 'ATTENUATED', 'ATTENUATION', 'ATTITUDE', 'ATTITUDES', 'ATTITUDINAL', 'ATTRACT', 'ATTRACTANT', 'ATTRACTANTBASED', 'ATTRACTED', 'ATTRACTION', 'ATTRACTIONS', 'ATTRACTIVE', 'ATTRACTS', 'ATTRIBUTABLE', 'ATTRIBUTED', 'ATTRIBUTES', 'ATTRITION', 'ATYPICAL', 'AU', 'AUB', 'AUCTION', 'AUD20', 'AUDIENCE', 'AUDIENCES', 'AUDIENCESTHE', 'AUDIOVISUAL', 'AUDIOVISUALS', 'AUDIT', 'AUDITING', 'AUDITS', 'AUGER', 'AUGERBASED', 'AUGMENT', 'AUGMENTANT', 'AUGMENTATION', 'AUGMENTED', 'AUGMENTER', 'AUGMENTING', 'AUGUST', 'AUGUSTA', 'AUGUSTUS', 'AUHC', 'AUP', 'AUREUS', 'AURUM', 'AUSAID', 'AUSAIDINITIATED', 'AUSAIDS', 'AUSCULTATION', 'AUSSIE', 'AUSTIN', 'AUSTRALASIAN', 'AUSTRALIA', 'AUSTRALIAINDONESIA', 'AUSTRALIAN', 'AUSTRALIAS', 'AUSTRIA', 'AUTHOR', 'AUTHORED', 'AUTHORIES', 'AUTHORISATION', 'AUTHORITATIVE', 'AUTHORITIES', 'AUTHORITIESALL', 'AUTHORITIESBESIDES', 'AUTHORITY', 'AUTHORITYS', 'AUTHORIZATION', 'AUTHORIZED', 'AUTHORIZES', 'AUTHORS', 'AUTISM', 'AUTMN', 'AUTNOMA', 'AUTO', 'AUTOANTHRO', 'AUTOCHTHONAL', 'AUTOCHTHONIC', 'AUTOCHTONES', 'AUTOIMMUNE', 'AUTOMATED', 'AUTOMATIC', 'AUTOMATICALLY', 'AUTOMATION', 'AUTOMATON', 'AUTONOMOUS', 'AUTONOMOUSLY', 'AUTONOMY', 'AUTOPHAGY', 'AUTOPSY', 'AUTOSUFICIENCIA', 'AUTOVISUAL', 'AUTRES', 'AUTUMN', 'AUX', 'AUXILIARY', 'AVADAR', 'AVAHAN', 'AVAIL', 'AVAILABILITY', 'AVAILABLE', 'AVAILABLEFOR', 'AVAILABLENESS', 'AVAILABLERESULT', 'AVAIT', 'AVANZADA', 'AVANZADOS', 'AVAREF', 'AVEC', 'AVENIR', 'AVERAGE', 'AVERT', 'AVERTABLE', 'AVERTED', 'AVERTING', 'AVH', 'AVHBONE', 'AVHUPCH', 'AVIAN', 'AVIANO', 'AVIATE', 'AVIV', 'AVOCACY', 'AVOID', 'AVOIDABLE', 'AVOIDING', 'AVOIDS', 'AVRDC', 'AWAIL', 'AWAITED', 'AWAITING', 'AWARD', 'AWARDED', 'AWARDEES', 'AWARDING', 'AWARDS', 'AWARE', 'AWARENESRISING', 'AWARENESS', 'AWARENESSRAISING', 'AWAY', 'AWEIL', 'AWKA', 'AWWS', 'AXE', 'AXIS', 'AY', 'AYACUCHO', 'AYAM', 'AYAMT', 'AYURVEDA', 'AYUSH', 'AZ', 'AZAR', 'AZERBAIJAN', 'AZERBAIJANI', 'AZERBAIJANS', 'AZITHROMYCIN', 'AZRIELI', 'AZT', 'B', 'B10', 'B11', 'B12', 'B13', 'B14', 'B3', 'B4', 'B5', 'BA', 'BAA', 'BAATAR', 'BABE', 'BABIES', 'BABIESMATERNAL', 'BABOON', 'BABY', 'BAC', 'BACCY', 'BACHELOR', 'BACHELORS', 'BACILLUS', 'BACK', 'BACKBONE', 'BACKED', 'BACKEND', 'BACKGROUND', 'BACKGROUNDINFECTIOUS', 'BACKGROUNDS', 'BACKING', 'BACKMAN', 'BACKSLIDING', 'BACKSTOPPING', 'BACKUP', 'BACKWASH', 'BACKYARD', 'BACON', 'BACTEREMIA', 'BACTERIA', 'BACTERIAANTIBACTERIAL', 'BACTERIAL', 'BACTERICIDAL', 'BACTERIOLOGY', 'BACTERIOPHAGE', 'BACTERIOPHAGES', 'BACTERIUM', 'BACTIERIA', 'BACTIVAC', 'BACTROCERA', 'BAD', 'BADGHIS', 'BADRAN', 'BADULLA', 'BAFATA', 'BAFFLE', 'BAG', 'BAGAMOYO', 'BAGDAD', 'BAGHDAD', 'BAGMEDIATED', 'BAHIA', 'BAHRAIN', 'BAHRAINMENTAL', 'BAHRAINNATIONAL', 'BAHRAINNONCOMMUNICABLE', 'BAHRAINTUBERCULOSIS', 'BAHRAINVIOLENCE', 'BAILIWICK', 'BAIT', 'BAITS', 'BAJENU', 'BAKERIES', 'BAKERS', 'BAKGRUND', 'BAKU', 'BALAKA', 'BALANCE', 'BALANCED', 'BALINESE', 'BALIPEND', 'BALKH', 'BALL', 'BALLAD', 'BALLOON', 'BALSILLIE', 'BALTIMORE', 'BALUCHISTAN', 'BALUCHISTANPROJECT', 'BAMAKO', 'BAMIANYAKAWLANG', 'BAN202G01H00', 'BANANAS', 'BANCROFTI', 'BANCROFTIAN', 'BAND', 'BANDIM', 'BANG', 'BANGALORE', 'BANGKOK', 'BANGLA', 'BANGLADESH', 'BANGLADESHS', 'BANGUI', 'BANJA', 'BANJUL', 'BANK', 'BANKING', 'BANKRUPTCY', 'BANKS', 'BANKWHO', 'BANNER', 'BANNING', 'BANQUET', 'BANSWARA', 'BANYAN', 'BAPTIST', 'BAR', 'BARBADOS', 'BARBARIAN', 'BARCELONA', 'BARCODES', 'BARGAINING', 'BARILAN', 'BARK', 'BARN', 'BARRIER', 'BARRIERS', 'BARRIERSOR', 'BARRIOS', 'BARRT', 'BARS', 'BARTER', 'BAS', 'BAS2', 'BASAL', 'BASE', 'BASEBALL', 'BASED', 'BASELINE', 'BASELINES', 'BASEOFTHEPYRAMID', 'BASES', 'BASEYEAR', 'BASHANET', 'BASIC', 'BASICMEDICAL', 'BASICS', 'BASIN', 'BASINS', 'BASIS', 'BASISRESULTS', 'BASKET', 'BASKETBALL', 'BASSE', 'BATAVIA', 'BATHROOM', 'BATHROOMS', 'BATKEN', 'BATS', 'BATTERS', 'BATTERY', 'BATTERYOPERATED', 'BATTLE', 'BATTLEGROUND', 'BATTLES', 'BAUCHI', 'BAY', 'BAYESIAN', 'BAYLOR', 'BB', 'BBASED', 'BBSOME', 'BBSRC', 'BBSRCESRCNERCDFID', 'BBSRCMRC', 'BCC', 'BCELL', 'BCG', 'BE', 'BEAD', 'BEADBASED', 'BEAM', 'BEANS', 'BEAR', 'BEARD', 'BEARERS', 'BEARING', 'BEARS', 'BEAST', 'BEAT', 'BEAU', 'BEAVER', 'BECAME', 'BECAS', 'BECAUSE', 'BECOME', 'BECOMES', 'BECOMING', 'BECUASE', 'BED', 'BEDCOVER', 'BEDRE', 'BEDS', 'BEDSIDE', 'BEDSIZED', 'BEE', 'BEEF', 'BEEHYV', 'BEES', 'BEFITAKA', 'BEFORE', 'BEGAN', 'BEGET', 'BEGGERS', 'BEGIN', 'BEGINNING', 'BEGINS', 'BEGUN', 'BEHALF', 'BEHAVE', 'BEHAVIOR', 'BEHAVIORAL', 'BEHAVIORALLY', 'BEHAVIORCHANGE', 'BEHAVIORS', 'BEHAVIOUR', 'BEHAVIOURAL', 'BEHAVIOURFURTHER', 'BEHAVIOURS', 'BEHAVIOURSTHE', 'BEHIND', 'BEHOLDER', 'BEIJING', 'BEING', 'BEINGS', 'BEINGSCALEDUP', 'BEINTEGRATED', 'BEIRA', 'BEIRUT', 'BEIT', 'BEITRAG', 'BEL', 'BELARUS', 'BELARUSIAN', 'BELDIFOOD', 'BELGIAN', 'BELGIUM', 'BELGRADE', 'BELIEF', 'BELIEFS', 'BELIEVE', 'BELIEVED', 'BELIEVES', 'BELITTLE', 'BELIZE', 'BELLAGIO', 'BELLIED', 'BELLO', 'BELONG', 'BELONGING', 'BELOW', 'BELOW1REDUCE', 'BELT', 'BEMONC', 'BEMPU', 'BENCH', 'BENCHMARK', 'BENCHMARKED', 'BENCHMARKING', 'BENCHTOBEDSIDE', 'BENEATH', 'BENEFICIAL', 'BENEFICIALLY', 'BENEFICIARIES', 'BENEFICIARIESPRISONERS', 'BENEFICIARIESTHE', 'BENEFICIARY', 'BENEFIT', 'BENEFITED', 'BENEFITING', 'BENEFITS', 'BENEFITTHE', 'BENEFITTING', 'BENGAL', 'BENGALI', 'BENGUELA', 'BENIN', 'BENINRESULT', 'BENJAMIN', 'BENNI', 'BENPORAT', 'BENZIMIDAZOLE', 'BENZOXABOROLES', 'BEQUEATH', 'BEREAVEMENT', 'BERGEN', 'BERGENUB', 'BERGHEI', 'BERKELEY', 'BERNHARD', 'BERRIES', 'BERTH', 'BERTRAND', 'BESEDEL', 'BESIDES', 'BESIEGE', 'BEST', 'BET', 'BETA', 'BETACELLS', 'BETAL', 'BETEL', 'BETH', 'BETHLEHEM', 'BETIO', 'BETROTHAL', 'BETTER', 'BETTERMENT', 'BETTOR', 'BETWEEN', 'BEVALUATION', 'BEVERAGE', 'BEVERAGES', 'BEYOND', 'BF', 'BGCHA', 'BGTIR', 'BHARAT', 'BHC', 'BHCS', 'BHUTAN', 'BI', 'BIAKOYE', 'BIALLELIC', 'BIANNUAL', 'BIASED', 'BIBLE', 'BIBLICAL', 'BIBLIOGRAPHIES', 'BIBLIOGRAPHIESWRITE', 'BIBLIOGRAPHY', 'BID', 'BIDI', 'BIENHEREUX', 'BIENHEUREUX', 'BIENNIAL', 'BIENNIUM', 'BIG', 'BIGGER', 'BIGGEST', 'BIH', 'BIHAR', 'BIJAGOS', 'BILATERAL', 'BILATERALLY', 'BILHARZIA', 'BILINGUAL', 'BILL', 'BILLET', 'BILLION', 'BILLS', 'BILTRICIDE', 'BIN', 'BINATIONAL', 'BIND', 'BINDING', 'BIO', 'BIOACTIVE', 'BIOACTIVES', 'BIOACTIVITIES', 'BIOACTIVITY', 'BIOASSAY', 'BIOAVAILABLE', 'BIOBANK', 'BIOBASED', 'BIOCHANCE', 'BIOCHEM', 'BIOCHEMICAL', 'BIOCHEMISTRY', 'BIOCHIP', 'BIOCLINICS', 'BIOCLINIQUES', 'BIOCONTROL', 'BIODEGRADABLE', 'BIODIVERSITY', 'BIODIVERSITYHEALTH', 'BIODIVERSITYJJVS', 'BIOECONOMY', 'BIOENGINEERING', 'BIOEQUIVALENCE', 'BIOEQUIVALENT', 'BIOETHICS', 'BIOFARMA', 'BIOFEATURE', 'BIOFILM', 'BIOFILMS', 'BIOFLUIDS', 'BIOFORTIFICATED', 'BIOFORTIFICATION', 'BIOFORTIFIED', 'BIOGENESIS', 'BIOGRAPHY', 'BIOHEAL', 'BIOINDICATOR', 'BIOINFORMATIC', 'BIOINFORMATICS', 'BIOINSPIRED', 'BIOINTENSIVE', 'BIOLABS', 'BIOLOGIC', 'BIOLOGICAL', 'BIOLOGICALLY', 'BIOLOGICALS', 'BIOLOGICS', 'BIOLOGIE', 'BIOLOGISTS', 'BIOLOGY', 'BIOLOGY4', 'BIOLOGYHELMINTHOLOGY', 'BIOM', 'BIOMARKAPD', 'BIOMARKER', 'BIOMARKERS', 'BIOMASS', 'BIOMATERIALS', 'BIOMATRIAUX', 'BIOMATRICES', 'BIOMATTRIAUX', 'BIOMCANIQUE', 'BIOMDICALE', 'BIOMDICOS', 'BIOMECHANICS', 'BIOMECHANICSSPECIFIC', 'BIOMED', 'BIOMEDICAL', 'BIOMEDICALLABORATORY', 'BIOMEDICINE', 'BIOMEDICINES', 'BIOMOLECULAR', 'BIOMOLECULES', 'BIOMTCANIQUE', 'BIOMTDICALE', 'BIOMTDICOS', 'BIONANOMEDTECH', 'BIONOMICS', 'BIOPHARMACEUTIC', 'BIOPHARMACEUTICAL', 'BIOPHYSICAL', 'BIOPROCESS', 'BIOPROSPECTING', 'BIOPSY', 'BIORESOURCE', 'BIORISK', 'BIOSAFETY', 'BIOSAFETYBIOSECURITY', 'BIOSCIENCES', 'BIOSECURITY', 'BIOSECURITYPREVENTION', 'BIOSIGNATURE', 'BIOSOLUTIONS', 'BIOSPECIMEN', 'BIOSPHERE', 'BIOSTATISTICS', 'BIOSYNTHESIS', 'BIOSYSTEM', 'BIOSYSTEMS', 'BIOTA', 'BIOTEC', 'BIOTECH', 'BIOTECHNOLOGICAL', 'BIOTECHNOLOGIES', 'BIOTECHNOLOGY', 'BIOTERRORIST', 'BIOTHERAPEUTICS', 'BIOTHREAT', 'BIOTIC', 'BIOTRANSFORMATION', 'BIPAI', 'BIPAIS', 'BIPHASIC', 'BIRD', 'BIRDS', 'BIRTH', 'BIRTHDAY', 'BIRTHIN', 'BIRTHING', 'BIRTHS', 'BIRTHSCULTURAL', 'BIRTHSTHESE', 'BIRTHTHE', 'BIRTHWEIGHT', 'BIRZEIT', 'BISEXUALS', 'BISHKEK', 'BISPECIFIC', 'BISSAU', 'BIT', 'BITE', 'BITING', 'BITOLA', 'BITSTRENGTHENING', 'BITTEN', 'BITTER', 'BIVALENT', 'BLACK', 'BLACKGUARD', 'BLAIR', 'BLANCO', 'BLANK', 'BLANTVRE', 'BLANTYRE', 'BLANTYREBLANTYRE', 'BLAST', 'BLASTOCYSTIS', 'BLEACH', 'BLEAK', 'BLEND', 'BLENDED', 'BLICA', 'BLIND', 'BLINDED', 'BLINDING', 'BLINDNESS', 'BLIP', 'BLO', 'BLOCK', 'BLOCKCHAIN', 'BLOCKING', 'BLOCKINGRADICAL', 'BLOCKS', 'BLOGS', 'BLOOD', 'BLOODBORNE', 'BLOODED', 'BLOODFEEDING', 'BLOODSTAGE', 'BLOODSTREAM', 'BLOODSUCKING', 'BLOOM', 'BLOOMBERG', 'BLOOMS', 'BLOW', 'BLOWUP', 'BLUE', 'BLUEFIELDS', 'BLUEPRINT', 'BLUEPRINTS', 'BM', 'BMC', 'BMCT', 'BMI', 'BMMRD', 'BNAB', 'BNABS', 'BNIN', 'BO', 'BOARD', 'BOARDAPPROVED', 'BOARDS', 'BOASTED', 'BOAT', 'BOB', 'BODIED', 'BODIES', 'BODILY', 'BODY', 'BOGOT', 'BOGOTA', 'BOIL', 'BOKK', 'BOL', 'BOL1067', 'BOL1082', 'BOL1082BY', 'BOL307G07H', 'BOLDAK', 'BOLGATANGA', 'BOLIVIA', 'BOLIVIAN', 'BOLSA', 'BOLSHEVIK', 'BOLSHIE', 'BOLSHY', 'BOLSTER', 'BOLSTERING', 'BOLVIA', 'BOMBALI', 'BOMBAY', 'BOMBER', 'BOMCA', 'BOMI', 'BON', 'BOND', 'BONE', 'BONES', 'BONG', 'BONIFACE', 'BONK', 'BONKO', 'BONNES', 'BONO', 'BOOK', 'BOOKER', 'BOOKING', 'BOOKLETS', 'BOOKS', 'BOOM', 'BOOST', 'BOOSTED', 'BOOSTER', 'BOOSTING', 'BOOT', 'BOOTH', 'BORAD', 'BORDER', 'BORDERING', 'BORDERS', 'BOREHOLES', 'BORENA', 'BORIS', 'BORLAUG', 'BORN', 'BORNE', 'BORNO', 'BORON', 'BORROW', 'BORROWING', 'BORSTEL', 'BOSNIA', 'BOSNIAHERZEGOVINA', 'BOSQUE', 'BOSTON', 'BOTH', 'BOTSWANA', 'BOTSWANADRUG', 'BOTSWANAS', 'BOTSWANATANZANIAZAMBIA', 'BOTTLENECK', 'BOTTLENECKS', 'BOTTLENECS', 'BOTTOMUPSTRATEGY', 'BOUGHT', 'BOUISSON', 'BOUNCY', 'BOUND', 'BOUNDARY', 'BOUSS', 'BOUSSF', 'BOUSST', 'BOUT', 'BOUVARDIN', 'BOVINE', 'BOWEL', 'BOWELS', 'BOX', 'BOY', 'BOYS', 'BOYSPREVENTING', 'BP', 'BPA', 'BPHS', 'BPKIHS', 'BPRC', 'BPS', 'BRAC', 'BRACELET', 'BRACKET', 'BRACSUPPORTED', 'BRADYPUS', 'BRAILLE', 'BRAIN', 'BRAINPOWER', 'BRAINSTORM', 'BRAINWE', 'BRAKE', 'BRAN', 'BRANCH', 'BRANCHES', 'BRAND', 'BRANDED', 'BRANDEIS', 'BRASIL', 'BRASILEIRO', 'BRASS', 'BRAVO', 'BRAZIL', 'BRAZILIAN', 'BRAZILIANS', 'BRAZILIDENTIFICATION', 'BRAZILS', 'BRAZZAVILLE', 'BREACH', 'BREAD', 'BREADTH', 'BREAK', 'BREAKAGE', 'BREAKAGEFUSION', 'BREAKBONE', 'BREAKDOWN', 'BREAKFAST', 'BREAKING', 'BREAKTHROUGH', 'BREAKTHROUGHACTION', 'BREAKTHROUGHRESEARCH', 'BREAKUP', 'BREAST', 'BREASTFED', 'BREASTFEED', 'BREASTFEEDING', 'BREATH', 'BREATHBASED', 'BREATHE', 'BREATHER', 'BREATHING', 'BREATHTESTING', 'BREEDING', 'BREEDS', 'BREVETTE', 'BRIDGE', 'BRIDGES', 'BRIDGING', 'BRIEF', 'BRIEFINGS', 'BRIEFLY', 'BRIEFS', 'BRIGADAS', 'BRIGHAM', 'BRIGHT', 'BRIJESH', 'BRING', 'BRINGING', 'BRINGS', 'BRITAIN', 'BRITAINNEPAL', 'BRITISH', 'BRN202G05M', 'BRN910G09M', 'BROAD', 'BROADBAND', 'BROADBASED', 'BROADCAST', 'BROADCASTED', 'BROADCASTING', 'BROADEN', 'BROADENED', 'BROADENING', 'BROADER', 'BROADLY', 'BROADREACH', 'BROKER', 'BROKERING', 'BROKERS', 'BRONCHITIS', 'BRONHOSKOPIJA', 'BROOK', 'BROOKINGS', 'BROTHERHOOD', 'BROTHERS', 'BROUGHT', 'BROWSING', 'BRUCE', 'BRUCEI', 'BRUCELLA', 'BRUCELLOSIS', 'BRUGIA', 'BRUNDTLAND', 'BRUNEI', 'BRUNO', 'BRUNT', 'BRUSHUP', 'BRUSK', 'BRUTE', 'BRUYFRE', 'BSCI', 'BSI', 'BSIS', 'BSL2', 'BSS', 'BT20', 'BTH', 'BTIR', 'BTNIN', 'BTNINOISE', 'BU', 'BUCKETS', 'BUDGET', 'BUDGETACCESS', 'BUDGETAGEING', 'BUDGETARY', 'BUDGETDISABILITIES', 'BUDGETED', 'BUDGETFOOD', 'BUDGETGENDER', 'BUDGETHEALTH', 'BUDGETING', 'BUDGETINTERGRATED', 'BUDGETLEADERSHIP', 'BUDGETMALARIA', 'BUDGETMENTAL', 'BUDGETNATIONAL', 'BUDGETNEGLCTED', 'BUDGETNONCOMMUNICABLE', 'BUDGETNUTRITION', 'BUDGETREPRODUCTIVE', 'BUDGETS', 'BUDGETSOCIAL', 'BUDGETSTRATEGIC', 'BUDGETTRANSPARENCY', 'BUDGETTUBERCULOSIS', 'BUDGETVACCINE', 'BUDGETVACCINEPREVENTABLE', 'BUDGETVIOLENCE', 'BUENOS', 'BUFFER', 'BUG', 'BUGGY', 'BUIDING', 'BUILD', 'BUILDERS', 'BUILDI', 'BUILDING', 'BUILDINGS', 'BUILDINGUP', 'BUILDS', 'BUILIDNG', 'BUILING', 'BUILT', 'BUKAVU', 'BULGARIAHEALTH', 'BULGARIAINTERGRATED', 'BULGARIALEADERSHIP', 'BULGARIAMENTAL', 'BULGARIANATIONAL', 'BULGARIANUTRITION', 'BULGARIASOCIAL', 'BULGARIASTRATEGIC', 'BULGARIATUBERCULOSIS', 'BULK', 'BULLET', 'BULLETIN', 'BULLYING', 'BULWARK', 'BUM', 'BUNCH', 'BUNDLE', 'BUNGU', 'BUNYAVIRIDAE', 'BUOS', 'BUOSCENTRE', 'BURDE', 'BURDEN', 'BURDENED', 'BURDENEVIDENCE', 'BURDENS', 'BUREAU', 'BUREAUCRATIC', 'BUREAUS', 'BURHOLDERIA', 'BURKINA', 'BURMA', 'BURN', 'BURNER', 'BURNING', 'BURNS', 'BURRILL', 'BURSTING', 'BURULI', 'BURUNDI', 'BURUNDIDEMONSTRATE', 'BUSCA', 'BUSHMEAT', 'BUSINESS', 'BUSINESSES', 'BUSINESSESTABLISHMENT', 'BUSINESSORIENTED', 'BUSSLIS', 'BUT', 'BUTCHERING', 'BUTEMBO', 'BUTT', 'BUTTER', 'BUTTONHOLE', 'BUY', 'BUYENZI', 'BUYIN', 'BUYING', 'BUYINS', 'BUYS', 'BV', 'BW', 'BY', 'BY1', 'BYA', 'BYDECISIONS', 'BYELORUSSIA', 'BYLAWS', 'BYPLAY', 'C', 'C1', 'C6', 'CA', 'CA075', 'CA1', 'CA35M', 'CA36', 'CA57', 'CA850', 'CAB', 'CABI', 'CABINET', 'CABO', 'CABOODLE', 'CABOTEGRAVIR', 'CAC', 'CACINCLUDING', 'CAD', 'CADENCE', 'CADMIUM', 'CADMIUMINDUCED', 'CADRE', 'CADRES', 'CAEAREAN', 'CAESAREAN', 'CAGE', 'CAI', 'CAII', 'CAISSES', 'CALAMITOUS', 'CALAMITY', 'CALCIFEROL', 'CALCIUM', 'CALCULATE', 'CALCULATED', 'CALCULATION', 'CALEDONIA', 'CALENDAR', 'CALGARY', 'CALI', 'CALIBER', 'CALIBR', 'CALIBRATION', 'CALIBRE', 'CALIF', 'CALIFORNIA', 'CALIFORNIADAVIS', 'CALL', 'CALLAO', 'CALLED', 'CALLER', 'CALLIN', 'CALLOFF', 'CALLS', 'CALORIE', 'CALORIES', 'CALOUSTE', 'CAMARGO', 'CAMBER', 'CAMBODGE', 'CAMBODIA', 'CAMBODIAN', 'CAMBODIANS', 'CAMBODIAS', 'CAMBRIDGECHENNAI', 'CAME', 'CAMEL', 'CAMERA', 'CAMERINO', 'CAMEROON', 'CAMEROUN', 'CAMES', 'CAMILLUS', 'CAMP', 'CAMPA', 'CAMPAIGN', 'CAMPAIGNER', 'CAMPAIGNING', 'CAMPAIGNS', 'CAMPAING', 'CAMPINAS', 'CAMPO', 'CAMPS', 'CAMPUS', 'CAMPYLOBACTER', 'CAN', 'CANADA', 'CANADAAFRICA', 'CANADAINTERVENTION', 'CANADAISRAEL', 'CANADAPHASES', 'CANADAS', 'CANADIAN', 'CANADIANDEVELOPING', 'CANADIANISRAELI', 'CANADIANS', 'CANADIANSPLAN', 'CANADIANSPROJECT', 'CANADIEN', 'CANALIZATION', 'CANCEL', 'CANCER', 'CANCERINDUCING', 'CANCERPLAN10', 'CANCERS', 'CANCERTHE', 'CANDID', 'CANDIDA', 'CANDIDATE', 'CANDIDATES', 'CANDIDATESFUNDS', 'CANDY', 'CANFUL', 'CANIS', 'CANNOT', 'CANONIC', 'CANSINO', 'CANSINOS', 'CANTEEN2', 'CANTONS', 'CANUSE', 'CANVAS', 'CANVASS', 'CAO', 'CAP', 'CAPABILITIES', 'CAPABILITY', 'CAPABLE', 'CAPACIDADES', 'CAPACITACI', 'CAPACITACIN', 'CAPACITANCE', 'CAPACITATING', 'CAPACITIES', 'CAPACITS', 'CAPACITTS', 'CAPACITY', 'CAPACITY12220', 'CAPACITYBUILDING', 'CAPACITYENABLE', 'CAPACITYNEEDS', 'CAPACITYPLUS', 'CAPAITALISE', 'CAPASITY', 'CAPE', 'CAPES', 'CAPILLARY', 'CAPITA', 'CAPITAL', 'CAPITALISE', 'CAPITALISTS', 'CAPITOL', 'CAPMALARIA', 'CAPPELLANO', 'CAPRICORN', 'CAPRISA', 'CAPSIDS', 'CAPT', 'CAPTAIN', 'CAPTB', 'CAPTURE', 'CAPTURED', 'CAPTURES', 'CAPTURING', 'CAR', 'CARA', 'CARACTRISATION', 'CARACTTRISATION', 'CARAPIRA', 'CARAVAN', 'CARAVANSARY', 'CARAVANSERAI', 'CARBAPENEMAS', 'CARBAPENEMASES', 'CARBAPENEMASPRODUCING', 'CARBAPENEMS', 'CARBOHYDRATE', 'CARBON', 'CARBONATE', 'CARBOXYMALTOSE', 'CARCINOGENIC', 'CARCINOGENS', 'CARCINOMA', 'CARD', 'CARDIAC', 'CARDIFF', 'CARDINAL', 'CARDIO', 'CARDIOLOGICAL', 'CARDIOLOGY', 'CARDIOMYOPATHIES', 'CARDIOMYOPATHY', 'CARDIOPATIC', 'CARDIOPROT', 'CARDIOVASCULAR', 'CARDS', 'CARE', 'CAREA', 'CAREBASED', 'CAREBUILDING', 'CAREENSURING', 'CAREER', 'CAREERS', 'CAREEXTENDING', 'CAREFULLY', 'CAREGEOGRAPHIC', 'CAREGIVERS', 'CAREINCLUDING', 'CARELEVEL', 'CAREPREVENTION', 'CARERES', 'CARERESEARCHERS', 'CARERS', 'CARES', 'CARESEEKING', 'CARETAKERS', 'CARETHE', 'CARETHIS', 'CARETO', 'CARETRANSPORTATION', 'CAREWORKING', 'CARGILL', 'CARI', 'CARIBBEAN', 'CARIBBEANHOW', 'CARING', 'CARITAS', 'CARITASRWANDA', 'CARLA', 'CARMICHAEL', 'CARNAL', 'CARNERI', 'CAROLINA', 'CAROLINAS', 'CARPENTER', 'CARPENTERS', 'CARPHA', 'CARRIAGE', 'CARRIED', 'CARRIER', 'CARRIERS', 'CARRY', 'CARRYING', 'CARS', 'CART', 'CARTA', 'CARTAAPHRC', 'CARTATHE', 'CARTER', 'CARTESIAN', 'CARTOGRAPHY', 'CARVE', 'CARY', 'CAS9', 'CASCADE', 'CASCADESSPECIFICALLY', 'CASE', 'CASEBASED', 'CASEBYCASE', 'CASECONTROL', 'CASEFINDING', 'CASEFUL', 'CASERIO', 'CASES', 'CASESTUDY', 'CASH', 'CASING', 'CASO', 'CASOS', 'CASSAVA', 'CAST', 'CASTE', 'CASTR', 'CASTRIES', 'CASUAL', 'CASUATIVE', 'CASUS', 'CATABOLISM', 'CATACLYSM', 'CATALOG', 'CATALOGUE', 'CATALYSE', 'CATALYSING', 'CATALYST', 'CATALYTIC', 'CATALYZE', 'CATALYZING', 'CATAMENIA', 'CATAMENIAL', 'CATARACT', 'CATASTROPHE', 'CATASTROPHES', 'CATASTROPHIC', 'CATAZLYING', 'CATCH', 'CATCHING', 'CATCHMENT', 'CATCHMENTS', 'CATEGORIES', 'CATEGORY', 'CATER', 'CATERING', 'CATGUT', 'CATH', 'CATHETER', 'CATHLAB', 'CATHMENT', 'CATHODIC', 'CATHOLIC', 'CATO', 'CATOLICA', 'CATTLE', 'CAU', 'CAUCA', 'CAUCASIA', 'CAUCASUS', 'CAULIFOLIA', 'CAUSA', 'CAUSAL', 'CAUSATIVE', 'CAUSE', 'CAUSEANDEFFECT', 'CAUSED', 'CAUSES', 'CAUSING', 'CAUTION', 'CAVAILABILITYCREATING', 'CAVD', 'CAVITE', 'CAY', 'CAYETANO', 'CBHI', 'CBHIPP', 'CBO', 'CBOS', 'CBRN', 'CCA', 'CCAC', 'CCGH', 'CCGHR', 'CCHANGE', 'CCHF', 'CCHFV', 'CCIR', 'CCM', 'CCME', 'CCO', 'CCP', 'CCR', 'CCR5', 'CCR532', 'CCRDA', 'CCS', 'CCT', 'CCYCLE', 'CD', 'CD1', 'CD1GLYCOLIPIDSPECIFIC', 'CD32', 'CD4', 'CD8', 'CD8T', 'CDA', 'CDC', 'CDCMEXICO', 'CDCRFAGH161719', 'CDCS', 'CDEL', 'CDETERMINING', 'CDFU', 'CDHTS', 'CDRF', 'CDROM', 'CDRS', 'CDT', 'CE', 'CEAR', 'CEBHA', 'CECITY', 'CEDAW', 'CEFM', 'CEFTRIAXONE', 'CEHAT', 'CEILING', 'CELFACA', 'CELL', 'CELLINTRINSIC', 'CELLPHONE', 'CELLPHONEBASED', 'CELLPHONES', 'CELLS', 'CELLULAR', 'CELLULARMOLECULAR', 'CELLULOID', 'CELSIUS', 'CEMENTING', 'CEMONC', 'CENAFOD', 'CENSURE', 'CENSUS', 'CENSUSES', 'CENT', 'CENTER', 'CENTERED', 'CENTERING', 'CENTERS', 'CENTERSLABORATORIES', 'CENTIGRADE', 'CENTRA', 'CENTRAL', 'CENTRALE', 'CENTRALIZATION', 'CENTRALIZE', 'CENTRALIZED', 'CENTRALIZING', 'CENTRALLY', 'CENTRE', 'CENTRE2', 'CENTRED', 'CENTREOBJECTIVES', 'CENTRES', 'CENTREUGANDA', 'CENTRIFUGE', 'CENTRIFUGEIMMUNOENZYMATIC', 'CENTRO', 'CENTROAMTRICA', 'CENTRUM', 'CEPAT', 'CEPATJKM', 'CEPATNU', 'CEPATRCD', 'CEPBU', 'CEPHALITIS', 'CEPHALOSPORINS', 'CEPI', 'CERANA', 'CEREAL', 'CEREALE', 'CEREBRAL', 'CEREBRO', 'CEREBROSPINAL', 'CEREBROVASCULAR', 'CEREMONIES', 'CERES', 'CEREVISIAE', 'CERMEL', 'CERP', 'CERTAIN', 'CERTES', 'CERTIFICATE', 'CERTIFICATION', 'CERTIFICATIONS', 'CERTIFIED', 'CERTIFY', 'CERUS', 'CERVICAL', 'CERVICALVAGINAL', 'CERVICOVAGINAL', 'CERVIX', 'CES', 'CESAREAN', 'CESSATION', 'CET', 'CETTE', 'CEUME', 'CGMP', 'CGMPDEPENDENT', 'CGMRC', 'CGPP', 'CGPPETHIOPIA', 'CH', 'CHABAUDI', 'CHAD', 'CHADIC', 'CHAGA', 'CHAGAS', 'CHAGGA', 'CHAI', 'CHAIN', 'CHAINS', 'CHAINSUSING', 'CHAINTECHNICAL', 'CHAIR', 'CHAIRING', 'CHAIRS', 'CHALLE', 'CHALLENGE', 'CHALLENGED', 'CHALLENGES', 'CHALLENGESSINCE', 'CHALLENGESSTRENGTH', 'CHALLENGESTHE', 'CHALLENGESTHIS', 'CHALLENGING', 'CHALMERS', 'CHAM', 'CHAMKAR', 'CHAMPAIGN', 'CHAMPIONS', 'CHAMPS', 'CHAN', 'CHANCE', 'CHANCES', 'CHANEL', 'CHANGE', 'CHANGED', 'CHANGEOVER', 'CHANGER', 'CHANGERS', 'CHANGES', 'CHANGESIDENTIFY', 'CHANGESTHE', 'CHANGETHE', 'CHANGETHIS', 'CHANGING', 'CHANNEL', 'CHANNELISE', 'CHANNELIZE', 'CHANNELLING', 'CHANNELS', 'CHAP', 'CHAPEAU', 'CHAPEL', 'CHAR', 'CHARACTER', 'CHARACTERISATION', 'CHARACTERISE', 'CHARACTERISING', 'CHARACTERISTICS', 'CHARACTERIZATION', 'CHARACTERIZATIONS', 'CHARACTERIZE', 'CHARACTERIZED', 'CHARACTERIZING', 'CHARACTERS', 'CHARG', 'CHARGE', 'CHARGED', 'CHARGES', 'CHARITABLE', 'CHARITIES', 'CHARITY', 'CHARLES', 'CHARLOTTE', 'CHARRON', 'CHART', 'CHARTER', 'CHARTS', 'CHARWOMAN', 'CHASE', 'CHAU', 'CHCS', 'CHE', 'CHEAP', 'CHEAPER', 'CHEAPLY', 'CHECK', 'CHECKING', 'CHECKLIST', 'CHECKS', 'CHECKUP', 'CHEI', 'CHEIKH', 'CHEM', 'CHEMES', 'CHEMICAL', 'CHEMICALPHYSICOCHEMICAL', 'CHEMICALS', 'CHEMIRESISTIVE', 'CHEMISTRY', 'CHEMO', 'CHEMOELIMINATION', 'CHEMOKINERELATED', 'CHEMOPREVENTION', 'CHEMOTHERAPY', 'CHEMOTHERAPYFAILURE', 'CHEP', 'CHEST', 'CHESTER', 'CHEW', 'CHEWING', 'CHEZ', 'CHI', 'CHIBOMBO', 'CHICAGO', 'CHICKEN', 'CHICKENHEARTED', 'CHICKENS', 'CHICKPEA', 'CHIEF', 'CHIEFS', 'CHIETI', 'CHIGARI', 'CHIINAU', 'CHIKUNGUNYA', 'CHIKUNGUNYAIN', 'CHIKV', 'CHILD', 'CHILDBEARING', 'CHILDBIRTH', 'CHILDCARE', 'CHILDHOOD', 'CHILDREN', 'CHILDREN2', 'CHILDRENADDRESSING', 'CHILDRENBRAIN', 'CHILDRENHOW', 'CHILDRENIN', 'CHILDRENOUTCOME', 'CHILDRENS', 'CHILDRENSTRENGTHEN', 'CHILDRENTHE', 'CHILDRENTHERE', 'CHILDS', 'CHILE', 'CHILEAN', 'CHILEPROJECT', 'CHILETHIS', 'CHILI', 'CHILIAD', 'CHILLI', 'CHILLY', 'CHIMERIC', 'CHIMNEY', 'CHIN', 'CHINA', 'CHINACARE', 'CHINAS', 'CHINATHE', 'CHINATHIS', 'CHINESE', 'CHIP', 'CHIPENE', 'CHIQUIMULA', 'CHLORHEXIDINE', 'CHLORINATION', 'CHLOROPLASTIDARY', 'CHLOROQUINE', 'CHO', 'CHOICE', 'CHOICEDISABILITY', 'CHOICEDISABLED', 'CHOICES', 'CHOKEPOINT', 'CHOKW', 'CHOKWT', 'CHOLANGIOCA', 'CHOLANGIOCARCINOMA', 'CHOLECALCIFEROL', 'CHOLERA', 'CHOLERAE', 'CHOLERATOXINDERIVED', 'CHOOSE', 'CHOPINE', 'CHOSEN', 'CHPTE', 'CHRF', 'CHRISTIAN', 'CHRISTIANS', 'CHROMATIN', 'CHROMATOGRAPHY', 'CHROMOSOMAL', 'CHROMOSOME', 'CHRONIC', 'CHRONICALLY', 'CHRONICLE', 'CHRONICOBSTRUCTIVEPULMONARY', 'CHSB', 'CHU', 'CHUI', 'CHUQUISACA', 'CHUQUISACAAMLIORER', 'CHUQUISACAAMTLIORER', 'CHURCES', 'CHURCH', 'CHURCHES', 'CHURCHESTHE', 'CHURCHPARTNER', 'CHUY', 'CHVI', 'CHVS', 'CHW', 'CHWS', 'CHX', 'CI', 'CIAL', 'CIBLTS', 'CICILY', 'CIDA', 'CIDRZ', 'CIENTIFICA', 'CIET', 'CIFOR', 'CIFSRF', 'CIGARET', 'CIGARETTE', 'CIGARETTES', 'CIHR', 'CINCINNATI', 'CINQ', 'CINQUE', 'CIP', 'CIPHER', 'CIRCLE', 'CIRCLES', 'CIRCUITRY', 'CIRCULARISE', 'CIRCULATE', 'CIRCULATING', 'CIRCULATION', 'CIRCUMCISION', 'CIRCUMCISIONS', 'CIRCUMFERENCES', 'CIRCUMSTANCE', 'CIRCUMSTANCES', 'CIRCUMVENT', 'CIRRHOSIS', 'CISA', 'CISTRON', 'CITC', 'CITIES', 'CITIZEN', 'CITIZENCIVIL', 'CITIZENLED', 'CITIZENRY', 'CITIZENS', 'CITIZENSHIP', 'CITIZENSMEXICOS', 'CITY', 'CITYKAROLINSKA', 'CITYS', 'CITYSTATES', 'CIVI', 'CIVIC', 'CIVIL', 'CIVILIAN', 'CIVILIANS', 'CK11', 'CK111106NU51', 'CK13', 'CK13001U01CK', 'CK14', 'CK141402NU50', 'CK15', 'CK15001U18CK', 'CK151505NU50', 'CK16', 'CK161605NU50', 'CKB', 'CKD', 'CKDU', 'CLADE', 'CLAIM', 'CLAIMS', 'CLAMPING', 'CLAREMONT', 'CLARIFY', 'CLASS', 'CLASSES', 'CLASSICAL', 'CLASSIFICATION', 'CLASSIFIED', 'CLASSIFY', 'CLASSIFYING', 'CLASSROOM', 'CLASSROOMBASED', 'CLASSTHIS', 'CLAUSE', 'CLAUSES', 'CLAY', 'CLEAN', 'CLEANED', 'CLEANING', 'CLEANLINESS', 'CLEANROOM', 'CLEAR', 'CLEARANCE', 'CLEARING', 'CLEARINGHOUSE', 'CLEARLY', 'CLEFT', 'CLEOMA', 'CLFNICAS', 'CLIENT', 'CLIENTCENTERED', 'CLIENTCENTEREDNESS', 'CLIENTCENTRED', 'CLIENTELE', 'CLIENTELISM', 'CLIENTS', 'CLIENTUNFRIENDLY', 'CLIMAT', 'CLIMATE', 'CLIMATERELATED', 'CLIMATERESILIENT', 'CLIMATES', 'CLIMATESENSITIVE', 'CLIMATIC', 'CLIME', 'CLINCAL', 'CLINIC', 'CLINICAL', 'CLINICALLABORATORY', 'CLINICALLY', 'CLINICALRESEARCH', 'CLINICBASED', 'CLINICIAN', 'CLINICIANS', 'CLINICO', 'CLINICOEPIDEMIOLOGICAL', 'CLINICS', 'CLINIQUE', 'CLINIQUES', 'CLINTON', 'CLMV', 'CLOBETASOL', 'CLONE', 'CLONES', 'CLORINE', 'CLOSE', 'CLOSED', 'CLOSELY', 'CLOSEOUT', 'CLOSING', 'CLOSURE', 'CLOTH', 'CLOTHESHORSE', 'CLOTS', 'CLOTTING', 'CLOUD', 'CLOUDBASED', 'CLRS', 'CLTS', 'CLUB', 'CLUBS', 'CLUMP', 'CLUSTER', 'CLUSTERING', 'CLUSTERRANDOMISED', 'CLUSTERRANDOMIZED', 'CLUSTERS', 'CMAM', 'CMAP', 'CMC', 'CMHP', 'CMHS', 'CMLAP', 'CMNHS', 'CMNHSFNU', 'CMS', 'CMV', 'CMVHIV', 'CNAM', 'CNCCD', 'CNHE', 'CNHR', 'CNM', 'CNS', 'CNTD', 'CO', 'COACHES', 'COACHING', 'COACTION', 'COADMINISTRATION', 'COAGULOMETER', 'COAGULOMETERURINE', 'COALESCENCE', 'COALESCENCY', 'COALICI', 'COALITION', 'COALITIONBUILDING', 'COALITIONS', 'COARSE', 'COAST', 'COASTAL', 'COCCIDIOSIS', 'COCHAIR', 'COCHRANE', 'COCHRANEREVIEWS', 'COCK', 'COCKROACH', 'COCOA', 'COCONVENED', 'COCREATE', 'COD', 'CODE', 'CODED', 'CODES', 'CODEVELOPING', 'CODEX', 'CODING', 'CODS', 'COEPIDEMIC', 'COES', 'COESCONTINUE', 'COESSUPPORT', 'COEXIST', 'COFACILITATED', 'COFFEE', 'COFINANCIER', 'COFINANCING', 'COFUND', 'COFUNDED', 'COFUNDING', 'COGITATION', 'COGNISANCE', 'COGNITION', 'COGNITIVE', 'COGNIZANCE', 'COGNIZANT', 'COHABIT', 'COHABITING', 'COHERENCE', 'COHERENT', 'COHESIN', 'COHESION', 'COHESIVE', 'COHORT', 'COHORT3', 'COHORTS', 'COHRED', 'COIF', 'COIFFURE', 'COIL', 'COIN', 'COINCIDES', 'COINED', 'COINFECTED', 'COINFECTING', 'COINFECTION', 'COINFECTIONS', 'COINPETENCIES', 'COINVESTIGATOR', 'COINVESTMENT', 'COITION', 'COITUS', 'COLABORACIN', 'COLABORACION', 'COLABORATION', 'COLD', 'COLDCHAIN', 'COLDNESS', 'COLE', 'COLEAD', 'COLECTIVO', 'COLI', 'COLLAB', 'COLLABORATE', 'COLLABORATED', 'COLLABORATES', 'COLLABORATING', 'COLLABORATION', 'COLLABORATIONS', 'COLLABORATIVE', 'COLLABORATIVELY', 'COLLABORATOR', 'COLLABORATORS', 'COLLABORT', 'COLLAGEN', 'COLLATE', 'COLLEAGUES', 'COLLECT', 'COLLECTED', 'COLLECTING', 'COLLECTION', 'COLLECTIVE', 'COLLECTIVELY', 'COLLECTIVES', 'COLLEGE', 'COLLEGES', 'COLLIGATE', 'COLLOQUE', 'COLLOQUIUM', 'COLMENA', 'COLOMBIA', 'COLOMBO', 'COLONIA', 'COLONIAL', 'COLONIES', 'COLONIZATION', 'COLONY', 'COLOR', 'COLORADO', 'COLORECTAL', 'COLORIMETRIC', 'COLORIMETRICAL', 'COLSC', 'COLTART', 'COLUMBIA', 'COLUMN', 'COM', 'COMACROSS', 'COMBAT', 'COMBATING', 'COMBATIR', 'COMBATTING', 'COMBINATION', 'COMBINATIONS', 'COMBINE', 'COMBINED', 'COMBINES', 'COMBINING', 'COMBUSTION', 'COMDIS', 'COME', 'COMEDORES', 'COMES', 'COMFORTABLE', 'COMFORTABLY', 'COMING', 'COMISSIONS', 'COMM', 'COMMAND', 'COMMANDER', 'COMMANDERS', 'COMMENCE', 'COMMENCED', 'COMMENCEMENT', 'COMMENCING', 'COMMEND', 'COMMENDATION', 'COMMENT', 'COMMENTARY', 'COMMENTATOR', 'COMMERCIAL', 'COMMERCIALISATION', 'COMMERCIALIZATION', 'COMMERCIALLY', 'COMMERCIALS', 'COMMISION', 'COMMISSION', 'COMMISSIONED', 'COMMISSIONER', 'COMMISSIONERGENERAL', 'COMMISSIONERGENERALS', 'COMMISSIONERS', 'COMMISSIONING', 'COMMISSIONS', 'COMMIT', 'COMMITMENT', 'COMMITMENTS', 'COMMITMENTSD', 'COMMITTAL', 'COMMITTED', 'COMMITTEDNESS', 'COMMITTEE', 'COMMITTEES', 'COMMITTMENT', 'COMMODITIES', 'COMMODITY', 'COMMODORE', 'COMMON', 'COMMONALITIES', 'COMMONLY', 'COMMONLYAGREED', 'COMMONS', 'COMMONWEALTH', 'COMMUNAL', 'COMMUNAUTS', 'COMMUNAUTTS', 'COMMUNE', 'COMMUNES', 'COMMUNICABLE', 'COMMUNICATE', 'COMMUNICATED', 'COMMUNICATING', 'COMMUNICATION', 'COMMUNICATION4', 'COMMUNICATIONS', 'COMMUNICATIONS12181', 'COMMUNICATIONSTHE', 'COMMUNICTY', 'COMMUNIST', 'COMMUNIT', 'COMMUNITIES', 'COMMUNITIESBETTER', 'COMMUNITIESMATERNAL', 'COMMUNITIESPROJECT', 'COMMUNITIESRESEARCH', 'COMMUNITIESTHE', 'COMMUNITY', 'COMMUNITYADHERENCE', 'COMMUNITYBASED', 'COMMUNITYD', 'COMMUNITYDIRECTED', 'COMMUNITYEDUCATION', 'COMMUNITYFOCUSED', 'COMMUNITYGBVHIVAIDS', 'COMMUNITYLEVEL', 'COMMUNITYMOBILIZATION', 'COMMUNITYORIENTED', 'COMMUNITYOWNED', 'COMMUNITYPARTNERS', 'COMMUNITYRELIGIOUS', 'COMMUNITYS', 'COMMUNITYSYSTEMS', 'COMMUTATION', 'COMORBIDITIES', 'COMORBIDITY', 'COMOROS', 'COMP', 'COMPACTNESS', 'COMPANIES', 'COMPANION', 'COMPANIONS', 'COMPANIONSHIP', 'COMPANY', 'COMPANYS', 'COMPARABLE', 'COMPARAR', 'COMPARATIVE', 'COMPARATIVELY', 'COMPARATOR', 'COMPARE', 'COMPARED', 'COMPARING', 'COMPARISON', 'COMPARISONS', 'COMPARTMENT', 'COMPASS', 'COMPATIBLE', 'COMPEL', 'COMPELS', 'COMPENSATION', 'COMPETENCE', 'COMPETENCES', 'COMPETENCIES', 'COMPETENCY', 'COMPETENT', 'COMPETING', 'COMPETITION', 'COMPETITIONS', 'COMPETITIVE', 'COMPETITIVELY', 'COMPETITIVENESS', 'COMPETITOR', 'COMPETITORY', 'COMPILATION', 'COMPILE', 'COMPILED', 'COMPLAINTS', 'COMPLEMENT', 'COMPLEMENTARY', 'COMPLEMENTED', 'COMPLEMENTING', 'COMPLEMENTOS', 'COMPLEMENTS', 'COMPLETE', 'COMPLETED', 'COMPLETELY', 'COMPLETENESS', 'COMPLETES', 'COMPLETING', 'COMPLETION', 'COMPLEX', 'COMPLEXES', 'COMPLEXHEREINAFTER', 'COMPLEXITIES', 'COMPLEXITY', 'COMPLIANCE', 'COMPLIANCETHIS', 'COMPLIANT', 'COMPLICATE', 'COMPLICATED', 'COMPLICATION', 'COMPLICATIONS', 'COMPLIMENTARY', 'COMPLIMENTED', 'COMPLUTENSE', 'COMPLY', 'COMPLYING', 'COMPONENETS', 'COMPONENT', 'COMPONENTS', 'COMPONENTSORIENTATIONS', 'COMPONENTTHE', 'COMPOSE', 'COMPOSED', 'COMPOSITES', 'COMPOSITION', 'COMPOST', 'COMPOUND', 'COMPOUNDING', 'COMPOUNDS', 'COMPREHENSEIVE', 'COMPREHENSION', 'COMPREHENSIVE', 'COMPREHENSIVELY', 'COMPRISE', 'COMPRISED', 'COMPRISES', 'COMPRISING', 'COMPROMISE', 'COMPROMISED', 'COMPROMISING', 'COMPROMISO', 'COMPTTENCES', 'COMPULSORY', 'COMPUTATIONAL', 'COMPUTER', 'COMPUTERASSISTED', 'COMPUTING', 'COMUNAL', 'COMUNICAAO', 'COMUNITARIAS', 'COMUNITY', 'CON', 'CONAKRY', 'CONCATENATION', 'CONCEIVED', 'CONCEIVING', 'CONCENRATION', 'CONCENTER', 'CONCENTRATE', 'CONCENTRATED', 'CONCENTRATION', 'CONCENTRATIONS', 'CONCENTRATOR', 'CONCENTRE', 'CONCEPT', 'CONCEPTION', 'CONCEPTS', 'CONCEPTUAL', 'CONCEPTUALISATION', 'CONCEPTUALIZATION', 'CONCEPTUALIZE', 'CONCEPTUALIZED', 'CONCERN', 'CONCERNANT', 'CONCERNED', 'CONCERNING', 'CONCERNINTEREST', 'CONCERNS', 'CONCERNSACCORDING', 'CONCERNTS', 'CONCERT', 'CONCERTED', 'CONCESSION', 'CONCESSIONAL', 'CONCESSIONS', 'CONCISE', 'CONCLUDE', 'CONCLUDED', 'CONCLUSION', 'CONCLUSIONS', 'CONCLUSIVE', 'CONCOMITANT', 'CONCOMITANTLY', 'CONCORD', 'CONCORDANCIA', 'CONCORDAT', 'CONCRETE', 'CONCRETIZED', 'CONCUR', 'CONCURRENTLY', 'CONDAMNATION', 'CONDEMNATION', 'CONDENSIN', 'CONDITION', 'CONDITIONAL', 'CONDITIONS', 'CONDITIONSAND', 'CONDOM', 'CONDOMS', 'CONDOMUSE', 'CONDUCE', 'CONDUCING', 'CONDUCIVE', 'CONDUCT', 'CONDUCTAS', 'CONDUCTED', 'CONDUCTIN', 'CONDUCTING', 'CONDUCTION', 'CONDUCTIVITY', 'CONDUCTS', 'CONE', 'CONF', 'CONFECTED', 'CONFEDERACY', 'CONFEDERATE', 'CONFEDERATION', 'CONFER', 'CONFERENCE', 'CONFERENCEIN', 'CONFERENCES', 'CONFERENCESINNOVATING', 'CONFERENCESTHIS', 'CONFERENCETHE', 'CONFERS', 'CONFIDENCE', 'CONFIDENT', 'CONFIDENTIAL', 'CONFIDENTIALITY', 'CONFINE', 'CONFINED', 'CONFIRM', 'CONFIRMATORY', 'CONFIRMED', 'CONFLIC', 'CONFLICT', 'CONFLICTAFFECTED', 'CONFLICTS', 'CONFLUENCE', 'CONFOCAL', 'CONFORMANCE', 'CONFORMATION', 'CONFORMATIONAL', 'CONFORMISM', 'CONFORMITY', 'CONFOUNDERS', 'CONFRENCE', 'CONFRONTING', 'CONFTRENCE', 'CONFUSION', 'CONGEAN', 'CONGENITAL', 'CONGLUTINATION', 'CONGO', 'CONGOLESE', 'CONGREGATIONS', 'CONGRESS', 'CONGRESSSECURE', 'CONGRESSTHE', 'CONGRUENT', 'CONJOINT', 'CONJOINTE', 'CONJOINTS', 'CONJUGATE', 'CONJUGATEPOLYSACCHARIDE', 'CONJUGATES', 'CONJUGATING', 'CONJUGATION', 'CONJUNCTION', 'CONJUNTA', 'CONNAISSANCES', 'CONNECT', 'CONNECTED', 'CONNECTEDNESS', 'CONNECTING', 'CONNECTION', 'CONNECTIONS', 'CONNECTIONSIN', 'CONNECTIVITY', 'CONNEXION', 'CONRAD', 'CONRADEASTERN', 'CONSCIENTIOUSNESS', 'CONSCIOUS', 'CONSCIOUSLY', 'CONSCIOUSNESS', 'CONSECUTIVE', 'CONSEIL', 'CONSENSUS', 'CONSENSUSDRIVEN', 'CONSEQUENCE', 'CONSEQUENCES', 'CONSEQUENCESALTHOUGH', 'CONSEQUENT', 'CONSEQUENTLY', 'CONSERVATION', 'CONSERVE', 'CONSERVED', 'CONSIDER', 'CONSIDERABLE', 'CONSIDERABLY', 'CONSIDERATION', 'CONSIDERATIONS', 'CONSIDERED', 'CONSIDERING', 'CONSIDERS', 'CONSIGNMENT', 'CONSIST', 'CONSISTENCE', 'CONSISTENCY', 'CONSISTENT', 'CONSISTENTLY', 'CONSISTING', 'CONSISTS', 'CONSOCIATE', 'CONSOIDATED', 'CONSOIDATION', 'CONSOLIDATE', 'CONSOLIDATED', 'CONSOLIDATES', 'CONSOLIDATIIN', 'CONSOLIDATING', 'CONSOLIDATION', 'CONSONANT', 'CONSORT', 'CONSORTIA', 'CONSORTIATHE', 'CONSORTIUM', 'CONSTANT', 'CONSTELLATION', 'CONSTITUENCIES', 'CONSTITUENCY', 'CONSTITUENT', 'CONSTITUENTS', 'CONSTITUTE', 'CONSTITUTED', 'CONSTITUTES', 'CONSTITUTION', 'CONSTITUTIONAL', 'CONSTITUTIVE', 'CONSTRAIN', 'CONSTRAINED', 'CONSTRAINT', 'CONSTRAINTS', 'CONSTRICTION', 'CONSTRUCT', 'CONSTRUCTED', 'CONSTRUCTING', 'CONSTRUCTION', 'CONSTRUCTS', 'CONSULT', 'CONSULTANCIES', 'CONSULTANCY', 'CONSULTANT', 'CONSULTANTS', 'CONSULTATION', 'CONSULTATIONS', 'CONSULTATIVE', 'CONSULTING', 'CONSUMABLE', 'CONSUMABLES', 'CONSUME', 'CONSUMER', 'CONSUMERACCEPTABLE', 'CONSUMERCITIZEN', 'CONSUMERFRIENDLY', 'CONSUMERS', 'CONSUMIDOR', 'CONSUMING', 'CONSUMO', 'CONSUMPTION', 'CONT', 'CONTACT', 'CONTACTS', 'CONTAGION', 'CONTAGIOUS', 'CONTAIN', 'CONTAIN1416', 'CONTAINED', 'CONTAINERS', 'CONTAINING', 'CONTAINMENT', 'CONTAINS', 'CONTAMINATED', 'CONTAMINATION', 'CONTENT', 'CONTENTION', 'CONTENTS', 'CONTESTATION', 'CONTEXT', 'CONTEXTAPPROPRIATE', 'CONTEXTS', 'CONTEXTSPECIFIC', 'CONTEXTSSOCIAL', 'CONTEXTSTHE', 'CONTEXTUAL', 'CONTEXTUALLY', 'CONTEXTUALLYBASED', 'CONTGRIBUTION', 'CONTINENT', 'CONTINENTS', 'CONTINENTTHE', 'CONTINENTWIDE', 'CONTINGENCY', 'CONTINUAL', 'CONTINUALLY', 'CONTINUANCE', 'CONTINUATION', 'CONTINUE', 'CONTINUED', 'CONTINUES', 'CONTINUEWHILE', 'CONTINUING', 'CONTINUITY', 'CONTINUOUS', 'CONTINUOUSLY', 'CONTINUUM', 'CONTR', 'CONTRA', 'CONTRACEPTIC', 'CONTRACEPTION', 'CONTRACEPTIVE', 'CONTRACEPTIVES', 'CONTRACEPTIVESTIGMA', 'CONTRACEPTIVEUSE', 'CONTRACT', 'CONTRACTABLE', 'CONTRACTED', 'CONTRACTING', 'CONTRACTOR', 'CONTRACTORS', 'CONTRACTS', 'CONTRACTUAL', 'CONTRAST', 'CONTRATOR', 'CONTRCATS', 'CONTRE', 'CONTRIB', 'CONTRIBUER', 'CONTRIBUIR', 'CONTRIBUTE', 'CONTRIBUTED', 'CONTRIBUTES', 'CONTRIBUTING', 'CONTRIBUTION', 'CONTRIBUTIONS', 'CONTRIBUTIONTHE', 'CONTRIBUTIONTHIS', 'CONTRIBUTNG', 'CONTRIBUTOR', 'CONTRIBUTORS', 'CONTRIVE', 'CONTRIVED', 'CONTRLE', 'CONTRLELIMINATION', 'CONTRLETLIMINATION', 'CONTROL', 'CONTROL2', 'CONTROLANTIBIOTIC', 'CONTROLDECOMPOSITION', 'CONTROLDEVELOP', 'CONTROLE', 'CONTROLELIMINATION', 'CONTROLLED', 'CONTROLLEDCLINICAL', 'CONTROLLER', 'CONTROLLING', 'CONTROLOF', 'CONTROLS', 'CONTROLTHE', 'CONTUMELY', 'CONVALESCENCE', 'CONVALESCENT', 'CONVENANT', 'CONVENE', 'CONVENED', 'CONVENES', 'CONVENIENT', 'CONVENING', 'CONVENIO', 'CONVENTION', 'CONVENTIONAL', 'CONVENTIONALISM', 'CONVENTIONALITY', 'CONVENTIONCADRE', 'CONVENTIONS', 'CONVERGENCE', 'CONVERNS', 'CONVERSATION', 'CONVERSION', 'CONVERT', 'CONVERTER', 'CONVEY', 'CONVINCE', 'CONVINCED', 'CONVINCING', 'COOK', 'COOKED', 'COOKING', 'COOKSTOVE', 'COOKSTOVES', 'COOL', 'COOLING', 'COOMUNITIES', 'COONCENTRATIONS', 'COOP', 'COOPERATE', 'COOPERATING', 'COOPERATION', 'COOPERATIONDEVELOPMENT', 'COOPERATIONS', 'COOPERATIONTHE', 'COOPERATIVE', 'COOPERATIVES', 'COOPERATOR', 'COOPPROFILE', 'COOPRATION', 'COOPTEDCORRUPTED', 'COOPTRATION', 'COORDINADA', 'COORDINATE', 'COORDINATED', 'COORDINATES', 'COORDINATING', 'COORDINATION', 'COORDINATIONEXCELLENT', 'COORDINATOR', 'COORDINATORS', 'COORDONNT', 'COORGANIZER', 'COP', 'COPACKAGED', 'COPAN', 'COPD', 'COPE', 'COPEH', 'COPEHLAC', 'COPEHLACS', 'COPIES', 'COPING', 'COPPER', 'COPPERBELT', 'COPRECOS', 'COPRODUCEKNOWLEDGE', 'COPS', 'COPULATE', 'COPULATION', 'COPYCAT', 'COR', 'CORAZON', 'CORD', 'CORDUROY', 'CORE', 'COREFUNDED', 'CORGENIX', 'CORHA', 'CORHAS', 'CORNELL', 'CORNERSTONE', 'CORNFLOUR', 'CORNTD', 'CORONA', 'CORONARY', 'CORONAVIRUS', 'CORONAVIRUSES', 'CORP', 'CORPORACIN', 'CORPORACTI', 'CORPORACTIN', 'CORPORATE', 'CORPORATION', 'CORPORATIONS', 'CORPS', 'CORPULENCY', 'CORPUS', 'CORRECT', 'CORRECTED', 'CORRECTIVE', 'CORRECTLY', 'CORRECTREPAIR', 'CORREDOR', 'CORREL', 'CORRELATE', 'CORRELATED', 'CORRELATES', 'CORRELATION', 'CORRESPOND', 'CORRESPONDENCE', 'CORRESPONDING', 'CORRESPONDS', 'CORRIDOR', 'CORRIDORS', 'CORROBORATE', 'CORROBORATION', 'CORROW', 'CORRUPTION', 'CORTI', 'CORTICAL', 'CORTTS', 'COSMETIC', 'COSMOPOLITAN', 'COSMOS', 'COSPONSOR', 'COSPONSORS', 'COST', 'COSTA', 'COSTBENEFIT', 'COSTED', 'COSTEFFECTED', 'COSTEFFECTIVE', 'COSTEFFECTIVELY', 'COSTEFFECTIVENESS', 'COSTEFFECTIVENSS', 'COSTEFFICIENCY', 'COSTEFFICIENT', 'COSTING', 'COSTLESS', 'COSTLY', 'COSTOP', 'COSTS', 'COSTSHARING', 'COSTUTILITY', 'COTE', 'COTONOU', 'COTTAGE', 'COUGH', 'COULD', 'COULOMB', 'COUNCEL', 'COUNCELING', 'COUNCIL', 'COUNCILDFID', 'COUNCILDPFS', 'COUNCILORS', 'COUNCILS', 'COUNCILTHE', 'COUNSEL', 'COUNSELING', 'COUNSELLING', 'COUNSELLOR', 'COUNSELLORS', 'COUNSELOR', 'COUNSELORS', 'COUNT', 'COUNTENANCE', 'COUNTER', 'COUNTERARGUMENTS', 'COUNTERFEIT', 'COUNTERMEASURES', 'COUNTERPANE', 'COUNTERPART', 'COUNTERPARTNATIONAL', 'COUNTERPARTS', 'COUNTIES', 'COUNTR', 'COUNTRIES', 'COUNTRIES2', 'COUNTRIESIDENTIFY', 'COUNTRIESINTEGRATE', 'COUNTRIESLESSONS', 'COUNTRIESMIRROR', 'COUNTRIESRES', 'COUNTRIESRESEARCH', 'COUNTRIESRESULT', 'COUNTRIESTHE', 'COUNTRIESTHROUGH', 'COUNTRIESYES', 'COUNTRY', 'COUNTRYA', 'COUNTRYBASED', 'COUNTRYLED', 'COUNTRYLEVEL', 'COUNTRYMAIN', 'COUNTRYOWNED', 'COUNTRYREGIONAL', 'COUNTRYS', 'COUNTRYSPECIFIC', 'COUNTRYWIDE', 'COUNTY', 'COUPLE', 'COUPLED', 'COUPLES', 'COUPLESGSP', 'COUPLING', 'COUPON', 'COURIER', 'COURSE', 'COURSES', 'COURSETHIS', 'COURT', 'COURTS', 'COUTRIES', 'COUTRY', 'COV', 'COVAC', 'COVENANT', 'COVER', 'COVERAGE', 'COVERAGE6NON', 'COVERED', 'COVEREDTHE', 'COVERING', 'COVERS', 'COVT', 'CP', 'CPCS', 'CPED', 'CPEDS', 'CPHL', 'CPICI', 'CPLP', 'CPS', 'CRAB', 'CRACK', 'CRAFT', 'CRAPULENCE', 'CRASH3', 'CRATAEGUS', 'CRATION', 'CRC', 'CRDF', 'CRDI', 'CREACIN', 'CREAT', 'CREATE', 'CREATED', 'CREATES', 'CREATING', 'CREATION', 'CREATIVE', 'CREATIVITY', 'CREATOR', 'CREATURE', 'CREDENTIAL', 'CREDENTIALS', 'CREDIBILITY', 'CREDIT', 'CREDITS', 'CREDITWORTHY', 'CREEK', 'CRESCENT', 'CRICK', 'CRIER', 'CRIES', 'CRIICAL', 'CRIM', 'CRIMCONGEAN', 'CRIME', 'CRIMEAN', 'CRIMEANCONGOHAEMORRHAGIC', 'CRIMES', 'CRIMINAL', 'CRISE', 'CRISES', 'CRISIS', 'CRISPR', 'CRISPRCAS9', 'CRITERIA', 'CRITERION', 'CRITICAL', 'CRITICALLY', 'CRO', 'CROATIAACCESS', 'CROATIAHEALTH', 'CROATIAHIV', 'CROATIAHIVAIDS', 'CROATIAINTERGRATED', 'CROATIALEADERSHIP', 'CROATIANONCOMMUNICABLE', 'CROATIASOCIAL', 'CROATIATUBERCULOSIS', 'CROIX', 'CROIXROUGE', 'CROP', 'CROPS', 'CROSS', 'CROSSBORDER', 'CROSSBREED', 'CROSSBREEDING', 'CROSSCOUNCIL', 'CROSSCOUNTRY', 'CROSSCRESCENT', 'CROSSCUTTING', 'CROSSDISCIPLINARY', 'CROSSES', 'CROSSFERTILIZATION', 'CROSSING', 'CROSSINGS', 'CROSSLEARNING', 'CROSSOVER', 'CROSSPRODUCT', 'CROSSPROTECTION', 'CROSSREGIONAL', 'CROSSRESEARCH', 'CROSSRESISTANCE', 'CROSSROADS', 'CROSSSECTION', 'CROSSSECTIONAL', 'CROSSSECTORAL', 'CROSSSITE', 'CROSSSUBSIDIZE', 'CROSSSUPERVISION', 'CROSSTALK', 'CROSSTRAINING', 'CROWD', 'CROWDSOURCING', 'CROWN', 'CRP', 'CRS', 'CRT', 'CRTATION', 'CRTF', 'CRTU', 'CRUCIAL', 'CRUDE', 'CRUMBS', 'CRUN', 'CRUSADE', 'CRUSHED', 'CRUSTACEAN', 'CRUZ', 'CRUZI', 'CRVS', 'CRY', 'CRYPTOCOCCAL', 'CRYPTOCOCCUS', 'CRYPTOSPORIDIOSIS', 'CRYPTOSPORIDIUM', 'CRYSTALLINE', 'CS', 'CS6', 'CSDC', 'CSDCS', 'CSE', 'CSF', 'CSF0341401', 'CSIC', 'CSIS', 'CSO', 'CSOS', 'CSP', 'CSPBASED', 'CSR', 'CST', 'CSW', 'CSWS', 'CT', 'CTB', 'CTE', 'CTU', 'CTVD', 'CTYPE', 'CUBA', 'CUBAACADEMIC', 'CUBAINS', 'CUBAN', 'CUBANOFLAMAND', 'CUBIC', 'CUBS', 'CUENTAS', 'CUERNO', 'CUI', 'CUISINE', 'CULINARY', 'CULLIN', 'CULLINS', 'CULTIVATE', 'CULTIVATION', 'CULTURAL', 'CULTURALLY', 'CULTURALLYAPPROPRIATE', 'CULTURE', 'CULTUREBASED', 'CULTURED', 'CULTURES', 'CUMBER', 'CUMULATED', 'CUMULATIVE', 'CUP', 'CUPIDS', 'CUPS', 'CURATING', 'CURATION', 'CURATIVE', 'CURB', 'CURBING', 'CURE', 'CURES', 'CUREVAC', 'CURIE', 'CURING', 'CURRENLTY', 'CURRENT', 'CURRENTLY', 'CURRICULA', 'CURRICULULM', 'CURRICULUM', 'CURRICULUMS', 'CURRY', 'CURSAR', 'CURSE', 'CURTAIL', 'CUSTOMER', 'CUSTOMISE', 'CUSTOMISED', 'CUSTOMIZE', 'CUSTOMIZED', 'CUSTOMIZING', 'CUSTOMS', 'CUT', 'CUTANEOUS', 'CUTE', 'CUTOFF', 'CUTOFFS', 'CUTS', 'CUTTING', 'CUTTINGEDGE', 'CV', 'CVCA', 'CVCA298ACCESS', 'CVCA298HEALTH', 'CVCA298HIV', 'CVCA298LEADERSHIP', 'CVCA298MALARIA12262', 'CVCA298MENTAL', 'CVCA298NATIONAL', 'CVCA298NEGLECTED', 'CVCA298NUTRITION12240', 'CVCA298REPRODUCTIVE', 'CVCA298SOCIAL', 'CVCA298TUBERCULOSIS12263', 'CVCA298VACCINE', 'CVCA298VIOLENCE', 'CVCA498ACCESS', 'CVCA498DISABILITY', 'CVCA498GENDER', 'CVCA498HEALTH', 'CVCA498HIV', 'CVCA498INFECTIOUS', 'CVCA498MALARIA12262', 'CVCA498MENTAL', 'CVCA498NATIONAL', 'CVCA498POLIO', 'CVCA498REPRODUCTIVE', 'CVCA498SOCIAL', 'CVCA498VIOLENCE', 'CVCA589ACCESS', 'CVCA589AGEING', 'CVCA589ANTIMICROBIAL', 'CVCA589DISABILITY', 'CVCA589GENDER', 'CVCA589HEALTH', 'CVCA589HIV', 'CVCA589INFECTIOUS', 'CVCA589INTEGRATED', 'CVCA589MALARIA12262', 'CVCA589MENTAL', 'CVCA589NEGLECTED', 'CVCA589NONCOMMUNICABLE', 'CVCA589NUTRITION12240', 'CVCA589REPRODUCTIVE', 'CVCA589SOCIAL', 'CVCA589TUBERCULOSIS12263', 'CVCA589VACCINE', 'CVCA679ACCESS', 'CVCA679AGEING', 'CVCA679ANTIMICROBIAL', 'CVCA679DISABILITY', 'CVCA679FOOD', 'CVCA679GENDER', 'CVCA679HEALTH', 'CVCA679INFECTIOUS', 'CVCA679MALARIA12262', 'CVCA679MENTAL', 'CVCA679NATIONAL', 'CVCA679NEGLECTED', 'CVCA679NUTRITION12240', 'CVCA679REPRODUCTIVE', 'CVCA679SOCIAL', 'CVCA679TUBERCULOSIS12263', 'CVCA679VACCINE', 'CVCA679VIOLENCE', 'CVCA789AGEING', 'CVCA789DISABILITY', 'CVCA789GENDER', 'CVCA789HEALTH', 'CVCA789HIV', 'CVCA789INTEGRATED', 'CVCA789MALARIA12262', 'CVCA789NEGLECTED', 'CVCA789NONCOMMUNICABLE', 'CVCA789REPRODUCTIVE', 'CVCA789SOCIAL', 'CVCA789TUBERCULOSIS12263', 'CVCA789VACCINE', 'CVCA789VIOLENCE', 'CVCA889ACCESS', 'CVCA889GENDER', 'CVCA889HEALTH', 'CVCA889HIV', 'CVCA889MENTAL', 'CVCA889NATIONAL', 'CVCA889NEGLECTED', 'CVCA889NONCOMMUNICABLE', 'CVCA889REPRODUCTIVE', 'CVCA889VACCINE', 'CVCA89AGEING', 'CVCA89ANTIMICROBIAL', 'CVCA89DISABILITY', 'CVCA89FOOD', 'CVCA89GENDER', 'CVCA89HEALTH', 'CVCA89HIV', 'CVCA89INFECTIOUS', 'CVCA89INTEGRATED', 'CVCA89MALARIA12262', 'CVCA89MENTAL', 'CVCA89NATIONAL', 'CVCA89NONCOMMUNICABLE', 'CVCA89NUTRITION12240', 'CVCA89REPRODUCTIVE', 'CVCA89SOCIAL', 'CVCA89TUBERCULOSIS12263', 'CVCA89VIOLENCE', 'CVCA998ACCESS', 'CVCA998AGEING', 'CVCA998DISABILITY', 'CVCA998FOOD', 'CVCA998GENDER', 'CVCA998HEALTH', 'CVCA998HIV', 'CVCA998INFECTIOUS', 'CVCA998INTEGRATED', 'CVCA998MENTAL', 'CVCA998NEGLECTED', 'CVCA998NONCOMMUNICABLE', 'CVCA998REPRODUCTIVE', 'CVCA998TUBERCULOSIS12263', 'CVCA998VACCINE', 'CVCA998VIOLENCE', 'CVCAAFRICA', 'CVCAAMERICA', 'CVCAAMERICAN', 'CVCAAMR', 'CVCABAHRAINMENTAL', 'CVCABAHRAINNATIONAL', 'CVCABAHRAINTUBERCULOSIS', 'CVCABAHRAINVIOLENCE', 'CVCACYPRUSNATIONAL', 'CVCAEUROPE', 'CVCAFAR', 'CVCAGLOBALACCESS', 'CVCAGLOBALAGEING', 'CVCAGLOBALCHRONIC', 'CVCAGLOBALCOMMUNICABLE', 'CVCAGLOBALDISABILITIES', 'CVCAGLOBALFOOD', 'CVCAGLOBALGENDER', 'CVCAGLOBALHEALTH', 'CVCAGLOBALHEALTHY', 'CVCAGLOBALHIV', 'CVCAGLOBALHIVAIDS', 'CVCAGLOBALHIVAIDSTBMALARIA', 'CVCAGLOBALIMPROVED', 'CVCAGLOBALKEY', 'CVCAGLOBALLEADERSHIP', 'CVCAGLOBALMANAGEMENT', 'CVCAGLOBALNATIONAL', 'CVCAGLOBALNEGLCTED', 'CVCAGLOBALNONCOMMUNICABLE', 'CVCAGLOBALNUTRITION', 'CVCAGLOBALREDUCTION', 'CVCAGLOBALSOCIAL', 'CVCAGLOBALSTRATEGIC', 'CVCAGLOBALTRANSPARENCY', 'CVCAGLOBALTUBERCULOSIS', 'CVCAGLOBALVACCINE', 'CVCAGLOBALVACCINEPREVENTABLE', 'CVCAGLOBALVIOLENCE', 'CVCAHUNGARYTUBERCULOSIS', 'CVCAHUNGARYVIOLENCE', 'CVCALITHUANIANATIONAL', 'CVCAMIDDLE', 'CVCAOCEANIA', 'CVCAOMANACCESS', 'CVCAOMANDISABILITIES', 'CVCAOMANHEALTH', 'CVCAOMANINTERGRATED', 'CVCAOMANNATIONAL', 'CVCAOMANNONCOMMUNICABLE', 'CVCAOMANREPRODUCTIVE', 'CVCAOMANVACCINE', 'CVCAOMANVACCINEPREVENTABLE', 'CVCAQATARHEALTH', 'CVCAQATARHIV', 'CVCAQATARHIVAIDS', 'CVCAQATARINTERGRATED', 'CVCAQATARVACCINE', 'CVCAQATARVACCINEPREVENTABLE', 'CVCARUSSIAN', 'CVCASAUDI', 'CVCASOUTH', 'CVD', 'CVDPV', 'CVDSHAVE', 'CWD', 'CWDS', 'CWFD', 'CYCLE', 'CYCLES', 'CYCLING', 'CYCLONE', 'CYNOMOLGI', 'CYP', 'CYPHER', 'CYPRUSNATIONAL', 'CYSTIC', 'CYSTICERCOSIS', 'CYSTICERCOSISCOMMITMENTS', 'CYTOCHROME', 'CYTOGENETICS', 'CYTOKINE', 'CYTOKINES', 'CYTOLOGY', 'CYTOMETER', 'CYTOMETRY', 'CYTOPLASM', 'CYTOSKELETON', 'CYTOTOXIC', 'CZECH', 'D', 'D1LEADERSHIP', 'D2R', 'DA', 'DABIDJAN', 'DAC', 'DACCOUCHEMENTS', 'DADAAB', 'DAFFECTATION', 'DAFRIQUE', 'DAGNOSTIC', 'DAGO', 'DAHOMEY', 'DAHPU', 'DAI', 'DAILY', 'DAIRY', 'DAKAR', 'DALAL', 'DALARNA', 'DALHOUSIE', 'DALLA', 'DALLAS', 'DALYS', 'DAMAGE', 'DAMAGED', 'DAMASCUS', 'DAMBULANCE', 'DAME', 'DAMS', 'DAMTLIORATION', 'DAN', 'DANANG', 'DANDE', 'DANDY', 'DANFORTH', 'DANG', 'DANGER', 'DANGEROUS', 'DANGERS', 'DANIEL', 'DANS', 'DAO', 'DAPIVARINE', 'DAPIVIRINE', 'DAPS', 'DAR', 'DARAISUF', 'DARESSALAAM', 'DARFUR', 'DARIO', 'DARTMOUTH', 'DARUSSALAM', 'DARUSSALAMACCESS', 'DARUSSALAMINTERGRATED', 'DARUSSALAMNONCOMMUNICABLE', 'DASHBOARD', 'DASIE', 'DASSISTANCE', 'DATA', 'DATAANALYSIS', 'DATABASE', 'DATABASEHHF', 'DATABASES', 'DATADRIVEN', 'DATAFIRST', 'DATAS', 'DATASET', 'DATASETS', 'DATE', 'DATED', 'DATES', 'DATING', 'DATUM', 'DAVIDSON', 'DAVIS', 'DAVYS', 'DAWN', 'DAY', 'DAY3', 'DAY5', 'DAYEBOLA', 'DAYS', 'DAYTIME', 'DBA', 'DBTMRC', 'DC', 'DCD22515', 'DCI', 'DCIDEURS', 'DCINSAPVD2008', 'DCS', 'DCSIGN', 'DE', 'DEACONESS', 'DEACTIVATION', 'DEAD', 'DEADLINE', 'DEADLY', 'DEAF', 'DEAL', 'DEALING', 'DEALINGS', 'DEALT', 'DEAR', 'DEARTH', 'DEATH', 'DEATHRATE', 'DEATHS', 'DEATHSSTOMACH', 'DEATHSTHE', 'DEATHSYEAR', 'DEBATE', 'DEBATES', 'DEBILITATING', 'DEBRIEFING', 'DEBT', 'DEC', 'DECADE', 'DECADES', 'DECADESLONG', 'DECADESSTOMACH', 'DECAY', 'DECEASE', 'DECEASED', 'DECEASES', 'DECEMBER', 'DECENT', 'DECENTRALISATION', 'DECENTRALISED', 'DECENTRALIZATION', 'DECENTRALIZE', 'DECENTRALIZED', 'DECENTRALIZING', 'DECIDE', 'DECIDED', 'DECIDEDTHIS', 'DECIGRAM', 'DECIMATED', 'DECIMETER', 'DECIPHERING', 'DECISES', 'DECISION', 'DECISIONENABLED', 'DECISIONMAKERS', 'DECISIONMAKERSPROJECT', 'DECISIONMAKING', 'DECISIONMAKINGBETTER', 'DECISIONMAKINGIMPROVED', 'DECISIONMAKINGRAPID', 'DECISIONMAKINGTHE', 'DECISIONPROCESSES', 'DECISIONS', 'DECISIONSTHIS', 'DECISIVE', 'DECISIVELY', 'DECISIVENESS', 'DECLARADA', 'DECLARARA', 'DECLARATION', 'DECLARATIONS', 'DECLARE', 'DECLARED', 'DECLARER', 'DECLINE', 'DECLINES', 'DECLINING', 'DECOCT', 'DECOY', 'DECREASE', 'DECREASED', 'DECREASES', 'DECREASING', 'DECREE', 'DEDICATE', 'DEDICATED', 'DEDICATION', 'DEDOUGOU', 'DEDUCTION', 'DEDZA', 'DEEMED', 'DEEP', 'DEEPAK', 'DEEPEN', 'DEEPENED', 'DEEPENING', 'DEEPER', 'DEEPLY', 'DEEPNESS', 'DEF', 'DEFEAT', 'DEFECATE', 'DEFECTS', 'DEFEND', 'DEFENDED', 'DEFENDER', 'DEFENSE', 'DEFENSES', 'DEFENSIBLE', 'DEFERENCE', 'DEFESA', 'DEFICIENCIES', 'DEFICIENCY', 'DEFICIENT', 'DEFICITS', 'DEFINE', 'DEFINED', 'DEFINES', 'DEFINICIN', 'DEFINING', 'DEFINITION', 'DEFINITIONAL', 'DEFINITIONS', 'DEFINITIVE', 'DEFLORNITHINE', 'DEFORESTATION', 'DEFORMITIES', 'DEFRAYAL', 'DEFRAYMENT', 'DEGENERATION', 'DEGRADATION', 'DEGRADE', 'DEGRADED', 'DEGREDATION', 'DEGREE', 'DEGREES', 'DEHYDRATION', 'DEL', 'DELAFIELD', 'DELAWARE', 'DELAY', 'DELAYED', 'DELAYS', 'DELEGACY', 'DELEGATED', 'DELEGATES', 'DELEGATING', 'DELEGATION', 'DELEGATIONS', 'DELETION', 'DELGADO', 'DELHI', 'DELIBERATE', 'DELIBERATIONS', 'DELICACY', 'DELIMITATION', 'DELINEATE', 'DELINEATED', 'DELIVER', 'DELIVERABLE', 'DELIVERABLES', 'DELIVERED', 'DELIVERIES', 'DELIVERING', 'DELIVERS', 'DELIVERY', 'DELIVERY6', 'DELL', 'DELOCALIZING', 'DELOITTE', 'DELTA', 'DEM', 'DEMAND', 'DEMANDDRIVEN', 'DEMANDORIENTED', 'DEMANDS', 'DEMANDSEXPECTED', 'DEMANDSIDE', 'DEMANDTHIS', 'DEMARCATION', 'DEMEANOR', 'DEMENTIA', 'DEMISE', 'DEMO', 'DEMOCR', 'DEMOCRACY', 'DEMOCRACYBOLIVIA', 'DEMOCRATIC', 'DEMOGRAPHIC', 'DEMOGRAPHICAL', 'DEMOGRAPHICS', 'DEMOGRAPHY', 'DEMONSTRATE', 'DEMONSTRATED', 'DEMONSTRATES', 'DEMONSTRATING', 'DEMONSTRATION', 'DEMONSTRATIONS', 'DEMONSTRATIVE', 'DEMTREND', 'DEMYELINATING', 'DEN', 'DENDRIMERS', 'DENDRITIC', 'DENGUE', 'DENIAL', 'DENMARK', 'DENOMINATIONS', 'DENOMINATOR', 'DENOMINATORS', 'DENOTATION', 'DENPREV', 'DENSE', 'DENSELY', 'DENSITIES', 'DENSITY', 'DENTAL', 'DENTIST', 'DENTISTRY', 'DENVER', 'DENYING', 'DEORGANIZACIONES', 'DEOXIDIZE', 'DEOXYADENOSINE', 'DEPART', 'DEPARTAMENTALES', 'DEPARTAMENTO', 'DEPARTMENT', 'DEPARTMENT4', 'DEPARTMENTAL', 'DEPARTMENTALWORKING', 'DEPARTMENTS', 'DEPARTURE', 'DEPEC', 'DEPEND', 'DEPENDABLE', 'DEPENDANCE', 'DEPENDANCY', 'DEPENDENCE', 'DEPENDENCETHIS', 'DEPENDENCIES', 'DEPENDENCY', 'DEPENDENT', 'DEPENDENTS', 'DEPENDING', 'DEPENDS', 'DEPLETED', 'DEPLOY', 'DEPLOYABLE', 'DEPLOYED', 'DEPLOYING', 'DEPLOYMENT', 'DEPORT', 'DEPORTATION', 'DEPORTMENT', 'DEPOSITORY', 'DEPOT', 'DEPRESSED', 'DEPRESSION', 'DEPRESSIONINNOVATING', 'DEPRIVATION', 'DEPRIVED', 'DEPTH', 'DEPUIS', 'DEPUTATION', 'DEPUTISE', 'DEPUTIZE', 'DER', 'DERECHOS', 'DERES', 'DERIVATIVE', 'DERIVED', 'DERMAL', 'DERMATITIS', 'DERMATOLOGICAL', 'DERMATOLOGISTS', 'DERMATOLOGY', 'DERRIERE', 'DES', 'DESARROLLO', 'DESCALE', 'DESCENDING', 'DESCENT', 'DESCRIBE', 'DESCRIBED', 'DESCRIBES', 'DESCRIBING', 'DESCRIPTION', 'DESCRIPTIONHEALTH', 'DESCRIPTIONTHIS', 'DESCRIPTIVE', 'DESDUNES', 'DESEADO', 'DESEASES', 'DESEGREGATE', 'DESEGREGATION', 'DESERT', 'DESERTIFICATION', 'DESERVE', 'DESH', 'DESICCATION', 'DESIGN', 'DESIGNATED', 'DESIGNATION', 'DESIGNED', 'DESIGNEDTO', 'DESIGNER', 'DESIGNING', 'DESIGNS', 'DESIRE', 'DESIRED', 'DESK', 'DESKSTUDY', 'DESNUTRICIN', 'DESPITE', 'DESSERVIS', 'DESTINATION', 'DESTITUTE', 'DESTROY', 'DESTROYED', 'DESTROYING', 'DESTRUCCIN', 'DESTRUCTION', 'DET', 'DETACHED', 'DETAIL', 'DETAILED', 'DETAILS', 'DETAINED', 'DETAINEES', 'DETECT', 'DETECTADOS', 'DETECTED', 'DETECTING', 'DETECTION', 'DETECTIONTHIS', 'DETECTIVE', 'DETERIORATE', 'DETERIORATED', 'DETERIORATING', 'DETERIORATION', 'DETERMINANT', 'DETERMINANTS', 'DETERMINANTSWHILE', 'DETERMINATION', 'DETERMINATIVE', 'DETERMINE', 'DETERMINED', 'DETERMINER', 'DETERMINES', 'DETERMINING', 'DETRIMENTAL', 'DETUDES', 'DEUCE', 'DEUTSCHLAND', 'DEV', 'DEVASTATING', 'DEVCO', 'DEVEASTATING', 'DEVELOMENT', 'DEVELOP', 'DEVELOPED', 'DEVELOPED6', 'DEVELOPEDRESULT', 'DEVELOPEMNT', 'DEVELOPERS', 'DEVELOPING', 'DEVELOPM', 'DEVELOPMENT', 'DEVELOPMENTAL', 'DEVELOPMENTEXPLORE', 'DEVELOPMENTFUNDS', 'DEVELOPMENTORIENTED', 'DEVELOPMENTPHASE', 'DEVELOPMENTPREVIOUS', 'DEVELOPMENTS', 'DEVELOPMENTTHE', 'DEVELOPMENTTHIS', 'DEVELOPMENTWATER', 'DEVELOPPEMENT', 'DEVELOPS', 'DEVIANCE', 'DEVICE', 'DEVICES', 'DEVISE', 'DEVISING', 'DEVLOPMENT', 'DEVOID', 'DEVOLUTION', 'DEVOLVE', 'DEVOTED', 'DEVT', 'DEWORMING', 'DEXAMETHASOME', 'DEXAMETHASONE', 'DFA', 'DFAT', 'DFATD', 'DFATGENDER', 'DFID', 'DFIDMEDICAL', 'DFIDS', 'DFIDSUPPORTED', 'DFIDWELLCOME', 'DG', 'DGCDIMT', 'DGDC', 'DGDCFA', 'DHA', 'DHABI', 'DHAEMPOWER', 'DHAKA', 'DHAMRAI', 'DHAPP', 'DHIMS', 'DHIS', 'DHIS2', 'DHOBLEY', 'DHS', 'DHS7', 'DHUN', 'DI', 'DIABESIT', 'DIABETE', 'DIABETES', 'DIABETESASSOCIATED', 'DIABETESRESEARCH', 'DIABETIC', 'DIACHARGE', 'DIAGNOSE', 'DIAGNOSED', 'DIAGNOSES', 'DIAGNOSING', 'DIAGNOSIS', 'DIAGNOSISTREATMENTREFERRAL', 'DIAGNOSTIC', 'DIAGNOSTICIANS', 'DIAGNOSTICS', 'DIAGNSTICO', 'DIAKONIA', 'DIAKONIAS', 'DIALOG', 'DIALOGUE', 'DIALOGUES', 'DIALOGUETHE', 'DIALYSIS', 'DIAMOND', 'DIAMONDS', 'DIAPER', 'DIAPHRAGM', 'DIARHEA', 'DIARIES', 'DIARRHEA', 'DIARRHEAL', 'DIARRHOEA', 'DIARRHOEAL', 'DIARRHOEARELATED', 'DIARRHOETIC', 'DIARY', 'DIASPORA', 'DICEMINATION', 'DICOS', 'DICREASE', 'DIDACTIC', 'DIDCONFLICT', 'DIE', 'DIED', 'DIEGO', 'DIEMS', 'DIES', 'DIESASES', 'DIET', 'DIETARY', 'DIETETICAL', 'DIETING', 'DIETRELATED', 'DIETS', 'DIF', 'DIFERENCES', 'DIFFER', 'DIFFERENCE', 'DIFFERENCES', 'DIFFERENCETHE', 'DIFFERENT', 'DIFFERENTIAL', 'DIFFERENTIALLY', 'DIFFERENTIATE', 'DIFFERENTIATED', 'DIFFERENTIATION', 'DIFFERENTIATIONLIKE', 'DIFFERENTLY', 'DIFFERING', 'DIFFERS', 'DIFFICULT', 'DIFFICULTIES', 'DIFFICULTTHIS', 'DIFFTRANSFVALORIS', 'DIFFUSE', 'DIFFUSION', 'DIGEST', 'DIGITAL', 'DIGITALENHANCED', 'DIGITALLY', 'DIGITATA', 'DIGITIZE', 'DIGITIZES', 'DIGITIZING', 'DIGNINORWAY', 'DIGNITY', 'DIGNOSIS', 'DIGNOSTICS', 'DIHYDROARTEMISININ', 'DIHYDROARTEMISININPIPERAQUINE', 'DIIF', 'DILAASA', 'DILATE', 'DILATED', 'DILEMMAS', 'DILIGENCE', 'DILUTE', 'DIMAGI', 'DIMENSION', 'DIMENSIONS', 'DIMIDIATA', 'DIMINISH', 'DIMINISHED', 'DIMINISHING', 'DIMINUTION', 'DINNOVATION', 'DINTERVENTIONS', 'DINVESTISSEMENT', 'DIOCESE', 'DIODE', 'DIOP', 'DIOS', 'DIOXIDE', 'DIPHTHERIA', 'DIPLOMA', 'DIPLOMACY', 'DIPLOMACYTHE', 'DIPLOMATIC', 'DIPS', 'DIPTERAN', 'DIRE', 'DIRECT', 'DIRECTED', 'DIRECTING', 'DIRECTION', 'DIRECTIONAL', 'DIRECTIONS', 'DIRECTIVES', 'DIRECTLY', 'DIRECTOR', 'DIRECTORATE', 'DIRECTORATES', 'DIRECTORGENERAL', 'DIRECTORS', 'DIRECTORY', 'DIRECTS', 'DIREKTE', 'DIREKTED', 'DIRT', 'DISABILITIES', 'DISABILITY', 'DISABILITYADJUSTED', 'DISABILITYBASED', 'DISABILITYINCLUSIVE', 'DISABLED', 'DISABLEMENT', 'DISADVANTAGE', 'DISADVANTAGED', 'DISADVANTAGEDESTABLISHED', 'DISADVANTAGES', 'DISAPPOINTING', 'DISASTER', 'DISASTERS', 'DISASTERSAFER', 'DISASTROUS', 'DISBURSAL', 'DISBURSE', 'DISBURSED', 'DISBURSEMENT', 'DISBURSEMENTIN', 'DISCAPACIDAD', 'DISCERNMENT', 'DISCHARGE', 'DISCIPLINAL', 'DISCIPLINARY', 'DISCIPLINE', 'DISCIPLINES', 'DISCIPLINESPECIFIC', 'DISCONNECTED', 'DISCONTINUATION', 'DISCORD', 'DISCORDANT', 'DISCOURAGE', 'DISCOURSE', 'DISCOVER', 'DISCOVERED', 'DISCOVERIES', 'DISCOVERING', 'DISCOVERY', 'DISCREET', 'DISCREPANCIES', 'DISCRET', 'DISCRETE', 'DISCRETECONTINUUM', 'DISCRETION', 'DISCRIMATION', 'DISCRIMINACIN', 'DISCRIMINATED', 'DISCRIMINATION', 'DISCRIMINATORY', 'DISCUSS', 'DISCUSSED', 'DISCUSSING', 'DISCUSSION', 'DISCUSSIONS', 'DISEA', 'DISEASE', 'DISEASEBURDEN', 'DISEASECAUSING', 'DISEASECHAGAS', 'DISEASECONTROL', 'DISEASEENDEMIC', 'DISEASERELATED', 'DISEASERELEVANT', 'DISEASERESISTANT', 'DISEASES', 'DISEASES12191', 'DISEASES12250', 'DISEASES5ACHIEVE', 'DISEASES7CLIMATE', 'DISEASESA', 'DISEASESANALYZE', 'DISEASESAND', 'DISEASESLYMPHATIC', 'DISEASESPECIFIC', 'DISEASESREDUCE', 'DISEASESTHE', 'DISEASESTHIS', 'DISEASESTRAINING', 'DISEASESWHILE', 'DISEASETHIS', 'DISEEASE', 'DISENTANGLE', 'DISENTANGLING', 'DISFAVOR', 'DISFAVOUR', 'DISH', 'DISINTEGRATED', 'DISJOINTED', 'DISMAL', 'DISMAY', 'DISORDER', 'DISORDERLINESS', 'DISORDERS', 'DISORDERSDETERMINE', 'DISPARATE', 'DISPARITIES', 'DISPARITY', 'DISPATCH', 'DISPEL', 'DISPENSARIES', 'DISPENSARY', 'DISPENSE', 'DISPERSAL', 'DISPERSE', 'DISPERSION', 'DISPIRITED', 'DISPLACE', 'DISPLACED', 'DISPLACEMENT', 'DISPLAY', 'DISPLAYING', 'DISPLAYS', 'DISPONIBILITT', 'DISPOSABLE', 'DISPOSAL', 'DISPROPORTIONAL', 'DISPROPORTIONALLY', 'DISPROPORTIONATE', 'DISPROPORTIONATELY', 'DISPUTE', 'DISREGARD', 'DISRUPT', 'DISRUPTED', 'DISRUPTING', 'DISRUPTION', 'DISRUPTIONS', 'DISSECT', 'DISSECTING', 'DISSECTION', 'DISSEMBLE', 'DISSEMINAT', 'DISSEMINATE', 'DISSEMINATED', 'DISSEMINATES', 'DISSEMINATING', 'DISSEMINATION', 'DISSERTATION', 'DISSIMILAR', 'DISSOLUTE', 'DISTAFF', 'DISTAL', 'DISTANCE', 'DISTANCELEARNING', 'DISTANCES', 'DISTANT', 'DISTINCT', 'DISTINCTIVENESS', 'DISTINGUISH', 'DISTINGUISHES', 'DISTINGUISHING', 'DISTRESS', 'DISTRIBUTE', 'DISTRIBUTED', 'DISTRIBUTI', 'DISTRIBUTING', 'DISTRIBUTION', 'DISTRIBUTIONAL', 'DISTRIBUTIONS', 'DISTRICT', 'DISTRICTBASED', 'DISTRICTCOUNTIES', 'DISTRICTCOUNTY', 'DISTRICTLED', 'DISTRICTLEVEL', 'DISTRICTPRIMARY', 'DISTRICTRESULT', 'DISTRICTS', 'DISTRICTSCOUNTIES', 'DISTRICTWIDE', 'DISTRITO', 'DISTURBANCES', 'DISTURBING', 'DISUNITE', 'DITGO', 'DITTO', 'DIV', 'DIVERGENT', 'DIVERS', 'DIVERSE', 'DIVERSENESS', 'DIVERSES', 'DIVERSIFICATION', 'DIVERSIFIED', 'DIVERSIFY', 'DIVERSITIES', 'DIVERSITY', 'DIVIDE', 'DIVIDED', 'DIVIDES', 'DIVIDING', 'DIVINE', 'DIVISIBLE', 'DIVISION', 'DIVISIONS', 'DIVOIRE', 'DIVORCE', 'DIXIE', 'DIXIELAND', 'DIYARBAKIR', 'DJAKARTA', 'DJAM', 'DJAMENA', 'DJAMENAGOUNDI', 'DJAMTNA', 'DJIBOUTI', 'DKFZ', 'DKT', 'DLE', 'DMAGIC', 'DMC', 'DMLT', 'DMP', 'DMT', 'DNA', 'DNABASE', 'DNACOPYING', 'DNAREPAIR', 'DNARNA', 'DNDI', 'DNDIS', 'DNS', 'DO2', 'DOABLE', 'DOB', 'DOBLEY', 'DOC', 'DOCENTES', 'DOCKET', 'DOCS', 'DOCTOR', 'DOCTORAL', 'DOCTORL', 'DOCTORS', 'DOCUMENT', 'DOCUMENTARY', 'DOCUMENTATION', 'DOCUMENTATIONINTERVIEWS', 'DOCUMENTED', 'DOCUMENTING', 'DOCUMENTS', 'DOD', 'DODGE', 'DODGING', 'DODOMA', 'DOE', 'DOER', 'DOES', 'DOG', 'DOGGED', 'DOH', 'DOINGS', 'DOJ', 'DOLAKHA', 'DOLE', 'DOLLAR', 'DOLLARS', 'DOMAIN', 'DOMAINES', 'DOMAINS', 'DOMCCP', 'DOMCCPS', 'DOMESTIC', 'DOMESTICATED', 'DOMINANCE', 'DOMINANT', 'DOMINATE', 'DOMINATED', 'DOMINGOS', 'DOMINICAN', 'DOMINICANA', 'DOMINICANS', 'DOMINICUS', 'DOMINION', 'DOMINIQUE', 'DOMINISSINI', 'DON', 'DONALD', 'DONATES', 'DONATING', 'DONATION', 'DONATIONS', 'DONATORS', 'DONE', 'DONOR', 'DONORFINANCED', 'DONORFRIENDLY', 'DONORS', 'DONOVANI', 'DONOVANIESTABLISHEDRESULT', 'DONT', 'DOOLE', 'DOOR', 'DOORS', 'DOORTODOOR', 'DOPED', 'DORMANT', 'DOS', 'DOSAGE', 'DOSAGES', 'DOSE', 'DOSEEFFECT', 'DOSERESPONSE', 'DOSES', 'DOSING', 'DOSSIER', 'DOT', 'DOTACIN', 'DOTS', 'DOUBLE', 'DOUBLED', 'DOUGH', 'DOWNHEARTED', 'DOWNPLAY', 'DOWNTURNS', 'DOWNWARDS', 'DOZEN', 'DOZES', 'DPARTEMENT', 'DPFS', 'DPFSDCS', 'DPHOS', 'DPO', 'DPR', 'DPV', 'DPVLNG', 'DPZ', 'DQUIPEMENT', 'DR', 'DRADICATION', 'DRAFT', 'DRAFTED', 'DRAFTING', 'DRAG', 'DRAIN', 'DRAMA', 'DRAMAS', 'DRAMATIC', 'DRAMATICALLY', 'DRASTICALLY', 'DRAW', 'DRAWDOWN', 'DRAWERS', 'DRAWING', 'DRAWN', 'DRAWS', 'DRC', 'DREAMS', 'DRG', 'DRGUS', 'DRIC', 'DRIED', 'DRIFT', 'DRILL', 'DRINK', 'DRINKING', 'DRINKINGWATER', 'DRINKS', 'DRINKSGUATEMALA', 'DRIV', 'DRIVE', 'DRIVEN', 'DRIVER', 'DRIVERS', 'DRIVES', 'DRIVING', 'DRMS', 'DROGAS', 'DRONE', 'DROP', 'DROPIN', 'DROPOUT', 'DROPOUTS', 'DROUGHT', 'DROUGHTAND', 'DROUPOUT', 'DRTB', 'DRUG', 'DRUGRELATED', 'DRUGRESISTANCE', 'DRUGRESISTANT', 'DRUGS', 'DRUGSENSITIVE', 'DRUGSMARKETSUPPLY', 'DRUGSPECIFIC', 'DRUGSTECHNOLOGIES', 'DRUGSTORES', 'DRUM', 'DRUS', 'DRUUGS', 'DRY', 'DRYING', 'DRYLAND', 'DRYLANDS', 'DRYWET', 'DSCHANG', 'DSM', 'DSO', 'DSRNAS', 'DSS', 'DTBUTT', 'DTCIDEURS', 'DTMOGRAPHIQUES', 'DTP', 'DTPARTEMENT', 'DTPHEPBHIB', 'DTQUIPEMENT', 'DTRADICATION', 'DTU', 'DTVELOPPEME', 'DTVELOPPEMENT', 'DTVELOPPER', 'DU', 'DUAL', 'DUALFINANCING', 'DUALLY', 'DUALTRACK', 'DUBIETY', 'DUBLIN', 'DUCATION', 'DUCES', 'DUCKWEED', 'DUCKY', 'DUE', 'DUES', 'DUKE', 'DUKORAL', 'DULCORATE', 'DUMMY', 'DUN', 'DUNCAN', 'DUNDEE', 'DUNE', 'DUPLE', 'DUPLICABILITY', 'DURABLE', 'DURATION', 'DURBAN', 'DURING', 'DUROLOGIE', 'DUST', 'DUSTING', 'DUSTUP', 'DUTCH', 'DUTIES', 'DUTY', 'DUTYBEARERS', 'DVELOPPEME', 'DVELOPPEMENT', 'DVELOPPER', 'DVPT', 'DWELLER', 'DWELLERS', 'DWELLING', 'DWIGHT', 'DWINDLING', 'DWS', 'DYING', 'DYNAMIC', 'DYNAMICAL', 'DYNAMICS', 'DYNAMIQUES', 'DYSENTERY', 'DYSFUNCTION', 'DYSFUNCTIONAL', 'DYSREGULATION', 'DZIKWA', 'DZIVARESEKWA', 'E', 'E3', 'E4D', 'E4H', 'EA', 'EAC', 'EACH', 'EACS', 'EAE', 'EALTH', 'EAN', 'EARL', 'EARLIER', 'EARLIEST', 'EARLY', 'EARLYLIFE', 'EARMARKED', 'EARMARKS', 'EARN', 'EARPHONE', 'EARTH', 'EARTHLY', 'EARTHQUAKE', 'EAS', 'EASE', 'EASIER', 'EASILY', 'EAST', 'EASTAFRICA', 'EASTAFRICAN', 'EASTERLY', 'EASTERN', 'EASTWARD', 'EASY', 'EASYTOADMINISTER', 'EASYTOUSE', 'EATEN', 'EATING', 'EAVES', 'EBA', 'EBOKON', 'EBOLA', 'EBOLAAFFECTED', 'EBOLARELATED', 'EBOLASENSITIZATION', 'EBOLASTRICKEN', 'EBOV', 'EC', 'ECCENTRIC', 'ECD', 'ECD4', 'ECD4IG', 'ECDC', 'ECG', 'ECH', 'ECHAM', 'ECHELONING', 'ECHINOCOCCOSIS', 'ECHO', 'ECHOCFEDF201501010', 'ECHOHFEDF201501018', 'ECHOSSDEDF201401008', 'ECHOWFEDF201402002', 'ECHOWFEDF201402003', 'ECHOWFEDF201402004', 'ECHOWFEDF201402007', 'ECHOWFEDF201402008', 'ECLAMPSIA', 'ECMS', 'ECODISPOSABLE', 'ECOEID', 'ECOFRIENDLYDISCREET', 'ECOHEALTH', 'ECOHEALTHBASED', 'ECOLOGICAL', 'ECOLOGICALLY', 'ECOLOGY', 'ECON', 'ECONMICAS', 'ECONOMETRIC', 'ECONOMETRICS', 'ECONOMIC', 'ECONOMICAL', 'ECONOMICALLY', 'ECONOMICALLYVIABLE', 'ECONOMICS', 'ECONOMIES', 'ECONOMISTS', 'ECONOMY', 'ECONOMYS', 'ECONOMYSUPPORT', 'ECORYS', 'ECOSENSITIVE', 'ECOSYSTEM', 'ECOSYSTEMBASED', 'ECOSYSTEMS', 'ECOWAS', 'ECOWASRCDC', 'ECS', 'ECUADOR', 'ECUADORS', 'ECUMENICAL', 'ECURITY', 'EDAD', 'EDCTP', 'EDCTP2', 'EDCTPPROJEKT', 'EDCTPTBDIAGNOSTICS', 'EDF', 'EDGAR', 'EDGE', 'EDIBLE', 'EDICATION', 'EDIFICATION', 'EDIFICE', 'EDINBURGH', 'EDITED', 'EDITING', 'EDITORIAL', 'EDITORIALS', 'EDMUND', 'EDS', 'EDUARDO', 'EDUCAITON', 'EDUCATE', 'EDUCATED', 'EDUCATEDCOMMUNITY', 'EDUCATEE', 'EDUCATIFS', 'EDUCATING', 'EDUCATION', 'EDUCATIONAL', 'EDUCATIONALEC', 'EDUCATIONALLY', 'EDUCATIONDEVELOPMENT', 'EDUCATIONINFORMATION', 'EDUCATIONTRAINING', 'EDUCATIVOS', 'EDUCATORS', 'EDUTAINMENT', 'EDWARD', 'EEA', 'EEAEEPRI', 'EEAS', 'EEC', 'EECA', 'EER', 'EFAVIRENZ', 'EFFECT', 'EFFECTER', 'EFFECTIVE', 'EFFECTIVELY', 'EFFECTIVENES', 'EFFECTIVENESS', 'EFFECTIVENESSIMPLEMENTATION', 'EFFECTIVITY', 'EFFECTOR', 'EFFECTORMEMORY', 'EFFECTORS', 'EFFECTS', 'EFFECTUAL', 'EFFECTUALITY', 'EFFECTUALNESS', 'EFFECTUATION', 'EFFICACE', 'EFFICACIOUS', 'EFFICACIOUSLY', 'EFFICACIOUSNESS', 'EFFICACIT', 'EFFICACITT', 'EFFICACY', 'EFFICACYEFFECTIVENESS', 'EFFICIACY', 'EFFICIENCIES', 'EFFICIENCY', 'EFFICIENCYTRANSPARE', 'EFFICIENT', 'EFFICIENTLY', 'EFFO', 'EFFORT', 'EFFORTS', 'EFLORNITHINE', 'EFV', 'EG', 'EGAN', 'EGGS', 'EGGSTHIS', 'EGO', 'EGOVERNANCE', 'EGOVERNMENT', 'EGPAF', 'EGRESS', 'EGYPT', 'EGYPTE', 'EGYPTIAN', 'EGYPTSWISS', 'EGYTPSWISS', 'EHEALTH', 'EHEMALS', 'EHIF', 'EHP', 'EHR', 'EHS', 'EIA', 'EID', 'EIDS', 'EIF2', 'EIF2ADEPENDENT', 'EIGHT', 'EIGHTEEN', 'EIGHTY', 'EINE', 'EINSTEIN', 'EITHER', 'EJECT', 'EJERZAN', 'EKWENDENI', 'EL', 'ELABORATE', 'ELABORATED', 'ELABORATEDRESULT', 'ELABORATING', 'ELABORATION', 'ELASTIC', 'ELASTICITIES', 'ELASTICITY', 'ELASTOMERS', 'ELBOW', 'ELD', 'ELDERLY', 'ELEARNING', 'ELECTED', 'ELECTION', 'ELECTIVE', 'ELECTRIC', 'ELECTRICAL', 'ELECTRICITY', 'ELECTRICITYINDEPENDENT', 'ELECTRIFICATION', 'ELECTRO', 'ELECTROLYTE', 'ELECTROLYTES', 'ELECTRONEGATIVE', 'ELECTRONIC', 'ELECTROPHORESIS', 'ELECTROPOSITIVE', 'ELECTROSURGERY', 'ELEMENT', 'ELEMENTAL', 'ELEMENTARY', 'ELEMENTS', 'ELEPHANTIASIS', 'ELEVATE', 'ELEVATED', 'ELEVATOR', 'ELEVEN', 'ELGEYO', 'ELGON', 'ELIAS', 'ELICIT', 'ELICITED', 'ELICITING', 'ELIGIBILITY', 'ELIGIBLE', 'ELIMINATE', 'ELIMINATED', 'ELIMINATES', 'ELIMINATING', 'ELIMINATION', 'ELIMINATIONLEARN', 'ELIMINATIONPHASE', 'ELIMINATIONS', 'ELISABETH', 'ELITES', 'ELIYA', 'ELIZA', 'ELIZABETH', 'ELLICE', 'ELMER', 'ELSEWHERE', 'ELSIE', 'ELUCIDATE', 'ELUCIDATING', 'ELUCIDATION', 'ELVIS', 'EM', 'EMAIL', 'EMANATORS', 'EMANCIPATION', 'EMBARAZO', 'EMBARAZOS', 'EMBARK', 'EMBARKED', 'EMBARRASS', 'EMBASSY', 'EMBASSYS', 'EMBED', 'EMBEDDED', 'EMBEDDING', 'EMBODIED', 'EMBODY', 'EMBRACE', 'EMBRACING', 'EMBRYO', 'EMBRYONATED', 'EMBRYYO', 'EMCAB', 'EMERGE', 'EMERGED', 'EMERGENCE', 'EMERGENCES', 'EMERGENCIA', 'EMERGENCIES', 'EMERGENCY', 'EMERGENCYS', 'EMERGENT', 'EMERGES', 'EMERGING', 'EMERSION', 'EMHEALTH', 'EMINENT', 'EMIS', 'EMISSION', 'EMISSIONS', 'EMITTERS', 'EMITTING', 'EMM', 'EMMANUEL', 'EMMS', 'EMORY', 'EMPHAS', 'EMPHASIS', 'EMPHASISE', 'EMPHASISES', 'EMPHASIZE', 'EMPHASIZED', 'EMPHASIZES', 'EMPHASIZING', 'EMPHNET', 'EMPIRE', 'EMPIRIC', 'EMPIRICAL', 'EMPLACEMENT', 'EMPLEO', 'EMPLOY', 'EMPLOYABILITY', 'EMPLOYED', 'EMPLOYEES', 'EMPLOYER', 'EMPLOYERS', 'EMPLOYING', 'EMPLOYMENT', 'EMPLOYS', 'EMPOWER', 'EMPOWERED', 'EMPOWERING', 'EMPOWERMENT', 'EMPOWERS', 'EMPTY', 'EMR', 'EN', 'ENABLE', 'ENABLED', 'ENABLER', 'ENABLERS', 'ENABLES', 'ENABLING', 'ENACT', 'ENACTMENT', 'ENALBED', 'ENATE', 'ENATIC', 'ENCAPSIDATION', 'ENCAPSULATING', 'ENCEPHALITIS', 'ENCEPHALOPATHY', 'ENCODE', 'ENCODING', 'ENCOMPASS', 'ENCOMPASSED', 'ENCOMPASSES', 'ENCOMPASSING', 'ENCONTEXTOS', 'ENCOUNTER', 'ENCOUNTERED', 'ENCOURAGE', 'ENCOURAGED', 'ENCOURAGES', 'ENCOURAGING', 'ENCROACHED', 'ENCROACHING', 'ENCROACHMENT', 'ENCUMBRANCE', 'END', 'ENDA', 'ENDANGERMENT', 'ENDANGERS', 'ENDEAVOR', 'ENDEAVOUR', 'ENDEAVOURS', 'ENDED', 'ENDEMIC', 'ENDEMICITY', 'ENDGAME', 'ENDING', 'ENDOCYTOSIS', 'ENDOFLIFE', 'ENDOFPROJECT', 'ENDOGENIC', 'ENDOGENOUS', 'ENDOPHYTES', 'ENDOPHYTIC', 'ENDORSE', 'ENDORSED', 'ENDORSEMENT', 'ENDORSES', 'ENDOSURGERY', 'ENDOTHELIAL', 'ENDOWED', 'ENDOWMENT', 'ENDPOINTS', 'ENDS', 'ENDTOEND', 'ENDUNFPA', 'ENDURANCE', 'ENDURE', 'ENDURING', 'ENDUSERRELATED', 'ENDUSERS', 'ENERGIES', 'ENERGY', 'ENERGYDENSE', 'ENFANTS', 'ENFANTSSTRENGTHENING', 'ENFERMERFA', 'ENFORCE', 'ENFORCEMENT', 'ENFORCEMENTS', 'ENFORCING', 'ENG', 'ENGAGE', 'ENGAGED', 'ENGAGEMENT', 'ENGAGEMENTENSURING', 'ENGAGEMENTTHE', 'ENGAGES', 'ENGAGING', 'ENGENDER', 'ENGENDERS', 'ENGINE', 'ENGINEER', 'ENGINEERED', 'ENGINEERING', 'ENGINEERS', 'ENGLAND', 'ENGLISH', 'ENGLISHLANGUAGE', 'ENHANCE', 'ENHANCED', 'ENHANCEMENT', 'ENHANCES', 'ENHANCING', 'ENHANSE', 'ENI2015351055', 'ENJOY', 'ENJOYED', 'ENJOYING', 'ENJOYMENT', 'ENLARGE', 'ENLARGEMENT', 'ENLISTING', 'ENN', 'ENNEAD', 'ENORMOUS', 'ENOUGH', 'ENP', 'ENPI2013335420', 'ENQUIRE', 'ENQUIRY', 'ENRICHED', 'ENRICHING', 'ENROLLED', 'ENROLLING', 'ENROLLMENT', 'ENROLMENT', 'ENS', 'ENSEIGNEMENT', 'ENSEMBLE', 'ENSURE', 'ENSURED', 'ENSURES', 'ENSURING', 'ENTAILS', 'ENTER', 'ENTERED', 'ENTERIC', 'ENTERICA', 'ENTERICS', 'ENTERING', 'ENTEROCOCCI', 'ENTEROCOCCUS', 'ENTEROPATHOGENS', 'ENTEROPATHY', 'ENTEROTOXIGENIC', 'ENTEROTOXIN', 'ENTEROTOXINPRODUCING', 'ENTERPRISE', 'ENTERPRISEBASED', 'ENTERPRISES', 'ENTERPRISINGNESS', 'ENTERS', 'ENTERTAINMENT', 'ENTHALPY', 'ENTIRE', 'ENTIRELY', 'ENTIRETYTHE', 'ENTITIES', 'ENTITLED', 'ENTITLEMENT', 'ENTITLEMENTS', 'ENTITY', 'ENTOMOLOGIC', 'ENTOMOLOGICAL', 'ENTOMOLOGY', 'ENTRAP', 'ENTRE', 'ENTRED', 'ENTREE', 'ENTRENCHED', 'ENTREPRENEURIAL', 'ENTREPRENEURS', 'ENTREPRENEURSHIP', 'ENTRIES', 'ENTROPY', 'ENTRY', 'ENUGU', 'ENUMERATION', 'ENV', 'ENVELOPE', 'ENVIROMENTAL', 'ENVIRONMENT', 'ENVIRONMENT12110', 'ENVIRONMENTAL', 'ENVIRONMENTALFRIENDLY', 'ENVIRONMENTALLY', 'ENVIRONMENTRELATED', 'ENVIRONMENTS', 'ENVIRONMENTSIDENTIFY', 'ENVIRONMENTSREDUCE', 'ENVIRONMENTSTRENGTHENING', 'ENVIRONMENTTHE', 'ENVIRONS', 'ENVISAGE', 'ENVISAGED', 'ENVISAGING', 'ENVISION', 'ENVISIONED', 'ENVISIONS', 'ENVOY', 'ENZOOTIC', 'ENZYME', 'ENZYMELINKED', 'ENZYMES', 'EONE', 'EOSG', 'EOSGS', 'EPCMD', 'EPF', 'EPI', 'EPIBIOME', 'EPIC', 'EPICEMIC', 'EPICENTRE', 'EPICPMTCT', 'EPIDEMIA', 'EPIDEMIC', 'EPIDEMICS', 'EPIDEMICTHE', 'EPIDEMIOLOGFA', 'EPIDEMIOLOGIA', 'EPIDEMIOLOGIC', 'EPIDEMIOLOGIC7', 'EPIDEMIOLOGICAL', 'EPIDEMIOLOGICALLY', 'EPIDEMIOLOGY', 'EPIDEMIOLOGYIN', 'EPIDEMOLOGY', 'EPIDEMY', 'EPIDERMAL', 'EPIGENETIC', 'EPIGENOME', 'EPIK', 'EPILAB', 'EPILEPSY', 'EPILEPTIC', 'EPIPEDIOMOLOGISKLABORATORY', 'EPISODE', 'EPISODES', 'EPISODIC', 'EPISTAT', 'EPITOME', 'EPITOPE', 'EPITOPES', 'EPITRANSCRIPTOME', 'EPLATFORM', 'EPOCSATELITE', 'EPRESCRIPTION', 'EPT', 'EPZPROMOTE', 'EQA', 'EQUAL', 'EQUALITY', 'EQUALITYBANGLADESH', 'EQUALLY', 'EQUATE', 'EQUATION', 'EQUATORIA', 'EQUINET', 'EQUINETFOR', 'EQUINETS', 'EQUIP', 'EQUIPE', 'EQUIPEMENT', 'EQUIPING', 'EQUIPMENT', 'EQUIPMENTDATA', 'EQUIPMENTPHOTOCOPIER', 'EQUIPMENTS', 'EQUIPMMENT', 'EQUIPPED', 'EQUIPPEMENTS', 'EQUIPPING', 'EQUITABLE', 'EQUITABLY', 'EQUITY', 'EQUITYIN', 'EQUITYORIENTED', 'EQUIVALENCE', 'EQUIVALENT', 'EQUO', 'ER', 'ERA', 'ERADI', 'ERADICATE', 'ERADICATED', 'ERADICATING', 'ERADICATION', 'ERADICATION12250', 'ERANET', 'ERARE', 'ERASERS', 'ERASMUS', 'ERFORMING', 'ERITREA', 'ERIWAN', 'ERNST', 'EROSION', 'ERRADICACI', 'ERRATIC', 'ERROR', 'ERSTELLUNG', 'ERUPTION', 'ERV', 'ERYTHEMATOSUS', 'ERYTHROCYTE', 'ERYTHROCYTES', 'ERYTHROCYTIC', 'ES', 'ESA', 'ESBL', 'ESCALATE', 'ESCALATING', 'ESCALATION', 'ESCAPE', 'ESCAPING', 'ESCARGOT', 'ESCHERICHIA', 'ESCPECIALLY', 'ESCUELA', 'ESEARCH', 'ESEI', 'ESERVICE', 'ESERVICES', 'ESI', 'ESPACIOS', 'ESPECIAL', 'ESPECIALLY', 'ESPECIALMENTE', 'ESPEN', 'ESRC', 'ESSAY', 'ESSENCE', 'ESSENTIAL', 'ESSENTIALLY', 'EST', 'ESTABLIMENT', 'ESTABLISH', 'ESTABLISHED', 'ESTABLISHES', 'ESTABLISHING', 'ESTABLISHMENT', 'ESTADO', 'ESTEEM', 'ESTERIFIED', 'ESTHER', 'ESTHERITALYB', 'ESTIMABLE', 'ESTIMATE', 'ESTIMATED', 'ESTIMATES', 'ESTIMATION', 'ESTIMATIONS', 'ESTONIA', 'ESTONIAACCESS', 'ESTONIAHEALTH', 'ESTONIALEADERSHIP', 'ESTONIAMENTAL', 'ESTONIAN', 'ESTONIANATIONAL', 'ESTONIANONCOMMUNICABLE', 'ESTONIASTRATEGIC', 'ESTROGEN', 'ESTUDIO', 'ESTUDIOS', 'ET', 'ETC', 'ETEC', 'ETEM', 'ETHI', 'ETHICAL', 'ETHICISTS', 'ETHICS', 'ETHICSRELATED', 'ETHIOPIA', 'ETHIOPIAN', 'ETHIOPIANEED', 'ETHIOPIAS', 'ETHIPIA', 'ETHNIC', 'ETHNICITY', 'ETHNOBOTANICAL', 'ETHNOGRAPHIC', 'ETHNOGRAPHY', 'ETHNOMEDICAL', 'ETIOLOGIC', 'ETIOLOGIES', 'ETIOLOGY', 'ETIOPIA', 'ETIOPIAMOZAMBICOTANZANIAUGANDA', 'ETOOLS', 'EU', 'EUBSTANCE', 'EUINDIA', 'EUR', 'EUR1950000', 'EURECA', 'EURESIST', 'EURO', 'EUROCGD', 'EUROPA', 'EUROPE', 'EUROPEAID', 'EUROPEAID130227CSUPVN', 'EUROPEAN', 'EUROPEANAFRICAN', 'EUROPEANGAZA', 'EUROPIUM', 'EUROS', 'EUSA', 'EUSIGN', 'EV', 'EVA', 'EVACUATION', 'EVACUATIONS', 'EVADE', 'EVALUACIN', 'EVALUATE', 'EVALUATED', 'EVALUATEDRESULT', 'EVALUATES', 'EVALUATING', 'EVALUATION', 'EVALUATIONAFTER', 'EVALUATIONLOW', 'EVALUATIONS', 'EVALUATIONSO', 'EVALUATIONSTHE', 'EVALUATIVE', 'EVALUATOR', 'EVALUATORS', 'EVALUERING', 'EVALUETEDAS', 'EVANGELIST', 'EVAPORATION', 'EVASION', 'EVAULATE', 'EVAULATION', 'EVD', 'EVEN', 'EVENT', 'EVENTS', 'EVENTSTHIS', 'EVENTUAL', 'EVENTUALLY', 'EVER', 'EVERGREEN', 'EVERINCREASING', 'EVERWELL', 'EVERY', 'EVERYDAY', 'EVERYONE', 'EVERYWHERE', 'EVIDENCE', 'EVIDENCE12182', 'EVIDENCEBASE', 'EVIDENCEBASED', 'EVIDENCED', 'EVIDENCEDBASED', 'EVIDENCEINFORMED', 'EVIDENCETHE', 'EVIDENCETO', 'EVIDENT', 'EVIPNET', 'EVISIT', 'EVOCATION', 'EVOLUTION', 'EVOLUTIONARY', 'EVOLUTIONS', 'EVOLVE', 'EVOLVED', 'EVOLVES', 'EVOLVING', 'EVOUCHERS', 'EWARS', 'EWEC', 'EWECINITIATIVE', 'EWHAUHS', 'EX', 'EXACERBATES', 'EXACERBATING', 'EXACT', 'EXACTLY', 'EXAM', 'EXAMINATION', 'EXAMINATIONS', 'EXAMINE', 'EXAMINED', 'EXAMINES', 'EXAMINING', 'EXAMPLE', 'EXAMPLES', 'EXAMS', 'EXASPERATED', 'EXCAVATION', 'EXCEED', 'EXCEEDING', 'EXCEEDS', 'EXCELLENCE', 'EXCELLENCES', 'EXCELLENT', 'EXCEPCIONALES', 'EXCEPT', 'EXCEPTION', 'EXCEPTIONAL', 'EXCERPT', 'EXCERPTION', 'EXCESS', 'EXCESSIVE', 'EXCHANGE', 'EXCHANGED', 'EXCHANGEIN', 'EXCHANGES', 'EXCHANGING', 'EXCISE', 'EXCISTING', 'EXCITING', 'EXCLUDE', 'EXCLUDED', 'EXCLUDING', 'EXCLUSIN', 'EXCLUSION', 'EXCLUSIVE', 'EXCLUSIVELY', 'EXCOGITATE', 'EXCOGITATION', 'EXCRETA', 'EXCRETING', 'EXCRETION', 'EXCUSE', 'EXECUTE', 'EXECUTED', 'EXECUTING', 'EXECUTION', 'EXECUTIVE', 'EXECUTIVES', 'EXEMPLARY', 'EXEMPLIFIED', 'EXEMPLIFIES', 'EXEMPTION', 'EXERCISE', 'EXERT', 'EXERTED', 'EXERTION', 'EXHALED', 'EXHIBIT', 'EXIGENCY', 'EXISITNG', 'EXIST', 'EXISTENCE', 'EXISTENT', 'EXISTI', 'EXISTING', 'EXISTS', 'EXIT', 'EXKLUSIVE', 'EXLUSIVE', 'EXOTIC', 'EXPAND', 'EXPANDED', 'EXPANDING', 'EXPANDS', 'EXPANSE', 'EXPANSIN', 'EXPANSION', 'EXPANTION', 'EXPATIATE', 'EXPATRIATION', 'EXPECT', 'EXPECTANCY', 'EXPECTANT', 'EXPECTED', 'EXPECTS', 'EXPEDITE', 'EXPEDITION', 'EXPEND', 'EXPENDED', 'EXPENDING', 'EXPENDITURE', 'EXPENDITURES', 'EXPENSED', 'EXPENSES', 'EXPENSIVE', 'EXPERIENCE', 'EXPERIENCED', 'EXPERIENCES', 'EXPERIENCESADVOCACY', 'EXPERIENCING', 'EXPERIENTIAL', 'EXPERIMENT', 'EXPERIMENTAL', 'EXPERIMENTALLY', 'EXPERIMENTING', 'EXPERIMENTS', 'EXPERT', 'EXPERTISE', 'EXPERTISEGATHER', 'EXPERTNESS', 'EXPERTS', 'EXPERTSTHE', 'EXPIATION', 'EXPIRATION', 'EXPIRE', 'EXPIRING', 'EXPIRY', 'EXPLAIN', 'EXPLANATION', 'EXPLANATIONS', 'EXPLICATE', 'EXPLICIT', 'EXPLICITLY', 'EXPLOIT', 'EXPLOITATION', 'EXPLOITED', 'EXPLOITING', 'EXPLORATION', 'EXPLORATORY', 'EXPLORE', 'EXPLORED', 'EXPLORING', 'EXPLOSIVE', 'EXPLOSIVELY', 'EXPO', 'EXPORT', 'EXPOSE', 'EXPOSED', 'EXPOSES', 'EXPOSURE', 'EXPOSURES', 'EXPOUND', 'EXPRESS', 'EXPRESSED', 'EXPRESSES', 'EXPRESSING', 'EXPRESSION', 'EXPSOURE', 'EXPTRIMENTAL', 'EXQUISITE', 'EXTEND', 'EXTENDABLE', 'EXTENDED', 'EXTENDEDBEYOND', 'EXTENDEDRELEASE', 'EXTENDING', 'EXTENDS', 'EXTENSION', 'EXTENSION1', 'EXTENSION2', 'EXTENSIVE', 'EXTENSIVELY', 'EXTENT', 'EXTERIOR', 'EXTERMINATE', 'EXTERN', 'EXTERNAL', 'EXTERNALITIES', 'EXTERNALLY', 'EXTINGUISH', 'EXTRA', 'EXTRACT', 'EXTRACTED', 'EXTRACTING', 'EXTRACTION', 'EXTRACTIVE', 'EXTRACTIVEINDUSTRY', 'EXTRACTS', 'EXTRANEOUS', 'EXTRAPOLATED', 'EXTRAPOLATION', 'EXTREME', 'EXTREMELY', 'EXTREMITY', 'EXYUGOSLAVIA', 'EYE', 'EYEGLASSES', 'EYEHEALTH', 'EYELID', 'EYESURGERIES', 'EZRA', 'F', 'FA', 'FA1', 'FA2', 'FA3', 'FA3I', 'FA3II', 'FABRIC', 'FABRICATION', 'FACE', 'FACED', 'FACEPEDIATRIC', 'FACES', 'FACETOFACE', 'FACIAL', 'FACICLITT', 'FACILITATE', 'FACILITATED', 'FACILITATES', 'FACILITATING', 'FACILITATION', 'FACILITATOR', 'FACILITATORS', 'FACILITIES', 'FACILITIESHIGH', 'FACILITY', 'FACILITYAS', 'FACILITYBASED', 'FACILITYS', 'FACILITYSTRENGTHENING', 'FACING', 'FACT', 'FACTFINDING', 'FACTOR', 'FACTORIAL', 'FACTORS', 'FACTORSFOOD', 'FACTORY', 'FACTS', 'FACULTAD', 'FACULTIES', 'FACULTT', 'FACULTY', 'FADEL', 'FAECES', 'FAFI', 'FAHRENHEIT', 'FAI', 'FAIDD', 'FAIII', 'FAIL', 'FAILED', 'FAILING', 'FAILURE', 'FAILURES', 'FAIM', 'FAIR', 'FAIRE', 'FAIRFIELD', 'FAIRLY', 'FAIRNESS', 'FAISONS', 'FAIT', 'FAITH', 'FAITHBASED', 'FAITHFUL', 'FAITHFULLY', 'FALCIPARUM', 'FALCIPARUMANDP', 'FALCIPARUMP', 'FALL', 'FALLS', 'FALTERING', 'FAMBUL', 'FAMILIA', 'FAMILIAL', 'FAMILIAR', 'FAMILIARIS', 'FAMILIARIZATION', 'FAMILIARIZE', 'FAMILIES', 'FAMILIESSUPPORTING', 'FAMILILIES', 'FAMILLES', 'FAMILY', 'FAMILYAPPROACH', 'FAMILYBASED', 'FAMILYCENTERED', 'FAMINE', 'FAN', 'FANCY', 'FANNIE', 'FANRPAN', 'FANTA', 'FANTAIII', 'FAO', 'FAOIAEA', 'FAP', 'FAPESP', 'FAR', 'FARA', 'FARAFENNI', 'FARAH', 'FARM', 'FARMACOVIGILANCIA', 'FARMED', 'FARMER', 'FARMERLED', 'FARMERMARKETCONSUMER', 'FARMERS', 'FARMING', 'FARMS', 'FARMTOSCHOOL', 'FARSIGHTED', 'FARTHER', 'FARWEST', 'FAS', 'FASHION', 'FASHIONING', 'FASO', 'FASORESULT', 'FAST', 'FASTER', 'FASTERACTING', 'FASTGROWING', 'FASTING', 'FASTLY', 'FAT', 'FATAL', 'FATALITIES', 'FATALITY', 'FATE', 'FATEFUL', 'FATHER', 'FATI', 'FATI1', 'FATIHA', 'FATIMA', 'FATS', 'FATTY', 'FAUNA', 'FAVOR', 'FAVORABLE', 'FAVORITE', 'FAVOUR', 'FAVOURABLE', 'FAVOURED', 'FAVOURITISM', 'FAVOURS', 'FBOS', 'FBOS5PLAN', 'FBPD', 'FC', 'FC436RIIB', 'FCG', 'FCII', 'FCRSAI', 'FCTC', 'FCTC2030', 'FCTCTHE', 'FDA', 'FDC', 'FE', 'FEAR', 'FEARED', 'FEASABILITY', 'FEASIBIITY', 'FEASIBILITY', 'FEASIBLE', 'FEASIBLENESS', 'FEAST', 'FEAT', 'FEATURE', 'FEATURED', 'FEATURES', 'FEB', 'FEBRICITY', 'FEBRILE', 'FEBRILITY', 'FEBRUARY', 'FEC', 'FECAL', 'FECES', 'FED', 'FED2013', 'FEDERAL', 'FEDERATED', 'FEDERATION', 'FEDERATION3', 'FEDERATIONACCESS', 'FEDERATIONGENDER', 'FEDERATIONGUF', 'FEDERATIONHEALTH', 'FEDERATIONHIV', 'FEDERATIONHIVAIDS', 'FEDERATIONMANAGEMENT', 'FEDERATIONMENTAL', 'FEDERATIONNATIONAL', 'FEDERATIONNONCOMMUNICABLE', 'FEDERATIONS', 'FEDERATIONSOCIAL', 'FEDERATIONSTRATEGIC', 'FEDERATIONVIOLENCE', 'FEDERATIVE', 'FEE', 'FEED', 'FEEDBACK', 'FEEDING', 'FEEDS', 'FEELER', 'FEELING', 'FEES', 'FEIGN', 'FEKADU', 'FELINE', 'FELL', 'FELLER', 'FELLOSHIP', 'FELLOW', 'FELLOWS', 'FELLOWSHIP', 'FELLOWSHIPS', 'FELT', 'FELTP', 'FEMALE', 'FEMALEINITIATED', 'FEMALES', 'FEMINIST', 'FEMMES', 'FEMMINILE', 'FENCE', 'FEND', 'FERBEYRE', 'FERMENTATION', 'FERMIUM', 'FEROCITY', 'FERRIC', 'FERTILE', 'FERTILITY', 'FETAL', 'FETOPROTEIN', 'FETPSFELTPS', 'FETUS', 'FETUSES', 'FEVER', 'FEVERCAUSING', 'FEVERISH', 'FEVERISHNESS', 'FEVERS', 'FEW', 'FEWER', 'FEXINIDAZOLE', 'FGC', 'FGCS', 'FGM', 'FGMC', 'FGMCEREMONY', 'FGMCTHE', 'FGPS', 'FGS', 'FGSS', 'FHI', 'FHJN', 'FIANANCIAL', 'FIBERGASTROSCOPE', 'FIBRE', 'FIBRILS', 'FIBROGENESIS', 'FIBROSIS', 'FIC', 'FICCI', 'FICCIS', 'FICHE', 'FIDA', 'FIDEC', 'FIDELITY', 'FIDIDA', 'FIDUCIARY', 'FIELD', 'FIELDDEPLOYABLE', 'FIELDEXPERIMENTAL', 'FIELDEXPERIMENTS', 'FIELDFRIENDLY', 'FIELDS', 'FIELDSBOTH', 'FIELDSTHOUGH', 'FIELDTHE', 'FIELDTO', 'FIELDVALIDATE', 'FIERCENESS', 'FIFTEEN', 'FIFTH', 'FIFTY', 'FIGHT', 'FIGHTING', 'FIGURE', 'FIGURED', 'FIGUREHEAD', 'FIGURES', 'FIJI', 'FIJISPECIFIC', 'FILARIAL', 'FILARIASIS', 'FILARISIS', 'FILHA', 'FILL', 'FILLED', 'FILLEY', 'FILLING', 'FILLS', 'FILM', 'FILMMAKING', 'FILMS', 'FILOVIRUSES', 'FILTER', 'FILTRATION', 'FIN', 'FINAGLE', 'FINAL', 'FINALISED', 'FINALITY', 'FINALLY', 'FINANCE', 'FINANCED', 'FINANCER', 'FINANCES', 'FINANCIAL', 'FINANCIALLY', 'FINANCIALLYSUSTAINABLE', 'FINANCIERA', 'FINANCING', 'FINANCT', 'FINANING', 'FINANZAS', 'FIND', 'FINDING', 'FINDINGS', 'FINDINGSPAKISTANI', 'FINDINGSTHE', 'FINE', 'FINETUNE', 'FINGERPRINTING', 'FINGERPRINTS', 'FINICKY', 'FINISH', 'FINISHED', 'FINLAND', 'FINLANDBECAUSE', 'FINLANDIPAS', 'FINLANDS', 'FINNISH', 'FINNPARTNERSHIP', 'FIOCRUZ', 'FIPSR', 'FIPV', 'FIRE', 'FIRM', 'FIRMLY', 'FIRMS', 'FIRST', 'FIRSTGENERATION', 'FIRSTHAND', 'FIRSTINCHILDREN', 'FIRSTINHUMAN', 'FIRSTLEVEL', 'FIRSTLINE', 'FIRSTLY', 'FIRSTRESPONDERS', 'FISCAL', 'FISD', 'FISH', 'FISHER', 'FISHERIES', 'FISHERY', 'FISHGARDENS', 'FISHING', 'FISHRESEARCHERS', 'FISIOLOGFA', 'FISTULA', 'FIT', 'FITNESS', 'FITS', 'FITTEST', 'FIVE', 'FIVEPART', 'FIVESOME', 'FIVEYEAR', 'FIX', 'FIXED', 'FK', 'FLABBY', 'FLACCID', 'FLACSAM', 'FLAGELLUM', 'FLAGSHIP', 'FLAMAND', 'FLANDERS', 'FLASH', 'FLAT', 'FLAVIVIRIDAE', 'FLEET', 'FLEMING', 'FLEMISH', 'FLESHED', 'FLESHINESS', 'FLESHLY', 'FLEXIBILITIES', 'FLEXIBILITY', 'FLEXIBLE', 'FLIES', 'FLIP', 'FLIPCHART', 'FLIPCHARTS', 'FLOOD', 'FLOODED', 'FLOODING', 'FLOODS', 'FLOOR', 'FLOORS', 'FLORA', 'FLORIDA', 'FLOUR', 'FLOURISH', 'FLOURS', 'FLOW', 'FLOWCHARTS', 'FLOWER', 'FLOWS', 'FLU', 'FLUCONAZOLE', 'FLUCTUATION', 'FLUCTUATIONS', 'FLUCYTOSINE', 'FLUID', 'FLUKE', 'FLUKES', 'FLUORESCENCE', 'FLUORESCENT', 'FLUORINE', 'FLY', 'FLYERS', 'FLYING', 'FM', 'FMOH', 'FMOHS', 'FNU', 'FO', 'FOCAL', 'FOCALISE', 'FOCALIZE', 'FOCCISA', 'FOCI', 'FOCUS', 'FOCUSED', 'FOCUSES', 'FOCUSING', 'FOCUSSED', 'FOCUSSES', 'FOCUSSING', 'FOEMA', 'FOETOPROTEIN', 'FOGARTY', 'FOIL', 'FOLATE', 'FOLD', 'FOLIC', 'FOLK', 'FOLL', 'FOLLICULAR', 'FOLLOW', 'FOLLOWED', 'FOLLOWEDUP', 'FOLLOWING', 'FOLLOWON', 'FOLLOWS', 'FOLLOWTHROUGH', 'FOLLOWUP', 'FOLLOWUPCROSSCUTTING', 'FOLLOWUPS', 'FOLLWOING', 'FOMENT', 'FOMITE', 'FONADE', 'FONDATION', 'FONDS', 'FONT', 'FOOD', 'FOODBORNE', 'FOODLABELLING', 'FOODODOR', 'FOODRELATED', 'FOODS', 'FOODSECURE', 'FOODSMEALS', 'FOOT', 'FOOTPATH', 'FOOTPRINT', 'FOOTSTEP', 'FOP', 'FOR', 'FORA', 'FORADDRESSING', 'FORAGING', 'FORBID', 'FORBIDDEN', 'FORCE', 'FORCED', 'FORCEDEARLY', 'FORCES', 'FORCIBLE', 'FORCING', 'FORDILAB', 'FORECARIAH', 'FORECAST', 'FORECASTING', 'FORECLOSE', 'FOREFRONT', 'FOREGATHER', 'FOREIGN', 'FOREIGNERS', 'FOREING', 'FOREMOST', 'FORESEEN', 'FORESEES', 'FORESHORTEN', 'FORESIGHTED', 'FORESIGHTFUL', 'FOREST', 'FORESTALL', 'FORESTED', 'FORESTRY', 'FORESTS', 'FORETELL', 'FORETHOUGHT', 'FORGE', 'FORGERY', 'FORHEALTH', 'FORK', 'FORM', 'FORMA', 'FORMACIN', 'FORMAL', 'FORMALDEHYDE', 'FORMALISE', 'FORMALIZE', 'FORMALIZED', 'FORMALLY', 'FORMAT', 'FORMATION', 'FORMATIVE', 'FORMATS', 'FORMED', 'FORMER', 'FORMERLY', 'FORMERS', 'FORMIDABLE', 'FORMING', 'FORMS', 'FORMULA', 'FORMULATE', 'FORMULATED', 'FORMULATING', 'FORMULATION', 'FORMULATIONS', 'FORPROFIT', 'FORRADER', 'FORRARD', 'FORSA', 'FORSYTHE', 'FORT', 'FORTALECIDAS', 'FORTALECIENDO', 'FORTALEZA', 'FORTH', 'FORTHCOMING', 'FORTIFICATION', 'FORTIFIED', 'FORTIFY', 'FORTUNE', 'FORTY', 'FORUM', 'FORUMS', 'FORUMSCONSIDERED', 'FORUMTHIS', 'FORVIDA', 'FORWARD', 'FORWARDED', 'FOSSILFUELFREE', 'FOSTER', 'FOSTERED', 'FOSTERING', 'FOSTERS', 'FOT', 'FOTS', 'FOUL', 'FOUMBEA', 'FOUND', 'FOUNDATION', 'FOUNDATIONAL', 'FOUNDATIONS', 'FOUNDED', 'FOUNDING', 'FOUNTAIN', 'FOUR', 'FOURARMED', 'FOURDAY', 'FOURFOLD', 'FOURIER', 'FOURNISSANT', 'FOURNITURE', 'FOURNITURES', 'FOURSOME', 'FOURTEEN', 'FOURTH', 'FOURWEEK', 'FOURYEAR', 'FOWL', 'FOXES', 'FOZIVUDINE', 'FP', 'FP2020', 'FPD', 'FPDS', 'FPM', 'FPMCH', 'FPMNCHN', 'FPRH', 'FRA', 'FRACTION', 'FRACTIONAL', 'FRACTIONATED', 'FRAGILE', 'FRAGILITY', 'FRAGMENT', 'FRAGMENTATION', 'FRAGMENTED', 'FRAME', 'FRAMED', 'FRAMEWORK', 'FRAMEWORKS', 'FRANCE', 'FRANCETHE', 'FRANCHISES', 'FRANCHISING', 'FRANCIS', 'FRANCISCO', 'FRANCOPHONE', 'FRANKFURT', 'FRAUDULENT', 'FRAUGHT', 'FRAUNHOFER', 'FRCS', 'FRED', 'FREDERICK', 'FREE', 'FREEDOM', 'FREEING', 'FREELY', 'FREETOWN', 'FREEZE', 'FRENCH', 'FRENTE', 'FREQUENCY', 'FREQUENT', 'FREQUENTLY', 'FRESH', 'FRG', 'FRICA', 'FRIDGE', 'FRIEND', 'FRIENDLIER', 'FRIENDLY', 'FRIENDS', 'FRIENDSHIP', 'FRIGID', 'FRIZ', 'FRO', 'FROM', 'FRONT', 'FRONTIERRESEARCH', 'FRONTIFRES', 'FRONTLINE', 'FRONTOFPACKAGE', 'FRUIT', 'FRUITFUL', 'FRUITODOR', 'FRUITS', 'FRY', 'FS', 'FSMED', 'FSN', 'FSR', 'FSW', 'FSWS', 'FTF', 'FU', 'FUANDA', 'FUEL', 'FUELLED', 'FUELLING', 'FUELS', 'FULFIL', 'FULFILING', 'FULFILL', 'FULFILLED', 'FULFILLING', 'FULFILLMENT', 'FULFILMENT', 'FULFILS', 'FULL', 'FULLER', 'FULLGENOME', 'FULLSCALE', 'FULLY', 'FULLYEQUIPPED', 'FUME', 'FUNCTION', 'FUNCTIONAL', 'FUNCTIONALITY', 'FUNCTIONALIZED', 'FUNCTIONALLY', 'FUNCTIONARY', 'FUNCTIONING', 'FUNCTIONS', 'FUND', 'FUNDABLE', 'FUNDACI', 'FUNDACIN', 'FUNDACION', 'FUNDAMENT', 'FUNDAMENTAL', 'FUNDED', 'FUNDER', 'FUNDERS', 'FUNDFINANCED', 'FUNDING', 'FUNDING1HEAIRISH', 'FUNDING1HEATO', 'FUNDINGTHIS', 'FUNDINGWHAT', 'FUNDRAISING', 'FUNDS', 'FUNDSTIMULATE', 'FUNDSUPPORTED', 'FUNESTUS', 'FUNGAL', 'FUNGI', 'FUNGICIDAL', 'FUNGOUS', 'FUNGUS', 'FURIOUS', 'FURIOUSNESS', 'FURNISH', 'FURNISHED', 'FURNISHING', 'FURNITURE', 'FURROW', 'FURRY', 'FURTHER', 'FURTHERANCE', 'FURTHERING', 'FURTHERMORE', 'FURY', 'FUSION', 'FUSSY', 'FUTHERMORE', 'FUTURE', 'FUTUREIT', 'FY', 'FY13', 'FZ', 'FZD', 'FZLLC', 'G', 'G02', 'G2G', 'G8', 'GA', 'GAAP', 'GABON', 'GABORONE', 'GABU', 'GABUN', 'GAC', 'GACD', 'GACHI', 'GADON', 'GAG', 'GAGE', 'GAH', 'GAIN', 'GAINED', 'GAINING', 'GAINS', 'GALECTINES', 'GALGADUD', 'GALI', 'GALLA', 'GALLANT', 'GALLE', 'GALLOPING', 'GALT', 'GALVANIZE', 'GALVANIZED', 'GALVMED', 'GAM', 'GAMBELLA', 'GAMBIA', 'GAMBIAE', 'GAMBIAIDENTIFICATION', 'GAMBIAN', 'GAMBIENSE', 'GAME', 'GAMETOCYTES', 'GAMETOCYTOCIDAL', 'GAMEY', 'GAMIFICACIN', 'GAMMA', 'GAMPAHA', 'GAMRIF', 'GAMY', 'GANDHI', 'GANJA', 'GANSUPINGLIAND', 'GAO', 'GAP', 'GAPC17', 'GAPP', 'GAPS', 'GAPSEARLY', 'GAPSINNOVATING', 'GAPSTHE', 'GARANTING', 'GARDEN', 'GARDENING', 'GARDENS', 'GARDP', 'GARISSA', 'GARMENT', 'GARNERING', 'GARSILA', 'GAS', 'GASBAG', 'GASOPHARM', 'GASTRIC', 'GASTRITIS', 'GASTRO', 'GASTROENTERITIS', 'GASTROENTEROLOGY', 'GASTROINTESTINAL', 'GAT', 'GATB', 'GATE', 'GATES', 'GATHER', 'GATHERED', 'GATHERING', 'GATING', 'GATS', 'GAUGE', 'GAUTENG', 'GAVI', 'GAVIELIGIBLE', 'GAVIS', 'GAVISUPPORTED', 'GAYMSM', 'GAYS', 'GAZA', 'GAZASTRIP', 'GAZILLION', 'GAZIRA', 'GBG', 'GBIP', 'GBS', 'GBV', 'GBVNUTRITIONAGRICULTURE', 'GC', 'GCC', 'GCCAD', 'GCCS', 'GCLP', 'GCP', 'GCPCOMPLIANT', 'GCRF', 'GDA', 'GDD', 'GEAR', 'GEARED', 'GEARJUMP', 'GEEZERHOOD', 'GEHS', 'GEL', 'GELATIN', 'GEMIGILIPTIN', 'GEMIGLIPTIN', 'GEMS', 'GENDER', 'GENDERBASED', 'GENDERBIASED', 'GENDERED', 'GENDERFOCUSED', 'GENDERRELATED', 'GENDERRESPONSIVE', 'GENDERRESPONSIVENESS', 'GENDERS', 'GENDERSENSITIVE', 'GENDERSPECIFIC', 'GENE', 'GENERAL', 'GENERAL1HEAINFECTIOUS', 'GENERAL1HEAPDP', 'GENERAL1HEASUPPORT', 'GENERAL1HIVADVANCING', 'GENERAL1HIVGENDER', 'GENERAL1HIVPREPAYMENT', 'GENERALACADEMIC', 'GENERALE', 'GENERALEVALUATION', 'GENERALFOOD', 'GENERALHEALTH', 'GENERALIFAKARA', 'GENERALINNOVATION', 'GENERALISED', 'GENERALITY', 'GENERALIZABLE', 'GENERALIZED', 'GENERALLY', 'GENERALS', 'GENERATE', 'GENERATED', 'GENERATEDRESULT', 'GENERATES', 'GENERATING', 'GENERATION', 'GENERATIONAL', 'GENERATIONKENYA', 'GENERATIONMALARIA', 'GENERATIONS', 'GENERATIVE', 'GENERIC', 'GENERICS', 'GENEROUSLY', 'GENES', 'GENESIS', 'GENETIC', 'GENETICAL', 'GENETICALLY', 'GENETICALLYSTABILIZED', 'GENETICS', 'GENEVA', 'GENEXPERT', 'GENFVE', 'GENHIV1HIV', 'GENHIVHIVAIDSHIV', 'GENIAL', 'GENITAL', 'GENOME', 'GENOMES', 'GENOMEWIDE', 'GENOMIC', 'GENOMICS', 'GENOTYPE', 'GENOTYPED', 'GENOTYPES', 'GENOTYPING', 'GENUINE', 'GENUS', 'GENVBG505', 'GEO', 'GEOGRAPHIC', 'GEOGRAPHICAL', 'GEOGRAPHICALLY', 'GEOGRAPHIES', 'GEOHELMINTHS', 'GEOINFORMATION', 'GEOLOGICAL', 'GEOMORPHOLOGICAL', 'GEOPOLITICAL', 'GEOREFERENCED', 'GEORGE', 'GEORGETOWN', 'GEORGIA', 'GEORGIAMOLDOVA', 'GEORGIAOS', 'GEOSPATIAL', 'GEOTHERMAL', 'GERARD', 'GERARDO', 'GERM', 'GERMAN', 'GERMANCHILEAN', 'GERMANCHINESE', 'GERMANINDONESIAN', 'GERMANNAMIBIAN', 'GERMANY', 'GERMANYEUROPE', 'GERMANYMEDICAL', 'GERMINATE', 'GERMLINE', 'GESCI', 'GESTATION', 'GESTATIONAL', 'GESTIN', 'GESTION', 'GET', 'GETHEALTH', 'GETTING', 'GEZIRA', 'GFF', 'GFN', 'GFP', 'GH', 'GH101001COOPERATIVE', 'GH101001NU19', 'GH11001', 'GH111199NU19', 'GH12', 'GH12004', 'GH12004U19GH', 'GH12005', 'GH121201NU2G', 'GH121258NU51', 'GH13', 'GH13001', 'GH13003', 'GH13003U01GH', 'GH13006U01GH', 'GH131305NU2G', 'GH131366NU2G', 'GH14', 'GH14002U01GH', 'GH15', 'GH15002U2GGH', 'GH15003U01GH', 'GH15006U01GH', 'GH151532NU2G', 'GH151607NU2G', 'GH151612NU2G', 'GH151621', 'GH151621NU19', 'GH151622', 'GH151622NU2G', 'GH151627', 'GH151629NU2G', 'GH151632', 'GH151632NU2G', 'GH16', 'GH16006', 'GH16006U01GH', 'GH161602NU2R', 'GH161719', 'GH161719NU2G', 'GH161720NU2G', 'GH161721NU66', 'GHANA', 'GHANAIAN', 'GHANAIANS', 'GHANAIN', 'GHANARESEARCHERS', 'GHANAS', 'GHANATOGOSRK', 'GHAR', 'GHARP', 'GHAT', 'GHATS', 'GHAWA', 'GHAZANFAR', 'GHCPROJECT', 'GHE2', 'GHENT', 'GHFP', 'GHFPII', 'GHI', 'GHIF', 'GHP', 'GHPOD', 'GHPODS', 'GHRI', 'GHRIS', 'GHRISUPPORTED', 'GHS', 'GHSA', 'GHSC', 'GHSCTA', 'GHSI', 'GHSIII', 'GHSIIII', 'GHWA', 'GI', 'GIANG', 'GIANT', 'GIBACHT', 'GIDEON', 'GIE', 'GIFA', 'GIFT', 'GIFTED', 'GIHON', 'GIHS', 'GILD', 'GIMBUKA', 'GIMMICK', 'GINAICO', 'GINECOLOGY', 'GIPA', 'GIQUE', 'GIRL', 'GIRLS', 'GIS', 'GISRS', 'GIST', 'GIVE', 'GIVEN', 'GIVER', 'GIVERS', 'GIVES', 'GIVING', 'GJELDER', 'GLA', 'GLACTAMASES', 'GLASGOW', 'GLASS', 'GLASSES', 'GLAUCIA', 'GLAUCOMA', 'GLAXOSMITHKLINE', 'GLIDE', 'GLIOBLASTOMA', 'GLOBAL', 'GLOBALACCESS', 'GLOBALAGEING', 'GLOBALCHRONIC', 'GLOBALCOMMUNICABLE', 'GLOBALDISABILITIES', 'GLOBALFOOD', 'GLOBALGENDER', 'GLOBALHEALTH', 'GLOBALHEALTHY', 'GLOBALHIV', 'GLOBALHIVAIDS', 'GLOBALHIVAIDSTBMALARIA', 'GLOBALIMPROVED', 'GLOBALINTERGRATED', 'GLOBALIZATION', 'GLOBALKEY', 'GLOBALL', 'GLOBALLEADERSHIP', 'GLOBALLEVEL', 'GLOBALLY', 'GLOBALLYADVANCING', 'GLOBALLYCOMPARABLE', 'GLOBALLYCOMPETITIVE', 'GLOBALLYVALIDATED', 'GLOBALMALARIA', 'GLOBALMANAGEMENT', 'GLOBALMENTAL', 'GLOBALNATIONAL', 'GLOBALNEGLCTED', 'GLOBALNONCOMMUNICABLE', 'GLOBALNUTRITION', 'GLOBALREDUCTION', 'GLOBALREPRODUCTIVE', 'GLOBALSOCIAL', 'GLOBALSTRATEGIC', 'GLOBALTRANSPARENCY', 'GLOBALTUBERCULOSIS', 'GLOBALVACCINE', 'GLOBALVACCINEPREVENTABLE', 'GLOBALVIOLENCE', 'GLOBE', 'GLOBL', 'GLOBOSE', 'GLOBULAR', 'GLOBULIN', 'GLOBVAC', 'GLOOMY', 'GLUCOSE', 'GLUTEN', 'GLYCAEMIC', 'GLYCANS', 'GLYCEROL', 'GLYCOBIOTECHNOLOGY', 'GLYCOLIPID', 'GLYCONANOPARTICLE', 'GLYCOPROTEINS', 'GLYCOPROTEOMICS', 'GLYCOSIDES', 'GMBH', 'GMP', 'GMS', 'GNAWER', 'GNCBP', 'GNEREATION', 'GNHE', 'GNOTOBIOTIC', 'GNP', 'GO', 'GO4BSB', 'GOA', 'GOAL', 'GOALS', 'GOALS1', 'GOALSIN', 'GOALSTHE', 'GOARN', 'GOAT', 'GOATS', 'GOB', 'GOBIERNO', 'GOD', 'GODERICH', 'GODMOTHER', 'GOE', 'GOES', 'GOH', 'GOI', 'GOING', 'GOIS', 'GOL', 'GOLD', 'GOLDEN', 'GOM', 'GOMBE', 'GOMEL', 'GOMS', 'GON', 'GONDAR', 'GONDARCOLLEGE', 'GONDARCONSOLIDATE', 'GOOD', 'GOODGOVERNANCE', 'GOODNESS', 'GOODS', 'GOOGLE', 'GOOK', 'GOR', 'GORDON', 'GORONGOSA', 'GOSA', 'GOSAS', 'GOSPEL', 'GOT', 'GOTAP', 'GOTHENBURG', 'GOTHENBURGAND', 'GOTO', 'GOUNDI', 'GOV', 'GOVERN', 'GOVERNANCE', 'GOVERNANCE12110', 'GOVERNANCECOSTSVALIDATING', 'GOVERNANCERAPID', 'GOVERNATAO', 'GOVERNED', 'GOVERNEMENT', 'GOVERNING', 'GOVERNMENT', 'GOVERNMENTAL', 'GOVERNMENTCIVIL', 'GOVERNMENTLED', 'GOVERNMENTPRIORITIZED', 'GOVERNMENTS', 'GOVERNMENTSUPPORTED', 'GOVERNMENTTOGOVERNMENT', 'GOVERNOR', 'GOVERNORATE', 'GOVERNORATELEVEL', 'GOVERNORATES', 'GOVT', 'GOWLAND', 'GOX', 'GP', 'GPEI', 'GPS', 'GPSGRAM', 'GQUADRUPLEX', 'GR', 'GRABEN', 'GRACIAS', 'GRAD', 'GRADE', 'GRADES', 'GRADIENT', 'GRADIENTFROM', 'GRADING', 'GRADO', 'GRADUAL', 'GRADUALLY', 'GRADUAT', 'GRADUATE', 'GRADUATED', 'GRADUATES', 'GRADUATING', 'GRAM', 'GRAMINIS', 'GRAMMATICAL', 'GRAMNEGATIVE', 'GRAMS', 'GRAND', 'GRANDE', 'GRANDMOTHERS', 'GRANDNESS', 'GRANDPARENTS', 'GRANGER', 'GRANT', 'GRANTED', 'GRANTEE', 'GRANTEES', 'GRANTEESCOLLABORATORS', 'GRANTS', 'GRANULOMA', 'GRANULOMAS', 'GRANULOMATOSIS', 'GRAPHIC', 'GRAPHICAL', 'GRASP', 'GRASS', 'GRASSROOTS', 'GRATIS', 'GRATUITOUS', 'GRAVE', 'GRAVITATIONAL', 'GRAZING', 'GRCE', 'GREA', 'GREASE', 'GREAT', 'GREATER', 'GREATEST', 'GREATLY', 'GREEN', 'GREENHOUSE', 'GREENWICH', 'GRENADA', 'GRENSER', 'GREY', 'GRGCE', 'GRIFFITHSIN', 'GRIM', 'GRINDER', 'GRIPP', 'GRIPPE', 'GRIPPRESULT', 'GRITTY', 'GRN', 'GRO', 'GROCERY', 'GROIN', 'GROOMING', 'GROSS', 'GROSSLY', 'GROUND', 'GROUNDBREAKING', 'GROUNDED', 'GROUNDING', 'GROUNDS', 'GROUNDWATER', 'GROUNDWORK', 'GROUP', 'GROUPBENEFICIARIES', 'GROUPED', 'GROUPING', 'GROUPMEMBERS', 'GROUPS', 'GROUPSFOLLOW', 'GROUS', 'GROW', 'GROWING', 'GROWN', 'GROWNUP', 'GROWS', 'GROWTH', 'GROWTHTHE', 'GROWTHTHIS', 'GRP', 'GRZ', 'GRZS', 'GS', 'GS2', 'GS20', 'GSA', 'GSFNIPN', 'GSK', 'GSKDALARNA', 'GSP', 'GSPS', 'GTEBORG', 'GTR', 'GTTAC', 'GU', 'GUADALUPE', 'GUAMINTERGRATED', 'GUANGDONG', 'GUANGXI', 'GUANGZHOU', 'GUARANI', 'GUARANTEE', 'GUARANTEED', 'GUARANTEES', 'GUARD', 'GUARDIAN', 'GUARDIANSHIP', 'GUATEMALA', 'GUATEMALAN', 'GUATEMALAS', 'GUF', 'GUGMV', 'GUIDANCE', 'GUIDE', 'GUIDED', 'GUIDEDINFECTIONS', 'GUIDELINE', 'GUIDELINES', 'GUIDELINES2', 'GUIDELINESFORECASTING', 'GUIDELINESTOOLS', 'GUIDELINS', 'GUIDEPOST', 'GUIDES', 'GUIDING', 'GUILD', 'GUILLAINBARR', 'GUIN', 'GUINE', 'GUINEA', 'GUINEABISSAU', 'GUINEAN', 'GUINTE', 'GUJARAT', 'GULBENKIAN', 'GULF', 'GULLELE', 'GULU', 'GUNI', 'GUNIS', 'GUNNILLA', 'GUSGS', 'GUT', 'GUTASSOCIATED', 'GUTBRAIN', 'GUTTMACHER', 'GUYANA', 'GUYANESE', 'GUYS', 'GVT', 'GWEMBE', 'GWEP', 'GYAPONG', 'GYNAECOLOGICAL', 'GYNAECOLOGY', 'GYNANDRA', 'GYNECOLOGICAL', 'GYNECOLOGY', 'H', 'H1N1SWINE', 'H2O', 'H5N1', 'H7N9', 'HA', 'HAART', 'HABANA', 'HABIBEH', 'HABIT', 'HABITAT', 'HABITATION', 'HABITATS', 'HABITATSAS', 'HABITS', 'HABITUATE', 'HACIA', 'HACK', 'HADASSAH', 'HADJER', 'HAEMAPHYSALOIDES', 'HAEMATOLOGY', 'HAEMOGLOBIN', 'HAEMOPHILUS', 'HAEMORRHAGIC', 'HAIFA', 'HAIR', 'HAIRDO', 'HAITI', 'HAITIAN', 'HAITIS', 'HAJJ', 'HAJJA', 'HAKEEM', 'HAKHA', 'HALF', 'HALFWAY', 'HALL', 'HALLE', 'HALLEWITTENBERG', 'HALO', 'HALT', 'HALTED', 'HALTING', 'HALVE', 'HALVED', 'HAMBANTOTA', 'HAMILTON', 'HAMLIN', 'HAMPER', 'HAMPERED', 'HAMPERING', 'HAN', 'HAND', 'HANDBILL', 'HANDED', 'HANDGEL', 'HANDHELD', 'HANDICAP', 'HANDICAPPED', 'HANDINESS', 'HANDING', 'HANDLE', 'HANDLING', 'HANDOVE', 'HANDOVER', 'HANDS', 'HANDSON', 'HANDWASHING', 'HANOI', 'HANOIS', 'HANSEN', 'HANSENS', 'HANSHEP', 'HANTAVIRUS', 'HANTI', 'HAPLESS', 'HAPPEN', 'HAPPENS', 'HAPTOGLOBIN', 'HAPTOGLOBINHEMOGLOBIN', 'HAR', 'HARARE', 'HARASSMENT', 'HARBOR', 'HARBORING', 'HARBOURING', 'HARD', 'HARDEN', 'HARDEST', 'HARDHIT', 'HARDSHIP', 'HARDSHIPS', 'HARDTOREACH', 'HARDWARE', 'HARE', 'HARGEISA', 'HARINA', 'HARLEM', 'HARM', 'HARMFUL', 'HARMONISATION', 'HARMONISE', 'HARMONISING', 'HARMONIZATION', 'HARMONIZE', 'HARMONIZED', 'HARMONIZING', 'HARNESS', 'HARNESSING', 'HARSH', 'HARVARD', 'HARVESTED', 'HARVESTING', 'HARVESTPLUS', 'HARVEYI', 'HARYANA', 'HASHI', 'HASSAN', 'HAT', 'HATI', 'HAUTE', 'HAVANA', 'HAVANA4', 'HAVE', 'HAVEBEEN', 'HAVENOTS', 'HAVENOTSGLOBAL', 'HAVES', 'HAVING', 'HAWKERS', 'HAWKEYE', 'HAWTHORN', 'HAYAKAVAN', 'HAYDOM', 'HAZARD', 'HAZARDOUS', 'HAZARDS', 'HBBQIC', 'HBE', 'HBGAS', 'HBV', 'HC', 'HC3', 'HCC', 'HCD', 'HCMII', 'HCP', 'HCSP', 'HCU', 'HCV', 'HCWM', 'HCWS', 'HDI', 'HDL', 'HDSS', 'HE', 'HEA', 'HEAD', 'HEADACHE', 'HEADED', 'HEADING', 'HEADQUARTER', 'HEADQUARTERED', 'HEADQUARTERS', 'HEADS', 'HEADSTONE', 'HEADWAY', 'HEAHEAGENHEALTH', 'HEAHIVHIVAIDSHIV', 'HEAL', 'HEALERS', 'HEALHTY', 'HEALING', 'HEALT', 'HEALTH', 'HEALTH12110', 'HEALTH13020', 'HEALTH2CFEEIRISH', 'HEALTH4', 'HEALTHABOUT', 'HEALTHAGREEMENT', 'HEALTHARCHIVE', 'HEALTHBRIDGE', 'HEALTHCARE', 'HEALTHCHINA', 'HEALTHCOST', 'HEALTHDFID', 'HEALTHDUE', 'HEALTHEVALUATE', 'HEALTHFAMILY', 'HEALTHFEW', 'HEALTHFUNDED', 'HEALTHGHANA', 'HEALTHHIV', 'HEALTHIER', 'HEALTHIMCHA', 'HEALTHIN', 'HEALTHINFORMATICS', 'HEALTHNUTRITION', 'HEALTHONE', 'HEALTHORIENTED', 'HEALTHPARTICIPANTS', 'HEALTHPOINT', 'HEALTHPOLICY', 'HEALTHPROJECT', 'HEALTHPROMOTING', 'HEALTHPROMOTION', 'HEALTHRELATED', 'HEALTHRESEARCH', 'HEALTHRESULT', 'HEALTHS', 'HEALTHSAKSNUMMER', 'HEALTHSECURITY', 'HEALTHSEEKING', 'HEALTHSEXUAL', 'HEALTHSUPPORT', 'HEALTHSUPPORTING', 'HEALTHTECH', 'HEALTHTHE', 'HEALTHTHIS', 'HEALTHTOGETHER', 'HEALTHWORKER', 'HEALTHY', 'HEARD', 'HEARDRESEARCH', 'HEARDS', 'HEARING', 'HEART', 'HEARTFILE', 'HEARTH', 'HEARTSCVDS', 'HEAT', 'HEATH', 'HEATHCARE', 'HEATING', 'HEATLABILE', 'HEATLH', 'HEATSTRESS', 'HEAVIEST', 'HEAVILY', 'HEAVY', 'HEBREW', 'HEBRIDES', 'HEBRON', 'HED', 'HEE', 'HEED', 'HEELED', 'HEFTY', 'HEIDELBERG', 'HEIGHT', 'HEIGHTEN', 'HEILIGENDAMM', 'HEILONGJIANG', 'HEIS', 'HELATH', 'HELD', 'HELEN', 'HELICOBACTER', 'HELMINTH', 'HELMINTHES', 'HELMINTHIC', 'HELMINTHS', 'HELP', 'HELPED', 'HELPER', 'HELPFUL', 'HELPING', 'HELPS', 'HELSEBERGEN', 'HEM', 'HEMAGGLUTININ', 'HEMALYTICS', 'HEMATOLOGIC', 'HEMATOPOIETIC', 'HEMIPARESIS', 'HEMISPHERE', 'HEMOGLOBIN', 'HEMORRHAGE', 'HEMORRHAGI', 'HEMORRHAGIC', 'HENAGGLUTININ', 'HENAN', 'HENCE', 'HENHOUSE', 'HENIPAVIRUSES', 'HENRY', 'HENRYS', 'HEPACIVIRUS', 'HEPARIN', 'HEPATIC', 'HEPATITIS', 'HEPATITIS13040', 'HEPATOCELLULAR', 'HEPB', 'HEPCIDIN', 'HEPTAD', 'HER', 'HER2', 'HERAT', 'HERBAL', 'HERBS', 'HERD', 'HERE', 'HEREDIA', 'HEREDITARY', 'HERITABLITY', 'HERNIA', 'HERNIAS', 'HERORATS', 'HERPES', 'HERVANA', 'HERZEGOVINA', 'HESED', 'HETEROGENEITY', 'HETEROGENEOUS', 'HETEROMERS', 'HETERORECEPTOR', 'HETEROSEXUAL', 'HEXAD', 'HFA', 'HFAABOUT', 'HFGC', 'HFGK', 'HGSKDALARNA', 'HH', 'HHANDO', 'HHF', 'HHRDC', 'HHS', 'HHSCDC', 'HHSOGA', 'HI', 'HIA', 'HIB', 'HIC', 'HICD', 'HIDDEN', 'HIGH', 'HIGHBURDEN', 'HIGHCONTENT', 'HIGHCOST', 'HIGHDENSITY', 'HIGHENDEMIC', 'HIGHENERGY', 'HIGHER', 'HIGHERINCOME', 'HIGHEST', 'HIGHFIBRE', 'HIGHIMPACT', 'HIGHINCIDENCE', 'HIGHINCOME', 'HIGHLAND', 'HIGHLANDS', 'HIGHLEVEL', 'HIGHLIGHT', 'HIGHLIGHTED', 'HIGHLIGHTING', 'HIGHLIGHTS', 'HIGHLY', 'HIGHLYCONSERVED', 'HIGHPOTENTIAL', 'HIGHPREVALENCE', 'HIGHPRIORITY', 'HIGHPROFILE', 'HIGHPROTEIN', 'HIGHQUALITY', 'HIGHRESOLUTION', 'HIGHRISK', 'HIGHSCIENTIFIC', 'HIGHTAIL', 'HIGHTECH', 'HIGHTHROUGHPUT', 'HIGHVALUE', 'HIGHVOLUME', 'HIGHWAYS', 'HIGIENE', 'HIJRAS', 'HIKES', 'HILARY', 'HILL', 'HILLS', 'HIND', 'HINDER', 'HINDERED', 'HINDERING', 'HINT', 'HINTERLAND', 'HINTS', 'HIP', 'HIPA', 'HIRAM', 'HIRE', 'HIRED', 'HIRING', 'HIRJAS', 'HIRP', 'HIS', 'HISHER', 'HISP', 'HISPANIOLA', 'HISTO', 'HISTOBLOOD', 'HISTORICAL', 'HISTORY', 'HIT', 'HITCH', 'HITHER', 'HITS', 'HIV', 'HIV1', 'HIV12250ECTED', 'HIV1HIV2', 'HIV2', 'HIVAFFECTED', 'HIVAID', 'HIVAIDS', 'HIVAIDSAFFECTED', 'HIVAIDSOVERALL', 'HIVAIDSRELATED', 'HIVAIDSSTI', 'HIVAIDSSTITB', 'HIVASSOCIATED', 'HIVC', 'HIVCHLAMYDIA', 'HIVCOMB', 'HIVD', 'HIVDRUGS', 'HIVERA', 'HIVFREE', 'HIVHEALTH', 'HIVHIV', 'HIVHIVHIVAIDSVICECHAIRCHAIRPOINT7GLOBALFUNDAIDSHIVMALARIA2CFEEIRISH', 'HIVINFECTED', 'HIVINFECTION', 'HIVINNOVATIONS', 'HIVLF', 'HIVNEGATIVE', 'HIVPATIENTS', 'HIVPOSITIVE', 'HIVPREVALENCE', 'HIVPROJECT', 'HIVRELATED', 'HIVSRHR', 'HIVSTD', 'HIVSTI', 'HIVTARGET', 'HIVTB', 'HIVTESTES', 'HIVVL', 'HLAD', 'HLATESTING', 'HLGP', 'HLL', 'HLM', 'HMIS', 'HMU', 'HNPSP', 'HO', 'HOA', 'HOAGIE', 'HOAGY', 'HOC', 'HOGA', 'HOI', 'HOKEY', 'HOLD', 'HOLDER', 'HOLDERS', 'HOLDING', 'HOLDINGS', 'HOLDS', 'HOLISTIC', 'HOLISTICALLY', 'HOLLANDS', 'HOLO', 'HOLY', 'HOM', 'HOME', 'HOMEBASED', 'HOMECOMMUNITYBASED', 'HOMELESS', 'HOMEOPATHY', 'HOMEOWNER', 'HOMES', 'HOMESTEAD', 'HOMEVISIST', 'HOMEVISIT', 'HOMEVISITS', 'HOMEWORK', 'HOMINIS', 'HOMO', 'HOMOCYSTEINE', 'HOMOPHOBIA', 'HON', 'HONDURAS', 'HONEST', 'HONEY', 'HONEYBEE', 'HONG', 'HONOR', 'HONORABLE', 'HONORARY', 'HONOUR', 'HOOD', 'HOOKWORM', 'HOOSIER', 'HOPE', 'HOPED', 'HOPES', 'HOPING', 'HOPKINS', 'HORIZON2020', 'HORIZONTAL', 'HORMONAL', 'HORMONE', 'HORMONES', 'HORN', 'HORNOESCUELA', 'HORSE', 'HORTICULTURAL', 'HOSP', 'HOSPIT', 'HOSPITAL', 'HOSPITALACQUIRED', 'HOSPITALBASED', 'HOSPITALCAPACITY', 'HOSPITALES', 'HOSPITALHEREINAFTER', 'HOSPITALIER', 'HOSPITALIZATION', 'HOSPITALIZATIONS', 'HOSPITALIZED', 'HOSPITALS', 'HOSPITALSERVES', 'HOSPITALSSPECIFIC', 'HOSPITALTHE', 'HOSPITATION', 'HOST', 'HOSTCOUNTRY', 'HOSTDIRECTED', 'HOSTED', 'HOSTEL', 'HOSTGENETIC', 'HOSTING', 'HOSTPATHOGEN', 'HOSTPATHOGENENVIRONMENT', 'HOSTS', 'HOT', 'HOTELS', 'HOTLINE', 'HOTMANGARADJA', 'HOTMANS', 'HOTSPOT', 'HOTSPOTS', 'HOTSPOTSQUOT', 'HOTSPRINGS', 'HOUR', 'HOURS', 'HOUSE', 'HOUSED', 'HOUSEH', 'HOUSEHOLD', 'HOUSEHOLDER', 'HOUSEHOLDRANDOMISED', 'HOUSEHOLDS', 'HOUSEHOLDSTHE', 'HOUSES', 'HOUSETOHOUSE', 'HOUSEWIVES', 'HOUSING', 'HOW', 'HOWARD', 'HOWEVER', 'HOWTO', 'HP', 'HPA', 'HPAI', 'HPB', 'HPDP2', 'HPF', 'HPITAUX', 'HPN', 'HPNSDP', 'HPSR', 'HPSS', 'HPV', 'HPVBASED', 'HPVRELATED', 'HQ', 'HR', 'HRCS', 'HRFT', 'HRH', 'HRHR', 'HRP', 'HRPS', 'HRSA', 'HRW', 'HSAS', 'HSDN', 'HSDP', 'HSFR', 'HSFRMAJOR', 'HSI', 'HSMO', 'HSP72', 'HSPH', 'HSPS', 'HSR', 'HSRI', 'HSS', 'HSSP', 'HSSR', 'HSV', 'HT', 'HTA', 'HTAI', 'HTC', 'HTF', 'HTLV', 'HTRA3', 'HTS', 'HTTPABTASSOCIATESCOMIMPACT2013PROJECTSTRENGTHENSLOCALLEADERSHIPINTANZANIAASPXSTHASHFAJWERX2DPUF', 'HTTPS', 'HTTPSDOCSGOOGLECOMFILED0BIUZKYANQSEDVPZLH3WEZTYTGEDITUSPSHARING', 'HTTPSDOCSGOOGLECOMFILED0BIUZKYANQSEXZQVED4TG1EEWMEDIT', 'HTTPSDOCSGOOGLECOMOPENID0BIUZKYANQSBTJ4A2ZKDHZRWKK', 'HTTPSDOCSGOOGLECOMOPENID0BIUZKYANQSLWRBRU93CKCXRFU', 'HTTPSDOCSGOOGLECOMOPENID0BIUZKYANQSR05OQTLETHNZCFK', 'HTTPSDOCSGOOGLECOMOPENID0BIUZKYANQSR2FLCWLOTMXBWNM', 'HTTPSDOCSGOOGLECOMOPENID0BIUZKYANQSWUFNCWLRDDBHY1UHTTPSDOCSGOOGLECOMFILED0BIUZKYANQSV1CTBNIYAJFREFKEDIT', 'HTTPSDRIVEGOOGLECOMFILED0BIUZKYANQSY0ZBZU5TZTJ2CTGEDITUSPSHARING', 'HTTPSDRIVEGOOGLECOMFILED0BIUZKYANQSZZLVNVNMM0RMY1EEDITUSPSHARING', 'HTTPSWWWUPCEDUCCDCAACCIONSALSUDPROJECTES2017U009', 'HTTPWWWBROADREACHHEALTHCARECOMGHNEWSPRESSRELEASESTHASH5BOJ1JB4DPUF', 'HU', 'HUAMBO', 'HUAYI', 'HUB', 'HUBS', 'HUE', 'HUF', 'HUGE', 'HUMABS', 'HUMAN', 'HUMANANIMAL', 'HUMANANIMALENVIRONMENT', 'HUMANBITING', 'HUMANCENTERED', 'HUMANE', 'HUMANHEALTH', 'HUMANINDUCED', 'HUMANINFECTIVE', 'HUMANIST', 'HUMANISTIC', 'HUMANITARIAN', 'HUMANITIES', 'HUMANITY', 'HUMANKIND', 'HUMANMADE', 'HUMANOS', 'HUMANRELEVANT', 'HUMANS', 'HUMBLE', 'HUMBOLDT', 'HUMIDITY', 'HUMILIATED', 'HUMINS', 'HUMORAL', 'HUNDRED', 'HUNDREDS', 'HUNG', 'HUNGARYACCESS', 'HUNGARYHEALTH', 'HUNGARYINTERGRATED', 'HUNGARYLEADERSHIP', 'HUNGARYNONCOMMUNICABLE', 'HUNGARYSTRATEGIC', 'HUNGARYTUBERCULOSIS', 'HUNGARYVIOLENCE', 'HUNGER', 'HUNGERACIVIL', 'HUNGERHIVHIVAIDSRESEARCH1HIVHEA', 'HUNGERHUNGERHUNGER', 'HUNGRINESS', 'HUNGRY', 'HUNTERS', 'HUNTING', 'HUNTINGTONS', 'HURDLE', 'HURRICANE', 'HURT', 'HUSBAND', 'HUSBANDMAN', 'HUSBANDRY', 'HUSBANDS', 'HUSKS', 'HUSSEIN', 'HUTCHINSON', 'HV', 'HVC', 'HVTN', 'HYBRID', 'HYBRIDISATION', 'HYBRIDIZATION', 'HYDERABAD', 'HYDRATED', 'HYDROGELS', 'HYDROGEN', 'HYDROGEOLOGICAL', 'HYDROLYSED', 'HYDROPHILIC', 'HYDROPHOBIA', 'HYDROPOWER', 'HYGIENE', 'HYGIENIA', 'HYGIENIC', 'HYGIENICALLY', 'HYGIENICS', 'HYGIENIE', 'HYGIENY', 'HYLF', 'HYPER', 'HYPERENDEMIC', 'HYPERGLYCEMIA', 'HYPERTENSION', 'HYPERTENSIVE', 'HYPERVARIABILITY', 'HYPNOZOITE', 'HYPO', 'HYPOENDEMIC', 'HYPOGLYCAEMIA', 'HYPOGLYCEMIA', 'HYPOPIGMENTATION', 'HYPORESPONSIVENESS', 'HYPOTHERMIA', 'HYPOTHERMIC', 'HYPOTHESES', 'HYPOTHESIS', 'HYPOTHESISE', 'HYPOTHESISED', 'HYPOTHESIZE', 'HYPOTHESIZES', 'HYPOXIA', 'HYPOXIC', 'I', 'IA', 'IAA', 'IAC', 'IAEA', 'IAF', 'IAGNOSIS', 'IAND', 'IAP', 'IAQ', 'IARC', 'IAS', 'IASHVILI', 'IAVI', 'IAVIINTERNATIONAL', 'IAVIS', 'IBADAN', 'IBBS', 'IBFAN', 'IBOM', 'IBTCI', 'IC', 'ICA', 'ICASS', 'ICB', 'ICCM', 'ICDDR', 'ICDDRB', 'ICDDRBS', 'ICELAND', 'ICFS', 'ICIDANT', 'ICIPE', 'ICLINICSYS', 'ICMRMRC', 'ICPARTNERS', 'ICPD', 'ICPMS', 'ICPVR', 'ICT', 'ICTERIC', 'ICTERUS', 'ICTM', 'ICTRESOURCES', 'ICTS', 'ICTSUPPORTED', 'ICU', 'ID', 'IDBSUPPORTED', 'IDD', 'IDEA', 'IDEAL', 'IDEALLY', 'IDEAS', 'IDEAS42', 'IDEATION', 'IDEC', 'IDEEAL', 'IDENTICAL', 'IDENTIFIABLE', 'IDENTIFICACION', 'IDENTIFICATION', 'IDENTIFIED', 'IDENTIFIER', 'IDENTIFIES', 'IDENTIFY', 'IDENTIFYING', 'IDENTITY', 'IDF', 'IDI', 'IDIA', 'IDIQ', 'IDPS', 'IDPSRETURNEES', 'IDRC', 'IDRCFANRPAN', 'IDRCFUNDED', 'IDRCS', 'IDRCSPONSORED', 'IDRCSUPPORTED', 'IDRI', 'IDRIS', 'IDS', 'IDSR', 'IDU', 'IDURELATED', 'IDUS', 'IE', 'IEC', 'IECINFORMATION', 'IED', 'IF', 'IFA', 'IFAKARA', 'IFC', 'IFFIM', 'IFG', 'IFN', 'IFNA', 'IFNG', 'IFPRI', 'IFRC', 'IFTIM3', 'IGA', 'IGAD', 'IGANGA', 'IGF', 'IGF1', 'IGFSYSTEM', 'IGG', 'IGNORANCE', 'IGNORANT', 'IGNORE', 'IGNORED', 'IGNORING', 'IGNOU', 'IGT', 'IHEA', 'IHI', 'IHOSY', 'IHP', 'IHR', 'IHR2005', 'IHV', 'IHVNIGERIA', 'II', 'IIB', 'IIDEFINITION', 'IIFONDS', 'III', 'IIIGLOBAL', 'IIIIII', 'IIS', 'IISUPPORTED', 'IKON', 'IKP', 'IL', 'IL17', 'IL17A', 'IL1G', 'IL23', 'IL23IL17TH17', 'ILL', 'ILLEGAL', 'ILLENESS', 'ILLEQUIPPED', 'ILLHEALTH', 'ILLICIT', 'ILLINOIS', 'ILLITERACY', 'ILLNESS', 'ILLNESSDEATH', 'ILLNESSES', 'ILLNESSESAAROGYASRI', 'ILLNESSQUANTIFY', 'ILLUMINATING', 'ILLUSTRATION', 'ILLUSTRATIVE', 'ILO', 'ILOASSESSED', 'ILOS', 'ILRI', 'IM', 'IMAD', 'IMAGE', 'IMAGEBASED', 'IMAGES', 'IMAGINATION', 'IMAGING', 'IMAI', 'IMAMS', 'IMBALANCE', 'IMC', 'IMCHA', 'IMCI', 'IMF', 'IMFORMATION', 'IMMACULATE', 'IMMATURE', 'IMMEDIATE', 'IMMEDIATELY', 'IMMENSE', 'IMMENSELY', 'IMMERSE', 'IMMERSED', 'IMMIGRANT', 'IMMIGRANTS', 'IMMIGRATION', 'IMMINENT', 'IMMORTALISE', 'IMMUNE', 'IMMUNEMEDIATED', 'IMMUNISATION', 'IMMUNISED', 'IMMUNITY', 'IMMUNIZATION', 'IMMUNIZATIONDAYS', 'IMMUNIZATIONS', 'IMMUNIZE', 'IMMUNIZING', 'IMMUNOASSAY', 'IMMUNOASSAYS', 'IMMUNOBIOLOGY', 'IMMUNOBRIDGING', 'IMMUNOCOMPROMISED', 'IMMUNODEFICIENCY', 'IMMUNODIAGNOSIS', 'IMMUNOENZYMATIC', 'IMMUNOGEN', 'IMMUNOGENIC', 'IMMUNOGENICITY', 'IMMUNOGENS', 'IMMUNOHISTOCHEMISTRY', 'IMMUNOLOGIC', 'IMMUNOLOGICAL', 'IMMUNOLOGICALLY', 'IMMUNOLOGY', 'IMMUNOMODULATION', 'IMMUNOPATHOLOGY', 'IMMUNOPROTEOMIC', 'IMMUNOSTIMULATORY', 'IMMUNOSUPPRESSIVE', 'IMMUNOTHERAPEUTIC', 'IMMUNOTHERAPIES', 'IMMUNOTHERAPY', 'IMO', 'IMP', 'IMPAC', 'IMPACT', 'IMPACTAT', 'IMPACTED', 'IMPACTESTIMATE', 'IMPACTFUL', 'IMPACTING', 'IMPACTS', 'IMPAIRED', 'IMPAIRMENT', 'IMPAIRMENTS', 'IMPART', 'IMPARTED', 'IMPARTIAL', 'IMPARTIALITY', 'IMPEDANCE', 'IMPEDE', 'IMPEDIMENT', 'IMPEDIMENTS', 'IMPEDING', 'IMPERIAL', 'IMPETUS', 'IMPINGE', 'IMPINGEMENT', 'IMPLANT', 'IMPLANTACIN', 'IMPLANTATION', 'IMPLANTS', 'IMPLEM', 'IMPLEMEN', 'IMPLEMENT', 'IMPLEMENTABLE', 'IMPLEMENTAION', 'IMPLEMENTAR', 'IMPLEMENTATING', 'IMPLEMENTATION', 'IMPLEMENTATIONHIV', 'IMPLEMENTATIONNEEDS', 'IMPLEMENTATIONTHE', 'IMPLEMENTED', 'IMPLEMENTEDBY', 'IMPLEMENTEDRESULT', 'IMPLEMENTER', 'IMPLEMENTERS', 'IMPLEMENTING', 'IMPLEMENTION', 'IMPLEMENTS', 'IMPLEMTATION', 'IMPLICATED', 'IMPLICATION', 'IMPLICATIONS', 'IMPLICATIONSDEMONSTRATE', 'IMPLICATIONSRESULT', 'IMPLICATIONSUNDERSTANDING', 'IMPLIES', 'IMPLMENTAITON', 'IMPLY', 'IMPORT', 'IMPORTANCE', 'IMPORTANT', 'IMPORTANTLY', 'IMPORTATION', 'IMPORTED', 'IMPORTS', 'IMPOSING', 'IMPOSSIBILITY', 'IMPOSSIBLE', 'IMPOVERISHED', 'IMPOVERISHING', 'IMPOVERISHMENT', 'IMPRECISE', 'IMPREGRATED', 'IMPRESS', 'IMPRESSION', 'IMPREST', 'IMPRISONMENT', 'IMPRO', 'IMPROTANT', 'IMPROVE', 'IMPROVED', 'IMPROVEDBETWEEN', 'IMPROVEDRESULT', 'IMPROVEDTDRC', 'IMPROVEMENT', 'IMPROVEMENTMAIN', 'IMPROVEMENTS', 'IMPROVEMENTS2', 'IMPROVES', 'IMPROVIN', 'IMPROVING', 'IMPT', 'IMPULSE', 'IMPUTABLE', 'IMPUTED', 'IMRS', 'IMSS', 'IMT', 'IMTAVH', 'IMTAVHITMCOLLABORATIVE', 'IMTIMTAVH', 'IMTINHEMIPK', 'IMTTDRC', 'IMTUMSS', 'IN', 'INA', 'INABILITY', 'INACCESSIBLE', 'INACTION', 'INACTIVATE', 'INACTIVATED', 'INACTIVATION', 'INACTIVE', 'INACTIVENESS', 'INACTIVITY', 'INADDITION', 'INADEQUACY', 'INADEQUATE', 'INADVERTENT', 'INAPPROPRIATE', 'INAUGURAL', 'INBUILT', 'INC', 'INCAP', 'INCARCERATED', 'INCARCERATION', 'INCASE', 'INCENTIVE', 'INCENTIVES', 'INCENTIVESTHE', 'INCENTIVIZE', 'INCENTIVIZES', 'INCENTIVIZING', 'INCEPTION', 'INCH', 'INCIDENCE', 'INCIDENCETHE', 'INCIDENTALS', 'INCIDENTS', 'INCINERATOR', 'INCISIVE', 'INCITE', 'INCL', 'INCLEN', 'INCLUDE', 'INCLUDEA', 'INCLUDEADDRESS', 'INCLUDEASSESS', 'INCLUDECONDUCT', 'INCLUDED', 'INCLUDEMILLENNIUM', 'INCLUDEPROJECT', 'INCLUDES', 'INCLUDESA', 'INCLUDESAFRICA', 'INCLUDESERVICE', 'INCLUDETHE', 'INCLUDETO', 'INCLUDEWORKFORCE', 'INCLUDING', 'INCLUDINGCONDUCTING', 'INCLUIDAS', 'INCLUSION', 'INCLUSIVA', 'INCLUSIVE', 'INCLUSIVENESS', 'INCOME', 'INCOMEDISTRIBUTION', 'INCOMEGENERATING', 'INCOMES', 'INCOMETHE', 'INCOMPATIBLE', 'INCOMPLETE', 'INCONTROVERTIBLE', 'INCORPORATE', 'INCORPORATED', 'INCORPORATES', 'INCORPORATING', 'INCORPORATION', 'INCORRECTLY', 'INCOUNTRY', 'INCR', 'INCRD', 'INCREASE', 'INCREASED', 'INCREASES', 'INCREASESTHE', 'INCREASING', 'INCREASINGLY', 'INCREASINGTHE', 'INCREMENT', 'INCUBATE', 'INCUBATING', 'INCUBATION', 'INCUBATOR', 'INCULTURATED', 'INCUMBRANCE', 'IND', 'INDEBTEDNESS', 'INDEED', 'INDEFINITE', 'INDEPENDENCE', 'INDEPENDENT', 'INDEPENDENTLY', 'INDEPTH', 'INDEVELOP', 'INDEX', 'INDIA', 'INDIACANADA', 'INDIAEU', 'INDIAN', 'INDIANA', 'INDIAPROJECT', 'INDIAS', 'INDIATHIS', 'INDICA', 'INDICANT', 'INDICATE', 'INDICATED', 'INDICATES', 'INDICATING', 'INDICATION', 'INDICATIONS', 'INDICATIVA', 'INDICATIVE', 'INDICATIVES', 'INDICATOR', 'INDICATORS', 'INDICATORSEXAMPLES', 'INDICATORSTHE', 'INDICENCE', 'INDIES', 'INDIGENCE', 'INDIGENOUS', 'INDIRA', 'INDIRECT', 'INDIRECTLY', 'INDISCRIMINATE', 'INDISPENSABLE', 'INDIUM', 'INDIV', 'INDIVIDUAL', 'INDIVIDUALIZED', 'INDIVIDUALLY', 'INDIVIDUALS', 'INDO', 'INDOAUSTRALIAN', 'INDONESIA', 'INDONESIAN', 'INDONESIANS', 'INDONESIAS', 'INDOOR', 'INDOORS', 'INDOPACIFIC', 'INDORSE', 'INDORSEMENT', 'INDS', 'INDUCE', 'INDUCED', 'INDUCERS', 'INDUCES', 'INDUCING', 'INDUCT', 'INDUCTION', 'INDUCTIVE', 'INDUSTRIAL', 'INDUSTRIALIZATION', 'INDUSTRIALIZED', 'INDUSTRIALL', 'INDUSTRIES', 'INDUSTRIOUSNESS', 'INDUSTRY', 'INDUSTRYRELATED', 'INDUSTRYS', 'INEBRIANT', 'INEFFECTIVE', 'INEFFECTUAL', 'INEFFICIENCIES', 'INEFFICIENT', 'INEQUALITIES', 'INEQUALITIESSHARING', 'INEQUALITIESTHROUGH', 'INEQUALITY', 'INEQUITABLE', 'INEQUITABLY', 'INEQUITIES', 'INEQUITIESTHE', 'INEQUITY', 'INERTIA', 'INEXPENSIVE', 'INEXTRICABLY', 'INF', 'INFANCY', 'INFANT', 'INFANTILE', 'INFANTS', 'INFARCTION', 'INFECT', 'INFECTCONTROL', 'INFECTED', 'INFECTI', 'INFECTIIOUS', 'INFECTING', 'INFECTION', 'INFECTION5', 'INFECTIONINFLAMMATION', 'INFECTIONOUS', 'INFECTIONS', 'INFECTIOS', 'INFECTIOU', 'INFECTIOUS', 'INFECTIVE', 'INFECTIVES', 'INFECTS', 'INFER', 'INFERIOR', 'INFEST', 'INFESTATION', 'INFIBULATION', 'INFIRMARY', 'INFLAMMASOME', 'INFLAMMATION', 'INFLAMMATORY', 'INFLATION', 'INFLUENCE', 'INFLUENCED', 'INFLUENCERS', 'INFLUENCES', 'INFLUENCING', 'INFLUENTAL', 'INFLUENTIAL', 'INFLUENZA', 'INFLUENZALIKE', 'INFLUX', 'INFO', 'INFOCARDS', 'INFODISS', 'INFONOMICS', 'INFORAMTION', 'INFORM', 'INFORMAL', 'INFORMALITY', 'INFORMANT', 'INFORMANTS', 'INFORMANTSSURVEY', 'INFORMAS', 'INFORMASIA', 'INFORMATICS', 'INFORMATION', 'INFORMATIONEVALUATION', 'INFORMATIONGATHERING', 'INFORMATIONREDUCTIONERADICATION', 'INFORMATIONSHARING', 'INFORMATIONTECHNOLOGY', 'INFORMATIONTHE', 'INFORMATON', 'INFORMED', 'INFORMEDON', 'INFORMING', 'INFORMS', 'INFRA', 'INFRARED', 'INFRASTRUCTURAL', 'INFRASTRUCTURE', 'INFRASTRUCTURES', 'INFREQUENTLY', 'ING', 'INGESTED', 'INGESTION', 'INGO', 'INGRAINED', 'INGREDIENT', 'INGREDIENTS', 'INGUINAL', 'INH', 'INHABITANTS', 'INHABITANTSDAY', 'INHABITING', 'INHACA', 'INHAMBANE', 'INHEM', 'INHEMIPK', 'INHERENT', 'INHERIT', 'INHERITED', 'INHIBIT', 'INHIBITED', 'INHIBITING', 'INHIBITION', 'INHIBITOR', 'INHIBITORS', 'INHIBITORY', 'INHIBITS', 'INHUMAN', 'INI', 'INICIAL', 'INITATIVE', 'INITIAIVE', 'INITIAL', 'INITIALLY', 'INITIATE', 'INITIATED', 'INITIATING', 'INITIATION', 'INITIATIVA', 'INITIATIVE', 'INITIATIVEDOCUMENTARY', 'INITIATIVEFUNDED', 'INITIATIVES', 'INITIATIVESHEALTH', 'INITIATIVETHE', 'INITIATORY', 'INITIO', 'INITITATED', 'INJECT', 'INJECTABLE', 'INJECTABLES', 'INJECTING', 'INJECTION', 'INJURIES', 'INJURIES12110', 'INJURY', 'INK', 'INKED', 'INKIND', 'INLINE', 'INLOW', 'INLOWRESOURCE', 'INMATES', 'INMUNIZANDO', 'INN', 'INNATE', 'INNDELT', 'INNER', 'INNERVATION', 'INNOCENT', 'INNOVA', 'INNOVADORES', 'INNOVATING', 'INNOVATION', 'INNOVATIONAL', 'INNOVATIONS', 'INNOVATIONSTHE', 'INNOVATIONTHE', 'INNOVATIONXCHANGE', 'INNOVATIVE', 'INNOVATIVELY', 'INNOVATORS', 'INNVOATION', 'INOCULATED', 'INOCULATION', 'INONE', 'INORGANIC', 'INPARTICULAR', 'INPATIENT', 'INPODOCONIOSIS', 'INPUT', 'INPUTS', 'INPUTSTO', 'INQUIRE', 'INQUIRY', 'INRB', 'INRBSPONSORED', 'INROADS', 'INS', 'INSALUBRIOUS', 'INSANE', 'INSECT', 'INSECTARIUM', 'INSECTDERIVED', 'INSECTICI', 'INSECTICIDAL', 'INSECTICIDE', 'INSECTICIDEBASED', 'INSECTICIDES', 'INSECTICIDETREATED', 'INSECTS', 'INSECTTRANSMITTED', 'INSECURE', 'INSECURITY', 'INSECURITYTHE', 'INSEMINATION', 'INSERT', 'INSERTION', 'INSERVICE', 'INSFIOCRUS', 'INSIDE', 'INSIDERS', 'INSIGHT', 'INSIGHTFULNESS', 'INSIGHTS', 'INSITUTE', 'INSP', 'INSPAI', 'INSPECT', 'INSPECTION', 'INSPECTIONS', 'INSPECTOR', 'INSPIRE', 'INSPIRED', 'INST', 'INSTABILITY', 'INSTALATION', 'INSTALL', 'INSTALLATION', 'INSTALLED', 'INSTALLEDB', 'INSTALLING', 'INSTALLMENT', 'INSTALLMENTS', 'INSTANCE', 'INSTANCES', 'INSTANT', 'INSTAURATION', 'INSTEAD', 'INSTIGATING', 'INSTITU', 'INSTITUE', 'INSTITUT', 'INSTITUTE', 'INSTITUTE1HEAIMPACT', 'INSTITUTES', 'INSTITUTET', 'INSTITUTETTHE', 'INSTITUTI', 'INSTITUTION', 'INSTITUTIONAL', 'INSTITUTIONALISATION', 'INSTITUTIONALIZATION', 'INSTITUTIONALIZE', 'INSTITUTIONALIZED', 'INSTITUTIONALIZES', 'INSTITUTIONALIZING', 'INSTITUTIONALLY', 'INSTITUTIONBUILDING', 'INSTITUTIONNEL', 'INSTITUTIONNELLE', 'INSTITUTIONNELLES', 'INSTITUTIONRESULT', 'INSTITUTIONS', 'INSTITUTIONSBASED', 'INSTITUTIONSTHIS', 'INSTITUTIONWIDE', 'INSTITUTO', 'INSTO', 'INSTRUCTION', 'INSTRUCTIONAL', 'INSTRUCTOR', 'INSTRUCTORS', 'INSTRUMENT', 'INSTRUMENTAL', 'INSTRUMENTATION', 'INSTRUMENTS', 'INSTUTUTIONAL', 'INSUFFICIENCIES', 'INSUFFICIENT', 'INSULAR', 'INSULIN', 'INSULINLIKE', 'INSULT', 'INSURANCE', 'INSURE', 'INT', 'INTAKE', 'INTAKES', 'INTALLATION', 'INTEGATED', 'INTEGRACIN', 'INTEGRAION', 'INTEGRAL', 'INTEGRATE', 'INTEGRATED', 'INTEGRATEDA', 'INTEGRATES', 'INTEGRATING', 'INTEGRATION', 'INTEGRATIVE', 'INTEGRETAD', 'INTEGRITY', 'INTEL', 'INTELLECT', 'INTELLECTION', 'INTELLECTUAL', 'INTELLECTUALLY', 'INTELLIGENCE', 'INTELLIGENT', 'INTENATIONAL', 'INTEND', 'INTENDED', 'INTENDS', 'INTENSE', 'INTENSIFICATION', 'INTENSIFIED', 'INTENSIFY', 'INTENSIFYING', 'INTENSITIES', 'INTENSITY', 'INTENSIVE', 'INTENSIVELY', 'INTENT', 'INTENTION', 'INTENTIONAL', 'INTENTIONS', 'INTER', 'INTERACT', 'INTERACTION', 'INTERACTIONDELINEATE', 'INTERACTIONS', 'INTERACTIVE', 'INTERACTIVES', 'INTERAGENCY', 'INTERAHAMWE', 'INTERAMERICAN', 'INTERAMERICANA', 'INTERBREED', 'INTERBREEDING', 'INTERCEPT', 'INTERCESSION', 'INTERCHANGE', 'INTERCOMMUNICATE', 'INTERCONNECTED', 'INTERCOUNTRY', 'INTERCOURSE', 'INTERCULTURAL', 'INTERDISCIPLINARY', 'INTERDISCPLINARY', 'INTERDISEASE', 'INTERDTPARTEMENTALE', 'INTEREST', 'INTERESTED', 'INTERESTS', 'INTERFACE', 'INTERFACES', 'INTERFERENCE', 'INTERGENERATIONAL', 'INTERGOVERNMENTAL', 'INTERGRATED', 'INTERGROWTH21ST', 'INTERIM', 'INTERIOR', 'INTERLINKED', 'INTERLOCKING', 'INTERMEDIATE', 'INTERMITTENT', 'INTERN', 'INTERNACIONAL', 'INTERNAL', 'INTERNALLY', 'INTERNATIO', 'INTERNATION', 'INTERNATIONAL', 'INTERNATIONALE', 'INTERNATIONALLY', 'INTERNATIONALPARTNERS', 'INTERNATIONALPOLICY', 'INTERNATIONALS', 'INTERNET', 'INTERNETBASED', 'INTERNETRESULT', 'INTERNS', 'INTERNSHIPS', 'INTEROPERABILITY', 'INTEROPERATE', 'INTERPERSONAL', 'INTERPLAY', 'INTERPOSITION', 'INTERPRETABILITY', 'INTERPRETATION', 'INTERPRETER', 'INTERPRETING', 'INTERREGIONAL', 'INTERRELATE', 'INTERRELATED', 'INTERRELATIONS', 'INTERROGATE', 'INTERRUPT', 'INTERRUPTED', 'INTERRUPTING', 'INTERRUPTION', 'INTERSECTION', 'INTERSECTIONS', 'INTERSECTOR', 'INTERSECTORAL', 'INTERSEX', 'INTERTABLISSEMENTS', 'INTERTTABLISSEMENTS', 'INTERTXT2HEART', 'INTERUNIVERSITAIRE', 'INTERUNIVERSITY', 'INTERV', 'INTERVENCI', 'INTERVENCIN', 'INTERVENE', 'INTERVENING', 'INTERVENT', 'INTERVENTION', 'INTERVENTIONAL', 'INTERVENTIONS', 'INTERVENTIONSANC', 'INTERVENTIONSBETTER', 'INTERVENTIONSGENERATE', 'INTERVENTIONSIN', 'INTERVENTIONSPOLICIES', 'INTERVENTIONSPROGRAMS', 'INTERVENTIONSTHE', 'INTERVENTIONTS', 'INTERVENTIOSN', 'INTERVIEW', 'INTERVIEWING', 'INTERVIEWS', 'INTERWOVEN', 'INTESTINAL', 'INTESTINE', 'INTEVENTIONS', 'INTGR', 'INTGRATION', 'INTHE', 'INTIBUC', 'INTIIATIVES', 'INTIMACY', 'INTIMATE', 'INTIMATELY', 'INTL', 'INTO', 'INTOXICANT', 'INTRA', 'INTRAACP', 'INTRACELLULAR', 'INTRACTABLE', 'INTRAHEALTH', 'INTRAHOUSEHOLD', 'INTRAMURAL', 'INTRAMUSCULAR', 'INTRAMUSCULARLY', 'INTRANASAL', 'INTRATUMORAL', 'INTRAUTERINE', 'INTRAVENOUS', 'INTREGRATION', 'INTRICATE', 'INTRINSIC', 'INTRMURAL', 'INTRO', 'INTRODUCE', 'INTRODUCED', 'INTRODUCING', 'INTRODUCTION', 'INTRODUCTIONS', 'INTRODUCTORY', 'INTTGRATION', 'INTTGRT', 'INUKA', 'INV', 'INVAC', 'INVACTV3', 'INVADE', 'INVARIABLY', 'INVASION', 'INVASIVE', 'INVENTED', 'INVENTION', 'INVERTEBRATES', 'INVEST', 'INVESTED', 'INVESTIGACI', 'INVESTIGACIN', 'INVESTIGATE', 'INVESTIGATED', 'INVESTIGATES', 'INVESTIGATING', 'INVESTIGATION', 'INVESTIGATIONAL', 'INVESTIGATIONS', 'INVESTIGATIVE', 'INVESTIGATOR', 'INVESTIGATORINITIATED', 'INVESTIGATORS', 'INVESTIGATPO', 'INVESTING', 'INVESTITURE', 'INVESTMEN', 'INVESTMENT', 'INVESTMENTS', 'INVESTORS', 'INVETERATE', 'INVIOLABLE', 'INVITAITONAL', 'INVITE', 'INVITED', 'INVITES', 'INVITING', 'INVITRO', 'INVOICE', 'INVOICES', 'INVOKE', 'INVOLUTION', 'INVOLVE', 'INVOLVED', 'INVOLVEMENT', 'INVOLVES', 'INVOLVING', 'INWARDNESS', 'IODIN', 'IODINE', 'IODIZED', 'IOM', 'ION', 'IONAL', 'IONE', 'IONIZING', 'IONOSELECTIVE', 'IOWA', 'IOWAY', 'IP', 'IP13', 'IP131306NU51', 'IP16', 'IP16003U01IP', 'IP161607', 'IPA', 'IPAS', 'IPASS', 'IPC', 'IPH', 'IPK', 'IPM', 'IPMADVANCING', 'IPMS', 'IPN', 'IPO', 'IPPF', 'IPPFS', 'IPPFTHE', 'IPS', 'IPT', 'IPTP', 'IPU', 'IPV', 'IQC', 'IQSCI', 'IR', 'IR13TNRESEARCH', 'IR15', 'IR15DEL', 'IR17', 'IR17BIH', 'IR17UP', 'IR2', 'IR22POLIO', 'IR52ORIADDRESSING', 'IR61', 'IR92POLIO', 'IRAN', 'IRAQ', 'IRAQI', 'IRC', 'IRCCS', 'IRELAND', 'IRELANDS', 'IRIF', 'IRINGA', 'IRIS', 'IRISH', 'IRON', 'IRONFOLATE', 'IRONFORTIFIED', 'IRONIC', 'IRONICALLY', 'IRRATIONAL', 'IRREGULAR', 'IRRIGATION', 'IRRITATION', 'IRRUPTION', 'IRS', 'IRTS', 'IRTSTHE', 'IS', 'IS1', 'IS50', 'ISABEL', 'ISCA', 'ISCHEMIC', 'ISCOS', 'ISIDRO', 'ISINGLASS', 'ISIOLO', 'ISLAMABAD', 'ISLAMIC', 'ISLAND', 'ISLANDMENTAL', 'ISLANDNATIONAL', 'ISLANDNONCOMMUNICABLE', 'ISLANDREPRODUCTIVE', 'ISLANDS', 'ISLANDSAUSTRALIA', 'ISLANDSNONCOMMUNICABLE', 'ISLANDSREPRODUCTIVE', 'ISLANDVIOLENCE', 'ISOIEC', 'ISOLATE', 'ISOLATED', 'ISOLATES', 'ISOLATING', 'ISOLATION', 'ISOLATIONTREATMENT', 'ISP', 'ISP20112015', 'ISRAEL', 'ISRAELI', 'ISRHML', 'ISSP', 'ISSTDR', 'ISSUE', 'ISSUEBETTER', 'ISSUED', 'ISSUES', 'ISSUESDEMONSTRATE', 'ISSUESIT', 'ISSUESTHIS', 'ISSUK', 'ISSUKKUL', 'ISTANBUL', 'ISU', 'IT', 'ITALIAN', 'ITBASED', 'ITCH', 'ITDHST', 'ITEMS', 'ITEMSA', 'ITERATION', 'ITERATIVELY', 'ITINERARY', 'ITM', 'ITM2011', 'ITNS', 'ITPROGRAMMING', 'ITRACONAZOLE', 'ITS', 'ITSELFTHE', 'ITSO', 'ITTAI', 'IUATLD', 'IUC', 'IUD', 'IUGR', 'IUZKYAN', 'IV', 'IVAN', 'IVCC', 'IVERMECTIN', 'IVI', 'IVIL', 'IVIS', 'IVO', 'IVOIRE', 'IVORY', 'IVVN', 'IWG', 'IWHC', 'IX', 'IYCF', 'IZ', 'IZMIR', 'IZOBRAPEVANJA', 'IZOBRAPEVANJE', 'IZWPROJEKT', 'J', 'JA', 'JACARANDA', 'JACK', 'JACKSON', 'JAFFNA', 'JAFFNACREATE', 'JAKARTA', 'JALAL', 'JALALABAD', 'JAMAICA', 'JAMAICAS', 'JAMES', 'JAMM', 'JAN', 'JANEIRO', 'JANET', 'JANFEB', 'JANITORIAL', 'JANJUNE', 'JANSSEN', 'JANTRA', 'JANUARY', 'JAPAN', 'JAPANESE', 'JAPE', 'JASPER', 'JATN', 'JAUNDICED', 'JAVA', 'JAVIER', 'JAWZJAN', 'JE', 'JEAN', 'JEBEL', 'JEEX', 'JEFFERSON', 'JELL', 'JEMIMAH', 'JENA', 'JEOPARDIZE', 'JEOPARDY', 'JERUSALEM', 'JFA', 'JFR', 'JGHT', 'JH', 'JHARKHAND', 'JHPIEGO', 'JHSR', 'JHUCCP', 'JIBE', 'JIBS', 'JIGAWA', 'JIJINI', 'JILLION', 'JIMMY', 'JINGLES', 'JJVS', 'JOB', 'JOBHEAT', 'JOBS', 'JOBSDELIVER', 'JOE', 'JOHANNESBURG', 'JOHN', 'JOHNS', 'JOIE', 'JOIN', 'JOINED', 'JOINS', 'JOINT', 'JOINTLY', 'JOINTS', 'JOINTURE', 'JOMO', 'JORDAN', 'JORDANIANS', 'JOSE', 'JOSEPH', 'JOSKA', 'JOURNAL', 'JOURNALAS', 'JOURNALISM', 'JOURNALISTS', 'JOURNALS', 'JOURNALSINNOVATING', 'JOURNEYS', 'JOVEN', 'JOWZJAN', 'JPIAMR', 'JPND', 'JPO', 'JPR', 'JR', 'JSI', 'JT', 'JUBA', 'JUDGE', 'JUDGEMENT', 'JUDGMENT', 'JUDICATURE', 'JUDICIAL', 'JUEGO', 'JUGADORES', 'JUGSPLASTIC', 'JUICY', 'JULIAN', 'JULIO', 'JULIUS', 'JULY', 'JUMP', 'JUMPSTART', 'JUMPSTARTING', 'JUN', 'JUNCTION', 'JUNCTURE', 'JUNE', 'JUNGLE', 'JUNIOR', 'JUNTO', 'JURISDICTION', 'JURISDICTIONAL', 'JUST', 'JUSTICE', 'JUSTICELEBANON', 'JUSTIFIED', 'JUSTIFY', 'JUSTINE', 'JUTIAPA', 'JUVENILES', 'JUVENILITY', 'JUZZOR', 'JVENES', 'K', 'K12240ST', 'K13', 'K4H', 'K4HEALTH', 'K4HEALTHS', 'K4HII', 'KABISA', 'KABUL', 'KADOORIE', 'KAGAMEGA', 'KAITUMA', 'KAKAMEGA', 'KAKEEGA', 'KALA', 'KALAAZAR', 'KALEGARI', 'KALIBU', 'KALULUSHI', 'KAMBIA', 'KAMPALA', 'KAMPENE', 'KAMPONG', 'KAMPUCHEA', 'KAMRU', 'KAMUZU', 'KAN', 'KANEKO', 'KANGAROO', 'KANGWON', 'KANGYI', 'KANO', 'KANSAS', 'KAP', 'KAPPOST', 'KARABAKH', 'KARAMOJA', 'KARAMOJONGTHAT', 'KARNATAKA', 'KAROLINSKA', 'KASAI', 'KASAICENTR', 'KASP', 'KATANGA', 'KATHMANDU', 'KATHOLIEKE', 'KAVI', 'KAZAKHSTAN', 'KAZAKHSTANS', 'KAZAKSTAN', 'KBFH', 'KCH', 'KEBBI', 'KECCA', 'KEEP', 'KEEPERS', 'KEEPING', 'KEISKAMMA', 'KEITH', 'KELLER', 'KEMRI', 'KEMRICGMRC', 'KENEMA', 'KENIA', 'KENTUCKY', 'KENYA', 'KENYAN', 'KENYANS', 'KENYAS', 'KENYATTA', 'KEPT', 'KERALA', 'KERNBEITRAG', 'KERNEL', 'KERNICTERUS', 'KETEMA', 'KETU', 'KEY', 'KEYACTORS', 'KEYS', 'KEYSTONE', 'KFW', 'KG', 'KGAA', 'KHALIFA', 'KHALIL', 'KHAMRANG', 'KHAN', 'KHANN', 'KHARTOUM', 'KHATLON', 'KHP', 'KHYBER', 'KI', 'KIBAHA', 'KIBERA', 'KIBRA', 'KICHAGA', 'KICK', 'KICKING', 'KICKSHAW', 'KID', 'KIDNEY', 'KIDS', 'KIEN', 'KIEV', 'KIGALI', 'KIGALIIMPROVE', 'KILIMANJARO', 'KILL', 'KILLER', 'KILLERS', 'KILLING', 'KILLINGTHIS', 'KILLS', 'KILOBYTE', 'KILOMETER', 'KILOMETERS', 'KIMBERLEY', 'KIMIRINA', 'KIN', 'KINANGO', 'KINASE', 'KIND', 'KINDA', 'KINERJA', 'KINETICS', 'KINETOPLASTIDA', 'KINFOLK', 'KING', 'KINGDOM', 'KINGS', 'KINGSTON', 'KINSFOLK', 'KINSHASA', 'KINSHIP', 'KINSPERSON', 'KIP', 'KIRAMBI', 'KIRGIZIA', 'KIRIBATI', 'KISANGANI', 'KISARAWE', 'KISSI', 'KISUMU', 'KIT', 'KITCHEN', 'KITCHENS', 'KITS', 'KITUI', 'KIVU', 'KK', 'KKELPOPULASJONER', 'KLIMENT', 'KM', 'KM2', 'KMT', 'KNCV', 'KNOCK', 'KNOCKDOWN', 'KNOCKOUT', 'KNOW', 'KNOWDEDGE', 'KNOWDO', 'KNOWHOW', 'KNOWINGNESS', 'KNOWLEDGE', 'KNOWLEDGE2', 'KNOWLEDGEABILITY', 'KNOWLEDGEABLE', 'KNOWLEDGEBUILDING', 'KNOWLEDGEMENT', 'KNOWLEDGESHARING', 'KNOWLEDGETOPOLICY', 'KNOWLEDGETRANSLATION', 'KNOWLESI', 'KNOWLGE', 'KNOWN', 'KNUST', 'KNWOLEDGE', 'KOBI', 'KOCH', 'KOFI', 'KOICA', 'KOLASIB', 'KOLENF', 'KOLOKANI', 'KOLOKOUNDE', 'KOLOKOUNDEFOUMBEA', 'KOMPETITIVE', 'KONEKTE', 'KONESANS', 'KONG', 'KONPETANS', 'KOORDINATION', 'KOR', 'KORDOFAN', 'KOREA', 'KOREAEU', 'KOREAN', 'KOREAS', 'KOREASRI', 'KOREN', 'KOSOVO', 'KOUR', 'KOURF', 'KOZENT', 'KP', 'KPLED', 'KPMG', 'KPS', 'KRG', 'KRITH', 'KRIZHANOVSKY', 'KS', 'KSA', 'KU', 'KUALA', 'KUANGCHOU', 'KUL', 'KUM', 'KUMINDA', 'KUP', 'KURABAR', 'KURDISH', 'KURDISTAN', 'KURU', 'KURZGESAGT', 'KWALE', 'KWAME', 'KWARA', 'KWAZULU', 'KWAZULUNATAL', 'KYD', 'KYIVMOHYLA', 'KYRGYZ', 'KYRGYZFINNISH', 'KYRGYZSTAN', 'KYRGYZSTANTHE', 'L', 'L3107', 'L39ERRADICACI', 'L994', 'LA', 'LAAMSCIENCE', 'LAAND', 'LAB', 'LABARATORY', 'LABBASED', 'LABEL', 'LABELFREE', 'LABELING', 'LABELLING', 'LABELLINGTHIS', 'LABELS', 'LABELSMANY', 'LABILE', 'LABOR', 'LABORATOIRE', 'LABORATOIRES', 'LABORATORIES', 'LABORATORIESHEALTHFOOD', 'LABORATORIO', 'LABORATORIOS', 'LABORATORIUM', 'LABORATORY', 'LABORATORY5', 'LABORATORYBASED', 'LABORATORYCLINIC', 'LABORATORYRESULTS', 'LABORATORYS', 'LABORERS', 'LABORIOUS', 'LABOUR', 'LABS', 'LABSPACES', 'LAC', 'LACCAN', 'LACCFS', 'LACERATIONS', 'LACK', 'LACKING', 'LACKLAND', 'LACKS', 'LACOR', 'LACORSOUTH', 'LACTAMASES', 'LACTATING', 'LACTATION', 'LACTION', 'LACTOBACILLUS', 'LACTOFERRIN', 'LACTOH', 'LADY', 'LAEVIGATA', 'LAFGHANISTA', 'LAFGHANISTAN', 'LAG', 'LAGGING', 'LAGOS', 'LAGS', 'LAH', 'LAI', 'LAID', 'LAIDE', 'LAKE', 'LAKKA', 'LALIMENTATION', 'LALIMENTATIONACHATS', 'LAMBARTNT', 'LAMBAYEQUE', 'LAMINAR', 'LAMIS', 'LAMP', 'LANA', 'LANCET', 'LAND', 'LANDBASED', 'LANDOMYCIN', 'LANDS', 'LANDSCAPE', 'LANDSCAPES', 'LANDSURFACE', 'LANDURY', 'LANDUSE', 'LANDUSES', 'LANGUAGE', 'LANGUAGERESULT', 'LANGUAGES', 'LANGUAGESGSP', 'LANKA', 'LANKENAU', 'LANSA', 'LAO', 'LAOS', 'LAOTIAN', 'LAOVIE', 'LAPIS', 'LAPSE', 'LARBOARD', 'LARCS', 'LARCS3', 'LARG', 'LARGE', 'LARGELY', 'LARGER', 'LARGERSCALE', 'LARGESCALE', 'LARGEST', 'LAROTID', 'LARVAE', 'LAS', 'LASER', 'LASHKARGAH', 'LASSA', 'LASSOMYCIN', 'LAST', 'LASTED', 'LASTING', 'LASTLY', 'LASTS', 'LATE', 'LATENCY', 'LATENT', 'LATER', 'LATERALFLOW', 'LATEST', 'LATESTAGE', 'LATIN', 'LATINAMERICA', 'LATINAMERICAN', 'LATION', 'LATRINE', 'LATRINES', 'LATTER', 'LATVIAHEALTH', 'LATVIAINTERGRATED', 'LATVIALEADERSHIP', 'LATVIAMENTAL', 'LATVIANATIONAL', 'LATVIANONCOMMUNICABLE', 'LATVIAREPRODUCTIVE', 'LATVIASTRATEGIC', 'LATVIAVIOLENCE', 'LAUCA', 'LAUGH', 'LAUGMENTATION', 'LAUNCH', 'LAUNCHED', 'LAUNCHEDTO', 'LAUNCHES', 'LAUNCHING', 'LAUNDERING', 'LAURELS', 'LAURIER', 'LAV', 'LAVATORY', 'LAW', 'LAWS', 'LAWSUIT', 'LAWSUITS', 'LAWSUITSRESEARCHERS', 'LAWYERS', 'LAY', 'LAYER', 'LAYHEALTH', 'LAYOVER', 'LAYWOMEN', 'LAZOS', 'LBR', 'LCF', 'LCHWS', 'LCTBA', 'LDL', 'LE', 'LEAD', 'LEADE', 'LEADER', 'LEADERS', 'LEADERSEFFECTIVE', 'LEADERSHI', 'LEADERSHIP', 'LEADERSHIPEIGHTEEN', 'LEADERSHIPTHE', 'LEADERSHIPTHIS', 'LEADING', 'LEADS', 'LEAF', 'LEAFLETS', 'LEAGUE', 'LEAKING', 'LEAN', 'LEAP', 'LEAPING', 'LEARN', 'LEARNED', 'LEARNEDARE', 'LEARNER', 'LEARNERS', 'LEARNING', 'LEARNINGMCGILL', 'LEARNINGS', 'LEASH', 'LEAST', 'LEASTECONOMICALLYDEVELOPEDCOUNTRIES', 'LEAVE', 'LEAVES', 'LEAVING', 'LEBANESE', 'LEBANON', 'LECANICILLIUM', 'LECTINE', 'LECTURE', 'LECTURERS', 'LECTURES', 'LED', 'LEDC', 'LEDELSE', 'LEDERSHIP', 'LEE', 'LEECH', 'LEEDS', 'LEER', 'LEFLORNITHINE', 'LEFT', 'LEGACY', 'LEGACYEFFECTS', 'LEGAL', 'LEGALLY', 'LEGENDS', 'LEGER', 'LEGION', 'LEGISLATING', 'LEGISLATION', 'LEGISLATIVE', 'LEGUMES', 'LEIBNITZ', 'LEISHMANAISIS', 'LEISHMANIA', 'LEISHMANIAL', 'LEISHMANIALS', 'LEISHMANIASIS', 'LEISHMANIASISASSESS', 'LEISHMANIE', 'LEISHMANIOSE', 'LEISHMANIOSIS', 'LEISMANIASIS', 'LELAND', 'LEMPIRA', 'LEND', 'LENDING', 'LENDS', 'LENGTH', 'LENGTHY', 'LENS', 'LENTILS', 'LENTIVIRUS', 'LEON', 'LEONARD', 'LEONE', 'LEONES', 'LEPIDOPTERAN', 'LEPRO', 'LEPROS', 'LEPROSY', 'LEPTOSPIROSIS', 'LES', 'LESBIANS', 'LESION', 'LESIONS', 'LESIONSTHIS', 'LESOTHO', 'LESS', 'LESSEN', 'LESSON', 'LESSONS', 'LESTE', 'LET', 'LETHAL', 'LETTER', 'LETTERS', 'LEU', 'LEUKEMIA', 'LEUKEMIAS', 'LEURS', 'LEUVEN', 'LEVEL', 'LEVEL1', 'LEVELDEMONSTRATE', 'LEVELFP', 'LEVELHEADED', 'LEVELPROVIDING', 'LEVELS', 'LEVELSINDEPTH', 'LEVELSTRENGTHENING', 'LEVELTHE', 'LEVELTHIS', 'LEVELWITH', 'LEVERAGE', 'LEVERAGED', 'LEVERAGES', 'LEVERAGING', 'LEVERS', 'LEVIN', 'LEWIS', 'LEWISNEGATIVE', 'LEZ', 'LF', 'LG', 'LGA', 'LGAS', 'LGBTIQ', 'LGU', 'LHLEPIDEMOLOGISK', 'LHLI', 'LHLTRIAGE', 'LHWS', 'LIABILITY', 'LIAISON', 'LIBERAL', 'LIBERALIZATION', 'LIBERATION', 'LIBERIA', 'LIBERIAINDIANA', 'LIBERIAN', 'LIBERIAS', 'LIBERTAD', 'LIBRARIES', 'LIBRARY', 'LIBRE', 'LIBREVILLE', 'LIBYA', 'LIC', 'LICENCE', 'LICENCES', 'LICENSE', 'LICENSED', 'LICENSING', 'LICENSURE', 'LICK', 'LICS', 'LID', 'LIE', 'LIEBERMANN', 'LIES', 'LIEUTENANT', 'LIF', 'LIFE', 'LIFECARE', 'LIFECOURSE', 'LIFECYCLE', 'LIFECYCLETARGETED', 'LIFELIKE', 'LIFELONG', 'LIFESAVING', 'LIFESCIENCES', 'LIFESPAN', 'LIFESTYLE', 'LIFESTYLES', 'LIFETHE', 'LIFETHREATENING', 'LIFETHREATING', 'LIFETIME', 'LIFETIMEAN', 'LIFETO', 'LIFEWITHOUT', 'LIFEWORKS', 'LIFEYEAR', 'LIFT', 'LIGASES', 'LIGATION', 'LIGHT', 'LIGHTER', 'LIGHTS', 'LIITTO', 'LIKE', 'LIKELIHOOD', 'LIKELY', 'LIKEMINDED', 'LIKEN', 'LIKEWISE', 'LILONGWE', 'LILY', 'LIMA', 'LIMAS', 'LIMB', 'LIMBIC', 'LIMINATION', 'LIMIT', 'LIMITATION', 'LIMITATIONS', 'LIMITED', 'LIMITEDDURING', 'LIMITEDIDRCS', 'LIMITING', 'LIMITS', 'LIMPOPO', 'LIMS', 'LINE', 'LINEAGE', 'LINEAGES', 'LINEAL', 'LINEAMENT', 'LINEAR', 'LINER', 'LINES', 'LINGUISTIC', 'LINING', 'LINK', 'LINKAGE', 'LINKAGES', 'LINKED', 'LINKING', 'LINKS', 'LINKTHE', 'LINSTITUT', 'LIOTHYRONINE', 'LIP', 'LIPID', 'LIPOPOLYSACCHARIDE', 'LIPOSOME', 'LIPOSOMES', 'LIPS', 'LIQUID', 'LIQUIDATION', 'LIRA', 'LIS', 'LISIS', 'LIST', 'LISTBAS', 'LISTED', 'LIT', 'LITE', 'LITERACY', 'LITERATE', 'LITERATURE', 'LITERATURETHE', 'LITHIASIS', 'LITHIUM', 'LITHUANIAHEALTH', 'LITHUANIAHIV', 'LITHUANIAHIVAIDS', 'LITHUANIALEADERSHIP', 'LITHUANIAMENTAL', 'LITHUANIAN', 'LITHUANIANATIONAL', 'LITHUANIANONCOMMUNICABLE', 'LITHUANIASTRATEGIC', 'LITHUANIATUBERCULOSIS', 'LITHUANIAVIOLENCE', 'LITIGATION', 'LITRE', 'LITS', 'LITTLE', 'LIU', 'LIVE', 'LIVEDEAD', 'LIVELIHOOD', 'LIVELIHOODS', 'LIVER', 'LIVERED', 'LIVERPOOL', 'LIVERSTAGE', 'LIVERY', 'LIVES', 'LIVESTHIS', 'LIVESTOCK', 'LIVESTOCKKEEPING', 'LIVING', 'LKA', 'LKNU', 'LLC', 'LLIN', 'LLINS', 'LMC', 'LMEP', 'LMG', 'LMIC', 'LMICS', 'LMICSBUILDING', 'LMICSRESEARCHERS', 'LMPROVEMENT', 'LMS', 'LMSKENYAS', 'LNDER', 'LNG', 'LNRCS', 'LNSTITUTO', 'LNTEGRATED', 'LO', 'LOAD', 'LOADED', 'LOADING', 'LOAN', 'LOANS', 'LOBBY', 'LOBBYING', 'LOCAL', 'LOCALITIES', 'LOCALITY', 'LOCALIZED', 'LOCALLEVELS', 'LOCALLY', 'LOCALLYOWNED', 'LOCALS', 'LOCAMSSA', 'LOCATE', 'LOCATED', 'LOCATING', 'LOCATION', 'LOCATIONS', 'LOCATIONSA', 'LOCI', 'LOCK', 'LOCKJAW', 'LODGE', 'LODGING', 'LODGINGS', 'LOGIC', 'LOGICAL', 'LOGISTIC', 'LOGISTICAL', 'LOGISTICS', 'LOGO', 'LOGRANDO', 'LOIASIS', 'LOKO', 'LOKOMASAMA', 'LOLLY', 'LOME', 'LONDON', 'LONE', 'LONG', 'LONGACTING', 'LONGAWAITED', 'LONGER', 'LONGERTERM', 'LONGEVITY', 'LONGEXPRESSED', 'LONGITUDINAL', 'LONGLASTING', 'LONGSIGHTED', 'LONGSTANDING', 'LONGTERM', 'LONGTIME', 'LOOK', 'LOOKED', 'LOOKING', 'LOOMING', 'LOONY', 'LOOSE', 'LOOSENESS', 'LOPIN', 'LOPINOVC', 'LORD', 'LORETO', 'LOS', 'LOSE', 'LOSING', 'LOSS', 'LOSSES', 'LOST', 'LOT', 'LOTCO', 'LOTS', 'LOUD', 'LOUIS', 'LOUISIANA', 'LOUSE', 'LOVELACE', 'LOW', 'LOWAND', 'LOWANDMIDDLE', 'LOWCOST', 'LOWEMISSION', 'LOWER', 'LOWERINCOME', 'LOWERING', 'LOWERLEVEL', 'LOWERMIDDLE', 'LOWERMIDDLEINCOME', 'LOWEST', 'LOWINCOME', 'LOWLAND', 'LOWLEVEL', 'LOWLY', 'LOWMIDDLE', 'LOWMIDDLEINCOME', 'LOWPATHOGENIC', 'LOWPERFORMING', 'LOWPREVALENCE', 'LOWPRICED', 'LOWRESOURCE', 'LOWRESOURCED', 'LOWSKILLED', 'LOWTECHNOLOGY', 'LOYALTY', 'LPA', 'LPAND', 'LPFM', 'LQMS', 'LRC', 'LRM', 'LRMCOTONOU', 'LS', 'LSDIRECTED', 'LSHTM', 'LSM', 'LSNDER', 'LSTM', 'LSU', 'LTBI', 'LTCHELLE', 'LTD', 'LTHCARE', 'LTI', 'LU', 'LUANDA', 'LUBAGA', 'LUBUMBASHI', 'LUBUMBASHIUN', 'LUCIA', 'LUCILLE', 'LUCK', 'LUCY', 'LUEGO', 'LUIS', 'LUKA', 'LUKE', 'LUMEFANTRINE', 'LUMINESCENT', 'LUMP', 'LUMPUR', 'LUNCHES', 'LUND', 'LUNENFELDTANENBAUM', 'LUNETTE', 'LUNG', 'LUNGA', 'LUNGS', 'LUNIVERSITT', 'LUNSAR', 'LUPUS', 'LURE', 'LUSAKA', 'LUSOPHONE', 'LUTHERAN', 'LUTILISATION', 'LUTTE', 'LUXOR', 'LWA', 'LX', 'LXX', 'LXXIV', 'LXXVI', 'LXXX', 'LYMPHATIC', 'LYMPHEDEMA', 'LYMPHOCYTE', 'LYMPHOCYTES', 'LYMPHOID', 'LYMPHOMALEUKAEMIA', 'LYNTON', 'LYSOSOMAL', 'LYSOSOME', 'LYSSA', 'LYTIC', 'M', 'M1', 'MA', 'MAA', 'MAATHRI', 'MAC', 'MACEDONIA', 'MACHINE', 'MACHINELEARNING', 'MACHINERIES', 'MACHINERY', 'MACHINES', 'MACHINGA', 'MACRO', 'MACROCOSM', 'MACROECONOMIC', 'MACROMYCETE', 'MACROMYCETES', 'MACROPHAGE', 'MACROPHAGEINDUCED', 'MACROPHAGES', 'MACROSEIZURES', 'MACULAR', 'MADAGASCAR', 'MADE', 'MADHYA', 'MADNESS', 'MADRE', 'MADRID', 'MAE', 'MAEDOTS', 'MAFRAQ', 'MAGBURAKA', 'MAGEE', 'MAGEEWOMENS', 'MAGNETIC', 'MAGNIFICATION', 'MAGNIFIED', 'MAGNITUDE', 'MAHARASHTRA', 'MAHIDOL', 'MAHWEET', 'MAIDEN', 'MAIL', 'MAILING', 'MAILMAN', 'MAIN', 'MAINLAND', 'MAINLY', 'MAINSTAY', 'MAINSTREAM', 'MAINSTREAMED', 'MAINSTREAMING', 'MAINSTREAMING12110', 'MAINTAIN', 'MAINTAINANCE', 'MAINTAINED', 'MAINTAINEDUPTODATE', 'MAINTAINING', 'MAINTAINS', 'MAINTENANCE', 'MAIS', 'MAISHA', 'MAIZE', 'MAJOR', 'MAJORITY', 'MAK', 'MAKA', 'MAKASSED', 'MAKCHS', 'MAKE', 'MAKENI', 'MAKER', 'MAKERERE', 'MAKERS', 'MAKERSRES', 'MAKES', 'MAKING', 'MAKINGPROJECT', 'MAL', 'MALADIES', 'MALADMINISTRATION', 'MALADY', 'MALARAI', 'MALARI', 'MALARIA', 'MALARIAAND', 'MALARIABORNE', 'MALARIACAUSING', 'MALARIAE', 'MALARIAEXPOSED', 'MALARIAFROM', 'MALARIAL', 'MALARIAPARASITECONTAINING', 'MALARIAREFRACTORY', 'MALARIARELATED', 'MALARIARESULT', 'MALARIAS', 'MALARIASPOT', 'MALARIATHIS', 'MALARIATRANSMITTING', 'MALARIAVACCINE', 'MALARIOLOGY', 'MALARIOMETRIC', 'MALAWI', 'MALAWIAN', 'MALAWIANS', 'MALAWIS', 'MALAWITHIS', 'MALAYA', 'MALAYI', 'MALAYSIA', 'MALAYSIAN', 'MALDIVES', 'MALE', 'MALEADOLESCENTVULNERABLE', 'MALED', 'MALENESS', 'MALES', 'MALFORMATIONS', 'MALI', 'MALIAN', 'MALIGNANCY', 'MALIGNANT', 'MALINDI', 'MALIS', 'MALL', 'MALLEABILITY', 'MALNOURISHED', 'MALNOURISHMENT', 'MALNUTRIION', 'MALNUTRIOTION', 'MALNUTRITION', 'MALNUTRITIONBY', 'MALPAISILLO', 'MALRIA', 'MALTAINTERGRATED', 'MALTANATIONAL', 'MALTANUTRITION', 'MALTREATMENT', 'MAMA', 'MAMATOTO', 'MAMMALIAN', 'MAMMALIANBLOOD', 'MAMMALS', 'MAMS', 'MAN', 'MANABI', 'MANAGE', 'MANAGEABLE', 'MANAGED', 'MANAGEMANT', 'MANAGEMENT', 'MANAGEMENT12110', 'MANAGEMENT12250', 'MANAGEMENTIN', 'MANAGEMENTRESULT', 'MANAGEMENTTHERE', 'MANAGEMENTTREATMENT', 'MANAGER', 'MANAGERIAL', 'MANAGERS', 'MANAGERSDIRECTOR', 'MANAGES', 'MANAGING', 'MANAGMENET', 'MANAGMENT', 'MANAGUA', 'MANAGUANICARAGUA', 'MANARELA', 'MANDALAY', 'MANDATE', 'MANDATED', 'MANDATES', 'MANDATORY', 'MANGANESE', 'MANGEMENT', 'MANGIFERA', 'MANGIFERIN', 'MANGO', 'MANGOCHI', 'MANGOTREE', 'MANHI', 'MANHICA', 'MANHITA', 'MANICA', 'MANIEMA', 'MANIFESTATION', 'MANIFESTATIONSTHE', 'MANIFESTED', 'MANIKANDAN', 'MANILA', 'MANIPAL', 'MANIPULATION', 'MANITA', 'MANITOBA', 'MANKIND', 'MANLEY', 'MANLIKE', 'MANMADE', 'MANNEQUIN', 'MANNER', 'MANNERHEIM', 'MANO', 'MANS', 'MANSONI', 'MANTLE', 'MANUAL', 'MANUALS', 'MANUEL', 'MANUFACTURABILITY', 'MANUFACTURE', 'MANUFACTURER', 'MANUFACTURERS', 'MANUFACTURES', 'MANUFACTURING', 'MANUSCRIPTS', 'MANY', 'MANYAMANYAMA', 'MANYARA', 'MAP', 'MAPPING', 'MAPPINGTHIS', 'MAPUTO', 'MARA', 'MARAKWET', 'MARASH', 'MARBURG', 'MARC', 'MARCELA', 'MARCH', 'MARCHA', 'MARCHE', 'MARCHLAND', 'MARERGUR', 'MARGARIDA', 'MARGIBI', 'MARGIN', 'MARGINAL', 'MARGINALES', 'MARGINALISED', 'MARGINALIZATION', 'MARGINALIZED', 'MARGINALIZEDREALIZING', 'MARIANA', 'MARIDI', 'MARIE', 'MARIHUANA', 'MARIJUANA', 'MARINE', 'MARIO', 'MARK', 'MARKED', 'MARKEDLY', 'MARKER', 'MARKERS', 'MARKET', 'MARKETBASED', 'MARKETING', 'MARKETPLACE', 'MARKETS', 'MARKETSHAPING', 'MARKETSIN', 'MARKING', 'MARKS', 'MAROODI', 'MAROSO', 'MAROSTICA', 'MARP', 'MARPS', 'MARRA', 'MARRE', 'MARRERE', 'MARRIAGE', 'MARRIAGES', 'MARRIED', 'MARROW', 'MARSHAL', 'MARSHALL', 'MART', 'MARTHA', 'MARTI', 'MARTIN', 'MARTINO', 'MARTTALIITTO', 'MARXIST', 'MARY', 'MARYLAND', 'MARYS', 'MAS', 'MASANJA', 'MASASI', 'MASASIMUHEZA', 'MASCULINITIES', 'MASCULINITY', 'MASCULINITYBASED', 'MASERU', 'MASHONALAND', 'MASINDI', 'MASKING', 'MASKS', 'MASS', 'MASSACHUSET', 'MASSACHUSETTS', 'MASSCOMMUNICATION', 'MASSES', 'MASSEY', 'MASSIVE', 'MASTER', 'MASTERCARD', 'MASTERLEVEL', 'MASTERMIND', 'MASTERS', 'MASTERTRACK', 'MASTERY', 'MASTRE', 'MAT', 'MATA', 'MATAGALPA', 'MATAGALPATHE', 'MATALE', 'MATCH', 'MATCHED', 'MATE', 'MATEMBE', 'MATERIAL', 'MATERIALMARKING', 'MATERIALS', 'MATERIALSA', 'MATERNAL', 'MATERNALAND', 'MATERNALANDNEWBORN', 'MATERNALCHILD', 'MATERNANJOUA', 'MATERNELLE', 'MATERNITIES', 'MATERNITT', 'MATERNITY', 'MATERNITYGYNECOLOGY', 'MATHARA', 'MATHEMATICAL', 'MATHEMATICS', 'MATHS', 'MATIFRE', 'MATING', 'MATIRE', 'MATLOSANA', 'MATRICES', 'MATRIEL', 'MATRIMONY', 'MATRIX', 'MATSINHE', 'MATTER', 'MATTERS', 'MATTERSTHIS', 'MATTRESS', 'MATTRESSES', 'MATTRIEL', 'MATURATE', 'MATURATION', 'MATURE', 'MATUTINE', 'MATUTUINE', 'MAURITANIA', 'MAURITANIE', 'MAURITIANS', 'MAURITIUS', 'MAX', 'MAXILLOFACIAL', 'MAXIMISE', 'MAXIMISING', 'MAXIMIZATION', 'MAXIMIZE', 'MAXIMIZING', 'MAXIMUM', 'MAY', 'MAYBE', 'MAYENDIT', 'MAYJUN', 'MAYO', 'MAYOR', 'MAYORS', 'MAZARESHARIF', 'MB', 'MBABANE', 'MBANDA', 'MBANDAKA', 'MBARARA', 'MBITA', 'MBR', 'MBULU', 'MC', 'MCC', 'MCDI', 'MCF', 'MCGILL', 'MCH', 'MCHERE', 'MCHIP', 'MCHN', 'MCHOPD', 'MCHS', 'MCHSS', 'MCLASS', 'MCMASTER', 'MCMB', 'MCMH', 'MCSP', 'MD', 'MDA', 'MDECINE', 'MDECINS', 'MDEE', 'MDG', 'MDG5', 'MDG6', 'MDGPF', 'MDGS', 'MDICAL', 'MDICAMENTS', 'MDR', 'MDRTB', 'ME', 'MEAGER', 'MEAL', 'MEALS', 'MEAN', 'MEANING', 'MEANINGFUL', 'MEANINGFULLY', 'MEANS', 'MEANT', 'MEANWHILE', 'MEASLES', 'MEASLESRUBELLA', 'MEASURABLE', 'MEASURE', 'MEASURED', 'MEASUREMENT', 'MEASUREMENTS', 'MEASURES', 'MEASURESPROJECT', 'MEASURESTHIS', 'MEASURETHIS', 'MEASURING', 'MEAT', 'MEC', 'MECANISMOS', 'MECHANICAL', 'MECHANICS', 'MECHANISM', 'MECHANISMS', 'MECHANISTIC', 'MECHANSIMS', 'MECLEP', 'MECONIUM', 'MEDECINE', 'MEDELLIN', 'MEDEVAC', 'MEDIA', 'MEDIAL', 'MEDIATE', 'MEDIATED', 'MEDIATING', 'MEDIATORS', 'MEDICA', 'MEDICAL', 'MEDICALLY', 'MEDICALLYORIENTED', 'MEDICALTECHNICAL', 'MEDICAMENT', 'MEDICAMENTOS', 'MEDICAMENTS', 'MEDICATING', 'MEDICATION', 'MEDICATIONS', 'MEDICI', 'MEDICINA', 'MEDICINAL', 'MEDICINE', 'MEDICINEHEALTH', 'MEDICINES', 'MEDICINESURGERY', 'MEDICUS', 'MEDIO', 'MEDITATE', 'MEDITERRANEAN', 'MEDIUM', 'MEDIUMENTERPRISE', 'MEDIUMSIZED', 'MEDIUMTERMSTRATEGY', 'MEDIZINISCHE', 'MEET', 'MEETING', 'MEETINGS', 'MEETINGSTHESE', 'MEETS', 'MEGET', 'MEHATA', 'MEILLEURE', 'MEIOSIS', 'MEJORA', 'MEKONG', 'MELANESIAN', 'MELANOCYTE', 'MELANOCYTES', 'MELARSOPROL', 'MELARSOPROLPENTAMIDINE', 'MELBOURNE', 'MELBOURNEHARVARD', 'MELEAGRIS', 'MELINDA', 'MELIOIDOSIS', 'MELIORATE', 'MELIORATION', 'MELLIFERA', 'MELLITUS', 'MELLOW', 'MELODIC', 'MELT', 'MEM', 'MEMBER', 'MEMBERS', 'MEMBERSHIP', 'MEMBERSTHIS', 'MEMBRANE', 'MEMBRANES', 'MEMO', 'MEMORANDUM', 'MEMORIAL', 'MEMORY', 'MEN', 'MENA', 'MENACE', 'MENAFRIVAC', 'MENAGE', 'MENAND', 'MENBUILDING', 'MENDED', 'MENENGAGE', 'MENINGITIS', 'MENINGOCOCCAL', 'MENISCUS2', 'MENNONITE', 'MENON', 'MENOR', 'MENORES', 'MENS', 'MENSTRUAL', 'MENSTRUATION', 'MENSURATE', 'MENT', 'MENTAL', 'MENTALITY', 'MENTALLY', 'MENTIONED', 'MENTOR', 'MENTORING', 'MENTORING2GOAL', 'MENTORS', 'MENTORSHIP', 'MENTS', 'MENUS', 'MENZIES', 'MERCHANDISE', 'MERCHANDISING', 'MERCHANTS', 'MERCK', 'MERCOSUR', 'MERCY', 'MERE', 'MERELY', 'MERGE', 'MERGED', 'MERGER', 'MERGING', 'MERIDA', 'MERIDIAN', 'MERIT', 'MERITBASED', 'MERITS', 'MERL', 'MERLIN', 'MEROZOITE', 'MEROZOITES', 'MERRITT', 'MERS', 'MERSCOV', 'MERT', 'MESH', 'MESHING', 'MESHWORK', 'MESO', 'MESOAMERICA', 'MESOENDEMIC', 'MESSAGE', 'MESSAGES', 'MESSAGING', 'MESSENGER', 'MESSINA', 'MET', 'META', 'METAANALYSES', 'METABIOTA', 'METABOLIC', 'METABOLISM', 'METABOLITE', 'METABOLITES', 'METABOLOMIC', 'METABOLOMICS', 'METAGENOMES', 'METAGENOMICS', 'METAL', 'METALFUNCTIONALIZED', 'METALS', 'METALUND', 'METAPLASIA', 'METASTASIS', 'METASTATIC', 'METE', 'METEOROLOGICAL', 'METEOROLOGICALCLIMATE', 'METER', 'METERS', 'METHADONE', 'METHOD', 'METHODOLOGICAL', 'METHODOLOGIES', 'METHODOLOGIES3', 'METHODOLOGY', 'METHODS', 'METHODSOUR', 'METHYLTRANSFERASE', 'METOFLUTHRIN', 'METRE', 'METRIC', 'METRICS', 'METRICSEHMIS', 'METROPOLITAN', 'METZLER', 'MEUR', 'MEXICAN', 'MEXICO', 'MEXICOOUR', 'MEXICOS', 'MFA', 'MFAT', 'MFC', 'MFDS', 'MFRES', 'MG', 'MGKG', 'MGM', 'MH', 'MHA', 'MHC', 'MHEALTH', 'MHM', 'MHMPACKAGETHE', 'MHO', 'MHSI', 'MI', 'MIB', 'MICA', 'MICE', 'MICHAELS', 'MICHIGAN', 'MICRO', 'MICROALGAE', 'MICROARRAY', 'MICROARRAYS', 'MICROASSURANCE', 'MICROBES', 'MICROBIAL', 'MICROBIALRESILIENCE', 'MICROBIC', 'MICROBICIDE', 'MICROBICIDES', 'MICROBILOLOGY', 'MICROBIOLOGFAAND', 'MICROBIOLOGIA', 'MICROBIOLOGICAL', 'MICROBIOLOGY', 'MICROBIOME', 'MICROBIOMEGUTBRAIN', 'MICROBIOMEMEDIATED', 'MICROBIOMICS', 'MICROBIOTA', 'MICROBIOTAGUTBRAIN', 'MICROCEPHALY', 'MICROCREDIT', 'MICROELECTROMECHANICAL', 'MICROELEMENTS', 'MICROENTERPRISE', 'MICROEPIDEMIOLOGICAL', 'MICROEPIDEMIOLOGY', 'MICROFINANCE', 'MICROFLORA', 'MICROFRANCHISE', 'MICRONEEDLE', 'MICRONESIA', 'MICRONUTRIE', 'MICRONUTRIENT', 'MICRONUTRIENTENRICHED', 'MICRONUTRIENTS', 'MICROORGANISMS', 'MICROPARTICLES', 'MICROPELLET', 'MICROPEMS', 'MICROPHAGE', 'MICROPROJECTS', 'MICROPROJECTSHOM', 'MICRORESEARCH', 'MICRORNA', 'MICROROUGH', 'MICROSCOPE', 'MICROSCOPES', 'MICROSCOPISTAS', 'MICROSCOPISTS', 'MICROSCOPY', 'MICROSEIZURES', 'MICROSOFT', 'MICROSPECTROSCOPY', 'MICROSTUDY', 'MICS3', 'MID', 'MID1970S', 'MID2015', 'MIDBCC', 'MIDDLE', 'MIDDLEEAST', 'MIDDLEINCOME', 'MIDLEVEL', 'MIDONGY', 'MIDRIFF', 'MIDSECTION', 'MIDSIZED', 'MIDST', 'MIDTERM', 'MIDTERMEVAL', 'MIDWAY', 'MIDWEST', 'MIDWIFE', 'MIDWIFERY', 'MIDWIFERYNURSING', 'MIDWIFES', 'MIDWIVES', 'MIF', 'MIGHT', 'MIGHTINESS', 'MIGRANT', 'MIGRANTS', 'MIGRANTSENDING', 'MIGRATION', 'MIGRATOR', 'MIGRATORY', 'MIH', 'MIHAIL', 'MIILLION', 'MIL', 'MILD', 'MILES', 'MILESTONES', 'MILITARISATION', 'MILITARIZATION', 'MILITARY', 'MILITATES', 'MILK', 'MILL', 'MILLENIUM', 'MILLENNIUM', 'MILLET', 'MILLI', 'MILLIGRAM', 'MILLION', 'MILLIONS', 'MILLS', 'MILOSEVIC', 'MILTON', 'MIME', 'MIMETICS', 'MIMIC', 'MIMICKING', 'MIN', 'MINAGRI', 'MIND', 'MINDANAO', 'MINDORO', 'MINDS', 'MINDY', 'MINE', 'MINED', 'MINELAYING', 'MINER', 'MINERAL', 'MINERFA', 'MINERS', 'MINH', 'MINI', 'MINIATURE', 'MINIATURIZED', 'MINIFY', 'MINIMAL', 'MINIMALINVASIVE', 'MINIMALLY', 'MINIMAT', 'MINIMISE', 'MINIMISING', 'MINIMIZE', 'MINIMIZING', 'MINIMUM', 'MINING', 'MINIPARASITES', 'MINISTER', 'MINISTERIAL', 'MINISTERS', 'MINISTRIES', 'MINISTRIESTHE', 'MINISTRY', 'MINISTRYLEVEL', 'MINISTRYS', 'MINISTY', 'MINITORING', 'MINNESOTA', 'MINOR', 'MINORITIES', 'MINSK', 'MINT', 'MINTAGE', 'MINUS', 'MINUTES', 'MINUTESLEVELS', 'MIPAA', 'MIRACLE', 'MIRIA', 'MIRNA', 'MIRROR', 'MIS', 'MISALIGNMENT', 'MISCARRIAGE', 'MISCELLANEOUS', 'MISCONCEPTION', 'MISCONCEPTIONS', 'MISDIRECTED', 'MISE', 'MISEAN', 'MISERABLE', 'MISEXPRESSED', 'MISFORTUNATE', 'MISGUIDED', 'MISINFORMATION', 'MISINFORMED', 'MISION', 'MISLEAD', 'MISLEADING', 'MISMAS', 'MISMATCH', 'MISOPROSTOL', 'MISP', 'MISS', 'MISSING', 'MISSION', 'MISSIONARIES', 'MISSIONARY', 'MISSIONS', 'MISTAKES', 'MISTREATED', 'MISUNGWI', 'MISUSE', 'MIT', 'MITE', 'MITES', 'MITIGATE', 'MITIGATES', 'MITIGATING', 'MITIGATION', 'MITOCHONDRIA', 'MITOCHONDRIAL', 'MITOSIS', 'MITS', 'MIX', 'MIXED', 'MIXEDFINANCED', 'MIXEDMETHOD', 'MIXEDMETHODS', 'MIXER', 'MIXMETHODS', 'MIXTURE', 'MIXTURES', 'MIZORAM', 'MLEARNING', 'MLL', 'MLPS', 'MLU', 'MM', 'MMC', 'MMED', 'MMOLL', 'MMS', 'MMV', 'MMVNEW', 'MMVS', 'MNAZI', 'MNCH', 'MNCHSRH', 'MNDRS', 'MNE', 'MNH', 'MNTE', 'MNUTRITION', 'MOBIEL', 'MOBILE', 'MOBILEBASED', 'MOBILEHEALTH', 'MOBILISATION', 'MOBILISE', 'MOBILISED', 'MOBILITY', 'MOBILIZATION', 'MOBILIZE', 'MOBILIZED', 'MOBILIZERS', 'MOBILIZES', 'MOBILIZING', 'MOBIS', 'MOCAMBIQUE', 'MODALITIES', 'MODALITY', 'MODE', 'MODEL', 'MODELDEPENDENT', 'MODELED', 'MODELERS', 'MODELING', 'MODELINGCONSTRUCTION', 'MODELLING', 'MODELS', 'MODELSAND', 'MODELSTHIS', 'MODEM', 'MODERATE', 'MODERATELY', 'MODERATETOSEVERE', 'MODERN', 'MODERNISATION', 'MODERNISE', 'MODERNISED', 'MODERNISTIC', 'MODERNIZATION', 'MODERNIZE', 'MODERNIZED', 'MODERNIZING', 'MODES', 'MODEST', 'MODHUMITA', 'MODHUMITABANGLADESH', 'MODIFIABLE', 'MODIFICATION', 'MODIFICATIONS', 'MODIFIED', 'MODIFIERS', 'MODIFY', 'MODIFYING', 'MODIQUE', 'MODUL', 'MODULAR', 'MODULATE', 'MODULATED', 'MODULATES', 'MODULATING', 'MODULATION', 'MODULATORY', 'MODULE', 'MODULES', 'MOE', 'MOES', 'MOETO', 'MOGADISCIO', 'MOGADISHU', 'MOH', 'MOHCW', 'MOHFW', 'MOHP', 'MOHS', 'MOHSW', 'MOI', 'MOIST', 'MOISTURE', 'MOJA', 'MOLACULAR', 'MOLAR', 'MOLARITY', 'MOLCULAIRE', 'MOLD', 'MOLDAVIAN', 'MOLDOVA', 'MOLDOVAN', 'MOLDOVAS', 'MOLECULAR', 'MOLECULARBIOLOGY', 'MOLECULE', 'MOLECULES', 'MOLTCULAIRE', 'MOMENT', 'MOMENTUM', 'MONASH', 'MONASTIC', 'MONDE', 'MONDIALE', 'MONDLANE', 'MONELL', 'MONERAGALA', 'MONETARY', 'MONEY', 'MONGOLIA', 'MONITION', 'MONITOR', 'MONITORED', 'MONITORING', 'MONITORINGAND', 'MONITORINGMANAGEMENT', 'MONITORS', 'MONO', 'MONOCLONAL', 'MONOINFECTED', 'MONONUCLEOSIS', 'MONOPHOSPHATE', 'MONOPOLIZED', 'MONOTHERAPIES', 'MONOTHERAPY', 'MONOVALENT', 'MONOXIDE', 'MONROVIA', 'MONT', 'MONTE', 'MONTENEGRO', 'MONTEVIDEO', 'MONTH', 'MONTHLY', 'MONTHS', 'MONTREAL', 'MONTREUX', 'MONTRTAL', 'MOO', 'MOOD', 'MOON', 'MOORE', 'MOP', 'MOPACUR', 'MOPH', 'MOPTI', 'MOPV', 'MOR', 'MORAL', 'MORALITY', 'MORBIDITIES', 'MORBIDITT', 'MORBIDITY', 'MORBIDNESS', 'MORBIFIC', 'MORBILLI', 'MORE', 'MORELOS', 'MOREOVER', 'MORESBY', 'MORGUE', 'MORIBUND', 'MOROCCAN', 'MOROCCO', 'MOROCO', 'MOROGORO', 'MORONI', 'MORPHOLOGIC', 'MORR', 'MORTALITT', 'MORTALITY', 'MORTALITY2PREVENT', 'MORTALITYIN', 'MORTALITYSTRATEGIES', 'MORTALITYTO', 'MOSHE', 'MOSHI', 'MOSLEM', 'MOSQUES', 'MOSQUITO', 'MOSQUITOBASED', 'MOSQUITOBORNE', 'MOSQUITOES', 'MOSQUITOFORM', 'MOSQUITOS', 'MOSQUITOTRANSMITTED', 'MOST', 'MOSTATRISK', 'MOSTATRISKPOPULATION', 'MOSTATRISKPOPULATIONS', 'MOSTLY', 'MOSTTHE', 'MOTHER', 'MOTHERBABY', 'MOTHERCHILD', 'MOTHERHOOD', 'MOTHERS', 'MOTHERSCOMMUNITY', 'MOTHERTOCHILD', 'MOTHERTOMOTHER', 'MOTIF', 'MOTION', 'MOTIVATE', 'MOTIVATED', 'MOTIVATION', 'MOTIVATIONAL', 'MOTIVATIONS', 'MOTIVATORS', 'MOTIVE', 'MOTOR', 'MOTORBIKES', 'MOTORCYCLE', 'MOTORCYCLISTS', 'MOU', 'MOUD', 'MOULD', 'MOULDING', 'MOULDS', 'MOUNT', 'MOUNTAIN', 'MOUNTAINS', 'MOUNTED', 'MOUNTING', 'MOUS', 'MOUSE', 'MOUTH', 'MOVABLE', 'MOVE', 'MOVEMENT', 'MOVEMENTS', 'MOVIMIENTO', 'MOVING', 'MOYEN', 'MOZ', 'MOZAMBICAN', 'MOZAMBICO', 'MOZAMBIQUE', 'MOZAMBIQUES', 'MOZRESEARCH', 'MP', 'MPER', 'MPI', 'MPL', 'MPS', 'MPT', 'MPTS', 'MPTSBIOMED', 'MPUMALANGA', 'MPW', 'MR', 'MRC', 'MRCBBSRCESRCNSFC', 'MRCCRT', 'MRCCRTF', 'MRCDBT', 'MRCDBTDFID', 'MRCDFID', 'MRCDFIDDBT', 'MRCDFIDNIHRWT', 'MRCESRCCONFAP', 'MRCFAPESP', 'MRCHSRI', 'MRCICMR', 'MRCIIB', 'MRCJGHT', 'MRCJOINT', 'MRCLSHTM', 'MRCMCMB', 'MRCMETHODOLOGY', 'MRCMOST', 'MRCNSFC', 'MRCNSTDATRF', 'MRCPCHRD', 'MRCPHIND', 'MRCPSMB', 'MRCSAMRC', 'MRCSAMRCGSK', 'MRCTHAILAND', 'MRCTRANSLATIONAL', 'MRCTRF', 'MRCUVRI', 'MRCWELLCOME', 'MRCWTDFID', 'MRCWTDFIDESRC', 'MRES', 'MRF', 'MRNA', 'MRNAS', 'MRNASEQUENCING', 'MRT', 'MRTMANI', 'MS', 'MSA', 'MSABAHA', 'MSAMBWENI', 'MSC', 'MSCPROGRAMMES', 'MSD', 'MSEK', 'MSH', 'MSI', 'MSIS', 'MSL', 'MSM', 'MSM2', 'MSMTRANSGENDER', 'MSN', 'MSNPROJECT', 'MSNSERVICES', 'MSP', 'MSPP', 'MSPYBS', 'MSTAR', 'MSW', 'MT', 'MTB', 'MTBCONTAINING', 'MTBINFECTED', 'MTBTOLERANCE', 'MTCANISME', 'MTCT', 'MTCTRANSMISSION', 'MTDECINE', 'MTDECINS', 'MTDICAL', 'MTDICALES', 'MTDICAMENTS', 'MTDICAS', 'MTM', 'MTOR', 'MTOTO', 'MTRIEUX', 'MTS', 'MTTODOS', 'MTWARA', 'MU', 'MUCH', 'MUCHNEEDED', 'MUCOADHESIVE', 'MUCOSA', 'MUCOSAL', 'MUCOSALLY', 'MUD', 'MUESTRAS', 'MUFULIRA', 'MUGS', 'MUHANGA', 'MUHAS', 'MUHEZA', 'MUHIMBILI', 'MUHIMBILY', 'MUJERES', 'MUKONO', 'MULAGO', 'MULITDONOR', 'MULTDRUG', 'MULTI', 'MULTIACTOR', 'MULTIAGE', 'MULTIAGENCY', 'MULTIAMR', 'MULTIANNUAL', 'MULTIANTIGEN', 'MULTIBILATERAL', 'MULTIBILLION', 'MULTICASE', 'MULTICENTER', 'MULTICENTRE', 'MULTICLONAL', 'MULTICOMPONENT', 'MULTICOUNTRY', 'MULTIDISCIPLINARY', 'MULTIDONOR', 'MULTIDRUG', 'MULTIDRUGRESISTANT', 'MULTIFACETED', 'MULTIFUNCTIONAL', 'MULTIFUNDER', 'MULTIINDICATOR', 'MULTILATERAL', 'MULTILATERALS', 'MULTILAYER', 'MULTILAYERED', 'MULTILEVEL', 'MULTIMEDIA', 'MULTIMETHODOLOGY', 'MULTINATIONAL', 'MULTIPARTNER', 'MULTIPLE', 'MULTIPLEEPITOPE', 'MULTIPLEXED', 'MULTIPLICATION', 'MULTIPLY', 'MULTIPOLAR', 'MULTIPROFESSIONAL', 'MULTIPURPOSE', 'MULTIRESISTANT', 'MULTIRESITENT', 'MULTISCIENTIFIC', 'MULTISECTOR', 'MULTISECTORAL', 'MULTISECTORIAL', 'MULTISTAGE', 'MULTISTAKEHOLDER', 'MULTITIERED', 'MULTITUDE', 'MULTIVALENT', 'MULTIVARIABLE', 'MULTIVARIATE', 'MULTIVITAMINS', 'MULTIYEAR', 'MUMBAI', 'MUMS', 'MUNDANE', 'MUNDI', 'MUNICHPART', 'MUNICIPAL', 'MUNICIPALITIES', 'MUNICIPALITY', 'MUNICIPIOS', 'MURAZ', 'MURAZBURKINA', 'MURDOCH', 'MURINE', 'MUSCLE', 'MUSCLES', 'MUSCULARITY', 'MUSIC', 'MUSICAL', 'MUSLIM', 'MUSLIMDOMINATED', 'MUST', 'MUSTAPHA', 'MUTABLE', 'MUTANT', 'MUTANTS', 'MUTATE', 'MUTATED', 'MUTATION', 'MUTATIONS', 'MUTATIONSTHE', 'MUTILATED', 'MUTILATION', 'MUTILATIONCUTTING', 'MUTILATIONHEALTH', 'MUTISECTORAL', 'MUTUAL', 'MUTUALLY', 'MVA', 'MVA85A', 'MVDP', 'MVIL', 'MVILES', 'MVP', 'MWALI', 'MWANZA', 'MWH', 'MWHS', 'MWI', 'MWV', 'MYANMAR', 'MYCOBACTERIA', 'MYCOBACTERIAL', 'MYCOBACTERIOLOGIE', 'MYCOBACTERIOLOGY', 'MYCOBACTERIUM', 'MYCOBACTRIES', 'MYCOBACTTRIES', 'MYCOBACTTRIOLOGIE', 'MYCOLIC', 'MYCOTOXIN', 'MYCOTOXINS', 'MYELOID', 'MYOCARDIAL', 'MYRCIARIA', 'MYSORE', 'MYSTERY', 'MYTHS', 'MYXOBACTERIA', 'MYXOBACTERIAL', 'N', 'N10', 'N1251', 'N1500', 'N240', 'N400', 'N49', 'N4G', 'N86Y', 'NAAPR1', 'NABAUNAKT', 'NACALA', 'NACIONAL', 'NACO', 'NACP', 'NACTE', 'NADR', 'NADRGTR', 'NADU', 'NAFUNDI', 'NAGBIOUNGOU', 'NAGORNO', 'NAGORNOKARABAKH', 'NAGST', 'NAGST1', 'NAHUM', 'NAHYAN', 'NAIR', 'NAIROBI', 'NAKURU', 'NAM', 'NAME', 'NAMED', 'NAMELY', 'NAMIBIA', 'NAMPULA', 'NANCE', 'NANG', 'NANGHSHOUK', 'NANNY', 'NANO', 'NANOBEADS', 'NANOBIOTECHNOLOGY', 'NANOBODIES', 'NANOCAPSULES', 'NANOCARRIER', 'NANOCRYSTALLINE', 'NANOCUBE', 'NANODIATER', 'NANOENCAPSULATED', 'NANOFABRICATION', 'NANOFIBER', 'NANOGRAM', 'NANOHYDROXYAPATITE', 'NANOMEDICINE', 'NANOMOLECULES', 'NANOPARTICLE', 'NANOPARTICLEBASED', 'NANOPARTICLES', 'NANOPATCH', 'NANOSACS', 'NANOSCALE', 'NANOSCIENCES', 'NANOSTRUCTURES', 'NANOTECHNOLOGIES', 'NANOTECHNOLOGY', 'NANOTECHNOLOGYBASED', 'NANOTUBE', 'NAO', 'NAP', 'NAPHDA', 'NAPKIN', 'NAPKINS', 'NARC', 'NARCOTIC', 'NARCOTICS', 'NARGIS', 'NARK', 'NARYN', 'NAS', 'NASAL', 'NASARAWA', 'NASOPHARYNGEAL', 'NASOPHARYNX', 'NAT', 'NATA', 'NATAL', 'NATARAJAN', 'NATES', 'NATI', 'NATIIONS', 'NATIKIRI', 'NATIO', 'NATION', 'NATIONAL', 'NATIONALE', 'NATIONALITY', 'NATIONALLEVEL', 'NATIONALLY', 'NATIONALLYSTRENGTHENING', 'NATIONALREGIONAL', 'NATIONALS', 'NATIONS', 'NATIONSTHE', 'NATIONWIDE', 'NATIVE', 'NATURAL', 'NATURALLY', 'NATURE', 'NATURELS', 'NAURU', 'NAURUS', 'NAUSEA', 'NAVAL', 'NAVIGATION', 'NAVIGATORS', 'NB', 'NB1', 'NCD', 'NCDC', 'NCDIS', 'NCDP', 'NCDS', 'NCDSDEMOGRAPHIC', 'NCDSTHIS', 'NCHADS', 'NCHP', 'NCY', 'NDER', 'NDJAMENA', 'NDJAMNA', 'NDJAMTNA', 'NDOH', 'NDOLA', 'NEAR', 'NEARBY', 'NEARELIMINATION', 'NEAREST', 'NEARFULLLENGTHGENOME', 'NEARINFRARED', 'NEARING', 'NEARLY', 'NEAT', 'NEC', 'NECESIDADES', 'NECESSARILY', 'NECESSARY', 'NECESSITIES', 'NECESSITY', 'NEDERLAND', 'NEED', 'NEEDDESPITE', 'NEEDED', 'NEEDFUL', 'NEEDING', 'NEEDLE', 'NEEDS', 'NEEDSAVAILABILITY', 'NEEDSBASED', 'NEEDSENCOURAGE', 'NEEDSFEASIBILITY', 'NEEDSUNDERSTAND', 'NEEDY', 'NEGARA', 'NEGATIVE', 'NEGATIVELY', 'NEGLCTED', 'NEGLECT', 'NEGLECTED', 'NEGOTIATE', 'NEGOTIATED', 'NEGOTIATION', 'NEGOTIATIONS', 'NEGRO', 'NEHSI', 'NEIGHBOR', 'NEIGHBORHOOD', 'NEIGHBORHOODS', 'NEIGHBORING', 'NEIGHBOUR', 'NEIGHBOURHOOD', 'NEIGHBOURHOODS', 'NEIGHBOURING', 'NEIGHTBOURING', 'NEITHER', 'NELSON', 'NEMATODE', 'NEOFORMANS', 'NEOKIP', 'NEONAT', 'NEONATAL', 'NEONATE', 'NEONATES', 'NEONATIAL', 'NEONATOLOGY', 'NEONTAL', 'NEOPLASTIC', 'NEP', 'NEPAD', 'NEPAL', 'NEPALABN', 'NEPALESE', 'NEPALI', 'NEPALIMANAGED', 'NEPALS', 'NEPHROLOGY', 'NEPHRON', 'NEPHROTIC', 'NEPHROTOXICITY', 'NERC', 'NERI', 'NERTITI', 'NERVE', 'NERVES', 'NERVOUS', 'NESS', 'NESTLING', 'NET', 'NETBALL', 'NETHER', 'NETHERLANDS', 'NETHERLANDSSINCE', 'NETHOPE', 'NETOS', 'NETOWRKING', 'NETS', 'NETWERK', 'NETWKI', 'NETWORK', 'NETWORK2', 'NETWORKED', 'NETWORKING', 'NETWORKINGCONSOLIDATEDRESULT', 'NETWORKPARTNERS', 'NETWORKS', 'NETWORKSIN', 'NETWORKTHIS', 'NETWORKWABA', 'NEU4', 'NEURO', 'NEUROCIENCIAS', 'NEUROCOGNITIVE', 'NEUROCYSTICERCOSIS', 'NEURODEGENERATIVE', 'NEURODEVELOPMENTAL', 'NEUROGENESIS', 'NEUROHORMONAL', 'NEUROLOGICAL', 'NEUROLOGY', 'NEURON', 'NEUROSCIENCE', 'NEUROSURGERY', 'NEUROSURGICAL', 'NEUROTOXIC', 'NEUROTOXIN', 'NEUROTRANSMITTER', 'NEUTRAL', 'NEUTRALIZATION', 'NEUTRALIZE', 'NEUTRALIZING', 'NEVADA', 'NEVER', 'NEVERTHELESS', 'NEVIRAPINE', 'NEW', 'NEWBOR', 'NEWBORD', 'NEWBORN', 'NEWBORNCHILD', 'NEWBORNS', 'NEWCASTLE', 'NEWEST', 'NEWFANGLED', 'NEWFOUNDLAND', 'NEWLINK', 'NEWLY', 'NEWS', 'NEWSBREAK', 'NEWSLETTER', 'NEWSLETTERS', 'NEWSLETTERTHE', 'NEWSPAPERS', 'NEXT', 'NEXTGENERATION', 'NFLG', 'NFR', 'NFRGLOBVAC', 'NG', 'NGAFULA', 'NGAZIDJA', 'NGLIGES', 'NGO', 'NGOES', 'NGOS', 'NGOZI', 'NGPOLIO', 'NGS', 'NGT', 'NHAMI', 'NHI', 'NHIS', 'NHLS', 'NHP', 'NHRL', 'NHRLQASI', 'NHRLS', 'NHRR', 'NHSP', 'NHTD', 'NI', 'NIAMEY', 'NIASSA', 'NICARAGUA', 'NICARAGUAN', 'NICARAGUANS', 'NICHE', 'NICODEMUS', 'NICOLAS', 'NICOLAUS', 'NICOTINAMIDE', 'NIDUS', 'NIF', 'NIGER', 'NIGERIA', 'NIGERIAINNOVATING', 'NIGERIAN', 'NIGERIANS', 'NIGERIAPOLIO', 'NIGERIAS', 'NIGERIEN', 'NIGH', 'NIHR', 'NIHRD', 'NIKAT', 'NIKKAI', 'NILE', 'NIMPE', 'NIMPECNM', 'NINA', 'NINE', 'NINER', 'NINETEEN', 'NINETY', 'NINETYFIVE', 'NINFOODS', 'NINH', 'NINOS', 'NIOPH', 'NIPAH', 'NIPH', 'NIPI', 'NIPN', 'NIPPER', 'NIPPONESE', 'NIRAPOD', 'NIRAPOD2', 'NIRG', 'NIRP', 'NIRS', 'NIS', 'NISCVT', 'NISP', 'NISREEN', 'NISTRU', 'NITRIC', 'NITROCELLULOSE', 'NITROGEN', 'NITTY', 'NIUE', 'NIVANUATU', 'NIX', 'NJ', 'NJINIKOM', 'NJOMBE', 'NJUKI', 'NK', 'NKANGALA', 'NKRUMAH', 'NMCHC', 'NMCHCRESULT', 'NMCP', 'NML', 'NMQCL', 'NMR', 'NMRC', 'NO', 'NO2', 'NOBELIUM', 'NOCHOLERA', 'NOCHT', 'NODDING', 'NOESIS', 'NOFSWS', 'NOGUCHI', 'NOK', 'NOMA', 'NOMADIC', 'NOMADS', 'NOMBRE', 'NOMINATE', 'NOMINEE', 'NON', 'NONALCOHOLIC', 'NONARVBASED', 'NONAVAILABILITY', 'NONBENEFICIARIES', 'NONCLINICAL', 'NONCOLD', 'NONCOMMUNICABLE', 'NONCONTAGIOUS', 'NONCONVENTIONAL', 'NONDIABETIC', 'NONDIRECT', 'NONE', 'NONEPIDEMIC', 'NONETHELESS', 'NONFACILITY', 'NONFECAL', 'NONFINANCIAL', 'NONFORMAL', 'NONGOVERNMENT', 'NONGOVERNMENTAL', 'NONHEALTH', 'NONHEMATOPOIETIC', 'NONHORMONAL', 'NONHUMAN', 'NONIMMUNE', 'NONINDIGENOUS', 'NONINFECTED', 'NONINFECTIOUS', 'NONINVASIVE', 'NONINVASIVELY', 'NONLEGISLATIVE', 'NONLIVE', 'NONLYTIC', 'NONMALARIAL', 'NONMEDICAL', 'NONMIGRATORY', 'NONPAINFUL', 'NONPAREIL', 'NONPATHOGENIC', 'NONPHYSICIAN', 'NONPOC', 'NONPOLIO', 'NONPREGNANT', 'NONPRICE', 'NONPROFIT', 'NONPROFITS', 'NONPROLIFERATION', 'NONREFUGEE', 'NONREGULATED', 'NONREPLICATING', 'NONSEVERE', 'NONSMOKING', 'NONSPECIALISTS', 'NONSPENDING', 'NONSTATE', 'NONSUBSIDIZED', 'NONSURGICAL', 'NONTEXTUAL', 'NONTHERAPEUTIC', 'NONTOBACCO', 'NONTRADITIONAL', 'NONTRANSMISSIBLE', 'NONTYPHOIDAL', 'NONUNIFORMED', 'NONURBAN', 'NONUSG', 'NONVIOLENT', 'NONVOLATILE', 'NOPV', 'NORAD', 'NORADS', 'NORD', 'NORDIC', 'NORESTE', 'NORK', 'NORM', 'NORMAL', 'NORMALABNORMAL', 'NORMALCY', 'NORMALISATION', 'NORMALITY', 'NORMALIZE', 'NORMALIZED', 'NORMALLY', 'NORMATIF', 'NORMATIVE', 'NORMO', 'NORMS', 'NORMSBASED', 'NORSE', 'NORSEMAN', 'NORTH', 'NORTHERLY', 'NORTHERN', 'NORTHSOUTH', 'NORTHSOUTHSOUTH', 'NORTHWARD', 'NORTHWEST', 'NORTHWESTERN', 'NORWAY', 'NORWAYS', 'NORWEGIAN', 'NOSE', 'NOSOLOGY', 'NOT', 'NOTABLY', 'NOTCH', 'NOTE', 'NOTED', 'NOTES', 'NOTFORPROFIT', 'NOTICE', 'NOTIFICATION', 'NOTIFIED', 'NOTORIOUS', 'NOTTINGHAM', 'NOTWITHSTANDING', 'NOUAKCHOTT', 'NOUGHT', 'NOURISHING', 'NOURISHMENT', 'NOUS', 'NOUVEAUNTS', 'NOV', 'NOVARTIS', 'NOVAVAX', 'NOVEL', 'NOVEMBER', 'NOVOBIOTIC', 'NOW', 'NOWADAYS', 'NP', 'NPC', 'NR', 'NRA', 'NRANATIONAL', 'NRAS', 'NRHM', 'NRM', 'NRRV', 'NS', 'NSAPVD2008', 'NSDA', 'NSP', 'NSTDA', 'NSTOP', 'NTD', 'NTDS', 'NTGLIGTES', 'NTL', 'NTLP', 'NTONATALE', 'NTP', 'NU', 'NU19', 'NU2G', 'NU2R', 'NU50', 'NU51', 'NU60', 'NU66', 'NUANCED', 'NUB', 'NUCLEAR', 'NUCLEASES', 'NUCLEIC', 'NUCLEOPROTEIN', 'NUCLEUS', 'NUEVO', 'NUFFIELD', 'NUM', 'NUMBER', 'NUMBERING', 'NUMBERS', 'NUMBERSTHE', 'NUMERACY', 'NUMERATE', 'NUMERICAL', 'NUMEROUS', 'NUMIDA', 'NUMRIQUE', 'NUMTRIQUE', 'NUOC', 'NUR', 'NURSE', 'NURSES', 'NURSES2', 'NURSING', 'NURTURE', 'NUSA', 'NUT', 'NUTRICI', 'NUTRICIN', 'NUTRICION', 'NUTRICIONAL', 'NUTRICIONALES', 'NUTRICIONALESTUDIOS', 'NUTRIENT', 'NUTRIENTDENSE', 'NUTRIENTPOOR', 'NUTRIENTS', 'NUTRIENTS4', 'NUTRIITION', 'NUTRIMENT', 'NUTRITIO', 'NUTRITION', 'NUTRITION10', 'NUTRITIONAL', 'NUTRITIONALLY', 'NUTRITIONARY', 'NUTRITIONCOUNSELLING', 'NUTRITIONRELATED', 'NUTRITIONSENSITIVE', 'NUTRITIOUS', 'NUTSHELL', 'NUWARA', 'NV', 'NVS', 'NWPC', 'NYAH', 'NYALA', 'NYANZA', 'NYASALAND', 'NYUMAKELE', 'NZRKOR', 'NZTRTKORT', 'NZWANI', 'O', 'O1', 'O25B', 'O25BST131', 'OAKLAND', 'OB', 'OBEDIENCE', 'OBESE', 'OBESITY', 'OBESITYNONCOMMUNICABLE', 'OBESOGENIC', 'OBGYN', 'OBJ', 'OBJECT', 'OBJECTIF', 'OBJECTIVE', 'OBJECTIVES', 'OBJECTIVES1', 'OBJECTIVES1PROVIDE', 'OBJECTIVES1TO', 'OBJECTIVESDEVELOPMENT', 'OBJECTIVESMORE', 'OBJECTIVESRES', 'OBJECTIVESTO', 'OBJECTIVESTRAINING', 'OBJECTIVETO', 'OBLAST', 'OBLASTS', 'OBLIGATED', 'OBLIGATION', 'OBLIGATIONS', 'OBLIGATORY', 'OBLIGING', 'OBLIGINGNESS', 'OBLITERATION', 'OBSERVANCE', 'OBSERVATION', 'OBSERVATIONAL', 'OBSERVATIONS', 'OBSERVE', 'OBSERVED', 'OBSERVER', 'OBSERVERS', 'OBSERVING', 'OBSTACLE', 'OBSTACLES', 'OBSTETRIC', 'OBSTETRICAL', 'OBSTETRICALGYNECOLOGICAL', 'OBSTETRICIANSGYNECOLOGISTS', 'OBSTETRICS', 'OBSTRUCTED', 'OBSTRUCTION', 'OBSTRUCTIVE', 'OBSTRUCTS', 'OBSTTTRICAUX', 'OBTAIN', 'OBTAINED', 'OBTAINEDRESULTS', 'OBTAINING', 'OBVIATE', 'OBVIOUS', 'OBVIOUSLY', 'OCAL', 'OCCASION', 'OCCASIONAL', 'OCCIDENTA', 'OCCIDENTAL', 'OCCIDENTALE', 'OCCLUSIVE', 'OCCUPATION', 'OCCUPATIONAL', 'OCCUPIED', 'OCCUR', 'OCCURING', 'OCCURRED', 'OCCURRENCE', 'OCCURRING', 'OCCURS', 'OCEAN', 'OCEANIA', 'OCEANIC', 'OCEANICA', 'OCEANOGRAPHIC', 'OCHAMCHIRETKHVARCHELI', 'OCM', 'OCNITA', 'OCOTEPEQUE', 'OCT', 'OCTOBER', 'OCTONARY', 'OCULAR', 'OCV', 'OCVS', 'OD', 'ODA', 'ODISHA', 'ODOR', 'ODORBASED', 'ODPAD', 'ODPADEM', 'ODS', 'OE15', 'OE151501NU60', 'OECS', 'OECUMENICAL', 'OEPA', 'OESOPHAGEAL', 'OEUVRE', 'OF', 'OFBURULI', 'OFEXCELLENCE', 'OFF', 'OFFENCES', 'OFFENSE', 'OFFER', 'OFFERED', 'OFFERING', 'OFFERINTEGRATION', 'OFFERS', 'OFFICE', 'OFFICEBANGKOK', 'OFFICECAIRO', 'OFFICEESA', 'OFFICEISTANBUL', 'OFFICEKINGSTON', 'OFFICEPANAMA', 'OFFICER', 'OFFICERS', 'OFFICES', 'OFFICESUVA', 'OFFICETOGETHER', 'OFFICEWCA', 'OFFICIAL', 'OFFICIALLY', 'OFFICIALS', 'OFFICIALSPOLICYMAKERS', 'OFFRE', 'OFFSPRING', 'OFFTASTES', 'OFID', 'OFPUBLIC', 'OFSP', 'OFTEN', 'OFTENFATAL', 'OFTHE', 'OFTHESE', 'OG', 'OGA', 'OGAC', 'OGANIZATION', 'OGTT', 'OH', 'OHCEA', 'OHDACA', 'OHDCA', 'OHM', 'OHMIC', 'OHRIDSKI', 'OHW', 'OI', 'OIE', 'OIG', 'OIL', 'OINTMENT', 'OIS', 'OK', 'OKEKE', 'OKLAHOMA', 'OLANCHO', 'OLD', 'OLDER', 'OLDEST', 'OLDS', 'OLFACTORY', 'OM', 'OMAN', 'OMANACCESS', 'OMANDISABILITIES', 'OMANHEALTH', 'OMANHIV', 'OMANHIVAIDS', 'OMANINTERGRATED', 'OMANLEADERSHIP', 'OMANMANAGEMENT', 'OMANMENTAL', 'OMANNATIONAL', 'OMANNONCOMMUNICABLE', 'OMANREPRODUCTIVE', 'OMANVACCINE', 'OMANVACCINEPREVENTABLE', 'OMEGA3FATTY', 'OMICS', 'OMMA', 'OMO', 'OMRH', 'OMRY', 'OMS', 'ON', 'ONBOARDING', 'ONCE', 'ONCHOCERCIASIS', 'ONCOGENESIS', 'ONCOGENIC', 'ONCOLOGICAL', 'ONCOLOGIE', 'ONCOLOGISTS', 'ONCOLOGY', 'ONCOMING', 'ONDEMAND', 'ONE', 'ONEDOSEFITALL', 'ONEHALF', 'ONEHEALTH', 'ONEOFF', 'ONEQUARTER', 'ONES', 'ONESELF', 'ONESIZEFITSMOST', 'ONESTOPSHOP', 'ONETHIRD', 'ONG', 'ONGOING', 'ONGPVD2007134889', 'ONJOB', 'ONLINE', 'ONLY', 'ONPOPULATION', 'ONPROVIDING', 'ONSET', 'ONSITE', 'ONSLAUGHT', 'ONT', 'ONTHEGROUND', 'ONTIME', 'ONTO', 'ONTOGENESIS', 'ONTOGENY', 'ONUS', 'ONWARD', 'OP', 'OPD', 'OPDS', 'OPE', 'OPE1', 'OPEN', 'OPENACCESS', 'OPENED', 'OPENING', 'OPENINGS', 'OPENLABEL', 'OPENLY', 'OPENS', 'OPENSOURCE', 'OPERA', 'OPERABLE', 'OPERATE', 'OPERATED', 'OPERATES', 'OPERATING', 'OPERATION', 'OPERATIONAL', 'OPERATIONALDISTRICTS', 'OPERATIONALIZATION', 'OPERATIONALIZE', 'OPERATIONALIZING', 'OPERATIONALLY', 'OPERATIONS', 'OPERATIVE', 'OPERATORS', 'OPHID', 'OPHTHALMOLOGICAL', 'OPHTHALMOLOGIST', 'OPHTHALMOLOGISTICAL', 'OPHTHALMOLOGISTS', 'OPININ', 'OPINION', 'OPINIONFORMERS', 'OPINIONS', 'OPIOID', 'OPORTUNISITIC', 'OPP', 'OPP1067751', 'OPPORT', 'OPPORTUNISTIC', 'OPPORTUNITIES', 'OPPORTUNITIESTHROUGH', 'OPPORTUNITY', 'OPPOSED', 'OPPOSITE', 'OPPOSITION', 'OPPRESSION', 'OPRATION', 'OPREATING', 'OPTI12262', 'OPTICAL', 'OPTICIANS', 'OPTICSRECENTLY', 'OPTIMAL', 'OPTIMALISATION', 'OPTIMALLY', 'OPTIMISATION', 'OPTIMISE', 'OPTIMISED', 'OPTIMISING', 'OPTIMISTIC', 'OPTIMIZATION', 'OPTIMIZE', 'OPTIMIZED', 'OPTIMIZES', 'OPTIMIZING', 'OPTIMUM', 'OPTION', 'OPTIONALLY', 'OPTIONS', 'OPTIONSBACKYARD', 'OPTIONSSCENARIOS', 'OPTOGENETICS', 'OPTOMETRIST', 'OPTRATION', 'OPV', 'OPV2', 'OR', 'ORA', 'ORADEXON', 'ORAL', 'ORAMGE', 'ORANGE', 'ORBICULAR', 'ORBIT', 'ORCHESTRATE', 'ORDER', 'ORDERHC', 'ORDERING', 'ORDERS', 'ORDINANCE', 'ORDINARILY', 'ORDINARY', 'ORDINATE', 'ORDINATION', 'OREGON', 'OREN', 'ORG', 'ORGAN', 'ORGANELLE', 'ORGANI', 'ORGANIC', 'ORGANISAM', 'ORGANISATION', 'ORGANISATIONAL', 'ORGANISATIONAPPUI', 'ORGANISATIONOS', 'ORGANISATIONS', 'ORGANISE', 'ORGANISED', 'ORGANISING', 'ORGANISM', 'ORGANISMS', 'ORGANIZATION', 'ORGANIZATIONAFRICA', 'ORGANIZATIONAL', 'ORGANIZATIONGLOBAL', 'ORGANIZATIONRECOMMENDED', 'ORGANIZATIONS', 'ORGANIZATIONSAND', 'ORGANIZATIONSTHE', 'ORGANIZE', 'ORGANIZED', 'ORGANIZERS', 'ORGANIZES', 'ORGANIZING', 'ORGANS', 'ORHANISATIONS', 'ORIE', 'ORIENT', 'ORIENTALE', 'ORIENTATING', 'ORIENTATION', 'ORIENTATIONS', 'ORIENTED', 'ORIGAMI', 'ORIGIN', 'ORIGINAATES', 'ORIGINAL', 'ORIGINALLY', 'ORIGINATE', 'ORIGINATED', 'ORIGINATION', 'ORIGINS', 'ORION', 'ORK', 'OROMIA', 'OROTTA', 'ORPHANAGE', 'ORPHANED', 'ORPHANS', 'ORS', 'ORSZINC', 'ORSZN', 'ORTHERN', 'ORTHOLOG', 'ORTHOPAEDIC', 'ORTHOPAEDICS', 'ORTHOPEDIC', 'ORTHOPEDICS', 'ORTHOPTISTS', 'OS', 'OSCILLATION', 'OSEL', 'OSH', 'OSHAKATI', 'OSIER', 'OSLO', 'OSONG', 'OSPEDALE', 'OSSIFICATION', 'OSTEOPOROSIS', 'OSUN', 'OSWALDO', 'OT', 'OTHER', 'OTHERS', 'OTHERWISE', 'OTROS', 'OTS', 'OTTAWA', 'OU', 'OUAGADOUGOU', 'OUCRU', 'OUEST', 'OUR', 'OUT', 'OUT4', 'OUTAND', 'OUTBACK', 'OUTBREAK', 'OUTBREAKS', 'OUTBURST', 'OUTCOM', 'OUTCOME', 'OUTCOMEORIENTED', 'OUTCOMES', 'OUTCOMESACCESS', 'OUTCOMESDESPITE', 'OUTCOMESMITIGATING', 'OUTCOMESOUTCOME', 'OUTCOMESTHE', 'OUTCOMESTHERE', 'OUTCOMESTHIS', 'OUTCOMESWOMEN', 'OUTCOMMES', 'OUTCOMPETE', 'OUTDATED', 'OUTDOOR', 'OUTDOORS', 'OUTER', 'OUTFIT', 'OUTFLOW', 'OUTGO', 'OUTGROWTH', 'OUTILS', 'OUTLAW', 'OUTLAY', 'OUTLET', 'OUTLETS', 'OUTLINE', 'OUTLINED', 'OUTLOOK', 'OUTMIGRATION', 'OUTOFPOCKET', 'OUTOFSCHOOL', 'OUTPATIENT', 'OUTPATIENTS', 'OUTPUT', 'OUTPUTS', 'OUTPUTS1', 'OUTPUTSOUTPUT', 'OUTREACH', 'OUTS', 'OUTSIDE', 'OUTSKIRTS', 'OUTSOURCE', 'OUTSOURCING', 'OUTSTANDING', 'OUTTURN', 'OUTWARD', 'OV', 'OV16', 'OVALE', 'OVARIAN', 'OVC', 'OVCS', 'OVEN', 'OVER', 'OVERACHIEVED', 'OVERALL', 'OVERARCHING', 'OVERCOME', 'OVERCOMING', 'OVERCONSUMPTION', 'OVERCROWDING', 'OVERDOSING', 'OVEREXPRESS', 'OVEREXPRESSING', 'OVERHAUL', 'OVERHEAD', 'OVERLAPS', 'OVERLAY', 'OVERLEAP', 'OVERLOOK', 'OVERLOOKED', 'OVERLY', 'OVERNUTRITION', 'OVERPRESCRIBING', 'OVERPRESCRIPTION', 'OVERSEAS', 'OVERSEASACADEMIC', 'OVERSEE', 'OVERSEEN', 'OVERSIG', 'OVERSIGHT', 'OVERSTATE', 'OVERSTRETCHED', 'OVERTHECOUNTER', 'OVERTURE', 'OVERVIEW', 'OVERWEIGHT', 'OVERWHELMING', 'OVERWORKED', 'OVITZ', 'OWN', 'OWNED', 'OWNERS', 'OWNERSHIP', 'OWNS', 'OXFAM', 'OXFAMAMERICA', 'OXFORD', 'OXFORDINSTITUTE', 'OXIDASES', 'OXIDE', 'OXTR', 'OXTRALPHA2ADRENERGIC', 'OXTRALPHA2AR', 'OXTRD2R', 'OXYGEN', 'OXYTOCIN', 'OY', 'P', 'P2VP8', 'P360', 'P450', 'P4H', 'P5', 'P53', 'P80', 'PA', 'PACAR', 'PACE', 'PACIENTES', 'PACIFIC', 'PACK', 'PACKAGE', 'PACKAGED', 'PACKAGES', 'PACKAGING', 'PACKET', 'PACT', 'PACTO', 'PACTS', 'PAD', 'PADLOCK', 'PADS', 'PAEDIATRIC', 'PAEDIATRICS', 'PAGE', 'PAGES', 'PAHAR', 'PAHO', 'PAID', 'PAIN', 'PAINFUL', 'PAINT', 'PAINTED', 'PAINTERS', 'PAINTING', 'PAIR', 'PAIRING', 'PAKHTUNKHWA', 'PAKISTAN', 'PAKISTANI', 'PAKISTANS', 'PALATE', 'PALAU', 'PALESTINE', 'PALESTINIAN', 'PALESTINIANS', 'PALLIATE', 'PALLIATIVE', 'PALMETTO', 'PALOMA', 'PALS', 'PALSY', 'PAM', 'PAN', 'PANACEA', 'PANADERFA', 'PANAFRICAN', 'PANAFRICANRESEARCH', 'PANAMA', 'PANAMANIANS', 'PANAMERICAN', 'PANBIOME', 'PANCANADIAN', 'PANCHAYAT', 'PANCHAYATI', 'PANCHAYATS', 'PANCHAYTHE', 'PANCREAS', 'PANCREATIC', 'PANDEMIC', 'PANDEMICS', 'PANDER', 'PANDERER', 'PANDJAITAN', 'PANE', 'PANEL', 'PANELS', 'PANGAEA', 'PANGEA', 'PANJAKENT', 'PANMOLECULAR', 'PANORAMA', 'PAPA', 'PAPER', 'PAPERBASED', 'PAPERS', 'PAPILLOMAVIRUS', 'PAPUA', 'PAR', 'PARA', 'PARADIGM', 'PARADISO', 'PARAGRAM', 'PARAGUAY', 'PARALLEL', 'PARALLELFUNDED', 'PARALYSIS', 'PARALYTIC', 'PARALYTICAL', 'PARALYZED', 'PARAMEDICAL', 'PARAMEDICS', 'PARAMETER', 'PARAMETERS', 'PARAMOUNT', 'PARANA', 'PARANAPANEMA', 'PARAPHEROMONE', 'PARASITE', 'PARASITECARRYING', 'PARASITEMIA', 'PARASITES', 'PARASITIC', 'PARASITOLOGICAL', 'PARASITOLOGY', 'PARATRANSGENESIS', 'PARATUS', 'PARCELLING', 'PARDNER', 'PARECIDS', 'PARENT', 'PARENTAGE', 'PARENTAL', 'PARENTHOOD', 'PARENTING', 'PARENTS', 'PARIS', 'PARISH', 'PARISHES', 'PARITULARLY', 'PARK', 'PARKING', 'PARKINSONS', 'PARKISON', 'PARKS', 'PARLIAMENT', 'PARLIAMENTARIAN', 'PARLIAMENTARIANS', 'PARLIAMENTARY', 'PARLIAMENTS', 'PAROMOMYCIN', 'PART', 'PARTENAIRES', 'PARTHERSHIP', 'PARTIAL', 'PARTIALLY', 'PARTICCULARLY', 'PARTICIPA', 'PARTICIPANT', 'PARTICIPANTS', 'PARTICIPANTSRESULT', 'PARTICIPATE', 'PARTICIPATED', 'PARTICIPATEIN', 'PARTICIPATES', 'PARTICIPATING', 'PARTICIPATION', 'PARTICIPATORY', 'PARTICLE', 'PARTICLES', 'PARTICULAR', 'PARTICULARLY', 'PARTICULIFREMENT', 'PARTICULIREMENT', 'PARTIES', 'PARTLY', 'PARTNE', 'PARTNER', 'PARTNERDRIVEN', 'PARTNERED', 'PARTNERING', 'PARTNERL', 'PARTNERREDUCTION', 'PARTNERS', 'PARTNERSFOR', 'PARTNERSHIP', 'PARTNERSHIPBUILDING', 'PARTNERSHIPS', 'PARTNERSHIPSGOI', 'PARTNERSHIPSONE', 'PARTNERSIN', 'PARTNERSPROJECT', 'PARTNERSRESEARCH', 'PARTNERSTHIS', 'PARTNERSUNDERSTANDING', 'PARTS', 'PARTY', 'PARVA', 'PARVUM', 'PASA', 'PASAS', 'PASS', 'PASSAGE', 'PASSED', 'PASSEDEGOVERNMENTRELATED', 'PASSIVE', 'PASSPORT', 'PAST', 'PAST5', 'PASTES', 'PASTEUR', 'PASTEURIZATION', 'PASTORA', 'PASTORAL', 'PASTORALIST', 'PASTORALISTS', 'PASTURES', 'PASUFONS', 'PASW', 'PATCH', 'PATCHY', 'PATENT', 'PATERN', 'PATERNAL', 'PATH', 'PATHEIN', 'PATHETIC', 'PATHFINDER', 'PATHO', 'PATHOGEN', 'PATHOGENESIS', 'PATHOGENIC', 'PATHOGENICITY', 'PATHOGENS', 'PATHOLOGICAL', 'PATHOLOGIES', 'PATHOLOGIST', 'PATHOLOGU', 'PATHOLOGY', 'PATHOPHYSIOLOGICALLYBASED', 'PATHS', 'PATHWAY', 'PATHWAYS', 'PATIENT', 'PATIENTCENTERED', 'PATIENTFRIENDLY', 'PATIENTPROVIDER', 'PATIENTS', 'PATIENTS2', 'PATNA', 'PATOLOGFA', 'PATRICIA', 'PATRICK', 'PATRONAGE', 'PATRONISE', 'PATRONIZE', 'PATTERN', 'PATTERNS', 'PAUCITY', 'PAUL', 'PAULO', 'PAULOBRAZIL', 'PAUPERISM', 'PAUPERIZATION', 'PAUVRES', 'PAY', 'PAYER', 'PAYFORPERFORMANCE', 'PAYING', 'PAYM', 'PAYMENT', 'PAYMENTSTHE', 'PAYOFF', 'PAYS', 'PAZ', 'PB', 'PBF', 'PBLICA', 'PC', 'PCHRD', 'PCM', 'PCMBASED', 'PCR', 'PCRDNA', 'PCRRFLP', 'PCV', 'PD', 'PDC', 'PDF', 'PDL', 'PDP', 'PDPNEGLECTED', 'PDPS', 'PDR', 'PDRCAMBODIA', 'PDSACYCLE', 'PE', 'PEACE', 'PEACEBUILDING', 'PEACETIME', 'PEAK', 'PEAKING', 'PEANUT', 'PECADOM', 'PECKER', 'PECULIAR', 'PECULIARLY', 'PECUNIARY', 'PEDADOGIC', 'PEDAGOGICAL', 'PEDAGOGY', 'PEDANTIC', 'PEDESTRIAN', 'PEDESTRIANS', 'PEDIATRFA', 'PEDIATRIC', 'PEDIATRICDOSAGE', 'PEDIATRICIANS', 'PEDIATRICS', 'PEDIGREE', 'PEDRO', 'PEE', 'PEER', 'PEEREDUCATION', 'PEERNOMINATED', 'PEERREVIEW', 'PEERREVIEWED', 'PEERS', 'PEERSUPPORT', 'PEERTOPEER', 'PEF', 'PEFA', 'PEFAR', 'PEI', 'PEIPING', 'PEKING', 'PEKOT', 'PELF', 'PENALTY', 'PENDANT', 'PENDING', 'PENETRATE', 'PENH', 'PENH8', 'PENHRESULTS', 'PENICILLINS', 'PENICILLIOSI', 'PENINSULA', 'PENIS', 'PENITENTIARIES', 'PENITENTIARY', 'PENNSYLVANIA', 'PENNY', 'PENSIFRES', 'PENTAD', 'PENTAMIDINE', 'PENTAVALENT', 'PENTECOSTAL', 'PENURY', 'PEOPLE', 'PEOPLECENTERED', 'PEOPLECENTRED', 'PEOPLERESEARCH', 'PEOPLERESULTS', 'PEOPLES', 'PEOPLESC', 'PEOPLESSRHR', 'PEOPLETHE', 'PEOPLETOPEOPLE', 'PEOPLEULTIMATELY', 'PEP', 'PEPFAR', 'PEPFAROGAC', 'PEPFARS', 'PEPPER', 'PEPTIC', 'PEPTIDE', 'PEPTIDES', 'PEPUBLIC', 'PER', 'PERC6', 'PERCEIVE', 'PERCEIVED', 'PERCEIVER', 'PERCENT', 'PERCENTAGE', 'PERCEPTION', 'PERCEPTIONS', 'PERCH', 'PERCIPIENT', 'PEREGRINE', 'PERFECT', 'PERFORM', 'PERFORMANCE', 'PERFORMANCE2', 'PERFORMANCEAS', 'PERFORMANCEBASED', 'PERFORMANCETHE', 'PERFORMANCEUP', 'PERFORMED', 'PERFORMING', 'PERFROMANCE', 'PERFUSION', 'PERI', 'PERICONCEPTIONFIRST', 'PERIDOMESTIC', 'PERIL', 'PERINATAL', 'PERINATOLOGY', 'PERIOD', 'PERIODIC', 'PERIODICAL', 'PERIODONTITIS', 'PERIODS', 'PERIODWE', 'PERIPARTUM', 'PERIPHERAL', 'PERITONEAL', 'PERIURBAN', 'PERIURBANAS', 'PERMANENT', 'PERMEABILITY', 'PERMET', 'PERMISSION', 'PERMISSIVE', 'PERMIT', 'PERMITTED', 'PERMUTATION', 'PEROSNS', 'PERPETRATORS', 'PERPETUATE', 'PERSISENT', 'PERSIST', 'PERSISTENCE', 'PERSISTENT', 'PERSISTER', 'PERSISTERS', 'PERSISTS', 'PERSON', 'PERSONAL', 'PERSONALISED', 'PERSONALISING', 'PERSONALIZED', 'PERSONALLY', 'PERSONAS', 'PERSONATION', 'PERSONELL', 'PERSONIFY', 'PERSONNEL', 'PERSONS', 'PERSPECTIVAS', 'PERSPECTIVE', 'PERSPECTIVES', 'PERSUADE', 'PERTAIN', 'PERTAINING', 'PERTINENT', 'PERTINENTS', 'PERTOTAL', 'PERTUSSIS', 'PERU', 'PERUANA', 'PERUEVIDENCE', 'PERUS', 'PERUVIAN', 'PERUVIANS', 'PERVASIVE', 'PESA', 'PESCARA', 'PESTICIDE', 'PESTICIDES', 'PESTIS', 'PESTS', 'PET', 'PETCT', 'PETER', 'PETIT', 'PETTING', 'PF', 'PFALCIPARUM', 'PFM', 'PFMDR1', 'PFRH5', 'PFS', 'PFS25', 'PFS48', 'PFS4845', 'PFSCM', 'PFSRHR', 'PGHST', 'PH', 'PH1B', 'PHA', 'PHAGE', 'PHAGEBIOTICS', 'PHAGES', 'PHAGOCYTOSIS', 'PHAMESA', 'PHARMA', 'PHARMACEUTI', 'PHARMACEUTIC', 'PHARMACEUTICAL', 'PHARMACEUTICALS', 'PHARMACEUTICS', 'PHARMACIES', 'PHARMACIST', 'PHARMACISTS', 'PHARMACODYNAMIC', 'PHARMACODYNAMICS', 'PHARMACOGENETIC', 'PHARMACOGENETICS', 'PHARMACOKINETIC', 'PHARMACOKINETICS', 'PHARMACOLOGIC', 'PHARMACOLOGICAL', 'PHARMACOLOGICALLY', 'PHARMACOMETRIC', 'PHARMACOVIGILANCE', 'PHARMACY', 'PHARMACYSHORTTERM', 'PHARMOCOKINETICS', 'PHASE', 'PHASE1', 'PHASECORE', 'PHASED', 'PHASES', 'PHASING', 'PHC', 'PHCS', 'PHCU', 'PHD', 'PHDI', 'PHDMASTERS', 'PHDS', 'PHDSTUDENTS', 'PHEIC', 'PHENEPLATE', 'PHENOMENON', 'PHENOTYPE', 'PHENOTYPES', 'PHENOTYPIC', 'PHENOTYPICALLY', 'PHENYLBUTYRATE', 'PHEROMONE', 'PHI', 'PHIL', 'PHILANTHROPIC', 'PHILANTHROPIES', 'PHILANTHROPY', 'PHILHEALTH', 'PHILIP', 'PHILIPPINE', 'PHILIPPINES', 'PHILLIPS', 'PHILOSOPHY', 'PHIND', 'PHLEBO', 'PHLEBOVIRUSES', 'PHLEGM', 'PHM', 'PHNOM', 'PHNOMPENH', 'PHOBIA', 'PHOEBE', 'PHOENIX', 'PHONE', 'PHONEBASED', 'PHONECOUNSELLING', 'PHONES', 'PHOSPHATASES', 'PHOSPHORUS', 'PHOTOACTIVATED', 'PHOTOCALORIMETERS', 'PHOTODYNAMIC', 'PHOTOGRAPH', 'PHOTOLUMINESCENT', 'PHOTONIC', 'PHPR', 'PHRASE', 'PHRATRY', 'PHRENITIS', 'PHRST', 'PHSTABLE', 'PHTALOCYANINEQUANTUM', 'PHTHISIS', 'PHYLOGEOGRAPHIC', 'PHYLOGEOPGRAPHIC', 'PHYSICAL', 'PHYSICALLY', 'PHYSICIAN', 'PHYSICIANS', 'PHYSICOCHEMICAL', 'PHYSIOLOGICAL', 'PHYSIOLOGY', 'PHYSIOTHERAPY', 'PHYTOCHEMICAL', 'PHYTOMEDICINAL', 'PHYTOPLANKTON', 'PHYTOSTEROIDS', 'PI', 'PIAN', 'PIBOTS', 'PIC', 'PICK', 'PICKER', 'PICKERS', 'PICKY', 'PICORNAVIRUS', 'PICS', 'PICTURE', 'PICTURES', 'PIDDLE', 'PIDM', 'PIDMIOLOGIQUE', 'PIECE', 'PIECEMEAL', 'PIECES', 'PIERO', 'PIFTE', 'PIG', 'PIGBOAT', 'PIGLET', 'PIGMENT', 'PIGS', 'PIHT', 'PILE', 'PILLAR', 'PILLARS', 'PILOT', 'PILOTED', 'PILOTING', 'PILOTS', 'PILOTTEST', 'PIMP', 'PIMS', 'PINCH', 'PINCHING', 'PING', 'PIO', 'PIOET', 'PIONEERED', 'PIONEERING', 'PIONEERS', 'PIP', 'PIPE', 'PIPELINE', 'PIPERAQUINE', 'PIPF', 'PIPOC', 'PIPPSE', 'PIS', 'PISS', 'PIT', 'PITCH', 'PITCHED', 'PITEOUS', 'PITH', 'PITIABLE', 'PITIFUL', 'PITS', 'PITTSBURGH', 'PIVOT', 'PIVOTAL', 'PK', 'PKDL', 'PKPD', 'PLA', 'PLACE', 'PLACEBO', 'PLACEBOCONTROLLED', 'PLACED', 'PLACEMENT', 'PLACEMENTS', 'PLACENTA', 'PLACENTAL', 'PLACES', 'PLACING', 'PLAGUE', 'PLAIN', 'PLAINS', 'PLAN', 'PLAN5', 'PLANAT', 'PLANCK', 'PLANEFFORTS', 'PLANETARY', 'PLANHEALTH', 'PLANIFICATION', 'PLANKTON', 'PLANKTONIC', 'PLANNED', 'PLANNERS', 'PLANNING', 'PLANNINGREPRODUCTIVE', 'PLANNINGTHIS', 'PLANS', 'PLANS12110', 'PLANSINCREASE', 'PLANT', 'PLANTBASED', 'PLANTFLUVAC', 'PLANTHE', 'PLANTS', 'PLANTSWE', 'PLASM', 'PLASMA', 'PLASMODIA', 'PLASMODIAL', 'PLASMODIUM', 'PLASMONIC', 'PLASTIC', 'PLASTICITY', 'PLATE', 'PLATEAU', 'PLATELETS', 'PLATFORM', 'PLATFORMRESOURCES', 'PLATFORMS', 'PLAUGE', 'PLAUSIBLE', 'PLAY', 'PLAYACTING', 'PLAYED', 'PLAYER', 'PLAYERS', 'PLAYERSGOOD', 'PLAYING', 'PLAYS', 'PLC', 'PLEADER', 'PLEASE', 'PLEASURABLE', 'PLEBEIAN', 'PLEDGE', 'PLEDGED', 'PLENARY', 'PLETHORA', 'PLHA', 'PLHAONE', 'PLHAS', 'PLHIV', 'PLOT', 'PLOUGHSHARE', 'PLOW', 'PLOWSHARE', 'PLUCKING', 'PLUG', 'PLUGANDDISPLAY', 'PLUMP', 'PLUNK', 'PLURIANNUELS', 'PLURIANUAL', 'PLURIPOTENT', 'PLUS', 'PLW', 'PLWH', 'PLWH1', 'PLWHA', 'PLWHAS', 'PLY', 'PM', 'PME', 'PMI', 'PMNCH', 'PMNCHS', 'PMT', 'PMTCT', 'PNEUMOCOCAL', 'PNEUMOCOCCAL', 'PNEUMOCOCCI', 'PNEUMOCOCCUS', 'PNEUMONIA', 'PNEUMONIAE', 'PNG', 'PNIPH', 'PNN', 'PNS', 'PO', 'POACHED', 'POACHING', 'POBLACIN', 'POBREZA', 'POC', 'POCKETS', 'PODER', 'PODOCONIOSIS', 'POE', 'POETRY', 'POFILING', 'POINT', 'POINTED', 'POINTOFCARE', 'POINTS', 'POISED', 'POKE', 'POLANDHEALTH', 'POLANDINTERGRATED', 'POLANDLEADERSHIP', 'POLANDNATIONAL', 'POLANDNONCOMMUNICABLE', 'POLANDNUTRITION', 'POLANDSOCIAL', 'POLE', 'POLES', 'POLFTICA', 'POLICE', 'POLICIES', 'POLICIESRESEARCH', 'POLICIESTHIS', 'POLICLINICO', 'POLICY', 'POLICY1', 'POLICYADVICE', 'POLICYADVOCACY', 'POLICYCOUNTRIES', 'POLICYDEVELOPMENT', 'POLICYDISCUSSIONS', 'POLICYINFORMED', 'POLICYISSUES', 'POLICYMAKERS', 'POLICYMAKERSLITTLE', 'POLICYMAKERSTECHNICAL', 'POLICYMAKERSTHE', 'POLICYMAKING', 'POLICYMAKINGBETTER', 'POLICYPRACTICE', 'POLICYRELEVANT', 'POLICYSAVVY', 'POLICYSPECIFICALLY', 'POLIO', 'POLIOBEGGERS', 'POLIOENDEMIC', 'POLIOERADICATION', 'POLIOFREE', 'POLIOMIELITIS', 'POLIOMY', 'POLIOMYELITIS', 'POLIOMYLITE', 'POLIOMYTLITE', 'POLIOPLUS', 'POLIOTECHNICAL', 'POLIOVIRUS', 'POLIOVIRUSES', 'POLISES', 'POLISHING', 'POLITE', 'POLITIC', 'POLITICAL', 'POLITICALLY', 'POLITICALLYAWARE', 'POLITICALSECURITY', 'POLITICIANS', 'POLITIQUE', 'POLITIQUES', 'POLL', 'POLLINATION', 'POLLINATOR', 'POLLINATORS', 'POLLOI', 'POLLUTANT', 'POLLUTANTS', 'POLLUTION', 'POLLUTIONEXPOSURE', 'POLTICA', 'POLY', 'POLYGLYCEROL', 'POLYMER', 'POLYMERIC', 'POLYMERS', 'POLYMERSOMES', 'POLYMORPHIC', 'POLYMORPHISM', 'POLYMORPHISMS', 'POLYNESIANATIONAL', 'POLYNEUROPATHY', 'POLYOMIELITIS', 'POLYPARASITIC', 'POLYPARASITISM', 'POLYPHENOLS', 'POLYPHOSPHATE', 'POLYSACCHARIDE', 'POLYSPECIFIC', 'POLYTECHNICS', 'POLYURETHANE', 'POLYVALENT', 'PONCE', 'PONDS', 'PONTAL', 'PONTIFICIA', 'POOL', 'POOLED', 'POOLING', 'POOR', 'POORE', 'POORER', 'POOREST', 'POORLY', 'POORNESS', 'POP', 'POPDA', 'POPOLAZIONE', 'POPU', 'POPULACE', 'POPULAR', 'POPULARES', 'POPULARLY', 'POPULATED', 'POPULATIO', 'POPULATION', 'POPULATION4STRATEGIES', 'POPULATIONBASED', 'POPULATIONGIVEN', 'POPULATIONLEVEL', 'POPULATIONS', 'POPULATIONS2', 'POPULATIONSONLY', 'POPULATIONSPECIFIC', 'POPULATIONTARGET', 'POPULATIONWIDE', 'POR', 'PORE', 'PORRES', 'PORRIDGE', 'PORT', 'PORTABLE', 'PORTAL', 'PORTAUPRINCE', 'PORTENT', 'PORTERS', 'PORTFOLIO', 'PORTION', 'PORTO', 'PORTRAIT', 'PORTS', 'PORTTE', 'PORTUGAL', 'PORTUGUESE', 'POS', 'POSE', 'POSED', 'POSES', 'POSING', 'POSITION', 'POSITIONED', 'POSITIONING', 'POSITIONS', 'POSITIONUNIVERSITY', 'POSITIVE', 'POSITIVELY', 'POSITIVES', 'POSITIVIST', 'POSITIVISTIC', 'POSITIVITY', 'POSSESS', 'POSSESSING', 'POSSESSION', 'POSSIBILITIES', 'POSSIBILITY', 'POSSIBLE', 'POSSIBLITY', 'POSSIBLY', 'POST', 'POST2015', 'POSTABORTION', 'POSTAL', 'POSTARMED', 'POSTCERTIFICATION', 'POSTCONFLICT', 'POSTDATE', 'POSTDISASTER', 'POSTDOC', 'POSTDOCTORAL', 'POSTDROUGHT', 'POSTEARTHQUAKE', 'POSTEBOLA', 'POSTED', 'POSTER', 'POSTERADICATION', 'POSTERIOR', 'POSTERS', 'POSTGRAD', 'POSTGRADUATE', 'POSTGRADUATES', 'POSTHARVEST', 'POSTHELD', 'POSTHOC', 'POSTINTERVENTION', 'POSTIVE', 'POSTKALAAZAR', 'POSTMILLENNIUM', 'POSTNATAL', 'POSTNATALLY', 'POSTOPERATIVE', 'POSTPARTUM', 'POSTROTAVIRUS', 'POSTS', 'POSTSCRIPT', 'POSTSECONDARY', 'POSTSOVIET', 'POSTTEST', 'POSTTRAINING', 'POSTTRANINING', 'POSTTREATMENT', 'POSTULATE', 'POSTURE', 'POSTWAR', 'POT', 'POTABLE', 'POTASSIUM', 'POTATO', 'POTATOE', 'POTATOES', 'POTBELLY', 'POTENCY', 'POTENT', 'POTENTIAL', 'POTENTIALLY', 'POTOS', 'POTOSF', 'POTOSI', 'POTS', 'POULTRY', 'POULTRYGARDENS', 'POUND', 'POUR', 'POURSUITE', 'POVERTY', 'POVERTYDRUGS', 'POVERTYRELAETED', 'POVERTYRELATED', 'POVERY', 'POVERYRELATED', 'POVODNMI', 'POW', 'POWDER', 'POWER', 'POWERED', 'POWERFUL', 'POWERHOUSE', 'POWERS', 'POXPROTEIN', 'PPFP', 'PPMVS', 'PPP', 'PPPGDM', 'PPPS', 'PPTC', 'PR', 'PRACTICABLE', 'PRACTICAL', 'PRACTICALLY', 'PRACTICE', 'PRACTICECONNECTING', 'PRACTICED', 'PRACTICEHEALTH', 'PRACTICERESULT', 'PRACTICES', 'PRACTICESAND', 'PRACTICESP360', 'PRACTICESRES', 'PRACTICESROUTINE', 'PRACTICETHE', 'PRACTICING', 'PRACTISED', 'PRACTISES', 'PRACTISING', 'PRACTITIONER', 'PRACTITIONERS', 'PRADESH', 'PRAGMATIC', 'PRAT', 'PRATIQUES', 'PRAXIS', 'PRAZIQUANTEL', 'PRC', 'PRE', 'PREACCESSION', 'PREACH', 'PREAND', 'PREANTIMICROBIAL', 'PRECANCEROUS', 'PRECAUTION', 'PRECAUTIONARY', 'PRECEDE', 'PRECEDENCE', 'PRECEDENCY', 'PRECEPTOR', 'PRECIPITATION', 'PRECISE', 'PRECISELY', 'PRECLINICAL', 'PRECLUDE', 'PRECONCEPTIONAL', 'PRECONDITION', 'PRECONDITIONS', 'PRECONFERENCE', 'PREDEFINED', 'PREDICITIVE', 'PREDICT', 'PREDICT2', 'PREDICTABLE', 'PREDICTED', 'PREDICTING', 'PREDICTION', 'PREDICTIONS', 'PREDICTIVE', 'PREDICTOR', 'PREDICTS', 'PREDISPOSES', 'PREDISPOSING', 'PREDISPOSITION', 'PREDOMINANT', 'PREDOMINANTELY', 'PREDOMINANTLY', 'PREECLAMPSIA', 'PREECLAMPSIAECLAMPSIA', 'PREECLAMPSIAMALARIA', 'PREECLAMPTIC', 'PREELIMINATION', 'PREEMINENT', 'PREERADICATION', 'PREERYTHROCYTIC', 'PREEXISTING', 'PREEXPOSURE', 'PREFERABLE', 'PREFERABLY', 'PREFERENCE', 'PREFERENCES', 'PREFERENCESIN', 'PREFERENTIALLY', 'PREFERRED', 'PREGNANCIES', 'PREGNANCY', 'PREGNANCYASSOCIATED', 'PREGNANCYINDUCED', 'PREGNANCYRELATED', 'PREGNANT', 'PREJUDICE', 'PRELATE', 'PRELIMINARY', 'PREMATURE', 'PREMIER', 'PREMISE', 'PREMISES', 'PRENATAL', 'PRENATALLY', 'PREOPENING', 'PREOPERATIVE', 'PREP', 'PREPACKAGED', 'PREPACKED', 'PREPANDEMIC', 'PREPARATION', 'PREPARATIONS', 'PREPARATIONTWO', 'PREPARATIVE', 'PREPARATORY', 'PREPARE', 'PREPARED', 'PREPAREDNESS', 'PREPARING', 'PREPAYMENT', 'PREPONDERANCE', 'PREPREGNANCY', 'PREQUALIFICATION', 'PREREQUISITE', 'PREREQUISITES', 'PRESCHOOL', 'PRESCRIBE', 'PRESCRIBED', 'PRESCRIBING', 'PRESCRIPTION', 'PRESCRIPTIONS', 'PRESCRIPTIVE', 'PRESENCE', 'PRESENT', 'PRESENTATION', 'PRESENTATIONS', 'PRESENTATIONSFULL', 'PRESENTATIONSPROJECT', 'PRESENTED', 'PRESENTERS', 'PRESENTING', 'PRESENTLY', 'PRESENTS', 'PRESERVATION', 'PRESERVE', 'PRESERVED', 'PRESERVICE', 'PRESIDENCY', 'PRESIDENT', 'PRESIDENTIAL', 'PRESIDENTS', 'PRESS', 'PRESSING', 'PRESSURE', 'PRESSURES', 'PRESTASI', 'PRESTIGIOUS', 'PRESTON', 'PRESUMPTIVE', 'PRESUMPTIVELY', 'PRESYMPTOMATIC', 'PRETEND', 'PRETERM', 'PRETERMLOW', 'PRETESTEDRESULT', 'PRETORIA', 'PRETRIAL', 'PREV', 'PREVACCINE', 'PREVAIL', 'PREVAILING', 'PREVALENCE', 'PREVALENCES', 'PREVALENT', 'PREVENAO', 'PREVENCIN', 'PREVENT', 'PREVENTABLE', 'PREVENTATIVE', 'PREVENTED', 'PREVENTING', 'PREVENTION', 'PREVENTIONCARE', 'PREVENTIONDENGUE', 'PREVENTIONGREATER', 'PREVENTIONHIV', 'PREVENTIONS', 'PREVENTIVE', 'PREVENTREDUCE', 'PREVENTS', 'PREVENZIONE', 'PREVETNION', 'PREVIOUS', 'PREVIOUSLY', 'PREY', 'PRG', 'PRI', 'PRIAMRY', 'PRICE', 'PRICED', 'PRICEELASTICITIES', 'PRICES', 'PRICING', 'PRICK', 'PRIMAI', 'PRIMAIRES', 'PRIMAL', 'PRIMAQUINE', 'PRIMAQUINES', 'PRIMARIA', 'PRIMARILY', 'PRIMARY', 'PRIMATE', 'PRIMATES', 'PRIME', 'PRIMEBOOSTREBOOST', 'PRIMED', 'PRIMING', 'PRINCE', 'PRINCETON', 'PRINCIPAL', 'PRINCIPALLY', 'PRINCIPALS', 'PRINCIPE', 'PRINCIPLE', 'PRINCIPLES', 'PRINT', 'PRINTED', 'PRINTING', 'PRION', 'PRIOR', 'PRIORITIES', 'PRIORITIESGOOD', 'PRIORITIESNCDP', 'PRIORITIESRESULT', 'PRIORITIESTHIS', 'PRIORITISATION', 'PRIORITISE', 'PRIORITISED', 'PRIORITISING', 'PRIORITIZATION', 'PRIORITIZE', 'PRIORITIZED', 'PRIORITIZES', 'PRIORITIZING', 'PRIORITY', 'PRIORITYDRIVEN', 'PRIORITYSETTING', 'PRISON', 'PRISONCREATING', 'PRISONER', 'PRISONERS', 'PRISONERSSINCE', 'PRISONS', 'PRISONS2', 'PRISTINA', 'PRIVAT', 'PRIVATE', 'PRIVATEHEALTH', 'PRIVATEPUBLIC', 'PRIVATESECTOR', 'PRIVATSPITAL', 'PRIVILEDGED', 'PRIVILEGED', 'PRIVILEGES', 'PRIVY', 'PRIZE', 'PRL1051', 'PRO', 'PROACT', 'PROACTIVELY', 'PROATENCION', 'PROBABLE', 'PROBABLY', 'PROBE', 'PROBED', 'PROBES', 'PROBETAGGED', 'PROBING', 'PROBIOTIC', 'PROBLEM', 'PROBLEMATIC', 'PROBLEMBASED', 'PROBLEMIN', 'PROBLEMS', 'PROBLEMTHE', 'PROBLFMES', 'PROBLMES', 'PROCARCINOGENIC', 'PROCEDURE', 'PROCEDURES', 'PROCEDURES1', 'PROCEDURESUNITED', 'PROCEED', 'PROCEEDS', 'PROCESOS', 'PROCESS', 'PROCESSED', 'PROCESSES', 'PROCESSESSENTIAL', 'PROCESSIMPROVING', 'PROCESSING', 'PROCESSION', 'PROCESSORS', 'PROCREATION', 'PROCREATIVE', 'PROCTOR', 'PROCURAL', 'PROCURANCE', 'PROCURE', 'PROCUREMEN', 'PROCUREMENT', 'PROCUREMENTS', 'PROCURER', 'PROCURERS', 'PROCURES', 'PROCURING', 'PROCURMENT', 'PRODCUED', 'PRODUCE', 'PRODUCED', 'PRODUCEKNOWLEDGE', 'PRODUCER', 'PRODUCERS', 'PRODUCERSBUSINESSES', 'PRODUCES', 'PRODUCING', 'PRODUCT', 'PRODUCTBASED', 'PRODUCTION', 'PRODUCTIONS', 'PRODUCTIVE', 'PRODUCTIVITY', 'PRODUCTNEUTRAL', 'PRODUCTS', 'PRODUITS', 'PROFESIONAL', 'PROFESS', 'PROFESSION', 'PROFESSIONAL', 'PROFESSIONALS', 'PROFESSIONS', 'PROFESSOR', 'PROFESSORS', 'PROFICIENCY', 'PROFICIENT', 'PROFILE', 'PROFILES', 'PROFILING', 'PROFIT', 'PROFITABILITY', 'PROFOUND', 'PROFOUNDLY', 'PROFOUNDNESS', 'PROG', 'PROGAM', 'PROGESTIN', 'PROGESTINONLY', 'PROGNOSES', 'PROGNOSIS', 'PROGNOSTIC', 'PROGNOSTICATIVE', 'PROGPLURIANNUELS', 'PROGR', 'PROGRAM', 'PROGRAMA', 'PROGRAMABOUT', 'PROGRAMACIN', 'PROGRAMBENCHMARKING', 'PROGRAMDEVELOPMENT', 'PROGRAME', 'PROGRAMEXPECTED', 'PROGRAMFUNDED', 'PROGRAMGHANA', 'PROGRAMIMPLEMENTATION', 'PROGRAMM', 'PROGRAMMA', 'PROGRAMMATIC', 'PROGRAMMATICALLY', 'PROGRAMME', 'PROGRAMME3', 'PROGRAMMED', 'PROGRAMMEPAEDIATRIC', 'PROGRAMMES', 'PROGRAMMESHAS', 'PROGRAMMESOCIAL', 'PROGRAMMESPOLICIES', 'PROGRAMMETO', 'PROGRAMMING', 'PROGRAMMINGTHIS', 'PROGRAMMRE', 'PROGRAMMS', 'PROGRAMS', 'PROGRAMSTHE', 'PROGRAMTHE', 'PROGRAMTHIS', 'PROGRESS', 'PROGRESSED', 'PROGRESSES', 'PROGRESSION', 'PROGRESSIONWE', 'PROGRESSIVE', 'PROGRESSIVELY', 'PROGRESSOR', 'PROGRESSORS', 'PROINFLAMMATORY', 'PROJ', 'PROJECT', 'PROJECT2', 'PROJECTA', 'PROJECTAN', 'PROJECTED', 'PROJECTFOOD', 'PROJECTFOR', 'PROJECTFUNDED', 'PROJECTING', 'PROJECTION', 'PROJECTIONS', 'PROJECTRESEARCHERS', 'PROJECTS', 'PROJECTTHE', 'PROJECTWE', 'PROJEKT', 'PROJET', 'PROJETS', 'PROLE', 'PROLETARIAN', 'PROLIFERATION', 'PROLONG', 'PROLONGATION', 'PROLONGED', 'PROLONGING', 'PROMEQUALAB', 'PROMGRAMA', 'PROMINENCE', 'PROMINENT', 'PROMISCUOUS', 'PROMISE', 'PROMISES', 'PROMISING', 'PROMOTE', 'PROMOTED', 'PROMOTERS', 'PROMOTES', 'PROMOTING', 'PROMOTION', 'PROMOTIONAL', 'PROMOTIVE', 'PROMOVER', 'PROMPT', 'PROMPTED', 'PROMPTING', 'PROMPTLY', 'PROMPTS', 'PROMULGATION', 'PROMUNDO', 'PRONE', 'PRONGED', 'PRONOUNCE', 'PRONOUNCED', 'PROOF', 'PROOFOFCONCEPT', 'PROOFOFPRINCIPLE', 'PROPAGATE', 'PROPAGATION', 'PROPEL', 'PROPELLER', 'PROPER', 'PROPERLY', 'PROPERTIES', 'PROPERTY', 'PROPHYLACTIC', 'PROPHYLAXIS', 'PROPONENT', 'PROPONENTS', 'PROPOOR', 'PROPORTION', 'PROPORTIONS', 'PROPOSAL', 'PROPOSALA', 'PROPOSALMEETINGS', 'PROPOSALS', 'PROPOSALS3', 'PROPOSE', 'PROPOSED', 'PROPOSES', 'PROPRE', 'PROPRIETARY', 'PROSECUTE', 'PROSECUTING', 'PROSJEKT', 'PROSPECT', 'PROSPECTIVE', 'PROSPECTS', 'PROSPECTUS', 'PROSPERITY', 'PROSTHESES', 'PROSTHETIC', 'PROSTHETICS', 'PROSTITUTES', 'PROTAGONISM', 'PROTE', 'PROTEASES', 'PROTEC', 'PROTECT', 'PROTECTED', 'PROTECTING', 'PROTECTIO', 'PROTECTION', 'PROTECTIVE', 'PROTECTOR', 'PROTECTPROLONG', 'PROTECTS', 'PROTEIN', 'PROTEINCARBON', 'PROTEINCOUPLED', 'PROTEINS', 'PROTEOGENOMIC', 'PROTEOLYSIS', 'PROTEOME', 'PROTEOMIC', 'PROTEOMICS', 'PROTESTING', 'PROTOCOL', 'PROTOCOLS', 'PROTOMER', 'PROTOTYPE', 'PROTOTYPES', 'PROTOZOA', 'PROTOZOAN', 'PROTRACTED', 'PROVDE', 'PROVE', 'PROVED', 'PROVEN', 'PROVENANCE', 'PROVENDER', 'PROVENTION', 'PROVERY', 'PROVERYRELATED', 'PROVES', 'PROVIDE', 'PROVIDEAVH', 'PROVIDED', 'PROVIDEDACADEMIC', 'PROVIDER', 'PROVIDERS', 'PROVIDES', 'PROVIDING', 'PROVIDNG', 'PROVIN', 'PROVINCE', 'PROVINCES', 'PROVINCESDISTRICTS', 'PROVINCETHE', 'PROVINCIA', 'PROVINCIAL', 'PROVINCIALCOUNTY', 'PROVING', 'PROVISION', 'PROVISIONS', 'PROVISO', 'PROVITAMIN', 'PROVOKE', 'PROXIMAL', 'PROXIMITY', 'PROYECTO', 'PROYOUTH', 'PRSP', 'PRTCTDTE', 'PRTVENTION', 'PRTVENTIVE', 'PRVENTION', 'PRVENTIVE', 'PS10', 'PS1010141NU2G', 'PSA', 'PSAMIMETICS', 'PSC', 'PSCS', 'PSED', 'PSEUDOMALLEI', 'PSHIS', 'PSI', 'PSMB', 'PSNP', 'PSP1', 'PSPONE', 'PSPONES', 'PSTC', 'PSYCH', 'PSYCHIATRIC', 'PSYCHIATRISTS', 'PSYCHIATRY', 'PSYCHIATRY2', 'PSYCHOANALYSE', 'PSYCHOANALYSIS', 'PSYCHOANALYZE', 'PSYCHOLOGICAL', 'PSYCHOLOGIST', 'PSYCHOLOGISTS', 'PSYCHOLOGY', 'PSYCHOMETRIC', 'PSYCHOMOTOR', 'PSYCHOREHAB', 'PSYCHOREHABILITATION', 'PSYCHOSIS', 'PSYCHOSOCIAL', 'PSYCHOTIC', 'PSYCHOTROPICS', 'PTA', 'PTP', 'PTP1B', 'PTPOMES', 'PTPRO', 'PTPS', 'PTY', 'PTYCHOGRAPHIC', 'PUB', 'PUBERTY', 'PUBLIC', 'PUBLICA', 'PUBLICALLY', 'PUBLICALLYACCESSIBLE', 'PUBLICATION', 'PUBLICATIONS', 'PUBLICITY', 'PUBLICLY', 'PUBLICPARTNERSHIPS', 'PUBLICPRIVATE', 'PUBLICS', 'PUBLICSECTOR', 'PUBLIQUE', 'PUBLISH', 'PUBLISHED', 'PUBLISHING', 'PUCCINIA', 'PUENTE', 'PUERILITY', 'PUESTA', 'PUJEHUN', 'PULL', 'PULMONARY', 'PULSE', 'PULSED', 'PUMP', 'PUNJAB', 'PUNTER', 'PUNTLAND', 'PUPILS', 'PUPPET', 'PURCHASE', 'PURCHASED', 'PURCHASERPROVIDER', 'PURCHASES', 'PURCHASING', 'PURDUE', 'PURIFICATION', 'PURPOSE', 'PURPOSEFUL', 'PURPOSES', 'PURPOSESSTRENGTHENS', 'PURSUE', 'PURSUING', 'PURSUIT', 'PUSH', 'PUSHPULL', 'PUT', 'PUTATIVE', 'PUTRIDNESS', 'PUTS', 'PUTTALAM', 'PUTTING', 'PUTZ', 'PV', 'PVD', 'PVDBPRII', 'PVDS', 'PVDSTHE', 'PVO', 'PVS', 'PVT', 'PWANI', 'PWC', 'PWD', 'PWDS', 'PWID', 'PYLORI', 'PYLORIINDUCED', 'PYLORUS', 'PYONGYANG', 'PYRAMID', 'PYRETHROID', 'PYREXIA', 'PYROPHOSPHATASES', 'PYRROLOPYRIMIDINES', 'PZA', 'QA', 'QASI', 'QASIS', 'QATARHEALTH', 'QATARHIV', 'QATARHIVAIDS', 'QATARINTERGRATED', 'QATARVACCINE', 'QATARVACCINEPREVENTABLE', 'QENA', 'QHCP', 'QINGDAO', 'QMGMPSI', 'QMUMUNOPS', 'QOQANI', 'QPCR', 'QS', 'QSBACTERIAL', 'QSR2FLCWLOTMXBWNM', 'QUADRUPLET', 'QUADRUPLEX', 'QUALIFICATION', 'QUALIFICATIONS', 'QUALIFIED', 'QUALIFIT', 'QUALIFY', 'QUALIFYING', 'QUALIT', 'QUALITATIVE', 'QUALITATIVELY', 'QUALITIVELY', 'QUALITT', 'QUALITY', 'QUALITY2', 'QUALITYADJUSTED', 'QUALITYASSURED', 'QUALITYENSUREDLABORATORY', 'QUALITYTHIS', 'QUALTITY', 'QUAMED', 'QUANG', 'QUANTIATIVE', 'QUANTIFICATION', 'QUANTIFIED', 'QUANTIFY', 'QUANTIFYING', 'QUANTITATIVE', 'QUANTITIES', 'QUANTITY', 'QUARANTINE', 'QUARRY', 'QUARTER', 'QUARTERLY', 'QUARTET', 'QUARTIERS', 'QUASH', 'QUASIEXPERIMENTAL', 'QUASISPECIES', 'QUATERN', 'QUATERNARY', 'QUATERNION', 'QUATERNITY', 'QUE', 'QUEEN', 'QUEENSLAND', 'QUEM', 'QUENA', 'QUERY', 'QUEST', 'QUESTION', 'QUESTIONED', 'QUESTIONNAIRES', 'QUESTIONS', 'QUETCH', 'QUI', 'QUICK', 'QUICKEN', 'QUICKENING', 'QUICKLY', 'QUICKNESS', 'QUID', 'QUIMICOS', 'QUININE', 'QUINT', 'QUINTET', 'QUINTUPLET', 'QUISLINGISM', 'QUIT', 'QUITE', 'QUITO', 'QUIZ', 'QUORUM', 'QUOTHOTTEST', 'QUOTIDIAN', 'QUT', 'QUTBEC', 'R', 'R1', 'R2', 'R3', 'R4D', 'RA', 'RAAD', 'RABAT', 'RABBITS', 'RABE', 'RABIES', 'RABIESENDEMIC', 'RACE', 'RACEMATE', 'RACES', 'RACIAL', 'RACK', 'RACS', 'RAD', 'RADAR', 'RADBOUD', 'RADIATION', 'RADIATIONATTENUATED', 'RADIATIONS', 'RADICAL', 'RADICATION', 'RADIO', 'RADIOBIOLOGICAL', 'RADIOBIOLOGY', 'RADIOCAMPAIGN', 'RADIOCAMPAING', 'RADIOLOGY', 'RADIOPROGRAMS', 'RADIOS', 'RADIOTHERAPY', 'RADIUS', 'RADPN', 'RADPW', 'RAF', 'RAI', 'RAIL', 'RAILS', 'RAILWAY', 'RAINFALL', 'RAINY', 'RAISE', 'RAISED', 'RAISES', 'RAISING', 'RAJAGOPALAN', 'RAJASTHAN', 'RAJIV', 'RAKAI', 'RALE', 'RALLY', 'RAM', 'RAMALLAH', 'RAMAN', 'RAMON', 'RAMP', 'RAMSAR', 'RAN', 'RANCH', 'RANDOM', 'RANDOMISE', 'RANDOMISED', 'RANDOMIZE', 'RANDOMIZED', 'RANDOMLY', 'RANDOMNESS', 'RANGARAJAN', 'RANGE', 'RANGES', 'RANGING', 'RANGOON', 'RANK', 'RANKING', 'RANKS', 'RAPID', 'RAPIDLY', 'RARE', 'RARELY', 'RASC', 'RASCREGIONAL', 'RASH', 'RASHT', 'RASSEMBLANT', 'RAT', 'RATAN', 'RATE', 'RATES', 'RATESALL', 'RATESMUNICIPAL', 'RATHER', 'RATHNAPURA', 'RATIFIED', 'RATING', 'RATIO', 'RATION', 'RATIONAL', 'RATIONALE', 'RATIONALIZATION', 'RATIONALLY', 'RATIONNEL', 'RATIONS', 'RATIOS', 'RATS', 'RAW', 'RAY', 'RAYS', 'RBARA', 'RBF', 'RBSA', 'RCA', 'RCC', 'RCDC', 'RCDCP', 'RCHS', 'RCSICOSECA', 'RCT', 'RD', 'RDC', 'RDT', 'RDTS', 'RE', 'REACH', 'REACHED', 'REACHES', 'REACHING', 'REACHPOLICY', 'REACHTHE', 'REACT', 'REACTION', 'REACTIONS', 'REACTIVE', 'REACTIVITY', 'REACTOGENICITY', 'REACTS', 'READ', 'READER', 'READERS', 'READILY', 'READINESS', 'READING', 'READINGS', 'READJUSTMENT', 'READMISSION', 'READS', 'READWRITE', 'READY', 'READYTOUSE', 'REAFFIRM', 'REAGENTS', 'REAHABILITATION', 'REAL', 'REALISATION', 'REALISE', 'REALISED2', 'REALISED5', 'REALISM', 'REALITIES', 'REALITY', 'REALIZACIN', 'REALIZATION', 'REALIZAZO', 'REALIZE', 'REALIZING', 'REALLIFE', 'REALLY', 'REALM', 'REALTIME', 'REALWORLD', 'REANALYSED', 'REAPPEARANCE', 'REAPPEARED', 'REAPPRAISAL', 'REAR', 'REARED', 'REARING', 'REASON', 'REASONABLE', 'REASONABLY', 'REASONED', 'REASONING', 'REASONS', 'REASSURE', 'REBECCA', 'REBOOST', 'REBUILD', 'RECALL', 'RECAP', 'RECCOMMENDATIONS', 'RECEIPT', 'RECEIPTS', 'RECEIVE', 'RECEIVED', 'RECEIVER', 'RECEIVES', 'RECEIVING', 'RECENT', 'RECENTLY', 'RECEPTION', 'RECEPTOR', 'RECEPTOR2AR', 'RECEPTORMEDIATED', 'RECEPTORNEGATIVE', 'RECEPTOROXTRD2R', 'RECEPTORRECEPTOR', 'RECEPTORS', 'RECESSION', 'RECH', 'RECHAVI', 'RECHERC', 'RECHERCHE', 'RECHERCHES', 'RECIPIENT', 'RECIPIENTS', 'RECIPIENTSEVALUATORS', 'RECIPROCAL', 'RECITATION', 'RECKON', 'RECKONING', 'RECLAIMING', 'RECLAMATION', 'RECOGNISED', 'RECOGNITION', 'RECOGNIZE', 'RECOGNIZED', 'RECOGNIZES', 'RECOGNIZING', 'RECOLLECTIVE', 'RECOMBINANT', 'RECOMBINANTLY', 'RECOMMANDATIONS', 'RECOMMEND', 'RECOMMENDATION', 'RECOMMENDATIONS', 'RECOMMENDATIONSARE', 'RECOMMENDED', 'RECOMMENDING', 'RECOMMENDS', 'RECONFIRM', 'RECONSIDERATION', 'RECONSTITUTING', 'RECONSTRUCT', 'RECONSTRUCTION', 'RECONSTRUCTIVE', 'RECORD', 'RECORDED', 'RECORDEDTHE', 'RECORDING', 'RECORDS', 'RECOURSES', 'RECOVE', 'RECOVER', 'RECOVERED', 'RECOVERING', 'RECOVERY', 'RECREATIONAL', 'RECRUDESCE', 'RECRUIT', 'RECRUITED', 'RECRUITING', 'RECRUITMENT', 'RECTAL', 'RECTUM', 'RECUMBENT', 'RECUPERATE', 'RECUPERATION', 'RECURRENCE', 'RECURRENT', 'RECURRING', 'RECYCLED', 'RECYCLINGAND', 'RED', 'REDE', 'REDEEM', 'REDESIGN', 'REDEVELOPMENT', 'REDIRECT', 'REDISSE', 'REDISTRIBUTION', 'REDNAJCER', 'REDRESS', 'REDRESSING', 'REDUCE', 'REDUCED', 'REDUCEDREMOVING', 'REDUCES', 'REDUCING', 'REDUCIR', 'REDUCTI', 'REDUCTION', 'REDUCTIONASSESSMENT', 'REDUCTIONS', 'REDUPLICATE', 'REED', 'REEFER', 'REEMERGED', 'REEMERGENCE', 'REEMERGING', 'REENERGIZE', 'REENFORCE', 'REENFORCEMENT', 'REENGINEERING', 'REENTRY', 'REEXAMINATION', 'REEXAMINING', 'REEXPOSURE', 'REF', 'REFER', 'REFERABLE', 'REFERAL', 'REFERENCE', 'REFERENCED', 'REFERRAL', 'REFERRALS', 'REFERRED', 'REFERRING', 'REFERS', 'REFFERRAL', 'REFINE', 'REFINED', 'REFINEMENT', 'REFINEMENTS', 'REFINING', 'REFLECT', 'REFLECTED', 'REFLECTING', 'REFLECTION', 'REFLECTS', 'REFMAP', 'REFOCUSING', 'REFORM', 'REFORMED', 'REFORMING', 'REFORMS', 'REFRACTORY', 'REFRAME', 'REFRESHER', 'REFRESHERS', 'REFRESHING', 'REFRIGERATOR', 'REFUGE', 'REFUGEE', 'REFUGEES', 'REFUGEESTIMELY', 'REFUGIADOS', 'REFURBISH', 'REFURBISHED', 'REFURBISHING', 'REFURBISHMENT', 'REFURBISHMENTMANAGEMENT', 'REG', 'REGAIN', 'REGARD', 'REGARDI', 'REGARDING', 'REGARDLESS', 'REGARDS', 'REGARIND', 'REGENERATION', 'REGENERATIVE', 'REGIME', 'REGIMEN', 'REGIMENS', 'REGIMES', 'REGIN', 'REGIO', 'REGION', 'REGIONAL', 'REGIONALACCESS', 'REGIONALAGEING', 'REGIONALCHRONIC', 'REGIONALCOMMUNICABLE', 'REGIONALDISABILITIES', 'REGIONALFOOD', 'REGIONALGENDER', 'REGIONALHEALTH', 'REGIONALHEALTHY', 'REGIONALHIV', 'REGIONALHIVAIDS', 'REGIONALHIVAIDSTBMALARIA', 'REGIONALIMPROVED', 'REGIONALINTERGRATED', 'REGIONALIZATION', 'REGIONALKEY', 'REGIONALLEADERSHIP', 'REGIONALLY', 'REGIONALMALARIA', 'REGIONALMANAGEMENT', 'REGIONALMENTAL', 'REGIONALNATIONAL', 'REGIONALNEGLCTED', 'REGIONALNONCOMMUNICABLE', 'REGIONALNUTRITION', 'REGIONALPOLIO', 'REGIONALREDUCTION', 'REGIONALREPRODUCTIVE', 'REGIONALSOCIAL', 'REGIONALSTRATEGIC', 'REGIONALTRANSPARENCY', 'REGIONALTUBERCULOSIS', 'REGIONALVACCINE', 'REGIONALVACCINEPREVENTABLE', 'REGIONALVIOLENCE', 'REGIONAS', 'REGIONBUILDING', 'REGIONIMPLEMENT', 'REGIONIN', 'REGIONRESEARCHERS', 'REGIONS', 'REGIONSNORTHERN', 'REGIONSPECIFIC', 'REGIONTHE', 'REGIONTHIS', 'REGIONUZAZI', 'REGISER', 'REGISTER', 'REGISTERATION', 'REGISTERED', 'REGISTERING', 'REGISTERS', 'REGISTERSEGOVERNMENT', 'REGISTRATION', 'REGISTRATIONS', 'REGISTRIES', 'REGISTRY', 'REGRESSED', 'REGRESSIVE', 'REGROUPANT', 'REGROWTH', 'REGUL', 'REGULAR', 'REGULARISATION', 'REGULARISE', 'REGULARIZATION', 'REGULARLY', 'REGULATE', 'REGULATED', 'REGULATES', 'REGULATING', 'REGULATION', 'REGULATIONS', 'REGULATIONS4', 'REGULATIVE', 'REGULATOR', 'REGULATORS', 'REGULATORY', 'REHAB', 'REHABILIATION', 'REHABILITATE', 'REHABILITATED', 'REHABILITATION', 'REHABILITATION12110', 'REHABILITATIVE', 'REHABILITATORY', 'REHYDRATION', 'REIGN', 'REIMAGINE', 'REIMBURSABLE', 'REIMBURSEMENT', 'REIMBURSEMENTS', 'REIMICOM', 'REINFECTION', 'REINFECTIONS', 'REINFEST', 'REINFESTATION', 'REINFORCE', 'REINFORCED', 'REINFORCEMENT', 'REINFORCES', 'REINFORCING', 'REINTEGRATE', 'REINTEGRATION', 'REINTRODUCED', 'REINVISIONING', 'RELACIONADA', 'RELAETED', 'RELAPSE', 'RELATE', 'RELATED', 'RELATES', 'RELATING', 'RELATION', 'RELATIONS', 'RELATIONSHIP', 'RELATIONSHIPS', 'RELATIONSSHIPS', 'RELATIVE', 'RELATIVELY', 'RELATIVES', 'RELAY', 'RELEASE', 'RELEASED', 'RELEASES', 'RELEASING', 'RELEGATING', 'RELEGATION', 'RELEVANCE', 'RELEVANCY', 'RELEVANT', 'RELEVANTMASTER', 'RELIABILITY', 'RELIABLE', 'RELIABLY', 'RELIANCE', 'RELIANT', 'RELIEF', 'RELIES', 'RELIEVE', 'RELIEVING', 'RELIGIOUS', 'RELOCATION', 'RELY', 'RELYING', 'REMAIN', 'REMAINDER', 'REMAINED', 'REMAINING', 'REMAINS', 'REMARKABLE', 'REMARKABLY', 'REMEDIAL', 'REMEDIC', 'REMEDIES', 'REMEDY', 'REMIND', 'REMINDERS', 'REMINDING', 'REMISSION', 'REMISSIONCURE', 'REMITTANCE', 'REMITTANCES', 'REMNANT', 'REMNANTS', 'REMODELLING', 'REMOTE', 'REMOTELY', 'REMOVAL', 'REMOVE', 'REMOVED', 'REMOVING', 'REMUNERATED', 'RENAL', 'RENCE', 'RENDER', 'RENDERED', 'RENDERS', 'RENDICIN', 'RENEW', 'RENEWABLE', 'RENEWAL', 'RENEWED', 'RENFOCREMENT', 'RENFORCEMENT', 'RENK', 'RENOMAB', 'RENOUNCE', 'RENOVATED', 'RENOVATING', 'RENOVATION', 'RENOVATIONS', 'RENOWNED', 'RENT', 'REORGANISED', 'REORGANIZATION', 'REORIENT', 'REORIENTING', 'REP', 'REPAID', 'REPAIR', 'REPAIRING', 'REPAST', 'REPEAT', 'REPEATED', 'REPEATEDLY', 'REPEL', 'REPELLANT', 'REPELLANTS', 'REPELLENT', 'REPELLENTS', 'REPETITIVE', 'REPLACE', 'REPLACED', 'REPLACEMENT', 'REPLACES', 'REPLACING', 'REPLENISHMENT', 'REPLENISHMENTS', 'REPLICA', 'REPLICABLE', 'REPLICATE', 'REPLICATED', 'REPLICATION', 'REPLY', 'REPONSE', 'REPORDUCTIVE', 'REPORT', 'REPORTABLE', 'REPORTAGE', 'REPORTED', 'REPORTER', 'REPORTING', 'REPORTING12110', 'REPORTS', 'REPOSITIONING', 'REPOSITORY', 'REPOSTERFS', 'REPRESENT', 'REPRESENTATION', 'REPRESENTATIONREGARDING', 'REPRESENTATIVE', 'REPRESENTATIVES', 'REPRESENTED', 'REPRESENTING', 'REPRESENTS', 'REPRESS', 'REPRESSIVE', 'REPRODUCIBILITY', 'REPRODUCIVE', 'REPRODUCTION', 'REPRODUCTIV', 'REPRODUCTIVA', 'REPRODUCTIVE', 'REPRODUCTIVOS', 'REPRSENTATION', 'REPRTSENTATION', 'REPUBLIC', 'REPUBLICAN', 'REPUBLICS', 'REPUBLICTOPICS', 'REPURPOSE', 'REPUTABLE', 'REPUTATION', 'REQUEST', 'REQUESTED', 'REQUESTING', 'REQUESTS', 'REQUIRE', 'REQUIRED', 'REQUIREMENT', 'REQUIREMENTS', 'REQUIRES', 'REQUIRING', 'REQUISITE', 'REQUITAL', 'RES', 'RESALE', 'RESCRIPT', 'RESCUE', 'RESEACH', 'RESEACHERS', 'RESEARCH', 'RESEARCHACTION', 'RESEARCHADVOCACY', 'RESEARCHAPPLY', 'RESEARCHAT', 'RESEARCHBASED', 'RESEARCHCAPACITY', 'RESEARCHCROSSDISCIPLINARY', 'RESEARCHDEVELOPING', 'RESEARCHED', 'RESEARCHER', 'RESEARCHERS', 'RESEARCHERS2', 'RESEARCHERSPROGRAM', 'RESEARCHES', 'RESEARCHEXTENSION', 'RESEARCHEXTENSION1', 'RESEARCHFINALLY', 'RESEARCHFISH', 'RESEARCHING', 'RESEARCHON', 'RESEARCHORIENTED', 'RESEARCHRELATED', 'RESEARCHRES', 'RESEARCHRESULTS', 'RESEARCHS', 'RESEARCHTHE', 'RESEARCHTHESE', 'RESEARCHTOUSE', 'RESEARCHVERY', 'RESEAU', 'RESEMBLANCE', 'RESERVATION', 'RESERVE', 'RESERVOIR', 'RESERVOIRS', 'RESETTING', 'RESIDE', 'RESIDENCES', 'RESIDENCY', 'RESIDENT', 'RESIDENTIAL', 'RESIDENTS', 'RESIDING', 'RESIDUAL', 'RESIDUUM', 'RESILIENCE', 'RESILIENCY', 'RESILIENT', 'RESIST', 'RESISTAN', 'RESISTANCE', 'RESISTANCE12220', 'RESISTANCEAMR', 'RESISTANCEFREE', 'RESISTANCETB', 'RESISTANT', 'RESISTENCE', 'RESISTIVE', 'RESISTIVITY', 'RESISTOR', 'RESOLUTION', 'RESOLVE', 'RESOLVED', 'RESOLVING', 'RESORTS', 'RESOURCE', 'RESOURCECONSTRAINED', 'RESOURCED', 'RESOURCEFULNESS', 'RESOURCELIMITED', 'RESOURCEPOOR', 'RESOURCES', 'RESOURCESCAMPAIGNING', 'RESOURCESHAS', 'RESOURCESLONG', 'RESOURCESWHILE', 'RESP', 'RESPEC', 'RESPECT', 'RESPECTABLE', 'RESPECTED', 'RESPECTIVE', 'RESPECTIVELY', 'RESPECTS', 'RESPIRATORAL', 'RESPIRATORY', 'RESPIRE', 'RESPITORY', 'RESPOND', 'RESPONDENTS', 'RESPONDERS', 'RESPONDING', 'RESPONDS', 'RESPONISBILITY', 'RESPONS', 'RESPONSE', 'RESPONSE201314', 'RESPONSE2CFEE50', 'RESPONSERESULT', 'RESPONSES', 'RESPONSESTHE', 'RESPONSIBILITIES', 'RESPONSIBILITY', 'RESPONSIBLE', 'RESPONSIBLENESS', 'RESPONSIVE', 'RESPONSIVENESS', 'RESPONT', 'RESSOURCES', 'REST', 'RESTARTING', 'RESTLESS', 'RESTORATION', 'RESTORE', 'RESTORED', 'RESTORING', 'RESTRAIN', 'RESTRAINT', 'RESTRICT', 'RESTRICTED', 'RESTRICTING', 'RESTRICTION', 'RESTRICTIONS', 'RESTRICTIVE', 'RESTRUCT', 'RESTRUCTURING', 'RESTS', 'RESTTZ', 'RESULT', 'RESULTANT', 'RESULTED', 'RESULTING', 'RESULTS', 'RESULTSBASED', 'RESULTSFOCUSED', 'RESULTSGENERAL', 'RESULTSI', 'RESULTSREPORTS', 'RESULTSTHE', 'RESULTSTHERE', 'RESULTSTHIS', 'RESUME', 'RESURGENCE', 'RESURGENT', 'RESURRECT', 'RESUSCITATION', 'RESUSCITATOR', 'RESYST', 'RETAIL', 'RETAILERS', 'RETAILS', 'RETAIN', 'RETAINED', 'RETAINING', 'RETENTION', 'RETENTIONINCARE', 'RETENTIVE', 'RETESTING', 'RETHINK', 'RETHINKING', 'RETINAL', 'RETINOPATHY', 'RETIRED', 'RETIRING', 'RETOOL', 'RETREATMENT', 'RETREATS', 'RETRIEVAL', 'RETRIEVING', 'RETRO', 'RETROFIT', 'RETROFLEX', 'RETROSPECTIVE', 'RETROVIRAL', 'RETROVIROLOGY', 'RETROVIRUSES', 'RETTEN', 'RETURN', 'RETURNEES', 'RETURNING', 'RETURNS', 'REULTS', 'REUMATOLOGY', 'REUNIFICATION', 'REUNION', 'REUSABLE', 'REUSING', 'REUTILIZATION', 'REVE', 'REVEAL', 'REVEALED', 'REVEALING', 'REVENUE', 'REVENUES', 'REVERSE', 'REVERSED', 'REVERSIBLE', 'REVERSING', 'REVIEW', 'REVIEWED', 'REVIEWEDDEVELOPED', 'REVIEWING', 'REVIEWS', 'REVIEWSINTERACTION', 'REVILEMENT', 'REVISE', 'REVISED', 'REVISING', 'REVISION', 'REVISIONS', 'REVISITED', 'REVITALIZE', 'REVITALIZED', 'REVIVE', 'REVOLUTION', 'REVOLUTIONIZE', 'REVOLUTIONIZING', 'REWARD', 'REWARDS', 'REWETTING', 'RFA', 'RFAGH151627', 'RFLP', 'RFRENCE', 'RFSU', 'RGENCY', 'RGION', 'RGIONAL', 'RH', 'RHCS', 'RHCSPATH', 'RHD', 'RHENIUM', 'RHESUS', 'RHEUMATIC', 'RHEUMATOID', 'RHINEWAAL', 'RHIPHICEPHALUS', 'RHODE', 'RHODESIA', 'RHODESIENSE', 'RHODY', 'RHOMB', 'RHR', 'RHRU', 'RHRUWHRI', 'RHYTHM', 'RI', 'RIB', 'RIBONUCLEIC', 'RICA', 'RICAN', 'RICANS', 'RICE', 'RICEBASED', 'RICH', 'RICHNESS', 'RIDDANCE', 'RIDDLE', 'RIDE', 'RIDER', 'RIDES', 'RIEL', 'RIEUR', 'RIFAMPICIN', 'RIFASHORT', 'RIFE', 'RIFLE', 'RIFT', 'RIG', 'RIGHT', 'RIGHTFIELD', 'RIGHTFULNESS', 'RIGHTS', 'RIGHTSBASED', 'RIGHTSINVESTING', 'RIGHTSIPAS', 'RIGHTSNATIONALLY', 'RIGHTSORIENTED', 'RIGOR', 'RIGOROUS', 'RIIB', 'RILIMA', 'RIM', 'RING', 'RINGS', 'RIO', 'RIP', 'RIPE', 'RIPENING', 'RIS', 'RISE', 'RISEN', 'RISERESEARCHERS', 'RISING', 'RISK', 'RISKMITIGATION', 'RISKOVERALL', 'RISKS', 'RISKTHE', 'RISKWOMEN', 'RISKY', 'RITC', 'RITH', 'RITUALCENTRAL', 'RITUALS', 'RIVER', 'RIVERS', 'RIVET', 'RKI', 'RM', 'RMNCAH', 'RMNCH', 'RMNCHA', 'RMNCHAN', 'RNA', 'RNABASE', 'RNADNA', 'RNAI', 'RNM', 'ROAD', 'ROADBLOCK', 'ROADMAP', 'ROADS', 'ROAST', 'ROBERT', 'ROBOTICS', 'ROBUST', 'ROBUSTNESS', 'ROCEPHIN', 'ROCHESTER', 'ROCKEFELLER', 'ROD', 'RODENT', 'RODENTBORNE', 'RODENTS', 'RODHAM', 'ROENTGEN', 'ROJIROTI', 'ROKUPAWELLINGTON', 'ROLE', 'ROLES', 'ROLL', 'ROLLING', 'ROLLOUT', 'ROLLOUTCIET', 'ROMA', 'ROMANIAFOOD', 'ROMANIAHEALTH', 'ROMANIALEADERSHIP', 'ROMANIAMENTAL', 'ROMANIANONCOMMUNICABLE', 'ROMANIASOCIAL', 'ROMANIAVIOLENCE', 'ROMMELAG', 'RONDONIA', 'ROO', 'ROOF', 'ROOM', 'ROOMS', 'ROOT', 'ROOTAGE', 'ROOTED', 'ROOTS', 'ROSARIO', 'ROSE', 'ROSENBLUM', 'ROSEOLA', 'ROSS', 'ROSTER', 'ROSTOCK', 'ROTARY', 'ROTATION', 'ROTAVIRUS', 'ROTUND', 'ROUGE', 'ROUGH', 'ROUGHLY', 'ROUND', 'ROUNDS', 'ROUNDTABLE', 'ROUNDTABLES', 'ROUNDUP', 'ROUNDWORM', 'ROUTE', 'ROUTES', 'ROUTINE', 'ROUTINELY', 'ROUTINES', 'ROUTINIZED', 'ROVE', 'ROVING', 'ROYAL', 'RPC', 'RPG', 'RPJMN', 'RPM', 'RPSA', 'RRH', 'RRNA', 'RRP', 'RSDGIVNING', 'RSEAU', 'RSILIENTES', 'RSP', 'RSSAS', 'RST', 'RSULTATS', 'RSV', 'RTDUCTION', 'RTDUIRE', 'RTFTRENCE', 'RTGION', 'RTGIONAL', 'RTI', 'RTIS', 'RTM', 'RTS', 'RTSEAU', 'RTSILIENTES', 'RTSS', 'RTSSAS01', 'RTSULTATS', 'RU', 'RUANDA', 'RUBBER', 'RUBE', 'RUBELLA', 'RUBEOLA', 'RUBRIC', 'RUDE', 'RUIN', 'RUINOUS', 'RULE', 'RULES', 'RUMINANTS', 'RUN', 'RUNNING', 'RUNS', 'RUNTHERE', 'RUPERT', 'RURAL', 'RURALES', 'RURALURBAN', 'RUSSIA', 'RUSSIAN', 'RUST', 'RUTGERS', 'RUTSIRO', 'RV', 'RV144', 'RV21', 'RV3', 'RV3BB', 'RVF', 'RVFV', 'RVICES', 'RVTH', 'RVTHUTG', 'RVV', 'RWA', 'RWANDA', 'RWANDAN', 'RWANDAS', 'RWPC', 'RY', 'RYERSON', 'S', 'S2020', 'S4BH', 'S4SIPMS', 'SA', 'SAAF', 'SAATCHI', 'SABAH', 'SABAL', 'SABAS', 'SABASCALE', 'SABHAS', 'SABIN', 'SABIN2', 'SABINY', 'SABINYS', 'SABLAYAN', 'SACRED', 'SACS', 'SADC', 'SADE', 'SADEC', 'SADR', 'SAFAIDS', 'SAFARI', 'SAFE', 'SAFEGUARD', 'SAFEGUARDING', 'SAFELY', 'SAFER', 'SAFETY', 'SAFETY12240', 'SAFETYAND', 'SAFETYHEILONGJIANG', 'SAFETYQUALITY', 'SAG', 'SAGE', 'SAGEBRUSH', 'SAGO', 'SAHARA', 'SAHARAN', 'SAHARAUI', 'SAHARAWI', 'SAHED', 'SAHEL', 'SAHELIAN', 'SAHLGRENSKA', 'SAHRAWI', 'SAHS', 'SAID', 'SAIEBAC', 'SAINT', 'SAINTE', 'SAINTEJUSTINE', 'SAKARTVELO', 'SALAAM', 'SALAD', 'SALAM', 'SALARIES', 'SALARY', 'SALE', 'SALES', 'SALINITY', 'SALIVA', 'SALK', 'SALMONELLA', 'SALT', 'SALTBASED', 'SALTRA', 'SALTS', 'SALTSMART', 'SALTSZINC', 'SALUBRIOUS', 'SALUD', 'SALUTARY', 'SALVADOR', 'SALVADORANS', 'SALVAGE', 'SALVATION', 'SAM', 'SAMAC', 'SAMARA', 'SAMARITAIN', 'SAMARITAN', 'SAMBODHI', 'SAME', 'SAMOA', 'SAMOAINTERGRATED', 'SAMPLE', 'SAMPLES', 'SAMPLING', 'SAMRC', 'SAMRS20120104', 'SAMRS2013KEN0108', 'SAMRS201511', 'SAMSUNG', 'SAMURDHI', 'SAN', 'SANAA', 'SANCTION', 'SANDFLIES', 'SANDIA', 'SANDWICH', 'SANDWICHPROGRAMME', 'SANDY', 'SANITA', 'SANITAIRES', 'SANITARIO', 'SANITARY', 'SANITATION', 'SANITATIONRELATED', 'SANITISATION', 'SANITIZATION', 'SANOFI', 'SANS', 'SANT', 'SANTA', 'SANTE', 'SANTEHEALTH', 'SANTIAGO', 'SANTT', 'SAO', 'SAPHE', 'SAR', 'SARAHAWI', 'SARAJEVO', 'SARC', 'SARPAM', 'SARR', 'SARS', 'SAS', 'SASKATCHEWAN', 'SATELLITE', 'SATIAGO', 'SATISFACTION', 'SATISFACTORY', 'SATISFIED', 'SATURATED', 'SAUDE', 'SAUDI', 'SAVA', 'SAVAR', 'SAVE', 'SAVED', 'SAVES', 'SAVING', 'SAVINGS', 'SAWBONES', 'SAY', 'SAYANA', 'SBA', 'SBC', 'SBCC', 'SBIR', 'SBV', 'SC', 'SCABIES', 'SCAFFOLDS', 'SCAFFOLDSIMPLANTS', 'SCALABILITY', 'SCALABLE', 'SCALE', 'SCALEBACK', 'SCALED', 'SCALEDCROSSCUTTING', 'SCALEDDOWN', 'SCALEDUP', 'SCALES', 'SCALESUP', 'SCALETHE', 'SCALETHIS', 'SCALEUP', 'SCALING', 'SCALINGUP', 'SCALINGUPTHIS', 'SCAN', 'SCANDALMONGERING', 'SCANNER', 'SCANNERS', 'SCANNING', 'SCANT', 'SCAR', 'SCARCE', 'SCARCITY', 'SCATHE', 'SCATTER', 'SCATTERED', 'SCENARIO', 'SCENARIOS', 'SCENARIOSQUANTIFY', 'SCF', 'SCFV', 'SCHEDULE', 'SCHEDULED', 'SCHEDULES', 'SCHEDULING', 'SCHEMA', 'SCHEMAS', 'SCHEME', 'SCHEMES', 'SCHISTOSOMA', 'SCHISTOSOMIASIS', 'SCHOLARS', 'SCHOLARSHIP', 'SCHOLARSHIPS', 'SCHOLARSTHIS', 'SCHOLASTIC', 'SCHOOL', 'SCHOOLAGED', 'SCHOOLBASED', 'SCHOOLBOOK', 'SCHOOLCHILDREN', 'SCHOOLGIRLS', 'SCHOOLHOUSE', 'SCHOOLING', 'SCHOOLS', 'SCHOOLSCIENCECOMMUNITY', 'SCHOOLTHIS', 'SCHOOLTIME', 'SCHRAMEK', 'SCI', 'SCIENCE', 'SCIENCEBASED', 'SCIENCES', 'SCIENCESDEVELOPMENT', 'SCIENCESDSS', 'SCIENTIFIC', 'SCIENTIFICALLY', 'SCIENTIFICCOOPERATION', 'SCIENTIFICMISSIONS', 'SCIENTIFIQUE', 'SCIENTIFIQUES', 'SCIENTIST', 'SCIENTISTS', 'SCIGENOM', 'SCLEROSIS', 'SCMS', 'SCOMBEROMORUS', 'SCOPE', 'SCOPING', 'SCORE', 'SCORECARD', 'SCORECARDS', 'SCORING', 'SCOTLAND', 'SCOURGE', 'SCPRID', 'SCRAP', 'SCREAM', 'SCREEN', 'SCREENING', 'SCREENINGEMERGING', 'SCREENINGS', 'SCREENS', 'SCRIPPS', 'SCRIPTURES', 'SCRUTINIZED', 'SCRUTINIZING', 'SCRUTINY', 'SCULPTURE', 'SCURIT', 'SCURVY', 'SD', 'SDC', 'SDCS', 'SDG', 'SDGS', 'SDGSC', 'SDH', 'SDIA', 'SDM', 'SDS', 'SDSN', 'SDSNS', 'SE', 'SEA', 'SEAL', 'SEALED', 'SEAN', 'SEARCH', 'SEARCHED', 'SEARCHES', 'SEARCHING', 'SEARO', 'SEASON', 'SEASONABLE', 'SEASONAL', 'SEASONALITY', 'SEASONS', 'SEAT', 'SEATCA', 'SEATED', 'SEATTLE', 'SEAU', 'SEBACATE', 'SEC', 'SECALE', 'SECO', 'SECOND', 'SECONDARY', 'SECONDED', 'SECONDEE', 'SECONDGENERATION', 'SECONDHAND', 'SECONDLINE', 'SECONDMENT', 'SECONDOPINION', 'SECRET', 'SECRETARFA', 'SECRETARIAT', 'SECRETARIATE', 'SECRETARIT', 'SECRETARY', 'SECRETARYGENERAL', 'SECRETE', 'SECRETING', 'SECRETION', 'SECRETIONS', 'SECRETORY', 'SECTEUR', 'SECTION', 'SECTION27', 'SECTIONALISATION', 'SECTIONS', 'SECTOR', 'SECTORAL', 'SECTORIAL', 'SECTORLED', 'SECTORPROGRAM', 'SECTORS', 'SECTORTEACHER', 'SECTORWIDE', 'SECULAR', 'SECURE', 'SECURED', 'SECURER', 'SECURING', 'SECURITIES', 'SECURITY', 'SECURITY2CFEEIRISH', 'SECURITYAT', 'SECURITYFOOD', 'SEDENTARY', 'SEDES', 'SEDESOL', 'SEE', 'SEED', 'SEEK', 'SEEKERS', 'SEEKING', 'SEEKS', 'SEEM', 'SEEMS', 'SEEN', 'SEGMENT', 'SEGMENTED', 'SEGMENTS', 'SEGURA', 'SEGURIDAD', 'SEHAT', 'SEIZED', 'SEIZURE', 'SEK', 'SEK16249131', 'SELCTED', 'SELECT', 'SELECTA', 'SELECTED', 'SELECTING', 'SELECTION', 'SELECTIVE', 'SELECTIVELY', 'SELECTIVITY', 'SELECTS', 'SELENIUM', 'SELEX', 'SELF', 'SELFCONTAINED', 'SELFESTEEM', 'SELFEVALUATION', 'SELFGOVERNMENTS', 'SELFHARM', 'SELFHELP', 'SELFIDENTIFIED', 'SELFIMAGE', 'SELFLIMITING', 'SELFMANAGEMENT', 'SELFPERCEIVED', 'SELFRELIANCE', 'SELFREPORTED', 'SELFSAME', 'SELFSELECT', 'SELFSUFFICIENCY', 'SELFSUSTAINABLE', 'SELFSUSTAINING', 'SELL', 'SELLERS', 'SELLING', 'SELVA', 'SEMI', 'SEMIACUTE', 'SEMINAR', 'SEMINARS', 'SEMIQUANTITATIVE', 'SEMISTRUCTURED', 'SEMIURBAN', 'SEND', 'SENDING', 'SENEGAL', 'SENEGALS', 'SENESCENCE', 'SENESCENT', 'SENIOR', 'SENOLYTICS', 'SENS', 'SENSATION', 'SENSATIONALISTIC', 'SENSE', 'SENSES', 'SENSIBILIZACIN', 'SENSING', 'SENSITISATION', 'SENSITISED', 'SENSITIVE', 'SENSITIVE4', 'SENSITIVENESS', 'SENSITIVITY', 'SENSITIZATION', 'SENSITIZE', 'SENSITIZED', 'SENSOR', 'SENSORIMOTOR', 'SENSORS', 'SENSUAL', 'SENSUNG', 'SENT', 'SENTENCE', 'SENTER', 'SENTIENCE', 'SENTINEL', 'SEO', 'SEOUL', 'SEP', 'SEPARATE', 'SEPARATELY', 'SEPARATION', 'SEPO', 'SEPOCT', 'SEPRESIST', 'SEPSIS', 'SEPT', 'SEPTEMBER', 'SEPTIC', 'SEQUELAE', 'SEQUENCE', 'SEQUENCED', 'SEQUENCES', 'SEQUENCESTRUCTURE', 'SEQUENCING', 'SEQUENTIAL', 'SEQUESTRATE', 'SER', 'SERBIA', 'SERENGETI', 'SERENITY', 'SERIAL', 'SERIES', 'SERIOUS', 'SERIOUSLY', 'SERMONS', 'SERO', 'SEROINCIDENT', 'SEROLOGICAL', 'SEROLOGY', 'SEROLOGYRESULT', 'SEROPREVALENCE', 'SEROTONERGIC', 'SEROTYPE', 'SEROTYPEINDEPENDENT', 'SEROTYPES', 'SERTRALINE', 'SERUM', 'SERV', 'SERVANTS', 'SERVE', 'SERVED', 'SERVER', 'SERVES', 'SERVICE', 'SERVICEDELIVERY', 'SERVICEMEN', 'SERVICES', 'SERVICES12281', 'SERVICES3', 'SERVICESARE', 'SERVICESAS', 'SERVICESBUILDING', 'SERVICESC', 'SERVICESCISAS', 'SERVICESDEMOCRACY', 'SERVICESEQUINETS', 'SERVICESIMPLEMENTING', 'SERVICESIMPROVING', 'SERVICESINTO', 'SERVICESNONGOVERNMENTAL', 'SERVICESRECOGNIZING', 'SERVICESTHIS', 'SERVICESUPPLY', 'SERVICIES', 'SERVICING', 'SERVICIOS', 'SERVING', 'SES', 'SESAL', 'SESAME', 'SESSION', 'SESSIONS', 'SESTET', 'SET', 'SETARIA', 'SETIF', 'SETS', 'SETSAN', 'SETTI', 'SETTING', 'SETTINGS', 'SETTINGSFURTHER', 'SETTINGTHE', 'SETTLE', 'SETTLEMENT', 'SETTLEMENTS', 'SETUP', 'SEVEN', 'SEVENFOLD', 'SEVENTY', 'SEVENYEAR', 'SEVER', 'SEVERAL', 'SEVERE', 'SEVERELY', 'SEVERELYMODERATELY', 'SEVERITY', 'SEWAGE', 'SEX', 'SEXDISAGGREGATED', 'SEXE', 'SEXES', 'SEXSELECTION', 'SEXTET', 'SEXTUAL', 'SEXUAL', 'SEXUALES', 'SEXUALITY', 'SEXUALLY', 'SEXUALREPRODUCTIVE', 'SEXWORKERS', 'SEYCHELLES', 'SFANTUL', 'SFCSOVC', 'SFKBERADICTION', 'SFLT1', 'SGBV', 'SHADI', 'SHADOWING', 'SHAFA', 'SHAFT', 'SHALL', 'SHAME', 'SHANCHOL', 'SHANGHAI', 'SHAPE', 'SHAPED', 'SHAPEMEMORY', 'SHAPING', 'SHARE', 'SHARED', 'SHARES', 'SHARING', 'SHARINGRESULT', 'SHARP', 'SHARPEN', 'SHARPENED', 'SHARPLY', 'SHARPNESS', 'SHASTIN', 'SHAVER', 'SHCS', 'SHEATH', 'SHEBA', 'SHED', 'SHEDDING', 'SHEEP', 'SHEER', 'SHEETS', 'SHEIK', 'SHEIKH', 'SHELF', 'SHELL', 'SHELTERS', 'SHELVES', 'SHEW', 'SHGS', 'SHIELD', 'SHIELDER', 'SHIFA', 'SHIFAHOSPITAL', 'SHIFT', 'SHIFTED', 'SHIFTING', 'SHIFTS', 'SHIGELLA', 'SHIGELLOSIS', 'SHIMANTIK', 'SHINE', 'SHINNY', 'SHINYANGA', 'SHIP', 'SHIPMENT', 'SHIPMENTS', 'SHIPPED', 'SHIPPING', 'SHIPS', 'SHIRATI', 'SHIRKAT', 'SHIRTS', 'SHIT', 'SHIV', 'SHOA', 'SHOAL', 'SHOCK', 'SHOCKS', 'SHOOTING', 'SHOP', 'SHOPKEEPERS', 'SHOPPING', 'SHOPS', 'SHORT', 'SHORTAGE', 'SHORTAGES', 'SHORTCOMINGS', 'SHORTEN', 'SHORTENED', 'SHORTENING', 'SHORTER', 'SHORTFALLS', 'SHORTLISTED', 'SHORTLIVED', 'SHORTLY', 'SHORTSTOP', 'SHORTTERM', 'SHOT', 'SHOULD', 'SHOULDERED', 'SHOUTITNOWUPPSALA', 'SHOW', 'SHOWCASE', 'SHOWCASES', 'SHOWCASING', 'SHOWED', 'SHOWING', 'SHOWN', 'SHOWS', 'SHP', 'SHRH', 'SHRIMP', 'SHRINK', 'SHTP', 'SHUN', 'SHUT', 'SIA', 'SIALIDASE', 'SIAM', 'SIAPS', 'SIAS', 'SIBLINGS', 'SIBURU', 'SICHROCAR', 'SICK', 'SICKKIDS', 'SICKNESS', 'SIDA', 'SIDACIVSAM', 'SIDAMA', 'SIDAS', 'SIDDHA', 'SIDE', 'SIDED', 'SIDEEVENT', 'SIDEKICK', 'SIDEREAL', 'SIDES', 'SIEMENS', 'SIERRA', 'SIGAS', 'SIGHT', 'SIGHTLESSNESS', 'SIGHTSAVERS', 'SIGN', 'SIGNAL', 'SIGNALING', 'SIGNALLING', 'SIGNALS', 'SIGNATORIES', 'SIGNATORY', 'SIGNATURE', 'SIGNATURES', 'SIGNED', 'SIGNER', 'SIGNIFICANCE', 'SIGNIFICANT', 'SIGNIFICANTLY', 'SIGNIFY', 'SIGNING', 'SIGNS', 'SIKIKA', 'SIKKIM', 'SILCS', 'SILICON', 'SILICONE', 'SILOAH', 'SILOED', 'SILVER', 'SIMILAR', 'SIMILARINSTITUTES', 'SIMILARLY', 'SIMIYU', 'SIMON', 'SIMPLE', 'SIMPLETON', 'SIMPLEX', 'SIMPLIFICATION', 'SIMPLIFIED', 'SIMPLIFY', 'SIMPLIFYING', 'SIMPLISTIC', 'SIMPLY', 'SIMPSON', 'SIMS', 'SIMULATION', 'SIMULATIONENHANCED', 'SIMULATIONS', 'SIMULTANEOUS', 'SIMULTANEOUSLY', 'SIN', 'SINAI', 'SINCE', 'SINDH', 'SINEWY', 'SING', 'SINGAPORE', 'SINGAPORENONCOMMUNICABLE', 'SINGAPOREVACCINE', 'SINGAPOREVACCINEPREVENTABLE', 'SINGIDA', 'SINGLE', 'SINGLEDOSE', 'SINGLEINJECTION', 'SINGLEMOLECULE', 'SINGLEPAYER', 'SINGLESTRAIN', 'SINGLESTRAINSINGLEFORMULATION', 'SINGULAR', 'SINK', 'SINOGERMAN', 'SIPU', 'SIPUORGUT', 'SIR', 'SIRE', 'SIRENAS', 'SISCAS', 'SISME', 'SISMEPHASE', 'SISTEMA', 'SISTER', 'SISTERS', 'SITE', 'SITES', 'SITS', 'SITU', 'SITUACIN', 'SITUACINDE', 'SITUACIONES', 'SITUASJON', 'SITUATED', 'SITUATION', 'SITUATIONAL', 'SITUATIONS', 'SITUATIONSTHIS', 'SIU', 'SIX', 'SIXER', 'SIXMONTH', 'SIXTEEN', 'SIXTH', 'SIXTY', 'SIXWEEK', 'SIXYEAR', 'SIYASOKA', 'SIZABLE', 'SIZE', 'SIZEABLE', 'SIZED', 'SIZES', 'SIZING', 'SJC', 'SK', 'SKELETAL', 'SKELETON', 'SKETCH', 'SKETCHES', 'SKEWED', 'SKI', 'SKILFUL', 'SKILL', 'SKILLED', 'SKILLFUL', 'SKILLS', 'SKILLSETS', 'SKIN', 'SKINFOLDS', 'SKINLIKE', 'SKINTOSKIN', 'SKIRTS', 'SKY', 'SKYPE', 'SL', 'SLAB', 'SLAMF6', 'SLATED', 'SLC30A10', 'SLE', 'SLEACF201701', 'SLEEP', 'SLEEPING', 'SLEEVE', 'SLENDERIZE', 'SLEUTHING', 'SLIDE', 'SLIDES', 'SLIGHT', 'SLIGHTLY', 'SLIM', 'SLOBODAN', 'SLOPE', 'SLOTH', 'SLOUGH', 'SLOVAK', 'SLOVAKIAAGEING', 'SLOVAKIAHEALTH', 'SLOVAKIAINTERGRATED', 'SLOVAKIALEADERSHIP', 'SLOVAKIAMENTAL', 'SLOVAKIANATIONAL', 'SLOVAKIANONCOMMUNICABLE', 'SLOVAKIANUTRITION', 'SLOVAKIAREPRODUCTIVE', 'SLOVAKIASOCIAL', 'SLOVAKIASTRATEGIC', 'SLOVENIA', 'SLOVENIAHEALTH', 'SLOVENIAINTERGRATED', 'SLOVENIALEADERSHIP', 'SLOVENIAMENTAL', 'SLOVENIANATIONAL', 'SLOVENIANONCOMMUNICABLE', 'SLOVENIAREPRODUCTIVE', 'SLOVENIASOCIAL', 'SLOVENIASTRATEGIC', 'SLOW', 'SLOWED', 'SLOWER', 'SLOWING', 'SLOWLY', 'SLOWS', 'SLU', 'SLU238', 'SLUGGISHNESS', 'SLUM', 'SLUMDWELLERS', 'SLUMS', 'SLUPP', 'SLUS', 'SLUTTISH', 'SMALL', 'SMALLER', 'SMALLEST', 'SMALLHOLDER', 'SMALLHOLDERS', 'SMALLMOLECULE', 'SMALLSCALE', 'SMART', 'SMARTER', 'SMARTPHONE', 'SMC', 'SMCS', 'SMEARS', 'SMELL', 'SMES', 'SMG', 'SMI', 'SMIG', 'SMILE', 'SMILES', 'SMILING', 'SMINAIRES', 'SMINCDC', 'SMITHSONIAN', 'SMITTSKYDDSINSTITUTETSWEDEN', 'SMMES', 'SMOKE', 'SMOKED', 'SMOKEFREE', 'SMOKER', 'SMOKERS', 'SMOKERSTHE', 'SMOKING', 'SMOOTH', 'SMP80GLASE', 'SMS', 'SMUGGLING', 'SN', 'SNACK', 'SNACKS', 'SNAIL', 'SNAILS', 'SNAKE', 'SNAKEBITE', 'SNAP', 'SNAPPER', 'SNL', 'SNOW', 'SNP', 'SNPMAPPING', 'SNSF', 'SNSFS', 'SO', 'SOAP', 'SOAR', 'SOC', 'SOCA', 'SOCALLED', 'SOCH', 'SOCHARA', 'SOCHARAS', 'SOCI', 'SOCIABLE', 'SOCIAL', 'SOCIALCOMMUNITY', 'SOCIALE', 'SOCIALECOLOGICAL', 'SOCIALEDUCATIONAL', 'SOCIALES', 'SOCIALGENDER', 'SOCIALHEALTH', 'SOCIALISATION', 'SOCIALIST', 'SOCIALLY', 'SOCIEDAD', 'SOCIETAL', 'SOCIETE', 'SOCIETIES', 'SOCIETY', 'SOCIETYDEVELOPMENT', 'SOCIETYGOVERNMENT', 'SOCIETYIMRS', 'SOCIETYLED', 'SOCIETYORGANIZATIONS', 'SOCIETYS', 'SOCIETYTHIS', 'SOCIO', 'SOCIOBEHAVIORAL', 'SOCIOCONOMIQUES', 'SOCIOCULTURAL', 'SOCIODEMOGRAPHICAL', 'SOCIOECONOMIC', 'SOCIOECONOMICAL', 'SOCIOECONOMICALLY', 'SOCIOECONOMICS', 'SOCIOENVIRONMENTALAND', 'SOCIOHEALTH', 'SOCIOLOGISTS', 'SOCIOTCONOMIQUES', 'SOCIT', 'SOCITTT', 'SOCS', 'SOCS3', 'SOCS3REGULATED', 'SODA', 'SODAS', 'SODBUSTER', 'SODIS', 'SODIUM', 'SODO', 'SOFALA', 'SOFT', 'SOFTBODIED', 'SOFTER', 'SOFTWARE', 'SOFTWAREEPITROP', 'SOGI', 'SOHAG', 'SOIL', 'SOIL2', 'SOILS', 'SOILTRANSMITTED', 'SOINS', 'SOKOINE', 'SOKOTO', 'SOL', 'SOLAR', 'SOLD', 'SOLE', 'SOLELY', 'SOLICIT', 'SOLID', 'SOLIDARITESANTE', 'SOLIDARITY', 'SOLIDIFIES', 'SOLIUM', 'SOLOMON', 'SOLUTE', 'SOLUTION', 'SOLUTIONS', 'SOLVE', 'SOLVENT', 'SOM', 'SOMA', 'SOMALI', 'SOMALIA', 'SOMALILAND', 'SOMATOTROPIC', 'SOME', 'SOMEBODY', 'SOMEONE', 'SOMETHING', 'SOMETIME', 'SOMETIMES', 'SOML', 'SONENBERG', 'SONGS', 'SONKE', 'SONKESUPPORT', 'SOON', 'SOPHISTICATED', 'SOPHISTICATION', 'SORE', 'SORT', 'SORTING', 'SOTH', 'SOU', 'SOUDAN', 'SOUGHT', 'SOUL', 'SOUM', 'SOUND', 'SOUNDBOX', 'SOUNDNESS', 'SOUNDS', 'SOUP', 'SOURCE', 'SOURCED', 'SOURCES', 'SOURCING', 'SOURT', 'SOUTH', 'SOUTH3', 'SOUTHCAUCASUS', 'SOUTHEAST', 'SOUTHEASTERLY', 'SOUTHEASTERN', 'SOUTHEASTWARD', 'SOUTHERLY', 'SOUTHERN', 'SOUTHERNEAST', 'SOUTHNORTH', 'SOUTHSOUTH', 'SOUTHTOSOUTH', 'SOUTHWARD', 'SOUTHWEST', 'SOUTHWESTERN', 'SOUTIEN', 'SOVEREIGN', 'SOVEREIGNTY', 'SOVIET', 'SOWETO', 'SOYCORN', 'SP', 'SPACE', 'SPACES', 'SPACIAL', 'SPACING', 'SPAIN', 'SPANISH', 'SPANISHOTHER', 'SPANISHSPEAKING', 'SPANNED', 'SPANNING', 'SPARE', 'SPARK', 'SPARSELY', 'SPASTIC', 'SPASTICITY', 'SPATIAL', 'SPATIALLY', 'SPATIALLYRESOLVED', 'SPATIALTEMPORAL', 'SPATIOTEMPORAL', 'SPAWNED', 'SPC', 'SPCIAL', 'SPCIALE', 'SPCIALISS', 'SPEAK', 'SPEAKERS', 'SPEAKING', 'SPEAR', 'SPEARHEAD', 'SPEARHEADED', 'SPEC', 'SPECIAL', 'SPECIALISED', 'SPECIALISING', 'SPECIALIST', 'SPECIALISTS', 'SPECIALIZATION', 'SPECIALIZE', 'SPECIALIZED', 'SPECIALLY', 'SPECIALTIES', 'SPECIALTY', 'SPECIES', 'SPECIFIALLY', 'SPECIFIC', 'SPECIFICALLY', 'SPECIFICATION', 'SPECIFICATIONS', 'SPECIFICITY', 'SPECIFIED', 'SPECIFY', 'SPECIMEN', 'SPECIMENS', 'SPECKLE', 'SPECOBJ', 'SPECTROMETRY', 'SPECTROMETRYBASED', 'SPECTROMETRYIMAGING', 'SPECTROSCOPIC', 'SPECTROSCOPY', 'SPECTRUM', 'SPECULATION', 'SPEECH', 'SPEED', 'SPEEDY', 'SPELL', 'SPEND', 'SPENDING', 'SPENT', 'SPERMICIDES', 'SPH', 'SPHANTILAB', 'SPHATILAB', 'SPHERE', 'SPHERIC', 'SPHERICAL', 'SPHINGOLIPID', 'SPHP', 'SPHS', 'SPILLING', 'SPILLOVER', 'SPIN', 'SPINAL', 'SPINAP', 'SPIRALLED', 'SPIRIT', 'SPIRITED', 'SPIRITS', 'SPIRITUAL', 'SPITE', 'SPLANCHNIC', 'SPLIFF', 'SPLINTERING', 'SPLIT', 'SPLM', 'SPO', 'SPONGE', 'SPONGER', 'SPONSOR', 'SPONSORED', 'SPONSORING', 'SPONSORS', 'SPONSORSHIP', 'SPONTANEOUS', 'SPORANOX', 'SPOROZOITE', 'SPOROZOITES', 'SPORT', 'SPORTFORDEVELOPMENT', 'SPORTING', 'SPORTS', 'SPOT', 'SPOTS', 'SPOTTING', 'SPOUSAL', 'SPOUSE', 'SPOUSES', 'SPP', 'SPPM', 'SPR', 'SPRAIN', 'SPRAY', 'SPRAYING', 'SPREAD', 'SPREADHEAD', 'SPREADING', 'SPREADINGTHE', 'SPREADTHIS', 'SPRING', 'SPRINGGHANA', 'SPRINGGHANAS', 'SPRINGINESS', 'SPRINGS', 'SPRINT', 'SPRUNG', 'SPS', 'SPTCIAL', 'SPTCIALE', 'SPTCIALISTS', 'SPUR', 'SPUTUM', 'SPW', 'SQUAD', 'SQUARE', 'SR', 'SR59', 'SRCS', 'SRG', 'SRGR', 'SRH', 'SRHR', 'SRHRB', 'SRHRS', 'SRI', 'SRK', 'SRL', 'SRLHOSPITAL', 'SROP', 'SRRS', 'SSA', 'SSCSIP', 'SSD', 'SSF', 'SSR', 'SSRN', 'SSRPREVENCIN', 'SSUDAN', 'ST', 'ST131', 'STABILISATION', 'STABILITY', 'STABILIZATION', 'STABILIZE', 'STABILIZED', 'STABLE', 'STAFF', 'STAFFAT', 'STAFFED', 'STAFFIN', 'STAFFING', 'STAFFS', 'STAFMEETINGS', 'STAG', 'STAGE', 'STAGECOACH', 'STAGEICDDRBS', 'STAGES', 'STAGGER', 'STAGGERED', 'STAGING', 'STAGNANT', 'STAIN', 'STAINING', 'STAKE', 'STAKEHOLDER', 'STAKEHOLDERS', 'STAKEHOLDERSTOPICS', 'STAMP', 'STAND', 'STANDALONE', 'STANDAR', 'STANDARD', 'STANDARDISATION', 'STANDARDISE', 'STANDARDISED', 'STANDARDIZATION', 'STANDARDIZE', 'STANDARDIZED', 'STANDARDIZING', 'STANDARDS', 'STANDARDSBASED', 'STANDING', 'STANDS', 'STANFORD', 'STAPHYLOCOCCUS', 'STAPLE', 'STAR', 'STARCH', 'STARK', 'START', 'STARTED', 'STARTED3', 'STARTED7', 'STARTING', 'STARTINGUP', 'STARTUP', 'STAT3', 'STAT3ACTIVATION', 'STAT3MUC1', 'STATE', 'STATEBUILDING', 'STATED', 'STATELESS', 'STATELEVEL', 'STATEMENT', 'STATENS', 'STATEOFART', 'STATEOFTHE', 'STATEOFTHEART', 'STATES', 'STATIC', 'STATION', 'STATIONED', 'STATISTIC', 'STATISTICAL', 'STATISTICS', 'STATPALM', 'STATUS', 'STATUTE', 'STAVE', 'STAWI', 'STAWIS', 'STAY', 'STCURITT', 'STD', 'STDF', 'STE', 'STEAD', 'STEADILY', 'STEADY', 'STEADYSTATE', 'STEEP', 'STEER', 'STEERAGE', 'STEERING', 'STELLENBOSCH', 'STEM', 'STEMMA', 'STEMS', 'STENGTHENING', 'STEP', 'STEPPED', 'STEPPEDWEDGE', 'STEPS', 'STEPUP', 'STEPWISE', 'STEREOISOMERS', 'STERILIZATION', 'STERILIZING', 'STEROID', 'STEWARD', 'STEWARDS', 'STEWARDSHIP', 'STEWARDSHIPGOVERNANCE', 'STEWARDSHIPS', 'STH', 'STHS', 'STI', 'STICHTING', 'STICK', 'STIE2', 'STIGMA', 'STIGMAS', 'STIGMATIZATION', 'STIGMATIZATIONS', 'STIGMATIZING', 'STIHIV', 'STIKO', 'STILL', 'STILLBIRTH', 'STILLBIRTHS', 'STILTED', 'STIMULATE', 'STIMULATED', 'STIMULATES', 'STIMULATING', 'STIMULATION', 'STIMULUS', 'STINGLESS', 'STIPULATED', 'STIPULATES', 'STIPULATION', 'STIRELATED', 'STIRRED', 'STIRS', 'STIS', 'STLSBYLUNDBORGANTIBIOTIC', 'STMINAIRES', 'STNTGAL', 'STOCK', 'STOCKHOLM', 'STOCKOUTS', 'STOCKPILE', 'STOCKPILING', 'STOCKS', 'STOCKTAKE', 'STOCKTS', 'STOMA', 'STOMACH', 'STOMATITIS', 'STONES', 'STONY', 'STOOL', 'STOOLS', 'STOP', 'STOPE', 'STOPES', 'STOPHCV', 'STOPHCV1', 'STOPING', 'STOPPED', 'STOPPER', 'STOPPING', 'STORAGE', 'STORE', 'STORED', 'STORES', 'STOREY', 'STORIES', 'STORING', 'STORY', 'STORYTELLING', 'STORYTHINGS', 'STOUTNESS', 'STOVE', 'STOVES', 'STPA', 'STR', 'STRAIGHTAWAY', 'STRAIN', 'STRAINS', 'STRAINTRANSCENDING', 'STRAND', 'STRANGE', 'STRAT', 'STRATA', 'STRATEGIC', 'STRATEGICAL', 'STRATEGICALLY', 'STRATEGIES', 'STRATEGIESFOR', 'STRATEGIESTHE', 'STRATEGIESTHESE', 'STRATEGIESTHIS', 'STRATEGIESTO', 'STRATEGISTS', 'STRATEGIZE', 'STRATEGY', 'STRATGIES', 'STRATGIQUE', 'STRATIEGIES', 'STRATIFICATION', 'STRATIFIED', 'STRATIFYING', 'STRATTGIES', 'STRATTGIQUE', 'STRATUM', 'STRAWMAN', 'STREAM', 'STREAMLINE', 'STREAMLINED', 'STREAMLINING', 'STREAMS', 'STREET', 'STREETS', 'STRENGHEN', 'STRENGHENING', 'STRENGHT', 'STRENGHTEN', 'STRENGHTENING', 'STRENGT', 'STRENGTH', 'STRENGTHEN', 'STRENGTHENED', 'STRENGTHENEDCHURCH', 'STRENGTHENEDRESULT', 'STRENGTHENING', 'STRENGTHENS', 'STRENGTHNENING', 'STRENGTHS', 'STRENTHENED', 'STRENTHENING', 'STREPTOCOCCUS', 'STRESS', 'STRESSES', 'STRESSORS', 'STRESSORSTHIS', 'STRETCH', 'STRETCHES', 'STRETCHINESS', 'STRICKEN', 'STRICT', 'STRICTER', 'STRIDES', 'STRIFE', 'STRIKE', 'STRIKING', 'STRING', 'STRINGENT', 'STRIP', 'STRIPLING', 'STRIPS', 'STRIVE', 'STRIVES', 'STRIVING', 'STROKE', 'STROKEDETERMINE', 'STROKES', 'STRONG', 'STRONGER', 'STRONGLY', 'STRUCTUR', 'STRUCTURAL', 'STRUCTURALLY', 'STRUCTURATION', 'STRUCTURE', 'STRUCTUREBASED', 'STRUCTURED', 'STRUCTURES', 'STRUCTURESNEW', 'STRUCTURESWITH', 'STRUCUTE', 'STRUGGLE', 'STRUGGLES', 'STRUGGLING', 'STSFF', 'STSLSBYLUNDBORGANTIBIOTIC', 'STUDENT', 'STUDENTS', 'STUDENTSCONDUCT', 'STUDENTSTO', 'STUDIE', 'STUDIED', 'STUDIES', 'STUDIESA', 'STUDIESADEVELOPMENT', 'STUDIESRESEARCH', 'STUDIESTRAINING', 'STUDY', 'STUDYBDS', 'STUDYEXPECTED', 'STUDYING', 'STUDYS', 'STUDYTHIS', 'STUFF', 'STUNT', 'STUNTED', 'STUNTING', 'STURMABTEILUNG', 'STYLE', 'STYMIED', 'STYPHI', 'SU', 'SUAAHARA', 'SUAREZ', 'SUB', 'SUBACUTE', 'SUBCELLULAR', 'SUBCITIES', 'SUBCLINICALLY', 'SUBCONTRACTORS', 'SUBCOUNTIES', 'SUBDISTRICT', 'SUBDISTRICTS', 'SUBELEMENT', 'SUBELEMENTS', 'SUBGRANT', 'SUBGROUP', 'SUBGROUPS', 'SUBJECT', 'SUBJECTED', 'SUBJECTS', 'SUBJUNCTION', 'SUBLINGUAL', 'SUBMARINE', 'SUBMISSION', 'SUBMIT', 'SUBMITTED', 'SUBNACIONAL', 'SUBNATIONAL', 'SUBPARTNERS', 'SUBPOPULATION', 'SUBPOPULATIONS', 'SUBPROJECT', 'SUBRECIPIENT', 'SUBRECIPIENTS', 'SUBREGION', 'SUBREGIONAL', 'SUBROUTINE', 'SUBSAHARA', 'SUBSAHARAN', 'SUBSAHARIENNE', 'SUBSAMPLE', 'SUBSCRIBE', 'SUBSCRIPTION', 'SUBSECTOR', 'SUBSEQUENT', 'SUBSEQUENTLY', 'SUBSET', 'SUBSETS', 'SUBSIDIARY', 'SUBSIDIE', 'SUBSIDIES', 'SUBSIDISATION', 'SUBSIDIZATION', 'SUBSIDIZE', 'SUBSIDIZED', 'SUBSIDIZING', 'SUBSIDY', 'SUBSIST', 'SUBSISTENCE', 'SUBSTANCE', 'SUBSTANCES', 'SUBSTANDARD', 'SUBSTANTIAL', 'SUBSTANTIALLY', 'SUBSTANTIATE', 'SUBSTANTIVE', 'SUBSTITUTE', 'SUBSTITUTING', 'SUBSTITUTION', 'SUBSTRATES', 'SUBSTRUCTURE', 'SUBSTUDIES', 'SUBSTUDY', 'SUBSYSTEM', 'SUBSYSTEMS', 'SUBTASKS', 'SUBTLE', 'SUBTROPICAL', 'SUBTYPE', 'SUBTYPES', 'SUBUNIT', 'SUBURBAN', 'SUBVENTION', 'SUCCEED', 'SUCCEEDED', 'SUCCEEDING', 'SUCCEEDS', 'SUCCESS', 'SUCCESSES', 'SUCCESSFUL', 'SUCCESSFULLY', 'SUCCESSION', 'SUCCESSOR', 'SUCEPTOMETER', 'SUCH', 'SUCK', 'SUCKING', 'SUD', 'SUDAN', 'SUDANESE', 'SUDANFIFTYFIVE', 'SUDANTHE', 'SUDDEN', 'SUDERECHO', 'SUFFER', 'SUFFERED', 'SUFFERING', 'SUFFERS', 'SUFFICE', 'SUFFICIENT', 'SUFFICIENTLY', 'SUGAR', 'SUGARCANE', 'SUGARS', 'SUGARSWEETENED', 'SUGARY', 'SUGGEST', 'SUGGESTED', 'SUGGESTION', 'SUGGESTS', 'SUING', 'SUIT', 'SUITABILITY', 'SUITABLE', 'SUITABLENESS', 'SUITE', 'SUITED', 'SUITES', 'SUITS', 'SUKKUR', 'SUKUTA', 'SUL', 'SULFUR', 'SULLEN', 'SULPHUR', 'SUM', 'SUMINISTRO', 'SUMMARIZE', 'SUMMARIZED', 'SUMMARIZING', 'SUMMARY', 'SUMMATIONAL', 'SUMMATIVE', 'SUMMER', 'SUMMERTIME', 'SUMMIT', 'SUMMON', 'SUMMONS', 'SUN', 'SUNFLOWER', 'SUNLIGHT', 'SUNPOWERED', 'SUNSHINE', 'SUNSTRENGTHENING', 'SUP', 'SUPE', 'SUPERELASTOMERS', 'SUPERFICIAL', 'SUPERIEUR', 'SUPERIOR', 'SUPERIORS', 'SUPERSCRIPT', 'SUPERVISE', 'SUPERVISED', 'SUPERVISING', 'SUPERVISION', 'SUPERVISIONS', 'SUPERVISOR', 'SUPERVISORS', 'SUPERVISORY', 'SUPORT', 'SUPP', 'SUPPLEMENT', 'SUPPLEMENTAL', 'SUPPLEMENTARY', 'SUPPLEMENTATION', 'SUPPLEMENTING', 'SUPPLEMENTS', 'SUPPLIED', 'SUPPLIER', 'SUPPLIERS', 'SUPPLIES', 'SUPPLY', 'SUPPLYCHAIN', 'SUPPLYCOOPERATION', 'SUPPLYING', 'SUPPLYSIDE', 'SUPPO', 'SUPPOR', 'SUPPORT', 'SUPPORT20162021', 'SUPPORTASSAY', 'SUPPORTED', 'SUPPORTEDRESULT', 'SUPPORTER', 'SUPPORTERS', 'SUPPORTET', 'SUPPORTING', 'SUPPORTIVE', 'SUPPORTS', 'SUPPORTTHE', 'SUPPOSE', 'SUPPOT', 'SUPPRESS', 'SUPPRESSING', 'SUPPRESSION', 'SUPPRESSOR', 'SUPPRT', 'SUPRANATIONAL', 'SUPRIEURE', 'SUPTRIEURE', 'SUR', 'SURCEASE', 'SURE', 'SURENESS', 'SURETY', 'SURFACE', 'SURFACES', 'SURGE', 'SURGEON', 'SURGEONS', 'SURGERIES', 'SURGERY', 'SURGERYOBSTETRIC', 'SURGICAL', 'SURINAME', 'SURJER', 'SURMOUNT', 'SURPASSED', 'SURPRISINGLY', 'SURROGATE', 'SURROUND', 'SURROUNDING', 'SURROUNDINGS', 'SURV', 'SURVAILLANCE', 'SURVEI', 'SURVEIL', 'SURVEILLANCE', 'SURVEILLANCE2', 'SURVEILLANCE5', 'SURVEILLANCE5PLANNED', 'SURVEILLANCES', 'SURVEILLANCESURVEY', 'SURVEILLENCE', 'SURVEY', 'SURVEYALTHOUGH', 'SURVEYED', 'SURVEYS', 'SURVIVAL', 'SURVIVALTHE', 'SURVIVE', 'SURVIVES', 'SURVIVING', 'SURVIVORS', 'SUSCEBLIBLE', 'SUSCEPTIBILITY', 'SUSCEPTIBILITYRESISTANCE', 'SUSCEPTIBLE', 'SUSCEPTIBLENESS', 'SUSPECTED', 'SUSPICION', 'SUST', 'SUSTAIN', 'SUSTAINABILITY', 'SUSTAINABILITYTHE', 'SUSTAINABLE', 'SUSTAINABLERESEARCH', 'SUSTAINABLY', 'SUSTAINED', 'SUSTAINEDDELIVERY', 'SUSTAINING', 'SUSTAINMENT', 'SUSTENANCE', 'SUTHORITIES', 'SUUPORT', 'SUZANA', 'SV', 'SVENNERHOLM', 'SVERIGE', 'SVG', 'SVPS', 'SW', 'SWALLOW', 'SWAP', 'SWAPHS', 'SWAPS', 'SWASTHYA', 'SWAY', 'SWAZILAND', 'SWE', 'SWE2012153', 'SWEAR', 'SWEAT', 'SWEDEN', 'SWEDENKENYA', 'SWEDENMALAYSIA', 'SWEDENS', 'SWEDENSIDA', 'SWEDENWE', 'SWEDES', 'SWEDISH', 'SWEDISHCENTAL', 'SWEDISHEURESIST', 'SWEEPING', 'SWEET', 'SWEETEN', 'SWEETENED', 'SWEETENING', 'SWELL', 'SWIFT', 'SWIFTER', 'SWINE', 'SWISS', 'SWITCH', 'SWITCHED', 'SWITCHING', 'SWITZERLAND', 'SWOP', 'SWS', 'SYDNEY', 'SYLLABUS', 'SYMMETRIC', 'SYMMETRICAL', 'SYMPATHIZE', 'SYMPOSIA', 'SYMPOSIUM', 'SYMPOSIUMSUPPORT', 'SYMPTOM', 'SYMPTOMATIC', 'SYMPTOMFREE', 'SYMPTOMLESS', 'SYMPTOMS', 'SYNAPTIC', 'SYNCYTIAL', 'SYNDICATE', 'SYNDROM', 'SYNDROMATIC', 'SYNDROME', 'SYNDROMES', 'SYNDROMIC', 'SYNERGETIC', 'SYNERGIC', 'SYNERGIES', 'SYNERGISM', 'SYNERGIST', 'SYNERGISTIC', 'SYNERGY', 'SYNTHESES', 'SYNTHESIS', 'SYNTHESISE', 'SYNTHESIZE', 'SYNTHESIZED', 'SYNTHESIZES', 'SYNTHESIZING', 'SYNTHETIC', 'SYNTHETICALLY', 'SYRIA', 'SYRIAN', 'SYRIAS', 'SYRINGE', 'SYSTE', 'SYSTEM', 'SYSTEMATIC', 'SYSTEMATICALLY', 'SYSTEMENSURING', 'SYSTEMIC', 'SYSTEMIDENTIFY', 'SYSTEMINTEGRATED', 'SYSTEMLEVEL', 'SYSTEMS', 'SYSTEMS1', 'SYSTEMS3', 'SYSTEMSASSESS', 'SYSTEMSBASED', 'SYSTEMSESTABLISHED', 'SYSTEMSMONITORING', 'SYSTEMSRESULT', 'SYSTEMSTHE', 'SYSTEMSTO', 'SYSTEMSUPPORT', 'SYSTEMSWIDE', 'SYSTEMTHE', 'SYSTEMWIDE', 'SYSTFME', 'SYSTFMES', 'SYSTME', 'SYSTMES', 'SYSTOLIC', 'SYTEMS', 'T', 'T2D', 'TA', 'TABLE', 'TABLES', 'TABLET', 'TABLETS', 'TABOO', 'TABORI', 'TABS', 'TAC', 'TACAIDS', 'TACBASED', 'TACIT', 'TACKLE', 'TACKLED', 'TACKLES', 'TACKLING', 'TACT', 'TADJ', 'TAENIA', 'TAENIOSIS', 'TAG', 'TAGGED', 'TAGGING', 'TAIL', 'TAILOR', 'TAILORED', 'TAIWAN', 'TAIWANESE', 'TAJIK', 'TAJIKISTAN', 'TAKE', 'TAKEDA', 'TAKEN', 'TAKES', 'TAKING', 'TAKOFF', 'TALAND', 'TALAS', 'TALENT', 'TALENTED', 'TALENTO', 'TALIAFERRO', 'TALIT', 'TALITA', 'TALK', 'TALKING', 'TALLY', 'TALSMANNSARBEID', 'TAMALE', 'TAMARINDO', 'TAMBOPATA', 'TAMIL', 'TAMPONS', 'TANGIBLE', 'TANGIBLY', 'TANK', 'TANKS', 'TANSANIA', 'TANSANIAN', 'TANTALUM', 'TANZAMBO', 'TANZANI', 'TANZANIA', 'TANZANIA4STRATEGIES', 'TANZANIAALL', 'TANZANIABETTER', 'TANZANIAGOVERNANCE', 'TANZANIAHEALTHY', 'TANZANIAN', 'TANZANIANS', 'TANZANIAPROJECT', 'TANZANIAS', 'TANZANIATANZANIA', 'TANZANIE', 'TAP', 'TAPPING', 'TAQMAN', 'TAR', 'TARABA', 'TARAI', 'TARAWA', 'TARGET', 'TARGETED', 'TARGETGROUP', 'TARGETING', 'TARGETS', 'TARGETSACHIEVEMENTS', 'TARGETSPECIFIC', 'TARGETTHE', 'TARGETTING', 'TARTU', 'TASHKENT', 'TASK', 'TASKED', 'TASKFORCE', 'TASKS', 'TASKSHIFTING', 'TASPIN', 'TASTE', 'TASTES', 'TATA', 'TATF', 'TAUGHT', 'TAX', 'TAXATION', 'TAXES', 'TAXI', 'TAXING', 'TAXIS', 'TAXONOMIC', 'TAXONOMICAL', 'TAYLOR', 'TAYSACHS', 'TB', 'TBA', 'TBD', 'TBDETECTION', 'TBDS', 'TBHIV', 'TBI', 'TBILISI', 'TBIT', 'TBMODELS', 'TBNET', 'TBPATIENTS2', 'TBPROGRAM', 'TBSCORE', 'TBVI', 'TC', 'TCC', 'TCCS', 'TCELLS', 'TCF', 'TCHAD', 'TCLIKE', 'TCN', 'TCO', 'TDB', 'TDR', 'TDRC', 'TDRMRCEDCTP', 'TDRS', 'TDUCATION', 'TE', 'TEA', 'TEACH', 'TEACHER', 'TEACHERLED', 'TEACHERS', 'TEACHERSLECTURERS', 'TEACHING', 'TEACHINGS', 'TEACHINGSTAFFRESULT', 'TEAM', 'TEAMED', 'TEAMS', 'TEAMSCOMMUNICATING', 'TEAMWORK', 'TEAR', 'TEARING', 'TEASDALECORTI', 'TEBIBYTE', 'TEBORG', 'TECH', 'TECHNICAL', 'TECHNICALASSISTANCE', 'TECHNICALCULTURAL', 'TECHNICALLY', 'TECHNICALPROFESSIONAL', 'TECHNICIAN', 'TECHNICIANFREE', 'TECHNICIANS', 'TECHNION', 'TECHNIQUE', 'TECHNIQUES', 'TECHNIQUESQUESTIONNAIRES', 'TECHNOECONOMIC', 'TECHNOLOGICAL', 'TECHNOLOGIE', 'TECHNOLOGIES', 'TECHNOLOGIESACADEMIC', 'TECHNOLOGIESPARTNERSHIP', 'TECHNOLOGIESSTRATEGIES', 'TECHNOLOGISTS', 'TECHNOLOGY', 'TECHNOLOGYENABLED', 'TECHNOSERVE', 'TECHPROFESSIONAL', 'TECNICA', 'TECNICAINSTO', 'TECNOLOGFA', 'TECNOLOGIES', 'TEEN', 'TEENAGE', 'TEENAGER', 'TEENS', 'TEGUCIGALPA', 'TEHERAN', 'TEIXOBACTIN', 'TEKNIK', 'TEL', 'TELECONSULTATION', 'TELEDERMATOLOGICAL', 'TELEEXPERTS', 'TELEGRAPH', 'TELEHEALTH', 'TELEMEDICIN', 'TELEMEDICINE', 'TELEPHONE', 'TELERADIOLOGY', 'TELESCOPE', 'TELEVISION', 'TELL', 'TELLING', 'TEMA', 'TEMPERATENESS', 'TEMPERATURE', 'TEMPERATURES', 'TEMPLATES', 'TEMPLE', 'TEMPORAL', 'TEMPORARY', 'TEMPT', 'TEN', 'TENDANCES', 'TENDER', 'TENDERING', 'TENDING', 'TENDONS', 'TENDS', 'TENDU', 'TENGGARA', 'TENNESSEE', 'TENOFOVIR', 'TENS', 'TENSOR', 'TENT', 'TENTATIVE', 'TENYEAR', 'TERABIT', 'TERABYTE', 'TERBIUM', 'TERCET', 'TERM', 'TERM2', 'TERMED', 'TERMINAL', 'TERMINATE', 'TERMINATED', 'TERMINATION', 'TERMINUS', 'TERMKEY', 'TERMS', 'TERNARY', 'TERNION', 'TERRESTRIAL', 'TERRITORIAL', 'TERRITORIES', 'TERRITORY', 'TERROR', 'TERRORIST', 'TERTIAN', 'TERTIARY', 'TERZETTO', 'TES', 'TEST', 'TESTABLE', 'TESTAMENT', 'TESTED', 'TESTEDRESULT', 'TESTEMITATU', 'TESTIMONIAL', 'TESTING', 'TESTS', 'TESTSTHE', 'TETANUS', 'TETE', 'TETRACYCLINE', 'TETRAD', 'TETRAGENETICS', 'TEXAS', 'TEXISTEPEQUE', 'TEXT', 'TEXTBOOKS', 'TEXTMESSAGING', 'TEXTUAL', 'TEXTURE', 'TF', 'TFA', 'TFP', 'TFPTV5', 'TFR', 'TFV', 'TG', 'TGA', 'TGAS', 'TGF', 'TGFBETA', 'TH', 'TH1', 'TH17', 'TH2', 'THA', 'THABAUNG', 'THAI', 'THAILAND', 'THAILANDS', 'THAKUGAONIN', 'THAKURGAON', 'THALAS', 'THALASSAEMIA', 'THAN', 'THANKS', 'THAR', 'THAT', 'THATCH', 'THE', 'THE1000', 'THEATER', 'THEATERS', 'THEATRE', 'THEATRICAL', 'THECARBON', 'THECNICAL', 'THECOMMUNITY', 'THEGLOBE', 'THEHIGH', 'THEILERIA', 'THEIR', 'THEMATIC', 'THEMATICALLY', 'THEME', 'THEMEII', 'THEMES', 'THEMONITORING', 'THEMSELVESINTERVIEWS', 'THEMTHE', 'THEN', 'THEORETICAL', 'THEORETICALLY', 'THEORIES', 'THEORY', 'THEORYBASED', 'THEPROJECT', 'THEPROJECTS', 'THERAPEUTI', 'THERAPEUTIC', 'THERAPEUTICAL', 'THERAPEUTICALLY', 'THERAPEUTICS', 'THERAPIES', 'THERAPIST', 'THERAPY', 'THERE', 'THEREAFTER', 'THEREBY', 'THEREFORE', 'THEREIN', 'THERMAL', 'THERMO', 'THERMOGRAPHY', 'THERMOSTABLE', 'THESE', 'THESIS', 'THESPIAN', 'THESSALONIKI', 'THEY', 'THHROUGH', 'THI', 'THIAMINE', 'THICKNESS', 'THIMEROSAL', 'THIMPHU', 'THIN', 'THING', 'THINGS', 'THINK', 'THINKING', 'THINKPLACE', 'THINNER', 'THIOPIEN', 'THIRD', 'THIRDS', 'THIRST', 'THIRSTINESS', 'THIRTEEN', 'THIRTY', 'THIS', 'THISPROJECT', 'THITHER', 'THLV1', 'THLV1ASSOCIATED', 'THO', 'THOMAS', 'THORACIC', 'THORNS', 'THOROUGH', 'THOROUGHLY', 'THOROUGHLYTHE', 'THORSELLIA', 'THOSE', 'THOU', 'THOUGH', 'THOUGHT', 'THOUGHTLEADERS', 'THOUSAND', 'THOUSANDS', 'THREAT', 'THREATEN', 'THREATENING', 'THREATENS', 'THREATING', 'THREATS', 'THREE', 'THREEDAY', 'THREEDIMENSIONAL', 'THREEPHASE', 'THREEPRONGED', 'THREESCORE', 'THREESOME', 'THREETUBES', 'THREEWEEK', 'THREEYEAR', 'THRESHOLD', 'THRESHOLDS', 'THRIVING', 'THROU', 'THROUGH', 'THROUGHDEVELOPING', 'THROUGHOUT', 'THROUGHPUT', 'THROUGHSITUATION', 'THROUGHT', 'THROW', 'THULIUM', 'THUMB', 'THUS', 'THUSLY', 'THUTHUZELA', 'THY', 'THYMINE', 'THYROID', 'THYROXIN', 'TIANJIN', 'TIB', 'TICA', 'TICK', 'TICKBORNE', 'TICKS', 'TIDDLER', 'TIDY', 'TIE', 'TIER', 'TIERCE', 'TIERED', 'TIERS', 'TIES', 'TIGER', 'TIGHTEN', 'TIGRAY', 'TIKE', 'TIL', 'TILAPIA', 'TILDELINGSBREV', 'TILL', 'TIMBER', 'TIMBRE', 'TIME', 'TIMED', 'TIMEFRAME', 'TIMEFRAMERAPID', 'TIMELINES', 'TIMELINESS', 'TIMELY', 'TIMES', 'TIMETHE', 'TIMING', 'TIMOR', 'TIMORLESTE', 'TIN', 'TINDOUF', 'TINTINNABULATION', 'TINY', 'TIPPING', 'TIRANA', 'TISSUE', 'TISSUES', 'TITER', 'TITERS', 'TITLE', 'TITLED', 'TITRES', 'TIVE', 'TL', 'TLIMINATION', 'TLR3', 'TLYMPHOCYTES', 'TM', 'TMAP', 'TNF', 'TNIMA', 'TO', 'TO1', 'TOASSESS', 'TOASSIST', 'TOBAC', 'TOBACCO', 'TOBACCOCAUSED', 'TOBACCOCONTROL', 'TOBACCOFREE', 'TOBACCOGROWING', 'TOBACCORELATED', 'TOBIN', 'TOBUILD', 'TOC', 'TOCOPHEROL', 'TOCREATE', 'TODAY', 'TODAYS', 'TODESIGNING', 'TODEVELOP', 'TODO', 'TODOS', 'TOED', 'TOFIGHT', 'TOFORMULATE', 'TOFULLY', 'TOGAVIRIDAE', 'TOGETHER', 'TOGO', 'TOGOLESE', 'TOHOST', 'TOILET', 'TOILETS', 'TOLERANCE', 'TOLERANCERESISTANCE', 'TOLERANT', 'TOLERATE', 'TOLERATED', 'TOLERIZATION', 'TOLERIZING', 'TOLL', 'TOME', 'TON', 'TONE', 'TONGA', 'TONGANS', 'TONGAS', 'TONY', 'TOOK', 'TOOL', 'TOOLKIT', 'TOOLKITS', 'TOOLS', 'TOONS', 'TOOTH', 'TOP', 'TOPIC', 'TOPICAL', 'TOPICALLY', 'TOPICS', 'TOPISIROVIC', 'TOPLINE', 'TOPOGRAPHICAL', 'TOPPRIORITY', 'TOPROJECT', 'TOPV', 'TOR', 'TORIT', 'TORO', 'TORONTO', 'TORONTOS', 'TORS', 'TORSO', 'TORTURE', 'TOSOUTH', 'TOT', 'TOTAL', 'TOTALLY', 'TOTALS', 'TOTEST', 'TOUCH', 'TOUCHED', 'TOUCHING', 'TOUCHSTONE', 'TOUGH', 'TOUNDERSTAND', 'TOUNDERTAKE', 'TOUR', 'TOURISM', 'TOURIST', 'TOURISTS', 'TOURISTSRESEARCHERS', 'TOURS', 'TOWA', 'TOWARD', 'TOWARDS', 'TOWN', 'TOWNS', 'TOWNSHIP', 'TOWNSHIPS', 'TOWNSPEOPLE', 'TOXBOL', 'TOXIC', 'TOXICANT', 'TOXICITY', 'TOXICOLOGY', 'TOXIN', 'TOXINS', 'TOXOID', 'TOXOPLASMOSIS', 'TPE', 'TPIDTM', 'TPIDTMIOLOGIQUE', 'TPPS', 'TR', 'TRABAJAR', 'TRACE', 'TRACEABILITY', 'TRACER', 'TRACHEALIS', 'TRACHOMA', 'TRACHOMATOUS', 'TRACING', 'TRACK', 'TRACKED', 'TRACKING', 'TRACKINGTHE', 'TRACKS', 'TRACT', 'TRACTION', 'TRADE', 'TRADEOFFS', 'TRADERELATED', 'TRADERS', 'TRADES', 'TRADICATION', 'TRADIONS', 'TRADITION', 'TRADITIONAL', 'TRADITIONALLY', 'TRADITIONS', 'TRAFFIC', 'TRAFFICKING', 'TRAFFICKINGSMUGGLING', 'TRAGEDY', 'TRAIL', 'TRAILING', 'TRAIN', 'TRAINED', 'TRAINEDQUALIFIED', 'TRAINEES', 'TRAINEESHIPS', 'TRAINERS', 'TRAINI', 'TRAINING', 'TRAININGFREE', 'TRAININGINCREASE', 'TRAININGS', 'TRAININGSUPPORTING', 'TRAINS', 'TRAINTHETRAINER', 'TRAITEMENT', 'TRAITS', 'TRANCHE', 'TRANEXAMIC', 'TRANINING', 'TRANLSATIONAL', 'TRANS', 'TRANSACTIONAL', 'TRANSCEND', 'TRANSCENDING', 'TRANSCRIBED', 'TRANSCRIPTION', 'TRANSCRIPTOME', 'TRANSCRIPTOMICS', 'TRANSCRIPTS', 'TRANSDISCIPLINARY', 'TRANSFAT', 'TRANSFATTY', 'TRANSFER', 'TRANSFERRAL', 'TRANSFERRED', 'TRANSFERRING', 'TRANSFERS', 'TRANSFORM', 'TRANSFORMATION', 'TRANSFORMATIONAL', 'TRANSFORMATIVE', 'TRANSFORMED', 'TRANSFORMING', 'TRANSFUSION', 'TRANSFUSIONS', 'TRANSGENDER', 'TRANSGENDERED', 'TRANSGENIC', 'TRANSIENT', 'TRANSIT', 'TRANSITION', 'TRANSITIONAL', 'TRANSITIONING', 'TRANSLATE', 'TRANSLATED', 'TRANSLATES', 'TRANSLATING', 'TRANSLATION', 'TRANSLATIONAL', 'TRANSLATIONS', 'TRANSLOCATION', 'TRANSMISS', 'TRANSMISSIBILITY', 'TRANSMISSIBLE', 'TRANSMISSION', 'TRANSMISSION3', 'TRANSMISSIONBLOCKING', 'TRANSMISSIONELIMINATION', 'TRANSMISSIONS', 'TRANSMIT', 'TRANSMITS', 'TRANSMITTABLE', 'TRANSMITTAL', 'TRANSMITTANCE', 'TRANSMITTED', 'TRANSMITTER', 'TRANSMITTING', 'TRANSMITTION', 'TRANSMUTE', 'TRANSNATIONAL', 'TRANSNISTRIA', 'TRANSPARANCY', 'TRANSPARENCE', 'TRANSPARENCY', 'TRANSPARENT', 'TRANSPARENTNESS', 'TRANSPHOBIA', 'TRANSPLANTATION', 'TRANSPORT', 'TRANSPORTATION', 'TRANSPORTATIONLACK', 'TRANSPORTNONMOTORIZED', 'TRANSSECTORAL', 'TRANSSEXUAL', 'TRANSSEXUALS', 'TRANSVERSAL', 'TRAP', 'TRASCRIPTOMICS', 'TRASH', 'TRASTUZUMABTDM1', 'TRATANDO', 'TRAUMA', 'TRAUMATIC', 'TRAUMATIZATION', 'TRAVAIL', 'TRAVAILLEURSEUSES', 'TRAVAUX', 'TRAVEL', 'TRAVELERS', 'TRAVELING', 'TRAVELLED', 'TRAVELLER', 'TRAVELLERS', 'TRAVERSE', 'TRAVTS', 'TRE', 'TREA', 'TREASURY', 'TREAT', 'TREATABLE', 'TREATED', 'TREATED4', 'TREATEMENT', 'TREATING', 'TREATMENT', 'TREATMENT3', 'TREATMENTARV', 'TREATMENTBTO', 'TREATMENTPREVENTIONFOLLOWUP', 'TREATMENTPROCEDURES', 'TREATMENTRESULT', 'TREATMENTS', 'TREATMENTTHE', 'TREATMETN', 'TREATY', 'TREBLING', 'TREES', 'TREMENDOUS', 'TREND', 'TRENDS', 'TREY', 'TRF', 'TRI', 'TRIAD', 'TRIAGE', 'TRIAL', 'TRIALLING', 'TRIALS', 'TRIALSDURING', 'TRIALSRESEARCHFOR', 'TRIALSTHE', 'TRIANGLE', 'TRIANGULAR', 'TRIATOMA', 'TRIBE', 'TRIBENDIMIDINE', 'TRIBULATION', 'TRICHIASIS', 'TRICHURIS', 'TRICK', 'TRICKLE', 'TRIDACTYLUS', 'TRIES', 'TRIGGER', 'TRIGGERED', 'TRIGGERING', 'TRIGGERS', 'TRIGLYCERIDES', 'TRIIODOTHYRONINE', 'TRILLION', 'TRIM', 'TRIMERIC', 'TRIMESTER', 'TRINE', 'TRINIDAD', 'TRINING', 'TRINITY', 'TRIO', 'TRIP', 'TRIPARTITE', 'TRIPLE', 'TRIPLET', 'TRIPLY', 'TRIPS', 'TRITERPENES', 'TRITICI', 'TRITICUM', 'TRIVALENT', 'TRO', 'TROIKA', 'TROOPS', 'TROPIC', 'TROPICAL', 'TROPICALE', 'TROPICALES', 'TROPICLA', 'TROPICS', 'TROPIQ', 'TROPISM', 'TROTH', 'TROUBLE', 'TROUBLESHOOTING', 'TROUPE', 'TRPM8', 'TRPOICAL', 'TRUCK', 'TRUDEAU', 'TRUDEAUS', 'TRUE', 'TRULY', 'TRUNCATE', 'TRUNCATETB', 'TRUNK', 'TRUST', 'TRUSTED', 'TRUSTEE', 'TRUSTEES', 'TRUSTINGNESS', 'TRUSTMRC', 'TRUSTS', 'TRUSTWORTHY', 'TRUTH', 'TRY', 'TRYING', 'TRYOUT', 'TRYPANOLYTIC', 'TRYPANOSOMA', 'TRYPANOSOMAL', 'TRYPANOSOMATID', 'TRYPANOSOME', 'TRYPANOSOMES', 'TRYPANOSOMIASES', 'TRYPANOSOMIASIS', 'TRYPANOSOMOSIS', 'TSE', 'TSETSE', 'TSETSEBORNE', 'TSH', 'TSHIRTS', 'TSHWANEMETSWEDING', 'TSKIRTS', 'TSP', 'TSUNAMI', 'TT', 'TTE', 'TTEN', 'TTI', 'TTINGEN', 'TTL', 'TTT', 'TUBERCLE', 'TUBERCULAR', 'TUBERCULOSE', 'TUBERCULOSES', 'TUBERCULOSIS', 'TUBMAN', 'TUDES', 'TUFTS', 'TUITION', 'TULANE', 'TUMID', 'TUMOR', 'TUMORI', 'TUMORS', 'TUMOUR', 'TUMOURS', 'TUNDRA', 'TUNIKA', 'TUNING', 'TUNIS', 'TUNISCARE', 'TUNISIA', 'TUNISIAN', 'TUP', 'TURBULENT', 'TURINTENC010', 'TURKEY', 'TURKISH', 'TURKMENISTAN', 'TURMOIL', 'TURN', 'TURNED', 'TURNOUT', 'TUSCAN', 'TUSCANY', 'TUSH', 'TUTELAGE', 'TUTORATPLUS', 'TUTORIAL', 'TUVALU', 'TUVALUANS', 'TUVALUS', 'TUVALUTHE', 'TV', 'TV2', 'TV3', 'TV5', 'TVFNEMENTS', 'TWAWEZA', 'TWELVE', 'TWELVEMONTH', 'TWENTY', 'TWENTY20', 'TWICE', 'TWINS', 'TWO', 'TWOARM', 'TWODAY', 'TWOFOLD', 'TWOMONTH', 'TWOPHDGRANTSPROVIDED', 'TWOPRONGED', 'TWOTHIRDS', 'TWOYEAR', 'TX', 'TYGBVHIVAIDS', 'TYKE', 'TYPE', 'TYPE2', 'TYPEFACE', 'TYPES', 'TYPHI', 'TYPHOID', 'TYPICAL', 'TYPICALLY', 'TYRE', 'TYROSINE', 'TZ', 'U', 'U01', 'U01CK', 'U01GH', 'U01IP', 'U18CK', 'UAC', 'UAE', 'UBANGI', 'UBETA', 'UBINIG', 'UBIQ', 'UBIQUITIN', 'UBRAF', 'UBS', 'UC', 'UCAD', 'UCAYALI', 'UD', 'UDERS', 'UDSM', 'UE', 'UEM', 'UEP', 'UFBA', 'UG', 'UGA', 'UGANDA', 'UGANDA2017', 'UGANDA4', 'UGANDAASSESSMENT', 'UGANDAN', 'UGANDANCANADIAN', 'UGANDANS', 'UGANDAPLANNED', 'UGANDAS', 'UGANDATHIS', 'UGNDA', 'UHC', 'UHS', 'UIC', 'UJA', 'UK', 'UKAID', 'UKBRAZIL', 'UKCHINA', 'UKCHINESE', 'UKDURING', 'UKICATMA', 'UKINDIA', 'UKRAINE', 'UKRAINIAN', 'UKS', 'UKZN', 'UL', 'ULAAN', 'ULCER', 'ULCERANS', 'ULCERATION', 'ULCERS', 'ULCFRE', 'ULCRE', 'ULIKE', 'ULTIMATE', 'ULTIMATELY', 'ULTRA', 'ULTRAHYPERMUTANT', 'ULTRAPOOR', 'ULTRAPROCESSED', 'ULTRASOUND', 'ULYSSES', 'UMA', 'UMBILICAL', 'UMBRELLA', 'UME', 'UMEA', 'UMES', 'UMRWABA', 'UMSA', 'UMSS', 'UN', 'UNA', 'UNABLE', 'UNACCEPTABLY', 'UNAFFORDABLE', 'UNAIDS', 'UNAIDSGSP', 'UNALMS', 'UNANI', 'UNANSWERED', 'UNARMED', 'UNATTENDED', 'UNAVAILABILITY', 'UNAVAILABLE', 'UNAVOIDABLE', 'UNAWARE', 'UNBIASED', 'UNCCH', 'UNCERTAINTIES', 'UNCERTAINTY', 'UNCHANGED', 'UNCHANGING', 'UNCIVILISED', 'UNCLEAR', 'UNCLEARINSIGHTS', 'UNCOMMITTED', 'UNCOMMON', 'UNCOMPLICATED', 'UNCONDITIONAL', 'UNCONSCIOUS', 'UNCOVER', 'UNCOVERED', 'UNCOVERING', 'UND', 'UNDE', 'UNDECIDED', 'UNDECOMPOSED', 'UNDER', 'UNDER5', 'UNDERACHIEVEMENT', 'UNDERCOUNTED', 'UNDERDEVELOPED', 'UNDERDEVELOPMENT', 'UNDERESTIMATE', 'UNDERESTIMATED', 'UNDEREXPLORED', 'UNDERFIVE', 'UNDERFUNDED', 'UNDERGO', 'UNDERGOING', 'UNDERGONE', 'UNDERGRADUATE', 'UNDERGROUND', 'UNDERLIE', 'UNDERLYING', 'UNDERMENTIONED', 'UNDERMINE', 'UNDERNOURISHED', 'UNDERNOURISHMENT', 'UNDERNUTRITION', 'UNDERPERFORMING', 'UNDERPIN', 'UNDERPINNING', 'UNDERPRIVILEDGED', 'UNDERPRIVILEGED', 'UNDERREPRESENTED', 'UNDERRESOURCED', 'UNDERSCORES', 'UNDERSCORING', 'UNDERSERVED', 'UNDERSTAFFED', 'UNDERSTAND', 'UNDERSTANDD', 'UNDERSTANDING', 'UNDERSTANDINGINFLUENCING', 'UNDERSTANDINGS', 'UNDERSTOOD', 'UNDERSTOODTHIS', 'UNDERSTRUCTURE', 'UNDERTAING', 'UNDERTAKE', 'UNDERTAKEN', 'UNDERTAKES', 'UNDERTAKING', 'UNDERTOOK', 'UNDERUSED', 'UNDERUTILIZED', 'UNDERWAY', 'UNDERWEIGHT', 'UNDERWENT', 'UNDESIGNATED', 'UNDIAGNOSED', 'UNDP', 'UNDPS', 'UNDPUNFPAUNICEFWHOWORLD', 'UNE', 'UNEARMARKED', 'UNECE', 'UNEMPLOYED', 'UNEP', 'UNEQUAL', 'UNEQUALITY', 'UNESCO', 'UNEVEN', 'UNEXAMPLED', 'UNEXPECTED', 'UNEXPLOITED', 'UNEXPLORED', 'UNFAIR', 'UNFORESEEN', 'UNFORESIGHTFUL', 'UNFORTUNATELY', 'UNFPA', 'UNFRIENDLY', 'UNHEALTHFUL', 'UNHEALTHY', 'UNHEEDED', 'UNICAR', 'UNICEF', 'UNICEFS', 'UNICEFUNDPWORLD', 'UNICEFUNFPA', 'UNIFICATION', 'UNIFIED', 'UNIFORM', 'UNIFORMED', 'UNIFORMITY', 'UNIFORMLY', 'UNIFORMS', 'UNILEVER', 'UNINFECTED', 'UNINSURED', 'UNINTENDED', 'UNINTENTIONAL', 'UNINTERRUPTED', 'UNION', 'UNIONISE', 'UNIONS', 'UNIONSAND', 'UNIQUE', 'UNIQUELY', 'UNIT', 'UNITAFGHANISTAN', 'UNITAID', 'UNITARY', 'UNITED', 'UNITEDLY', 'UNITING', 'UNITMAIN', 'UNITS', 'UNITT', 'UNITTHE', 'UNITY', 'UNIV', 'UNIVALENT', 'UNIVERCELLS', 'UNIVERSAL', 'UNIVERSALACCESS', 'UNIVERSALITY', 'UNIVERSALLY', 'UNIVERSE', 'UNIVERSIDAD', 'UNIVERSIDADE', 'UNIVERSIT', 'UNIVERSITAIRE', 'UNIVERSITAIRES', 'UNIVERSITARIO', 'UNIVERSITE', 'UNIVERSITEIT', 'UNIVERSITIES', 'UNIVERSITS', 'UNIVERSITST', 'UNIVERSITT', 'UNIVERSITTS', 'UNIVERSITY', 'UNIVERSITYHD', 'UNIVERSITYIMPROVING', 'UNIVERSITYS', 'UNIVERSITYUNIVERSITY', 'UNIVERSL', 'UNJUST', 'UNKNOWN', 'UNLED', 'UNLESS', 'UNLIKE', 'UNLOCK', 'UNLOCKING', 'UNMARRIED', 'UNMATCHABLE', 'UNMATCHED', 'UNMET', 'UNMETHYLATED', 'UNNECESSARILY', 'UNNECESSARY', 'UNNEEDED', 'UNODC', 'UNODCS', 'UNOFFICIAL', 'UNPARALLELED', 'UNPLANNED', 'UNPRECEDENTED', 'UNPREDICTABLE', 'UNPREJUDICED', 'UNPRIVILEGED', 'UNPUBLISHED', 'UNRAVEL', 'UNRAVELING', 'UNRAVELLING', 'UNREGULATED', 'UNRELIABLE', 'UNREMARKABLE', 'UNREMARKABLY', 'UNRESOLVED', 'UNRESTRICTED', 'UNRIVALED', 'UNRIVALLED', 'UNRWA', 'UNRWAS', 'UNS', 'UNSAFE', 'UNSCATHED', 'UNSGS', 'UNSHACKLED', 'UNSOPHISTICATED', 'UNSPECIFIED', 'UNSPOILED', 'UNSPOILT', 'UNSTABLE', 'UNSUBDIVIDED', 'UNSUBTLE', 'UNSUPPORTIVE', 'UNSUSCEPTIBILITY', 'UNTAPPED', 'UNTENABLE', 'UNTIED', 'UNTIL', 'UNTOWARD', 'UNTREATED', 'UNTRIED', 'UNTRMA', 'UNUINWEH', 'UNUSUAL', 'UNV', 'UNVEILING', 'UNWANTED', 'UNWARRANTED', 'UNWASHED', 'UNWELLNESS', 'UNWHOLESOMENESS', 'UNWRAP', 'UNWRITTEN', 'UOG', 'UP', 'UPAZILA', 'UPBRINGING', 'UPCOMING', 'UPDATE', 'UPDATED', 'UPDATES', 'UPDATING', 'UPGARDES', 'UPGRADE', 'UPGRADEDRESULTS', 'UPGRADES', 'UPGRADI', 'UPGRADING', 'UPHCP', 'UPHCPI', 'UPHCPII', 'UPHCSDP', 'UPHEAVAL', 'UPHOLD', 'UPIMMUNIZATION', 'UPKEEP', 'UPLAND', 'UPLOADED', 'UPMC', 'UPON', 'UPPER', 'UPPSALA', 'UPRESULT', 'UPRIGHT', 'UPRISE', 'UPROOT', 'UPSCALING', 'UPSET', 'UPSHOT', 'UPSTAIRS', 'UPSTREAM', 'UPSURGE', 'UPTAKE', 'UPTAKEEQUINET', 'UPTODATE', 'UPWARD', 'UPWARDLY', 'UR', 'URACIL', 'URANIUM', 'URBAN', 'URBANIZATION', 'URBANIZING', 'URBANLEVEL', 'URBANSCALE', 'URC', 'URCS', 'URETHRA', 'URGE', 'URGED', 'URGENCY', 'URGENT', 'URGENTLY', 'URI', 'URINAL', 'URINARY', 'URINE', 'URINEBASED', 'URIS', 'UROLOGICAL', 'URSWEDEN', 'URUGUAY', 'URUGUAYEXPECTED', 'URUGUAYIMPACT', 'US', 'US7', 'USA', 'USABILITY', 'USABLE', 'USAGE', 'USAID', 'USAIDAPII', 'USAIDASSISTED', 'USAIDCAMBODIA', 'USAIDCENTRAL', 'USAIDCOMMUNITY', 'USAIDDONATED', 'USAIDETHIOPIA', 'USAIDFUNDED', 'USAIDGHANA', 'USAIDINDIA', 'USAIDINDONESIA', 'USAIDINDONESIAS', 'USAIDLIBERIA', 'USAIDMADAGASCAR', 'USAIDMALI', 'USAIDMOZAMBIQUES', 'USAIDNIGERIA', 'USAIDS', 'USAIDSOUTHERN', 'USAIDSUPPORTED', 'USAIDUGANDA', 'USAIDWA', 'USAIDWASHINGTONS', 'USAIDWEST', 'USAIDYAAJEENDE', 'USAIDZAMBIA', 'USANCE', 'USBASED', 'USCHINA', 'USD1958836', 'USDA', 'USE', 'USEABLE', 'USEAND', 'USED', 'USEDESPITE', 'USEFUL', 'USEFULNESS', 'USER', 'USERCENTRIC', 'USERFRIENDLY', 'USERS', 'USERSASSESS', 'USES', 'USFDA', 'USG', 'USGFUNDED', 'USGMOE', 'USGSUPPORTED', 'USHER', 'USHERED', 'USHIRIKIANO', 'USING', 'USO', 'USP', 'USPOSABLJANJE', 'USTDA', 'USTDAS', 'USUAL', 'USUALLY', 'UTAMD', 'UTEN', 'UTENSILS', 'UTERINE', 'UTERUS', 'UTG', 'UTILISATION', 'UTILISE', 'UTILISED', 'UTILISING', 'UTILITIES', 'UTILITY', 'UTILITYOF', 'UTILIZANDO', 'UTILIZATION', 'UTILIZE', 'UTILIZED', 'UTILIZES', 'UTILIZING', 'UTMOST', 'UTTAR', 'UTTARAKHAND', 'UTTER', 'UVRE', 'UWC', 'UZAZI', 'UZB', 'UZB405G02M', 'UZBE', 'UZBEK', 'UZBEKISTAN', 'UZIMA', 'V', 'VA', 'VACCINATED', 'VACCINATING', 'VACCINATION', 'VACCINATIONS', 'VACCINATORS', 'VACCINE', 'VACCINE2', 'VACCINEASSOCIATED', 'VACCINEDRUG', 'VACCINEDURING', 'VACCINEELICITED', 'VACCINEINDUCED', 'VACCINELIKE', 'VACCINEPREVENTABLE', 'VACCINERELATED', 'VACCINES', 'VACCINESABIN', 'VACCINOLOGY', 'VACCINS', 'VACCINUM', 'VACINE', 'VACINEES', 'VACUNACI', 'VACUNACIN', 'VACUOLAR', 'VACUUM', 'VACV', 'VAGINA', 'VAGINAL', 'VAGINOSIS', 'VALENCES', 'VALENT', 'VALERY', 'VALID', 'VALIDATE', 'VALIDATED', 'VALIDATING', 'VALIDATION', 'VALIDATIONS', 'VALLEY', 'VALORISATION', 'VALPARAISO', 'VALUABLE', 'VALUATE', 'VALUATION', 'VALUE', 'VALUED', 'VALUEFORMONEY', 'VALUES', 'VANCOUVER', 'VANDERBILT', 'VANE', 'VANSKELIG', 'VANTAGE', 'VANUATU', 'VAPAR', 'VAPP', 'VAR', 'VARELA', 'VARIABILITY', 'VARIABLE', 'VARIABLES', 'VARIANT', 'VARIANTS', 'VARIATION', 'VARIATIONS', 'VARIED', 'VARIEGATION', 'VARIES', 'VARIETAL', 'VARIETIES', 'VARIETY', 'VARIOUS', 'VARIOUSLY', 'VARLET', 'VARY', 'VARYING', 'VAS', 'VASANTHAN', 'VASCO', 'VASCULAR', 'VASCULARBRAIN', 'VASCULARITY', 'VASODILATORS', 'VAST', 'VASTE', 'VASTLY', 'VAUDOIS', 'VAX', 'VAXESS', 'VAXXAS', 'VC', 'VCT', 'VD', 'VECTOR', 'VECTORBASED', 'VECTORBORNE', 'VECTORED', 'VECTORS', 'VECTORWORKS', 'VEG', 'VEGETABLE', 'VEGETABLES', 'VEGETABLESTHIS', 'VEGETATIONBASED', 'VEGGIE', 'VEHEMENCE', 'VEHICLE', 'VEHICLES', 'VEHICLESEVEN', 'VEIN', 'VEL', 'VELLORE', 'VELOPPEMENT', 'VELOPPER', 'VENDORS', 'VENEREAL', 'VENEZUELA', 'VENIR', 'VENTILATION', 'VENTURE', 'VENTURES', 'VENTUREWELL', 'VENUE', 'VENUES', 'VENUSS', 'VERACIOUS', 'VERANDA', 'VERBAL', 'VERBATIM', 'VERBOTEN', 'VERDE', 'VERIFICATION', 'VERIFIED', 'VERIFIER', 'VERIFIES', 'VERIFY', 'VERNACULAR', 'VERONA', 'VERSATILE', 'VERSION', 'VERSIONS', 'VERSUS', 'VERTEBRAL', 'VERTEBRATE', 'VERTEBRATES', 'VERTICAL', 'VERTICALLY', 'VERY', 'VESICULAR', 'VESS', 'VESSEL', 'VETERINARIAN', 'VETERINARIANS', 'VETERINARY', 'VFM', 'VHC', 'VHCS', 'VHEMBE', 'VHF', 'VHR', 'VI', 'VIA', 'VIABILITY', 'VIABLE', 'VIAL', 'VIBRANT', 'VIBRIO', 'VIBRIOS', 'VIBRIOSIS', 'VICARIOUS', 'VICIOUS', 'VICTIMISATION', 'VICTIMIZATION', 'VICTIMS', 'VICTORIA', 'VICTUALS', 'VIDA', 'VIDEO', 'VIDEOEDUCATION', 'VIDEOS', 'VIDOVICE', 'VIE', 'VIENNA', 'VIENTIANE', 'VIET', 'VIETHEALTH', 'VIETNAM', 'VIETNAMESE', 'VIETNAMESEGERMAN', 'VIETNAMS', 'VIETNAMSOUTHEAST', 'VIEW', 'VIEWING', 'VIEWPOINT', 'VIEWS', 'VIGILANCIA', 'VIGMED', 'VIGOROUS', 'VIH', 'VIHARA', 'VIHSIDA', 'VII', 'VIII', 'VILES', 'VILIFICATION', 'VILLAGE', 'VILLAGEOISES', 'VILLAGEREACH', 'VILLAGERS', 'VILLAGES', 'VILLAGETHE', 'VILLASECA', 'VIMANG', 'VINDICO', 'VIOLATION', 'VIOLATIONS', 'VIOLENCE', 'VIOLENCETHE', 'VIOLENCIA', 'VIOLENT', 'VIOSTEROL', 'VIPERIN', 'VIRAL', 'VIRGINIA', 'VIROLOGIC', 'VIROLOGICAL', 'VIROLOGY', 'VIROLOGYNIGERIA', 'VIRTUAL', 'VIRTUALLY', 'VIRULENCE', 'VIRULENCY', 'VIRUS', 'VIRUSBASED', 'VIRUSES', 'VIRUSESTHIS', 'VIRUSHOST', 'VIRUSLIKE', 'VIRUSRELATED', 'VIRUSSPECIFIC', 'VIRUSZIKA', 'VIS', 'VISA', 'VISC', 'VISCERAL', 'VISCERALLEISHMANIASIS', 'VISCRALE', 'VISCTRALE', 'VISE', 'VISIBILITY', 'VISIBLE', 'VISIBLENESS', 'VISION', 'VISIONARY', 'VISIT', 'VISITATION', 'VISITED', 'VISITING', 'VISITS', 'VISJON2030', 'VISUAL', 'VISUALISE', 'VISUALISED', 'VISUALIZATION', 'VISUALLY', 'VIT', 'VITAL', 'VITALIZING', 'VITAMIN', 'VITAMINS', 'VITILIGO', 'VITMAIN', 'VITRO', 'VITRO5', 'VIVA', 'VIVAX', 'VIVAXMALARIA', 'VIVIANE', 'VIVID', 'VIVIENDO', 'VIVO', 'VIVORESULTS', 'VIVRE', 'VL', 'VLAAMSE', 'VLIR', 'VLPS', 'VMMC', 'VN', 'VNAVIAN', 'VNEMENTS', 'VNT', 'VOC', 'VOCAL', 'VOCATION', 'VOCATIONAL', 'VOCE', 'VOICE', 'VOICES', 'VOID', 'VOIDING', 'VOLATILE', 'VOLATOMICS', 'VOLITION', 'VOLT', 'VOLTA', 'VOLTAGE', 'VOLUME', 'VOLUNTARY', 'VOLUNTEER', 'VOLUNTEERS', 'VOLUNTIERS', 'VON', 'VONJI', 'VOOR', 'VOR', 'VOTER', 'VOUCHER', 'VOUCHERBASED', 'VOUCHERS', 'VPAN', 'VR', 'VREDENDAL', 'VRFUNDED', 'VS', 'VSEST', 'VSHC', 'VSHSMSKI', 'VSR', 'VSSTRA', 'VSV', 'VSVEBOV', 'VUE', 'VULARABLE', 'VULGARISING', 'VULNARABLE', 'VULNERABILITIES', 'VULNERABILITY', 'VULNERABLE', 'VULNERABLEHEALTH', 'VULNERABLES', 'VULVERABLE', 'W', 'WA', 'WABA', 'WAD', 'WADE', 'WAGE', 'WAHO', 'WAHOS', 'WAIT', 'WAITING', 'WAIVED', 'WAJIBIKA', 'WAKE', 'WALA', 'WALDENSES', 'WALIA', 'WALIAN', 'WALKABILITY', 'WALKING', 'WALL', 'WALLED', 'WALLOP', 'WALLS', 'WALTER', 'WAMBA', 'WAMPUM', 'WANDERING', 'WANING', 'WANT', 'WANTS', 'WAPHIR', 'WAR', 'WARD', 'WARDS', 'WARE', 'WAREHOUSE', 'WAREHOUSES', 'WAREHOUSING', 'WARENESS', 'WARFARIN', 'WARIA', 'WARM', 'WARMBLOODED', 'WARMING', 'WARNING', 'WARNINGS', 'WARP', 'WARSAW', 'WARTIME', 'WARWICK', 'WAS', 'WASH', 'WASHABLES', 'WASHING', 'WASHINGTON', 'WASHPALS', 'WASHPLUS', 'WASTAGE', 'WASTE', 'WASTEPICKER', 'WASTES', 'WASTEWATER', 'WASTING', 'WASY', 'WAT', 'WATCH', 'WATCHDOG', 'WATCHED', 'WATER', 'WATERBORN', 'WATERBORNE', 'WATERING', 'WATERLOO', 'WATERRELATED', 'WATERS', 'WATERSANITATIONHYGIENE', 'WATERSHED', 'WATERSHEDS', 'WATERY', 'WAVE', 'WAVEFRONT', 'WAY', 'WAYRESULT', 'WAYS', 'WB', 'WBVHAWEST', 'WCAR', 'WCBA', 'WCBAS', 'WE', 'WEAK', 'WEAKENED', 'WEAKER', 'WEAKNESSES', 'WEAKTHIS', 'WEALTH', 'WEALTHIER', 'WEANING', 'WEAPON', 'WEAPONS', 'WEARABLE', 'WEATHER', 'WEB', 'WEBBASED', 'WEBINARS', 'WEBMICROSCOPE', 'WEBSITE', 'WEBSITES', 'WEBSTER', 'WEDGE', 'WEDGED', 'WEDLOCK', 'WEEDS', 'WEEK', 'WEEKLY', 'WEEKS', 'WEIGHING', 'WEIGHT', 'WEIGHTBASED', 'WEIGHTY', 'WEILL', 'WEIZMANN', 'WELBODI', 'WELCOME', 'WELCOMES', 'WELFARE', 'WELL', 'WELLAMONG', 'WELLBEING', 'WELLCHARACTERIZED', 'WELLCOME', 'WELLCONTROLLED', 'WELLCOORDINATED', 'WELLDEFINED', 'WELLDESIGNED', 'WELLEQUIPPED', 'WELLESTABLISHED', 'WELLFUNCTIONING', 'WELLIMPLEMENTED', 'WELLINFORMED', 'WELLKNOWN', 'WELLMANAGED', 'WELLNESS', 'WELLNOURISHED', 'WELLQUALIFIED', 'WELLSPRING', 'WELLSUPPORTED', 'WELLTRAINED', 'WELTEL', 'WERE', 'WEST', 'WESTAFRICA', 'WESTERLY', 'WESTERN', 'WESTERNIZED', 'WESTROCK', 'WESTWARD', 'WETCHAKARURASM', 'WEWE', 'WF', 'WFEDF201402002', 'WFEDF201402003', 'WFEDF201402004', 'WFEDF201402007', 'WFEDF201402008', 'WH', 'WHAT', 'WHEAT', 'WHEATRYE', 'WHEEL', 'WHEN', 'WHERE', 'WHEREAS', 'WHEREBY', 'WHEREFORE', 'WHEREVER', 'WHETHER', 'WHICH', 'WHILE', 'WHILST', 'WHIPWORM', 'WHITE', 'WHITESIDE', 'WHITETHORN', 'WHO', 'WHOAFRO', 'WHODOCUMENTS', 'WHOEVIPNET', 'WHOGOARN', 'WHOHRP', 'WHOIARC', 'WHOLE', 'WHOLEGENOME', 'WHOLEOFGOVERNMENT', 'WHOLESALE', 'WHOOPING', 'WHOPROJECT', 'WHORECOMMENDED', 'WHOREMASTER', 'WHOREMONGER', 'WHOS', 'WHOSE', 'WHOUNICEF', 'WHOWPRO', 'WHWC', 'WHY', 'WIC', 'WICH', 'WICKED', 'WIDDOWSON', 'WIDE', 'WIDELY', 'WIDELYTHE', 'WIDEN', 'WIDENING', 'WIDER', 'WIDERANGE', 'WIDEREACHING', 'WIDESPREAD', 'WIDOWS', 'WIELD', 'WIEN', 'WIL', 'WILD', 'WILDERNESS', 'WILDLIFE', 'WILDLIFELIVESTOCKHUMAN', 'WILDLIFEPROTECTED', 'WILDLIFERELATED', 'WILDNESS', 'WILEY', 'WILFRID', 'WILL', 'WILLALSO', 'WILLANALYZE', 'WILLHAVE', 'WILLIAM', 'WILLIDENTIFY', 'WILLIMPROVE', 'WILLING', 'WILLINGNESS', 'WILLPROVIDE', 'WILLQUANTIFY', 'WILLREVIEW', 'WIND', 'WINDER', 'WINDHOEK', 'WINDMILL', 'WINDOW', 'WINE', 'WING', 'WINGS', 'WINNING', 'WINNOW', 'WINROCK', 'WIPE', 'WIRE', 'WIRELESS', 'WIRELESSLY', 'WISCONSIN', 'WISE', 'WISH', 'WISHES', 'WISTAR', 'WIT', 'WITCH', 'WITCHCRAFT', 'WITH', 'WITHAL', 'WITHDRAWN', 'WITHIN', 'WITHOUT', 'WITHSTAND', 'WITKOPPEN', 'WITNESS', 'WITNESSED', 'WITNESSING', 'WITS', 'WITTENBERG', 'WITTICISM', 'WIVES', 'WK', 'WMW', 'WMWS', 'WOEFULLY', 'WOES', 'WOLBACHIA', 'WOLISO', 'WOLOF', 'WOMAN', 'WOMANCENTERED', 'WOMANHOOD', 'WOMB', 'WOME', 'WOMEN', 'WOMEN4STRATEGIES', 'WOMENCHILDREN', 'WOMENCONTROLLED', 'WOMENCOORDINATING', 'WOMENS', 'WOMENTHE', 'WOMENTHIS', 'WOOD', 'WOODMAN', 'WOODSMAN', 'WOODWORKER', 'WOP', 'WORD', 'WORDS', 'WOREDA', 'WOREDABASED', 'WOREDAS', 'WORK', 'WORKABLE', 'WORKADAY', 'WORKBENCH', 'WORKDURING', 'WORKED', 'WORKER', 'WORKERS', 'WORKERSERVICES', 'WORKFLOWSTHE', 'WORKFORCE', 'WORKIMPROVING', 'WORKING', 'WORKLOAD', 'WORKPLACE', 'WORKPLACEBASED', 'WORKPLACES', 'WORKPLAN', 'WORKREDUCING', 'WORKS', 'WORKSFUND', 'WORKSHARING', 'WORKSHOP', 'WORKSHOPS', 'WORKSHOPSYMPOSIUM', 'WORKTHERE', 'WORLD', 'WORLDCLASS', 'WORLDLEADING', 'WORLDLY', 'WORLDPROJECT', 'WORLDRENOWNED', 'WORLDS', 'WORLDTHE', 'WORLDWIDE', 'WORLDWIDEETHIOPIA', 'WORM', 'WORMING', 'WORMS', 'WORN', 'WORSE', 'WORSENED', 'WORSENING', 'WORST', 'WORTH', 'WORTHY', 'WOULD', 'WOUND', 'WOUNDED', 'WP', 'WPRO', 'WPROSEARO', 'WPV', 'WPV1', 'WRETCHED', 'WRISTWORN', 'WRITE', 'WRITERS', 'WRITING', 'WRITTEN', 'WRONG', 'WRONGLY', 'WSS', 'WSW', 'WT', 'WUCHERERIA', 'WUHAN', 'WWDS', 'WWW', 'WWWAIDSPANORG', 'WYLLIS', 'X', 'XANTHOUS', 'XAPTAMER', 'XAVIER', 'XCV', 'XDR', 'XDRTB', 'XENETIC', 'XENOMONITORING', 'XI', 'XIII', 'XIV', 'XIX', 'XPERT', 'XRAY', 'XV', 'XVI', 'XVIII', 'XXI', 'XXX', 'XXXII', 'XXXVI', 'XXXVIII', 'Y', 'Y4', 'Y5', 'YAAJEENDE', 'YALE', 'YALGO', 'YALI', 'YALTOPYA', 'YANGONG', 'YAOUNDE', 'YARD', 'YAUTHLED', 'YEAR', 'YEARLY', 'YEAROLD', 'YEAROLDS', 'YEARS', 'YEAST', 'YECE', 'YELLOW', 'YELLOWED', 'YELLOWISH', 'YELLOWNESS', 'YEMEN', 'YEMENIS', 'YEN', 'YEREVAN', 'YERSINIA', 'YET', 'YF', 'YIELD', 'YIELDS', 'YIROL', 'YOBE', 'YOGA', 'YOGABASED', 'YOGACARE', 'YOKEL', 'YORK', 'YORKBASED', 'YOUNG', 'YOUNGER', 'YOUNGINFANTS', 'YOUNGSTER', 'YOUNGSTERS', 'YOUNKER', 'YOUTH', 'YOUTHCENTERED', 'YOUTHFRIENDLINESS', 'YOUTHFRIENDLY', 'YOUTHFULNESS', 'YOUTHGROWTH', 'YOUTHLED', 'YOUTHPOWER', 'YOUTHS', 'YOUTHSERVING', 'YOUTHSSEXUAL', 'YOUTHTHE', 'YPROVEEDORESAS', 'YR', 'YR3', 'YUCAT', 'YUNNIS', 'Z', 'ZA', 'ZACH', 'ZAEPD', 'ZAFZENF', 'ZALINGEI', 'ZAMBEZIA', 'ZAMBIA', 'ZAMBIAN', 'ZAMBIANS', 'ZAMBIAS', 'ZAMBIATO', 'ZAMBOANGA', 'ZAMFARA', 'ZAMFLC', 'ZAMFOHR', 'ZAMRA', 'ZANZIBAR', 'ZANZIBAR3TARGET', 'ZAYED', 'ZDRAV', 'ZDRAVNIKOV', 'ZEAL', 'ZEALAND', 'ZEALANDS', 'ZELS', 'ZENF', 'ZENUFA', 'ZENYSIS', 'ZEP', 'ZERO', 'ZERUN', 'ZEWAY', 'ZICORE', 'ZIDOVUDINE', 'ZIKA', 'ZIKAAFFECTED', 'ZIKACHIKUNGUNYA', 'ZIKV', 'ZILLION', 'ZIMBABWE', 'ZIMBABWES', 'ZINC', 'ZION', 'ZMCP', 'ZN', 'ZOALIA', 'ZOMBA', 'ZONAL', 'ZONAS', 'ZONE', 'ZONES', 'ZONESTO', 'ZONGO', 'ZOO', 'ZOOLINK', 'ZOOLOGY', 'ZOONOSES', 'ZOONOSESCONTROLRESULT', 'ZOONOSESWITHIN', 'ZOONOSIS', 'ZOONOTIC', 'ZPCT', 'ZTRTKORT', 'ZU', 'ZUR', 'ZVITAMBO', 'ZZHEAGENHEALTH']\n"
     ]
    }
   ],
   "source": [
    "##Here we use two types of vectorizers--TF-IDF  \n",
    "##We can use either to check which gives better results with the algorithms\n",
    "\n",
    "#TF-IDF--Vectorizing for train data\n",
    "tfidf_vect= TfidfVectorizer(analyzer=clean_text)\n",
    "x_tfidf= tfidf_vect.fit_transform(train[\"description\"])\n",
    "print(x_tfidf.shape)\n",
    "print(tfidf_vect.get_feature_names())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>...</th>\n",
       "      <th>22247</th>\n",
       "      <th>22248</th>\n",
       "      <th>22249</th>\n",
       "      <th>22250</th>\n",
       "      <th>22251</th>\n",
       "      <th>22252</th>\n",
       "      <th>22253</th>\n",
       "      <th>22254</th>\n",
       "      <th>22255</th>\n",
       "      <th>22256</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24778</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24779</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24780</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24781</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24782</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>24783 rows  22257 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       0      1      2      3      4      5      6      7      8      9      \\\n",
       "0        0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "1        0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2        0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "3        0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "4        0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "...      ...    ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "24778    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "24779    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "24780    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "24781    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "24782    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "\n",
       "       ...  22247  22248  22249  22250  22251  22252  22253  22254  22255  \\\n",
       "0      ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "1      ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2      ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "3      ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "4      ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "...    ...    ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "24778  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "24779  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "24780  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "24781  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "24782  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "\n",
       "       22256  \n",
       "0        0.0  \n",
       "1        0.0  \n",
       "2        0.0  \n",
       "3        0.0  \n",
       "4        0.0  \n",
       "...      ...  \n",
       "24778    0.0  \n",
       "24779    0.0  \n",
       "24780    0.0  \n",
       "24781    0.0  \n",
       "24782    0.0  \n",
       "\n",
       "[24783 rows x 22257 columns]"
      ]
     },
     "execution_count": 75,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#the x_tfidf is sparse matrix. Lets look at it in data frame form\n",
    "x_tfidf_df= pd.DataFrame(x_tfidf.toarray())\n",
    "\n",
    "x_tfidf_df\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>000</th>\n",
       "      <th>001</th>\n",
       "      <th>001ELIMINATION</th>\n",
       "      <th>002</th>\n",
       "      <th>003</th>\n",
       "      <th>005</th>\n",
       "      <th>007</th>\n",
       "      <th>01</th>\n",
       "      <th>...</th>\n",
       "      <th>ZOONOSESCONTROLRESULT</th>\n",
       "      <th>ZOONOSESWITHIN</th>\n",
       "      <th>ZOONOSIS</th>\n",
       "      <th>ZOONOTIC</th>\n",
       "      <th>ZPCT</th>\n",
       "      <th>ZTRTKORT</th>\n",
       "      <th>ZU</th>\n",
       "      <th>ZUR</th>\n",
       "      <th>ZVITAMBO</th>\n",
       "      <th>ZZHEAGENHEALTH</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24778</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24779</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24780</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24781</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24782</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>24783 rows  22257 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              0  000  001  001ELIMINATION  002  003  005  007   01  ...  \\\n",
       "0      0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "1      0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2      0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "3      0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "4      0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "...    ...  ...  ...  ...             ...  ...  ...  ...  ...  ...  ...   \n",
       "24778  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "24779  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "24780  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "24781  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "24782  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "\n",
       "       ZOONOSESCONTROLRESULT  ZOONOSESWITHIN  ZOONOSIS  ZOONOTIC  ZPCT  \\\n",
       "0                        0.0             0.0       0.0       0.0   0.0   \n",
       "1                        0.0             0.0       0.0       0.0   0.0   \n",
       "2                        0.0             0.0       0.0       0.0   0.0   \n",
       "3                        0.0             0.0       0.0       0.0   0.0   \n",
       "4                        0.0             0.0       0.0       0.0   0.0   \n",
       "...                      ...             ...       ...       ...   ...   \n",
       "24778                    0.0             0.0       0.0       0.0   0.0   \n",
       "24779                    0.0             0.0       0.0       0.0   0.0   \n",
       "24780                    0.0             0.0       0.0       0.0   0.0   \n",
       "24781                    0.0             0.0       0.0       0.0   0.0   \n",
       "24782                    0.0             0.0       0.0       0.0   0.0   \n",
       "\n",
       "       ZTRTKORT   ZU  ZUR  ZVITAMBO  ZZHEAGENHEALTH  \n",
       "0           0.0  0.0  0.0       0.0             0.0  \n",
       "1           0.0  0.0  0.0       0.0             0.0  \n",
       "2           0.0  0.0  0.0       0.0             0.0  \n",
       "3           0.0  0.0  0.0       0.0             0.0  \n",
       "4           0.0  0.0  0.0       0.0             0.0  \n",
       "...         ...  ...  ...       ...             ...  \n",
       "24778       0.0  0.0  0.0       0.0             0.0  \n",
       "24779       0.0  0.0  0.0       0.0             0.0  \n",
       "24780       0.0  0.0  0.0       0.0             0.0  \n",
       "24781       0.0  0.0  0.0       0.0             0.0  \n",
       "24782       0.0  0.0  0.0       0.0             0.0  \n",
       "\n",
       "[24783 rows x 22257 columns]"
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# lets change the name of coulmns from number to actual words which these coulmns represent\n",
    "x_tfidf_df.columns= tfidf_vect.get_feature_names()\n",
    "\n",
    "x_tfidf_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>...</th>\n",
       "      <th>22247</th>\n",
       "      <th>22248</th>\n",
       "      <th>22249</th>\n",
       "      <th>22250</th>\n",
       "      <th>22251</th>\n",
       "      <th>22252</th>\n",
       "      <th>22253</th>\n",
       "      <th>22254</th>\n",
       "      <th>22255</th>\n",
       "      <th>22256</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2.120574</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.376422</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2.408240</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.254616</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1.949390</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.442250</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2.451786</td>\n",
       "      <td>0.60206</td>\n",
       "      <td>1.254616</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2.826723</td>\n",
       "      <td>0.69897</td>\n",
       "      <td>1.207518</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  22260 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   body_len  body_sent    punct%    0    1    2    3    4    5    6  ...  \\\n",
       "0  2.120574    0.60206  1.376422  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "1  2.408240    0.60206  1.254616  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2  1.949390    0.60206  1.442250  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "3  2.451786    0.60206  1.254616  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "4  2.826723    0.69897  1.207518  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "\n",
       "   22247  22248  22249  22250  22251  22252  22253  22254  22255  22256  \n",
       "0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "1    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "2    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "3    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "4    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "\n",
       "[5 rows x 22260 columns]"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#concatenating all  the features\n",
    "\n",
    "x_tfidf_feat = pd.concat([train[\"body_len\"],train[\"body_sent\"], train[\"punct%\"], pd.DataFrame(x_tfidf.toarray())], axis=1)\n",
    "x_tfidf_feat.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Countvectorizer--Vectorizing for train data\n",
    "#count_vect=CountVectorizer(analyzer=clean_text)\n",
    "#x_count=count_vect.fit_transform(train[\"description\"])\n",
    "#x_count_feat=pd.concat([train[\"body_len\"], train[\"punct%\"], pd.DataFrame(x_count.toarray())], axis=1)\n",
    "#x_count_feat.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(2634, 22257)\n"
     ]
    }
   ],
   "source": [
    "#vectorizing test data\n",
    "\n",
    "##Here we use two types of vectorizers--TF-IDF and Countvectorizer. \n",
    "##We can use either to check which gives better results with the algorithms\n",
    "\n",
    "#TF-IDF--Vectorizing for test data\n",
    "x_tfidf_test= tfidf_vect.transform(test[\"description\"])\n",
    "print(x_tfidf_test.shape)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>...</th>\n",
       "      <th>22247</th>\n",
       "      <th>22248</th>\n",
       "      <th>22249</th>\n",
       "      <th>22250</th>\n",
       "      <th>22251</th>\n",
       "      <th>22252</th>\n",
       "      <th>22253</th>\n",
       "      <th>22254</th>\n",
       "      <th>22255</th>\n",
       "      <th>22256</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2629</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2630</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2631</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2632</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2633</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2634 rows  22257 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      0      1      2      3      4      5      6      7      8      9      \\\n",
       "0       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "1       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "3       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "4       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "...     ...    ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "2629    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2630    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2631    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2632    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2633    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "\n",
       "      ...  22247  22248  22249  22250  22251  22252  22253  22254  22255  \\\n",
       "0     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "1     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "3     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "4     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "...   ...    ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "2629  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2630  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2631  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2632  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2633  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "\n",
       "      22256  \n",
       "0       0.0  \n",
       "1       0.0  \n",
       "2       0.0  \n",
       "3       0.0  \n",
       "4       0.0  \n",
       "...     ...  \n",
       "2629    0.0  \n",
       "2630    0.0  \n",
       "2631    0.0  \n",
       "2632    0.0  \n",
       "2633    0.0  \n",
       "\n",
       "[2634 rows x 22257 columns]"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#the x_tfidf is sparse matrix. Lets look at it in data frame form\n",
    "x_tfidf_test_df= pd.DataFrame(x_tfidf_test.toarray())\n",
    "\n",
    "x_tfidf_test_df\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>000</th>\n",
       "      <th>001</th>\n",
       "      <th>001ELIMINATION</th>\n",
       "      <th>002</th>\n",
       "      <th>003</th>\n",
       "      <th>005</th>\n",
       "      <th>007</th>\n",
       "      <th>01</th>\n",
       "      <th>...</th>\n",
       "      <th>ZOONOSESCONTROLRESULT</th>\n",
       "      <th>ZOONOSESWITHIN</th>\n",
       "      <th>ZOONOSIS</th>\n",
       "      <th>ZOONOTIC</th>\n",
       "      <th>ZPCT</th>\n",
       "      <th>ZTRTKORT</th>\n",
       "      <th>ZU</th>\n",
       "      <th>ZUR</th>\n",
       "      <th>ZVITAMBO</th>\n",
       "      <th>ZZHEAGENHEALTH</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2629</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2630</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2631</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2632</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2633</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2634 rows  22257 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "             0  000  001  001ELIMINATION  002  003  005  007   01  ...  \\\n",
       "0     0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "1     0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2     0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "3     0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "4     0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "...   ...  ...  ...  ...             ...  ...  ...  ...  ...  ...  ...   \n",
       "2629  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2630  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2631  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2632  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2633  0.0  0.0  0.0  0.0             0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "\n",
       "      ZOONOSESCONTROLRESULT  ZOONOSESWITHIN  ZOONOSIS  ZOONOTIC  ZPCT  \\\n",
       "0                       0.0             0.0       0.0       0.0   0.0   \n",
       "1                       0.0             0.0       0.0       0.0   0.0   \n",
       "2                       0.0             0.0       0.0       0.0   0.0   \n",
       "3                       0.0             0.0       0.0       0.0   0.0   \n",
       "4                       0.0             0.0       0.0       0.0   0.0   \n",
       "...                     ...             ...       ...       ...   ...   \n",
       "2629                    0.0             0.0       0.0       0.0   0.0   \n",
       "2630                    0.0             0.0       0.0       0.0   0.0   \n",
       "2631                    0.0             0.0       0.0       0.0   0.0   \n",
       "2632                    0.0             0.0       0.0       0.0   0.0   \n",
       "2633                    0.0             0.0       0.0       0.0   0.0   \n",
       "\n",
       "      ZTRTKORT   ZU  ZUR  ZVITAMBO  ZZHEAGENHEALTH  \n",
       "0          0.0  0.0  0.0       0.0             0.0  \n",
       "1          0.0  0.0  0.0       0.0             0.0  \n",
       "2          0.0  0.0  0.0       0.0             0.0  \n",
       "3          0.0  0.0  0.0       0.0             0.0  \n",
       "4          0.0  0.0  0.0       0.0             0.0  \n",
       "...        ...  ...  ...       ...             ...  \n",
       "2629       0.0  0.0  0.0       0.0             0.0  \n",
       "2630       0.0  0.0  0.0       0.0             0.0  \n",
       "2631       0.0  0.0  0.0       0.0             0.0  \n",
       "2632       0.0  0.0  0.0       0.0             0.0  \n",
       "2633       0.0  0.0  0.0       0.0             0.0  \n",
       "\n",
       "[2634 rows x 22257 columns]"
      ]
     },
     "execution_count": 81,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# lets change the name of coulmns from number to actual words which these coulmns represent\n",
    "x_tfidf_test_df.columns= tfidf_vect.get_feature_names()\n",
    "\n",
    "x_tfidf_test_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>...</th>\n",
       "      <th>22247</th>\n",
       "      <th>22248</th>\n",
       "      <th>22249</th>\n",
       "      <th>22250</th>\n",
       "      <th>22251</th>\n",
       "      <th>22252</th>\n",
       "      <th>22253</th>\n",
       "      <th>22254</th>\n",
       "      <th>22255</th>\n",
       "      <th>22256</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3.447778</td>\n",
       "      <td>1.361728</td>\n",
       "      <td>1.157094</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2.356026</td>\n",
       "      <td>0.698970</td>\n",
       "      <td>1.399083</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2.665581</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.254616</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2.622214</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.220166</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2.809560</td>\n",
       "      <td>0.954243</td>\n",
       "      <td>1.112907</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  22260 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   body_len  body_sent    punct%    0    1    2    3    4    5    6  ...  \\\n",
       "0  3.447778   1.361728  1.157094  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "1  2.356026   0.698970  1.399083  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2  2.665581   0.778151  1.254616  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "3  2.622214   0.778151  1.220166  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "4  2.809560   0.954243  1.112907  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "\n",
       "   22247  22248  22249  22250  22251  22252  22253  22254  22255  22256  \n",
       "0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "1    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "2    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "3    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "4    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "\n",
       "[5 rows x 22260 columns]"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#concatenating all  the features\n",
    "\n",
    "x_tfidf_test_feat = pd.concat([test[\"body_len\"],test[\"body_sent\"], test[\"punct%\"], pd.DataFrame(x_tfidf_test.toarray())], axis=1)\n",
    "x_tfidf_test_feat.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "***Exploring RandomForestClassifier***"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Applying tf-idf"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Cross-Validation for Hyperparameter tuning--Random forest"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 776,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Parameters currently in use:\n",
      "\n",
      "{'bootstrap': True,\n",
      " 'ccp_alpha': 0.0,\n",
      " 'class_weight': None,\n",
      " 'criterion': 'gini',\n",
      " 'max_depth': None,\n",
      " 'max_features': 'auto',\n",
      " 'max_leaf_nodes': None,\n",
      " 'max_samples': None,\n",
      " 'min_impurity_decrease': 0.0,\n",
      " 'min_impurity_split': None,\n",
      " 'min_samples_leaf': 1,\n",
      " 'min_samples_split': 2,\n",
      " 'min_weight_fraction_leaf': 0.0,\n",
      " 'n_estimators': 100,\n",
      " 'n_jobs': None,\n",
      " 'oob_score': False,\n",
      " 'random_state': 8,\n",
      " 'verbose': 0,\n",
      " 'warm_start': False}\n"
     ]
    }
   ],
   "source": [
    "rf_0 = RandomForestClassifier(random_state = 8)\n",
    "\n",
    "print('Parameters currently in use:\\n')\n",
    "pprint(rf_0.get_params())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "We'll tune the following ones:\n",
    "\n",
    "* n_estimators = number of trees in the forest.\n",
    "* max_features = max number of features considered for splitting a node\n",
    "* max_depth = max number of levels in each decision tree\n",
    "* min_samples_split = min number of data points placed in a node before the node is split\n",
    "* min_samples_leaf = min number of data points allowed in a leaf node\n",
    "* bootstrap = method for sampling data points (with or without replacement)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#####  Grid Search Cross Validation (GRIDSEARCHCV)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fitting 3 folds for each of 16 candidates, totalling 48 fits\n"
     ]
    }
   ],
   "source": [
    "\n",
    "# Create the parameter grid based on the results of random search \n",
    "\n",
    "# n_estimators\n",
    "n_estimators = [int(x) for x in np.linspace(start = 200, stop = 800, num = 4)]\n",
    "\n",
    "# max_depth\n",
    "max_depth = [int(x) for x in np.linspace(20, 100, num = 3)]\n",
    "max_depth.append(None)\n",
    "\n",
    "param_grid = {\n",
    "    #'bootstrap': bootstrap,\n",
    "    'max_depth': max_depth,\n",
    "    #'max_features': max_features,\n",
    "    #'min_samples_leaf': min_samples_leaf,\n",
    "    #'min_samples_split': min_samples_split,\n",
    "    'n_estimators': n_estimators\n",
    "}\n",
    "\n",
    "# Create a base model\n",
    "rfc = RandomForestClassifier(random_state=8)\n",
    "\n",
    "# Manually create the splits in CV in order to be able to fix a random_state (GridSearchCV doesn't have that argument)\n",
    "cv_sets = ShuffleSplit(n_splits = 3, test_size = .33, random_state = 8)\n",
    "\n",
    "# Instantiate the grid search model\n",
    "grid_search = GridSearchCV(estimator=rfc, \n",
    "                           param_grid=param_grid,\n",
    "                           scoring='accuracy',\n",
    "                           cv=cv_sets,\n",
    "                           verbose=1)\n",
    "\n",
    "# Fit the grid search to the data\n",
    "grid_search.fit(x_tfidf_feat, train[\"label\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "print(\"The best hyperparameters from Grid Search are:\")\n",
    "print(grid_search.best_params_)\n",
    "print(\"\")\n",
    "print(\"The mean accuracy of a model with these hyperparameters is:\")\n",
    "print(grid_search.best_score_)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 765,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "ename": "MemoryError",
     "evalue": "Unable to allocate 1.44 GiB for an array with shape (17679, 21914) and data type float32",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31m_RemoteTraceback\u001b[0m                          Traceback (most recent call last)",
      "\u001b[1;31m_RemoteTraceback\u001b[0m: \n\"\"\"\nTraceback (most recent call last):\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\joblib\\externals\\loky\\process_executor.py\", line 431, in _process_worker\n    r = call_item()\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\joblib\\externals\\loky\\process_executor.py\", line 285, in __call__\n    return self.fn(*self.args, **self.kwargs)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\joblib\\_parallel_backends.py\", line 595, in __call__\n    return self.func(*args, **kwargs)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\joblib\\parallel.py\", line 262, in __call__\n    return [func(*args, **kwargs)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\joblib\\parallel.py\", line 262, in <listcomp>\n    return [func(*args, **kwargs)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\sklearn\\utils\\fixes.py\", line 222, in __call__\n    return self.function(*args, **kwargs)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\sklearn\\model_selection\\_validation.py\", line 946, in _fit_and_predict\n    estimator.fit(X_train, y_train, **fit_params)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\sklearn\\ensemble\\_forest.py\", line 304, in fit\n    X, y = self._validate_data(X, y, multi_output=True,\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\sklearn\\base.py\", line 433, in _validate_data\n    X, y = check_X_y(X, y, **check_params)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\sklearn\\utils\\validation.py\", line 63, in inner_f\n    return f(*args, **kwargs)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\sklearn\\utils\\validation.py\", line 814, in check_X_y\n    X = check_array(X, accept_sparse=accept_sparse,\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\sklearn\\utils\\validation.py\", line 63, in inner_f\n    return f(*args, **kwargs)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\sklearn\\utils\\validation.py\", line 616, in check_array\n    array = np.asarray(array, order=order, dtype=dtype)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\numpy\\core\\_asarray.py\", line 83, in asarray\n    return array(a, dtype, copy=False, order=order)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\pandas\\core\\generic.py\", line 1899, in __array__\n    return np.asarray(self._values, dtype=dtype)\n  File \"C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\numpy\\core\\_asarray.py\", line 83, in asarray\n    return array(a, dtype, copy=False, order=order)\nnumpy.core._exceptions._ArrayMemoryError: Unable to allocate 1.44 GiB for an array with shape (17679, 21914) and data type float32\n\"\"\"",
      "\nThe above exception was the direct cause of the following exception:\n",
      "\u001b[1;31mMemoryError\u001b[0m                               Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-765-57ab01291225>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n\u001b[0;32m      2\u001b[0m \u001b[0mrf\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mRandomForestClassifier\u001b[0m \u001b[1;33m(\u001b[0m\u001b[0mn_estimators\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;36m500\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmax_depth\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;32mNone\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mn_jobs\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;33m-\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      3\u001b[0m \u001b[1;31m# generate your cross-validation prediction with 5 fold Stratified sampling\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 4\u001b[1;33m \u001b[0my_pred\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mcross_val_predict\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mrf\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mx_tfidf_feat\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mtrain\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;34m\"label\"\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcv\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;36m5\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mn_jobs\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;33m-\u001b[0m\u001b[1;36m1\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m      5\u001b[0m \u001b[0mprint\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mclassification_report\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtrain\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;34m\"label\"\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0my_pred\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sklearn\\utils\\validation.py\u001b[0m in \u001b[0;36minner_f\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m     61\u001b[0m             \u001b[0mextra_args\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mlen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;33m-\u001b[0m \u001b[0mlen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mall_args\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     62\u001b[0m             \u001b[1;32mif\u001b[0m \u001b[0mextra_args\u001b[0m \u001b[1;33m<=\u001b[0m \u001b[1;36m0\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m---> 63\u001b[1;33m                 \u001b[1;32mreturn\u001b[0m \u001b[0mf\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     64\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     65\u001b[0m             \u001b[1;31m# extra_args > 0\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\sklearn\\model_selection\\_validation.py\u001b[0m in \u001b[0;36mcross_val_predict\u001b[1;34m(estimator, X, y, groups, cv, n_jobs, verbose, fit_params, pre_dispatch, method)\u001b[0m\n\u001b[0;32m    864\u001b[0m     parallel = Parallel(n_jobs=n_jobs, verbose=verbose,\n\u001b[0;32m    865\u001b[0m                         pre_dispatch=pre_dispatch)\n\u001b[1;32m--> 866\u001b[1;33m     predictions = parallel(delayed(_fit_and_predict)(\n\u001b[0m\u001b[0;32m    867\u001b[0m         clone(estimator), X, y, train, test, verbose, fit_params, method)\n\u001b[0;32m    868\u001b[0m         for train, test in splits)\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\joblib\\parallel.py\u001b[0m in \u001b[0;36m__call__\u001b[1;34m(self, iterable)\u001b[0m\n\u001b[0;32m   1052\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1053\u001b[0m             \u001b[1;32mwith\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_backend\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mretrieval_context\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1054\u001b[1;33m                 \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mretrieve\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   1055\u001b[0m             \u001b[1;31m# Make sure that we get a last message telling us we are done\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1056\u001b[0m             \u001b[0melapsed_time\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mtime\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtime\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;33m-\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_start_time\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\joblib\\parallel.py\u001b[0m in \u001b[0;36mretrieve\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    931\u001b[0m             \u001b[1;32mtry\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    932\u001b[0m                 \u001b[1;32mif\u001b[0m \u001b[0mgetattr\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_backend\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m'supports_timeout'\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;32mFalse\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 933\u001b[1;33m                     \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_output\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mextend\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mjob\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mget\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtimeout\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtimeout\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    934\u001b[0m                 \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    935\u001b[0m                     \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_output\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mextend\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mjob\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mget\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\site-packages\\joblib\\_parallel_backends.py\u001b[0m in \u001b[0;36mwrap_future_result\u001b[1;34m(future, timeout)\u001b[0m\n\u001b[0;32m    540\u001b[0m         AsyncResults.get from multiprocessing.\"\"\"\n\u001b[0;32m    541\u001b[0m         \u001b[1;32mtry\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 542\u001b[1;33m             \u001b[1;32mreturn\u001b[0m \u001b[0mfuture\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mresult\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtimeout\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mtimeout\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    543\u001b[0m         \u001b[1;32mexcept\u001b[0m \u001b[0mCfTimeoutError\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    544\u001b[0m             \u001b[1;32mraise\u001b[0m \u001b[0mTimeoutError\u001b[0m \u001b[1;32mfrom\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\concurrent\\futures\\_base.py\u001b[0m in \u001b[0;36mresult\u001b[1;34m(self, timeout)\u001b[0m\n\u001b[0;32m    437\u001b[0m                 \u001b[1;32mraise\u001b[0m \u001b[0mCancelledError\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    438\u001b[0m             \u001b[1;32melif\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_state\u001b[0m \u001b[1;33m==\u001b[0m \u001b[0mFINISHED\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 439\u001b[1;33m                 \u001b[1;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m__get_result\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    440\u001b[0m             \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    441\u001b[0m                 \u001b[1;32mraise\u001b[0m \u001b[0mTimeoutError\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\Anaconda3\\lib\\concurrent\\futures\\_base.py\u001b[0m in \u001b[0;36m__get_result\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m    386\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0m__get_result\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    387\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_exception\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 388\u001b[1;33m             \u001b[1;32mraise\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_exception\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    389\u001b[0m         \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    390\u001b[0m             \u001b[1;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_result\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mMemoryError\u001b[0m: Unable to allocate 1.44 GiB for an array with shape (17679, 21914) and data type float32"
     ]
    }
   ],
   "source": [
    "#Exploring RandomForestClassifier using tfidf\n",
    "rf = RandomForestClassifier (n_estimators=500, max_depth=None, n_jobs = -1)\n",
    "# generate your cross-validation prediction with 5 fold Stratified sampling\n",
    "y_pred=cross_val_predict(rf, x_tfidf_feat, train[\"label\"], cv=5, n_jobs=-1)\n",
    "print(classification_report(train[\"label\"], y_pred))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 445,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[1547,    0,   17,   18,    4,    3,    0,    0,    1,    1,    8],\n",
       "       [   0, 1656,    0,    2,    0,    0,    0,    0,    0,    0,    1],\n",
       "       [   2,    0, 1481,    0,    2,    1,    0,    5,    7,    0,    6],\n",
       "       [   7,    3,    1, 1366,    9,    0,    0,    0,    6,    2,   12],\n",
       "       [  12,    3,    8,    6, 1248,    5,    4,   13,  199,    5,  166],\n",
       "       [   0,    0,    0,    0,    0, 1667,    0,    0,    0,    0,    2],\n",
       "       [   0,    0,    0,    0,    0,    0, 1669,    0,    0,    0,    0],\n",
       "       [   0,    0,    2,    4,    6,    0,    0, 1657,    0,    0,    0],\n",
       "       [  18,    0,    7,    3,   76,    2,    0,    8, 1527,    0,   28],\n",
       "       [   0,    0,    0,    0,    3,    0,    0,    0,    0, 1653,    0],\n",
       "       [  25,    2,   46,   16,  120,    5,    3,    0,  100,    9, 1343]],\n",
       "      dtype=int64)"
      ]
     },
     "execution_count": 445,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#creating confusion matrix\n",
    "confusion_matrix(list(train[\"label\"]), list(y_pred))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 447,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x576 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#heatmap of confusion matrix \n",
    "conf_mat_rf=confusion_matrix(list(train[\"label\"]),list(y_pred))\n",
    "conf_mat_df_rf= pd.DataFrame(conf_mat_rf,\n",
    "                     index = ['not_global_func',\n",
    " 'Health_Advocacy',\n",
    " 'Knowledge_Gen_Sharing',\n",
    " 'Dev_Harmonization_Int_Reg',\n",
    " 'Epidemic_Pandemic_Prep',\n",
    " 'Control_Cross_Border_Disease',\n",
    " 'Response_Unhealthy_Products',\n",
    " 'Market_Shaping',\n",
    " 'RD_New_Health_Tools',\n",
    " 'Promotion_Aid_Effectiveness',\n",
    " 'RD_Blueprint_Diseases_Pandemic_Flu'], \n",
    "                             \n",
    "                     columns = ['not_global_func',\n",
    " 'Health_Advocacy',\n",
    " 'Knowledge_Gen_Sharing',\n",
    " 'Dev_Harmonization_Int_Reg',\n",
    " 'Epidemic_Pandemic_Prep',\n",
    " 'Control_Cross_Border_Disease',\n",
    " 'Response_Unhealthy_Products',\n",
    " 'Market_Shaping',\n",
    " 'RD_New_Health_Tools',\n",
    " 'Promotion_Aid_Effectiveness',\n",
    " 'RD_Blueprint_Diseases_Pandemic_Flu'])\n",
    "\n",
    "plt.figure(figsize=(10, 8))\n",
    "sns.heatmap(conf_mat_df_rf, annot=True, cmap=\"Blues\",  fmt='g')          \n",
    "plt.ylabel('True Label')\n",
    "plt.xlabel('Predicted Label')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Applying the classifier on Holdout Test set (Train and Test set separately)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Random Forest classifier"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [],
   "source": [
    "#instantiating the model and fitting it on the train set\n",
    "rf=RandomForestClassifier(n_estimators=150, max_depth=None, class_weight=\"balanced\")\n",
    "\n",
    "#fitting the model on training data\n",
    "rf_model=rf.fit(x_tfidf_feat, train[\"label\"])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(0.01406884828187627, 'body_len'),\n",
       " (0.013596000852279418, 'punct%'),\n",
       " (0.0117001025789697, 103),\n",
       " (0.011242446348542729, 21382),\n",
       " (0.010128326727385078, 14074),\n",
       " (0.009306932480380812, 1973),\n",
       " (0.009296777085480119, 112),\n",
       " (0.008799989592929507, 108),\n",
       " (0.008501522586901431, 19695),\n",
       " (0.007856264630539404, 17468)]"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#most important list of features that random forest uses for learning\n",
    "sorted(zip(rf_model.feature_importances_, x_tfidf_feat.columns), reverse=True)[0:10]\n",
    "\n",
    "#our created features are in top 10 importance"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                              precision    recall  f1-score   support\n",
      "\n",
      "Control_Cross_Border_Disease       0.95      0.95      0.95       310\n",
      "   Dev_Harmonization_Int_Reg       0.83      0.81      0.82        53\n",
      "      Epidemic_Pandemic_Prep       0.92      0.85      0.88       328\n",
      "             Health_Advocacy       0.92      0.91      0.91       203\n",
      "       Knowledge_Gen_Sharing       0.76      0.76      0.76       585\n",
      "              Market_Shaping       0.98      0.95      0.96       224\n",
      " Promotion_Aid_Effectiveness       0.77      0.35      0.48        57\n",
      "         RD_New_Health_Tools       0.67      0.80      0.73       330\n",
      " Response_Unhealthy_Products       0.85      0.77      0.81        60\n",
      "             not_global_func       0.79      0.80      0.80       484\n",
      "\n",
      "                    accuracy                           0.83      2634\n",
      "                   macro avg       0.84      0.80      0.81      2634\n",
      "                weighted avg       0.83      0.83      0.83      2634\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#predicting the categories using the trained model on test set \n",
    "y_pred_rf=rf_model.predict(x_tfidf_test_feat)\n",
    "\n",
    "#printing classification results\n",
    "print(classification_report(test[\"label\"], y_pred_rf)) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x576 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#heatmap of confusion matrix \n",
    "conf_mat_rf=confusion_matrix(list(test[\"label\"]),list(y_pred_rf))\n",
    "conf_mat_df_rf= pd.DataFrame(conf_mat_rf,\n",
    "                     index = np.unique(test[\"label\"]), \n",
    "                     columns = np.unique(y_pred_rf))\n",
    "\n",
    "plt.figure(figsize=(10, 8))\n",
    "sns.heatmap(conf_mat_df_rf, annot=True, cmap=\"Blues\",  fmt='g')          \n",
    "plt.ylabel('True Label')\n",
    "plt.xlabel('Predicted Label')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### saving the RF model on disk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 152,
   "metadata": {},
   "outputs": [],
   "source": [
    "filename = 'finalized_model_rf.sav'\n",
    "pickle.dump(rf_model, open(filename, 'wb'))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Checking how well finance prediction match:calculating the finance based on the predicted categories from RF model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 153,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>class_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2013</td>\n",
       "      <td>Projet de coopTration universitaire - Initiati...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Projet de coopTration universitaire - I...</td>\n",
       "      <td>0.073950</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>3.447778</td>\n",
       "      <td>1.361728</td>\n",
       "      <td>1.157094</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>0.096651</td>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>2.356026</td>\n",
       "      <td>0.698970</td>\n",
       "      <td>1.399083</td>\n",
       "      <td>Market_Shaping</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015</td>\n",
       "      <td>EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...</td>\n",
       "      <td>3.040122</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>2.665581</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.254616</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Scientific cooperation with other countries (n...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Scientific cooperation with other count...</td>\n",
       "      <td>0.038746</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>2.622214</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.220166</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2015</td>\n",
       "      <td>INT/Fund of the United Nations International D...</td>\n",
       "      <td>13010</td>\n",
       "      <td>13010. INT/Fund of the United Nations Internat...</td>\n",
       "      <td>0.914221</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>2.809560</td>\n",
       "      <td>0.954243</td>\n",
       "      <td>1.112907</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2013  Projet de coopTration universitaire - Initiati...         12182   \n",
       "1  2013                          New vaccine support (NVS)         12220   \n",
       "2  2015  EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...         12182   \n",
       "3  2017  Scientific cooperation with other countries (n...         12182   \n",
       "4  2015  INT/Fund of the United Nations International D...         13010   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12182. Projet de coopTration universitaire - I...  0.073950   \n",
       "1  12220. New vaccine support (NVS). NEW VACCINE ...  0.096651   \n",
       "2  12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...  3.040122   \n",
       "3  12182. Scientific cooperation with other count...  0.038746   \n",
       "4  13010. INT/Fund of the United Nations Internat...  0.914221   \n",
       "\n",
       "                         label  body_len  body_sent    punct%  \\\n",
       "0              not_global_func  3.447778   1.361728  1.157094   \n",
       "1               Market_Shaping  2.356026   0.698970  1.399083   \n",
       "2          RD_New_Health_Tools  2.665581   0.778151  1.254616   \n",
       "3        Knowledge_Gen_Sharing  2.622214   0.778151  1.220166   \n",
       "4  Response_Unhealthy_Products  2.809560   0.954243  1.112907   \n",
       "\n",
       "              class_pred  \n",
       "0        not_global_func  \n",
       "1         Market_Shaping  \n",
       "2    RD_New_Health_Tools  \n",
       "3  Knowledge_Gen_Sharing  \n",
       "4        Health_Advocacy  "
      ]
     },
     "execution_count": 153,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_fin_calc=pd.concat([test, pd.DataFrame(y_pred_rf)], axis=1)\n",
    "\n",
    "test_fin_calc=test_fin_calc.rename(columns={0:\"class_pred\"})\n",
    "\n",
    "test_fin_calc.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 154,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "not_global_func: 484\n",
      "Control_Cross_Border_Disease: 310\n",
      "Health_Advocacy: 203\n",
      "Knowledge_Gen_Sharing: 585\n",
      "Dev_Harmonization_Int_Reg: 53\n",
      "Epidemic_Pandemic_Prep: 328\n",
      "Response_Unhealthy_Products: 60\n",
      "Market_Shaping: 224\n",
      "RD_New_Health_Tools: 330\n",
      "Promotion_Aid_Effectiveness: 57\n"
     ]
    }
   ],
   "source": [
    "#Counting the number of projects in actual label categories\n",
    "print(\"not_global_func:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"not_global_func\"]))\n",
    "print(\"Control_Cross_Border_Disease:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"Control_Cross_Border_Disease\"]))\n",
    "print(\"Health_Advocacy:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"Health_Advocacy\"]))\n",
    "print(\"Knowledge_Gen_Sharing:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"Knowledge_Gen_Sharing\"]))\n",
    "print(\"Dev_Harmonization_Int_Reg:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"Dev_Harmonization_Int_Reg\"]))\n",
    "print(\"Epidemic_Pandemic_Prep:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"Epidemic_Pandemic_Prep\"]))\n",
    "print(\"Response_Unhealthy_Products:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"Response_Unhealthy_Products\"]))\n",
    "print(\"Market_Shaping:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"Market_Shaping\"]))\n",
    "print(\"RD_New_Health_Tools:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"RD_New_Health_Tools\"]))\n",
    "print(\"Promotion_Aid_Effectiveness:\", len(test_fin_calc[test_fin_calc[\"label\"]==\"Promotion_Aid_Effectiveness\"]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 155,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "not_global_func: 489\n",
      "Control_Cross_Border_Disease: 310\n",
      "Health_Advocacy: 202\n",
      "Knowledge_Gen_Sharing: 588\n",
      "Dev_Harmonization_Int_Reg: 52\n",
      "Epidemic_Pandemic_Prep: 301\n",
      "Response_Unhealthy_Products: 54\n",
      "Market_Shaping: 218\n",
      "RD_New_Health_Tools: 394\n",
      "Promotion_Aid_Effectiveness: 26\n"
     ]
    }
   ],
   "source": [
    "#Counting the number of projects in predicted categories\n",
    "print(\"not_global_func:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"not_global_func\"]))\n",
    "print(\"Control_Cross_Border_Disease:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"Control_Cross_Border_Disease\"]))\n",
    "print(\"Health_Advocacy:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"Health_Advocacy\"]))\n",
    "print(\"Knowledge_Gen_Sharing:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"Knowledge_Gen_Sharing\"]))\n",
    "print(\"Dev_Harmonization_Int_Reg:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"Dev_Harmonization_Int_Reg\"]))\n",
    "print(\"Epidemic_Pandemic_Prep:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"Epidemic_Pandemic_Prep\"]))\n",
    "print(\"Response_Unhealthy_Products:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"Response_Unhealthy_Products\"]))\n",
    "print(\"Market_Shaping:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"Market_Shaping\"]))\n",
    "print(\"RD_New_Health_Tools:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"RD_New_Health_Tools\"]))\n",
    "print(\"Promotion_Aid_Effectiveness:\", len(test_fin_calc[test_fin_calc[\"class_pred\"]==\"Promotion_Aid_Effectiveness\"]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 156,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>class_pred</th>\n",
       "      <th>Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>19.17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>21.81</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>35.69</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>220.50</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>239.70</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>271.72</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>316.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>485.64</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>628.95</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>911.98</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     class_pred   Value\n",
       "0     Dev_Harmonization_Int_Reg   19.17\n",
       "1   Response_Unhealthy_Products   21.81\n",
       "2   Promotion_Aid_Effectiveness   35.69\n",
       "3         Knowledge_Gen_Sharing  220.50\n",
       "4               Health_Advocacy  239.70\n",
       "5        Epidemic_Pandemic_Prep  271.72\n",
       "6           RD_New_Health_Tools  316.07\n",
       "7  Control_Cross_Border_Disease  485.64\n",
       "8                Market_Shaping  628.95\n",
       "9               not_global_func  911.98"
      ]
     },
     "execution_count": 156,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg amount based on the predicted categories\n",
    "dah_gpg=test_fin_calc.groupby([\"class_pred\"]).agg({\"Value\":np.sum})\n",
    "\n",
    "dah_gpg=dah_gpg.sort_values(\"Value\").reset_index()\n",
    "\n",
    "dah_gpg=dah_gpg.round(2)\n",
    "dah_gpg"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 157,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "class_pred    Dev_Harmonization_Int_RegResponse_Unhealthy_Pr...\n",
       "Value                                                   2239.25\n",
       "dtype: object"
      ]
     },
     "execution_count": 157,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg finance based on predicted categories in the test dataset\n",
    "dah_gpg[dah_gpg[\"class_pred\"]!=\"not_global_func\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 158,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>label</th>\n",
       "      <th>Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>18.40</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>22.02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>32.14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>222.27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>242.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>276.48</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>293.64</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>527.31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>611.52</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>905.36</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                          label   Value\n",
       "0   Response_Unhealthy_Products   18.40\n",
       "1     Dev_Harmonization_Int_Reg   22.02\n",
       "2   Promotion_Aid_Effectiveness   32.14\n",
       "3         Knowledge_Gen_Sharing  222.27\n",
       "4               Health_Advocacy  242.07\n",
       "5        Epidemic_Pandemic_Prep  276.48\n",
       "6           RD_New_Health_Tools  293.64\n",
       "7  Control_Cross_Border_Disease  527.31\n",
       "8                Market_Shaping  611.52\n",
       "9               not_global_func  905.36"
      ]
     },
     "execution_count": 158,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg finance based on human classification in the test dataset\n",
    "\n",
    "dah_gpg_human=test_fin_calc.groupby([\"label\"]).agg({\"Value\":np.sum})\n",
    "\n",
    "dah_gpg_human=dah_gpg_human.sort_values(\"Value\").reset_index()\n",
    "\n",
    "dah_gpg_human=dah_gpg_human.round(2)\n",
    "dah_gpg_human"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 159,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "label    Response_Unhealthy_ProductsDev_Harmonization_I...\n",
       "Value                                              2245.85\n",
       "dtype: object"
      ]
     },
     "execution_count": 159,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg finance based on human classified categories in the test dataset\n",
    "dah_gpg_human[dah_gpg_human[\"label\"]!=\"not_global_func\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 160,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#plotting the distribution of categories. Creating column chart\n",
    "\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(dah_gpg[\"class_pred\"], dah_gpg[\"Value\"])\n",
    "plt.xticks(rotation=90)\n",
    "plt.title(\"Machine Predicted Finance\")\n",
    "\n",
    "for i, v in enumerate(dah_gpg[\"Value\"]):\n",
    "    plt.text(i, v, str(v))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 161,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#actual values in different categories\n",
    "\n",
    "dah_gpg_act=test_fin_calc.groupby([\"label\"]).agg({\"Value\":np.sum})\n",
    "\n",
    "dah_gpg_act=dah_gpg_act.sort_values(\"Value\").reset_index()\n",
    "\n",
    "dah_gpg_act=dah_gpg_act.round(2)\n",
    "\n",
    "#plotting the distribution of categories. Creating column chart\n",
    "\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(dah_gpg_act[\"label\"], dah_gpg_act[\"Value\"])\n",
    "plt.xticks(rotation=90)\n",
    "plt.title(\"Human Classified Finance\")\n",
    "\n",
    "for i, v in enumerate(dah_gpg_act[\"Value\"]):\n",
    "    plt.text(i, v, str(v))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### XgBOOST"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\sd282\\Anaconda3\\lib\\site-packages\\xgboost\\sklearn.py:888: UserWarning: The use of label encoder in XGBClassifier is deprecated and will be removed in a future release. To remove this warning, do the following: 1) Pass option use_label_encoder=False when constructing XGBClassifier object; and 2) Encode your labels (y) as integers starting with 0, i.e. 0, 1, 2, ..., [num_class - 1].\n",
      "  warnings.warn(label_encoder_deprecation_msg, UserWarning)\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[00:22:30] WARNING: ..\\src\\learner.cc:1061: Starting in XGBoost 1.3.0, the default evaluation metric used with the objective 'multi:softprob' was changed from 'merror' to 'mlogloss'. Explicitly set eval_metric if you'd like to restore the old behavior.\n"
     ]
    }
   ],
   "source": [
    "# xgb = XGBClassifier( n_estimators=150, learning_rate=0.3, \n",
    "#                           max_depth=None)\n",
    "\n",
    "xgb = XGBClassifier(n_estimators=150)\n",
    "\n",
    "\n",
    "#fitting the model on training data\n",
    "xgb_model=xgb.fit(x_tfidf_feat, train[\"label\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [],
   "source": [
    "#predicting the categories using the trained model on test set \n",
    "y_pred_xgb=xgb_model.predict(x_tfidf_test_feat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                              precision    recall  f1-score   support\n",
      "\n",
      "Control_Cross_Border_Disease       0.94      0.95      0.94       310\n",
      "   Dev_Harmonization_Int_Reg       0.86      0.83      0.85        53\n",
      "      Epidemic_Pandemic_Prep       0.92      0.87      0.89       328\n",
      "             Health_Advocacy       0.89      0.91      0.90       203\n",
      "       Knowledge_Gen_Sharing       0.75      0.82      0.78       585\n",
      "              Market_Shaping       0.97      0.96      0.97       224\n",
      " Promotion_Aid_Effectiveness       0.77      0.35      0.48        57\n",
      "         RD_New_Health_Tools       0.73      0.75      0.74       330\n",
      " Response_Unhealthy_Products       0.88      0.85      0.86        60\n",
      "             not_global_func       0.81      0.79      0.80       484\n",
      "\n",
      "                    accuracy                           0.84      2634\n",
      "                   macro avg       0.85      0.81      0.82      2634\n",
      "                weighted avg       0.84      0.84      0.83      2634\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#printing classification results\n",
    "print(classification_report(test[\"label\"], y_pred_xgb)) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x576 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#heatmap of confusion matrix \n",
    "conf_mat_rf=confusion_matrix(list(test[\"label\"]),list(y_pred_xgb))\n",
    "conf_mat_df_rf= pd.DataFrame(conf_mat_rf,\n",
    "                     index = np.unique(test[\"label\"]), \n",
    "                     columns = np.unique(y_pred_xgb))\n",
    "\n",
    "plt.figure(figsize=(10, 8))\n",
    "sns.heatmap(conf_mat_df_rf, annot=True, cmap=\"Blues\",  fmt='g')          \n",
    "plt.ylabel('True Label')\n",
    "plt.xlabel('Predicted Label')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### saving the xgboost model on disk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [],
   "source": [
    "filename = 'finalized_model_xgboost.sav'\n",
    "pickle.dump(xgb_model, open(filename, 'wb'))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Checking how well finance prediction match:calculating the finance based on the predicted categories from XGBoost model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>YEAR</th>\n",
       "      <th>Project.title</th>\n",
       "      <th>Purpose.Code</th>\n",
       "      <th>description</th>\n",
       "      <th>Value</th>\n",
       "      <th>label</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>class_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2013</td>\n",
       "      <td>Projet de coopTration universitaire - Initiati...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Projet de coopTration universitaire - I...</td>\n",
       "      <td>0.073950</td>\n",
       "      <td>not_global_func</td>\n",
       "      <td>3.447778</td>\n",
       "      <td>1.361728</td>\n",
       "      <td>1.157094</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2013</td>\n",
       "      <td>New vaccine support (NVS)</td>\n",
       "      <td>12220</td>\n",
       "      <td>12220. New vaccine support (NVS). NEW VACCINE ...</td>\n",
       "      <td>0.096651</td>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>2.356026</td>\n",
       "      <td>0.698970</td>\n",
       "      <td>1.399083</td>\n",
       "      <td>Market_Shaping</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2015</td>\n",
       "      <td>EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...</td>\n",
       "      <td>3.040122</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>2.665581</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.254616</td>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2017</td>\n",
       "      <td>Scientific cooperation with other countries (n...</td>\n",
       "      <td>12182</td>\n",
       "      <td>12182. Scientific cooperation with other count...</td>\n",
       "      <td>0.038746</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>2.622214</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.220166</td>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2015</td>\n",
       "      <td>INT/Fund of the United Nations International D...</td>\n",
       "      <td>13010</td>\n",
       "      <td>13010. INT/Fund of the United Nations Internat...</td>\n",
       "      <td>0.914221</td>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>2.809560</td>\n",
       "      <td>0.954243</td>\n",
       "      <td>1.112907</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   YEAR                                      Project.title  Purpose.Code  \\\n",
       "0  2013  Projet de coopTration universitaire - Initiati...         12182   \n",
       "1  2013                          New vaccine support (NVS)         12220   \n",
       "2  2015  EDCTP2: EUROPEAN AND DEVELOPING COUNTRIES CLIN...         12182   \n",
       "3  2017  Scientific cooperation with other countries (n...         12182   \n",
       "4  2015  INT/Fund of the United Nations International D...         13010   \n",
       "\n",
       "                                         description     Value  \\\n",
       "0  12182. Projet de coopTration universitaire - I...  0.073950   \n",
       "1  12220. New vaccine support (NVS). NEW VACCINE ...  0.096651   \n",
       "2  12182. EDCTP2: EUROPEAN AND DEVELOPING COUNTRI...  3.040122   \n",
       "3  12182. Scientific cooperation with other count...  0.038746   \n",
       "4  13010. INT/Fund of the United Nations Internat...  0.914221   \n",
       "\n",
       "                         label  body_len  body_sent    punct%  \\\n",
       "0              not_global_func  3.447778   1.361728  1.157094   \n",
       "1               Market_Shaping  2.356026   0.698970  1.399083   \n",
       "2          RD_New_Health_Tools  2.665581   0.778151  1.254616   \n",
       "3        Knowledge_Gen_Sharing  2.622214   0.778151  1.220166   \n",
       "4  Response_Unhealthy_Products  2.809560   0.954243  1.112907   \n",
       "\n",
       "              class_pred  \n",
       "0        not_global_func  \n",
       "1         Market_Shaping  \n",
       "2    RD_New_Health_Tools  \n",
       "3  Knowledge_Gen_Sharing  \n",
       "4        Health_Advocacy  "
      ]
     },
     "execution_count": 119,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_fin_calc_xg=pd.concat([test, pd.DataFrame(y_pred_xgb)], axis=1)\n",
    "\n",
    "test_fin_calc_xg=test_fin_calc_xg.rename(columns={0:\"class_pred\"})\n",
    "\n",
    "test_fin_calc_xg.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "not_global_func: 484\n",
      "Control_Cross_Border_Disease: 310\n",
      "Health_Advocacy: 203\n",
      "Knowledge_Gen_Sharing: 585\n",
      "Dev_Harmonization_Int_Reg: 53\n",
      "Epidemic_Pandemic_Prep: 328\n",
      "Response_Unhealthy_Products: 60\n",
      "Market_Shaping: 224\n",
      "RD_New_Health_Tools: 330\n",
      "Promotion_Aid_Effectiveness: 57\n"
     ]
    }
   ],
   "source": [
    "#Counting the number of projects in actual label categories\n",
    "print(\"not_global_func:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"not_global_func\"]))\n",
    "print(\"Control_Cross_Border_Disease:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"Control_Cross_Border_Disease\"]))\n",
    "print(\"Health_Advocacy:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"Health_Advocacy\"]))\n",
    "print(\"Knowledge_Gen_Sharing:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"Knowledge_Gen_Sharing\"]))\n",
    "print(\"Dev_Harmonization_Int_Reg:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"Dev_Harmonization_Int_Reg\"]))\n",
    "print(\"Epidemic_Pandemic_Prep:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"Epidemic_Pandemic_Prep\"]))\n",
    "print(\"Response_Unhealthy_Products:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"Response_Unhealthy_Products\"]))\n",
    "print(\"Market_Shaping:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"Market_Shaping\"]))\n",
    "print(\"RD_New_Health_Tools:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"RD_New_Health_Tools\"]))\n",
    "print(\"Promotion_Aid_Effectiveness:\", len(test_fin_calc_xg[test_fin_calc_xg[\"label\"]==\"Promotion_Aid_Effectiveness\"]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "not_global_func: 470\n",
      "Control_Cross_Border_Disease: 313\n",
      "Health_Advocacy: 209\n",
      "Knowledge_Gen_Sharing: 637\n",
      "Dev_Harmonization_Int_Reg: 51\n",
      "Epidemic_Pandemic_Prep: 309\n",
      "Response_Unhealthy_Products: 58\n",
      "Market_Shaping: 221\n",
      "RD_New_Health_Tools: 340\n",
      "Promotion_Aid_Effectiveness: 26\n"
     ]
    }
   ],
   "source": [
    "#Counting the number of projects in projected label categories\n",
    "print(\"not_global_func:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"not_global_func\"]))\n",
    "print(\"Control_Cross_Border_Disease:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"Control_Cross_Border_Disease\"]))\n",
    "print(\"Health_Advocacy:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"Health_Advocacy\"]))\n",
    "print(\"Knowledge_Gen_Sharing:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"Knowledge_Gen_Sharing\"]))\n",
    "print(\"Dev_Harmonization_Int_Reg:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"Dev_Harmonization_Int_Reg\"]))\n",
    "print(\"Epidemic_Pandemic_Prep:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"Epidemic_Pandemic_Prep\"]))\n",
    "print(\"Response_Unhealthy_Products:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"Response_Unhealthy_Products\"]))\n",
    "print(\"Market_Shaping:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"Market_Shaping\"]))\n",
    "print(\"RD_New_Health_Tools:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"RD_New_Health_Tools\"]))\n",
    "print(\"Promotion_Aid_Effectiveness:\", len(test_fin_calc_xg[test_fin_calc_xg[\"class_pred\"]==\"Promotion_Aid_Effectiveness\"]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 122,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>class_pred</th>\n",
       "      <th>Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>17.87</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>22.40</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>35.69</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>238.67</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>261.35</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>275.92</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>281.73</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>493.53</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>637.52</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>886.56</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     class_pred   Value\n",
       "0     Dev_Harmonization_Int_Reg   17.87\n",
       "1   Response_Unhealthy_Products   22.40\n",
       "2   Promotion_Aid_Effectiveness   35.69\n",
       "3         Knowledge_Gen_Sharing  238.67\n",
       "4               Health_Advocacy  261.35\n",
       "5        Epidemic_Pandemic_Prep  275.92\n",
       "6           RD_New_Health_Tools  281.73\n",
       "7  Control_Cross_Border_Disease  493.53\n",
       "8                Market_Shaping  637.52\n",
       "9               not_global_func  886.56"
      ]
     },
     "execution_count": 122,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#CGH amount based on the predicted categories\n",
    "dah_gpg_xg=test_fin_calc_xg.groupby([\"class_pred\"]).agg({\"Value\":np.sum})\n",
    "\n",
    "dah_gpg_xg=dah_gpg_xg.sort_values(\"Value\").reset_index()\n",
    "\n",
    "dah_gpg_xg=dah_gpg_xg.round(2)\n",
    "dah_gpg_xg"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 123,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "class_pred    Dev_Harmonization_Int_RegResponse_Unhealthy_Pr...\n",
       "Value                                                   2264.68\n",
       "dtype: object"
      ]
     },
     "execution_count": 123,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#CGH finance based on predicted categories in the test dataset\n",
    "dah_gpg_xg[dah_gpg_xg[\"class_pred\"]!=\"not_global_func\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 124,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>label</th>\n",
       "      <th>Value</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>18.40</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>22.02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>32.14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>222.27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>242.07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>276.48</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>293.64</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>527.31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>611.52</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>905.36</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                          label   Value\n",
       "0   Response_Unhealthy_Products   18.40\n",
       "1     Dev_Harmonization_Int_Reg   22.02\n",
       "2   Promotion_Aid_Effectiveness   32.14\n",
       "3         Knowledge_Gen_Sharing  222.27\n",
       "4               Health_Advocacy  242.07\n",
       "5        Epidemic_Pandemic_Prep  276.48\n",
       "6           RD_New_Health_Tools  293.64\n",
       "7  Control_Cross_Border_Disease  527.31\n",
       "8                Market_Shaping  611.52\n",
       "9               not_global_func  905.36"
      ]
     },
     "execution_count": 124,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#CGH finance based on human classification in the test dataset\n",
    "\n",
    "dah_gpg_human_xg=test_fin_calc_xg.groupby([\"label\"]).agg({\"Value\":np.sum})\n",
    "\n",
    "dah_gpg_human_xg=dah_gpg_human_xg.sort_values(\"Value\").reset_index()\n",
    "\n",
    "dah_gpg_human_xg=dah_gpg_human_xg.round(2)\n",
    "dah_gpg_human_xg"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 125,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "label    Response_Unhealthy_ProductsDev_Harmonization_I...\n",
       "Value                                              2245.85\n",
       "dtype: object"
      ]
     },
     "execution_count": 125,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#CGH finance based on human classified categories in the test dataset\n",
    "dah_gpg_human_xg[dah_gpg_human_xg[\"label\"]!=\"not_global_func\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#plotting the distribution of categories. Creating column chart\n",
    "\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(dah_gpg_xg[\"class_pred\"], dah_gpg_xg[\"Value\"])\n",
    "plt.xticks(rotation=90)\n",
    "plt.title(\"Machine Predicted Finance\")\n",
    "\n",
    "for i, v in enumerate(dah_gpg_xg[\"Value\"]):\n",
    "    plt.text(i, v, str(v))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 127,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#actual values in different categories\n",
    "\n",
    "dah_gpg_act_xg=test_fin_calc_xg.groupby([\"label\"]).agg({\"Value\":np.sum})\n",
    "\n",
    "dah_gpg_act_xg=dah_gpg_act_xg.sort_values(\"Value\").reset_index()\n",
    "\n",
    "dah_gpg_act_xg=dah_gpg_act_xg.round(2)\n",
    "\n",
    "#plotting the distribution of categories. Creating column chart\n",
    "\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(dah_gpg_act_xg[\"label\"], dah_gpg_act_xg[\"Value\"])\n",
    "plt.xticks(rotation=90)\n",
    "plt.title(\"Human Classified Finance\")\n",
    "\n",
    "for i, v in enumerate(dah_gpg_act_xg[\"Value\"]):\n",
    "    plt.text(i, v, str(v))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Support Vector Machine"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 147,
   "metadata": {},
   "outputs": [],
   "source": [
    "svc = svm.SVC(kernel='rbf')\n",
    "\n",
    "#fitting the model on training data\n",
    "svc_model=svc.fit(x_tfidf_feat, train[\"label\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 148,
   "metadata": {},
   "outputs": [],
   "source": [
    "#predicting the categories using the trained model on test set \n",
    "y_pred=svc_model.predict(x_tfidf_test_feat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 150,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                              precision    recall  f1-score   support\n",
      "\n",
      "Control_Cross_Border_Disease       0.90      0.91      0.91       310\n",
      "   Dev_Harmonization_Int_Reg       0.71      0.91      0.79        53\n",
      "      Epidemic_Pandemic_Prep       0.94      0.80      0.86       328\n",
      "             Health_Advocacy       0.87      0.89      0.88       203\n",
      "       Knowledge_Gen_Sharing       0.77      0.76      0.76       585\n",
      "              Market_Shaping       0.99      0.94      0.96       224\n",
      " Promotion_Aid_Effectiveness       0.83      0.42      0.56        57\n",
      "         RD_New_Health_Tools       0.65      0.82      0.73       330\n",
      " Response_Unhealthy_Products       0.82      0.78      0.80        60\n",
      "             not_global_func       0.78      0.78      0.78       484\n",
      "\n",
      "                    accuracy                           0.81      2634\n",
      "                   macro avg       0.83      0.80      0.80      2634\n",
      "                weighted avg       0.82      0.81      0.81      2634\n",
      "\n"
     ]
    }
   ],
   "source": [
    "#printing classification results\n",
    "print(classification_report(test[\"label\"], y_pred)) "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 151,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x576 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#heatmap of confusion matrix \n",
    "conf_mat_rf=confusion_matrix(list(test[\"label\"]),list(y_pred))\n",
    "conf_mat_df_rf= pd.DataFrame(conf_mat_rf,\n",
    "                     index = np.unique(test[\"label\"]), \n",
    "                     columns = np.unique(y_pred))\n",
    "\n",
    "plt.figure(figsize=(10, 8))\n",
    "sns.heatmap(conf_mat_df_rf, annot=True, cmap=\"Blues\", center=0, fmt='g')          \n",
    "plt.ylabel('True Label')\n",
    "plt.xlabel('Predicted Label')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "***MultinomialNB()***"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 143,
   "metadata": {},
   "outputs": [],
   "source": [
    "mnbc = MultinomialNB()\n",
    "\n",
    "#fitting the model on training data\n",
    "mnbc_model=mnbc.fit(x_tfidf_feat, train[\"label\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 144,
   "metadata": {},
   "outputs": [],
   "source": [
    "#predicting the categories using the trained model on test set \n",
    "y_pred=mnbc_model.predict(x_tfidf_test_feat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 145,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                              precision    recall  f1-score   support\n",
      "\n",
      "Control_Cross_Border_Disease       0.86      0.84      0.85       310\n",
      "   Dev_Harmonization_Int_Reg       0.66      0.89      0.76        53\n",
      "      Epidemic_Pandemic_Prep       0.93      0.74      0.82       328\n",
      "             Health_Advocacy       0.86      0.87      0.87       203\n",
      "       Knowledge_Gen_Sharing       0.79      0.68      0.73       585\n",
      "              Market_Shaping       0.99      0.88      0.93       224\n",
      " Promotion_Aid_Effectiveness       0.50      0.89      0.65        57\n",
      "         RD_New_Health_Tools       0.65      0.81      0.72       330\n",
      " Response_Unhealthy_Products       0.69      0.87      0.77        60\n",
      "             not_global_func       0.76      0.78      0.77       484\n",
      "\n",
      "                    accuracy                           0.79      2634\n",
      "                   macro avg       0.77      0.83      0.79      2634\n",
      "                weighted avg       0.80      0.79      0.79      2634\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(classification_report(test[\"label\"], y_pred))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 146,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x576 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#heatmap of confusion matrix \n",
    "conf_mat_rf=confusion_matrix(list(test[\"label\"]),list(y_pred))\n",
    "conf_mat_df_rf= pd.DataFrame(conf_mat_rf,\n",
    "                     index = np.unique(test[\"label\"]), \n",
    "                     columns = np.unique(y_pred))\n",
    "\n",
    "plt.figure(figsize=(10, 8))\n",
    "sns.heatmap(conf_mat_df_rf, annot=True, cmap=\"Blues\", center=0, fmt='g')          \n",
    "plt.ylabel('True Label')\n",
    "plt.xlabel('Predicted Label')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "***GaussianNB()***"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "metadata": {},
   "outputs": [],
   "source": [
    "gbnb = GaussianNB()\n",
    "\n",
    "\n",
    "#fitting the model on training data\n",
    "gbnb_model=gbnb.fit(x_tfidf_feat, train[\"label\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {},
   "outputs": [],
   "source": [
    "#predicting the categories using the trained model on test set \n",
    "y_pred=gbnb_model.predict(x_tfidf_test_feat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                              precision    recall  f1-score   support\n",
      "\n",
      "Control_Cross_Border_Disease       0.85      0.82      0.83       282\n",
      "   Dev_Harmonization_Int_Reg       0.57      0.72      0.64        47\n",
      "      Epidemic_Pandemic_Prep       0.84      0.77      0.80       305\n",
      "             Health_Advocacy       0.77      0.87      0.82       198\n",
      "       Knowledge_Gen_Sharing       0.60      0.50      0.54       593\n",
      "              Market_Shaping       0.89      0.96      0.92       225\n",
      " Promotion_Aid_Effectiveness       0.46      0.89      0.61        54\n",
      "         RD_New_Health_Tools       0.54      0.70      0.61       345\n",
      " Response_Unhealthy_Products       0.77      0.65      0.71        55\n",
      "             not_global_func       0.75      0.66      0.70       491\n",
      "\n",
      "                    accuracy                           0.71      2595\n",
      "                   macro avg       0.70      0.75      0.72      2595\n",
      "                weighted avg       0.71      0.71      0.70      2595\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(classification_report(test[\"label\"], y_pred))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "***MLPclassifier()***"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [],
   "source": [
    "mlp = MLPClassifier(max_iter=300)\n",
    "\n",
    "#fitting the model on training data\n",
    "mlp_model=mlp.fit(x_tfidf_feat, train[\"label\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [],
   "source": [
    "#predicting the categories using the trained model on test set \n",
    "y_pred=mlp_model.predict(x_tfidf_test_feat)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "                              precision    recall  f1-score   support\n",
      "\n",
      "Control_Cross_Border_Disease       0.90      0.94      0.92       282\n",
      "   Dev_Harmonization_Int_Reg       0.81      0.74      0.78        47\n",
      "      Epidemic_Pandemic_Prep       0.91      0.89      0.90       305\n",
      "             Health_Advocacy       0.91      0.88      0.90       198\n",
      "       Knowledge_Gen_Sharing       0.74      0.76      0.75       593\n",
      "              Market_Shaping       0.97      0.98      0.97       225\n",
      " Promotion_Aid_Effectiveness       0.83      0.28      0.42        54\n",
      "         RD_New_Health_Tools       0.69      0.75      0.72       345\n",
      " Response_Unhealthy_Products       0.86      0.80      0.83        55\n",
      "             not_global_func       0.80      0.80      0.80       491\n",
      "\n",
      "                    accuracy                           0.82      2595\n",
      "                   macro avg       0.84      0.78      0.80      2595\n",
      "                weighted avg       0.82      0.82      0.82      2595\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(classification_report(test[\"label\"], y_pred))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 720x576 with 2 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#heatmap of confusion matrix \n",
    "conf_mat_rf=confusion_matrix(list(test[\"label\"]),list(y_pred))\n",
    "conf_mat_df_rf= pd.DataFrame(conf_mat_rf,\n",
    "                     index = np.unique(test[\"label\"]), \n",
    "                     columns = np.unique(y_pred))\n",
    "\n",
    "plt.figure(figsize=(10, 8))\n",
    "sns.heatmap(conf_mat_df_rf, annot=True, cmap=\"Blues\", center=0, fmt='g')          \n",
    "plt.ylabel('True Label')\n",
    "plt.xlabel('Predicted Label')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Running the model on the unseen 2019 data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 186,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Year</th>\n",
       "      <th>DonorName</th>\n",
       "      <th>RecipientName</th>\n",
       "      <th>ProjectTitle</th>\n",
       "      <th>PurposeCode</th>\n",
       "      <th>ShortDescription</th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2019</td>\n",
       "      <td>Sweden</td>\n",
       "      <td>Niger</td>\n",
       "      <td>Swedish Mission Council Humanitarian frame 201...</td>\n",
       "      <td>72010</td>\n",
       "      <td>SWEDISH MISSION COUNCIL HUMANITARIAN FRAME 201...</td>\n",
       "      <td>72010. Swedish Mission Council Humanitarian fr...</td>\n",
       "      <td>0.546554</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2019</td>\n",
       "      <td>Sweden</td>\n",
       "      <td>Africa, regional</td>\n",
       "      <td>Reg SRHR - Social marketing of reproductive he...</td>\n",
       "      <td>13020</td>\n",
       "      <td>REG SRHR - SOCIAL MARKETING OF REPRODUCTIVE HE...</td>\n",
       "      <td>13020. Reg SRHR - Social marketing of reproduc...</td>\n",
       "      <td>3.666802</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2019</td>\n",
       "      <td>Germany</td>\n",
       "      <td>West Bank and Gaza Strip</td>\n",
       "      <td>Support of pediatric nursing education in Qube...</td>\n",
       "      <td>12281</td>\n",
       "      <td>SUPPORT OF PEDIATRIC NURSING EDUCATION IN QUBE...</td>\n",
       "      <td>12281. Support of pediatric nursing education ...</td>\n",
       "      <td>0.252715</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2019</td>\n",
       "      <td>World Health Organisation</td>\n",
       "      <td>Nepal</td>\n",
       "      <td>AC_660_3.1 Reproductive, maternal, newborn, ch...</td>\n",
       "      <td>13020</td>\n",
       "      <td>AC_660_3.1 REPRODUCTIVE, MATERNAL, NEWBORN, CH...</td>\n",
       "      <td>13020. AC_660_3.1 Reproductive, maternal, newb...</td>\n",
       "      <td>0.203367</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2019</td>\n",
       "      <td>World Health Organisation</td>\n",
       "      <td>Djibouti</td>\n",
       "      <td>AC_274_4.2 Integrated people-centred health se...</td>\n",
       "      <td>12281</td>\n",
       "      <td>AC_274_4.2 INTEGRATED PEOPLE-CENTRED HEALTH SE...</td>\n",
       "      <td>12281. AC_274_4.2 Integrated people-centred he...</td>\n",
       "      <td>0.065166</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2008</th>\n",
       "      <td>2019</td>\n",
       "      <td>International Development Association</td>\n",
       "      <td>Nicaragua</td>\n",
       "      <td>Health Sector Modernization Credit</td>\n",
       "      <td>12110</td>\n",
       "      <td>HEALTH SECTOR MODERNIZATION CREDIT</td>\n",
       "      <td>12110. Health Sector Modernization Credit. HEA...</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2009</th>\n",
       "      <td>2019</td>\n",
       "      <td>International Development Association</td>\n",
       "      <td>India</td>\n",
       "      <td>National AIDS Control Support Project</td>\n",
       "      <td>12110</td>\n",
       "      <td>NATIONAL AIDS CONTROL SUPPORT PROJECT</td>\n",
       "      <td>12110. National AIDS Control Support Project. ...</td>\n",
       "      <td>2.939634</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2010</th>\n",
       "      <td>2019</td>\n",
       "      <td>David &amp; Lucile Packard Foundation</td>\n",
       "      <td>Mexico</td>\n",
       "      <td>Fundacin Unidos por un Mxico Vivo, A.C. Esti...</td>\n",
       "      <td>13020</td>\n",
       "      <td>FUNDACIN UNIDOS POR UN MXICO VIVO, A.C. ESTI...</td>\n",
       "      <td>13020. Fundacin Unidos por un Mxico Vivo, A....</td>\n",
       "      <td>0.100000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2011</th>\n",
       "      <td>2019</td>\n",
       "      <td>David &amp; Lucile Packard Foundation</td>\n",
       "      <td>Ethiopia</td>\n",
       "      <td>Guttmacher Institute, Inc. Estimated.</td>\n",
       "      <td>13030</td>\n",
       "      <td>GUTTMACHER INSTITUTE, INC. ESTIMATED.</td>\n",
       "      <td>13030. Guttmacher Institute, Inc. Estimated.. ...</td>\n",
       "      <td>0.265000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2012</th>\n",
       "      <td>2019</td>\n",
       "      <td>Rockefeller Foundation</td>\n",
       "      <td>South of Sahara, regional</td>\n",
       "      <td>CONSUMER FUND III, LP TO IMPROVE THE LIVELIHOO...</td>\n",
       "      <td>12220</td>\n",
       "      <td>PRI TO CONSUMER FUND III</td>\n",
       "      <td>12220. CONSUMER FUND III, LP TO IMPROVE THE LI...</td>\n",
       "      <td>0.233251</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2013 rows  8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Year                              DonorName              RecipientName  \\\n",
       "0     2019                                 Sweden                      Niger   \n",
       "1     2019                                 Sweden           Africa, regional   \n",
       "2     2019                                Germany   West Bank and Gaza Strip   \n",
       "3     2019              World Health Organisation                      Nepal   \n",
       "4     2019              World Health Organisation                   Djibouti   \n",
       "...    ...                                    ...                        ...   \n",
       "2008  2019  International Development Association                  Nicaragua   \n",
       "2009  2019  International Development Association                      India   \n",
       "2010  2019      David & Lucile Packard Foundation                     Mexico   \n",
       "2011  2019      David & Lucile Packard Foundation                   Ethiopia   \n",
       "2012  2019                 Rockefeller Foundation  South of Sahara, regional   \n",
       "\n",
       "                                           ProjectTitle  PurposeCode  \\\n",
       "0     Swedish Mission Council Humanitarian frame 201...        72010   \n",
       "1     Reg SRHR - Social marketing of reproductive he...        13020   \n",
       "2     Support of pediatric nursing education in Qube...        12281   \n",
       "3     AC_660_3.1 Reproductive, maternal, newborn, ch...        13020   \n",
       "4     AC_274_4.2 Integrated people-centred health se...        12281   \n",
       "...                                                 ...          ...   \n",
       "2008                 Health Sector Modernization Credit        12110   \n",
       "2009              National AIDS Control Support Project        12110   \n",
       "2010  Fundacin Unidos por un Mxico Vivo, A.C. Esti...        13020   \n",
       "2011              Guttmacher Institute, Inc. Estimated.        13030   \n",
       "2012  CONSUMER FUND III, LP TO IMPROVE THE LIVELIHOO...        12220   \n",
       "\n",
       "                                       ShortDescription  \\\n",
       "0     SWEDISH MISSION COUNCIL HUMANITARIAN FRAME 201...   \n",
       "1     REG SRHR - SOCIAL MARKETING OF REPRODUCTIVE HE...   \n",
       "2     SUPPORT OF PEDIATRIC NURSING EDUCATION IN QUBE...   \n",
       "3     AC_660_3.1 REPRODUCTIVE, MATERNAL, NEWBORN, CH...   \n",
       "4     AC_274_4.2 INTEGRATED PEOPLE-CENTRED HEALTH SE...   \n",
       "...                                                 ...   \n",
       "2008                 HEALTH SECTOR MODERNIZATION CREDIT   \n",
       "2009              NATIONAL AIDS CONTROL SUPPORT PROJECT   \n",
       "2010  FUNDACIN UNIDOS POR UN MXICO VIVO, A.C. ESTI...   \n",
       "2011              GUTTMACHER INSTITUTE, INC. ESTIMATED.   \n",
       "2012                           PRI TO CONSUMER FUND III   \n",
       "\n",
       "                                        LongDescription  USD_Disbursement_Defl  \n",
       "0     72010. Swedish Mission Council Humanitarian fr...               0.546554  \n",
       "1     13020. Reg SRHR - Social marketing of reproduc...               3.666802  \n",
       "2     12281. Support of pediatric nursing education ...               0.252715  \n",
       "3     13020. AC_660_3.1 Reproductive, maternal, newb...               0.203367  \n",
       "4     12281. AC_274_4.2 Integrated people-centred he...               0.065166  \n",
       "...                                                 ...                    ...  \n",
       "2008  12110. Health Sector Modernization Credit. HEA...               0.000000  \n",
       "2009  12110. National AIDS Control Support Project. ...               2.939634  \n",
       "2010  13020. Fundacin Unidos por un Mxico Vivo, A....               0.100000  \n",
       "2011  13030. Guttmacher Institute, Inc. Estimated.. ...               0.265000  \n",
       "2012  12220. CONSUMER FUND III, LP TO IMPROVE THE LI...               0.233251  \n",
       "\n",
       "[2013 rows x 8 columns]"
      ]
     },
     "execution_count": 186,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "##loading the 2019 data\n",
    "crs_2019_health= pd.read_csv(\"crs_2019_health.csv\", engine=\"python\")\n",
    "\n",
    "#dropping some column\n",
    "crs_2019_health=crs_2019_health.drop([\"Unnamed: 0\"], axis=1)\n",
    "\n",
    "crs_2019_health\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 187,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72010. Swedish Mission Council Humanitarian fr...</td>\n",
       "      <td>0.546554</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13020. Reg SRHR - Social marketing of reproduc...</td>\n",
       "      <td>3.666802</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>12281. Support of pediatric nursing education ...</td>\n",
       "      <td>0.252715</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13020. AC_660_3.1 Reproductive, maternal, newb...</td>\n",
       "      <td>0.203367</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>12281. AC_274_4.2 Integrated people-centred he...</td>\n",
       "      <td>0.065166</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     LongDescription  USD_Disbursement_Defl\n",
       "0  72010. Swedish Mission Council Humanitarian fr...               0.546554\n",
       "1  13020. Reg SRHR - Social marketing of reproduc...               3.666802\n",
       "2  12281. Support of pediatric nursing education ...               0.252715\n",
       "3  13020. AC_660_3.1 Reproductive, maternal, newb...               0.203367\n",
       "4  12281. AC_274_4.2 Integrated people-centred he...               0.065166"
      ]
     },
     "execution_count": 187,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#dropping some other columns column\n",
    "crs_2019_health=crs_2019_health.drop([\"Year\", \"DonorName\", \"RecipientName\", \"ProjectTitle\", \"PurposeCode\", \"ShortDescription\"], \n",
    "                                     axis=1)\n",
    "crs_2019_health.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Feature creation for 2019 test data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 188,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Feature creation\n",
    "\n",
    "#Creating function for calculating the length and punctuation percentage feature in the description column of data\n",
    "def count_punct(text):\n",
    "    count = sum([1 for char in text if char in string.punctuation])\n",
    "    return round(count/(len(text)-text.count(\" \")), 3)*100\n",
    "\n",
    "#creating feature of number of sentences in the text\n",
    "def count_sent(text):\n",
    "    return len(nltk.sent_tokenize(text))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {},
   "outputs": [],
   "source": [
    "#creating features for the train dataframe\n",
    "crs_2019_health[\"body_len\"]=crs_2019_health[\"LongDescription\"].apply(lambda x: len(x)- x.count(\" \"))\n",
    "crs_2019_health[\"body_sent\"]=crs_2019_health[\"LongDescription\"].apply(lambda x: count_sent(x))\n",
    "crs_2019_health[\"punct%\"]=crs_2019_health[\"LongDescription\"].apply(lambda x: count_punct(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 190,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72010. Swedish Mission Council Humanitarian fr...</td>\n",
       "      <td>0.546554</td>\n",
       "      <td>1600</td>\n",
       "      <td>9</td>\n",
       "      <td>3.5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13020. Reg SRHR - Social marketing of reproduc...</td>\n",
       "      <td>3.666802</td>\n",
       "      <td>1240</td>\n",
       "      <td>5</td>\n",
       "      <td>4.1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>12281. Support of pediatric nursing education ...</td>\n",
       "      <td>0.252715</td>\n",
       "      <td>209</td>\n",
       "      <td>4</td>\n",
       "      <td>2.9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13020. AC_660_3.1 Reproductive, maternal, newb...</td>\n",
       "      <td>0.203367</td>\n",
       "      <td>193</td>\n",
       "      <td>4</td>\n",
       "      <td>9.8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>12281. AC_274_4.2 Integrated people-centred he...</td>\n",
       "      <td>0.065166</td>\n",
       "      <td>145</td>\n",
       "      <td>4</td>\n",
       "      <td>9.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2008</th>\n",
       "      <td>12110. Health Sector Modernization Credit. HEA...</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>101</td>\n",
       "      <td>4</td>\n",
       "      <td>3.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2009</th>\n",
       "      <td>12110. National AIDS Control Support Project. ...</td>\n",
       "      <td>2.939634</td>\n",
       "      <td>107</td>\n",
       "      <td>4</td>\n",
       "      <td>2.8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2010</th>\n",
       "      <td>13020. Fundacin Unidos por un Mxico Vivo, A....</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>302</td>\n",
       "      <td>6</td>\n",
       "      <td>5.3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2011</th>\n",
       "      <td>13030. Guttmacher Institute, Inc. Estimated.. ...</td>\n",
       "      <td>0.265000</td>\n",
       "      <td>225</td>\n",
       "      <td>6</td>\n",
       "      <td>5.8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2012</th>\n",
       "      <td>12220. CONSUMER FUND III, LP TO IMPROVE THE LI...</td>\n",
       "      <td>0.233251</td>\n",
       "      <td>336</td>\n",
       "      <td>4</td>\n",
       "      <td>1.5</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2013 rows  5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        LongDescription  \\\n",
       "0     72010. Swedish Mission Council Humanitarian fr...   \n",
       "1     13020. Reg SRHR - Social marketing of reproduc...   \n",
       "2     12281. Support of pediatric nursing education ...   \n",
       "3     13020. AC_660_3.1 Reproductive, maternal, newb...   \n",
       "4     12281. AC_274_4.2 Integrated people-centred he...   \n",
       "...                                                 ...   \n",
       "2008  12110. Health Sector Modernization Credit. HEA...   \n",
       "2009  12110. National AIDS Control Support Project. ...   \n",
       "2010  13020. Fundacin Unidos por un Mxico Vivo, A....   \n",
       "2011  13030. Guttmacher Institute, Inc. Estimated.. ...   \n",
       "2012  12220. CONSUMER FUND III, LP TO IMPROVE THE LI...   \n",
       "\n",
       "      USD_Disbursement_Defl  body_len  body_sent  punct%  \n",
       "0                  0.546554      1600          9     3.5  \n",
       "1                  3.666802      1240          5     4.1  \n",
       "2                  0.252715       209          4     2.9  \n",
       "3                  0.203367       193          4     9.8  \n",
       "4                  0.065166       145          4     9.0  \n",
       "...                     ...       ...        ...     ...  \n",
       "2008               0.000000       101          4     3.0  \n",
       "2009               2.939634       107          4     2.8  \n",
       "2010               0.100000       302          6     5.3  \n",
       "2011               0.265000       225          6     5.8  \n",
       "2012               0.233251       336          4     1.5  \n",
       "\n",
       "[2013 rows x 5 columns]"
      ]
     },
     "execution_count": 190,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "crs_2019_health"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 191,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x360 with 3 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#lets evaluate the new features that we created and see if any of these need any transformation\n",
    "plt.figure(figsize=(12,5))\n",
    "plt.subplot(221)\n",
    "plt.hist(crs_2019_health[\"punct%\"], bins=20, label=\"punct%\");\n",
    "plt.legend();\n",
    "plt.subplot(222)\n",
    "plt.hist(crs_2019_health[\"body_len\"], bins=20, label=\"body_len\");\n",
    "plt.legend();\n",
    "plt.subplot(223)\n",
    "plt.hist(crs_2019_health[\"body_sent\"], bins=20, label=\"body_sent\");\n",
    "plt.legend();"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**** We can see from the above charts that they have similar skew as the train data. So, we will use the same box-cox transformation with the same powers as used in the train data transformation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72010. Swedish Mission Council Humanitarian fr...</td>\n",
       "      <td>0.546554</td>\n",
       "      <td>3.204120</td>\n",
       "      <td>0.954243</td>\n",
       "      <td>1.232191</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13020. Reg SRHR - Social marketing of reproduc...</td>\n",
       "      <td>3.666802</td>\n",
       "      <td>3.093422</td>\n",
       "      <td>0.698970</td>\n",
       "      <td>1.265117</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>12281. Support of pediatric nursing education ...</td>\n",
       "      <td>0.252715</td>\n",
       "      <td>2.320146</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.194170</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13020. AC_660_3.1 Reproductive, maternal, newb...</td>\n",
       "      <td>0.203367</td>\n",
       "      <td>2.285557</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.462865</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>12281. AC_274_4.2 Integrated people-centred he...</td>\n",
       "      <td>0.065166</td>\n",
       "      <td>2.161368</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.442250</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     LongDescription  USD_Disbursement_Defl  \\\n",
       "0  72010. Swedish Mission Council Humanitarian fr...               0.546554   \n",
       "1  13020. Reg SRHR - Social marketing of reproduc...               3.666802   \n",
       "2  12281. Support of pediatric nursing education ...               0.252715   \n",
       "3  13020. AC_660_3.1 Reproductive, maternal, newb...               0.203367   \n",
       "4  12281. AC_274_4.2 Integrated people-centred he...               0.065166   \n",
       "\n",
       "   body_len  body_sent    punct%  \n",
       "0  3.204120   0.954243  1.232191  \n",
       "1  3.093422   0.698970  1.265117  \n",
       "2  2.320146   0.602060  1.194170  \n",
       "3  2.285557   0.602060  1.462865  \n",
       "4  2.161368   0.602060  1.442250  "
      ]
     },
     "execution_count": 192,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#applying logrithmic transformation on \"body_len\" column\n",
    "crs_2019_health[\"body_len\"]=crs_2019_health[\"body_len\"].apply(lambda x: np.log10(x))\n",
    "\n",
    "#applying logrithmic transformation on \"body_len\" column\n",
    "crs_2019_health[\"body_sent\"]=crs_2019_health[\"body_sent\"].apply(lambda x: np.log10(x))\n",
    "\n",
    "crs_2019_health[\"punct%\"]=crs_2019_health[\"punct%\"].apply(lambda x: x**(1/6))\n",
    "\n",
    "crs_2019_health.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(2013, 22257)\n"
     ]
    }
   ],
   "source": [
    "#vectorizing 2019 test data\n",
    "#TF-IDF--Vectorizing for raw data\n",
    "x_tfidf_test_2019= tfidf_vect.transform(crs_2019_health[\"LongDescription\"])\n",
    "print(x_tfidf_test_2019.shape)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 194,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>...</th>\n",
       "      <th>22247</th>\n",
       "      <th>22248</th>\n",
       "      <th>22249</th>\n",
       "      <th>22250</th>\n",
       "      <th>22251</th>\n",
       "      <th>22252</th>\n",
       "      <th>22253</th>\n",
       "      <th>22254</th>\n",
       "      <th>22255</th>\n",
       "      <th>22256</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2008</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2009</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2010</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2011</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2012</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2013 rows  22257 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      0      1      2      3      4      5      6      7      8      9      \\\n",
       "0       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "1       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "3       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "4       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "...     ...    ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "2008    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2009    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2010    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2011    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2012    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "\n",
       "      ...  22247  22248  22249  22250  22251  22252  22253  22254  22255  \\\n",
       "0     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "1     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "3     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "4     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "...   ...    ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "2008  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2009  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2010  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2011  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2012  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "\n",
       "      22256  \n",
       "0       0.0  \n",
       "1       0.0  \n",
       "2       0.0  \n",
       "3       0.0  \n",
       "4       0.0  \n",
       "...     ...  \n",
       "2008    0.0  \n",
       "2009    0.0  \n",
       "2010    0.0  \n",
       "2011    0.0  \n",
       "2012    0.0  \n",
       "\n",
       "[2013 rows x 22257 columns]"
      ]
     },
     "execution_count": 194,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#the x_tfidf_test_2019 is sparse matrix. Lets look at it in data frame form\n",
    "x_tfidf_test_df2019= pd.DataFrame(x_tfidf_test_2019.toarray())\n",
    "\n",
    "x_tfidf_test_df2019"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>...</th>\n",
       "      <th>22247</th>\n",
       "      <th>22248</th>\n",
       "      <th>22249</th>\n",
       "      <th>22250</th>\n",
       "      <th>22251</th>\n",
       "      <th>22252</th>\n",
       "      <th>22253</th>\n",
       "      <th>22254</th>\n",
       "      <th>22255</th>\n",
       "      <th>22256</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>3.204120</td>\n",
       "      <td>0.954243</td>\n",
       "      <td>1.232191</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>3.093422</td>\n",
       "      <td>0.698970</td>\n",
       "      <td>1.265117</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2.320146</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.194170</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2.285557</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.462865</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2.161368</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.442250</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  22260 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   body_len  body_sent    punct%    0    1    2    3    4    5    6  ...  \\\n",
       "0  3.204120   0.954243  1.232191  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "1  3.093422   0.698970  1.265117  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2  2.320146   0.602060  1.194170  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "3  2.285557   0.602060  1.462865  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "4  2.161368   0.602060  1.442250  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "\n",
       "   22247  22248  22249  22250  22251  22252  22253  22254  22255  22256  \n",
       "0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "1    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "2    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "3    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "4    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "\n",
       "[5 rows x 22260 columns]"
      ]
     },
     "execution_count": 195,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#concatenating all the features\n",
    "\n",
    "x_tfidf_test_feat2019 = pd.concat([crs_2019_health[\"body_len\"],crs_2019_health[\"body_sent\"], crs_2019_health[\"punct%\"], \n",
    "                               pd.DataFrame(x_tfidf_test_2019.toarray())], axis=1)\n",
    "x_tfidf_test_feat2019.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Prediction using RF model"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### load the saved RF model from disk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 196,
   "metadata": {},
   "outputs": [],
   "source": [
    "filename = 'finalized_model_rf.sav'\n",
    "loaded_model_rf = pickle.load(open(filename, 'rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['not_global_func', 'not_global_func', 'not_global_func', ...,\n",
       "       'not_global_func', 'Knowledge_Gen_Sharing', 'not_global_func'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 197,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#predicting the categories using the saved trained model on 2019 test set \n",
    "result2019=loaded_model_rf.predict(x_tfidf_test_feat2019)\n",
    "\n",
    "result2019"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**calculating the finance based on categories predicted** "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 198,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>class_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72010. Swedish Mission Council Humanitarian fr...</td>\n",
       "      <td>0.546554</td>\n",
       "      <td>3.204120</td>\n",
       "      <td>0.954243</td>\n",
       "      <td>1.232191</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13020. Reg SRHR - Social marketing of reproduc...</td>\n",
       "      <td>3.666802</td>\n",
       "      <td>3.093422</td>\n",
       "      <td>0.698970</td>\n",
       "      <td>1.265117</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>12281. Support of pediatric nursing education ...</td>\n",
       "      <td>0.252715</td>\n",
       "      <td>2.320146</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.194170</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13020. AC_660_3.1 Reproductive, maternal, newb...</td>\n",
       "      <td>0.203367</td>\n",
       "      <td>2.285557</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.462865</td>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>12281. AC_274_4.2 Integrated people-centred he...</td>\n",
       "      <td>0.065166</td>\n",
       "      <td>2.161368</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.442250</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     LongDescription  USD_Disbursement_Defl  \\\n",
       "0  72010. Swedish Mission Council Humanitarian fr...               0.546554   \n",
       "1  13020. Reg SRHR - Social marketing of reproduc...               3.666802   \n",
       "2  12281. Support of pediatric nursing education ...               0.252715   \n",
       "3  13020. AC_660_3.1 Reproductive, maternal, newb...               0.203367   \n",
       "4  12281. AC_274_4.2 Integrated people-centred he...               0.065166   \n",
       "\n",
       "   body_len  body_sent    punct%                    class_pred  \n",
       "0  3.204120   0.954243  1.232191               not_global_func  \n",
       "1  3.093422   0.698970  1.265117               not_global_func  \n",
       "2  2.320146   0.602060  1.194170               not_global_func  \n",
       "3  2.285557   0.602060  1.462865  Control_Cross_Border_Disease  \n",
       "4  2.161368   0.602060  1.442250               Health_Advocacy  "
      ]
     },
     "execution_count": 198,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_fin_calc2019=pd.concat([crs_2019_health, pd.DataFrame(result2019)], axis=1)\n",
    "\n",
    "test_fin_calc2019=test_fin_calc2019.rename(columns={0:\"class_pred\"})\n",
    "\n",
    "test_fin_calc2019.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 199,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "not_global_func: 1283\n",
      "Control_Cross_Border_Disease: 139\n",
      "Health_Advocacy: 217\n",
      "Knowledge_Gen_Sharing: 102\n",
      "Dev_Harmonization_Int_Reg: 6\n",
      "Epidemic_Pandemic_Prep: 115\n",
      "Response_Unhealthy_Products: 8\n",
      "Market_Shaping: 27\n",
      "RD_New_Health_Tools: 116\n",
      "Promotion_Aid_Effectiveness: 0\n"
     ]
    }
   ],
   "source": [
    "#Counting the predicted number of label in each categories \n",
    "print(\"not_global_func:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"not_global_func\"]))\n",
    "print(\"Control_Cross_Border_Disease:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"Control_Cross_Border_Disease\"]))\n",
    "print(\"Health_Advocacy:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"Health_Advocacy\"]))\n",
    "print(\"Knowledge_Gen_Sharing:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"Knowledge_Gen_Sharing\"]))\n",
    "print(\"Dev_Harmonization_Int_Reg:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"Dev_Harmonization_Int_Reg\"]))\n",
    "print(\"Epidemic_Pandemic_Prep:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"Epidemic_Pandemic_Prep\"]))\n",
    "print(\"Response_Unhealthy_Products:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"Response_Unhealthy_Products\"]))\n",
    "print(\"Market_Shaping:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"Market_Shaping\"]))\n",
    "print(\"RD_New_Health_Tools:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"RD_New_Health_Tools\"]))\n",
    "#print(\"RD_Blueprint_Diseases_Pandemic_Flu:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"RD_Blueprint_Diseases_Pandemic_Flu\"]))\n",
    "print(\"Promotion_Aid_Effectiveness:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"Promotion_Aid_Effectiveness\"]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>class_pred</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>5.35</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>13.56</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>34.01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>45.12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>97.08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>112.17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>293.67</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>1062.22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>2091.06</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     class_pred  USD_Disbursement_Defl\n",
       "0     Dev_Harmonization_Int_Reg                   5.35\n",
       "1   Response_Unhealthy_Products                  13.56\n",
       "2         Knowledge_Gen_Sharing                  34.01\n",
       "3                Market_Shaping                  45.12\n",
       "4        Epidemic_Pandemic_Prep                  97.08\n",
       "5           RD_New_Health_Tools                 112.17\n",
       "6  Control_Cross_Border_Disease                 293.67\n",
       "7               not_global_func                1062.22\n",
       "8               Health_Advocacy                2091.06"
      ]
     },
     "execution_count": 200,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg amount based on the predicted categories\n",
    "dah_gpg2019=test_fin_calc2019.groupby([\"class_pred\"]).agg({\"USD_Disbursement_Defl\":np.sum})\n",
    "\n",
    "dah_gpg2019=dah_gpg2019.sort_values(\"USD_Disbursement_Defl\").reset_index()\n",
    "\n",
    "dah_gpg2019=dah_gpg2019.round(2)\n",
    "dah_gpg2019"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 201,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "class_pred               Dev_Harmonization_Int_RegResponse_Unhealthy_Pr...\n",
       "USD_Disbursement_Defl                                              2692.02\n",
       "dtype: object"
      ]
     },
     "execution_count": 201,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg finance based on predicted categories in the test dataset\n",
    "dah_gpg2019[dah_gpg2019[\"class_pred\"]!=\"not_global_func\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 202,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#plotting the distribution of categories. Creating column chart\n",
    "\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(dah_gpg2019[\"class_pred\"], dah_gpg2019[\"USD_Disbursement_Defl\"])\n",
    "plt.xticks(rotation=90)\n",
    "plt.title(\"Machine Predicted Finance 2019 (millions)\")\n",
    "\n",
    "for i, v in enumerate(dah_gpg2019[\"USD_Disbursement_Defl\"]):\n",
    "    plt.text(i, v, str(v))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "##### Prediction using XGBoost model"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "###### load the saved RF model from disk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 179,
   "metadata": {},
   "outputs": [],
   "source": [
    "filename = 'finalized_model_xgboost.sav'\n",
    "loaded_model_xgb = pickle.load(open(filename, 'rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 180,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['not_global_func', 'not_global_func', 'not_global_func', ...,\n",
       "       'Health_Advocacy', 'Knowledge_Gen_Sharing', 'not_global_func'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 180,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#predicting the categories using the saved trained model on 2019 test set \n",
    "result2019_xgb=loaded_model_xgb.predict(x_tfidf_test_feat2019)\n",
    "\n",
    "result2019_xgb"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**calculating the finance based on categories predicted** "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 181,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>class_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72010. Swedish Mission Council Humanitarian fr...</td>\n",
       "      <td>0.546554</td>\n",
       "      <td>3.204120</td>\n",
       "      <td>0.954243</td>\n",
       "      <td>1.232191</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13020. Reg SRHR - Social marketing of reproduc...</td>\n",
       "      <td>3.666802</td>\n",
       "      <td>3.093422</td>\n",
       "      <td>0.698970</td>\n",
       "      <td>1.265117</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>12281. Support of pediatric nursing education ...</td>\n",
       "      <td>0.252715</td>\n",
       "      <td>2.320146</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.194170</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13020. AC_660_3.1 Reproductive, maternal, newb...</td>\n",
       "      <td>0.203367</td>\n",
       "      <td>2.285557</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.462865</td>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>12281. AC_274_4.2 Integrated people-centred he...</td>\n",
       "      <td>0.065166</td>\n",
       "      <td>2.161368</td>\n",
       "      <td>0.602060</td>\n",
       "      <td>1.442250</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     LongDescription  USD_Disbursement_Defl  \\\n",
       "0  72010. Swedish Mission Council Humanitarian fr...               0.546554   \n",
       "1  13020. Reg SRHR - Social marketing of reproduc...               3.666802   \n",
       "2  12281. Support of pediatric nursing education ...               0.252715   \n",
       "3  13020. AC_660_3.1 Reproductive, maternal, newb...               0.203367   \n",
       "4  12281. AC_274_4.2 Integrated people-centred he...               0.065166   \n",
       "\n",
       "   body_len  body_sent    punct%                    class_pred  \n",
       "0  3.204120   0.954243  1.232191               not_global_func  \n",
       "1  3.093422   0.698970  1.265117               not_global_func  \n",
       "2  2.320146   0.602060  1.194170               not_global_func  \n",
       "3  2.285557   0.602060  1.462865  Control_Cross_Border_Disease  \n",
       "4  2.161368   0.602060  1.442250               Health_Advocacy  "
      ]
     },
     "execution_count": 181,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_fin_calc2019_xgb=pd.concat([crs_2019_health, pd.DataFrame(result2019_xgb)], axis=1)\n",
    "\n",
    "test_fin_calc2019_xgb=test_fin_calc2019_xgb.rename(columns={0:\"class_pred\"})\n",
    "\n",
    "test_fin_calc2019_xgb.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 182,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "not_global_func: 1370\n",
      "Control_Cross_Border_Disease: 122\n",
      "Health_Advocacy: 119\n",
      "Knowledge_Gen_Sharing: 157\n",
      "Dev_Harmonization_Int_Reg: 9\n",
      "Epidemic_Pandemic_Prep: 77\n",
      "Response_Unhealthy_Products: 3\n",
      "Market_Shaping: 39\n",
      "RD_New_Health_Tools: 116\n",
      "Promotion_Aid_Effectiveness: 1\n"
     ]
    }
   ],
   "source": [
    "#Counting the number of each label categories in the prediction\n",
    "print(\"not_global_func:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"not_global_func\"]))\n",
    "print(\"Control_Cross_Border_Disease:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"Control_Cross_Border_Disease\"]))\n",
    "print(\"Health_Advocacy:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"Health_Advocacy\"]))\n",
    "print(\"Knowledge_Gen_Sharing:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"Knowledge_Gen_Sharing\"]))\n",
    "print(\"Dev_Harmonization_Int_Reg:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"Dev_Harmonization_Int_Reg\"]))\n",
    "print(\"Epidemic_Pandemic_Prep:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"Epidemic_Pandemic_Prep\"]))\n",
    "print(\"Response_Unhealthy_Products:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"Response_Unhealthy_Products\"]))\n",
    "print(\"Market_Shaping:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"Market_Shaping\"]))\n",
    "print(\"RD_New_Health_Tools:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"RD_New_Health_Tools\"]))\n",
    "#print(\"RD_Blueprint_Diseases_Pandemic_Flu:\", len(test_fin_calc2019[test_fin_calc2019[\"class_pred\"]==\"RD_Blueprint_Diseases_Pandemic_Flu\"]))\n",
    "print(\"Promotion_Aid_Effectiveness:\", len(test_fin_calc2019_xgb[test_fin_calc2019_xgb[\"class_pred\"]==\"Promotion_Aid_Effectiveness\"]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 183,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>class_pred</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>0.09</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>1.51</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>7.10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>30.46</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>40.08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>48.65</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>68.29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>118.58</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>349.33</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>3090.15</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     class_pred  USD_Disbursement_Defl\n",
       "0   Response_Unhealthy_Products                   0.09\n",
       "1   Promotion_Aid_Effectiveness                   1.51\n",
       "2     Dev_Harmonization_Int_Reg                   7.10\n",
       "3        Epidemic_Pandemic_Prep                  30.46\n",
       "4               Health_Advocacy                  40.08\n",
       "5                Market_Shaping                  48.65\n",
       "6         Knowledge_Gen_Sharing                  68.29\n",
       "7           RD_New_Health_Tools                 118.58\n",
       "8  Control_Cross_Border_Disease                 349.33\n",
       "9               not_global_func                3090.15"
      ]
     },
     "execution_count": 183,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#CGH amount based on the predicted categories\n",
    "dah_gpg2019_xgb=test_fin_calc2019_xgb.groupby([\"class_pred\"]).agg({\"USD_Disbursement_Defl\":np.sum})\n",
    "\n",
    "dah_gpg2019_xgb=dah_gpg2019_xgb.sort_values(\"USD_Disbursement_Defl\").reset_index()\n",
    "\n",
    "dah_gpg2019_xgb=dah_gpg2019_xgb.round(2)\n",
    "dah_gpg2019_xgb"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 184,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "class_pred               Response_Unhealthy_ProductsPromotion_Aid_Effec...\n",
       "USD_Disbursement_Defl                                               664.09\n",
       "dtype: object"
      ]
     },
     "execution_count": 184,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg finance based on predicted categories in the test dataset\n",
    "dah_gpg2019_xgb[dah_gpg2019_xgb[\"class_pred\"]!=\"not_global_func\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 185,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#plotting the distribution of categories. Creating column chart\n",
    "\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(dah_gpg2019_xgb[\"class_pred\"], dah_gpg2019_xgb[\"USD_Disbursement_Defl\"])\n",
    "plt.xticks(rotation=90)\n",
    "plt.title(\"Machine Predicted Finance 2019 (millions)\")\n",
    "\n",
    "for i, v in enumerate(dah_gpg2019_xgb[\"USD_Disbursement_Defl\"]):\n",
    "    plt.text(i, v, str(v))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Running the model on the unseen 2018 data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#load the saved model\n",
    "loaded_model = pickle.load(open(filename, 'rb'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 189,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Year</th>\n",
       "      <th>DonorName</th>\n",
       "      <th>RecipientName</th>\n",
       "      <th>ProjectTitle</th>\n",
       "      <th>PurposeCode</th>\n",
       "      <th>ShortDescription</th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2018</td>\n",
       "      <td>UNFPA</td>\n",
       "      <td>Nicaragua</td>\n",
       "      <td>Nicaragua - Managua. 08 - Youth leadership and...</td>\n",
       "      <td>72050</td>\n",
       "      <td>NICARAGUA - MANAGUA. 08 - YOUTH LEADERSHIP AND...</td>\n",
       "      <td>72050. Nicaragua - Managua. 08 - Youth leaders...</td>\n",
       "      <td>0.022965</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2018</td>\n",
       "      <td>UNFPA</td>\n",
       "      <td>Mexico</td>\n",
       "      <td>Mexico - Mexico City. 01 - SRH Policies</td>\n",
       "      <td>13010</td>\n",
       "      <td>MEXICO - MEXICO CITY. 01 - SRH POLICIES</td>\n",
       "      <td>13010. Mexico - Mexico City. 01 - SRH Policies...</td>\n",
       "      <td>0.023190</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2018</td>\n",
       "      <td>UNFPA</td>\n",
       "      <td>Cuba</td>\n",
       "      <td>Cuba - Havana. 14 - Demographic intelligence</td>\n",
       "      <td>13010</td>\n",
       "      <td>CUBA - HAVANA. 14 - DEMOGRAPHIC INTELLIGENCE</td>\n",
       "      <td>13010. Cuba - Havana. 14 - Demographic intelli...</td>\n",
       "      <td>0.006837</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2018</td>\n",
       "      <td>UNFPA</td>\n",
       "      <td>Tanzania</td>\n",
       "      <td>Tanzania - Dar-es-Salaam. 03 - Health workforc...</td>\n",
       "      <td>13081</td>\n",
       "      <td>TANZANIA - DAR-ES-SALAAM. 03 - HEALTH WORKFORC...</td>\n",
       "      <td>13081. Tanzania - Dar-es-Salaam. 03 - Health w...</td>\n",
       "      <td>0.006151</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2018</td>\n",
       "      <td>UNFPA</td>\n",
       "      <td>Bilateral, unspecified</td>\n",
       "      <td>Humanitarian Office. 11 - Prevention and addre...</td>\n",
       "      <td>72050</td>\n",
       "      <td>HUMANITARIAN OFFICE. 11 - PREVENTION AND ADDRE...</td>\n",
       "      <td>72050. Humanitarian Office. 11 - Prevention an...</td>\n",
       "      <td>0.000118</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1999</th>\n",
       "      <td>2018</td>\n",
       "      <td>Open Society Foundations</td>\n",
       "      <td>Caribbean, regional</td>\n",
       "      <td>UNDP Multi-Partner Trust Fund Office</td>\n",
       "      <td>12250</td>\n",
       "      <td>UNDP MULTI-PARTNER TRUST FUND OFFICE</td>\n",
       "      <td>12250. UNDP Multi-Partner Trust Fund Office. U...</td>\n",
       "      <td>0.274820</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2000</th>\n",
       "      <td>2018</td>\n",
       "      <td>Open Society Foundations</td>\n",
       "      <td>Bilateral, unspecified</td>\n",
       "      <td>International Treatment Preparedness Coalition</td>\n",
       "      <td>16064</td>\n",
       "      <td>INTERNATIONAL TREATMENT PREPAREDNESS COALITION</td>\n",
       "      <td>16064. International Treatment Preparedness Co...</td>\n",
       "      <td>0.646336</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2001</th>\n",
       "      <td>2018</td>\n",
       "      <td>Open Society Foundations</td>\n",
       "      <td>South Asia, regional</td>\n",
       "      <td>Bangladesh Legal Aid and Services Trust (BLAST)</td>\n",
       "      <td>13020</td>\n",
       "      <td>BANGLADESH LEGAL AID AND SERVICES TRUST (BLAST)</td>\n",
       "      <td>13020. Bangladesh Legal Aid and Services Trust...</td>\n",
       "      <td>0.305355</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2002</th>\n",
       "      <td>2018</td>\n",
       "      <td>Japan</td>\n",
       "      <td>Tanzania</td>\n",
       "      <td>TC AGGREGATED ACTIVITIES</td>\n",
       "      <td>12110</td>\n",
       "      <td>TC AGGREGATED ACTIVITIES</td>\n",
       "      <td>12110. TC AGGREGATED ACTIVITIES. TC AGGREGATED...</td>\n",
       "      <td>0.373384</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2003</th>\n",
       "      <td>2018</td>\n",
       "      <td>Japan</td>\n",
       "      <td>Yemen</td>\n",
       "      <td>Yemen Cholera Response Mechanism</td>\n",
       "      <td>12240</td>\n",
       "      <td>YEMEN CHOLERA RESPONSE MECHANISM</td>\n",
       "      <td>12240. Yemen Cholera Response Mechanism. YEMEN...</td>\n",
       "      <td>0.203744</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2004 rows  8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Year                 DonorName           RecipientName  \\\n",
       "0     2018                     UNFPA               Nicaragua   \n",
       "1     2018                     UNFPA                  Mexico   \n",
       "2     2018                     UNFPA                    Cuba   \n",
       "3     2018                     UNFPA                Tanzania   \n",
       "4     2018                     UNFPA  Bilateral, unspecified   \n",
       "...    ...                       ...                     ...   \n",
       "1999  2018  Open Society Foundations     Caribbean, regional   \n",
       "2000  2018  Open Society Foundations  Bilateral, unspecified   \n",
       "2001  2018  Open Society Foundations    South Asia, regional   \n",
       "2002  2018                     Japan                Tanzania   \n",
       "2003  2018                     Japan                   Yemen   \n",
       "\n",
       "                                           ProjectTitle  PurposeCode  \\\n",
       "0     Nicaragua - Managua. 08 - Youth leadership and...        72050   \n",
       "1               Mexico - Mexico City. 01 - SRH Policies        13010   \n",
       "2          Cuba - Havana. 14 - Demographic intelligence        13010   \n",
       "3     Tanzania - Dar-es-Salaam. 03 - Health workforc...        13081   \n",
       "4     Humanitarian Office. 11 - Prevention and addre...        72050   \n",
       "...                                                 ...          ...   \n",
       "1999               UNDP Multi-Partner Trust Fund Office        12250   \n",
       "2000     International Treatment Preparedness Coalition        16064   \n",
       "2001    Bangladesh Legal Aid and Services Trust (BLAST)        13020   \n",
       "2002                           TC AGGREGATED ACTIVITIES        12110   \n",
       "2003                   Yemen Cholera Response Mechanism        12240   \n",
       "\n",
       "                                       ShortDescription  \\\n",
       "0     NICARAGUA - MANAGUA. 08 - YOUTH LEADERSHIP AND...   \n",
       "1               MEXICO - MEXICO CITY. 01 - SRH POLICIES   \n",
       "2          CUBA - HAVANA. 14 - DEMOGRAPHIC INTELLIGENCE   \n",
       "3     TANZANIA - DAR-ES-SALAAM. 03 - HEALTH WORKFORC...   \n",
       "4     HUMANITARIAN OFFICE. 11 - PREVENTION AND ADDRE...   \n",
       "...                                                 ...   \n",
       "1999               UNDP MULTI-PARTNER TRUST FUND OFFICE   \n",
       "2000     INTERNATIONAL TREATMENT PREPAREDNESS COALITION   \n",
       "2001    BANGLADESH LEGAL AID AND SERVICES TRUST (BLAST)   \n",
       "2002                           TC AGGREGATED ACTIVITIES   \n",
       "2003                   YEMEN CHOLERA RESPONSE MECHANISM   \n",
       "\n",
       "                                        LongDescription  USD_Disbursement_Defl  \n",
       "0     72050. Nicaragua - Managua. 08 - Youth leaders...               0.022965  \n",
       "1     13010. Mexico - Mexico City. 01 - SRH Policies...               0.023190  \n",
       "2     13010. Cuba - Havana. 14 - Demographic intelli...               0.006837  \n",
       "3     13081. Tanzania - Dar-es-Salaam. 03 - Health w...               0.006151  \n",
       "4     72050. Humanitarian Office. 11 - Prevention an...               0.000118  \n",
       "...                                                 ...                    ...  \n",
       "1999  12250. UNDP Multi-Partner Trust Fund Office. U...               0.274820  \n",
       "2000  16064. International Treatment Preparedness Co...               0.646336  \n",
       "2001  13020. Bangladesh Legal Aid and Services Trust...               0.305355  \n",
       "2002  12110. TC AGGREGATED ACTIVITIES. TC AGGREGATED...               0.373384  \n",
       "2003  12240. Yemen Cholera Response Mechanism. YEMEN...               0.203744  \n",
       "\n",
       "[2004 rows x 8 columns]"
      ]
     },
     "execution_count": 189,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "##loading the 2019 data\n",
    "crs_2018_health= pd.read_csv(\"crs_2018_health.csv\", engine=\"python\")\n",
    "\n",
    "#dropping some column\n",
    "crs_2018_health=crs_2018_health.drop([\"Unnamed: 0\"], axis=1)\n",
    "\n",
    "crs_2018_health"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 190,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72050. Nicaragua - Managua. 08 - Youth leaders...</td>\n",
       "      <td>0.022965</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13010. Mexico - Mexico City. 01 - SRH Policies...</td>\n",
       "      <td>0.023190</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>13010. Cuba - Havana. 14 - Demographic intelli...</td>\n",
       "      <td>0.006837</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13081. Tanzania - Dar-es-Salaam. 03 - Health w...</td>\n",
       "      <td>0.006151</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>72050. Humanitarian Office. 11 - Prevention an...</td>\n",
       "      <td>0.000118</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     LongDescription  USD_Disbursement_Defl\n",
       "0  72050. Nicaragua - Managua. 08 - Youth leaders...               0.022965\n",
       "1  13010. Mexico - Mexico City. 01 - SRH Policies...               0.023190\n",
       "2  13010. Cuba - Havana. 14 - Demographic intelli...               0.006837\n",
       "3  13081. Tanzania - Dar-es-Salaam. 03 - Health w...               0.006151\n",
       "4  72050. Humanitarian Office. 11 - Prevention an...               0.000118"
      ]
     },
     "execution_count": 190,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#dropping some other columns column\n",
    "crs_2018_health=crs_2018_health.drop([\"Year\", \"DonorName\", \"RecipientName\", \"ProjectTitle\", \"PurposeCode\", \"ShortDescription\"], \n",
    "                                     axis=1)\n",
    "crs_2018_health.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Feature creation for 2018 test data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 191,
   "metadata": {},
   "outputs": [],
   "source": [
    "#creating features for the train dataframe\n",
    "crs_2018_health[\"body_len\"]=crs_2018_health[\"LongDescription\"].apply(lambda x: len(x)- x.count(\" \"))\n",
    "crs_2018_health[\"body_sent\"]=crs_2018_health[\"LongDescription\"].apply(lambda x: count_sent(x))\n",
    "crs_2018_health[\"punct%\"]=crs_2018_health[\"LongDescription\"].apply(lambda x: count_punct(x))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 192,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72050. Nicaragua - Managua. 08 - Youth leaders...</td>\n",
       "      <td>0.022965</td>\n",
       "      <td>158</td>\n",
       "      <td>6</td>\n",
       "      <td>6.3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13010. Mexico - Mexico City. 01 - SRH Policies...</td>\n",
       "      <td>0.023190</td>\n",
       "      <td>115</td>\n",
       "      <td>6</td>\n",
       "      <td>7.8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>13010. Cuba - Havana. 14 - Demographic intelli...</td>\n",
       "      <td>0.006837</td>\n",
       "      <td>127</td>\n",
       "      <td>6</td>\n",
       "      <td>7.1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13081. Tanzania - Dar-es-Salaam. 03 - Health w...</td>\n",
       "      <td>0.006151</td>\n",
       "      <td>144</td>\n",
       "      <td>6</td>\n",
       "      <td>9.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>72050. Humanitarian Office. 11 - Prevention an...</td>\n",
       "      <td>0.000118</td>\n",
       "      <td>154</td>\n",
       "      <td>6</td>\n",
       "      <td>5.2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1999</th>\n",
       "      <td>12250. UNDP Multi-Partner Trust Fund Office. U...</td>\n",
       "      <td>0.274820</td>\n",
       "      <td>214</td>\n",
       "      <td>6</td>\n",
       "      <td>5.6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2000</th>\n",
       "      <td>16064. International Treatment Preparedness Co...</td>\n",
       "      <td>0.646336</td>\n",
       "      <td>366</td>\n",
       "      <td>5</td>\n",
       "      <td>2.7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2001</th>\n",
       "      <td>13020. Bangladesh Legal Aid and Services Trust...</td>\n",
       "      <td>0.305355</td>\n",
       "      <td>791</td>\n",
       "      <td>8</td>\n",
       "      <td>3.5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2002</th>\n",
       "      <td>12110. TC AGGREGATED ACTIVITIES. TC AGGREGATED...</td>\n",
       "      <td>0.373384</td>\n",
       "      <td>74</td>\n",
       "      <td>4</td>\n",
       "      <td>4.1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2003</th>\n",
       "      <td>12240. Yemen Cholera Response Mechanism. YEMEN...</td>\n",
       "      <td>0.203744</td>\n",
       "      <td>95</td>\n",
       "      <td>4</td>\n",
       "      <td>3.2</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2004 rows  5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        LongDescription  \\\n",
       "0     72050. Nicaragua - Managua. 08 - Youth leaders...   \n",
       "1     13010. Mexico - Mexico City. 01 - SRH Policies...   \n",
       "2     13010. Cuba - Havana. 14 - Demographic intelli...   \n",
       "3     13081. Tanzania - Dar-es-Salaam. 03 - Health w...   \n",
       "4     72050. Humanitarian Office. 11 - Prevention an...   \n",
       "...                                                 ...   \n",
       "1999  12250. UNDP Multi-Partner Trust Fund Office. U...   \n",
       "2000  16064. International Treatment Preparedness Co...   \n",
       "2001  13020. Bangladesh Legal Aid and Services Trust...   \n",
       "2002  12110. TC AGGREGATED ACTIVITIES. TC AGGREGATED...   \n",
       "2003  12240. Yemen Cholera Response Mechanism. YEMEN...   \n",
       "\n",
       "      USD_Disbursement_Defl  body_len  body_sent  punct%  \n",
       "0                  0.022965       158          6     6.3  \n",
       "1                  0.023190       115          6     7.8  \n",
       "2                  0.006837       127          6     7.1  \n",
       "3                  0.006151       144          6     9.0  \n",
       "4                  0.000118       154          6     5.2  \n",
       "...                     ...       ...        ...     ...  \n",
       "1999               0.274820       214          6     5.6  \n",
       "2000               0.646336       366          5     2.7  \n",
       "2001               0.305355       791          8     3.5  \n",
       "2002               0.373384        74          4     4.1  \n",
       "2003               0.203744        95          4     3.2  \n",
       "\n",
       "[2004 rows x 5 columns]"
      ]
     },
     "execution_count": 192,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "crs_2018_health"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 193,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 864x360 with 3 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#lets evaluate the new features that we created and see if any of these need any transformation\n",
    "plt.figure(figsize=(12,5))\n",
    "plt.subplot(221)\n",
    "plt.hist(crs_2018_health[\"punct%\"], bins=20, label=\"punct%\");\n",
    "plt.legend();\n",
    "plt.subplot(222)\n",
    "plt.hist(crs_2018_health[\"body_len\"], bins=20, label=\"body_len\");\n",
    "plt.legend();\n",
    "plt.subplot(223)\n",
    "plt.hist(crs_2018_health[\"body_sent\"], bins=20, label=\"body_sent\");\n",
    "plt.legend();"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**** We can see from the above charts that they have similar skew as the train data. So, we will use the same box-cox transformation with the same powers as used in the train data transformation\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 194,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72050. Nicaragua - Managua. 08 - Youth leaders...</td>\n",
       "      <td>0.022965</td>\n",
       "      <td>2.198657</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.359012</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13010. Mexico - Mexico City. 01 - SRH Policies...</td>\n",
       "      <td>0.023190</td>\n",
       "      <td>2.060698</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.408259</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>13010. Cuba - Havana. 14 - Demographic intelli...</td>\n",
       "      <td>0.006837</td>\n",
       "      <td>2.103804</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.386361</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13081. Tanzania - Dar-es-Salaam. 03 - Health w...</td>\n",
       "      <td>0.006151</td>\n",
       "      <td>2.158362</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.442250</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>72050. Humanitarian Office. 11 - Prevention an...</td>\n",
       "      <td>0.000118</td>\n",
       "      <td>2.187521</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.316236</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     LongDescription  USD_Disbursement_Defl  \\\n",
       "0  72050. Nicaragua - Managua. 08 - Youth leaders...               0.022965   \n",
       "1  13010. Mexico - Mexico City. 01 - SRH Policies...               0.023190   \n",
       "2  13010. Cuba - Havana. 14 - Demographic intelli...               0.006837   \n",
       "3  13081. Tanzania - Dar-es-Salaam. 03 - Health w...               0.006151   \n",
       "4  72050. Humanitarian Office. 11 - Prevention an...               0.000118   \n",
       "\n",
       "   body_len  body_sent    punct%  \n",
       "0  2.198657   0.778151  1.359012  \n",
       "1  2.060698   0.778151  1.408259  \n",
       "2  2.103804   0.778151  1.386361  \n",
       "3  2.158362   0.778151  1.442250  \n",
       "4  2.187521   0.778151  1.316236  "
      ]
     },
     "execution_count": 194,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#applying logrithmic transformation on \"body_len\" column\n",
    "crs_2018_health[\"body_len\"]=crs_2018_health[\"body_len\"].apply(lambda x: np.log10(x))\n",
    "\n",
    "#applying logrithmic transformation on \"body_len\" column\n",
    "crs_2018_health[\"body_sent\"]=crs_2018_health[\"body_sent\"].apply(lambda x: np.log10(x))\n",
    "\n",
    "crs_2018_health[\"punct%\"]=crs_2018_health[\"punct%\"].apply(lambda x: x**(1/6))\n",
    "\n",
    "crs_2018_health.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(2004, 22342)\n"
     ]
    }
   ],
   "source": [
    "#vectorizing 2018 test data\n",
    "#TF-IDF--Vectorizing for train data\n",
    "\n",
    "x_tfidf_test_2018= tfidf_vect.transform(crs_2018_health[\"LongDescription\"])\n",
    "print(x_tfidf_test_2018.shape)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 196,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>7</th>\n",
       "      <th>8</th>\n",
       "      <th>9</th>\n",
       "      <th>...</th>\n",
       "      <th>22332</th>\n",
       "      <th>22333</th>\n",
       "      <th>22334</th>\n",
       "      <th>22335</th>\n",
       "      <th>22336</th>\n",
       "      <th>22337</th>\n",
       "      <th>22338</th>\n",
       "      <th>22339</th>\n",
       "      <th>22340</th>\n",
       "      <th>22341</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1999</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2000</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2001</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2002</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2003</th>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2004 rows  22342 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      0      1      2      3      4      5      6      7      8      9      \\\n",
       "0       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "1       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "3       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "4       0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "...     ...    ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "1999    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2000    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2001    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2002    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2003    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "\n",
       "      ...  22332  22333  22334  22335  22336  22337  22338  22339  22340  \\\n",
       "0     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "1     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "3     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "4     ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "...   ...    ...    ...    ...    ...    ...    ...    ...    ...    ...   \n",
       "1999  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2000  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2001  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2002  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "2003  ...    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0   \n",
       "\n",
       "      22341  \n",
       "0       0.0  \n",
       "1       0.0  \n",
       "2       0.0  \n",
       "3       0.0  \n",
       "4       0.0  \n",
       "...     ...  \n",
       "1999    0.0  \n",
       "2000    0.0  \n",
       "2001    0.0  \n",
       "2002    0.0  \n",
       "2003    0.0  \n",
       "\n",
       "[2004 rows x 22342 columns]"
      ]
     },
     "execution_count": 196,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#the x_tfidf_test_2018 is sparse matrix. Lets look at it in data frame form\n",
    "x_tfidf_test_df2018= pd.DataFrame(x_tfidf_test_2018.toarray())\n",
    "\n",
    "x_tfidf_test_df2018"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>0</th>\n",
       "      <th>1</th>\n",
       "      <th>2</th>\n",
       "      <th>3</th>\n",
       "      <th>4</th>\n",
       "      <th>5</th>\n",
       "      <th>6</th>\n",
       "      <th>...</th>\n",
       "      <th>22332</th>\n",
       "      <th>22333</th>\n",
       "      <th>22334</th>\n",
       "      <th>22335</th>\n",
       "      <th>22336</th>\n",
       "      <th>22337</th>\n",
       "      <th>22338</th>\n",
       "      <th>22339</th>\n",
       "      <th>22340</th>\n",
       "      <th>22341</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2.198657</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.359012</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2.060698</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.408259</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2.103804</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.386361</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2.158362</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.442250</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2.187521</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.316236</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>...</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "      <td>0.0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  22345 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   body_len  body_sent    punct%    0    1    2    3    4    5    6  ...  \\\n",
       "0  2.198657   0.778151  1.359012  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "1  2.060698   0.778151  1.408259  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "2  2.103804   0.778151  1.386361  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "3  2.158362   0.778151  1.442250  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "4  2.187521   0.778151  1.316236  0.0  0.0  0.0  0.0  0.0  0.0  0.0  ...   \n",
       "\n",
       "   22332  22333  22334  22335  22336  22337  22338  22339  22340  22341  \n",
       "0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "1    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "2    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "3    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "4    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0    0.0  \n",
       "\n",
       "[5 rows x 22345 columns]"
      ]
     },
     "execution_count": 197,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#concatenating all  the features\n",
    "\n",
    "x_tfidf_test_feat2018 = pd.concat([crs_2018_health[\"body_len\"],crs_2018_health[\"body_sent\"], crs_2018_health[\"punct%\"], \n",
    "                               pd.DataFrame(x_tfidf_test_2018.toarray())], axis=1)\n",
    "x_tfidf_test_feat2018.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 198,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array(['not_global_func', 'Health_Advocacy', 'Health_Advocacy', ...,\n",
       "       'not_global_func', 'not_global_func', 'Epidemic_Pandemic_Prep'],\n",
       "      dtype=object)"
      ]
     },
     "execution_count": 198,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#predicting the categories using the saved trained model on 2019 test set \n",
    "result2018=loaded_model.predict(x_tfidf_test_feat2018)\n",
    "\n",
    "result2018"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**calculating the finance for 2018 based on categories predicted** "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 199,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>LongDescription</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "      <th>body_len</th>\n",
       "      <th>body_sent</th>\n",
       "      <th>punct%</th>\n",
       "      <th>class_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>72050. Nicaragua - Managua. 08 - Youth leaders...</td>\n",
       "      <td>0.022965</td>\n",
       "      <td>2.198657</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.359012</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>13010. Mexico - Mexico City. 01 - SRH Policies...</td>\n",
       "      <td>0.023190</td>\n",
       "      <td>2.060698</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.408259</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>13010. Cuba - Havana. 14 - Demographic intelli...</td>\n",
       "      <td>0.006837</td>\n",
       "      <td>2.103804</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.386361</td>\n",
       "      <td>Health_Advocacy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>13081. Tanzania - Dar-es-Salaam. 03 - Health w...</td>\n",
       "      <td>0.006151</td>\n",
       "      <td>2.158362</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.442250</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>72050. Humanitarian Office. 11 - Prevention an...</td>\n",
       "      <td>0.000118</td>\n",
       "      <td>2.187521</td>\n",
       "      <td>0.778151</td>\n",
       "      <td>1.316236</td>\n",
       "      <td>not_global_func</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                     LongDescription  USD_Disbursement_Defl  \\\n",
       "0  72050. Nicaragua - Managua. 08 - Youth leaders...               0.022965   \n",
       "1  13010. Mexico - Mexico City. 01 - SRH Policies...               0.023190   \n",
       "2  13010. Cuba - Havana. 14 - Demographic intelli...               0.006837   \n",
       "3  13081. Tanzania - Dar-es-Salaam. 03 - Health w...               0.006151   \n",
       "4  72050. Humanitarian Office. 11 - Prevention an...               0.000118   \n",
       "\n",
       "   body_len  body_sent    punct%       class_pred  \n",
       "0  2.198657   0.778151  1.359012  not_global_func  \n",
       "1  2.060698   0.778151  1.408259  Health_Advocacy  \n",
       "2  2.103804   0.778151  1.386361  Health_Advocacy  \n",
       "3  2.158362   0.778151  1.442250  not_global_func  \n",
       "4  2.187521   0.778151  1.316236  not_global_func  "
      ]
     },
     "execution_count": 199,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_fin_calc2018=pd.concat([crs_2018_health, pd.DataFrame(result2018)], axis=1)\n",
    "\n",
    "test_fin_calc2018=test_fin_calc2018.rename(columns={0:\"class_pred\"})\n",
    "\n",
    "test_fin_calc2018.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>class_pred</th>\n",
       "      <th>USD_Disbursement_Defl</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Response_Unhealthy_Products</td>\n",
       "      <td>0.06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Promotion_Aid_Effectiveness</td>\n",
       "      <td>2.11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Dev_Harmonization_Int_Reg</td>\n",
       "      <td>2.18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Knowledge_Gen_Sharing</td>\n",
       "      <td>11.99</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Market_Shaping</td>\n",
       "      <td>20.54</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Health_Advocacy</td>\n",
       "      <td>49.78</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>RD_New_Health_Tools</td>\n",
       "      <td>90.00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Epidemic_Pandemic_Prep</td>\n",
       "      <td>99.37</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Control_Cross_Border_Disease</td>\n",
       "      <td>151.24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>not_global_func</td>\n",
       "      <td>1143.42</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                     class_pred  USD_Disbursement_Defl\n",
       "0   Response_Unhealthy_Products                   0.06\n",
       "1   Promotion_Aid_Effectiveness                   2.11\n",
       "2     Dev_Harmonization_Int_Reg                   2.18\n",
       "3         Knowledge_Gen_Sharing                  11.99\n",
       "4                Market_Shaping                  20.54\n",
       "5               Health_Advocacy                  49.78\n",
       "6           RD_New_Health_Tools                  90.00\n",
       "7        Epidemic_Pandemic_Prep                  99.37\n",
       "8  Control_Cross_Border_Disease                 151.24\n",
       "9               not_global_func                1143.42"
      ]
     },
     "execution_count": 200,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg amount based on the predicted categories\n",
    "dah_gpg2018=test_fin_calc2018.groupby([\"class_pred\"]).agg({\"USD_Disbursement_Defl\":np.sum})\n",
    "\n",
    "dah_gpg2018=dah_gpg2018.sort_values(\"USD_Disbursement_Defl\").reset_index()\n",
    "\n",
    "dah_gpg2018=dah_gpg2018.round(2)\n",
    "dah_gpg2018"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 201,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "class_pred               Response_Unhealthy_ProductsPromotion_Aid_Effec...\n",
       "USD_Disbursement_Defl                                               427.27\n",
       "dtype: object"
      ]
     },
     "execution_count": 201,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#gpg finance based on predicted categories in the test dataset\n",
    "dah_gpg2018[dah_gpg2018[\"class_pred\"]!=\"not_global_func\"].sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 204,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1008x432 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#plotting the distribution of categories. Creating column chart\n",
    "\n",
    "#plotting the observation cat\n",
    "plt.figure(figsize=(14,6))\n",
    "plt.bar(dah_gpg2018[\"class_pred\"], dah_gpg2018[\"USD_Disbursement_Defl\"])\n",
    "plt.xticks(rotation=90)\n",
    "plt.title(\"Machine Predicted Finance 2018 (millions)\")\n",
    "\n",
    "for i, v in enumerate(dah_gpg2018[\"USD_Disbursement_Defl\"]):\n",
    "    plt.text(i, v, str(v))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
